

FEATURE:
; OTHER INFORMATION: DNA excision repair protein ERCC5
; OTHER INFORMATION: The letter "s" stands for g or c.
US-09-782-837-15

Query Match 0.4%; Score 15.6; DB 1; Length 21;
Best Local Similarity 93.8%; Pred. No. 6e+02;
Matches 15; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1294 GTGAAGATGCTGAAG 1309
|||||:|||||
DB 6 GTGAATGCTGAAG 21

RESULT 672
US-10-005-956-1081
; Sequence 1081, Application US/10005956
; Publication No. US20030113726A1
; GENERAL INFORMATION:
; APPLICANT: Bristol-Myers Squibb Company
; TITLE OF INVENTION: HUMAN SINGLE NUCLEOTIDE POLYMORPHISMS
; FILE REFERENCE: D0053NP
; CURRENT APPLICATION NUMBER: US/10/005,956
; CURRENT FILING DATE: 2001-12-03
; PRIOR APPLICATION NUMBER: 60/251,015
; PRIOR FILING DATE: 2000-12-04
; PRIOR APPLICATION NUMBER: 60/263,678
; PRIOR FILING DATE: 2001-01-23
; PRIOR APPLICATION NUMBER: 60/273,037
; PRIOR FILING DATE: 2001-03-02
; NUMBER OF SEQ ID NOS: 1579
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1081
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-005-956-1081

Query Match 0.4%; Score 15.6; DB 1; Length 22;
Best Local Similarity 81.8%; Pred. No. 6.3e+02;
Matches 18; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 2326 TGTGTGCGGTGTGTGTGTG 2347
|||||:|||||
DB 1 TGTGTGTCATGAGTAGGTG 22

RESULT 673
US-10-259-451-11
; Sequence 11, Application US/10259451
; Publication No. US20030162796A1
; GENERAL INFORMATION:
; APPLICANT: Boehringer Ingelheim International GmbH
; TITLE OF INVENTION: Pharmaceutical composition for the treatment of disorders of
; FILE REFERENCE: Case 12 221
; CURRENT APPLICATION NUMBER: US/10/259,451
; CURRENT FILING DATE: 2002-09-30
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 11
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-259-451-11

Query Match 0.4%; Score 15.6; DB 1; Length 22;
Best Local Similarity 81.8%; Pred. No. 6.3e+02;
Matches 18; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1748 TGAAGTGGATGGCGCTGAGGC 1769

DB 1 TCAAGTGGATGGCGCTGGAGTC 22
|||||:|||||

RESULT 674
US-10-094-466-79
; Sequence 79, Application US/10094466
; Publication No. US20030203363A1
; GENERAL INFORMATION:
; APPLICANT: Spytek et al.
; TITLE OF INVENTION: NOVEL HUMAN PROTEINS, POLYNUCLEOTIDES ENCODING THEM
; TITLE OF INVENTION: AND METHODS OF USING
; TITLE OF INVENTION: THE SAME
; FILE REFERENCE: 21402-290D
; CURRENT APPLICATION NUMBER: US/10/094,466
; CURRENT FILING DATE: 2002-03-07
; PRIOR APPLICATION NUMBER: 60/274,281
; PRIOR FILING DATE: 2001-03-08
; PRIOR APPLICATION NUMBER: 60/288,148
; PRIOR FILING DATE: 2001-05-02
; PRIOR APPLICATION NUMBER: 60/274,849
; PRIOR FILING DATE: 2001-03-09
; PRIOR APPLICATION NUMBER: 60/275,235
; PRIOR FILING DATE: 2001-03-12
; PRIOR APPLICATION NUMBER: 60/338,375
; PRIOR FILING DATE: 2001-12-04
; PRIOR APPLICATION NUMBER: 60/275,579
; PRIOR FILING DATE: 2001-03-13
; PRIOR APPLICATION NUMBER: 60/335,302
; PRIOR FILING DATE: 2001-10-31
; PRIOR APPLICATION NUMBER: 60/275,601
; PRIOR FILING DATE: 2001-03-13
; PRIOR APPLICATION NUMBER: 60/276,000
; PRIOR FILING DATE: 2001-03-14
; PRIOR APPLICATION NUMBER: 60/277,338
; PRIOR FILING DATE: 2001-03-20
; Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 114
; SOFTWARE: PatentIn 2.1
; SEQ ID NO 79
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Forward Primer
US-10-094-466-79

Query Match 0.4%; Score 15.6; DB 1; Length 22;
Best Local Similarity 81.8%; Pred. No. 6.3e+02;
Matches 18; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1361 TGAAGATGATCGGAAACAA 1382
|||||:|||||
DB 1 TGAACATGTTGGAAACAA 22

RESULT 675
US-10-409-107A-55
; Sequence 55, Application US/10409107A
; Publication No. US20040053288A1
; GENERAL INFORMATION:
; APPLICANT: YANAI, Yoshiaki
; APPLICANT: YAMAMOTO, Shigeto
; APPLICANT: YAMAMOTO, Kozo
; APPLICANT: IKEGAMI, Hakuo
; TITLE OF INVENTION: Method for estimating therapeutic efficacy of tumor necrosis
; TITLE OF INVENTION: Factor
; FILE REFERENCE: YANAI-3
; CURRENT APPLICATION NUMBER: US/10/409,107A
; CURRENT FILING DATE: 2003-04-19
; PRIOR APPLICATION NUMBER: JP 107126/2002
; PRIOR FILING DATE: 2002-04-09
; NUMBER OF SEQ ID NOS: 100

```
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 55
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Oligonucleotide used as primer for PCR detection of ERK1 mRNA
US-10-409-107A-55

Query Match          0.4%; Score 15.6; DB 1; Length 22;
Best Local Similarity 81.8%; Pred. No. 6.3e+02;
Matches 18; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY      855 GGAGGACCTGGTGAGGCTGAC 876
Db      1 GCAGGACCTGATGGAGACTGAC 22

RESULT 676
US-10-455-470-22
; Sequence 22, Application US/10455470
; Publication No. US20040170613A1
; GENERAL INFORMATION:
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Le Couter, Jennifer
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR LIVER GROWTH AND LIVER PROTECTION
; FILE REFERENCE: P1849R1US
; CURRENT APPLICATION NUMBER: US/10/455,470
; CURRENT FILING DATE: 2003-06-05
; PRIOR APPLICATION NUMBER: US 60/386,637
; PRIOR FILING DATE: 2002-06-05
; NUMBER OF SEQ ID NOS: 36
; SEQ ID NO 22
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: sequence is synthesized
; NAME/KEY: PCR primer
; LOCATION: Full
; OTHER INFORMATION: bPGF forward
US-10-455-470-22

Query Match          0.4%; Score 15.6; DB 1; Length 22;
Best Local Similarity 81.8%; Pred. No. 6.3e+02;
Matches 18; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY      1979 CCTCCAGAGCCACCTTCAA 2000
Db      1 CCTCAGAGACCTACGTTCAA 22

RESULT 677
US-10-219-195-35
; Sequence 35, Application US/10219195
; Publication No. US20030165917A1
; GENERAL INFORMATION:
; APPLICANT: ULLMAN, EDWIN
; APPLICANT: WU, MING
; APPLICANT: LIU, YEN PING
; TITLE OF INVENTION: ISOTHERMAL AMPLIFICATION IN NUCLEIC ACID ANALYSIS
; FILE REFERENCE: 3817.05-1
; CURRENT APPLICATION NUMBER: US/10/219,195
; CURRENT FILING DATE: 2002-08-14
; PRIOR APPLICATION NUMBER: 60/312,505
; PRIOR FILING DATE: 2001-08-14
; NUMBER OF SEQ ID NOS: 49
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 35
; LENGTH: 39
; TYPE: DNA
```

```
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: Oligonucleotide
US-10-219-195-35

Query Match          0.4%; Score 15.6; DB 1; Length 39;
Best Local Similarity 70.0%; Pred. No. 1.1e+03;
Matches 21; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

QY      3262 TATTTATTGCTTGTCTCTTTTCAGGAG 3291
Db      3 TTTTTCCTTTTTCCTTTTTCAGGAG 32

RESULT 678
US-09-866-108-7996
; Sequence 7996, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 7996
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108-7996

Query Match          0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 5.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```


QY 1992 CACCTTCAAGCAGCTGG 2008
 Db 1 CACCATCAAGCAGCTGG 17

RESULT 679
 US-09-825-805-771
 ; Sequence 771, Application US/09825805
 ; Publication No. US20030004122A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: Beigelman, Leo
 ; APPLICANT: Beaudry, Amber
 ; APPLICANT: Karpeisky, Alex
 ; APPLICANT: Adamic, Jasenka Matulic
 ; APPLICANT: Sweedler, Dave
 ; APPLICANT: Zinnen, Shawn
 ; TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleot
 ; FILE REFERENCE: MEHB00-831-F (400/009)
 ; CURRENT APPLICATION NUMBER: US/09/825,805
 ; CURRENT FILING DATE: 2001-09-27
 ; PRIOR APPLICATION NUMBER: 09/578,223
 ; PRIOR FILING DATE: 2000-05-23
 ; PRIOR APPLICATION NUMBER: 09/476,387
 ; PRIOR FILING DATE: 1999-12-30
 ; PRIOR APPLICATION NUMBER: 09/474,432
 ; PRIOR FILING DATE: 1999-12-29
 ; PRIOR APPLICATION NUMBER: 09/301,511
 ; PRIOR FILING DATE: 1999-04-28
 ; PRIOR APPLICATION NUMBER: 09/186,675
 ; PRIOR FILING DATE: 1998-11-04
 ; PRIOR APPLICATION NUMBER: 60/083,727
 ; PRIOR FILING DATE: 1998-04-29
 ; PRIOR APPLICATION NUMBER: 60/064,866
 ; PRIOR FILING DATE: 1997-11-05
 ; NUMBER OF SEQ ID NOS: 1558
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 771
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-09-825-805-771

Query Match 0.4%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 76.5%; Pred. No. 5.1e+02;
 Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 1678 GACTTCGGCTGGCCCG 1694
 Db 1 GACUUCGGCGGCGUCUG 17

RESULT 680
 US-09-730-289B-154
 ; Sequence 154, Application US/09730289B
 ; Publication No. US20030050259A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: Blatt, Larry
 ; APPLICANT: McSwiggen, Jim
 ; TITLE OF INVENTION: Method and Reagent for Treatment of Cardiac Disease
 ; FILE REFERENCE: MEHB00-864-A (400/006)
 ; CURRENT APPLICATION NUMBER: US/09/730,289B
 ; CURRENT FILING DATE: 2000-12-05
 ; PRIOR APPLICATION NUMBER: US 60/169,100
 ; PRIOR FILING DATE: 1999-12-06
 ; NUMBER OF SEQ ID NOS: 3897
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 154
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-09-730-289B-154

Query Match 0.4%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 47.1%; Pred. No. 5.1e+02;
 Matches 8; Conservative 8; Mismatches 1; Indels 0; Gaps 0;

QY 3003 AGTTTGTGTTTAAACT 3019
 Db 1 AGUUUAGUUUAAAACU 17

RESULT 681
 US-09-730-289B-155
 ; Sequence 155, Application US/09730289B
 ; Publication No. US20030050259A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: Blatt, Larry
 ; APPLICANT: McSwiggen, Jim
 ; TITLE OF INVENTION: Method and Reagent for Treatment of Cardiac Disease
 ; FILE REFERENCE: MEHB00-864-A (400/006)
 ; CURRENT APPLICATION NUMBER: US/09/730,289B
 ; CURRENT FILING DATE: 2000-12-05
 ; PRIOR APPLICATION NUMBER: US 60/169,100
 ; PRIOR FILING DATE: 1999-12-06
 ; NUMBER OF SEQ ID NOS: 3897
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 155
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-09-730-289B-155

Query Match 0.4%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 47.1%; Pred. No. 5.1e+02;
 Matches 8; Conservative 8; Mismatches 1; Indels 0; Gaps 0;

QY 3004 GTTTGTGTTTAAACTG 3020
 Db 1 GUUUAGUUUAAAACUG 17

RESULT 682
 US-09-848-754A-3493
 ; Sequence 3493, Application US/09848754A
 ; Publication No. US20030073207A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
 ; FILE REFERENCE: MEHB00-958-I (400/018)
 ; CURRENT APPLICATION NUMBER: US/09/848,754A
 ; CURRENT FILING DATE: 2001-05-03
 ; NUMBER OF SEQ ID NOS: 9645
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 3493
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-09-848-754A-3493

Query Match 0.4%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 76.5%; Pred. No. 5.1e+02;
 Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 1793 ACCAGAGTGAGCTCTGG 1809
 Db 1 ACCAGAGUGAUGUCUG 17

RESULT 683
 US-10-163-552-649
 ; Sequence 649, Application US/10163552
 ; Publication No. US20030105051A1


```
; Sequence 2009, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2009
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-2009

Query Match      0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 5.1e+02;
Matches 10; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

Qy      1798 AGTGACGTCTGGTCTT 1814
Db      1 AGUGACGUCUGGUCUU 17

RESULT 688
US-10-138-674-6729
; Sequence 6729, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6729
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-6729

Query Match      0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.1e+02;
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy      1610 AGTGCATCCACAGGGAC 1626
Db      1 AGUGAUCCACAGGGAC 17

RESULT 689
US-10-138-674-6730
; Sequence 6730, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
```

```
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6730
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-6730

Query Match      0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.1e+02;
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy      1611 GTGCATCCACAGGGACC 1627
Db      1 GUGUAUCCACAGGGACC 17

RESULT 690
US-10-138-674-6731
; Sequence 6731, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6731
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-6731

Query Match      0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.1e+02;
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy      1613 GCATCCACAGGGACCTG 1629
Db      1 GUAUCCACAGGGACCUG 17

RESULT 691
US-10-138-674-6762
; Sequence 6762, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6762
; LENGTH: 17
; TYPE: RNA
```



```
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 8510
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-8510

Query Match          0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 5.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      2997 CACCGCAGTTTGTGTTT 3013
Db      17 CACCACAGTTTGTGTTT 1

RESULT 697
US-10-138-674-8949
; Sequence 8949, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 8949
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-8949

Query Match          0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 5.1e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy      1585 GGCATGGAGTACTTGGC 1601
Db      1 GGCAUGGAGUUCUUGGC 17

RESULT 698
US-10-138-674-8954
; Sequence 8954, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
```

```
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 8954
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-8954

Query Match          0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.1e+02;
Matches 15; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy      1617 CCACAGGACCTGGCTG 1633
Db      1 CCACAGGACCUUGCGG 17

RESULT 699
US-10-138-674-8985
; Sequence 8985, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 8985
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-8985

Query Match          0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 5.1e+02;
Matches 10; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

Qy      1801 GACGCTGCTCCTTTGG 1817
Db      1 GACGUCUGUCUUGG 17

RESULT 700
US-10-287-949A-1977
; Sequence 1977, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1977
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-1977

Query Match          0.4%; Score 15.4; DB 1; Length 17;
```

Best Local Similarity 82.4%; Pred. No. 5.1e+02;
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 1609 AAGTGCATCCACAGGA 1625
|||:|:|||||
Db 1 AAGUUAUCCACAGGA 17

RESULT 701

US-10-287-949A-2009
; Sequence 2009, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2009
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-2009

Query Match 0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 5.1e+02;
Matches 10; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

Qy 1798 AGTGCATCTGTCCTT 1814
|||:|:|||||
Db 1 AGUACGUCUGGUCUU 17

RESULT 702

US-10-287-949A-6729
; Sequence 6729, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6729
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-6729

Query Match 0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.1e+02;
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 1610 AGTGCATCCACAGGAC 1626
|||:|:|||||
Db 1 AGUUAUCCACAGGAC 17

RESULT 703

US-10-287-949A-6730
; Sequence 6730, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6730
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-6730

Query Match 0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.1e+02;
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 1611 GTGCATCCACAGGACC 1627
|||:|:|||||
Db 1 GUGUAUCCACAGGACC 17

RESULT 704

US-10-287-949A-6731
; Sequence 6731, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6731
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-6731

Query Match 0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.1e+02;
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 1613 GCATCCACAGGACCTG 1629
|||:|:|||||
Db 1 GUAUCCACAGGACCU 17

RESULT 705

US-10-287-949A-6762
; Sequence 6762, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime


```

; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 7996
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-7996

Query Match      0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 5.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1992 CACCTTCAAGCAGCTGG 2008
||| ||||| ||||| |||||
Db 1 CACCATCAAGCAGCTGG 17

RESULT 715
US-09-802-207-14/c
; Sequence 14, Application US/09802207
; Publication No. US20020086824A1
; GENERAL INFORMATION:
; APPLICANT: Warman, Matthew
; APPLICANT: Carpten, John
; APPLICANT: Trent, Jeffrey
; APPLICANT: Marcelino, Jose
; TITLE OF INVENTION: Novel Methods and Reagents for the Treatment of Osteoarthritis
; FILE REFERENCE: Case-06212
; CURRENT APPLICATION NUMBER: US/09/802,207
; CURRENT FILING DATE: 2001-08-29
; PRIOR APPLICATION NUMBER: 09/619,175
; PRIOR FILING DATE: 2000-07-19
; PRIOR APPLICATION NUMBER: 60/145,328
; PRIOR FILING DATE: 1999-07-23
; NUMBER OF SEQ ID NOS: 30
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 14
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-802-207-14

Query Match      0.4%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 5.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2600 CCCACACCCAAAGCTGA 2616
||| ||||| ||||| |||||

```

```

Db 18 CCTACACCCAAAGCTGA 2

RESULT 716
US-09-969-373-1877/c
; Sequence 1877, Application US/09969373
; Patent No. US20020133852A1
; GENERAL INFORMATION:
; APPLICANT: Effertz, Roger J.
; APPLICANT: Hauge, Brian M.
; TITLE OF INVENTION: Soybean SSRs and Methods of Genotyping
; FILE REFERENCE: 38-10(52679)A
; CURRENT APPLICATION NUMBER: US/09/969,373
; CURRENT FILING DATE: 2001-10-02
; PRIOR APPLICATION NUMBER: US 09/754,853
; PRIOR FILING DATE: 2001-01-05
; PRIOR APPLICATION NUMBER: US 09/760,427
; PRIOR FILING DATE: 2001-01-13
; PRIOR APPLICATION NUMBER: US 09/855,768
; PRIOR FILING DATE: 2001-05-15
; NUMBER OF SEQ ID NOS: 4593
; SEQ ID NO 1877
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Glycine max
US-09-969-373-1877

Query Match      0.4%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 5.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2690 CTTTCCCACTTCCCAACC 2706
||| ||||| ||||| |||||
Db 17 CTATCCCACTTCCCAACC 1

RESULT 717
US-09-969-373-2975/c
; Sequence 2975, Application US/09969373
; Patent No. US20020133852A1
; GENERAL INFORMATION:
; APPLICANT: Effertz, Roger J.
; APPLICANT: Hauge, Brian M.
; TITLE OF INVENTION: Soybean SSRs and Methods of Genotyping
; FILE REFERENCE: 38-10(52679)A
; CURRENT APPLICATION NUMBER: US/09/969,373
; CURRENT FILING DATE: 2001-10-02
; PRIOR APPLICATION NUMBER: US 09/754,853
; PRIOR FILING DATE: 2001-01-05
; PRIOR APPLICATION NUMBER: US 09/760,427
; PRIOR FILING DATE: 2001-01-13
; PRIOR APPLICATION NUMBER: US 09/855,768
; PRIOR FILING DATE: 2001-05-15
; NUMBER OF SEQ ID NOS: 4593
; SEQ ID NO 2975
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Glycine max
US-09-969-373-2975

Query Match      0.4%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 5.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2322 TGTGTGTGTGTGCGTGT 2338
||| ||||| ||||| |||||
Db 17 TGTGTGTGTGTGCGAGT 1

RESULT 718
US-09-263-959-983/c
; Sequence 983, Application US/09263959
; Patent No. US20020150891A1

```


; CURRENT APPLICATION NUMBER: US/10/773,951
 ; CURRENT FILING DATE: 2004-02-06
 ; PRIOR APPLICATION NUMBER: 60/445,968
 ; PRIOR FILING DATE: 2003-02-06
 ; NUMBER OF SEQ ID NOS: 108
 ; SOFTWARE: FastSeq for Windows Version 4.0
 ; SEQ ID NO 53
 ; LENGTH: 19
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: reverse primer
 US-10-773-951-53

Query Match 0.4%; Score 15.4; DB 1; Length 19;
 Best Local Similarity 94.1%; Pred. No. 5.8e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1747 GTGAAGTGGATGGCC 1763
 Db 18 GTGAAGTGGATGGCACC 2

RESULT 722

US-10-683-990-23/c
 ; Sequence 23, Application US/10683990
 ; Publication No. US20040198682A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Sirna Therapeutics
 ; APPLICANT: McSwiggen, James
 ; APPLICANT: Usman, Nasim
 ; APPLICANT: Pavco, Pamela
 ; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Placental Growth Factor
 ; FILE REFERENCE: 400/134 (02-742-H)
 ; CURRENT APPLICATION NUMBER: US/10/683,990
 ; CURRENT FILING DATE: 2003-10-10
 ; PRIOR APPLICATION NUMBER: PCT/US03/05022
 ; PRIOR FILING DATE: 2003-02-20
 ; PRIOR APPLICATION NUMBER: US 60/358,580
 ; PRIOR FILING DATE: 2002-02-20
 ; PRIOR APPLICATION NUMBER: US 60/363,124
 ; PRIOR FILING DATE: 2002-03-11
 ; PRIOR APPLICATION NUMBER: US 60/386,782
 ; PRIOR FILING DATE: 2002-06-06
 ; PRIOR APPLICATION NUMBER: US 60/393,796
 ; PRIOR FILING DATE: 2002-07-03
 ; PRIOR APPLICATION NUMBER: US 60/399,348
 ; PRIOR FILING DATE: 2002-07-29
 ; PRIOR APPLICATION NUMBER: US 60/406,784
 ; PRIOR FILING DATE: 2002-08-29
 ; PRIOR APPLICATION NUMBER: US 60/408,378
 ; PRIOR FILING DATE: 2002-09-05
 ; PRIOR APPLICATION NUMBER: US 60/409,293
 ; PRIOR FILING DATE: 2002-09-09
 ; Remaining Prior Application data removed - See File Wrapper or PALM.
 ; NUMBER OF SEQ ID NOS: 256
 ; SOFTWARE: PatentIn version 3.2
 ; SEQ ID NO 23
 ; LENGTH: 19
 ; TYPE: RNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense

US-10-683-990-23
 ; Sequence 23, Application US/10683990
 ; Publication No. US20040198682A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Sirna Therapeutics
 ; APPLICANT: McSwiggen, James
 ; APPLICANT: Usman, Nasim
 ; APPLICANT: Pavco, Pamela
 ; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Placental Growth Factor
 ; FILE REFERENCE: 400/134 (02-742-H)
 ; CURRENT APPLICATION NUMBER: US/10/683,990
 ; CURRENT FILING DATE: 2003-10-10
 ; PRIOR APPLICATION NUMBER: PCT/US03/05022
 ; PRIOR FILING DATE: 2003-02-20
 ; PRIOR APPLICATION NUMBER: US 60/358,580
 ; PRIOR FILING DATE: 2002-02-20
 ; PRIOR APPLICATION NUMBER: US 60/363,124
 ; PRIOR FILING DATE: 2002-03-11
 ; PRIOR APPLICATION NUMBER: US 60/386,782
 ; PRIOR FILING DATE: 2002-06-06
 ; PRIOR APPLICATION NUMBER: US 60/393,796
 ; PRIOR FILING DATE: 2002-07-03
 ; PRIOR APPLICATION NUMBER: US 60/399,348
 ; PRIOR FILING DATE: 2002-07-29
 ; PRIOR APPLICATION NUMBER: US 60/406,784
 ; PRIOR FILING DATE: 2002-08-29
 ; PRIOR APPLICATION NUMBER: US 60/408,378
 ; PRIOR FILING DATE: 2002-09-05
 ; PRIOR APPLICATION NUMBER: US 60/409,293
 ; PRIOR FILING DATE: 2002-09-09
 ; PRIOR APPLICATION NUMBER: US 60/440,129
 ; PRIOR FILING DATE: 2003-01-15
 ; Remaining Prior Application data removed - See File Wrapper or PALM.
 ; NUMBER OF SEQ ID NOS: 256
 ; SOFTWARE: PatentIn version 3.2
 ; SEQ ID NO 23
 ; LENGTH: 19
 ; TYPE: RNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense

Query Match 0.4%; Score 15.4; DB 1; Length 19;
 Best Local Similarity 94.1%; Pred. No. 5.8e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2893 GGGGGCACAGGAGCAG 2909

Db 19 GGGGGCACAGGAGCAG 3

RESULT 723

US-10-683-990-120
 ; Sequence 120, Application US/10683990
 ; Publication No. US20040198682A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Sirna Therapeutics
 ; APPLICANT: McSwiggen, James
 ; APPLICANT: Usman, Nasim
 ; APPLICANT: Pavco, Pamela
 ; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Placental Growth Factor
 ; FILE REFERENCE: 400/134 (02-742-H)
 ; CURRENT APPLICATION NUMBER: US/10/683,990
 ; CURRENT FILING DATE: 2003-10-10
 ; PRIOR APPLICATION NUMBER: PCT/US03/05022
 ; PRIOR FILING DATE: 2003-02-20
 ; PRIOR APPLICATION NUMBER: US 60/358,580
 ; PRIOR FILING DATE: 2002-02-20
 ; PRIOR APPLICATION NUMBER: US 60/363,124
 ; PRIOR FILING DATE: 2002-03-11
 ; PRIOR APPLICATION NUMBER: US 60/386,782
 ; PRIOR FILING DATE: 2002-06-06
 ; PRIOR APPLICATION NUMBER: US 60/393,796
 ; PRIOR FILING DATE: 2002-07-03
 ; PRIOR APPLICATION NUMBER: US 60/399,348
 ; PRIOR FILING DATE: 2002-07-29
 ; PRIOR APPLICATION NUMBER: US 60/406,784
 ; PRIOR FILING DATE: 2002-08-29
 ; PRIOR APPLICATION NUMBER: US 60/408,378
 ; PRIOR FILING DATE: 2002-09-05
 ; PRIOR APPLICATION NUMBER: US 60/409,293
 ; PRIOR FILING DATE: 2002-09-09
 ; Remaining Prior Application data removed - See File Wrapper or PALM.
 ; NUMBER OF SEQ ID NOS: 256
 ; SOFTWARE: PatentIn version 3.2
 ; SEQ ID NO 120
 ; LENGTH: 19
 ; TYPE: RNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region

Qy 2893 GGGGGCACAGGAGCAG 2909

Db 1 GGGGGCACAGGAGCAG 17

RESULT 724

US-09-953-047-91
 ; Sequence 91, Application US/09953047
 ; Publication No. US20030087854A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Brett P. Monia
 ; APPLICANT: Jacqueline Wyatt
 ; TITLE OF INVENTION: ANTISENSE MODULATION OF FIBROBLAST GROWTH FACTOR RECEPTOR 3 EXPRE
 ; FILE REFERENCE: RFS-0157
 ; CURRENT APPLICATION NUMBER: US/09/953,047
 ; CURRENT FILING DATE: 2001-09-10
 ; NUMBER OF SEQ ID NOS: 95
 ; SEQ ID NO 91
 ; LENGTH: 20
 ; TYPE: DNA

Query Match 0.4%; Score 15.4; DB 1; Length 19;
 Best Local Similarity 94.1%; Pred. No. 5.8e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2893 GGGGGCACAGGAGCAG 2909

Db 1 GGGGGCACAGGAGCAG 17

RESULT 724

US-09-953-047-91
 ; Sequence 91, Application US/09953047
 ; Publication No. US20030087854A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Brett P. Monia
 ; APPLICANT: Jacqueline Wyatt
 ; TITLE OF INVENTION: ANTISENSE MODULATION OF FIBROBLAST GROWTH FACTOR RECEPTOR 3 EXPRE
 ; FILE REFERENCE: RFS-0157
 ; CURRENT APPLICATION NUMBER: US/09/953,047
 ; CURRENT FILING DATE: 2001-09-10
 ; NUMBER OF SEQ ID NOS: 95
 ; SEQ ID NO 91
 ; LENGTH: 20
 ; TYPE: DNA

```
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-953-047-91

Query Match      0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 6.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3464 ATATATATCTATATATA 3480
Db 1 ATATATATGTATATATA 17

RESULT 725
US-10-630-401-91
; Sequence 91, Application US/10630401
; Publication No. US20040048824A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF FIBROBLAST GROWTH FACTOR RECEPTOR 3 EXPRE
; FILE REFERENCE: RTS-0157
; CURRENT APPLICATION NUMBER: US/10/630,401
; CURRENT FILING DATE: 2003-07-30
; PRIOR APPLICATION NUMBER: US/09/953,047
; PRIOR FILING DATE: 2001-09-10
; NUMBER OF SEQ ID NOS: 95
; SEQ ID NO 91
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-630-401-91

Query Match      0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 6.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3464 ATATATATCTATATATA 3480
Db 1 ATATATATGTATATATA 17

RESULT 726
US-10-467-008-110
; Sequence 110, Application US/10467008
; Publication No. US20040116366A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF PROTEIN PHOSPHATASE 2 CATALYTIC SUBUNIT B
; FILE REFERENCE: ISPH-0746
; CURRENT APPLICATION NUMBER: US/10/467,008
; CURRENT FILING DATE: 2003-08-01
; PRIOR APPLICATION NUMBER: PCT/US02/02805
; PRIOR FILING DATE: 2002-01-31
; PRIOR APPLICATION NUMBER: US 09/780,045
; PRIOR FILING DATE: 2001-02-09
; NUMBER OF SEQ ID NOS: 135
; SEQ ID NO 110
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-467-008-110

Query Match      0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 6.1e+02;
```

```
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3465 TATATATCTATATATAT 3481
Db 1 TATATATGTATATATAT 17

RESULT 727
US-08-459-455-89/c
; Sequence 89, Application US/08459455
; Publication No. US20030124105A1
; GENERAL INFORMATION:
; APPLICANT: Yuan, Junying
; APPLICANT: Miura, Masayuki
; TITLE OF INVENTION: Programmed Cell Death Genes and Proteins
; NUMBER OF SEQUENCES: 95
; CORRESPONDENCE ADDRESS:
; ADDRESSES: Sterne, Kessler, Goldstein & Fox
; STREET: 1100 New York Avenue, Suite 600
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20005
; COMPUTER READABLE FORM: disk
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/459,455
; FILING DATE: 2-JUN-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/368,704
; FILING DATE: 4-JAN-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/258,287
; FILING DATE: 10-JUN-1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/080,850
; FILING DATE: 24-JUN-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Bugalsky, Lawrence B.
; REGISTRATION NUMBER: 35,086
; REFERENCE/DOCKET NUMBER: 0609.3920003
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 371-2600
; TELEFAX: (202) 371-2540
; TELEX: 248636 SSK
; INFORMATION FOR SEQ ID NO: 89:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: both
; TOPOLOGY: both
; US-08-459-455-89

Query Match      0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 6.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1353 GGAGATGATGAAGATGA 1369
Db 20 GGAGTTCATGAGATGA 4

RESULT 728
US-09-976-782-72
; Sequence 72, Application US/09976782
; Publication No. US20030190715A1
; GENERAL INFORMATION:
```

APPLICANT: Grosse et al
; TITLE OF INVENTION: No. US20030190715A1el Proteins and Nucleic Acids Encoding Same
; FILE REFERENCE: 21402-157
; CURRENT APPLICATION NUMBER: US/09/976,782
; CURRENT FILING DATE: 2001-10-12
; PRIOR APPLICATION NUMBER: 60/240,113
; PRIOR FILING DATE: 2000-10-12
; PRIOR APPLICATION NUMBER: 60/240,662
; PRIOR FILING DATE: 2000-10-16
; PRIOR APPLICATION NUMBER: 60/240,732
; PRIOR FILING DATE: 2000-10-16
; PRIOR APPLICATION NUMBER: 60/240,625
; PRIOR FILING DATE: 2000-10-16
; PRIOR APPLICATION NUMBER: 60/240,703
; PRIOR FILING DATE: 2000-10-16
; PRIOR APPLICATION NUMBER: 60/241,190
; PRIOR FILING DATE: 2000-10-16
; PRIOR APPLICATION NUMBER: 60/240,637
; PRIOR FILING DATE: 2000-10-16
; PRIOR APPLICATION NUMBER: 60/240,669
; PRIOR FILING DATE: 2000-10-16
; PRIOR APPLICATION NUMBER: 60/262,455
; PRIOR FILING DATE: 2001-01-18
; PRIOR APPLICATION NUMBER: 60/240,648
; PRIOR FILING DATE: 2000-10-16
; NUMBER OF SEQ ID NOS: 127
; SOFTWARE: Patent in Ver. 2.1
; SEQ ID NO 72
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: oligonucleotide
; OTHER INFORMATION: primer
US-09-976-782-72

Query Match 0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 6.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 854 AGGAGGAGCTGGTGGAG 870
|||||
Db 2 AGGAGGAGCTGGGAG 18

RESULT 729
US-10-091-625-51/c
; Sequence 51, Application US/10091625
; Publication No. US20030170636A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF JAGGED 2 EXPRESSION
; FILE REFERENCE: RTS-0244
; CURRENT APPLICATION NUMBER: US/10/091,625
; CURRENT FILING DATE: 2002-03-05
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 51
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-091-625-51

Query Match 0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 6.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1542 CACCTTCAAGGACCTGG 1558
|||||
Db 17 CACCTGCAAGGACCTGG 1

RESULT 730
US-10-326-185-15/c
; Sequence 15, Application US/10326185
; Publication No. US20030175902A1
; GENERAL INFORMATION:
; APPLICANT: Sloma, Alan
; APPLICANT: Behr, Regine
; APPLICANT: Widner, William
; APPLICANT: Tang, Maria
; APPLICANT: Sternberg, David
; APPLICANT: Brown, Stephen
; TITLE OF INVENTION: Methods for Producing Hyaluronan In a Recombinant Host Cell
; FILE REFERENCE: 10241.200-US
; CURRENT APPLICATION NUMBER: US/10/326,185
; CURRENT FILING DATE: 2002-12-20
; PRIOR APPLICATION NUMBER: US 60/342,644
; PRIOR FILING DATE: 2001-12-21
; NUMBER OF SEQ ID NOS: 108
; SOFTWARE: Patent in version 3.1
; SEQ ID NO 15
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Bacillus subtilis
US-10-326-185-15

Query Match 0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 6.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1288 GTAGCCGTGAAGATGCT 1304
|||||
Db 17 GTAGCCGTGAAGATGCT 1

RESULT 731
US-10-326-185-18
; Sequence 18, Application US/10326185
; Publication No. US20030175902A1
; GENERAL INFORMATION:
; APPLICANT: Sloma, Alan
; APPLICANT: Behr, Regine
; APPLICANT: Widner, William
; APPLICANT: Tang, Maria
; APPLICANT: Sternberg, David
; APPLICANT: Brown, Stephen
; TITLE OF INVENTION: Methods for Producing Hyaluronan In a Recombinant Host Cell
; FILE REFERENCE: 10241.200-US
; CURRENT APPLICATION NUMBER: US/10/326,185
; CURRENT FILING DATE: 2002-12-20
; PRIOR APPLICATION NUMBER: US 60/342,644
; PRIOR FILING DATE: 2001-12-21
; NUMBER OF SEQ ID NOS: 108
; SOFTWARE: Patent in version 3.1
; SEQ ID NO 18
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Bacillus subtilis
US-10-326-185-18

Query Match 0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 6.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1288 GTAGCCGTGAAGATGCT 1304
|||||
Db 4 GTAGCCGTGAAGATGCT 20

RESULT 732
US-10-096-399A-51/c
; Sequence 51, Application US/10096399A
; Publication No. US20030185829A1
; GENERAL INFORMATION:

; APPLICANT: Koller, Erich
; APPLICANT: Shepard, Peter J.
; TITLE OF INVENTION: JAGGED 2 INHIBITORS FOR INDUCING APOPTOSIS
; FILE REFERENCE: ISPH-0660
; CURRENT APPLICATION NUMBER: US/10/096.399A
; CURRENT FILING DATE: 2002-03-12
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 51
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense oligonucleotide
US-10-096-399A-51

Query Match 0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 6.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1542 CACCTTCAAGGACCTGG 1558
Db 17 CACCTGCAAGGACCTGG 1

RESULT 733
US-10-461-668-51/c
; Sequence 51, Application US/10461668
; Publication No. US20030207839A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF JAGGED 2 EXPRESSION
; FILE REFERENCE: RTS-0244
; CURRENT APPLICATION NUMBER: US/10/461.668
; CURRENT FILING DATE: 2003-06-13
; PRIOR FILING DATE: US/10/091.625
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 51
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-461-668-51

Query Match 0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 6.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1542 CACCTTCAAGGACCTGG 1558
Db 17 CACCTGCAAGGACCTGG 1

RESULT 734
US-10-388-263-421/c
; Sequence 421, Application US/10388263
; Publication No. US20030228597A1
; GENERAL INFORMATION:
; APPLICANT: Cowser, Lex M.
; APPLICANT: Baker, Brenda F.
; APPLICANT: McNeil, John
; APPLICANT: Freier, Susan M.
; APPLICANT: Sasnor, Henri M.
; APPLICANT: Brooks, Douglas G.
; APPLICANT: Chashi, Cara
; APPLICANT: Wyatt, Jacqueline R.
; APPLICANT: Borchers, Alexander
; APPLICANT: Vickers, Timothy A.
; TITLE OF INVENTION: IDENTIFICATION OF GENETIC TARGETS FOR
; MODULATION BY OLIGONUCLEOTIDES AND
; TITLE OF INVENTION: GENERATION OF OLIGONUCLEOTIDES FOR GENE MODULATION

; FILE REFERENCE: ISIS-4503
; CURRENT APPLICATION NUMBER: US/10/388.263
; CURRENT FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 947
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 421
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-388-263-421

Query Match 0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 6.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1542 CACCTTCAAGGACCTGG 1558
Db 17 CACCTGCAAGGACCTGG 1

RESULT 735
US-10-199-199-21
; Sequence 21, Application US/10199199
; Publication No. US20040014047A1
; GENERAL INFORMATION:
; APPLICANT: Lex M. Cowser
; TITLE OF INVENTION: ANTISENSE MODULATION OF LIM DOMAIN KINASE 1 EXPRESSION
; FILE REFERENCE: RTS-0375
; CURRENT APPLICATION NUMBER: US/10/199.199
; CURRENT FILING DATE: 2002-07-18
; NUMBER OF SEQ ID NOS: 148
; SEQ ID NO 21
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-199-199-21

Query Match 0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 6.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2382 TCTTGCCTCCAGGTGCA 2398
Db 2 TCTTCCCTCCAGGTGCA 18

RESULT 736
US-10-199-199-98/c
; Sequence 98, Application US/10199199
; Publication No. US20040014047A1
; GENERAL INFORMATION:
; APPLICANT: Lex M. Cowser
; TITLE OF INVENTION: ANTISENSE MODULATION OF LIM DOMAIN KINASE 1 EXPRESSION
; FILE REFERENCE: RTS-0375
; CURRENT APPLICATION NUMBER: US/10/199.199
; CURRENT FILING DATE: 2002-07-18
; NUMBER OF SEQ ID NOS: 148
; SEQ ID NO 98
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-199-199-98

Query Match 0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 6.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2382 TCTTCCCTCCAGGTGCA 2398
 Db 19 TCTTCCCTCCAGGTGCA 3

RESULT 737
 US-10-262-445-72/c
 ; Sequence 72, Application US/10262445
 ; Publication No. US20040014058A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Alsobrook II, John
 ; APPLICANT: Burgess, Catherine
 ; APPLICANT: Catterton, Elina
 ; APPLICANT: Chant, John
 ; APPLICANT: Chaudhuri, Amitabha
 ; APPLICANT: Edinger, Shlomit
 ; APPLICANT: Gerlach, Valerie
 ; APPLICANT: Giot, Loic
 ; APPLICANT: Gorman, Linda
 ; APPLICANT: Guo, Xiaojia
 ; APPLICANT: Kekuda, Ramesh
 ; APPLICANT: Mezes, Peter
 ; APPLICANT: Millet, Isabelle
 ; APPLICANT: Ooi, Chean Eng
 ; APPLICANT: Patturajan, Meera
 ; APPLICANT: Rieger, Daniel
 ; APPLICANT: Rieger, Kimberly
 ; APPLICANT: Taupier Jr., Raymond J.
 ; APPLICANT: Zerhusen, Bryan
 ; APPLICANT: Zhong, Haihong
 ; APPLICANT: Zhong, Mei
 ; TITLE OF INVENTION: NOVEL HUMAN PROTEINS, POLYNUCLEOTIDES ENCODING THEM AND METHODS
 ; FILE REFERENCE: 21402-462D
 ; CURRENT APPLICATION NUMBER: US/10/262,445
 ; CURRENT FILING DATE: 2002-10-01
 ; PRIOR FILING DATE: 2001-10-05
 ; PRIOR FILING DATE: 2001-10-05
 ; PRIOR FILING DATE: 2001-10-09
 ; PRIOR FILING DATE: 2001-10-09
 ; PRIOR FILING DATE: 2001-10-09
 ; PRIOR FILING DATE: 2001-10-09
 ; PRIOR FILING DATE: 2001-10-12
 ; PRIOR FILING DATE: 2001-10-15
 ; PRIOR FILING DATE: 2001-10-17
 ; PRIOR FILING DATE: 2001-10-17
 ; PRIOR FILING DATE: 2001-10-22
 ; PRIOR FILING DATE: 2001-10-24
 ; PRIOR FILING DATE: 2001-10-29
 ; PRIOR FILING DATE: 2001-10-29
 ; Remaining Prior Application data removed - See File Wrapper or PALM.
 ; NUMBER OF SEQ ID NOS: 133
 ; SOFTWARE: CuraseqList version 0.1
 ; SEQ ID NO 72
 ; LENGTH: 20
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Description of Artificial Sequence: Primer/Probe
 US-10-262-445-72

Query Match 0.4%; Score 15.4; DB 1; Length 20;
 Best Local Similarity 94.1%; Pred. No. 6.1e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2734 TACCTGAAGATGGGAGC 2750

Db 19 TACCTGGAGATGGGAGC 3
 RESULT 738
 US-10-210-833-50/c
 ; Sequence 50, Application US/10210833
 ; Publication No. US20040023383A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Sanjay Bhanot
 ; APPLICANT: Susan M. Freier
 ; TITLE OF INVENTION: ANTISENSE MODULATION OF RESISTIN EXPRESSION
 ; FILE REFERENCE: RTS-0396
 ; CURRENT APPLICATION NUMBER: US/10/210,833
 ; CURRENT FILING DATE: 2002-07-31
 ; NUMBER OF SEQ ID NOS: 165
 ; SEQ ID NO 50
 ; LENGTH: 20
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Antisense Oligonucleotide
 US-10-210-833-50

Query Match 0.4%; Score 15.4; DB 1; Length 20;
 Best Local Similarity 94.1%; Pred. No. 6.1e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1352 TGGAGATGATGAAGATG 1368
 Db 17 TGGAGATGATGATGATG 1

RESULT 739
 US-10-210-833-149
 ; Sequence 149, Application US/10210833
 ; Publication No. US20040023383A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Sanjay Bhanot
 ; APPLICANT: Susan M. Freier
 ; TITLE OF INVENTION: ANTISENSE MODULATION OF RESISTIN EXPRESSION
 ; FILE REFERENCE: RTS-0396
 ; CURRENT APPLICATION NUMBER: US/10/210,833
 ; CURRENT FILING DATE: 2002-07-31
 ; NUMBER OF SEQ ID NOS: 165
 ; SEQ ID NO 149
 ; LENGTH: 20
 ; TYPE: DNA
 ; ORGANISM: H. sapiens
 ; FEATURE:
 US-10-210-833-149

Query Match 0.4%; Score 15.4; DB 1; Length 20;
 Best Local Similarity 94.1%; Pred. No. 6.1e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1352 TGGAGATGATGAAGATG 1368
 Db 4 TGGAGATGATGATGATG 20

RESULT 740
 US-10-304-109-45
 ; Sequence 45, Application US/10304109
 ; Publication No. US20040101856A1
 ; GENERAL INFORMATION:
 ; APPLICANT: C. Frank Bennett
 ; APPLICANT: Kenneth W. Dobie
 ; TITLE OF INVENTION: MODULATION OF MAD2-LIKE 1 EXPRESSION
 ; FILE REFERENCE: RTS-0372
 ; CURRENT APPLICATION NUMBER: US/10/304,109
 ; CURRENT FILING DATE: 2002-11-23
 ; NUMBER OF SEQ ID NOS: 151

```

; SEQ ID NO 45
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-304-109-45

Query Match      0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 6.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1281 TGTCCCGTAGCCGTGA 1297
Db 2 TGTCCCGTAGCTGTA 18

RESULT 741
US-10-671-395-1171/c
; Sequence 1171, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; PRIOR FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1171
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1171

Query Match      0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 6.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2316 TCTGTGTGTGTGTGTGT 2332
Db 17 TCCGTGTGTGTGTGTGT 1

RESULT 742
US-10-671-395-1187/c
; Sequence 1187, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; PRIOR FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1187
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1187

```

```

Query Match      0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 6.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2334 CGTGTGTGTGTGTGTGT 2350
Db 18 CGTGTGTGTGTGTGTGT 2

RESULT 743
US-10-671-395-1204/c
; Sequence 1204, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; PRIOR FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1204
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1204

Query Match      0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 6.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2334 CGTGTGTGTGTGTGTGT 2350
Db 17 CGTGTGTGTGTGTGTGT 1

RESULT 744
US-10-671-395-1333/c
; Sequence 1333, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; PRIOR FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1333
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1333

Query Match      0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 6.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2334 CGTGTGTGTGTGTGTGT 2350

```



```
Db      19  CGTGTGTGTGTGTGTGT 3

RESULT 745
US-10-671-395-1595/c
; Sequence 1595, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671.395
; CURRENT FILING DATE: 2003-09-25
; PRIOR FILING DATE: 60/413,549
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 1595
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1595

Query Match      0.4%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 6.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      2334  CGTGTGTGTGTGTGTGT 2350
Db      20  CGTGTGTGTGTGTGTGT 4

RESULT 746
US-10-000-864-28
; Sequence 28, Application US/10000864
; Publication No. US20020146798A1
; GENERAL INFORMATION:
; APPLICANT: CADUS PHARMACEUTICAL CORPORATION
; TITLE OF INVENTION: HUMAN MEKK PROTEIN AND NUCLEIC ACID MOLECULES
; FILE REFERENCE: CPI-085CPCP
; CURRENT APPLICATION NUMBER: US/10/000,864
; CURRENT FILING DATE: 2001-10-31
; EARLIER APPLICATION NUMBER: 09/423,890
; EARLIER FILING DATE: 2000-06-03
; EARLIER APPLICATION NUMBER: PCT/US99/05556
; EARLIER FILING DATE: 1999-03-15
; EARLIER APPLICATION NUMBER: USSN 60/078,153
; EARLIER FILING DATE: 1998-03-16
; EARLIER APPLICATION NUMBER: USSN 60/099,165
; EARLIER FILING DATE: 1998-09-04
; NUMBER OF SEQ ID NOS: 38
; SOFTWARE: Patent In Ver. 2.0
; SEQ ID NO 28
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic construct
US-10-000-864-28

Query Match      0.4%; Score 15.4; DB 1; Length 21;
Best Local Similarity 94.1%; Pred. No. 6.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      2001  GCAGCTGGTGAGGACC 2017
Db      1  GGAGCTGGTGAGGACC 17
```

```
RESULT 747
US-10-151-320-26/c
; Sequence 26, Application US/10151320
; Publication No. US20030092114A1
; GENERAL INFORMATION:
; APPLICANT: Luche, Ralf M.
; APPLICANT: Wei, Bo
; TITLE OF INVENTION: DSP-18 DUAL-SPECIFICITY PHOSPHATASE
; FILE REFERENCE: 200125.436
; CURRENT APPLICATION NUMBER: US/10/151,320
; CURRENT FILING DATE: 2002-05-16
; NUMBER OF SEQ ID NOS: 42
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 26
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide primer used for PCR.
US-10-151-320-26

Query Match      0.4%; Score 15.4; DB 1; Length 21;
Best Local Similarity 94.1%; Pred. No. 6.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      1880  AGCTCTTCAGCTGCTG 1896
Db      18  AACTCTTCAGCTGCTG 2

RESULT 748
US-10-466-347-17
; Sequence 17, Application US/10466347
; Publication No. US20040109849A1
; GENERAL INFORMATION:
; APPLICANT: Fazio, Vito M.
; TITLE OF INVENTION: DNA VACCINES EXPRESSING HYPERVARIABLE VH-CDR3 IDIOTYPIC DETERMIN
; FILE REFERENCE: 02901/000028-USO
; CURRENT APPLICATION NUMBER: US/10/466,347
; CURRENT FILING DATE: 2003-12-08
; PRIOR APPLICATION NUMBER: PCT/IT01/00014
; PRIOR FILING DATE: 2002-07-18
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: Patent In version 3.1
; SEQ ID NO 17
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR primer
US-10-466-347-17

Query Match      0.4%; Score 15.4; DB 1; Length 21;
Best Local Similarity 76.2%; Pred. No. 6.5e+02;
Matches 16; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

Qy      853  GAGGAGGAGCTGGTGAGGCT 873
Db      1  SAGGTGCAGCTGGTGSAGTCT 21

RESULT 749
US-10-627-253A-351
; Sequence 351, Application US/10627253A
; Publication No. US20040161768A1
; GENERAL INFORMATION:
; APPLICANT: BRINKMANN, ULRICH
; APPLICANT: HOFFMEYER, SVEN
; APPLICANT: MORNHINWEG, ESTHER
; TITLE OF INVENTION: POLYMORPHISMS IN THE HUMAN GENE FOR THE MULTIDRUG
; TITLE OF INVENTION: RESISTANCE-ASSOCIATED PROTEIN 1 (MRP-1) AND THEIR USE IN
; TITLE OF INVENTION: DIAGNOSTIC AND THERAPEUTIC APPLICATIONS
```

FILE REFERENCE: VOS-42 CON
CURRENT APPLICATION NUMBER: US/10/627,253A
CURRENT FILING DATE: 2003-07-24
PRIOR APPLICATION NUMBER: PCT/EP02/00796
PRIOR FILING DATE: 2002-01-25
PRIOR APPLICATION NUMBER: EP 01101651.6
PRIOR FILING DATE: 2001-01-26
NUMBER OF SEQ ID NOS: 406
SOFTWARE: PatentIn version 3.2
SEQ ID NO 351
LENGTH: 21
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Synthetic oligonucleotide
US-10-627-253A-351

Query Match 0.4%; Score 15.4; DB 1; Length 21;
Best Local Similarity 84.2%; Pred. No. 6.5e+02;
Matches 16; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 3 GGATGGCACAGGCTGGTG 21
||| ||||| ||||| |||||
Db 2 GGGTGGCACRGTGCTGGTG 20

RESULT 750
US-10-627-253A-352/c
Sequence 352, Application US/10627253A
Publication No. US20040161768A1
GENERAL INFORMATION:
APPLICANT: BRINKMANN, ULRICH
APPLICANT: HOFFMEYER, SVEN
TITLE OF INVENTION: POLYMORPHISMS IN THE HUMAN GENE FOR THE MULTIDRUG
TITLE OF INVENTION: RESISTANCE-ASSOCIATED PROTEIN 1 (MRP-1) AND THEIR USE IN
TITLE OF INVENTION: DIAGNOSTIC AND THERAPEUTIC APPLICATIONS
FILE REFERENCE: VOS-42 CON
CURRENT APPLICATION NUMBER: US/10/627,253A
CURRENT FILING DATE: 2003-07-24
PRIOR APPLICATION NUMBER: PCT/EP02/00796
PRIOR FILING DATE: 2002-01-25
PRIOR APPLICATION NUMBER: EP 01101651.6
PRIOR FILING DATE: 2001-01-26
NUMBER OF SEQ ID NOS: 406
SOFTWARE: PatentIn version 3.2
SEQ ID NO 352
LENGTH: 21
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Synthetic oligonucleotide
US-10-627-253A-352

Query Match 0.4%; Score 15.4; DB 1; Length 21;
Best Local Similarity 84.2%; Pred. No. 6.5e+02;
Matches 16; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 3 GGATGGCACAGGCTGGTG 21
||| ||||| ||||| |||||
Db 20 GGGTGGCACRGTGCTGGTG 2

RESULT 751
US-09-874-991C-11/c
Sequence 11, Application US/09874991C
Publication No. US20040052763A1
GENERAL INFORMATION:
APPLICANT: MOND, JAMES J.
APPLICANT: FLORA, MICHAEL
APPLICANT: KLINMAN, DENNIS M.
TITLE OF INVENTION: IMMUNOSTIMULATORY RNA/DNA HYBRID MOLECULES
FILE REFERENCE: 07787.0042-0

CURRENT APPLICATION NUMBER: US/09/874,991C
CURRENT FILING DATE: 2001-06-07
PRIOR APPLICATION NUMBER: 60/209,797
PRIOR FILING DATE: 2000-06-07
NUMBER OF SEQ ID NOS: 620
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 11
LENGTH: 30
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
OTHER INFORMATION: oligonucleotide
US-09-874-991C-11

Query Match 0.4%; Score 15.4; DB 1; Length 30;
Best Local Similarity 76.0%; Pred. No. 9.1e+02;
Matches 19; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

Qy 3310 TTTTCTTTAGGAGATTATTTT 3334
||||| ||| ||| ||| ||| ||| |||
Db 29 TTTTCTTTTAAAGCTTTT 5

RESULT 752
US-09-918-186A-235/c
Sequence 235, Application US/09918186A
Patent No. US20020137708A1
GENERAL INFORMATION:
APPLICANT: C. Frank Bennett
APPLICANT: Elizabeth J. Ackermann
APPLICANT: Eric E. Swayze
APPLICANT: Lex M. Cowbert
TITLE OF INVENTION: ANTISENSE MODULATION OF SURVIVIN EXPRESSION
FILE REFERENCE: ISPH-0585
CURRENT APPLICATION NUMBER: US/09/918,186A
CURRENT FILING DATE: 2001-07-30
PRIOR APPLICATION NUMBER: 09/496,694
PRIOR FILING DATE: 2000-02-02
PRIOR APPLICATION NUMBER: 09/286,407
PRIOR FILING DATE: 1999-04-05
PRIOR APPLICATION NUMBER: 09/163,162
PRIOR FILING DATE: 1998-09-29
NUMBER OF SEQ ID NOS: 250
SEQ ID NO 235
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense oligonucleotide
US-09-918-186A-235

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 6.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 3458 AAGTTATATATATCTATAT 3477
||||| ||||| ||||| |||||
Db 20 ATGTTATATATATATATGT 1

RESULT 753
US-10-181-316-235/c
Sequence 235, Application US/10181316
Publication No. US20030211607A1
GENERAL INFORMATION:
APPLICANT: C. Frank Bennett
APPLICANT: Elizabeth J. Ackermann
APPLICANT: Eric E. Swayze
APPLICANT: Lex M. Cowbert
TITLE OF INVENTION: ANTISENSE MODULATION OF SURVIVIN EXPRESSION
FILE REFERENCE: ISPH-0650
CURRENT APPLICATION NUMBER: US/10/181,316

```
; CURRENT FILING DATE: 2002-07-16
; PRIOR APPLICATION NUMBER: PCT/US01/02939
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: 09/496,694
; PRIOR FILING DATE: 2000-02-02
; PRIOR APPLICATION NUMBER: 09/286,407
; PRIOR FILING DATE: 1999-04-05
; PRIOR APPLICATION NUMBER: 09/163,162
; PRIOR FILING DATE: 1998-09-29
; NUMBER OF SEQ ID NOS: 249
; SEQ ID NO 235
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-181-316-235

Query Match          0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 6.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Oy 3458 AAGTTATATATATCTATAT 3477
Db 20 ATGTTATATATATATATGT 1

RESULT 754
US-09-725-265-23
; Sequence 23, Application US/09725265
; Publication No. US20010000175A1
; GENERAL INFORMATION:
; APPLICANT: KURANE, RYUICHIRO
; APPLICANT: KANAGAWA, TAKAHIRO
; APPLICANT: KAMAGATA, YOICHI
; APPLICANT: YAMADA, KAZUTAKA
; APPLICANT: YOKOMAKU, TOYOKAZU
; APPLICANT: KOYAMA, OSAMU
; APPLICANT: FURUSHO, KENTA
; TITLE OF INVENTION: METHOD FOR DETERMINING A CONCENTRATION OF TARGET NUCLEIC ACID MOL
; TITLE OF INVENTION: NUCLEIC ACID PROBES FOR THE METHOD, AND METHOD FOR ANALYZING DAT
; TITLE OF INVENTION: THE METHOD
; FILE REFERENCE: 1999SUSOXDIV
; CURRENT APPLICATION NUMBER: US/09/725,265
; CURRENT FILING DATE: 2000-11-29
; PRIOR APPLICATION NUMBER: US 09/556,127
; PRIOR FILING DATE: 2000-04-20
; PRIOR APPLICATION NUMBER: JP 1999-111601
; PRIOR FILING DATE: 1999-04-20
; NUMBER OF SEQ ID NOS: 70
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 23
; LENGTH: 20
; TYPE: DNA
; ORGANISM: ARTIFICIAL SEQUENCE
; FEATURE:
; OTHER INFORMATION: SYNTHETIC DNA
US-09-725-265-23

Query Match          0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 6.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Oy 3473 TATATATATATTTTATTCGAG 3492
Db 1 TATATATATATTTTTCGG 20

RESULT 755
US-09-752-983-147/c
; Sequence 147, Application US/09752983
; Patent No. US20010016575A1
; GENERAL INFORMATION:
; APPLICANT: LOREN J. MIRAGLIA, PAMELA NERO, MARK J.
; APPLICANT: GRAHAM, BRETT P. MONIA
; TITLE OF INVENTION: ANTISENSE MODULATION OF HUMAN MDM2
; TITLE OF INVENTION: EXPRESSION
; NUMBER OF SEQUENCES: 271
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: U.S.A.
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 MB STORAGE
; COMPUTER: IBM PC
; OPERATING SYSTEM: WINDOWS 95
; SOFTWARE: WORDPERFECT 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/752,983
```

```
; APPLICANT: LOREN J. MIRAGLIA, PAMELA NERO, MARK J.
; APPLICANT: GRAHAM, BRETT P. MONIA
; TITLE OF INVENTION: ANTISENSE MODULATION OF HUMAN MDM2
; TITLE OF INVENTION: EXPRESSION
; NUMBER OF SEQUENCES: 271
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: U.S.A.
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 MB STORAGE
; COMPUTER: IBM PC
; OPERATING SYSTEM: WINDOWS 95
; SOFTWARE: WORDPERFECT 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/752,983
; FILING DATE: 02-Jan-2001
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/280,805
; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: Licata, Jane Massey
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0346
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 609-810-1515
; TELEFAX: 609-810-1454
; INFORMATION FOR SEQ ID NO: 147:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
US-09-752-983-147

Query Match          0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 6.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Oy 1346 CTGAGATGGAGATGATGAAG 1365
Db 20 CTCGATGAGATGATGAGG 1

RESULT 756
US-09-752-983-209/c
; Sequence 209, Application US/09752983
; Patent No. US20010016575A1
; GENERAL INFORMATION:
; APPLICANT: LOREN J. MIRAGLIA, PAMELA NERO, MARK J.
; APPLICANT: GRAHAM, BRETT P. MONIA
; TITLE OF INVENTION: ANTISENSE MODULATION OF HUMAN MDM2
; TITLE OF INVENTION: EXPRESSION
; NUMBER OF SEQUENCES: 271
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: U.S.A.
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 MB STORAGE
; COMPUTER: IBM PC
; OPERATING SYSTEM: WINDOWS 95
; SOFTWARE: WORDPERFECT 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/752,983
```

;; FILING DATE: 02-Jan-2001
;; CLASSIFICATION:
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 09/280,805
;; FILING DATE: <Unknown>
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Licata, Jane Massey
;; REGISTRATION NUMBER: 32,257
;; REFERENCE/DOCKET NUMBER: ISPH-0346
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: 609-810-1515
;; TELEFAX: 609-810-1454
;; INFORMATION FOR SEQ ID NO: 209:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 20 base pairs
;; TYPE: Nucleic Acid
;; STRANDEDNESS: Single
;; TOPOLOGY: Linear
;; ANTI-SENSE: Yes
US-09-752-983-209

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 6.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 3462 TTATATATATCTATATATAT 3481
Db 20 TTATATATTTCTAACTATAT 1

RESULT 757
US-09-854-883-305
; Sequence 305, Application US/09854883
; Patent No. US20020055479A1
; GENERAL INFORMATION:
; APPLICANT: Lex M. Cowser
; APPLICANT: Jacqueline Wyatt
; APPLICANT: Susan M. Freier
; APPLICANT: Brett P. Monia
; APPLICANT: Madeline M. Butler
; APPLICANT: Robert McKay
; TITLE OF INVENTION: ANTISENSE MODULATION OF FTP1B EXPRESSION
; FILE REFERENCE: ISPH-0576
; CURRENT APPLICATION NUMBER: US/09/854,883
; CURRENT FILING DATE: 2001-05-14
; PRIOR APPLICATION NUMBER: US 09/629,644
; PRIOR FILING DATE: 2000-07-31
; PRIOR APPLICATION NUMBER: US 09/487,368
; PRIOR FILING DATE: 2000-01-18
; NUMBER OF SEQ ID NOS: 389
; SEQ ID NO 305
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide

US-09-854-883-305

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 6.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 416 TCATGGAAGCGTGTGCC 435
Db 1 TCATGGAAGCGTGTGCC 20

RESULT 758
US-09-885-188-13/c
; Sequence 13, Application US/09885188
; Patent No. US20020104125A1
; GENERAL INFORMATION:
; APPLICANT: Chris Somerville

;; Pierre Broun
;; Frank van de Loo
;; TITLE OF INVENTION: Production of Hydroxylated Patty Acids in
;; APPLICATION: Genetically Modified Plants
;; NUMBER OF SEQUENCES: 15
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Pillsbury Winthrop, L.L.P.
;; STREET: 1600 Tysons Boulevard
;; CITY: McLean
;; STATE: VA
;; COUNTRY: USA
;; ZIP: 22102
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: Diskette, 3.50 inch
;; COMPUTER: IBM PC-compatible
;; OPERATING SYSTEM: MS-DOS
;; SOFTWARE: MS Word
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/09/885,188
;; FILING DATE: 21-Jun-2001
;; CLASSIFICATION: <Unknown>
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US/08/530,862B
;; FILING DATE: 06-Feb-1996
;; APPLICATION NUMBER: PCT/US95/11855
;; FILING DATE: September 25, 1995
;; APPLICATION NUMBER: US 08/530,862
;; FILING DATE: September 20, 1995
;; APPLICATION NUMBER: US 08/320,982
;; FILING DATE: October 11, 1994
;; APPLICATION NUMBER: US 08/314,596
;; FILING DATE: September 26, 1994
;; INFORMATION FOR SEQ ID NO: 13
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 20 nucleotides
;; TYPE: nucleotide
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: cdna
;; SEQUENCE DESCRIPTION: SEQ ID NO: 13:
US-09-885-188-13

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 6.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2982 CAGGGCTTTTCTGGCACCG 3001
Db 20 CAAGGCGTTTCTGTACCG 1

RESULT 759
US-09-891-517-23
; Sequence 23, Application US/09891517
; Patent No. US20020106653A1
; GENERAL INFORMATION:
; APPLICANT: KURANE, RYUICHIRO
; APPLICANT: KANAGAWA, TAKAHIRO
; APPLICANT: KAMAGATA, YOICHI
; APPLICANT: TORIMURA, MASAKI
; APPLICANT: KURATA, SHINYA
; APPLICANT: YAMADA, KAZUTAKA
; APPLICANT: YOKOMAKU, TOYOKAZU
; TITLE OF INVENTION: NOVEL NUCLEIC ACID PROBES, METHOD FOR DETERMINING CONCENTRATIONS
; TITLE OF INVENTION: NUCLEIC ACID BY USING THE PROBES, AND METHOD FOR ANALYZING DATA
; TITLE OF INVENTION: METHOD
; FILE REFERENCE: 210352US-1994-163-0-X
; CURRENT APPLICATION NUMBER: US/09/891,517
; CURRENT FILING DATE: 2001-06-27
; PRIOR APPLICATION NUMBER: JP2000-193133
; PRIOR FILING DATE: 2000-06-27
; PRIOR APPLICATION NUMBER: JP2000-236115
; PRIOR FILING DATE: 2000-08-03

; PRIOR APPLICATION NUMBER: JP2000-292483
; PRIOR FILING DATE: 2000-09-26
; NUMBER OF SEQ ID NOS: 108
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 23
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic DNA
US-09-891-517-23

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 6.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 3473 TATATATATATTTTTCGAG 3492
|||||
Db 1 TATATATATATTTTTCGG 20

RESULT 760

US-09-891-517-34/c
; Sequence 34, Application US/09891517
; Patent No. US20020106653A1
; GENERAL INFORMATION:
; APPLICANT: KURANE, RYUICHIRO
; APPLICANT: KANAGAWA, TAKAHIRO
; APPLICANT: KAWAGATA, YOICHI
; APPLICANT: TORIMURA, MASAKI
; APPLICANT: KURATA, SHINYA
; APPLICANT: YAMADA, KAZUTAKA
; APPLICANT: YOKOMAKU, TOYOKAZU
; TITLE OF INVENTION: NOVEL NUCLEIC ACID PROBES, METHOD FOR DETERMINING CONCENTRATIONS
; TITLE OF INVENTION: NUCLEIC ACID BY USING THE PROBES, AND METHOD FOR ANALYZING DATA
; TITLE OF INVENTION: METHOD
; FILE REFERENCE: 2103520S-1994-163-0-X
; CURRENT APPLICATION NUMBER: US/09/891,517
; CURRENT FILING DATE: 2001-06-27
; PRIOR APPLICATION NUMBER: JP2000-193133
; PRIOR FILING DATE: 2000-06-27
; PRIOR APPLICATION NUMBER: JP2000-236115
; PRIOR FILING DATE: 2000-08-03
; PRIOR APPLICATION NUMBER: JP2000-292483
; PRIOR FILING DATE: 2000-09-26
; NUMBER OF SEQ ID NOS: 108
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 34
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic DNA
US-09-891-517-34

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 6.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 3473 TATATATATATTTTTCGAG 3492
|||||
Db 20 TATATATATATTTTTCGG 1

RESULT 761

US-09-885-189-13/c
; Sequence 13, Application US/09885189
; Patent No. US20020151699A1
; GENERAL INFORMATION:
; APPLICANT: Chris SOMERVILLE
; APPLICANT: PIERRE BROWN
; APPLICANT: Frank VAN DE LOO
; TITLE OF INVENTION: Production of Hydroxylated Fatty Acids in

; TITLE OF INVENTION: Genetically Modified Plants
; NUMBER OF SEQUENCES: 15
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: PILLSBURY MADISON & SUTRO, LLP
; STREET: 1100 NEW YORK AVENUE, N.W.
; CITY: WASHINGTON
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20005-3918
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: MS-DOS/PC-DOS
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/885,189
; FILING DATE: 21-June-2001
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/597,313D
; FILING DATE: February 6, 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/530,862
; FILING DATE: September 20, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/320,982
; FILING DATE: October 11, 1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/314,596
; FILING DATE: September 26, 1994
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 nucleotides
; TYPE: nucleotide
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-885-189-13

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 6.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2982 CAGGCGTTTTCGACCG 3001
|||||
Db 20 CAGGCGTTTTCGTACCG 1

RESULT 762

US-09-949-427-252
; Sequence 252, Application US/09949427
; Publication No. US20030054418A1
; GENERAL INFORMATION:
; APPLICANT: Bodnar, Jackie S.
; APPLICANT: Castellani, Lawrence W.
; APPLICANT: Chatterjee, Aurobindo
; APPLICANT: de Jong, Pieter
; APPLICANT: Lusi, Aldons J.
; APPLICANT: Ohmen, Jeff
; APPLICANT: Ross, David
; APPLICANT: Tafari, Sherrie
; APPLICANT: Wu, Chenyan
; TITLE OF INVENTION: Gene and Sequence Variation Associated with Cancer
; FILE REFERENCE: 02810.0014.NPUS02
; CURRENT APPLICATION NUMBER: US/09/949,427
; CURRENT FILING DATE: 2001-09-07
; PRIOR APPLICATION NUMBER: 60/231,322
; PRIOR FILING DATE: 2000-09-08
; NUMBER OF SEQ ID NOS: 405
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 252
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence

FEATURE:
OTHER INFORMATION: Synthetic Primer
US-09-949-427-252

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 6.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 3651 CTTGCTTGCCTGCAGGGCCA 3670
|||||
Db 1 CTTGCATGCTGCAGGTGCA 20

RESULT 763
US-09-949-428-252
; Sequence 252, Application US/09949428
; Publication No. US20030064372A1
; GENERAL INFORMATION:
; APPLICANT: Bodnar, Jackie S.
; APPLICANT: Castellani, Lawrence W.
; APPLICANT: Chatterjee, Aurobindo
; APPLICANT: de Jong, Pieter
; APPLICANT: Lusia, Aldons J.
; APPLICANT: Ohmen, Jeff
; APPLICANT: Ross, David
; APPLICANT: Tafuri, Sherrie
; APPLICANT: Wu, Chenyan
; TITLE OF INVENTION: Gene and Sequence Variation Associated with Lipid Disorder
; FILE REFERENCE: 02810.0014.NPUS01
; CURRENT APPLICATION NUMBER: US/09/949,428
; CURRENT FILING DATE: 2001-09-07
; PRIOR APPLICATION NUMBER: 60/231,322
; PRIOR FILING DATE: 2000-09-08
; NUMBER OF SEQ ID NOS: 405
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 252
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Primer
US-09-949-428-252

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 6.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 3651 CTTGCTTGCCTGCAGGGCCA 3670
|||||
Db 1 CTTGCATGCTGCAGGTGCA 20

RESULT 764
US-09-954-556-98/c
; Sequence 98, Application US/09954556
; Publication No. US20030078219A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; APPLICANT: Scott Cooper
; TITLE OF INVENTION: ANTISENSE MODULATION OF FIBROBLAST GROWTH FACTOR RECEPTOR 2 EXPRESSION
; FILE REFERENCE: RTS-0250
; CURRENT APPLICATION NUMBER: US/09/954,556
; CURRENT FILING DATE: 2001-09-14
; NUMBER OF SEQ ID NOS: 108
; SEQ ID NO 98
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-954-556-98

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 6.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1945 TACATGATCATCGCGGAGTG 1964
|||||
Db 20 TACATGATGATGAGGACTG 1

RESULT 765
US-09-919-197-76/c
; Sequence 76, Application US/09919197
; Publication No. US20030083484A1
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; TITLE OF INVENTION: ANTISENSE MODULATION OF SHORT HETERODIMER PARTNER-1 EXPRESSION
; FILE REFERENCE: ISPH-0593
; CURRENT APPLICATION NUMBER: US/09/919,197
; CURRENT FILING DATE: 2001-07-31
; NUMBER OF SEQ ID NOS: 89
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 76
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-919-197-76

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 6.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2396 GCAGAGGTACCTGGGTGTC 2415
|||||
Db 20 GCAGCGGTACCCAGGGTGCC 1

RESULT 766
US-09-953-318-72/c
; Sequence 72, Application US/09953318
; Publication No. US20030105036A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR
; FILE REFERENCE: RTS-0232
; CURRENT APPLICATION NUMBER: US/09/953,318
; CURRENT FILING DATE: 2001-09-13
; NUMBER OF SEQ ID NOS: 154
; SEQ ID NO 72
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-953-318-72

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 6.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1573 CAGGTGGCCGCGGCGCATGGA 1592
|||||
Db 20 CAAGTGGCCAGAGGCATGGA 1

RESULT 767
US-09-953-318-74/c
; Sequence 74, Application US/09953318
; Publication No. US20030105036A1

```
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR EXPRESSION
; FILE REFERENCE: RTS-0232
; CURRENT APPLICATION NUMBER: US/09/953,318
; CURRENT FILING DATE: 2001-09-13
; NUMBER OF SEQ ID NOS: 154
; SEQ ID NO 74
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-953-318-74

Query Match      0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 6.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1610 AGTCATCCACAGGACCTG 1629
Db 20 AGTCATTCATCGGACCTG 1

RESULT 768
US-10-209-608-23
; Sequence 23, Application US/10209608
; Publication No. US20030082592A1
; GENERAL INFORMATION:
; APPLICANT: KURANE, RYUICHIRO
; APPLICANT: KANAGAWA, TAKAHIRO
; APPLICANT: KANAGATA, YOICHI
; APPLICANT: YAMADA, KAZUTAKA
; APPLICANT: YOKOMAKU, TOYOKAZU
; APPLICANT: KOYAMA, OSAMU
; APPLICANT: FURUSHO, KENTA
; TITLE OF INVENTION: METHOD FOR DETERMINING A CONCENTRATION OF TARGET NUCLEIC ACID MOLECULES
; TITLE OF INVENTION: NUCLEIC ACID PROBES FOR THE METHOD, AND METHOD FOR ANALYZING DATA
; FILE REFERENCE: 19993USOXDIV
; CURRENT APPLICATION NUMBER: US/10/209,608
; CURRENT FILING DATE: 2002-08-01
; PRIOR APPLICATION NUMBER: US/09/725,265
; PRIOR FILING DATE: 2000-11-29
; PRIOR APPLICATION NUMBER: US 09/556,127
; PRIOR FILING DATE: 2000-04-20
; PRIOR APPLICATION NUMBER: JP 1999-111601
; PRIOR FILING DATE: 1999-04-20
; NUMBER OF SEQ ID NOS: 70
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 23
; LENGTH: 20
; TYPE: DNA
; ORGANISM: ARTIFICIAL SEQUENCE
; FEATURE:
; OTHER INFORMATION: SYNTHETIC DNA
US-10-209-608-23

Query Match      0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 6.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 3473 TATATATATATTTTATTCAG 3492
Db 1 TATATATATATTTTTCGG 20

RESULT 769
US-10-001-844-33/c
; Sequence 33, Application US/10001844
; Publication No. US20030105041A1
```

```
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Lex M. Cowsett
; TITLE OF INVENTION: ANTISENSE MODULATION OF SHH EXPRESSION
; FILE REFERENCE: ISPH-0617
; CURRENT APPLICATION NUMBER: US/10/001,844
; CURRENT FILING DATE: 2001-11-16
; NUMBER OF SEQ ID NOS: 49
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 33
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-001-844-33

Query Match      0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 6.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2004 GCTGCTGGAGGACCTGGACC 2023
Db 20 GCTGCTGAAGGACCTGGACC 1

RESULT 770
US-10-229-346-34/c
; Sequence 34, Application US/10229346
; Publication No. US20030120054A1
; GENERAL INFORMATION:
; APPLICANT: Chen, Eric
; APPLICANT: Stacy, Cheryl
; TITLE OF INVENTION: Modified Cry3A Toxins
; FILE REFERENCE: 60065A
; CURRENT APPLICATION NUMBER: US/10/229,346
; CURRENT FILING DATE: 2002-08-27
; PRIOR APPLICATION NUMBER: 60/316,421
; PRIOR FILING DATE: 2001-08-31
; NUMBER OF SEQ ID NOS: 38
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 34
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(20)
; OTHER INFORMATION: CMS16 Primer
US-10-229-346-34

Query Match      0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 6.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1995 CTTCAAGCAGCTGGTGAGG 2014
Db 20 CTTCAATGAGCAGGTGGAGG 1

RESULT 771
US-10-007-010-56/c
; Sequence 56, Application US/10007010
; Publication No. US20030125275A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF HCK EXPRESSION
; FILE REFERENCE: RTS-0345
; CURRENT APPLICATION NUMBER: US/10/007,010
; CURRENT FILING DATE: 2001-12-04
; NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 56
```

```
;
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-007-010-56

Query Match          0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 6.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1679 ACTTCGGGCTGCGCCGGGAC 1698
Db 20 ACTTTGGGCTGCGCCGGGTC 1

RESULT 772
US-10-238-442-22/c
; Sequence 22, Application US/10238442
; Publication No. US20030176383A1
; GENERAL INFORMATION:
; APPLICANT: Monia, Brett P.
; APPLICANT: Gaarde, William A.
; APPLICANT: Nero, Pamela S.
; APPLICANT: McKay, Robert
; TITLE OF INVENTION: Antisense Modulation of p38 Mitogen
; FILE REFERENCE: ISPH-0488
; CURRENT APPLICATION NUMBER: US/10/238,442
; CURRENT FILING DATE: 2002-09-09
; PRIOR APPLICATION NUMBER: 09/640,101
; PRIOR FILING DATE: 2000-08-15
; PRIOR APPLICATION NUMBER: 09/286,904
; PRIOR FILING DATE: 1999-04-06
; NUMBER OF SEQ ID NOS: 107
; SOFTWARE: Patent In Ver. 2.0
; SEQ ID NO 22
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: antisense sequence
US-10-238-442-22

Query Match          0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 6.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2321 GTGTGTGTGTGTGTGTGTGTGT 2340
Db 20 GTTAGTGTGTGTGTGTGTGTGT 1

RESULT 773
US-10-331-907-75/c
; Sequence 75, Application US/10331907
; Publication No. US20030181660A1
; GENERAL INFORMATION:
; APPLICANT: Todd, John A
; APPLICANT: Hess, John W
; APPLICANT: Caskey, Charles T
; APPLICANT: Cox, Roger D
; APPLICANT: Gerhold, David
; APPLICANT: Hammond, Holly
; APPLICANT: Hey, Patricia
; APPLICANT: Kawaguchi, Yoshihiko
; APPLICANT: Merriman, Tony R
; APPLICANT: Metzker, Michael L
; TITLE OF INVENTION: No. US20030181660A1el LDL-Receptor
; NUMBER OF SEQUENCES: 455
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Nixon and Vanderhye
; STREET: 1100 No. US20030181660A1th Glebe Road, Eighth Floor
```

```
;
; CITY: Arlington
; STATE: Virginia
; COUNTRY: US
; ZIP: VA 22201-4714
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; SOFTWARE: Patent In Release #1.0, Version #1.25 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/331,907
; FILING DATE: 31-Dec-2002
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/402,923A
; FILING DATE: 14-Feb-2001
; APPLICATION NUMBER: PCT/GB98/01102
; FILING DATE: 15-APR-1998
; APPLICATION NUMBER: US 60/043,553
; FILING DATE: 15-APR-1997
; APPLICATION NUMBER: US 60/048,740
; FILING DATE: 05-JUN-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: B.J.Sadoff
; REGISTRATION NUMBER: 36,663
; REFERENCE/DOCKET NUMBER: 620-81
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703)816-4091
; TELEFAX: (703)816-4100
; INFORMATION FOR SEQ ID NO: 75:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 75:
US-10-331-907-75

Query Match          0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 6.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 157 GCTCCATCCTCGGAGATGA 176
Db 20 GCTGCATCCTCTGGAGAAGA 1

RESULT 774
US-10-005-344-147/c
; Sequence 147, Application US/10005344
; Publication No. US20030203862A1
; GENERAL INFORMATION:
; APPLICANT: Loren J. Miraglia
; APPLICANT: Pamela Nero
; APPLICANT: Mark J. Graham
; APPLICANT: Brett P. Monia
; APPLICANT: Erich Koller
; APPLICANT: Mingyi Chiang
; APPLICANT: Mano Manoharan
; TITLE OF INVENTION: Antisense Modulation of mdm2 expression.
; FILE REFERENCE: ISPH-0622
; CURRENT APPLICATION NUMBER: US/10/005,344
; CURRENT FILING DATE: 2001-12-04
; PRIOR APPLICATION NUMBER: US 09/048,810
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: US 09/280,805
; PRIOR FILING DATE: 1999-03-26
; NUMBER OF SEQ ID NOS: 379
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 147
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
```



```
RESULT 779
US-10-360-510-305
; Sequence 305, Application US/10360510
; Publication No. US20030220282A1
; GENERAL INFORMATION:
; APPLICANT: Lex M. Cowsett
; APPLICANT: Jacqueline Wyatt
; APPLICANT: Susan M. Freier
; APPLICANT: Brett P. Monia
; APPLICANT: Madeline M. Butler
; APPLICANT: Robert McKay
; TITLE OF INVENTION: ANTISENSE MODULATION OF PTP1B EXPRESSION
; FILE REFERENCE: ISPH-0576
; CURRENT APPLICATION NUMBER: US/10/360,510
; CURRENT FILING DATE: 2003-02-07
; PRIOR APPLICATION NUMBER: US/09/854,883
; PRIOR FILING DATE: 2001-05-14
; PRIOR APPLICATION NUMBER: US 09/629,644
; PRIOR FILING DATE: 2000-07-31
; PRIOR APPLICATION NUMBER: US 09/487,368
; PRIOR FILING DATE: 2000-01-18
; NUMBER OF SEQ ID NOS: 389
; SEQ ID NO 305
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-360-510-305

Query Match      0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 6.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      416 TCATGGAAGCGTGTGCC 435
      ||||| ||||| ||||| |||||
DB      1 TCATGAAGGCTTGTGCC 20

RESULT 780
US-10-160-497-22/c
; Sequence 22, Application US/10160497
; Publication No. US20030224513A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; APPLICANT: Erich Koller
; TITLE OF INVENTION: ANTISENSE MODULATION OF NOTCH1 EXPRESSION
; FILE REFERENCE: RTS-0386
; CURRENT APPLICATION NUMBER: US/10/160,497
; CURRENT FILING DATE: 2002-05-30
; NUMBER OF SEQ ID NOS: 145
; SEQ ID NO 22
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-497-22

Query Match      0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 6.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      410 GCCTGTCATGGAAGCGTG 429
      ||||| ||||| ||||| |||||
DB      20 GCCTGTCAGGGAATCGTG 1

RESULT 781
US-10-348-750-22/c
```

```
; Sequence 22, Application US/10348750
; Publication No. US20030225019A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; APPLICANT: Erich Koller
; TITLE OF INVENTION: NOTCH1 INHIBITORS FOR INDUCING APOPTOSIS
; FILE REFERENCE: ISPH-0729
; CURRENT APPLICATION NUMBER: US/10/348,750
; CURRENT FILING DATE: 2003-01-21
; PRIOR APPLICATION NUMBER: 10/160,497
; PRIOR FILING DATE: 2002-02-20
; NUMBER OF SEQ ID NOS: 146
; SEQ ID NO 22
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-348-750-22

Query Match      0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 6.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      410 GCCTGTCATGGAAGCGTG 429
      ||||| ||||| ||||| |||||
DB      20 GCCTGTCAGGGAATCGTG 1

RESULT 782
US-10-372-909-15/c
; Sequence 15, Application US/10372909
; Publication No. US20030237109A1
; GENERAL INFORMATION:
; APPLICANT: KOTODA, NOBUHIRO
; APPLICANT: WADA, MASATO
; APPLICANT: SOEJIMA, JUNICHI
; TITLE OF INVENTION: FLOWER-BUD FORMATION SUPPRESSOR GENE AND EARLY FLOWERING PLANT
; FILE REFERENCE: 234267USO
; CURRENT APPLICATION NUMBER: US/10/372,909
; CURRENT FILING DATE: 2003-02-26
; PRIOR APPLICATION NUMBER: JP 2002-180289
; PRIOR FILING DATE: 2002-06-20
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 15
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic oligonucleotide
US-10-372-909-15

Query Match      0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 6.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      3126 AACTATTATGACACCGAGAA 3145
      ||||| ||||| ||||| |||||
DB      20 AACTATTATGACATGTGAGAA 1

RESULT 783
US-10-210-290-74
; Sequence 74, Application US/10210290
; Publication No. US20040023378A1
; GENERAL INFORMATION:
; APPLICANT: Ming-Yi Chiang
; APPLICANT: Eric G. Marcussen
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF KIAA1531 PROTEIN EXPRESSION
; FILE REFERENCE: RTS-0367
```

; CURRENT APPLICATION NUMBER: US/10/210,290
 ; CURRENT FILING DATE: 2002-07-31
 ; NUMBER OF SEQ ID NOS: 134
 ; SEQ ID NO 74
 ; LENGTH: 20
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Antisense Oligonucleotide
 US-10-210-290-74

Query Match 0.4%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 6.6e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1610 AGTGCATCCACAGGACCTG 1629
 Db 1 AGTTCACCCACAGGACCTG 20

RESULT 784
 US-10-210-290-128/c
 ; Sequence 128, Application US/10210290
 ; Publication No. US20040023378A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ming-Yi Chiang
 ; APPLICANT: Eric G. Marcusson
 ; APPLICANT: Kenneth W. Dobie
 ; TITLE OF INVENTION: ANTISENSE MODULATION OF KIAA1531 PROTEIN EXPRESSION
 ; FILE REFERENCE: RTS-0367
 ; CURRENT APPLICATION NUMBER: US/10/210,290
 ; CURRENT FILING DATE: 2002-07-31
 ; NUMBER OF SEQ ID NOS: 134
 ; SEQ ID NO 128
 ; LENGTH: 20
 ; TYPE: DNA
 ; ORGANISM: H. sapiens
 ; FEATURE:
 ; OTHER INFORMATION: SYNTHETIC DNA
 US-10-210-290-128

Query Match 0.4%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 6.6e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1610 AGTGCATCCACAGGACCTG 1629
 Db 20 AGTTCACCCACAGGACCTG 1

RESULT 785
 US-10-380-124-39/c
 ; Sequence 39, Application US/10380124
 ; Publication No. US20040053874A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Isis Pharmaceuticals, Inc.
 ; APPLICANT: Brett P. Monia
 ; APPLICANT: Susan M. Preiser
 ; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
 ; FILE REFERENCE: RTS-0156
 ; CURRENT APPLICATION NUMBER: US/10/380,124
 ; CURRENT FILING DATE: 2003-03-10
 ; NUMBER OF SEQ ID NOS: 90
 ; SEQ ID NO 39
 ; LENGTH: 20
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Antisense Oligonucleotide
 US-10-380-124-39

Query Match 0.4%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 6.6e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 489 GCAGACGTACACGCTGGACG 508
 Db 20 GCAGACGCACATGCTGGATG 1

RESULT 786
 US-10-683-386-23
 ; Sequence 23, Application US/10683386
 ; Publication No. US20040063137A1
 ; GENERAL INFORMATION:
 ; APPLICANT: KURANE, RYUICHIRO
 ; APPLICANT: KANAGAWA, TAKAHIRO
 ; APPLICANT: KAWAGATA, YOICHI
 ; APPLICANT: YAMADA, KAZUTAKA
 ; APPLICANT: YOKOMAKU, TOYOKAZU
 ; APPLICANT: KOYAMA, OSAMU
 ; APPLICANT: FURUSHO, KENTA
 ; TITLE OF INVENTION: METHOD FOR DETERMINING A CONCENTRATION OF TARGET NUCLEIC ACID MOL
 ; TITLE OF INVENTION: NUCLEIC ACID PROBES FOR THE METHOD, AND METHOD FOR ANALYZING DAT
 ; FILE REFERENCE: 0163-0758-0X
 ; CURRENT APPLICATION NUMBER: US/10/683,386
 ; CURRENT FILING DATE: 2000-04-20
 ; PRIOR APPLICATION NUMBER: US/09/556,127
 ; PRIOR FILING DATE: 2000-04-20
 ; PRIOR APPLICATION NUMBER: JP 1999-111601
 ; PRIOR FILING DATE: 1999-04-20
 ; NUMBER OF SEQ ID NOS: 70
 ; SOFTWARE: PatentIn version 3.1
 ; SEQ ID NO 23
 ; LENGTH: 20
 ; TYPE: DNA
 ; ORGANISM: ARTIFICIAL SEQUENCE
 ; FEATURE:
 ; OTHER INFORMATION: SYNTHETIC DNA
 US-10-683-386-23

Query Match 0.4%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 6.6e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 3473 TATATATATATTTTATTTGAG 3492
 Db 1 TATATATATATTTTATTTGAG 20

RESULT 787
 US-10-619-284A-52
 ; Sequence 52, Application US/10619284A
 ; Publication No. US20040077099A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Argonne National Laboratory
 ; APPLICANT: Yershov, Gennadiy
 ; APPLICANT: Alferov, Oleg
 ; APPLICANT: Kukhtin, Alexander
 ; TITLE OF INVENTION: BIOCHIP READER WITH ENHANCED ILLUMINATION AND BIOARRAY
 ; FILE REFERENCE: ANL-IN-01-052
 ; CURRENT APPLICATION NUMBER: US/10/619,284A
 ; CURRENT FILING DATE: 2003-07-14
 ; PRIOR APPLICATION NUMBER: US 10/139842
 ; PRIOR FILING DATE: 2002-05-06
 ; NUMBER OF SEQ ID NOS: 74
 ; SOFTWARE: PatentIn version 3.2
 ; SEQ ID NO 52
 ; LENGTH: 20
 ; TYPE: DNA
 ; ORGANISM: Artificial
 ; FEATURE:
 ; OTHER INFORMATION: Completely Synthesized
 US-10-619-284A-52

```
Query Match      0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 6.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1350 GATGAGATGATGAAGATGA 1369
    ||||| ||||| ||||| |||||
Db 1 GATGATGATGATGATGA 20

RESULT 788
US-10-619-284A-74
; Sequence 74, Application US/10619284A
; Publication No. US20040077099A1
; GENERAL INFORMATION:
; APPLICANT: Argonne National Laboratory
; APPLICANT: Yerushov, Gennadiy
; APPLICANT: Alfierov, Oleg
; APPLICANT: Kukhtin, Alexander
; TITLE OF INVENTION: BIOCHIP READER WITH ENHANCED ILLUMINATION AND BIOARRAY
; TITLE OF INVENTION: POSITIONING
; FILE REFERENCE: ANL-IN-01-052
; CURRENT APPLICATION NUMBER: US/10/619,284A
; CURRENT FILING DATE: 2003-07-14
; PRIOR APPLICATION NUMBER: US 10/139842
; PRIOR FILING DATE: 2002-05-06
; NUMBER OF SEQ ID NOS: 74
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 74
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Completely Synthesized
; US-10-619-284A-74

Query Match      0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 6.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1350 GATGAGATGATGAAGATGA 1369
    ||||| ||||| ||||| |||||
Db 1 GATGATGATGATGATGA 20

RESULT 789
US-10-274-085-33/c
; Sequence 33, Application US/10274085
; Publication No. US20040077570A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; APPLICANT: Sanjay Bhanot
; TITLE OF INVENTION: ANTISENSE MODULATION OF FATTY ACID SYNTHASE EXPRESSION
; FILE REFERENCE: ISPH-0714
; CURRENT APPLICATION NUMBER: US/10/274,085
; CURRENT FILING DATE: 2002-10-17
; NUMBER OF SEQ ID NOS: 225
; SEQ ID NO 33
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
; US-10-274-085-33

Query Match      0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 6.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3628 GCCCTGAGTCTGGGCGCTG 3647
    ||||| ||||| ||||| |||||
Db 20 GCCCTCAGTCTGGGCTGCGG 1
```

```
RESULT 790
US-10-274-085-64/c
; Sequence 64, Application US/10274085
; Publication No. US20040077570A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; APPLICANT: Sanjay Bhanot
; TITLE OF INVENTION: ANTISENSE MODULATION OF FATTY ACID SYNTHASE EXPRESSION
; FILE REFERENCE: ISPH-0714
; CURRENT APPLICATION NUMBER: US/10/274,085
; CURRENT FILING DATE: 2002-10-17
; NUMBER OF SEQ ID NOS: 225
; SEQ ID NO 64
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
; US-10-274-085-64

Query Match      0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 6.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1891 CTGCTGAAGGAGGGCCACCG 1910
    ||||| ||||| ||||| |||||
Db 20 CTGCTGAGCAGGGCCTCCG 1

RESULT 791
US-10-274-085-145
; Sequence 145, Application US/10274085
; Publication No. US20040077570A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; APPLICANT: Sanjay Bhanot
; TITLE OF INVENTION: ANTISENSE MODULATION OF FATTY ACID SYNTHASE EXPRESSION
; FILE REFERENCE: ISPH-0714
; CURRENT APPLICATION NUMBER: US/10/274,085
; CURRENT FILING DATE: 2002-10-17
; NUMBER OF SEQ ID NOS: 225
; SEQ ID NO 145
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; US-10-274-085-145

Query Match      0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 6.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3628 GCCCTGAGTCTGGGCGCTG 3647
    ||||| ||||| ||||| |||||
Db 1 GCCCTCAGTCTGGGCTGCGG 20

RESULT 792
US-10-274-085-172
; Sequence 172, Application US/10274085
; Publication No. US20040077570A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; APPLICANT: Sanjay Bhanot
; TITLE OF INVENTION: ANTISENSE MODULATION OF FATTY ACID SYNTHASE EXPRESSION
; FILE REFERENCE: ISPH-0714
; CURRENT APPLICATION NUMBER: US/10/274,085
; CURRENT FILING DATE: 2002-10-17
; NUMBER OF SEQ ID NOS: 225
; SEQ ID NO 172
```

```
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
US-10-274-085-172

Query Match      0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 6.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1891 CTGCTGAAGGAGGCGCACCG 1910
||||| ||||| ||||| |||||
Db 1 CTGCTGGAGCAGGCGCTCG 20

RESULT 793
US-10-210-802-74
; Sequence 74, Application US/10210802
; Publication No. US20040087523A1
; GENERAL INFORMATION:
; APPLICANT: Ming-Yi Chiang
; TITLE OF INVENTION: ANTISENSE MODULATION OF KIAA1531 PROTEIN EXPRESSION
; FILE REFERENCE: RTS-0367
; CURRENT APPLICATION NUMBER: US/10/210,802
; CURRENT FILING DATE: 2002-07-31
; NUMBER OF SEQ ID NOS: 134
; SEQ ID NO 74
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-210-802-74

Query Match      0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 6.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1610 AGTGCATCCACAGGACCTG 1629
||||| ||||| ||||| |||||
Db 1 AGTTCACCCACAGGACCTG 20

RESULT 794
US-10-210-802-128/c
; Sequence 128, Application US/10210802
; Publication No. US20040087523A1
; GENERAL INFORMATION:
; APPLICANT: Ming-Yi Chiang
; TITLE OF INVENTION: ANTISENSE MODULATION OF KIAA1531 PROTEIN EXPRESSION
; FILE REFERENCE: RTS-0367
; CURRENT APPLICATION NUMBER: US/10/210,802
; CURRENT FILING DATE: 2002-07-31
; NUMBER OF SEQ ID NOS: 134
; SEQ ID NO 128
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-210-802-128

Query Match      0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 6.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1610 AGTGCATCCACAGGACCTG 1629
||||| ||||| ||||| |||||
Db 20 AGTTCACCCACAGGACCTG 1

RESULT 795
US-10-300-642-33/c

; Sequence 33, Application US/10300642
; Publication No. US20040096836A1
; GENERAL INFORMATION:
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF MITOGEN-ACTIVATED PROTEIN KINASE 13 EXPRESSION
; FILE REFERENCE: HTS-0045
; CURRENT APPLICATION NUMBER: US/10/300,642
; CURRENT FILING DATE: 2002-11-19
; NUMBER OF SEQ ID NOS: 78
; SEQ ID NO 33
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-300-642-33

Query Match      0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 6.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2962 CACCCATGCAAGCAGGAGGAC 2981
||||| ||||| ||||| |||||
Db 20 CAGCCTTTCAGCAGGAGGAC 1

RESULT 796
US-10-300-642-65
; Sequence 65, Application US/10300642
; Publication No. US20040096836A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: MODULATION OF MITOGEN-ACTIVATED PROTEIN KINASE 13 EXPRESSION
; FILE REFERENCE: HTS-0045
; CURRENT APPLICATION NUMBER: US/10/300,642
; CURRENT FILING DATE: 2002-11-19
; NUMBER OF SEQ ID NOS: 78
; SEQ ID NO 65
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-300-642-65

Query Match      0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 6.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2962 CACCCATGCAAGCAGGAGGAC 2981
||||| ||||| ||||| |||||
Db 1 CAGCCTTTCAGCAGGAGGAC 20

RESULT 797
US-10-688-706-88
; Sequence 88, Application US/10688706
; Publication No. US20040102412A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; TITLE OF INVENTION: ANTISENSE MODULATION OF GPAT EXPRESSION
; FILE REFERENCE: 01393/1
; CURRENT APPLICATION NUMBER: US/10/688,706
; CURRENT FILING DATE: 2003-10-17
; PRIOR APPLICATION NUMBER: 60/419,268
; PRIOR FILING DATE: 2002-10-17
; NUMBER OF SEQ ID NOS: 3071
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 88
; LENGTH: 20
; TYPE: DNA
```

```
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: human GFAT antisense
US-10-688-706-88

Query Match          0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 6.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 3238 AGTTGGAGGTGATTCACGTG 3257
||||| ||||| ||||| |||||
Db 1 AGTTGGTATGATTCACATTG 20

RESULT 798
US-10-688-706-102
; Sequence 102, Application US/10688706
; Publication No. US20040102412A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; TITLE OF INVENTION: ANTISENSE MODULATION OF GFAT EXPRESSION
; FILE REFERENCE: 01393/1
; CURRENT APPLICATION NUMBER: US/10/688,706
; CURRENT FILING DATE: 2003-10-17
; PRIOR APPLICATION NUMBER: 60/419,268
; PRIOR FILING DATE: 2002-10-17
; NUMBER OF SEQ ID NOS: 3071
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 102
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: human GFAT antisense
US-10-688-706-102

Query Match          0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 6.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 3237 TAGTTGGAGGTGATTCACGT 3256
||||| ||||| ||||| |||||
Db 1 TAGTTGGTATGATTCACATT 20

RESULT 799
US-10-319-915-120/c
; Sequence 120, Application US/10319915
; Publication No. US20040115653A1
; GENERAL INFORMATION:
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF ENDOTHELIAL LIPASE EXPRESSION
; FILE REFERENCE: RTS-0447
; CURRENT APPLICATION NUMBER: US/10/319,915
; CURRENT FILING DATE: 2002-12-12
; NUMBER OF SEQ ID NOS: 279
; SEQ ID NO 120
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-319-915-120

Query Match          0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 6.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 485 TCCGCGACAGGTACACGCTG 504
||||| ||||| ||||| |||||
Db 20 TCCTGCATACCTACACGCTG 1

RESULT 800
US-10-319-915-247
; Sequence 247, Application US/10319915
; Publication No. US20040115653A1
; GENERAL INFORMATION:
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF ENDOTHELIAL LIPASE EXPRESSION
; FILE REFERENCE: RTS-0447
; CURRENT APPLICATION NUMBER: US/10/319,915
; CURRENT FILING DATE: 2002-12-12
; NUMBER OF SEQ ID NOS: 279
; SEQ ID NO 247
; LENGTH: 20
; TYPE: DNA
; ORGANISM: M. musculus
; FEATURE:
; OTHER INFORMATION:
US-10-319-915-247

Query Match          0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 6.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 485 TCCGCGACAGGTACACGCTG 504
||||| ||||| ||||| |||||
Db 1 TCCTGCATACCTACACGCTG 20

RESULT 801
US-10-671-395-174
; Sequence 174, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 174
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-174

Query Match          0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 6.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1612 TGCATCCACAGGACCTGGC 1631
||||| ||||| ||||| |||||
Db 1 TGCTTCCACAGAGAACTGGC 20

RESULT 802
US-10-671-395-1138/c
; Sequence 1138, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
```

; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1138
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1138

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 6.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2361 GTGTGCGCTGTGTGTGCGC 2380
Db 20 GTGGCCGTGTGTGTGCCCC 1

RESULT 803
US-10-671-395-1175/c
; Sequence 1175, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1175
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1175

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 6.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2327 GTGTGCGCTGTGTGTGTGT 2346
Db 20 GTGTGCCGTGTGTGTGTAT 1

RESULT 804
US-10-671-395-1279/c
; Sequence 1279, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1279
; LENGTH: 20
; TYPE: DNA

; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1279

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 6.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2002 CAGCTGGTGAGGACCTGGA 2021
Db 20 CAGTGGTGAGGACCGGGA 1

RESULT 805
US-10-671-395-1312/c
; Sequence 1312, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1312
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1312

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 6.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2001 GCAGCTGGTGAGGACCTGG 2020
Db 20 GCAGTGGGTGAGGACCGGG 1

RESULT 806
US-10-671-395-1350/c
; Sequence 1350, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1350
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1350

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 6.6e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2329 GTGTGCGTGTGTGTGTGTGTGT 2348
||| ||||| ||||| ||||| |||||
Db 20 GTGCCGTGTGTGTGTGTGTGT 1

RESULT 807

US-10-671-395-1399/c
; Sequence 1399, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1399
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1399

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 6.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 924 CTTCTGTTCATCTGTGTGG 943
||||| ||||| ||||| ||||| |||||
Db 20 CTTCTGTGTCTCTCTGTGG 1

RESULT 808

US-10-671-395-1406/c
; Sequence 1406, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1406
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1406

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 6.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2330 TGTGCGTGTGTGTGTGTGTGT 2349
||| ||||| ||||| ||||| |||||
Db 20 TGCCGTGTGTGTGTGTGTGT 1

RESULT 809

US-10-671-395-1423/c
; Sequence 1423, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1423
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1423

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 6.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2325 GTGTGTGTGCGTGTGTGTGT 2344
||||| ||||| ||||| ||||| |||||
Db 20 GTGTGTGTGTGTGTGTGTGT 1

RESULT 810

US-10-671-395-1431/c
; Sequence 1431, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1431
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1431

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 6.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2328 TGTGTGCGTGTGTGTGTGTGT 2347
||||| ||||| ||||| ||||| |||||
Db 20 TGTGCGGTGTGTGTGTGTGTGT 1

RESULT 811

US-10-671-395-1505/c
; Sequence 1505, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K


```
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE OF INVENTION: EXPRESSION
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1505
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1505

Query Match          0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 6.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      2326  TGTGTGCGGTGTGTGTG 2345
          ||||| ||||| |||||
Db      20  TGTGTATGTGTGTGTATG 1

RESULT 812
US-10-671-395-1566/c
; Sequence 1566, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1566
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1566

Query Match          0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 6.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      2326  TGTGTGCGGTGTGTGTG 2345
          ||||| ||||| |||||
Db      20  TGTGTATGTGTGTGTATG 1

RESULT 813
US-10-671-395-1627/c
; Sequence 1627, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
```

```
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1627
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1627

Query Match          0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 6.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      2326  TGTGTGCGGTGTGTGTG 2345
          ||||| ||||| |||||
Db      20  TGTGTATGTGTGTGTATG 1

RESULT 814
US-10-671-395-1628/c
; Sequence 1628, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1628
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1628

Query Match          0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 6.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      2325  GTGTGTGCGGTGTGTGTG 2344
          ||||| ||||| |||||
Db      20  GTGTATGTGTATGTGTGTG 1

RESULT 815
US-10-671-395-1640/c
; Sequence 1640, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1640
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
```

```
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1640

Query Match          0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 6.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2325 GTGTGTGCGTGTGTGTGTGT 2344
      ||||| ||||| ||||| |||||
Db 20 GTGTGTGTGTGTGTGTGTGTGT 1

RESULT 816
US-10-671-395-1641/c
; Sequence 1641, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1641
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1641

Query Match          0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 6.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2325 GTGTGTGCGTGTGTGTGTGT 2344
      ||||| ||||| ||||| |||||
Db 20 GTGTGTGTGTGTGTGTGTGTGT 1

RESULT 817
US-10-671-395-1665/c
; Sequence 1665, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1665
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1665

Query Match          0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 6.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2325 GTGTGTGCGTGTGTGTGTGT 2344
      ||||| ||||| ||||| |||||
Db 20 GTGTGTGTGTGTGTGTGTGTGT 1

RESULT 818
US-10-671-395-1670/c
; Sequence 1670, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1670
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1670

Query Match          0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 6.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2335 GTGTGTGTGTGTGTGTGTGT 2354
      ||||| ||||| ||||| |||||
Db 20 GTGTGTGTGTGTGTGTGTGTGT 1

RESULT 819
US-10-671-395-1685/c
; Sequence 1685, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1685
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1685

Query Match          0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 6.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2326 TGTGTGTGCGTGTGTGTGTGT 2345
      ||||| ||||| ||||| |||||
Db 20 TGTGTGTGTGTGTGTGTGTGTGT 1

RESULT 820
US-10-654-102-126/c
```

; Sequence 126, Application US/10654102
; Publication No. US20040132679A1
; GENERAL INFORMATION:

; APPLICANT: CHAN, LAWRENCE

; APPLICANT: KOJIMA, HIDEOTO

; TITLE OF INVENTION: INDUCTION OF PANCREATIC ISLET FORMATION

; FILE REFERENCE: P024090US1

; CURRENT APPLICATION NUMBER: US/10/654,102

; CURRENT FILING DATE: 2003-09-03

; NUMBER OF SEQ ID NOS: 194

; SOFTWARE: PatentIn Ver. 2.1

; SEQ ID NO 126

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: Synthetic

; OTHER INFORMATION: Primer

US-10-654-102-126

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 6.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1609 AAGTGCATCCACAGGACCT 1628

Db 20 AAGCGCATCCACAGGCCAT 1

RESULT 821

US-10-641-455A-22/c

; Sequence 22, Application US/10641455A

; Publication No. US20040171566A1

; GENERAL INFORMATION:

; APPLICANT: Monia, Brett P.

; APPLICANT: Gaarde, William A.

; APPLICANT: Nero, Pamela S.

; APPLICANT: McKay, Robert

; APPLICANT: Popoff, Ian

; APPLICANT: Wong, Wai Shiu Fred

; TITLE OF INVENTION: Antisense Oligonucleotide Modulation of p38 Mitogen

; FILE REFERENCE: ISPH-0762

; CURRENT APPLICATION NUMBER: US/10/641,455A

; CURRENT FILING DATE: 2003-08-15

; PRIOR FILING DATE: 2003-08-15

; PRIOR FILING DATE: 2002-09-09

; PRIOR APPLICATION NUMBER: US 09/640,101

; PRIOR FILING DATE: 2000-08-15

; PRIOR APPLICATION NUMBER: US 09/286,904

; PRIOR FILING DATE: 1999-04-06

; NUMBER OF SEQ ID NOS: 265

; SOFTWARE: PatentIn Ver. 2.0

; SEQ ID NO 22

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: antisense sequence

US-10-641-455A-22

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 6.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2321 GTGTGTGTGTGTGTGTGTGT 2340

Db 20 GTTAGTGTGTGTGTGTGTGT 1

RESULT 822

US-10-835-208-76/c

; Sequence 76, Application US/10835208

; Publication No. US20040192633A1

; GENERAL INFORMATION:

; APPLICANT: Rosanne M. Crooke

; APPLICANT: Mark J. Graham

; TITLE OF INVENTION: ANTISENSE MODULATION OF SHORT HETERODIMER PARTNER-1 EXPRESSION

; FILE REFERENCE: ISPH-0593

; CURRENT APPLICATION NUMBER: US/10/835,208

; CURRENT FILING DATE: 2004-04-29

; PRIOR APPLICATION NUMBER: US/09/919,197

; PRIOR FILING DATE: 2001-07-31

; NUMBER OF SEQ ID NOS: 89

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 76

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-10-835-208-76

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 6.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2396 GCAGAGGTACCTGGGTGTC 2415

Db 20 GCAGCGGTACCCAGGGTGCC 1

RESULT 823

US-10-487-846-34/c

; Sequence 34, Application US/10487846

; Publication No. US20040199939A1

; GENERAL INFORMATION:

; APPLICANT: Syngenta Participations AG

; TITLE OF INVENTION: Modified Cry3A Toxins and Nucleic Acid Sequences Coding Therefor

; FILE REFERENCE: 60065/PCT

; CURRENT APPLICATION NUMBER: US/10/487,846

; CURRENT FILING DATE: 2004-02-25

; PRIOR APPLICATION NUMBER: US 60/316421

; PRIOR FILING DATE: 2001-08-31

; NUMBER OF SEQ ID NOS: 34

; SOFTWARE: PatentIn Ver. 3.0

; SEQ ID NO 34

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; NAME/KEY: misc feature

; LOCATION: (1)..(20)

; OTHER INFORMATION: CMS16 Primer

US-10-487-846-34

Query Match 0.4%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 6.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1995 CTTCAAGCAGCTGGTGAGG 2014

Db 20 CTTCATGGAGCAGGTGGAGG 1

RESULT 824

US-09-771-730-103

; Sequence 103, Application US/09771730

; Patent No. US20020146807A1

; GENERAL INFORMATION:

; APPLICANT: Prayaga, Sudhirdas K.

; APPLICANT: Li, Li

; APPLICANT: Padigaru, Muralidhara

; APPLICANT: MacDougall, John R.

; APPLICANT: Sytek, Kimberly Ann

; APPLICANT: Tchernev, Velizar T.

```

; APPLICANT: Vernet, Corine A. M.
; TITLE OF INVENTION: NOVEL POLYPEPTIDES AND NUCLEIC ACIDS ENCODING SAME
; FILE REFERENCE: 15966-645
; CURRENT APPLICATION NUMBER: US/09/771,730
; CURRENT FILING DATE: 2001-08-21
; PRIOR APPLICATION NUMBER: 60/178,413
; PRIOR FILING DATE: 2000-01-27
; PRIOR APPLICATION NUMBER: 60/178,371
; PRIOR FILING DATE: 2000-01-27
; PRIOR APPLICATION NUMBER: 60/178,408
; PRIOR FILING DATE: 2000-01-27
; PRIOR APPLICATION NUMBER: 60/178,370
; PRIOR FILING DATE: 2000-01-27
; PRIOR APPLICATION NUMBER: 60/178,406
; PRIOR FILING DATE: 2000-01-27
; PRIOR APPLICATION NUMBER: 60/178,414
; PRIOR FILING DATE: 2000-01-27
; PRIOR APPLICATION NUMBER: 60/178,409
; PRIOR FILING DATE: 2000-01-27
; PRIOR APPLICATION NUMBER: 60/180,634
; PRIOR FILING DATE: 2000-02-07
; PRIOR APPLICATION NUMBER: 60/220,516
; PRIOR FILING DATE: 2000-07-24
; PRIOR APPLICATION NUMBER: 60/221,408
; PRIOR FILING DATE: 2000-07-28
; PRIOR APPLICATION NUMBER: 60/221,943
; PRIOR FILING DATE: 2000-07-31
; PRIOR APPLICATION NUMBER: 60/257,599
; PRIOR FILING DATE: 2000-12-21
; PRIOR APPLICATION NUMBER: 60/260,290
; PRIOR FILING DATE: 2001-01-08
; NUMBER OF SEQ ID NOS: 148
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 103
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: NOV 12 Probe
; OTHER INFORMATION: Primer Sequence
US-09-771-730-103

Query Match      0.4%; Score 15.2; DB 1; Length 21;
Best Local Similarity 85.0%; Pred. No. 6.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      1182  GGCCCGGCTGACCCCTGGCA 1201
          ||||| ||||| ||||| ||||| ||
Db      2  GGCCAGCTGACCCCTGCTCA 21

RESULT 825
US-09-808-602-35
; Sequence 35, Application US/09808602
; Publication No. US20020155115A1
; GENERAL INFORMATION:
; APPLICANT: Vernet, Corine A
; APPLICANT: Fernandes, Elma
; APPLICANT: Shinkets, Richard A
; APPLICANT: Heriman, John L
; APPLICANT: Majumder, Kumud
; APPLICANT: Mishra, Vishnu
; APPLICANT: Mezes, Peter S
; APPLICANT: MacDougall, John
; TITLE OF INVENTION: No. US20020155115A1el Proteins and Nuclec Acids Encoding Same
; FILE REFERENCE: 15966-697 CIP
; CURRENT APPLICATION NUMBER: US/09/808,602
; CURRENT FILING DATE: 2001-03-14
; PRIOR APPLICATION NUMBER: 09/800,198
; PRIOR FILING DATE: 2001-03-05
; PRIOR APPLICATION NUMBER: 60/186,596
; PRIOR FILING DATE: 2000-03-03
; NUMBER OF SEQ ID NOS: 114
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 103
; LENGTH: 114

```

```

; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 35
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:Ag427 Probe
US-09-808-602-35

Query Match      0.4%; Score 15.2; DB 1; Length 21;
Best Local Similarity 85.0%; Pred. No. 6.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      1182  GGCCCGGCTGACCCCTGGCA 1201
          ||||| ||||| ||||| ||||| ||
Db      2  GGCCAGCTGACCCCTGCTCA 21

RESULT 826
US-09-232-785-390
; Sequence 390, Application US/09232785
; Publication No. US20030049612A1
; GENERAL INFORMATION:
; APPLICANT: International Paper Co.
; APPLICANT: Echt, Craig S
; APPLICANT: Nelson, C. Dana
; TITLE OF INVENTION: MICROSATELLITE DNA MARKERS AND USES
; TITLE OF INVENTION: THEREOF
; FILE REFERENCE: 4481/1818US1
; CURRENT APPLICATION NUMBER: US/09/232,785
; CURRENT FILING DATE: 1999-01-19
; PRIOR APPLICATION NUMBER: 09/232,884
; PRIOR FILING DATE: 1999-01-15
; NUMBER OF SEQ ID NOS: 397
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 390
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Pinus taeda L.
; OTHER INFORMATION:
US-09-232-785-390

Query Match      0.4%; Score 15.2; DB 1; Length 21;
Best Local Similarity 85.0%; Pred. No. 6.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      1351  ATGGAGATGATGAGATGATGAT 1370
          ||||| ||||| ||||| ||||| ||
Db      1  ATGATGATGATGATGATGAT 20

RESULT 827
US-09-800-198-33
; Sequence 33, Application US/09800198
; Publication No. US20030087816A1
; GENERAL INFORMATION:
; APPLICANT: Vernet, Corine AM
; APPLICANT: Fernandes, Elma
; APPLICANT: Shinkets, Richard A
; APPLICANT: Herrmann, John L
; APPLICANT: Majumder, Kumud
; APPLICANT: Mishra, Vishna
; APPLICANT: Mezes, Peter S
; APPLICANT: Rastelli, Luca
; TITLE OF INVENTION: NOVEL PROTEINS AND NUCLEIC ACIDS ENCODING SAME
; FILE REFERENCE: 15966-697
; CURRENT APPLICATION NUMBER: US/09/800,198
; CURRENT FILING DATE: 2001-03-05
; PRIOR APPLICATION NUMBER: 60/186,596
; PRIOR FILING DATE: 2000-03-03
; NUMBER OF SEQ ID NOS: 98
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 33
; LENGTH: 21

```

```
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: misc feature
; OTHER INFORMATION: Description of Artificial Sequence:Ag427 Probe
US-09-800-198-33

Query Match          0.4%; Score 15.2; DB 1; Length 21;
Best Local Similarity 85.0%; Pred. No. 6.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1182 GCGCGGCTGACCTGGGCA 1201
      ||||| ||||| ||||| |||||
Db 2 GCGCCAGCTGACCTGCTCA 21

RESULT 828
US-10-142-566-49
; Sequence 49, Application US/10142566
; Publication No. US20030119016A1
; GENERAL INFORMATION:
; APPLICANT: Riley, Timothy A.
; APPLICANT: Brown, Bob D.
; APPLICANT: Arnold, Lyle J.
; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDES WITH INCREASED RNASE SENSITIVITY
; FILE REFERENCE: OASBIO.003DV1
; CURRENT APPLICATION NUMBER: US/10/142,566
; CURRENT FILING DATE: 2002-08-06
; PRIOR APPLICATION NUMBER: US 09/136,080
; PRIOR FILING DATE: 1998-08-18
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 49
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic oligonucleotide
; NAME/KEY: misc feature
; LOCATION: (16)...(16)
; OTHER INFORMATION: Glen research spacer 9 (cat # 10-1909-90) between c 15 and c 16
; LOCATION: (21)...(21)
; OTHER INFORMATION: propyl linker attached to t 21
US-10-142-566-49

Query Match          0.4%; Score 15.2; DB 1; Length 21;
Best Local Similarity 70.0%; Pred. No. 6.9e+02;
Matches 14; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

Qy 1434 GCTGGTGAGTACGCGGCA 1453
      ||||| ||||| ||||| |||||
Db 1 GCUGGUGAGUACUCCGCCA 20

RESULT 829
US-10-253-967-36
; Sequence 36, Application US/10253967
; Publication No. US20030165925A1
; GENERAL INFORMATION:
; APPLICANT: SAITO et al.
; TITLE OF INVENTION: DIAGNOSTIC PROBE DETECTION SYSTEM
; FILE REFERENCE: 27978/37504A
; CURRENT APPLICATION NUMBER: US/10/253,967
; CURRENT FILING DATE: 2002-09-24
; PRIOR APPLICATION NUMBER: US 60/324,421
; PRIOR FILING DATE: 2001-09-24
; NUMBER OF SEQ ID NOS: 53
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 36
; LENGTH: 21
; TYPE: DNA
```

```
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc feature
; OTHER INFORMATION: Allele DQB1*06011
US-10-253-967-36

Query Match          0.4%; Score 15.2; DB 1; Length 21;
Best Local Similarity 85.0%; Pred. No. 6.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 231 CTGGACACGGCCCGAGCGGA 250
      ||||| ||||| ||||| |||||
Db 1 CTGGAGAGGACCCGAGCGGA 20

RESULT 830
US-10-418-182-112
; Sequence 112, Application US/10418182
; Publication No. US20030228302A1
; GENERAL INFORMATION:
; APPLICANT: Crea, Roberto
; TITLE OF INVENTION: UNIVERSAL LIBRARIES FOR IMMUNOGLOBULINS
; FILE REFERENCE: 1551.2001-001
; CURRENT APPLICATION NUMBER: US/10/418,182
; CURRENT FILING DATE: 2003-04-16
; PRIOR APPLICATION NUMBER: 60/373,558
; PRIOR FILING DATE: 2002-04-17
; NUMBER OF SEQ ID NOS: 423
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 112
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: oligonucleotide
US-10-418-182-112

Query Match          0.4%; Score 15.2; DB 1; Length 21;
Best Local Similarity 85.0%; Pred. No. 6.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1351 ATGGAGATGATGAAGATGAT 1370
      ||||| ||||| ||||| |||||
Db 1 ATGATGATGATGATGATGAT 20

RESULT 831
US-10-388-263-203/c
; Sequence 203, Application US/10388263
; Publication No. US20030228597A1
; GENERAL INFORMATION:
; APPLICANT: Cowsert, Lex M.
; APPLICANT: Baker, Brenda F.
; APPLICANT: McNeil, John
; APPLICANT: Freier, Susan M.
; APPLICANT: Sasnor, Henri M.
; APPLICANT: Brooks, Douglas G.
; APPLICANT: Ohashi, Cara
; APPLICANT: Wyatt, Jacqueline R.
; APPLICANT: Borchers, Alexander
; APPLICANT: Vickers, Timothy A.
; TITLE OF INVENTION: IDENTIFICATION OF GENETIC TARGETS FOR
; MODULATION BY OLIGONUCLEOTIDES AND
; GENERATION OF OLIGONUCLEOTIDES FOR GENE MODULATION
; FILE REFERENCE: ISIS-4503
; CURRENT APPLICATION NUMBER: US/10/388,263
; CURRENT FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 947
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 203
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
```

```

;
; FEATURE:
; OTHER INFORMATION: PCR Primer
US-10-388-263-203

Query Match          0.4%; Score 15.2; DB 1; Length 21;
Best Local Similarity 85.0%; Pred. No. 6.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      860 AGCTGGTGGAGCTGACGAG 879
Db      20 AGCTGGTGGATGCAGAGAG 1

RESULT 832
US-10-377-079-82/C
; Sequence 82, Application US/10377079
; Publication No. US20030236395A1
; GENERAL INFORMATION:
; APPLICANT: Huang, Shi
; TITLE OF INVENTION: PR-Domain Containing Nucleic Acids, Polypeptides,
; FILE REFERENCE: P-LJ 3611
; CURRENT APPLICATION NUMBER: US/10/377,079
; CURRENT FILING DATE: 2003-02-28
; PRIOR APPLICATION NUMBER: US/09/389,956.
; PRIOR FILING DATE: 1999-09-03
; NUMBER OF SEQ ID NOS: 93
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 82
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-377-079-82

Query Match          0.4%; Score 15.2; DB 1; Length 21;
Best Local Similarity 85.0%; Pred. No. 6.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      1722 GAAGACACCAACGCGCGGC 1741
Db      21 GAAGACAATCAACGCGGCG 2

RESULT 833
US-10-210-281-127
; Sequence 127, Application US/10210281
; Publication No. US20040030096A1
; GENERAL INFORMATION:
; APPLICANT: Gorman, Linda
; APPLICANT: Zerhusen, Bryan D.
; APPLICANT: Edinger, Shlomit R.
; APPLICANT: Padigar, Muralidhara
; APPLICANT: Guo, Xiaojia
; APPLICANT: Kekuda, Ramesh
; APPLICANT: Zhong, Mei
; APPLICANT: Patturajan, Meera
; APPLICANT: Miller, Charles E.
; APPLICANT: Ji, Weizhen
; APPLICANT: Pena, Carol E.A.
; APPLICANT: Burgess, Catherine E.
; APPLICANT: Sciore, Paul
; APPLICANT: Stone, David J.
; APPLICANT: Taupier, Raymond J., Jr.
; APPLICANT: Casman, Stacie
; APPLICANT: Rothenberg, Mark E.
; APPLICANT: Malyankar, Uriel M.
; APPLICANT: Boldog, Ferenc L.
; TITLE OF INVENTION: NOVEL HUMAN PROTEINS, POLYNUCLEOTIDES ENCODING THEM AND METHODS
; FILE REFERENCE: THE SAME
; CURRENT APPLICATION NUMBER: US/10/210,281
; CURRENT FILING DATE: 2003-02-05
; PRIOR APPLICATION NUMBER: 60/309,501

```

```

;
; PRIOR FILING DATE: 2001-08-02
; PRIOR APPLICATION NUMBER: 60/310,291
; PRIOR FILING DATE: 2001-08-03
; PRIOR APPLICATION NUMBER: 60/361,775
; PRIOR FILING DATE: 2002-03-05
; PRIOR APPLICATION NUMBER: 60/310,951
; PRIOR FILING DATE: 2001-08-08
; PRIOR APPLICATION NUMBER: 60/361,832
; PRIOR FILING DATE: 2002-03-05
; PRIOR APPLICATION NUMBER: 60/311,292
; PRIOR FILING DATE: 2001-08-09
; PRIOR APPLICATION NUMBER: 60/311,979
; PRIOR FILING DATE: 2001-08-13
; PRIOR APPLICATION NUMBER: 60/312,203
; PRIOR FILING DATE: 2001-08-14
; PRIOR APPLICATION NUMBER: 60/313,201
; PRIOR FILING DATE: 2001-08-17
; PRIOR APPLICATION NUMBER: 60/313,702
; PRIOR FILING DATE: 2001-08-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 191
; SOFTWARE: Curaseqdist version 0.1
; SEQ ID NO 127
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer/Probe
US-10-210-281-127

Query Match          0.4%; Score 15.2; DB 1; Length 21;
Best Local Similarity 85.0%; Pred. No. 6.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      3669 CATGGCTCAGGTGCTCTCT 3688
Db      2 CATGGGTCAGGATGTTCTCT 21

RESULT 834
US-10-380-195A-44/C
; Sequence 44, Application US/10380195A
; Publication No. US20040072776A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Kiyama, Satoshi
; APPLICANT: Nelson, Colleen
; APPLICANT: Rennie, Paul
; TITLE OF INVENTION: Antisense Insulin-Like Growth Factor Binding Protein (IGFBP)-2
; FILE REFERENCE: UBC-P-023
; CURRENT APPLICATION NUMBER: US/10/380,195A
; CURRENT FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: PCT/US01/28748
; PRIOR FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: US 60/232,641
; PRIOR FILING DATE: 2000-09-14
; NUMBER OF SEQ ID NOS: 63
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 44
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: IGFBP2 antisense
US-10-380-195A-44

Query Match          0.4%; Score 15.2; DB 1; Length 21;
Best Local Similarity 85.0%; Pred. No. 6.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      2504 CCACCCGGTGGACCCCGTG 2523

```

```
Db      20 CCATCCGGGGGACCCCGAG 1
RESULT 835
US-10-432-364-35/c
; Sequence 35, Application US/10432364
; Publication No. US20040091996A1
; GENERAL INFORMATION:
; APPLICANT: VIRGENE BIOTECHNOLOGY LIMITED
; TITLE OF INVENTION: A VIRUS WHICH CAN EXPRESS TUMOR ANGIOSTATIN FACTOR WITH HIGH EFFI
; FILE REFERENCE: iec010042pct
; CURRENT APPLICATION NUMBER: US/10/432,364
; CURRENT FILING DATE: 2003-11-06
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 35
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Primer 31: 3'-primer (containing a KpaI site)
US-10-432-364-35

Query Match      0.4%; Score 15.2; DB 1; Length 21;
Best Local Similarity 85.0%; Pred. No. 6.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      1457 GTAACCTCGGGAGTTTCTG 1476
      |||||
Db      21 GTTACCTGCTGGATTTCGTG 2

RESULT 836
US-10-702-496-154
; Sequence 154, Application US/10702496
; Publication No. US20040121383A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Liu, Wei
; APPLICANT: Wu, Leeying
; TITLE OF INVENTION: COMPOSITIONS, ORGANISMS AND METHODOLOGIES EMPLOYING A NOVEL HUMAN
; FILE REFERENCE: AM101071
; CURRENT APPLICATION NUMBER: US/10/702,496
; CURRENT FILING DATE: 2003-11-07
; PRIOR APPLICATION NUMBER: 60/429,381
; PRIOR FILING DATE: 2002-11-27
; NUMBER OF SEQ ID NOS: 306
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 154
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-702-496-154

Query Match      0.4%; Score 15.2; DB 1; Length 21;
Best Local Similarity 85.0%; Pred. No. 6.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      1354 GAGATGATGAAGATGATCGG 1373
      |||||
Db      1 GAGATCTTGAAGGTGATCGG 20

RESULT 837
US-10-702-496-161
; Sequence 161, Application US/10702496
; Publication No. US20040121383A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Liu, Wei
; APPLICANT: Wu, Leeying
```

```
; TITLE OF INVENTION: COMPOSITIONS, ORGANISMS AND METHODOLOGIES EMPLOYING A NOVEL HUMAN
; TITLE OF INVENTION: KINASE
; FILE REFERENCE: AM101071
; CURRENT APPLICATION NUMBER: US/10/702,496
; CURRENT FILING DATE: 2003-11-07
; PRIOR APPLICATION NUMBER: 60/429,381
; PRIOR FILING DATE: 2002-11-27
; NUMBER OF SEQ ID NOS: 306
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 161
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-702-496-161

Query Match      0.4%; Score 15.2; DB 1; Length 21;
Best Local Similarity 65.0%; Pred. No. 6.9e+02;
Matches 13; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

Qy      2046 CGACGAGTACTGACCTGT 2065
      |||||
Db      1 CGAGGAGUACCUUACCUU 20

RESULT 838
US-10-702-496-289
; Sequence 289, Application US/10702496
; Publication No. US20040121383A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Liu, Wei
; APPLICANT: Wu, Leeying
; TITLE OF INVENTION: COMPOSITIONS, ORGANISMS AND METHODOLOGIES EMPLOYING A NOVEL HUMAN
; FILE REFERENCE: AM101071
; CURRENT APPLICATION NUMBER: US/10/702,496
; CURRENT FILING DATE: 2003-11-07
; PRIOR APPLICATION NUMBER: 60/429,381
; PRIOR FILING DATE: 2002-11-27
; NUMBER OF SEQ ID NOS: 306
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 289
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-702-496-289

Query Match      0.4%; Score 15.2; DB 1; Length 21;
Best Local Similarity 85.0%; Pred. No. 6.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      1354 GAGATGATGAAGATGATCGG 1373
      |||||
Db      1 GAGATCTTGAAGGTGATCGG 20

RESULT 839
US-10-728-491-9/c
; Sequence 9, Application US/10728491
; Publication No. US20040142896A1
; GENERAL INFORMATION:
; APPLICANT: Wang, Jui, H
; TITLE OF INVENTION: High Efficacy Antisense RI alpha PKA Poly-DNP Oligoribonucleotide
; FILE REFERENCE: 11520.0338
; CURRENT APPLICATION NUMBER: US/10/728,491
; CURRENT FILING DATE: 2003-12-05
; PRIOR APPLICATION NUMBER: US 60/431,694
; PRIOR FILING DATE: 2002-12-05
; NUMBER OF SEQ ID NOS: 27
; SEQ ID NO 9
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial sequence
```

```
;
; FEATURE:
; OTHER INFORMATION: 5-base mismatched strand
US-10-728-491-9

Query Match          0.4%; Score 15.2; DB 1; Length 21;
Best Local Similarity 85.0%; Pred. No. 6.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 885 CAGTGTGATCGAGCATCC 904
Db 20 CTGTTGGATCGAGCACCC 1

-RESULT 840
US-10-786-720-11203
; Sequence 11203, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; TITLE OF INVENTION: DISEASES
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11203
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-786-720-11203

Query Match          0.4%; Score 15.2; DB 1; Length 21;
Best Local Similarity 85.0%; Pred. No. 6.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2234 CAGCCACCCCTGGCTGGT 2253
Db 1 CAGTCCACCTGGCTGGT 20

-RESULT 841
US-10-786-720-11219/c
; Sequence 11219, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; TITLE OF INVENTION: DISEASES
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11219
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai-sense strand
US-10-786-720-11219

Query Match          0.4%; Score 15.2; DB 1; Length 21;
Best Local Similarity 85.0%; Pred. No. 6.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 398 ATCAGCATGGAGCTCGTC 417
Db 20 ATCAGCTCGAGCATGTC 1

-RESULT 842
US-10-786-720-11538
; Sequence 11538, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; TITLE OF INVENTION: DISEASES
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11538
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai-antisense strand
US-10-786-720-11538

Query Match          0.4%; Score 15.2; DB 1; Length 21;
Best Local Similarity 50.0%; Pred. No. 6.9e+02;
Matches 10; Conservative 7; Mismatches 3; Indels 0; Gaps 0;

Qy 2321 GTGTGTGTGTGCTGGTGT 2340
Db 1 GCGCGUGUGUGCAUGUGU 20

-RESULT 843
US-10-786-720-12987/c
; Sequence 12987, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; TITLE OF INVENTION: DISEASES
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 12987
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai-antisense strand
US-10-786-720-12987

Query Match          0.4%; Score 15.2; DB 1; Length 21;
Best Local Similarity 85.0%; Pred. No. 6.9e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2102 ACACCCCGAGCTCCAGCTCC 2121
Db 20 AGACTTCAGCTCCAGCTCC 1

-RESULT 844
US-10-786-720-17100
; Sequence 17100, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; TITLE OF INVENTION: DISEASES
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
```



```

; Patent No. US20020150891A1
; GENERAL INFORMATION:
; APPLICANT: Hood, Leroy E.
; APPLICANT: Rowen, Lee
; APPLICANT: Koop, Ben F.
; TITLE OF INVENTION: DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS AND METHODS WHICH UTI
; NUMBER OF SEQUENCES: 1279
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Seed and Berry LLP
; STREET: 6300 Columbia Center, 701 Fifth Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: US
; ZIP: 98104-7092
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/263,959
; FILING DATE: 05-MAR-1999
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: McMasters, David D.
; REGISTRATION NUMBER: 33,963
; REFERENCE/DOCKET NUMBER: 920010.426C2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 682-6031
; INFORMATION FOR SEQ ID NO: 543:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-263-959-543

Query Match 0.4%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred.No. 5.1e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2823 TATATATACATATAT 2837
DB 15 TATATATACATATAT 1
|||||
|||||

RESULT 855
US-09-263-959-545/c
; Sequence 545, Application US/09263959
; Patent No. US20020150891A1
; GENERAL INFORMATION:
; APPLICANT: Hood, Leroy E.
; APPLICANT: Rowen, Lee
; APPLICANT: Koop, Ben F.
; TITLE OF INVENTION: DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS AND METHODS WHICH UTI
; NUMBER OF SEQUENCES: 1279
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Seed and Berry LLP
; STREET: 6300 Columbia Center, 701 Fifth Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: US
; ZIP: 98104-7092
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/263,959
; FILING DATE: 05-MAR-1999
; CLASSIFICATION:

```

```

; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6070
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-6070

Query Match      0.4%; Score 15; DB 1; Length 16;
Best Local Similarity 53.3%; Pred. No. 5.5e+02;
Matches 8; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY 2319 GTGTGTGTGTGTGTG 2333
DB 1 GUGUGUGUGUGUGUG 15

RESULT 858
US-10-287-949A-6070
; Sequence 6070, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6070
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-6070

Query Match      0.4%; Score 15; DB 1; Length 16;
Best Local Similarity 53.3%; Pred. No. 5.5e+02;
Matches 8; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY 2319 GTGTGTGTGTGTGTG 2333
DB 1 GUGUGUGUGUGUGUG 15

RESULT 859
US-10-238-700-3390/c
; Sequence 3390, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
; FILE REFERENCE: 400/057 (MBH01-1158-A)
; CURRENT APPLICATION NUMBER: US/10/238,700
; CURRENT FILING DATE: 2002-09-18
; PRIOR APPLICATION NUMBER: PCT/US 02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/318,471
; PRIOR FILING DATE: 2001-09-10
; NUMBER OF SEQ ID NOS: 4666
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3390
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-238-700-3390

```

```

Query Match      0.4%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 5.9e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1197 GGGCAAGCCCTTGG 1211
DB 16 GGGCAAGCCCTTGG 2

RESULT 860
US-10-138-674-8256
; Sequence 8256, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 8256
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-8256

Query Match      0.4%; Score 15; DB 1; Length 17;
Best Local Similarity 53.3%; Pred. No. 5.9e+02;
Matches 8; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY 2317 CTGTGTGTGTGTGTG 2331
DB 3 CUGUGUGUGUGUGUG 17

RESULT 861
US-10-287-949A-8256
; Sequence 8256, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 8256
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-8256

Query Match      0.4%; Score 15; DB 1; Length 17;
Best Local Similarity 53.3%; Pred. No. 5.9e+02;
Matches 8; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY 2317 CTGTGTGTGTGTGTG 2331
DB 3 CUGUGUGUGUGUGUG 17

```

```
RESULT 862
US-10-464-158-21/c
; Sequence 21, Application US/10464158
; Publication No. US20040009599A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF CELLULAR INHIBITOR OF APOPTOSIS-1 EXPRES
; FILE REFERENCE: ISPH-0749
; CURRENT APPLICATION NUMBER: US/10/464,158
; CURRENT FILING DATE: 2003-06-18
; PRIOR FILING DATE: 2001-09-24
; PRIOR APPLICATION NUMBER: PCT/US99/13624
; PRIOR FILING DATE: 1999-06-16
; PRIOR APPLICATION NUMBER: 09/205,204
; PRIOR FILING DATE: 1998-12-03
; NUMBER OF SEQ ID NOS: 48
; SEQ ID NO 21
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-464-158-21

Query Match      0.4%; Score 15; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 6.3e+02; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 0;

Qy 1606 CAGAAGTGCATCCAC 1620
Db 17 CAGAAGTGCATCCAC 3

RESULT 863
US-10-016-490C-25/c
; Sequence 25, Application US/10016490C
; Publication No. US20040072769A1
; GENERAL INFORMATION:
; APPLICANT: Yin, James Q.
; TITLE OF INVENTION: Methods for design and selection of short double-stranded
; TITLE OF INVENTION: oligonucleotides, and compounds of gene drugs
; FILE REFERENCE: 01-2793
; CURRENT APPLICATION NUMBER: US/10/016,490C
; CURRENT FILING DATE: 2002-11-22
; NUMBER OF SEQ ID NOS: 51
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 25
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: The same as those in human.
US-10-016-490C-25

Query Match      0.4%; Score 15; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.6e+02; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 0;

Qy 2990 TTTCTGGCACCACCGAG 3004
Db 19 TTTCTGGCACCACCGAG 5

RESULT 864
US-10-055-728-45
; Sequence 45, Application US/10055728
; Publication No. US20030170720A1
; GENERAL INFORMATION:
; APPLICANT: van der Kuyt, Antoinette C.
; APPLICANT: Cornelissen, Marion
```

```
; TITLE OF INVENTION: MEANS AND METHODS FOR TREATMENT EVALUATION
; FILE REFERENCE: 5244US (REN/P55190US00)
; CURRENT APPLICATION NUMBER: US/10/055,728
; CURRENT FILING DATE: 2002-04-19
; PRIOR APPLICATION NUMBER: 60/325,722
; PRIOR FILING DATE: 2001-09-28
; PRIOR APPLICATION NUMBER: EP 0120373.2
; PRIOR FILING DATE: 2001-09-28
; PRIOR APPLICATION NUMBER: EP 01200228.3
; PRIOR FILING DATE: 2001-01-23
; NUMBER OF SEQ ID NOS: 156
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 45
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: TAG019
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (1)..(5)
; OTHER INFORMATION: a stands for inosine
US-10-055-728-45

Query Match      0.4%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 7e+02; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 0;

Qy 3704 CATGGTGGCCAGAGG 3718
Db 6 CATGGTGGCCAGAGG 20

RESULT 865
US-10-310-677-45
; Sequence 45, Application US/10310677
; Publication No. US20030219772A1
; GENERAL INFORMATION:
; APPLICANT: Kuyt v.d., Antoinette C.
; TITLE OF INVENTION: Means and methods for treatment evaluation
; FILE REFERENCE: P55190US10
; CURRENT APPLICATION NUMBER: US/10/310,677
; CURRENT FILING DATE: 2002-12-05
; PRIOR APPLICATION NUMBER: EP 01200228.3
; PRIOR FILING DATE: 2001-01-23
; PRIOR APPLICATION NUMBER: EP 01203703.2
; PRIOR FILING DATE: 2001-09-28
; PRIOR APPLICATION NUMBER: US 60/325,722
; PRIOR FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 165
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 45
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: TAG019
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (1)..(5)
; OTHER INFORMATION: /note="A stands for inosine"
US-10-310-677-45

Query Match      0.4%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 7e+02; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 0;

Qy 3704 CATGGTGGCCAGAGG 3718
Db 6 CATGGTGGCCAGAGG 20
```

RESULT 866
US-10-380-124-47
; Sequence 47, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Preier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RFS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 47
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-47

Query Match 0.4%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 7e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 382 GGCAATCAAGCTCGCG 396
Db 2 GGCAATCAAGCTCGCG 16

RESULT 867
US-10-274-300-55
; Sequence 55, Application US/10274300
; Publication No. US20040076960A1
; GENERAL INFORMATION:
; APPLICANT: Taylor, Kent D.
; APPLICANT: Rotter, Jerome I.
; APPLICANT: Yang, Huiying
; APPLICANT: Sugimura, Kazuhito
; APPLICANT: Targan, Stephen
; TITLE OF INVENTION: Methods of Using a NOD2/CARD 15
; FILE REFERENCE: P-CE 5451
; CURRENT APPLICATION NUMBER: US/10/274,300
; CURRENT FILING DATE: 2002-10-18
; NUMBER OF SEQ ID NOS: 89
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 55
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-274-300-55

Query Match 0.4%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 7e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1874 TGGAGGAGCTCTTCA 1888
Db 2 TGGAGGAGCTCTTCA 16

RESULT 868
US-10-671-395-1491/c
; Sequence 1491, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395

; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1491
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1491

Query Match 0.4%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 7e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 2318 TGTGTGTGTGTGT 2332
Db 20 TGTGTGTGTGTGT 6

RESULT 869
US-09-971-353-31
; Sequence 31, Application US/09971353
; Publication No. US20030113723A1
; GENERAL INFORMATION:
; APPLICANT: Bapat, Bharati
; APPLICANT: Rose, Melanie Anne
; TITLE OF INVENTION: METHOD FOR EVALUATING MICROSATELLITE INSTABILITY IN A TUMOR SAMPLE
; FILE REFERENCE: 11757.54USUI
; CURRENT APPLICATION NUMBER: US/09/971,353
; CURRENT FILING DATE: 2001-10-04
; PRIOR APPLICATION NUMBER: US 60/237,884
; PRIOR FILING DATE: 2000-10-04
; NUMBER OF SEQ ID NOS: 35
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 31
; LENGTH: 38
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-971-353-31

Query Match 0.4%; Score 15; DB 1; Length 38;
Best Local Similarity 78.3%; Pred. No. 1.2e+03;
Matches 18; Conservative 0; Mismatches 5; Indels 0; Gaps 0;
Qy 3264 TTTATTGTCTTGTCTTTTC 3286
Db 13 TTTTCTTTTCTTTCTTTTC 35

RESULT 870
US-10-219-195-37
; Sequence 37, Application US/10219195
; Publication No. US20030165917A1
; GENERAL INFORMATION:
; APPLICANT: ULLMAN, EDWIN
; APPLICANT: WU, MING
; APPLICANT: LIU, YEN PING
; TITLE OF INVENTION: ISOTHERMAL AMPLIFICATION IN NUCLEIC ACID ANALYSIS
; FILE REFERENCE: 3817.05-1
; CURRENT APPLICATION NUMBER: US/10/219,195
; CURRENT FILING DATE: 2002-08-14
; PRIOR APPLICATION NUMBER: 60/312,505
; PRIOR FILING DATE: 2001-08-14
; NUMBER OF SEQ ID NOS: 49
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 37
; LENGTH: 39
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:

Query Match 0.48; Score 15; DB 1; Length 42;

```

RESULT 874
US-09-943-944E-119
; Sequence 119, Application US/09943944E
; Publication No. US20040014036A1
; GENERAL INFORMATION:
; APPLICANT: Prashne, et al.,
; TITLE OF INVENTION: Transcriptional Activation System, Activators, and Uses
; FILE REFERENCE: 0342941-0065
; CURRENT APPLICATION NUMBER: US/09/943,944E
; CURRENT FILING DATE: 2001-08-31
; NUMBER OF SEQ ID NOS: 238
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 119
; LENGTH: 18

```

```

; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
;
; OTHER INFORMATION: Description of Artificial Sequence:Random
; OTHER INFORMATION: nucleotide sequences.
US-09-943-944E-119

```

```

Query Match      0.48;   Score 14.8; DB 1; Length 18;
Best Local Similarity 89.9%; Pred. No. 6.7e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      2698  CTTCCCAACCTGCCCTC 2715
                |||||
Db      1  CTGCCACCATGCCCTC 18

```

```

RESULT 875
US-10-327-805-42
; Sequence 42, Application US/10327805
; Publication No. US20030144241A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Lex M. Cowsett
; TITLE OF INVENTION: ANTISENSE MODULATION OF SMAD6 EXPRESSION
; FILE REFERENCE: RIS-0045
; CURRENT APPLICATION NUMBER: US/10/327,805
; CURRENT FILING DATE: 2002-12-20
; PRIOR APPLICATION NUMBER: US/09/679,298
; PRIOR FILING DATE: 2001-03-05
; NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 42
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-327-805-42

```

	Query Match	0.4%	Score 14.9;	DB 1;	Length 18;
	Best Local Similarity	88.9%;	Pred.No. 6.7e+00;		
	Matches 16;	Conservative 0;	Mismatches 2;	Indels 0;	Gaps 0;
Qy	168	GGGAGATGCACGAACGG	185		
Db	1	GGCGTTTGACGAAGATGG	18		

```

RESULT 876
US/10-461-790-129/c
; Sequence 129, Application US/10461790
; Publication No. US20040029111A1
; GENERAL INFORMATION:
; APPLICANT: Linnen, Jeffery M.
; APPLICANT: Kolk, Daniel P.
; APPLICANT: Dockter, Janet M.
; APPLICANT: Getman, Damon K.
; APPLICANT: Yoshimura, Tadaashi
; APPLICANT: Ho-Sing-Loy, Marcy
; APPLICANT: Stringfellow, Leslie A.
; TITLE OF INVENTION: Compositions and Methods
; TITLE OF INVENTION: Hepatitis B Virus
; FILE REFERENCE: GPL34-02.UT
; CURRENT APPLICATION NUMBER: US/10/461,790
; CURRENT FILING DATE: 2003-06-13
; PRIOR APPLICATION NUMBER: 60/389,393
; PRIOR FILING DATE: 2002-06-14
; NUMBER OF SEQ ID NOS: 142
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 129
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Hepatitis B Virus
; FEATURE:

```

```

; NAME/KEY: misc_feature
; LOCATION: (1)...(18)
; OTHER INFORMATION: 2'-OME nucleotide analogs
US-10-461-790-129

```

Query Match	0.4%	Score 14.8	DB 1	Length 18
Best Local Similarity	88.9%	Pred. No. 6.7e+02		
Matches 16	Conservative 0	Mismatches 2	Indels	
Qy	925	TTCCCTGTTTCATCCTGGTG	942	
Db	18	TTCCCTTTTCATCCTGCTG	1	

```

RESULT 877
US-10-138-674-1449
; Sequence 1449, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and reagent for
; TITLE OF INVENTION: Levels of Vascular E
; FILE REFERENCE: MHHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1449
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-1449

```

```

Query Match      0.4%;   Score 14.8; DB 1; Length 18;
Best Local Similarity 66.7%;   Pred. NO. 6.7e+02;
Matches 12; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 1391 TCAACCTGTGGGCGCT 1408
      :||||:|||||
Db 1 UUAACCGUCGGAGCCU 18

```

```

RESULT 878
US-10-138-674-3004
; Sequence 3004, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for
; TITLE OF INVENTION: Levels of Vascular E
; FILE REFERENCE: MHHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3004
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-138-674-3004

```

Query Match 0.4%; Score 14.8; DB 1; Length 18;
Best Local Similarity 72.2%; Pred. No. 6.7e+02;
Matches 13; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

; APPLICANT: Escobedo, Jaime
 ; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
 ; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
 ; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor

Qy 1678 GACTTCGGCTGGCCCGG 1695
 |||::||| :|||
 Db 1 GACUUCGCGUGGCCCGG 18

RESULT 879
 US-10-203-102A-12
 ; Sequence 12, Application US/10203102A
 ; Publication No. US20040086483A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Karlin, Nathan
 ; TITLE OF INVENTION: PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING RHEUMATOID
 ; TITLE OF INVENTION: ARTHRITIS
 ; FILE REFERENCE: 02/23710
 ; CURRENT APPLICATION NUMBER: US/10/203.102A
 ; CURRENT FILING DATE: 2003-03-17
 ; NUMBER OF SEQ ID NOS: 12
 ; SOFTWARE: PatentIn version 3.2
 ; SEQ ID NO 12
 ; LENGTH: 18
 ; TYPE: DNA
 ; ORGANISM: Artificial sequence
 ; FEATURE:
 ; OTHER INFORMATION: Single strand DNA oligonucleotide
 US-10-203-102A-12

Query Match 0.4%; Score 14.8; DB 1; Length 18;
 Best Local Similarity 88.9%; Pred. No. 6.7e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 550 CTGCGCGCAACCGACG 567
 |||::||| :|||
 Db 1 CTACCGCGCCAGCGACG 18

RESULT 880
 US-10-287-949A-1449
 ; Sequence 1449, Application US/10287949A
 ; Publication No. US20040102389A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: Pavco, Pam
 ; APPLICANT: McSwiggen, Jim
 ; APPLICANT: Stinchcomb, Dan
 ; APPLICANT: Escobedo, Jaime
 ; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
 ; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
 ; FILE REFERENCE: MEHB00-876-N (400/049)
 ; CURRENT APPLICATION NUMBER: US/10/287.949A
 ; CURRENT FILING DATE: 2003-04-11
 ; NUMBER OF SEQ ID NOS: 20822
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 1449
 ; LENGTH: 18
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-10-287-949A-1449

Query Match 0.4%; Score 14.8; DB 1; Length 18;
 Best Local Similarity 66.7%; Pred. No. 6.7e+02;
 Matches 12; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 1391 TCAACCTGCTGGCGGCGCT 1408
 :|||::||| :|||
 Db 1 UUAACCGUGGAGGAGCU 18

RESULT 881
 US-10-287-949A-3004
 ; Sequence 3004, Application US/10287949A
 ; Publication No. US20040102389A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: Pavco, Pam
 ; APPLICANT: McSwiggen, Jim
 ; APPLICANT: Stinchcomb, Dan
 ; APPLICANT: Escobedo, Jaime
 ; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
 ; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
 ; FILE REFERENCE: MEHB00-876-N (400/049)
 ; CURRENT APPLICATION NUMBER: US/10/287.949A
 ; CURRENT FILING DATE: 2003-04-11
 ; NUMBER OF SEQ ID NOS: 20822
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 3004
 ; LENGTH: 18
 ; TYPE: RNA
 ; ORGANISM: Mus musculus
 US-10-287-949A-3004

Query Match 0.4%; Score 14.8; DB 1; Length 18;
 Best Local Similarity 72.2%; Pred. No. 6.7e+02;
 Matches 13; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 1678 GACTTCGGCTGGCCCGG 1695
 |||::||| :|||
 Db 1 GACUUCGCGUGGCCCGG 18

RESULT 882
 US-08-983-605-118/c
 ; Sequence 118, Application US/08983605A
 ; Publication No. US20020066118A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Roger, Marion
 ; TITLE OF INVENTION: Microsatellite Markers for Plants of the Species
 ; TITLE OF INVENTION: Triticum Aestivum and Tribe Triticeae and the Use of
 ; TITLE OF INVENTION: Said Markers
 ; FILE REFERENCE: 2936.10400
 ; CURRENT APPLICATION NUMBER: US/08/983.605A
 ; CURRENT FILING DATE: 1998-05-01
 ; EARLIER APPLICATION NUMBER: DE 195 25 284.5
 ; EARLIER FILING DATE: 1995-06-28
 ; NUMBER OF SEQ ID NOS: 466
 ; SOFTWARE: PatentIn Ver. 2.0
 ; SEQ ID NO 118
 ; LENGTH: 19
 ; TYPE: DNA
 ; ORGANISM: Triticum aestivum
 US-08-983-605-118

Query Match 0.4%; Score 14.8; DB 1; Length 19;
 Best Local Similarity 88.9%; Pred. No. 7.1e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 404 AGTGGAGCCTGCTCATCG 421
 |||::||| :|||
 Db 18 AGTGGATGCTGGTCATCG 1

RESULT 883
 US-09-813-289-22/c
 ; Sequence 22, Application US/09813289
 ; Patent No. US20020061571A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Mahadevan, M.S.
 ; APPLICANT: Tiscornia, G
 ; TITLE OF INVENTION: No. US20020061571A1 isoform of myotonic dystrophy associated pr
 ; TITLE OF INVENTION: thereof
 ; FILE REFERENCE: 800.027US1
 ; CURRENT APPLICATION NUMBER: US/09/813,289
 ; CURRENT FILING DATE: 2001-03-20
 ; PRIOR APPLICATION NUMBER: US 60/190,590
 ; PRIOR FILING DATE: 2000-03-20
 ; NUMBER OF SEQ ID NOS: 22
 ; SOFTWARE: FastSeq for Windows Version 4.0

```

; SEQ ID NO 22
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: A mutated DMPK 3'UTR fragment.
US-09-813-289-22

Query Match          0.4%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 7.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3194 CCCCGAGCTGGAGGATC 3211
    ||||| ||||| |||||
Db 18 CCCGAGCTGCAGGATC 1

RESULT 884
US-09-901-484A-483
; Sequence 483, Application US/09901484A
; Patent No. US20020119460A1
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; APPLICANT: Bougueleret, Lydie
; TITLE OF INVENTION: Prostate Cancer Gene
; FILE REFERENCE: GEN-T111XC3D2
; CURRENT APPLICATION NUMBER: US/09/901,484A
; CURRENT FILING DATE: 2001-07-09
; PRIOR APPLICATION NUMBER: US 08/996,306
; PRIOR FILING DATE: 1997-12-22
; PRIOR APPLICATION NUMBER: US 60/099,658
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: US 09/218,207
; PRIOR FILING DATE: 1998-12-22
; PRIOR APPLICATION NUMBER: US 09/338,907
; PRIOR FILING DATE: 1999-06-23
; PRIOR APPLICATION NUMBER: US 09/853,526
; PRIOR FILING DATE: 2001-05-11
; NUMBER OF SEQ ID NOS: 578
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 483
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(19)
; OTHER INFORMATION: potential microsequencing oligo for 99-148-129.mis1
US-09-901-484A-483

Query Match          0.4%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 7.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3469 TATCTATATATATATTT 3486
    ||||| ||||| |||||
Db 1 TATCTATACAAATATTT 18

RESULT 885
US-09-901-484A-546
; Sequence 546, Application US/09901484A
; Patent No. US20020119460A1
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; APPLICANT: Bougueleret, Lydie
; TITLE OF INVENTION: Prostate Cancer Gene
; FILE REFERENCE: GEN-T111XC3D2
; CURRENT APPLICATION NUMBER: US/09/901,484A

```

```

; CURRENT FILING DATE: 2001-07-09
; PRIOR APPLICATION NUMBER: US 08/996,306
; PRIOR FILING DATE: 1997-12-22
; PRIOR APPLICATION NUMBER: US 60/099,658
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: US 09/218,207
; PRIOR FILING DATE: 1998-12-22
; PRIOR APPLICATION NUMBER: US 09/338,907
; PRIOR FILING DATE: 1999-06-23
; PRIOR APPLICATION NUMBER: US 09/853,526
; PRIOR FILING DATE: 2001-05-11
; NUMBER OF SEQ ID NOS: 578
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 546
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(19)
; OTHER INFORMATION: potential microsequencing oligo for 99-128-202.mis2
US-09-901-484A-546

Query Match          0.4%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 7.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2315 GTCGTGTGTGTGTGTGT 2332
    ||||| ||||| |||||
Db 1 GTAATGTGTGTGTGTGT 18

RESULT 886
US-09-853-526-483
; Sequence 483, Application US/09853526
; Patent No. US20020165345A1
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Ilya, Chumakov
; APPLICANT: Bougueleret, Lydie
; TITLE OF INVENTION: PROSTATE CANCER GENE
; FILE REFERENCE: GENSET.18CPCIP
; CURRENT APPLICATION NUMBER: US/09/853,526
; CURRENT FILING DATE: 2001-05-11
; PRIOR APPLICATION NUMBER: 09/338,907
; PRIOR FILING DATE: 1999-06-23
; PRIOR APPLICATION NUMBER: 08/996,306
; PRIOR FILING DATE: 1997-12-22
; PRIOR APPLICATION NUMBER: 60/099,658
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 09/218,207
; PRIOR FILING DATE: 1998-12-22
; NUMBER OF SEQ ID NOS: 578
; SOFTWARE: Patent.pm
; SEQ ID NO 483
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 1..19
; OTHER INFORMATION: potential microsequencing oligo for 99-148-129.mis1
US-09-853-526-483

Query Match          0.4%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 7.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3469 TATCTATATATATATTT 3486
    ||||| ||||| |||||
Db 1 TATCTATACAAATATTT 18

```

RESULT 887
 US-09-853-526-546
 ; Sequence 546, Application US/09853526
 ; Patent No. US20020165345A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Cohen, Daniel
 ; APPLICANT: Blumenfeld, Marta
 ; APPLICANT: Ilya, Chumakov
 ; APPLICANT: Bougueleret, Lydie
 ; TITLE OF INVENTION: PROSTATE CANCER GENE
 ; FILE REFERENCE: GENSET.18CPICP
 ; CURRENT APPLICATION NUMBER: US/09/853,526
 ; PRIOR FILING DATE: 2001-05-11
 ; PRIOR APPLICATION NUMBER: 09/338,907
 ; PRIOR FILING DATE: 1999-06-23
 ; PRIOR APPLICATION NUMBER: 08/996,306
 ; PRIOR FILING DATE: 1997-12-22
 ; PRIOR APPLICATION NUMBER: 60/099,658
 ; PRIOR FILING DATE: 1998-09-09
 ; PRIOR APPLICATION NUMBER: 09/218,207
 ; PRIOR FILING DATE: 1998-12-22
 ; NUMBER OF SEQ ID NOS: 578
 ; SOFTWARE: Patent.pm
 ; SEQ ID NO 546
 ; LENGTH: 19
 ; TYPE: DNA
 ; ORGANISM: Homo Sapiens
 ; FEATURE:
 ; NAME/KEY: misc_feature
 ; LOCATION: 1..19
 ; OTHER INFORMATION: potential microsequencing oligo for 99-128-202.mis2
 US-09-853-526-546

Query Match 0.4%; Score 14.8; DB 1; Length 19;
 Best Local Similarity 88.9%; Pred. No. 7.1e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2315 GTCTGTGTGTGTGTGTGT 2332
 Db 1 GTATGTATGTGTGTGTGT 18

RESULT 888
 US-09-766-450-48/c
 ; Sequence 48, Application US/09766450
 ; Publication No. US20030022166A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Collins, Colin
 ; APPLICANT: Volik, Stanislav
 ; APPLICANT: Gray, Joe W.
 ; APPLICANT: Albertson, Donna G.
 ; APPLICANT: Pinkel, Daniel
 ; APPLICANT: The Regents of the University of California
 ; TITLE OF INVENTION: Repeat-Free Probes for Molecular
 ; FILE REFERENCE: Cytogenetics
 ; CURRENT APPLICATION NUMBER: US/09/766,450
 ; CURRENT FILING DATE: 2001-01-19
 ; NUMBER OF SEQ ID NOS: 112
 ; SOFTWARE: FastSeq for Windows Version 3.0
 ; SEQ ID NO 48
 ; LENGTH: 19
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: primer 768.348.r1
 US-09-766-450-48

Query Match 0.4%; Score 14.8; DB 1; Length 19;
 Best Local Similarity 88.9%; Pred. No. 7.1e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2323 GTGTGTGTGTGTGTGTGT 2340
 Db 19 GTGTGTGTGTGTGTGTGT 2
 RESULT 889
 US-10-251-117-68
 ; Sequence 68, Application US/10251117
 ; Publication No. US20030170891A1
 ; GENERAL INFORMATION:
 ; APPLICANT: McSwiggen, James
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Epidermal Growth Factor R
 ; FILE REFERENCE: 900/042 (MBHB02-468-A)
 ; CURRENT APPLICATION NUMBER: US/10/251,117
 ; CURRENT FILING DATE: 2003-02-24
 ; PRIOR APPLICATION NUMBER: US 60/393,924
 ; PRIOR FILING DATE: 2002-07-03
 ; PRIOR APPLICATION NUMBER: US 10/163,552
 ; PRIOR FILING DATE: 2002-06-06
 ; PRIOR APPLICATION NUMBER: US 60/358,580
 ; PRIOR FILING DATE: 2002-02-20
 ; PRIOR APPLICATION NUMBER: US 09/916,466
 ; PRIOR FILING DATE: 2001-07-25
 ; PRIOR APPLICATION NUMBER: US 60/296,249
 ; PRIOR FILING DATE: 2001-06-06
 ; NUMBER OF SEQ ID NOS: 1213
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 68
 ; LENGTH: 19
 ; TYPE: RNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Description of Artificial Sequence: Target sequence/siNA sense r
 US-10-251-117-68

Query Match 0.4%; Score 14.8; DB 1; Length 19;
 Best Local Similarity 72.2%; Pred. No. 7.1e+02;
 Matches 13; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 1582 CGGGCGATGGAGTACTTG 1599
 Db 1 CUGGCGAUGGAGCACUUG 18

RESULT 890
 US-10-251-117-180
 ; Sequence 180, Application US/10251117
 ; Publication No. US20030170891A1
 ; GENERAL INFORMATION:
 ; APPLICANT: McSwiggen, James
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Epidermal Growth Factor R
 ; FILE REFERENCE: 900/042 (MBHB02-468-A)
 ; CURRENT APPLICATION NUMBER: US/10/251,117
 ; CURRENT FILING DATE: 2003-02-24
 ; PRIOR APPLICATION NUMBER: US 60/393,924
 ; PRIOR FILING DATE: 2002-07-03
 ; PRIOR APPLICATION NUMBER: US 10/163,552
 ; PRIOR FILING DATE: 2002-06-06
 ; PRIOR APPLICATION NUMBER: US 60/358,580
 ; PRIOR FILING DATE: 2002-02-20
 ; PRIOR APPLICATION NUMBER: US 09/916,466
 ; PRIOR FILING DATE: 2001-07-25
 ; PRIOR APPLICATION NUMBER: US 60/296,249
 ; PRIOR FILING DATE: 2001-06-06
 ; NUMBER OF SEQ ID NOS: 1213
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 180
 ; LENGTH: 19
 ; TYPE: RNA

```
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target sequence/siNA sense r
US-10-251-117-180

Query Match      0.4%; Score 14.8; DB 1; Length 19;
Best Local Similarity 72.2%; Pred. No. 7.1e+02;
Matches 13; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy      862 CTGGTGGAGGCTGACGAG 879
Db      1 CUGGUGAUGCUGGAGGAG 18

RESULT 891
US-10-251-117-317/c
; Sequence 317, Application US/10251117
; Publication No. US20030170891A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Epidermal Growth Factor R
; FILE REFERENCE: 900/042 (MBHB02-468-A)
; CURRENT APPLICATION NUMBER: US/10/251,117
; CURRENT FILING DATE: 2003-02-24
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/393,924
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 09/916,466
; PRIOR FILING DATE: 2001-07-25
; PRIOR APPLICATION NUMBER: US 60/296,249
; PRIOR FILING DATE: 2001-06-06
; NUMBER OF SEQ ID NOS: 1213
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 317
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-251-117-317

Query Match      0.4%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 7.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1582 CGGGGCATGGAGTACTTG 1599
Db      19 CTGGGCATGGAGCATTG 2

RESULT 892
US-10-251-117-429/c
; Sequence 429, Application US/10251117
; Publication No. US20030170891A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Epidermal Growth Factor R
; FILE REFERENCE: 900/042 (MBHB02-468-A)
; CURRENT APPLICATION NUMBER: US/10/251,117
; CURRENT FILING DATE: 2003-02-24
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/393,924
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 10/163,552
; PRIOR FILING DATE: 2002-02-20
```

```
; PRIOR APPLICATION NUMBER: US 09/916,466
; PRIOR FILING DATE: 2001-07-25
; PRIOR APPLICATION NUMBER: US 60/296,249
; PRIOR FILING DATE: 2001-06-06
; NUMBER OF SEQ ID NOS: 1213
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 429
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-251-117-429

Query Match      0.4%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 7.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      862 CTGGTGGAGGCTGACGAG 879
Db      19 CTGGTGGATCTGAGGAG 2

RESULT 893
US-10-244-647-515
; Sequence 515, Application US/10244647
; Publication No. US20030206887A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceutical, Inc.
; APPLICANT: Morrissey, David
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Hepatitis B Virus (HBV) U
; FILE REFERENCE: 400/060 (MBHB02-1000)
; CURRENT APPLICATION NUMBER: US/10/244,647
; CURRENT FILING DATE: 2003-04-14
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: PCT US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; NUMBER OF SEQ ID NOS: 1524
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 515
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target sequence/siNA sense r
US-10-244-647-515

Query Match      0.4%; Score 14.8; DB 1; Length 19;
Best Local Similarity 44.4%; Pred. No. 7.1e+02;
Matches 8; Conservative 8; Mismatches 2; Indels 0; Gaps 0;

Qy      925 TTCTGTTTCATCTCTGGTG 942
Db      1 UUCUCUUCUCCUGCUG 18

RESULT 894
US-10-244-647-1161/c
; Sequence 1161, Application US/10244647
; Publication No. US20030206887A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceutical, Inc.
; APPLICANT: Morrissey, David
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
```

```

; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Hepatitis B Virus (HBV)
; FILE REFERENCE: 400/060 (MBHB02-1000)
; CURRENT APPLICATION NUMBER: US/10/244,647
; PRIOR FILING DATE: 2003-04-14
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/393,924
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: PCT US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; NUMBER OF SEQ ID NOS: 1524
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1161
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-244-647-1161

Query Match 0.4%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 7.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 925 TTCCTGTTTCATCTCGTG 942
Db 19 TTCCTCTTCATCTCGTG 2

RESULT 895
US-10-477-726-133/c
; Sequence 133, Application US/10477726
; Publication No. US20040110231a1
; GENERAL INFORMATION:
; APPLICANT: Takeda Chemical Industries, Ltd.
; TITLE OF INVENTION: Screening method
; FILE REFERENCE: P02-0058PCT
; CURRENT APPLICATION NUMBER: US/10/477,726
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 2001-145411
; PRIOR FILING DATE: 2001-05-15
; NUMBER OF SEQ ID NOS: 135
; SEQ ID NO 133
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-10-477-726-133

Query Match 0.4%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 7.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1876 GAGGAGCTCTTCACGCTG 1893
Db 19 GACGAGCTCTTCACGCTG 2

RESULT 896
US-10-655-951-2244
; Sequence 2244, Application US/10665951
; Publication No. US20040138163a1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; FILE REFERENCE: 400/060 (MBHB02-1000)
; CURRENT APPLICATION NUMBER: US/10/665,951
; CURRENT FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/287,949
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: PCT/US 02/17674
; PRIOR FILING DATE: 2002-05-29

```

```

; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/131 (MBHB02-742-F)
; CURRENT APPLICATION NUMBER: US/10/665,951
; CURRENT FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/287,949
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: PCT/US 02/17674
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2455
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2244
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-665-951-2244

Query Match 0.4%; Score 14.8; DB 1; Length 19;
Best Local Similarity 72.2%; Pred. No. 7.1e+02;
Matches 13; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 1953 CATGGGGAGTGTGGCA 1970
Db 1 CAUGCUGACUGCUGGCA 18

RESULT 897
US-10-665-951-2265
; Sequence 2265, Application US/10665951
; Publication No. US20040138163a1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; FILE REFERENCE: 400/131 (MBHB02-742-F)
; CURRENT APPLICATION NUMBER: US/10/665,951
; CURRENT FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/287,949
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: PCT/US 02/17674
; PRIOR FILING DATE: 2002-05-29

```

```

; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2455
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2265
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-665-951-2265

Query Match      0.4%; Score 14.8; DB 1; Length 19;
Best Local Similarity 72.2%; Pred. No. 7.1e+02;
Matches 13; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy    1953 CATGCGGAGTGTGGCA 1970
      ||:|||||:||:|||
Db     2 CAUGCUGACUCCUGGCA 19

RESULT 898
US-09-801-968-5/c
; Sequence 5, Application US/09801968
; Patent No. US20020082205A1
; GENERAL INFORMATION:
; APPLICANT: Itoh, No. US20020082205Aluyuki
; APPLICANT: Kavanaugh, W. Michael
; TITLE OF INVENTION: HUMAN EGF-23 GENE AND GENE EXPRESSION
; TITLE OF INVENTION: PRODUCTS
; FILE REFERENCE: PP-17150.001/201130.40901
; CURRENT APPLICATION NUMBER: US/09/801,968
; CURRENT FILING DATE: 2001-03-07
; NUMBER OF SEQ ID NOS: 46
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 5
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Sense PCR primer
US-09-801-968-5

Query Match      0.4%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 7.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy    825 CTCGTGCTGCCTGTGTGT 842
      ||||| ||||| |||||
Db     18 CTCGTGCTGCCTGTGTGT 1

RESULT 899
US-09-454-394-33
; Sequence 33, Application US/09454394
; Patent No. US20020094525A1
; GENERAL INFORMATION:
; APPLICANT: Tina McIntosh
; APPLICANT: Steven Head
; APPLICANT: Philip Goelet
; APPLICANT: Michael T. Boyce-Jacino
; TITLE OF INVENTION: Methods for the Detection of Multiple
; TITLE OF INVENTION: Single Nucleotide Polymorphisms in a Single Reaction
; FILE REFERENCE: 04990.0029
; CURRENT APPLICATION NUMBER: US/09/454,394
; CURRENT FILING DATE: 1999-12-03
; EARLIER APPLICATION NUMBER: 08/216,538
; EARLIER FILING DATE: 1994-03-23

```

```

; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 35
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Equus caballus
US-09-454-394-35

Query Match      0.4%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 7.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2335 GTGTGTGTGTGTGTGC 2352
Db 19 GTGTGTGTGTGTATTGC 2

RESULT 902
US-09-454-394-36/c
; Sequence 36, Application US/09454394
; Patent No. US20020094525A1
; GENERAL INFORMATION:
; APPLICANT: Tina McIntosh
; APPLICANT: Steven Head
; APPLICANT: Philip Golet
; APPLICANT: Michael T. Boyce-Jacino
; TITLE OF INVENTION: Methods for the Detection of Multiple
; FILE REFERENCE: 04990.0029
; CURRENT APPLICATION NUMBER: US/09/454,394
; CURRENT FILING DATE: 1999-12-03
; EARLIER APPLICATION NUMBER: 08/216,538
; EARLIER FILING DATE: 1994-03-23
; EARLIER APPLICATION NUMBER: 08/145,145
; EARLIER FILING DATE: 1993-11-03
; NUMBER OF SEQ ID NOS: 72
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 36
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Equus caballus
US-09-454-394-36

Query Match      0.4%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 7.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2826 ATATCATATATATATAT 2843
Db 18 ATATCAATATATATATAT 1

RESULT 903
US-09-924-417-24
; Sequence 24, Application US/09924417
; Patent No. US20020142441A1
; GENERAL INFORMATION:
; APPLICANT: Palb, Dean
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR
; THE TREATMENT AND DIAGNOSIS OF CARDIOVASCULAR
; DISEASE
; NUMBER OF SEQUENCES: 67
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: PENNIE & EDMONDS LLP
; STREET: 1155 Avenue of the Americas
; CITY: New York
; STATE: NY
; COUNTRY: USA
; ZIP: 10036-2711
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq Version 2.0

```

```

; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/924,417
; FILING DATE: 07-Aug-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/034,286
; FILING DATE: 04-MAR-1998
; APPLICATION NUMBER: 08/870,434
; FILING DATE: 06-JUN-1997
; APPLICATION NUMBER: 08/799,910
; FILING DATE: 13-FEB-1997
; APPLICATION NUMBER: 60/011,787
; FILING DATE: 16-FEB-1996
; APPLICATION NUMBER: 08/599,654
; FILING DATE: 09-FEB-1996
; APPLICATION NUMBER: 08/485,573
; FILING DATE: 07-JUN-1995
; APPLICATION NUMBER: 08/386,844
; FILING DATE: 10-FEB-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Coruzzi, Laura A
; REGISTRATION NUMBER: 30,742
; REFERENCE/DOCKET NUMBER: 7853-114-999
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 7909090
; TELEFAX: (212) 8699741
; TELEX: 66141 PENNIE
; INFORMATION FOR SEQ ID NO: 24:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: Other
; SEQUENCE DESCRIPTION: SEQ ID NO: 24:
US-09-924-417-24

Query Match      0.4%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 7.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 168 GGGAGATGACGACGACG 185
Db 3 GGGAGTTGACGAGATGCG 20

RESULT 904
US-09-263-959-1214/c
; Sequence 1214, Application US/09263959
; Patent No. US20020150891A1
; GENERAL INFORMATION:
; APPLICANT: Hood, Leroy E.
; APPLICANT: Rowen, Lee
; APPLICANT: Koop, Ben F.
; TITLE OF INVENTION: DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS AND METHODS WHICH UTI
; NUMBER OF SEQUENCES: 1279
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Seed and Berry LLP
; STREET: 6300 Columbia Center, 701 Fifth Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: US
; ZIP: 98104-7092
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/263,959
; FILING DATE: 05-MAR-1999
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:

```

NAME: Mcmasters, David D.
 REGISTRATION NUMBER: 33,963
 REFERENCE/DOCKET NUMBER: 920010.426C2
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (206) 622-4900
 TELEFAX: (206) 682-6031
 INFORMATION FOR SEQ ID NO: 1214:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 20 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 US-09-263-959-1214

Query Match 0.4%; Score 14.8; DB 1; Length 20;
 Best Local Similarity 88.9%; Pred. No. 7.5e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3377 TTGCTGTGTCTCCAGGC 3394
 Db 18 TTGCTGTCTCCAGGC 1

RESULT 905
 US-09-774-809-31/c
 Sequence 31, Application US/09774809
 Publication No. US20030004120A1
 GENERAL INFORMATION:

APPLICANT: McKay, Robert A.
 APPLICANT: Dean, Nicholas M.
 APPLICANT: Monia, Brett
 APPLICANT: Nero, Pam
 APPLICANT: Gaarde, William A.
 TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS AND METHODS
 FILE REFERENCE: ISPH-0412
 CURRENT APPLICATION NUMBER: US/09/774,809
 PRIOR FILING DATE: 2001-01-31
 PRIOR FILING DATE: 1999-09-15
 PRIOR FILING DATE: 1998-08-07
 PRIOR FILING DATE: 1997-08-03
 NUMBER OF SEQ ID NOS: 165
 SEQ ID NO 31
 LENGTH: 20
 TYPE: DNA
 ORGANISM: Artificial Sequence
 FEATURE:
 OTHER INFORMATION: Synthetic Sequence
 US-09-774-809-31

Query Match 0.4%; Score 14.8; DB 1; Length 20;
 Best Local Similarity 88.9%; Pred. No. 7.5e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1678 GACTTCGGCTGCGCCGG 1695
 Db 20 GACTTGGCCTGCGCCGG 3

RESULT 906
 US-09-774-809-42
 Sequence 42, Application US/09774809
 Publication No. US20030004120A1
 GENERAL INFORMATION:

APPLICANT: McKay, Robert A.
 APPLICANT: Dean, Nicholas M.
 APPLICANT: Monia, Brett
 APPLICANT: Nero, Pam
 APPLICANT: Gaarde, William A.
 TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS AND METHODS

TITLE OF INVENTION: FOR THE MODULATION OF JNK PROTEINS
 FILE REFERENCE: ISPH-0412
 CURRENT APPLICATION NUMBER: US/09/774,809
 CURRENT FILING DATE: 2001-01-31
 PRIOR FILING DATE: 1999-09-15
 PRIOR FILING DATE: 1998-08-07
 PRIOR FILING DATE: 1997-08-03
 NUMBER OF SEQ ID NOS: 165
 SEQ ID NO 42
 LENGTH: 20
 TYPE: DNA
 ORGANISM: Artificial Sequence
 FEATURE:
 OTHER INFORMATION: Synthetic Sequence
 US-09-774-809-42

Query Match 0.4%; Score 14.8; DB 1; Length 20;
 Best Local Similarity 88.9%; Pred. No. 7.5e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1678 GACTTCGGCTGCGCCGG 1695
 Db 1 GACTTGGCCTGCGCCGG 18

RESULT 907
 US-09-996-263-11/c
 Sequence 11, Application US/09996263
 Publication No. US20030004325A1
 GENERAL INFORMATION:
 APPLICANT: Phillip Dan Cook
 APPLICANT: Andrew Kawasaki
 TITLE OF INVENTION: Sugar Modified Oligonucleotides
 NUMBER OF SEQUENCES: 37
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz and No. US20030004325A1
 STREET: One Liberty Place - 46th Floor
 CITY: Philadelphia
 STATE: PA
 COUNTRY: U.S.A.
 ZIP: 19103
 COMPUTER READABLE FORM:
 MEDIUM TYPE: 3.5 inch disk, 720 Kb
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: Wordperfect 5.1
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/09/996,263
 FILING DATE: 28-No. US20030004325A1-2001
 CLASSIFICATION: <Unknown>
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: 08/471,973
 FILING DATE: <Unknown>
 ATTORNEY/AGENT INFORMATION:
 NAME: Joseph Lucci
 REGISTRATION NUMBER: 33,307
 REFERENCE/DOCKET NUMBER: ISIS-2005
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: 215-568-3100
 TELEFAX: 215-568-3439
 INFORMATION FOR SEQ ID NO: 11:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 20 bases
 TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 ANTI-SENSE: Yes
 SEQUENCE DESCRIPTION: SEQ ID NO: 11:
 US-09-996-263-11

Query Match 0.4%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 7.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 844 CTGCCAGCGGAGGAGG 861
Db 20 CTGCCAGCGGAGGAGG 3

RESULT 908

US-09-888-326-463/c
; Sequence 463, Application US/09888326
; Publication No. US20030026801A1
; GENERAL INFORMATION:
; APPLICANT: Weiner, George
; TITLE OF INVENTION: Methods for Enhancing Antibody-Induced
; TITLE OF INVENTION: Cell Lysis and Treating Cancer
; FILE REFERENCE: C1039/7052 (AWS)
; CURRENT APPLICATION NUMBER: US/09/888,326
; CURRENT FILING DATE: 2001-06-22
; PRIOR APPLICATION NUMBER: US 60/213,346
; PRIOR FILING DATE: 2000-06-22
; NUMBER OF SEQ ID NOS: 848
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 463
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide
; NAME/KEY: misc.feature
; LOCATION: (0)...(0)
; OTHER INFORMATION: phosphorothioate backbone
US-09-888-326-463

Query Match 0.4%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 7.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1678 GACTTCGGCTGGCCCGG 1695
Db 20 GACTTCGGCTGGCCCGG 3

RESULT 909

US-09-860-836B-36
; Sequence 36, Application US/09860836B
; Publication No. US20030054002A1
; GENERAL INFORMATION:
; APPLICANT: WAKELAND, WARD
; APPLICANT: WANDSTRADT, AMY
; APPLICANT: MOREL, LAURENCE
; TITLE OF INVENTION: ISOLATION OF GENES WITHIN SLE-1B THAT MEDIATE A BREAK
; TITLE OF INVENTION: IN IMMUNE TOLERANCE
; FILE REFERENCE: UTSD:722US
; CURRENT APPLICATION NUMBER: US/09/860,836B
; CURRENT FILING DATE: 2002-08-13
; PRIOR APPLICATION NUMBER: 60/204,963
; PRIOR FILING DATE: 2000-09-21
; NUMBER OF SEQ ID NOS: 37
; SOFTWARE: Patent In Ver. 2.1
; SEQ ID NO 36
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapien
US-09-860-836B-36

Query Match 0.4%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 7.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2325 GTGTGTGTGTGTGTGT 2342

Db 3 GGGTGTGTGTGTGTGT 20

RESULT 910

US-09-776-479-311/c
; Sequence 311, Application US/09776479
; Publication No. US20030087848A1
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; APPLICANT: Fouron, Yves
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
; TITLE OF INVENTION: Treatment of Asthma and Allergy
; FILE REFERENCE: C1037/7013 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/09/776,479
; CURRENT FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: US 60/179,991
; PRIOR FILING DATE: 2000-02-03
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 311
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-09-776-479-311

Query Match 0.4%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 7.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1678 GACTTCGGCTGGCCCGG 1695
Db 20 GACTTCGGCTGGCCCGG 3

RESULT 911

US-09-776-479-311/c
; Sequence 311, Application US/09776479
; Publication No. US20040067902A9
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; APPLICANT: Fouron, Yves
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
; TITLE OF INVENTION: Treatment of Asthma and Allergy
; FILE REFERENCE: C1037/7013 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/09/776,479
; CURRENT FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: US 60/179,991
; PRIOR FILING DATE: 2000-02-03
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 311
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-09-776-479-311

Query Match 0.4%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 7.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1678 GACTTCGGCTGGCCCGG 1695
Db 20 GACTTCGGCTGGCCCGG 3

RESULT 912

```

US-09-915-814-132/c
; Sequence 132, Application US/09915814
; Publication No. US20030096771A1
; GENERAL INFORMATION:
; APPLICANT: Madeline M. Butler
; APPLICANT: Andrew T. Watt
; APPLICANT: Susan M. Freier
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF HORMONE-SENSITIVE LIPASE EXPRESSION
; FILE REFERENCE: ISPH-0587
; CURRENT APPLICATION NUMBER: US/09/915,814
; CURRENT FILING DATE: 2001-07-26
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 132
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-915-814-132

Query Match      0.4%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 7.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2705 CCCTGCCCTCCAGACT 2722
Db      19 CCCTGCTCTCCGAGCT 2

RESULT 913
US-09-953-318-97
; Sequence 97, Application US/09953318
; Publication No. US20030105036A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR EXPRESSION
; FILE REFERENCE: RFS-0232
; CURRENT APPLICATION NUMBER: US/09/953,318
; CURRENT FILING DATE: 2001-09-13
; NUMBER OF SEQ ID NOS: 154
; SEQ ID NO 97
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-953-318-97

Query Match      0.4%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 7.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1352 TGGGATGATGAAGATGA 1369
Db      1 TGGTATGATGACGATGA 18

RESULT 914
US-09-802-154-5/c
; Sequence 5, Application US/09802154
; Publication No. US20030105302A1
; GENERAL INFORMATION:
; APPLICANT: Itoh, No. US20030105302A1uyuki
; APPLICANT: Kavanaugh, W. Michael
; TITLE OF INVENTION: HUMAN FGF-23 GENE AND GENE EXPRESSION
; FILE REFERENCE: PP-17149.001/201130.409
; CURRENT APPLICATION NUMBER: US/09/802,154
; CURRENT FILING DATE: 2001-03-07
; NUMBER OF SEQ ID NOS: 46

```

```

; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 5
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Sense PCR primer
US-09-802-154-5

Query Match      0.4%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 7.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      825 CTCTGGTGGCTGGTGT 842
Db      18 CTCTGAGTGGCTGGTGT 1

RESULT 915
US-09-846-863-33
; Sequence 33, Application US/09846863
; Publication No. US20030170624A1
; GENERAL INFORMATION:
; APPLICANT: GOELET, PHILIP
; APPLICANT: KNAPP, MICHAEL R.
; TITLE OF INVENTION: SINGLE NUCLEOTIDE POLYMORPHISMS AND THEIR USE IN GENETIC ANALYSIS
; NUMBER OF SEQUENCES: 95
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: HOWREY & SIMON
; STREET: 1299 PENNSYLVANIA AVENUE, N.W.
; CITY: WASHINGTON
; STATE: D.C.
; COUNTRY: US
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/846,863
; FILING DATE: 01-May-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/216,538
; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: AUERBACH, JEFFREY I
; REGISTRATION NUMBER: 32,680
; REFERENCE/DOCKET NUMBER: 683-104-CIP
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 383-7451
; TELEFAX: (202) 383-6610
; INFORMATION FOR SEQ ID NO: 33:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Equus caballus
; IMMEDIATE SOURCE:
; CLONE: 595-1
; SEQUENCE DESCRIPTION: SEQ ID NO: 33:
US-09-846-863-33

Query Match      0.4%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 7.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

Qy 2826 ATATACATATATATATAT 2843
Db 3 ATATCAATATATATAT 20

RESULT 916
US-09-846-863-34
; Sequence 34, Application US/09846863
; Publication No. US20030170624A1
; GENERAL INFORMATION:
; APPLICANT: GOELET, PHILIP
; TITLE OF INVENTION: SINGLE NUCLEOTIDE POLYMORPHISMS AND
; THEIR USE IN GENETIC ANALYSIS
; NUMBER OF SEQUENCES: 95
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: HOWREY & SIMON
; STREET: 1299 PENNSYLVANIA AVENUE, N.W.
; CITY: WASHINGTON
; STATE: D.C.
; COUNTRY: US
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/846,863
; FILING DATE: 01-May-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/216,538
; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: AUERBACH, JEFFREY I
; REGISTRATION NUMBER: 32,680
; REFERENCE/DOCKET NUMBER: 683-104-CIP
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 383-7451
; TELEFAX: (202) 383-6610
; INFORMATION FOR SEQ ID NO: 34:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Equus caballus
; IMMEDIATE SOURCE:
; CLONE: 595-1
; SEQUENCE DESCRIPTION: SEQ ID NO: 34:
US-09-846-863-34
Query Match 0.4%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 7.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2335 GTGTGTGTGTGTGTGC 2352
Db 2 GTGTGTGTGTGTATTC 19

RESULT 917
US-09-846-863-35/c
; Sequence 35, Application US/09846863
; Publication No. US20030170624A1
; GENERAL INFORMATION:
; APPLICANT: GOELET, PHILIP
; TITLE OF INVENTION: SINGLE NUCLEOTIDE POLYMORPHISMS AND
; THEIR USE IN GENETIC ANALYSIS
; NUMBER OF SEQUENCES: 95
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: HOWREY & SIMON
; STREET: 1299 PENNSYLVANIA AVENUE, N.W.
; CITY: WASHINGTON
; STATE: D.C.
; COUNTRY: US
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/846,863
; FILING DATE: 01-May-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/216,538
; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: AUERBACH, JEFFREY I
; REGISTRATION NUMBER: 32,680
; REFERENCE/DOCKET NUMBER: 683-104-CIP
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 383-7451
; TELEFAX: (202) 383-6610
; INFORMATION FOR SEQ ID NO: 35:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Equus caballus
; IMMEDIATE SOURCE:
; CLONE: 595-1
; SEQUENCE DESCRIPTION: SEQ ID NO: 35:
US-09-846-863-35
Query Match 0.4%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 7.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2335 GTGTGTGTGTGTGTGC 2352
Db 19 GTGTGTGTGTGTATTC 2

RESULT 918
US-09-846-863-36/c
; Sequence 36, Application US/09846863
; Publication No. US20030170624A1
; GENERAL INFORMATION:
; APPLICANT: GOELET, PHILIP
; KNAPP, MICHAEL R.
; TITLE OF INVENTION: SINGLE NUCLEOTIDE POLYMORPHISMS AND
; THEIR USE IN GENETIC ANALYSIS
; NUMBER OF SEQUENCES: 95
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: HOWREY & SIMON
; STREET: 1299 PENNSYLVANIA AVENUE, N.W.
; CITY: WASHINGTON
; STATE: D.C.
; COUNTRY: US
; ZIP: 20004
; COMPUTER READABLE FORM:

```

MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/846,863
FILING DATE: 01-May-2001
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/216,538
FILING DATE: <Unknown>
ATTORNEY/AGENT INFORMATION:
NAME: AUERBACH, JEFFREY I
REGISTRATION NUMBER: 32,680
REFERENCE/DOCKET NUMBER: 683-104-CIP
TELECOMMUNICATION INFORMATION:
TELEPHONE: (202) 383-7451
TELEFAX: (202) 383-6610
INFORMATION FOR SEQ ID NO: 36:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ANTI-SENSE: NO
ORIGINAL SOURCE:
ORGANISM: Equus caballus
IMMEDIATE SOURCE:
CLONE: 595-1
SEQUENCE DESCRIPTION: SEQ ID NO: 36:
US-09-846-863-36

Query Match 0.4%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 7.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2826 ATATACATATATATATAT 2843
Db 18 ATATCATATATATATAT 1

RESULT 919
US-10-004-551-101
Sequence 101, Application US/10004551
Publication No. US20030004310A1
GENERAL INFORMATION:
APPLICANT: SHIMKETS, RICHARD A
APPLICANT: FERNANDES, ELMA
TITLE OF INVENTION: POLYNUCLEOTIDES AND POLYPEPTIDES ENCODED THEREBY
FILE REFERENCE: 15966-559
CURRENT APPLICATION NUMBER: US/10/004,551
CURRENT FILING DATE: 2001-12-05
PRIOR APPLICATION NUMBER: 09/635,949
PRIOR FILING DATE: 2000-08-10
NUMBER OF SEQ ID NOS: 110
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 101
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: PCR PRIMER
US-10-004-551-101

Query Match 0.4%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 7.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1495 GGCCTGGACTACTCTTC 1512
Db 3 GGCCTGGACTCTTC 20

RESULT 920
US-10-057-550-27/c
Sequence 27, Application US/10057550
Publication No. US20030032607A1
GENERAL INFORMATION:
APPLICANT: Monia, Brett P.
TITLE OF INVENTION: Antisense Oligonucleotide Modulation of raf Gene Expression
FILE REFERENCE:
CURRENT APPLICATION NUMBER: US/10/057,550
CURRENT FILING DATE: 2002-01-25
PRIOR APPLICATION NUMBER: 09/506,073
PRIOR FILING DATE: 2000-02-18
PRIOR APPLICATION NUMBER: US 09/143,214
PRIOR FILING DATE: 1998-08-28
PRIOR APPLICATION NUMBER: PCT/US98/13961
PRIOR FILING DATE: 1998-07-06
PRIOR APPLICATION NUMBER: US 08/888,982
PRIOR FILING DATE: 1997-07-07
PRIOR APPLICATION NUMBER: US 08/756,806
PRIOR FILING DATE: 1996-11-26
PRIOR APPLICATION NUMBER: PCT/US95/07111
PRIOR FILING DATE: 1995-05-31
PRIOR APPLICATION NUMBER: US 08/250,856
PRIOR FILING DATE: 1994-05-31
NUMBER OF SEQ ID NOS: 130
SEQ ID NO 27
LENGTH: 20
TYPE: DNA
ORGANISM: artificial sequence
FEATURE:
OTHER INFORMATION: antisense sequence
US-10-057-550-27

Query Match 0.4%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 7.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 844 CTGCCAGCGGAGGAGGAG 861
Db 20 CTGCCAGCGGAGGAGGAG 3

RESULT 921
US-10-112-653-301/c
Sequence 301, Application US/10112653
Publication No. US20030050288A1
GENERAL INFORMATION:
APPLICANT: Krieg, Daniel J.
APPLICANT: Berg, Arthur M.
TITLE OF INVENTION: IMMUNOSTIMULATORY NUCLEIC ACID FOR
TREATMENT OF NON-ALLERGIC INFLAMMATORY DISEASES
FILE REFERENCE: C01039/70060(AWS)
CURRENT APPLICATION NUMBER: US/10/112,653
CURRENT FILING DATE: 2002-03-29
PRIOR APPLICATION NUMBER: US 60/279,642
PRIOR FILING DATE: 2001-03-29
NUMBER OF SEQ ID NOS: 1040
SOFTWARE: FastSEQ for Windows Version 3.0
SEQ ID NO 301
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic Oligonucleotide
US-10-112-653-301

Query Match 0.4%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 7.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1678 GACTTCGGCTGCCCGG 1695

```
Db      20 GACTTGGCCTGGCCCGG 3
||||| || |||||
; TITLE OF INVENTION: ANTISENSE MODULATION OF DAXX EXPRESSION
; FILE REFERENCE: RISP-0363
; CURRENT APPLICATION NUMBER: US/10/181.846
; CURRENT FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: PCT/US01/01416
; PRIOR FILING DATE: 2001-01-16
; PRIOR APPLICATION NUMBER: 09/490,692
; PRIOR FILING DATE: 2000-01-24
; NUMBER OF SEQ ID NOS: 176
; SEQ ID NO 32
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-181-846-32

Query Match      0.4%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 7.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1169 GGGAGCTGCTCTCGGGCCC 1186
||||| |||||
Db      18 GGGTCTGTCTCGGGCCC 1

RESULT 925
US-10-238-042-20
; Sequence 20, Application US/10238042
; Publication No. US20030115618A1
; GENERAL INFORMATION:
; APPLICANT: Murray, James D.
; APPLICANT: Maga, Elizabeth A.
; APPLICANT: Anderson, Gary B.
; APPLICANT: Oppenheim, Stefanie M.
; TITLE OF INVENTION: METHOD OF GENERATING A TRANSGENIC
; FILE REFERENCE: UCAL-245
; CURRENT APPLICATION NUMBER: US/10/238.042
; CURRENT FILING DATE: 2002-09-06
; PRIOR APPLICATION NUMBER: 60/317,925
; PRIOR FILING DATE: 2001-09-07
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 20
; LENGTH: 20
; TYPE: DNA
; ORGANISM: goat
US-10-238-042-20

Query Match      0.4%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 7.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      386 TCAAGCTGGCGCATCAGC 403
||||| |||||
Db      2 TCAAGCTACAGCATCAGC 19

RESULT 926
US-10-173-225B-26/c
; Sequence 26, Application US/10173225B
; Publication No. US20030119769A1
; GENERAL INFORMATION:
; APPLICANT: Monia, Brett P.
; TITLE OF INVENTION: Antisense Oligonucleotide Modulation of raf Gene Expression
; FILE REFERENCE: ISPH-0665
; CURRENT APPLICATION NUMBER: US/10/173.225B
; CURRENT FILING DATE: 2002-12-06
; PRIOR APPLICATION NUMBER: US 10/057,550
; PRIOR FILING DATE: 2002-01-25
; PRIOR APPLICATION NUMBER: US 09/143,214
; PRIOR FILING DATE: 1998-08-28

Db      20 GACTTGGCCTGGCCCGG 3
||||| || |||||
; TITLE OF INVENTION: Inhibition of Angiogenesis by Nucleic Acids
; FILE REFERENCE: C1037/7025 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/10/017,995
; CURRENT FILING DATE: 2001-12-18
; PRIOR APPLICATION NUMBER: US 60/255,534
; PRIOR FILING DATE: 2000-12-14
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 311
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-10-017-995-311

Query Match      0.4%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 7.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1678 GACTTCGGGCTGGCCCGG 1695
||||| |||||
Db      20 GACTTGGCCTGGCCCGG 3

RESULT 923
US-10-231-302-72/c
; Sequence 72, Application US/10231302
; Publication No. US20030082602A1
; GENERAL INFORMATION:
; APPLICANT: Yamamoto, No. US20030082602A1uko
; APPLICANT: Okamoto, Tadaishi
; APPLICANT: Suzuki, Tomohiro
; TITLE OF INVENTION: Method for analyzing base sequence of nucleic acid
; FILE REFERENCE: 03500.015203
; CURRENT APPLICATION NUMBER: US/10/231.302
; CURRENT FILING DATE: 2002-08-30
; PRIOR APPLICATION NUMBER: PCT/JF00/07244
; PRIOR FILING DATE: 2000-10-18
; NUMBER OF SEQ ID NOS: 74
; SOFTWARE: Patent In Ver. 2.1
; SEQ ID NO 72
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-231-302-72

Query Match      0.4%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 7.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      2695 CCACTTCCACCCCTGCC 2712
||||| |||||
Db      19 CCACTTGCACCCCTGCAC 2

RESULT 924
US-10-181-846-32/c
; Sequence 32, Application US/10181846
; Publication No. US20030083297A1
; GENERAL INFORMATION:
; APPLICANT: Nicholas M. Dean
; APPLICANT: Lex M. Cowser
```

; PRIOR APPLICATION NUMBER: PCT/US98/13961
 ; PRIOR FILING DATE: 1998-07-06
 ; PRIOR APPLICATION NUMBER: US 08/888,982
 ; PRIOR FILING DATE: 1997-07-07
 ; PRIOR APPLICATION NUMBER: US 08/756,806
 ; PRIOR FILING DATE: 1996-11-26
 ; PRIOR APPLICATION NUMBER: PCT/US95/07111
 ; PRIOR FILING DATE: 1995-05-31
 ; PRIOR APPLICATION NUMBER: US 08/250,856
 ; PRIOR FILING DATE: 1994-05-31
 ; NUMBER OF SEQ ID NOS: 109
 ; SEQ ID NO 26
 ; LENGTH: 20
 ; TYPE: DNA
 ; ORGANISM: artificial sequence
 ; FEATURE:
 ; OTHER INFORMATION: antisense sequence
 US-10-173-225B-26

Query Match 0.4%; Score 14.8; DB 1; Length 20;
 Best Local Similarity 88.9%; Pred. No. 7.5e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 844 CTGCCAGCCGAGGAGGAG 861
 Db 20 CTGCCAGGGGAGGAGGAG 3

RESULT 927
 US-10-008-789-21/c
 ; Sequence 21, Application US/10008789
 ; Publication No. US20030125276A1
 ; GENERAL INFORMATION:
 ; APPLICANT: C. Frank Bennett
 ; TITLE OF INVENTION: ANTISENSE MODULATION OF THYROID HORMONE RECEPTOR INTERACTOR 6 EXP
 ; FILE REFERENCE: RTS-0333
 ; CURRENT APPLICATION NUMBER: US/10/008,789
 ; CURRENT FILING DATE: 2001-11-08
 ; NUMBER OF SEQ ID NOS: 89
 ; SEQ ID NO 21
 ; LENGTH: 20
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Antisense Oligonucleotide
 US-10-008-789-21

Query Match 0.4%; Score 14.8; DB 1; Length 20;
 Best Local Similarity 88.9%; Pred. No. 7.5e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1116 GGGCCCAACGCTGGCCAA 1133
 Db 18 GAGCACCACGCTGGCCAA 1

RESULT 928
 US-10-321-555-10/c
 ; Sequence 10, Application US/10321555
 ; Publication No. US20030134315A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Warenius, Hilmar Meek
 ; APPLICANT: Seabra, Laurence Anthony
 ; TITLE OF INVENTION: METHODS FOR DETERMINING CHEMOSENSITIVITY OF CANCER CELLS BASED UP
 ; FILE REFERENCE: 1417-188
 ; CURRENT APPLICATION NUMBER: US/10/321,555
 ; CURRENT FILING DATE: 2002-12-18
 ; PRIOR APPLICATION NUMBER: US/09/622,277
 ; PRIOR FILING DATE: 2000-10-25
 ; PRIOR APPLICATION NUMBER: PCT/GB99/00500
 ; PRIOR FILING DATE: 1999-02-18

; PRIOR APPLICATION NUMBER: GB 9903035.5
 ; PRIOR FILING DATE: 1999-02-10
 ; PRIOR APPLICATION NUMBER: GB 9814545.1
 ; PRIOR FILING DATE: 1998-07-03
 ; PRIOR APPLICATION NUMBER: GB 9812151.0
 ; PRIOR FILING DATE: 1998-06-05
 ; PRIOR APPLICATION NUMBER: GB 9803447.3
 ; PRIOR FILING DATE: 1998-02-18
 ; PRIOR APPLICATION NUMBER: GB 9803446.5
 ; PRIOR FILING DATE: 1998-02-18
 ; NUMBER OF SEQ ID NOS: 15
 ; SOFTWARE: PatentIn version 3.1
 ; SEQ ID NO 10
 ; LENGTH: 20
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: PCR and DNA sequencing primer for exon 7 antisense
 US-10-321-555-10

Query Match 0.4%; Score 14.8; DB 1; Length 20;
 Best Local Similarity 88.9%; Pred. No. 7.5e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2695 CCACCTCCACCCCTGCC 2712
 Db 19 CCACCTGCCACCCCTGCAC 2

RESULT 929
 US-10-171-319-48
 ; Sequence 48, Application US/10171319
 ; Publication No. US20030157633A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ardem Patapoutian
 ; APPLICANT: Andrea Peier
 ; APPLICANT: Peter McIntyre
 ; APPLICANT: Stuart Bevan
 ; APPLICANT: Chuanzheng Song
 ; APPLICANT: Ramdosh Ganju
 ; TITLE OF INVENTION: VANILLOID RECEPTOR-RELATED NUCLEIC ACIDS
 ; FILE REFERENCE: 4-32048A
 ; CURRENT APPLICATION NUMBER: US/10/171,319
 ; CURRENT FILING DATE: 2002-10-24
 ; PRIOR APPLICATION NUMBER: 60/297,835
 ; PRIOR FILING DATE: 2001-06-13
 ; PRIOR APPLICATION NUMBER: 60/351,238
 ; PRIOR FILING DATE: 2002-01-22
 ; PRIOR APPLICATION NUMBER: 60/352,914
 ; PRIOR FILING DATE: 2002-01-29
 ; PRIOR APPLICATION NUMBER: 60/357,161
 ; PRIOR FILING DATE: 2002-02-12
 ; PRIOR APPLICATION NUMBER: 60/381,086
 ; PRIOR FILING DATE: 2002-05-15
 ; PRIOR APPLICATION NUMBER: 60/381,739
 ; PRIOR FILING DATE: 2002-05-16
 ; NUMBER OF SEQ ID NOS: 114
 ; SOFTWARE: FastSeq for Windows Version 4.0
 ; SEQ ID NO 48
 ; LENGTH: 20
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Oligonucleotide primer
 US-10-171-319-48

Query Match 0.4%; Score 14.8; DB 1; Length 20;
 Best Local Similarity 88.9%; Pred. No. 7.5e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 186 GGAGGACGAGCTGACGA 203
 Db 186 GGAGGACGAGCTGACGA 203

Db 2 GGAGGACGAGGTGAGGA 19

RESULT 930

US-10-171-319-73/c

; Sequence 73, Application US/10171319

; Publication No. US20030157633A1

; GENERAL INFORMATION:

; APPLICANT: Ardem Patapoutian

; APPLICANT: Andrea Peler

; APPLICANT: Peter McIntyre

; APPLICANT: Stuart Bevan

; APPLICANT: Chuanzheng Song

; APPLICANT: Pamposh Ganju

; TITLE OF INVENTION: VANILLOID RECEPTOR-RELATED NUCLEIC ACIDS

; TITLE OF INVENTION: AND POLYPEPTIDES

; FILE REFERENCE: 4-32048A

; CURRENT APPLICATION NUMBER: US/10/171,319

; CURRENT FILING DATE: 2002-10-24

; PRIOR APPLICATION NUMBER: 60/297,835

; PRIOR FILING DATE: 2001-06-13

; PRIOR APPLICATION NUMBER: 60/351,238

; PRIOR FILING DATE: 2002-01-22

; PRIOR APPLICATION NUMBER: 60/352,914

; PRIOR FILING DATE: 2002-01-29

; PRIOR APPLICATION NUMBER: 60/357,161

; PRIOR FILING DATE: 2002-02-12

; PRIOR APPLICATION NUMBER: 60/381,086

; PRIOR FILING DATE: 2002-05-15

; PRIOR APPLICATION NUMBER: 60/381,739

; PRIOR FILING DATE: 2002-05-16

; NUMBER OF SEQ ID NOS: 114

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 73

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Oligonucleotide primer

US-10-171-319-73

Query Match 0.4%; Score 14.8; DB 1; Length 20;

Best Local Similarity 88.9%; Pred. No. 7.5e+02;

Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 186 GGAGGACGAGGCTGAGGA 203

Db 19 GGAGGACGAGGTGAGGA 2

RESULT 931

US-10-167-547C-32

; Sequence 32, Application US/10167547C

; Publication No. US20030170653A1

; GENERAL INFORMATION:

; APPLICANT: E.I. du Pont de Nemours and Company

; APPLICANT: Damude, Howard G.

; TITLE OF INVENTION: A Biological Method for the Production of Alpha-Methylene-Gamma

; TITLE OF INVENTION: Butyrolactone and its Intermediates

; FILE REFERENCE: CUI804 US NA

; CURRENT APPLICATION NUMBER: US/10/167,547C

; CURRENT FILING DATE: 2003-03-17

; PRIOR APPLICATION NUMBER: 60/297198

; PRIOR FILING DATE: 2001-06-08

; NUMBER OF SEQ ID NOS: 67

; SOFTWARE: Microsoft Office 07

; SEQ ID NO 32

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Primer NW12

US-10-167-547C-32

Query Match 0.4%; Score 14.8; DB 1; Length 20;

Best Local Similarity 88.9%; Pred. No. 7.5e+02;

Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 186 GGAGGACGAGGCTGAGGA 203

Db 19 GGAGGACGAGGTGAGGA 2

Query Match 0.4%; Score 14.8; DB 1; Length 20;

Best Local Similarity 88.9%; Pred. No. 7.5e+02;

Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 885 CAGTGTGTATGCAGGCAT 902

Db 1 CATTGTGTATGCAGGAAT 18

RESULT 932

US-10-032-585-4779/c

; Sequence 4779, Application US/10032585

; Publication No. US20030180953A1

; GENERAL INFORMATION:

; APPLICANT: Terry, Roemer D.

; APPLICANT: Bo, Jiang

; APPLICANT: Charles, Boone

; APPLICANT: Howard, Bussey

; TITLE OF INVENTION: Gene Disruption Methodologies for Drug Target Discovery

; FILE REFERENCE: 10182-005-999

; CURRENT APPLICATION NUMBER: US/10/032,585

; CURRENT FILING DATE: 2001-12-20

; NUMBER OF SEQ ID NOS: 8000

; SOFTWARE: PatentIn version 3.1

; SEQ ID NO 4779

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Candida albicans

US-10-032-585-4779

Query Match 0.4%; Score 14.8; DB 1; Length 20;

Best Local Similarity 88.9%; Pred. No. 7.5e+02;

Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 829 GCGTGGCTGTGTGCTG 846

Db 19 GTGTGTCTGTGTGCTG 2

RESULT 933

US-10-352-586-11/c

; Sequence 11, Application US/10352586

; Publication No. US20030187240A1

; GENERAL INFORMATION:

; APPLICANT: Cook, Phillip Dan

; APPLICANT: Kawasaki, Andrew

; TITLE OF INVENTION: 2'-Modified Oligonucleotides

; FILE REFERENCE: ISIS137

; CURRENT APPLICATION NUMBER: US/10/352,586

; CURRENT FILING DATE: 2003-01-28

; PRIOR APPLICATION NUMBER: 09/389,283

; PRIOR FILING DATE: 1999-09-02

; NUMBER OF SEQ ID NOS: 37

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 11

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Synthetic construct

US-10-352-586-11

Query Match 0.4%; Score 14.8; DB 1; Length 20;

Best Local Similarity 88.9%; Pred. No. 7.5e+02;

Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 844 CTGCCAGCCGAGGAGGAG 861

Db 20 CTGCCAGGCGAGGAGGAG 3

RESULT 934

```

US-10-446-373-97
; Sequence 97, Application US/10446373
; Publication No. US20030204076A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR
; FILE REFERENCE: RTS-0232
; CURRENT APPLICATION NUMBER: US/10/446,373
; CURRENT FILING DATE: 2003-05-28
; PRIOR APPLICATION NUMBER: US/09/953,318
; PRIOR FILING DATE: 2001-09-13
; NUMBER OF SEQ ID NOS: 154
; SEQ ID NO 97
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-446-373-97

Query Match      0.4%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 7.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1352 TGGAGATGATCAAGATCA 1369
Db 1 TGGTATGATGACGATGA 18

RESULT 935
US-10-314-578-311/c
; Sequence 311, Application US/10314578
; Publication No. US20030212026A1
; GENERAL INFORMATION:
; APPLICANT: Krieg, Arthur M.
; APPLICANT: Vollmer, Jorg
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids
; FILE REFERENCE: C1039/7035 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/10/314,578
; CURRENT FILING DATE: 2002-12-09
; PRIOR APPLICATION NUMBER: US 60/156,113
; PRIOR FILING DATE: 1999-09-25
; PRIOR APPLICATION NUMBER: US 60/156,135
; PRIOR FILING DATE: 1999-09-27
; PRIOR APPLICATION NUMBER: US 60/227,436
; PRIOR FILING DATE: 2000-08-23
; NUMBER OF SEQ ID NOS: 1145
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 311
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-10-314-578-311

Query Match      0.4%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 7.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1678 GACTTCGGCTGGCCCGG 1695
Db 20 GACTTGGCTGGCCCGG 3

RESULT 936
US-10-159-856-74/c
; Sequence 74, Application US/10159856
; Publication No. US2003022869A1
; GENERAL INFORMATION:

```

```

; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF G PROTEIN-COUPLED RECEPTOR KINASE 6 EXPRESSION
; FILE REFERENCE: RTS-0365
; CURRENT APPLICATION NUMBER: US/10/159,856
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 134
; SEQ ID NO 74
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-159-856-74

Query Match      0.4%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 7.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3670 ATGGCTCAGGGTGGTCTC 3687
Db 19 ATGGCTCAGGGTGGTCTC 2

RESULT 937
US-10-176-277-17
; Sequence 17, Application US/10176277
; Publication No. US20030232443A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF CENTROMERE PROTEIN B EXPRESSION
; FILE REFERENCE: HTS-0022
; CURRENT APPLICATION NUMBER: US/10/176,277
; CURRENT FILING DATE: 2002-06-18
; NUMBER OF SEQ ID NOS: 77
; SEQ ID NO 17
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-176-277-17

Query Match      0.4%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 7.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1262 AGGACCGGGCGCCCAAGC 1279
Db 1 AGGACTGGGCGAGCCAAGC 18

RESULT 938
US-10-094-886-232
; Sequence 232, Application US/10094886
; Publication No. US20040002120A1
; GENERAL INFORMATION:
; APPLICANT: Kekuda, Ramesh
; APPLICANT: Tchernev, Velizar T.
; APPLICANT: Liu, Xiaohong
; APPLICANT: Spytek, Kimberly A.
; APPLICANT: Patturajan, Meera
; APPLICANT: Burgess, Catherine
; APPLICANT: Vernet, Corine A.
; APPLICANT: Li, Li
; APPLICANT: Gorman, Linda
; APPLICANT: Malyankar, Uriel M.
; APPLICANT: Boldog, Ferenc
; APPLICANT: Guo, Xiaojia
; APPLICANT: Shenoy, Suresh
; APPLICANT: Padigar, Muralidhara
; APPLICANT: Taupier, Raymond J., Jr.

```



```

; APPLICANT: Miller, Charles
; APPLICANT: Casman, Stacie
; APPLICANT: Pena, Carol
; APPLICANT: Gangolli, Esha
; APPLICANT: Gusev, Vladimir
; APPLICANT: Smithson, Glennda
; APPLICANT: Zernhusen, Bryan
; APPLICANT: Gerlach, Valerie
; APPLICANT: Pochart, Pascal
; APPLICANT: Fernandes, Elma
; APPLICANT: Shimkets, Richard
; APPLICANT: Rastelli, Luca
; APPLICANT: Spaderna, Steven
; APPLICANT: LaRocheville, William
; APPLICANT: Zhong, Mei
; TITLE OF INVENTION: THERAPEUTIC POLYPEPTIDES, NUCLEIC ACIDS ENCODING SAME, AND METHOD
; FILE REFERENCE: 21402-290 B
; CURRENT APPLICATION NUMBER: US/10/094,886
; CURRENT FILING DATE: 2002-03-07
; PRIOR APPLICATION NUMBER: 60/274,322
; PRIOR FILING DATE: 2001-03-08
; PRIOR APPLICATION NUMBER: 60/313,182
; PRIOR FILING DATE: 2001-08-17
; PRIOR APPLICATION NUMBER: 60/288,052
; PRIOR FILING DATE: 2001-05-02
; PRIOR APPLICATION NUMBER: 60/318,510
; PRIOR FILING DATE: 2001-09-10
; PRIOR APPLICATION NUMBER: 60/274,281
; PRIOR FILING DATE: 2001-03-08
; PRIOR APPLICATION NUMBER: 60/314,018
; PRIOR FILING DATE: 2001-08-21
; PRIOR APPLICATION NUMBER: 60/274,194
; PRIOR FILING DATE: 2001-03-08
; PRIOR APPLICATION NUMBER: 60/274,849
; PRIOR FILING DATE: 2001-03-09
; PRIOR APPLICATION NUMBER: 60/296,693
; PRIOR FILING DATE: 2001-06-07
; PRIOR APPLICATION NUMBER: 60/313,626
; PRIOR FILING DATE: 2001-08-21
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 298
; SOFTWARE: PatentIn 2.1
; SEQ ID NO 232
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Reverse Primer
; US-10-094-886-232

Query Match      0.4%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 7.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      2008 GTGAGGACCTGGACCGT 2025
Db      3 GAGGAGGACCTGGACAGT 20

RESULT 939
US-10-349-143-7832/c
; Sequence 7832, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Blallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CPI
; CURRENT APPLICATION NUMBER: US/10/349,143
; CURRENT FILING DATE: 2003-01-21
; PRIOR APPLICATION NUMBER: US/09/422,978
; PRIOR FILING DATE: 1999-10-20

```

```

; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
; PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 7832
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..20
; OTHER INFORMATION: upstream amplification primer 99-8614 for SEQ 3898,
US-10-349-143-7832

Query Match      0.4%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 7.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      2974 CAGAGGACCGGCTTTT 2991
Db      20 CAGAGACCGGCTTGT 3

RESULT 940
US-10-407-449-5
; Sequence 5, Application US/10407449
; Publication No. US20040005601A1
; GENERAL INFORMATION:
; APPLICANT: Siddiqui-Jain, Adam
; APPLICANT: Hurley, Laurence
; APPLICANT: Farrell, Thomas
; APPLICANT: Grand, Cory
; APPLICANT: Bearsse, David
; TITLE OF INVENTION: METHODS FOR TARGETING QUADRUPLX DNA
; FILE REFERENCE: 53223-20004.00
; CURRENT APPLICATION NUMBER: US/10/407,449
; CURRENT FILING DATE: 2003-04-04
; PRIOR APPLICATION NUMBER: US 60/404,966
; PRIOR FILING DATE: 2002-08-04
; PRIOR APPLICATION NUMBER: US 60/370,358
; PRIOR FILING DATE: 2002-04-05
; PRIOR APPLICATION NUMBER: Unknown
; PRIOR FILING DATE: 2003-03-20
; NUMBER OF SEQ ID NOS: 64
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 5
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-407-449-5

Query Match      0.4%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 7.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      2920 GGGCGGGCGGTGGGGGG 2937
Db      3 GGGCGGGCGGGCGGGG 20

RESULT 941
US-10-407-449-9
; Sequence 9, Application US/10407449
; Publication No. US20040005601A1
; GENERAL INFORMATION:
; APPLICANT: Siddiqui-Jain, Adam
; APPLICANT: Hurley, Laurence
; APPLICANT: Farrell, Thomas
; APPLICANT: Grand, Cory
; APPLICANT: Bearsse, David

```

```
; TITLE OF INVENTION: METHODS FOR TARGETING QUADRUPLX DNA
; FILE REFERENCE: 53223-20004.00
; CURRENT APPLICATION NUMBER: US/10/407,449
; CURRENT FILING DATE: 2003-04-04
; PRIOR APPLICATION NUMBER: US 60/404,966
; PRIOR FILING DATE: 2002-08-04
; PRIOR APPLICATION NUMBER: US 60/370,358
; PRIOR FILING DATE: 2002-04-05
; PRIOR APPLICATION NUMBER: Unknown
; PRIOR FILING DATE: 2003-03-20
; NUMBER OF SEQ ID NOS: 64
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 9
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-407-449-9

Query Match      0.4%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 7.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2920 GGGCGGGGGCTGGGGGGG 2937
Db      3 GGGCGGGGGCTGGGGGGG 20

RESULT 942
US-10-422-466-21/c
; Sequence 21, Application US/10422466
; Publication No. US2004006036A1
; GENERAL INFORMATION:
; APPLICANT: Hu, Ji-Fan
; APPLICANT: Bowersox, Scott
; TITLE OF INVENTION: Silencing transcription by methylation
; FILE REFERENCE: 112029.00005
; CURRENT APPLICATION NUMBER: US/10/422,466
; CURRENT FILING DATE: 2003-04-22
; PRIOR APPLICATION NUMBER: 09/643,128
; PRIOR FILING DATE: 2000-08-21
; PRIOR APPLICATION NUMBER: 60/196,749
; PRIOR FILING DATE: 2000-04-12
; PRIOR APPLICATION NUMBER: 60/214,148
; PRIOR FILING DATE: 2000-06-26
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 21
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (2)
; OTHER INFORMATION: m5c at base 2
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: DNA inhibitor
US-10-422-466-21

Query Match      0.4%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 7.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2527 CAGGGAGCTGGGCCCGAC 2544
Db      20 CATGGAACCTGGGCCCGAC 3

RESULT 943
US-10-289-762-6513/c
; Sequence 6513, Application US/10289762
; Publication No. US20040006218A1
; GENERAL INFORMATION:
; APPLICANT: Griffiths, R.
```

```
; TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments
; TITLE OF INVENTION: thereof and uses thereof, in particular for the diagnosis, prevention
; TITLE OF INVENTION: and treatment of infection
; FILE REFERENCE: 9710-003-999
; CURRENT APPLICATION NUMBER: US/10/289,762
; CURRENT FILING DATE: 2003-03-27
; NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 6513
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Chlamydia pneumoniae
; US-10-289-762-6513

Query Match      0.4%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 7.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      743 TTCTCTCTTGCACACG 760
Db      19 TCCTCTCTTAGCACACG 2

RESULT 944
US-10-210-429-56
; Sequence 56, Application US/10210429
; Publication No. US20040023379A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF HEPATOMA-DERIVED GROWTH FACTOR EXPRESSION
; FILE REFERENCE: PTS-0048
; CURRENT APPLICATION NUMBER: US/10/210,429
; CURRENT FILING DATE: 2002-07-31
; NUMBER OF SEQ ID NOS: 148
; SEQ ID NO 56
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-210-429-56

Query Match      0.4%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 7.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      920 GCTTCTCTCTGTTCAATCC 937
Db      3 GCCTCTCTCTTCAATCC 20

RESULT 945
US-10-210-429-127/c
; Sequence 127, Application US/10210429
; Publication No. US20040023379A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF HEPATOMA-DERIVED GROWTH FACTOR EXPRESSION
; FILE REFERENCE: PTS-0048
; CURRENT APPLICATION NUMBER: US/10/210,429
; CURRENT FILING DATE: 2002-07-31
; NUMBER OF SEQ ID NOS: 148
; SEQ ID NO 127
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
; OTHER INFORMATION:
US-10-210-429-127

Query Match      0.4%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 7.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
Qy 920 GCTTCTCCTCTTCATCC 937
|||
Db 18 GCCTCTCCTCTTCATCC 1

RESULT 946
US-10-210-479-50/c
; Sequence 50, Application US/10210479
; Publication No. US20040023380A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF G PROTEIN-COUPLED RECEPTOR 6 EXPRESSION
; FILE REFERENCE: RTS-0385
; CURRENT APPLICATION NUMBER: US/10/210,479
; CURRENT FILING DATE: 2002-07-31
; NUMBER OF SEQ ID NOS: 123
; SEQ ID NO 50
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-210-479-50

Query Match 0.4%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 7.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2015 ACCTGGACCGTGTCCTTA 2032
|||
Db 20 ACTTGGACCGTGTCCTTA 3

RESULT 947
US-10-210-479-112
; Sequence 112, Application US/10210479
; Publication No. US20040023380A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF G PROTEIN-COUPLED RECEPTOR 6 EXPRESSION
; FILE REFERENCE: RTS-0385
; CURRENT APPLICATION NUMBER: US/10/210,479
; CURRENT FILING DATE: 2002-07-31
; NUMBER OF SEQ ID NOS: 123
; SEQ ID NO 112
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-210-479-112

Query Match 0.4%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 7.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2015 ACCTGGACCGTGTCCTTA 2032
|||
Db 1 ACTTGGACCGTGTCCTTA 18

RESULT 948
US-10-210-723-14
; Sequence 14, Application US/10210723
; Publication No. US20040023382A1
; GENERAL INFORMATION:
; APPLICANT: Nicholas M. Dean
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PPP3CB EXPRESSION
; FILE REFERENCE: PTS-0028
```

```
; CURRENT APPLICATION NUMBER: US/10/210,723
; CURRENT FILING DATE: 2002-07-31
; NUMBER OF SEQ ID NOS: 141
; SEQ ID NO 14
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-210-723-14

Query Match 0.4%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 7.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2112 CTCACGCTCTCGGGGA 2129
|||||
Db 3 CTCACGCTCTCGGGTGA 20

RESULT 949
US-10-210-723-86/c
; Sequence 86, Application US/10210723
; Publication No. US20040023382A1
; GENERAL INFORMATION:
; APPLICANT: Nicholas M. Dean
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PPP3CB EXPRESSION
; FILE REFERENCE: PTS-0028
; CURRENT APPLICATION NUMBER: US/10/210,723
; CURRENT FILING DATE: 2002-07-31
; NUMBER OF SEQ ID NOS: 141
; SEQ ID NO 86
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-210-723-86

Query Match 0.4%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 7.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2112 CTCACGCTCTCGGGGA 2129
|||||
Db 18 CTCACGCTCTCGGGTGA 1

RESULT 950
US-10-345-444B-31/c
; Sequence 31, Application US/10345444B
; Publication No. US20040029823A1
; GENERAL INFORMATION:
; APPLICANT: McKay, Robert A.
; APPLICANT: Dean, Nicholas M.
; APPLICANT: Monia, Brett
; APPLICANT: Nero, Pam
; APPLICANT: Gaarde, William A.
; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THE MODULA
; FILE REFERENCE: ISPH-0726
; CURRENT APPLICATION NUMBER: US/10/345,444B
; CURRENT FILING DATE: 2003-01-15
; PRIOR APPLICATION NUMBER: US 09/774,809
; PRIOR FILING DATE: 2001-01-31
; PRIOR APPLICATION NUMBER: US 09/396,902
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: US 09/287,796
; PRIOR FILING DATE: 1999-04-07
; PRIOR APPLICATION NUMBER: US 09/130,616
; PRIOR FILING DATE: 1998-08-07
```

; PRIOR APPLICATION NUMBER: US 08/910,629
 ; PRIOR FILING DATE: 1997-08-03
 ; NUMBER OF SEQ ID NOS: 168
 ; SEQ ID NO 31
 ; LENGTH: 20
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Synthetic Sequence
 US-10-345-444B-31

Query Match 0.4%; Score 14.8; DB 1; Length 20;
 Best Local Similarity 88.9%; Pred. No. 7.5e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1678 GACTTCGGCTGGCCCGG 1695
 |||||
 Db 20 GACTTTGGCTGGCCCGG 3

RESULT 951
 US-10-345-444B-42
 ; Sequence 42, Application US/10345444B
 ; Publication No. US20040029823A1
 ; GENERAL INFORMATION:
 ; APPLICANT: McKay, Robert A.
 ; APPLICANT: Dean, Nicholas M.
 ; APPLICANT: Monia, Brett
 ; APPLICANT: Nero, Pam
 ; APPLICANT: Gaarde, William A.
 ; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THE MODULA
 ; FILE REFERENCE: ISPH-0726
 ; CURRENT APPLICATION NUMBER: US/10/345,444B
 ; CURRENT FILING DATE: 2003-01-15
 ; PRIOR APPLICATION NUMBER: US 09/774,809
 ; PRIOR FILING DATE: 2001-01-31
 ; PRIOR APPLICATION NUMBER: US 09/396,902
 ; PRIOR FILING DATE: 1999-09-15
 ; PRIOR APPLICATION NUMBER: US 09/287,796
 ; PRIOR FILING DATE: 1999-04-07
 ; PRIOR APPLICATION NUMBER: US 09/130,616
 ; PRIOR FILING DATE: 1998-08-07
 ; PRIOR APPLICATION NUMBER: US 08/910,629
 ; PRIOR FILING DATE: 1997-08-03
 ; NUMBER OF SEQ ID NOS: 168
 ; SEQ ID NO 42
 ; LENGTH: 20
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Synthetic Sequence
 US-10-345-444B-42

Query Match 0.4%; Score 14.8; DB 1; Length 20;
 Best Local Similarity 88.9%; Pred. No. 7.5e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1678 GACTTCGGCTGGCCCGG 1695
 |||||
 Db 1 GACTTTGGCTGGCCCGG 18

RESULT 952
 US-10-236-392-393
 ; Sequence 393, Application US/10236392
 ; Publication No. US20040067490A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Anderson, David W
 ; APPLICANT: Boldos, Ferenc L
 ; APPLICANT: Burgess, Catherine, E
 ; APPLICANT: Casman, Stacie J
 ; APPLICANT: Catterton, Elina

; APPLICANT: Chapoval, Andrei
 ; APPLICANT: Crabtree, Julie
 ; APPLICANT: Edinger, Shlomit, R
 ; APPLICANT: Ellerman, Karen
 ; APPLICANT: Gerlach, Valerie
 ; APPLICANT: Gorman, Linda
 ; APPLICANT: Grosse, William M
 ; APPLICANT: Gusev, Vladamir
 ; APPLICANT: Kekuda, Ramesh
 ; APPLICANT: LaRoche, William J
 ; APPLICANT: Li, Li
 ; APPLICANT: MacDougall, John R
 ; APPLICANT: Malyankar, Uriel M
 ; APPLICANT: Miller, Charles E
 ; APPLICANT: Millet, Isabelle
 ; APPLICANT: Padigaru, Muralidhara
 ; APPLICANT: Patturajan, Weera
 ; APPLICANT: Pena, Carol A
 ; APPLICANT: Peyman, John A
 ; APPLICANT: Rastelli, Luca
 ; APPLICANT: Reiger, Daniel K
 ; APPLICANT: Rothenberg, Mark E
 ; APPLICANT: Shenoy, Suresh
 ; APPLICANT: Shimkets, Richard A
 ; APPLICANT: Smithson, Glennda
 ; TITLE OF INVENTION: THERAPEUTIC POLYPEPTIDES, NUCLEIC ACIDS ENCODING SAME
 ; FILE REFERENCE: 21402-442A
 ; CURRENT APPLICATION NUMBER: US/10/236,392
 ; CURRENT FILING DATE: 2002-09-06
 ; PRIOR APPLICATION NUMBER: US09/540,763
 ; PRIOR FILING DATE: 2000-03-30
 ; PRIOR APPLICATION NUMBER: US60/390,155
 ; PRIOR FILING DATE: 2002-06-19
 ; PRIOR APPLICATION NUMBER: US09/635,949
 ; PRIOR FILING DATE: 2000-08-10
 ; PRIOR APPLICATION NUMBER: US60/318,765
 ; PRIOR FILING DATE: 2001-09-12
 ; PRIOR APPLICATION NUMBER: US60/357,303
 ; PRIOR FILING DATE: 2002-02-15
 ; PRIOR APPLICATION NUMBER: US60/367,753
 ; PRIOR FILING DATE: 2002-03-25
 ; PRIOR APPLICATION NUMBER: US60/369,479
 ; PRIOR FILING DATE: 2002-04-02
 ; PRIOR APPLICATION NUMBER: US09/659,634
 ; PRIOR FILING DATE: 2000-09-12
 ; PRIOR APPLICATION NUMBER: US60/318,120
 ; PRIOR FILING DATE: 2001-09-07
 ; PRIOR APPLICATION NUMBER: US60/318,130
 ; Remaining Prior Application data removed - See File Wrapper or PALM.
 ; NUMBER OF SEQ ID NOS: 794
 ; SOFTWARE: Custom
 ; SEQ ID NO 393
 ; LENGTH: 20
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Description of Artificial Sequence: Forward Primer
 US-10-236-392-393

Query Match 0.4%; Score 14.8; DB 1; Length 20;
 Best Local Similarity 88.9%; Pred. No. 7.5e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1495 GGCTGGACTACTCTTC 1512
 |||||
 Db 3 GGCTGGACTGCTTTC 20

RESULT 953
 US-10-236-392-402
 ; Sequence 402, Application US/10236392
 ; Publication No. US20040067490A1

; Publication No. US20040102412A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Broschat, Kay
; TITLE OF INVENTION: ANTISENSE MODULATION OF GFAT EXPRESSION
; FILE REFERENCE: 01393/1
; CURRENT APPLICATION NUMBER: US/10/688,706
; CURRENT FILING DATE: 2003-10-17
; PRIOR APPLICATION NUMBER: 60/419,268
; PRIOR FILING DATE: 2002-10-17
; NUMBER OF SEQ ID NOS: 3071
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 153
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: human GFAT antisense
US-10-688-706-153

Query Match 0.4%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 7.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3237 TAGTTGGAGGTGATCCCA 3254
|||||
Db 2 TAGTTGGTGAATCCCA 19

RESULT 961

US-10-688-706-285
; Sequence 285, Application US/10688706
; Publication No. US20040102412A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Broschat, Kay
; TITLE OF INVENTION: ANTISENSE MODULATION OF GFAT EXPRESSION
; FILE REFERENCE: 01393/1
; CURRENT APPLICATION NUMBER: US/10/688,706
; CURRENT FILING DATE: 2003-10-17
; PRIOR APPLICATION NUMBER: 60/419,268
; PRIOR FILING DATE: 2002-10-17
; NUMBER OF SEQ ID NOS: 3071
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 285
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: human GFAT antisense
US-10-688-706-285

Query Match 0.4%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 7.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3237 TAGTTGGAGGTGATCCCA 3254
|||||
Db 3 TAGTTGGTGAATCCCA 20

RESULT 962

US-10-688-706-507
; Sequence 507, Application US/10688706
; Publication No. US20040102412A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Broschat, Kay
; TITLE OF INVENTION: ANTISENSE MODULATION OF GFAT EXPRESSION
; FILE REFERENCE: 01393/1
; CURRENT APPLICATION NUMBER: US/10/688,706
; CURRENT FILING DATE: 2003-10-17
; PRIOR APPLICATION NUMBER: 60/419,268

; PRIOR FILING DATE: 2002-10-17
; NUMBER OF SEQ ID NOS: 3071
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 507
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: human GFAT antisense
US-10-688-706-507

Query Match 0.4%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 7.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1473 TCTCGGGCGCGGGGCC 1490
|||||
Db 1 TCTCGGGCTCGGGGGCC 18

RESULT 963

US-10-688-706-508
; Sequence 508, Application US/10688706
; Publication No. US20040102412A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Broschat, Kay
; TITLE OF INVENTION: ANTISENSE MODULATION OF GFAT EXPRESSION
; FILE REFERENCE: 01393/1
; CURRENT APPLICATION NUMBER: US/10/688,706
; CURRENT FILING DATE: 2003-10-17
; PRIOR APPLICATION NUMBER: 60/419,268
; PRIOR FILING DATE: 2002-10-17
; NUMBER OF SEQ ID NOS: 3071
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 508
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: human GFAT antisense
US-10-688-706-508

Query Match 0.4%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 7.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1473 TCTCGGGCGCGGGGCC 1490
|||||
Db 3 TCTCGGGCTCGGGGGCC 20

RESULT 964

US-10-688-706-828
; Sequence 828, Application US/10688706
; Publication No. US20040102412A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Broschat, Kay
; TITLE OF INVENTION: ANTISENSE MODULATION OF GFAT EXPRESSION
; FILE REFERENCE: 01393/1
; CURRENT APPLICATION NUMBER: US/10/688,706
; CURRENT FILING DATE: 2003-10-17
; PRIOR APPLICATION NUMBER: 60/419,268
; PRIOR FILING DATE: 2002-10-17
; NUMBER OF SEQ ID NOS: 3071
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 828
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: human GFAT antisense

US-10-688-706-828

Query Match 0.4%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 7.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1473 TCTGCGGCGCGGGGCC 1490
|||||

Db 2 TCTGCGGCTCGGGGCC 19
|||||

RESULT 965

US-10-316-243-96
; Sequence 96, Application US/10316243
; Publication No. US20040110147A1
; GENERAL INFORMATION:
; APPLICANT: Kenneth W. Dobie
; APPLICANT: Ravi Jain
; TITLE OF INVENTION: MODULATION OF BAF53 EXPRESSION
; FILE REFERENCE: RTS-0462
; CURRENT APPLICATION NUMBER: US/10/316,243
; CURRENT FILING DATE: 2002-12-09
; NUMBER OF SEQ ID NOS: 168
; SEQ ID NO 96
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-316-243-96

Query Match 0.4%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 7.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3067 TCCACACCCCAACACTT 3084
|||||

Db 2 TCACACATCCCAACACTT 19
|||||

RESULT 966

US-10-316-243-167/c
; Sequence 167, Application US/10316243
; Publication No. US20040110147A1
; GENERAL INFORMATION:
; APPLICANT: Kenneth W. Dobie
; APPLICANT: Ravi Jain
; TITLE OF INVENTION: MODULATION OF BAF53 EXPRESSION
; FILE REFERENCE: RTS-0462
; CURRENT APPLICATION NUMBER: US/10/316,243
; CURRENT FILING DATE: 2002-12-09
; NUMBER OF SEQ ID NOS: 168
; SEQ ID NO 167
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-316-243-167

Query Match 0.4%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 7.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3067 TCCACACCCCAACACTT 3084
|||||

Db 19 TCACACATCCCAACACTT 2
|||||

RESULT 967

US-10-660-897-9
; Sequence 9, Application US/10660897
; Publication No. US20040115706A1
; GENERAL INFORMATION:

; APPLICANT: Jin, Cheng
; APPLICANT: Chung, Mary
; APPLICANT: Siddiqui-Jain, Adam
; APPLICANT: Whitten, Jeffrey
; APPLICANT: Farrell, Thomas
; TITLE OF INVENTION: HIGH-THROUGHPUT METHODS FOR IDENTIFYING
; FILE REFERENCE: QUADRUPLUX FORMING NUCLEIC ACIDS AND MODULATORS THEREOF
; FILE REFERENCE: 532232000800
; CURRENT APPLICATION NUMBER: US/10/660,897
; CURRENT FILING DATE: 2003-09-11
; PRIOR APPLICATION NUMBER: 60/410,475
; PRIOR FILING DATE: 2002-09-12
; NUMBER OF SEQ ID NOS: 40
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 9
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: quadruplex forming sequence
US-10-660-897-9

Query Match 0.4%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 7.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy ~ 2920 GGGCGGGCGTGGGGGG 2937
|||||

Db 3 GGGCGGGCGGGCGGGG 20
|||||

RESULT 968

US-10-303-588-42
; Sequence 42, Application US/10303588
; Publication No. US20040116364A1
; GENERAL INFORMATION:
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DEATH-ASSOCIATED PROTEIN KINASE 1 EXPRESSION
; FILE REFERENCE: HTS-0071
; CURRENT APPLICATION NUMBER: US/10/303,588
; CURRENT FILING DATE: 2002-11-22
; NUMBER OF SEQ ID NOS: 78
; SEQ ID NO 42
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-303-588-42

Query Match 0.4%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 7.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2824 ATATATACATATATATAT 2841
|||||

Db 2 ATATATATATACATAT 19
|||||

RESULT 969

US-10-303-588-42/c
; Sequence 42, Application US/10303588
; Publication No. US20040116364A1
; GENERAL INFORMATION:
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DEATH-ASSOCIATED PROTEIN KINASE 1 EXPRESSION
; FILE REFERENCE: HTS-0071
; CURRENT APPLICATION NUMBER: US/10/303,588
; CURRENT FILING DATE: 2002-11-22
; NUMBER OF SEQ ID NOS: 78
; SEQ ID NO 42
; LENGTH: 20
; TYPE: DNA


```

; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-303-588-42

Query Match      0.4%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 7.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2824 ATATATACATATATATAT 2841
Db 19 ATATGATATATATATAT 2

RESULT 970
US-10-763-992-21
; Sequence 21, Application US/10763992
; Publication No. US2004012139A1
; GENERAL INFORMATION:
; APPLICANT: COHEN, Maurice
; FRIEDMAN, Paula N.
; GORDON, Julian
; HODGES, Steven C.
; KLASS, Michael R.
; KRATOCHVIL, Jon D.
; ROBERTS-RAPP, Lisa
; RUSSELL, John C.
; STROUPE, Steven D.
; TITLE OF INVENTION: REAGENTS AND METHODS USEFUL
; FOR DETECTING DISEASES OF THE PROSTATE
; NUMBER OF SEQUENCES: 35
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Abbott Laboratories
; STREET: 100 Abbott Park Road
; CITY: Abbott Park
; STATE: IL
; COUNTRY: USA
; ZIP: 60064-3500
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/763,992
; FILING DATE: 22-Jan-2004
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/418,887
; FILING DATE: 15-OCT-1999
; APPLICATION NUMBER: US/08/946,869
; FILING DATE: 08-OCT-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Becker, Cheryl L.
; REGISTRATION NUMBER: 35,441
; REFERENCE/DOCKET NUMBER: 5697.US.P1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 847/935-1729
; TELEFAX: 847/938-2623
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 21:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 21:
US-10-763-992-21

Query Match      0.4%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 7.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

QY 921 CTTCTTCCTGTTTCATCCT 938
Db 2 CTTCTTCCTGTTTCATCCT 19

RESULT 971
US-10-316-540-18
; Sequence 18, Application US/10316540
; Publication No. US20040126761A1
; GENERAL INFORMATION:
; APPLICANT: Kenneth W. Dobie
; APPLICANT: Ravi Jain
; TITLE OF INVENTION: MODULATION OF ALPHA-METHYLACYL-COA RACEMASE EXPRESSION
; FILE REFERENCE: RTS-0471
; CURRENT APPLICATION NUMBER: US/10/316,540
; CURRENT FILING DATE: 2002-12-10
; NUMBER OF SEQ ID NOS: 156
; SEQ ID NO 18
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-316-540-18

Query Match      0.4%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 7.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3659 CCTGCAGGGCCATGGCTC 3676
Db 3 CCTGCAGTGCATGGCGC 20

RESULT 972
US-10-316-540-95/c
; Sequence 95, Application US/10316540
; Publication No. US20040126761A1
; GENERAL INFORMATION:
; APPLICANT: Kenneth W. Dobie
; APPLICANT: Ravi Jain
; TITLE OF INVENTION: MODULATION OF ALPHA-METHYLACYL-COA RACEMASE EXPRESSION
; FILE REFERENCE: RTS-0471
; CURRENT APPLICATION NUMBER: US/10/316,540
; CURRENT FILING DATE: 2002-12-10
; NUMBER OF SEQ ID NOS: 156
; SEQ ID NO 95
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-316-540-95

Query Match      0.4%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 7.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3659 CCTGCAGGGCCATGGCTC 3676
Db 18 CCTGCAGTGCATGGCGC 1

RESULT 973
US-10-671-395-1039/c
; Sequence 1039, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K.
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395

```

```
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1039
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1039

Query Match      0.4%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 7.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2361 GTGTGCTGTGTGCTGTC 2378
Db 19 GTGGGCTGTGTGTGTC 2

RESULT 974
US-10-671-395-1106/c
; Sequence 1106, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; PRIOR FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1106
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1106

Query Match      0.4%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 7.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2361 GTGTGCTGTGTGCTGTC 2378
Db 19 GTGGGCTGTGTGTGTC 1

RESULT 975
US-10-671-395-1219/c
; Sequence 1219, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; PRIOR FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1219
; LENGTH: 20
```

```
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1219

Query Match      0.4%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 7.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2322 TGTGTGTGTGTGCTGTG 2339
Db 18 TGTGTGTGTGCCGTGTG 1

RESULT 976
US-10-671-395-1343/c
; Sequence 1343, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; PRIOR FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1343
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1343

Query Match      0.4%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 7.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2315 GTCTGTGTGTGTGTGT 2332
Db 19 GTATGTGTGTGTGTGT 2

RESULT 977
US-10-671-395-1366/c
; Sequence 1366, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; PRIOR FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1366
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1366

Query Match      0.4%; Score 14.8; DB 1; Length 20;
```

Best Local Similarity 88.9%; Pred. No. 7.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2315 GTCTGTGTGTGTGTGT 2332
Db 20 GTATGTGTGTGTATGT 3

RESULT 978
US-10-671-395-1597/c
; Sequence 1597, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR FILING DATE: 2002-09-25
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1597
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1597

Query Match 0.4%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 7.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2336 TGTGTGTGTGTGTGCA 2353
Db 19 TGTGTGTGTGTGTGTA 2

RESULT 979
US-10-671-395-1728/c
; Sequence 1728, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR FILING DATE: 2002-09-25
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1728
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1728

Query Match 0.4%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 7.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2316 TCTGTGTGTGTGTGTG 2333
Db 20 TATGTGTGTGTGTGTG 3

RESULT 980
US-10-744-730-5/c
; Sequence 5, Application US/10744730
; Publication No. US20040137491A1
; GENERAL INFORMATION:
; APPLICANT: Tadashi, OKAMOTO
; APPLICANT: Hiromitsu, TAKASE
; APPLICANT: Hiroyuki, HASHIMOTO
; TITLE OF INVENTION: METHOD OF ANALYZING PROBE CARRIER USING TIME-OF-FLIGHT SECONDARY
; TITLE OF INVENTION: ION MASS SPECTROMETRY
; FILE REFERENCE: CF017354US
; CURRENT APPLICATION NUMBER: US/10/744,730
; CURRENT FILING DATE: 2003-12-23
; PRIOR APPLICATION NUMBER: JP 2002-190010
; PRIOR FILING DATE: 2002-06-28
; PRIOR APPLICATION NUMBER: JP 2002-191391
; PRIOR FILING DATE: 2002-06-28
; PRIOR APPLICATION NUMBER: JP 2002-191414
; PRIOR FILING DATE: 2002-06-28
; NUMBER OF SEQ ID NOS: 11
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 5
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Sequence for Target
US-10-744-730-5

Query Match 0.4%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 7.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2695 CCACCTCCACCCCTGCC 2712
Db 19 CCACCTGCCACCCCTGCAC 2

RESULT 981
US-09-765-081-37/c
; Sequence 37, Application US/09765081
; Patent No. US20020037508A1
; GENERAL INFORMATION:
; APPLICANT: Cargill, Michele
; APPLICANT: Ireland, James S.
; APPLICANT: Lander, Eric S.
; TITLE OF INVENTION: HUMAN SINGLE NUCLEOTIDE POLYMORPHISMS
; FILE REFERENCE: 2825.2008-001
; CURRENT APPLICATION NUMBER: US/09/765,081
; CURRENT FILING DATE: 2001-01-18
; PRIOR APPLICATION NUMBER: US 60/176,861
; PRIOR FILING DATE: 2000-01-19
; NUMBER OF SEQ ID NOS: 461
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 37
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-765-081-37

Query Match 0.4%; Score 14.8; DB 1; Length 21;
Best Local Similarity 88.9%; Pred. No. 7.9e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 839 TGGTGTGCCAGCCGAG 856
Db 19 TGGTGTGTCAGCCAGG 2

RESULT 982
US-09-765-081-266/c
; Sequence 266, Application US/09765081

<p>Patent No. US20020037508A1</p> <p>GENERAL INFORMATION:</p> <p>APPLICANT: Cargill, Michele</p> <p>APPLICANT: Ireland, James S.</p> <p>APPLICANT: Lander, Eric S.</p> <p>TITLE OF INVENTION: HUMAN SINGLE NUCLEOTIDE POLYMORPHISMS</p> <p>FILE REFERENCE: 2825-2008-001</p> <p>CURRENT APPLICATION NUMBER: US/09/765,081</p> <p>CURRENT FILING DATE: 2001-01-18</p> <p>PRIOR APPLICATION NUMBER: US 60/176,861</p> <p>PRIOR FILING DATE: 2000-01-19</p> <p>NUMBER OF SEQ ID NOS: 461</p> <p>SOFTWARE: FastSeq for Windows Version 4.0</p> <p>SEQ ID NO 266</p> <p>LENGTH: 21</p> <p>TYPE: DNA</p> <p>ORGANISM: Homo sapiens</p> <p>US-09-765-081-266</p>	<p>Query Match 0.4%; Score 14.8; DB 1; Length 21;</p> <p>Best Local Similarity 80.0%; Pred. No. 7.9e+02;</p> <p>Matches 16; Conservative 1; Mismatches 3; Indels 0; Gaps 0;</p>
<p>QY 2082 GTACTCCCGGGTGGCCAGG 2101</p> <p>DB 20 GTCTGCGCGGAGGCCAGG 1</p>	
<p>RESULT 983</p> <p>US-09-932-300-43</p> <p>Sequence 43, Application US/09932300</p> <p>Publication No. US20030032788A1</p> <p>GENERAL INFORMATION:</p> <p>APPLICANT: GARVER, Eric</p> <p>APPLICANT: TU, Guang-Chou</p> <p>APPLICANT: ISRAEL, Yedy</p> <p>TITLE OF INVENTION: METHODS OF INHIBITING ALCOHOL CONSUMPTION</p> <p>FILE REFERENCE: 9855-302</p> <p>CURRENT APPLICATION NUMBER: US/09/932,300</p> <p>CURRENT FILING DATE: 2001-08-20</p> <p>PRIOR APPLICATION NUMBER: US 60/051,705</p> <p>PRIOR FILING DATE: 1997-07-03</p> <p>PRIOR APPLICATION NUMBER: US 09/109,663</p> <p>PRIOR FILING DATE: 1998-07-02</p> <p>NUMBER OF SEQ ID NOS: 111</p> <p>SOFTWARE: PatentIn Ver. 2.1</p> <p>SEQ ID NO 43</p> <p>LENGTH: 21</p> <p>TYPE: DNA</p> <p>ORGANISM: Artificial Sequence</p> <p>FEATURE:</p> <p>OTHER INFORMATION: Description of Artificial Sequence: Candidate</p> <p>OTHER INFORMATION: TNF(alpha) ASO</p> <p>US-09-932-300-43</p>	
<p>Query Match 0.4%; Score 14.8; DB 1; Length 21;</p> <p>Best Local Similarity 88.9%; Pred. No. 7.9e+02;</p> <p>Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;</p>	
<p>QY 1806 CTGGTCCTTTGGGGTCTT 1823</p> <p>DB 1 CTGGTCCTTTGGGTCTT 18</p>	
<p>RESULT 984</p> <p>US-09-864-636A-1134</p> <p>Sequence 1134, Application US/09864636A</p> <p>Publication No. US20030104378A1</p> <p>GENERAL INFORMATION:</p> <p>APPLICANT: Third Wave Technologies</p> <p>APPLICANT: Allwai, Hatim</p> <p>APPLICANT: Bartholomay, Christian</p> <p>APPLICANT: Chehak, LuAnne</p>	
<p>Query Match 0.4%; Score 14.8; DB 1; Length 21;</p> <p>Best Local Similarity 88.9%; Pred. No. 7.9e+02;</p> <p>Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;</p>	
<p>QY 2276 GACTCAGTGCAGATGGAG 2293</p> <p>DB 1 GAATCAGTGAAGATGGAG 18</p>	
<p>RESULT 985</p> <p>US-09-864-426A-1134</p> <p>Sequence 1134, Application US/09864426A</p> <p>Publication No. US20040018489A1</p> <p>GENERAL INFORMATION:</p> <p>APPLICANT: Third Wave Technologies</p> <p>APPLICANT: Ma, Wu Po</p> <p>APPLICANT: Lyamichev, Victor</p> <p>APPLICANT: Saiser, Michael</p> <p>TITLE OF INVENTION: Enzymes for the Detection of RNA Sequences</p> <p>FILE REFERENCE: FORS-04946</p> <p>CURRENT APPLICATION NUMBER: US/09/864,426A</p> <p>CURRENT FILING DATE: 2001-05-24</p> <p>NUMBER OF SEQ ID NOS: 2640</p> <p>SOFTWARE: PatentIn version 3.0</p> <p>SEQ ID NO 1134</p> <p>LENGTH: 21</p> <p>TYPE: DNA</p> <p>ORGANISM: Artificial Sequence</p> <p>FEATURE:</p> <p>OTHER INFORMATION: Synthetic</p> <p>US-09-864-426A-1134</p>	
<p>Query Match 0.4%; Score 14.8; DB 1; Length 21;</p> <p>Best Local Similarity 88.9%; Pred. No. 7.9e+02;</p> <p>Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;</p>	
<p>QY 2276 GACTCAGTGCAGATGGAG 2293</p> <p>DB 1 GAATCAGTGAAGATGGAG 18</p>	
<p>RESULT 986</p> <p>US-10-016-505-6</p> <p>Sequence 6, Application US/10016505</p> <p>Publication No. US20020086324A1</p> <p>GENERAL INFORMATION:</p> <p>APPLICANT: Peter W. Laird, Cindy A. Eads and Kathleen D. Danenberg</p> <p>TITLE OF INVENTION: PROCESS FOR HIGH THROUGHPUT DNA METHYLATION</p> <p>NUMBER OF SEQUENCES: 54</p> <p>CORRESPONDENCE ADDRESS:</p> <p>ADDRESSEE: Davis Wright Tremaine LLP</p> <p>STREET: 1501 Fourth Avenue</p> <p>2600 Century Square</p> <p>CITY: Seattle</p> <p>STATE: Washington</p> <p>COUNTRY: USA</p> <p>ZIP: 98101-1688</p> <p>COMPUTER READABLE FORM:</p>	
<p>Query Match 0.4%; Score 14.8; DB 1; Length 21;</p> <p>Best Local Similarity 88.9%; Pred. No. 7.9e+02;</p> <p>Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;</p>	
<p>QY 2276 GACTCAGTGCAGATGGAG 2293</p> <p>DB 1 GAATCAGTGAAGATGGAG 18</p>	

MEDIUM TYPE: Diskette-3.5 inch, 1.44 MB storage
COMPUTER: PC compatible
OPERATING SYSTEM: Windows 95
SOFTWARE: Word 97
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/10/016,505
FILING DATE: 10-Dec-2001
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 09/311,912
FILING DATE: May 14, 1999
ATTORNEY/AGENT INFORMATION:
NAME: Barry L. Davison
REGISTRATION NUMBER: 47,309
REFERENCE/DOCKET NUMBER: 47675-9
TELECOMMUNICATION INFORMATION:
TELEPHONE: (206) 628-7621
TELEFAX: (206) 628-7699
INFORMATION FOR SEQ ID NO: 6:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
HYPOTHETICAL: NO
SEQUENCE DESCRIPTION: SEQ ID NO: 6:
US-10-016-505-6

Query Match 0.4%; Score 14.8; DB 1; Length 21;
Best Local Similarity 88.9%; Pred. No. 7.9e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 857 AGGAGCTGGTGGAGGCTG 874
|||||
Db 1 AGGAGTTGGTGGAGGCTG 18

RESULT 987
US-10-085-906-490/c
Sequence 490, Application US/10085906
Publication No. US20030054371A1
GENERAL INFORMATION:
APPLICANT: Ying, Vincent
APPLICANT: Wu, Paul
APPLICANT: Gray, Gary S.
TITLE OF INVENTION: POLYMORPHIC ELEMENTS IN THE
FILE OF INVENTION: COSTIMULATORY RECEPTOR LOCUS AND USES THEREOF
FILE REFERENCE: GNN-5343CP2
CURRENT APPLICATION NUMBER: US/10/085,906
CURRENT FILING DATE: 2002-02-27
PRIOR APPLICATION NUMBER: US 60/126,215
PRIOR FILING DATE: 1999-03-25
PRIOR APPLICATION NUMBER: US 09/534,061
PRIOR FILING DATE: 2000-03-24
PRIOR APPLICATION NUMBER: PCT/US00/07938
PRIOR FILING DATE: 2000-03-24
NUMBER OF SEQ ID NOS: 545
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 490
LENGTH: 21
TYPE: DNA
ORGANISM: Homo sapiens
US-10-085-906-490

Query Match 0.4%; Score 14.8; DB 1; Length 21;
Best Local Similarity 88.9%; Pred. No. 7.9e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2835 TATATATACATATAT 2852
|||||
Db 21 TATATGACACATATAT 4

RESULT 988
US-10-023-066A-46/c
Sequence 46, Application US/10023066A
Publication No. US20030056242A1
GENERAL INFORMATION:
APPLICANT: E. I. DU PONT DE NEMOURS AND COMPANY
TITLE OF INVENTION: CHIMERIC GENES AND METHODS FOR INCREASING THE LYSINE AND THREONINE CONTENT OF THE SEEDS OF PLANTS
NUMBER OF SEQUENCES: 107
CORRESPONDENCE ADDRESS:
ADDRESSEE: E. I. DU PONT DE NEMOURS AND COMPANY
STREET: 1007 MARKET STREET
CITY: WILMINGTON
STATE: DELAWARE
COUNTRY: U.S.A.
ZIP: 19898
COMPUTER READABLE FORM:
MEDIUM TYPE: FLOPPY DISK
COMPUTER: IBM PC COMPATIBLE
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: MICROSOFT WORD VERSION 2.0C
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/10/023,066A
FILING DATE: 29-Apr-2002
CLASSIFICATION: <Unknown>
ATTORNEY/AGENT INFORMATION:
NAME: BARBARA C. SIEGELL
REGISTRATION NUMBER: 30,684
REFERENCE/DOCKET NUMBER: BB-1037-C
TELECOMMUNICATION INFORMATION:
TELEPHONE: 302-992-4931
TELEFAX: 302-773-0164
TELEX: 835420
INFORMATION FOR SEQ ID NO: 46:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
FEATURE:
NAME/KEY: misc_feature
LOCATION: 1..21
OTHER INFORMATION: /product= "synthetic"
oligonucleotide
/standard_name= "SM
91"
SEQUENCE DESCRIPTION: SEQ ID NO: 46:
US-10-023-066A-46

Query Match 0.4%; Score 14.8; DB 1; Length 21;
Best Local Similarity 88.9%; Pred. No. 7.9e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1353 GGAGATGATGAAGATGAT 1370
|||||
Db 18 GGAGAGATGAAGAAGAT 1

RESULT 989
US-10-261-189-5/c
Sequence 5, Application US/10261189
Publication No. US20030074690A1
GENERAL INFORMATION:
APPLICANT: Kavanagh, T.
APPLICANT: Lao, N.
TITLE OF INVENTION: A NOVEL PLASTID-TARGETING NUCLEIC ACID SEQUENCE, A NOVEL BETA-AMYLASE SEQUENCE, A STIMULUS-RESPONSIVE

```
; TITLE OF INVENTION: PROMOTER AND USES THEREOF
; FILE REFERENCE: 9341-017
; CURRENT APPLICATION NUMBER: US/10/261,189
; CURRENT FILING DATE: 2002-09-30
; PRIOR APPLICATION NUMBER: US/09/375,140
; PRIOR FILING DATE: 1999-08-16
; NUMBER OF SEQ ID NOS: 11
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 5
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-261-189-5

Query Match      0.4%; Score 14.8; DB 1; Length 21;
Best Local Similarity 88.9%; Pred. No. 7.9e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2213 AACAAATGTGAGGGTCCC 2230
Db 19 AACAAATGTGAGGGATCCC 2

RESULT 990
US-10-090-011-49/c
; Sequence 49, Application US/10090011
; Publication No. US20030082810A1
; GENERAL INFORMATION:
; APPLICANT: Serup, Palle
; APPLICANT: Heimberg, Harry
; APPLICANT: Gradwohl, Gerard
; TITLE OF INVENTION: Methods For Generating Insulin-Secreting
; TITLE OF INVENTION: Cells Suitable for Transplantation
; FILE REFERENCE: 6246.200-US
; CURRENT APPLICATION NUMBER: US/10/090,011
; CURRENT FILING DATE: 2002-02-26
; PRIOR APPLICATION NUMBER: US 60/271,474
; PRIOR FILING DATE: 2001-02-26
; NUMBER OF SEQ ID NOS: 70
; SOFTWARE: Fast-SEQ for Windows Version 4.0
; SEQ ID NO 49
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-090-011-49

Query Match      0.4%; Score 14.8; DB 1; Length 21;
Best Local Similarity 88.9%; Pred. No. 7.9e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 472 AAGTTTGGCAGATCCGG 489
Db 18 AAGTTTGGCGTCATCCGG 1

RESULT 991
US-10-311-946-21
; Sequence 21, Application US/10311946
; Publication No. US20030109481A1
; GENERAL INFORMATION:
; APPLICANT: Anne Isabelle Gallani, Georges Imbert, Wilhelm Krek
; TITLE OF INVENTION: Tumour-Cell Specific Gene Expression and its Use in Cancer Therap
; FILE REFERENCE: 1-31520PI/FWI
; CURRENT APPLICATION NUMBER: US/10/311,946
; CURRENT FILING DATE: 2002-12-19
; NUMBER OF SEQ ID NOS: 37
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 21
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
```

```
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:oligonucleotide
US-10-311-946-21

Query Match      0.4%; Score 14.8; DB 1; Length 21;
Best Local Similarity 88.9%; Pred. No. 7.9e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2700 TCCACCCCTGCCCTCAG 2717
Db 3 TCCACCCCGGCACCTCAG 20

RESULT 992
US-10-084-839-1134
; Sequence 1134, Application US/10084839
; Publication No. US20030186238A1
; GENERAL INFORMATION:
; APPLICANT: Third Wave Technologies
; APPLICANT: Allawi, Hatim
; APPLICANT: Argue, Brad T.
; APPLICANT: Bartholomay, Christian T.
; APPLICANT: Chehak, InAnne
; APPLICANT: Curtis, Michelle L.
; APPLICANT: Eis, Peggy S.
; APPLICANT: Hall, Jeff G.
; APPLICANT: Ip, Hon S.
; APPLICANT: Ji, Lin
; APPLICANT: Kaiser, Michael
; APPLICANT: Kwiatkowski, Jr., Robert W.
; APPLICANT: Lukowiak, Andrew A.
; APPLICANT: Lyamichev, Victor
; APPLICANT: Lymaicheva, Natalie E.
; APPLICANT: Ma, WuPo
; APPLICANT: Neri, Bruce P.
; APPLICANT: Olson, Sarah M.
; APPLICANT: Olson-Munoz, Marilyn C.
; APPLICANT: Schaefer, James J.
; APPLICANT: Skrzypczynski, Zbigniew
; APPLICANT: Takova, Tsatska Y.
; APPLICANT: Thompson, Lisa C.
; APPLICANT: Vedvik, Kevin L.
; TITLE OF INVENTION: RNA Detection Assays
; FILE REFERENCE: FORS-06666
; CURRENT APPLICATION NUMBER: US/10/084,839
; CURRENT FILING DATE: 2002-02-26
; NUMBER OF SEQ ID NOS: 4004
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 1134
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-084-839-1134

Query Match      0.4%; Score 14.8; DB 1; Length 21;
Best Local Similarity 88.9%; Pred. No. 7.9e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2276 GACTCAGTCGATCGAG 2293
Db 1 GAATCAGTGAAGATCGAG 18

RESULT 993
US-10-452-510-204
; Sequence 204, Application US/10452510
; Publication No. US20040005666A1
; GENERAL INFORMATION:
; APPLICANT: Hayden, Michael R.
; APPLICANT: Brooks-Wilson, Angela R.
; TITLE OF INVENTION: METHODS AND REAGENTS FOR MODULATING CHOLESTEROL LEVELS
```

```
; FILE REFERENCE: 760050-93
; CURRENT APPLICATION NUMBER: US/10/452,510
; CURRENT FILING DATE: 2003-06-02
; PRIOR APPLICATION NUMBER: US 09/526,193
; PRIOR FILING DATE: 2000-03-15
; PRIOR APPLICATION NUMBER: 60/124,702
; PRIOR FILING DATE: 1999-03-15
; PRIOR APPLICATION NUMBER: 60/138,048
; PRIOR FILING DATE: 1999-06-08
; PRIOR APPLICATION NUMBER: 60/139,600
; PRIOR FILING DATE: 1999-06-17
; PRIOR APPLICATION NUMBER: 60/151,977
; PRIOR FILING DATE: 1999-09-01
; NUMBER OF SEQ ID NOS: 287
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 204
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-452-510-204

Query Match          0.4%; Score 14.8; DB 1; Length 21;
Best Local Similarity 88.9%; Pred. No. 7.9e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 497 ACACGCTGGACGTGCTGG 514
|||||
Db 1 ACACGCTGGGGTGTCTGG 18

RESULT 994
US-10-401-520-135/c
; Sequence 135, Application US/10401520
; Publication No. US2004009506A1
; GENERAL INFORMATION:
; APPLICANT: Stephen, Jean-Philippe F.
; APPLICANT: Tsai, Siao Ping
; APPLICANT: Wong, Wai Lee Tan
; APPLICANT: Billeci, Todd
; TITLE OF INVENTION: Methods and Compositions for Detection and
; TITLE OF INVENTION: Quantitation of Nucleic Acid Analytes
; FILE REFERENCE: P1806R1US
; CURRENT APPLICATION NUMBER: US/10/401,520
; CURRENT FILING DATE: 2003-03-28
; PRIOR APPLICATION NUMBER: US 60/368,669
; PRIOR FILING DATE: 2002-03-29
; NUMBER OF SEQ ID NOS: 138
; SEQ ID NO 135
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Synthetic primer
US-10-401-520-135

Query Match          0.4%; Score 14.8; DB 1; Length 21;
Best Local Similarity 88.9%; Pred. No. 7.9e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1522 AAGCCGCCGAGGAGCAG 1539
|||||
Db 18 AAGCCGCCGAGGAGCAG 1

RESULT 995
US-10-398-757-3/c
; Sequence 3, Application US/10398757
; Publication No. US20040029247A1
; GENERAL INFORMATION:
; APPLICANT: Bayer AG
; TITLE OF INVENTION: REGULATION OF HUMAN ADENYLATE CYCLASE, TYPE IV
; FILE REFERENCE: RCK-6 Foreign Countries
; CURRENT APPLICATION NUMBER: US/10/398,757
```

```
; CURRENT FILING DATE: 2003-04-10
; PRIOR APPLICATION NUMBER: US 60/241,306
; PRIOR FILING DATE: 2000-10-18
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 3
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc feature
; OTHER INFORMATION: Primer: AC4-L1
US-10-398-757-3

Query Match          0.4%; Score 14.8; DB 1; Length 21;
Best Local Similarity 88.9%; Pred. No. 7.9e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 868 GAGGCTGACGAGCGGCG 885
|||||
Db 21 GGGGCTGAAGAGCGGCG 4

RESULT 996
US-10-617-334-204
; Sequence 204, Application US/10617334
; Publication No. US20040058869A1
; GENERAL INFORMATION:
; APPLICANT: Hayden, Michael R.
; APPLICANT: Brooks-Wilson, Angela R.
; TITLE OF INVENTION: METHODS AND REAGENTS FOR MODULATING CHOLESTEROL LEVELS
; FILE REFERENCE: 760050-91
; CURRENT APPLICATION NUMBER: US/10/617,334
; CURRENT FILING DATE: 2003-07-10
; PRIOR APPLICATION NUMBER: US 09/526,193
; PRIOR FILING DATE: 2000-03-15
; PRIOR APPLICATION NUMBER: 60/124,702
; PRIOR FILING DATE: 1999-03-15
; PRIOR APPLICATION NUMBER: 60/138,048
; PRIOR FILING DATE: 1999-06-08
; PRIOR APPLICATION NUMBER: 60/139,600
; PRIOR FILING DATE: 1999-06-17
; PRIOR APPLICATION NUMBER: 60/151,977
; PRIOR FILING DATE: 1999-09-01
; NUMBER OF SEQ ID NOS: 287
; SOFTWARE: PatentIn 3.0
; SEQ ID NO 204
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-617-334-204

Query Match          0.4%; Score 14.8; DB 1; Length 21;
Best Local Similarity 88.9%; Pred. No. 7.9e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 497 ACACGCTGGACGTGCTGG 514
|||||
Db 1 ACACGCTGGGGTGTCTGG 18

RESULT 997
US-10-648-593-311/c
; Sequence 311, Application US/10648593
; Publication No. US20040106132A1
; GENERAL INFORMATION:
; APPLICANT: Bristol-Myers Squibb Company
; TITLE OF INVENTION: IDENTIFICATION OF GENES FOR PREDICTING ACTIVITY OF COMPOUNDS THAT
; TITLE OF INVENTION: INTERACT WITH AND/OR MODULATE PROTEIN TYROSINE KINASES AND/OR
; TITLE OF INVENTION: PROTEIN TYROSINE KINASE PATHWAYS IN BREAST CELLS
; FILE REFERENCE: D0273 NP
; CURRENT APPLICATION NUMBER: US/10/648,593
; CURRENT FILING DATE: 2003-08-26
```

; PRIOR APPLICATION NUMBER: 60/406,385
; PRIOR FILING DATE: 2002-08-27
; NUMBER OF SEQ ID NOS: 557
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 311
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-648-593-311

Query Match 0.4%; Score 14.8; DB 1; Length 21;
Best Local Similarity 88.9%; Pred. No. 7.9e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2316 TCTGTGTGTGTGTGTG 2333
Db 18 TCTGTGTGTGTGTGTCATG 1

RESULT 998
US-10-702-496-160
; Sequence 160, Application US/10702496
; Publication No. US20040121383A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Liu, Wei
; APPLICANT: Wu, Leeyang
; TITLE OF INVENTION: COMPOSITIONS, ORGANISMS AND METHODOLOGIES EMPLOYING A NOVEL HUMAN
; TITLE OF INVENTION: KINASE
; FILE REFERENCE: AM101071
; CURRENT APPLICATION NUMBER: US/10/702,496
; CURRENT FILING DATE: 2003-11-07
; PRIOR APPLICATION NUMBER: 60/429,381
; PRIOR FILING DATE: 2002-11-27
; NUMBER OF SEQ ID NOS: 306
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 160
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-702-496-160

Query Match 0.4%; Score 14.8; DB 1; Length 21;
Best Local Similarity 88.9%; Pred. No. 7.9e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2046 CGAGGACTACTGTGACCT 2063
Db 3 CGAGGAGTACCTGTACCT 20

RESULT 999
US-10-745-377-118
; Sequence 118, Application US/10745377
; Publication No. US20040137423A1
; GENERAL INFORMATION:
; APPLICANT: Hayden, Michael R.
; APPLICANT: Pimstone, Simon
; APPLICANT: Brooks-Wilson, Angela R.
; APPLICANT: Clee, Susanne M.
; TITLE OF INVENTION: Compositions and Methods for Modulating
; TITLE OF INVENTION: HDL Cholesterol and Triglyceride Levels
; FILE REFERENCE: 760050-109
; CURRENT APPLICATION NUMBER: US/10/745,377
; CURRENT FILING DATE: 2003-12-23
; PRIOR APPLICATION NUMBER: 09/654,323
; PRIOR FILING DATE: 2000-09-01
; PRIOR APPLICATION NUMBER: US 60/124,702
; PRIOR FILING DATE: 1999-03-15
; PRIOR APPLICATION NUMBER: US 60/138,048
; PRIOR FILING DATE: 1999-06-08
; PRIOR APPLICATION NUMBER: US 60/139,600
; PRIOR FILING DATE: 1999-06-17

; PRIOR APPLICATION NUMBER: US 60/151,977
; PRIOR FILING DATE: 1999-09-01
; PRIOR APPLICATION NUMBER: US 09/526,193
; PRIOR FILING DATE: 2000-03-15
; PRIOR APPLICATION NUMBER: US 60/213,958
; PRIOR FILING DATE: 2000-06-23
; NUMBER OF SEQ ID NOS: 256
; SOFTWARE: Word for Windows Version 6.0 (ASCII Text)
; SEQ ID NO 118
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapien
US-10-745-377-118

Query Match 0.4%; Score 14.8; DB 1; Length 21;
Best Local Similarity 88.9%; Pred. No. 7.9e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 497 ACACGCTGGACGTCTGG 514
Db 1 ACACGCTGGGGTGTCTGG 18

RESULT 1000
US-10-665-951-2275
; Sequence 2275, Application US/10665951
; Publication No. US20040138163A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: 400/131 (MEHB02-742-F)
; CURRENT APPLICATION NUMBER: US/10/665,951
; CURRENT FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/287,949
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: PCT/US 02/17674
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2455
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2275
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)-(21)
; OTHER INFORMATION: n stands for thymidine
US-10-665-951-2275

; PRIOR APPLICATION NUMBER: US 60/399,348
 ; PRIOR FILING DATE: 2002-07-29
 ; PRIOR APPLICATION NUMBER: US 60/393,796
 ; PRIOR FILING DATE: 2002-07-03
 ; PRIOR APPLICATION NUMBER: US 10/287,949
 ; PRIOR FILING DATE: 2002-11-04
 ; PRIOR APPLICATION NUMBER: US 10/306,747
 ; PRIOR FILING DATE: 2002-11-27
 ; PRIOR APPLICATION NUMBER: PCT/US 02/17674
 ; PRIOR FILING DATE: 2002-05-29
 ; PRIOR APPLICATION NUMBER: US 60/358,580
 ; PRIOR FILING DATE: 2002-02-20
 ; PRIOR APPLICATION NUMBER: US 60/363,124
 ; PRIOR FILING DATE: 2002-03-11
 ; PRIOR APPLICATION NUMBER: US 60/386,782
 ; PRIOR FILING DATE: 2002-06-06
 ; Remaining prior Application data removed - See File Wrapper or PALM.
 ; NUMBER OF SEQ ID NOS: 2455
 ; SOFTWARE: PatentIn version 3.2
 ; SEQ ID NO 2386
 ; LENGTH: 21
 ; TYPE: RNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
 ; NAME/KEY: misc.feature
 ; LOCATION: (20)..(21)
 ; OTHER INFORMATION: n stands for thymidine
 ; US-10-665-951-2386

Query Match 0.4%; Score 14.8; DB 1; Length 21;
 Best Local Similarity 88.9%; Pred. No. 7.9e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1953 CATCGGAGTGTGGCA 1970
 Db 18 CATGCTGACTGTGGCA 1

RESULT 1004
 US-10-744-465-204
 ; Sequence 204, Application US/10744465
 ; Publication No. US20040157250A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Hayden, Michael R.
 ; APPLICANT: Brooks-Wilson, Angela R.
 ; APPLICANT: Pimstone, Simon N.
 ; TITLE OF INVENTION: METHODS AND REAGENTS FOR MODULATING CHOLESTEROL LEVELS
 ; FILE REFERENCE: 760050-92
 ; CURRENT APPLICATION NUMBER: US/10/744,465
 ; CURRENT FILING DATE: 2003-12-23
 ; PRIOR APPLICATION NUMBER: 10/617,334
 ; PRIOR FILING DATE: 2003-07-10
 ; PRIOR APPLICATION NUMBER: US 09/526,193
 ; PRIOR FILING DATE: 2000-03-15
 ; PRIOR APPLICATION NUMBER: 60/124,702
 ; PRIOR FILING DATE: 1999-03-15
 ; PRIOR APPLICATION NUMBER: 60/138,048
 ; PRIOR FILING DATE: 1999-06-08
 ; PRIOR APPLICATION NUMBER: 60/139,600
 ; PRIOR FILING DATE: 1999-06-17
 ; PRIOR APPLICATION NUMBER: 60/151,977
 ; PRIOR FILING DATE: 1999-09-01
 ; NUMBER OF SEQ ID NOS: 287
 ; SOFTWARE: FastSeq for Windows Version 4.0
 ; SEQ ID NO 204
 ; LENGTH: 21
 ; TYPE: DNA
 ; ORGANISM: Homo sapiens
 ; US-10-744-465-204

Query Match 0.4%; Score 14.8; DB 1; Length 21;

Best Local Similarity 88.9%; Pred. No. 7.9e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 Qy 497 ACACGCTGGACGTGTGG 514
 Db 1 ACACGCTGGGGTGTGG 18
 RESULT 1005
 US-10-627-253A-245/c
 ; Sequence 245, Application US/10627253A
 ; Publication No. US20040161768A1
 ; GENERAL INFORMATION:
 ; APPLICANT: BRINKMANN, ULRICH
 ; APPLICANT: HOFFMEYER, SVEN
 ; APPLICANT: MORNHINWEG, ESTHER
 ; TITLE OF INVENTION: POLYMORPHISMS IN THE HUMAN GENE FOR THE MULTIDRUG
 ; TITLE OF INVENTION: RESISTANCE-ASSOCIATED PROTEIN 1 (MRP-1) AND THEIR USE IN
 ; TITLE OF INVENTION: DIAGNOSTIC AND THERAPEUTIC APPLICATIONS
 ; FILE REFERENCE: VOS-42 CON
 ; CURRENT APPLICATION NUMBER: US/10/627,253A
 ; CURRENT FILING DATE: 2003-07-24
 ; PRIOR APPLICATION NUMBER: PCT/EP02/00796
 ; PRIOR FILING DATE: 2002-01-25
 ; PRIOR APPLICATION NUMBER: EP 01101651.6
 ; NUMBER OF SEQ ID NOS: 406
 ; SOFTWARE: PatentIn version 3.2
 ; SEQ ID NO 245
 ; LENGTH: 21
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Description of Artificial Sequence: Synthetic oligonucleotide
 ; US-10-627-253A-245

Query Match 0.4%; Score 14.8; DB 1; Length 21;
 Best Local Similarity 88.9%; Pred. No. 7.9e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2791 TACATTTCTATAATAGA 2808
 Db 20 TCATTTCTATAATAGA 3

RESULT 1006
 US-10-627-253A-246
 ; Sequence 246, Application US/10627253A
 ; Publication No. US20040161768A1
 ; GENERAL INFORMATION:
 ; APPLICANT: BRINKMANN, ULRICH
 ; APPLICANT: HOFFMEYER, SVEN
 ; APPLICANT: MORNHINWEG, ESTHER
 ; TITLE OF INVENTION: POLYMORPHISMS IN THE HUMAN GENE FOR THE MULTIDRUG
 ; TITLE OF INVENTION: RESISTANCE-ASSOCIATED PROTEIN 1 (MRP-1) AND THEIR USE IN
 ; TITLE OF INVENTION: DIAGNOSTIC AND THERAPEUTIC APPLICATIONS
 ; FILE REFERENCE: VOS-42 CON
 ; CURRENT APPLICATION NUMBER: US/10/627,253A
 ; CURRENT FILING DATE: 2003-07-24
 ; PRIOR APPLICATION NUMBER: PCT/EP02/00796
 ; PRIOR FILING DATE: 2002-01-25
 ; PRIOR APPLICATION NUMBER: EP 01101651.6
 ; NUMBER OF SEQ ID NOS: 406
 ; SOFTWARE: PatentIn version 3.2
 ; SEQ ID NO 246
 ; LENGTH: 21
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Description of Artificial Sequence: Synthetic oligonucleotide
 ; US-10-627-253A-246

Query Match 0.4%; Score 14.8; DB 1; Length 21;
Best Local Similarity 88.9%; Pred. No. 7.9e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2791 TACATTTCTATAAATAGA 2808
| | | | | | | | | | | | | | | | | | | | | |
Db 2 TCCATTTCTATAAATAGA 19

RESULT 1007

US-10-833-679-204
; Sequence 204, Application US/10833679
; Publication No. US20040185508A1
; GENERAL INFORMATION:
; APPLICANT: Brooks-Wilson, Angela R.
; APPLICANT: Pinstone, Simon N.
; TITLE OF INVENTION: METHODS AND REAGENTS FOR MODULATING CHOLESTEROL LEVELS
; FILE REFERENCE: 760050-135
; CURRENT APPLICATION NUMBER: US/10/833,679
; CURRENT FILING DATE: 2004-04-28
; PRIOR APPLICATION NUMBER: 10/452,510
; PRIOR FILING DATE: 2003-06-02
; PRIOR APPLICATION NUMBER: 10/617,334
; PRIOR FILING DATE: 2003-07-10
; PRIOR APPLICATION NUMBER: 09/526,193
; PRIOR FILING DATE: 2000-03-15
; PRIOR APPLICATION NUMBER: 60/124,702
; PRIOR FILING DATE: 1999-03-15
; PRIOR APPLICATION NUMBER: 60/138,048
; PRIOR FILING DATE: 1999-06-08
; PRIOR APPLICATION NUMBER: 60/139,600
; PRIOR FILING DATE: 1999-06-17
; PRIOR APPLICATION NUMBER: 60/151,977
; PRIOR FILING DATE: 1999-09-01
; NUMBER OF SEQ ID NOS: 287
; SOFTWARE: PatentIn 3.0
; SEQ ID NO 204
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-833-679-204

Query Match 0.4%; Score 14.8; DB 1; Length 21;
Best Local Similarity 88.9%; Pred. No. 7.9e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 497 ACACGCTGGAGCTGCTGG 514
| | | | | | | | | | | | | | | | | | | | | |
Db 1 ACACGCTGGGGTGTCTGG 18

RESULT 1008

US-10-786-720-3817/c
; Sequence 3817, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 3817
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-786-720-3817

Query Match 0.4%; Score 14.8; DB 1; Length 21;
Best Local Similarity 88.9%; Pred. No. 7.9e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 497 ACACGCTGGAGCTGCTGG 514
| | | | | | | | | | | | | | | | | | | | | |
Db 20 ACACGCTGTACGTGCTCG 3

RESULT 1009

US-10-786-720-3818/c
; Sequence 3818, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Liu, Wei
; APPLICANT: O'Toole, Margot
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 3818
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi-sense strand
US-10-786-720-3818

Query Match 0.4%; Score 14.8; DB 1; Length 21;
Best Local Similarity 88.9%; Pred. No. 7.9e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 497 ACACGCTGGAGCTGCTGG 514
| | | | | | | | | | | | | | | | | | | | | |
Db 18 ACACGCTGTACGTGCTCG 1

RESULT 1010

US-10-786-720-3819
; Sequence 3819, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 3819
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi-antisense strand
US-10-786-720-3819

Query Match 0.4%; Score 14.8; DB 1; Length 21;
Best Local Similarity 72.2%; Pred. No. 7.9e+02;
Matches 13; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 497 ACACGCTGGAGCTGCTGG 514
| | | | | | | | | | | | | | | | | | | | | |
Db 2 ACACGCTGUGACGUGCUCG 19

RESULT 1011

US-10-786-720-3820/c
; Sequence 3820, Application US/10786720
; Publication No. US20040191818A1

```
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 3820
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-786-720-3820

Query Match      0.4%; Score 14.8; DB 1; Length 21;
Best Local Similarity 88.9%; Pred. No. 7.9e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      495 GTACACGCTGACGTGCT 512
Db      19 GCACACGCTGTACGTGCT 2

RESULT 1012
US-10-786-720-3822
; Sequence 3822, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 3822
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai-antisense strand
US-10-786-720-3822

Query Match      0.4%; Score 14.8; DB 1; Length 21;
Best Local Similarity 72.2%; Pred. No. 7.9e+02;
Matches 13; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy      495 GTACACGCTGACGTGCT 512
Db      3 GCACACGUGUACGUGCU 20

RESULT 1013
US-10-786-720-4525/c
; Sequence 4525, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 4525
; LENGTH: 21
```

```
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-786-720-4525

Query Match      0.4%; Score 14.8; DB 1; Length 21;
Best Local Similarity 88.9%; Pred. No. 7.9e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      497 ACACGCTGGACGTGCTGG 514
Db      20 ACACGCTGTACGTGCTCG 3

RESULT 1014
US-10-786-720-4526/c
; Sequence 4526, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 4526
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai-sense strand
US-10-786-720-4526

Query Match      0.4%; Score 14.8; DB 1; Length 21;
Best Local Similarity 88.9%; Pred. No. 7.9e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      497 ACACGCTGGACGTGCTGG 514
Db      18 ACACGCTGTACGTGCTCG 1

RESULT 1015
US-10-786-720-4527
; Sequence 4527, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 4527
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai-antisense strand
US-10-786-720-4527

Query Match      0.4%; Score 14.8; DB 1; Length 21;
Best Local Similarity 72.2%; Pred. No. 7.9e+02;
Matches 13; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy      497 ACACGCTGGACGTGCTGG 514
Db      2 ACACGCTGUGACGUGCUG 19
```

```
RESULT 1016
US-10-786-720-4528/c
; Sequence 4528, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; TITLE OF INVENTION: DISEASES
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 4528
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-786-720-4528

Query Match      0.4%; Score 14.8; DB 1; Length 21;
Best Local Similarity 88.9%; Pred. No. 7.9e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 495 GTACACGCTGACGTGCT 512
Db 19 GCACACGCTGACGTGCT 2

RESULT 1017
US-10-786-720-4530
; Sequence 4530, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; TITLE OF INVENTION: DISEASES
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 4530
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai-antisense strand
US-10-786-720-4530

Query Match      0.4%; Score 14.8; DB 1; Length 21;
Best Local Similarity 72.2%; Pred. No. 7.9e+02;
Matches 13; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 495 GTACACGCTGACGTGCT 512
Db 3 GCACACGUGUACUGCU 20

RESULT 1018
US-10-786-720-5257/c
; Sequence 5257, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; TITLE OF INVENTION: DISEASES
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
```

```
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 5257
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-786-720-5257

Query Match      0.4%; Score 14.8; DB 1; Length 21;
Best Local Similarity 88.9%; Pred. No. 7.9e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 497 ACACGCTGGACGTGCTGG 514
Db 20 ACACGCTGTACGTGCTCG 3

RESULT 1019
US-10-786-720-5258/c
; Sequence 5258, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; TITLE OF INVENTION: DISEASES
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 5258
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai-sense strand
US-10-786-720-5258

Query Match      0.4%; Score 14.8; DB 1; Length 21;
Best Local Similarity 88.9%; Pred. No. 7.9e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 497 ACACGCTGGACGTGCTGG 514
Db 18 ACACGCTGTACGTGCTCG 1

RESULT 1020
US-10-786-720-5259
; Sequence 5259, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; TITLE OF INVENTION: DISEASES
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 5259
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai-antisense strand
US-10-786-720-5259

Query Match      0.4%; Score 14.8; DB 1; Length 21;
Best Local Similarity 72.2%; Pred. No. 7.9e+02;
Matches 13; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 497 ACACGCTGGACGTGCTGG 514
Db 18 ACACGCTGTACGTGCTCG 1
```

Db 2 ACACGUGUACGUGCUG 19
|||||:|||||:|
RESULT 1021
US-10-786-720-5260/c
; Sequence 5260, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 5260
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-786-720-5260
Query Match 0.4%; Score 14.8; DB 1; Length 21;
Best Local Similarity 88.9%; Pred. No. 7.9e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 495 GTACACGCTGACGTGCT 512
| |||||:|||||:
Db 19 GCACACGCTGACGTGCT 2
RESULT 1022
US-10-786-720-5262
; Sequence 5262, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 5262
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi-antisense strand
US-10-786-720-5262
Query Match 0.4%; Score 14.8; DB 1; Length 21;
Best Local Similarity 72.2%; Pred. No. 7.9e+02;
Matches 13; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
Qy 495 GTACACGCTGACGTGCT 512
| |||||:|||||:
Db 3 GCACACGUGUACGUGCU 20
RESULT 1023
US-10-786-720-17096/c
; Sequence 17096, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE

; TITLE OF INVENTION: DISEASES
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17096
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi-sense strand
US-10-786-720-17096
Query Match 0.4%; Score 14.8; DB 1; Length 21;
Best Local Similarity 88.9%; Pred. No. 7.9e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 2332 TGGCTGTGTGTGTGTGTG 2349
| |||||:|||||:
Db 18 TGCTTGTGTGTGTGTGTG 1
RESULT 1024
US-10-786-720-17105/c
; Sequence 17105, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17105
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi-sense strand
US-10-786-720-17105
Query Match 0.4%; Score 14.8; DB 1; Length 21;
Best Local Similarity 88.9%; Pred. No. 7.9e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 2325 GTGTGTGTGTGTGTGTGTG 2342
| |||||:|||||:
Db 19 GTGTGTGTGTGTGTGTG 2
RESULT 1025
US-10-786-720-17108/c
; Sequence 17108, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17108
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi-sense strand
US-10-786-720-17108
Query Match 0.4%; Score 14.8; DB 1; Length 21;

Best Local Similarity 88.9%; Pred. No. 7.9e+02; Mismatches 2; Indels 0; Gaps 0;
Matches 16; Conservative 0;
QY 2322 TGTGTGTGTGCGTGTG 2339
DB 18 TGTGTGTGTGCTGTGTG 1

RESULT 1026
US-10-786-720-18281/c
; Sequence 18281, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Liu, Wei
; APPLICANT: O'Toole, Margot
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 18281
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai-sense strand
US-10-786-720-18281

Query Match 0.4%; Score 14.8; DB 1; Length 21;
Best Local Similarity 88.9%; Pred. No. 7.9e+02; Mismatches 2; Indels 0; Gaps 0;
Matches 16; Conservative 0;
QY 2332 TGTGTGTGTGCGTGTG 2349
DB 18 TGCTGTGTGTGCTGTGTG 1

RESULT 1027
US-10-786-720-18290/c
; Sequence 18290, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Liu, Wei
; APPLICANT: O'Toole, Margot
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 18290
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai-sense strand
US-10-786-720-18290

Query Match 0.4%; Score 14.8; DB 1; Length 21;
Best Local Similarity 88.9%; Pred. No. 7.9e+02; Mismatches 2; Indels 0; Gaps 0;
Matches 16; Conservative 0;
QY 2325 GTGTGTGTGCGTGTGTG 2342
DB 19 GTGTGTGTGCTGTGTGTG 2

RESULT 1028
US-10-786-720-18293/c
; Sequence 18293, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:

; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 18293
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai-sense strand
US-10-786-720-18293

Query Match 0.4%; Score 14.8; DB 1; Length 21;
Best Local Similarity 88.9%; Pred. No. 7.9e+02; Mismatches 2; Indels 0; Gaps 0;
Matches 16; Conservative 0;
QY 2322 TGTGTGTGTGCGTGTG 2339
DB 18 TGTGTGTGTGCTGTGTG 1

RESULT 1029
US-10-786-720-20857/c
; Sequence 20857, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Liu, Wei
; APPLICANT: O'Toole, Margot
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 20857
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-786-720-20857

Query Match 0.4%; Score 14.8; DB 1; Length 21;
Best Local Similarity 88.9%; Pred. No. 7.9e+02; Mismatches 2; Indels 0; Gaps 0;
Matches 16; Conservative 0;
QY 1350 GATGGAGATGATGAAGAT 1367
DB 21 GATGAGAGAGATGAAGAT 4

RESULT 1030
US-10-786-720-20859
; Sequence 20859, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Liu, Wei
; APPLICANT: O'Toole, Margot
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 20859
; LENGTH: 21
; TYPE: RNA

```
; ORGANISM: RNAi-antisense strand
US-10-786-720-20859

Query Match      0.4%; Score 14.8; DB 1; Length 21;
Best Local Similarity 72.2%; Pred. No. 7.9e+02;
Matches 13; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1350 GATGGAGATGATGAAGAT 1367
   ||||| |||||
Db 1 GAUGAAGAGGAUGAAGAU 18

RESULT 1031
US-10-786-720-20990/c
; Sequence 20990, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; DISEASES
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 20990
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi-sense strand
US-10-786-720-20990

Query Match      0.4%; Score 14.8; DB 1; Length 21;
Best Local Similarity 88.9%; Pred. No. 7.9e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1349 AGATGGAGATGATGAAGA 1366
   ||||| |||||
Db 18 AGATGAAGAGGATGAAGA 1

RESULT 1032
US-10-085-906-144
; Sequence 144, Application US/10085906
; Publication No. US20030054371A1
; GENERAL INFORMATION:
; APPLICANT: Ying, Vincent
; APPLICANT: Wu, Paul
; APPLICANT: Gray, Gary S.
; TITLE OF INVENTION: POLYMORPHIC ELEMENTS IN THE
; COSTIMULATORY RECEPTOR LOCUS AND USES THEREOF
; FILE REFERENCE: GNN-5343CP2
; CURRENT APPLICATION NUMBER: US/10/085,906
; CURRENT FILING DATE: 2002-02-27
; PRIOR FILING DATE: 2000-03-25
; PRIOR FILING DATE: 1999-03-25
; PRIOR APPLICATION NUMBER: US 09/534,061
; PRIOR FILING DATE: 2000-03-24
; PRIOR APPLICATION NUMBER: PCT/US00/07938
; PRIOR FILING DATE: 2000-03-24
; NUMBER OF SEQ ID NOS: 545
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 144
; LENGTH: 26
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-085-906-144

Query Match      0.4%; Score 14.8; DB 1; Length 26;
Best Local Similarity 73.1%; Pred. No. 9.7e+02;
Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;
```

```
QY 3309 ATTTTCTTTTAGAGATTTATTTT 3334
   ||||| |||||
Db 1 ATTTTATTTTATTTTATTTT 26

RESULT 1033
US-09-725-265-6
; Sequence 6, Application US/09725265
; Publication No. US20010000175A1
; GENERAL INFORMATION:
; APPLICANT: KURANE, RYUICHIRO
; APPLICANT: KANAGAWA, TAKAHIRO
; APPLICANT: KANAGATA, YOICHI
; APPLICANT: YAMADA, KAZUTAKA
; APPLICANT: YOKOMAKU, TOYOKAZU
; APPLICANT: KOYAMA, OSAMU
; APPLICANT: FURUSHO, KENTA
; TITLE OF INVENTION: METHOD FOR DETERMINING A CONCENTRATION OF TARGET NUCLEIC ACID MOLE
; CULEIC ACID PROBES FOR THE METHOD, AND METHOD FOR ANALYZING DATA
; TITLE OF INVENTION: THE METHOD
; FILE REFERENCE: 199953USOXDIV
; CURRENT APPLICATION NUMBER: US/09/725,265
; CURRENT FILING DATE: 2000-11-29
; PRIOR APPLICATION NUMBER: US 09/556,127
; PRIOR FILING DATE: 2000-04-20
; PRIOR APPLICATION NUMBER: JP 1999-111601
; PRIOR FILING DATE: 1999-04-20
; NUMBER OF SEQ ID NOS: 70
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 6
; LENGTH: 30
; TYPE: DNA
; ORGANISM: ARTIFICIAL SEQUENCE
; OTHER INFORMATION: SYNTHETIC DNA
US-09-725-265-6

Query Match      0.4%; Score 14.8; DB 1; Length 30;
Best Local Similarity 73.1%; Pred. No. 1.1e+03;
Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 3259 AGATATTTTATTTGCTTTCCTTTT 3284
   ||||| |||||
Db 5 ATATTTTGTGTTTTTTT 30

RESULT 1034
US-09-725-265-7
; Sequence 7, Application US/09725265
; Publication No. US20010000175A1
; GENERAL INFORMATION:
; APPLICANT: KURANE, RYUICHIRO
; APPLICANT: KANAGAWA, TAKAHIRO
; APPLICANT: KANAGATA, YOICHI
; APPLICANT: YAMADA, KAZUTAKA
; APPLICANT: YOKOMAKU, TOYOKAZU
; APPLICANT: KOYAMA, OSAMU
; APPLICANT: FURUSHO, KENTA
; TITLE OF INVENTION: METHOD FOR DETERMINING A CONCENTRATION OF TARGET NUCLEIC ACID MOLE
; CULEIC ACID PROBES FOR THE METHOD, AND METHOD FOR ANALYZING DATA
; TITLE OF INVENTION: THE METHOD
; FILE REFERENCE: 199953USOXDIV
; CURRENT APPLICATION NUMBER: US/09/725,265
; CURRENT FILING DATE: 2000-11-29
; PRIOR APPLICATION NUMBER: US 09/556,127
; PRIOR FILING DATE: 2000-04-20
; PRIOR APPLICATION NUMBER: JP 1999-111601
; PRIOR FILING DATE: 1999-04-20
; NUMBER OF SEQ ID NOS: 70
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 7
; LENGTH: 30
; TYPE: DNA
```


; APPLICANT: KURANE, RYUICHIRO
 ; APPLICANT: KANAGAWA, TAKAHIRO
 ; APPLICANT: KANAGATA, YOICHI
 ; APPLICANT: YAMADA, KAZUTAKA
 ; APPLICANT: YOKOMAKU, TOYOKAZU
 ; APPLICANT: KOYAMA, OSAMU
 ; APPLICANT: FURUSHO, KENTA
 ; TITLE OF INVENTION: METHOD FOR DETERMINING A CONCENTRATION OF TARGET NUCLEIC ACID MOI
 ; TITLE OF INVENTION: NUCLEIC ACID PROBES FOR THE METHOD, AND METHOD FOR ANALYZING DAT
 ; TITLE OF INVENTION: THE METHOD
 ; FILE REFERENCE: 199953USOXDIV
 ; CURRENT APPLICATION NUMBER: US/10/209,608
 ; CURRENT FILING DATE: 2002-08-01
 ; PRIOR APPLICATION NUMBER: US/09/725,265
 ; PRIOR FILING DATE: 2000-11-29
 ; PRIOR APPLICATION NUMBER: US 09/556,127
 ; PRIOR FILING DATE: 2000-04-20
 ; PRIOR APPLICATION NUMBER: JP 1999-111601
 ; PRIOR FILING DATE: 1999-04-20
 ; NUMBER OF SEQ ID NOS: 70
 ; SOFTWARE: PatentIn version 3.1
 ; SEQ ID NO 6
 ; LENGTH: 30
 ; TYPE: DNA
 ; ORGANISM: ARTIFICIAL SEQUENCE
 ; FEATURE:
 ; OTHER INFORMATION: SYNTHETIC DNA
 US-10-209-608-6

Query Match 0.4%; Score 14.8; DB 1; Length 30;
 Best Local Similarity 73.1%; Pred. No. 1.1e+03;
 Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

Qy 3259 AGATATTTTATTTGCTTGTGCTTTT 3284
 Db 5 ATATTTTTTTTCTTTTCTTTT 30

RESULT 1039
 US-10-209-608-7
 ; Sequence 7, Application US/10209608
 ; Publication No. US20030082592A1
 ; GENERAL INFORMATION:
 ; APPLICANT: KURANE, RYUICHIRO
 ; APPLICANT: KANAGAWA, TAKAHIRO
 ; APPLICANT: KANAGATA, YOICHI
 ; APPLICANT: YAMADA, KAZUTAKA
 ; APPLICANT: YOKOMAKU, TOYOKAZU
 ; APPLICANT: KOYAMA, OSAMU
 ; APPLICANT: FURUSHO, KENTA
 ; TITLE OF INVENTION: METHOD FOR DETERMINING A CONCENTRATION OF TARGET NUCLEIC ACID MOI
 ; TITLE OF INVENTION: NUCLEIC ACID PROBES FOR THE METHOD, AND METHOD FOR ANALYZING DAT
 ; TITLE OF INVENTION: THE METHOD
 ; FILE REFERENCE: 199953USOXDIV
 ; CURRENT APPLICATION NUMBER: US/10/209,608
 ; CURRENT FILING DATE: 2002-08-01
 ; PRIOR APPLICATION NUMBER: US/09/725,265
 ; PRIOR FILING DATE: 2000-11-29
 ; PRIOR APPLICATION NUMBER: US 09/556,127
 ; PRIOR FILING DATE: 2000-04-20
 ; PRIOR APPLICATION NUMBER: JP 1999-111601
 ; PRIOR FILING DATE: 1999-04-20
 ; NUMBER OF SEQ ID NOS: 70
 ; SOFTWARE: PatentIn version 3.1
 ; SEQ ID NO 7
 ; LENGTH: 30
 ; TYPE: DNA
 ; ORGANISM: ARTIFICIAL SEQUENCE
 ; FEATURE:
 ; OTHER INFORMATION: SYNTHETIC DNA
 US-10-209-608-7

Query Match 0.4%; Score 14.8; DB 1; Length 30;

Best Local Similarity 73.1%; Pred. No. 1.1e+03;
 Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;
 Qy 3259 AGATATTTTATTTGCTTGTGCTTTT 3284
 Db 5 ATATTTTTTTTCTTTTCTTTT 30

RESULT 1040
 US-10-209-608-12
 ; Sequence 12, Application US/10209608
 ; Publication No. US20030082592A1
 ; GENERAL INFORMATION:
 ; APPLICANT: KURANE, RYUICHIRO
 ; APPLICANT: KANAGAWA, TAKAHIRO
 ; APPLICANT: KANAGATA, YOICHI
 ; APPLICANT: YAMADA, KAZUTAKA
 ; APPLICANT: YOKOMAKU, TOYOKAZU
 ; APPLICANT: KOYAMA, OSAMU
 ; APPLICANT: FURUSHO, KENTA
 ; TITLE OF INVENTION: METHOD FOR DETERMINING A CONCENTRATION OF TARGET NUCLEIC ACID MOI
 ; TITLE OF INVENTION: NUCLEIC ACID PROBES FOR THE METHOD, AND METHOD FOR ANALYZING DAT
 ; TITLE OF INVENTION: THE METHOD
 ; FILE REFERENCE: 199953USOXDIV
 ; CURRENT APPLICATION NUMBER: US/10/209,608
 ; CURRENT FILING DATE: 2002-08-01
 ; PRIOR APPLICATION NUMBER: US/09/725,265
 ; PRIOR FILING DATE: 2000-11-29
 ; PRIOR APPLICATION NUMBER: US 09/556,127
 ; PRIOR FILING DATE: 2000-04-20
 ; PRIOR APPLICATION NUMBER: JP 1999-111601
 ; PRIOR FILING DATE: 1999-04-20
 ; NUMBER OF SEQ ID NOS: 70
 ; SOFTWARE: PatentIn version 3.1
 ; SEQ ID NO 12
 ; LENGTH: 30
 ; TYPE: DNA
 ; ORGANISM: ARTIFICIAL SEQUENCE
 ; FEATURE:
 ; OTHER INFORMATION: SYNTHETIC DNA
 US-10-209-608-12

Query Match 0.4%; Score 14.8; DB 1; Length 30;
 Best Local Similarity 73.1%; Pred. No. 1.1e+03;
 Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

Qy 3259 AGATATTTTATTTGCTTGTGCTTTT 3284
 Db 5 ATATTTTTTTTCTTTTCTTTT 30

RESULT 1041
 US-10-683-386-6
 ; Sequence 6, Application US/10683386
 ; Publication No. US20040063137A1
 ; GENERAL INFORMATION:
 ; APPLICANT: KURANE, RYUICHIRO
 ; APPLICANT: KANAGAWA, TAKAHIRO
 ; APPLICANT: KANAGATA, YOICHI
 ; APPLICANT: YAMADA, KAZUTAKA
 ; APPLICANT: YOKOMAKU, TOYOKAZU
 ; APPLICANT: KOYAMA, OSAMU
 ; APPLICANT: FURUSHO, KENTA
 ; TITLE OF INVENTION: METHOD FOR DETERMINING A CONCENTRATION OF TARGET NUCLEIC ACID MOI
 ; TITLE OF INVENTION: NUCLEIC ACID PROBES FOR THE METHOD, AND METHOD FOR ANALYZING DAT
 ; TITLE OF INVENTION: THE METHOD
 ; FILE REFERENCE: 0163-0758-0X
 ; CURRENT APPLICATION NUMBER: US/10/683,386
 ; CURRENT FILING DATE: 2000-04-20
 ; PRIOR APPLICATION NUMBER: US/09/556,127
 ; PRIOR FILING DATE: 2000-04-20
 ; PRIOR APPLICATION NUMBER: JP 1999-111601
 ; PRIOR FILING DATE: 1999-04-20

```

; NUMBER OF SEQ ID NOS: 70
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 6
; LENGTH: 30
; TYPE: DNA
; ORGANISM: ARTIFICIAL SEQUENCE
; FEATURE:
; OTHER INFORMATION: SYNTHETIC DNA
US-10-683-386-6

Query Match          0.4%; Score 14.8; DB 1; Length 30;
Best Local Similarity 73.1%; Pred. No. 1.1e+03;
Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

Qy 3259 AGATATTTTATTTGCTTTGCTTTT 3284
    ||||| ||||| ||||| ||||| |||||
Db 5 ATATTTTTTTTGTCTTTTCTTTT 30

RESULT 1042
US-10-683-386-7
; Sequence 7, Application US/10683386
; Publication No. US20040063137A1
; GENERAL INFORMATION:
; APPLICANT: KURANE, RYUICHIRO
; APPLICANT: KANAGAWA, TAKAHIRO
; APPLICANT: KANAGATA, YOICHI
; APPLICANT: YAMADA, KAZUTAKA
; APPLICANT: YOKOMAKU, TOYOKAZU
; APPLICANT: KOYAMA, OSAMU
; APPLICANT: FURUSHO, KENTA
; TITLE OF INVENTION: METHOD FOR DETERMINING A CONCENTRATION OF TARGET NUCLEIC ACID MOL
; TITLE OF INVENTION: NUCLEIC ACID PROBES FOR THE METHOD, AND METHOD FOR ANALYZING DAT
; TITLE OF INVENTION: THE METHOD
; FILE REFERENCE: 0163-0758-0X
; CURRENT APPLICATION NUMBER: US/10/683,386
; PRIOR FILING DATE: 2000-04-20
; PRIOR APPLICATION NUMBER: US/09/556,127
; PRIOR FILING DATE: 2000-04-20
; PRIOR APPLICATION NUMBER: JP 1999-111601
; NUMBER OF SEQ ID NOS: 70
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 7
; LENGTH: 30
; TYPE: DNA
; ORGANISM: ARTIFICIAL SEQUENCE
; FEATURE:
; OTHER INFORMATION: SYNTHETIC DNA
US-10-683-386-7

Query Match          0.4%; Score 14.8; DB 1; Length 30;
Best Local Similarity 73.1%; Pred. No. 1.1e+03;
Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

Qy 3259 AGATATTTTATTTGCTTTGCTTTT 3284
    ||||| ||||| ||||| ||||| |||||
Db 5 ATATTTTTTTTGTCTTTTCTTTT 30

RESULT 1043
US-10-683-386-12
; Sequence 12, Application US/10683386
; Publication No. US20040063137A1
; GENERAL INFORMATION:
; APPLICANT: KURANE, RYUICHIRO
; APPLICANT: KANAGAWA, TAKAHIRO
; APPLICANT: KANAGATA, YOICHI
; APPLICANT: YAMADA, KAZUTAKA
; APPLICANT: YOKOMAKU, TOYOKAZU
; APPLICANT: KOYAMA, OSAMU
; APPLICANT: FURUSHO, KENTA
; TITLE OF INVENTION: METHOD FOR DETERMINING A CONCENTRATION OF TARGET NUCLEIC ACID MOL

```

```

; TITLE OF INVENTION: NUCLEIC ACID PROBES FOR THE METHOD, AND METHOD FOR ANALYZING DAT
; TITLE OF INVENTION: THE METHOD
; FILE REFERENCE: 0163-0758-0X
; CURRENT APPLICATION NUMBER: US/10/683,386
; PRIOR FILING DATE: 2000-04-20
; PRIOR APPLICATION NUMBER: US/09/556,127
; PRIOR FILING DATE: 2000-04-20
; PRIOR APPLICATION NUMBER: JP 1999-111601
; PRIOR FILING DATE: 1999-04-20
; NUMBER OF SEQ ID NOS: 70
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 12
; LENGTH: 30
; TYPE: DNA
; ORGANISM: ARTIFICIAL SEQUENCE
; FEATURE:
; OTHER INFORMATION: SYNTHETIC DNA
US-10-683-386-12

Query Match          0.4%; Score 14.8; DB 1; Length 30;
Best Local Similarity 73.1%; Pred. No. 1.1e+03;
Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

Qy 3259 AGATATTTTATTTGCTTTGCTTTT 3284
    ||||| ||||| ||||| ||||| |||||
Db 5 ATATTTTTTTTGTCTTTTCTTTT 30

RESULT 1044
US-10-219-195-30
; Sequence 30, Application US/10219195
; Publication No. US20030165917A1
; GENERAL INFORMATION:
; APPLICANT: ULLMAN, EDWIN
; APPLICANT: WU, MING
; APPLICANT: LIU, YEN PING
; TITLE OF INVENTION: ISOTHERMAL AMPLIFICATION IN NUCLEIC ACID ANALYSIS
; FILE REFERENCE: 3817.05-1
; CURRENT APPLICATION NUMBER: US/10/219,195
; PRIOR FILING DATE: 2002-08-14
; PRIOR APPLICATION NUMBER: 60/312,505
; PRIOR FILING DATE: 2001-08-14
; NUMBER OF SEQ ID NOS: 49
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 30
; LENGTH: 39
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-219-195-30

Query Match          0.4%; Score 14.8; DB 1; Length 39;
Best Local Similarity 73.1%; Pred. No. 1.3e+03;
Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

Qy 3262 TATTTTATTTGCTTTGCTTTTCA 3287
    ||||| ||||| ||||| ||||| |||||
Db 4 TTTTCTTTTCTTTTCTTTTCTTTTCA 29

RESULT 1045
US-10-219-195-31
; Sequence 31, Application US/10219195
; Publication No. US20030165917A1
; GENERAL INFORMATION:
; APPLICANT: ULLMAN, EDWIN
; APPLICANT: WU, MING
; APPLICANT: LIU, YEN PING
; TITLE OF INVENTION: ISOTHERMAL AMPLIFICATION IN NUCLEIC ACID ANALYSIS
; FILE REFERENCE: 3817.05-1
; CURRENT APPLICATION NUMBER: US/10/219,195

```



```

; LOCATION: (6)..(6)
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (9)..(9)
; OTHER INFORMATION: Any nucleotide
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (12)..(12)
; OTHER INFORMATION: Any nucleotide
US-10-362-010-2

Query Match          0.4%; Score 14.6; DB 1; Length 20;
Best Local Similarity 70.0%; Pred. No. 8e+02;
Matches 14; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

Qy 1750 AAGTGGATGGCGCTGAGGC 1769
    ||||| ||||| ||||| |||||
Db 20 AARTGGACNGCNCNGARGC 1

RESULT 1050
US-09-263-959-524/c
; Sequence 524, Application US/09263959
; Patent No. US20020150891A1
; GENERAL INFORMATION:
; APPLICANT: Hood, Leroy E.
; APPLICANT: Koop, Ben F.
; APPLICANT: Rowen, Lee
; TITLE OF INVENTION: DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS AND METHODS WHICH UTI
; NUMBER OF SEQUENCES: 1279
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Seed and Berry LLP
; STREET: 6300 Columbia Center, 701 Fifth Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: US
; ZIP: 98104-7092
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/263,959
; FILING DATE: 05-MAR-1999
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: McMasters, David D.
; REGISTRATION NUMBER: 33,963
; REFERENCE/DOCKET NUMBER: 920010.426C2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 682-6031
; INFORMATION FOR SEQ ID NO: 524:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 27 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-09-263-959-524

Query Match          0.4%; Score 14.6; DB 1; Length 27;
Best Local Similarity 81.0%; Pred. No. 1.1e+03;
Matches 17; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 3264 TTTTATTGCTTTCCTTTT 3284
    ||||| ||||| ||||| |||||
Db 26 TTTTATTCCTTTCTTTT 6

RESULT 1051
US-10-208-357-4/c

```

```

; Sequence 4, Application US/10208357
; Publication No. US20020182687A1
; GENERAL INFORMATION:
; APPLICANT: Kurz, Markus
; APPLICANT: Lohse, Peter
; APPLICANT: Wagner, Richard
; TITLE OF INVENTION: Peptide Acceptor Ligation Methods
; FILE REFERENCE: 50036/031002
; CURRENT APPLICATION NUMBER: US/10/208,357
; CURRENT FILING DATE: 2002-07-30
; PRIOR APPLICATION NUMBER: US/09/619,103
; PRIOR FILING DATE: 2000-07-19
; PRIOR APPLICATION NUMBER: 60/145,834
; PRIOR FILING DATE: 1999-07-27
; NUMBER OF SEQ ID NOS: 26
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 4
; LENGTH: 39
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: designed sequence to act as a linker
US-10-208-357-4

Query Match          0.4%; Score 14.6; DB 1; Length 39;
Best Local Similarity 69.0%; Pred. No. 1.4e+03;
Matches 20; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

Qy 3262 TATTATTGCTTTCCTTTT 3290
    ||||| ||||| ||||| |||||
Db 35 TTTTATTCCTTTCTTTT 7

RESULT 1052
US-09-828-034-1/c
; Sequence 1, Application US/09828034
; Patent No. US20020064771A1
; GENERAL INFORMATION:
; APPLICANT: Zhong, Weidong
; APPLICANT: Hong, Zhi
; APPLICANT: Ferrari, Eric
; TITLE OF INVENTION: HCV REPLICASE COMPLEXES
; FILE REFERENCE: IN01165
; CURRENT APPLICATION NUMBER: US/09/828,034
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: U.S. 60/195,852
; PRIOR FILING DATE: 2000-04-06
; NUMBER OF SEQ ID NOS: 33
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 1
; LENGTH: 40
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic RNA
US-09-828-034-1

Query Match          0.4%; Score 14.6; DB 1; Length 40;
Best Local Similarity 69.0%; Pred. No. 1.4e+03;
Matches 20; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

Qy 3257 GAAGATATTTTATTTGCTTTCCTTTT 3285
    ||||| ||||| ||||| |||||
Db 35 GAAGTCCTTTTCTTTTCTTTT 7

RESULT 1053
US-09-876-143-867
; Sequence 867, Application US/09876143
; Publication No. US20040081958A1
; GENERAL INFORMATION:
; APPLICANT: Infigen Inc.
; APPLICANT: EILERTSEN, KENNETH J.

```

```

; APPLICANT: PFISTER-GENSKOW, MARTHA
; APPLICANT: CHILDS, LYNETTE
; APPLICANT: FORSYTHE, TODD
; APPLICANT: BISHOP, MICHAEL D.
; TITLE OF INVENTION: IDENTIFICATION AND USE OF MOLECULAR MARKERS INDICATING
; TITLE OF INVENTION: CELLULAR REPROGRAMMING
; FILE REFERENCE: 028040-0202
; CURRENT APPLICATION NUMBER: US/09/876,143
; CURRENT FILING DATE: 2001-06-06
; PRIOR APPLICATION NUMBER: 60/209,874
; PRIOR FILING DATE: 2000-06-07
; NUMBER OF SEQ ID NOS: 1744
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 867
; LENGTH: 41
; TYPE: DNA
; ORGANISM: Bovine
US-09-876-143-867

Query Match 0.4%; Score 14.6; DB 1; Length 41;
Best Local Similarity 69.0%; Pred.No.1.4e+03;
Matches 20; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

QY 3306 AGGATTTTCCTTTAGGAGATTATTTTT 3334
Db ||||| ||||| ||||| ||||| |||||
6 AGGGTTTTTTTTTTTTTTTTTTTTTTTTTTT 34

RESULT 1054
US-09-263-959-541/c
; Sequence 541, Application US/09263959
; Patent No. US20020150891A1
; GENERAL INFORMATION:
; APPLICANT: Hood, Leroy E.
; APPLICANT: Rowen, Lee
; APPLICANT: Koop, Ben F.
; TITLE OF INVENTION: DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS AND METHODS WHICH UTI
; NUMBER OF SEQUENCES: 1279
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Seed and Berry LLP
; STREET: 6300 Columbia Center, 701 Fifth Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: US
; ZIP: 98104-7092
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/263,959
; FILING DATE: 05-MAR-1999
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: McMasters, David D.
; REGISTRATION NUMBER: 33,963
; REFERENCE/DOCKET NUMBER: 920010.426C2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 682-6031
; INFORMATION FOR SEQ ID NO: 541:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-263-959-541

Query Match 0.4%; Score 14.4; DB 1; Length 16;
Best Local Similarity 93.8%; Pred.No.6.8e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/463,404
FILING DATE: 05-JUN-1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/060,952
FILING DATE: May 13, 1993
APPLICATION NUMBER: 07/882,438
FILING DATE: May 13, 1992
APPLICATION NUMBER: 08/038,766
FILING DATE: March 24, 1993
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 202/045
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 57:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-463-404-57

Query Match 0.4%; Score 14.4; DB 1; Length 16;
Best Local Similarity 93.8%; Pred. No. 6.8e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2318 TGTGTGTGTGTGTGTG 2333
Db 1 TGGGTGTGTGTGTGTG 16

RESULT 1057
US-09-263-959-540
; Sequence 540, Application US/09263959
; Patent No. US20020150891A1
; GENERAL INFORMATION:
; APPLICANT: Hood, Leroy E.
; APPLICANT: Rowen, Lee
; APPLICANT: Koop, Ben F.
; TITLE OF INVENTION: DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS AND METHODS WHICH UTI
; NUMBER OF SEQUENCES: 1279
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Seed and Berry LLP
; STREET: 6300 Columbia Center, 701 Fifth Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: US
; ZIP: 98104-7092
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/263,959
; FILING DATE: 05-MAR-1999
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: McMasters, David D.

REGISTRATION NUMBER: 33,963
REFERENCE/DOCKET NUMBER: 920010.426C2
TELECOMMUNICATION INFORMATION:
TELEPHONE: (206) 622-4900
TELEFAX: (206) 682-6031
INFORMATION FOR SEQ ID NO: 540:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-263-959-540

Query Match 0.4%; Score 14.4; DB 1; Length 16;
Best Local Similarity 93.8%; Pred. No. 6.8e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2824 ATATATACATATATAT 2839
Db 1 ATATATATATATATAT 16

RESULT 1058
US-09-263-959-540/c
; Sequence 540, Application US/09263959
; Patent No. US20020150891A1
; GENERAL INFORMATION:
; APPLICANT: Hood, Leroy E.
; APPLICANT: Rowen, Lee
; APPLICANT: Koop, Ben F.
; TITLE OF INVENTION: DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS AND METHODS WHICH UTI
; NUMBER OF SEQUENCES: 1279
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Seed and Berry LLP
; STREET: 6300 Columbia Center, 701 Fifth Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: US
; ZIP: 98104-7092
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/263,959
; FILING DATE: 05-MAR-1999
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: McMasters, David D.
; REGISTRATION NUMBER: 33,963
; REFERENCE/DOCKET NUMBER: 920010.426C2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 682-6031
; INFORMATION FOR SEQ ID NO: 540:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-263-959-540

Query Match 0.4%; Score 14.4; DB 1; Length 16;
Best Local Similarity 93.8%; Pred. No. 6.8e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2824 ATATATACATATATAT 2839
Db 16 ATATATATATATATAT 1

RESULT 1059

US-10-085-906-231
; Sequence 231, Application US/10085906
; Publication No. US20030054371A1
; GENERAL INFORMATION:
; APPLICANT: Ying, Vincent
; APPLICANT: Wu, Paul
; APPLICANT: Gray, Gary S.
; TITLE OF INVENTION: POLYMORPHIC ELEMENTS IN THE
; FILE REFERENCE: GNN-5343CP2
; CURRENT APPLICATION NUMBER: US/10/085,906
; CURRENT FILING DATE: 2002-02-27
; PRIOR APPLICATION NUMBER: US 60/126,215
; PRIOR FILING DATE: 1999-03-25
; PRIOR APPLICATION NUMBER: US 09/534,061
; PRIOR FILING DATE: 2000-03-24
; PRIOR APPLICATION NUMBER: PCT/US00/07938
; PRIOR FILING DATE: 2000-03-24
; NUMBER OF SEQ ID NOS: 545
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 231
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-085-906-231

Query Match 0.4%; Score 14.4; DB 1; Length 16;
Best Local Similarity 93.8%; Pred. No. 6.8e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2824 ATATATACATATATAT 2839
Db 1 ATATATATATATATAT 16

RESULT 1060
US-10-085-906-231/c
; Sequence 231, Application US/10085906
; Publication No. US20030054371A1
; GENERAL INFORMATION:
; APPLICANT: Ying, Vincent
; APPLICANT: Wu, Paul
; APPLICANT: Gray, Gary S.
; TITLE OF INVENTION: POLYMORPHIC ELEMENTS IN THE
; FILE REFERENCE: GNN-5343CP2
; CURRENT APPLICATION NUMBER: US/10/085,906
; CURRENT FILING DATE: 2002-02-27
; PRIOR APPLICATION NUMBER: US 60/126,215
; PRIOR FILING DATE: 1999-03-25
; PRIOR APPLICATION NUMBER: US 09/534,061
; PRIOR FILING DATE: 2000-03-24
; PRIOR APPLICATION NUMBER: PCT/US00/07938
; PRIOR FILING DATE: 2000-03-24
; NUMBER OF SEQ ID NOS: 545
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 231
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-085-906-231

Query Match 0.4%; Score 14.4; DB 1; Length 16;
Best Local Similarity 93.8%; Pred. No. 6.8e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2824 ATATATACATATATAT 2839
Db 16 ATATATATATATATAT 1

RESULT 1061
US-10-092-885-28

; Sequence 28, Application US/10092885
; Publication No. US20030190638A1
; GENERAL INFORMATION:
; APPLICANT: SAMAL, BABRU
; APPLICANT: LI, YUAN
; APPLICANT: HERMIDA, LEANDRO C.
; APPLICANT: HOPPA, NANCY L.
; APPLICANT: JOHE, KARL K.
; TITLE OF INVENTION: METHOD FOR GENERATING FIVE PRIME BIASED TANDEM TAG
; LIBRARIES OF CDNAS
; FILE REFERENCE: 0109015/026
; CURRENT APPLICATION NUMBER: US/10/092,885
; CURRENT FILING DATE: 2002-03-06
; NUMBER OF SEQ ID NOS: 60
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 28
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-092-885-28

Query Match 0.4%; Score 14.4; DB 1; Length 16;
Best Local Similarity 93.8%; Pred. No. 6.8e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2315 GTCTGTGTGTGTGTGT 2330
Db 1 GTTTGTGTGTGTGTGT 16

RESULT 1062
US-10-232-927A-80
; Sequence 80, Application US/10232927A
; Publication No. US20030190638A1
; GENERAL INFORMATION:
; APPLICANT: Michael D. West
; Calvin B. Harley
; Scott L. Weinrich
; Catherine M. Strahl
; Michael J. Meeachern
; Jerry Shay
; Woodring E. Wright
; Elizabeth H. Blackburn
; Nam Woo Kim
; Homayoun Vaziri
; TITLE OF INVENTION: THERAPY AND DIAGNOSIS OF
; CONDITIONS RELATED TO
; TELOMERE LENGTH AND/OR
; TELOMERASE ACTIVITY
; NUMBER OF SEQUENCES: 80
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ for Windows 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/232,927A
; FILING DATE: 29-Aug-2002
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/378,535
; FILING DATE: 20-Aug-1999
; APPLICATION NUMBER: 08/819,867
; FILING DATE: <Unknown>


```

; ATTORNEY/AGENT INFORMATION:
; NAME: Chambers, Daniel M.
; REGISTRATION NUMBER: 34,561
; REFERENCE/DOCKET NUMBER: 224/232
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 80:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 80:
US-10-232-927A-80

Query Match          0.4%; Score 14.4; DB 1; Length 16;
Best Local Similarity 93.8%; Pred. No. 6.8e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2318 TGTGTGTGTGTGTGTG 2333
DB 1 TGGTGTGTGTGTGTG 16

RESULT 1063
US-10-138-674-5819
; Sequence 5819, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5819
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-5819

Query Match          0.4%; Score 14.4; DB 1; Length 16;
Best Local Similarity 75.0%; Pred. No. 6.8e+02;
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 1295 TGAAGATGCTGAAGA 1310
DB 1 UGAAAAGCUGAAGA 16

RESULT 1064
US-10-138-674-5848
; Sequence 5848, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03

```

```

; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5848
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-5848

Query Match          0.4%; Score 14.4; DB 1; Length 16;
Best Local Similarity 75.0%; Pred. No. 6.8e+02;
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 1658 ACAACGTGATGAAGAT 1673
DB 1 ACAACGUGUGAAGAU 16

RESULT 1065
US-10-138-674-6071
; Sequence 6071, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6071
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-6071

Query Match          0.4%; Score 14.4; DB 1; Length 16;
Best Local Similarity 50.0%; Pred. No. 6.8e+02;
Matches 8; Conservative 7; Mismatches 1; Indels 0; Gaps 0;

QY 2321 GTGTGTGTGTGTGCGT 2336
DB 1 GUGUGUGUGUGGUGU 16

RESULT 1066
US-10-287-949A-5819
; Sequence 5819, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5819
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-5819

Query Match          0.4%; Score 14.4; DB 1; Length 16;

```

Best Local Similarity 75.0%; Pred. No. 6.8e+02;
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 1295 TGAAGATGCTGAAGA 1310
Db 1 UGAAAUGCUGAAGA 16

RESULT 1067
US-10-287-949A-5848
; Sequence 5848, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5848
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-5848

Query Match 0.4%; Score 14.4; DB 1; Length 16;
Best Local Similarity 75.0%; Pred. No. 6.8e+02;
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 1658 ACAACGTGTGAAGAT 1673
Db 1 ACAACGUGUGAGAGU 16

RESULT 1068
US-10-287-949A-6071
; Sequence 6071, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6071
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-6071

Query Match 0.4%; Score 14.4; DB 1; Length 16;
Best Local Similarity 50.0%; Pred. No. 6.8e+02;
Matches 8; Conservative 7; Mismatches 1; Indels 0; Gaps 0;

QY 2321 GTGTGTGTGTGGT 2336
Db 1 GUGUGUGUGUGGU 16

RESULT 1069

US-10-691-633-57
; Sequence 57, Application US/10691633
; Publication No. US20040198659A1
; GENERAL INFORMATION:
; APPLICANT: Michael D. West
; Jerry W. Shay
; Woodring E. Wright
; Elizabeth Blackburn
; TITLE OF INVENTION: THERAPY AND DIAGNOSIS OF CONDITIONS
; RELATED TO TELOMERE LENGTH AND/OR
; TELOMERASE ACTIVITY
; NUMBER OF SEQUENCES: 57
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/691,633
; FILING DATE: 22-Oct-2003
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/060,952C
; FILING DATE: May 13, 1993
; APPLICATION NUMBER: 07/882,438
; FILING DATE: May 13, 1992
; APPLICATION NUMBER: 08/038,766
; FILING DATE: March 24, 1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 202/045
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 57:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 57:
US-10-691-633-57

Query Match 0.4%; Score 14.4; DB 1; Length 16;
Best Local Similarity 93.8%; Pred. No. 6.8e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2318 TGTGTGTGTGTGTG 2333
Db 1 TGGGTGTGTGTGTG 16

RESULT 1070
US-09-866-108-2002/c
; Sequence 2002, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.

```

; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, MYOSIN
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEWICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/006666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006657
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006655
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006663
; PRIOR APPLICATION NUMBER: PCT/US01/006662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecmica Sequence Listing Engine
; SEQ ID NO 2002
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-2002

```

Query Match	0.4%	Score 14.4;	DB 1;	Length 17;
Best Local Similarity	93.8%	Pred. No. 7.2e+02;		
Matches 15;	Conservative	0;	Mismatches 1;	Indels 0;
				Gaps 0;

QY 3194 CCCCGAGCTGGAGGA 3209
Db 17 CCCCGGGCTGGAGGA 2

RESULT 1071
US-09-866-108-2003/c
; Sequence 2003, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOmica-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04

```

; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/006666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006657
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006659
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006655
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006658
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006653
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006652
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006651
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 2003
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-2003

```

Query Match 0.4%; Score 14.4; DB 1;
Best Local Similarity 93.8%;
Pred. No. 7.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels

Qy 3194 CCCCGAGCTGGAGGA 3209
Db 16 CCCCGGGCTGGAGGA 1

RESULT 1072

US-09-866-108-2005/c
; Sequence 2005, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:

```

, APPLICANT: GU, Yizhong
, APPLICANT: JI, Yonggang
, APPLICANT: PENN, Shaorong G.
, APPLICANT: HANZBL, David K.
, APPLICANT: RANK, David R.
, APPLICANT: CHEN, Wensheng
, APPLICANT: SHANNON, Mark
, TITLE OF INVENTION: MYOSIN-L
, FILE REFERENCE: AEOMICA-7
, CURRENT APPLICATION NUMBER:
, CURRENT FILING DATE: 2001-0-
, PRIOR APPLICATION NUMBER: US
, PRIOR FILING DATE: 2000-05-2
, PRIOR APPLICATION NUMBER: GB
, PRIOR FILING DATE: 2000-10-0
, PRIOR APPLICATION NUMBER: US
, PRIOR FILING DATE: 2000-09-2
, PRIOR APPLICATION NUMBER: PC
, PRIOR FILING DATE: 2001-01-3
, PRIOR APPLICATION NUMBER: PC
, PRIOR FILING DATE: 2001-01-3
, PRIOR APPLICATION NUMBER: PC
, PRIOR FILING DATE: 2001-01-3
, PRIOR APPLICATION NUMBER: PC
, PRIOR FILING DATE: 2001-01-3
, PRIOR APPLICATION NUMBER: PC
, PRIOR FILING DATE: 2001-01-3

```

; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 2005
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108-2005

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 7.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1487 GGCCCCCGGGCTGGA 1502
Db 17 GGCCCCCGGGCTGGA 2

RESULT 1073
US-09-866-108-2006/c
; Sequence 2006, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: ACOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 2006
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108-2006

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 7.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1487 GGCCCCCGGGCTGGA 1502
Db 16 GGCCCCCGGGCTGGA 1

RESULT 1074
US-09-866-108-7995
; Sequence 7995, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: ACOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 7995
; LENGTH: 17

; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-7995

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 7.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1992 CACCTTCAAGCAGCTG 2007
|||||
Db 2 CACCATCAAGCAGCTG 17

RESULT 1075

US-09-866-108-7997
; Sequence 7997, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: A6MICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 7997
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-7997

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 7.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1993 ACCTTCAAGCAGCTGG 2008
|||||

Db 1 ACCATCAAGCAGCTGG 16

RESULT 1076

US-09-730-289B-156
; Sequence 156, Application US/09730289B
; Publication No. US20030050259A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for Treatment of Cardiac Disease
; FILE REFERENCE: MBH00-864-A (400/006)
; CURRENT APPLICATION NUMBER: US/09/730,289B
; CURRENT FILING DATE: 2000-12-05
; PRIOR APPLICATION NUMBER: US 60/169,100
; PRIOR FILING DATE: 1999-12-06
; NUMBER OF SEQ ID NOS: 3897
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 156
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-730-289B-156

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 43.8%; Pred. No. 7.2e+02;
Matches 7; Conservative 8; Mismatches 1; Indels 0; Gaps 0;

Qy 3005 TTTTGTTTAAACTG 3020
:::|:::|:::|:::|
Db 1 UUUAGUUUUAAACUG 16

RESULT 1077

US-09-780-533A-1807
; Sequence 1807, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haeblerli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBH00.878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1807
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-1807

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 7.2e+02;
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 501 GCTGACGCTGCTGGAG 516
|||::|::|::|::|
Db 2 GCUGAGGUGCUGGAG 17

RESULT 1078

US-09-877-478-41/c
; Sequence 41, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.

```

; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: MBH00-845-H (400/029)
; CURRENT APPLICATION NUMBER: US/09/877,478
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 08/433,993
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 08/434,504
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 41
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-09-877-478-41

Query Match      0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 7.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3626 GGGCCCTGAGTCTGGG 3641
Db 16 GGGCCCTGACTCTGGG 1

RESULT 1079
US-09-877-478-1412/c
; Sequence 1412, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: MBH00-845-H (400/029)
; CURRENT APPLICATION NUMBER: US/09/877,478
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 08/433,993
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 08/434,504
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 41
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-09-877-478-41

```

```

; SEQ ID NO 1412
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-09-877-478-1412

Query Match      0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 7.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 853 GAGGAGGAGCTGGTGG 868
Db 16 GAGGAGGAGCTGCTGG 1

RESULT 1080
US-09-877-478-2089
; Sequence 2089, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: MBH00-845-H (400/029)
; CURRENT APPLICATION NUMBER: US/09/877,478
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 08/433,993
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 08/434,504
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2089
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-09-877-478-2089

Query Match      0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 7.2e+02;
Matches 10; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Qy 2776 TTCGGGAAGTACTGT 2791
Db 1 UUCGGGAACUACUGU 16

RESULT 1081
US-09-848-754A-2482
; Sequence 2482, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Growth Factor Receptors
; FILE REFERENCE: MBH00-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03

```

; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2482
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-2482

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 7.2e+02;
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 1792 CACCAGTGCAGCTCT 1807
|||||:|:|:|:|:
Db 2 CACCAGUGAUGUCU 17

RESULT 1082

US-09-848-754A-2907
; Sequence 2907, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Growth Factor Receptors
; FILE REFERENCE: MHB00-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2907
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-2907

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 7.2e+02;
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 1794 CCAGAGTGACCTCTGG 1809
|||||:|:|:|:|:
Db 1 CCAGAGUGAUGUCUGG 16

RESULT 1083

US-09-930-423-390/c
; Sequence 390, Application US/09930423
; Publication No. US20030092003A1
; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: MHB00,918-A 400/027
; CURRENT APPLICATION NUMBER: US/09/930,423
; CURRENT FILING DATE: 2001-08-15
; NUMBER OF SEQ ID NOS: 4553
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 390
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-930-423-390

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 7.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3658 GCCTGCAGGGCCATGG 3673
|||||:|:|:|:|:
Db 17 GCCTGCAGGGCCCTGG 2

RESULT 1084

US-09-930-423-391/c
; Sequence 391, Application US/09930423
; Publication No. US20030092003A1
; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: MHB00,918-A 400/027
; CURRENT APPLICATION NUMBER: US/09/930,423
; CURRENT FILING DATE: 2001-08-15
; NUMBER OF SEQ ID NOS: 4553
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 391
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-930-423-391

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 7.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3658 GCCTGCAGGGCCATGG 3673
|||||:|:|:|:|:
Db 16 GCCTGCAGGGCCCTGG 1

RESULT 1085

US-09-780-164-723
; Sequence 723, Application US/09780164
; Publication No. US20030092646A1
; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Inhibition of CD20
; FILE REFERENCE: 400/010
; CURRENT APPLICATION NUMBER: US/09/780,164
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/185,516
; PRIOR FILING DATE: 2000-02-28
; NUMBER OF SEQ ID NOS: 2603
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 723
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-164-723

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 7.2e+02;
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 3754 CAGCGACGAACCTTCC 3769
|||||:|:|:|:|:
Db 2 CAGAGACGAACUUCU 17

RESULT 1086

US-09-827-395A-424
; Sequence 424, Application US/09827395A
; Publication No. US20030113891A1
; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowira
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MHB00-878-C (400/017)
; CURRENT APPLICATION NUMBER: US/09/827,395A

; CURRENT FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 424
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-09-827-395A-424

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 7.2e+02;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1312 GATGCCACTGACAAAG 1327
||:|||||
Db 1 GAUGCCGUGACAAAG 16

RESULT 1087

US-09-792-818-382
; Sequence 382, Application US/09792818
; Publication No. US20030134806A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Jarvis, Thale
; APPLICANT: Von Carlowitz, Ira
; APPLICANT: McSwiggen, Jim
; APPLICANT: Hamblin, Paul
; APPLICANT: Ellis, Jonathan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Grb-2-related with Insert
; FILE REFERENCE: MEHB00-901-A (400/013)
; CURRENT APPLICATION NUMBER: US/09/792,818
; CURRENT FILING DATE: 2001-02-23
; NUMBER OF SEQ ID NOS: 2304
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 382
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-09-792-818-382

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 45 GCCCCAGCGGTGCAG 60
|||||||
Db 1 GCCCCAGCAGCUGCAG 16

RESULT 1088

US-09-792-818-645
; Sequence 645, Application US/09792818
; Publication No. US20030134806A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Jarvis, Thale
; APPLICANT: Von Carlowitz, Ira
; APPLICANT: McSwiggen, Jim
; APPLICANT: Hamblin, Paul
; APPLICANT: Ellis, Jonathan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Grb-2-related with Insert
; FILE REFERENCE: MEHB00-901-A (400/013)
; CURRENT APPLICATION NUMBER: US/09/792,818
; CURRENT FILING DATE: 2001-02-23
; NUMBER OF SEQ ID NOS: 2304
; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 645
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-09-792-818-645

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 7.2e+02;
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 2006 TGGTGGAGGACCTGGA 2021
:|||||
Db 1 UGGUGAGGUGCCUGGA 16

RESULT 1089

US-09-792-818-880
; Sequence 880, Application US/09792818
; Publication No. US20030134806A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Jarvis, Thale
; APPLICANT: Von Carlowitz, Ira
; APPLICANT: McSwiggen, Jim
; APPLICANT: Hamblin, Paul
; APPLICANT: Ellis, Jonathan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Grb-2-related with Insert
; FILE REFERENCE: MEHB00-901-A (400/013)
; CURRENT APPLICATION NUMBER: US/09/792,818
; CURRENT FILING DATE: 2001-02-23
; NUMBER OF SEQ ID NOS: 2304
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 880
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-09-792-818-880

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 7.2e+02;
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 2006 TGGTGGAGGACCTGGA 2021
:|||||
Db 2 UGGUGAGGUGCCUGGA 17

RESULT 1090

US-09-745-237A-390/c
; Sequence 390, Application US/09745237A
; Publication No. US20030143708A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: 400/007 (MEHB00-918-A)
; CURRENT APPLICATION NUMBER: US/09/745,237A
; CURRENT FILING DATE: 2002-04-15
; NUMBER OF SEQ ID NOS: 4550
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 390
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-09-745-237A-390

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 7.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3658 GCCTGCAGGCCATGG 3673


```
Db      17 GCCTGCAGGGCCCTGG 2
|||||
RESULT 1091
US-09-745-237A-391/c
; Sequence 391, Application US/09745237A
; Publication No. US20030143708A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: 400/007 (MBH00-918-A)
; CURRENT APPLICATION NUMBER: US/09/745,237A
; CURRENT FILING DATE: 2002-04-15
; NUMBER OF SEQ ID NOS: 4550
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 391
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-745-237A-391

Query Match      0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 7.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      3658 GCCTGCAGGGCCCTGG 3673
|||||
Db      16 GCCTGCAGGGCCCTGG 1

RESULT 1092
US-10-211-059-166/c
; Sequence 166, Application US/10211059
; Publication No. US20030100495A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; TITLE OF INVENTION: HUMAN NAC-1 PROTEIN
; FILE REFERENCE: PB0149
; CURRENT APPLICATION NUMBER: US/10/211,059
; CURRENT FILING DATE: 2002-08-02
; PRIOR APPLICATION NUMBER: US 60/311,034
; PRIOR FILING DATE: 2001-08-08
; NUMBER OF SEQ ID NOS: 322
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 166
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-211-059-166

Query Match      0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 7.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      2110 AGCTCCAGCTCTCTCAG 2125
|||||
Db      17 AGCTCCAGCTCTCTCAG 2

RESULT 1093
US-10-238-700-2806/c
; Sequence 2806, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
; FILE REFERENCE: 400/057 (MBH01-1158-A)
; CURRENT APPLICATION NUMBER: US/10/238,700
; CURRENT FILING DATE: 2002-09-18
```

```
; PRIOR APPLICATION NUMBER: PCT/US 02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/318,471
; PRIOR FILING DATE: 2001-09-10
; NUMBER OF SEQ ID NOS: 4666
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2806
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-238-700-2806

Query Match      0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 7.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      2158 CCCCGCGGCCACCCA 2173
|||||
Db      16 CGCCGCGGCCACCCA 1

RESULT 1094
US-10-238-700-3350/c
; Sequence 3350, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
; FILE REFERENCE: 400/057 (MBH01-1158-A)
; CURRENT APPLICATION NUMBER: US/10/238,700
; CURRENT FILING DATE: 2002-09-18
; PRIOR APPLICATION NUMBER: PCT/US 02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/318,471
; PRIOR FILING DATE: 2001-09-10
; NUMBER OF SEQ ID NOS: 4666
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3350
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-238-700-3350

Query Match      0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 7.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      2900 CAGGAGCGCGCATGG 2915
|||||
Db      16 CAGGAGCGCGCATGG 1

RESULT 1095
US-10-061-201-441
; Sequence 441, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT APPLICATION NUMBER: US/10/061,201
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
```


; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; PRIOR FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 445
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-445

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 7.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 549 GCTGCGCGCCACAG 564
|||||
Db 1 GCTGCGCGCCACAG 16

RESULT 1099
US-10-430-882-424
; Sequence 424, Application US/10430882
; Publication No. US20030203870A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowrira
; APPLICANT: Peter Haeberli
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor C
; FILE REFERENCE: MBH00-878-H (400/112)
; CURRENT APPLICATION NUMBER: US/10/430,882
; CURRENT FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 09/827,395
; PRIOR FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: PCT/US01/04273
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: PCT/US02/10512
; PRIOR FILING DATE: 2002-04-03
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 424
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-430-882-424

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 7.2e+02;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 1312 GATCCCACTGCAAGG 1327
|||||
Db 1 GAUGCCGCGCAAGG 16

RESULT 1100
US-10-342-902-41/c
; Sequence 41, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave

; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: 400/075 (MBH00-845-I)
; CURRENT APPLICATION NUMBER: US/10/342,902
; CURRENT FILING DATE: 2003-01-15
; PRIOR APPLICATION NUMBER: US 09/877,478
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6592
; SOFTWARE: Patentin version 3.2
; SEQ ID NO 41
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-10-342-902-41

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 7.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3626 GGGCCCTGACTCTGGG 3641
|||||
Db 16 GGGCCCTGACTCTGGG 1

RESULT 1101
US-10-342-902-1412/c
; Sequence 1412, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: 400/075 (MBH00-845-I)
; CURRENT APPLICATION NUMBER: US/10/342,902
; CURRENT FILING DATE: 2003-01-15
; PRIOR APPLICATION NUMBER: US 09/877,478
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6592
; SOFTWARE: Patentin version 3.2
; SEQ ID NO 1412
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-10-342-902-1412

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 7.2e+02;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 853 GAGGAGGAGCTGGTGG 868
Db 16 GAGGAGGAGCTGGTGG 1

RESULT 1102
US-10-342-902-2089
; Sequence 2089, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: 400/075 (MHB00-845-1)
; CURRENT APPLICATION NUMBER: US/10/342,902
; CURRENT FILING DATE: 2003-01-15
; PRIOR APPLICATION NUMBER: US 09/877,478
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6592
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2089
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-10-342-902-2089

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 7.2e+02;
Matches 10; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Qy 2776 TTCGGGAACAGTAGTGT 2791
Db 1 UUCGGGAACACUACUGU 16

RESULT 1103
US-10-138-674-2650
; Sequence 2650, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2650
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus

US-10-138-674-2650

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 7.2e+02;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 1608 GAAGTGATCCACAGG 1623
Db 2 GAAGUGUAUCCACAGG 17

RESULT 1104
US-10-138-674-4753
; Sequence 4753, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4753
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-4753

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 7.2e+02;
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 1393 AACCTGCTGGCGCCT 1408
Db 2 AACCGUGGAGCCU 17

RESULT 1105
US-10-138-674-6732
; Sequence 6732, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6732
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-6732

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1619 ACAGGGACCTGGCTGC 1634
Db 1 ACAGGGACCGGCGGC 16

RESULT 1106
US-10-138-674-7632
; Sequence 7632, Application US/10138674
; Publication No. US2004007756A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7632
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-7632

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 7.2e+02;
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 1397 TGTGGGGCGCTGCAC 1412
Db 1 UGUGGGAGCGCUGCAC 16

RESULT 1107
US-10-138-674-7696
; Sequence 7696, Application US/10138674
; Publication No. US2004007756A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7696
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-7696

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 7.2e+02;
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 1658 ACAACGTGATGAAGAT 1673
Db 1 ACAACGUGGAGAGAU 16

RESULT 1108
US-10-287-949A-2650
; Sequence 2650, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam

; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2650
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-287-949A-2650

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 7.2e+02;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 1608 GAAAGTCATCCACAGG 1623
Db 2 GAAGUGAUCCACAGG 17

RESULT 1109
US-10-287-949A-4753
; Sequence 4753, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4753
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-4753

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 7.2e+02;
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 1393 AACCTGCTGGCGCCT 1408
Db 2 AACCGUGGAGGCCU 17

RESULT 1110
US-10-287-949A-6732
; Sequence 6732, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822

; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6732
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-6732

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1619 ACAGGACCTGGCTGC 1634
Db 1 ACAGGACCTGGCTGC 16

RESULT 1111

US-10-287-949A-7632
; Sequence 7632, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MEHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7632
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-7632

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 7.2e+02;
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 1397 TGCTGGCGCTGCAC 1412
Db 1 UGUGGGAGCGUGCAC 16

RESULT 1112

US-10-287-949A-7696
; Sequence 7696, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MEHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7696
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-7696

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 7.2e+02;

Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
Qy 1658 AACACGTGATGAAGAT 1673
Db 1 AACACGTGATGAAGAU 16

RESULT 1113

US-10-712-672-27
; Sequence 27, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Chowrira, Bharat
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MEHB00-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 5586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 27
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-712-672-27

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 7.2e+02;
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 1563 CTGTGCTACCGGTG 1578
Db 1 CUGCGCUACCGGUG 16

RESULT 1114

US-10-712-672-526
; Sequence 526, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Chowrira, Bharat
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MEHB00-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 5586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 526
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-712-672-526

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 7.2e+02;
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 1563 CTGTGCTTACCAAGTG 1578
|:|:|:|:|:|:|:|:|:|
Db 2 CUGCGCCUACCAAGG 17

RESULT 1115
US-10-712-672-2019
; Sequence 2019, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Chowrira, Bharat
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MBH00-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 5586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2019
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-712-672-2019

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 2087 CCCCGGTGGCCAGGA 2102
|:|:|:|:|:|:|:|:|:|
Db 1 CCCCGGGUGGCGAGGA 16

RESULT 1116
US-10-712-672-2330
; Sequence 2330, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Chowrira, Bharat
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MBH00-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 5586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2330
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-712-672-2330

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 7.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1479 GCGCGCGCGCGCCCG 1494
|:|:|:|:|:|:|:|:|:|
Db 1 GCGCGCGCGCGCCCG 16

RESULT 1117
US-10-712-672-2341
; Sequence 2341, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Chowrira, Bharat
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MBH00-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 5586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2341
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-712-672-2341

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 7.2e+02;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 1616 TCACAGGGGACCTGGC 1631
|:|:|:|:|:|:|:|:|:|
Db 1 UCCACAGGGGCGUGGC 16

RESULT 1118
US-10-712-672-2682
; Sequence 2682, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Chowrira, Bharat
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MBH00-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 5586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2682
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-712-672-2682

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 7.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3410 AGGAGGGGCGCGCC 3425

Db 1 AGGAGGGGGGGGCC 16
|||||

RESULT 1119
US-10-669-841-41/c
; Sequence 41, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPATITIS B VIRUS REPLICATION
; FILE REFERENCE: 400/042US (MBHB02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 41
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B Virus
US-10-669-841-41

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 7.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3626 GGGCCCTGAGTCTGGG 3641
|||||

Db 16 GGGCCCTGAGTCTGGG 1
RESULT 1120
US-10-669-841-1412/c
; Sequence 1412, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patrice, Lee

; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPATITIS B VIRUS REPLICATION
; FILE REFERENCE: 400/042US (MBHB02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1412
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B Virus
US-10-669-841-1412

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 7.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 853 GAGGAGGAGCTGTGG 868
|||||

Db 16 GAGGAGGAGCTGTGG 1
RESULT 1121
US-10-669-841-1944
; Sequence 1944, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPATITIS B VIRUS REPLICATION
; FILE REFERENCE: 400/042US (MBHB02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580


```
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1944
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B Virus
US-10-869-841-1944

Query Match      0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 7.2e+02;
Matches 10; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY      2776 TTCCGGAACCTAGTGT 2791
Db      1 UUCGGAACUACUGU 16

RESULT 1122
US-10-723-361-2002/c
; Sequence 2002, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 2002
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-2002

Query Match      0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 7.2e+02;
Matches 10; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY      2776 TTCCGGAACCTAGTGT 2791
Db      1 UUCGGAACUACUGU 16

RESULT 1122
US-10-723-361-2002/c
; Sequence 2002, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 2002
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-2002
```

```
Query Match      0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 7.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      3194 CCCCCGGAGCTGGAGGA 3209
Db      17 CCCCCGGGCTGGAGGA 2
```

RESULT 1123

```
US-10-723-361-2003/c
; Sequence 2003, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 2003
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-2003
```

```
Query Match      0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 7.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      3194 CCCCCGGAGCTGGAGGA 3209
Db      16 CCCCCGGGCTGGAGGA 1
```

RESULT 1124

```
US-10-723-361-2005/c
; Sequence 2005, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
```

; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PR0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; PRIOR FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 2005
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-2005

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 7.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1487 GGCCCCCGGCGCTGGA 1502
Db 17 GGCCCCCGGCGCTGGA 2

RESULT 1125
US-10-723-361-2006/c
; Sequence 2006, Application US/10/723,361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PR0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; PRIOR FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 2005
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-2005

; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 2006
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-2006

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 7.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1487 GGCCCCCGGCGCTGGA 1502
Db 16 GGCCCCCGGCGCTGGA 1

RESULT 1126
US-10-723-361-7995
; Sequence 7995, Application US/10/723,361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PR0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; PRIOR FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 7995
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-7995

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 7.2e+02;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1992 CACCTTCAGCAGCTG 2007
|||||
Db 2 CACCATCAGCAGCTG 17

RESULT 1127

US-10-723-361-7997
; Sequence 7997, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wenheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723.361
; CURRENT FILING DATE: 2003-11-26
; PRIOR FILING DATE: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR FILING DATE: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 7997
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-7997

Query Match 0.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 7.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1993 ACCTTCAGCAGCTGG 2008
|||||
Db 1 ACCATCAGCAGCTGG 16

RESULT 1128

US-09-350-206-24
; Sequence 24, Application US/09350206
; Patent No. US20020099199A1
; GENERAL INFORMATION:
; APPLICANT: Andrew D.J. Goodearl and Sandra Gluckman
; TITLE OF INVENTION: Muscarinic Receptors and Uses Therefor
; NUMBER OF SEQUENCES: 39
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LAHIVE & COCKFIELD, LLP
; STREET: 28 State Street
; CITY: Boston

; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/350,206
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/042,780
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Elizabeth A. Hanley
; REGISTRATION NUMBER: 33,505
; REFERENCE/DOCKET NUMBER: MNI-032CP
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617)227-7400
; TELEFAX: (617)742-4214
; INFORMATION FOR SEQ ID NO: 24:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
US-09-350-206-24

Query Match 0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 7.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3658 GCCTGCAGGCCCATGG 3673
|||||
Db 1 GCCTGCTGGCCCATGG 16

RESULT 1129

US-09-892-325-6
; Sequence 6, Application US/09892325
; Patent No. US20020116735A1
; GENERAL INFORMATION:
; APPLICANT: Kunst et al.
; TITLE OF INVENTION: Nucleic Acids Encoding Plant Enzyme
; INVOLVED IN Very Long Chain Fatty Acid Synthesis
; NUMBER OF SEQUENCES: 12
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Klarquist Sparkman Campbell
; Leigh & Whinston, LLP
; STREET: One World Trade Center, Suite
; 1600, 121 S.W. Salmon Street
; CITY: Portland
; STATE: OR
; COUNTRY: USA
; ZIP: 97204-2988
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Disk, 3.5-inch
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: Windows NT
; SOFTWARE: Word97 & ASCII
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/892,325
; FILING DATE: 26-Jun-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/058,947
; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: David J. Earp, Ph.D.
; REGISTRATION NUMBER: 41,401

```
; REFERENCE/DOCKET NUMBER: 5493-50032/DJE
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (503) 226-7391
; TELEFAX: (503) 228-9446
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 6:
US-09-892-325-6
Query Match 0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 7.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 3106 GCGGAGAGTTTAAAT 3121
DB 2 GTCGAGAGTTTAAAT 17
RESULT 1130
US-09-909-320-229
; Sequence 229, Application US/09909320
; Patent No. US20020132240A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/909,320
; CURRENT FILING DATE: 2002-01-04
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
```

```
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-909-320-229
Query Match 0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 7.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1101 GCTGCTCTCAGGGGAG 1116
DB 3 GCTGCCACAGGGGAG 18
RESULT 1131
US-09-969-373-3935/c
; Sequence 3935, Application US/09969373
; Patent No. US20020133852A1
; GENERAL INFORMATION:
; APPLICANT: Effertz, Roger J.
; APPLICANT: Hauge, Brian M.
; TITLE OF INVENTION: Soybean SSRs and Methods of Genotyping
; FILE REFERENCE: 38-10(52679)A
; CURRENT APPLICATION NUMBER: US/09/969,373
; CURRENT FILING DATE: 2001-10-02
; PRIOR APPLICATION NUMBER: US 09/754,853
; PRIOR FILING DATE: 2001-01-05
; PRIOR APPLICATION NUMBER: US 09/760,427
; PRIOR FILING DATE: 2001-01-13
; PRIOR APPLICATION NUMBER: US 09/855,768
; PRIOR FILING DATE: 2001-05-15
; NUMBER OF SEQ ID NOS: 4593
; SEQ ID NO 3935
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Glycine max
US-09-969-373-3935
Query Match 0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 7.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2339 GTGTGTGTGTGTGCAC 2354
DB 18 GTGTGTGTGTGTGCC 3
RESULT 1132
US-09-909-088B-229
; Sequence 229, Application US/09909088B
```

```

; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description

```

; PRIOR APPLICATION NUMBER: PCT/US99/30095
 ; PRIOR FILING DATE: 1999-12-16
 ; PRIOR APPLICATION NUMBER: PCT/US99/30911
 ; PRIOR FILING DATE: 1999-12-20
 ; PRIOR APPLICATION NUMBER: PCT/US99/30999
 ; PRIOR FILING DATE: 1999-12-20
 ; PRIOR APPLICATION NUMBER: PCT/US00/00219
 ; PRIOR FILING DATE: 2000-01-05
 ; NUMBER OF SEQ ID NOS: 423
 ; SEQ ID NO 229
 ; LENGTH: 18
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 ; OTHER INFORMATION: oligonucleotide probe
 US-09-905-291A-229

Query Match 0.4%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 93.8%; Pred. No. 7.7e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1101 GCTGCTCTCAGGGGAG 1116
 Db 3 GCTGCTCAGGGGAG 18

RESULT 1134
 US-09-349-755-24
 ; Sequence 24, Application US/09349755
 ; Patent No. US20020166131A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Andrew D.J. Goodearl and Sandra Glucksmann
 ; TITLE OF INVENTION: Muscarinic Receptors and Uses Therefor
 ; NUMBER OF SEQUENCES: 39
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: LAHIVE & COCKFIELD, LLP
 ; STREET: 28 State Street
 ; CITY: Boston
 ; STATE: Massachusetts
 ; COUNTRY: USA
 ; ZIP: 02109
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: Floppy disk
 ; COMPUTER: IBM PC compatible
 ; OPERATING SYSTEM: PC-DOS/MS-DOS
 ; SOFTWARE: PatentIn Release #1.0, Version #1.25
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/09/349,755
 ; FILING DATE: 08-Jul-1999
 ; CLASSIFICATION: <Unknown>
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: US/09/042,780
 ; FILING DATE: <Unknown>
 ; APPLICATION NUMBER: US 08/985,090
 ; FILING DATE: 04-DEC-1997
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Elizabeth A. Hanley
 ; REGISTRATION NUMBER: 33,505
 ; REFERENCE/DOCKET NUMBER: MNI-032CP
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: (617)742-4214
 ; TELEFAX: (617)742-4214
 ; INFORMATION FOR SEQ ID NO: 24:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 18 base pairs
 ; TYPE: nucleic acid
 ; STRANDEDNESS: single
 ; TOPOLOGY: linear
 ; MOLECULE TYPE: cDNA
 ; SEQUENCE DESCRIPTION: SEQ ID NO: 24:
 US-09-349-755-24

Query Match 0.4%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 93.8%; Pred. No. 7.7e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Qy 3658 GCCTGCAGGGCCATGG 3673
 Db 1 GCCTGCTGGCCATGG 16
 RESULT 1135
 US-09-166-334-24
 ; Sequence 24, Application US/09166334
 ; Patent No. US20020166708A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Andrew D.J. Goodearl and Sandra Glucksmann
 ; TITLE OF INVENTION: Muscarinic Receptors and Uses Therefor
 ; NUMBER OF SEQUENCES: 39
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: LAHIVE & COCKFIELD, LLP
 ; STREET: 28 State Street
 ; CITY: Boston
 ; STATE: Massachusetts
 ; COUNTRY: USA
 ; ZIP: 02109
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: Floppy disk
 ; COMPUTER: IBM PC compatible
 ; OPERATING SYSTEM: PC-DOS/MS-DOS
 ; SOFTWARE: PatentIn Release #1.0, Version #1.25
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/09/166,334
 ; FILING DATE:
 ; CLASSIFICATION:
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: US/09/042,780
 ; FILING DATE:
 ; APPLICATION NUMBER: US 08/985,090
 ; FILING DATE: 04-DEC-1997
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Elizabeth A. Hanley
 ; REGISTRATION NUMBER: 33,505
 ; REFERENCE/DOCKET NUMBER: MNI-032CP
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: (617)227-7400
 ; TELEFAX: (617)742-4214
 ; INFORMATION FOR SEQ ID NO: 24:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 18 base pairs
 ; TYPE: nucleic acid
 ; STRANDEDNESS: single
 ; TOPOLOGY: linear
 ; MOLECULE TYPE: cDNA
 ; US-09-166-334-24

Query Match 0.4%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 93.8%; Pred. No. 7.7e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3658 GCCTGCAGGGCCATGG 3673
 Db 1 GCCTGCTGGCCATGG 16

RESULT 1136
 US-09-902-853-229
 ; Sequence 229, Application US/09902853
 ; Publication No. US20020192659A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Genentech, Inc.
 ; APPLICANT: Ashkenazi, Avi
 ; APPLICANT: Botstein, David
 ; APPLICANT: Desnoyers, Luc
 ; APPLICANT: Eaton, Dan L.

; APPLICANT: Ferrara, Napoleone
 ; APPLICANT: Filvaroff, Ellen
 ; APPLICANT: Fong, Sherman
 ; APPLICANT: Gao, Wei-Qiang
 ; APPLICANT: Gerber, Hanspeter
 ; APPLICANT: Gerritsen, Mary E.
 ; APPLICANT: Goddard, A.
 ; APPLICANT: Godowski, Paul J.
 ; APPLICANT: Grimaldi, Christopher J.
 ; APPLICANT: Gurney, Austin L.
 ; APPLICANT: Hillan, Kenneth, J.
 ; APPLICANT: Kljavin, Ivar J.
 ; APPLICANT: Mather, Jennie P.
 ; APPLICANT: Pan, James
 ; APPLICANT: Paoni, Nicholas F.
 ; APPLICANT: Roy, Margaret Ann
 ; APPLICANT: Stewart, Timothy A.
 ; APPLICANT: Tumas, Daniel
 ; APPLICANT: Williams, P. Mickey
 ; APPLICANT: Wood, William, I.
 ; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
 ; FILE REFERENCE: 10466-14
 ; CURRENT APPLICATION NUMBER: US/09/902,853
 ; CURRENT FILING DATE: 2001-07-10
 ; PRIOR APPLICATION NUMBER: US/09/665,350
 ; PRIOR FILING DATE: 2000-09-18
 ; PRIOR APPLICATION NUMBER: US 60/143,048
 ; PRIOR FILING DATE: 1999-07-07
 ; PRIOR APPLICATION NUMBER: US 60/145,698
 ; PRIOR FILING DATE: 1999-07-26
 ; PRIOR APPLICATION NUMBER: US 60/146,222
 ; PRIOR FILING DATE: 1999-07-28
 ; PRIOR APPLICATION NUMBER: PCT/US99/20594
 ; PRIOR FILING DATE: 1999-09-08
 ; PRIOR APPLICATION NUMBER: PCT/US99/20944
 ; PRIOR FILING DATE: 1999-09-13
 ; PRIOR APPLICATION NUMBER: PCT/US99/21090
 ; PRIOR FILING DATE: 1999-09-15
 ; PRIOR APPLICATION NUMBER: PCT/US99/21547
 ; PRIOR FILING DATE: 1999-09-15
 ; PRIOR APPLICATION NUMBER: PCT/US99/23089
 ; PRIOR FILING DATE: 1999-11-29
 ; PRIOR APPLICATION NUMBER: PCT/US99/28214
 ; PRIOR FILING DATE: 1999-11-30
 ; PRIOR APPLICATION NUMBER: PCT/US99/28564
 ; PRIOR FILING DATE: 1999-12-02
 ; PRIOR APPLICATION NUMBER: PCT/US99/28565
 ; PRIOR FILING DATE: 1999-12-02
 ; PRIOR APPLICATION NUMBER: PCT/US99/28565
 ; PRIOR FILING DATE: 1999-12-02
 ; PRIOR APPLICATION NUMBER: PCT/US99/30095
 ; PRIOR FILING DATE: 1999-12-16
 ; PRIOR APPLICATION NUMBER: PCT/US99/30911
 ; PRIOR FILING DATE: 1999-12-20
 ; PRIOR APPLICATION NUMBER: PCT/US00/00219
 ; PRIOR FILING DATE: 2000-01-05
 ; NUMBER OF SEQ ID NOS: 423
 ; SEQ ID NO 229
 ; LENGTH: 18
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Synthetic Oligonucleotide Probe
 ; US-09-902-853-229

Query Match 0.4% Score 14.4; DB 1; Length 18;
 Best Local Similarity 93.8%; Pred. No. 7.7e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1101 GCTGTCTCAGGGGAG 1116

Db 3 GCTGTCCACAGGGGAG 18
 RESULT 1137
 US-09-907-824-229
 ; Sequence 229, Application US/09907824
 ; Publication No. US20020197671A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Genentech, Inc.
 ; APPLICANT: Ashkenazi, Avi
 ; APPLICANT: Botstein, David
 ; APPLICANT: Desnoyers, Luc
 ; APPLICANT: Eaton, Dan L.
 ; APPLICANT: Ferrara, Napoleone
 ; APPLICANT: Filvaroff, Ellen
 ; APPLICANT: Fong, Sherman
 ; APPLICANT: Gao, Wei-Qiang
 ; APPLICANT: Gerber, Hanspeter
 ; APPLICANT: Gerritsen, Mary E.
 ; APPLICANT: Goddard, A.
 ; APPLICANT: Godowski, Paul J.
 ; APPLICANT: Grimaldi, Christopher J.
 ; APPLICANT: Gurney, Austin L.
 ; APPLICANT: Hillan, Kenneth, J.
 ; APPLICANT: Kljavin, Ivar J.
 ; APPLICANT: Mather, Jennie P.
 ; APPLICANT: Pan, James
 ; APPLICANT: Paoni, Nicholas F.
 ; APPLICANT: Roy, Margaret Ann
 ; APPLICANT: Stewart, Timothy A.
 ; APPLICANT: Tumas, Daniel
 ; APPLICANT: Williams, P. Mickey
 ; APPLICANT: Wood, William, I.
 ; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
 ; FILE REFERENCE: 10466-14
 ; CURRENT APPLICATION NUMBER: US/09/907,824
 ; CURRENT FILING DATE: 2001-07-17
 ; PRIOR APPLICATION NUMBER: 09/665,350
 ; PRIOR FILING DATE: 2000-09-18
 ; PRIOR APPLICATION NUMBER: PCT/US00/04414
 ; PRIOR FILING DATE: 2000-02-22
 ; PRIOR APPLICATION NUMBER: US 60/143,048
 ; PRIOR FILING DATE: 1999-07-07
 ; PRIOR APPLICATION NUMBER: US 60/145,698
 ; PRIOR FILING DATE: 1999-07-26
 ; PRIOR APPLICATION NUMBER: US 60/146,222
 ; PRIOR FILING DATE: 1999-07-28
 ; PRIOR APPLICATION NUMBER: PCT/US99/20594
 ; PRIOR FILING DATE: 1999-09-08
 ; PRIOR APPLICATION NUMBER: PCT/US99/20944
 ; PRIOR FILING DATE: 1999-09-13
 ; PRIOR APPLICATION NUMBER: PCT/US99/21090
 ; PRIOR FILING DATE: 1999-09-15
 ; PRIOR APPLICATION NUMBER: PCT/US99/21547
 ; PRIOR FILING DATE: 1999-09-15
 ; PRIOR APPLICATION NUMBER: PCT/US99/23089
 ; PRIOR FILING DATE: 1999-10-05
 ; PRIOR APPLICATION NUMBER: PCT/US99/28214
 ; PRIOR FILING DATE: 1999-11-29
 ; PRIOR APPLICATION NUMBER: PCT/US99/28313
 ; PRIOR FILING DATE: 1999-11-30
 ; PRIOR APPLICATION NUMBER: PCT/US99/28564
 ; PRIOR FILING DATE: 1999-12-02
 ; PRIOR APPLICATION NUMBER: PCT/US99/28565
 ; PRIOR FILING DATE: 1999-12-02
 ; PRIOR APPLICATION NUMBER: PCT/US99/30095
 ; PRIOR FILING DATE: 1999-12-16
 ; PRIOR APPLICATION NUMBER: PCT/US99/30911
 ; PRIOR FILING DATE: 1999-12-20
 ; PRIOR APPLICATION NUMBER: PCT/US99/30999
 ; PRIOR FILING DATE: 1999-12-20

; PRIOR APPLICATION NUMBER: PCT/US99/21547
 ; PRIOR FILING DATE: 1999-09-15
 ; PRIOR APPLICATION NUMBER: PCT/US99/23089
 ; PRIOR FILING DATE: 1999-10-05
 ; PRIOR APPLICATION NUMBER: PCT/US99/28214
 ; PRIOR FILING DATE: 1999-11-29
 ; PRIOR APPLICATION NUMBER: PCT/US99/28313
 ; PRIOR FILING DATE: 1999-11-30
 ; PRIOR APPLICATION NUMBER: PCT/US99/28564
 ; PRIOR FILING DATE: 1999-12-02
 ; PRIOR APPLICATION NUMBER: PCT/US99/28565
 ; PRIOR FILING DATE: 1999-12-02
 ; PRIOR APPLICATION NUMBER: PCT/US99/30095
 ; PRIOR FILING DATE: 1999-12-16
 ; PRIOR APPLICATION NUMBER: PCT/US99/30911
 ; PRIOR FILING DATE: 1999-12-20
 ; PRIOR APPLICATION NUMBER: PCT/US99/30999
 ; PRIOR FILING DATE: 1999-12-20
 ; PRIOR APPLICATION NUMBER: PCT/US00/00219
 ; PRIOR FILING DATE: 2000-01-05
 ; NUMBER OF SEQ ID NOS: 423
 ; SEQ ID NO 229
 ; LENGTH: 18
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Synthetic Oligonucleotide Probe
 US-09-904-011-229

Query Match 0.4%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 93.8%; Pred. No. 7.7e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1101 GCTGTCTCTCAGGGGAG 1116
 |||||
 Db 3 GCTGTCCACAGGGGAG 18

RESULT 1140
 US-09-903-640-229
 ; Sequence 229, Application US/09903640
 ; Publication No. US20030017463A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Genentech, Inc.
 ; APPLICANT: Ashkenazi, Avi
 ; APPLICANT: Botstein, David
 ; APPLICANT: Desnoyers, Luc
 ; APPLICANT: Eaton, Dan L.
 ; APPLICANT: Ferrara, Napoleone
 ; APPLICANT: Filvaroff, Ellen
 ; APPLICANT: Fong, Sherman
 ; APPLICANT: Gao, Wei-Qiang
 ; APPLICANT: Gerber, Hanspeter
 ; APPLICANT: Gerritsen, Mary E.
 ; APPLICANT: Goddard, A.
 ; APPLICANT: Godowski, Paul J.
 ; APPLICANT: Grimaldi, Christopher J.
 ; APPLICANT: Hillan, Kenneth, J.
 ; APPLICANT: Kljavin, Ivar J.
 ; APPLICANT: Mather, Jennie P.
 ; APPLICANT: Pan, James
 ; APPLICANT: Paoni, Nicholas F.
 ; APPLICANT: Roy, Margaret Ann
 ; APPLICANT: Stewart, Timothy A.
 ; APPLICANT: Tumas, Daniel
 ; APPLICANT: Williams, P. Mickey
 ; APPLICANT: Wood, William, I.
 ; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
 ; FILE REFERENCE: 10466-14
 ; CURRENT APPLICATION NUMBER: US/09/903.640
 ; CURRENT FILING DATE: 2001-07-11

; PRIOR APPLICATION NUMBER: 09/665,350
 ; PRIOR FILING DATE: 2000-09-18
 ; NUMBER OF SEQ ID NOS: 423
 ; SEQ ID NO 229
 ; LENGTH: 18
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Synthetic Oligonucleotide Probe
 US-09-903-640-229

Query Match 0.4%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 93.8%; Pred. No. 7.7e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1101 GCTGTCTCTCAGGGGAG 1116
 |||||
 Db 3 GCTGTCCACAGGGGAG 18

RESULT 1141
 US-09-908-093-229
 ; Sequence 229, Application US/09908093
 ; Publication No. US20030017498A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Genentech, Inc.
 ; APPLICANT: Ashkenazi, Avi
 ; APPLICANT: Botstein, David
 ; APPLICANT: Desnoyers, Luc
 ; APPLICANT: Eaton, Dan L.
 ; APPLICANT: Ferrara, Napoleone
 ; APPLICANT: Filvaroff, Ellen
 ; APPLICANT: Fong, Sherman
 ; APPLICANT: Gao, Wei-Qiang
 ; APPLICANT: Gerber, Hanspeter
 ; APPLICANT: Gerritsen, Mary E.
 ; APPLICANT: Goddard, A.
 ; APPLICANT: Godowski, Paul J.
 ; APPLICANT: Grimaldi, Christopher J.
 ; APPLICANT: Gurney, Austin L.
 ; APPLICANT: Hillan, Kenneth, J.
 ; APPLICANT: Kljavin, Ivar J.
 ; APPLICANT: Mather, Jennie P.
 ; APPLICANT: Pan, James
 ; APPLICANT: Paoni, Nicholas F.
 ; APPLICANT: Roy, Margaret Ann
 ; APPLICANT: Stewart, Timothy A.
 ; APPLICANT: Tumas, Daniel
 ; APPLICANT: Williams, P. Mickey
 ; APPLICANT: Wood, William, I.
 ; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
 ; FILE REFERENCE: 10466-14
 ; CURRENT APPLICATION NUMBER: US/09/908,093
 ; CURRENT FILING DATE: 2001-07-17
 ; PRIOR APPLICATION NUMBER: 09/665,350
 ; PRIOR FILING DATE: 2000-09-18
 ; PRIOR APPLICATION NUMBER: PCT/US00/04414
 ; PRIOR FILING DATE: 2000-02-22
 ; PRIOR APPLICATION NUMBER: US 60/143,048
 ; PRIOR FILING DATE: 1999-07-07
 ; PRIOR APPLICATION NUMBER: US 60/145,698
 ; PRIOR FILING DATE: 1999-07-26
 ; PRIOR APPLICATION NUMBER: US 60/146,222
 ; PRIOR FILING DATE: 1999-07-28
 ; PRIOR APPLICATION NUMBER: PCT/US99/20594
 ; PRIOR FILING DATE: 1999-09-08
 ; PRIOR APPLICATION NUMBER: PCT/US99/20944
 ; PRIOR FILING DATE: 1999-09-13
 ; PRIOR APPLICATION NUMBER: PCT/US99/21090
 ; PRIOR FILING DATE: 1999-09-15
 ; PRIOR APPLICATION NUMBER: PCT/US99/21547
 ; PRIOR FILING DATE: 1999-09-15

;; PRIOR APPLICATION NUMBER: PCT/US99/23089
;; PRIOR FILING DATE: 1999-10-05
;; PRIOR APPLICATION NUMBER: PCT/US99/28214
;; PRIOR FILING DATE: 1999-11-29
;; PRIOR APPLICATION NUMBER: PCT/US99/28313
;; PRIOR FILING DATE: 1999-11-30
;; PRIOR APPLICATION NUMBER: PCT/US99/28564
;; PRIOR FILING DATE: 1999-12-02
;; PRIOR APPLICATION NUMBER: PCT/US99/28565
;; PRIOR FILING DATE: 1999-12-02
;; PRIOR APPLICATION NUMBER: PCT/US99/30095
;; PRIOR FILING DATE: 1999-12-16
;; PRIOR APPLICATION NUMBER: PCT/US99/30911
;; PRIOR FILING DATE: 1999-12-20
;; PRIOR APPLICATION NUMBER: PCT/US99/30999
;; PRIOR FILING DATE: 1999-12-20
;; PRIOR APPLICATION NUMBER: PCT/US00/00219
;; PRIOR FILING DATE: 2000-01-05
;; NUMBER OF SEQ ID NOS: 423
;; SEQ ID NO 229
;; LENGTH: 18
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-09-908-093-229

Query Match 0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 7.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1101 GCTGTCTCAGGGGAG 1116
|||||
Db 3 GCTGTCCACAGGGGAG 18

RESULT 1142
US-09-906-742-229
; Sequence 229, Application US/09906742
; Publication No. US20030023054A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kijavlin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/906,742
; CURRENT FILING DATE: 2001-07-16
; PRIOR APPLICATION NUMBER: 09/665,350
; PRIOR FILING DATE: 2000-09-18

;; PRIOR APPLICATION NUMBER: PCT/US00/04414
;; PRIOR FILING DATE: 2000-02-22
;; PRIOR APPLICATION NUMBER: US 60/143,048
;; PRIOR FILING DATE: 1999-07-07
;; PRIOR APPLICATION NUMBER: US 60/145,698
;; PRIOR FILING DATE: 1999-07-26
;; PRIOR APPLICATION NUMBER: US 60/146,222
;; PRIOR FILING DATE: 1999-07-28
;; PRIOR APPLICATION NUMBER: PCT/US99/20594
;; PRIOR FILING DATE: 1999-09-08
;; PRIOR APPLICATION NUMBER: PCT/US99/20944
;; PRIOR FILING DATE: 1999-09-13
;; PRIOR APPLICATION NUMBER: PCT/US99/21090
;; PRIOR FILING DATE: 1999-09-15
;; PRIOR APPLICATION NUMBER: PCT/US99/21547
;; PRIOR FILING DATE: 1999-09-15
;; PRIOR APPLICATION NUMBER: PCT/US99/23089
;; PRIOR FILING DATE: 1999-10-05
;; PRIOR APPLICATION NUMBER: PCT/US99/28214
;; PRIOR FILING DATE: 1999-11-29
;; PRIOR APPLICATION NUMBER: PCT/US99/28313
;; PRIOR FILING DATE: 1999-11-30
;; PRIOR APPLICATION NUMBER: PCT/US99/28564
;; PRIOR FILING DATE: 1999-12-02
;; PRIOR APPLICATION NUMBER: PCT/US99/28565
;; PRIOR FILING DATE: 1999-12-02
;; PRIOR APPLICATION NUMBER: PCT/US99/30095
;; PRIOR FILING DATE: 1999-12-16
;; PRIOR APPLICATION NUMBER: PCT/US99/30911
;; PRIOR FILING DATE: 1999-12-20
;; PRIOR APPLICATION NUMBER: PCT/US99/30999
;; PRIOR FILING DATE: 1999-12-20
;; PRIOR APPLICATION NUMBER: PCT/US00/00219
;; PRIOR FILING DATE: 2000-01-05
;; NUMBER OF SEQ ID NOS: 423
;; SEQ ID NO 229
;; LENGTH: 18
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-09-906-742-229

Query Match 0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 7.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1101 GCTGTCTCAGGGGAG 1116
|||||
Db 3 GCTGTCCACAGGGGAG 18

RESULT 1143
US-09-906-838-229
; Sequence 229, Application US/09906838
; Publication No. US20030027143A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.

APPLICANT: Kljavin, Ivar J.
APPLICANT: Mather, Jennie P.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William, I.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: 10466-14
CURRENT APPLICATION NUMBER: US/09/906,838
CURRENT FILING DATE: 2001-07-16
PRIOR APPLICATION NUMBER: 09/665,350
PRIOR FILING DATE: 2000-09-18
PRIOR APPLICATION NUMBER: PCT/US00/04414
PRIOR FILING DATE: 2000-02-22
PRIOR APPLICATION NUMBER: US 60/143,048
PRIOR FILING DATE: 1999-07-07
PRIOR APPLICATION NUMBER: US 60/145,698
PRIOR FILING DATE: 1999-07-26
PRIOR APPLICATION NUMBER: US 60/146,222
PRIOR FILING DATE: 1999-07-28
PRIOR APPLICATION NUMBER: PCT/US99/20594
PRIOR FILING DATE: 1999-09-08
PRIOR APPLICATION NUMBER: PCT/US99/20944
PRIOR FILING DATE: 1999-09-13
PRIOR APPLICATION NUMBER: PCT/US99/21090
PRIOR FILING DATE: 1999-09-15
PRIOR APPLICATION NUMBER: PCT/US99/21547
PRIOR FILING DATE: 1999-09-15
PRIOR APPLICATION NUMBER: PCT/US99/23089
PRIOR FILING DATE: 1999-10-05
PRIOR APPLICATION NUMBER: PCT/US99/28214
PRIOR FILING DATE: 1999-11-29
PRIOR APPLICATION NUMBER: PCT/US99/28313
PRIOR FILING DATE: 1999-11-30
PRIOR APPLICATION NUMBER: PCT/US99/28564
PRIOR FILING DATE: 1999-12-02
PRIOR APPLICATION NUMBER: PCT/US99/28565
PRIOR FILING DATE: 1999-12-02
PRIOR APPLICATION NUMBER: PCT/US99/30095
PRIOR FILING DATE: 1999-12-16
PRIOR APPLICATION NUMBER: PCT/US99/30911
PRIOR FILING DATE: 1999-12-20
PRIOR APPLICATION NUMBER: PCT/US99/30999
PRIOR FILING DATE: 1999-12-20
PRIOR APPLICATION NUMBER: PCT/US00/00219
PRIOR FILING DATE: 2000-01-05
NUMBER OF SEQ ID NOS: 423
SEQ ID NO 229
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-09-906-838-229

Query Match 0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 7.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1101 GCTGTCCTCAGGGAG 1116
Db 3 GCTGTCCACAGGGAG 18

RESULT 1144

US-09-907-613-229
Sequence 229, Application US/09907613
Publication No. US20030027145A1
GENERAL INFORMATION:
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
OTHER INFORMATION: oligonucleotide probe
US-09-907-613-229

APPLICANT: Genentech, Inc.
APPLICANT: Ashkenazi, Avi
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Filvaroff, Ellen
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerber, Hanspeter
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, A.
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth, J.
APPLICANT: Kljavin, Ivar J.
APPLICANT: Mather, Jennie P.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William, I.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: 10466-14
CURRENT APPLICATION NUMBER: US/09/907,613
CURRENT FILING DATE: 2001-07-17
PRIOR APPLICATION NUMBER: PCT/US00/04414
PRIOR FILING DATE: 2000-02-22
PRIOR APPLICATION NUMBER: US 60/143,048
PRIOR FILING DATE: 1999-07-07
PRIOR APPLICATION NUMBER: US 60/145,698
PRIOR FILING DATE: 1999-07-26
PRIOR APPLICATION NUMBER: US 60/146,222
PRIOR FILING DATE: 1999-07-28
PRIOR APPLICATION NUMBER: PCT/US99/20594
PRIOR FILING DATE: 1999-09-08
PRIOR APPLICATION NUMBER: PCT/US99/20944
PRIOR FILING DATE: 1999-09-13
PRIOR APPLICATION NUMBER: PCT/US99/21090
PRIOR FILING DATE: 1999-09-15
PRIOR APPLICATION NUMBER: PCT/US99/21547
PRIOR FILING DATE: 1999-09-15
PRIOR APPLICATION NUMBER: PCT/US99/23089
PRIOR FILING DATE: 1999-10-05
PRIOR APPLICATION NUMBER: PCT/US99/28214
PRIOR FILING DATE: 1999-11-29
PRIOR APPLICATION NUMBER: PCT/US99/28313
PRIOR FILING DATE: 1999-11-30
PRIOR APPLICATION NUMBER: PCT/US99/28564
PRIOR FILING DATE: 1999-12-02
PRIOR APPLICATION NUMBER: PCT/US99/28565
PRIOR FILING DATE: 1999-12-02
PRIOR APPLICATION NUMBER: PCT/US99/30095
PRIOR FILING DATE: 1999-12-16
PRIOR APPLICATION NUMBER: PCT/US99/30911
PRIOR FILING DATE: 1999-12-20
PRIOR APPLICATION NUMBER: PCT/US99/30999
PRIOR FILING DATE: 1999-12-20
PRIOR APPLICATION NUMBER: PCT/US00/00219
PRIOR FILING DATE: 2000-01-05
NUMBER OF SEQ ID NOS: 423
SEQ ID NO 229
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
OTHER INFORMATION: oligonucleotide probe
US-09-907-613-229

Query Match 0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 7.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1101 GCTGTCCTCAGGGGAG 1116
Db 3 GCTGTCCACAGGGGAG 18

RESULT 1145

US-09-907-942-229

; Sequence 229, Application US/09907942

; Publication No. US20030027146A1

; GENERAL INFORMATION:

; APPLICANT: Genentech, Inc.

; APPLICANT: Ashkenazi, Avi

; APPLICANT: Botstein, David

; APPLICANT: Desnoyers, Luc

; APPLICANT: Eaton, Dan L.

; APPLICANT: Ferrara, Napoleone

; APPLICANT: Filvaroff, Ellen

; APPLICANT: Fong, Sherman

; APPLICANT: Gao, Wei-Qiang

; APPLICANT: Gerber, Hanspeter

; APPLICANT: Gerritsen, Mary E.

; APPLICANT: Goddard, A.

; APPLICANT: Godowski, Paul J.

; APPLICANT: Grimaldi, Christopher J.

; APPLICANT: Gurney, Austin L.

; APPLICANT: Hillan, Kenneth, J.

; APPLICANT: Kljavin, Ivar J.

; APPLICANT: Mather, Jennie P.

; APPLICANT: Pan, James

; APPLICANT: Paoni, Nicholas F.

; APPLICANT: Roy, Margaret Ann

; APPLICANT: Stewart, Timothy A.

; APPLICANT: Tumas, Daniel

; APPLICANT: Williams, P. Mickey

; APPLICANT: Wood, William, I.

; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic

; FILE REFERENCE: 10466-14

; CURRENT APPLICATION NUMBER: US/09/907,942

; CURRENT FILING DATE: 2002-01-22

; PRIOR APPLICATION NUMBER: PCT/US00/04414

; PRIOR FILING DATE: 2000-02-22

; PRIOR APPLICATION NUMBER: US 60/143,048

; PRIOR FILING DATE: 1999-07-07

; PRIOR APPLICATION NUMBER: US 60/145,698

; PRIOR FILING DATE: 1999-07-26

; PRIOR APPLICATION NUMBER: US 60/146,222

; PRIOR FILING DATE: 1999-07-28

; PRIOR APPLICATION NUMBER: PCT/US99/20594

; PRIOR FILING DATE: 1999-09-08

; PRIOR APPLICATION NUMBER: PCT/US99/20944

; PRIOR FILING DATE: 1999-09-13

; PRIOR APPLICATION NUMBER: PCT/US99/21090

; PRIOR FILING DATE: 1999-09-15

; PRIOR APPLICATION NUMBER: PCT/US99/21547

; PRIOR FILING DATE: 1999-09-15

; PRIOR APPLICATION NUMBER: PCT/US99/23089

; PRIOR FILING DATE: 1999-10-05

; PRIOR APPLICATION NUMBER: PCT/US99/28214

; PRIOR FILING DATE: 1999-11-29

; PRIOR APPLICATION NUMBER: PCT/US99/28313

; PRIOR FILING DATE: 1999-11-30

; PRIOR APPLICATION NUMBER: PCT/US99/28564

; PRIOR FILING DATE: 1999-12-02

; PRIOR APPLICATION NUMBER: PCT/US99/28565

; PRIOR FILING DATE: 1999-12-02

; PRIOR APPLICATION NUMBER: PCT/US99/30095

; PRIOR FILING DATE: 1999-12-16

; PRIOR APPLICATION NUMBER: PCT/US99/30911

; PRIOR FILING DATE: 1999-12-20

; PRIOR APPLICATION NUMBER: PCT/US99/30999

; PRIOR FILING DATE: 1999-12-20

; PRIOR APPLICATION NUMBER: PCT/US00/00219

; PRIOR FILING DATE: 2000-01-05

; NUMBER OF SEQ ID NOS: 423

; SEQ ID NO 229

; LENGTH: 18

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: Synthetic

; OTHER INFORMATION: oligonucleotide probe

US-09-907-942-229

Query Match 0.4%; Score 14.4; DB 1; Length 18;

Best Local Similarity 93.8%; Pred. No. 7.7e+02;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1101 GCTGTCCTCAGGGGAG 1116
Db 3 GCTGTCCACAGGGGAG 18

RESULT 1146

US-09-904-859-229

; Sequence 229, Application US/09904859

; Publication No. US20030036060A1

; GENERAL INFORMATION:

; APPLICANT: Genentech, Inc.

; APPLICANT: Ashkenazi, Avi

; APPLICANT: Botstein, David

; APPLICANT: Desnoyers, Luc

; APPLICANT: Eaton, Dan L.

; APPLICANT: Ferrara, Napoleone

; APPLICANT: Filvaroff, Ellen

; APPLICANT: Fong, Sherman

; APPLICANT: Gao, Wei-Qiang

; APPLICANT: Gerber, Hanspeter

; APPLICANT: Gerritsen, Mary E.

; APPLICANT: Goddard, A.

; APPLICANT: Godowski, Paul J.

; APPLICANT: Grimaldi, Christopher J.

; APPLICANT: Gurney, Austin L.

; APPLICANT: Hillan, Kenneth, J.

; APPLICANT: Kljavin, Ivar J.

; APPLICANT: Mather, Jennie P.

; APPLICANT: Pan, James

; APPLICANT: Paoni, Nicholas F.

; APPLICANT: Roy, Margaret Ann

; APPLICANT: Stewart, Timothy A.

; APPLICANT: Tumas, Daniel

; APPLICANT: Williams, P. Mickey

; APPLICANT: Wood, William, I.

; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic

; FILE REFERENCE: 10466-14

; CURRENT APPLICATION NUMBER: US/09/904,859

; CURRENT FILING DATE: 2001-07-12

; PRIOR APPLICATION NUMBER: 09/665,350

; PRIOR FILING DATE: 2000-09-18

; PRIOR APPLICATION NUMBER: PCT/US00/04414

; PRIOR FILING DATE: 2000-02-22

; PRIOR APPLICATION NUMBER: US 60/143,048

; PRIOR FILING DATE: 1999-07-07

; PRIOR APPLICATION NUMBER: US 60/145,698

; PRIOR FILING DATE: 1999-07-26

; PRIOR APPLICATION NUMBER: US 60/146,222

; PRIOR FILING DATE: 1999-07-28

; PRIOR APPLICATION NUMBER: PCT/US99/20594

; PRIOR FILING DATE: 1999-09-08

; PRIOR APPLICATION NUMBER: PCT/US99/20944

;; PRIOR FILING DATE: 1999-09-13
;; PRIOR APPLICATION NUMBER: PCT/US99/21090
;; PRIOR FILING DATE: 1999-09-15
;; PRIOR APPLICATION NUMBER: PCT/US99/21547
;; PRIOR FILING DATE: 1999-09-15
;; PRIOR APPLICATION NUMBER: PCT/US99/23089
;; PRIOR FILING DATE: 1999-10-05
;; PRIOR APPLICATION NUMBER: PCT/US99/28214
;; PRIOR FILING DATE: 1999-11-29
;; PRIOR APPLICATION NUMBER: PCT/US99/28313
;; PRIOR FILING DATE: 1999-11-30
;; PRIOR APPLICATION NUMBER: PCT/US99/28564
;; PRIOR FILING DATE: 1999-12-02
;; PRIOR APPLICATION NUMBER: PCT/US99/28565
;; PRIOR FILING DATE: 1999-12-02
;; PRIOR APPLICATION NUMBER: PCT/US99/30095
;; PRIOR FILING DATE: 1999-12-16
;; PRIOR APPLICATION NUMBER: PCT/US99/30911
;; PRIOR FILING DATE: 1999-12-20
;; PRIOR APPLICATION NUMBER: PCT/US99/30999
;; PRIOR FILING DATE: 1999-12-20
;; PRIOR APPLICATION NUMBER: PCT/US00/00219
;; PRIOR FILING DATE: 2000-01-05
;; NUMBER OF SEQ ID NOS: 423
;; SEQ ID NO 229
;; LENGTH: 18
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-09-904-859-229

Query Match 0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 7.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1101 GCTGTCCTCAGGGGAG 1116
||||| |||||
Db 3 GCTGTCACAGGGGAG 18

RESULT 1147
US-09-909-204-229
; Sequence 229, Application US/09909204
; Publication No. US20030036061A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Kijavlin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas P.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same

;; FILE REFERENCE: 10466-14
;; CURRENT APPLICATION NUMBER: US/09/909,204
;; CURRENT FILING DATE: 2001-07-18
;; PRIOR APPLICATION NUMBER: PCT/US00/04414
;; PRIOR FILING DATE: 2000-02-22
;; PRIOR APPLICATION NUMBER: US 60/143,048
;; PRIOR FILING DATE: 1999-07-07
;; PRIOR APPLICATION NUMBER: US 60/145,698
;; PRIOR FILING DATE: 1999-07-26
;; PRIOR APPLICATION NUMBER: US 60/146,222
;; PRIOR FILING DATE: 1999-07-28
;; PRIOR APPLICATION NUMBER: PCT/US99/20594
;; PRIOR FILING DATE: 1999-09-08
;; PRIOR APPLICATION NUMBER: PCT/US99/20944
;; PRIOR FILING DATE: 1999-09-13
;; PRIOR APPLICATION NUMBER: PCT/US99/21090
;; PRIOR FILING DATE: 1999-09-15
;; PRIOR APPLICATION NUMBER: PCT/US99/21547
;; PRIOR FILING DATE: 1999-09-15
;; PRIOR APPLICATION NUMBER: PCT/US99/23089
;; PRIOR FILING DATE: 1999-10-05
;; PRIOR APPLICATION NUMBER: PCT/US99/28214
;; PRIOR FILING DATE: 1999-11-29
;; PRIOR APPLICATION NUMBER: PCT/US99/28313
;; PRIOR FILING DATE: 1999-11-30
;; PRIOR APPLICATION NUMBER: PCT/US99/28564
;; PRIOR FILING DATE: 1999-12-02
;; PRIOR APPLICATION NUMBER: PCT/US99/28565
;; PRIOR FILING DATE: 1999-12-02
;; PRIOR APPLICATION NUMBER: PCT/US99/30095
;; PRIOR FILING DATE: 1999-12-16
;; PRIOR APPLICATION NUMBER: PCT/US99/30911
;; PRIOR FILING DATE: 1999-12-20
;; PRIOR APPLICATION NUMBER: PCT/US99/30999
;; PRIOR FILING DATE: 1999-12-20
;; PRIOR APPLICATION NUMBER: PCT/US00/00219
;; PRIOR FILING DATE: 2000-01-05
;; NUMBER OF SEQ ID NOS: 423
;; SEQ ID NO 229
;; LENGTH: 18
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-909-204-229

Query Match 0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 7.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1101 GCTGTCCTCAGGGGAG 1116
||||| |||||
Db 3 GCTGTCACAGGGGAG 18

RESULT 1148
US-09-904-820-229
; Sequence 229, Application US/09904820
; Publication No. US20030036094A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.

US-09-906-700-229

Query Match 0.4%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 93.8%; Pred. No. 7.7e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1101 GCTGTCTCTCAGGGGAG 1116
 |||||
 Db 3 GCTGTCCACAGGGGAG 18

RESULT 1152

US-09-903-786-229
 ; Sequence 229, Application US/09903786

; Publication No. US20030044793A1

; GENERAL INFORMATION:

; APPLICANT: Genentech, Inc.

; APPLICANT: Ashkenazi, Avi

; APPLICANT: Botstein, David

; APPLICANT: Desnoyers, Luc

; APPLICANT: Eaton, Dan L.

; APPLICANT: Ferrara, Napoleone

; APPLICANT: Filvaroff, Ellen

; APPLICANT: Fong, Sherman

; APPLICANT: Gerber, Hanspeter

; APPLICANT: Gerritsen, Mary E.

; APPLICANT: Goddard, A.

; APPLICANT: Godowski, Paul J.

; APPLICANT: Grimaldi, Christopher J.

; APPLICANT: Gurney, Austin L.

; APPLICANT: Hillan, Kenneth, J.

; APPLICANT: Kijavin, Ivar J.

; APPLICANT: Mather, Jennie P.

; APPLICANT: Pan, James

; APPLICANT: Paoni, Nicholas F.

; APPLICANT: Roy, Margaret Ann

; APPLICANT: Stewart, Timothy A.

; APPLICANT: Tumas, Daniel

; APPLICANT: Williams, P. Mickey

; APPLICANT: Wood, William, I.

; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic

; FILE REFERENCE: 10466-14

; CURRENT APPLICATION NUMBER: US/09/903,786

; CURRENT FILING DATE: 2001-07-11

; PRIOR FILING DATE: 2000-09-18

; PRIOR APPLICATION NUMBER: PCT/US00/04414

; PRIOR FILING DATE: 2000-02-22

; PRIOR APPLICATION NUMBER: US 60/143,048

; PRIOR FILING DATE: 1999-07-07

; PRIOR APPLICATION NUMBER: US 60/145,698

; PRIOR FILING DATE: 1999-07-26

; PRIOR APPLICATION NUMBER: US 60/146,222

; PRIOR FILING DATE: 1999-07-28

; PRIOR APPLICATION NUMBER: PCT/US99/20594

; PRIOR FILING DATE: 1999-09-08

; PRIOR APPLICATION NUMBER: PCT/US99/20944

; PRIOR FILING DATE: 1999-09-13

; PRIOR APPLICATION NUMBER: PCT/US99/21090

; PRIOR FILING DATE: 1999-09-15

; PRIOR APPLICATION NUMBER: PCT/US99/21547

; PRIOR FILING DATE: 1999-09-15

; PRIOR APPLICATION NUMBER: PCT/US99/23089

; PRIOR FILING DATE: 1999-10-05

; PRIOR APPLICATION NUMBER: PCT/US99/28214

; PRIOR FILING DATE: 1999-11-29

; PRIOR APPLICATION NUMBER: PCT/US99/28313

; PRIOR FILING DATE: 1999-11-30

; PRIOR APPLICATION NUMBER: PCT/US99/28564

; PRIOR FILING DATE: 1999-12-02

; PRIOR APPLICATION NUMBER: PCT/US99/28565

; PRIOR FILING DATE: 1999-12-02

; PRIOR APPLICATION NUMBER: PCT/US99/30095

; PRIOR FILING DATE: 1999-12-16

; PRIOR APPLICATION NUMBER: PCT/US99/30911

; PRIOR FILING DATE: 1999-12-20

; PRIOR APPLICATION NUMBER: PCT/US99/30999

; PRIOR FILING DATE: 1999-12-20

; PRIOR APPLICATION NUMBER: PCT/US00/00219

; PRIOR FILING DATE: 2000-01-05

; NUMBER OF SEQ ID NOS: 423

; SEQ ID NO 229

; LENGTH: 18

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Synthetic Oligonucleotide Probe

US-09-903-786-229

Query Match 0.4%; Score 14.4; DB 1; Length 18;

Best Local Similarity 93.8%; Pred. No. 7.7e+02;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1101 GCTGTCTCTCAGGGGAG 1116
 |||||
 Db 3 GCTGTCCACAGGGGAG 18

RESULT 1153

US-09-902-903-229

; Sequence 229, Application US/09902903

; Publication No. US20030044839A1

; GENERAL INFORMATION:

; APPLICANT: Genentech, Inc.

; APPLICANT: Ashkenazi, Avi

; APPLICANT: Botstein, David

; APPLICANT: Desnoyers, Luc

; APPLICANT: Eaton, Dan L.

; APPLICANT: Ferrara, Napoleone

; APPLICANT: Filvaroff, Ellen

; APPLICANT: Fong, Sherman

; APPLICANT: Gao, Wei-Qiang

; APPLICANT: Gerber, Hanspeter

; APPLICANT: Gerritsen, Mary E.

; APPLICANT: Goddard, A.

; APPLICANT: Godowski, Paul J.

; APPLICANT: Grimaldi, Christopher J.

; APPLICANT: Gurney, Austin L.

; APPLICANT: Hillan, Kenneth, J.

; APPLICANT: Kijavin, Ivar J.

; APPLICANT: Mather, Jennie P.

; APPLICANT: Pan, James

; APPLICANT: Paoni, Nicholas F.

; APPLICANT: Roy, Margaret Ann

; APPLICANT: Stewart, Timothy A.

; APPLICANT: Tumas, Daniel

; APPLICANT: Williams, P. Mickey

; APPLICANT: Wood, William, I.

; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic

; FILE REFERENCE: 10466-14

; CURRENT APPLICATION NUMBER: US/09/902,903

; CURRENT FILING DATE: 2001-07-10

; PRIOR APPLICATION NUMBER: PCT/US00/04414

; PRIOR FILING DATE: 2000-02-22

; PRIOR APPLICATION NUMBER: US 60/143,048

; PRIOR FILING DATE: 1999-07-07

; PRIOR APPLICATION NUMBER: US 60/145,698

; PRIOR FILING DATE: 1999-07-26

; PRIOR APPLICATION NUMBER: US 60/146,222

; PRIOR FILING DATE: 1999-07-28

; PRIOR APPLICATION NUMBER: PCT/US99/20594

; PRIOR FILING DATE: 1999-09-08

; PRIOR APPLICATION NUMBER: PCT/US99/20944

;; PRIOR FILING DATE: 1999-09-13
;; PRIOR APPLICATION NUMBER: PCT/US99/21090
;; PRIOR FILING DATE: 1999-09-15
;; PRIOR APPLICATION NUMBER: PCT/US99/21547
;; PRIOR FILING DATE: 1999-09-15
;; PRIOR APPLICATION NUMBER: PCT/US99/23089
;; PRIOR FILING DATE: 1999-10-05
;; PRIOR APPLICATION NUMBER: PCT/US99/28214
;; PRIOR FILING DATE: 1999-11-29
;; PRIOR APPLICATION NUMBER: PCT/US99/28313
;; PRIOR FILING DATE: 1999-11-30
;; PRIOR APPLICATION NUMBER: PCT/US99/28564
;; PRIOR FILING DATE: 1999-12-02
;; PRIOR APPLICATION NUMBER: PCT/US99/28565
;; PRIOR FILING DATE: 1999-12-02
;; PRIOR APPLICATION NUMBER: PCT/US99/30095
;; PRIOR FILING DATE: 1999-12-16
;; PRIOR APPLICATION NUMBER: PCT/US99/30911
;; PRIOR FILING DATE: 1999-12-20
;; PRIOR APPLICATION NUMBER: PCT/US99/30999
;; PRIOR FILING DATE: 1999-12-20
;; PRIOR APPLICATION NUMBER: PCT/US00/00219
;; PRIOR FILING DATE: 2000-01-05
;; NUMBER OF SEQ ID NOS: 423
;; SEQ ID NO 229
;; LENGTH: 18
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;; OTHER INFORMATION: oligonucleotide probe
US-09-902-903-229

Query Match 0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 7.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1101 GCTGCTCTCAGGGGAG 1116
||||| |||||
Db 3 GCTGTCCACAGGGGAG 18

RESULT 1154

US-09-903-749A-229
; Sequence 229, Application US/09903749A
; Publication No. US20030045693A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas P.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic

;; TITLE OF INVENTION: Acids Encoding the Same
;; FILE REFERENCE: 10466-14
;; CURRENT APPLICATION NUMBER: US/09/903.749A
;; CURRENT FILING DATE: 2001-07-11
;; PRIOR APPLICATION NUMBER: PCT/US00/04414
;; PRIOR FILING DATE: 2000-02-22
;; PRIOR APPLICATION NUMBER: US 60/143,048
;; PRIOR FILING DATE: 1999-07-07
;; PRIOR APPLICATION NUMBER: US 60/145,698
;; PRIOR FILING DATE: 1999-07-26
;; PRIOR APPLICATION NUMBER: US 60/146,222
;; PRIOR FILING DATE: 1999-07-28
;; PRIOR APPLICATION NUMBER: PCT/US99/20594
;; PRIOR FILING DATE: 1999-09-08
;; PRIOR APPLICATION NUMBER: PCT/US99/20944
;; PRIOR FILING DATE: 1999-09-13
;; PRIOR APPLICATION NUMBER: PCT/US99/21090
;; PRIOR FILING DATE: 1999-09-15
;; PRIOR APPLICATION NUMBER: PCT/US99/21547
;; PRIOR FILING DATE: 1999-09-15
;; PRIOR APPLICATION NUMBER: PCT/US99/23089
;; PRIOR FILING DATE: 1999-10-05
;; PRIOR APPLICATION NUMBER: PCT/US99/28214
;; PRIOR FILING DATE: 1999-11-29
;; PRIOR APPLICATION NUMBER: PCT/US99/28313
;; PRIOR FILING DATE: 1999-11-30
;; PRIOR APPLICATION NUMBER: PCT/US99/28564
;; PRIOR FILING DATE: 1999-12-02
;; PRIOR APPLICATION NUMBER: PCT/US99/28565
;; PRIOR FILING DATE: 1999-12-02
;; PRIOR APPLICATION NUMBER: PCT/US99/30095
;; PRIOR FILING DATE: 1999-12-16
;; PRIOR APPLICATION NUMBER: PCT/US99/30911
;; PRIOR FILING DATE: 1999-12-20
;; PRIOR APPLICATION NUMBER: PCT/US99/30999
;; PRIOR FILING DATE: 1999-12-20
;; PRIOR APPLICATION NUMBER: PCT/US00/00219
;; PRIOR FILING DATE: 2000-01-05
;; NUMBER OF SEQ ID NOS: 423
;; SEQ ID NO 229
;; LENGTH: 18
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;; OTHER INFORMATION: oligonucleotide probe
US-09-903-749A-229

Query Match 0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 7.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1101 GCTGCTCTCAGGGGAG 1116
||||| |||||
Db 3 GCTGTCCACAGGGGAG 18

RESULT 1155

US-09-904-119-229
; Sequence 229, Application US/09904119
; Publication No. US20030049621A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.

APPLICANT: Goddard, A.
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth, J.
APPLICANT: Kljavin, Ivar J.
APPLICANT: Mather, Jennie P.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William, I.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
TITLE OF INVENTION: Acids Encoding the Same
FILE REFERENCE: 10466-14
CURRENT APPLICATION NUMBER: US/09/904,119
CURRENT FILING DATE: 2001-07-11
PRIOR APPLICATION NUMBER: 09/665,350
PRIOR FILING DATE: 2000-09-18
PRIOR APPLICATION NUMBER: PCT/US00/04414
PRIOR FILING DATE: 2000-02-22
PRIOR APPLICATION NUMBER: US 60/143,048
PRIOR FILING DATE: 1999-07-07
PRIOR APPLICATION NUMBER: US 60/145,698
PRIOR FILING DATE: 1999-07-26
PRIOR APPLICATION NUMBER: US 60/146,222
PRIOR FILING DATE: 1999-07-28
PRIOR APPLICATION NUMBER: PCT/US99/20594
PRIOR FILING DATE: 1999-09-08
PRIOR APPLICATION NUMBER: PCT/US99/20944
PRIOR FILING DATE: 1999-09-13
PRIOR APPLICATION NUMBER: PCT/US99/21090
PRIOR FILING DATE: 1999-09-15
PRIOR APPLICATION NUMBER: PCT/US99/21547
PRIOR FILING DATE: 1999-09-15
PRIOR APPLICATION NUMBER: PCT/US99/23089
PRIOR FILING DATE: 1999-10-05
PRIOR APPLICATION NUMBER: PCT/US99/28214
PRIOR FILING DATE: 1999-11-29
PRIOR APPLICATION NUMBER: PCT/US99/28564
PRIOR FILING DATE: 1999-12-02
PRIOR APPLICATION NUMBER: PCT/US99/28565
PRIOR FILING DATE: 1999-12-02
PRIOR APPLICATION NUMBER: PCT/US99/30095
PRIOR FILING DATE: 1999-12-16
PRIOR APPLICATION NUMBER: PCT/US99/30911
PRIOR FILING DATE: 1999-12-20
PRIOR APPLICATION NUMBER: PCT/US99/30999
PRIOR FILING DATE: 1999-12-20
PRIOR APPLICATION NUMBER: PCT/US00/00219
PRIOR FILING DATE: 2000-01-05
NUMBER OF SEQ ID NOS: 423
SEQ ID NO 229
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-09-904-119-229

Query Match 0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 7,7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1101 GCTGTCTCTCAGGGGAG 1116
Db 3 GCTGTCCACAGGGGAG 18

RESULT 1156
US-09-904-956-229
Sequence 229, Application US/09904956
Publication No. US20030049622A1
GENERAL INFORMATION:
APPLICANT: Genentech, Inc.
APPLICANT: Ashkenazi, Avi
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Filvaroff, Ellen
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerber, Hanspeter
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, A.
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth, J.
APPLICANT: Kljavin, Ivar J.
APPLICANT: Mather, Jennie P.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William, I.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
TITLE OF INVENTION: Acids Encoding the Same
FILE REFERENCE: 10466-14
CURRENT APPLICATION NUMBER: US/09/904,956
CURRENT FILING DATE: 2001-07-12
PRIOR APPLICATION NUMBER: PCT/US00/04414
PRIOR FILING DATE: 2000-02-22
PRIOR APPLICATION NUMBER: US 60/143,048
PRIOR FILING DATE: 1999-07-07
PRIOR APPLICATION NUMBER: US 60/145,698
PRIOR FILING DATE: 1999-07-26
PRIOR APPLICATION NUMBER: US 60/146,222
PRIOR FILING DATE: 1999-07-28
PRIOR APPLICATION NUMBER: PCT/US99/20594
PRIOR FILING DATE: 1999-09-08
PRIOR APPLICATION NUMBER: PCT/US99/20944
PRIOR FILING DATE: 1999-09-13
PRIOR APPLICATION NUMBER: PCT/US99/21090
PRIOR FILING DATE: 1999-09-15
PRIOR APPLICATION NUMBER: PCT/US99/21547
PRIOR FILING DATE: 1999-09-15
PRIOR APPLICATION NUMBER: PCT/US99/23089
PRIOR FILING DATE: 1999-10-05
PRIOR APPLICATION NUMBER: PCT/US99/28214
PRIOR FILING DATE: 1999-11-29
PRIOR APPLICATION NUMBER: PCT/US99/28313
PRIOR FILING DATE: 1999-11-30
PRIOR APPLICATION NUMBER: PCT/US99/28564
PRIOR FILING DATE: 1999-12-02
PRIOR APPLICATION NUMBER: PCT/US99/28565
PRIOR FILING DATE: 1999-12-02
PRIOR APPLICATION NUMBER: PCT/US99/30095
PRIOR FILING DATE: 1999-12-16
PRIOR APPLICATION NUMBER: PCT/US99/30911
PRIOR FILING DATE: 1999-12-20
PRIOR APPLICATION NUMBER: PCT/US99/30999
PRIOR FILING DATE: 1999-12-20
PRIOR APPLICATION NUMBER: PCT/US00/00219
PRIOR FILING DATE: 2000-01-05
NUMBER OF SEQ ID NOS: 423
SEQ ID NO 229
LENGTH: 18
TYPE: DNA

; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 ; OTHER INFORMATION: oligonucleotide probe
 US-09-904-956-229

Query Match 0.4%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 93.8%; Pred. No. 7.7e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1101 GCTGTCTCTCAGGGGAG 1116
 Db 3 GCTGTCCACAGGGGAG 18

RESULT 1157
 US-09-902-736-229
 ; Sequence 229, Application US/09902736
 ; Publication No. US20030049676A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Genentech, Inc.
 ; APPLICANT: Ashkenazi, Avi
 ; APPLICANT: Botstein, David
 ; APPLICANT: Desnoyers, Luc
 ; APPLICANT: Eaton, Dan L.
 ; APPLICANT: Ferrara, Napoleone
 ; APPLICANT: Filvaroff, Ellen
 ; APPLICANT: Fong, Sherman
 ; APPLICANT: Gao, Wei-Qiang
 ; APPLICANT: Gerber, Hanspeter
 ; APPLICANT: Gerritsen, Mary E.
 ; APPLICANT: Goddard, A.
 ; APPLICANT: Godowski, Paul J.
 ; APPLICANT: Grimaldi, Christopher J.
 ; APPLICANT: Gurney, Austin L.
 ; APPLICANT: Hillan, Kenneth, J.
 ; APPLICANT: Kijavin, Ivar J.
 ; APPLICANT: Mather, Jennie P.
 ; APPLICANT: Pan, James
 ; APPLICANT: Paoni, Nicholas F.
 ; APPLICANT: Roy, Margaret Ann
 ; APPLICANT: Stewart, Timothy A.
 ; APPLICANT: Tumas, Daniel
 ; APPLICANT: Williams, P. Mickey
 ; APPLICANT: Wood, William, I.
 ; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
 ; TITLE OF INVENTION: Acids Encoding the Same
 ; FILE REFERENCE: 10466-14
 ; CURRENT APPLICATION NUMBER: US/09/902,736
 ; CURRENT FILING DATE: 2001-07-10
 ; PRIOR APPLICATION NUMBER: 09/665,350
 ; PRIOR FILING DATE: 2000-09-18
 ; PRIOR APPLICATION NUMBER: PCT/US00/04414
 ; PRIOR FILING DATE: 2000-02-22
 ; PRIOR APPLICATION NUMBER: US 60/143,048
 ; PRIOR FILING DATE: 1999-07-07
 ; PRIOR APPLICATION NUMBER: US 60/145,698
 ; PRIOR FILING DATE: 1999-07-26
 ; PRIOR APPLICATION NUMBER: US 60/146,222
 ; PRIOR FILING DATE: 1999-07-28
 ; PRIOR APPLICATION NUMBER: PCT/US99/20594
 ; PRIOR FILING DATE: 1999-09-08
 ; PRIOR APPLICATION NUMBER: PCT/US99/20944
 ; PRIOR FILING DATE: 1999-09-13
 ; PRIOR APPLICATION NUMBER: PCT/US99/21090
 ; PRIOR FILING DATE: 1999-09-15
 ; PRIOR APPLICATION NUMBER: PCT/US99/21547
 ; PRIOR FILING DATE: 1999-09-15
 ; PRIOR APPLICATION NUMBER: PCT/US99/23089
 ; PRIOR FILING DATE: 1999-10-05
 ; PRIOR APPLICATION NUMBER: PCT/US99/28214
 ; PRIOR FILING DATE: 1999-11-29
 ; PRIOR APPLICATION NUMBER: PCT/US99/28313

; PRIOR FILING DATE: 1999-11-30
 ; PRIOR APPLICATION NUMBER: PCT/US99/28564
 ; PRIOR FILING DATE: 1999-12-02
 ; PRIOR APPLICATION NUMBER: PCT/US99/28565
 ; PRIOR FILING DATE: 1999-12-02
 ; PRIOR APPLICATION NUMBER: PCT/US99/30095
 ; PRIOR FILING DATE: 1999-12-16
 ; PRIOR APPLICATION NUMBER: PCT/US99/30911
 ; PRIOR FILING DATE: 1999-12-20
 ; PRIOR APPLICATION NUMBER: PCT/US99/30999
 ; PRIOR FILING DATE: 1999-12-20
 ; PRIOR APPLICATION NUMBER: PCT/US00/00219
 ; NUMBER OF SEQ ID NOS: 423
 ; SEQ ID NO 229
 ; LENGTH: 18
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Synthetic Oligonucleotide Probe
 US-09-902-736-229

Query Match 0.4%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 93.8%; Pred. No. 7.7e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1101 GCTGTCTCTCAGGGGAG 1116
 Db 3 GCTGTCCACAGGGGAG 18

RESULT 1158
 US-09-907-794-229
 ; Sequence 229, Application US/09907794
 ; Publication No. US20030049677A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Genentech, Inc.
 ; APPLICANT: Ashkenazi, Avi
 ; APPLICANT: Botstein, David
 ; APPLICANT: Desnoyers, Luc
 ; APPLICANT: Eaton, Dan L.
 ; APPLICANT: Ferrara, Napoleone
 ; APPLICANT: Filvaroff, Ellen
 ; APPLICANT: Fong, Sherman
 ; APPLICANT: Gao, Wei-Qiang
 ; APPLICANT: Gerber, Hanspeter
 ; APPLICANT: Gerritsen, Mary E.
 ; APPLICANT: Goddard, A.
 ; APPLICANT: Godowski, Paul J.
 ; APPLICANT: Grimaldi, Christopher J.
 ; APPLICANT: Gurney, Austin L.
 ; APPLICANT: Hillan, Kenneth, J.
 ; APPLICANT: Kijavin, Ivar J.
 ; APPLICANT: Mather, Jennie P.
 ; APPLICANT: Pan, James
 ; APPLICANT: Paoni, Nicholas F.
 ; APPLICANT: Roy, Margaret Ann
 ; APPLICANT: Stewart, Timothy A.
 ; APPLICANT: Tumas, Daniel
 ; APPLICANT: Williams, P. Mickey
 ; APPLICANT: Wood, William, I.
 ; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
 ; TITLE OF INVENTION: Acids Encoding the Same
 ; FILE REFERENCE: 10466-14
 ; CURRENT APPLICATION NUMBER: US/09/907,794
 ; CURRENT FILING DATE: 2001-07-17
 ; PRIOR APPLICATION NUMBER: 09/665,350
 ; PRIOR FILING DATE: 2000-09-18
 ; PRIOR APPLICATION NUMBER: PCT/US00/04414
 ; PRIOR FILING DATE: 2000-02-22
 ; PRIOR APPLICATION NUMBER: US 60/143,048
 ; PRIOR FILING DATE: 1999-07-07
 ; PRIOR APPLICATION NUMBER: US 60/145,698

APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William, I.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: 10466-14
CURRENT APPLICATION NUMBER: US/09/903,943
CURRENT FILING DATE: 2001-07-11
PRIOR APPLICATION NUMBER: 09/665,350
PRIOR FILING DATE: 2000-09-18
PRIOR APPLICATION NUMBER: PCT/US00/04414
PRIOR FILING DATE: 2000-02-22
PRIOR APPLICATION NUMBER: US 60/143,048
PRIOR FILING DATE: 1999-07-07
PRIOR APPLICATION NUMBER: US 60/145,698
PRIOR FILING DATE: 1999-07-26
PRIOR APPLICATION NUMBER: US 60/146,222
PRIOR FILING DATE: 1999-07-28
PRIOR APPLICATION NUMBER: PCT/US99/20594
PRIOR FILING DATE: 1999-09-08
PRIOR APPLICATION NUMBER: PCT/US99/20944
PRIOR FILING DATE: 1999-09-13
PRIOR APPLICATION NUMBER: PCT/US99/21090
PRIOR FILING DATE: 1999-09-15
PRIOR APPLICATION NUMBER: PCT/US99/21547
PRIOR FILING DATE: 1999-09-15
PRIOR APPLICATION NUMBER: PCT/US99/23089
PRIOR FILING DATE: 1999-10-05
PRIOR APPLICATION NUMBER: PCT/US99/28214
PRIOR FILING DATE: 1999-11-29
PRIOR APPLICATION NUMBER: PCT/US99/28313
PRIOR FILING DATE: 1999-11-30
PRIOR APPLICATION NUMBER: PCT/US99/28564
PRIOR FILING DATE: 1999-12-02
PRIOR APPLICATION NUMBER: PCT/US99/28565
PRIOR FILING DATE: 1999-12-02
PRIOR APPLICATION NUMBER: PCT/US99/30095
PRIOR FILING DATE: 1999-12-16
PRIOR APPLICATION NUMBER: PCT/US99/30911
PRIOR FILING DATE: 1999-12-20
PRIOR APPLICATION NUMBER: PCT/US99/30999
PRIOR FILING DATE: 1999-12-20
PRIOR APPLICATION NUMBER: PCT/US00/00219
NUMBER OF SEQ ID NOS: 423
SEQ ID NO 229
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic Oligonucleotide Probe

US-09-903-943-229

Query Match 0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 7.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1101 GCTGCTCTCAGGGGAG 1116
Db 3 GCTGTCACAGGGGAG 18

RESULT 1159

US-09-903-943-229
Sequence 229, Application US/09903943
Publication No. US2003005439A1
GENERAL INFORMATION:
APPLICANT: Genentech, Inc.
APPLICANT: Ashkenazi, Avi
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Filvaroff, Ellen
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerber, Hanspeter
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, A.
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth, J.
APPLICANT: Kljavin, Ivar J.
APPLICANT: Mather, Jennie P.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann

US-09-903-943-229

Query Match 0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 7.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1101 GCTGCTCTCAGGGGAG 1116
Db 3 GCTGTCACAGGGGAG 18

RESULT 1160

US-09-904-462-229
Sequence 229, Application US/09904462
Publication No. US20030054351A1
GENERAL INFORMATION:
APPLICANT: Genentech, Inc.
APPLICANT: Ashkenazi, Avi
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Filvaroff, Ellen
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerber, Hanspeter
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, A.
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth, J.
APPLICANT: Kljavin, Ivar J.
APPLICANT: Mather, Jennie P.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann

APPLICANT: Ferrara, Napoleone
 APPLICANT: Filvaroff, Ellen
 APPLICANT: Fong, Sherman
 APPLICANT: Gao, Wei-Qiang
 APPLICANT: Gerber, Hanspeter
 APPLICANT: Gerritsen, Mary E.
 APPLICANT: Goddard, A.
 APPLICANT: Godowski, Paul J.
 APPLICANT: Grimaldi, Christopher J.
 APPLICANT: Gurney, Austin L.
 APPLICANT: Hillan, Kenneth, J.
 APPLICANT: Kljavin, Ivar J.
 APPLICANT: Mather, Jennie P.
 APPLICANT: Pan, James
 APPLICANT: Paoni, Nicholas F.
 APPLICANT: Roy, Margaret Ann
 APPLICANT: Stewart, Timothy A.
 APPLICANT: Tumas, Daniel
 APPLICANT: Williams, P. Mickey
 TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
 TITLE OF INVENTION: Acids Encoding the Same
 FILE REFERENCE: 10466-14
 CURRENT APPLICATION NUMBER: US/09/904,462
 CURRENT FILING DATE: 2001-07-13
 PRIOR APPLICATION NUMBER: 09/665,350
 PRIOR FILING DATE: 2000-09-18
 PRIOR APPLICATION NUMBER: PCT/US00/04414
 PRIOR FILING DATE: 2000-02-22
 PRIOR APPLICATION NUMBER: US 60/143,048
 PRIOR FILING DATE: 1999-07-07
 PRIOR APPLICATION NUMBER: US 60/145,698
 PRIOR FILING DATE: 1999-07-26
 PRIOR APPLICATION NUMBER: US 60/146,222
 PRIOR FILING DATE: 1999-07-28
 PRIOR APPLICATION NUMBER: PCT/US99/20594
 PRIOR FILING DATE: 1999-09-08
 PRIOR APPLICATION NUMBER: PCT/US99/20944
 PRIOR FILING DATE: 1999-09-13
 PRIOR APPLICATION NUMBER: PCT/US99/21090
 PRIOR FILING DATE: 1999-09-15
 PRIOR APPLICATION NUMBER: PCT/US99/21547
 PRIOR FILING DATE: 1999-09-18
 PRIOR APPLICATION NUMBER: PCT/US99/23089
 PRIOR FILING DATE: 1999-10-05
 PRIOR APPLICATION NUMBER: PCT/US99/28214
 PRIOR FILING DATE: 1999-11-29
 PRIOR APPLICATION NUMBER: PCT/US99/28313
 PRIOR FILING DATE: 1999-11-30
 PRIOR APPLICATION NUMBER: PCT/US99/28564
 PRIOR FILING DATE: 1999-12-02
 PRIOR APPLICATION NUMBER: PCT/US99/28565
 PRIOR FILING DATE: 1999-12-02
 PRIOR APPLICATION NUMBER: PCT/US99/30095
 PRIOR FILING DATE: 1999-12-20
 PRIOR APPLICATION NUMBER: PCT/US00/00219
 PRIOR FILING DATE: 2000-01-05
 NUMBER OF SEQ ID NOS: 423
 SEQ ID NO 229
 LENGTH: 18
 TYPE: DNA
 ORGANISM: Artificial Sequence
 FEATURE:
 OTHER INFORMATION: Synthetic Oligonucleotide Probe
 US-09-904-462-229

Query Match 0.4%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 93.8%; Pred. No. 7.7e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1101 GCTGTCTCTCAGGGGAG 1116
 Db 3 GCTGTCTCAGGGGAG 18
 RESULT 1161
 US-09-907-925-229
 Sequence 229, Application US/09907925
 Publication No. US20030054352A1
 GENERAL INFORMATION:
 APPLICANT: Genentech, Inc.
 APPLICANT: Ashkenazi, Avi
 APPLICANT: Botstein, David
 APPLICANT: Deenoyers, Luc
 APPLICANT: Eaton, Dan L.
 APPLICANT: Ferrara, Napoleone
 APPLICANT: Filvaroff, Ellen
 APPLICANT: Fong, Sherman
 APPLICANT: Gao, Wei-Qiang
 APPLICANT: Gerber, Hanspeter
 APPLICANT: Gerritsen, Mary E.
 APPLICANT: Goddard, A.
 APPLICANT: Godowski, Paul J.
 APPLICANT: Grimaldi, Christopher J.
 APPLICANT: Gurney, Austin L.
 APPLICANT: Hillan, Kenneth, J.
 APPLICANT: Kljavin, Ivar J.
 APPLICANT: Mather, Jennie P.
 APPLICANT: Pan, James
 APPLICANT: Paoni, Nicholas F.
 APPLICANT: Roy, Margaret Ann
 APPLICANT: Stewart, Timothy A.
 APPLICANT: Tumas, Daniel
 APPLICANT: Williams, P. Mickey
 APPLICANT: Wood, William, I.
 TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
 TITLE OF INVENTION: Acids Encoding the Same
 FILE REFERENCE: 10466-14
 CURRENT APPLICATION NUMBER: US/09/907,925
 CURRENT FILING DATE: 2001-07-17
 PRIOR APPLICATION NUMBER: 09/665,350
 PRIOR FILING DATE: 2000-09-18
 PRIOR APPLICATION NUMBER: PCT/US00/04414
 PRIOR FILING DATE: 2000-02-22
 PRIOR APPLICATION NUMBER: US 60/143,048
 PRIOR FILING DATE: 1999-07-07
 PRIOR APPLICATION NUMBER: US 60/145,698
 PRIOR FILING DATE: 1999-07-26
 PRIOR APPLICATION NUMBER: US 60/146,222
 PRIOR FILING DATE: 1999-07-28
 PRIOR APPLICATION NUMBER: PCT/US99/20594
 PRIOR FILING DATE: 1999-09-08
 PRIOR APPLICATION NUMBER: PCT/US99/20944
 PRIOR FILING DATE: 1999-09-13
 PRIOR APPLICATION NUMBER: PCT/US99/21090
 PRIOR FILING DATE: 1999-09-15
 PRIOR APPLICATION NUMBER: PCT/US99/21547
 PRIOR FILING DATE: 1999-09-18
 PRIOR APPLICATION NUMBER: PCT/US99/23089
 PRIOR FILING DATE: 1999-10-05
 PRIOR APPLICATION NUMBER: PCT/US99/28214
 PRIOR FILING DATE: 1999-11-29
 PRIOR APPLICATION NUMBER: PCT/US99/28313
 PRIOR FILING DATE: 1999-11-30
 PRIOR APPLICATION NUMBER: PCT/US99/28564
 PRIOR FILING DATE: 1999-12-02
 PRIOR APPLICATION NUMBER: PCT/US99/28565
 PRIOR FILING DATE: 1999-12-02
 PRIOR APPLICATION NUMBER: PCT/US99/30095
 PRIOR FILING DATE: 1999-12-16
 PRIOR APPLICATION NUMBER: PCT/US99/30911
 PRIOR FILING DATE: 1999-12-20

```

; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-09-907-925-229

Query Match          0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 7.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1101 GCTGCTCTCAGGGGAG 1116
      ||||| |||||
Db 3 GCTGTCCACAGGGGAG 18

RESULT 1162
US-09-902-692-229
; Sequence 229, Application US/09902692
; Publication No. US2003005440A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary B.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secretd and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/902,692
; CURRENT FILING DATE: 2001-07-10
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15

```

```

; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide probe
US-09-902-692-229

Query Match          0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 7.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1101 GCTGCTCTCAGGGGAG 1116
      ||||| |||||
Db 3 GCTGTCCACAGGGGAG 18

RESULT 1163
US-09-903-520-229
; Sequence 229, Application US/09903520
; Publication No. US2003005440A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secretd and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/903,520
; CURRENT FILING DATE: 2001-07-11
; PRIOR APPLICATION NUMBER: 09/665,350

```

;; PRIOR FILING DATE: 2000-09-18
;; PRIOR APPLICATION NUMBER: PCT/US00/04414
;; PRIOR FILING DATE: 2000-02-22
;; PRIOR APPLICATION NUMBER: US 60/143,048
;; PRIOR FILING DATE: 1999-07-07
;; PRIOR APPLICATION NUMBER: US 60/145,698
;; PRIOR FILING DATE: 1999-07-26
;; PRIOR APPLICATION NUMBER: US 60/146,222
;; PRIOR FILING DATE: 1999-07-28
;; PRIOR APPLICATION NUMBER: PCT/US99/20594
;; PRIOR FILING DATE: 1999-09-08
;; PRIOR APPLICATION NUMBER: PCT/US99/20944
;; PRIOR FILING DATE: 1999-09-13
;; PRIOR APPLICATION NUMBER: PCT/US99/21090
;; PRIOR FILING DATE: 1999-09-15
;; PRIOR APPLICATION NUMBER: PCT/US99/21547
;; PRIOR FILING DATE: 1999-09-15
;; PRIOR APPLICATION NUMBER: PCT/US99/23089
;; PRIOR FILING DATE: 1999-10-05
;; PRIOR APPLICATION NUMBER: PCT/US99/28214
;; PRIOR FILING DATE: 1999-11-29
;; PRIOR APPLICATION NUMBER: PCT/US99/28313
;; PRIOR FILING DATE: 1999-11-30
;; PRIOR APPLICATION NUMBER: PCT/US99/28564
;; PRIOR FILING DATE: 1999-12-02
;; PRIOR APPLICATION NUMBER: PCT/US99/28565
;; PRIOR FILING DATE: 1999-12-02
;; PRIOR APPLICATION NUMBER: PCT/US99/30095
;; PRIOR FILING DATE: 1999-12-16
;; PRIOR APPLICATION NUMBER: PCT/US99/30911
;; PRIOR FILING DATE: 1999-12-20
;; PRIOR APPLICATION NUMBER: PCT/US99/30999
;; PRIOR FILING DATE: 1999-12-20
;; PRIOR APPLICATION NUMBER: PCT/US00/00219
;; PRIOR FILING DATE: 2000-01-05
;; NUMBER OF SEQ ID NOS: 423
;; SEQ ID NO 229
;; LENGTH: 18
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-09-903-520-229

Query Match 0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 7.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1101 GCTGTCTCTCAGGGGAG 1116
||||| |||||
Db 3 GCTGTCCACAGGGGAG 18

RESULT 1164
US-09-905-056-229
;; Sequence 229, Application US/09905056
;; Publication No. US2003005441A1
;; GENERAL INFORMATION:
;; APPLICANT: Genentech, Inc.
;; APPLICANT: Ashkenazi, Avi
;; APPLICANT: Botstein, David
;; APPLICANT: Desnoyers, Luc
;; APPLICANT: Eaton, Dan L.
;; APPLICANT: Ferrara, Napoleone
;; APPLICANT: Flivaroff, Ellen
;; APPLICANT: Fong, Sherman
;; APPLICANT: Gao, Wei-Qiang
;; APPLICANT: Gerber, Hanspeter
;; APPLICANT: Gerritsen, Mary E.
;; APPLICANT: Goddard, A.
;; APPLICANT: Godowski, Paul J.
;; APPLICANT: Grimaldi, Christopher J.
;; APPLICANT: Gurney, Austin L.

;; APPLICANT: Hillan, Kenneth, J.
;; APPLICANT: Kljavin, Ivar J.
;; APPLICANT: Mather, Jennie P.
;; APPLICANT: Pan, James
;; APPLICANT: Paoni, Nicholas F.
;; APPLICANT: Roy, Margaret Ann
;; APPLICANT: Stewart, Timothy A.
;; APPLICANT: Tumas, Daniel
;; APPLICANT: Williams, P. Mickey
;; APPLICANT: Wood, William, I.
;; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
;; FILE REFERENCE: 10466-14
;; CURRENT APPLICATION NUMBER: US/09/905,056
;; CURRENT FILING DATE: 2002-01-22
;; PRIOR APPLICATION NUMBER: PCT/US00/04414
;; PRIOR FILING DATE: 2000-02-22
;; PRIOR APPLICATION NUMBER: US 60/143,048
;; PRIOR FILING DATE: 1999-07-07
;; PRIOR APPLICATION NUMBER: US 60/145,698
;; PRIOR FILING DATE: 1999-07-26
;; PRIOR APPLICATION NUMBER: US 60/146,222
;; PRIOR FILING DATE: 1999-07-28
;; PRIOR APPLICATION NUMBER: PCT/US99/20594
;; PRIOR FILING DATE: 1999-09-08
;; PRIOR APPLICATION NUMBER: PCT/US99/20944
;; PRIOR FILING DATE: 1999-09-13
;; PRIOR APPLICATION NUMBER: PCT/US99/21090
;; PRIOR FILING DATE: 1999-09-15
;; PRIOR APPLICATION NUMBER: PCT/US99/21547
;; PRIOR FILING DATE: 1999-09-15
;; PRIOR APPLICATION NUMBER: PCT/US99/23089
;; PRIOR FILING DATE: 1999-10-05
;; PRIOR APPLICATION NUMBER: PCT/US99/28214
;; PRIOR FILING DATE: 1999-11-29
;; PRIOR APPLICATION NUMBER: PCT/US99/28313
;; PRIOR FILING DATE: 1999-11-30
;; PRIOR APPLICATION NUMBER: PCT/US99/28564
;; PRIOR FILING DATE: 1999-12-02
;; PRIOR APPLICATION NUMBER: PCT/US99/28565
;; PRIOR FILING DATE: 1999-12-02
;; PRIOR APPLICATION NUMBER: PCT/US99/30095
;; PRIOR FILING DATE: 1999-12-16
;; PRIOR APPLICATION NUMBER: PCT/US99/30911
;; PRIOR FILING DATE: 1999-12-20
;; PRIOR APPLICATION NUMBER: PCT/US99/30999
;; PRIOR FILING DATE: 1999-12-20
;; PRIOR APPLICATION NUMBER: PCT/US00/00219
;; PRIOR FILING DATE: 2000-01-05
;; NUMBER OF SEQ ID NOS: 423
;; SEQ ID NO 229
;; LENGTH: 18
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;; OTHER INFORMATION: oligonucleotide probe
US-09-905-056-229

Query Match 0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 7.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1101 GCTGTCTCTCAGGGGAG 1116
||||| |||||
Db 3 GCTGTCCACAGGGGAG 18

RESULT 1165
US-09-909-064-229
;; Sequence 229, Application US/09909064
;; Publication No. US2003005977A1
;; GENERAL INFORMATION:

; APPLICANT: Genentech, Inc.
 ; APPLICANT: Ashkenazi, Avi
 ; APPLICANT: Botstein, David
 ; APPLICANT: Desnoyers, Luc
 ; APPLICANT: Eaton, Dan L.
 ; APPLICANT: Ferrara, Napoleone
 ; APPLICANT: Filvaroff, Ellen
 ; APPLICANT: Fong, Sherman
 ; APPLICANT: Gao, Wei-Qiang
 ; APPLICANT: Gerber, Hanspeter
 ; APPLICANT: Gerritsen, Mary E.
 ; APPLICANT: Goddard, A.
 ; APPLICANT: Godowski, Paul J.
 ; APPLICANT: Grimaldi, Christopher J.
 ; APPLICANT: Hillan, Kenneth, J.
 ; APPLICANT: Kijavin, Ivar J.
 ; APPLICANT: Mather, Jennie P.
 ; APPLICANT: Pan, James
 ; APPLICANT: Paoni, Nicholas F.
 ; APPLICANT: Roy, Margaret Ann
 ; APPLICANT: Stewart, Timothy A.
 ; APPLICANT: Tumas, Daniel
 ; APPLICANT: Williams, P. Mickey
 ; APPLICANT: Wood, William, I.
 ; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
 ; FILE REFERENCE: 10466-14
 ; CURRENT APPLICATION NUMBER: US/09/909,064
 ; CURRENT FILING DATE: 2001-07-18
 ; PRIOR APPLICATION NUMBER: PCT/US00/04414
 ; PRIOR FILING DATE: 2000-02-22
 ; PRIOR APPLICATION NUMBER: US 60/143,048
 ; PRIOR FILING DATE: 1999-07-07
 ; PRIOR APPLICATION NUMBER: US 60/145,698
 ; PRIOR FILING DATE: 1999-07-26
 ; PRIOR APPLICATION NUMBER: US 60/146,222
 ; PRIOR FILING DATE: 1999-07-28
 ; PRIOR APPLICATION NUMBER: PCT/US99/20594
 ; PRIOR FILING DATE: 1999-09-08
 ; PRIOR APPLICATION NUMBER: PCT/US99/20944
 ; PRIOR FILING DATE: 1999-09-13
 ; PRIOR APPLICATION NUMBER: PCT/US99/21090
 ; PRIOR FILING DATE: 1999-09-15
 ; PRIOR APPLICATION NUMBER: PCT/US99/21547
 ; PRIOR FILING DATE: 1999-09-15
 ; PRIOR APPLICATION NUMBER: PCT/US99/23089
 ; PRIOR FILING DATE: 1999-10-05
 ; PRIOR APPLICATION NUMBER: PCT/US99/28214
 ; PRIOR FILING DATE: 1999-11-29
 ; PRIOR APPLICATION NUMBER: PCT/US99/28313
 ; PRIOR FILING DATE: 1999-11-30
 ; PRIOR APPLICATION NUMBER: PCT/US99/28564
 ; PRIOR FILING DATE: 1999-12-02
 ; PRIOR APPLICATION NUMBER: PCT/US99/28565
 ; PRIOR FILING DATE: 1999-12-02
 ; PRIOR APPLICATION NUMBER: PCT/US99/30095
 ; PRIOR FILING DATE: 1999-12-16
 ; PRIOR APPLICATION NUMBER: PCT/US99/30911
 ; PRIOR FILING DATE: 1999-12-20
 ; PRIOR APPLICATION NUMBER: PCT/US99/30999
 ; PRIOR FILING DATE: 1999-12-20
 ; PRIOR APPLICATION NUMBER: PCT/US00/00219
 ; PRIOR FILING DATE: 2000-01-05
 ; NUMBER OF SEQ ID NOS: 423
 ; SEQ ID NO 229
 ; LENGTH: 18
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 ; OTHER INFORMATION: oligonucleotide probe
 ; US-09-909-064-229

Query Match 0.4%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 93.8%; Pred. No. 7.7e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1101 GCTGTCCTCAGGGAG 1116
 Db 3 GCTGTCACAGGGAG 18
 RESULT 1166
 US-09-904-553-229
 ; Sequence 229, Application US/09904553
 ; Publication No. US20030059828A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Genentech, Inc.
 ; APPLICANT: Ashkenazi, Avi
 ; APPLICANT: Botstein, David
 ; APPLICANT: Desnoyers, Luc
 ; APPLICANT: Eaton, Dan L.
 ; APPLICANT: Ferrara, Napoleone
 ; APPLICANT: Filvaroff, Ellen
 ; APPLICANT: Fong, Sherman
 ; APPLICANT: Gao, Wei-Qiang
 ; APPLICANT: Gerber, Hanspeter
 ; APPLICANT: Gerritsen, Mary E.
 ; APPLICANT: Goddard, A.
 ; APPLICANT: Godowski, Paul J.
 ; APPLICANT: Grimaldi, Christopher J.
 ; APPLICANT: Gurney, Austin L.
 ; APPLICANT: Hillan, Kenneth, J.
 ; APPLICANT: Kijavin, Ivar J.
 ; APPLICANT: Mather, Jennie P.
 ; APPLICANT: Pan, James
 ; APPLICANT: Paoni, Nicholas F.
 ; APPLICANT: Roy, Margaret Ann
 ; APPLICANT: Stewart, Timothy A.
 ; APPLICANT: Tumas, Daniel
 ; APPLICANT: Williams, P. Mickey
 ; APPLICANT: Wood, William, I.
 ; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
 ; FILE REFERENCE: 10466-14
 ; CURRENT APPLICATION NUMBER: US/09/904,553
 ; CURRENT FILING DATE: 2002-01-22
 ; PRIOR APPLICATION NUMBER: PCT/US00/04414
 ; PRIOR FILING DATE: 2000-02-22
 ; PRIOR APPLICATION NUMBER: US 60/143,048
 ; PRIOR FILING DATE: 1999-07-07
 ; PRIOR APPLICATION NUMBER: US 60/145,698
 ; PRIOR FILING DATE: 1999-07-26
 ; PRIOR APPLICATION NUMBER: US 60/146,222
 ; PRIOR FILING DATE: 1999-07-28
 ; PRIOR APPLICATION NUMBER: PCT/US99/20594
 ; PRIOR FILING DATE: 1999-09-08
 ; PRIOR APPLICATION NUMBER: PCT/US99/20944
 ; PRIOR FILING DATE: 1999-09-13
 ; PRIOR APPLICATION NUMBER: PCT/US99/21090
 ; PRIOR FILING DATE: 1999-09-15
 ; PRIOR APPLICATION NUMBER: PCT/US99/21547
 ; PRIOR FILING DATE: 1999-09-15
 ; PRIOR APPLICATION NUMBER: PCT/US99/23089
 ; PRIOR FILING DATE: 1999-10-05
 ; PRIOR APPLICATION NUMBER: PCT/US99/28214
 ; PRIOR FILING DATE: 1999-11-29
 ; PRIOR APPLICATION NUMBER: PCT/US99/28313
 ; PRIOR FILING DATE: 1999-11-30
 ; PRIOR APPLICATION NUMBER: PCT/US99/28564
 ; PRIOR FILING DATE: 1999-12-02
 ; PRIOR APPLICATION NUMBER: PCT/US99/28565
 ; PRIOR FILING DATE: 1999-12-02
 ; PRIOR APPLICATION NUMBER: PCT/US99/30095
 ; PRIOR FILING DATE: 1999-12-16

; PRIOR APPLICATION NUMBER: PCT/US99/30911
 ; PRIOR FILING DATE: 1999-12-20
 ; PRIOR APPLICATION NUMBER: PCT/US99/30999
 ; PRIOR FILING DATE: 1999-12-20
 ; PRIOR APPLICATION NUMBER: PCT/US00/00219
 ; PRIOR FILING DATE: 2000-01-05
 ; NUMBER OF SEQ ID NOS: 423
 ; SEQ ID NO 229
 ; LENGTH: 18
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 ; OTHER INFORMATION: oligonucleotide probe
 US-09-904-553-229

Query Match 0.4%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 93.8%; Pred. No. 7.7e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 1101 GCTGTCTCAGGGGAG 1116
 ||||| |||||
 Db 3 GCTGTCCACAGGGGAG 18

RESULT 1167
 US-09-905-381-229
 ; Sequence 229, Application US/09905381
 ; Publication No. US20030059829A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Genentech, Inc.
 ; APPLICANT: Ashkenazi, Avi
 ; APPLICANT: Botstein, David
 ; APPLICANT: Desnovers, Luc
 ; APPLICANT: Eaton, Dan L.
 ; APPLICANT: Ferrara, Napoleone
 ; APPLICANT: Filvaroff, Ellen
 ; APPLICANT: Fong, Sherman
 ; APPLICANT: Gao, Wei-Qiang
 ; APPLICANT: Gerber, Hanspeter
 ; APPLICANT: Gerritsen, Mary E.
 ; APPLICANT: Goddard, A.
 ; APPLICANT: Godowski, Paul J.
 ; APPLICANT: Grimaldi, Christopher J.
 ; APPLICANT: Gurney, Austin L.
 ; APPLICANT: Hillan, Kenneth, J.
 ; APPLICANT: Kljavin, Ivar J.
 ; APPLICANT: Mather, Jennie P.
 ; APPLICANT: Pan, James
 ; APPLICANT: Paoni, Nicholas F.
 ; APPLICANT: Roy, Margaret Ann
 ; APPLICANT: Stewart, Timothy A.
 ; APPLICANT: Tumas, Daniel
 ; APPLICANT: Williams, P. Mickey
 ; APPLICANT: Wood, William, I.
 ; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
 ; FILE REFERENCE: 10466-14
 ; CURRENT APPLICATION NUMBER: US/09/905,381
 ; CURRENT FILING DATE: 2001-07-13
 ; PRIOR APPLICATION NUMBER: 09/665,350
 ; PRIOR FILING DATE: 2000-09-18
 ; PRIOR APPLICATION NUMBER: PCT/US00/04414
 ; PRIOR FILING DATE: 2000-02-22
 ; PRIOR APPLICATION NUMBER: US 60/143,048
 ; PRIOR FILING DATE: 1999-07-07
 ; PRIOR APPLICATION NUMBER: US 60/145,698
 ; PRIOR FILING DATE: 1999-07-26
 ; PRIOR APPLICATION NUMBER: US 60/146,222
 ; PRIOR FILING DATE: 1999-07-28
 ; PRIOR APPLICATION NUMBER: PCT/US99/20594
 ; PRIOR FILING DATE: 1999-09-08
 ; PRIOR APPLICATION NUMBER: PCT/US99/20944

; PRIOR FILING DATE: 1999-09-13
 ; PRIOR APPLICATION NUMBER: PCT/US99/21090
 ; PRIOR FILING DATE: 1999-09-15
 ; PRIOR APPLICATION NUMBER: PCT/US99/21547
 ; PRIOR FILING DATE: 1999-09-15
 ; PRIOR APPLICATION NUMBER: PCT/US99/23089
 ; PRIOR FILING DATE: 1999-10-05
 ; PRIOR APPLICATION NUMBER: PCT/US99/28214
 ; PRIOR FILING DATE: 1999-11-29
 ; PRIOR APPLICATION NUMBER: PCT/US99/28313
 ; PRIOR FILING DATE: 1999-11-30
 ; PRIOR APPLICATION NUMBER: PCT/US99/28564
 ; PRIOR FILING DATE: 1999-12-02
 ; PRIOR APPLICATION NUMBER: PCT/US99/28565
 ; PRIOR FILING DATE: 1999-12-02
 ; PRIOR APPLICATION NUMBER: PCT/US99/30095
 ; PRIOR FILING DATE: 1999-12-16
 ; PRIOR APPLICATION NUMBER: PCT/US99/30911
 ; PRIOR FILING DATE: 1999-12-20
 ; PRIOR APPLICATION NUMBER: PCT/US99/30999
 ; PRIOR FILING DATE: 1999-12-20
 ; PRIOR APPLICATION NUMBER: PCT/US00/00219
 ; PRIOR FILING DATE: 2000-01-05
 ; NUMBER OF SEQ ID NOS: 423
 ; SEQ ID NO 229
 ; LENGTH: 18
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Synthetic Oligonucleotide Probe
 US-09-905-381-229

Query Match 0.4%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 93.8%; Pred. No. 7.7e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 1101 GCTGTCTCAGGGGAG 1116
 ||||| |||||
 Db 3 GCTGTCCACAGGGGAG 18

RESULT 1168
 US-09-904-485-229
 ; Sequence 229, Application US/09904485
 ; Publication No. US20030064367A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Genentech, Inc.
 ; APPLICANT: Ashkenazi, Avi
 ; APPLICANT: Botstein, David
 ; APPLICANT: Desnovers, Luc
 ; APPLICANT: Eaton, Dan L.
 ; APPLICANT: Ferrara, Napoleone
 ; APPLICANT: Filvaroff, Ellen
 ; APPLICANT: Fong, Sherman
 ; APPLICANT: Gao, Wei-Qiang
 ; APPLICANT: Gerber, Hanspeter
 ; APPLICANT: Gerritsen, Mary E.
 ; APPLICANT: Goddard, A.
 ; APPLICANT: Godowski, Paul J.
 ; APPLICANT: Grimaldi, Christopher J.
 ; APPLICANT: Gurney, Austin L.
 ; APPLICANT: Hillan, Kenneth, J.
 ; APPLICANT: Kljavin, Ivar J.
 ; APPLICANT: Mather, Jennie P.
 ; APPLICANT: Pan, James
 ; APPLICANT: Paoni, Nicholas F.
 ; APPLICANT: Roy, Margaret Ann
 ; APPLICANT: Stewart, Timothy A.
 ; APPLICANT: Tumas, Daniel
 ; APPLICANT: Williams, P. Mickey
 ; APPLICANT: Wood, William, I.
 ; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
 ; FILE REFERENCE: 10466-14
 ; CURRENT APPLICATION NUMBER: US/09/905,381
 ; CURRENT FILING DATE: 2001-07-13
 ; PRIOR APPLICATION NUMBER: 09/665,350
 ; PRIOR FILING DATE: 2000-09-18
 ; PRIOR APPLICATION NUMBER: PCT/US00/04414
 ; PRIOR FILING DATE: 2000-02-22
 ; PRIOR APPLICATION NUMBER: US 60/143,048
 ; PRIOR FILING DATE: 1999-07-07
 ; PRIOR APPLICATION NUMBER: US 60/145,698
 ; PRIOR FILING DATE: 1999-07-26
 ; PRIOR APPLICATION NUMBER: US 60/146,222
 ; PRIOR FILING DATE: 1999-07-28
 ; PRIOR APPLICATION NUMBER: PCT/US99/20594
 ; PRIOR FILING DATE: 1999-09-08
 ; PRIOR APPLICATION NUMBER: PCT/US99/20944

<hr/>					
FILE REFERENCE: 10466-14					
CURRENT APPLICATION NUMBER: US/09/904,485					
CURRENT FILING DATE: 2001-07-13					
PRIOR APPLICATION NUMBER: 09/665,350					
PRIOR FILING DATE: 2000-09-18					
PRIOR APPLICATION NUMBER: PCT/US00/04414					
PRIOR FILING DATE: 2000-02-22					
PRIOR APPLICATION NUMBER: US 60/143,048					
PRIOR FILING DATE: 1999-07-07					
PRIOR APPLICATION NUMBER: US 60/145,698					
PRIOR FILING DATE: 1999-07-26					
PRIOR APPLICATION NUMBER: US 60/146,222					
PRIOR FILING DATE: 1999-07-28					
PRIOR APPLICATION NUMBER: PCT/US99/20594					
PRIOR FILING DATE: 1999-09-08					
PRIOR APPLICATION NUMBER: PCT/US99/20944					
PRIOR FILING DATE: 1999-11-29					
PRIOR APPLICATION NUMBER: PCT/US99/28214					
PRIOR FILING DATE: 1999-11-30					
PRIOR APPLICATION NUMBER: PCT/US99/28564					
PRIOR FILING DATE: 1999-12-02					
PRIOR APPLICATION NUMBER: PCT/US99/28313					
PRIOR FILING DATE: 1999-11-29					
PRIOR APPLICATION NUMBER: PCT/US99/28565					
PRIOR FILING DATE: 1999-12-16					
PRIOR APPLICATION NUMBER: PCT/US99/30095					
PRIOR FILING DATE: 1999-12-20					
PRIOR APPLICATION NUMBER: PCT/US99/30999					
PRIOR FILING DATE: 1999-12-20					
PRIOR APPLICATION NUMBER: PCT/US00/00219					
PRIOR FILING DATE: 2000-01-05					
NUMBER OF SEQ ID NOS: 423					
SEQ ID NO 229					
LENGTH: 18					
TYPE: DNA					
ORGANISM: Artificial Sequence					
FEATURE:					
OTHER INFORMATION: Synthetic Oligonucleotide Probe					
US-09-904-485-229					
Query Match 0.4%; Score 14.4; DB 1; Length 18;					
Best Local Similarity 93.8%; Pred. No. 7.7e+02;					
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;					
Qy	1101	GCTGTCCTCAGGGGAG	1116		
Db	3	GCTGCCACACAGGGGAG	18		
RESULT 1169					
US-09-905-348-229					
Sequence 229, Application US/09905348					
Publication No. US20030064923A1					
GENERAL INFORMATION:					
APPLICANT: Genentech, Inc.					
APPLICANT: Ashkenazi, Avi					
APPLICANT: Botstein, David					
APPLICANT: Desnoyers, Luc					
APPLICANT: Eaton, Dan L.					
APPLICANT: Ferrara, Napoleone					
APPLICANT: Filvaroff, Ellen					
APPLICANT: Fong, Sherman					
APPLICANT: Gao, Wei-Qiang					
APPLICANT: Gerber, Hanspeter					
APPLICANT: Gerritsen, Mary E.					
Query Match 0.4%; Score 14.4; DB 1; Length 18;					
Best Local Similarity 93.8%; Pred. No. 7.7e+02;					
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;					
Qy	1101	GCTGTCCTCAGGGGAG	1116		
Db	3	GCTGCCACACAGGGGAG	18		
RESULT 1170					
US-09-905-348-229					
Sequence 229, Application US/09905348					
Publication No. US20030064923A1					
GENERAL INFORMATION:					
APPLICANT: Genentech, Inc.					
APPLICANT: Ashkenazi, Avi					
APPLICANT: Botstein, David					
APPLICANT: Desnoyers, Luc					
APPLICANT: Eaton, Dan L.					
APPLICANT: Ferrara, Napoleone					
APPLICANT: Filvaroff, Ellen					
APPLICANT: Fong, Sherman					
APPLICANT: Gao, Wei-Qiang					
APPLICANT: Gerber, Hanspeter					
APPLICANT: Gerritsen, Mary E.					
Query Match 0.4%; Score 14.4; DB 1; Length 18;					
Best Local Similarity 93.8%; Pred. No. 7.7e+02;					
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;					
Qy	1101	GCTGTCCTCAGGGGAG	1116		
Db	3	GCTGCCACACAGGGGAG	18		
RESULT 1170					
US-09-905-348-229					
Sequence 229, Application US/09905348					
Publication No. US20030064923A1					
GENERAL INFORMATION:					
APPLICANT: Genentech, Inc.					
APPLICANT: Ashkenazi, Avi					
APPLICANT: Botstein, David					
APPLICANT: Desnoyers, Luc					
APPLICANT: Eaton, Dan L.					
APPLICANT: Ferrara, Napoleone					
APPLICANT: Filvaroff, Ellen					
APPLICANT: Fong, Sherman					
APPLICANT: Gao, Wei-Qiang					
APPLICANT: Gerber, Hanspeter					
APPLICANT: Gerritsen, Mary E.					
Query Match 0.4%; Score 14.4; DB 1; Length 18;					
Best Local Similarity 93.8%; Pred. No. 7.7e+02;					
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;					
Qy	1101	GCTGTCCTCAGGGGAG	1116		
Db	3	GCTGCCACACAGGGGAG	18		
RESULT 1170					
US-09-905-348-229					
Sequence 229, Application US/09905348					
Publication No. US20030064923A1					
GENERAL INFORMATION:					
APPLICANT: Genentech, Inc.					
APPLICANT: Ashkenazi, Avi					
APPLICANT: Botstein, David					
APPLICANT: Desnoyers, Luc					
APPLICANT: Eaton, Dan L.					
APPLICANT: Ferrara, Napoleone					
APPLICANT: Filvaroff, Ellen					
APPLICANT: Fong, Sherman					
APPLICANT: Gao, Wei-Qiang					
APPLICANT: Gerber, Hanspeter					
APPLICANT: Gerritsen, Mary E.					
Query Match 0.4%; Score 14.4; DB 1; Length 18;					
Best Local Similarity 93.8%; Pred. No. 7.7e+02;					
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;					
Qy	1101	GCTGTCCTCAGGGGAG	1116		
Db	3	GCTGCCACACAGGGGAG	18		
RESULT 1170					
US-09-905-348-229					
Sequence 2					

```

US-09-905-088-229
; Sequence 229, Application US/09905088
; Publication No. US20030073077A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kijavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/905,088
; CURRENT FILING DATE: 2001-07-12
; PRIOR APPLICATION NUMBER: 09/665,350
; PRIOR FILING DATE: 2000-09-18
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18

```

```

; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-09-905-088-229
Query Match 0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 7.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1101 GCTGTCTCTCAGGGGAG 1116
Db 3 GCTGTCTCACAGGGGAG 18
RESULT 1171
US-09-907-575-229
; Sequence 229, Application US/09907575
; Publication No. US20030073079A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kijavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/907,575
; CURRENT FILING DATE: 2001-12-18
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18

```

OTHER INFORMATION: oligonucleotide probe
US-09-905-075-229

Query Match 0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 7.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1101 GCTGTCCTCAGGGGAG 1116
Db 3 GCTGTCCACAGGGGAG 18

RESULT 1173
US-09-902-759-229
Sequence 229, Application US/09902759
Publication No. US20030077654A1
GENERAL INFORMATION:
APPLICANT: Genentech, Inc.
APPLICANT: Ashkenazi, David
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Filvaroff, Ellen
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerber, Hanspeter
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, A.
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth, J.
APPLICANT: Kljavin, Ivar J.
APPLICANT: Mather, Jennie P.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William, I.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
TITLE OF INVENTION: Acids Encoding the Same
FILE REFERENCE: 10466-14
CURRENT APPLICATION NUMBER: US/09/902,759
CURRENT FILING DATE: 2001-07-10
PRIOR APPLICATION NUMBER: PCT/US00/04414
PRIOR FILING DATE: 2000-02-22
PRIOR APPLICATION NUMBER: US 60/143,048
PRIOR FILING DATE: 1999-07-07
PRIOR APPLICATION NUMBER: US 60/145,698
PRIOR FILING DATE: 1999-07-26
PRIOR APPLICATION NUMBER: US 60/146,222
PRIOR FILING DATE: 1999-07-28
PRIOR APPLICATION NUMBER: PCT/US99/20594
PRIOR FILING DATE: 1999-09-08
PRIOR APPLICATION NUMBER: PCT/US99/20944
PRIOR FILING DATE: 1999-09-13
PRIOR APPLICATION NUMBER: PCT/US99/21090
PRIOR FILING DATE: 1999-09-15
PRIOR APPLICATION NUMBER: PCT/US99/21547
PRIOR FILING DATE: 1999-09-15
PRIOR APPLICATION NUMBER: PCT/US99/23089
PRIOR FILING DATE: 1999-10-05
PRIOR APPLICATION NUMBER: PCT/US99/28214
PRIOR FILING DATE: 1999-11-29
PRIOR APPLICATION NUMBER: PCT/US99/28313
PRIOR FILING DATE: 1999-11-30
PRIOR APPLICATION NUMBER: PCT/US99/28564
PRIOR FILING DATE: 1999-12-02
PRIOR APPLICATION NUMBER: PCT/US99/28565
PRIOR FILING DATE: 1999-12-02

PRIOR FILING DATE: 1999-12-02
PRIOR APPLICATION NUMBER: PCT/US99/28565
PRIOR FILING DATE: 1999-12-02
PRIOR APPLICATION NUMBER: PCT/US99/30095
PRIOR FILING DATE: 1999-12-16
PRIOR APPLICATION NUMBER: PCT/US99/30911
PRIOR FILING DATE: 1999-12-20
PRIOR APPLICATION NUMBER: PCT/US99/30999
PRIOR FILING DATE: 1999-12-20
PRIOR APPLICATION NUMBER: PCT/US00/00219
PRIOR FILING DATE: 2000-01-05
NUMBER OF SEQ ID NOS: 423
SEQ ID NO 229
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
OTHER INFORMATION: oligonucleotide probe
US-09-907-575-229

Query Match 0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 7.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1101 GCTGTCCTCAGGGGAG 1116
Db 3 GCTGTCCACAGGGGAG 18

RESULT 1172
US-09-905-075-229
Sequence 229, Application US/09905075
Publication No. US20030077583A1
GENERAL INFORMATION:
APPLICANT: Genentech, Inc.
APPLICANT: Ashkenazi, David
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Filvaroff, Ellen
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerber, Hanspeter
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, A.
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth, J.
APPLICANT: Kljavin, Ivar J.
APPLICANT: Mather, Jennie P.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William, I.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
TITLE OF INVENTION: Acids Encoding the Same
FILE REFERENCE: 10466-14
CURRENT APPLICATION NUMBER: US/09/905,075
CURRENT FILING DATE: 2001-07-13
PRIOR APPLICATION NUMBER: PCT/US99/28565
PRIOR FILING DATE: 1999-12-02
NUMBER OF SEQ ID NOS: 423
SEQ ID NO 229
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Synthetic

; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide probe
US-09-902-759-229

Query Match 0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 7.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1101 GCTGTCTCTCAGGGGAG 1116
|||||
Db 3 GCTGTCCACAGGGGAG 18

RESULT 1174

US-09-902-634-229
; Sequence 229, Application US/09902634
; Publication No. US20030082540A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/902,634
; CURRENT FILING DATE: 2001-07-10
; PRIOR APPLICATION NUMBER: US/09/665,350
; PRIOR FILING DATE: 2000-09-18
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944

; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-09-902-634-229

Query Match 0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 7.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1101 GCTGTCTCTCAGGGGAG 1116
|||||
Db 3 GCTGTCCACAGGGGAG 18

RESULT 1175

US-09-902-713-229
; Sequence 229, Application US/09902713
; Publication No. US20030082541A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same

FILE REFERENCE: 10466-14
CURRENT APPLICATION NUMBER: US/09/902,713
CURRENT FILING DATE: 2001-07-10
PRIOR APPLICATION NUMBER: 09/665,350
PRIOR FILING DATE: 2000-09-18
PRIOR APPLICATION NUMBER: PCT/US00/04414
PRIOR FILING DATE: 2000-02-22
PRIOR APPLICATION NUMBER: US 60/143,048
PRIOR FILING DATE: 1999-07-07
PRIOR APPLICATION NUMBER: US 60/145,698
PRIOR FILING DATE: 1999-07-26
PRIOR APPLICATION NUMBER: US 60/146,222
PRIOR FILING DATE: 1999-07-28
PRIOR APPLICATION NUMBER: PCT/US99/20594
PRIOR FILING DATE: 1999-09-08
PRIOR APPLICATION NUMBER: PCT/US99/20944
PRIOR FILING DATE: 1999-09-13
PRIOR APPLICATION NUMBER: PCT/US99/21090
PRIOR FILING DATE: 1999-09-15
PRIOR APPLICATION NUMBER: PCT/US99/21547
PRIOR FILING DATE: 1999-09-15
PRIOR APPLICATION NUMBER: PCT/US99/23089
PRIOR FILING DATE: 1999-10-05
PRIOR APPLICATION NUMBER: PCT/US99/28214
PRIOR FILING DATE: 1999-11-29
PRIOR APPLICATION NUMBER: PCT/US99/28313
PRIOR FILING DATE: 1999-11-30
PRIOR APPLICATION NUMBER: PCT/US99/28564
PRIOR FILING DATE: 1999-12-02
PRIOR APPLICATION NUMBER: PCT/US99/28565
PRIOR FILING DATE: 1999-12-02
PRIOR APPLICATION NUMBER: PCT/US99/30095
PRIOR FILING DATE: 1999-12-16
PRIOR APPLICATION NUMBER: PCT/US99/30911
PRIOR FILING DATE: 1999-12-20
PRIOR APPLICATION NUMBER: PCT/US99/30999
PRIOR FILING DATE: 1999-12-20
PRIOR APPLICATION NUMBER: PCT/US00/00219
PRIOR FILING DATE: 2000-01-05
NUMBER OF SEQ ID NOS: 423
SEQ ID NO 229
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-09-902-713-229
Query Match 0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 7.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1101 GCTGTCTCAGGGGAG 1116
Db 3 GCTGTCCACAGGGGAG 18
RESULT 1176
US-09-907-979-229
Sequence 229, Application US/09907979
Publication No. US20030082542A1
GENERAL INFORMATION:
APPLICANT: Genentech, Inc.
APPLICANT: Ashkenazi, Avi
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Filvaroff, Ellen
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerber, Hanspeter
APPLICANT: Gerritsen, Mary E.

APPLICANT: Goddard, A.
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth, J.
APPLICANT: Kljavin, Ivar J.
APPLICANT: Mather, Jennie P.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William, I.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
TITLE OF INVENTION: Acids Encoding the Same
FILE REFERENCE: 10466-14
CURRENT APPLICATION NUMBER: US/09/907,979
CURRENT FILING DATE: 2001-07-17
PRIOR APPLICATION NUMBER: PCT/US00/04414
PRIOR FILING DATE: 2000-02-22
PRIOR APPLICATION NUMBER: US 60/143,048
PRIOR FILING DATE: 1999-07-07
PRIOR APPLICATION NUMBER: US 60/145,698
PRIOR FILING DATE: 1999-07-26
PRIOR APPLICATION NUMBER: US 60/146,222
PRIOR FILING DATE: 1999-07-28
PRIOR APPLICATION NUMBER: PCT/US99/20594
PRIOR FILING DATE: 1999-09-08
PRIOR APPLICATION NUMBER: PCT/US99/20944
PRIOR FILING DATE: 1999-09-13
PRIOR APPLICATION NUMBER: PCT/US99/21090
PRIOR FILING DATE: 1999-09-15
PRIOR APPLICATION NUMBER: PCT/US99/21547
PRIOR FILING DATE: 1999-09-15
PRIOR APPLICATION NUMBER: PCT/US99/23089
PRIOR FILING DATE: 1999-10-05
PRIOR APPLICATION NUMBER: PCT/US99/28214
PRIOR FILING DATE: 1999-11-29
PRIOR APPLICATION NUMBER: PCT/US99/28313
PRIOR FILING DATE: 1999-11-30
PRIOR APPLICATION NUMBER: PCT/US99/28564
PRIOR FILING DATE: 1999-12-02
PRIOR APPLICATION NUMBER: PCT/US99/28565
PRIOR FILING DATE: 1999-12-02
PRIOR APPLICATION NUMBER: PCT/US99/30095
PRIOR FILING DATE: 1999-12-16
PRIOR APPLICATION NUMBER: PCT/US99/30911
PRIOR FILING DATE: 1999-12-20
PRIOR APPLICATION NUMBER: PCT/US99/30999
PRIOR FILING DATE: 1999-12-20
PRIOR APPLICATION NUMBER: PCT/US00/00219
PRIOR FILING DATE: 2000-01-05
NUMBER OF SEQ ID NOS: 423
SEQ ID NO 229
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
OTHER INFORMATION: oligonucleotide probe
US-09-907-979-229
Query Match 0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 7.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1101 GCTGTCTCAGGGGAG 1116
Db 3 GCTGTCCACAGGGGAG 18
RESULT 1177

```

US-09-902-615-229
; Sequence 229, Application US/09902615
; Publication No. US20030092002A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: 10466-14
; CURRENT FILING DATE: 2001-07-11
; PRIOR APPLICATION NUMBER: US/09/902,615
; PRIOR FILING DATE: 2001-12-14
; PRIOR APPLICATION DATA REMOVED. Check file wrapper or PALM.
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide probe
US-09-902-615-229

Query Match          0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 7.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1101 GCTGTCTCTCAGGGGAG 1116
Db 3 GCTGTCCACAGGGGAG 18

RESULT 1178
US-09-903-925-229
; Sequence 229, Application US/09903925
; Publication No. US20030096233A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.

```

```

; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: 10466-14
; CURRENT FILING DATE: 2001-07-11
; PRIOR APPLICATION NUMBER: US/09/903,925
; PRIOR FILING DATE: 2000-09-18
; PRIOR APPLICATION NUMBER: 09/665,350
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-09-903-925-229

Query Match          0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 7.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1101 GCTGTCTCTCAGGGGAG 1116
Db 3 GCTGTCCACAGGGGAG 18

RESULT 1179
US-09-906-760A-229
; Sequence 229, Application US/09906760A

```

```

; Publication No. US20030096340A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Flivaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kijavin, Ivar J.
; APPLICANT: Kijavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/906,760A
; CURRENT FILING DATE: 2001-07-16
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;
; OTHER INFORMATION: oligonucleotide probe
; US-09-906-760A-229
; Query Match 0.4%; Score 14.4; DB 1; Length 18;
; Best Local Similarity 93.8%; Pred. No. 7.7e+02;
; Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
;
; QY 1101 GCTGTCTCTCAGGGGAG 1116
; Db 3 GCTGTCTCAGGGGAG 18
;
; RESULT 1180
; US-09-903-823-229
; Sequence 229, Application US/09903823
; Publication No. US20030104381A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Flivaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kijavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/903,823
; CURRENT FILING DATE: 2001-07-11
; PRIOR APPLICATION NUMBER: US/09/665,350
; PRIOR FILING DATE: 2000-09-18
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02

```


; PRIOR APPLICATION NUMBER: PCT/US99/30095
 ; PRIOR FILING DATE: 1999-12-16
 ; PRIOR APPLICATION NUMBER: PCT/US99/30911
 ; PRIOR FILING DATE: 1999-12-20
 ; PRIOR APPLICATION NUMBER: PCT/US99/30999
 ; PRIOR FILING DATE: 1999-12-20
 ; PRIOR APPLICATION NUMBER: PCT/US00/00219
 ; PRIOR FILING DATE: 2000-01-05
 ; NUMBER OF SEQ ID NOS: 423
 ; SEQ ID NO 229
 ; LENGTH: 18
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Synthetic Oligonucleotide Probe
 US-09-903-823-229

Query Match 0.4%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 93.8%; Pred. No. 7.7e+02;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1101 GCTGTCTTCAGGGGAG 1116
 ||||| |||||
 Db 3 GCTGTCCACAGGGGAG 18

RESULT 1181

US-09-907-652-229
 ; Sequence 229, Application US/09907652
 ; Publication No. US20030104469A1

GENERAL INFORMATION:

; APPLICANT: Genentech, Inc.
 ; APPLICANT: Ashkenazi, Avi
 ; APPLICANT: Botstein, David
 ; APPLICANT: Desnovers, Luc
 ; APPLICANT: Eaton, Dan L.
 ; APPLICANT: Ferrara, Napoleone
 ; APPLICANT: Filvaroff, Ellen
 ; APPLICANT: Fong, Sherman
 ; APPLICANT: Gao, Wei-Qiang
 ; APPLICANT: Gerber, Hanspeter
 ; APPLICANT: Gerritsen, Mary E.
 ; APPLICANT: Goddard, A.
 ; APPLICANT: Godowski, Paul J.
 ; APPLICANT: Grimaldi, Christopher J.
 ; APPLICANT: Gurney, Austin L.
 ; APPLICANT: Hillan, Kenneth, J.
 ; APPLICANT: Kljavin, Ivar J.
 ; APPLICANT: Mather, Jennie P.
 ; APPLICANT: Pan, James
 ; APPLICANT: Roy, Margaret Ann
 ; APPLICANT: Stewart, Timothy A.
 ; APPLICANT: Tumas, Daniel
 ; APPLICANT: Williams, P. Mickey
 ; APPLICANT: Wood, William, I.
 ; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
 ; FILE REFERENCE: 10466-14
 ; CURRENT APPLICATION NUMBER: US/09/907,652
 ; CURRENT FILING DATE: 2002-01-16
 ; PRIOR APPLICATION NUMBER: PCT/US00/04414
 ; PRIOR FILING DATE: 2000-02-22
 ; PRIOR APPLICATION NUMBER: US 60/143,048
 ; PRIOR FILING DATE: 1999-07-07
 ; PRIOR APPLICATION NUMBER: US 60/145,698
 ; PRIOR FILING DATE: 1999-07-26
 ; PRIOR APPLICATION NUMBER: US 60/146,222
 ; PRIOR FILING DATE: 1999-07-28
 ; PRIOR APPLICATION NUMBER: PCT/US99/20594
 ; PRIOR FILING DATE: 1999-09-08
 ; PRIOR APPLICATION NUMBER: PCT/US99/20944
 ; PRIOR FILING DATE: 1999-09-13

; PRIOR APPLICATION NUMBER: PCT/US99/21090
 ; PRIOR FILING DATE: 1999-09-15
 ; PRIOR APPLICATION NUMBER: PCT/US99/21547
 ; PRIOR FILING DATE: 1999-09-15
 ; PRIOR APPLICATION NUMBER: PCT/US99/23089
 ; PRIOR FILING DATE: 1999-10-05
 ; PRIOR APPLICATION NUMBER: PCT/US99/28214
 ; PRIOR FILING DATE: 1999-11-29
 ; PRIOR APPLICATION NUMBER: PCT/US99/28313
 ; PRIOR FILING DATE: 1999-11-30
 ; PRIOR APPLICATION NUMBER: PCT/US99/28564
 ; PRIOR FILING DATE: 1999-12-02
 ; PRIOR APPLICATION NUMBER: PCT/US99/28565
 ; PRIOR FILING DATE: 1999-12-02
 ; PRIOR APPLICATION NUMBER: PCT/US99/30095
 ; PRIOR FILING DATE: 1999-12-16
 ; PRIOR APPLICATION NUMBER: PCT/US99/30911
 ; PRIOR FILING DATE: 1999-12-20
 ; PRIOR APPLICATION NUMBER: PCT/US99/30999
 ; PRIOR FILING DATE: 1999-12-20
 ; PRIOR APPLICATION NUMBER: PCT/US00/00219
 ; PRIOR FILING DATE: 2000-01-05
 ; NUMBER OF SEQ ID NOS: 423
 ; SEQ ID NO 229
 ; LENGTH: 18
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 ; OTHER INFORMATION: oligonucleotide probe
 US-09-907-652-229

Query Match 0.4%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 93.8%; Pred. No. 7.7e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1101 GCTGTCTTCAGGGGAG 1116
 ||||| |||||
 Db 3 GCTGTCCACAGGGGAG 18

RESULT 1182

US-09-902-572A-229
 ; Sequence 229, Application US/09902572A
 ; Publication No. US20030108983A1

GENERAL INFORMATION:

; APPLICANT: Genentech, Inc.
 ; APPLICANT: Ashkenazi, Avi
 ; APPLICANT: Botstein, David
 ; APPLICANT: Desnovers, Luc
 ; APPLICANT: Eaton, Dan L.
 ; APPLICANT: Ferrara, Napoleone
 ; APPLICANT: Filvaroff, Ellen
 ; APPLICANT: Fong, Sherman
 ; APPLICANT: Gao, Wei-Qiang
 ; APPLICANT: Gerber, Hanspeter
 ; APPLICANT: Gerritsen, Mary E.
 ; APPLICANT: Goddard, A.
 ; APPLICANT: Godowski, Paul J.
 ; APPLICANT: Grimaldi, Christopher J.
 ; APPLICANT: Gurney, Austin L.
 ; APPLICANT: Hillan, Kenneth, J.
 ; APPLICANT: Kljavin, Ivar J.
 ; APPLICANT: Mather, Jennie P.
 ; APPLICANT: Pan, James
 ; APPLICANT: Paoni, Nicholas F.
 ; APPLICANT: Roy, Margaret Ann
 ; APPLICANT: Stewart, Timothy A.
 ; APPLICANT: Tumas, Daniel
 ; APPLICANT: Williams, P. Mickey
 ; APPLICANT: Wood, William, I.
 ; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
 ; FILE REFERENCE: 10466-14
 ; CURRENT APPLICATION NUMBER: US/09/907,652
 ; CURRENT FILING DATE: 2002-01-16
 ; PRIOR APPLICATION NUMBER: PCT/US00/04414
 ; PRIOR FILING DATE: 2000-02-22
 ; PRIOR APPLICATION NUMBER: US 60/143,048
 ; PRIOR FILING DATE: 1999-07-07
 ; PRIOR APPLICATION NUMBER: US 60/145,698
 ; PRIOR FILING DATE: 1999-07-26
 ; PRIOR APPLICATION NUMBER: US 60/146,222
 ; PRIOR FILING DATE: 1999-07-28
 ; PRIOR APPLICATION NUMBER: PCT/US99/20594
 ; PRIOR FILING DATE: 1999-09-08
 ; PRIOR APPLICATION NUMBER: PCT/US99/20944
 ; PRIOR FILING DATE: 1999-09-13

FILE REFERENCE: 10466-14
CURRENT APPLICATION NUMBER: US/09/902,572A
CURRENT FILING DATE: 2001-07-10
PRIOR APPLICATION NUMBER: PCT/US00/04414
PRIOR FILING DATE: 2000-02-22
PRIOR APPLICATION NUMBER: US 60/143,048
PRIOR FILING DATE: 1999-07-07
PRIOR APPLICATION NUMBER: US 60/145,698
PRIOR FILING DATE: 1999-07-26
PRIOR APPLICATION NUMBER: US 60/146,222
PRIOR FILING DATE: 1999-07-28
PRIOR APPLICATION NUMBER: PCT/US99/20594
PRIOR FILING DATE: 1999-09-08
PRIOR APPLICATION NUMBER: PCT/US99/20944
PRIOR FILING DATE: 1999-09-13
PRIOR APPLICATION NUMBER: PCT/US99/21090
PRIOR FILING DATE: 1999-09-15
PRIOR APPLICATION NUMBER: PCT/US99/21547
PRIOR FILING DATE: 1999-09-15
PRIOR APPLICATION NUMBER: PCT/US99/23089
PRIOR FILING DATE: 1999-10-05
PRIOR APPLICATION NUMBER: PCT/US99/28214
PRIOR FILING DATE: 1999-11-29
Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 423
SEQ ID NO 229
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-902-572A-229

Query Match 0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 7.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1101 GCTGTCTCTCAGGGGAG 1116
Db 3 GCTGTCCACAGGGGAG 18

RESULT 1183
US-09-902-979-229
Sequence 229, Application US/09902979
Publication No. US20030113718A1
GENERAL INFORMATION:
APPLICANT: Genentech, Inc.
APPLICANT: Ashkenazi, Avi
APPLICANT: Botstein, David
APPLICANT: Desnovers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Filvaroff, Ellen
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerber, Hanspeter
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, A.
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth, J.
APPLICANT: Kijavin, Ivar J.
APPLICANT: Mather, Jennie P.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William, I.

TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE OF INVENTION: Acids Encoding the Same
FILE REFERENCE: 10466-14
CURRENT APPLICATION NUMBER: US/09/902,979
CURRENT FILING DATE: 2001-07-10
PRIOR APPLICATION NUMBER: US/09/665,350
PRIOR FILING DATE: 2000-09-18
PRIOR APPLICATION NUMBER: US 60/143,048
PRIOR FILING DATE: 1999-07-07
PRIOR APPLICATION NUMBER: US 60/145,698
PRIOR FILING DATE: 1999-07-26
PRIOR APPLICATION NUMBER: US 60/146,222
PRIOR FILING DATE: 1999-07-28
PRIOR APPLICATION NUMBER: PCT/US99/20594
PRIOR FILING DATE: 1999-09-08
PRIOR APPLICATION NUMBER: PCT/US99/20944
PRIOR FILING DATE: 1999-09-13
PRIOR APPLICATION NUMBER: PCT/US99/21090
PRIOR FILING DATE: 1999-09-15
PRIOR APPLICATION NUMBER: PCT/US99/21547
PRIOR FILING DATE: 1999-09-15
PRIOR APPLICATION NUMBER: PCT/US99/23089
PRIOR FILING DATE: 1999-10-05
PRIOR APPLICATION NUMBER: PCT/US99/28214
PRIOR FILING DATE: 1999-11-29
PRIOR APPLICATION NUMBER: PCT/US99/28313
PRIOR FILING DATE: 1999-11-30
PRIOR APPLICATION NUMBER: PCT/US99/28564
PRIOR FILING DATE: 1999-12-02
PRIOR APPLICATION NUMBER: PCT/US99/28565
PRIOR FILING DATE: 1999-12-02
PRIOR APPLICATION NUMBER: PCT/US99/30095
PRIOR FILING DATE: 1999-12-16
PRIOR APPLICATION NUMBER: PCT/US99/30911
PRIOR FILING DATE: 1999-12-20
PRIOR APPLICATION NUMBER: PCT/US99/30999
PRIOR FILING DATE: 1999-12-20
PRIOR APPLICATION NUMBER: PCT/US00/00219
PRIOR FILING DATE: 2000-01-05
NUMBER OF SEQ ID NOS: 423
SEQ ID NO 229
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-09-902-979-229

Query Match 0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 7.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1101 GCTGTCTCTCAGGGGAG 1116
Db 3 GCTGTCCACAGGGGAG 18

RESULT 1184
US-09-905-125-229
Sequence 229, Application US/09905125
Publication No. US20030113719A1
GENERAL INFORMATION:
APPLICANT: Genentech, Inc.
APPLICANT: Ashkenazi, Avi
APPLICANT: Botstein, David
APPLICANT: Desnovers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Filvaroff, Ellen
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerber, Hanspeter
APPLICANT: Gerritsen, Mary E.

```

; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/905,125
; PRIOR FILING DATE: 2001-07-12
; PRIOR APPLICATION NUMBER: 09/665,350
; PRIOR FILING DATE: 2000-09-18
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-09-905-125-229

Query Match      0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 7.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1101 GCTGTCCTCAGGGGAG 1116
Db 3 GCTGTCCACAGGGGAG 18

```

```

RESULT 1185
US-09-906-815A-229
; Sequence 229, Application US/09906815A
; Publication No. US20030113838A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/906,815A
; PRIOR FILING DATE: 2001-07-16
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA

```

```

; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide probe
US-09-305-449-229

Query Match          0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. NO. 7.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1101 GCTGTCCTCAGGGGAG 1116
          ||||| ||||| |||||
Db       3   GCTGTCACAGGGGAG 18

RESULT 1187
US-09-903-806-229
; Sequence 229, Application US/09903806
; Publication No. US20030130489A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Flivaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/903,806
; CURRENT FILING DATE: 2001-07-11
; PRIOR APPLICATION NUMBER: 09/665,350
; PRIOR FILING DATE: 2000-09-18
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:

```

```

; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide probe
US-09-906-815A-229

Query Match          0.4%   Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%   Pred. No. 7.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1101 GCTGTCTCTCAGGGGAG 1116
          ||||| |||||
Db       3 GCTGTCCACAGGGGAG 18

RESULT 1186
US-09-905-449-229
; Sequence 229, Application US/09905449
; Publication No. US2003012952A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secured and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/905,449
; CURRENT FILING DATE: 2000-09-18
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564

```

; OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-09-903-806-229

Query Match 0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 7.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1101 GCTGCTCTCAGGGGAG 1116
||||| |||||
Db 3 GCTGTCCACAGGGGAG 18

RESULT 1188

US-09-904-992-229

; Sequence 229, Application US/09904992

; Publication No. US20030135025A1

; GENERAL INFORMATION:

; APPLICANT: Genentech, Inc.

; APPLICANT: Ashkenazi, Avi

; APPLICANT: Botstein, David

; APPLICANT: Desnoyers, Luc

; APPLICANT: Eaton, Dan L.

; APPLICANT: Ferrara, Napoleone

; APPLICANT: Filvaroff, Ellen

; APPLICANT: Fong, Sherman

; APPLICANT: Gao, Wei-Qiang

; APPLICANT: Gerber, Hanspeter

; APPLICANT: Gerritsen, Mary E.

; APPLICANT: Goddard, A.

; APPLICANT: Godowski, Paul J.

; APPLICANT: Grimaldi, Christopher J.

; APPLICANT: Gurney, Austin L.

; APPLICANT: Hillan, Kenneth, J.

; APPLICANT: Kljavin, Ivar J.

; APPLICANT: Mather, Jennie P.

; APPLICANT: Pan, James

; APPLICANT: Paoni, Nicholas F.

; APPLICANT: Roy, Margaret Ann

; APPLICANT: Stewart, Timothy A.

; APPLICANT: Tumas, Daniel

; APPLICANT: Williams, P. Mickey

; APPLICANT: Wood, William, I.

; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic

; FILE REFERENCE: 10466-14

; CURRENT APPLICATION NUMBER: US/09/904,992

; PRIOR FILING DATE: 2002-01-22

; PRIOR APPLICATION NUMBER: PCT/US00/04414

; PRIOR FILING DATE: 2000-02-22

; PRIOR APPLICATION NUMBER: US 60/143,048

; PRIOR FILING DATE: 1999-07-07

; PRIOR APPLICATION NUMBER: US 60/145,698

; PRIOR FILING DATE: 1999-07-26

; PRIOR APPLICATION NUMBER: US 60/146,222

; PRIOR FILING DATE: 1999-07-28

; PRIOR APPLICATION NUMBER: PCT/US99/20594

; PRIOR FILING DATE: 1999-09-08

; PRIOR APPLICATION NUMBER: PCT/US99/20944

; PRIOR FILING DATE: 1999-09-13

; PRIOR APPLICATION NUMBER: PCT/US99/21090

; PRIOR FILING DATE: 1999-09-15

; PRIOR APPLICATION NUMBER: PCT/US99/21547

; PRIOR FILING DATE: 1999-09-15

; PRIOR APPLICATION NUMBER: PCT/US99/23089

; PRIOR FILING DATE: 1999-10-05

; PRIOR APPLICATION NUMBER: PCT/US99/28214

; PRIOR FILING DATE: 1999-11-29

; PRIOR APPLICATION NUMBER: PCT/US99/28313

; PRIOR FILING DATE: 1999-11-30

; PRIOR APPLICATION NUMBER: PCT/US99/28564

; PRIOR FILING DATE: 1999-12-02

; PRIOR APPLICATION NUMBER: PCT/US99/28565

; PRIOR FILING DATE: 1999-12-02

; PRIOR APPLICATION NUMBER: PCT/US99/28565

; PRIOR FILING DATE: 1999-12-02

; PRIOR APPLICATION NUMBER: PCT/US99/28565

; PRIOR FILING DATE: 1999-12-02

; PRIOR APPLICATION NUMBER: PCT/US99/28565

; PRIOR FILING DATE: 1999-12-02

; PRIOR APPLICATION NUMBER: PCT/US99/28565

; PRIOR APPLICATION NUMBER: PCT/US99/30095

; PRIOR FILING DATE: 1999-12-16

; PRIOR APPLICATION NUMBER: PCT/US99/30911

; PRIOR FILING DATE: 1999-12-20

; PRIOR APPLICATION NUMBER: PCT/US99/30999

; PRIOR FILING DATE: 1999-12-20

; PRIOR APPLICATION NUMBER: PCT/US00/00219

; PRIOR FILING DATE: 2000-01-05

; NUMBER OF SEQ ID NOS: 423

; SEQ ID NO 229

; LENGTH: 18

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: Synthetic

; OTHER INFORMATION: oligonucleotide probe

US-09-904-992-229

Query Match 0.4%; Score 14.4; DB 1; Length 18;

Best Local Similarity 93.8%; Pred. No. 7.7e+02;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1101 GCTGCTCTCAGGGGAG 1116

||||| |||||

Db 3 GCTGTCCACAGGGGAG 18

||||| |||||

||||| |||||

||||| |||||

||||| |||||

||||| |||||

||||| |||||

||||| |||||

||||| |||||

||||| |||||

||||| |||||

||||| |||||

||||| |||||

||||| |||||

||||| |||||

||||| |||||

||||| |||||

||||| |||||

||||| |||||

||||| |||||

||||| |||||

||||| |||||

||||| |||||

||||| |||||

||||| |||||

||||| |||||

||||| |||||

||||| |||||

||||| |||||

||||| |||||

||||| |||||

||||| |||||

||||| |||||

||||| |||||

||||| |||||

||||| |||||

||||| |||||

||||| |||||

||||| |||||

||||| |||||

||||| |||||

||||| |||||

||||| |||||

||||| |||||

||||| |||||

||||| |||||

||||| |||||

||||| |||||

||||| |||||

||||| |||||

||||| |||||

||||| |||||

||||| |||||

||||| |||||

||||| |||||

||||| |||||

; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/906,777
; CURRENT FILING DATE: 2001-07-16
; PRIOR APPLICATION NUMBER: 09/665,350
; PRIOR FILING DATE: 2000-09-18
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide probe
US-09-904-838-229

Query Match 0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 7.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1101 GCTGCTCTCAGGGGAG 1116
Db 3 GCTGTCCACAGGGGAG 18

RESULT 1190
US-09-906-777-229
; Sequence 229, Application US/09906777
; Publication No. US20030148371A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Goddard, A.
; APPLICANT: Gottstein, Mary E.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kijavich, Ivar J.
; APPLICANT: Math, James
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pao, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic

APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, A.
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth, J.
APPLICANT: Kljavin, Ivar J.
APPLICANT: Mather, Jennie P.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William, I.
TITLE OF INVENTION: Acids Encoding the Same
FILE REFERENCE: GNE.1618P2C12
CURRENT APPLICATION NUMBER: US/09/303,603A
CURRENT FILING DATE: 2001-07-11
PRIOR APPLICATION NUMBER: PCT/US00/04414
PRIOR FILING DATE: 2000-02-22
PRIOR APPLICATION NUMBER: US 60/143,048
PRIOR FILING DATE: 1999-07-07
PRIOR APPLICATION NUMBER: US 60/145,698
PRIOR FILING DATE: 1999-07-26
PRIOR APPLICATION NUMBER: US 60/146,222
PRIOR FILING DATE: 1999-07-28
PRIOR APPLICATION NUMBER: PCT/US99/20594
PRIOR FILING DATE: 1999-09-08
PRIOR APPLICATION NUMBER: PCT/US99/20944
PRIOR FILING DATE: 1999-09-13
PRIOR APPLICATION NUMBER: PCT/US99/21090
PRIOR FILING DATE: 1999-09-15
PRIOR APPLICATION NUMBER: PCT/US99/21547
PRIOR FILING DATE: 1999-09-15
PRIOR APPLICATION NUMBER: PCT/US99/28214
PRIOR FILING DATE: 1999-11-29
PRIOR APPLICATION NUMBER: PCT/US99/28313
PRIOR FILING DATE: 1999-11-30
PRIOR APPLICATION NUMBER: PCT/US99/28564
PRIOR FILING DATE: 1999-12-02
PRIOR APPLICATION NUMBER: PCT/US99/28565
PRIOR FILING DATE: 1999-12-02
PRIOR APPLICATION NUMBER: PCT/US99/30095
PRIOR FILING DATE: 1999-12-16
PRIOR APPLICATION NUMBER: PCT/US99/30911
PRIOR FILING DATE: 1999-12-20
PRIOR APPLICATION NUMBER: PCT/US99/30999
PRIOR FILING DATE: 1999-12-20
PRIOR APPLICATION NUMBER: PCT/US00/00219
PRIOR FILING DATE: 2000-01-05
NUMBER OF SEQ ID NOS: 423
SEQ ID NO 229
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-303-603A-229

Query Match 0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Fred. No. 7.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1101 GCTGCTCTCAGGGGAG 1116
Db 3 GCTGTCCACAGGGGAG 18

RESULT 1192
US-09-304-532-229
Sequence 229, Application US/0904532
Publication No. US20030152922A1
GENERAL INFORMATION:
APPLICANT: Genentech, Inc.
APPLICANT: Ashkenazi, Avi
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Filvaroff, Ellen
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerber, Hanspeter
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, A.
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth, J.
APPLICANT: Kljavin, Ivar J.
APPLICANT: Mather, Jennie P.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William, I.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: 10466-14
CURRENT APPLICATION NUMBER: US/09/304,532
CURRENT FILING DATE: 2001-07-13
PRIOR APPLICATION NUMBER: PCT/US00/04414
PRIOR FILING DATE: 2000-09-18
PRIOR APPLICATION NUMBER: PCT/US00/04414
PRIOR FILING DATE: 2000-02-22
PRIOR APPLICATION NUMBER: US 60/143,048
PRIOR FILING DATE: 1999-07-07
PRIOR APPLICATION NUMBER: US 60/145,698
PRIOR FILING DATE: 1999-07-26
PRIOR APPLICATION NUMBER: US 60/146,222
PRIOR FILING DATE: 1999-07-28
PRIOR APPLICATION NUMBER: PCT/US99/20594
PRIOR FILING DATE: 1999-09-08
PRIOR APPLICATION NUMBER: PCT/US99/20944
PRIOR FILING DATE: 1999-09-13
PRIOR APPLICATION NUMBER: PCT/US99/21090
PRIOR FILING DATE: 1999-09-15
PRIOR APPLICATION NUMBER: PCT/US99/21547
PRIOR FILING DATE: 1999-09-15
PRIOR APPLICATION NUMBER: PCT/US99/23089
PRIOR FILING DATE: 1999-10-05
PRIOR APPLICATION NUMBER: PCT/US99/28214
PRIOR FILING DATE: 1999-11-29
PRIOR APPLICATION NUMBER: PCT/US99/28313
PRIOR FILING DATE: 1999-11-30
PRIOR APPLICATION NUMBER: PCT/US99/28564
PRIOR FILING DATE: 1999-12-02
PRIOR APPLICATION NUMBER: PCT/US99/28565
PRIOR FILING DATE: 1999-12-02
PRIOR APPLICATION NUMBER: PCT/US99/30095
PRIOR FILING DATE: 1999-12-16
PRIOR APPLICATION NUMBER: PCT/US99/30911
PRIOR FILING DATE: 1999-12-20
PRIOR APPLICATION NUMBER: PCT/US99/30999
PRIOR FILING DATE: 1999-12-20
PRIOR APPLICATION NUMBER: PCT/US00/00219
PRIOR FILING DATE: 2000-01-05
NUMBER OF SEQ ID NOS: 423
SEQ ID NO 229

```

; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-09-904-532-229

Query Match          0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 7.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1101 GCTGTCCTCAGGGGAG 1116
      |||||
Db 3 GCTGTCCACAGGGGAG 18

RESULT 1193
US-09-904-766-229
; Sequence 229, Application US/09904766
; Publication No. US2003015299A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kijavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/904,766
; CURRENT FILING DATE: 2001-07-12
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30

; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide probe
US-09-904-766-229

Query Match          0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 7.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1101 GCTGTCCTCAGGGGAG 1116
      |||||
Db 3 GCTGTCCACAGGGGAG 18

RESULT 1194
US-09-904-920A-229
; Sequence 229, Application US/09904920A
; Publication No. US20030166051A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kijavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/904,920A
; CURRENT FILING DATE: 2001-07-13
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
```



```

; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-904-920A-229

```

```

Query Match      0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 7.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1101 GCTGTCTCTCAGGGGAG 1116
      ||||| |||||
Db 3 GCTGTCCACAGGGGAG 18

```

```

RESULT 1195
US-09-904-877A-229
; Sequence 229, Application US/09904877A
; Publication No. US20030186358A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.

```

```

; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/904.877A
; PRIOR FILING DATE: 2002-08-08
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-904-877A-229

```

```

Query Match      0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 7.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1101 GCTGTCTCTCAGGGGAG 1116
      ||||| |||||
Db 3 GCTGTCCACAGGGGAG 18

```

```

RESULT 1196
US-09-903-562-229
; Sequence 229, Application US/09903562
; Publication No. US20030187238A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.

```

Thu Oct 28 12:48:26 2004

```

; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/903,562
; CURRENT FILING DATE: 2001-07-11
; PRIOR FILING DATE: 2000-09-18
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-09-903-562-229

Query Match 0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 7.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1101 GCTGTCTCAGGGGAG 1116
Db 3 GCTGTCCACAGGGGAG 18

RESULT 1197
US-09-906-618-229
; Sequence 229, Application US/09906618
; Publication No. US20030190610A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Aekhenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Deenoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
```

```

; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/906,618
; CURRENT FILING DATE: 2001-07-16
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide probe
US-09-906-618-229

Query Match 0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 7.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1101 GCTGTCTCAGGGGAG 1116
```

```
Db      ||||| ||||| ||||| ||||| |||||
      3 GCTGTCCACAGGGGAG 18

RESULT 1198
US-09-907-728-229
; Sequence 229, Application US/09907728
; Publication No. US20030190611A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Goddard, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/907,728
; PRIOR FILING DATE: 2001-07-17
; PRIOR APPLICATION NUMBER: 09/665,350
; PRIOR FILING DATE: 2000-09-18
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
```

```
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-09-907-728-229

Query Match      0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Fred. No. 7.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      1101 GCTGTCTCCAGGGGAG 1116
      ||||| ||||| ||||| ||||| |||||
Db      3 GCTGTCCACAGGGGAG 18

RESULT 1199
US-09-904-805-229
; Sequence 229, Application US/09904805
; Publication No. US20030211568A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/904,805
; PRIOR FILING DATE: 2001-07-12
; PRIOR APPLICATION NUMBER: 09/665,350
; PRIOR FILING DATE: 2000-09-18
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
```

; PRIOR APPLICATION NUMBER: PCT/US99/23089
 ; PRIOR FILING DATE: 1999-10-05
 ; PRIOR APPLICATION NUMBER: PCT/US99/28214
 ; PRIOR FILING DATE: 1999-11-29
 ; PRIOR APPLICATION NUMBER: PCT/US99/28313
 ; PRIOR FILING DATE: 1999-11-30
 ; PRIOR APPLICATION NUMBER: PCT/US99/28564
 ; PRIOR FILING DATE: 1999-12-02
 ; PRIOR APPLICATION NUMBER: PCT/US99/28565
 ; PRIOR FILING DATE: 1999-12-02
 ; PRIOR APPLICATION NUMBER: PCT/US99/30095
 ; PRIOR FILING DATE: 1999-12-16
 ; PRIOR APPLICATION NUMBER: PCT/US99/30911
 ; PRIOR FILING DATE: 1999-12-20
 ; PRIOR APPLICATION NUMBER: PCT/US99/30999
 ; PRIOR FILING DATE: 1999-12-20
 ; PRIOR APPLICATION NUMBER: PCT/US00/00219
 ; PRIOR FILING DATE: 2000-01-05
 ; NUMBER OF SEQ ID NOS: 423
 ; SEQ ID NO 229
 ; LENGTH: 18
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Synthetic Oligonucleotide Probe
 US-09-904-805-229

Query Match 0.4%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 93.8%; Pred. No. 7.7e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1101 GCTGTCTCAGGGGAG 1116
 Db 3 GCTGTCCACAGGGGAG 18

RESULT 1200
 US-09-904-938A-229
 ; Sequence 229, Application US/09904938A
 ; Publication No. US20030211569A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Genentech, Inc.
 ; APPLICANT: Ashkenazi, Avi
 ; APPLICANT: Botstein, David
 ; APPLICANT: Desnoyers, Luc
 ; APPLICANT: Eaton, Dan L.
 ; APPLICANT: Ferrara, Napoleone
 ; APPLICANT: Filvaroff, Ellen
 ; APPLICANT: Fong, Sherman
 ; APPLICANT: Gao, Wei-Qiang
 ; APPLICANT: Gerber, Hanspeter
 ; APPLICANT: Gerritsen, Mary E.
 ; APPLICANT: Goddard, A.
 ; APPLICANT: Godowski, Paul J.
 ; APPLICANT: Grimaldi, Christopher J.
 ; APPLICANT: Gurney, Austin L.
 ; APPLICANT: Hillan, Kenneth, J.
 ; APPLICANT: Kljavin, Ivar J.
 ; APPLICANT: Mather, Jennie P.
 ; APPLICANT: Pan, James
 ; APPLICANT: Paoni, Nicholas F.
 ; APPLICANT: ROY, Margaret Ann
 ; APPLICANT: Stewart, Timothy A.
 ; APPLICANT: Tumas, Daniel
 ; APPLICANT: Williams, P. Mickey
 ; APPLICANT: Wood, William, I.
 ; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
 ; FILE REFERENCE: 10466-14
 ; CURRENT APPLICATION NUMBER: US/09/904,938A
 ; CURRENT FILING DATE: 2001-07-12
 ; PRIOR APPLICATION NUMBER: PCT/US00/04414
 ; PRIOR FILING DATE: 2000-02-22

; PRIOR APPLICATION NUMBER: US 60/143,048
 ; PRIOR FILING DATE: 1999-07-07
 ; PRIOR APPLICATION NUMBER: US 60/145,698
 ; PRIOR FILING DATE: 1999-07-26
 ; PRIOR APPLICATION NUMBER: US 60/146,222
 ; PRIOR FILING DATE: 1999-07-28
 ; PRIOR APPLICATION NUMBER: PCT/US99/20594
 ; PRIOR FILING DATE: 1999-09-08
 ; PRIOR APPLICATION NUMBER: PCT/US99/20944
 ; PRIOR FILING DATE: 1999-09-13
 ; PRIOR APPLICATION NUMBER: PCT/US99/21090
 ; PRIOR FILING DATE: 1999-09-15
 ; PRIOR APPLICATION NUMBER: PCT/US99/21547
 ; PRIOR FILING DATE: 1999-09-15
 ; PRIOR APPLICATION NUMBER: PCT/US99/23089
 ; PRIOR FILING DATE: 1999-10-05
 ; PRIOR APPLICATION NUMBER: PCT/US99/28214
 ; PRIOR FILING DATE: 1999-11-29
 ; PRIOR APPLICATION NUMBER: PCT/US99/28313
 ; PRIOR FILING DATE: 1999-11-30
 ; PRIOR APPLICATION NUMBER: PCT/US99/28564
 ; PRIOR FILING DATE: 1999-12-02
 ; PRIOR APPLICATION NUMBER: PCT/US99/28565
 ; PRIOR FILING DATE: 1999-12-02
 ; PRIOR APPLICATION NUMBER: PCT/US99/30095
 ; PRIOR FILING DATE: 1999-12-16
 ; PRIOR APPLICATION NUMBER: PCT/US99/30911
 ; PRIOR FILING DATE: 1999-12-20
 ; PRIOR APPLICATION NUMBER: PCT/US99/30999
 ; PRIOR FILING DATE: 1999-12-20
 ; PRIOR APPLICATION NUMBER: PCT/US00/00219
 ; PRIOR FILING DATE: 2000-01-05
 ; NUMBER OF SEQ ID NOS: 423
 ; SEQ ID NO 229
 ; LENGTH: 18
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 US-09-904-938A-229

Query Match 0.4%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 93.8%; Pred. No. 7.7e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1101 GCTGTCTCAGGGGAG 1116
 Db 3 GCTGTCCACAGGGGAG 18

RESULT 1201
 US-09-906-722A-229
 ; Sequence 229, Application US/09906722A
 ; Publication No. US20030215904A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Genentech, Inc.
 ; APPLICANT: Ashkenazi, Avi
 ; APPLICANT: Botstein, David
 ; APPLICANT: Desnoyers, Luc
 ; APPLICANT: Eaton, Dan L.
 ; APPLICANT: Ferrara, Napoleone
 ; APPLICANT: Filvaroff, Ellen
 ; APPLICANT: Fong, Sherman
 ; APPLICANT: Gao, Wei-Qiang
 ; APPLICANT: Gerber, Hanspeter
 ; APPLICANT: Gerritsen, Mary E.
 ; APPLICANT: Goddard, A.
 ; APPLICANT: Godowski, Paul J.
 ; APPLICANT: Grimaldi, Christopher J.
 ; APPLICANT: Gurney, Austin L.
 ; APPLICANT: Hillan, Kenneth, J.
 ; APPLICANT: Kljavin, Ivar J.

```

; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas P.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: GNE.1618P2C61
; CURRENT APPLICATION NUMBER: US/09/906,722A
; CURRENT FILING DATE: 2001-07-16
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: PCT/US99/28313
; PRIOR FILING DATE: 1999-11-30
; PRIOR APPLICATION NUMBER: PCT/US99/28564
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/28565
; PRIOR FILING DATE: 1999-12-02
; PRIOR APPLICATION NUMBER: PCT/US99/30095
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: PCT/US99/30911
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US99/30999
; PRIOR FILING DATE: 1999-12-20
; PRIOR APPLICATION NUMBER: PCT/US00/00219
; PRIOR FILING DATE: 2000-01-05
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-906-722A-229

Query Match 0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 7.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1101 GCTGTCCTCAGGGGAG 1116
Db 3 GCTGTCCACAGGGGAG 18

RESULT 1202
US-09-576-229
; Sequence 229, Application US/09908576
; Publication No. US2004000553A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi

```

```

; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kijavlin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas P.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/09/908,576
; CURRENT FILING DATE: 2001-07-18
; PRIOR APPLICATION NUMBER: US/09/665,350B
; PRIOR FILING DATE: 2000-09-18
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-908-576-229

Query Match 0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 7.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1101 GCTGTCCTCAGGGGAG 1116
Db 3 GCTGTCCACAGGGGAG 18

RESULT 1203
US-10-282-958-24
; Sequence 24, Application US/10282958
; Publication No. US20030110519A1
; GENERAL INFORMATION:

```

APPLICANT: Andrew D.J. Godearl and Sandra Gluckman
TITLE OF INVENTION: Muscarinic Receptors and Uses Therefor
NUMBER OF SEQUENCES: 39
CORRESPONDENCE ADDRESS:
ADDRESSEE: LAHIVE & COCKFIELD, LLP
STREET: 28 State Street
CITY: Boston
STATE: Massachusetts
COUNTRY: USA
ZIP: 02109
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/10/282,958
FILING DATE: 28-Oct-2002
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/09/349,755
FILING DATE: 08-Jul-1999
APPLICATION NUMBER: US/09/042,780
FILING DATE: <Unknown>
APPLICATION NUMBER: US 08/985,090
FILING DATE: 04-DEC-1997
ATTORNEY/AGENT INFORMATION:
NAME: Elizabeth A. Hanley
REGISTRATION NUMBER: 33,505
REFERENCE/POCKET NUMBER: MNI-032CP
TELECOMMUNICATION INFORMATION:
TELEPHONE: (617)227-7400
TELEFAX: (617)742-4214
INFORMATION FOR SEQ ID NO: 24:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
SEQUENCE DESCRIPTION: SEQ ID NO: 24:
US-10-282-958-24

Query Match 0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 7.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 3658 GCCTGCAGGGCATGG 3673
Db 1 GCCTGCTGGGCATGG 16

RESULT 1204
US-10-299-976-229
Sequence 229, Application US/10299976
Publication No. US20030180312A1
GENERAL INFORMATION:
APPLICANT: Genentech, Inc.
APPLICANT: Ashkenazi, Avi
APPLICANT: Botstein, David
APPLICANT: Desnovers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Filvaroff, Ellen
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerber, Hanspeter
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, A.
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth, J.

APPLICANT: Kijavin, Ivar J.
APPLICANT: Mather, Jennie P.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William, I.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
TITLE OF INVENTION: Acids Encoding the Same
FILE REFERENCE: P1618P2C85
CURRENT APPLICATION NUMBER: US/10/299,976
CURRENT FILING DATE: 2002-11-18
PRIOR APPLICATION NUMBER: PCT/US00/04414
PRIOR FILING DATE: 2000-02-22
PRIOR APPLICATION NUMBER: US 60/143,048
PRIOR FILING DATE: 1999-07-07
PRIOR APPLICATION NUMBER: US 60/145,698
PRIOR FILING DATE: 1999-07-26
PRIOR APPLICATION NUMBER: US 60/146,222
PRIOR FILING DATE: 1999-07-28
PRIOR APPLICATION NUMBER: PCT/US99/20594
PRIOR FILING DATE: 1999-09-08
PRIOR APPLICATION NUMBER: PCT/US99/20944
PRIOR FILING DATE: 1999-09-13
PRIOR APPLICATION NUMBER: PCT/US99/21090
PRIOR FILING DATE: 1999-09-15
PRIOR APPLICATION NUMBER: PCT/US99/21547
PRIOR FILING DATE: 1999-09-15
PRIOR APPLICATION NUMBER: PCT/US99/23089
PRIOR FILING DATE: 1999-10-05
PRIOR APPLICATION NUMBER: PCT/US99/28214
PRIOR FILING DATE: 1999-11-29
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 423
SEQ ID NO 229
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-10-299-976-229

Query Match 0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 7.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1101 GCTGTCTCTCAGGGGAG 1116
Db 3 GCTGTCCACAGGGGAG 18

RESULT 1205
US-10-299-937-229
Sequence 229, Application US/10299937
Publication No. US20030185846A1
GENERAL INFORMATION:
APPLICANT: Genentech, Inc.
APPLICANT: Ashkenazi, Avi
APPLICANT: Botstein, David
APPLICANT: Desnovers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Filvaroff, Ellen
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerber, Hanspeter
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, A.
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.

```

; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P1618P2C86
; CURRENT APPLICATION NUMBER: US/10/299,937
; CURRENT FILING DATE: 2002-11-18
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-11-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide probe
US-10-299-937-229

Query Match 0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 7.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1101 GCTGTCCTCAGGGGAG 1116
Db 3 GCTGTCCACAGGGGAG 18

RESULT 1206
US-10-440-850-1134/c
; Sequence 1134, Application US/10440850
; Publication No. US20030207837A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Induction of Graft Tolerance and Revea
; TITLE OF INVENTION: Immune Responses
; FILE REFERENCE: 250/130 (MEHQ00-900-A)
; CURRENT APPLICATION NUMBER: US/10/440,850
; CURRENT FILING DATE: 2003-05-19
; PRIOR APPLICATION NUMBER: US/09/650,012
; PRIOR FILING DATE: 2000-08-28
; PRIOR APPLICATION NUMBER: US 08/585,684

```

```

; PRIOR FILING DATE: 1996-01-12
; PRIOR APPLICATION NUMBER: US 60/000,951
; PRIOR FILING DATE: 1995-07-07
; PRIOR APPLICATION NUMBER: US 09/038,073
; PRIOR FILING DATE: 1998-03-11
; NUMBER OF SEQ ID NOS: 2285
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1134
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-440-850-1134

Query Match 0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 7.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2899 ACAGGAGGCGGCATG 2914
Db 16 ACAGGGGCGAGGCATG 1

RESULT 1207
US-10-298-993-229
; Sequence 229, Application US/10298993
; Publication No. US20030211576A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P1618P2C84
; CURRENT APPLICATION NUMBER: US/10/298,993
; CURRENT FILING DATE: 2002-11-18
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15

```

```
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-10-298-993-229

Query Match          0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 7.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1101 GCTGTCTCTCAGGGGAG 1116
      ||||| |||||
Db 3 GCTGTCCACAGGGGAG 18

RESULT 1208
US-10-448-923-229
; Sequence 229, Application US/10448923
; Publication No. US20030225253A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Deenoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/10/448,923
; CURRENT FILING DATE: 2003-05-29
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
```

```
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-10-448-923-229

Query Match          0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 7.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1101 GCTGTCTCTCAGGGGAG 1116
      ||||| |||||
Db 3 GCTGTCCACAGGGGAG 18

RESULT 1209
US-10-449-656-229
; Sequence 229, Application US/10449656
; Publication No. US20040005665A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Deenoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/10/449,656
; CURRENT FILING DATE: 2003-05-29
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
```



```
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-10-449-656-229

Query Match          0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 7.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1101 GCTGCTCTCAGGGGAG 1116
      ||||| |||||
Db 3 GCTGTCCACAGGGGAG 18

RESULT 1210
US-10-448-713-229
; Sequence 229, Application US/10448713
; Publication No. US20040006211A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/10/448,713
; CURRENT FILING DATE: 2003-05-29
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
```

```
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-10-448-713-229

Query Match          0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 7.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1101 GCTGCTCTCAGGGGAG 1116
      ||||| |||||
Db 3 GCTGTCCACAGGGGAG 18

RESULT 1211
US-10-206-618-33
; Sequence 33, Application US/10206618
; Publication No. US20040018497A1
; GENERAL INFORMATION:
; APPLICANT: Warden, Craig H.
; TITLE OF INVENTION: HUMAN OBESITY LIPIN3 POLYNUCLEOTIDE AND
; FILE OF INVENTION: POLYPEPTIDE SEQUENCES AND METHODS OF USE THEREOF
; FILE REFERENCE: 22002064100
; CURRENT APPLICATION NUMBER: US/10/206,618
; CURRENT FILING DATE: 2002-07-26
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 33
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-206-618-33

Query Match          0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 7.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 315 CAACCCCACTCCCTCC 330
      ||||| |||||
Db 2 CAACCCCTCTCCCTCC 17

RESULT 1212
US-10-425-447-229
; Sequence 229, Application US/10425447
; Publication No. US2004002331A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
```

```

; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: 10466-14
; CURRENT APPLICATION NUMBER: US/10/425,447
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: US 60/143,048
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: US 60/145,698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: US 60/146,222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: PCT/US99/20594
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: PCT/US99/20944
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: PCT/US99/21090
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/21547
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: PCT/US99/23089
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: PCT/US99/28214
; PRIOR FILING DATE: 1999-11-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide probe
US-10-425-447-229

Query Match 0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 7.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1101 GCTGTCTCTCAGGGGAG 1116
Db 3 GCTGTCCACAGGGGAG 18

RESULT 1213
US-10-425-371-229
; Sequence 229, Application US/10215371
; Publication No. US20040137561A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Chen, Jian
; APPLICANT: Goddard, Audrey
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth
; APPLICANT: Pennica, Diane
; APPLICANT: Wood, William I.
; APPLICANT: Yuan, Jean
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: 10215371
; CURRENT APPLICATION NUMBER: US/10215371
; CURRENT FILING DATE: 2004-02-02
; PRIOR FILING DATE: 2001-07-18
; PRIOR APPLICATION NUMBER: 09/909,064
; PRIOR FILING DATE: 2000-09-18
; PRIOR APPLICATION NUMBER: 09/665,350
; PRIOR FILING DATE: 2000-09-18
; PRIOR APPLICATION NUMBER: PCT/US00/04414

```

```

; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P1618P2C83
; CURRENT APPLICATION NUMBER: US/10/215,371
; CURRENT FILING DATE: 2002-08-08
; PRIOR APPLICATION NUMBER: US 09/665,350
; PRIOR FILING DATE: 2000-09-18
; PRIOR APPLICATION NUMBER: PCT/US00/04414
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: PCT/US98/18824
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: US 60/099,803
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: US 60/062,285
; PRIOR FILING DATE: 1997-10-17
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-10-215-371-229

Query Match 0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 7.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1101 GCTGTCTCTCAGGGGAG 1116
Db 3 GCTGTCCACAGGGGAG 18

RESULT 1214
US-10-771-187-229
; Sequence 229, Application US/10771187
; Publication No. US20040185531A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Aehkenazi, Avi
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth, J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Mather, Jennie P.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William, I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: 39780-1618P2C78C1
; CURRENT APPLICATION NUMBER: US/10/771,187
; CURRENT FILING DATE: 2004-02-02
; PRIOR FILING DATE: 2001-07-18
; PRIOR APPLICATION NUMBER: 09/909,064
; PRIOR FILING DATE: 2000-09-18
; PRIOR APPLICATION NUMBER: 09/665,350
; PRIOR FILING DATE: 2000-09-18
; PRIOR APPLICATION NUMBER: PCT/US00/04414

```

```

; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: PCT/US98/19437
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: PCT/US98/19330
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/088,026
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/066,770
; PRIOR FILING DATE: 1997-11-24
; PRIOR APPLICATION NUMBER: 60/065,186
; PRIOR FILING DATE: 1997-11-12
; NUMBER OF SEQ ID NOS: 423
; SEQ ID NO 229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide probe
US-10-771-187-229

```

```

Query Match      0.4%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 7.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

Qy 1101 GCTGCTCAGGGGAG 1116
Db 3 GCTGCTCAGGGGAG 18

```

```

RESULT 1215
US-09-881-012-230/c
; Sequence 230, Application US/09881012
; Publication No. US20020192655A1
; GENERAL INFORMATION:
; APPLICANT: Ginns, Edward I.
; APPLICANT: Egeland, Janice A.
; APPLICANT: Paul, Steven M.
; APPLICANT: The Government of the United States of America
; APPLICANT: as represented by The Secretary of the
; APPLICANT: Department of Health and Human Services
; TITLE OF INVENTION: Susceptibility and Resistance Genes for
; TITLE OF INVENTION: Bipolar Affective Disorder
; FILE REFERENCE: 015280-248110US
; CURRENT APPLICATION NUMBER: US/09/881,012
; CURRENT FILING DATE: 2001-06-13
; PRIOR APPLICATION NUMBER: US/09/175,158
; PRIOR FILING DATE: 1998-10-19
; PRIOR APPLICATION NUMBER: US 60/062,924
; PRIOR FILING DATE: 1997-10-20
; NUMBER OF SEQ ID NOS: 240
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 230
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: UT1585 primer
US-09-881-012-230

```

```

Query Match      0.4%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 8.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

Qy 2101 GACATCCCGAGTCCA 2116
Db 19 GACATCCCGAGTCCA 4

```

```

RESULT 1216
US-09-754-066-6/c
; Sequence 6, Application US/09754066
; Publication No. US20030013669A1

```

```

; GENERAL INFORMATION:
; APPLICANT: BURCOGLU, ARSINUR
; TITLE OF INVENTION: METHOD OF TREATING HIV INFECTION
; AND RELATED SECONDARY INFECTIONS THEREOF
; NUMBER OF SEQUENCES: 19
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Banner & Witcoff
; STREET: 1001 G Street, NW
; CITY: Washington
; STATE: DC
; COUNTRY: USA
; ZIP: 20001
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/754,066
; FILING DATE: 05-Jan-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/848,013
; FILING DATE: 2001-05-07
; APPLICATION NUMBER: 07/830,886
; FILING DATE: 04-FEB-1992
; APPLICATION NUMBER: 07/748,277
; FILING DATE: 21-AUG-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Kagan, Sarah A
; REGISTRATION NUMBER: 32141
; REFERENCE/DOCKET NUMBER: 02939,04541
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-508-9100
; TELEFAX: 202-508-9299
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 6:
US-09-754-066-6

```

```

Query Match      0.4%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 8.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

Qy 2814 TGTATATGGTATATAT 2829
Db 19 TGTATATGGTATATTT 4

```

```

RESULT 1217
US-10-251-117-712
; Sequence 712, Application US/10251117
; Publication No. US20030170891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA interference Mediated Inhibition of Epidermal Growth Factor R
; FILE REFERENCE: 900/042 (MBHB02-468-A)
; CURRENT APPLICATION NUMBER: US/10/251,117
; CURRENT FILING DATE: 2003-02-24
; PRIOR APPLICATION NUMBER: US 60/393,924
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/163,552
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 09/916,466

```

```

; PRIOR FILING DATE: 2001-07-25
; PRIOR APPLICATION NUMBER: US 60/296,249
; PRIOR FILING DATE: 2001-06-06
; NUMBER OF SEQ ID NOS: 1213
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 712
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target sequence/siNA sense r
US-10-251-117-712

Query Match      0.4%; Score 14.4; DB 1; Length 19;
Best Local Similarity 75.0%; Pred. No. 8.1e+02;
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 1794 CCAGAGTCAGCTCTGG 1809
Db 1 CCAGAGUGAGUCUGG 16

RESULT 1218
US-10-251-117-1019/c
; Sequence 1019, Application US/10251117
; Publication No. US20030170891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Epidermal Growth Factor R
; FILE REFERENCE: 900/042 (MBH02-468-A)
; CURRENT APPLICATION NUMBER: US/10/251,117
; CURRENT FILING DATE: 2003-02-24
; PRIOR APPLICATION NUMBER: US 60/393,924
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/163,552
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 09/916,466
; PRIOR FILING DATE: 2001-07-25
; PRIOR APPLICATION NUMBER: US 60/296,249
; PRIOR FILING DATE: 2001-06-06
; NUMBER OF SEQ ID NOS: 1213
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1019
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-251-117-1019

Query Match      0.4%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 8.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1794 CCAGAGTCAGCTCTGG 1809
Db 19 CCAGAGTCAGCTCTGG 4

RESULT 1219
US-10-244-647-370
; Sequence 370, Application US/10244647
; Publication No. US20030206887A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Morrissey, David
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Hepatitis B Virus (HBV) U

```

```

; TITLE OF INVENTION: Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/060 (MBH02-1000)
; CURRENT APPLICATION NUMBER: US/10/244,647
; CURRENT FILING DATE: 2003-04-14
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/393,924
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: PCT US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; NUMBER OF SEQ ID NOS: 1524
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 370
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target sequence/siNA sense r
US-10-244-647-370

Query Match      0.4%; Score 14.4; DB 1; Length 19;
Best Local Similarity 62.5%; Pred. No. 8.1e+02;
Matches 10; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Qy 2776 TTCGGAAACTAGTGT 2791
Db 3 UUCCGAAACUACUGU 18

RESULT 1220
US-10-244-647-380
; Sequence 380, Application US/10244647
; Publication No. US20030206887A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Morrissey, David
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Hepatitis B Virus (HBV) U
; FILE REFERENCE: 400/060 (MBH02-1000)
; CURRENT APPLICATION NUMBER: US/10/244,647
; CURRENT FILING DATE: 2003-04-14
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/393,924
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: PCT US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; NUMBER OF SEQ ID NOS: 1524
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 380
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target sequence/siNA sense r
US-10-244-647-380

Query Match      0.4%; Score 14.4; DB 1; Length 19;
Best Local Similarity 62.5%; Pred. No. 8.1e+02;
Matches 10; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Qy 2776 TTCGGAAACTAGTGT 2791
Db 4 UUCCGAAACUACUGU 19

RESULT 1221

```

US-10-244-647-411
; Sequence 411, Application US/10244647
; Publication No. US20030206887A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceutical, Inc.
; APPLICANT: Morrissey, David
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Hepatitis B Virus (HBV)
; TITLE OF INVENTION: Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/060 (MBH02-1000)
; CURRENT APPLICATION NUMBER: US/10/244,647
; CURRENT FILING DATE: 2003-04-14
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/393,924
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: PCT US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; NUMBER OF SEQ ID NOS: 1524
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 411
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target sequence/siNA sense
US-10-244-647-411

Query Match 0.4%; Score 14.4; DB 1; Length 19;
Best Local Similarity 62.5%; Pred. No. 8.1e+02;
Matches 10; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Qy 2776 TTCGGAAACTAGTGT 2791
::|||||::|:
Db 1 UUCCGAAACUACUGU 16

RESULT 1222
US-10-244-647-415
; Sequence 415, Application US/10244647
; Publication No. US20030206887A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceutical, Inc.
; APPLICANT: Morrissey, David
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Hepatitis B Virus (HBV)
; TITLE OF INVENTION: Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/060 (MBH02-1000)
; CURRENT APPLICATION NUMBER: US/10/244,647
; CURRENT FILING DATE: 2003-04-14
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/393,924
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: PCT US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; NUMBER OF SEQ ID NOS: 1524
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 415
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target sequence/siNA sense
US-10-244-647-415

Query Match 0.4%; Score 14.4; DB 1; Length 19;

Best Local Similarity 62.5%; Pred. No. 8.1e+02;
Matches 10; Conservative 5; Mismatches 1; Indels 0; Gaps 0;
Qy 2776 TTCGGAAACTAGTGT 2791
::|||||::|:
Db 2 UUCCGAAACUACUGU 17

RESULT 1223
US-10-244-647-1016/c
; Sequence 1016, Application US/10244647
; Publication No. US20030206887A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceutical, Inc.
; APPLICANT: Morrissey, David
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Hepatitis B Virus (HBV)
; TITLE OF INVENTION: Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/060 (MBH02-1000)
; CURRENT APPLICATION NUMBER: US/10/244,647
; CURRENT FILING DATE: 2003-04-14
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/393,924
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: PCT US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; NUMBER OF SEQ ID NOS: 1524
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1016
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-244-647-1016

Query Match 0.4%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 8.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2776 TTCGGAAACTAGTGT 2791
|||||::|:
Db 17 TTCGGAAACTACTGT 2

RESULT 1224
US-10-244-647-1026/c
; Sequence 1026, Application US/10244647
; Publication No. US20030206887A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceutical, Inc.
; APPLICANT: Morrissey, David
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Hepatitis B Virus (HBV)
; TITLE OF INVENTION: Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/060 (MBH02-1000)
; CURRENT APPLICATION NUMBER: US/10/244,647
; CURRENT FILING DATE: 2003-04-14
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/393,924
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: PCT US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; NUMBER OF SEQ ID NOS: 1524
; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 1026
 ; LENGTH: 19
 ; TYPE: RNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
 US-10-244-647-1026

Query Match 0.4%; Score 14.4; DB 1; Length 19;
 Best Local Similarity 93.8%; Pred. No. 8.1e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2776 TTCGGAACACTAGTGT 2791
 Db 16 TTCGGAACACTGT 1

RESULT 1225
 US-10-244-647-1057/c
 ; Sequence 1057, Application US/10244647
 ; Publication No. US20030206887A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceutical, Inc.
 ; APPLICANT: Morrissey, David
 ; APPLICANT: McSwiggen, James
 ; APPLICANT: Beigelman, Leonid
 ; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Hepatitis B Virus (HBV)
 ; TITLE OF INVENTION: Short Interfering Nucleic Acid (siNA)
 ; FILE REFERENCE: 400/060 (MHB02-1000)
 ; CURRENT APPLICATION NUMBER: US/10/244,647
 ; CURRENT FILING DATE: 2003-04-14
 ; PRIOR APPLICATION NUMBER: US 60/358,580
 ; PRIOR FILING DATE: 2002-02-20
 ; PRIOR APPLICATION NUMBER: US 60/393,924
 ; PRIOR FILING DATE: 2002-07-03
 ; PRIOR APPLICATION NUMBER: PCT US02/09187
 ; PRIOR FILING DATE: 2002-03-26
 ; PRIOR APPLICATION NUMBER: US 60/296,876
 ; PRIOR FILING DATE: 2001-06-08
 ; NUMBER OF SEQ ID NOS: 1524
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 1057
 ; LENGTH: 19
 ; TYPE: RNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
 US-10-244-647-1057

Query Match 0.4%; Score 14.4; DB 1; Length 19;
 Best Local Similarity 93.8%; Pred. No. 8.1e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2776 TTCGGAACACTAGTGT 2791
 Db 19 TTCGGAACACTGT 4

RESULT 1226
 US-10-244-647-1061/c
 ; Sequence 1061, Application US/10244647
 ; Publication No. US20030206887A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceutical, Inc.
 ; APPLICANT: Morrissey, David
 ; APPLICANT: McSwiggen, James
 ; APPLICANT: Beigelman, Leonid
 ; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Hepatitis B Virus (HBV)
 ; TITLE OF INVENTION: Short Interfering Nucleic Acid (siNA)
 ; FILE REFERENCE: 400/060 (MHB02-1000)
 ; CURRENT APPLICATION NUMBER: US/10/244,647
 ; CURRENT FILING DATE: 2003-04-14
 ; PRIOR APPLICATION NUMBER: US 60/358,580

; PRIOR FILING DATE: 2002-02-20
 ; PRIOR APPLICATION NUMBER: US 60/393,924
 ; PRIOR FILING DATE: 2002-07-03
 ; PRIOR APPLICATION NUMBER: PCT US02/09187
 ; PRIOR FILING DATE: 2002-03-26
 ; PRIOR APPLICATION NUMBER: US 60/296,876
 ; PRIOR FILING DATE: 2001-06-08
 ; NUMBER OF SEQ ID NOS: 1524
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 1061
 ; LENGTH: 19
 ; TYPE: RNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
 US-10-244-647-1061

Query Match 0.4%; Score 14.4; DB 1; Length 19;
 Best Local Similarity 93.8%; Pred. No. 8.1e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2776 TTCGGAACACTAGTGT 2791
 Db 18 TTCGGAACACTGT 3

RESULT 1227
 US-10-665-951-1042
 ; Sequence 1042, Application US/10665951
 ; Publication No. US20040138163A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Sirna Therapeutics, Inc.
 ; APPLICANT: McSwiggen, James
 ; APPLICANT: Beigelman, Leonid
 ; APPLICANT: Pavco, Pamela
 ; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
 ; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
 ; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
 ; FILE REFERENCE: 400/131 (MHB02-742-F)
 ; CURRENT APPLICATION NUMBER: US/10/665,951
 ; CURRENT FILING DATE: 2003-09-18
 ; PRIOR APPLICATION NUMBER: US 10/664,668
 ; PRIOR FILING DATE: 2003-09-18
 ; PRIOR APPLICATION NUMBER: PCT/US 03/05022
 ; PRIOR FILING DATE: 2003-02-20
 ; PRIOR APPLICATION NUMBER: US 60/399,348
 ; PRIOR FILING DATE: 2002-07-29
 ; PRIOR APPLICATION NUMBER: US 60/393,796
 ; PRIOR FILING DATE: 2002-07-03
 ; PRIOR APPLICATION NUMBER: US 10/287,949
 ; PRIOR FILING DATE: 2002-11-04
 ; PRIOR APPLICATION NUMBER: US 10/306,747
 ; PRIOR FILING DATE: 2002-11-27
 ; PRIOR APPLICATION NUMBER: PCT/US 02/17674
 ; PRIOR FILING DATE: 2002-05-29
 ; PRIOR APPLICATION NUMBER: US 60/358,580
 ; PRIOR FILING DATE: 2002-02-20
 ; PRIOR APPLICATION NUMBER: US 60/363,124
 ; PRIOR FILING DATE: 2002-03-11
 ; PRIOR APPLICATION NUMBER: US 60/386,782
 ; PRIOR FILING DATE: 2002-06-06
 ; Remaining Prior Application data removed - See File Wrapper or PALM.
 ; NUMBER OF SEQ ID NOS: 2455
 ; SOFTWARE: PatentIn version 3.2
 ; SEQ ID NO 1042
 ; LENGTH: 19
 ; TYPE: RNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
 US-10-665-951-1042

Query Match 0.4%; Score 14.4; DB 1; Length 19;

```

Best Local Similarity 81.2%; Pred. No. 8.1e+02; Indels 0; Gaps 0;
Matches 13; Conservative 2; Mismatches 1;

Qy 1609 AAGTCATCCACAGG 1624
Db 4 AAGUGAUCCACAGG 19

RESULT 1228
US-10-665-951-1366/c
; Sequence 1366, Application US/10665951
; Publication No. US20040138163A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: 400/131 (MBHB02-742-F)
; CURRENT APPLICATION NUMBER: US/10/665,951
; CURRENT FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2455
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1366
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: sirna antisense region
US-10-665-951-1366

Query Match 0.4%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 8.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1609 AAGTCATCCACAGG 1624
Db 16 AAGTGTATCCACAGG 1

RESULT 1229
US-10-665-951-1734
; Sequence 1734, Application US/10665951
; Publication No. US20040138163A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: 400/131 (MBHB02-742-F)
; CURRENT APPLICATION NUMBER: US/10/665,951
; CURRENT FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2455
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1366
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: sirna antisense region
US-10-665-951-1366

```

```

; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/131 (MBHB02-742-F)
; CURRENT APPLICATION NUMBER: US/10/665,951
; CURRENT FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/287,949
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: PCT/US 02/17674
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2455
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1734
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-665-951-1734

Query Match 0.4%; Score 14.4; DB 1; Length 19;
Best Local Similarity 81.2%; Pred. No. 8.1e+02;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 1998 CAAGCAGCTGGGAG 2013
Db 3 CAAGAGCUGGAGG 18

RESULT 1230
US-10-665-951-1981/c
; Sequence 1981, Application US/10665951
; Publication No. US20040138163A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: 400/131 (MBHB02-742-F)
; CURRENT APPLICATION NUMBER: US/10/665,951
; CURRENT FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/287,949
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: PCT/US 02/17674

```

```

; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2455
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1981
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: sina antisense region
US-10-665-951-1981

Query Match      0.4%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 8.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1998 CAAGCAGCTGGTGAG 2013
DB 17 CAAGAAGCTGGTGAG 2

RESULT 1231
US-10-768-089-6/c
; Sequence 6, Application US/10768089
; Publication No. US20040138167A1
; GENERAL INFORMATION:
; APPLICANT: BURCOGLU, ARSINUR
; TITLE OF INVENTION: METHOD OF TREATING HIV INFECTION
; NUMBER OF SEQUENCES: 19
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Banner & Witcoff
; STREET: 1001 G Street, NW
; CITY: Washington
; STATE: DC
; COUNTRY: USA
; ZIP: 20001
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; FILING DATE: 02-Feb-2004
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/754,066
; FILING DATE: 05-Jan-2001
; APPLICATION NUMBER: 08/848,013
; FILING DATE: 2001-05-07
; APPLICATION NUMBER: 07/830,886
; FILING DATE: 04-FEB-1992
; APPLICATION NUMBER: 07/748,277
; FILING DATE: 21-AUG-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Kagan, Sarah A
; REGISTRATION NUMBER: 32141
; REFERENCE/DOCKET NUMBER: 02939.04541
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-508-9100
; TELEFAX: 202-508-9299
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid

```

```

; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 6:
US-10-768-089-6

Query Match      0.4%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 8.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2814 TGTATATGCTATATAT 2829
DB 19 TGTATATGCTATATTT 4

RESULT 1232
US-09-752-110A-20/c
; Sequence 20, Application US/09752110A
; Patent No. US20010043921A1
; GENERAL INFORMATION:
; APPLICANT: Gunzburg, Walter
; APPLICANT: Salmons, Brian
; APPLICANT: Goller, Sabine
; APPLICANT: Klein, Dieter
; TITLE OF INVENTION: Targeted Integration Into Chromosomes
; FILE REFERENCE: 2316.2005-000
; CURRENT APPLICATION NUMBER: US/09/752,110A
; CURRENT FILING DATE: 2000-12-29
; PRIOR APPLICATION NUMBER: PCT/EP99/04521
; PRIOR FILING DATE: 1999-06-30
; PRIOR APPLICATION NUMBER: PA 1998 01016
; PRIOR FILING DATE: 1998-07-01
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 20
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Primer
US-09-752-110A-20

Query Match      0.4%; Score 14.4; DB 1; Length 20;
Best Local Similarity 93.8%; Pred. No. 8.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3781 ACACCTGGTGTCTAAC 3796
DB 16 ACACCTGGTGTCTGAC 1

RESULT 1233
US-09-755-004-10/c
; Sequence 10, Application US/09755004
; Patent No. US20020110810A1
; GENERAL INFORMATION:
; APPLICANT: Shuber, Anthony
; TITLE OF INVENTION: Methods for Detecting, Grading or Monitoring an H. pylori Infection
; FILE REFERENCE: EXT-048
; CURRENT APPLICATION NUMBER: US/09/755,004
; CURRENT FILING DATE: 2001-01-05
; NUMBER OF SEQ ID NOS: 11
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 10
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: APC forward primer
US-09-755-004-10

Query Match      0.4%; Score 14.4; DB 1; Length 20;
Best Local Similarity 93.8%; Pred. No. 8.5e+02;

```


Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 856 GAGGAGCTGGTGGAGG 871
 |||||
 Db 18 GAGGAGTGGTGGAGG 3

RESULT 1234

US-09-969-373-3262/c
 ; Sequence 362, Application US/09969373
 ; Patent No. US20020133852A1
 ; GENERAL INFORMATION:

; APPLICANT: Effertz, Roger J.
 ; APPLICANT: Hauge, Brian M.
 ; TITLE OF INVENTION: Soybean SSRs and Methods of Genotyping
 ; FILE REFERENCE: 38-10(52679)A
 ; CURRENT APPLICATION NUMBER: US/09/969,373

; CURRENT FILING DATE: 2001-10-02
 ; PRIOR APPLICATION NUMBER: US 09/754,853
 ; PRIOR FILING DATE: 2001-01-05
 ; PRIOR APPLICATION NUMBER: US 09/760,427
 ; PRIOR FILING DATE: 2001-01-13
 ; PRIOR APPLICATION NUMBER: US 09/855,768
 ; PRIOR FILING DATE: 2001-05-15
 ; NUMBER OF SEQ ID NOS: 4593
 ; SEQ ID NO 3262
 ; LENGTH: 20
 ; TYPE: DNA
 ; ORGANISM: Glycine max

US-09-969-373-3262

Query Match 0.4%; Score 14.4; DB 1; Length 20;
 Best Local Similarity 93.8%; Pred. No. 8.5e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2338 TGTGTGTGTGTGTGCA 2353
 |||||
 Db 20 TGTGTGTGTGTGTGAA 5

RESULT 1235

US-09-774-809-17
 ; Sequence 17, Application US/09774809
 ; Publication No. US20030004120A1
 ; GENERAL INFORMATION:

; APPLICANT: McKay, Robert A.
 ; APPLICANT: Dean, Nicholas M.
 ; APPLICANT: Monia, Brett
 ; APPLICANT: Nero, Pam
 ; APPLICANT: Gaarde, William A.
 ; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS AND METHODS
 ; FILE REFERENCE: ISPH-0412
 ; CURRENT APPLICATION NUMBER: US/09/774,809
 ; CURRENT FILING DATE: 2001-01-31
 ; PRIOR APPLICATION NUMBER: 09/396,902
 ; PRIOR FILING DATE: 1999-09-15
 ; PRIOR APPLICATION NUMBER: 09/130,616
 ; PRIOR FILING DATE: 1998-08-07
 ; PRIOR APPLICATION NUMBER: 08/910,629
 ; PRIOR FILING DATE: 1997-08-03
 ; NUMBER OF SEQ ID NOS: 165
 ; SEQ ID NO 17
 ; LENGTH: 20
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Synthetic Sequence

US-09-774-809-17

Query Match 0.4%; Score 14.4; DB 1; Length 20;
 Best Local Similarity 93.8%; Pred. No. 8.5e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1060 GCGTCCATGAGCTCCA 1075
 |||||
 Db 5 GCATCCATGAGCTCCA 20

RESULT 1236

US-09-232-785-389/c
 ; Sequence 389, Application US/09232785
 ; Publication No. US20030049612A1
 ; GENERAL INFORMATION:

; APPLICANT: International Paper Co.
 ; APPLICANT: Echt, Craig S.
 ; APPLICANT: Nelson, C. Dana
 ; TITLE OF INVENTION: MICROSATELLITE DNA MARKERS AND USES
 ; FILE REFERENCE: 4481/1E188US1
 ; CURRENT APPLICATION NUMBER: US/09/232,785

; CURRENT FILING DATE: 1999-01-19
 ; PRIOR APPLICATION NUMBER: 09/232,884
 ; PRIOR FILING DATE: 1999-01-15
 ; NUMBER OF SEQ ID NOS: 397
 ; SOFTWARE: Fast-Seq for Windows Version 3.0
 ; SEQ ID NO 389
 ; LENGTH: 20
 ; TYPE: DNA
 ; ORGANISM: Pinus taeda L.
 ; ORGANISM: Pinus taeda L.

US-09-232-785-389

Query Match 0.4%; Score 14.4; DB 1; Length 20;
 Best Local Similarity 93.8%; Pred. No. 8.5e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1364 AGATGATCGGAAACA 1379
 |||||
 Db 16 AGAGATCGGAAACA 1

RESULT 1237

US-09-920-671-14
 ; Sequence 14, Application US/09920671
 ; Publication No. US20030083283A1
 ; GENERAL INFORMATION:

; APPLICANT: C. Frank Bennett
 ; APPLICANT: Susan M. Freier
 ; TITLE OF INVENTION: ANTISENSE MODULATION OF COREST EXPRESSION
 ; FILE REFERENCE: RTS-0297
 ; CURRENT APPLICATION NUMBER: US/09/920,671
 ; CURRENT FILING DATE: 2001-08-01
 ; NUMBER OF SEQ ID NOS: 91
 ; SEQ ID NO 14
 ; LENGTH: 20
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Antisense Oligonucleotide

US-09-920-671-14

Query Match 0.4%; Score 14.4; DB 1; Length 20;
 Best Local Similarity 93.8%; Pred. No. 8.5e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1140 CGAGCTCGAGCTGCT 1155
 |||||
 Db 5 CGAGCTCGAGCTGCT 20

RESULT 1238

US-09-967-669-88/c
 ; Sequence 88, Application US/09967669
 ; Publication No. US20030092650A1
 ; GENERAL INFORMATION:

; APPLICANT: C. Frank Bennett

```

; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF SPHINGOSINE-1-PHOSPHATE LYASE EXPRESSION
; FILE REFERENCE: RTS-0259
; CURRENT APPLICATION NUMBER: US/09/967,669
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 88
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-967-669-88

Query Match          0.4%; Score 14.4; DB 1; Length 20;
Best Local Similarity 93.8%; Pred. No. 8.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3007 TGTGTTTAAACTGGA 3022
Db 20 TGTGTTTAACTGGA 5

RESULT 1239
US-10-090-011-38/c
; Sequence 38, Application US/10090011
; Publication No. US20030082810A1
; GENERAL INFORMATION:
; APPLICANT: Serup, Palle
; APPLICANT: Heimberg, Harry
; APPLICANT: Gradwohl, Gerard
; TITLE OF INVENTION: Methods For Generating Insulin-Secreting
; TITLE OF INVENTION: Cells Suitable for Transplantation
; FILE REFERENCE: 6246.200-US
; CURRENT APPLICATION NUMBER: US/10/090,011
; CURRENT FILING DATE: 2002-02-26
; PRIOR APPLICATION NUMBER: US 60/271,474
; PRIOR FILING DATE: 2001-02-26
; NUMBER OF SEQ ID NOS: 70
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 38
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-090-011-38

Query Match          0.4%; Score 14.4; DB 1; Length 20;
Best Local Similarity 93.8%; Pred. No. 8.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1281 TGTACCGTAGCCGTG 1296
Db 17 TGTACCGTAGCCGTG 2

RESULT 1240
US-10-282-174-363/c
; Sequence 363, Application US/10282174
; Publication No. US20030224380A1
; GENERAL INFORMATION:
; APPLICANT: Becker, Kenneth David
; APPLICANT: Velicelebi, Gonul
; APPLICANT: Elliot, Kathryn J.
; APPLICANT: Wang, Xin
; APPLICANT: Tanzi, Rudolph E.
; APPLICANT: Bertram, Lars
; APPLICANT: Saunders, Aleister J.
; APPLICANT: Mullin, Kristina M.
; APPLICANT: Sampson, Andrew Johnson
; APPLICANT: Blacker, Deborah Lynne
; TITLE OF INVENTION: GENES AND POLYMORPHISMS ON CHROMOSOME 10
; TITLE OF INVENTION: ASSOCIATED WITH ALZHEIMER'S DISEASE AND OTHER
; TITLE OF INVENTION: NEURODEGENERATIVE DISEASES

```

```

; FILE REFERENCE: 37481-3308
; CURRENT APPLICATION NUMBER: US/10/282,174
; CURRENT FILING DATE: 2002-10-25
; PRIOR APPLICATION NUMBER: US 60/339,525
; PRIOR FILING DATE: 2001-10-25
; PRIOR APPLICATION NUMBER: US 60/338,010
; PRIOR FILING DATE: 2001-11-08
; PRIOR APPLICATION NUMBER: US 60/336,929
; PRIOR FILING DATE: 2001-11-08
; PRIOR APPLICATION NUMBER: US 60/338,363
; PRIOR FILING DATE: 2001-11-09
; PRIOR APPLICATION NUMBER: US 60/337,052
; PRIOR FILING DATE: 2001-12-04
; PRIOR APPLICATION NUMBER: US 60/368,919
; PRIOR FILING DATE: 2002-03-28
; NUMBER OF SEQ ID NOS: 564
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 363
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-10-282-174-363

Query Match          0.4%; Score 14.4; DB 1; Length 20;
Best Local Similarity 93.8%; Pred. No. 8.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2214 ACAATGTGAGGGTCC 2229
Db 19 ACAATGTGAGGGTCC 4

RESULT 1241
US-10-374-932-12
; Sequence 12, Application US/10374932
; Publication No. US20030235586A1
; GENERAL INFORMATION:
; APPLICANT: van de Winkel, Jan G.J.
; APPLICANT: van Dijk, Marcus Antonius
; APPLICANT: Schuurman, Janine
; APPLICANT: Gerritsen, Arnout F.
; APPLICANT: Baadsgaard, Ole
; APPLICANT: Petersen, Jorgen
; TITLE OF INVENTION: HUMAN ANTIBODIES SPECIFIC FOR INTERLEUKIN 15 (IL-15)
; FILE REFERENCE: GMI-024CP
; CURRENT APPLICATION NUMBER: US/10/374,932
; CURRENT FILING DATE: 2003-02-26
; PRIOR APPLICATION NUMBER: US 60/314,731
; PRIOR FILING DATE: 2001-08-23
; PRIOR APPLICATION NUMBER: US 10/226615
; PRIOR FILING DATE: 2002-08-23
; NUMBER OF SEQ ID NOS: 31
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 12
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-374-932-12

Query Match          0.4%; Score 14.4; DB 1; Length 20;
Best Local Similarity 75.0%; Pred. No. 8.5e+02;
Matches 15; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

Qy 853 GAGGAGGAGCTGTGGAGGC 872
Db 1 SAGGTGCAGCTGTGGAGTC 20

RESULT 1242
US-10-345-444B-17
; Sequence 17, Application US/10345444B

```

Publication No. US20040029823A1
; GENERAL INFORMATION:
; APPLICANT: McKay, Robert A.
; APPLICANT: Dean, Nicholas M.
; APPLICANT: Monia, Brett
; APPLICANT: Nero, Pam
; APPLICANT: Garde, William A.
; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THE MODULATION OF JNK PROTEINS
; FILE REFERENCE: ISPH-0726
; CURRENT APPLICATION NUMBER: US/10/345,444B
; PRIOR FILING DATE: 2003-01-15
; PRIOR APPLICATION NUMBER: US 09/774,809
; PRIOR FILING DATE: 2001-01-31
; PRIOR APPLICATION NUMBER: US 09/396,902
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: US 09/287,796
; PRIOR FILING DATE: 1999-04-07
; PRIOR APPLICATION NUMBER: US 09/130,616
; PRIOR FILING DATE: 1998-08-07
; PRIOR APPLICATION NUMBER: US 08/910,629
; PRIOR FILING DATE: 1997-08-03
; NUMBER OF SEQ ID NOS: 168
; SEQ ID NO 17
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-10-345-444B-17

Query Match 0.4%; Score 14.4; DB 1; Length 20;
Best Local Similarity 93.8%; Pred. No. 8.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1060 GCGTCATGAGCTCCA 1075
||| ||||| ||||| |||||
Db 5 GCATCCATGAGCTCCA 20

RESULT 1243
US-10-264-958B-18
; Sequence 18, Application US/10264958B
; Publication No. US20040038224A1
; GENERAL INFORMATION:
; APPLICANT: Hoffman, Hal
; APPLICANT: Kolodner, Richard
; TITLE OF INVENTION: Isolated Cryopyrins, Nucleic Acid Molecules Encoding These, and Methods of Use
; FILE REFERENCE: LUD 5738.1 CIP (10209575)
; CURRENT APPLICATION NUMBER: US/10/264,958B
; CURRENT FILING DATE: 2002-10-04
; PRIOR APPLICATION NUMBER: US60/327,728
; PRIOR FILING DATE: 2001-10-05
; NUMBER OF SEQ ID NOS: 31
; SEQ ID NO 18
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-10-264-958B-18

Query Match 0.4%; Score 14.4; DB 1; Length 20;
Best Local Similarity 93.8%; Pred. No. 8.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2303 CACAGAGCTTTGGTCT 2318
||| ||||| ||||| |||||
Db 2 CACAGAGCTTTGGTCT 17

RESULT 1244
US-10-380-124-65/c

; Sequence 65, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Preier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RYS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 65
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-65

Query Match 0.4%; Score 14.4; DB 1; Length 20;
Best Local Similarity 93.8%; Pred. No. 8.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2407 CTGGGTGTCCCGCTG 2422
||| ||||| ||||| |||||
Db 20 CTGGGTGTCCCGCTG 5

RESULT 1245
US-10-425-037-1
; Sequence 1, Application US/10425037
; Publication No. US20040054162A1
; GENERAL INFORMATION:
; APPLICANT: Hanna, Michelle M.
; TITLE OF INVENTION: Molecular Detection Systems Utilizing Reiterative Oligonucleotide
; FILE REFERENCE: 2072.0010005
; CURRENT APPLICATION NUMBER: US/10/425,037
; CURRENT FILING DATE: 2003-04-29
; PRIOR APPLICATION NUMBER: PCT/US02/34419
; PRIOR FILING DATE: 2002-10-29
; PRIOR APPLICATION NUMBER: US 09/984,664
; PRIOR FILING DATE: 2001-10-30
; NUMBER OF SEQ ID NOS: 3
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 1
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Pl6DF2 Primer
US-10-425-037-1

Query Match 0.4%; Score 14.4; DB 1; Length 20;
Best Local Similarity 93.8%; Pred. No. 8.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1209 TGGGAGGGCTGCTTC 1224
||| ||||| ||||| |||||
Db 5 TGGGAGGGCTGCTTC 20

RESULT 1246
US-10-379-741-12
; Sequence 12, Application US/10379741
; Publication No. US20040071702A1
; GENERAL INFORMATION:
; APPLICANT: van de Winkel, Jan G.J.
; APPLICANT: van Dijk, Marcus Antonius
; APPLICANT: Schuurman, Janine
; APPLICANT: Gerritsen, Arnout F.
; APPLICANT: Baadsgaard, Ole
; APPLICANT: Petersen, Jorgen
US-10-379-741-12

```
; TITLE OF INVENTION: HUMAN ANTIBODIES SPECIFIC FOR INTERLEUKIN 15 (IL-15)
; FILE REFERENCE: GMI-024CP2
; CURRENT APPLICATION NUMBER: US/10/379,741
; CURRENT FILING DATE: 2003-03-05
; PRIOR APPLICATION NUMBER: US 60/314,731
; PRIOR FILING DATE: 2001-08-23
; PRIOR APPLICATION NUMBER: US 10/226615
; PRIOR FILING DATE: 2002-08-23
; NUMBER OF SEQ ID NOS: 31
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 12
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-379-741-12

Query Match          0.4%; Score 14.4; DB 1; Length 20;
Best Local Similarity 75.0%; Pred. No. 8.5e+02;
Matches 15; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

Qy      853 GAGGAGGAGCTGGTGAGGC 872
         :||| | ||||| ||||| |
Db      1 SAGGTGCAGCTGKTGGATC 20

RESULT 1247
US-10-303-266-54/c
; Sequence 54, Application US/10303266
; Publication No. US20040101848A1
; GENERAL INFORMATION:
; APPLICANT: Donna T. Ward
; APPLICANT: Alexander H. Borchers
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF GLUCOSE TRANSPORTER-4 EXPRESSION
; FILE REFERENCE: RTS-0426
; CURRENT APPLICATION NUMBER: US/10/303,266
; CURRENT FILING DATE: 2002-11-23
; NUMBER OF SEQ ID NOS: 157
; SEQ ID NO 54
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-303-266-54

Query Match          0.4%; Score 14.4; DB 1; Length 20;
Best Local Similarity 93.8%; Pred. No. 8.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      2107 CCCAGCTCCAGCTCCT 2122
         ||| ||||| ||||| |||
Db      18 CCCTGCTCCAGCTCCT 3

RESULT 1248
US-10-303-266-130
; Sequence 130, Application US/10303266
; Publication No. US20040101848A1
; GENERAL INFORMATION:
; APPLICANT: Donna T. Ward
; APPLICANT: Alexander H. Borchers
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF GLUCOSE TRANSPORTER-4 EXPRESSION
; FILE REFERENCE: RTS-0426
; CURRENT APPLICATION NUMBER: US/10/303,266
; CURRENT FILING DATE: 2002-11-23
; NUMBER OF SEQ ID NOS: 157
; SEQ ID NO 130
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
```

US-10-303-266-130

```
Query Match          0.4%; Score 14.4; DB 1; Length 20;
Best Local Similarity 93.8%; Pred. No. 8.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      2107 CCCAGCTCCAGCTCCT 2122
         ||| ||||| ||||| |||
Db      3 CCCTGCTCCAGCTCCT 18
```

RESULT 1249

```
US-10-316-243-82
; Sequence 82, Application US/10316243
; Publication No. US20040110147A1
; GENERAL INFORMATION:
; APPLICANT: Kenneth W. Dobie
; APPLICANT: Ravi Jain
; TITLE OF INVENTION: MODULATION OF BAF53 EXPRESSION
; FILE REFERENCE: RTS-0462
; CURRENT APPLICATION NUMBER: US/10/316,243
; CURRENT FILING DATE: 2002-12-09
; NUMBER OF SEQ ID NOS: 168
; SEQ ID NO 82
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-316-243-82
```

```
Query Match          0.4%; Score 14.4; DB 1; Length 20;
Best Local Similarity 93.8%; Pred. No. 8.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      3069 CCACACCCCAACACTT 3084
         ||||| ||||| ||||| |||
Db      4 CCACATCCCAACACTT 19
```

RESULT 1250

```
US-10-316-243-155/c
; Sequence 155, Application US/10316243
; Publication No. US20040110147A1
; GENERAL INFORMATION:
; APPLICANT: Kenneth W. Dobie
; APPLICANT: Ravi Jain
; TITLE OF INVENTION: MODULATION OF BAF53 EXPRESSION
; FILE REFERENCE: RTS-0462
; CURRENT APPLICATION NUMBER: US/10/316,243
; CURRENT FILING DATE: 2002-12-09
; NUMBER OF SEQ ID NOS: 168
; SEQ ID NO 155
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-316-243-155
```

```
Query Match          0.4%; Score 14.4; DB 1; Length 20;
Best Local Similarity 93.8%; Pred. No. 8.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      3069 CCACACCCCAACACTT 3084
         ||||| ||||| ||||| |||
Db      17 CCACATCCCAACACTT 2
```

RESULT 1251

```
US-10-317-279-22/c
; Sequence 22, Application US/10317279
; Publication No. US20040110703A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Ming-Yi Chiang
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DR1-ASSOCIATED PROTEIN 1 EXPRESSION
; FILE REFERENCE: HTS-0027
; CURRENT APPLICATION NUMBER: US/10/317,279
; CURRENT FILING DATE: 2002-12-10
; NUMBER OF SEQ ID NOS: 59
; SEQ ID NO 22
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-317-279-22

Query Match
Best Local Similarity 0.4%; Score 14.4; DB 1; Length 20;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1545 CTTCAAGGACCTGGTG 1560
Db 16 CTTGAAGGACCTGGTG 1

RESULT 1252
US-10-317-279-51
; Sequence 51, Application US/10317279
; Publication No. US20040110703A1
; GENERAL INFORMATION:
; APPLICANT: Ming-Yi Chiang
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DR1-ASSOCIATED PROTEIN 1 EXPRESSION
; FILE REFERENCE: HTS-0027
; CURRENT APPLICATION NUMBER: US/10/317,279
; CURRENT FILING DATE: 2002-12-10
; NUMBER OF SEQ ID NOS: 59
; SEQ ID NO 51
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-317-279-51

Query Match
Best Local Similarity 0.4%; Score 14.4; DB 1; Length 20;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1545 CTTCAAGGACCTGGTG 1560
Db 5 CTTGAAGGACCTGGTG 20

RESULT 1253
US-10-317-803-116/c
; Sequence 116, Application US/10317803
; Publication No. US20040115640A1
; GENERAL INFORMATION:
; APPLICANT: Kathleen Myers
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF ANGIOPOIETIN-2 EXPRESSION
; FILE REFERENCE: HTS-0454
; CURRENT APPLICATION NUMBER: US/10/317,803
; CURRENT FILING DATE: 2002-12-11
; NUMBER OF SEQ ID NOS: 244
; SEQ ID NO 116
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-317-803-116

Query Match
0.4%; Score 14.4; DB 1; Length 20;
```

```
Best Local Similarity 93.8%; Pred. No. 8.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 53 GGCTGCAGGTGCTGAA 68
Db 18 GGCTGCAGGTGCTGGA 3

RESULT 1254
US-10-671-395-1086/c
; Sequence 1086, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1086
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1086

Query Match
Best Local Similarity 0.4%; Score 14.4; DB 1; Length 20;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2316 TCTGTGTGTGTGTGTG 2331
Db 16 TCCGTGTGTGTGTGTG 1

RESULT 1255
US-10-687-799-34
; Sequence 34, Application US/10687799
; Publication No. US20040167319A1
; GENERAL INFORMATION:
; APPLICANT: Teeling, Jessica
; APPLICANT: Ruuls, Sigrd
; APPLICANT: Glennie, Martin
; APPLICANT: van de Winkel, Jan
; APPLICANT: Parren, Paul
; APPLICANT: Petersen, Jorgen
; APPLICANT: Baadsgaard, Ole
; APPLICANT: Huang, Haichun
; TITLE OF INVENTION: HUMAN MONOCLONAL ANTIBODIES AGAINST CD20
; FILE REFERENCE: GMI-055
; CURRENT APPLICATION NUMBER: US/10/687,799
; CURRENT FILING DATE: 2003-10-17
; PRIOR APPLICATION NUMBER: US 60/419,163
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: US 60/460,028
; PRIOR FILING DATE: 2002-04-02
; NUMBER OF SEQ ID NOS: 57
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 34
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: primer
US-10-687-799-34

Query Match
0.4%; Score 14.4; DB 1; Length 20;
```

Best Local Similarity 75.0%; Pred. No. 8.5e+02;
Matches 15; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 853 CAGGAGGAGCTGGTGGAGGC 872
:|||||:|||||:|||||
DB 1 SAGGTGCAGCTGKTGGAGTC 20

RESULT 1256
US-10-781-142-51
; Sequence 51, Application US/10781142
; Publication No. US20040192630A1
; GENERAL INFORMATION:
; APPLICANT: Kyrkanides, Stephanos
; TITLE OF INVENTION: VECTORS HAVING BOTH ISOFORMS OF
; TITLE OF INVENTION: BETA-HEXOSAMINIDASE AND USES OF THE SAME
; FILE REFERENCE: 21108.004001
; CURRENT APPLICATION NUMBER: US/10/781.142
; CURRENT FILING DATE: 2004-02-18
; PRIOR APPLICATION NUMBER: PCT/US03/13672
; PRIOR FILING DATE: 2003-05-03
; PRIOR APPLICATION NUMBER: 60/377,503
; PRIOR FILING DATE: 2002-05-02
; NUMBER OF SEQ ID NOS: 71
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 51
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence; note =
; OTHER INFORMATION: synthetic construct
US-10-781-142-51

Query Match 0.4%; Score 14.4; DB 1; Length 20;
Best Local Similarity 93.8%; Pred. No. 8.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 288 CGTCGCGCTCCGCTGC 303
|||||:|||||:|||||
DB 5 CGTCGCGCTCCGCTAC 20

RESULT 1257
US-10-085-906-78
; Sequence 78, Application US/10085906
; Publication No. US20030054371A1
; GENERAL INFORMATION:
; APPLICANT: Ying, Vincent
; APPLICANT: Wu, Paul
; APPLICANT: Gray, Gary S.
; TITLE OF INVENTION: POLYMORPHIC ELEMENTS IN THE
; TITLE OF INVENTION: COSTIMULATORY RECEPTOR LOCUS AND USES THEREOF
; FILE REFERENCE: GNN-5343CP2
; CURRENT APPLICATION NUMBER: US/10/085,906
; CURRENT FILING DATE: 2002-02-27
; PRIOR APPLICATION NUMBER: US 60/126,215
; PRIOR FILING DATE: 1999-03-25
; PRIOR APPLICATION NUMBER: US 09/534,061
; PRIOR FILING DATE: 2000-03-24
; PRIOR APPLICATION NUMBER: PCT/US00/07938
; PRIOR FILING DATE: 2000-03-24
; NUMBER OF SEQ ID NOS: 545
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 78
; LENGTH: 27
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-085-906-78

Query Match 0.4%; Score 14.4; DB 1; Length 27;
Best Local Similarity 75.0%; Pred. No. 1.1e+03;
Matches 18; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 3310 TTTTCTTTAGGAGATTATTTT 3333
|||||:|||||:|||||
DB 4 TTTTATTTTATTTTATTTT 27

RESULT 1258
US-10-085-906-147
; Sequence 147, Application US/10085906
; Publication No. US20030054371A1
; GENERAL INFORMATION:
; APPLICANT: Ying, Vincent
; APPLICANT: Wu, Paul
; APPLICANT: Gray, Gary S.
; TITLE OF INVENTION: POLYMORPHIC ELEMENTS IN THE
; TITLE OF INVENTION: COSTIMULATORY RECEPTOR LOCUS AND USES THEREOF
; FILE REFERENCE: GNN-5343CP2
; CURRENT APPLICATION NUMBER: US/10/085,906
; CURRENT FILING DATE: 2002-02-27
; PRIOR APPLICATION NUMBER: US 60/126,215
; PRIOR FILING DATE: 1999-03-25
; PRIOR APPLICATION NUMBER: US 09/534,061
; PRIOR FILING DATE: 2000-03-24
; PRIOR APPLICATION NUMBER: PCT/US00/07938
; PRIOR FILING DATE: 2000-03-24
; NUMBER OF SEQ ID NOS: 545
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 147
; LENGTH: 28
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-085-906-147

Query Match 0.4%; Score 14.4; DB 1; Length 28;
Best Local Similarity 75.0%; Pred. No. 1.2e+03;
Matches 18; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 2824 ATATATACATATATATATAACA 2847
|||||:|||||:|||||
DB 5 ATAATAATAATAATAAAAAA 28

RESULT 1259
US-09-725-265-11
; Sequence 11, Application US/09725265
; Publication No. US20010000175A1
; GENERAL INFORMATION:
; APPLICANT: KURANE, RYUICHIRO
; APPLICANT: KANAGAWA, TAKAHIRO
; APPLICANT: KANAGATA, YOICHI
; APPLICANT: YAMADA, KAZUTAKA
; APPLICANT: YOKOMAKU, TOYOKAZU
; APPLICANT: KOBAYASHI, OSAMU
; APPLICANT: FURUSHO, KENTA
; TITLE OF INVENTION: METHOD FOR DETERMINING A CONCENTRATION OF TARGET NUCLEIC ACID MOL
; TITLE OF INVENTION: NUCLEIC ACID PROBES FOR THE METHOD, AND METHOD FOR ANALYZING DAT
; TITLE OF INVENTION: THE METHOD
; FILE REFERENCE: 199953USOXDIV
; CURRENT APPLICATION NUMBER: US/09/725,265
; CURRENT FILING DATE: 2000-11-29
; PRIOR APPLICATION NUMBER: US 09/556,127
; PRIOR FILING DATE: 2000-04-20
; PRIOR APPLICATION NUMBER: JP 1999-111601
; PRIOR FILING DATE: 1999-04-20
; NUMBER OF SEQ ID NOS: 70
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 11
; LENGTH: 30
; TYPE: DNA
; ORGANISM: ARTIFICIAL SEQUENCE
; FEATURE:
; OTHER INFORMATION: SYNTHETIC DNA
US-09-725-265-11

```
Query Match      0.4%; Score 14.4; DB 1; Length 30;
Best Local Similarity 75.0%; Pred. No. 1.2e+03;
Matches 18; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

Qy 3474 ATATATATAATTATTGAGTTTTT 3497
||||| ||| ||| ||| |||
Db 1 ATATATATTTTTTTTTTCTTTTTT 24

RESULT 1260
US-09-891-517-11
; Sequence 11, Application US/09891517
; Patent No. US20020106653A1
; GENERAL INFORMATION:
; APPLICANT: KURANE, RYUICHIRO
; APPLICANT: KANAGAWA, TAKAHIRO
; APPLICANT: KANAGATA, YOICHI
; APPLICANT: TORIMURA, MASAKI
; APPLICANT: KURATA, SHINYA
; APPLICANT: YAMADA, KAZUTAKA
; APPLICANT: YOKOMAKU, TOYOKAZU
; TITLE OF INVENTION: NOVEL NUCLEIC ACID PROBES, METHOD FOR DETERMINING CONCENTRATIONS
; TITLE OF INVENTION: NUCLEIC ACID BY USING THE PROBES, AND METHOD FOR ANALYZING DATA
; TITLE OF INVENTION: METHOD
; FILE REFERENCE: 210352US-1994-163-0-X
; CURRENT APPLICATION NUMBER: US/09/891,517
; CURRENT FILING DATE: 2001-06-27
; PRIOR APPLICATION NUMBER: JP2000-193133
; PRIOR FILING DATE: 2000-06-27
; PRIOR APPLICATION NUMBER: JP2000-236115
; PRIOR FILING DATE: 2000-08-03
; PRIOR APPLICATION NUMBER: JP2000-292483
; PRIOR FILING DATE: 2000-09-26
; NUMBER OF SEQ ID NOS: 108
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 11
; LENGTH: 30
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic DNA
US-09-891-517-11

Query Match      0.4%; Score 14.4; DB 1; Length 30;
Best Local Similarity 75.0%; Pred. No. 1.2e+03;
Matches 18; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Qy 3474 ATATATATAATTATTGAGTTTTT 3497
||||| ||| ||| ||| |||
Db 1 ATATATATTTTTTTTTTCTTTTTT 24

RESULT 1261
US-10-209-608-11
; Sequence 11, Application US/10209608
; Publication No. US20030082592A1
; GENERAL INFORMATION:
; APPLICANT: KURANE, RYUICHIRO
; APPLICANT: KANAGAWA, TAKAHIRO
; APPLICANT: KANAGATA, YOICHI
; APPLICANT: YAMADA, KAZUTAKA
; APPLICANT: YOKOMAKU, TOYOKAZU
; APPLICANT: KOYAMA, OSAMU
; APPLICANT: FURUSHO, KENTA
; TITLE OF INVENTION: METHOD FOR DETERMINING A CONCENTRATION OF TARGET NUCLEIC ACID MO
; TITLE OF INVENTION: NUCLEIC ACID PROBES FOR THE METHOD, AND METHOD FOR ANALYZING DAT
; TITLE OF INVENTION: THE METHOD
; FILE REFERENCE: 199953USOXDIV
; CURRENT APPLICATION NUMBER: US/10/209,608
; CURRENT FILING DATE: 2002-08-01
; PRIOR APPLICATION NUMBER: US/09/725,265
; PRIOR FILING DATE: 2000-11-29
```

```
; PRIOR APPLICATION NUMBER: US 09/556,127
; PRIOR FILING DATE: 2000-04-20
; PRIOR APPLICATION NUMBER: JP 1999-111601
; PRIOR FILING DATE: 1999-04-20
; NUMBER OF SEQ ID NOS: 70
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 11
; LENGTH: 30
; TYPE: DNA
; ORGANISM: ARTIFICIAL SEQUENCE
; FEATURE:
; OTHER INFORMATION: SYNTHETIC DNA
US-10-209-608-11

Query Match      0.4%; Score 14.4; DB 1; Length 30;
Best Local Similarity 75.0%; Pred. No. 1.2e+03;
Matches 18; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

Qy 3474 ATATATATAATTATTGAGTTTTT 3497
||||| ||| ||| ||| |||
Db 1 ATATATATTTTTTTTTTCTTTTTT 24

RESULT 1262
US-10-683-386-11
; Sequence 11, Application US/10683386
; Publication No. US20040063137A1
; GENERAL INFORMATION:
; APPLICANT: KURANE, RYUICHIRO
; APPLICANT: KANAGAWA, TAKAHIRO
; APPLICANT: KANAGATA, YOICHI
; APPLICANT: YAMADA, KAZUTAKA
; APPLICANT: YOKOMAKU, TOYOKAZU
; APPLICANT: KOYAMA, OSAMU
; APPLICANT: FURUSHO, KENTA
; TITLE OF INVENTION: METHOD FOR DETERMINING A CONCENTRATION OF TARGET NUCLEIC ACID MO
; TITLE OF INVENTION: NUCLEIC ACID PROBES FOR THE METHOD, AND METHOD FOR ANALYZING DAT
; TITLE OF INVENTION: THE METHOD
; FILE REFERENCE: 0163-0758-0X
; CURRENT APPLICATION NUMBER: US/10/683,386
; CURRENT FILING DATE: 2000-04-20
; PRIOR APPLICATION NUMBER: US/09/556,127
; PRIOR FILING DATE: 2000-04-20
; PRIOR APPLICATION NUMBER: JP 1999-111601
; PRIOR FILING DATE: 1999-04-20
; NUMBER OF SEQ ID NOS: 70
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 11
; LENGTH: 30
; TYPE: DNA
; ORGANISM: ARTIFICIAL SEQUENCE
; FEATURE:
; OTHER INFORMATION: SYNTHETIC DNA
US-10-683-386-11

Query Match      0.4%; Score 14.4; DB 1; Length 30;
Best Local Similarity 75.0%; Pred. No. 1.2e+03;
Matches 18; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

Qy 3474 ATATATATAATTATTGAGTTTTT 3497
||||| ||| ||| ||| |||
Db 1 ATATATATTTTTTTTTTCTTTTTT 24

RESULT 1263
US-10-306-630-2/c
; Sequence 2, Application US/10306630
; Publication No. US20030143604A1
; GENERAL INFORMATION:
; APPLICANT: Storhoff, James
; APPLICANT: Fritzz, Brett
; APPLICANT: Herrmann, Mark
; TITLE OF INVENTION: Real-Time Monitoring of PCR Amplification Using Nanoparticle Prob
```



```
;
;
; ZIP: 98104-7092
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/263,959
; FILING DATE: 05-MAR-1999
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: McMaisters, David D.
; REGISTRATION NUMBER: 33,963
; REFERENCE/DOCKET NUMBER: 920010.426C2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 682-6031
; INFORMATION FOR SEQ ID NO: 923:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-263-959-923

Query Match      0.4%; Score 14.2; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      2924 GGGGCGTGGGGGGGGTGG 2942
      ||||| ||||| ||||| |||||
Db      1 GGGGCGGGGAGGGGGGGG 19

RESULT 1268
US-09-860-784-18
; Sequence 18, Application US/09860784
; Patent No. US200201512A1
; GENERAL INFORMATION:
; APPLICANT: PEYMAN, Anushirvan
; TITLE OF INVENTION: G CAP-STABILIZED OLIGONUCLEOTIDES
; NUMBER OF SEQUENCES: 105
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Foley & Lardner
; STREET: 3000 K Street, N.W., Suite 500
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20007-5109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/860,784
; FILING DATE: 21-May-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/594,452
; FILING DATE: 04-APR-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: SANDERCOCK, Colin G.
; REGISTRATION NUMBER: 31,298
; REFERENCE/DOCKET NUMBER: 18748/264/HOCE
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 672-5300
; TELEFAX: (202) 672-5399
; TELEX: 904136
; INFORMATION FOR SEQ ID NO: 18:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-860-784-18

Query Match      0.4%; Score 14.2; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      184 GGGGAGGAGGAGGCTGAGG 202
      ||||| ||||| ||||| |||||
Db      1 GGGAGGAGGAGGATGAGG 19

RESULT 1270
US-09-835-370-19
; Sequence 19, Application US/09835370
; Publication No. US20030022172A1
; GENERAL INFORMATION:
; APPLICANT: UHLMANN, EUGEN
; APPLICANT: BREIPOHL, GERHARD
; APPLICANT: WILL, DAVID W
; TITLE OF INVENTION: POLYAMIDE NUCLEIC ACID DERIVATIVES AND AGENTS AND
; TITLE OF INVENTION: PROCESSES FOR PREPARING THEM
; FILE REFERENCE: 02481.1742 SEQUENCE LISTING
; CURRENT APPLICATION NUMBER: US/09/835,370
; CURRENT FILING DATE: 2001-04-17
; NUMBER OF SEQ ID NOS: 64
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 19
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: base sequence
; OTHER INFORMATION: of PNA targeting CMV
; US-09-835-371-19

Query Match      0.4%; Score 14.2; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      184 GGGGAGGAGGAGGCTGAGG 202
      ||||| ||||| ||||| |||||
Db      1 GGGAGGAGGAGGATGAGG 19

RESULT 1270
US-09-835-370-19
; Sequence 19, Application US/09835370
; Publication No. US20030022172A1
; GENERAL INFORMATION:
; APPLICANT: UHLMANN, EUGEN
; APPLICANT: BREIPOHL, GERHARD
; APPLICANT: WILL, DAVID W
; TITLE OF INVENTION: POLYAMIDE NUCLEIC ACID DERIVATIVES AND AGENTS AND
; TITLE OF INVENTION: PROCESSES FOR PREPARING THEM
; FILE REFERENCE: 02481.1742 SEQUENCE LISTING
; CURRENT APPLICATION NUMBER: US/09/835,370
; CURRENT FILING DATE: 2001-04-17
; NUMBER OF SEQ ID NOS: 64
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 19
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: nucleotide
; OTHER INFORMATION: base sequence of PNA derivatives that bind to
; OTHER INFORMATION: viral and cellular targets
; US-09-835-370-19
```

Query Match 0.4%; Score 14.2; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 184 GGGGAGGACGAGGCTGAGG 202
||| ||||| ||||| |||||
Db 1 GGGGAGGAGGAGGATGAGG 19

RESULT 1271

US-09-880-313A-47
; Sequence 47, Application US/09880313A
; Publication No. US20030044791A1
; GENERAL INFORMATION:
; APPLICANT: Flenington, Erik K
; TITLE OF INVENTION: Adaptors and Methods of Use
; FILE REFERENCE: 9397/1000
; CURRENT APPLICATION NUMBER: US/09/880.313A
; CURRENT FILING DATE: 2001-06-13
; NUMBER OF SEQ ID NOS: 276
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 47
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-09-880-313A-47

Query Match 0.4%; Score 14.2; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 3200 AGCTGGAGGATCCCTCCA 3218
||| | ||||| ||||| |||||
Db 1 AGCTTGGGATCCCTCGCA 19

RESULT 1272

US-09-864-636A-1955
; Sequence 1955, Application US/09864636A
; Publication No. US20030104378A1
; GENERAL INFORMATION:
; APPLICANT: Third Wave Technologies
; APPLICANT: Allwai Hatim
; APPLICANT: Bartholomay, Christian
; APPLICANT: Cherak, LuAnne
; TITLE OF INVENTION: Detection of RNA Sequences
; FILE REFERENCE: FORS-04944
; CURRENT APPLICATION NUMBER: US/09/864.636A
; CURRENT FILING DATE: 2002-10-15
; NUMBER OF SEQ ID NOS: 2640
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1955
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-864-636A-1955

Query Match 0.4%; Score 14.2; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2485 GTGCAGAATGTAGTGGGC 2503
||| ||||| ||||| |||||
Db 1 GTGGAGAATGTCA GTGGGC 19

RESULT 1273

US-09-793-146-17
; Sequence 17, Application US/09793146

; Publication No. US20030203359A1
; GENERAL INFORMATION:
; APPLICANT: UHLMANN, EUGEN
; APPLICANT: BREIPOHL, GERHARD
; TITLE OF INVENTION: POLYAMIDE-OLIGONUCLEOTIDE DERIVATIVES, THEIR
; FILE REFERENCE: 02481.1437-02
; CURRENT APPLICATION NUMBER: US/09/793.146
; CURRENT FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: P 44 08 528.1
; PRIOR FILING DATE: 1994-03-14
; PRIOR APPLICATION NUMBER: 08/402,838
; PRIOR FILING DATE: 1995-03-13
; NUMBER OF SEQ ID NOS: 70
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 17
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic PNA
US-09-793-146-17

Query Match 0.4%; Score 14.2; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 184 GGGGAGGACGAGGCTGAGG 202
||| ||||| ||||| |||||
Db 1 GGGGAGGAGGAGGATGAGG 19

RESULT 1274

US-09-864-426A-1955
; Sequence 1955, Application US/09864426A
; Publication No. US20040018489A1
; GENERAL INFORMATION:
; APPLICANT: Third Wave Technologies
; APPLICANT: Ma, Wu Po
; APPLICANT: Lyamichev, Victor
; APPLICANT: Saiser, Michael
; TITLE OF INVENTION: Enzymes for the Detection of RNA Sequences
; FILE REFERENCE: FORS-04946
; CURRENT APPLICATION NUMBER: US/09/864.426A
; CURRENT FILING DATE: 2001-05-24
; NUMBER OF SEQ ID NOS: 2640
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1955
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-864-426A-1955

Query Match 0.4%; Score 14.2; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2485 GTGCAGAATGTAGTGGGC 2503
||| ||||| ||||| |||||
Db 1 GTGGAGAATGTCA GTGGGC 19

RESULT 1275

US-10-005-338B-177/c
; Sequence 177, Application US/10005338B
; Publication No. US20030044895A1
; GENERAL INFORMATION:
; APPLICANT: DENEFFLE, Patrice
; APPLICANT: ROSIER-MONTUS, Marie-Francoise
; APPLICANT: PRADES, Catherine
; APPLICANT: ARNOULD-REGUIGNE, Isabelle

```
; APPLICANT: DUVERGER, Nicolas
; APPLICANT: ALLIKMETS, Rando
; APPLICANT: DEAN, Michael
; TITLE OF INVENTION: NUCLEIC ACIDS OF THE HUMAN ABCA5, ABCA6, ABCA9, AND ABCA10 GENES
; TITLE OF INVENTION: CONTAINING SUCH NUCLEIC ACIDS, AND USES THEREOF
; FILE REFERENCE: ABCA5 6, 9, 10
; CURRENT APPLICATION NUMBER: US/10/005,338B
; CURRENT FILING DATE: 2001-12-07
; PRIOR APPLICATION NUMBER: US 60/263,231
; PRIOR FILING DATE: 2001-01-23
; PRIOR APPLICATION NUMBER: FR 04043440.1
; PRIOR FILING DATE: 2000-12-07
; NUMBER OF SEQ ID NOS: 217
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 177
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-005-338B-177

Query Match      0.4%; Score 14.2; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2485 GTGCAGATGTAAGTGGGC 2503
Db 19 GTGAAGAATCCAAGTGGGC 1
||||| ||||| ||||| |||||

RESULT 1276
US-10-005-956-596/c
; Sequence 596, Application US/10005956
; Publication No. US20030113726A1
; GENERAL INFORMATION:
; APPLICANT: Bristol-Myers Squibb Company
; TITLE OF INVENTION: HUMAN SINGLE NUCLEOTIDE POLYMORPHISMS
; FILE REFERENCE: D0053NP
; CURRENT APPLICATION NUMBER: US/10/005,956
; CURRENT FILING DATE: 2001-12-03
; PRIOR APPLICATION NUMBER: 60/251,015
; PRIOR FILING DATE: 2000-12-04
; PRIOR APPLICATION NUMBER: 60/263,678
; PRIOR FILING DATE: 2001-01-23
; PRIOR APPLICATION NUMBER: 60/273,037
; PRIOR FILING DATE: 2001-03-02
; NUMBER OF SEQ ID NOS: 1579
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 596
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-005-956-596

Query Match      0.4%; Score 14.2; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3466 ATATATCTATATATATAT 3484
Db 19 ATATATTTATATCTATGAT 1
||||| ||||| ||||| |||||

RESULT 1277
US-10-226-992-24/c
; Sequence 24, Application US/10226992
; Publication No. US20030148507A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Fossnaugh, Kathy
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Prostaglandin D2 Receptor
; TITLE OF INVENTION: and Prostaglandin D2 Synthetase (PTGDS) Gene Expression Using SH
; TITLE OF INVENTION: RNA
```

```
; FILE REFERENCE: 400/055 (WBHE01-1110-B)
; CURRENT APPLICATION NUMBER: US/10/226,992
; CURRENT FILING DATE: 2003-02-24
; PRIOR APPLICATION NUMBER: US 60/315,315
; PRIOR FILING DATE: 2001-08-21
; NUMBER OF SEQ ID NOS: 184
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 24
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target sequence/siNA sense r
US-10-226-992-24

Query Match      0.4%; Score 14.2; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 508 GTGCTGAGCGCTCCCGC 526
Db 19 GTGCTGAAGAGCAGCCCGC 1
||||| ||||| ||||| |||||

RESULT 1278
US-10-226-992-107
; Sequence 107, Application US/10226992
; Publication No. US20030148507A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Fossnaugh, Kathy
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Prostaglandin D2 Receptor
; TITLE OF INVENTION: and Prostaglandin D2 Synthetase (PTGDS) Gene Expression Using SH
; TITLE OF INVENTION: RNA
; FILE REFERENCE: 400/055 (WBHE01-1110-B)
; CURRENT APPLICATION NUMBER: US/10/226,992
; CURRENT FILING DATE: 2003-02-24
; PRIOR APPLICATION NUMBER: US 60/315,315
; PRIOR FILING DATE: 2001-08-21
; NUMBER OF SEQ ID NOS: 184
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 107
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-226-992-107

Query Match      0.4%; Score 14.2; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 8.7e+02;
Matches 14; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 508 GTGCTGAGCGCTCCCGC 526
Db 1 GUGCTGAAGAGCAGCCCGC 19
||||| ||||| ||||| |||||

RESULT 1279
US-10-324-618-33/c
; Sequence 33, Application US/10324618
; Publication No. US20030170691A1
; GENERAL INFORMATION:
; APPLICANT: Gimeno, Ruth
; APPLICANT: Wu, Zhidan
; APPLICANT: Kapeller-Libermann, Rosana
; APPLICANT: Hubbard, Brian K.
; TITLE OF INVENTION: HUMAN DIACYLGLYCEROL ACYLTRANSFERASE 2
; TITLE OF INVENTION: (DGAT2) FAMILY MEMBERS AND USES THEREFOR
; FILE REFERENCE: MP101-263P2RM
; CURRENT APPLICATION NUMBER: US/10/324,618
; CURRENT FILING DATE: 2002-12-19
```

RESULT 1281
US-10-251-117-400/c
; Sequence 400, Application US/10251117
; Publication No. US20030170891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Epidermal Growth Factor R
; TITLE OF INVENTION: Gene Expression Using Short Interfering RNA

RESULT 1283
US-10-251-117-665
; Sequence 665, Application US/10251117
; Publication No. US20030170891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Epidermal Growth Factor R
; FILE REFERENCE: 900/042 (MBH02-468-A)
; CURRENT FILING DATE: 2003-02-24
; PRIOR FILING DATE: 2002-02-20
; PRIOR FILING DATE: 2002-07-03
; PRIOR FILING DATE: 2002-06-06
; PRIOR FILING DATE: 2002-02-20
; PRIOR FILING DATE: 2001-07-25
; PRIOR FILING DATE: 2001-06-06
; NUMBER OF SEQ ID NOS: 1213
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 665
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target sequence/siNA sense
US-10-251-117-665

Query Match 0.4%; Score 14.2; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 8.7e+02;
Matches 13; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

Qy 3414 AGGGCCCGCCCTGTGTGC 3432
Db 1 AGACGCCGCGCAUGUGGC 19

RESULT 1284
US-10-251-117-720
; Sequence 720, Application US/10251117
; Publication No. US20030170891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Epidermal Growth Factor R
; FILE REFERENCE: 900/042 (MBH02-468-A)
; CURRENT FILING DATE: 2003-02-24
; PRIOR FILING DATE: 2002-02-20
; PRIOR FILING DATE: 2002-07-03
; PRIOR FILING DATE: 2002-06-06
; PRIOR FILING DATE: 2002-02-20
; PRIOR FILING DATE: 2001-07-25
; PRIOR FILING DATE: 2001-06-06
; NUMBER OF SEQ ID NOS: 1213
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 720
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target sequence/siNA sense
US-10-251-117-720

Query Match 0.4%; Score 14.2; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 8.7e+02;
Matches 11; Conservative 5; Mismatches 3; Indels 0; Gaps 0;
Qy 1938 CGACCTGTACATGATCATG 1956
Db 1 CGAUGUCUACGAUGAUG 19

RESULT 1285
US-10-251-117-957
; Sequence 957, Application US/10251117
; Publication No. US20030170891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Epidermal Growth Factor R
; FILE REFERENCE: 900/042 (MBH02-468-A)
; CURRENT FILING DATE: 2003-02-24
; PRIOR FILING DATE: 2002-02-20
; PRIOR FILING DATE: 2002-07-03
; PRIOR FILING DATE: 2002-06-06
; PRIOR FILING DATE: 2002-02-20
; PRIOR FILING DATE: 2001-07-25
; PRIOR FILING DATE: 2001-06-06
; NUMBER OF SEQ ID NOS: 1213
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 957
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-251-117-957

Query Match 0.4%; Score 14.2; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 8.7e+02;
Matches 15; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

Qy 2267 CCGCATGAGACTCAGTGC 2285
Db 1 CCGCAAGACGACGAGUCC 19

RESULT 1286
US-10-251-117-972/c
; Sequence 972, Application US/10251117
; Publication No. US20030170891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Epidermal Growth Factor R
; FILE REFERENCE: 900/042 (MBH02-468-A)
; CURRENT FILING DATE: 2003-02-24
; PRIOR FILING DATE: 2002-02-20
; PRIOR FILING DATE: 2002-07-03
; PRIOR FILING DATE: 2002-06-06
; PRIOR FILING DATE: 2002-02-20
; PRIOR FILING DATE: 2001-07-25
; PRIOR FILING DATE: 2001-06-06
; NUMBER OF SEQ ID NOS: 1213
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 972
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target sequence/siNA sense
US-10-251-117-972/c

```
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 972
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-251-117-972

Query Match          0.4%; Score 14.2; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3414 AGGGCCCGCCCTGTCG 3432
Db 19 AGACGCCGGCCATGTGTC 1

RESULT 1287
US-10-251-117-1027/c
; Sequence 1027, Application US/10251117
; Publication No. US20030170891A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen Pharmaceuticals, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Epidermal Growth Factor R
; FILE REFERENCE: Gene Expression Using Short Interfering RNA
; CURRENT APPLICATION NUMBER: US/10/251,117
; CURRENT FILING DATE: 2003-02-24
; PRIOR APPLICATION NUMBER: US 60/393,924
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/163,552
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 09/916,466
; PRIOR FILING DATE: 2001-07-25
; PRIOR APPLICATION NUMBER: US 60/296,249
; PRIOR FILING DATE: 2001-06-06
; NUMBER OF SEQ ID NOS: 1213
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1027
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-251-117-1027

Query Match          0.4%; Score 14.2; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1938 CGACCTGTACATGATCATG 1956
Db 19 CGATGCTACATGATCATG 1

RESULT 1288
US-10-084-839-1955
; Sequence 1955, Application US/10084839
; Publication No. US20030186238A1
; GENERAL INFORMATION:
; APPLICANT: Third Wave Technologies
; APPLICANT: Allawi, Hatim
; APPLICANT: Argue, Brad T.
; APPLICANT: Bartholomay, Christian T.
; APPLICANT: Chehak, LuAnne
; APPLICANT: Curtis, Michelle L.
; APPLICANT: Eis, Peggy S.
; APPLICANT: Hall, Jeff G.
; APPLICANT: Ip, Hon S.
```

```
; APPLICANT: Ji, Lin
; APPLICANT: Kaiser, Michael
; APPLICANT: Kwiatkowski, Jr., Robert W.
; APPLICANT: Lukowiak, Andrew A.
; APPLICANT: Lyamichev, Victor
; APPLICANT: Lymaicheva, Natalie E.
; APPLICANT: Ma, WuPo
; APPLICANT: Neri, Bruce P.
; APPLICANT: Olson, Sarah M.
; APPLICANT: Olson-Munoz, Marilyn C.
; APPLICANT: Schaefer, James J.
; APPLICANT: Skrzypczynski, Zbigniew
; APPLICANT: Takova, Tsetska Y.
; APPLICANT: Thompson, Lisa C.
; APPLICANT: Vedvik, Kevin L.
; TITLE OF INVENTION: RNA Detection Assays
; FILE REFERENCE: FORS-06666
; CURRENT APPLICATION NUMBER: US/10/084,839
; CURRENT FILING DATE: 2002-02-26
; NUMBER OF SEQ ID NOS: 4004
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 1955
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-084-839-1955

Query Match          0.4%; Score 14.2; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2485 GTGCAGAAATGTAAGTGGC 2503
Db 1 GTGCAGAAATGTCAGTGGC 19

RESULT 1289
US-10-205-309-18/c
; Sequence 18, Application US/10205309
; Publication No. US20030190635A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Alzheimer's Disease Using
; FILE REFERENCE: Interfering RNA
; CURRENT APPLICATION NUMBER: US/10/205,309
; CURRENT FILING DATE: 2002-10-25
; NUMBER OF SEQ ID NOS: 674
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 18
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target sequence/siNA sense r
US-10-205-309-18

Query Match          0.4%; Score 14.2; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3659 CCTGCAGGGCCATGGCTCA 3677
Db 19 CCTGCAGGGCCCTGGCCA 1

RESULT 1290
US-10-205-309-343
; Sequence 343, Application US/10205309
; Publication No. US20030190635A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Alzheimer's Disease Using
; TITLE OF INVENTION: Interfering RNA
; FILE REFERENCE: 900/033
; CURRENT APPLICATION NUMBER: US/10/205,309
; CURRENT FILING DATE: 2002-10-25
; NUMBER OF SEQ ID NOS: 674
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 343
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-205-309-343

Query Match          0.4%; Score 14.2; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 8.7e+02;
Matches 14; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 3659 CCGCAGGCGCCATGCTCA 3677
      |||:|||||:|||||
DB 1 CCUGCAGGCGCCUGGCCA 19

RESULT 1291
US-10-244-647-511
; Sequence 511, Application US/10244647
; Publication No. US20030206887A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, David
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Hepatitis B Virus (HBV)
; TITLE OF INVENTION: Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/060 (MEH802-1000)
; CURRENT APPLICATION NUMBER: US/10/244,647
; CURRENT FILING DATE: 2003-04-14
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/393,924
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: PCT US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; NUMBER OF SEQ ID NOS: 1524
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 511
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target sequence/siNA sense
US-10-244-647-511

Query Match          0.4%; Score 14.2; DB 1; Length 19;
Best Local Similarity 42.1%; Pred. No. 8.7e+02;
Matches 8; Conservative 8; Mismatches 3; Indels 0; Gaps 0;

QY 926 TCCTGTTTCATCTCGTGGT 944
      |||:|||||:|||||
DB 1 UCCUCUUAUCCUGCUGCU 19

RESULT 1292
US-10-244-647-1157/c
; Sequence 1157, Application US/10244647
; Publication No. US20030206887A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Morrissey, David
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Hepatitis B Virus (HBV)
; TITLE OF INVENTION: Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/060 (MEH802-1000)
; CURRENT APPLICATION NUMBER: US/10/244,647
; CURRENT FILING DATE: 2003-04-14
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/393,924
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: PCT US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; NUMBER OF SEQ ID NOS: 1524
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1157
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-244-647-1157

Query Match          0.4%; Score 14.2; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 926 TCCTGTTTCATCTCGTGGT 944
      |||:|||||:|||||
DB 19 TCCTGTTTCATCTCGTGGT 1

RESULT 1293
US-10-454-323-3/c
; Sequence 3, Application US/10454323
; Publication No. US20040001833A1
; GENERAL INFORMATION:
; APPLICANT: Agus, David B.
; TITLE OF INVENTION: Method of Treating Cancer Using Kinase Inhibitors
; FILE REFERENCE: 81476-250159
; CURRENT APPLICATION NUMBER: US/10/454,323
; CURRENT FILING DATE: 2003-06-04
; PRIOR APPLICATION NUMBER: 60/386,622
; PRIOR FILING DATE: 2002-06-05
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 3
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo sapiens
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-454-323-3

Query Match          0.4%; Score 14.2; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1670 AGATGCGCAGACTTCGGGCT 1688
      |||:|||||:|||||
DB 19 AAATTACAGACTTCGGGCT 1

RESULT 1294
US-10-349-143-4702/c
; Sequence 4702, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
```

; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...

```

, FILE REFERENCE: GENSET.020CPI
, CURRENT APPLICATION NUMBER: US/10/349,143
, CURRENT FILING DATE: 2003-01-21
, PRIOR APPLICATION NUMBER: US/09/422,978
, PRIOR FILING DATE: 1999-10-20
, PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
, PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
, PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
, PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
, PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
, PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
, NUMBER OF SEQ ID NOS: 11796
, SEQ ID NO 4702
, LENGTH: 19
, TYPE: DNA
, ORGANISM: Homo Sapiens
, FEATURE:
, NAME/KEY: primer_bind
, LOCATION: 1..19
, OTHER INFORMATION: upstream amplification primer 99-17134 for SEQ 768,
US-10-349-143-4702

```

Query Match 0.4%; Score 14.2; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. NO. 8.7e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2770 GGTTATTTCGGAAACTAG 2788
 |||||
 Db 19 GGTTATTTCGGACAGTAG 1

RESULT 1295

RES001 1235
US-10-349-143-6383/c
; Sequence 6383, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.0206P1
; CURRENT APPLICATION NUMBER: US/10/349,143
; CURRENT FILING DATE: 2003-01-21
; PRIORITY APPLICATION NUMBER: US/09/422,978
; PRIOR FILING DATE: 1999-10-20
; PRIORITY APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
; PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
; PRIORITY APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
; PRIORITY APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796

Query Match 0.4%; Score 14.2; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 8.7e+02;
Matches 16: Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3502 GATGATTTGTTGTAGACT 3520
Dp 19 GTTGTGTTTGTGTAGCT 1

RESULT 1296

```

US-10-444-925-372/c
; Sequence 372, Application US/10444925
; Publication No. US20040009946A1
; GENERAL INFORMATION:
; APPLICANT: Lewis, Stephen Patrick
; APPLICANT: Klinghoffer, Richard
; APPLICANT: wilson, Linda K.
; TITLE OF INVENTION: MODULATION OF PTP1B SIGNAL TRANSDUCTION
; BY RNA INTERFERENCE
; FILE REFERENCE: 200125.441
; CURRENT APPLICATION NUMBER: US/10/444,925
; CURRENT FILING DATE: 2003-05-23
; NUMBER OF SEQ ID NOS: 599
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 372
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Small interfering RNA
US-10-444-925-372

```

```
Query Match      0.4%; Score 14.2; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 8.7e+02;
Matches 16: Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

Qy 2068 GCGCCTTTCGAGCAGTACT 2086
Db 19 GCGCATCTCCAGCAGTACT 1

RESULT 1297

```

US-10-444-925-392
; Sequence 392, Application US/10444925
; Publication No. US20040009946A1
; GENERAL INFORMATION:
; APPLICANT: Lewis, Stephen Patrick
; APPLICANT: Klinghoffer, Richard
; APPLICANT: Wilson, Linda K.
; TITLE OF INVENTION: MODULATION OF PTP1B SIGNAL TRANSDUCTION
; TITLE OF INVENTION: BY RNA INTERFERENCE
; FILE REFERENCE: 200125.441
; CURRENT APPLICATION NUMBER: US/10/444,925
; CURRENT FILING DATE: 2003-05-23
; NUMBER OF SEQ ID NOS: 599
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 392
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Small interfering RNA
US-10-444-925-392

```

Query Match 0.4%; Score 14.2; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 8.7e+02;
Matches 12: Conservative 4; Mismatches 3; Indels 0; Gaps 0;

Qy 3280 CTTTTCAGGAGAAATTGA 3298
pb 1 CCUGUUCAGGAGAAAGUAGA 19

RESULT 1298

```

US-10-444-925-486
; Sequence 486, Application US/1044925
; Publication No. US2004000946A1
;
; GENERAL INFORMATION:
; APPLICANT: Lewis, Stephen Patrick
; APPLICANT: Klinghoffer, Richard
; APPLICANT: Wilson, Linda K.
; TITLE OF INVENTION: MODULATION OF PTPIB SIGNAL TRANSDUCTION
; TITLE OF INVENTION: BY RNA INTERFERENCE

```



```

,
, CURRENT APPLICATION NUMBER: US/10/376,770
,
, CURRENT FILING DATE: 2003-02-28
,
, PRIOR APPLICATION NUMBER: US 10/093,618
,
, PRIOR FILING DATE: 2002-03-11
,
, PRIOR APPLICATION NUMBER: US 60/360,232
,
, PRIOR FILING DATE: 2002-03-01
,
, PRIOR APPLICATION NUMBER: US 60/378,354
,
, PRIOR FILING DATE: 2002-05-08
,
, NUMBER OF SEQ ID NOS: 262
,
, SOFTWARE: FastSeq for Windows Version 4.0
,
, SEQ ID NO 89
,
, LENGTH: 19
,

```

```

; FILE REFERENCE: 543312000420
; CURRENT APPLICATION NUMBER: US/10/661,165
; CURRENT FILING DATE: 2003-09-11
; PRIOR APPLICATION NUMBER: PCr/US03/06198
; PRIOR FILING DATE: 2003-02-28
; PRIOR APPLICATION NUMBER: US 60/378,354
; PRIOR FILING DATE: 2002-05-08
; PRIOR APPLICATION NUMBER: US 10/093,618
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/360,232
; PRIOR FILING DATE: 2002-03-01
; PRIOR APPLICATION NUMBER: PCr/US03/27308
; PRIOR FILING DATE: 2003-08-29
; PRIOR APPLICATION NUMBER: US 10/376,770
; PRIOR FILING DATE: 2003-02-28
; NUMBER OF SEQ ID NOS: 628

```

```
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 89
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (5)...(9)
; OTHER INFORMATION: These nucleotides may be absent
US-10-661-165-89

Query Match          0.4%; Score 14.2; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2687 AGGCTTCCCACTCCAC 2705
Db 19 ATGCTTTCACACTTCCAAC 1

RESULT 1303
; Sequence 388, Application US/10665951
; Publication No. US20040138163A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/131 (MBHB02-742-F)
; CURRENT APPLICATION NUMBER: US/10/665,951
; CURRENT FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/287,949
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: PCT/US 02/17674
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2455
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 815
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-665-951-815

Query Match          0.4%; Score 14.2; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2330 TGTGCGTGTGTGTGTGT 2348
Db 19 TGTAACTGTGTGTGTGTGT 1

RESULT 1305
; Sequence 1041, Application US/10665951
; Publication No. US20040138163A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/131 (MBHB02-742-F)
; CURRENT APPLICATION NUMBER: US/10/665,951
; CURRENT FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
```

```

; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/287,949
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: PCT/US 02/17674
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2455
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1041
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-665-951-1041

Query Match      0.4%; Score 14.2; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 8.7e+02;
Matches 11; Conservative 5; Mismatches 3; Indels 0; Gaps 0;

QY 1588 ATGGAGTACTTGGCTCC 1506
      |||||:|:|:|:|:|
DB 1 AUGGAGUUCUGGCAUCCG 19

RESULT 1306
US-10-665-951-1046
; Sequence 1046, Application US/10665951
; Publication No. US20040138163A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/131 (WBHB02-742-F)
; CURRENT APPLICATION NUMBER: US/10/665,951
; CURRENT FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/287,949
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: PCT/US 02/17674
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2455
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1041
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-665-951-1046

Query Match      0.4%; Score 14.2; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 8.7e+02;
Matches 11; Conservative 5; Mismatches 3; Indels 0; Gaps 0;

QY 1588 ATGGAGTACTTGGCTCC 1506
      |||||:|:|:|:|:|
DB 1 AUGGAGUUCUGGCAUCCG 19

```

```

; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2455
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1046
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-665-951-1046

Query Match      0.4%; Score 14.2; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 8.7e+02;
Matches 13; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 1678 GACTTCGGGCTGGCCGGG 1696
      |||||:|:|:|:|:|
DB 1 GACUUGGCUUGGCCGGG 19

RESULT 1307
US-10-665-951-1052
; Sequence 1052, Application US/10665951
; Publication No. US20040138163A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/131 (WBHB02-742-F)
; CURRENT APPLICATION NUMBER: US/10/665,951
; CURRENT FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/287,949
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: PCT/US 02/17674
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2455
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1052
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-665-951-1052

Query Match      0.4%; Score 14.2; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 8.7e+02;
Matches 14; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 1786 TACACTCAGAGTGACG 1804
      :|||||:|:|:|:|:|

```


; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2455
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1376
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-665-951-1376

Query Match 0.4%; Score 14.2; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1786 TACACTCACCAGAGTGACG 1804

Db 19 TACACATCCAGGTGACG 1

RESULT 1311

; Sequence 1674, Application US/10665951
; Publication No. US20040138163A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: 400/131 (MBH02-742-F)
; CURRENT APPLICATION NUMBER: US/10/665,951
; CURRENT FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/287,949
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: PCT/US 02/17674
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2455
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1674
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense

US-10-665-951-1674
Query Match 0.4%; Score 14.2; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 8.7e+02;
Matches 14; Conservative 2; Mismatches 3; Indels 0; Gaps 0;
Qy 1573 CAGGTGGCCGGCGCATGG 1591

Db 1573 CAGGTGGCCGGCGCATGG 1591

Db 1 CAGGUGGCCAGAGGAUGG 19

RESULT 1312

US-10-665-951-1683
; Sequence 1683, Application US/10665951
; Publication No. US20040138163A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: 400/131 (MBH02-742-F)
; CURRENT APPLICATION NUMBER: US/10/665,951
; CURRENT FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/287,949
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: PCT/US 02/17674
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2455
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1683
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-665-951-1683
Query Match 0.4%; Score 14.2; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 8.7e+02;
Matches 13; Conservative 3; Mismatches 3; Indels 0; Gaps 0;
Qy 1735 GGCCGGCTCCCGTGAAGT 1753

Db 1 GCCCGGCTGCCCGCUGAUGU 19

RESULT 1313

US-10-665-951-1921/c
; Sequence 1921, Application US/10665951
; Publication No. US20040138163A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: 400/131 (MBH02-742-F)
; CURRENT APPLICATION NUMBER: US/10/665,951

```

; CURRENT FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/287,949
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: PCT/US 02/17674
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2455
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 1921
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-665-951-1921

Query Match          0.4%; Score 14.2; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1573 CAGGTGGCCGGGATGG 1591
      |||||
DB 19 CAGGTGGCCAGGATGG 1

RESULT 1314
US-10-665-951-1930/c
; Sequence 1930, Application US/10665951
; Publication No. US20040138163A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: 400/131 (MBH02-742-F)
; CURRENT APPLICATION NUMBER: US/10/665,951
; CURRENT FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/287,949
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: PCT/US 02/17674
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/287,949
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: PCT/US 02/17674
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2455
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 1921
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-665-951-1921

```

```

; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2455
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 1930
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-665-951-1930

Query Match          0.4%; Score 14.2; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1735 GCGCGCTCCCGTGAAGT 1753
      |||||
DB 19 GCGCGCTCCCGTGAAGT 1

RESULT 1315
US-10-665-951-2263
; Sequence 2263, Application US/10665951
; Publication No. US20040138163A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: 400/131 (MBH02-742-F)
; CURRENT APPLICATION NUMBER: US/10/665,951
; CURRENT FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/287,949
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: PCT/US 02/17674
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2455
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 2263
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-665-951-2263

Query Match          0.4%; Score 14.2; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 8.7e+02;
Matches 13; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

```

Qy 1950 GATCATGCGGAGTGTCTGG 1968
|||:|||||:|||||
Db 1 GACCAUGCUGGACUGCGG 19

RESULT 1316

US-10-665-951-2264
; Sequence 2264, Application US/10665951
; Publication No. US2004013163A1
; GENERAL INFORMATION:
; APPLICANT: Sina Therapeutics, Inc.
; APPLICANT: McSwigen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/131 (MEHB02-742-F)
; CURRENT APPLICATION NUMBER: US/10/665,951
; CURRENT FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/287,949
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: PCT/US 02/17674
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2455
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 2264
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-665-951-2264

Query Match 0.4%; Score 14.2; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 8.7e+02;
Matches 13; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

Qy 1951 ATCATGCGGAGTGTCTGG 1969
|||:|||||:|||||
Db 1 ACCAUGCUGGACUGCGG 19

RESULT 1317

US-10-600-070-37/c
; Sequence 37, Application US/10600070
; Publication No. US2004013950A1
; GENERAL INFORMATION:
; APPLICANT: Oesteryoung, Katherine W.
; APPLICANT: Vitha, Stanislaw
; APPLICANT: Kosharova, Olga A.
; APPLICANT: Gao, Hongo
; TITLE OF INVENTION: Plastid Division and Related Genes and Proteins, and Methods of
; TITLE OF INVENTION: Use
; FILE REFERENCE: MSU-08153
; CURRENT APPLICATION NUMBER: US/10/600,070

; CURRENT FILING DATE: 2003-06-20
; NUMBER OF SEQ ID NOS: 206
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 37
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-600-070-37

Query Match 0.4%; Score 14.2; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 978 CCCCAAGAAAGCGCTGGCG 996
|||:|||||:|||||
Db 19 CCTCAAGAAAGGACTGCGC 1

RESULT 1318

US-10-715-117-13
; Sequence 13, Application US/10715117
; Publication No. US20040171037A1
; GENERAL INFORMATION:
; APPLICANT: LI, JING
; APPLICANT: POWERS, SCOTT
; APPLICANT: SIN, WUN CHEY
; APPLICANT: YANG, JIANXIN
; TITLE OF INVENTION: AMPLIFIED GENES INVOLVED IN CANCER
; FILE REFERENCE: 38002-0062
; CURRENT APPLICATION NUMBER: US/10/715,117
; CURRENT FILING DATE: 2003-11-18
; PRIOR APPLICATION NUMBER: 60/427,202
; PRIOR FILING DATE: 2002-11-19
; PRIOR APPLICATION NUMBER: 60/434,434
; PRIOR FILING DATE: 2002-12-19
; NUMBER OF SEQ ID NOS: 99
; SOFTWARE: Patent in Ver. 3.2
; SEQ ID NO 13
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-715-117-13

Query Match 0.4%; Score 14.2; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 293 GCTTCCGCTGCCAGCCGC 311
|||:|||||:|||||
Db 1 GCTCCGCGGCGCTGCGGC 19

RESULT 1319

US-10-715-117-14
; Sequence 14, Application US/10715117
; Publication No. US20040171037A1
; GENERAL INFORMATION:
; APPLICANT: LI, JING
; APPLICANT: POWERS, SCOTT
; APPLICANT: SIN, WUN CHEY
; APPLICANT: YANG, JIANXIN
; TITLE OF INVENTION: AMPLIFIED GENES INVOLVED IN CANCER
; FILE REFERENCE: 38002-0062
; CURRENT APPLICATION NUMBER: US/10/715,117
; CURRENT FILING DATE: 2003-11-18
; PRIOR APPLICATION NUMBER: 60/427,202
; PRIOR FILING DATE: 2002-11-19
; PRIOR APPLICATION NUMBER: 60/434,434
; PRIOR FILING DATE: 2002-12-19
; NUMBER OF SEQ ID NOS: 99
; SOFTWARE: Patent in Ver. 3.2

```
; SEQ ID NO 14
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-10-715-117-14
```

```
Query Match          0.4%; Score 14.2; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 8.7e+02;
Matches 15; Conservative 1; Mismatches 3; Indels 0; Gaps 0;
```

```
Qy 293 GCTTCCGCTGCCAGCGC 311
Db 1 GCUCGCGCGCCUCCGCGC 19
```

```
RESULT 1320
US-10-385-163-95/c
; Sequence 95, Application US/10385163
; Publication No. US200401808441
; GENERAL INFORMATION:
; APPLICANT: Fesik, Stephen W.
; APPLICANT: Halbert, Donald N.
; APPLICANT: McDowell, Jeffrey A.
; APPLICANT: Schurdak, Mark E.
; APPLICANT: Morgan-Lappe, Susan E.
; APPLICANT: Sathya, Aparna V.
; TITLE OF INVENTION: Method Of Killing Cancer Cells
; FILE REFERENCE: 7046.US.01
; CURRENT APPLICATION NUMBER: US/10/385,163
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 121
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 95
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: antisense oligonucleotide
US-10-385-163-95
```

```
Query Match          0.4%; Score 14.2; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
Qy 1950 GATCATGCGGAGTGCTGG 1968
Db 19 GATGATGCGAGAGTGTTGG 1
```

```
RESULT 1321
US-10-796-177-95/c
; Sequence 95, Application US/10796177
; Publication No. US20040180848A1
; GENERAL INFORMATION:
; APPLICANT: Fesik, Stephen W.
; APPLICANT: Halbert, Donald N.
; APPLICANT: McDowell, Jeffrey A.
; APPLICANT: Schurdak, Mark E.
; APPLICANT: Morgan-Lappe, Susan E.
; APPLICANT: Sathya, Aparna V.
; TITLE OF INVENTION: Method Of Killing Cancer Cells
; FILE REFERENCE: 7046.US.21
; CURRENT APPLICATION NUMBER: US/10/796,177
; CURRENT FILING DATE: 2004-03-09
; PRIOR APPLICATION NUMBER: US/60/453,420
; PRIOR FILING DATE: 2006-03-10
; NUMBER OF SEQ ID NOS: 121
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 95
; LENGTH: 19
```

```
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: antisense oligonucleotide
US-10-796-177-95
```

```
Query Match          0.4%; Score 14.2; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
Qy 1950 GATCATGCGGAGTGCTGG 1968
Db 19 GATGATGCGAGAGTGTTGG 1
```

```
RESULT 1322
US-10-683-990-22
; Sequence 22, Application US/10683990
; Publication No. US20040198682A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics
; APPLICANT: McSwiggen, James
; APPLICANT: Ueman, Nassim
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Placental Growth Factor
; FILE REFERENCE: 400/134 (02-742-H)
; CURRENT APPLICATION NUMBER: US/10/683,990
; CURRENT FILING DATE: 2003-10-10
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; PRIOR APPLICATION NUMBER: US 60/408,378
; PRIOR FILING DATE: 2002-09-05
; PRIOR APPLICATION NUMBER: US 60/409,293
; PRIOR FILING DATE: 2002-09-09
; PRIOR APPLICATION NUMBER: US 60/440,129
; PRIOR FILING DATE: 2003-01-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 256
; SOFTWARE: Patentin version 3.2
; SEQ ID NO 22
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-683-990-22
```

```
Query Match          0.4%; Score 14.2; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 8.7e+02;
Matches 14; Conservative 2; Mismatches 3; Indels 0; Gaps 0;
```

```
Qy 260 AGCTGCTGCCGCTGCCGC 278
Db 1 AGCUCCTGCCGCGCGCGC 19
```

```
RESULT 1323
US-10-683-990-119/c
; Sequence 119, Application US/10683990
; Publication No. US20040198682A1
```


GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics
; APPLICANT: McSwiggen, James
; APPLICANT: Usman, Nassim
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Placental Growth Factor
; FILE REFERENCE: 400/134 (02-742-H)
; CURRENT FILING DATE: 2003-10-10
; PRIOR APPLICATION NUMBER: US/10/683,990
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; PRIOR APPLICATION NUMBER: US 60/408,378
; PRIOR FILING DATE: 2002-09-05
; PRIOR APPLICATION NUMBER: US 60/409,293
; PRIOR FILING DATE: 2002-09-09
; PRIOR APPLICATION NUMBER: US 60/440,129
; PRIOR FILING DATE: 2003-01-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 119
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: sirna antisense region
US-10-683-990-119

Query Match 0.4%; Score 14.2; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 260 AGCTGCTGCGCGTGGCGC 278
Db 19 AGCTCTGCGCGGCTGGC 1

RESULT 1324
US-09-216-393-243
; Sequence 243, Application US/09216393
; Patent No. US2001001447A1
; GENERAL INFORMATION:
; APPLICANT: Milhausen, Michael James
; TITLE OF INVENTION: TOKOPLASMA GONDII PROTEINS, NUCLEIC ACID MOLECULES, AND
; FILE REFERENCE: TX-1-C2
; CURRENT APPLICATION NUMBER: US/09/216,393
; CURRENT FILING DATE: 1998-12-18
; EARLIER APPLICATION NUMBER: 08/994,825
; PRIOR FILING DATE: 1997-12-19
; NUMBER OF SEQ ID NOS: 364
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 243
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-216-393-243

Query Match 0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 2850 TATGGAAGAGGAAAAGGCT 2868
Db 1 TGTGCGAGAGCAAAAGGCT 19
RESULT 1325
US-09-758-881-138
; Sequence 138, Application US/09758881
; Patent No. US20010029250A1
; GENERAL INFORMATION:
; APPLICANT: Karas, James G
; TITLE OF INVENTION: Antisense Oligonucleotide Modulation of STAT3
; FILE REFERENCE: ISPH-0532
; CURRENT APPLICATION NUMBER: US/09/758,881
; CURRENT FILING DATE: 2001-01-11
; PRIOR APPLICATION NUMBER: PCT/US00/09054
; PRIOR FILING DATE: 2000-04-06
; PRIOR APPLICATION NUMBER: 09/288,461
; PRIOR FILING DATE: 1999-04-08
; NUMBER OF SEQ ID NOS: 152
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 138
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-758-881-138

Query Match 0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 1006 GTGCACAAGATCTCCCGCT 1024
Db 1 GTGCTCAAGATGGCCCGCT 19

RESULT 1326
US-09-915-229-3/c
; Sequence 3, Application US/09915229
; Publication No. US20020039789A1
; GENERAL INFORMATION:
; APPLICANT: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
; APPLICANT: Gage, Fred
; APPLICANT: Ray, Jasodhara
; TITLE OF INVENTION: METHOD FOR PRODUCTION OF NEUROBLASTS
; FILE REFERENCE: REGEN1160-5
; CURRENT APPLICATION NUMBER: US/09/915,229
; CURRENT FILING DATE: 2001-07-24
; PRIOR APPLICATION NUMBER: 08/884,427
; PRIOR FILING DATE: 1997-06-27
; PRIOR APPLICATION NUMBER: 08/445,075
; PRIOR FILING DATE: 1995-05-19
; PRIOR APPLICATION NUMBER: 08/147,843
; PRIOR FILING DATE: 1993-11-03
; PRIOR APPLICATION NUMBER: 08/001,543
; PRIOR FILING DATE: 1993-01-06
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Forward primer for PCR
US-09-915-229-3

Query Match 0.4%; Score 14.2; DB 1; Length 20;
 Best Local Similarity 84.2%; Pred. No. 9.1e+02;
 Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2385 TGCTCCAGGTGCAGAGT 2403
 Db 19 TGCCTCAGGTGCCGAGT 1

RESULT 1327

US-09-861-893-3/c
 ; Sequence 3, Application US/09861893
 ; Patent No. US20020045257A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Strichman, Andrew
 ; APPLICANT: Jiang, Shan
 ; TITLE OF INVENTION: METHODS FOR ASSAYING GENE IMPRINTING AND
 ; FILE REFERENCE: 01107.00128
 ; CURRENT APPLICATION NUMBER: US/09/861.893
 ; CURRENT FILING DATE: 2001-05-22
 ; PRIOR APPLICATION NUMBER: 60/206,158
 ; PRIOR FILING DATE: 2000-05-22
 ; PRIOR APPLICATION NUMBER: 60/206,161
 ; PRIOR FILING DATE: 2000-05-22
 ; NUMBER OF SEQ ID NOS: 77
 ; SOFTWARE: FastSeq for Windows Version 3.0
 ; SEQ ID NO 3
 ; LENGTH: 20
 ; TYPE: DNA
 ; ORGANISM: Homo sapiens
 US-09-861-893-3

Query Match 0.4%; Score 14.2; DB 1; Length 20;
 Best Local Similarity 84.2%; Pred. No. 9.1e+02;
 Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1346 CTGAGATGGATGATGAA 1364
 Db 20 CTGAGATGGATGAA 2

RESULT 1328

US-09-842-628-11/c
 ; Sequence 11, Application US/09842628
 ; Patent No. US20020064862A1
 ; GENERAL INFORMATION:
 ; APPLICANT: ROBERTS, JOSEPH
 ; APPLICANT: MACALLISTER, THOMAS W.
 ; APPLICANT: SETHURAMAN, NATARAJAN
 ; APPLICANT: FREEMAN, ABBIE G.
 ; TITLE OF INVENTION: GENETICALLY ENGINEERED GLUTAMINASE AND ITS USE IN
 ; FILE REFERENCE: 023032/0108
 ; CURRENT APPLICATION NUMBER: US/09/842.628
 ; CURRENT FILING DATE: 2001-04-27
 ; PRIOR APPLICATION NUMBER: 08/050,482
 ; PRIOR FILING DATE: 1995-04-25
 ; PRIOR APPLICATION NUMBER: PCT/US92/10421
 ; PRIOR FILING DATE: 1992-12-04
 ; PRIOR APPLICATION NUMBER: DE P 4140003.8
 ; PRIOR FILING DATE: 1991-12-04
 ; NUMBER OF SEQ ID NOS: 22
 ; SOFTWARE: PatentIn Ver. 2.1
 ; SEQ ID NO 11
 ; LENGTH: 20
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Description of Artificial Sequence: Primer
 US-09-842-628-11

Query Match 0.4%; Score 14.2; DB 1; Length 20;
 Best Local Similarity 84.2%; Pred. No. 9.1e+02;
 Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 845 TGCCAGCCGAGGAGGAGCT 863
 Db 19 TGCCAGCCCTGCAGGAGT 1

RESULT 1329

US-09-416-384A-29/c
 ; Sequence 29, Application US/09416384A
 ; Patent No. US20020081584A1
 ; GENERAL INFORMATION:
 ; APPLICANT: BLUMENFELD, Marta
 ; APPLICANT: BOUGUERET, Lydie
 ; APPLICANT: CHUMAKOV, Ilya
 ; APPLICANT: COHEN, Daniel
 ; TITLE OF INVENTION: Genes, proteins and biallelic markers related to central...
 ; FILE REFERENCE: GENSET.045AUS
 ; CURRENT FILING DATE: 1999-10-12
 ; CURRENT APPLICATION NUMBER: US/09/416.384A
 ; PRIOR APPLICATION NUMBER: 60/106,457
 ; PRIOR FILING DATE: 1999-10-30
 ; PRIOR APPLICATION NUMBER: 60/103,955
 ; PRIOR FILING DATE: 1998-10-12
 ; PRIOR APPLICATION NUMBER: 60/132,277
 ; PRIOR FILING DATE: 1999-05-03
 ; NUMBER OF SEQ ID NOS: 71
 ; SOFTWARE: Patent.pm
 ; SEQ ID NO 29
 ; LENGTH: 20
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: oligonucleotide moCTGSRACE1
 US-09-416-384A-29

Query Match 0.4%; Score 14.2; DB 1; Length 20;
 Best Local Similarity 84.2%; Pred. No. 9.1e+02;
 Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1648 GTGACCCGAGGACACGTGA 1666
 Db 19 GTGACCCGAGGACACTGTGA 1

RESULT 1330

US-09-774-809-61
 ; Sequence 61, Application US/09774809
 ; Publication No. US20030004120A1
 ; GENERAL INFORMATION:
 ; APPLICANT: McKay, Robert A.
 ; APPLICANT: Dean, Nicholas M.
 ; APPLICANT: Monia, Brett
 ; APPLICANT: Nero, Pam
 ; APPLICANT: Gaarde, William A.
 ; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS AND METHODS
 ; FILE REFERENCE: ISPH-0412
 ; CURRENT APPLICATION NUMBER: US/09/774.809
 ; CURRENT FILING DATE: 2001-01-31
 ; PRIOR APPLICATION NUMBER: 09/396,902
 ; PRIOR FILING DATE: 1999-09-15
 ; PRIOR APPLICATION NUMBER: 09/130,616
 ; PRIOR FILING DATE: 1998-08-07
 ; PRIOR APPLICATION NUMBER: 08/910,629
 ; PRIOR FILING DATE: 1997-08-03
 ; NUMBER OF SEQ ID NOS: 165
 ; SEQ ID NO 61
 ; LENGTH: 20

```
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-09-774-809-61

Query Match          0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3379 GCTGTGTGTCAGGAGGAGG 3397
|||||
Db 2 GCTGTGTGTCAGGAGGAGG 20

RESULT 1333
US-09-771-933-160/c
; Sequence 160, Application US/09771933
; Publication No. US20030023387A1
; GENERAL INFORMATION:
; APPLICANT: Gill-Garrison, Rosalynn D
; APPLICANT: Martin, Christopher J
; APPLICANT: Sanchez-Felix, Manuel V
; TITLE OF INVENTION: Computer-assisted Means for Assessing Lifestyle Risk
; FILE REFERENCE: 620-130
; CURRENT APPLICATION NUMBER: US/09/771,933
; CURRENT FILING DATE: 2001-01-30
; NUMBER OF SEQ ID NOS: 205
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 160
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-771-933-160

Query Match          0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1810 TCCTTGGGGTCCTGCTCT 1828
|||||
Db 20 TCCTTGGGGTCCTGCTCT 2

RESULT 1332
US-09-865-866-68
; Sequence 68, Application US/09865866
; Publication No. US20030045487A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOLIPASE A2, GROUP IIA (SYNOVIAL) EX
; FILE REFERENCE: RTG-0221
; CURRENT APPLICATION NUMBER: US/09/865,866
; CURRENT FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 173
; SEQ ID NO 68
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-865-866-68

Query Match          0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3400 GACGGTTTCCAGGAGGAGG 3418
|||||
Db 2 GACGGTTTCCAGGAGGAGG 20

RESULT 1334
US-09-760-285-4/c
; Sequence 4, Application US/09760285
; Publication No. US20030091997A1
; GENERAL INFORMATION:
; APPLICANT: Nicolaiades, Nicholas C
; APPLICANT: Grasso, Luigi
; APPLICANT: Sasse, Philip M
; TITLE OF INVENTION: CHEMICAL INHIBITORS OF MISMATCH REPAIR
; FILE REFERENCE: MOR-0017
; CURRENT APPLICATION NUMBER: US/09/760,285
; CURRENT FILING DATE: 2001-01-15
; NUMBER OF SEQ ID NOS: 44
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: oligonucleotide
US-09-760-285-4

Query Match          0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1777 GACCGAGTCTACACTCACC 1795
|||||
Db 2 GACCGAGTCTACACTCACC 20

RESULT 1333
US-09-982-262B-62
; Sequence 62, Application US/09982262B
; Publication No. US20030077565A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Christopher K. Mirabelli
; TITLE OF INVENTION: OLIGONUCLEOTIDE MODULATION OF CELL ADHESION
; FILE REFERENCE: ISPH-0612
; CURRENT APPLICATION NUMBER: US/09/982,262B
; CURRENT FILING DATE: 2001-10-18
; PRIOR APPLICATION NUMBER: 09/659,288
; PRIOR FILING DATE: 2000-09-12
; PRIOR APPLICATION NUMBER: 09/128,496
; PRIOR FILING DATE: 1998-08-03
; PRIOR APPLICATION NUMBER: 08/440,740
; PRIOR FILING DATE: 1995-05-12
; PRIOR APPLICATION NUMBER: 08/063,167
; PRIOR FILING DATE: 1993-05-17
; PRIOR APPLICATION NUMBER: 07/969,151
; PRIOR FILING DATE: 1993-02-10
; PRIOR APPLICATION NUMBER: 08/007,997
; PRIOR FILING DATE: 1993-01-21
; NUMBER OF SEQ ID NOS: 86
; SEQ ID NO 62
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-982-262B-62

Query Match          0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3380 CTGTGTGTCCAGGAGGAGG 3398
|||||
Db 2 CTGTGTGTCCAGGAGGAGG 20

RESULT 1334
US-09-760-285-4/c
; Sequence 4, Application US/09760285
; Publication No. US20030091997A1
; GENERAL INFORMATION:
; APPLICANT: Nicolaiades, Nicholas C
; APPLICANT: Grasso, Luigi
; APPLICANT: Sasse, Philip M
; TITLE OF INVENTION: CHEMICAL INHIBITORS OF MISMATCH REPAIR
; FILE REFERENCE: MOR-0017
; CURRENT APPLICATION NUMBER: US/09/760,285
; CURRENT FILING DATE: 2001-01-15
; NUMBER OF SEQ ID NOS: 44
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: oligonucleotide
US-09-760-285-4

Query Match          0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1777 GACCGAGTCTACACTCACC 1795
|||||
Db 2 GACCGAGTCTACACTCACC 20
```

```
Db      20 GACAGAGTCTTCACTAACC 2
;
; TITLE OF INVENTION: ANTISENSE MODULATION OF BCL2-ASSOCIATED X PROTEIN EXPRESSION
; FILE REFERENCE: RTS-0185
; CURRENT APPLICATION NUMBER: US/09/908,147
; CURRENT FILING DATE: 2001-07-17
; NUMBER OF SEQ ID NOS: 168
; SEQ ID NO 26
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-908-147-26
Query Match      0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      1844 TGGGGGGCTCCCGTACCC 1862
      ||||| ||||| ||||| |||||
Db      1 TGGGCTGCTCCCGGACCC 19
;
;
RESULT 1338
US-09-864-426A-2531
; Sequence 2531, Application US/09864426A
; Publication No. US20040018489A1
; GENERAL INFORMATION:
; APPLICANT: Third Wave Technologies
; APPLICANT: Ma, Wu Po
; APPLICANT: Lyamichiev, Victor
; APPLICANT: Saiser, Michael
; TITLE OF INVENTION: Enzymes for the Detection of RNA Sequences
; FILE REFERENCE: FORS-04946
; CURRENT APPLICATION NUMBER: US/09/864,426A
; CURRENT FILING DATE: 2001-05-24
; NUMBER OF SEQ ID NOS: 2640
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2531
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-864-426A-2531
Query Match      0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      470 ACAAGTTTGGCAGCATCCG 488
      ||||| ||||| ||||| |||||
Db      1 ACAAGTTTGGCAGGTGGC 19
;
;
RESULT 1339
US-10-262-130-11/c
; Sequence 11, Application US/10262130
; Publication No. US20030022311A1
; GENERAL INFORMATION:
; APPLICANT: Dunnington, Damien D.
; APPLICANT: Frantz, James D.
; APPLICANT: Shoelson, Steven E.
; TITLE OF INVENTION: HUMAN CIS PROTEIN
; NUMBER OF SEQUENCES: 12
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Smithkline Beecham Corporation
; STREET: 709 Swedeland Road
; CITY: King of Prussia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19406-0939
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
```

COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/10/262,130
FILING DATE: 01-Oct-2002
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/655,327
FILING DATE: 21-MAY-1996
ATTORNEY/AGENT INFORMATION:
NAME: Baumeister, Kirk
REGISTRATION NUMBER: 33,833
REFERENCE/DOCKET NUMBER: P50486
TELECOMMUNICATION INFORMATION:
TELEPHONE: 610-270-5096
TELEFAX: 610-270-5090
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 11:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
HYPOTHETICAL: NO
ANTI-SENSE: NO
FRAGMENT TYPE: <Unknown>
ORIGINAL SOURCE:
SEQUENCE DESCRIPTION: SEQ ID NO: 11:
US-10-262-130-11

Query Match 0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```

Query Match          0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1777 GACCGAGTCTACACTCACC 1795
      ||| ||| ||| ||| ||| ||| |||
Db      20 GACAGAGTCTTCACTAAC 2

RESULT 1341
US-10-079-429--66/c
; Sequence 66, Application US/10079429
; Publication No. US20030027177A1
; GENERAL INFORMATION:
; APPLICANT: Haseltine et al.
; TITLE OF INVENTION: Human DNA Mismatch Repair Proteins
; FILE REFERENCE: FPI06P3D1
; CURRENT APPLICATION NUMBER: US/10/079,429
; CURRENT FILING DATE: 2002-02-22
; PRIOR APPLICATION NUMBER: PCT/US95/01035
; PRIOR FILING DATE: 1995-01-25
; PRIOR APPLICATION NUMBER: 08/468,024
; PRIOR FILING DATE: 1995-06-06
; PRIOR APPLICATION NUMBER: 08/465,769
; PRIOR FILING DATE: 1995-06-06
; PRIOR APPLICATION NUMBER: 08/294,312
; PRIOR FILING DATE: 1994-08-23
; PRIOR APPLICATION NUMBER: 08/210,143
; PRIOR FILING DATE: 1994-03-16
; PRIOR APPLICATION NUMBER: 08/187,757
; PRIOR FILING DATE: 1994-01-27
; NUMBER OF SEQ ID NOS: 78
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 66
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: primer useful for amplifying codons 1 to 863 hMLH3
US-10-079-429--66

```

```

RESULT 1340
US-10-079-429-55/c
; Sequence 55, Application US/10079429
; Publication No. US20030027177A1
; GENERAL INFORMATION:
; APPLICANT: Haseltine et al.
; TITLE OF INVENTION: Human DNA Mismatch Repair Proteins
; FILE REFERENCE: PF106P3D1
; CURRENT APPLICATION NUMBER: US/10/079,429
; CURRENT FILING DATE: 2002-02-22
; PRIOR APPLICATION NUMBER: PCT/US95/01035
; PRIOR FILING DATE: 1995-01-25
; PRIOR APPLICATION NUMBER: 08/468,024
; PRIOR FILING DATE: 1995-06-06
; PRIOR APPLICATION NUMBER: 08/294,312
; PRIOR FILING DATE: 1994-08-23
; PRIOR APPLICATION NUMBER: 08/210,143
; PRIOR FILING DATE: 1994-03-16
; PRIOR APPLICATION NUMBER: 08/187,757
; PRIOR FILING DATE: 1994-01-27
; NUMBER OF SEQ ID NOS: 78
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 55
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: hMLH3 primer
US-10-079-429-55

Query Match      0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1777  GACCGAGTCTACACTACC 1795
           ||| ||||| ||||| |||
DB      20  GACGAGTCTTCACTAACC 2

RESULT 1342
US-10-079-429-69/c
; Sequence 69, Application US/10079429
; Publication No. US20030027177A1
; GENERAL INFORMATION:
; APPLICANT: Haseltine et al.
; TITLE OF INVENTION: Human DNA Mismatch Repair Proteins
; FILE REFERENCE: PF106P3D1
; CURRENT APPLICATION NUMBER: US/10/079,429
; CURRENT FILING DATE: 2002-02-22
; PRIOR APPLICATION NUMBER: PCT/US95/01035
; PRIOR FILING DATE: 1995-01-25
; PRIOR APPLICATION NUMBER: 08/468,024
; PRIOR FILING DATE: 1995-06-06
; PRIOR APPLICATION NUMBER: 08/465,769
; PRIOR FILING DATE: 1995-06-06
; PRIOR APPLICATION NUMBER: 08/294,312
; PRIOR FILING DATE: 1994-08-23
; PRIOR APPLICATION NUMBER: 08/210,143
; PRIOR FILING DATE: 1994-03-16
; PRIOR APPLICATION NUMBER: 08/187,757
; PRIOR FILING DATE: 1994-01-27
; NUMBER OF SEQ ID NOS: 78

```



```

; OTHER INFORMATION: PRIMER 353
US-10-216-373-30

Query Match      0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY   2585 GTGCGTCTGGCCCTCCCA 2603
     ||||| |||||
Db    20 GTTCGTCTGCCGCTCCCA 2

RESULT 1350
US-10-016-149-35/c
; Sequence 35, Application US/10016149
; Publication No. US20030100524A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOLIPASE A2, GROUP V (CA2+-
; TITLE OF INVENTION: (DEPENDENT) EXPRESSION
; FILE REFERENCE: RTS-0325
; CURRENT APPLICATION NUMBER: US/10/016,149
; CURRENT FILING DATE: 2001-11-01
; NUMBER OF SEQ ID NOS: 84
; SEQ ID NO 35
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-016-149-35

Query Match      0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY   647 TGGAGGTGAATGCACAA 665
     ||||| |||||
Db    20 TGGAGGAGAAGGCTGCAA 2

RESULT 1351
US-10-108-164-127/c
; Sequence 127, Application US/10108164
; Publication No. US20030104356A1
; GENERAL INFORMATION:
; APPLICANT: Berger, Shelley L.
; APPLICANT: Fraser, Nigel W.
; APPLICANT: Tal-Singer, Ruth
; APPLICANT: Leary, Jeffrey J.
; TITLE OF INVENTION: Compounds And Methods For Treating And
; TITLE OF INVENTION: Screening Viral Reactivation
; FILE REFERENCE: P50682C1
; CURRENT APPLICATION NUMBER: US/10/108,164
; CURRENT FILING DATE: 2002-03-26
; PRIOR FILING DATE: 09/424,348
; PRIOR APPLICATION NUMBER: 1999-07-01
; PRIOR FILING DATE: 1998-07-01
; PRIOR APPLICATION NUMBER: PCT/US98/13733
; PRIOR FILING DATE: 1998-07-01
; PRIOR APPLICATION NUMBER: 60/051,633
; PRIOR FILING DATE: 1997-07-03
; PRIOR APPLICATION NUMBER: 60/054,515
; PRIOR FILING DATE: 1997-08-01
; PRIOR APPLICATION NUMBER: 60/080,352
; PRIOR FILING DATE: 1998-04-01
; NUMBER OF SEQ ID NOS: 145
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 127
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-108-164-127

Query Match      0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY   2000 AGCAGCTGTGGAGGACCT 2018
     ||||| |||||
Db    20 AGCTGCTGTGGAGGTCAAT 2

RESULT 1352
US-10-001-844-11
; Sequence 11, Application US/10001844
; Publication No. US20030105041A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Lex M. Cowsett
; TITLE OF INVENTION: ANTISENSE MODULATION OF SHH EXPRESSION
; FILE REFERENCE: ISPH-0617
; CURRENT APPLICATION NUMBER: US/10/001,844
; CURRENT FILING DATE: 2001-11-16
; NUMBER OF SEQ ID NOS: 49
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 11
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-001-844-11

Query Match      0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY   2323 GTGTGTGTGTGCGTGCTG 2341
     ||||| |||||
Db    2 GCGGGTGTGTGCGTGCGG 20

RESULT 1353
US-10-149-352-13
; Sequence 13, Application US/10149352
; Publication No. US20030105050A1
; GENERAL INFORMATION:
; APPLICANT: Beri, Rajinder
; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDES
; FILE REFERENCE: 06275-254U1
; CURRENT APPLICATION NUMBER: US/10/149,352
; CURRENT FILING DATE: 2002-06-10
; PRIOR APPLICATION NUMBER: PCT/GB00/04741
; PRIOR FILING DATE: 2000-12-12
; PRIOR APPLICATION NUMBER: GB 9929487.8
; PRIOR FILING DATE: 1999-12-15
; NUMBER OF SEQ ID NOS: 14
; SOFTWARE: PatentIn Ver. 4.0
; SEQ ID NO 13
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: Antisense oligonucleotide
US-10-149-352-13

Query Match      0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY   3652 TTGCTTTGCTGCGAGGCGCA 3670
     ||||| |||||
Db    1 TTTCGCCAGCAGGCGCCA 19

```


RESULT 1354
US-10-269-501-20
; Sequence 20, Application US/10269501
; Publication No. US20030113347A1
; GENERAL INFORMATION:
; APPLICANT: Schweiz. Serum- & Impfinstitut Bern
; APPLICANT: Cusi, Maria, Grazia
; APPLICANT: Gluck, Reinhard
; APPLICANT: Walti, Ernst
; TITLE OF INVENTION: Immunostimulating and Immunopotentiating Reconstituted Influenza
; TITLE OF INVENTION: Virosomes and Vaccines Containing Them
; FILE REFERENCE: 005848-0290158
; CURRENT APPLICATION NUMBER: US/10/269,501
; CURRENT FILING DATE: 2003-02-28
; PRIOR APPLICATION NUMBER: 09/264,551
; PRIOR FILING DATE: 1999-03-08
; PRIOR APPLICATION NUMBER: 08/255,740
; PRIOR FILING DATE: 1994-04-11
; PRIOR APPLICATION NUMBER: 07/965,246
; PRIOR FILING DATE: 1993-03-03
; PRIOR APPLICATION NUMBER: PCT/EP98/03050
; PRIOR FILING DATE: 1998-05-22
; PRIOR APPLICATION NUMBER: PCT/EP92/01014
; PRIOR FILING DATE: 1992-05-08
; PRIOR APPLICATION NUMBER: EP97108390.2
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: EP91107527.3
; PRIOR FILING DATE: 1991-05-08
; PRIOR APPLICATION NUMBER: EP91107647.9
; PRIOR FILING DATE: 1991-05-10
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 20
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-269-501-20

Query Match 0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2961 TCACCCATGCAGCAGAGG 2979
Db 2 TTACCCATGCAGCAGG 20

RESULT 1355
US-10-309-362-75
; Sequence 75, Application US/10309362
; Publication No. US20030114412A1
; GENERAL INFORMATION:
; APPLICANT: Donna T. Ward
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF REQL5 EXPRESSION
; FILE REFERENCE: RTS-0203
; CURRENT APPLICATION NUMBER: US/10/309,362
; CURRENT FILING DATE: 2002-12-03
; PRIOR APPLICATION NUMBER: US/09/798,185
; PRIOR FILING DATE: 2001-03-01
; NUMBER OF SEQ ID NOS: 92
; SEQ ID NO 75
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-309-362-75

Query Match 0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2961 TCACCCATGCAGCAGAGG 2979
Db 2 TTACCCATGCAGCAGG 20

Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 46 CCCGAGCGCTGCAGGTGC 64
Db 1 CCCGATCGCTGCAGATGC 19

RESULT 1356
US-10-007-010-11/c
; Sequence 11, Application US/10007010
; Publication No. US20030125275A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF HCK EXPRESSION
; FILE REFERENCE: RTS-0345
; CURRENT APPLICATION NUMBER: US/10/007,010
; CURRENT FILING DATE: 2001-12-04
; NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 11
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-007-010-11

Query Match 0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1348 GAGATGAGATGATGAAGA 1366
Db 19 GAGATGAAGACGATGACGA 1

RESULT 1357
US-10-007-010-25/c
; Sequence 25, Application US/10007010
; Publication No. US20030125275A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF HCK EXPRESSION
; FILE REFERENCE: RTS-0345
; CURRENT APPLICATION NUMBER: US/10/007,010
; CURRENT FILING DATE: 2001-12-04
; NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 25
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-007-010-25

Query Match 0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1393 AACCTGCTGGCGCTGCA 1411
Db 20 AACATGCTGGGCTCCTTCA 2

RESULT 1358
US-10-017-621-32/c
; Sequence 32, Application US/10017621
; Publication No. US20030138952A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Mark P. Roach
; TITLE OF INVENTION: ANTISENSE MODULATION OF PCTAIRE PROTEIN KINASE 1 EXPRESSION

```
; FILE REFERENCE: RTS-0350
; CURRENT APPLICATION NUMBER: US/10/017,621
; CURRENT FILING DATE: 2001-12-07
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 32
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-017-621-32

Query Match      0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2729 ACGGTACTGAGATGGG 2747
Db 20 ACGAGGACTTGAAGATGGG 2

RESULT 1359
US-10-017-621-46
; Sequence 46, Application US/10017621
; Publication No. US20030138952A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Mark P. Roach
; TITLE OF INVENTION: ANTISENSE MODULATION OF PCTAIRE PROTEIN KINASE 1 EXPRESSION
; FILE REFERENCE: RTS-0350
; CURRENT APPLICATION NUMBER: US/10/017,621
; CURRENT FILING DATE: 2001-12-07
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 46
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-017-621-46

Query Match      0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2864 AGGCTGGTACACGAGGC 2882
Db 2 AGGCTGACACGAGGC 20

RESULT 1360
US-10-187-049-10/c
; Sequence 10, Application US/10187049
; Publication No. US20030143218A1
; GENERAL INFORMATION:
; APPLICANT: Xu, Wenfeng
; APPLICANT: Yee, David P.
; APPLICANT: Presnell, Scott R.
; APPLICANT: Foster, Donald C.
; TITLE OF INVENTION: PROTEASE-ACTIVATED RECEPTOR
; NUMBER OF SEQUENCES: 12
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ZymoGenetics, Inc.
; STREET: 1201 Eastlake Avenue East
; CITY: Seattle
; STATE: WA
; COUNTRY: USA
; ZIP: 98102
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS

; FILE REFERENCE: RTS-0350
; CURRENT APPLICATION NUMBER: US/10/017,621
; CURRENT FILING DATE: 2001-12-07
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 32
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-017-621-32

Query Match      0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2729 ACGGTACTGAGATGGG 2747
Db 20 ACGAGGACTTGAAGATGGG 2

RESULT 1359
US-10-017-621-46
; Sequence 46, Application US/10017621
; Publication No. US20030138952A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Mark P. Roach
; TITLE OF INVENTION: ANTISENSE MODULATION OF PCTAIRE PROTEIN KINASE 1 EXPRESSION
; FILE REFERENCE: RTS-0350
; CURRENT APPLICATION NUMBER: US/10/017,621
; CURRENT FILING DATE: 2001-12-07
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 46
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-017-621-46

Query Match      0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2864 AGGCTGGTACACGAGGC 2882
Db 2 AGGCTGACACGAGGC 20

RESULT 1360
US-10-187-049-10/c
; Sequence 10, Application US/10187049
; Publication No. US20030143218A1
; GENERAL INFORMATION:
; APPLICANT: Xu, Wenfeng
; APPLICANT: Yee, David P.
; APPLICANT: Presnell, Scott R.
; APPLICANT: Foster, Donald C.
; TITLE OF INVENTION: PROTEASE-ACTIVATED RECEPTOR
; NUMBER OF SEQUENCES: 12
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ZymoGenetics, Inc.
; STREET: 1201 Eastlake Avenue East
; CITY: Seattle
; STATE: WA
; COUNTRY: USA
; ZIP: 98102
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS

; FILE REFERENCE: RTS-0350
; CURRENT APPLICATION NUMBER: US/10/187,049
; FILING DATE: 28-Jun-2002
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: <Unknown>
; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: Leith, Debra K
; REGISTRATION NUMBER: 32,619
; REFERENCE/DOCKET NUMBER: 98-10
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 206-442-6674
; TELEFAX: 206-442-6678
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 10:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 10:
US-10-187-049-10

Query Match      0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2415 CCCGCTGCTGTGCAACGG 2433
Db 20 CCATGCTGCTGTGCTACGG 2

RESULT 1361
US-10-024-396-52
; Sequence 52, Application US/10024396
; Publication No. US20030147864A1
; GENERAL INFORMATION:
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF CD36L1 EXPRESSION
; FILE REFERENCE: RTS-0339
; CURRENT APPLICATION NUMBER: US/10/024,396
; CURRENT FILING DATE: 2001-12-18
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 52
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-396-52

Query Match      0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2334 CGTGTGTGTGTGTGTGTC 2352
Db 1 CGCATGTGTGTGTGTGTGTC 19

RESULT 1362
US-10-029-517-76
; Sequence 76, Application US/10029517
; Publication No. US20030148969A1
; GENERAL INFORMATION:
; APPLICANT: Kenneth W. Dobie
; APPLICANT: Susan J. Myers
; TITLE OF INVENTION: ANTISENSE MODULATION OF MUCIN 1, TRANSMEMBRANE EXPRESSION
; FILE REFERENCE: RTS-0352
; CURRENT APPLICATION NUMBER: US/10/029,517
; CURRENT FILING DATE: 2001-12-20
```

```
; NUMBER OF SEQ ID NOS: 107
; SEQ ID NO 76
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-029-517-76

Query Match          0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2380 CATTTGCTCTCCAGTGCA 2398
    |||||
Db 1 CATTTGCTCTCGGTGCA 19

RESULT 1363
US-10-348-485-83/c
; Sequence 83, Application US/10348485
; Publication No. US20030148989A1
; GENERAL INFORMATION:
; APPLICANT: Bennett, C. Frank
; APPLICANT: Dean, Nicholas M.
; APPLICANT: Holmlund, Jon T.
; APPLICANT: Dorr, F. Andrew
; TITLE OF INVENTION: Oligonucleotide Modulation Of Protein Kinase C
; FILE REFERENCE: ISIS4954
; CURRENT APPLICATION NUMBER: US/10/348,485
; CURRENT FILING DATE: 2003-01-21
; PRIOR APPLICATION NUMBER: US/10/025,139
; PRIOR FILING DATE: 2001-12-18
; PRIOR APPLICATION NUMBER: US 08/829,637
; PRIOR FILING DATE: 1997-03-31
; PRIOR APPLICATION NUMBER: US 08/478,178
; PRIOR FILING DATE: 1995-06-07
; PRIOR APPLICATION NUMBER: US 08/089,996
; PRIOR FILING DATE: 1993-07-09
; PRIOR APPLICATION NUMBER: US 07/852,852
; PRIOR FILING DATE: 1992-03-16
; NUMBER OF SEQ ID NOS: 121
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 83
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-348-485-83

Query Match          0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1812 CTTTGGGTCCTGCTCTGG 1830
    |||||
Db 19 CTGTGGGTCTCTGCTCTGG 1

RESULT 1364
US-10-339-604-66/c
; Sequence 66, Application US/10339604
; Publication No. US20030152982A1
; GENERAL INFORMATION:
; APPLICANT: DE BEENHOUWER, HANS
; APPLICANT: PORTAELS, FRANCOISE
; APPLICANT: MACHTELINCKX, LIEVE
; APPLICANT: JANNES, GERT
; APPLICANT: ROSSAU, RUDI
; TITLE OF INVENTION: Oligonucleotide Molecules for Use in Detection of Mycobacterium
; TITLE OF INVENTION: Antibiotic Resistance
; FILE REFERENCE: 1657.0010001
```

```
; CURRENT APPLICATION NUMBER: US/10/339,604
; CURRENT FILING DATE: 2003-01-10
; PRIOR APPLICATION NUMBER: US/09/722,319
; PRIOR FILING DATE: 2000-11-28
; ORGANISM: Artificial Sequence
; APPLICANT: US 08/750,088
; PRIOR FILING DATE: 1996-12-06
; PRIOR APPLICATION NUMBER: PCT/EP95/02230
; PRIOR FILING DATE: 1995-06-09
; PRIOR APPLICATION NUMBER: EP 94870093.5
; PRIOR FILING DATE: 1994-06-09
; NUMBER OF SEQ ID NOS: 73
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 66
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-10-339-604-66

Query Match          0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 355 GAGTTCGCGCGGAGCACC 373
    |||||
Db 20 GAGGTCCGCGACGTGCACC 2

RESULT 1365
US-10-376-566-67
; Sequence 67, Application US/10376566
; Publication No. US20030158144A1
; GENERAL INFORMATION:
; APPLICANT: Kenneth W. Dobie
; APPLICANT: Mark P. Roach
; APPLICANT: Erich Koller
; TITLE OF INVENTION: ANTISENSE MODULATION OF ESTROGEN RECEPTOR BETA EXPRESSION
; FILE REFERENCE: RTS-0347
; CURRENT APPLICATION NUMBER: US/10/376,566
; CURRENT FILING DATE: 2003-02-27
; PRIOR APPLICATION NUMBER: US/10/005,058
; PRIOR FILING DATE: 2001-12-07
; NUMBER OF SEQ ID NOS: 96
; SEQ ID NO 67
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-376-566-67

Query Match          0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2608 CAAAGCTGAGCCTGCAGGG 2625
    |||||
Db 2 CAAAGATGAGCTTGCCGGG 20

RESULT 1366
US-10-197-927-53/c
; Sequence 53, Application US/10197927
; Publication No. US20030166138A1
; GENERAL INFORMATION:
; APPLICANT: Kinsella, Todd
; APPLICANT: Ohashi, Cara
; APPLICANT: Anderson, Dave
; TITLE OF INVENTION: Cyclic Peptides and Analogs Useful to Treat Allergies
; FILE REFERENCE: RIGL-002/01US
; CURRENT APPLICATION NUMBER: US/10/197,927
; CURRENT FILING DATE: 2003-01-23
```

; PRIOR APPLICATION NUMBER: 60/358,827
 ; PRIOR FILING DATE: 2002-02-21
 ; NUMBER OF SEQ ID NOS: 59
 ; SOFTWARE: PatentIn version 3.1
 ; SEQ ID NO 53
 ; LENGTH: 20
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: synthetic primer
 US-10-197-53

Query Match 0.4%; Score 14.2; DB 1; Length 20;
 Best Local Similarity 84.2%; Pred. No. 9.1e+02;
 Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 866 TGGAGGCTGACGAGCGGG 884
 Db 20 TGGAGGCTGAAGCGCGGG 2

RESULT 1367

US-10-091-625-53
 ; Sequence 53, Application US/10091625
 ; Publication No. US20030170636A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Susan M. Freier
 ; TITLE OF INVENTION: ANTISENSE MODULATION OF JAGGED 2 EXPRESSION
 ; FILE REFERENCE: RTS-0244
 ; CURRENT APPLICATION NUMBER: US/10/091,625
 ; CURRENT FILING DATE: 2002-03-05
 ; NUMBER OF SEQ ID NOS: 90
 ; SEQ ID NO 53
 ; LENGTH: 20
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Antisense Oligonucleotide
 US-10-091-625-53

Query Match 0.4%; Score 14.2; DB 1; Length 20;
 Best Local Similarity 84.2%; Pred. No. 9.1e+02;
 Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 3048 GGGCCCTGGCAGCTTGT 3066
 Db 1 GGGCTGGCAGCACTTGT 19

RESULT 1368

US-10-091-625-72/c
 ; Sequence 72, Application US/10091625
 ; Publication No. US20030170636A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Susan M. Freier
 ; TITLE OF INVENTION: ANTISENSE MODULATION OF JAGGED 2 EXPRESSION
 ; FILE REFERENCE: RTS-0244
 ; CURRENT APPLICATION NUMBER: US/10/091,625
 ; CURRENT FILING DATE: 2002-03-05
 ; NUMBER OF SEQ ID NOS: 90
 ; SEQ ID NO 72
 ; LENGTH: 20
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Antisense Oligonucleotide
 US-10-091-625-72

Query Match 0.4%; Score 14.2; DB 1; Length 20;
 Best Local Similarity 84.2%; Pred. No. 9.1e+02;
 Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1621 AGGACCTGGTCCCGCA 1639

Db 20 AGGACCTGGTGCACGCA 2

RESULT 1369

US-10-032-585-4348
 ; Sequence 4348, Application US/10032585
 ; Publication No. US20030180953A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Terry, Roemer D.
 ; APPLICANT: Bo, Jiang
 ; APPLICANT: Howard, Bussey
 ; TITLE OF INVENTION: Gene Disruption Methodologies for Drug Target Discovery
 ; FILE REFERENCE: 10182-005-999
 ; CURRENT APPLICATION NUMBER: US/10/032,585
 ; CURRENT FILING DATE: 2001-12-20
 ; NUMBER OF SEQ ID NOS: 8000
 ; SOFTWARE: PatentIn version 3.1
 ; SEQ ID NO 4348
 ; LENGTH: 20
 ; TYPE: DNA
 ; ORGANISM: Candida albicans
 US-10-032-585-4348

Query Match 0.4%; Score 14.2; DB 1; Length 20;
 Best Local Similarity 84.2%; Pred. No. 9.1e+02;
 Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1638 CAATGCTGCTGACCGAG 1656
 Db 1 CAATGCTGCTGACCGTG 19

RESULT 1370

US-10-032-585-5557
 ; Sequence 5557, Application US/10032585
 ; Publication No. US20030180953A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Terry, Roemer D.
 ; APPLICANT: Bo, Jiang
 ; APPLICANT: Howard, Bussey
 ; TITLE OF INVENTION: Gene Disruption Methodologies for Drug Target Discovery
 ; FILE REFERENCE: 10182-005-999
 ; CURRENT APPLICATION NUMBER: US/10/032,585
 ; CURRENT FILING DATE: 2001-12-20
 ; NUMBER OF SEQ ID NOS: 8000
 ; SOFTWARE: PatentIn version 3.1
 ; SEQ ID NO 5557
 ; LENGTH: 20
 ; TYPE: DNA
 ; ORGANISM: Candida albicans
 US-10-032-585-5557

Query Match 0.4%; Score 14.2; DB 1; Length 20;
 Best Local Similarity 84.2%; Pred. No. 9.1e+02;
 Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 829 GCCTGCTGCTGCTGCTG 847
 Db 2 GAGTGGCTGGTGGTTTTC 20

RESULT 1371

US-10-096-399A-53
 ; Sequence 53, Application US/10096399A
 ; Publication No. US20030185829A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Koller, Erich
 ; APPLICANT: Shepard, Peter J.
 ; TITLE OF INVENTION: JAGGED 2 INHIBITORS FOR INDUCING APOPTOSIS
 ; FILE REFERENCE: ISPH-0660

; CURRENT APPLICATION NUMBER: US/10/096.399A
; CURRENT FILING DATE: 2002-03-12
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 53
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense oligonucleotide
US-10-096-399A-53

Query Match 0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 3048 GGGCCCTGGCAGCTTCT 3066
||||| ||||| ||||| |||||
Db 1 GGGCTGCTGGCAGCTTGT 19

RESULT 1372
US-10-096-399A-72/c
; Sequence 72, Application US/10096399A
; Publication No. US20030185829A1
; GENERAL INFORMATION:
; APPLICANT: Koller, Erich
; APPLICANT: Shepard, Peter J.
; TITLE OF INVENTION: JAGGED 2 INHIBITORS FOR INDUCING APOPTOSIS
; FILE REFERENCE: ISPH-0660
; CURRENT APPLICATION NUMBER: US/10/096.399A
; CURRENT FILING DATE: 2002-03-12
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 72
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense oligonucleotide
US-10-096-399A-72

Query Match 0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1621 AGGACCTGGTGGCCGCA 1639
||||| ||||| ||||| |||||
Db 20 AGGACCTGGCTGACGCA 2

RESULT 1373
US-10-084-839-2531
; Sequence 2531, Application US/10084839
; Publication No. US20030186238A1
; GENERAL INFORMATION:
; APPLICANT: Third Wave Technologies
; APPLICANT: Allawi, Hatim
; APPLICANT: Argue, Brad T.
; APPLICANT: Bartholomay, Christian T.
; APPLICANT: Chehak, LuAnne
; APPLICANT: Curtis, Michelle L.
; APPLICANT: Eis, Peggy S.
; APPLICANT: Hall, Jeff G.
; APPLICANT: Ip, Hon S.
; APPLICANT: Ji, Lin
; APPLICANT: Kaiser, Michael
; APPLICANT: Kwiatkowski, Jr., Robert W.
; APPLICANT: Lukowiak, Andrew A.
; APPLICANT: Lyamichuev, Victor
; APPLICANT: Lyamacheva, Natalie E.
; APPLICANT: Ma, WuPo
; APPLICANT: Neri, Bruce P.

; APPLICANT: Olson, Sarah M.
; APPLICANT: Olson-Munoz, Marilyn C.
; APPLICANT: Schaefer, James J.
; APPLICANT: Skrzypczynski, Zbigniew
; APPLICANT: Takova, Teeteka Y.
; APPLICANT: Thompson, Lisa C.
; APPLICANT: Vedvik, Kevin L.
; TITLE OF INVENTION: RNA Detection Assays
; FILE REFERENCE: FORS-06666
; CURRENT APPLICATION NUMBER: US/10/084.839
; CURRENT FILING DATE: 2002-02-26
; NUMBER OF SEQ ID NOS: 4004
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 2531
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-084-839-2531

Query Match 0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 470 ACAAGTTTGGCAGCATCCG 488
||||| ||||| ||||| |||||
Db 1 ACAAGTTTGGCAGCGTGGC 19

RESULT 1374
US-10-369-845-4/c
; Sequence 4, Application US/10369845
; Publication No. US20030186441A1
; GENERAL INFORMATION:
; APPLICANT: Nicolaides, Nicholas C
; APPLICANT: Grasso, Luigi
; APPLICANT: Sasse, Philip M
; TITLE OF INVENTION: METHODS FOR ISOLATING NOVEL ANTIMICROBIAL AGENTS FROM
; TITLE OF INVENTION: HYPERMUTABLE CELLS
; FILE REFERENCE: MOR-0005
; CURRENT APPLICATION NUMBER: US/10/369.845
; CURRENT FILING DATE: 2003-02-19
; PRIOR APPLICATION NUMBER: US/09/708,200
; PRIOR FILING DATE: 2000-11-07
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:oligonucleotide
US-10-369-845-4

Query Match 0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1777 GACCGAGTCTACACTACC 1795
||||| ||||| ||||| |||||
Db 20 GACAGAGTCTTCACTAAC 2

RESULT 1375
US-10-321-856-243
; Sequence 243, Application US/10321856
; Publication No. US20030194393A1
; GENERAL INFORMATION:
; APPLICANT: Milhausen, Michael James
; TITLE OF INVENTION: TOXOPLASMA GONDII PROTEINS, NUCLEIC ACID MOLECULES, AND USES THERE
; FILE REFERENCE: TX-1-C2-1

; CURRENT APPLICATION NUMBER: US/10/321,856
; CURRENT FILING DATE: 2002-12-17
; PRIOR APPLICATION NUMBER: 09/216,393
; PRIOR FILING DATE: 1998-12-18
; PRIOR APPLICATION NUMBER: 08/994,825
; PRIOR FILING DATE: 1997-12-19
; NUMBER OF SEQ ID NOS: 366
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 243
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Primer
US-10-321-856-243

Query Match 0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2850 TATGGAAGGAAAGGCT 2868
Db 1 TGTGGCAGCAAAAGGCT 19

RESULT 1376
US-10-311-886-45
; Sequence 45, Application US/10311886
; Publication No. US2003019515A1
; GENERAL INFORMATION:
; APPLICANT: K.U. LEUVEN Research and Development et al.
; TITLE OF INVENTION: Biocatalyst inhibitors
; FILE REFERENCE: PCT/BE 01/00106
; CURRENT APPLICATION NUMBER: US/10/311,886
; CURRENT FILING DATE: 2002-12-23
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 45
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer 10
US-10-311-886-45

Query Match 0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2034 CGTGACGTCCACCCACGAG 2052
Db 2 CTTGACGTCCACCATCGAG 20

RESULT 1377
US-10-193-477-105
; Sequence 105, Application US/10193477
; Publication No. US20030195163A1
; GENERAL INFORMATION:
; APPLICANT: Bristol-Myers Squibb Company
; TITLE OF INVENTION: POLYNUCLEOTIDES ENCODING THREE NOVEL HUMAN CELL SURFACE PROTEINS
; TITLE OF INVENTION: LEUCINE RICH REPEATS AND IMMUNOGLOBULIN FOLDS, BGS2, 3, AND 4,
; FILE REFERENCE: D0153 NP
; CURRENT APPLICATION NUMBER: US/10/193,477
; CURRENT FILING DATE: 2002-07-11
; PRIOR APPLICATION NUMBER: US 60/304,888
; PRIOR FILING DATE: 2001-07-11
; PRIOR APPLICATION NUMBER: US 60/372,147
; PRIOR FILING DATE: 2002-04-12
; NUMBER OF SEQ ID NOS: 229
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 105

; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-193-477-105

Query Match 0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2340 TGTGTGTGTGCACATCC 2358
Db 2 TGTGTGTGACTGCACCTCC 20

RESULT 1378
US-10-193-477-113
; Sequence 113, Application US/10193477
; Publication No. US20030195163A1
; GENERAL INFORMATION:
; APPLICANT: Bristol-Myers Squibb Company
; TITLE OF INVENTION: POLYNUCLEOTIDES ENCODING THREE NOVEL HUMAN CELL SURFACE PROTEINS
; TITLE OF INVENTION: LEUCINE RICH REPEATS AND IMMUNOGLOBULIN FOLDS, BGS2, 3, AND 4,
; FILE REFERENCE: D0153 NP
; CURRENT APPLICATION NUMBER: US/10/193,477
; CURRENT FILING DATE: 2002-07-11
; PRIOR APPLICATION NUMBER: US 60/304,888
; PRIOR FILING DATE: 2001-07-11
; PRIOR APPLICATION NUMBER: US 60/372,147
; PRIOR FILING DATE: 2002-04-12
; NUMBER OF SEQ ID NOS: 229
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 113
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-193-477-113

Query Match 0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2340 TGTGTGTGTGCACATCC 2358
Db 2 TGTGTGTGACTGCACCTCC 20

RESULT 1379
US-10-005-344-338/c
; Sequence 338, Application US/10005344
; Publication No. US20030203862A1
; GENERAL INFORMATION:
; APPLICANT: Loren J. Miraglia
; APPLICANT: Pamela Nero
; APPLICANT: Mark J. Graham
; APPLICANT: Brett P. Monia
; APPLICANT: Erich Koller
; APPLICANT: Mingyi Chiang
; APPLICANT: Mano Manoharan
; TITLE OF INVENTION: Antisense Modulation of mdm2 expression.
; FILE REFERENCE: ISPH-0622
; CURRENT APPLICATION NUMBER: US/10/005,344
; CURRENT FILING DATE: 2001-12-04
; PRIOR APPLICATION NUMBER: US 09/048,810
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: US 09/280,805
; PRIOR FILING DATE: 1999-03-26
; NUMBER OF SEQ ID NOS: 379
; SOFTWARE: Fast-Seq for Windows Version 4.0
; SEQ ID NO 338
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence

```
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-005-344-338

Query Match          0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2305 CAGAGCTTTGGTCTGTGTG 2323
Db 19 CCGAGCCTGGGCTCTGTGTG 1

RESULT 1380
US-10-461-668-53
; Sequence 53, Application US/10461668
; Publication No. US20030207839A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF JAGGED 2 EXPRESSION
; FILE REFERENCE: RTS-0244
; CURRENT APPLICATION NUMBER: US/10/461,668
; CURRENT FILING DATE: 2003-06-13
; PRIOR APPLICATION NUMBER: US/10/091,625
; PRIOR FILING DATE: 2002-03-05
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 53
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-461-668-53

Query Match          0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3048 GGGCCCTGGCAGCTCTGTG 3066
Db 1 GGGCTGCTGGCAGACTTGT 19

RESULT 1381
US-10-461-668-72/c
; Sequence 72, Application US/10461668
; Publication No. US20030207839A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF JAGGED 2 EXPRESSION
; FILE REFERENCE: RTS-0244
; CURRENT APPLICATION NUMBER: US/10/461,668
; CURRENT FILING DATE: 2003-06-13
; PRIOR APPLICATION NUMBER: US/10/091,625
; PRIOR FILING DATE: 2002-03-05
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 72
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-461-668-72

Query Match          0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1621 AGGACCTGGTGGCCGCA 1639
Db 20 AGGACCTGGCTGACACA 2
```

```
RESULT 1382
US-10-144-488-57/c
; Sequence 57, Application US/10144488
; Publication No. US20030212017A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF FARNESYL TRANSFERASE BETA SUBUNIT EXPRESSION
; FILE REFERENCE: RTS-0363
; CURRENT APPLICATION NUMBER: US/10/144,488
; CURRENT FILING DATE: 2002-05-10
; NUMBER OF SEQ ID NOS: 80
; SEQ ID NO 57
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-144-488-57

Query Match          0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 533 CCATCCTGCAGCGGGGCT 551
Db 19 CCTTCTGCAGCGGGGCT 1

RESULT 1383
US-10-181-873A-78
; Sequence 78, Application US/10181873A
; Publication No. US20030212019A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF COT ONCOGENE EXPRESSION
; FILE REFERENCE: RTSP-0346
; CURRENT APPLICATION NUMBER: US/10/181,873A
; CURRENT FILING DATE: 2002-12-13
; PRIOR APPLICATION NUMBER: PCT/US01/01417
; PRIOR FILING DATE: 2001-01-16
; PRIOR APPLICATION NUMBER: 09/489,868
; PRIOR FILING DATE: 2000-01-20
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 78
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-181-873A-78

Query Match          0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3447 TTAGATGTTACAAATTTAT 3465
Db 2 TTACATGTTACAAATATAT 20

RESULT 1384
US-10-400-670-4/c
; Sequence 4, Application US/10400670
; Publication No. US20030215854A1
; GENERAL INFORMATION:
; APPLICANT: CLAUSEN, PETER A.
; TITLE OF INVENTION: DETECTION OF DNA-BINDING PROTEINS
; FILE REFERENCE: 39147-0013
; CURRENT APPLICATION NUMBER: US/10/400,670
; CURRENT FILING DATE: 2003-06-28
; NUMBER OF SEQ ID NOS: 11
```

; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: hairpin oligonucleotide
US-10-400-670-4

Query Match 0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1193 CCCTGGGCAAGCCCTTGG 1211
Db 20 CACTGGGGAATCCCTTGG 2

RESULT 1385
US-10-438-075-14
; Sequence 14, Application US/10438075
; Publication No. US20030216345A1
; GENERAL INFORMATION:
; APPLICANT: Schering Aktiengesellschaft
; TITLE OF INVENTION: Histone deacetylase inhibitor and use thereof
; FILE REFERENCE: 1023370
; CURRENT APPLICATION NUMBER: US/10/438,075
; CURRENT FILING DATE: 2003-05-15
; NUMBER OF SEQ ID NOS: 31
; SEQ ID NO 14
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; NAME/KEY:
; LOCATION:
; OTHER INFORMATION: Antisense oligonucleotide no.12
US-10-438-075-14

Query Match 0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2117 GCTCCTCAGGGGAGCTC 2135
Db 2 GCTCCTCAGGGGAGCTGCC 20

RESULT 1386
US-10-114-279-68
; Sequence 68, Application US/10114279
; Publication No. US20030219742A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF HMGI-C EXPRESSION
; FILE REFERENCE: RTS-0296
; CURRENT APPLICATION NUMBER: US/10/114,279
; CURRENT FILING DATE: 2002-03-29
; NUMBER OF SEQ ID NOS: 98
; SEQ ID NO 68
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-114-279-68

Query Match 0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 573 GCTGGGCAAGCAGCTGGAG 591
Db 1 GCTGGGCAAGCAGCTGGAG 19

RESULT 1387
US-10-282-174-292/c
; Sequence 292, Application US/10282174
; Publication No. US20030224380A1
; GENERAL INFORMATION:
; APPLICANT: Becker, Kenneth David
; APPLICANT: Velicelebi, Gonul
; APPLICANT: Elliot, Kathryn J.
; APPLICANT: Wang, Xin
; APPLICANT: Tanzi, Rudolph E.
; APPLICANT: Bertram, Lars
; APPLICANT: Saunders, Aleister J.
; APPLICANT: Mullin, Kristina M.
; APPLICANT: Sampson, Andrew Johnson
; APPLICANT: Blacker, Deborah Lynne
; TITLE OF INVENTION: GENES AND POLYMORPHISMS ON CHROMOSOME 10
; TITLE OF INVENTION: ASSOCIATED WITH ALZHEIMER'S DISEASE AND OTHER
; FILE REFERENCE: 37481-3308
; CURRENT APPLICATION NUMBER: US/10/282,174
; CURRENT FILING DATE: 2002-10-25
; PRIOR APPLICATION NUMBER: US 60/339,525
; PRIOR FILING DATE: 2001-10-25
; PRIOR APPLICATION NUMBER: US 60/338,010
; PRIOR FILING DATE: 2001-11-08
; PRIOR APPLICATION NUMBER: US 60/336,929
; PRIOR FILING DATE: 2001-11-08
; PRIOR APPLICATION NUMBER: US 60/338,363
; PRIOR FILING DATE: 2001-11-09
; PRIOR APPLICATION NUMBER: US 60/337,052
; PRIOR FILING DATE: 2001-12-04
; PRIOR APPLICATION NUMBER: US 60/368,919
; PRIOR FILING DATE: 2002-03-28
; NUMBER OF SEQ ID NOS: 564
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 292
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-10-282-174-292

Query Match 0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1386 CATCATCAACCTGCTGGC 1404
Db 20 CAGCTTCAACCTGCTGGC 2

RESULT 1388
US-10-159-266-80
; Sequence 80, Application US/10159266
; Publication No. US20030224511A1
; GENERAL INFORMATION:
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF CATHEPSIN Z EXPRESSION
; FILE REFERENCE: RTS-0398
; CURRENT APPLICATION NUMBER: US/10/159,266
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 158
; SEQ ID NO 80
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide
US-10-159-266-80

Query Match 0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2232 AGCAGCCACCTGCTGCT 2250
|||||
DB 1 AGCAGCCTACCTGGTCT 19

RESULT 1389
US-10-159-266-152/c
; Sequence 152, Application US/10159266
; Publication No. US20030224511A1
; GENERAL INFORMATION:
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF CATHEPSIN Z EXPRESSION
; FILE REFERENCE: RTS-0398
; CURRENT APPLICATION NUMBER: US/10/159,266
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 158
; SEQ ID NO 152
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-159-266-152

Query Match 0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2232 AGCAGCCACCTGCTGCT 2250
|||||
DB 20 AGCAGCCTACCTGGTCT 2

RESULT 1390
US-10-159-942-28
; Sequence 28, Application US/10159942
; Publication No. US20030224512A1
; GENERAL INFORMATION:
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF BETA-SITE APP-CLEAVING ENZYME EXPRESSION
; FILE REFERENCE: RTS-0383
; CURRENT APPLICATION NUMBER: US/10/159,942
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 133
; SEQ ID NO 28
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-159-942-28

Query Match 0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 657 TGGCAGCAAGTGGGCCG 675
|||||
DB 1 TGGCAGCAATGTGGCAG 19

RESULT 1391
US-10-159-942-100/c
; Sequence 100, Application US/10159942
; Publication No. US20030224512A1
; GENERAL INFORMATION:
; APPLICANT: Kenneth W. Dobie

; TITLE OF INVENTION: ANTISENSE MODULATION OF BETA-SITE APP-CLEAVING ENZYME EXPRESSION
; FILE REFERENCE: RTS-0383
; CURRENT APPLICATION NUMBER: US/10/159,942
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 133
; SEQ ID NO 100
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-159-942-100

Query Match 0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 657 TGGCAGCAAGTGGGCCG 675
|||||
DB 20 TGGCAGCAATGTGGCAG 2

RESULT 1392
US-10-388-263-423
; Sequence 423, Application US/10388263
; Publication No. US20030228597A1
; GENERAL INFORMATION:
; APPLICANT: Cowsett, Lex M.
; APPLICANT: Baker, Brenda F.
; APPLICANT: McNeil, John
; APPLICANT: Freier, Susan M.
; APPLICANT: Sasmor, Henri M.
; APPLICANT: Brooks, Douglas G.
; APPLICANT: Ohashi, Cara
; APPLICANT: Wyatt, Jacqueline R.
; APPLICANT: Borchers, Alexander
; APPLICANT: Vickers, Timothy A.
; TITLE OF INVENTION: IDENTIFICATION OF GENETIC TARGETS FOR
; TITLE OF INVENTION: MODULATION BY OLIGONUCLEOTIDES AND
; TITLE OF INVENTION: GENERATION OF OLIGONUCLEOTIDES FOR GENE MODULATION
; FILE REFERENCE: ISIS-4503
; CURRENT APPLICATION NUMBER: US/10/388,263
; CURRENT FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 947
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 423
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-388-263-423

Query Match 0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3048 GGGCCCCCTGGCCTCTGT 3056
|||||
DB 1 GGGCTGCTGGCACACTGT 19

RESULT 1393
US-10-388-263-442/c
; Sequence 442, Application US/10388263
; Publication No. US20030228597A1
; GENERAL INFORMATION:
; APPLICANT: Cowsett, Lex M.
; APPLICANT: Baker, Brenda F.
; APPLICANT: McNeil, John
; APPLICANT: Freier, Susan M.
; APPLICANT: Sasmor, Henri M.
; APPLICANT: Brooks, Douglas G.
; APPLICANT: Ohashi, Cara

```
; APPLICANT: Wyatt, Jacqueline R.
; APPLICANT: Borchers, Alexander
; APPLICANT: Vickers, Timothy A.
; TITLE OF INVENTION: IDENTIFICATION OF GENETIC TARGETS FOR
; TITLE OF INVENTION: MODULATION BY OLIGONUCLEOTIDES AND
; TITLE OF INVENTION: GENERATION OF OLIGONUCLEOTIDES FOR GENE MODULATION
; FILE REFERENCE: ISIS-4503
; CURRENT APPLICATION NUMBER: US/10/388,263
; CURRENT FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 947
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 442
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-388-263-442

Query Match      0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1621 AGGACCTGGCTGCCGCA 1639
Db 20 AGGACCTGGCTGCACGCA 2

RESULT 1394
US-10-159-856-80/c
; Sequence 80, Application US/10159856
; Publication No. US20030228689A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF G PROTEIN-COUPLED RECEPTOR KINASE 6 EXPRE
; FILE REFERENCE: RTS-0365
; CURRENT APPLICATION NUMBER: US/10/159,856
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 134
; SEQ ID NO 80
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-159-856-80

Query Match      0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2545 ATGGCTCGGCTCTGCCTT 2563
Db 19 ATAGGTCTGCCTCTGCCTT 1

RESULT 1395
US-10-159-856-83/c
; Sequence 83, Application US/10159856
; Publication No. US20030228689A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF G PROTEIN-COUPLED RECEPTOR KINASE 6 EXPRE
; FILE REFERENCE: RTS-0365
; CURRENT APPLICATION NUMBER: US/10/159,856
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 134
; SEQ ID NO 83
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
```

```
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-159-856-83

Query Match      0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2327 GTGTGTCGGTGTGTGTG 2345
Db 20 GTGTGTACCTGTGTGGTG 2

RESULT 1396
US-10-159-856-130
; Sequence 130, Application US/10159856
; Publication No. US20030228689A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF G PROTEIN-COUPLED RECEPTOR KINASE 6 EXPRE
; FILE REFERENCE: RTS-0365
; CURRENT APPLICATION NUMBER: US/10/159,856
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 134
; SEQ ID NO 130
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-159-856-130

Query Match      0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2545 ATGGCTCGGCTCTGCCTT 2563
Db 2 ATAGGTCTGCCTCTGCCTT 20

RESULT 1397
US-10-173-240-28/c
; Sequence 28, Application US/10173240
; Publication No. US20030232436A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF E2-EPF EXPRESSION
; FILE REFERENCE: HTS-0021
; CURRENT APPLICATION NUMBER: US/10/173,240
; CURRENT FILING DATE: 2002-06-14
; NUMBER OF SEQ ID NOS: 80
; SEQ ID NO 28
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-173-240-28

Query Match      0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 687 CTACGTTACGTCCTCAAG 705
Db 19 CTGCGTCACGTCGTCAG 1

RESULT 1398
US-10-173-240-39/c
; Sequence 39, Application US/10173240
```



```
; APPLICANT: Eric G. Marcussen
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: EXTRACELLULAR-SIGNAL-REGULATED KINASE-6 INHIBITORS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS
; FILE REFERENCE: ISPH-0728
; CURRENT APPLICATION NUMBER: US/10/348,431
; CURRENT FILING DATE: 2003-01-17
; NUMBER OF SEQ ID NOS: 71
; SEQ ID NO 29
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-348-431-29

Query Match      0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1679 ACTTCGGCTGGCCGGCA 1697
Db 20 ACTTCGGCTGGCCAGCA 2

RESULT 1404
US-10-188-646-64/c
; Sequence 64, Application US/10188646
; Publication No. US20040005565A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF LIVIN EXPRESSION
; FILE REFERENCE: RTS-0373
; CURRENT APPLICATION NUMBER: US/10/188,646
; CURRENT FILING DATE: 2002-07-02
; NUMBER OF SEQ ID NOS: 153
; SEQ ID NO 64
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-188-646-64

Query Match      0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 663 CAAGGTGGCCCGGACGGC 681
Db 20 CAAGGTGTGCTGGACGC 2

RESULT 1405
US-10-188-646-134
; Sequence 134, Application US/10188646
; Publication No. US20040005565A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF LIVIN EXPRESSION
; FILE REFERENCE: RTS-0373
; CURRENT APPLICATION NUMBER: US/10/188,646
; CURRENT FILING DATE: 2002-07-02
; NUMBER OF SEQ ID NOS: 153
; SEQ ID NO 134
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-188-646-134
```

```
Query Match      0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 663 CAAGGTGGCCCGGACGGC 681
Db 1 CAAGGTGTGCTGGACGC 19

RESULT 1406
US-10-349-143-11617
; Sequence 11617, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CP1
; CURRENT APPLICATION NUMBER: US/10/349,143
; CURRENT FILING DATE: 2003-01-21
; PRIOR APPLICATION NUMBER: US/09/422,978
; PRIOR FILING DATE: 1999-10-20
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
; PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 11617
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..20
; OTHER INFORMATION: downstream amplification primer 99-11206 for SEQ 3752, in complete
US-10-349-143-11617

Query Match      0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2847 ATATATGGAAGAGGAAAG 2865
Db 2 AGATATGGAAGAGGAGAG 20

RESULT 1407
US-10-289-762-1841/C
; Sequence 1841, Application US/10289762
; Publication No. US20040006218A1
; GENERAL INFORMATION:
; APPLICANT: Grifais, R.
; TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments
; TITLE OF INVENTION: thereof and uses thereof, in particular for the diagnosis, prevent
; TITLE OF INVENTION: and treatment of infection
; FILE REFERENCE: 9710-003-999
; CURRENT APPLICATION NUMBER: US/10/289,762
; CURRENT FILING DATE: 2003-03-27
; NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 1841
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Chlamydia pneumoniae
US-10-289-762-1841

Query Match      0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
Qy 1208 TTGGGGAGGGCTGCTCGG 1226
Db 19 TTGAAGAAGGCTGCTCGG 1

RESULT 1408
US-10-289-762-3458
; Sequence 3458, Application US/10289762
; Publication No. US20040006218A1
; GENERAL INFORMATION:
; APPLICANT: Griffiths, R.
; TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments
; TITLE OF INVENTION: thereof and uses thereof, in particular for the diagnosis, prevention
; TITLE OF INVENTION: and treatment of infection
; FILE REFERENCE: 9710-003-999
; CURRENT APPLICATION NUMBER: US/10/289,762
; CURRENT FILING DATE: 2003-03-27
; NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 3458
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Chlamydia pneumoniae
US-10-289-762-3458

Query Match 0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 50 AGCGGCTGCAGGTCTGAA 68
Db 1 AGCTGCTGGAGGTGTGAA 19

RESULT 1409
US-10-289-762-4668/C
; Sequence 4668, Application US/10289762
; Publication No. US20040006218A1
; GENERAL INFORMATION:
; APPLICANT: Griffiths, R.
; TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments
; TITLE OF INVENTION: thereof and uses thereof, in particular for the diagnosis, prevention
; TITLE OF INVENTION: and treatment of infection
; FILE REFERENCE: 9710-003-999
; CURRENT APPLICATION NUMBER: US/10/289,762
; CURRENT FILING DATE: 2003-03-27
; NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 4668
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Chlamydia pneumoniae
US-10-289-762-4668

Query Match 0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1303 CTGAAGACGATGCCACTG 1321
Db 19 CTAAGACGATGCCCGTG 1

RESULT 1410
US-10-289-762-4798/C
; Sequence 4798, Application US/10289762
; Publication No. US20040006218A1
; GENERAL INFORMATION:
; APPLICANT: Griffiths, R.
; TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments
; TITLE OF INVENTION: thereof and uses thereof, in particular for the diagnosis, prevention
; TITLE OF INVENTION: and treatment of infection
; FILE REFERENCE: 9710-003-999
; CURRENT APPLICATION NUMBER: US/10/289,762
; CURRENT FILING DATE: 2003-03-27
```

```
; NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 4798
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Chlamydia pneumoniae
US-10-289-762-4798

Query Match 0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 931 TTCACTCCTGCTGGTGGCGG 949
Db 19 TTCACTCCTGCTGGTGGCGG 1

RESULT 1411
US-10-289-762-4985/C
; Sequence 4985, Application US/10289762
; Publication No. US20040006218A1
; GENERAL INFORMATION:
; APPLICANT: Griffiths, R.
; TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments
; TITLE OF INVENTION: thereof and uses thereof, in particular for the diagnosis, prevention
; TITLE OF INVENTION: and treatment of infection
; FILE REFERENCE: 9710-003-999
; CURRENT APPLICATION NUMBER: US/10/289,762
; CURRENT FILING DATE: 2003-03-27
; NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 4985
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Chlamydia pneumoniae
US-10-289-762-4985

Query Match 0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1644 GCTGGTGACGAGGACAAAC 1662
Db 19 GCTGTGTACCAAGACAAAC 1

RESULT 1412
US-10-289-762-5790
; Sequence 5790, Application US/10289762
; Publication No. US20040006218A1
; GENERAL INFORMATION:
; APPLICANT: Griffiths, R.
; TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments
; TITLE OF INVENTION: thereof and uses thereof, in particular for the diagnosis, prevention
; TITLE OF INVENTION: and treatment of infection
; FILE REFERENCE: 9710-003-999
; CURRENT APPLICATION NUMBER: US/10/289,762
; CURRENT FILING DATE: 2003-03-27
; NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 5790
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Chlamydia pneumoniae
US-10-289-762-5790

Query Match 0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1708 CTCGACTACTACAGAAGA 1726
Db 2 CTCGTCACTACAGCAGA 20

RESULT 1413
```

```
US-10-289-762-6696
; Sequence 6696, Application US/10289762
; Publication No. US20040006218A1
; GENERAL INFORMATION:
; APPLICANT: Griffais, R.
; TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments
; TITLE OF INVENTION: thereof and uses thereof, in particular for the diagnosis, prevention
; TITLE OF INVENTION: and treatment of infection
; FILE REFERENCE: 9710-003-999
; CURRENT APPLICATION NUMBER: US/10/289,762
; CURRENT FILING DATE: 2003-03-27
; NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 6696
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Chlamydia pneumoniae
US-10-289-762-6696
Query Match 0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2613 CTGAGCCTGCAGGAGCC 2631
DB 2 CTGACCTTGCAGGGAATCC 20

RESULT 1414
US-10-199-199-32/c
; Sequence 32, Application US/10199199
; Publication No. US20040014047A1
; GENERAL INFORMATION:
; APPLICANT: Lex M. Cowseert
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF LIM DOMAIN KINASE 1 EXPRESSION
; FILE REFERENCE: RYS-0375
; CURRENT APPLICATION NUMBER: US/10/199,199
; CURRENT FILING DATE: 2002-07-18
; NUMBER OF SEQ ID NOS: 148
; SEQ ID NO 32
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-199-199-32
Query Match 0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1874 TGGAGGAGCTCTTCAAGCT 1892
DB 19 TGGTGAGGAGCACTCCAAGCT 1

RESULT 1415
US-10-199-199-107
; Sequence 107, Application US/10199199
; Publication No. US20040014047A1
; GENERAL INFORMATION:
; APPLICANT: Lex M. Cowseert
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF LIM DOMAIN KINASE 1 EXPRESSION
; FILE REFERENCE: RYS-0375
; CURRENT APPLICATION NUMBER: US/10/199,199
; CURRENT FILING DATE: 2002-07-18
; NUMBER OF SEQ ID NOS: 148
; SEQ ID NO 107
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
```

```
US-10-199-199-107
Query Match 0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1874 TGGAGGAGCTCTTCAAGCT 1892
DB 2 TGGTGAGGAGCACTCCAAGCT 20

RESULT 1416
US-10-197-381-7/c
; Sequence 7, Application US/10197381
; Publication No. US20040014147A1
; GENERAL INFORMATION:
; APPLICANT: MASUDA, Esteban
; APPLICANT: KINSELLA, Todd M.
; APPLICANT: WARNER, Justin E.
; APPLICANT: KINOSHITA, Taisei
; APPLICANT: BENNETT, Mark K.
; APPLICANT: ANDERSON, David C.
; TITLE OF INVENTION: METHODS OF IDENTIFYING COMPOUNDS THAT MODULATE IL-4 RECEPTOR-MEDIATED
; FILE REFERENCE: RIGL-009/000S
; CURRENT APPLICATION NUMBER: US/10/197,381
; CURRENT FILING DATE: 2002-07-16
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 7
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic primer
US-10-197-381-7
Query Match 0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 866 TGGAGGCTGACGAGCGGG 884
DB 20 TGGAGGCTGAAGCGCGGG 2

RESULT 1417
US-10-197-945A-14/c
; Sequence 14, Application US/10197945A
; Publication No. US20040014148A1
; GENERAL INFORMATION:
; APPLICANT: Masuda, Esteban
; APPLICANT: Kinsella, Todd M.
; APPLICANT: Warner, Justin E.
; APPLICANT: Kinoshita, Taisei
; APPLICANT: Bennett, Mark K.
; APPLICANT: Anderson, David C.
; TITLE OF INVENTION: Methods of Identifying Compounds that Modulate IL-4 Receptor-Mediated
; FILE REFERENCE: RIGL-013/000S
; CURRENT APPLICATION NUMBER: US/10/197,945A
; CURRENT FILING DATE: 2002-10-15
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 14
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: DNA probe
US-10-197-945A-14
Query Match 0.4%; Score 14.2; DB 1; Length 20;
```

Best Local Similarity 84.2%; Pred. No. 9.1e+02; Gaps 0;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 866 TGGAGGCTGACGAGCGGG 884
|||||
Db 20 TGGAGGCTGAAGCGCGGG 2

RESULT 1418
US-10-197-962B-9/c
; Sequence 9, Application US/10197962B
; Publication No. US20040014149A1
; GENERAL INFORMATION:
; APPLICANT: Masuda, Esteban
; APPLICANT: Kinsella, Todd M
; APPLICANT: Warner, Justin E
; APPLICANT: Kinoshita, Taisei
; APPLICANT: Bennett, Mark K
; APPLICANT: Anderson, David C
; TITLE OF INVENTION: Methods of Identifying Compounds that Modulate IL-4 Receptor-Mediated
; TITLE OF INVENTION: Synthesis Utilizing a Thioredoxin-related 32 kDa Protein
; FILE REFERENCE: RIGL-012/00US
; CURRENT APPLICATION NUMBER: US/10/197,962B
; CURRENT FILING DATE: 2003-01-21
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 9
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: DNA probe
US-10-197-962B-9

Query Match 0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02; Gaps 0;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 866 TGGAGGCTGACGAGCGGG 884
|||||
Db 20 TGGAGGCTGAAGCGCGGG 2

RESULT 1419
US-10-197-368-13/c
; Sequence 13, Application US/10197368
; Publication No. US20040014638A1
; GENERAL INFORMATION:
; APPLICANT: MASUDA, Esteban
; APPLICANT: KINSELLA, Todd M.
; APPLICANT: WARNER, Justin E.
; APPLICANT: KINOSHITA, Taisei
; APPLICANT: BENNETT, Mark K.
; APPLICANT: ANDERSON, David C.
; TITLE OF INVENTION: METHODS OF IDENTIFYING COMPOUNDS THAT MODULATE IL-4 RECEPTOR-MEDIATED
; TITLE OF INVENTION: SYNTHESIS UTILIZING A CLLD8 PROTEIN
; FILE REFERENCE: RIGL-007/00US
; CURRENT APPLICATION NUMBER: US/10/197,368
; CURRENT FILING DATE: 2002-07-16
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 13
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic primer
US-10-197-368-13

Query Match 0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02; Gaps 0;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
; Publication No. US20040023378A1
; GENERAL INFORMATION:
; APPLICANT: Ming-Yi Chiang
; APPLICANT: Eric G. Marcussen
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF KIAA1531 PROTEIN EXPRESSION
; FILE REFERENCE: RTS-0367
; CURRENT APPLICATION NUMBER: US/10/210,290
; CURRENT FILING DATE: 2002-07-31
; NUMBER OF SEQ ID NOS: 134
; SEQ ID NO 111
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-210-290-111

Query Match      0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 467 AGAACAAAGTTGCGACAT 485
||| ||||| |||||
Db 20 AGCAACAAGTTCCAGCAGCAT 2

RESULT 1423
US-10-210-589-48/c
; Sequence 48, Application US/10210589
; Publication No. US20040023381A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Nicholas W. Dean
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PPP2R1A EXPRESSION
; FILE REFERENCE: PTS-0041
; CURRENT APPLICATION NUMBER: US/10/210,589
; CURRENT FILING DATE: 2002-07-30
; NUMBER OF SEQ ID NOS: 122
; SEQ ID NO 48
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-210-589-48

Query Match      0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1556 TGGTGCTCTGTGCTTACCA 1574
||||| ||||| |||||
Db 20 TGGTGCTCGATGCCAACCA 2

RESULT 1424
US-10-210-589-98
; Sequence 98, Application US/10210589
; Publication No. US20040023381A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Nicholas W. Dean
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PPP2R1A EXPRESSION
; FILE REFERENCE: PTS-0041
; CURRENT APPLICATION NUMBER: US/10/210,589
; CURRENT FILING DATE: 2002-07-30
; NUMBER OF SEQ ID NOS: 122
; SEQ ID NO 98
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
```

```
; FEATURE:
US-10-210-589-98

Query Match      0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1556 TGGTGCTCTGTGCTTACCA 1574
||||| ||||| |||||
Db 1 TGGTGCTCGATGCCAACCA 19

RESULT 1425
US-10-210-833-67/c
; Sequence 67, Application US/10210833
; Publication No. US20040023383A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF RESISTIN EXPRESSION
; FILE REFERENCE: RTS-0396
; CURRENT APPLICATION NUMBER: US/10/210,833
; CURRENT FILING DATE: 2002-07-31
; NUMBER OF SEQ ID NOS: 165
; SEQ ID NO 67
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-210-833-67

Query Match      0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1396 CTGCTGGCGCCTGCACGC 1414
||||| ||||| |||||
Db 19 CTGCTGGGCTCCAGCATGC 1

RESULT 1426
US-10-211-908-55/c
; Sequence 55, Application US/10211908
; Publication No. US20040023384A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF G PROTEIN-COUPLED RECEPTOR 12 EXPRESSION
; FILE REFERENCE: RTS-0420
; CURRENT APPLICATION NUMBER: US/10/211,908
; CURRENT FILING DATE: 2002-07-31
; NUMBER OF SEQ ID NOS: 121
; SEQ ID NO 55
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-211-908-55

Query Match      0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1819 GTCTGCTCTGGGAGATCT 1837
||||| ||||| |||||
Db 19 GTCATGCTCTGGGGACCT 1

RESULT 1427
US-10-215-448-55/c
; Sequence 55, Application US/10215448
```


; Publication No. US20040029273A1
; GENERAL INFORMATION:
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF EDC1 EXPRESSION
; FILE REFERENCE: RTS-0179
; CURRENT APPLICATION NUMBER: US/10/215,448
; CURRENT FILING DATE: 2002-08-09
; NUMBER OF SEQ ID NOS: 105
; SEQ ID NO 55
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-215-448-55

Query Match 0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 933 CATCTGTGTGTGGCGGCT 951
||| ||||| ||||| |||||
Db 19 CAGCCTGTGTGTGGCGGT 1

RESULT 1428
US-10-345-444B-61
; Sequence 61, Application US/10345444B
; Publication No. US20040029823A1
; GENERAL INFORMATION:
; APPLICANT: McKay, Robert A.
; APPLICANT: Dean, Nicholas M.
; APPLICANT: Monia, Brett
; APPLICANT: Nero, Pam
; APPLICANT: Gaarde, William A.
; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THE MODULA
; FILE REFERENCE: ISPH-0726
; CURRENT APPLICATION NUMBER: US/10/345,444B
; CURRENT FILING DATE: 2003-01-15
; PRIOR APPLICATION NUMBER: US 09/774,809
; PRIOR FILING DATE: 2001-01-31
; PRIOR APPLICATION NUMBER: US 09/396,902
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: US 09/287,796
; PRIOR FILING DATE: 1999-04-07
; PRIOR APPLICATION NUMBER: US 09/130,616
; PRIOR FILING DATE: 1998-08-07
; PRIOR APPLICATION NUMBER: US 08/910,629
; PRIOR FILING DATE: 1997-08-03
; NUMBER OF SEQ ID NOS: 168
; SEQ ID NO 61
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-10-345-444B-61

Query Match 0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3379 GCTGTGTGTCCCGGCGG 3397
||| ||||| ||||| |||||
Db 2 GCTGGGTTCGCGGCGG 20

RESULT 1429
US-10-222-729-15/c
; Sequence 15, Application US/10222729
; Publication No. US20040033538A1
; GENERAL INFORMATION:

; APPLICANT: MASUDA, ESTEBAN
; APPLICANT: KINSELLA, TODD M
; APPLICANT: WARNER, JUSTIN E
; APPLICANT: KINOSHITA, TAISEI
; APPLICANT: BENNETT, MARK K
; APPLICANT: ANDERSON, DAVID C
; TITLE OF INVENTION: METHODS OF IDENTIFYING COMPOUNDS THAT MODULATE IL-4 RECEPTOR-MEDI
; FILE REFERENCE: RIGLO15
; CURRENT APPLICATION NUMBER: US/10/222,729
; CURRENT FILING DATE: 2002-08-16
; NUMBER OF SEQ ID NOS: 21
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 15
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic primer
US-10-222-729-15

Query Match 0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 866 TGGAGGCTGACGAGCGGG 884
||| ||||| ||||| |||||
Db 20 TGGAGGCTGAAGCGCGGG 2

RESULT 1430
US-10-380-127A-83/c
; Sequence 83, Application US/10380127A
; Publication No. US20040033976A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Donna T. Ward
; APPLICANT: William A. Gaarde
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline R. Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF MEK3 EXPRESSION
; FILE REFERENCE: RTSP-0174
; CURRENT APPLICATION NUMBER: US/10/380,127A
; CURRENT FILING DATE: 2003-06-13
; PRIOR APPLICATION NUMBER: 09/658,688
; PRIOR FILING DATE: 2000-09-08
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 83
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-127A-83

Query Match 0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3377 TTGCTGTGTCCCGGCA 3395
||| ||||| ||||| |||||
Db 19 TTGCTGTCTTCTCCCGGCA 1

RESULT 1431
US-10-454-663-62
; Sequence 62, Application US/10454663
; Publication No. US20040033977A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Christopher K. Mirabelli
; TITLE OF INVENTION: OLIGONUCLEOTIDE MODULATION OF CELL ADHESION
; FILE REFERENCE: ISPH-0744

; CURRENT APPLICATION NUMBER: US/10/454,663
 ; CURRENT FILING DATE: 2003-06-04
 ; PRIOR APPLICATION NUMBER: 09/982,262
 ; PRIOR FILING DATE: 2001-10-18
 ; PRIOR APPLICATION NUMBER: 09/659,288
 ; PRIOR FILING DATE: 2000-09-12
 ; PRIOR APPLICATION NUMBER: 09/128,496
 ; PRIOR FILING DATE: 1998-08-03
 ; PRIOR APPLICATION NUMBER: 08/440,740
 ; PRIOR FILING DATE: 1995-05-12
 ; PRIOR APPLICATION NUMBER: 08/063,167
 ; PRIOR FILING DATE: 1993-05-17
 ; PRIOR APPLICATION NUMBER: 07/969,151
 ; PRIOR FILING DATE: 1993-02-10
 ; PRIOR APPLICATION NUMBER: 08/007,997
 ; PRIOR FILING DATE: 1993-01-21
 ; NUMBER OF SEQ ID NOS: 89
 ; SEQ ID NO 62
 ; LENGTH: 20
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Antisense Oligonucleotide
 US-10-454-663-62

Query Match 0.4%; Score 14.2; DB 1; Length 20;
 Best Local Similarity 84.2%; Pred. No. 9.1e+02;
 Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 3380 CTGTGTGTCCTGGAGGG 3398
 Db 2 CTGTGTGTCCTGGAGGG 20

RESULT 1432
 US-10-622-206-3/c
 ; Sequence 3, Application US/10622206
 ; Publication No. US20040048373A1
 ; GENERAL INFORMATION:
 ; APPLICANT: The Regents of the University of California
 ; APPLICANT: Gage, Fred
 ; APPLICANT: Ray, Jasodhara
 ; TITLE OF INVENTION: METHOD FOR PRODUCTION OF NEUROBLASTS
 ; FILE REFERENCE: REGN1160-5
 ; CURRENT APPLICATION NUMBER: US/10/622,206
 ; CURRENT FILING DATE: 2003-07-18
 ; PRIOR APPLICATION NUMBER: US/09/915,229
 ; PRIOR FILING DATE: 2001-07-24
 ; PRIOR APPLICATION NUMBER: 08/884,427
 ; PRIOR FILING DATE: 1997-06-27
 ; PRIOR APPLICATION NUMBER: 08/445,075
 ; PRIOR FILING DATE: 1995-05-19
 ; PRIOR APPLICATION NUMBER: 08/147,843
 ; PRIOR FILING DATE: 1993-11-03
 ; PRIOR APPLICATION NUMBER: 08/001,543
 ; PRIOR FILING DATE: 1993-01-06
 ; NUMBER OF SEQ ID NOS: 4
 ; SOFTWARE: PASTSEQ for Windows Version 4.0
 ; SEQ ID NO 3
 ; LENGTH: 20
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Forward primer for PCR
 US-10-622-206-3

Query Match 0.4%; Score 14.2; DB 1; Length 20;
 Best Local Similarity 84.2%; Pred. No. 9.1e+02;
 Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 2385 TGCCTCAGGTGCGAGGT 2403
 Db 19 TGCCTCAGGTGCGAGGT 1

RESULT 1433
 US-10-380-124-40/c
 ; Sequence 40, Application US/10380124
 ; Publication No. US20040053874A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Isis Pharmaceuticals, Inc.
 ; APPLICANT: Brett P. Monla
 ; APPLICANT: Susan M. Freier
 ; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
 ; FILE REFERENCE: RTS-0156
 ; CURRENT APPLICATION NUMBER: US/10/380,124
 ; CURRENT FILING DATE: 2003-03-10
 ; NUMBER OF SEQ ID NOS: 90
 ; SEQ ID NO 40
 ; LENGTH: 20
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Antisense Oligonucleotide
 US-10-380-124-40

Query Match 0.4%; Score 14.2; DB 1; Length 20;
 Best Local Similarity 84.2%; Pred. No. 9.1e+02;
 Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 491 AGACGTACGCTGGACGT 509
 Db 20 AGACGCACATGCTGGATGT 2

RESULT 1434
 US-10-380-195A-11
 ; Sequence 11, Application US/10380195A
 ; Publication No. US20040072776A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Gleave, Martin
 ; APPLICANT: Kiyama, Satoshi
 ; APPLICANT: Nelson, Colleen
 ; APPLICANT: Rennie, Paul
 ; TITLE OF INVENTION: Antisense Insulin-Like Growth Factor Binding Protein (IGFBP)-2
 ; FILE REFERENCE: UBC-P-023
 ; CURRENT APPLICATION NUMBER: US/10/380,195A
 ; CURRENT FILING DATE: 2003-03-12
 ; PRIOR APPLICATION NUMBER: PCT/US01/28748
 ; PRIOR FILING DATE: 2001-09-13
 ; PRIOR APPLICATION NUMBER: US 60/232,641
 ; PRIOR FILING DATE: 2000-09-14
 ; NUMBER OF SEQ ID NOS: 63
 ; SOFTWARE: PatentIn version 3.2
 ; SEQ ID NO 11
 ; LENGTH: 20
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: IGFBP2 antisense
 US-10-380-195A-11

Query Match 0.4%; Score 14.2; DB 1; Length 20;
 Best Local Similarity 84.2%; Pred. No. 9.1e+02;
 Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 2696 CACTTCCACCCCTGCCCT 2714
 Db 1 CACTCCCGACGCTGCCGT 19

RESULT 1435
 US-10-380-195A-54
 ; Sequence 54, Application US/10380195A
 ; Publication No. US20040072776A1

```

; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Kiyama, Satoshi
; APPLICANT: Nelson, Colleen
; APPLICANT: Rennie, Paul
; TITLE OF INVENTION: Antisense Insulin-Like Growth Factor Binding Protein (IGFBP)-2
; TITLE OF INVENTION: Oligodeoxynucleotides for Prostate and Endocrine Tumor Therapy
; FILE REFERENCE: UBC-P-023
; CURRENT APPLICATION NUMBER: US/10/380,195A
; CURRENT FILING DATE: 2003-03-12
; PRIOR FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: US 60/232,641
; PRIOR FILING DATE: 2000-09-14
; NUMBER OF SEQ ID NOS: 63
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 54
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: IGFBP2 antisense
US-10-380-195A-54

Query Match      0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2696 CACTTCCACCGTGCCTT 2714
      ||||| ||||| |||||
Db 1 CACTTCCACCGTGCCTT 19

RESULT 1436
US-10-273-826-16/c
; Sequence 16, Application US/10273826
; Publication No. US20040077083A1
; GENERAL INFORMATION:
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF HISTONE DEACETYLASE 4 EXPRESSION
; FILE REFERENCE: RTS-0161
; CURRENT APPLICATION NUMBER: US/10/273,826
; CURRENT FILING DATE: 2002-10-17
; NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 16
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-273-826-16

Query Match      0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2632 CCACATGTCCAGCACCTTG 2650
      ||||| ||||| |||||
Db 19 CCACATGTCCAGCACCGTG 1

RESULT 1437
US-10-274-347-16/c
; Sequence 16, Application US/10274347
; Publication No. US20040077084A1
; GENERAL INFORMATION:
; APPLICANT: Andrew T. Watt
; APPLICANT: Steven Davidsson
; APPLICANT: Junling Li
; APPLICANT: Keith Glaser
; TITLE OF INVENTION: ANTISENSE MODULATION OF HISTONE DEACETYLASE 4 EXPRESSION
; FILE REFERENCE: RTS-0264
; CURRENT APPLICATION NUMBER: US/10/274,347

```

```

; CURRENT FILING DATE: 2002-10-17
; NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 16
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-274-347-16

Query Match      0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2632 CCACATGTCCAGCACCTTG 2650
      ||||| ||||| |||||
Db 19 CCACATGTCCAGCACCGTG 1

RESULT 1438
US-10-274-387-14/c
; Sequence 14, Application US/10274387
; Publication No. US20040077085A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CDC14A EXPRESSION
; FILE REFERENCE: RTS-0172
; CURRENT APPLICATION NUMBER: US/10/274,387
; CURRENT FILING DATE: 2002-10-17
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 14
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-274-387-14

Query Match      0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1156 GCCGACCCCAATGGAGC 1174
      ||||| ||||| |||||
Db 20 GCCGAGTCCAAATAGGAGC 2

RESULT 1439
US-10-274-311-14/c
; Sequence 14, Application US/10274311
; Publication No. US20040077571A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Aparna Sarthy
; APPLICANT: Thomas McGonigal
; TITLE OF INVENTION: ANTISENSE MODULATION OF CDC14A EXPRESSION
; FILE REFERENCE: RTS-0262
; CURRENT APPLICATION NUMBER: US/10/274,311
; CURRENT FILING DATE: 2002-10-17
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 14
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-274-311-14

Query Match      0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1156 GCCGACCCCAATGGAGC 1174
      ||||| ||||| |||||
Db 20 GCCGAGTCCAAATAGGAGC 2

```

Db
20 GCGAGTCCAAATAGGAGC 2

```

RESULT 1440
US-10-728-509-26
; Sequence 26, Application US/10728509
; Publication No. US20040077583A1
; GENERAL INFORMATION:
; APPLICANT: Hong Zhang T
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF
; FILE REFERENCE: RFS-0185
; CURRENT APPLICATION NUMBER: US/10/728,509
; CURRENT FILING DATE: 2003-12-05
; PRIOR APPLICATION NUMBER: US/09/908,147
; PRIOR FILING DATE: 2001-07-17
; NUMBER OF SEQ ID NOS: 168
; SEQ ID NO 26
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleot
US-10-728-509-26

```

Query Match	0.48;	Score 14.2;	DB 1;	Length 20;
Best Local Similarity	84.2;	Pred. No. 9.1e+02;		
Matches 16;	Conservative 0;	Mismatches 3;	Indels 0;	Gaps 0;
QY	1844	TGGGGGCTCCCGTACCC	1862	
Db	1	TGGGCTGCTCCCGGACCC	19	

```

RESULT 1441
US-10-280-183A-230/c
; Sequence 230, Application US/10280183A
; Publication No. US20040081964A1
; GENERAL INFORMATION:
; APPLICANT: Pfizer Inc.
; APPLICANT: Bachmanov, Alexander A
; APPLICANT: Beauchamp, Gary K.
; APPLICANT: Chatterjee, Aurobindo
; APPLICANT: De Jong, Pieter J.
; APPLICANT: Li, Shanru
; APPLICANT: Li, Xia
; APPLICANT: Ohmen, Jeffrey D
; APPLICANT: Reed, Danielle R.
; APPLICANT: Ross, David
; APPLICANT: Tordoff, Michael G.
; TITLE OF INVENTION: GENE AND SEQUENCE VARIATION ASSOCIATED WITH SENSING
; FILE OF INVENTION: CARBOHYDRATE COMPOUNDS AND OTHER SWEETENERS
; FILE REFERENCE: PC18306A
; CURRENT APPLICATION NUMBER: US/10/280,183A
; CURRENT FILING DATE: 2002-10-25
; PRIOR APPLICATION NUMBER: 60/200,794
; PRIOR FILING DATE: 2000-04-28
; NUMBER OF SEQ ID NOS: 652
; SOFTWARE: PatentIn Ver. 3.1
; SEQ ID NO 230
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Mouse
US-10-280-183A-230

Query Match      0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps

QY      279  CGCCAACACGTCGCTTC 297
Db      19   CTCCAACACTGTCCTTC 1

```

RESULT 1442
 US-10-280-183A-528
 ; Sequence 528, Application US/10280183A
 ; Publication No. US20040081964A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Pfizer Inc.
 ; APPLICANT: Bachmanov, Alexander A
 ; APPLICANT: Beauchamp, Gary K.
 ; APPLICANT: Chatterjee, Aurolindo
 ; APPLICANT: De Jong, Pieter J.
 ; APPLICANT: Li, Shanru
 ; APPLICANT: Li, Xia
 ; APPLICANT: Ohmen, Jeffrey D
 ; APPLICANT: Reed, Danielle R.
 ; APPLICANT: Ross, David
 ; APPLICANT: Tordoff, Michael G.
 ; TITLE OF INVENTION: GENE AND SEQUENCE VARIATION ASSOCIATED WITH SENSING
 ; TITLE OF INVENTION: CARBOHYDRATE COMPOUNDS AND OTHER SWEETENERS
 ; FILE REFERENCE: PC18306A
 ; CURRENT APPLICATION NUMBER: US/10/280,183A
 ; CURRENT FILING DATE: 2002-10-25
 ; PRIOR APPLICATION NUMBER: 60/200,794
 ; PRIOR FILING DATE: 2000-04-28
 ; NUMBER OF SEQ ID NOS: 652
 ; SOFTWARE: PatentIn Ver. 3.1
 ; SEQ ID NO 528
 ; LENGTH: 20
 ; TYPE: DNA
 ; ORGANISM: Mouse
 US-10-280-183A-528

```

Query Match      0.4%;   Score 14.2; DB 1;   Length 20;
Best Local Similarity 84.2%;   Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      824  ACTCTGCGTGGCTGGTGT 842
          |||  |||||  |||||
Db       2  ACTGTACGTGGCTGCTGGT 20

```

```

RESULT 1443
US-10-210-802-47
; Sequence 47, Application US/10210802
; Publication No. US20040087523A1
; GENERAL INFORMATION:
; APPLICANT: Ming-Yi Chiang
; APPLICANT: Kenneth W. Dobbie
; TITLE OF INVENTION: ANTISENSE MODULATION OF KIAA1531 PROTEIN EXPRESSION
; FILE REFERENCE: RTS-0367
; CURRENT APPLICATION NUMBER: US/10/210,802
; CURRENT FILING DATE: 2002-07-31
; NUMBER OF SEQ ID NOS: 134
; SEQ ID NO 47
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-210-802-47

```

	Query Match	0.4%	Score 14.2;	DB 1;	Length 20;
	Best Local Similarity	84.2%;	Pred. NO. 9.1e+04;		
	Matches 16;	Conservative	0;	Mismatches 3;	Indels 0; Gaps 0;
QY	467	AGAACCAAGTTTGGCAGCAT	485		
Db	1	AGCACAAAGTTTCAGCAGCAT	19		

RESULT 1444
US-10-210-802-111/c

```
; Sequence 111, Application US/10210802
; Publication No. US20040087523A1
; GENERAL INFORMATION:
; APPLICANT: Ming-Yi Chiang
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF KIAA1531 PROTEIN EXPRESSION
; FILE REFERENCE: RTS-0367
; CURRENT APPLICATION NUMBER: US/10/210,802
; CURRENT FILING DATE: 2002-07-31
; NUMBER OF SEQ ID NOS: 134
; SEQ ID NO 111
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-210-802-111

Query Match      0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 467 AGACAAAGTTTGGCAGCAT 485
Db 20 AGCACAAGTTCAGCAGCAT 2

RESULT 1445
US-10-637-009-9
; Sequence 9, Application US/10637009
; Publication No. US20040091920A1
; GENERAL INFORMATION:
; APPLICANT: TSUJI, Toru
; APPLICANT: YANAGAWA, Hiroshi
; TITLE OF INVENTION: Method of Constructing DNA Library and Utilization Thereof
; FILE REFERENCE: P24048
; CURRENT APPLICATION NUMBER: US/10/637,009
; CURRENT FILING DATE: 2003-08-08
; PRIOR APPLICATION NUMBER: PCT 2000-293692
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: US 10/396334
; PRIOR FILING DATE: 2003-03-26
; PRIOR APPLICATION NUMBER: PCT 2001-29138
; PRIOR FILING DATE: 2001-02-06
; NUMBER OF SEQ ID NOS: 50
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 9
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Primer
US-10-637-009-9

Query Match      0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1679 ACTTCGGGCTGGCCGGGA 1697
Db 2 ACTTCGGGATCGCCAGGA 20

RESULT 1446
US-10-293-864-81
; Sequence 81, Application US/10293864
; Publication No. US20040092465A1
; GENERAL INFORMATION:
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF HUNTINGTIN INTERACTING PROTEIN 1 EXPRESSION
; FILE REFERENCE: RTS-0432
; CURRENT APPLICATION NUMBER: US/10/293,864
; CURRENT FILING DATE: 2002-11-11
; NUMBER OF SEQ ID NOS: 165

; Sequence 111, Application US/10210802
; Publication No. US20040087523A1
; GENERAL INFORMATION:
; APPLICANT: Ming-Yi Chiang
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF KIAA1531 PROTEIN EXPRESSION
; FILE REFERENCE: RTS-0367
; CURRENT APPLICATION NUMBER: US/10/210,802
; CURRENT FILING DATE: 2002-07-31
; NUMBER OF SEQ ID NOS: 134
; SEQ ID NO 111
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-210-802-111

Query Match      0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 979 CCCAAGAAAGCGCTGGCT 997
Db 2 CCCATAAAAGCGCTGAGCT 20

RESULT 1447
US-10-300-424-25/C
; Sequence 25, Application US/10300424
; Publication No. US20040096835A1
; GENERAL INFORMATION:
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF TNFSF14 EXPRESSION
; FILE REFERENCE: RTS-0437
; CURRENT APPLICATION NUMBER: US/10/300,424
; CURRENT FILING DATE: 2002-11-19
; NUMBER OF SEQ ID NOS: 129
; SEQ ID NO 25
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-300-424-25

Query Match      0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2603 ACACCCAAAGCTGAGCCTG 2621
Db 20 ACACCGAGAGCAGAGCCTG 2

RESULT 1448
US-10-300-424-94
; Sequence 94, Application US/10300424
; Publication No. US20040096835A1
; GENERAL INFORMATION:
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF TNFSF14 EXPRESSION
; FILE REFERENCE: RTS-0437
; CURRENT APPLICATION NUMBER: US/10/300,424
; CURRENT FILING DATE: 2002-11-19
; NUMBER OF SEQ ID NOS: 129
; SEQ ID NO 94
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-300-424-94

Query Match      0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2603 ACACCCAAAGCTGAGCCTG 2621
Db 1 ACACCGAGAGCAGAGCCTG 19

RESULT 1449
US-10-300-424-94
; Sequence 94, Application US/10300424
; Publication No. US20040096835A1
; GENERAL INFORMATION:
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF TNFSF14 EXPRESSION
; FILE REFERENCE: RTS-0437
; CURRENT APPLICATION NUMBER: US/10/300,424
; CURRENT FILING DATE: 2002-11-19
; NUMBER OF SEQ ID NOS: 129
; SEQ ID NO 94
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-300-424-94

Query Match      0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2603 ACACCCAAAGCTGAGCCTG 2621
Db 1 ACACCGAGAGCAGAGCCTG 19

RESULT 1449
```

```
US-10-671-074-36
; Sequence 36, Application US/10671074
; Publication No. US20040097459A1
; GENERAL INFORMATION:
; APPLICANT: Dobie, Kenneth W.
; APPLICANT: Bhanot, Sanjay
; APPLICANT: Veniant-Ellison, Murielle
; APPLICANT: Lindberg, Richard A.
; APPLICANT: Shutter, John R.
; TITLE OF INVENTION: MODULATION OF FORKHEAD BOX O1A EXPRESSION
; FILE REFERENCE: AMN0001-101
; CURRENT APPLICATION NUMBER: US/10/671,074
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: US 10/260,203
; PRIOR FILING DATE: 2002-09-26
; NUMBER OF SEQ ID NOS: 176
; SEQ ID NO 36
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-671-074-36

Query Match      0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 27 GGAGCGTCTCTGCTGGG 45
Db 2 GGAGCTTCTCTGCTGGAG 20

RESULT 1450
US-10-303-329-31
; Sequence 31, Application US/10303329
; Publication No. US20040101850A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Nicholas M. Dean
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF C-SRC TYROSINE KINASE EXPRESSION
; FILE REFERENCE: HTS-0005
; CURRENT APPLICATION NUMBER: US/10/303,329
; CURRENT FILING DATE: 2002-11-21
; NUMBER OF SEQ ID NOS: 70
; SEQ ID NO 31
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-303-329-31

Query Match      0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 572 TGCTGGCGACGACGTGGA 590
Db 2 TGCTGGCGACGTGCGTGGGA 20

RESULT 1451
US-10-303-329-59/c
; Sequence 59, Application US/10303329
; Publication No. US20040101850A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Nicholas M. Dean
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF C-SRC TYROSINE KINASE EXPRESSION
; FILE REFERENCE: HTS-0005
```

```
; CURRENT APPLICATION NUMBER: US/10/303,329
; CURRENT FILING DATE: 2002-11-21
; NUMBER OF SEQ ID NOS: 70
; SEQ ID NO 59
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-303-329-59

Query Match      0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 572 TGCTGGCGACGACGTGGA 590
Db 19 TGCTGGCGACGTGCGTGGGA 1

RESULT 1452
US-10-688-706-73
; Sequence 73, Application US/10688706
; Publication No. US20040102412A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Broschat, Kay
; TITLE OF INVENTION: ANTISENSE MODULATION OF GFAT EXPRESSION
; FILE REFERENCE: 01393/1
; CURRENT APPLICATION NUMBER: US/10/688,706
; CURRENT FILING DATE: 2003-10-17
; PRIOR APPLICATION NUMBER: 60/419,268
; PRIOR FILING DATE: 2002-10-17
; NUMBER OF SEQ ID NOS: 3071
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 73
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: human GFAT antisense
US-10-688-706-73

Query Match      0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3239 GTTGGAGGTGATTCAGTG 3257
Db 1 GTTGGTGTGATTCATTG 19

RESULT 1453
US-10-688-706-3049/c
; Sequence 3049, Application US/10688706
; Publication No. US20040102412A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Broschat, Kay
; TITLE OF INVENTION: ANTISENSE MODULATION OF GFAT EXPRESSION
; FILE REFERENCE: 01393/1
; CURRENT APPLICATION NUMBER: US/10/688,706
; CURRENT FILING DATE: 2003-10-17
; PRIOR APPLICATION NUMBER: 60/419,268
; PRIOR FILING DATE: 2002-10-17
; NUMBER OF SEQ ID NOS: 3071
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 3049
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: human GFAT antisense
US-10-688-706-3049
```

Query Match 0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3269 TTTGCTTTTCCTTTTCA 3287
DB 20 TTTGCTTTTCCTTTAGTCA 2

RESULT 1454
US-10-688-706-3054/c
; Sequence 3054, Application US/10688706
; Publication No. US20040102412A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Brotschat, Kay
; TITLE OF INVENTION: ANTISENSE MODULATION OF GFAT EXPRESSION
; FILE REFERENCE: 01393/1
; CURRENT APPLICATION NUMBER: US/10/688,706
; CURRENT FILING DATE: 2003-10-17
; PRIOR APPLICATION NUMBER: 60/419,268
; PRIOR FILING DATE: 2002-10-17
; NUMBER OF SEQ ID NOS: 3071
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 3054
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: human GFAT antisense
US-10-688-706-3054

Query Match 0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3269 TTTGCTTTTCCTTTTCA 3287
DB 19 TTTGCTTTTCCTTTAGTCA 1

RESULT 1455
US-10-332-406A-10/c
; Sequence 10, Application US/10332406A
; Publication No. US20040103453A1
; GENERAL INFORMATION:
; APPLICANT: Robert Dudley
; APPLICANT: Ulrich schaffrath
; APPLICANT: Kay Ann Lawton
; TITLE OF INVENTION: Lipoxigenase Genes, Promoters, Transit Peptides and Proteins Ther
; FILE REFERENCE: 31484USPT
; CURRENT APPLICATION NUMBER: US/10/332,406A
; CURRENT FILING DATE: 2003-06-19
; PRIOR APPLICATION NUMBER: GB 0017275.9
; PRIOR FILING DATE: 2000-07-13
; PRIOR APPLICATION NUMBER: GB 0022739.7
; PRIOR FILING DATE: 2000-09-15
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: Patent in Ver. 2.1
; SEQ ID NO 10
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: misc.feature
; LOCATION: (1)..(20)
; OTHER INFORMATION: oligonucleotide
US-10-332-406A-10

Query Match 0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1288 GTAGCCGTGAAGATGCTGA 1306
DB 20 GTGGCCGTGAGCATGCTGA 2

RESULT 1456
US-10-315-474-37/c
; Sequence 37, Application US/10315474
; Publication No. US20040110139A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF G PROTEIN-COUPLED RECEPTOR 3 EXPRESSION
; FILE REFERENCE: RTS-0338
; CURRENT APPLICATION NUMBER: US/10/315,474
; CURRENT FILING DATE: 2002-12-10
; NUMBER OF SEQ ID NOS: 156
; SEQ ID NO 37
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-315-474-37

Query Match 0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2905 GGCAGGCATGGCCCTGGGC 2923
DB 19 GGCAGGCCTGGGCCTGGTC 1

RESULT 1457
US-10-315-474-109
; Sequence 109, Application US/10315474
; Publication No. US20040110139A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF G PROTEIN-COUPLED RECEPTOR 3 EXPRESSION
; FILE REFERENCE: RTS-0338
; CURRENT APPLICATION NUMBER: US/10/315,474
; CURRENT FILING DATE: 2002-12-10
; NUMBER OF SEQ ID NOS: 156
; SEQ ID NO 109
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-315-474-109

Query Match 0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2905 GGCAGGCATGGCCCTGGGC 2923
DB 2 GGCAGGCCTGGGCCTGGTC 20

RESULT 1458
US-10-316-516-23
; Sequence 23, Application US/10316516
; Publication No. US20040110150A1
; GENERAL INFORMATION:
; APPLICANT: Erich Koller
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF EPHRIN-B2 EXPRESSION
; FILE REFERENCE: PTS-0057
; CURRENT APPLICATION NUMBER: US/10/316,516

; CURRENT FILING DATE: 2002-12-10
; NUMBER OF SEQ ID NOS: 134
; SEQ ID NO 23
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-316-516-23

Query Match 0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1352 TGGAGATGATGAGATGAT 1370
||| |||||
Db 1 TGATGACGATGAGATGAT 19

RESULT 1459

US-10-317-270-12/c
; Sequence 12, Application US/10317270
; Publication No. US20040110701A1
; GENERAL INFORMATION:
; APPLICANT: Kenneth W. Dobie
; APPLICANT: Tamara Balac Sipes
; TITLE OF INVENTION: MODULATION OF ZINEDIN EXPRESSION
; FILE REFERENCE: RTS-0479
; CURRENT APPLICATION NUMBER: US/10/317,270
; CURRENT FILING DATE: 2002-12-10
; NUMBER OF SEQ ID NOS: 160
; SEQ ID NO 12
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-317-270-12

Query Match 0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2613 CTGAGCCTGCGGGGATCC 2631
||||| |||||
Db 19 CTGAGCCTGCGGGGATCC 1

RESULT 1460

US-10-317-270-90
; Sequence 90, Application US/10317270
; Publication No. US20040110701A1
; GENERAL INFORMATION:
; APPLICANT: Kenneth W. Dobie
; APPLICANT: Tamara Balac Sipes
; TITLE OF INVENTION: MODULATION OF ZINEDIN EXPRESSION
; FILE REFERENCE: RTS-0479
; CURRENT APPLICATION NUMBER: US/10/317,270
; CURRENT FILING DATE: 2002-12-10
; NUMBER OF SEQ ID NOS: 160
; SEQ ID NO 90
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-317-270-90

Query Match 0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2613 CTGAGCCTGCGGGGATCC 2631
||||| |||||

Db 2 CTGAGCCTGCGGGGATCC 20

RESULT 1461

US-10-317-279-19/c
; Sequence 19, Application US/10317279
; Publication No. US20040110703A1
; GENERAL INFORMATION:
; APPLICANT: Ming-Yi Chiang
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DRI-ASSOCIATED PROTEIN 1 EXPRESSION
; FILE REFERENCE: HTS-0027
; CURRENT APPLICATION NUMBER: US/10/317,279
; CURRENT FILING DATE: 2002-12-10
; NUMBER OF SEQ ID NOS: 59
; SEQ ID NO 19
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-317-279-19

Query Match 0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1546 TTCAGGACCTGGTGCTCT 1564
||| |||||
Db 20 TTGAAGGACCTGGTGCGCAT 2

RESULT 1462

US-10-671-395-122
; Sequence 122, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 122
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-122

Query Match 0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1613 GCATCCACAGGACCTGGC 1631
||| |||||
Db 1 GCTTCCACAGAGAACTGGC 19

RESULT 1463

US-10-671-395-309
; Sequence 309, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE

; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 309
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-309

Query Match 0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1612 TGCATCCACAGGACCTGG 1630
||| ||||| ||||| |||||
Db 2 TCGTTCACAGAGACTGG 20

RESULT 1464
US-10-671-395-501
; Sequence 501, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 501
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-501

Query Match 0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2591 TGGGCCCTCCACACCCA 2609
||| ||||| ||||| |||||
Db 1 TGGGCCCTCCACCCACA 19

RESULT 1465
US-10-671-395-574/c
; Sequence 574, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809

; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 574
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-574

Query Match 0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2003 AGTGGTGGAGGACCTGGA 2021
||| ||||| ||||| |||||
Db 20 AGTGGTGGAGGACCGGA 2

RESULT 1466
US-10-671-395-966
; Sequence 966, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 966
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-966

Query Match 0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2591 TGGGCCCTCCACACCCA 2609
||| ||||| ||||| |||||
Db 2 TGGGCCCTCCACCCACA 20

RESULT 1467
US-10-671-395-1117/c
; Sequence 1117, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1117
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1117

US-10-671-395-1117

Query Match 0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2007 GGTGGAGGACCTGGACCGT 2025
DB 20 GGTGGAGGACCGGAGCTT 2

RESULT 1468
US-10-671-395-1140/c
; Sequence 1140, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; PRIOR FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1140
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1140

Query Match 0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2007 GGTGGAGGACCTGGACCGT 2025
DB 19 GGTGGAGGACCGGAGCTT 1

RESULT 1469
US-10-671-395-1174/c
; Sequence 1174, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; PRIOR FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1174
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1174

Query Match 0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2362 TGTGCTGTGTGCTGCGC 2380

DB 20 TGGCCTGTGTGTGTGCC 2

RESULT 1470
US-10-671-395-1180/c
; Sequence 1180, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; PRIOR FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1180
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1180

Query Match 0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 924 CTTCCTGTTTCATCCTGGTG 942
DB 19 CTTCCTGTTTCCTCTCGTG 1

RESULT 1471
US-10-671-395-1450/c
; Sequence 1450, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; PRIOR FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1450
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1450

Query Match 0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2001 GCAGCTGTTGGAGGACCTG 2019
DB 19 GCAGTGGGTGGAGGACCG 1

RESULT 1472
US-10-671-395-1499/c
; Sequence 1499, Application US/10671395

```
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1499
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1499

Query Match      0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 925 TTCCTGTTTCATCTCTGTGG 943
DB 20 TTCCTGTTTCATCTCTGTGG 2

RESULT 1473
US-10-671-395-1662/c
; Sequence 1662, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1662
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1662

Query Match      0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2336 TGTGTGTGTGTGTGTGCAC 2354
DB 20 TGTGTGTGTGTGTGTTC 2

RESULT 1474
US-10-671-395-1769
; Sequence 1769, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
```

```
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1769
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1769

Query Match      0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2893 GGGGGCAGGAGGAGCC 2911
DB 1 GGGGGCAGGAGGAGCC 19

RESULT 1475
US-10-671-395-1788
; Sequence 1788, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1788
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1788

Query Match      0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2893 GGGGGCAGGAGGAGCC 2911
DB 2 GGGGGCAGGAGGAGCC 20

RESULT 1476
US-10-682-130-23/c
; Sequence 23, Application US/10682130
; Publication No. US20040132682A1
; GENERAL INFORMATION:
; APPLICANT: THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS
; APPLICANT: REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND
; APPLICANT: HUMAN SERVICES
; APPLICANT: Klinkman, Dennis M.
; APPLICANT: Yamada, Hiroshi
; TITLE OF INVENTION: METHOD OF TREATING INFLAMMATORY LUNG DISEASE WITH SUPPRESSORS OF
; FILE REFERENCE: 4239-66902
; CURRENT APPLICATION NUMBER: US/10/682,130
; CURRENT FILING DATE: 2003-10-07
; PRIOR APPLICATION NUMBER: US 60/417,263
; PRIOR FILING DATE: 2002-10-08
```

```
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 23
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Suppressive oligonucleotide sequence.
US-10-682-130-23

Query Match      0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2105 CCCCAGCTCCAGCTCCTC 2123
Db 20 CCCCAGGTCACGCTTCCC 2

RESULT 1477
US-10-766-185-12/c
; Sequence 12, Application US/10766185
; Publication No. US20040152655A1
; GENERAL INFORMATION:
; APPLICANT: Yoon, Heejeong
; APPLICANT: Ahn, Chang Ho
; APPLICANT: Lee, Young Bok
; APPLICANT: Mao, Lingjun
; APPLICANT: Jiang, Xiaoming
; TITLE OF INVENTION: Antisense Oligonucleotides that inhibit expression of HIF-1
; FILE REFERENCE: REX 7034
; CURRENT APPLICATION NUMBER: US/10/766,185
; CURRENT FILING DATE: 2004-01-28
; NUMBER OF SEQ ID NOS: 130
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 12
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: antisense oligonucleotide
US-10-766-185-12

Query Match      0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 761 TCACCTTTGAGGACGCCG 779
Db 20 TCACCATGAGGCGCGCG 2

RESULT 1478
US-10-741-601-26226
; Sequence 26226, Application US/10741601
; Publication No. US20040166519A1
; GENERAL INFORMATION:
; APPLICANT: CARGILL, Michele et al.
; TITLE OF INVENTION: GENETIC POLYMORPHISMS ASSOCIATED WITH
; FILE REFERENCE: CL001500
; CURRENT APPLICATION NUMBER: US/10/741,601
; CURRENT FILING DATE: 2003-12-22
; NUMBER OF SEQ ID NOS: 26415
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 26226
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-741-601-26226

Query Match      0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
```

```
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2290 GGAGAGACAGCTACACAGA 2308
Db 2 GAAGAAACAGCTACCCAGA 20

RESULT 1479
US-10-476-962-104/c
; Sequence 104, Application US/10476962
; Publication No. US20040191904A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF SRC-C EXPRESSION
; FILE REFERENCE: RTS-0222
; CURRENT APPLICATION NUMBER: US/10/476,962
; CURRENT FILING DATE: 2003-11-05
; PRIOR APPLICATION NUMBER: PRIOP APPLICATION NUMBER: US/09/860,473
; PRIOR FILING DATE: 2001-05-18
; NUMBER OF SEQ ID NOS: 169
; SEQ ID NO 104
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-476-962-104

Query Match      0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1533 GGAGCAGCTCACCTTCAAG 1551
Db 20 GGAGCGGCCACCTTCGAG 2

RESULT 1480
US-10-476-962-105
; Sequence 105, Application US/10476962
; Publication No. US20040191904A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF SRC-C EXPRESSION
; FILE REFERENCE: RTS-0222
; CURRENT APPLICATION NUMBER: US/10/476,962
; CURRENT FILING DATE: 2003-11-05
; PRIOR APPLICATION NUMBER: PRIOP APPLICATION NUMBER: US/09/860,473
; PRIOR FILING DATE: 2001-05-18
; NUMBER OF SEQ ID NOS: 169
; SEQ ID NO 105
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-476-962-105

Query Match      0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 736 CTAGAGGTTCTCTCCTTGC 754
Db 1 CTAGAGGTTCTCCCGGC 19

RESULT 1481
US-10-476-962-150/c
; Sequence 150, Application US/10476962
; Publication No. US20040191904A1
```

GENERAL INFORMATION:
APPLICANT: C. Frank Bennett
FILE OF INVENTION: ANTISENSE MODULATION OF SRC-C EXPRESSION
FILE REFERENCE: RTS-0222
CURRENT APPLICATION NUMBER: US/10/476,962
PRIORITY FILING DATE: 2003-11-05
PRIORITY APPLICATION NUMBER: US/09/860,473
PRIORITY FILING DATE: 2001-05-18
NUMBER OF SEQ ID NOS: 169
SEQ ID NO 150
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-10-476-962-150

Query Match 0.4%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 9.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1214 AGGGCTGCTTCGCCAGGT 1232
DB 19 AGGGTTCGCGAGAGGT 1

RESULT 1482

US-09-988-899-17/c
Sequence 17, Application US/09988899
Patent No. US20020102613A1
GENERAL INFORMATION:
APPLICANT: HOOGENDOORN, HENDRICUS R.J.M.
TITLE OF INVENTION: NOVEL FAB FRAGMENT LIBRARIES AND METHOD FOR THEIR USE
FILE REFERENCE: DX/003 CON
CURRENT APPLICATION NUMBER: US/09/988,899
PRIORITY FILING DATE: 2001-11-19
PRIORITY APPLICATION NUMBER: PCT/US00/13682
PRIORITY FILING DATE: 2000-05-18
PRIORITY APPLICATION NUMBER: 99201558.6
PRIORITY FILING DATE: 1999-05-18
NUMBER OF SEQ ID NOS: 71
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 17
LENGTH: 23
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-988-899-17

Query Match 0.4%; Score 14.2; DB 1; Length 23;
Best Local Similarity 69.6%; Pred. No. 1e+03;
Matches 16; Conservative 2; Mismatches 5; Indels 0; Gaps 0;

QY 2098 CAGGACACCCCGAGCTCCAGCTC 2120
DB 23 CCRGWTCCACGAGCTGCACCTC 1

RESULT 1483

US-09-750-401-20
Sequence 20, Application US/09750401
Publication No. US20020004211A1
GENERAL INFORMATION:
APPLICANT: Keene, Jack D.
APPLICANT: Tenenbaum, Scott A.
TITLE OF INVENTION: Methods for isolating and characterizing endogenous mRNA-protein
FILE REFERENCE: RBN-001C
CURRENT APPLICATION NUMBER: US/09/750,401
PRIORITY FILING DATE: 2000-12-28

PRIORITY APPLICATION NUMBER: US 60/173,338
PRIORITY FILING DATE: 1999-12-28
NUMBER OF SEQ ID NOS: 37
SOFTWARE: PatentIn version 3.1
SEQ ID NO 20
LENGTH: 23
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: 3'-UTR sequence of Neuronal-Cadherin
US-09-750-401-20

Query Match 0.4%; Score 14.2; DB 1; Length 23;
Best Local Similarity 15.8%; Pred. No. 1e+03;
Matches 3; Conservative 13; Mismatches 3; Indels 0; Gaps 0;

QY 3115 TTTTAATTTTAACTTATT 3133
DB 2 UUUUAAUUUUUAAUUUUU 20

RESULT 1484

US-10-309-788-20
Sequence 20, Application US/10309788
Publication No. US2003021146A1
GENERAL INFORMATION:
APPLICANT: Keene, Jack D.
APPLICANT: Tenenbaum, Scott A.
APPLICANT: Carson, Craig C.
APPLICANT: Phelps, William C.
TITLE OF INVENTION: Method for Identifying Functionally Related Genes and Drug Targets
FILE REFERENCE: RBN-001CP
CURRENT APPLICATION NUMBER: US/10/309,788
PRIORITY FILING DATE: 2003-06-18
PRIORITY APPLICATION NUMBER: US 60/173,338
PRIORITY FILING DATE: 1999-12-28
PRIORITY APPLICATION NUMBER: US 09/750,401
PRIORITY FILING DATE: 2000-12-28
NUMBER OF SEQ ID NOS: 38
SOFTWARE: PatentIn version 3.1
SEQ ID NO 20
LENGTH: 23
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: 3'-UTR consensus sequence of Neuronal-Cadherin
US-10-309-788-20

Query Match 0.4%; Score 14.2; DB 1; Length 23;
Best Local Similarity 15.8%; Pred. No. 1e+03;
Matches 3; Conservative 13; Mismatches 3; Indels 0; Gaps 0;

QY 3115 TTTTAATTTTAACTTATT 3133
DB 2 UUUUAAUUUUUAAUUUUU 20

RESULT 1485

US-10-238-306B-20
Sequence 20, Application US/10238306B
Publication No. US20030235830A1
GENERAL INFORMATION:
APPLICANT: Keene, Jack D.
APPLICANT: Tenenbaum, Scott A.
APPLICANT: Carson, Craig C.
TITLE OF INVENTION: Methods for isolating and characterizing endogenous mRNA-protein
FILE REFERENCE: RBN-001CN
CURRENT APPLICATION NUMBER: US/10/238,306B
PRIORITY FILING DATE: 2002-09-10
PRIORITY APPLICATION NUMBER: US 09/750,401
PRIORITY FILING DATE: 2001-12-28
PRIORITY APPLICATION NUMBER: US 60/173,338

```

; PRIOR FILING DATE: 1999-12-28
; NUMBER OF SEQ ID NOS: 37
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 20
; LENGTH: 23
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: 3'-UTR sequence of Neuronal-Cadherin
US-10-238-3065-20

Query Match      0.4%; Score 14.2; DB 1; Length 23;
Best Local Similarity 15.8%; Pred. No. 1e+03;
Matches 3; Conservative 13; Mismatches 0; Gaps 0;

QY 3115 TTTTAATTTTACTTATT 3133
      :|||:||||:|:|:|:
Db 2 UUUUAAUUUUUUAAUUUU 20

RESULT 1486
US-10-629-453-20
; Sequence 20, Application US/10629453
; Publication No. US20040096878A1
; GENERAL INFORMATION:
; APPLICANT: Keene, Jack D.
; APPLICANT: Carson, Craig C.
; APPLICANT: Tenenbaum, Scott A.
; TITLE OF INVENTION: Methods for isolating and characterizing endogenous mRNA-protein
; FILE REFERENCE: RBN-001DV
; CURRENT APPLICATION NUMBER: US/10/629,453
; PRIOR FILING DATE: 2003-07-29
; PRIOR APPLICATION NUMBER: US 09/750,401
; PRIOR FILING DATE: 2000-12-28
; PRIOR APPLICATION NUMBER: US 60/173,338
; PRIOR FILING DATE: 1999-12-28
; NUMBER OF SEQ ID NOS: 37
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 20
; LENGTH: 23
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: 3 -UTR sequence of Neuronal-Cadherin
US-10-629-453-20

Query Match      0.4%; Score 14.2; DB 1; Length 23;
Best Local Similarity 15.8%; Pred. No. 1e+03;
Matches 3; Conservative 13; Mismatches 0; Gaps 0;

QY 3115 TTTTAATTTTACTTATT 3133
      :|||:||||:|:|:|:
Db 2 UUUUAAUUUUUUAAUUUU 20

RESULT 1487
US-09-725-265-13
; Sequence 13, Application US/09725265
; Publication No. US20010000175A1
; GENERAL INFORMATION:
; APPLICANT: KURANE, RYUICHIRO
; APPLICANT: KANAGAWA, TAKAHIRO
; APPLICANT: KANAGATA, YOICHI
; APPLICANT: YAMADA, KAZUTAKA
; APPLICANT: YOKOMAKU, TOYOKAZU
; APPLICANT: KOYAMA, OSAMU
; APPLICANT: FURUSHO, KENTA
; TITLE OF INVENTION: METHOD FOR DETERMINING A CONCENTRATION OF TARGET NUCLEIC ACID MOI
; TITLE OF INVENTION: NUCLEIC ACID PROBES FOR THE METHOD, AND METHOD FOR ANALYZING DAT
; FILE REFERENCE: 199953US0XDIV
; CURRENT APPLICATION NUMBER: US/09/725,265

```

```

; CURRENT FILING DATE: 2000-11-29
; PRIOR APPLICATION NUMBER: US 09/556,127
; PRIOR FILING DATE: 2000-04-20
; PRIOR APPLICATION NUMBER: JP 1999-111601
; PRIOR FILING DATE: 1999-04-20
; NUMBER OF SEQ ID NOS: 70
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 13
; LENGTH: 30
; TYPE: DNA
; ORGANISM: ARTIFICIAL SEQUENCE
; FEATURE:
; OTHER INFORMATION: SYNTHETIC DNA
US-09-725-265-13

Query Match      0.4%; Score 14.2; DB 1; Length 30;
Best Local Similarity 70.4%; Pred. No. 1.3e+03;
Matches 19; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 3259 AGATATTTTATTTGCTTGTCTCTTTT 3285
      |||||:||||:|:|:|:
Db 3 ATATATTTTCTTTTCTTTTCTTTT 29

RESULT 1488
US-09-891-517-13
; Sequence 13, Application US/09891517
; Patent No. US20020106653A1
; GENERAL INFORMATION:
; APPLICANT: KURANE, RYUICHIRO
; APPLICANT: KANAGAWA, TAKAHIRO
; APPLICANT: KANAGATA, YOICHI
; APPLICANT: TORIMURA, MASAKI
; APPLICANT: KURATA, SHINYA
; APPLICANT: YAMADA, KAZUTAKA
; APPLICANT: YOKOMAKU, TOYOKAZU
; TITLE OF INVENTION: NOVEL NUCLEIC ACID PROBES, METHOD FOR DETERMINING CONCENTRATIONS (
; TITLE OF INVENTION: NUCLEIC ACID BY USING THE PROBES, AND METHOD FOR ANALYZING DATA (
; TITLE OF INVENTION: METHOD
; FILE REFERENCE: 210352US-1994-163-0-X
; CURRENT APPLICATION NUMBER: US/09/891,517
; CURRENT FILING DATE: 2001-06-27
; PRIOR APPLICATION NUMBER: JP2000-193133
; PRIOR FILING DATE: 2000-06-27
; PRIOR APPLICATION NUMBER: JP2000-236115
; PRIOR FILING DATE: 2000-08-03
; PRIOR APPLICATION NUMBER: JP2000-292483
; PRIOR FILING DATE: 2000-09-26
; NUMBER OF SEQ ID NOS: 108
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 13
; LENGTH: 30
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic DNA
US-09-891-517-13

Query Match      0.4%; Score 14.2; DB 1; Length 30;
Best Local Similarity 70.4%; Pred. No. 1.3e+03;
Matches 19; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 3259 AGATATTTTATTTGCTTGTCTCTTTT 3285
      |||||:||||:|:|:|:
Db 3 ATATATTTTCTTTTCTTTTCTTTT 29

RESULT 1489
US-10-209-608-13
; Sequence 13, Application US/10209608
; Publication No. US20030082592A1
; GENERAL INFORMATION:
; APPLICANT: KURANE, RYUICHIRO

```

```

Qy      3259 AGATATTTTATTGCTTTGTCTCTTTT 3288
      |||||
Db      3  ATATATTTTCTTTTCTTTTCTTTT 29
      |||||

RESULT 1491
US-09-801-274-958/c
/ Sequence 958, Application US/09801274
/ Patent No. US20020032319A1
/ GENERAL INFORMATION:
/ APPLICANT: Cargill, Michele
/ APPLICANT: Ireland, James S.
/ APPLICANT: Lander, Eric S.
/ TITLE OF INVENTION: HUMAN SINGLE NUCLEOTIDE
/ FILE REFERENCE: 2825-2009-001
/ CURRENT APPLICATION NUMBER: US/09/801,274
/ CURRENT FILING DATE: 2001-03-07
/ PRIOR APPLICATION NUMBER: US 60/187,510
/ PRIOR FILING DATE: 2000-03-07
/ PRIOR APPLICATION NUMBER: US 60/206,129
/ PRIOR FILING DATE: 2000-05-22
/ NUMBER OF SEQ ID NOS: 1802
/ SOFTWARE: FastSeq for Windows Version 4.0
/ SEQ ID NO 958
/ LENGTH: 31
/ TYPE: DNA
/ ORGANISM: Homo sapiens
US-09-801-274-958

```

Query Match 0.4%; Score 14.2; DB 1; Length 31;
Best Local Similarity 65.5%; Pred. No. 1.3e+03;
Matches 19; Conservative 1; Mismatches 9; Indels 0; Gaps 0;

Qy 486 CCGCAGACGTACACGCTGGACGTCTGG 514
||||||| | : |||||
Db 30 CCGCAGCCCGCTCGCAGGATGGGCGG 2

```

RESULT 1492
US-10-108-969-8
; Sequence 8, Application US/10108969
; Publication No. US20030198959A1
; GENERAL INFORMATION:
; APPLICANT: Kurnit, David M.
; TITLE OF INVENTION: Methods and Compositions for Analysis of
; ; TITLE OF INVENTION: And Treatment of Kidney Diseases
; FILE REFERENCE: 65988-0001
; CURRENT APPLICATION NUMBER: US/10/108,969
; CURRENT FILING DATE: 2002-03-28
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 8
; LENGTH: 32
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Human beta-actin reverse primer
US-10-108-969-8

Query Match          0.4%;      Score 14.2;   DB 1;    Length 32;
Best Local Similarity 70.4%;    Pred. No. 1.4e+03;
Matches 19; Conservative 0; Mismatches 8; Indels

QY       3262 TATTTATTGCTTGTTCCTTTTTCAAG 3288
           ||||| |||| | ||| ||||| ||
Db        6 TTTTCTTTTCTTTTCTTTTCTTTTAAG 32

```

US-10-208-357-2/c
; Sequence 2, Application US/10208357
; Publication No. US20020182687A1
; GENERAL INFORMATION:

; APPLICANT: Kurz, Markus
 ; APPLICANT: Lohse, Peter
 ; APPLICANT: Wagner, Richard
 ; TITLE OF INVENTION: Peptide Acceptor Ligation Methods
 ; FILE REFERENCE: 50036/031002
 ; CURRENT APPLICATION NUMBER: US/10/208,357
 ; CURRENT FILING DATE: 2002-07-30
 ; PRIOR APPLICATION NUMBER: US/09/619,103
 ; PRIOR FILING DATE: 2000-07-19
 ; PRIOR APPLICATION NUMBER: 60/145,834
 ; PRIOR FILING DATE: 1999-07-27
 ; NUMBER OF SEQ ID NOS: 26
 ; SOFTWARE: FastSeq for Windows Version 4.0
 ; SEQ ID NO 2
 ; LENGTH: 38
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: designed sequence to act as a linker
 US-10-208-357-2

Query Match 0.4%; Score 14.2; DB 1; Length 38;
 Best Local Similarity 62.9%; Pred. No. 1.5e+03;
 Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 3307 GGATTTTCTTAGGAGATTATTTTGGACTTC 3341
 DB 38 GGTTTTTTTTTTTTTTTTTTTTTTTTTTTGGCATCC 4

RESULT 1494
 US-10-289-921-6
 ; Sequence 6, Application US/10289921
 ; Publication No. US20030113337A1
 ; GENERAL INFORMATION:
 ; APPLICANT: MERUELO, Daniel
 ; APPLICANT: OHNO, Kouichi
 ; APPLICANT: LEVIN, Brandi A.
 ; TITLE OF INVENTION: HIGH EFFICIENCY TISSUE SPECIFIC COMPOUND
 ; TITLE OF INVENTION: DELIVERY SYSTEM USING STREPTAVIDIN-PROTEIN A FUSION PROTEIN
 ; FILE REFERENCE: 5986/11123-US1
 ; CURRENT APPLICATION NUMBER: US/10/289,921
 ; CURRENT FILING DATE: 2003-02-27
 ; PRIOR APPLICATION NUMBER: US 08/566,421
 ; PRIOR FILING DATE: 1995-11-30
 ; NUMBER OF SEQ ID NOS: 6
 ; SOFTWARE: FastSeq for Windows Version 3.0
 ; SEQ ID NO 6
 ; LENGTH: 39
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: biotinylated poly(dT) oligonucleotide
 US-10-289-921-6

Query Match 0.4%; Score 14.2; DB 1; Length 39;
 Best Local Similarity 70.4%; Pred. No. 1.5e+03;
 Matches 19; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 3262 TATTTATTTGCTTTCCTTTTTCAG 3288
 DB 11 TTTTNTTTTTTTTTTTTTTTTTTTTAG 37

RESULT 1495
 US-09-735-363A-15
 ; Sequence 15, Application US/09735363A
 ; Patent No. US20010041681A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Filion, Mario
 ; APPLICANT: Phillip, Nigel
 ; TITLE OF INVENTION: Therapeutically Useful Synthetic Oligonucleotides
 ; FILE REFERENCE: 02811-0181

; CURRENT APPLICATION NUMBER: US/09/735,363A
 ; CURRENT FILING DATE: 2000-12-12
 ; PRIOR APPLICATION NUMBER: 60/170,325
 ; PRIOR FILING DATE: 1999-12-13
 ; PRIOR APPLICATION NUMBER: 60/228,925
 ; PRIOR FILING DATE: 2000-08-29
 ; NUMBER OF SEQ ID NOS: 87
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 15
 ; LENGTH: 14
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Synthetic Oligonucleotide
 US-09-735-363A-15

Query Match 0.4%; Score 14; DB 1; Length 14;
 Best Local Similarity 100.0%; Pred. No. 6.7e+02;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2318 TGTGTGTGTGTGTG 2331
 DB 1 TGTGTGTGTGTG 14

RESULT 1496
 US-09-263-959-479/c
 ; Sequence 479, Application US/09263959
 ; Patent No. US20020150891A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Hood, Leroy E.
 ; APPLICANT: Koop, Ben P.
 ; TITLE OF INVENTION: DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS AND METHODS WHICH UTI
 ; NUMBER OF SEQUENCES: 1279
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Seed and Berry LLP
 ; STREET: 6300 Columbia Center, 701 Fifth Avenue
 ; CITY: Seattle
 ; STATE: Washington
 ; COUNTRY: US
 ; ZIP: 98104-7092
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: Floppy disk
 ; COMPUTER: IBM PC compatible
 ; OPERATING SYSTEM: PC-DOS/MS-DOS
 ; SOFTWARE: PatentIn Release #1.0, Version #1.25
 ; CURRENT APPLICATION NUMBER: US/09/263,959
 ; FILING DATE: 05-MAR-1999
 ; CLASSIFICATION:
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Mcmasters, David D.
 ; REGISTRATION NUMBER: 33,963
 ; REFERENCE/DOCKET NUMBER: 920010.426C2
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: (206) 622-4900
 ; TELEFAX: (206) 682-6031
 ; INFORMATION FOR SEQ ID NO: 479:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 14 base pairs
 ; TYPE: nucleic acid
 ; STRANDEDNESS: single
 ; TOPOLOGY: linear
 US-09-263-959-479

Query Match 0.4%; Score 14; DB 1; Length 14;
 Best Local Similarity 100.0%; Pred. No. 6.7e+02;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2319 GTGTGTGTGTGTG 2332
 DB 14 GTGTGTGTGTGTG 1

RESULT 1497

US-09-263-959-530/c
; Sequence 530, Application US/09263959
; Patent No. US20020150891A1
; GENERAL INFORMATION:
; APPLICANT: Hood, Leroy E.
; APPLICANT: Rowen, Lee
; TITLE OF INVENTION: DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS AND METHODS WHICH UTI
; NUMBER OF SEQUENCES: 1279
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Seed and Berry LLP
; STREET: 6300 Columbia Center, 701 Fifth Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: US
; ZIP: 98104-7092
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA: US/09/263,959
; FILING DATE: 05-MAR-1999
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: McMasters, David D.
; REGISTRATION NUMBER: 33,963
; REFERENCE/DOCKET NUMBER: 920010.426C2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 682-6031
; INFORMATION FOR SEQ ID NO: 530:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 14 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-263-959-530

Query Match 0.4%; Score 14; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 6.7e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2826 ATATACATATAT 2839

DB 14 ATATACATATAT 1

RESULT 1498

US-09-263-959-532
; Sequence 532, Application US/09263959
; Patent No. US20020150891A1
; GENERAL INFORMATION:
; APPLICANT: Hood, Leroy E.
; APPLICANT: Rowen, Lee
; TITLE OF INVENTION: DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS AND METHODS WHICH UTI
; NUMBER OF SEQUENCES: 1279
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Seed and Berry LLP
; STREET: 6300 Columbia Center, 701 Fifth Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: US
; ZIP: 98104-7092
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS

Query Match 0.4%; Score 14; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 6.7e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/263,959
; FILING DATE: 05-MAR-1999
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: McMasters, David D.
; REGISTRATION NUMBER: 33,963
; REFERENCE/DOCKET NUMBER: 920010.426C2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 682-6031
; INFORMATION FOR SEQ ID NO: 532:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 14 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-263-959-532

Query Match 0.4%; Score 14; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 6.7e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3466 ATATATCTATAT 3479

DB 1 ATATATCTATAT 14

RESULT 1499

US-09-263-959-562
; Sequence 562, Application US/09263959
; Patent No. US20020150891A1
; GENERAL INFORMATION:
; APPLICANT: Hood, Leroy E.
; APPLICANT: Rowen, Lee
; TITLE OF INVENTION: DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS AND METHODS WHICH UTI
; NUMBER OF SEQUENCES: 1279
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Seed and Berry LLP
; STREET: 6300 Columbia Center, 701 Fifth Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: US
; ZIP: 98104-7092
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/263,959
; FILING DATE: 05-MAR-1999
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: McMasters, David D.
; REGISTRATION NUMBER: 33,963
; REFERENCE/DOCKET NUMBER: 920010.426C2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 682-6031
; INFORMATION FOR SEQ ID NO: 562:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 14 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-263-959-562

Query Match 0.4%; Score 14; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 6.7e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3466 ATATATCTATATAT 3479
Db 1 ATATATCTATATAT 14

RESULT 1500
US-09-263-959-592/C
; Sequence 592, Application US/09263959
; Patent No. US20020150891A1
; GENERAL INFORMATION:
; APPLICANT: Hood, Leroy E.
; APPLICANT: Rowen, Lee
; APPLICANT: Koop, Ben F.
; TITLE OF INVENTION: DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS AND METHODS WHICH UTI
; NUMBER OF SEQUENCES: 1279
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Seed and Berry LLP
; STREET: 6300 Columbia Center, 701 Fifth Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: US
; ZIP: 98104-7092

COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/263,959
; FILING DATE: 05-MAR-1999

CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Mcmasters, David D.
; REGISTRATION NUMBER: 33,963
; REFERENCE/DOCKET NUMBER: 920010.426C2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 682-6031
; INFORMATION FOR SEQ ID NO: 592:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 14 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear

US-09-263-959-592

Query Match 0.4%; Score 14; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 6.7e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2826 ATATACATATATAT 2839
Db 14 ATATACATATATAT 14

RESULT 1501
US-09-263-959-658
; Sequence 658, Application US/09263959
; Patent No. US20020150891A1
; GENERAL INFORMATION:
; APPLICANT: Hood, Leroy E.
; APPLICANT: Rowen, Lee
; APPLICANT: Koop, Ben F.
; TITLE OF INVENTION: DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS AND METHODS WHICH UTI
; NUMBER OF SEQUENCES: 1279
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Seed and Berry LLP
; STREET: 6300 Columbia Center, 701 Fifth Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: US
; ZIP: 98104-7092

COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/263,959
; FILING DATE: 05-MAR-1999

CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Mcmasters, David D.
; REGISTRATION NUMBER: 33,963
; REFERENCE/DOCKET NUMBER: 920010.426C2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 682-6031
; INFORMATION FOR SEQ ID NO: 592:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 14 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear

US-09-263-959-592

Query Match 0.4%; Score 14; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 6.7e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2826 ATATACATATATAT 2839
Db 14 ATATACATATATAT 14

RESULT 1501
US-09-263-959-658
; Sequence 658, Application US/09263959
; Patent No. US20020150891A1
; GENERAL INFORMATION:
; APPLICANT: Hood, Leroy E.
; APPLICANT: Rowen, Lee
; APPLICANT: Koop, Ben F.
; TITLE OF INVENTION: DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS AND METHODS WHICH UTI
; NUMBER OF SEQUENCES: 1279
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Seed and Berry LLP
; STREET: 6300 Columbia Center, 701 Fifth Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: US
; ZIP: 98104-7092

COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/263,959
; FILING DATE: 05-MAR-1999

CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Mcmasters, David D.
; REGISTRATION NUMBER: 33,963
; REFERENCE/DOCKET NUMBER: 920010.426C2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 682-6031
; INFORMATION FOR SEQ ID NO: 592:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 14 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear

US-09-263-959-658

Query Match 0.4%; Score 14; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 6.7e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2318 TGTGTGTGTGTGTG 2331
Db 1 TGTGTGTGTGTGTG 14

RESULT 1502
US-09-263-959-726/C
; Sequence 726, Application US/09263959
; Patent No. US20020150891A1
; GENERAL INFORMATION:
; APPLICANT: Hood, Leroy E.
; APPLICANT: Rowen, Lee
; APPLICANT: Koop, Ben F.
; TITLE OF INVENTION: DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS AND METHODS WHICH UTI
; NUMBER OF SEQUENCES: 1279
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Seed and Berry LLP
; STREET: 6300 Columbia Center, 701 Fifth Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: US
; ZIP: 98104-7092

COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/263,959
; FILING DATE: 05-MAR-1999

CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Mcmasters, David D.
; REGISTRATION NUMBER: 33,963
; REFERENCE/DOCKET NUMBER: 920010.426C2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 682-6031
; INFORMATION FOR SEQ ID NO: 726:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 14 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear

US-09-263-959-726

Query Match 0.4%; Score 14; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 6.7e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2824 ATATATACATATAT 2837
DB 14 ATATATACATATAT 1

RESULT 1503
US-09-263-959-752
; Sequence 822, Application US/09263959
; Patent No. US20020150891A1
; GENERAL INFORMATION:
; APPLICANT: Hood, Leroy E.
; APPLICANT: Rowen, Lee
; APPLICANT: Koop, Ben F.
; TITLE OF INVENTION: DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS AND METHODS WHICH UTI
; NUMBER OF SEQUENCES: 1279
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Seed and Berry LLP
; STREET: 6300 Columbia Center, 701 Fifth Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: US
; ZIP: 98104-7092
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/263,959
; FILING DATE: 05-MAR-1999
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Mcmasters, David D.
; REGISTRATION NUMBER: 33,963
; REFERENCE/DOCKET NUMBER: 920010.426C2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 682-6031
; INFORMATION FOR SEQ ID NO: 752:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 14 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-263-959-752

Query Match 0.4%; Score 14; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 6.7e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2824 ATATATACATATAT 2837
DB 1 ATATATACATATAT 14

RESULT 1504
US-09-263-959-822/c
; Sequence 822, Application US/09263959
; Patent No. US20020150891A1
; GENERAL INFORMATION:
; APPLICANT: Hood, Leroy E.
; APPLICANT: Rowen, Lee
; APPLICANT: Koop, Ben F.
; TITLE OF INVENTION: DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS AND METHODS WHICH UTI
; NUMBER OF SEQUENCES: 1279
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Seed and Berry LLP
; STREET: 6300 Columbia Center, 701 Fifth Avenue

CITY: Seattle
STATE: Washington
COUNTRY: US
ZIP: 98104-7092
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/263,959
FILING DATE: 05-MAR-1999
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: Mcmasters, David D.
REGISTRATION NUMBER: 33,963
REFERENCE/DOCKET NUMBER: 920010.426C2
TELECOMMUNICATION INFORMATION:
TELEPHONE: (206) 622-4900
TELEFAX: (206) 682-6031
INFORMATION FOR SEQ ID NO: 822:
SEQUENCE CHARACTERISTICS:
LENGTH: 14 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-263-959-822

Query Match 0.4%; Score 14; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 6.7e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2824 ATATATACATATAT 2837
DB 14 ATATATACATATAT 1

RESULT 1505
US-10-292-198-111
; Sequence 111, Application US/10292198
; Publication No. US20030157654A1
; GENERAL INFORMATION:
; APPLICANT: SHEN, Ben
; APPLICANT: LIU, Wen
; TITLE OF INVENTION: BIOSYNTHESIS OF ENEDIYNE COMPOUNDS BY MANIPULATION OF C-1027 GENE
; FILE REFERENCE: 054030-0007
; CURRENT APPLICATION NUMBER: US/10/292,198
; CURRENT FILING DATE: 2003-03-14
; PRIOR APPLICATION NUMBER: US 10/159,257
; PRIOR FILING DATE: 2002-05-31
; PRIOR APPLICATION NUMBER: US 09/478,188
; PRIOR FILING DATE: 2000-01-05
; PRIOR APPLICATION NUMBER: US 60/115,434
; PRIOR FILING DATE: 1999-01-06
; NUMBER OF SEQ ID NOS: 146
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 111
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Streptomyces globisporus
US-10-292-198-111

Query Match 0.4%; Score 14; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3104 ATGGCGGAGAGTTT 3117
DB 1 ATGGCGGAGAGTTT 14

RESULT 1506

```

US-10-159-257A-111
; Sequence 111, Application US/10159257A
; Publication No. US20040161828A1
; GENERAL INFORMATION:
; APPLICANT: SHEN, BEN
; APPLICANT: LIU, WEN
; APPLICANT: CHRISTENSON, STEVEN D.
; APPLICANT: STANDAGE, SCOTT
; TITLE OF INVENTION: GENE CLUSTER FOR PRODUCTION OF THE ENEDIYNE ANTI-TUMOR
; TITLE OF INVENTION: ANTIBIOTIC C-1027
; FILE REFERENCE: 407T-896020US
; CURRENT APPLICATION NUMBER: US/10/159,257A
; CURRENT FILING DATE: 2002-05-31
; PRIOR APPLICATION NUMBER: 09/478,188
; PRIOR FILING DATE: 2000-01-05
; PRIOR APPLICATION NUMBER: 60/115,434
; PRIOR FILING DATE: 1999-01-06
; NUMBER OF SEQ ID NOS: 207
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 111
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-159-257A-111

Query Match          0.4%; Score 14; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3104 ATGGCGGAGAGTTT 3117
DB 1 ATGGCGGAGAGTTT 14

RESULT 1507
US-10-138-674-6067
; Sequence 6067, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6067
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-6067

Query Match          0.4%; Score 14; DB 1; Length 16;
Best Local Similarity 50.0%; Pred. No. 7.7e+02;
Matches 7; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY 2317 CTGCTGTGTGTGT 2330
DB 3 CUGUGUGUGUGUGU 16

RESULT 1508
US-10-287-949A-6067
; Sequence 6067, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3576
; LENGTH: 17
; TYPE: RNA

```

```

; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6067
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-6067

Query Match          0.4%; Score 14; DB 1; Length 16;
Best Local Similarity 50.0%; Pred. No. 7.7e+02;
Matches 7; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY 2317 CTGCTGTGTGTGT 2330
DB 3 CUGUGUGUGUGUGU 16

RESULT 1509
US-10-156-306-2748/c
; Sequence 2748, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2748
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-2748

Query Match          0.4%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 8.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 798 GGGCAATTCTATTG 811
DB 15 GGGCAATTCTATTG 2

RESULT 1510
US-10-156-306-3576/c
; Sequence 3576, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3576
; LENGTH: 17
; TYPE: RNA

```

; ORGANISM: Homo sapiens
US-10-156-308-3576

Query Match 0.4%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 8.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 798 GGGCAATTCATTG 811
|||||
DB 17 GGGCAATTCATTG 4

RESULT 1511

US-10-108-732-17/c

; Sequence 17; Application US/10108732

; Publication No. US2003017572A1

; GENERAL INFORMATION:

; APPLICANT: Box, Neil F

; APPLICANT: Duffy, David L

; APPLICANT: Hayward, Nicholas K

; APPLICANT: Martin, Nicholas G

; APPLICANT: Sturm, Richard A

; APPLICANT: Gruis, Nelleke A

; APPLICANT: Van Der Velden, Pieter

; APPLICANT: Bergman, Wilma

; APPLICANT: Frants, Rune R

; TITLE OF INVENTION: MELANOMA RISK DETECTION

; FILE REFERENCE: 8795-27U1

; CURRENT APPLICATION NUMBER: US/10/108,732

; CURRENT FILING DATE: 2002-03-28

; PRIOR APPLICATION NUMBER: US 60/279,515

; PRIOR FILING DATE: 2001-03-28

; NUMBER OF SEQ ID NOS: 76

; SOFTWARE: PatentIn version 3.1

; SEQ ID NO 17

; LENGTH: 17

; TYPE: DNA

; ORGANISM: Artificial sequence

; FEATURE:

; OTHER INFORMATION: CDKN2A Exon 2 fragment primer

US-10-108-732-17

Query Match 0.4%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 8.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 834 GCTGGTGGTGCTGC 847
|||||
DB 14 GCTGGTGGTGCTGC 1

RESULT 1512

US-10-138-674-8982

; Sequence 8982; Application US/10138674

; Publication No. US20040077565A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: Pavco, Pam

; APPLICANT: McSwiggen, Jim

; APPLICANT: Stinchcomb, Dan

; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re

; FILE REFERENCE: MBH00-876-N (400/049)

; CURRENT APPLICATION NUMBER: US/10/138,674

; CURRENT FILING DATE: 2002-05-03

; NUMBER OF SEQ ID NOS: 20822

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 8982

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-138-674-8982

Query Match 0.4%; Score 14; DB 1; Length 17;
Best Local Similarity 78.6%; Pred. No. 8.2e+02;
Matches 11; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1794 CCAGAGTGACGTCT 1807
|||||
DB 4 CCAGAGUGAGGUCU 17

RESULT 1513

US-10-676-154-523

; Sequence 523; Application US/10676154

; Publication No. US20040081996A1

; GENERAL INFORMATION:

; APPLICANT: John Landers

; APPLICANT: David Houseman

; APPLICANT: Barbara Jordan

; APPLICANT: Alain Charest

; TITLE OF INVENTION: Methods and Products Related to

; FILE REFERENCE: M0656/7045 (HCL/MAT)

; CURRENT APPLICATION NUMBER: US/10/676,154

; CURRENT FILING DATE: 2003-09-29

; PRIOR APPLICATION NUMBER: US 60/101,757

; PRIOR FILING DATE: 1998-09-25

; PRIOR APPLICATION NUMBER: PCT/US99/22283

; PRIOR FILING DATE: 1999-09-24

; NUMBER OF SEQ ID NOS: 691

; SOFTWARE: FastSeq for Windows Version 3.0

; SEQ ID NO 523

; LENGTH: 17

; TYPE: DNA

; ORGANISM: Homo Sapiens

US-10-676-154-523

Query Match 0.4%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 8.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2327 GTGTGTGGTGTGT 2340
|||||
DB 4 GTGTGTGGTGTGT 17

RESULT 1514

US-10-287-949A-8982

; Sequence 8982; Application US/10287949A

; Publication No. US20040102389A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: Pavco, Pam

; APPLICANT: McSwiggen, Jim

; APPLICANT: Stinchcomb, Dan

; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re

; FILE REFERENCE: MBH00-876-N (400/049)

; CURRENT APPLICATION NUMBER: US/10/287,949A

; CURRENT FILING DATE: 2003-04-11

; NUMBER OF SEQ ID NOS: 20822

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 8982

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-287-949A-8982

Query Match 0.4%; Score 14; DB 1; Length 17;
Best Local Similarity 78.6%; Pred. No. 8.2e+02;
Matches 11; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1794 CCAGAGTGACGTCT 1807

|||||:||||:|

4 CCAGAGGACGUCU 17

RESULT 1515

US-10-712-672-2607
; Sequence 2607, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Chowrira, Bharat
; APPLICANT: McSwiggan, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MBH00-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 5586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2607
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-712-672-2607

Query Match 0.4%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 8.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 343 AAGAACGGCAGGGA 356

Db 3 AAGAACGGCAGGGA 16

RESULT 1516

US-10-416-110-12
; Sequence 12, Application US/10416110
; Publication No. US20040072198A1
; GENERAL INFORMATION:
; APPLICANT: OLEK, Alexander
; APPLICANT: FIENENBROCK, Christian
; APPLICANT: BERLIN, Kurt
; TITLE OF INVENTION: Diagnosis of Diseases Associated with Cdk4
; FILE REFERENCE: 5013.1018
; CURRENT APPLICATION NUMBER: US/10/416,110
; CURRENT FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: PCT/EP01/12827
; PRIOR FILING DATE: 2001-11-06
; PRIOR APPLICATION NUMBER: DE 10054974.8
; PRIOR FILING DATE: 2000-11-06
; NUMBER OF SEQ ID NOS: 20
; SEQ ID NO 12
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: chemically treated genomic DNA (Homo sapiens)
US-10-416-110-12

Query Match 0.4%; Score 14; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 8.7e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2695 CCACCTCCCAACCT 2708

Db 1 CCACCTCCCAACCT 14

RESULT 1517

US-10-432-422-27
; Sequence 27, Application US/10432422
; Publication No. US20040076981A1
; GENERAL INFORMATION:
; APPLICANT: Syngenta Participations AG
; APPLICANT: Cornell Research Foundation, Inc.
; APPLICANT: Yoder, Olen
; APPLICANT: Turgeon, Barbara G.
; APPLICANT: Lu, Shen-wen
; TITLE OF INVENTION: Fungal Iron Reductase Gene
; FILE REFERENCE: 1360.017W01
; CURRENT APPLICATION NUMBER: US/10/432,422
; CURRENT FILING DATE: 2003-05-21
; PRIOR APPLICATION NUMBER: US 60/252,732
; PRIOR FILING DATE: 2000-11-22
; PRIOR APPLICATION NUMBER: US 60/252,649
; PRIOR FILING DATE: 2000-11-22
; NUMBER OF SEQ ID NOS: 210
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 27
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-10-432-422-27

Query Match 0.4%; Score 14; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 8.7e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2242 CCTGCTGCTGTGC 2255

Db 1 CCTGCTGCTGTGC 14

RESULT 1518

US-09-953-562-15/c
; Sequence 15, Application US/09953562
; Publication No. US20030096241A1
; GENERAL INFORMATION:
; APPLICANT: ZERIA PHARMACEUTICALS CO., LTD.
; TITLE OF INVENTION: METHOD OF SCREENING A DRUG FOR TREATMENT OF SQUAMOUS
; TITLE OF INVENTION: CELL CARCINOMA
; FILE REFERENCE: E6114-01
; CURRENT APPLICATION NUMBER: US/09/953,562
; CURRENT FILING DATE: 2003-02-24
; PRIOR APPLICATION NUMBER: JP 2001-083352
; PRIOR FILING DATE: 2001-03-22
; NUMBER OF SEQ ID NOS: 27
; SEQ ID NO 15
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Exon 15 downstream primer
US-09-953-562-15

Query Match 0.4%; Score 14; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 9.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1722 GAAGCAACCAACG 1735

Db 19 GAAGCAACCAACG 6

RESULT 1519

US-09-733-294A-86/c
; Sequence 86, Application US/09733294A
; Patent No. US20020045588A1

GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: William Gaarde
; APPLICANT: Susan M. Freier
; APPLICANT: Edward V. Wanciewicz
; TITLE OF INVENTION: ANTISENSE MODULATION OF TERT EXPRESSION
; FILE REFERENCE: ISPH-0527
; CURRENT APPLICATION NUMBER: US/09/733,294A
; CURRENT FILING DATE: 2000-12-07
; PRIOR APPLICATION NUMBER: 09/572,423
; PRIOR FILING DATE: 2000-05-16
; NUMBER OF SEQ ID NOS: 108
; SEQ ID NO 86
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-733-294A-86

Query Match 0.4%; Score 14; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 9.7e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2318 TGTGTGTGTGTGTG 2331
Db 20 TGTGTGTGTGTGTG 7

RESULT 1520
US-09-969-037-5/c
; Sequence 5, Application US/09969037
; Publication No. US20030022247A1
; GENERAL INFORMATION:
; APPLICANT: KYOWA HAKKO KOGYO CO., LTD.
; TITLE OF INVENTION: Substance which inhibits binding of information transfer molecule
; TITLE OF INVENTION: for 1175-tyrosine phosphorylated KDR/Flk-1 and usages of the same
; FILE REFERENCE:
; CURRENT APPLICATION NUMBER: US/09/969,037
; CURRENT FILING DATE: 2001-10-03
; PRIOR APPLICATION NUMBER: JP 2000-303694
; PRIOR FILING DATE: 2000-10-03
; PRIOR APPLICATION NUMBER: US 60/263,512
; PRIOR FILING DATE: 2001-01-24
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 5
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: a primer for replacing of human KDR/Flk-1 tyrosine residue at position 801 to phenylalanine.
US-09-969-037-5

Query Match 0.4%; Score 14; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 9.7e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 249 GATGGACAGAGC 262
Db 19 GATGGACAGAGC 6

RESULT 1521
US-10-181-846-66/c
; Sequence 66, Application US/10181846
; Publication No. US20030083297A1
; GENERAL INFORMATION:
; APPLICANT: Nicholas M. Dean
; APPLICANT: Lex M. Cowbert
; TITLE OF INVENTION: ANTISENSE MODULATION OF DAXX EXPRESSION
; FILE REFERENCE: RTSP-0363

; CURRENT APPLICATION NUMBER: US/10/181,846
; CURRENT FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: PCT/US01/01416
; PRIOR FILING DATE: 2001-01-16
; PRIOR APPLICATION NUMBER: 09/490,692
; PRIOR FILING DATE: 2000-01-24
; NUMBER OF SEQ ID NOS: 176
; SEQ ID NO 66
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-181-846-66

Query Match 0.4%; Score 14; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 9.7e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 171 AGATGACGAAGACG 184
Db 16 AGATGACGAAGACG 3

RESULT 1522
US-10-126-355-60
; Sequence 60, Application US/10126355
; Publication No. US20030198965A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF HYDROXYSTEROID
; TITLE OF INVENTION: 11-BETA DEHYDROGENASE 1 EXPRESSION
; FILE REFERENCE: RTS-0428
; CURRENT APPLICATION NUMBER: US/10/126,355
; CURRENT FILING DATE: 2002-04-19
; NUMBER OF SEQ ID NOS: 122
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 60
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-126-355-60

Query Match 0.4%; Score 14; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 9.7e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1619 ACAGGGACCTGGCT 1632
Db 6 ACAGGGACCTGGCT 19

RESULT 1523
US-10-362-010-1
; Sequence 1, Application US/10362010
; Publication No. US20040038247A1
; GENERAL INFORMATION:
; APPLICANT: Brenner, Sidney
; APPLICANT: Venkatesh, Byrappa
; APPLICANT: Tan, Yin, Hwee
; TITLE OF INVENTION: NUCLEIC ACID CONSTRUCTS INCLUDING A NOVEL T-CELL ACTIVE PROMOTER,
; TITLE OF INVENTION: AND PHARMACEUTICAL COMPOSITIONS AND METHODS UTILIZING SAME FOR
; TITLE OF INVENTION: REGULATING T-CELL MEDIATED IMMUNE RESPONSE
; FILE REFERENCE: 01/22004
; CURRENT APPLICATION NUMBER: US/10/362,010
; CURRENT FILING DATE: 2003-08-19
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1
; LENGTH: 20
; TYPE: DNA

```

; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Single strand DNA oligonucleotide
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (12)..(12)
; OTHER INFORMATION: Any nucleotide
US-10-362-010-1

Query Match      0.4%; Score 14; DB 1; Length 20;
Best Local Similarity 70.6%; Pred. NO. 9.7e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 1669 AAGATCGCAGACTTCGG 1685
   ||:||: ||:||: ||:||:
DB 4 AARATHGCNGAYTTYGG 20

Search completed: October 28, 2004, 12:21:44
Job time : 110 secs

```


GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: October 28, 2004, 12:01:21 ; Search time 167 Seconds
(without alignments)

3.730 Million cell updates/sec

Title: US-10-630-401-10

Perfect score: 3799

Sequence: 1 aaggatggcagggctgtg.....gacacctgttgtaacctg 3799

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 0.5

Searched: 3741 seqs, 81979 residues

Total number of hits satisfying chosen parameters: 7482

Minimum DB seq length: 8

Maximum DB seq length: 50

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 2112 summaries

Database : rng10.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	36.4	1.0	48	1	Human clone cg4402
2	36.4	1.0	49	1	Hepstoma AS-30D Ty
3	35.6	0.9	50	1	Repeat sequence fr
4	35.6	0.9	50	1	Repeat sequence fr
5	35.6	0.9	50	1	H. discus derived
6	35.6	0.9	50	1	H. discus derived
7	35.6	0.9	50	1	Oligonucleotide us
8	35.2	0.9	48	1	Human microsatelli
9	34.8	0.9	48	1	Human clone cg4402
10	34.6	0.9	46	1	Repeat sequence fr
11	34.4	0.9	44	1	Repeat sequence fr
12	34.4	0.9	44	1	Human clone cg4402
13	34.2	0.9	42	1	Repeat sequence fr
14	34.2	0.9	47	1	Microsatellite seq
15	34.2	0.9	47	1	Repeat sequence fr
16	34.2	0.9	47	1	Repeat sequence fr
17	34.2	0.9	47	1	Repeat sequence fr
18	34.2	0.9	47	1	Human Vbeta gene r
19	33.8	0.9	37	1	Microsatellite seq
20	33.8	0.9	38	1	Repeat sequence fr
21	33.8	0.9	38	1	(dC-dA)n.(dG-dT)n
22	33.8	0.9	38	1	Porcine microsatelli
23	33.8	0.9	38	1	Human microsatelli
24	33.8	0.9	39	1	Microsatellite seq
25	33.8	0.9	39	1	Microsatellite seq
26	33.8	0.9	39	1	Microsatellite seq
27	33.8	0.9	39	1	Repeat sequence fr
28	33.8	0.9	39	1	Human Vbeta gene r
29	33.8	0.9	40	1	Sequence of a micr
30	33.8	0.9	40	1	(dC-dA)n.(dG-dT)n
31	33.8	0.9	40	1	Repeat sequence fr
32	33.8	0.9	40	1	(dC-dA)n.(dG-dT)n
33	33.8	0.9	40	1	Simple sequence re

C 34	33.8	0.9	40	1	ABK24300	Human microsatelli
C 35	33.8	0.9	41	1	AAT65710	Repeat sequence fr
C 36	33.8	0.9	41	1	AAT65745	Repeat sequence fr
C 37	33.8	0.9	41	1	AAT65758	Repeat sequence fr
C 38	33.8	0.9	41	1	ADH70301	Human Vbeta gene r
C 39	33.8	0.9	42	1	AAQ33770	Microsatellite seq
C 40	33.8	0.9	42	1	AAT65757	Repeat sequence fr
C 41	33.8	0.9	42	1	AAS13735	Simple sequence re
C 42	33.8	0.9	42	1	ABK24301	Human microsatelli
C 43	33.8	0.9	43	1	AAT65794	Repeat sequence fr
C 44	33.8	0.9	44	1	AAQ33636	Microsatellite seq
C 45	33.8	0.9	44	1	AAQ33983	Microsatellite seq
C 46	33.8	0.9	44	1	AAQ34113	Sequence of a micr
C 47	33.8	0.9	44	1	AAT65761	Repeat sequence fr
C 48	33.8	0.9	44	1	AAT65749	Repeat sequence fr
C 49	33.8	0.9	44	1	ABK24302	Human microsatelli
C 50	33.8	0.9	45	1	AAQ33915	Microsatellite seq
C 51	33.8	0.9	45	1	AAQ33968	Microsatellite seq
C 52	33.8	0.9	46	1	AAQ33840	Microsatellite seq
C 53	33.8	0.9	46	1	AAQ33939	Microsatellite seq
C 54	33.8	0.9	46	1	AAT65719	Repeat sequence fr
C 55	33.8	0.9	46	1	AAT65756	Repeat sequence fr
C 56	33.8	0.9	46	1	AAT65709	Repeat sequence fr
C 57	33.8	0.9	46	1	ABK24303	Human microsatelli
C 58	33.8	0.9	48	1	ADH70581	Human Vbeta gene r
C 59	33.6	0.9	45	1	AAT65786	Repeat sequence fr
C 60	33.4	0.9	35	1	AAT65711	Repeat sequence fr
C 61	33.4	0.9	43	1	AAQ34006	Microsatellite seq
C 62	33	0.9	41	1	AAK28288	Human CYP3A4 gene
C 63	32.8	0.9	36	1	AAQ33974	Microsatellite seq
C 64	32.8	0.9	36	1	AAQ33953	Microsatellite seq
C 65	32.8	0.9	36	1	AAQ34068	Microsatellite seq
C 66	32.8	0.9	36	1	AAQ33828	Microsatellite seq
C 67	32.8	0.9	36	1	AAQ33906	Microsatellite seq
C 68	32.8	0.9	36	1	AAQ33819	Microsatellite seq
C 69	32.8	0.9	36	1	AAQ33882	Microsatellite seq
C 70	32.8	0.9	36	1	AAT65784	Repeat sequence fr
C 71	32.8	0.9	36	1	AAT65720	Repeat sequence fr
C 72	32.8	0.9	36	1	AAS13713	Simple sequence re
C 73	32.8	0.9	36	1	ADK24298	Human microsatelli
C 74	32.8	0.9	36	1	ADK24298	Prion protein poly
C 75	32.8	0.9	36	1	ADK24298	Wheat SR containi
C 76	32.8	0.9	37	1	AAQ34041	Microsatellite seq
C 77	32.8	0.9	37	1	AAQ33900	Microsatellite seq
C 78	32.8	0.9	37	1	AAT65732	Repeat sequence fr
C 79	32.8	0.9	39	1	AAQ33737	Microsatellite seq
C 80	32.8	0.9	44	1	AAK77337	Human clone cg4402
C 81	32.8	0.9	45	1	AAT65751	Repeat sequence fr
C 82	32.4	0.9	34	1	AAQ33692	Microsatellite seq
C 83	32.4	0.9	34	1	AAQ33776	Microsatellite seq
C 84	32.4	0.9	34	1	AAQ33873	Microsatellite seq
C 85	32.4	0.9	34	1	AAT65744	Repeat sequence fr
C 86	32.4	0.9	34	1	ABK24297	Human microsatelli
C 87	32.4	0.9	35	1	AAT65747	Repeat sequence fr
C 88	32.4	0.9	37	1	AAQ33669	Microsatellite seq
C 89	32.4	0.9	38	1	AAQ68850	Human chromosomal
C 90	32.2	0.8	38	1	AAT65708	Repeat sequence fr
C 91	32.2	0.8	39	1	AAT65714	Repeat sequence fr
C 92	32.2	0.8	40	1	AAT65736	Repeat sequence fr
C 93	32.2	0.8	40	1	AAT65743	Repeat sequence fr
C 94	32.2	0.8	40	1	AAT65754	Repeat sequence fr
C 95	32.2	0.8	42	1	AAT65776	H. discus derived
C 96	32.2	0.8	44	1	ADH70603	Human Vbeta gene r
C 97	32.2	0.8	45	1	AAT65737	Repeat sequence fr
C 98	31.4	0.8	33	1	AAQ34037	Sequence of a micr
C 99	31.4	0.8	33	1	AAQ34009	Microsatellite seq
C 100	31.4	0.8	33	1	AAQ34009	Repeat sequence fr
C 101	31.4	0.8	33	1	AAT65705	Repeat sequence fr
C 102	31.4	0.8	33	1	ABK34806	Mouse FGFR3 allele
C 103	31.4	0.8	34	1	AAQ33921	Microsatellite seq
C 104	31.4	0.8	34	1	AAT65722	Repeat sequence fr
C 105	31.4	0.8	34	1	AAT65748	Repeat sequence fr
C 106	31.4	0.8	34	1	AAT65748	Repeat sequence fr

vivlemore401-10.rng

Thu Oct 28 12:48:21 2004

107	31.4	0.8	34	1	AAT65772	Repeat sequence fr	180	25.4	0.7	27	1	AAQ34012	Microsatellite seq
108	31.4	0.8	43	1	AAT65788	Repeat sequence fr	181	25.4	0.7	27	1	AAQ34143	Sequence of a micr
109	31.2	0.8	44	1	AAQ34104	Sequence of a micr	182	25.4	0.7	27	1	AAQ83951	Oligonucleotide cl
110	31	0.8	31	1	AAI30469	Human single nucle	183	25.4	0.7	27	1	AAT65733	Repeat sequence fr
111	31	0.8	31	1	AAI30470	Human single nucle	184	25.4	0.7	27	1	AAH24300	Synthetic antineop
112	31	0.8	31	1	AAI30472	Human single nucle	185	25.4	0.7	27	1	AAH46017	Synthetic oligonuc
113	30.8	0.8	34	1	ADH70517	Human Vbeta gene r	186	25.4	0.7	27	1	AAH46001	Synthetic oligonuc
114	30.8	0.8	35	1	AAQ33713	Microsatellite seq	187	25.4	0.7	27	1	AAH46005	Synthetic oligonuc
115	30.8	0.8	42	1	AAT65779	Repeat sequence fr	188	25.4	0.7	27	1	AAH60473	Oligonucleotide cl
116	30.4	0.8	32	1	AAQ33666	Microsatellite seq	189	25.4	0.7	30	1	ADH70576	Human Vbeta gene r
117	30.4	0.8	32	1	AAQ34119	Sequence of a micr	190	25.2	0.7	30	1	ADH70406	Human Vbeta gene r
118	30.4	0.8	32	1	AAT65790	Repeat sequence fr	191	25.2	0.7	30	1	AAH54587	Primer used for de
119	30.4	0.8	32	1	AAT65752	Repeat sequence fr	192	25	0.7	25	1	AAH54586	Primer used for de
120	30.4	0.8	32	1	AAH56155	Human alpha-7 nico	193	25	0.7	25	1	AAH54587	Kaposi's Sarcoma T
121	30.4	0.8	32	1	AAH298487	H. discus derived	194	25	0.7	25	1	AAH54586	Kaposi's Sarcoma T
122	30.4	0.8	32	1	AAH298487	Human microsatelli	195	25	0.7	25	1	AAH54586	Kaposi's Sarcoma T
123	30.4	0.8	32	1	AAT65778	Repeat sequence fr	196	24.8	0.7	28	1	AAQ33843	Microsatellite seq
124	29.8	0.8	42	1	AAT65778	Microsatellite seq	197	24.4	0.6	26	1	AAQ34083	Microsatellite seq
125	29.6	0.8	38	1	AAQ33894	Microsatellite seq	198	24.4	0.6	26	1	AAQ33684	Microsatellite seq
126	29.4	0.8	41	1	AAQ33681	Microsatellite seq	199	24.4	0.6	26	1	AAQ33704	Microsatellite seq
127	29.4	0.8	31	1	AAQ33867	Microsatellite seq	200	24.4	0.6	26	1	AAQ33831	Microsatellite seq
128	29.4	0.8	31	1	AAQ33822	Microsatellite seq	201	24.4	0.6	26	1	AAQ33837	Microsatellite seq
129	29.4	0.8	31	1	AAQ33822	Microsatellite seq	202	24.4	0.6	26	1	AAQ33837	Microsatellite seq
130	29.4	0.8	31	1	AAQ33657	Microsatellite seq	203	24.4	0.6	26	1	AAQ33837	Microsatellite seq
131	29.4	0.8	31	1	AAQ33657	Microsatellite seq	204	24.4	0.6	26	1	AAQ33837	Microsatellite seq
132	29.4	0.8	31	1	AAT65759	Repeat sequence fr	205	24.2	0.6	29	1	AAQ33630	SSR motif #19. Un
133	29.4	0.8	31	1	AAT65753	Repeat sequence fr	206	24.2	0.6	29	1	AAQ33630	SSR motif #19. Un
134	29.4	0.8	31	1	AAI30471	Human single nucle	207	24	0.6	24	1	ADH70576	Cow prion protein
135	29.4	0.8	41	1	AAT65782	Repeat sequence fr	208	24	0.6	24	1	ADH70576	Cow prion protein
136	29.4	0.8	41	1	AAT65783	Repeat sequence fr	209	24	0.6	24	1	ADH70576	Cow prion protein
137	29.2	0.8	41	1	ABZ43333	Human N-methyltran	210	24	0.6	24	1	ADH70576	Cow prion protein
138	29.2	0.8	41	1	ABZ43333	Human N-methyltran	211	23.8	0.6	30	1	AAQ33309	Microsatellite seq
139	29	0.8	37	1	AAQ33710	Microsatellite seq	212	23.6	0.6	33	1	ADH70576	Microsatellite seq
140	29	0.8	39	1	AAT65775	Repeat sequence fr	213	23.6	0.6	33	1	ADH70576	Microsatellite seq
141	29	0.8	41	1	ABZ45485	Human glutathione-	214	23.4	0.6	25	1	AAQ33918	Microsatellite seq
142	29	0.8	41	1	ABZ43946	Human glutathione-	215	23.4	0.6	25	1	AAQ33918	Microsatellite seq
143	28.8	0.7	30	1	AAT65782	Repeat sequence fr	216	23.4	0.6	25	1	AAQ33918	Microsatellite seq
144	28.4	0.7	30	1	AAT65789	Simple sequence re	217	23.4	0.6	25	1	AAQ33918	Microsatellite seq
145	28.4	0.7	30	1	AAI33788	Simple sequence re	218	23.4	0.6	25	1	AAQ33918	Microsatellite seq
146	28.4	0.7	30	1	AAI33787	Novel sand pear mi	219	23.4	0.6	25	1	AAQ33918	Microsatellite seq
147	28.4	0.7	30	1	AAI33787	Novel sand pear mi	220	23.4	0.6	25	1	AAQ33918	Microsatellite seq
148	28.4	0.7	30	1	AAI33787	Novel sand pear mi	221	23.4	0.6	25	1	AAQ33918	Microsatellite seq
149	28.2	0.7	33	1	AAQ33944	Microsatellite seq	222	23.2	0.6	28	1	AAQ33933	Microsatellite seq
150	28.2	0.7	33	1	AAQ33944	Microsatellite seq	223	23.2	0.6	28	1	AAQ33933	Microsatellite seq
151	27.6	0.7	35	1	AAQ33695	Microsatellite seq	224	23.2	0.6	32	1	AAQ34149	Microsatellite seq
152	27.6	0.7	35	1	AAQ33695	Microsatellite seq	225	23	0.6	23	1	AAH54428	Repeat sequence fo
153	27.4	0.7	38	1	AAQ33767	Microsatellite seq	226	23	0.6	23	1	AAH54428	Repeat sequence fo
154	27.4	0.7	29	1	AAQ33687	Microsatellite seq	227	23	0.6	24	1	ABZ70239	Murine tricarboxyl
155	27.4	0.7	29	1	AAQ33846	Microsatellite seq	228	22.6	0.6	32	1	ABL58122	Human p70 ribosome
156	27.4	0.7	29	1	AAQ33956	Microsatellite seq	229	22.4	0.6	32	1	ABL58122	Human p70 ribosome
157	27.4	0.7	29	1	AAQ33956	Microsatellite seq	230	22.4	0.6	24	1	AAQ33986	Sequence of a micr
158	27.4	0.7	29	1	AAQ33956	Microsatellite seq	231	22.4	0.6	24	1	AAQ33986	Sequence of a micr
159	27.4	0.7	29	1	AAQ33956	Microsatellite seq	232	22.4	0.6	24	1	AAQ33986	Sequence of a micr
160	27.4	0.7	29	1	AAQ33956	Microsatellite seq	233	22.4	0.6	24	1	AAQ33986	Sequence of a micr
161	26.6	0.7	33	1	AAQ33731	Oligonucleotide cl	234	22.4	0.6	24	1	AAQ33986	Sequence of a micr
162	26.4	0.7	28	1	AAQ34027	Repeat sequence fr	235	22.4	0.6	24	1	AAH46015	Repeat sequence fo
163	26.4	0.7	28	1	AAQ34027	Repeat sequence fr	236	22.4	0.6	24	1	AAH46015	Repeat sequence fo
164	26.4	0.7	28	1	AAQ34074	Repeat sequence fr	237	22.4	0.6	24	1	AAH46015	Repeat sequence fo
165	26.4	0.7	28	1	AAQ34074	Repeat sequence fr	238	22.4	0.6	24	1	AAH46015	Repeat sequence fo
166	26.4	0.7	28	1	AAQ34161	Repeat sequence fr	239	22.4	0.6	24	1	AAH46015	Repeat sequence fo
167	26.4	0.7	28	1	AAQ34035	Repeat sequence fr	240	22.4	0.6	24	1	AAH46015	Repeat sequence fo
168	26.4	0.7	28	1	AAQ34035	Repeat sequence fr	241	22.4	0.6	24	1	AAH46015	Repeat sequence fo
169	26.4	0.7	28	1	AAQ34035	Repeat sequence fr	242	22.4	0.6	24	1	AAH46015	Repeat sequence fo
170	26.4	0.7	28	1	AAQ34035	Repeat sequence fr	243	22.4	0.6	24	1	AAH46015	Repeat sequence fo
171	26	0.7	26	1	ADK51120	Human NOVX protein	244	22.4	0.6	24	1	ADH70471	Human NOVX protein
172	26	0.7	26	1	ADK51126	Human NOVX protein	245	22.4	0.6	24	1	ADH70471	Human NOVX protein
173	25.8	0.7	29	1	ADH70471	Human fibroblast g	246	22.4	0.6	24	1	ADH70471	Human fibroblast g
174	25.8	0.7	29	1	ADH70471	H. discus derived	247	22.4	0.6	24	1	ADH70471	H. discus derived
175	25.8	0.7	30	1	AAZ98502	Microsatellite seq	248	22.4	0.6	32	1	AAZ98502	Microsatellite seq
176	25.4	0.7	27	1	AAQ33678	Microsatellite seq	249	22.2	0.6	31	1	AAZ98502	Microsatellite seq
177	25.4	0.7	27	1	AAQ33678	Microsatellite seq	250	22.2	0.6	31	1	AAZ98502	Microsatellite seq
178	25.4	0.7	27	1	AAQ33678	Microsatellite seq	251	22.2	0.6	31	1	AAZ98502	Microsatellite seq
179	25.4	0.7	27	1	AAQ33678	Microsatellite seq	252	22	0.6	22	1	AAZ98502	Microsatellite seq

253	22	0.6	22	1	AA30353	FGFR3 mRNA PCR pri	C 326	20	0.5	20	1	AA55486	Human FGFR-3 antis
C 254	22	0.6	22	1	AA30354	FGFR3 mRNA PCR pri	C 327	20	0.5	20	1	AA55488	Human FGFR-3 antis
C 255	22	0.6	22	1	AA321621	Sheep FGFR3 gene a	C 328	20	0.5	20	1	AA55432	Human FGFR-3 antis
C 256	22	0.6	22	1	AA167714	Receptor FGFR3 cDN	C 329	20	0.5	20	1	AA55453	Human FGFR-3 antis
C 257	22	0.6	22	1	AA167715	Receptor FGFR3 cDN	C 330	20	0.5	20	1	AA55455	Human FGFR-3 antis
C 258	22	0.6	22	1	AA55414	Human FGFR-3 DNA s	C 331	20	0.5	20	1	AA55456	Human FGFR-3 antis
C 259	22	0.6	22	1	ACF04260	Murine embryonic c	C 332	20	0.5	20	1	AA55458	Human FGFR-3 antis
C 260	22	0.6	22	1	ADK51127	Human NOVX protein	C 333	20	0.5	20	1	AA55437	Human FGFR-3 antis
C 261	22	0.6	22	1	ADN03543	Mouse bFGF 3R cDNA	C 334	20	0.5	20	1	AA55443	Human FGFR-3 antis
C 262	22	0.6	28	1	AAV44045	Mouse bFGF recepto	C 335	20	0.5	20	1	AA55483	Human FGFR-3 antis
C 263	22	0.6	31	1	AB564553	Human K-alpha1.v2	C 336	20	0.5	20	1	AA55487	Human FGFR-3 antis
C 264	22	0.6	31	1	AB564556	Human K-alpha1.v1	C 337	20	0.5	20	1	AA55503	Human FGFR-3 antis
C 265	22	0.6	31	1	AB564541	Human K-alpha1.v1	C 338	20	0.5	20	1	AA55445	Human FGFR-3 antis
C 266	21.8	0.6	25	1	AAH40159	SNP specific SNPE	C 339	20	0.5	20	1	AA55460	Human FGFR-3 antis
C 267	21.6	0.6	28	1	AAQ34000	Microsatellite seq	C 340	20	0.5	20	1	AA55462	Human FGFR-3 antis
C 268	21.4	0.6	23	1	AAQ33663	Microsatellite seq	C 341	20	0.5	20	1	AA55490	Human FGFR-3 antis
C 269	21.4	0.6	23	1	AAQ33773	Microsatellite seq	C 342	20	0.5	20	1	AA55444	Human FGFR-3 antis
C 270	21.4	0.6	23	1	AAQ33885	Microsatellite seq	C 343	20	0.5	20	1	AA55447	Human FGFR-3 antis
C 271	21.4	0.6	23	1	AA166105	Repeat sequence fo	C 344	20	0.5	20	1	AA55457	Human FGFR-3 antis
C 272	21.4	0.6	23	1	AA166047	Oligonucleotide cl	C 345	20	0.5	20	1	AA55479	Human FGFR-3 antis
C 273	21.4	0.6	24	1	AB597836	Human NADPH quinon	C 346	20	0.5	20	1	AA55481	Human FGFR-3 antis
C 274	21.4	0.6	26	1	AAQ92938	NRAMP promoter pol	C 347	20	0.5	20	1	AA55499	Human FGFR-3 antis
C 275	21.2	0.6	26	1	AA164470	SSR motif #20. Un	C 348	20	0.5	20	1	AA55452	Human FGFR-3 antis
C 276	21.2	0.6	27	1	AAQ33740	Microsatellite seq	C 349	20	0.5	20	1	AA55463	Human FGFR-3 antis
C 277	21	0.6	21	1	AAQ33789	Microsatellite seq	C 350	20	0.5	20	1	AA55495	Human FGFR-3 antis
C 278	21	0.6	21	1	AAQ21620	Sheep FGFR-3 DNA s	C 351	20	0.5	20	1	AA55500	Human FGFR-3 antis
C 279	21	0.6	21	1	AA554413	Human FGFR-3 DNA s	C 352	20	0.5	20	1	AA55438	Human FGFR-3 antis
C 280	21	0.6	21	1	ADC64705	Fibroblast growth	C 353	20	0.5	20	1	AA55442	Human FGFR-3 antis
C 281	21	0.6	21	1	ADC64703	Fibroblast growth	C 354	20	0.5	20	1	AA55451	Human FGFR-3 antis
C 282	21	0.6	21	1	ADK51121	Human NOVX protein	C 355	20	0.5	20	1	AA55454	Human FGFR-3 antis
C 283	21	0.6	21	1	ADK51124	Human NOVX protein	C 356	20	0.5	20	1	AA55485	Human FGFR-3 antis
C 284	21	0.6	27	1	AAQ52728	Mouse fibroblast g	C 357	20	0.5	20	1	AA55489	Human FGFR-3 antis
C 285	21	0.6	30	1	ABK66084	Human gene specifi	C 358	20	0.5	20	1	AA55492	Human FGFR-3 antis
C 286	20.8	0.5	25	1	AAH40155	SNP specific SNPE	C 359	20	0.5	20	1	AA55431	Human FGFR-3 antis
C 287	20.6	0.5	27	1	AAQ95132	Spinocherebellar at	C 360	20	0.5	20	1	AA55434	Human FGFR-3 antis
C 288	20.6	0.5	27	1	AA880358	Human ASRH1 5' re	C 361	20	0.5	20	1	AA55446	Human FGFR-3 antis
C 289	20.6	0.5	27	1	ACC79667	Human fibroblast g	C 362	20	0.5	20	1	AA55482	Human FGFR-3 antis
C 290	20.4	0.5	22	1	AAQ33810	Microsatellite seq	C 363	20	0.5	20	1	AA55450	Human FGFR-3 antis
C 291	20.4	0.5	22	1	AAQ33675	Microsatellite seq	C 364	20	0.5	20	1	AA55480	Human FGFR-3 antis
C 292	20.4	0.5	22	1	AAQ34038	Microsatellite seq	C 365	20	0.5	20	1	AA55497	Human FGFR-3 antis
C 293	20.4	0.5	22	1	AAQ34080	Microsatellite seq	C 366	20	0.5	20	1	AA55430	Human FGFR-3 antis
C 294	20.4	0.5	22	1	AAQ33991	Microsatellite seq	C 367	20	0.5	20	1	AA55433	Human FGFR-3 antis
C 295	20.4	0.5	22	1	AAQ83952	Oligonucleotide cl	C 368	20	0.5	20	1	AA55439	Human FGFR-3 antis
C 296	20.4	0.5	22	1	AA167577	Repeat sequence fr	C 369	20	0.5	20	1	AA55498	Human FGFR-3 antis
C 297	20.4	0.5	22	1	AA164448	SSR motif #18. Un	C 370	20	0.5	20	1	AA55502	Human FGFR-3 antis
C 298	20.4	0.5	22	1	AA164448	SSR motif #8. Uni	C 371	20	0.5	20	1	AA55429	Human FGFR-3 antis
C 299	20.4	0.5	22	1	AA164456	SSR motif #16. Un	C 372	20	0.5	20	1	AA55441	Human FGFR-3 antis
C 300	20.4	0.5	22	1	AA150669	Human uridine diph	C 373	20	0.5	20	1	AA55448	Human FGFR-3 antis
C 301	20.4	0.5	22	1	AA150669	Human uridine diph	C 374	20	0.5	20	1	AA55501	Human FGFR-3 antis
C 302	20.4	0.5	22	1	AB597834	Human NADPH quinon	C 375	20	0.5	20	1	AA55494	Human FGFR-3 antis
C 303	20.4	0.5	22	1	AD081143	Prion protein poly	C 376	20	0.5	20	1	AA55459	Human FGFR-3 antis
C 304	20.4	0.5	22	1	AD081098	Sheep prion protei	C 377	20	0.5	20	1	AA55491	Human FGFR-3 antis
C 305	20.4	0.5	24	1	AA150670	Human uridine diph	C 378	20	0.5	20	1	AA55493	Human FGFR-3 antis
C 306	20.4	0.5	24	1	AA150670	Human uridine diph	C 379	20	0.5	20	1	AA55496	Human FGFR-3 antis
C 307	20.4	0.5	26	1	AA150671	Human uridine diph	380	20	0.5	20	1	ADH93220	Human gene PCR pri
C 308	20.4	0.5	26	1	AA150671	Human uridine diph	381	20	0.5	20	1	ADH93212	Human gene PCR pri
C 309	20.4	0.5	26	1	AB224782	Oligodeoxynucleic	C 382	20	0.5	20	1	ACC79688	Human fibroblast g
C 310	20.4	0.5	26	1	AB224782	Oligodeoxynucleic	C 383	20	0.5	20	1	ACC79688	Human fibroblast g
C 311	20.4	0.5	28	1	AA150672	Human uridine diph	384	20	0.5	20	1	ADK51119	Human NOVX protein
C 312	20.4	0.5	28	1	AA150672	Human uridine diph	385	20	0.5	20	1	ADK51122	5' mRNA DNA prepar
C 313	20.4	0.5	28	1	ADK61709	Base containing SS	386	20	0.5	20	1	ADK70840	PCR primer #6, use
C 314	20.4	0.5	28	1	ADK61709	Base containing SS	C 387	20	0.5	27	1	ABK50766	SSA primer 2 for a
C 315	20.2	0.5	25	1	AC158599	Human microarray D	388	19.8	0.5	28	1	AAZ89470	SNP specific upper
C 316	20.2	0.5	25	1	AC158598	Human microarray D	389	19.8	0.5	23	1	AAH39005	PIGF gene reverse
C 317	20.2	0.5	25	1	ADB38952	Human interleukin	C 390	19.8	0.5	23	1	ADG82642	bFGF gene probe.
C 318	20	0.5	20	1	AA34894	PCR primer used to	C 391	19.8	0.5	23	1	ADG82637	Human beta gene r
C 319	20	0.5	20	1	AA544426	Primer used for de	C 392	19.8	0.5	23	1	ADH70580	H. discus derived
C 320	20	0.5	20	1	AA554461	Human FGFR-3 antis	C 393	19.8	0.5	24	1	AAZ98498	Protein 9.90 PCR p
C 321	20	0.5	20	1	AA554428	Human FGFR-3 antis	394	19.8	0.5	24	1	ABZ70117	Human gene specifi
C 322	20	0.5	20	1	AA554435	Human FGFR-3 antis	395	19.8	0.5	26	1	ABK67019	Human gene specifi
C 323	20	0.5	20	1	AA554440	Human FGFR-3 antis	C 396	19.8	0.5	27	1	AAZ89469	SSA primer 1 for a
C 324	20	0.5	20	1	AA554449	Human FGFR-3 antis	C 397	19.8	0.5	27	1	ADQ39594	PCR primer #4 used
C 325	20	0.5	20	1	AA554484	Human FGFR-3 antis	398	19.6	0.5	23	1	ADB69512	5' anchored (ISSR)

C 399	19.6	0.5	27	1	AAH91377	Human inflammatory	472	18.6	0.5	25	1	ABS75681	Human PAPP-Ea asso
C 400	19.6	0.5	28	1	ABK66262	Human gene specific	C 473	18.6	0.5	25	1	ACI44270	Human microarray D
401	19.4	0.5	21	1	AAQ33891	Microsatellite seq	474	18.4	0.5	20	1	AAQ34170	Sequence of a micr
402	19.4	0.5	21	1	AAQ34015	Microsatellite seq	475	18.4	0.5	20	1	AAQ33816	Microsatellite seq
403	19.4	0.5	21	1	AAQ33879	Microsatellite seq	476	18.4	0.5	20	1	AAQ33672	Microsatellite seq
404	19.4	0.5	21	1	AAQ33879	Microsatellite seq	477	18.4	0.5	20	1	AAQ33672	Antitumoral phosph
C 405	19.4	0.5	21	1	AAQ33879	Oligonucleotide RT	478	18.4	0.5	20	1	AAQ33829	Oligonucleotide wh
406	19.4	0.5	21	1	AAH46013	Repeat sequence fr	479	18.4	0.5	20	1	AAV06824	20-mer oligonucleo
407	19.4	0.5	21	1	AAH46014	Synthetic oligonuc	480	18.4	0.5	20	1	AAA39091	Human oligonucleo
408	19.4	0.5	21	1	AAH46014	Immunostimulatory	481	18.4	0.5	20	1	AAA39091	Human MCIR gene re
C 409	19.4	0.5	21	1	ABS78423	Angiogenesis inhib	482	18.4	0.5	20	1	AAA73096	Human MCIR gene re
C 410	19.4	0.5	21	1	ABS78423	Human NADPH quinon	C 483	18.4	0.5	20	1	AAH73096	Simple sequence re
C 411	19.4	0.5	21	1	ACH03241	Immunostimulatory	484	18.4	0.5	20	1	AAH73096	Simple sequence re
412	19.4	0.5	21	1	ADG64706	Fibroblast growth	C 485	18.4	0.5	20	1	AAH73096	Simple sequence re
C 413	19.4	0.5	21	1	ADG64706	Porcine microsatel	C 486	18.4	0.5	20	1	AAH73096	Simple sequence re
C 414	19.4	0.5	21	1	ADG64706	Porcine microsatel	C 487	18.4	0.5	20	1	AAH73096	Simple sequence re
C 415	19.4	0.5	21	1	AAH465560	Immunostimulatory	C 488	18.4	0.5	20	1	AAH73096	Simple sequence re
416	19.4	0.5	22	1	AAH465560	Immunostimulatory	490	18.4	0.5	20	1	AAH73096	Simple sequence re
C 417	19.4	0.5	22	1	AAH465560	Immunostimulatory	C 491	18.4	0.5	20	1	AAH73096	Simple sequence re
C 418	19.4	0.5	22	1	AAH465560	Immunostimulatory	492	18.4	0.5	20	1	AAH73096	Simple sequence re
C 419	19.4	0.5	22	1	AAH465560	Immunostimulatory	C 493	18.4	0.5	20	1	AAH73096	Simple sequence re
420	19.4	0.5	22	1	AAH465560	Immunostimulatory	C 494	18.4	0.5	20	1	AAH73096	Simple sequence re
C 421	19.4	0.5	22	1	AAH465560	Immunostimulatory	C 495	18.4	0.5	20	1	AAH73096	Simple sequence re
C 422	19.4	0.5	22	1	AAH465560	Immunostimulatory	C 496	18.4	0.5	20	1	AAH73096	Simple sequence re
C 423	19.4	0.5	22	1	AAH465560	Immunostimulatory	C 497	18.4	0.5	20	1	AAH73096	Simple sequence re
424	19.4	0.5	22	1	AAH465560	Immunostimulatory	C 498	18.4	0.5	20	1	AAH73096	Simple sequence re
C 425	19.4	0.5	22	1	AAH465560	Immunostimulatory	499	18.4	0.5	20	1	AAH73096	Simple sequence re
C 426	19.4	0.5	22	1	AAH465560	Immunostimulatory	C 500	18.4	0.5	20	1	AAH73096	Simple sequence re
427	19.4	0.5	26	1	AAQ44016	SNP specific lower	C 501	18.4	0.5	20	1	AAH73096	Simple sequence re
C 428	19.4	0.5	26	1	AAQ44016	Target sequence #8	C 502	18.4	0.5	20	1	AAH73096	Simple sequence re
429	19.4	0.5	26	1	AAQ44016	KIT gene primer KI	C 503	18.4	0.5	20	1	AAH73096	Simple sequence re
C 430	19.2	0.5	24	1	AAH84034	FGFR-3 PCR antise	C 504	18.4	0.5	20	1	AAH73096	Simple sequence re
C 431	19.2	0.5	24	1	AAH84034	H. discus derived	C 505	18.4	0.5	20	1	AAH73096	Simple sequence re
C 432	19.2	0.5	24	1	AAH84034	Human NOV1 TET/TAM	C 506	18.4	0.5	20	1	AAH73096	Simple sequence re
C 433	19.2	0.5	25	1	AAH84034	Human microarray D	C 507	18.4	0.5	20	1	AAH73096	Simple sequence re
434	19.0	0.5	19	1	AAH84034	Forward RT-PCR pri	C 508	18.4	0.5	20	1	AAH73096	Simple sequence re
C 435	19.0	0.5	19	1	AAH84034	Reverse RT-PCR pri	C 509	18.4	0.5	20	1	AAH73096	Simple sequence re
436	19.0	0.5	19	1	AAH84034	Kaposi's sarcoma t	C 510	18.4	0.5	20	1	AAH73096	Simple sequence re
C 437	19.0	0.5	19	1	AAH84034	Human fibroblast g	C 511	18.4	0.5	20	1	AAH73096	Simple sequence re
C 438	19.0	0.5	19	1	AAH84034	Human fibroblast g	C 512	18.4	0.5	20	1	AAH73096	Simple sequence re
439	19.0	0.5	19	1	AAH84034	Human NOVX protein	C 513	18.4	0.5	20	1	AAH73096	Simple sequence re
440	19.0	0.5	19	1	AAH84034	RNA interference t	C 514	18.4	0.5	20	1	AAH73096	Simple sequence re
441	19.0	0.5	19	1	AAH84034	RNA interference t	C 515	18.4	0.5	20	1	AAH73096	Simple sequence re
442	19.0	0.5	19	1	AAH84034	RNA interference t	C 516	18.4	0.5	20	1	AAH73096	Simple sequence re
443	19.0	0.5	19	1	AAH84034	RNA interference t	C 517	18.4	0.5	20	1	AAH73096	Simple sequence re
444	19.0	0.5	19	1	AAH84034	RNA interference t	C 518	18.4	0.5	20	1	AAH73096	Simple sequence re
445	19.0	0.5	19	1	AAH84034	Anti-FGFR3 siRNA r	C 519	18.4	0.5	20	1	AAH73096	Simple sequence re
446	19.0	0.5	19	1	AAH84034	Anti-FGFR3 siRNA r	C 520	18.4	0.5	20	1	AAH73096	Simple sequence re
447	19.0	0.5	19	1	AAH84034	Anti-FGFR3 siRNA r	C 521	18.4	0.5	20	1	AAH73096	Simple sequence re
448	19.0	0.5	19	1	AAH84034	Anti-FGFR3 siRNA r	C 522	18.4	0.5	20	1	AAH73096	Simple sequence re
449	19.0	0.5	19	1	AAH84034	Anti-FGFR3 siRNA r	C 523	18.4	0.5	20	1	AAH73096	Simple sequence re
450	19.0	0.5	19	1	AAH84034	Human FLAP related	C 524	18.4	0.5	20	1	AAH73096	Simple sequence re
C 451	19.0	0.5	20	1	AAH84034	Tyrosine kinase an	C 525	18.4	0.5	20	1	AAH73096	Simple sequence re
C 452	19.0	0.5	24	1	AAH84034	Sequence of a micr	C 526	18.4	0.5	20	1	AAH73096	Simple sequence re
C 453	19.0	0.5	26	1	AAH84034	Isoenzyme transgeni	C 527	18.4	0.5	20	1	AAH73096	Simple sequence re
C 454	19.0	0.5	27	1	AAH84034	Microsatellite seq	C 528	18.4	0.5	20	1	AAH73096	Simple sequence re
455	18.8	0.5	22	1	AAQ33716	Microsatellite seq	C 529	18.4	0.5	20	1	AAH73096	Simple sequence re
456	18.8	0.5	22	1	AAQ33716	FGFR-3 PCR sense p	C 530	18.4	0.5	20	1	AAH73096	Simple sequence re
457	18.8	0.5	22	1	AAQ33716	Candida albicans G	C 531	18.4	0.5	20	1	AAH73096	Simple sequence re
C 458	18.8	0.5	22	1	AAQ33716	Human ASTH11 5' re	C 532	18.4	0.5	20	1	AAH73096	Simple sequence re
459	18.8	0.5	23	1	AAH80357	5' anchored (ISSR)	C 533	18.4	0.5	20	1	AAH73096	Simple sequence re
460	18.8	0.5	23	1	AAH80357	Modified DNA oligo	C 534	18.4	0.5	20	1	AAH73096	Simple sequence re
C 461	18.8	0.5	24	1	AAH59719	Modified oligonuc	C 535	18.4	0.5	20	1	AAH73096	Simple sequence re
C 462	18.8	0.5	24	1	AAH59719	Human prostate can	C 536	18.4	0.5	20	1	AAH73096	Simple sequence re
C 463	18.8	0.5	24	1	AAH59719	Prostate disease m	C 537	18.4	0.5	20	1	AAH73096	Simple sequence re
C 464	18.8	0.5	24	1	AAH59719	Primer specific fo	C 538	18.4	0.5	20	1	AAH73096	Simple sequence re
C 465	18.8	0.5	24	1	AAH59719	Biomarker UC band	C 539	18.4	0.5	20	1	AAH73096	Simple sequence re
C 466	18.8	0.5	24	1	AAH59719	Human microarray D	C 540	18.4	0.5	20	1	AAH73096	Simple sequence re
C 467	18.8	0.5	25	1	AAH59719	Human microarray D	C 541	18.4	0.5	20	1	AAH73096	Simple sequence re
C 468	18.8	0.5	25	1	AAH59719	Rat FGFR coding se	C 542	18.4	0.5	20	1	AAH73096	Simple sequence re
469	18.6	0.5	20	1	AAH59719	Kinase domain 5' p	C 543	18.4	0.5	20	1	AAH73096	Simple sequence re
470	18.6	0.5	25	1	AAH59719	Mammalian ZAP-70 P	C 544	18.4	0.5	20	1	AAH73096	Simple sequence re
471	18.6	0.5	25	1	AAH59719								

c 545	18.2	0.5	26	1	ABS78791	Human NOVX probe A	c 618	17.4	0.5	19	1	ADF37634	Human VEGFR3 short
c 546	18	0.5	18	1	AA577485	US5912147 primer 2	c 619	17.4	0.5	19	1	ADF37647	Human VEGFR3 short
c 547	18	0.5	18	1	AA513764	Simple sequence re	c 620	17.4	0.5	19	1	ADF36527	Human VEGFR1 short
c 548	18	0.5	18	1	AA314804	Human FGFR3 allele	c 621	17.4	0.5	19	1	ACC79668	Human fibroblast g
c 549	18	0.5	18	1	ABQ81992	Kaposi's Sarcoma T	c 622	17.4	0.5	19	1	ADN34364	Lower strand of cy
c 550	18	0.5	18	1	ADCI3477	Kaposi's sarcoma t	c 623	17.4	0.5	19	1	ADN34125	Upper strand of cy
c 551	18	0.5	18	1	ADH70777	Human Vbeta gene r	c 624	17.4	0.5	19	1	ADH70642	Human Vbeta gene r
c 552	18	0.5	19	1	ADQ15049	Human PDGFR-target	c 625	17.4	0.5	20	1	AA288880	Single stranded nu
c 553	18	0.5	19	1	ADQ14738	Human PDGFR-target	c 626	17.4	0.5	20	1	AA288880	Single stranded nu
c 554	18	0.5	20	1	AAQ49455	Primer for detecti	c 627	17.4	0.5	20	1	AA62964	Mouse PEPCK-cytoso
c 555	18	0.5	20	1	ADMI4399	Human mPGES-1 chim	c 628	17.4	0.5	20	1	ABO93169	T. tauschii/wheat
c 556	18	0.5	20	1	ADMI4344	Human mPGES-1 chim	c 629	17.4	0.5	20	1	ABS97833	Human NADPH quinon
c 557	18	0.5	21	1	ADK96577	Primer of the inve	c 630	17.4	0.5	20	1	ADH93219	Human gene PCR pri
c 558	18	0.5	21	1	ADJ98020	Human Fk-1/KDR DN	c 631	17.4	0.5	20	1	ADH93219	Human gene PCR pri
c 559	18	0.5	22	1	AAJ00049	FGFR PCR sense pri	c 632	17.4	0.5	20	1	ADM14780	Human mPGES-1 chim
c 560	17.8	0.5	21	1	AAV58080	ICAM-1 antisense o	c 633	17.4	0.5	20	1	ADM14772	Human mPGES-1 chim
c 561	17.8	0.5	21	1	AAV38616	Human ICAM-1, E-se	c 634	17.4	0.5	20	1	ADN58895	Mouse B7H antisens
c 562	17.8	0.5	21	1	AA218102	PTK 6 gene specifi	c 635	17.4	0.5	20	1	ADN58899	Mouse B7H target s
c 563	17.8	0.5	21	1	AA218094	PTK 2 gene specifi	c 636	17.4	0.5	21	1	AA85976	CA repeat fluoroge
c 564	17.8	0.5	21	1	AA218118	PTK 14 gene specifi	c 637	17.4	0.5	21	1	AAH49075	Human LDLR gene as
c 565	17.8	0.5	21	1	AA218110	PTK 10 gene specifi	c 638	17.4	0.5	21	1	ABX09519	Human mPGES-1 d
c 566	17.8	0.5	21	1	AA260082	Reverse PCR primer	c 639	17.4	0.5	21	1	ABS98543	Arteriosclerosis-d
c 567	17.8	0.5	21	1	AAH38434	SNP specific lower	c 640	17.4	0.5	22	1	ADH70559	Human acetyl choli
c 568	17.8	0.5	21	1	ABU44374	Human chromosome 1	c 641	17.4	0.5	23	1	AAH34331	Human Vbeta gene r
c 569	17.8	0.5	21	1	ABS98544	Human acetyl choli	c 642	17.4	0.5	24	1	AAU45613	Primer PTK3YK for
c 570	17.8	0.5	21	1	ABS98544	Human acetyl choli	c 643	17.4	0.5	24	1	ABZ25283	ATP dependent memb
c 571	17.8	0.5	21	1	ABS97829	Human NADPH quinon	c 644	17.4	0.5	30	1	ABL56894	Human zinc finger
c 572	17.8	0.5	21	1	ABS97831	Human NADPH quinon	c 645	17.4	0.5	30	1	ABL56888	Synthetic deoxyrib
c 573	17.8	0.5	21	1	ABK47993	Human MIP-3 beta R	c 646	17.4	0.5	30	1	ABA97612	Synthetic deoxyrib
c 574	17.8	0.5	21	1	ACA90116	Cardiovascular dis	c 647	17.4	0.5	30	1	ABA97618	Poly a nucleotide
c 575	17.8	0.5	21	1	ADJ57203	Human NOVX reverse	c 648	17.4	0.5	30	1	ABL95885	Poly g nucleotide
c 576	17.8	0.5	22	1	ABS78792	Human NOVX reverse	c 649	17.4	0.5	30	1	ABL95891	Probe poly a for a
c 577	17.8	0.5	23	1	ADG79947	Primer of the inve	c 650	17.2	0.5	22	1	AAQ62397	Probe poly g for a
c 578	17.8	0.5	24	1	AAO57339	Enzymatic RNA mole	c 651	17.2	0.5	22	1	AAQ21616	Vector pVAC1 const
c 579	17.8	0.5	24	1	AAV55817	Multimerization of	c 652	17.2	0.5	22	1	AAQ23702	5' PCR-RFLP primer
c 580	17.8	0.5	24	1	ACI70111	SNP specific upper	c 653	17.2	0.5	22	1	AA874089	Primer #23. Homo
c 581	17.8	0.5	25	1	AAI30472	Human microarray D	c 654	17.2	0.5	22	1	ADQ73475	Human B cell recep
c 582	17.8	0.5	31	1	AAI30472	Human single nucle	c 655	17.2	0.5	22	1	ADQ74810	Human NOVX PCR pri
c 583	17.6	0.5	24	1	AAA30842	Zebrafish PTHIR re	c 656	17.2	0.5	23	1	AAQ32277	Trypanosoma brucei
c 584	17.6	0.5	24	1	AA448458	Full length zebra	c 657	17.2	0.5	23	1	AAQ23702	Human heavy chain
c 585	17.6	0.5	24	1	AA468170	Zebrafish PTHIR CD	c 658	17.2	0.5	23	1	AAQ23702	Primer HU33ABACK
c 586	17.6	0.5	24	1	ABA05057	Human molecular ch	c 659	17.2	0.5	23	1	AAQ49744	PTK primer pTK2
c 587	17.6	0.5	24	1	ABA05057	Human phosphoester	c 660	17.2	0.5	23	1	AAQ39335	VH domain PCR ampl
c 588	17.6	0.5	24	1	ABA05057	Human endonuclease	c 661	17.2	0.5	23	1	AAQ48989	Multimeric (SAP) a
c 589	17.6	0.5	24	1	ACC69078	Human epidermal gr	c 662	17.2	0.5	23	1	AAQ30886	Protein tyrosine-k
c 590	17.6	0.5	24	1	ADG42320	Full length zebra	c 663	17.2	0.5	23	1	AAQ29179	HuVh3a 5' heavy ch
c 591	17.6	0.5	24	1	ADH61074	Zebrafish PTHIR CD	c 664	17.2	0.5	23	1	AAQ76600	Human sfv library
c 592	17.6	0.5	25	1	AAV05314	Human gene PCR pri	c 665	17.2	0.5	23	1	AA243845	Human IgG4 heavy c
c 593	17.6	0.5	25	1	ABS75680	Kinase domain 3' p	c 666	17.2	0.5	23	1	ABA03074	PCR primer Hu VH3-
c 594	17.6	0.5	25	1	ABS75679	Human PAPP-Ea asso	c 667	17.2	0.5	23	1	AAQ20057	Human antibody VH
c 595	17.6	0.5	25	1	ABS75678	Human PAPP-Ea asso	c 668	17.2	0.5	23	1	AAQ13302	Human VH domain am
c 596	17.6	0.5	25	1	ABS75682	Human PAPP-Ea asso	c 669	17.2	0.5	23	1	ABN87305	Human VH domain PC
c 597	17.6	0.5	25	1	ACT87320	Human microarray D	c 670	17.2	0.5	23	1	AAH23018	VEGFR-1 gene speci
c 598	17.6	0.5	25	1	ACT80279	Human microarray D	c 671	17.2	0.5	23	1	AAH23018	PCR primer #3 used
c 599	17.6	0.5	25	1	ACH54190	DNA target sequenc	c 672	17.2	0.5	23	1	ABS76647	Novel metalloprote
c 600	17.6	0.5	25	1	ACH58465	DNA target sequenc	c 673	17.2	0.5	23	1	AAQ28818	Human antibody VH
c 601	17.6	0.5	25	1	AO010905	Single multiplex p	c 674	17.2	0.5	23	1	ABQ82763	K+betaM3 antibody
c 602	17.4	0.5	19	1	AAQ33728	Microsatellite seq	c 675	17.2	0.5	23	1	ABS68573	Human immunoglobul
c 603	17.4	0.5	19	1	AAH66093	Repeat sequence fo	c 676	17.2	0.5	23	1	ABQ83145	Human HGPBMY27 an
c 604	17.4	0.5	19	1	AAH68506	Cyclin B1 ribozyme	c 677	17.2	0.5	23	1	ABT09824	K+beta M6 related
c 605	17.4	0.5	19	1	AAZ89471	SSA primer 3 for a	c 678	17.2	0.5	23	1	ABT09824	PCR primer #3 for
c 606	17.4	0.5	19	1	AAZ89472	SSA primer 4 for a	c 679	17.2	0.5	23	1	AAQ42429	Human HDGMR10 ant
c 607	17.4	0.5	19	1	AAAC66739	Heterologous inser	c 680	17.2	0.5	23	1	AAQ46081	Human K+betaM2 ant
c 608	17.4	0.5	19	1	AAAC66738	Heterologous inser	c 681	17.2	0.5	23	1	AAU49669	Anti-HGPR4 antibod
c 609	17.4	0.5	19	1	AAH60968	Cyclin B1 ribozyme	c 682	17.2	0.5	23	1	AAK98428	Human V gene libra
c 610	17.4	0.5	19	1	ABK90423	Human UGT1a1 promo	c 683	17.2	0.5	23	1	AAK98469	Human V gene libra
c 611	17.4	0.5	19	1	ABK90423	Human UGT1a1 promo	c 684	17.2	0.5	23	1	ADJ33353	Human VH domain PC
c 612	17.4	0.5	19	1	AAU50681	Human uridine diph	c 685	17.2	0.5	23	1	ABT42680	Human GPCR related
c 613	17.4	0.5	19	1	AAU50681	Human uridine diph	c 686	17.2	0.5	23	1	AAU59941	Human antibody VH
c 614	17.4	0.5	19	1	ADG69517	ISSR-related PCR p	c 687	17.2	0.5	23	1	ABQ76996	Human anti-VEGF2 a
c 615	17.4	0.5	19	1	ADF37387	Human VEGFR3 short	c 688	17.2	0.5	23	1	ABX08573	Human anti-TRAIL r
c 616	17.4	0.5	19	1	ADF36100	Human VEGFR1 short	c 689	17.2	0.5	23	1	AAQ49552	Human VH gene ampl
c 617	17.4	0.5	19	1	ADF37400	Human VEGFR3 short	c 690	17.2	0.5	23	1	ABX99237	Anti-CAN-12 antibo

691	17.2	0.5	1	ACC48653	Human antibody hea	c 764	17	0.4	18	1	AAS13723	Simple sequence re
692	17.2	0.5	23	AD54813	Human TR4 antibody	765	17	0.4	18	1	AAS13729	Simple sequence re
693	17.2	0.5	23	ACD28137	Human heavy chain	766	17	0.4	18	1	AH46012	Synthetic oligonuc
694	17.2	0.5	23	AAL62199	Human VH domain am	767	17	0.4	18	1	AH46011	Synthetic oligonuc
695	17.2	0.5	23	AD911445	Human heavy chain	768	17	0.4	18	1	AH37514	SNP specific lower
696	17.2	0.5	23	ADA09673	Human anti-HGPRMY	c 769	17	0.4	18	1	AA164454	SSR motif #14. Un
697	17.2	0.5	23	ADA59740	Human HGRBMV14 an	c 770	17	0.4	18	1	AD081096	Mouse transforming
698	17.2	0.5	23	AD064499	Human VH domain PC	c 771	17	0.4	20	1	AD180140	Mouse transforming
699	17.2	0.5	23	AD083653	LTRPC3 VH domain P	c 772	17	0.4	20	1	AD180261	Human mPGEs-1 chim
700	17.2	0.5	23	AD068036	Human VH domain DN	c 773	17	0.4	20	1	AD180261	Human CRLR gene 5'
701	17.2	0.5	23	AD061497	Human MMP-29 antib	c 774	17	0.4	20	1	AD040832	Extend primer 21 u
702	17.2	0.5	23	AD067296	Human antibody rel	c 775	17	0.4	20	1	AD040832	Sequence of a micr
703	17.2	0.5	23	AD062328	PCR primer used to	c 776	17	0.4	23	1	AAQ34146	Capture probe CAP2
704	17.2	0.5	23	AD0615971	Human albumin fusi	c 777	17	0.4	24	1	AAQ44813	Pur-specific RACE
705	17.2	0.5	23	AD072145	Human immunoglobul	c 778	16.8	0.4	20	1	AAQ44813	Modified oligonuc
706	17.2	0.5	23	AD072145	Human protease-42	c 779	16.8	0.4	20	1	AAQ44813	C-KIT protoonogen
707	17.2	0.5	23	AD070552	Human antibody VH	c 780	16.8	0.4	20	1	AAQ44813	Human PUR-alpha ge
708	17.2	0.5	23	AD063842	Human TEP-PLIK2 ge	c 781	16.8	0.4	20	1	AAQ44813	Nucleotide sequenc
709	17.2	0.5	23	AD0618235	Human VEGF-2 relat	c 782	16.8	0.4	20	1	AAQ44813	PUR-alpha RACE rea
710	17.2	0.5	23	AD0618235	Human NF-kappaB as	c 783	16.8	0.4	20	1	AAQ44813	H. discus derived se
711	17.2	0.5	23	AD0618235	PCR primer #3 for	c 784	16.8	0.4	20	1	AAQ44813	Rat FGFR coding se
712	17.2	0.5	23	AD0618235	B7-specific antibo	c 785	16.8	0.4	20	1	AAQ44813	Human E2F transcri
713	17.2	0.5	23	AD0618235	Human VH domains a	c 786	16.8	0.4	20	1	AAQ44813	Human hbeta4BP an
714	17.2	0.5	23	AD0618235	Human VEGFR-1 RT-p	c 787	16.8	0.4	20	1	AAQ44813	Human soluble LIGH
715	17.2	0.5	23	AD0618235	Human VEGFR-1 RT-p	c 788	16.8	0.4	20	1	AAQ44813	ESR polymorphic DN
716	17.2	0.5	23	AD0618235	Human neurokinin B	c 789	16.8	0.4	20	1	AAQ44813	PKA regulatory sub
717	17.2	0.5	23	AD0618235	Human VEGF-2-speci	c 790	16.8	0.4	20	1	AAQ44813	Human oligonucleot
718	17.2	0.5	23	AD0618235	Human G protein ch	c 791	16.8	0.4	20	1	AAQ44813	Human oligonucleot
719	17.2	0.5	23	AD0618235	Reg IV-specific si	c 792	16.8	0.4	20	1	AAQ44813	Human PDE4A oligon
720	17.2	0.5	23	AD0618235	Human BGS-42 prote	c 793	16.8	0.4	20	1	AAQ44813	Alstroemeria gad3
721	17.2	0.5	23	AD0618235	Human heavy variab	c 794	16.8	0.4	20	1	AAQ44813	Al095013-derived o
722	17.2	0.5	23	AD0618235	Human VH gene ampl	c 795	16.8	0.4	20	1	AAQ44813	Human PDE4A-deriv
723	17.2	0.5	23	AD0618235	PCR primer of the	c 796	16.8	0.4	20	1	AAQ44813	Human transglutami
724	17.2	0.5	23	AD0618235	Capture system rel	c 797	16.8	0.4	20	1	AAQ44813	Al095559-derived o
725	17.2	0.5	23	AD0618235	Modified DNA oligo	c 798	16.8	0.4	20	1	AAQ44813	Human Vbeta gene r
726	17.2	0.5	23	AD0618235	T-cell receptor pr	c 799	16.8	0.4	20	1	AAQ44813	Human Vbeta gene r
727	17.2	0.5	23	AD0618235	Rat melanocortin r	c 800	16.8	0.4	20	1	AAQ44813	Human Vbeta gene r
728	17.2	0.5	23	AD0618235	3' primer to ampli	c 801	16.8	0.4	20	1	AAQ44813	Rosa sp forward PC
729	17.2	0.5	23	AD0618235	5' variation gener	c 802	16.8	0.4	20	1	AAQ44813	Oligonucleotide as
730	17.2	0.5	23	AD0618235	5' variation gener	c 803	16.8	0.4	20	1	AAQ44813	Human mPGEs-1 chim
731	17.2	0.5	23	AD0618235	Human FGFR-3 allele	c 804	16.8	0.4	20	1	AAQ44813	Human mPGEs-1 chim
732	17.2	0.5	23	AD0618235	Sequence of a micr	c 805	16.8	0.4	20	1	AAQ44813	Human mPGEs-1 chim
733	17.2	0.5	23	AD0618235	Microsatellite seq	c 806	16.8	0.4	20	1	AAQ44813	Human mPGEs-1 chim
734	17.2	0.5	23	AD0618235	Microsatellite seq	c 807	16.8	0.4	20	1	AAQ44813	Human mPGEs-1 chim
735	17.2	0.5	23	AD0618235	Microsatellite seq	c 808	16.8	0.4	20	1	AAQ44813	Human ABC5 DNA an
736	17.2	0.5	23	AD0618235	Simple sequence re	c 809	16.8	0.4	20	1	AAQ44813	Human ABC5 DNA an
737	17.2	0.5	23	AD0618235	Nuclelease resistant	c 810	16.8	0.4	20	1	AAQ44813	Human ABC5 DNA an
738	17.2	0.5	23	AD0618235	US912147 primer 3	c 811	16.8	0.4	21	1	AAQ44813	Cross-linking choli
739	17.2	0.5	23	AD0618235	US912147 primer 6	c 812	16.8	0.4	21	1	AAQ44813	Oligomer TNF217 fo
740	17.2	0.5	23	AD0618235	US912147 primer 3	c 813	16.8	0.4	21	1	AAQ44813	Oligomer TNF217 fo
741	17.2	0.5	23	AD0618235	US912147 primer 2	c 814	16.8	0.4	21	1	AAQ44813	KhCV cDNA 3'-end r
742	17.2	0.5	23	AD0618235	US912147 primer 8	c 815	16.8	0.4	21	1	AAQ44813	Primer #1 for prep
743	17.2	0.5	23	AD0618235	US912147 primer 7	c 816	16.8	0.4	21	1	AAQ44813	HSV replication in
744	17.2	0.5	23	AD0618235	Sequencing reagent	c 817	16.8	0.4	21	1	AAQ44813	Peptide nucleic ac
745	17.2	0.5	23	AD0618235	Simple sequence re	c 818	16.8	0.4	21	1	AAQ44813	Human polymorphic
746	17.2	0.5	23	AD0618235	Simple sequence re	c 819	16.8	0.4	21	1	AAQ44813	Tyrosine kinase ge
747	17.2	0.5	23	AD0618235	Simple sequence re	c 820	16.8	0.4	21	1	AAQ44813	Arteriosclerosis-d
748	17.2	0.5	23	AD0618235	Simple sequence re	c 821	16.8	0.4	21	1	AAQ44813	Human B cell recep
749	17.2	0.5	23	AD0618235	Simple sequence re	c 822	16.8	0.4	21	1	AAQ44813	Human secreted pro
750	17.2	0.5	23	AD0618235	Simple sequence re	c 823	16.8	0.4	21	1	AAQ44813	Human Vbeta gene r
751	17.2	0.5	23	AD0618235	Simple sequence re	c 824	16.8	0.4	21	1	AAQ44813	PCR primer used to
752	17.2	0.5	23	AD0618235	Simple sequence re	c 825	16.8	0.4	21	1	AAQ44813	Human PBMC IL-12 p
753	17.2	0.5	23	AD0618235	Simple sequence re	c 826	16.8	0.4	21	1	AAQ44813	Pectinatus frising
754	17.2	0.5	23	AD0618235	Simple sequence re	c 827	16.8	0.4	21	1	AAQ44813	Human IL-2 cDNA PC
755	17.2	0.5	23	AD0618235	Simple sequence re	c 828	16.8	0.4	21	1	AAQ44813	Interleukin-12 (IL
756	17.2	0.5	23	AD0618235	Simple sequence re	c 829	16.8	0.4	21	1	AAQ44813	PCR primer for amp
757	17.2	0.5	23	AD0618235	Simple sequence re	c 830	16.8	0.4	21	1	AAQ44813	VH back PCR primer
758	17.2	0.5	23	AD0618235	Simple sequence re	c 831	16.8	0.4	21	1	AAQ44813	VH back PCR primer
759	17.2	0.5	23	AD0618235	Simple sequence re	c 832	16.8	0.4	21	1	AAQ44813	Left PCR primer us
760	17.2	0.5	23	AD0618235	Simple sequence re	c 833	16.8	0.4	21	1	AAQ44813	Zebrafish vasa PCR
761	17.2	0.5	23	AD0618235	Simple sequence re	c 834	16.8	0.4	21	1	AAQ44813	Human VH region an
762	17.2	0.5	23	AD0618235	Simple sequence re	c 835	16.8	0.4	21	1	AAQ44813	
763	17.2	0.5	23	AD0618235	Simple sequence re	c 836	16.8	0.4	21	1	AAQ44813	

vivlmore401-10.rng

Thu Oct 28 12:48:21 2004

c 983	16	0.4	17	1	AAAT66099	Repeat sequence fo	c1056	15.8	0.4	19	1	ADL71963	Human FIR DNA ampl
c 984	16	0.4	17	1	AAAT91062	Methylphosphonate	1057	15.8	0.4	19	1	ADQ61018	Anti-FGFR2 siRNA r
c 985	16	0.4	17	1	AAAT1599	5' variation gene	1058	15.8	0.4	20	1	AAQ97929	PNA oligomer targe
c 986	16	0.4	17	1	AAAT1599	5' variation gene	1059	15.8	0.4	20	1	AAQ84246	PKC-zeta coding re
c 987	16	0.4	17	1	AAAT1599	5' variation gene	c1060	15.8	0.4	20	1	AAAT30427	Compound simple se
c 988	16	0.4	17	1	AAAT1599	5' variation gene	1061	15.8	0.4	20	1	AAK99571	Fusion region of p
c 989	16	0.4	17	1	AAAT1599	5' variation gene	1062	15.8	0.4	20	1	AAV48702	JunB gene antisense
c 990	16	0.4	17	1	AAAT1599	5' variation gene	c1063	15.8	0.4	20	1	AAV73071	Human ras oncogene
c 991	16	0.4	17	1	AAAT1599	5' variation gene	1064	15.8	0.4	20	1	AAV73071	Human tumour necro
c 992	16	0.4	17	1	AAAT1599	5' variation gene	1065	15.8	0.4	20	1	AAV73071	Human XLI5 gene fr
c 993	16	0.4	17	1	AAAT1599	5' variation gene	1066	15.8	0.4	20	1	AAV73071	Human TRPC7 gene i
c 994	16	0.4	17	1	AAAT1599	5' variation gene	1067	15.8	0.4	20	1	AAV73071	Hepatitis B virus
c 995	16	0.4	17	1	AAAT1599	5' variation gene	c1068	15.8	0.4	20	1	AAV73071	H. discus derived
c 996	16	0.4	17	1	AAAT1599	5' variation gene	1069	15.8	0.4	20	1	AAV73071	Human fra-1 mRNA a
c 997	16	0.4	17	1	AAAT1599	5' variation gene	c1070	15.8	0.4	20	1	AAV73071	Murine p38beta ant
c 998	16	0.4	17	1	AAAT1599	5' variation gene	1071	15.8	0.4	20	1	AAV73071	PCR primer for mec
c 999	16	0.4	17	1	AAAT1599	5' variation gene	1072	15.8	0.4	20	1	AAV73071	Human C-Raf protei
c 1000	16	0.4	17	1	AAAT1599	5' variation gene	1073	15.8	0.4	20	1	AAV73071	Human C-Raf gene t
c1001	16	0.4	17	1	AAAT1599	5' variation gene	c1074	15.8	0.4	20	1	AAV73071	Integrin-linked ki
c1002	16	0.4	17	1	AAAT1599	5' variation gene	1075	15.8	0.4	20	1	AAV73071	Human cancer cell
c1003	16	0.4	17	1	AAAT1599	5' variation gene	c1076	15.8	0.4	20	1	AAV73071	Murine p38-alpha M
c1004	16	0.4	17	1	AAAT1599	5' variation gene	1077	15.8	0.4	20	1	AAV73071	Human p70 S6 kinase
c1005	16	0.4	17	1	AAAT1599	5' variation gene	c1078	15.8	0.4	20	1	AAV73071	Zinc finger protei
c1006	16	0.4	17	1	AAAT1599	5' variation gene	c1079	15.8	0.4	20	1	AAV73071	Porcine circovirus
c1007	16	0.4	17	1	AAAT1599	5' variation gene	c1080	15.8	0.4	20	1	AAV73071	Mouse connective t
c1008	16	0.4	17	1	AAAT1599	5' variation gene	c1081	15.8	0.4	20	1	AAV73071	Mouse connective t
c1009	16	0.4	17	1	AAAT1599	5' variation gene	c1082	15.8	0.4	20	1	AAV73071	Mouse TGF-beta rec
c1010	16	0.4	17	1	AAAT1599	5' variation gene	c1083	15.8	0.4	20	1	AAV73071	Human NOVX polypep
c1011	16	0.4	17	1	AAAT1599	5' variation gene	1084	15.8	0.4	20	1	AAV73071	Human FT-beta subu
c1012	16	0.4	17	1	AAAT1599	5' variation gene	c1085	15.8	0.4	20	1	AAV73071	Human gene PCR pri
c1013	16	0.4	17	1	AAAT1599	5' variation gene	1086	15.8	0.4	20	1	AAV73071	Human oligonucleot
c1014	16	0.4	17	1	AAAT1599	5' variation gene	c1087	15.8	0.4	20	1	AAV73071	Human oligonucleot
c1015	16	0.4	17	1	AAAT1599	5' variation gene	c1088	15.8	0.4	20	1	AAV73071	Human trypsinase a o
c1016	16	0.4	17	1	AAAT1599	5' variation gene	c1089	15.8	0.4	20	1	AAV73071	Human oligonucleot
c1017	16	0.4	17	1	AAAT1599	5' variation gene	c1090	15.8	0.4	20	1	AAV73071	Human trypsinase a o
c1018	16	0.4	17	1	AAAT1599	5' variation gene	c1091	15.8	0.4	20	1	AAV73071	Human oligonucleot
c1019	16	0.4	17	1	AAAT1599	5' variation gene	c1092	15.8	0.4	20	1	AAV73071	Human trypsinase a o
c1020	16	0.4	17	1	AAAT1599	5' variation gene	1093	15.8	0.4	20	1	AAV73071	Human oligonucleot
c1021	16	0.4	17	1	AAAT1599	5' variation gene	1094	15.8	0.4	20	1	AAV73071	Human oligonucleot
c1022	16	0.4	17	1	AAAT1599	5' variation gene	c1095	15.8	0.4	20	1	AAV73071	Human oligonucleot
c1023	16	0.4	17	1	AAAT1599	5' variation gene	1096	15.8	0.4	20	1	AAV73071	Human oligonucleot
c1024	16	0.4	17	1	AAAT1599	5' variation gene	1097	15.8	0.4	20	1	AAV73071	Human oligonucleot
c1025	16	0.4	17	1	AAAT1599	5' variation gene	c1098	15.8	0.4	20	1	AAV73071	Human oligonucleot
c1026	16	0.4	17	1	AAAT1599	5' variation gene	1100	15.8	0.4	20	1	AAV73071	Human oligonucleot
c1027	16	0.4	17	1	AAAT1599	5' variation gene	c1101	15.8	0.4	20	1	AAV73071	Human oligonucleot
c1028	16	0.4	17	1	AAAT1599	5' variation gene	c1102	15.8	0.4	20	1	AAV73071	Human oligonucleot
c1029	16	0.4	17	1	AAAT1599	5' variation gene	1103	15.8	0.4	20	1	AAV73071	Human oligonucleot
c1030	16	0.4	17	1	AAAT1599	5' variation gene	c1104	15.8	0.4	20	1	AAV73071	Human oligonucleot
c1031	16	0.4	17	1	AAAT1599	5' variation gene	1105	15.8	0.4	20	1	AAV73071	Human oligonucleot
c1032	16	0.4	17	1	AAAT1599	5' variation gene	1106	15.8	0.4	20	1	AAV73071	Human oligonucleot
c1033	16	0.4	17	1	AAAT1599	5' variation gene	1107	15.8	0.4	20	1	AAV73071	Human oligonucleot
c1034	16	0.4	17	1	AAAT1599	5' variation gene	1108	15.8	0.4	20	1	AAV73071	Human oligonucleot
c1035	16	0.4	17	1	AAAT1599	5' variation gene	c1109	15.8	0.4	20	1	AAV73071	Human oligonucleot
c1036	16	0.4	17	1	AAAT1599	5' variation gene	c1110	15.8	0.4	20	1	AAV73071	Human oligonucleot
c1037	16	0.4	17	1	AAAT1599	5' variation gene	c1111	15.8	0.4	20	1	AAV73071	Human oligonucleot
c1038	16	0.4	17	1	AAAT1599	5' variation gene	c1112	15.8	0.4	20	1	AAV73071	Human oligonucleot
c1039	16	0.4	17	1	AAAT1599	5' variation gene	1113	15.8	0.4	20	1	AAV73071	Human oligonucleot
c1040	16	0.4	17	1	AAAT1599	5' variation gene	1114	15.8	0.4	20	1	AAV73071	Human oligonucleot
c1041	16	0.4	17	1	AAAT1599	5' variation gene	c1115	15.8	0.4	20	1	AAV73071	Human oligonucleot
c1042	16	0.4	17	1	AAAT1599	5' variation gene	1116	15.8	0.4	20	1	AAV73071	Human oligonucleot
c1043	16	0.4	17	1	AAAT1599	5' variation gene	1117	15.8	0.4	20	1	AAV73071	Human oligonucleot
c1044	16	0.4	17	1	AAAT1599	5' variation gene	1118	15.8	0.4	20	1	AAV73071	Human oligonucleot
c1045	16	0.4	17	1	AAAT1599	5' variation gene	c1119	15.8	0.4	20	1	AAV73071	Human oligonucleot
c1046	16	0.4	17	1	AAAT1599	5' variation gene	1120	15.8	0.4	20	1	AAV73071	Human oligonucleot
c1047	16	0.4	17	1	AAAT1599	5' variation gene	1121	15.8	0.4	20	1	AAV73071	Human oligonucleot
c1048	16	0.4	17	1	AAAT1599	5' variation gene	c1122	15.8	0.4	20	1	AAV73071	Human oligonucleot
c1049	16	0.4	17	1	AAAT1599	5' variation gene	1123	15.8	0.4	20	1	AAV73071	Human oligonucleot
c1050	16	0.4	17	1	AAAT1599	5' variation gene	1124	15.8	0.4	20	1	AAV73071	Human oligonucleot
c1051	16	0.4	17	1	AAAT1599	5' variation gene	c1125	15.8	0.4	20	1	AAV73071	Human oligonucleot
c1052	16	0.4	17	1	AAAT1599	5' variation gene	1126	15.8	0.4	20	1	AAV73071	Human oligonucleot
c1053	16	0.4	17	1	AAAT1599	5' variation gene	1127	15.8	0.4	20	1	AAV73071	Human oligonucleot
c1054	16	0.4	17	1	AAAT1599	5' variation gene	1128	15.8	0.4	20	1	AAV73071	Human oligonucleot
c1055	16	0.4	17	1	AAAT1599	5' variation gene							

The present sequence represents a segment of the hepatoma AS-30D Type II hexokinase promoter region. Response elements (transcription factor binding site) in this fragment may consist of all or part of the present sequence. AS-30D is a new isolated hexokinase II. The present DNA fragment is capable of regulating transcription of a downstream open reading frame and contains at least one response element. The present DNA fragment may be coupled to a reporter gene and used to screen for potential drugs that affect regulated transcription of tumour hexokinase II. Alternatively it may be coupled to a toxic gene and used to treat cells that over-express hexokinase II, such as those present in patients with cancer. It may also be used in gene therapy to treat diabetes. The DNA fragment increases glycolysis in cells and express homologous or heterologous protein. Probes of the DNA fragment are used in the method for diagnosing a neoplasia that over-expresses hexokinase. The new response elements are active only in tumours, not in normal cells

Sequence 49 BP; 3 A; 5 C; 20 G; 21 T; 0 U; 0 Other;

Query Match 1.0%; Score 36.4; DB 1; Length 49;
Best Local Similarity 87.0%; Pred. No. 15;
Matches 40; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 2320 TGTGTTGTGTCGCCGTGTGTGTGTGTGCACATCCCGTGTG 2365
 |||||
Db 3 TGTGTTGTGTTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGAG 48
 |||||

RESULT 3
AAT65746/c
ID AAT65746 standard; DNA; 50 BP.
AC AAT65746;
XX XX
DT 25-MAR-2003 (revised)
DT 17-JUN-1997 (first entry)
DE Repeat sequence from polymorphic marker clone Mfd46.
XX Polymorphism; repeat sequence; genetic marker; primer; amplification;
KW PCR; polymerase chain reaction; paternity; maternity; human; pedigree;
KW linkage analysis; genetic disease; animal; plant; breeding; locus;
KW hybridisation; chromosome; ds.
XX Homo sapiens.
OS
XX US5582979-A.
PN
XX 10-DEC-1996.
PD
XX 04-APR-1994; 94US-00222177.
PP
XX 21-APR-1989; 89US-00341562.
PR
XX 05-SEP-1991; 91US-00754351.
PR
XX (MARS-) MARSHFIELD CLINIC.
PA
XX Weber JL;
PI
XX WPI; 1997-042299/04.
DR
XX Detection of polymorphic genetic markers of the form (dC-dA)n(dG-dT)n -
PT novel nucleic acid mols. as primers.
PT
XX Claim 1; Col 9-10; 186pp; English.
PS
XX The invention relates to the isolation of polymorphic repeat sequences
CC having the sequence (dC-dA)n.(dG-dT)n which can be used as genetic
CC markers. Primers based on these sequences can be used to detect these
CC repeats, especially for use in e.g paternity or maternity testing, human
CC genetic analysis such as linkage analysis of genetic disease, commercial
CC animal or plant breeding or pedigree analysis. Clones containing the
CC repeat sequences were isolated by hybridisation of chromosome-specific

using novel nucleic acid mols. as primers.

Disclosure; Col 11-12; 186pp; English.

The invention relates to the isolation of polymorphic repeat sequences having the sequence (dC-dA)n.(dG-dT)n which can be used as genetic markers. Primers based on these sequences can be used to detect these repeats, especially for use in e.g paternity or maternity testing, human genetic analysis such as linkage analysis of genetic disease, commercial animal or plant breeding or pedigree analysis. Clones containing the repeat sequences were isolated by hybridisation of chromosome-specific phase libraries with a synthetic poly(dC-dA).(dG-dT) probe. Over 100 repeat blocks were isolated. The inserts from the clones were amplified by primers AAT65798-T66047. Those clones where the repeat sequence has been determined are shown in AAT65704-797. This repeat sequence is from the marker clone Maf50 which contains the repeat sequence having the formula: (CA)19. (Updated on 25-MAR-2003 to correct PF field.)

Sequence 38 BP; 19 A; 19 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 0.9%; Score 33.8; DB 1; Length 38;
Best Local Similarity 94.6%; Pred. No. 23;
Matches 35; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2315 GTCTGTGTGTGTGTGGTGCGTGTCGTGTGTGTGTGTG 2351
|||
DB 37 GTG 1

RESULT 21
AAT6048/c
ID ID AAT66048 standard; DNA; 38 BP.
XX AC AAT66048;
DT 25-MAR-2003 (revised)
DT 18-JUN-1997 (first entry)
XX (dC-dA)n.(dG-dT)n polymorphic repeat sequence #1.
XX Polymorphism: repeat sequence; genetic marker; primer; amplification;
KW PCR; polymerase chain reaction; paternity; maternity; human; pedigree;
KW linkage analysis; genetic disease; animal; plant; breeding; locus;
KW hybridisation; chromosome; ds.
XX Homo sapiens.
OS US5582979-A.
XX PN PD 10-DEC-1996.
XX PP 04-APR-1994; 9AUS-00222177.
XX PR 21-APR-1989; 89US-00341562.
PR 05-SEP-1991; 91US-00754351.
XX (MARS-) MARSHFIELD CLINIC.
PA XX
XX Weber JL;
PI PT WPI; 1997-042299/04.
XX Detection of polymorphic genetic markers of the form (dC-dA)n(dG-dT)n -
PT using novel nucleic acid mols. as primers.
XX Example 8; Col 57-58; 186pp; English.
XX The invention relates to the isolation of polymorphic repeat sequences
CC having the sequence (dC-dA)n.(dG-dT)n which can be used as genetic
CC markers. Primers based on these sequences can be used to detect these
CC repeats, especially for use in e.g paternity or maternity testing, human
CC genetic analysis such as linkage analysis of genetic disease, commercial
CC animal or plant breeding or pedigree analysis. The repeats, when

Sequence 39 BP: 0 A; 0 C; 19 G; 20 T; 0 U; 0 Other;

Query Match: 0.9%; Score 33.8; DB 1; Length 39;

AAQ33825
22 200000 standard; DNA: 30 BP

XX

DE Microsatellite sequence from clone TGLA227.

xx PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
 kw genetic mapping; traits; amplification; ss.
 vz

OS Bos taurus.

PN WO9213102-A1

AA 06-AUG-1992.

XX
DE 15-JAN-1992. 92WO-US000340.

XX
—
01118 00642342

PA (GENM-) GENMARK.

PT Georges M. Massey JM;

XX
DP WPT: 1992-284684/34

XX Polymorphic bovine DNA markers - used in genetic identification, gene
PT mapping, and selective breeding.
pr

PT mapping, and selective breeding

Table 7: Page 259; 517pp; English.

XX
CC
The sequence is that of a bovine microsatellite sequence obtd. by

cc clones cross-hybridized

CC in the bovine genome

101 Ca: 230 such covering material
specification and indexed herein (see below). The sequences ups

CC downstream of the microsatellite
CC recombed PCR primers for in vitro

The sequence is that of a bovine microsatellite sequence obtd. by screening a library of bovine Mb1 DNA fragments of between 250 and 500 bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50 clones cross-hybridised. Assuming independent distribution of microsatellites and Mb1 sites, the frequency of (T6)n >9 microsatellites in the bovine genome is estimated at >100, 000. The sequence information for ca. 230 such bovine microsatellites is summarised in the specification and indexed herein (see below). The sequences upstream and downstream of the microsatellite sequence were used to generate the required PCR primers for in vitro amplification of the corresp. microsatellite (using the program OPTIPRIM). The microsatellites may be used to identify individuals, for parentage testing, and in the genetic mapping of economic trait loci, or genes involved the determinism of economically important traits esp. in cattle, to allow selective breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN field.)

1

	repeats, especially for use in e.g paternity or maternity testing.
	genetic analysis such as linkage analysis of genetic disease; commercial
	animal or plant breeding or pedigree analysis. Clones containing the
	repeat sequences were isolated by hybridisation of chromosome-specific
	probe libraries with a synthetic poly(dC-dA).(dG-dT) probe. Over 100
	repeat blocks were isolated. The inserts from the clones were amplified
	by primers AA65798-T66047. Those clones where the repeat sequence has
	been determined are shown in AA65704-797. This repeat sequence is from
	the marker clone Maf63 which contains the repeat sequence having the
	formula: (CA) ₂₀₋₅ . (Updated on 25-MAR-2003 to correct PF field.)
XX	Sequence 41 BP; 20 A; 21 C; 0 G; 0 T; 0 U; 0 Other;
SQ	
	Query Match 0.9%; Score 33.8; DB 1; Length 41;
	Best Local Similarity 94.6%; Pred. No. 25;
Matches	35; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY	2315 GTCTGTGTCGTGGTGCGTGTCGTGTGTGTGTGTG 2351
Db	41 GTGTGTGTCGTGGTGTCGTGTGTGTGTGTGTG 5
RESULT 38	
ID ADH70301	ADH70301 standard; DNA; 41 BP.
AC ADH70301;	
DT DT	25-MAR-2004 (first entry)
DE Human Vbeta gene repeat sequence #91.	
KW human; T-cell associated disease; Vbeta; autoimmune disease; KW degenerative nervous system disease; graft versus host disease; KW hypersensitivity disease; infectious disease; neoplastic disease; KW Addison's disease; atrophic gastritis; KW degenerative nervous system disease; multiple sclerosis; KW Alzheimer's disease; hypersensitivity disease; type I hypersensitivity; KW allergy; type II hypersensitivity; Goodpasture's syndrome; KW type IV hypersensitivity; leprosy; infectious disease; viral infection; KW HIV; fungal infection; Candida; parasitic infection; schistosoma; KW lymphatic bacterial infection; Mycobacterium; neoplastic disease; KW lymphoproliferative disease; leukaemia; lymphoma; cancer; brain cancer; KW breast cancer; ds. KW Homo sapiens. OS OS XX XX FN US2002150891-A1. XX XX PD 17-OCT-2002. XX XX PF 05-MAR-1999; 99US-00263959. XX XX PR 19-SEP-1994; 94US-00309335. PR 19-SEP-1995; 95US-00531241. XX XX PA (HOOD/) HOOD L E. PA (ROWE/) ROWEN L. XX XX PI Hood LE, Rowen L; XX XX DR WPT; 2004-059052/06. XX XX PT Kit for diagnosing and treating T-cell associated diseases e.g. PT autoimmune, degenerative nervous system and infectious disease, comprises PT nucleic acid primers specifically priming and allowing amplification of a PT Vbeta gene. XX XX PS Disclosure; SEQ ID NO 495; 164bp; English. XX XX CC The invention relates to a kit for diagnosing and treating T-cell CC associated diseases which comprises a panel of nucleic acid primers CC specifically priming and allowing amplification of each Vbeta gene,	


```

SQ      Sequence 44 BP; 1 A; 2 C; 21 G; 20 T; 0 U; 0 Other;

Query Match          .   0.9%; Score 32.8; DB 1; Length 44;
Best Local Similarity 84.1%; Pred. No. 36;
Matches 37; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

Qy      2316 TCCTGTCGTGTCGTGGTGCAGTGCGTGTGTCATCCG 2359
           |||||
Db       1 TCCTGTCGTGTCGTGTCGTGTGTAATGTCGTGTCGTCGCCG 44
           |

RESULT 81
AAT65751/c
ID    AAT65751 standard; DNA; 45 BP.
XX    AC
XX    AAT65751;
XX    XX
XX    25-MAR-2003 (revised)
DT     DT
DT     17-JUN-1997 (first entry)
DE     DE
XX    Repeat sequence from polymorphic marker clone Mfd52.
XX    Polymorphism; repeat sequence; genetic marker; primer; amplification;
KW    PCR; polymerase chain reaction; paternity; maternity; human; pedigree;
KW    linkage analysis; genetic disease; animal; plant; breeding; locus;
KW    hybridisation; chromosome; ds.
XX    Homo sapiens.
OS     OS
XX    US5582979-A.
PN     PN
XX    10-DEC-1996.
PD     PD
XX    04-APR-1994; 94US-00222177.
PF     PF
XX    21-APR-1989; 89US-00341562.
PR     PR
XX    05-SEP-1991; 91US-00754351.
PP     PP
XX    (MARS-) MARSHFIELD CLINIC.
PA     PA
XX    PI
XX    Weber JL;
PI     PI
XX    WPI; 1997-042299/04.
DR     DR
XX    XX
XX    Detection of polymorphic genetic markers of the form (dC-dA)n(dG-dT)n -
PT     PT
XX    using novel nucleic acid mols. as primers.
PS     PS
XX    Disclosure; Col 11-12; 186pp; English.
XX    CC
XX    The invention relates to the isolation of polymorphic repeat sequences
XX    having the sequence (dC-dA)n.(dG-dT)n which can be used as genetic
XX    markers. Primers based on these sequences can be used to detect these
XX    repeats, especially for use in e.g paternity or maternity testing, human
XX    genetic analysis such as linkage analysis of genetic disease, commercial
XX    animal or plant breeding or pedigree analysis. Clones containing the
XX    repeat sequences were isolated by hybridisation of chromosome-specific
XX    probe libraries with a synthetic poly(dC-dA).(dG-dT) probe. Over 100
XX    page blocks were isolated. The inserts from the clones were amplified
XX    by primers AAT65798-T66047. Those clones where the repeat sequence has
XX    been determined are shown in AAT65704-797. This repeat sequence is from
XX    the marker clone Mdf52 which contains the repeat sequence having the
XX    formula: (AC)18TTG(CA)3. (Updated on 25-MAR-2003 to correct PF field.)
XX    SQ      Sequence 45 BP; 21 A; 1 C; 1 G; 2 T; 0 U; 0 Other;

Query Match          .   0.9%; Score 32.8; DB 1; Length 45;
Best Local Similarity 94.4%; Pred. No. 37;
Matches 34; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      2315 GTCTGTCGTGTCGTGTCGTCGTGTCGTGTCGTGTCGT 2350
           |||||
Db       36 GTCTGTCGTGTCGTGTCGTGTCGTGTCGTGTCGTGTCGT 1
           |||||

```


RESULT 107


```
XX PI Cargill M, Ireland JS, Lander ES;
XX XX WPI; 2001-522952/57.
XX DR
XX PT Nucleic acid molecules from the human genome which include polymorphic
XX PT sites, useful in methods for predicting the presence, absence or severity
XX PT of a particular phenotype or disorder (e.g. diabetes) associated with a
XX PT particular genotype.
XX PS Claim 1; Page 87; 145pp; English.
XX CC The invention relates to the identification of nucleic acid molecules
XX CC (AAI29513-AAI31314) from the human genome which include polymorphic sites
XX CC which can predispose individuals to disease. Various genes from a number
XX CC of individuals were resequenced and single nucleotide polymorphisms
XX CC (SNPs) in these genes discovered. The method is useful for predicting the
XX CC presence, absence or severity of a particular phenotype or disorder (e.g.
XX CC diabetes) associated with a particular genotype. The nucleic acids
XX CC containing the polymorphic sites may be useful in forensics and paternity
XX CC testing.
XX SQ Sequence 31 BP; 9 A; 10 C; 6 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 0.8%; Score 31; DB 1; Length 31;
XX Best Local Similarity 100.0%; Pred. No. 38;
XX Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 1928 ACTGCACACGACCTGTACATGATCATGCG 1958
DB 1 ACTGCACACGACCTGTACATGATCATGCG 31
XX
RESULT 111
AAI30470
ID AAI30470 standard; DNA; 31 BP.
XX AC AAI30470;
XX DT 18-OCT-2001 (first entry)
XX DE Human single nucleotide polymorphism (SNP) FGR3 2.
XX KW Human; resequence; genotype; disease; forensic; paternity testing;
XX KW single nucleotide polymorphism; SNP; ss.
XX OS Homo sapiens.
XX FH Key Location/Qualifiers
XX FT Variation replace(16,G)
XX FT /*tag= a
XX FT /standard_name= "single nucleotide polymorphism"
XX
PN WO200166800-A2.
XX
XX 13-SEP-2001.
XX
XX 07-MAR-2001; 2001WO-US007268.
XX
XX 07-MAR-2000; 2000US-0187510P.
XX PR 22-MAY-2000; 2000US-0206129P.
XX
XX (WHED ) WHITEHEAD INST BIOMEDICAL RES.
XX
XX Cargill M, Ireland JS, Lander ES;
XX WPI; 2001-522952/57.
XX
XX Nucleic acid molecules from the human genome which include polymorphic
XX PT sites, useful in methods for predicting the presence, absence or severity
XX PT of a particular phenotype or disorder (e.g. diabetes) associated with a
XX PT particular genotype.
XX
```

```
PS Claim 1; Page 87; 145pp; English.
XX
XX The invention relates to the identification of nucleic acid molecules
XX CC (AAI29513-AAI31314) from the human genome which include polymorphic sites
XX CC which can predispose individuals to disease. Various genes from a number
XX CC of individuals were resequenced and single nucleotide polymorphisms
XX CC (SNPs) in these genes discovered. The method is useful for predicting the
XX CC presence, absence or severity of a particular phenotype or disorder (e.g.
XX CC diabetes) associated with a particular genotype. The nucleic acids
XX CC containing the polymorphic sites may be useful in forensics and paternity
XX CC testing.
XX SQ Sequence 31 BP; 3 A; 13 C; 12 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 0.8%; Score 31; DB 1; Length 31;
XX Best Local Similarity 100.0%; Pred. No. 38;
XX Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 527 ACCGGCCCATCTCGACGGCGGCTGCCGCG 557
DB 1 ACCGGCCCATCTCGACGGCGGCTGCCGCG 31
XX
RESULT 112
AAI30472
ID AAI30472 standard; DNA; 31 BP.
XX AC AAI30472;
XX DT 18-OCT-2001 (first entry)
XX DE Human single nucleotide polymorphism (SNP) FGR3 4.
XX KW Human; resequence; genotype; disease; forensic; paternity testing;
XX KW single nucleotide polymorphism; SNP; ss.
XX OS Homo sapiens.
XX FH Key Location/Qualifiers
XX FT Variation replace(16,T)
XX FT /*tag= a
XX FT /standard_name= "single nucleotide polymorphism"
XX
PN WO200166800-A2.
XX
XX 13-SEP-2001.
XX
XX 07-MAR-2001; 2001WO-US007268.
XX
XX 07-MAR-2000; 2000US-0187510P.
XX PR 22-MAY-2000; 2000US-0206129P.
XX
XX (WHED ) WHITEHEAD INST BIOMEDICAL RES.
XX
XX Cargill M, Ireland JS, Lander ES;
XX WPI; 2001-522952/57.
XX
XX Nucleic acid molecules from the human genome which include polymorphic
XX PT sites, useful in methods for predicting the presence, absence or severity
XX PT of a particular phenotype or disorder (e.g. diabetes) associated with a
XX PT particular genotype.
XX
XX Claim 1; Page 87; 145pp; English.
XX
XX The invention relates to the identification of nucleic acid molecules
XX CC (AAI29513-AAI31314) from the human genome which include polymorphic sites
XX CC which can predispose individuals to disease. Various genes from a number
XX CC of individuals were resequenced and single nucleotide polymorphisms
XX CC (SNPs) in these genes discovered. The method is useful for predicting the
XX CC presence, absence or severity of a particular phenotype or disorder (e.g.
XX CC diabetes) associated with a particular genotype. The nucleic acids
XX CC containing the polymorphic sites may be useful in forensics and paternity
XX CC testing.
```

CC Goodpasture's syndrome and Type IV hypersensitivities such as those
CC manifested in leprosy. Infectious diseases include viral infections
CC caused by viruses such as HIV, fungal infections such as those caused by
CC the yeast genus Candida, parasitic infections such as those caused by
CC schistosomes, filaria and bacterial infections such as those caused by
CC Mycobacterium. Neoplastic diseases include lymphoproliferative diseases
CC such as leukaemias, lymphomas and cancers such as cancer of the brain,
CC breast. The present sequence represents a Vbeta gene repeat sequence.
XX

SQ Sequence 34 BP; 0 A; 1 C; 17 G; 16 T; 0 U; 0 Other;

Query Match . 0.8%; Score 30.8; DB 1; Length 34;
Best Local Similarity 94.1%; Pred. No. 45;
Matches 33; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2318 TGCTGTGCTGTGTCGCCTGTGTGTGTGTGTGTGTG 2351
|||||
DB 1 TGTGTGTGTGTGCGTGTGTGTGTGTGTGTGTG 34

RESULT 114
AAQ33713
ID AAQ33713 standard; DNA; 35 BP.

XX AC AQ33713;
XX DT 25-MAR-2003 (revised)
DT 02-FEB-1993 (first entry)

XX DE Microsatellite sequence from clone TGLA134.
XX PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW genetic mapping; traits; amplification; ss.
KW Bos taurus.
OS WO9213102-A1.
XX PN 06-AUG-1992.
PD 15-JAN-1992; 92WO-US000340.
XX PF 15-JAN-1991; 91US-00642342.
PR (GENM-) GENMARK.
XX PA Georges M, Massey JM;
PI WPI; 1992-284684/34.
XX DR Polymorphic bovine DNA markers - used in genetic identification, gene
PT mapping, and selective breeding.
XX Table 7; Page 215; 517pp; English.

XX The sequence is that of a bovine microsatellite sequence obtd. by
CC screening a library of Bovine MboI DNA fragments of between 250 and 500
CC bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC clones cross-hybridised. Assuming independent distribution of
CC microsatellites and MboI sites, the frequency of (TG)n >9 microsatellites
CC in the bovine genome is estimated at >100,000. The sequence information
CC for ca. 230 such bovine microsatellites is summarised in the
CC specification and indexed herein (see below). The sequences upstream and
CC downstream of the microsatellite sequence were used to generate the
CC required PCR primers for in vitro amplification of the corresp.
CC microsatellite (using the program OPTIPRIM). The microsatellites may be
CC used to identify individuals, for parentage testing, and in the genetic
CC mapping of economic trait loci, or genes involved in the determination of
CC economically important traits esp. in cattle, to allow selective
CC breeding. See also AAQ33501-3437. (Updated on 25-MAR-2003 to correct PN
CC field.)
XX Sequence 35 BP; 1 A; 0 C; 17 G; 17 T; 0 U; 0 Other;

Qy 2319 GTGTGTTGTGTGTGGTGTGTGTGTGTGTGCACATCCG 2360
|||||
pB 42 GTGTGTGTGTGTGTGTGTGTGTGTGTATTAGCAC 1

DE Sequence of a microsatellite from clone TGLA67.

Thu Oct 28 12:48:21 2004

CC particular, current diagnosis of Huntington's disease relies heavily upon
 CC the use of gel electrophoresis, a process that has proved difficult to
 CC automate or miniaturise. The LASA method allows total avoidance of this
 CC limiting step, making it a strong candidate for future use in clinical
 CC and laboratory procedures. ABK24296-ABK24313 represent primers used to
 CC detect polymorphisms or microsatellites as described in the method of the
 CC invention

XX
 SQ Sequence 32 BP; 16 A; 16 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 0.8%; Score 30.4; DB 1; Length 32;
 Best Local Similarity 96.9%; Pred. No. 47;
 Matches 31; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 2318 TGTGTGTGTGTGCGGTGTGTGTGTGTGTG 2349
 |||||
 DB 32 TGTGTGTGTGTGTGTGTGTGTGTGTGTG 1

RESULT 123
 ABK24296/C
 ID ABK24296 standard; DNA; 32 BP.
 XX AC
 XX ABK24296;
 DT 09-APR-2002 (first entry)
 DE Human microsatellite D1S191 detection PCR primer #4.
 XX Microsatellite; ligase-assisted spacer addition assay; LASA; cancer;
 KW nucleotide length polymorphism detection; neurodegenerative disease;
 KW fragile X syndrome; Huntington's disease; muscular dystrophy; forensic;
 KW gene mapping; population study; human; primer; ss.
 XX Homo sapiens.
 XX WO200185987-A1.
 XX 15-NOV-2001.
 XX 09-MAY-2001; 2001WO-AU000526.
 XX 09-MAY-2000; 2000US-0202771P.
 XX 10-MAY-2000; 2000US-0202559P.
 XX (DIAT-) DIATECH PTY LTD.
 XX Brockhurst V, Timms P, Wolter L, Barnard R, Giffard PM;
 WPI; 2002-121948/16.
 XX Detecting a nucleotide repeat region in a nucleic acid having a
 XX particular length, useful for identifying nucleotide length polymorphism
 XX associated with a neurodegenerative disease, comprises using a ligase-
 XX assisted spacer addition assay.
 XX Example 10; Page 55; 89pp; English.

CC The invention relates to a method of identifying or detecting a
 CC nucleotide repeat region in a nucleic acid molecule characterised by a
 CC particular length, comprising employing ligase-assisted spacer addition
 CC (LASA) assay. The method is useful in the identifying or detecting a
 CC nucleotide repeat region in a nucleic acid molecule characterised by a
 CC particular length. In particular, the method is useful for identification
 CC of a nucleotide length polymorphism in animals or humans, which is
 CC associated with a neurodegenerative disease including fragile X syndrome,
 CC Huntington's disease, or muscular dystrophy. Furthermore, the method may
 CC be used for identifying and/or typing microorganisms including yeasts and
 CC lower uni- and multi-cellular organisms, as well as prokaryotic
 CC microorganisms; and for genotyping subjects including humans. The method
 CC is also useful for detecting certain cancers and other malignancies.
 CC Moreover, the method can be used to provide markers for use in
 CC identification of human and non-human individuals, plants and
 CC microorganisms, to ascertain parentage of human or non-human individual,
 CC and to monitor responses to therapies including the possibility of
 CC nucleic acid damage. The nucleotide polymorphisms may be used in forensic
 CC science to identify a particular victim or an alleged perpetrator of a
 CC crime, in gene mapping and population studies. LASA may also be used in
 CC the manufacture of a kit for detecting and/or identifying nucleotide
 CC repeat regions such as a nucleotide length polymorphism in a eukaryotic
 CC genome. The LASA method avoids the time and cost required by prior art
 CC methods using gel electrophoresis and Southern transfer analysis. In

CC Polymorphism; repeat sequence; genetic marker; primer; amplification;
 CC PCR; polymerase chain reaction; paternity; maternity; human; pedigree;
 CC linkage analysis; genetic disease; animal; plant; breeding; locus;
 CC hybridisation; chromosome; ds.
 XX Homo sapiens.
 XX US5582979-A.
 XX 10-DEC-1996.
 XX 04-APR-1994; 94US-00222177.
 XX 21-APR-1989; 89US-00341562.
 XX 05-SEP-1991; 91US-00754351.
 XX (MARS-) MARSHFIELD CLINIC.
 XX Weber JL;
 WPI; 1997-042299/04.
 XX Detection of polymorphic genetic markers of the form (dC-dA)n(dG-dT)n -
 XX using novel nucleic acid mols. as primers.
 XX Claim 1; Col 13-14; 186pp; English.

CC The invention relates to the isolation of polymorphic repeat sequences
 CC having the sequence (dC-dA)n.(dG-dT)n which can be used as genetic
 CC markers. Primers based on these sequences can be used to detect these
 CC repeats, especially for use in e.g. paternity or maternity testing, human
 CC genetic analysis such as linkage analysis of genetic disease, commercial
 CC animal or plant breeding or pedigree analysis. Clones containing the
 CC repeat sequences were isolated by hybridisation of chromosome-specific
 CC phage libraries with a synthetic poly(dC-dA).(dG-dT) probe. Over 100
 CC repeat blocks were isolated. The inserts from the clones were amplified
 CC by primers AAT65798-T66047. Those clones where the repeat sequence has
 CC been determined are shown in AAT65704-797. This repeat sequence is from
 CC the marker clone Maf107 which contains the repeat sequence having the
 CC formula: TGCCCGCCT(AC)16. (Updated on 25-MAR-2003 to correct PF field.)
 XX Sequence 42 BP; 16 A; 21 C; 3 G; 2 T; 0 U; 0 Other;

```
Query Match          0.8%; Score 30.4; DB 1; Length 42;
Best Local Similarity 96.9%; Pred. No. 65;
Matches 31; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2319 GTGTGTGTGTGTGCGGTGTGTGTGTGTGTGT 2350
    |||||
DB 42 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 11

RESULT 124
AAQ33894
ID AAQ33894 standard; DNA; 38 BP.
XX
AC AAQ33894;
XX
XX 25-MAR-2003 (revised)
DT 02-FEB-1993 (first entry)
XX
DE Microsatellite sequence from clone TGLA309.
XX
XX PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW genetic mapping; traits; amplification; ss.
XX
OS Bos taurus.
XX
XX WO9213102-A1.
PN
PD 06-AUG-1992.
XX
XX 15-JAN-1992; 92WO-US000340.
PF
XX 15-JAN-1991; 91US-00642342.
PR
XX (GENM-) GENMARK.
PA
XX Georges M, Massey JM;
PI
XX
XX WPI; 1992-284684/34.
DR
XX Polymorphic bovine DNA markers - used in genetic identification, gene
PT mapping, and selective breeding.
XX
XX Table 7; Page 287; 517pp; English.
XX
XX The sequence is that of a bovine microsatellite sequence obt'd. by
CC screening a library of bovine MbOI DNA fragments of between 250 and 500
CC bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC clones cross-hybridised. Assuming independent distribution of
CC microsatellites and MbOI sites, the frequency of (T6)n >9 microsatellites
CC in the bovine genome is estimated at >100, 000. The sequence information
CC for ca. 230 such bovine microsatellites is summarised in the
CC specification and indexed herein (see below). The sequences upstream and
CC downstream of the microsatellite sequence were used to generate the
CC required PCR primers for in vitro amplification of the corresp.
CC microsatellite (using the program OPTIPRIM). The microsatellites may be
CC used to identify individuals, for parentage testing, and in the genetic
CC mapping of economic trait loci, or genes involved in the determination of
CC economically important traits esp. in cattle, to allow selective
CC breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC field.)
XX
SQ Sequence 38 BP; 1 A; 0 C; 19 G; 18 T; 0 U; 0 Other;

Query Match          0.8%; Score 29.8; DB 1; Length 38;
Best Local Similarity 93.9%; Pred. No. 68;
Matches 31; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2319 GTGTGTGTGTGTGCGGTGTGTGTGTGTGTGT 2351
    |||||
DB 1 GTGTGTGTGAGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 33

RESULT 125
```

```
AAQ33681
ID AAQ33681 standard; DNA; 41 BP.
XX
AC AAQ33681;
XX
XX 25-MAR-2003 (revised)
DT 02-FEB-1993 (first entry)
XX
DE Microsatellite sequence from clone TGLA122.
XX
XX PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW genetic mapping; traits; amplification; ss.
XX
OS Bos taurus.
XX
XX WO9213102-A1.
PN
PD 06-AUG-1992.
XX
XX 15-JAN-1992; 92WO-US000340.
PF
XX 15-JAN-1991; 91US-00642342.
PR
XX (GENM-) GENMARK.
PA
XX Georges M, Massey JM;
PI
XX
XX WPI; 1992-284684/34.
DR
XX Polymorphic bovine DNA markers - used in genetic identification, gene
PT mapping, and selective breeding.
XX
XX Table 7; Page 202; 517pp; English.
XX
XX The sequence is that of a bovine microsatellite sequence obt'd. by
CC screening a library of bovine MbOI DNA fragments of between 250 and 500
CC bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC clones cross-hybridised. Assuming independent distribution of
CC microsatellites and MbOI sites, the frequency of (T6)n >9 microsatellites
CC in the bovine genome is estimated at >100, 000. The sequence information
CC for ca. 230 such bovine microsatellites is summarised in the
CC specification and indexed herein (see below). The sequences upstream and
CC downstream of the microsatellite sequence were used to generate the
CC required PCR primers for in vitro amplification of the corresp.
CC microsatellite (using the program OPTIPRIM). The microsatellites may be
CC used to identify individuals, for parentage testing, and in the genetic
CC mapping of economic trait loci, or genes involved in the determination of
CC economically important traits esp. in cattle, to allow selective
CC breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC field.)
XX
SQ Sequence 41 BP; 6 A; 0 C; 15 G; 20 T; 0 U; 0 Other;

Query Match          0.8%; Score 29.6; DB 1; Length 41;
Best Local Similarity 88.9%; Pred. No. 79;
Matches 32; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 2316 TCTGTGTGTGTGTGCGGTGTGTGTGTGTGTGTGT 2351
    |||||
DB 6 TATATATGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 41

RESULT 126
AAQ34047
ID AAQ34047 standard; DNA; 31 BP.
XX
AC AAQ34047;
XX
XX 25-MAR-2003 (revised)
DT 02-FEB-1993 (first entry)
XX
XX Microsatellite sequence from clone TGLA436.
DE
```


[illegible]

XX

CC repeat sequences were isolated by hybridisation of chromosome-specific
CC libraries with a synthetic poly(GC-GA) (dG-dr) probe. Over 100
CC repeat blocks were isolated. The inserts from the clones were amplified
CC by primers AA15798-T6047. Those clones where the repeat sequence has
CC been determined are shown in AA15704-797. This repeat sequence is from
CC the marker clone Maf65 which contains the repeat sequence having the
CC formula: (CA)14.5. (Updated on 25-MAR-2003 to correct pf field.)

Query Match 0.7%; Score 27.4; DB 1; Length 29;
Best Local Similarity 96.6%; Pred. No. 93;
Matches 28; Conservative 0; Mismatches 1; Indels

Qy 2319 GTGTGTGTGTGTGCGTGTGTGTGTG 2347
|||
Db 29 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1

RESULT 159
AAT65712/C
ID AAT65712 standard: DNA: 29 BP.

XX AAT65712;

DT 25-MAR-2003 (revised)

DT 17-JUN-1997 (first entry)

DE Repeat sequence from polymorphic marker clone Mfd10.

Polymorphism; repeat sequence; genetic marker; primer; amplification;
 PCR; polymerase chain reaction; paternity; maternity; human; pedigree;
 linkage analysis; genetic disease; animal; plant; breeding; locus;
 hybridisation; chromosome; ds.

OS Homo sapiens.

AA
PN
US5582979-A.

10-DEC-1996.

AA 04-APR-1994; 94US-00222177.

AA 21-APR-1989; 89US-00341562.

PR 05-SEP-1991; 91US-00754351.

PA (MARS-) MARSHFIELD CLINIC.

XX
PI
Weber JL:

XX
DR WPI: 1997-042299/04.

AA
PT
AA
PT

Detection of polymorphic genetic markers of the form $(dC-dA)n(dG-dT)n$ - using novel nucleic acid mols. as primers.

PS Claim 1: Col 9-10; 186pp; English.

The invention relates to the isolation of polymorphic repeat sequences having the sequence (dC-dA)_n. (dG-dT)_n which can be used as genetic markers. Primers based on these sequences can be used to detect these repeats, especially for use in e.g. paternity or maternity testing, human genetic analysis such as linkage analysis of genetic disease, commercial animal or plant breeding or pedigree analysis. Clones containing the repeat sequences were isolated by hybridisation of chromosome-specific phage libraries with a synthetic poly(dC-dA). (dG-dT) probe. Over 100 repeat blocks were isolated. The inserts from the clones were amplified by primers AAT65798-T66047. Those clones where the repeat sequence has been determined are shown in AAT65704-797. This repeat sequence is from the marker clone Wdf10 which contains the repeat sequence having the formula: (AC)_{14A}. (Updated on 25-MAR-2003 to correct pf field.)

Query Match	0.7%	Score 27.4	DB 1	Length 28;
Best Local Similarity	96.6%	Pred. No. 93;		
Matches 28; Conservative	0;	Mismatches 1;	Indels	
Qy	2318	TGTTGTGTGTGTGCCTGTGTGTGT	2346	
Dy	29	TGTTGTGTGTGTGTGTGTGTGTGT	1	

Qy	2318	TGTTGTGTGTGTGCGTGTGTGTGTGT	2346
Db	29	TGTTGTGTGTGTGTGTGTGTGTGTGT	1

RESULT 160
AAF60474/C
ID AAF60474 standard; DNA: 29 BP.

AA
AC AAF60474;

DT 27-APR-2001 (first entry)

DE Oligonucleotide clamp #23.

KW Oligonucleotide clamp; ds.

OS Unidentified.

PN US6180777-B1.

PD 30-JAN-2001.

AA
PF 03-JAN-1997; 97US-00787321.

PR 12-JAN-1996; 96US-0009918P.

PA (FARB) BAYER CORP.

PI Horn T;

DR WPI; 2001-201911/20.

PT Synthesizing branched nucleic acids useful as diagnostic and molecular probes, involves combining first units having haloalkylamino groups and second units having thiol or phosphorothioate groups.

XX PS Example 9; Col 19-20; 20pp; English.

The present invention relates to a method for synthesising a branched or multiply connected macromolecular structure, comprising oligonucleotide clamps (OC). The macromolecular structure is capable of specifically binding to a target molecule, and can therefore be used as probes. At least one OC comprises a target binding sequence that binds specifically and stably with the target molecule, and at least two OCs comprise signal generation moieties capable of generating a detectable signal in the presence of the target molecule. In addition the OCs are connected to one another by thioalkylamino, or thiophosphorylalkylamino bridges. The present sequence is an OC used in the present invention

Sequence 29 BP; 14 A; 15 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 0.7%; Score 27.4; DB 1; Length 29;
Best Local Similarity 96.6%; Pred. No. 93;
Matches 28: Conservative 0; Mismatches 1; Indels

QY 2319 GTGTGTGTGTGTGCGTGTGTGTGTG 2347
|||||
pb 29 GTGTGTGTGTGTGTGTGTGTGTGTG 1

RESULT 161
AAQ33731
ID AAQ33731 standard. DN: 33 BP

XX
AC
ΔΔ033731.

XX DT 25-MAR-2003 (revised)

DT	25-MAR-2003	(revised)
DT	02-FEB-1993	(first entry)

XX polymorphism; repeat sequence; genetic marker; primer; amplification;
XX PCR; polymerase chain reaction; paternity; maternity; human; pedigree;
KW linkage analysis; genetic disease; animal; plant; breeding; locus;
KW hybridisation; chromosome; ds.

PR 31-MAR-2003; 2003US-00403161.
 XX (CURA-) CURAGEN CORP.
 PA Anderson DW, Bento P, Boldog FL, Burgess CE, Casman SJ, Furtak K;
 PI Gorman L, Gould-Rothberg BE, Gunther E, Hayes MP, Li L, Spytek KA;
 PI Stone DJ, Zhong M, Malyankar UM, Edinger SR, Patturajan M;
 PI Rothenberg ME, Smithson G;
 XX WPI; 2003-812539/76.
 DR New NOVX polypeptide, useful for preparing a composition for treating or
 XX preventing e.g. cancer or for chromosome mapping.
 XX Example C; SEQ ID NO 141; 433pp; English.
 CC This invention relates to novel isolated polypeptides and the DNA
 CC sequences which encode them. The invention may be useful for the
 CC development of compounds with a cytostatic activity (as NOVX-agonists or
 CC antagonists) or vaccines. In addition, the disclosed sequences may be
 CC useful for gene therapy. The polypeptide is useful for preparing a
 CC composition for treating or preventing a pathological state in a mammal,
 CC for example cancer or for chromosome mapping. The present sequence is
 CC that of an oligonucleotide probe which was used in the exemplification of
 CC the invention.
 XX Sequence 26 BP; 9 A; 9 C; 6 G; 2 T; 0 U; 0 Other;
 SQ Query Match 0.7%; Score 26; DB 1; Length 26;
 Best Local Similarity 100.0%; Pred. No. 1.2e+02;
 Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 714 CGTACACACCGACGACGAGGCTAG 739
 DB 1 CGTACACACCGACGACGAGGCTAG 26
 RESULT 171
 ADK51126 standard; DNA; 26 BP.
 ID ADK51126;
 AC ADK51126;
 XX 17-JUN-2004 (first entry)
 DT Human NOVX protein-related oligonucleotide probe SeqID.
 DE cytostatic; NOVX-agonist; NOVX-antagonist; vaccine; gene therapy; cancer;
 XX chromosome mapping; human; probe; ss.
 KW Homo sapiens.
 OS WO2003083046-A2.
 XX 09-OCT-2003.
 PD 01-APR-2003; 2003WO-US010142.
 PF 02-APR-2002; 2002US-00115479.
 PR 05-APR-2002; 2002US-0370349P.
 PR 08-APR-2002; 2002US-0370969P.
 PR 12-APR-2002; 2002US-0372019P.
 PR 22-APR-2002; 2002US-0374379P.
 PR 30-MAY-2002; 2002US-0384543P.
 PR 03-JUN-2002; 2002US-00160619.
 PR 03-JUN-2002; 2002US-00160619.
 PR 15-AUG-2002; 2002US-0403748P.
 PR 04-NOV-2002; 2002US-00287226.
 PR 31-MAR-2003; 2003US-00403161.
 XX (CURA-) CURAGEN CORP.
 PA Anderson DW, Bento P, Boldog FL, Burgess CE, Casman SJ, Furtak K;
 XX Gorman L, Gould-Rothberg BE, Gunther E, Hayes MP, Li L, Spytek KA;
 PI Stone DJ, Zhong M, Malyankar UM, Edinger SR, Patturajan M;
 PI Rothenberg ME, Smithson G;
 XX WPI; 2003-812539/76.
 DR New NOVX polypeptide, useful for preparing a composition for treating or
 XX preventing e.g. cancer or for chromosome mapping.
 XX Example C; SEQ ID NO 141; 433pp; English.
 CC This invention relates to novel isolated polypeptides and the DNA
 CC sequences which encode them. The invention may be useful for the
 CC development of compounds with a cytostatic activity (as NOVX-agonists or
 CC antagonists) or vaccines. In addition, the disclosed sequences may be
 CC useful for gene therapy. The polypeptide is useful for preparing a
 CC composition for treating or preventing a pathological state in a mammal,
 CC for example cancer or for chromosome mapping. The present sequence is
 CC that of an oligonucleotide probe which was used in the exemplification of
 CC the invention.
 XX Sequence 26 BP; 9 A; 9 C; 6 G; 2 T; 0 U; 0 Other;
 SQ Query Match 0.7%; Score 26; DB 1; Length 26;
 Best Local Similarity 100.0%; Pred. No. 1.2e+02;
 Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 714 CGTACACACCGACGACGAGGCTAG 739
 DB 1 CGTACACACCGACGACGAGGCTAG 26

PI Stone DJ, Zhong M, Malyankar UM, Edinger SR, Patturajan M;
 PI Rothenberg ME, Smithson G;
 XX WPI; 2003-812539/76.
 DR New NOVX polypeptide, useful for preparing a composition for treating or
 XX preventing e.g. cancer or for chromosome mapping.
 XX Example C; SEQ ID NO 147; 433pp; English.
 CC This invention relates to novel isolated polypeptides and the DNA
 CC sequences which encode them. The invention may be useful for the
 CC development of compounds with a cytostatic activity (as NOVX-agonists or
 CC antagonists) or vaccines. In addition, the disclosed sequences may be
 CC useful for gene therapy. The polypeptide is useful for preparing a
 CC composition for treating or preventing a pathological state in a mammal,
 CC for example cancer or for chromosome mapping. The present sequence is
 CC that of an oligonucleotide probe which was used in the exemplification of
 CC the invention.
 XX Sequence 26 BP; 10 A; 7 C; 6 G; 3 T; 0 U; 0 Other;
 SQ Query Match 0.7%; Score 26; DB 1; Length 26;
 Best Local Similarity 100.0%; Pred. No. 1.2e+02;
 Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1306 AAAGACGATGCCTGACACGAGCCT 1331
 DB 1 AAAGACGATGCCTGACACGAGCCT 26
 RESULT 172
 ADK51123 standard; DNA; 26 BP.
 ID ADK51123;
 AC ADK51123;
 XX 17-JUN-2004 (first entry)
 DT Human NOVX protein-related oligonucleotide probe SeqID.
 DE cytostatic; NOVX-agonist; NOVX-antagonist; vaccine; gene therapy; cancer;
 XX chromosome mapping; human; probe; ss.
 KW Homo sapiens.
 OS WO2003083046-A2.
 XX 09-OCT-2003.
 PD 01-APR-2003; 2003WO-US010142.
 PF 02-APR-2002; 2002US-00115479.
 PR 05-APR-2002; 2002US-0370349P.
 PR 08-APR-2002; 2002US-0370969P.
 PR 12-APR-2002; 2002US-0372019P.
 PR 22-APR-2002; 2002US-0374379P.
 PR 30-MAY-2002; 2002US-0384543P.
 PR 03-JUN-2002; 2002US-00160619.
 PR 03-JUN-2002; 2002US-00160619.
 PR 15-AUG-2002; 2002US-0403748P.
 PR 04-NOV-2002; 2002US-00287226.
 PR 31-MAR-2003; 2003US-00403161.
 XX (CURA-) CURAGEN CORP.
 PA Anderson DW, Bento P, Boldog FL, Burgess CE, Casman SJ, Furtak K;
 XX Gorman L, Gould-Rothberg BE, Gunther E, Hayes MP, Li L, Spytek KA;
 PI Stone DJ, Zhong M, Malyankar UM, Edinger SR, Patturajan M;
 PI Rothenberg ME, Smithson G;
 XX WPI; 2003-812539/76.
 DR New NOVX polypeptide, useful for preparing a composition for treating or
 XX preventing e.g. cancer or for chromosome mapping.
 XX Example C; SEQ ID NO 147; 433pp; English.
 CC This invention relates to novel isolated polypeptides and the DNA
 CC sequences which encode them. The invention may be useful for the
 CC development of compounds with a cytostatic activity (as NOVX-agonists or
 CC antagonists) or vaccines. In addition, the disclosed sequences may be
 CC useful for gene therapy. The polypeptide is useful for preparing a
 CC composition for treating or preventing a pathological state in a mammal,
 CC for example cancer or for chromosome mapping. The present sequence is
 CC that of an oligonucleotide probe which was used in the exemplification of
 CC the invention.
 XX Sequence 26 BP; 10 A; 7 C; 6 G; 3 T; 0 U; 0 Other;
 SQ Query Match 0.7%; Score 26; DB 1; Length 26;
 Best Local Similarity 100.0%; Pred. No. 1.2e+02;
 Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1306 AAAGACGATGCCTGACACGAGCCT 1331
 DB 1 AAAGACGATGCCTGACACGAGCCT 26

PT preventing e.g. cancer or for chromosome mapping.
 PS Example C; SEQ ID NO 144; 433pp; English.
 XX This invention relates to novel isolated polypeptides and the DNA
 CC sequences which encode them. The invention may be useful for the
 CC development of compounds with a cytostatic activity (as NOVX-agonists or
 CC antagonists) or vaccines. In addition, the disclosed sequences may be
 CC useful for gene therapy. The polypeptide is useful for preparing a
 CC composition for treating or preventing a pathological state in a mammal,
 CC for example cancer or for chromosome mapping. The present sequence is
 CC that of an oligonucleotide probe which was used in the exemplification of
 CC the invention.
 XX
 XX Sequence 26 BP; 9 A; 9 C; 6 G; 2 T; 0 U; 0 Other;
 Query Match 0.7%; Score 26; DB 1; Length 26;
 Best Local Similarity 100.0%; Pred. No. 1.2e+02;
 Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 714 CGCTACACACCGACAGGAGCTAG 739
 DB 1 CGCTACACACCGACAGGAGCTAG 26
 RESULT 173
 ACC79666
 ID ACC79666 standard; DNA; 29 BP.
 XX ACC79666;
 AC ACC79666;
 DT 27-AUG-2003 (first entry)
 XX Human fibroblast growth factor 3 PCR primer SEQ ID NO:1.
 DE Human fibroblast growth factor 3; FGF3; flat epithelial cell; cancer;
 XX Human; fibroblast growth factor 3; FGF3; flat epithelial cell; cancer;
 KW flat epithelial cell cancer; PCR primer; ss.
 XX Homo sapiens.
 OS Synthetic.
 OS
 XX JP2002272474-A.
 PN 24-SEP-2002.
 XX 22-MAR-2001; 2001JP-00083352.
 PF 22-MAR-2001; 2001JP-00083352.
 PR (ZERI) ZERIA SHINYAKU KOGYO KK.
 XX WPI; 2003-345602/33.
 DR Inspection of flat epithelial cell, screening of treating or preventive
 PT agents for flat epithelial cancers, the treating or preventive agents for
 PT flat epithelial cancer.
 XX Example; Page 7; 18pp; Japanese.
 PS The present invention describes a method for the inspection of flat
 XX epithelial cells in which it is judged that flat epithelial cells
 CC separated from an organism can proceed to flat epithelial cancer when the
 CC 2128th base in fibroblast growth factor receptor (FGFR) gene of the cells
 CC is mutated from guanine to thymine. Also described is a method for
 CC screening treating or preventive agents for flat epithelial cancers in
 CC which a candidate substance of treating agent for flat epithelial cancer
 CC is applied to flat epithelial cancer cells producing FGFR protein in
 CC which the 2128th (exon 17) amino acid in FGFR3 gene is mutated from
 CC guanine to thymine or the 697th amino acid is mutated from glycine to
 CC cysteine and said candidate substance is selected by using the facts that
 CC the 2128th base in the flat epithelial cell FGFR3 gene after the
 CC application returned to guanine and that the 697th amino acid of FGFR3
 CC protein produced returned to glycine as the indices. The method is used

CC for the inspection of flat epithelial cells. The present sequence
 CC represents a PCR primer for human FGFR3, which is used in an example from
 CC the present invention
 XX Sequence 29 BP; 8 A; 9 C; 6 G; 6 T; 0 U; 0 Other;
 Query Match 0.7%; Score 25.8; DB 1; Length 29;
 Best Local Similarity 93.1%; Pred. No. 1.4e+02;
 Matches 27; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 OY 1049 TGGAGTCCAAACGCTCCATGAGCTCCAAAC 1077
 DB 1 TGGAGTCCAAACGCTCCATGAGCTCCAAAC 29
 RESULT 174
 ADH70471
 ID ADH70471 standard; DNA; 29 BP.
 XX ADH70471;
 AC ADH70471;
 DT 25-MAR-2004 (first entry)
 XX Human Vbeta gene repeat sequence #261.
 DE Human Vbeta gene repeat sequence #261.
 XX human; T-cell associated disease; Vbeta; autoimmune disease;
 KW degenerative nervous system disease; graft versus host disease;
 KW hypersensitivity disease; infectious disease; neoplastic disease;
 KW Addison's disease; atrophic gastritis;
 KW degenerative nervous system disease; multiple sclerosis;
 KW Alzheimer's disease; hypersensitivity disease; type I hypersensitivity;
 KW allergy; type II hypersensitivity; Goodpasture's syndrome;
 KW type IV hypersensitivity; leprosy; infectious disease; viral infection;
 KW HIV; fungal infection; Candida; parasitic infection; schistosoma;
 KW filaria; bacterial infection; Mycobacterium; neoplastic disease;
 KW lymphoproliferative disease; leukaemia; lymphoma; cancer; brain cancer;
 KW breast cancer; ds.
 XX Homo sapiens.
 OS US2002150891-A1.
 PN 17-OCT-2002.
 XX 05-MAR-1999; 99US-00263959.
 XX 19-SEP-1994; 94US-00309335.
 PR 19-SEP-1995; 95US-00531241.
 XX (HOOD/) HOOD L E.
 PA (ROWE/) ROWEN L.
 XX Hood LE, Rowen L;
 PI WPI; 2004-059052/06.
 DR Kit for diagnosing and treating T-cell associated diseases e.g.
 PT autoimmune, degenerative nervous system and infectious diseases, comprises
 PT nucleic acid primers specifically priming and allowing amplification of a
 PT Vbeta gene.
 XX Disclosure; SEQ ID NO 665; 164pp; English.
 PS The invention relates to a kit for diagnosing and treating T-cell
 CC associated diseases which comprises a panel of nucleic acid primers
 CC specifically priming and allowing amplification of each Vbeta gene,
 CC VbetaRNA or cDNA. The kit is useful for diagnosing organ transplant
 CC rejection and diagnosing and treating T-cell associated diseases,
 CC including autoimmune diseases, degenerative nervous system diseases,
 CC graft versus host disease, hypersensitivity diseases, infectious diseases
 CC and neoplastic diseases. Autoimmune diseases include Addison's disease,
 CC atrophic gastritis. Degenerative nervous system diseases include multiple
 CC sclerosis and Alzheimer's disease. Hypersensitivity diseases include Type

CC screening a library of bovine MboI DNA fragments of between 250 and 500
CC bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC clones cross-hybridised. Assuming independent distribution of
CC microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC in the bovine genome is estimated at >100,000. The sequence information
CC for ca. 230 such bovine microsatellites is summarised in the
CC specification and indexed herein (see below). The sequences upstream and
CC downstream of the microsatellite sequence were used to generate the
CC required PCR primers for in vitro amplification of the corresp.
CC microsatellite (using the program OPTIPRIM). The microsatellites may be
CC used to identify individuals, for parentage testing, and in the genetic
CC mapping of economic trait loci, or genes involved in the determination of
CC economically important traits esp. in cattle, to allow selective
CC breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC field.)
XX
XX
SQ Sequence 27 BP; 0 A; 0 C; 13 G; 14 T; 0 U; 0 Other;

Query Match 0.7% Score 25.4; DB 1; Length 27;
Best Local Similarity 96.3%; Pred. No. 1.5e+02;
Matches 26; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 2318 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 2344
Dd 1 TGTGTGTGTGTGTGTGTGTGTGTGTGTGT 27

RESULT 181
AAQ34143
ID AAQ34143; standard; DNA; 27 BP.
XX
AC AAQ34143;
XX
DT 25-MAR-2003 (revised)
DT 02-FEB-1993 (first entry)
XX
DE Sequence of a microsatellite from clone TGLA76.
XX
KW PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW genetic mapping; traits; amplification; ss.
XX
OS Bos taurus.
XX
PN WO9213102-A1.
XX
PD 06-AUG-1992.
XX
PF 15-JAN-1992; 92WO-US000340.
XX
PR 15-JAN-1991; 91US-00642342.
XX
PA (GENM-) GENMARK.
XX
XX Georges M, Massey JM;
PI
XX
DR WPI; 1992-284684/34.
XX
XX Polymorphic bovine DNA markers - used in genetic identification, gene
PT mapping, and selective breeding.
PT
XX
PS Table 7; Page 388; 517pp; English.
XX
CC The sequence is that of a bovine microsatellite sequence obtd. by
CC screening a library of bovine MboI DNA fragments of between 250 and 500
CC bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC clones cross-hybridised. Assuming independent distribution of
CC microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC in the bovine genome is estimated at >100,000. The sequence information
CC for ca. 230 such bovine microsatellites is summarised in the
CC specification and indexed herein (see below). The sequences upstream and
CC downstream of the microsatellite sequence were used to generate the
CC required PCR primers for in vitro amplification of the corresp.
CC microsatellite (using the program OPTIPRIM). The microsatellites may be

XX Georges M, Massey JM;
XX PI
XX DR
XX WPI; 1992-284684/34.
XX
XX Polymorphic bovine DNA markers - used in genetic identification, gene
XX PT mapping, and selective breeding.
XX PT
XX
XX PS
XX Table 7; Page 403; 517pp; English.
XX
XX The sequence is a bovine microsatellite sequence obtd. by screening a
XX CC library of bovine MboI DNA fragments of between 250 and 500 bp with an
XX CC (AC)15 and a (TC)15 oligonucleotide probe. One out of 50 clones cross-
XX CC hybridised. Assuming independent distribution of microsatellites and MboI
XX CC sites, the frequency of (76)n >9 microsatellites in the bovine genome is
XX CC estimated at >100,000. The sequence information for ca. 230 such bovine
XX CC microsatellites is summarised in the specification and indexed herein
XX CC (see below). The sequences upstream and downstream of the microsatellite
XX CC sequence were used to generate the required PCR primers for in vitro
XX CC amplification of the corresp. microsatellite (using the program
XX CC OPTIPRIM). The microsatellites may be used to identify individuals, for
XX CC parentage testing, and in the genetic mapping of economic trait loci, or
XX CC genes involved the determinism of economically important traits esp. in
XX CC cattle, to allow selective breeding. See also AAQ33501-34437. (Updated on
XX CC 25-MAR-2003 to correct PN field.)
XX
XX Sequence 27 BP; 0 A; 0 C; 13 G; 14 T; 0 U; 0 Other;
XX
XX Query Match 0.7%; Score 25.4; DB 1; Length 27;
XX Best Local Similarity 96.3%; Pred. No. 1.5e+02;
XX Matches 26; Conservative 0; Mismatches 1; Indels 0; Gaps 0
XX
Oy 2318 TGTGTGTGTGTGTGTGTGTGTGTGTGTGT 2344
Db 1 TGTGTGTGTGTGTGTGTGTGTGTGTGTGT 27
XX
RESULT 180
AAQ34012
ID AAQ34012 standard; DNA; 27 BP.
XX
XX AC AAQ34012;
XX
XX DT 25-MAR-2003 (revised)
XX DT 02-FEB-1993 (first entry)
XX
XX DE Microsatellite sequence from clone TGLA417.
XX
XX KW PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
XX KW genetic mapping; traits; amplification; ss.
XX
XX OS Bos taurus.
XX
XX PN WO9213102-A1.
XX
XX PD 06-AUG-1992.
XX
XX PF 15-JAN-1992; 92WO-US000340.
XX
XX PR 15-JAN-1991; 91US-00642342.
XX
XX PA (GENM-) GENMARK.
XX
XX PI Georges M, Massey JM;
XX DR WPI; 1992-284684/34.
XX
XX PT Polymorphic bovine DNA markers - used in genetic identification, gene
XX PT mapping, and selective breeding.
XX
XX PS Table 7; Page 335; 517pp; English.
XX
XX The sequence is that of a bovine microsatellite sequence obtd. by

RESULT 185
AAH46017
ID AAH46017 standard; DNA; 27 BP.
XX AC
XX AAH46017;
XX
XX 12-SEP-2001 (first entry)
XX DE
XX Synthetic oligonucleotide 17.
XX
XX Synthetic oligonucleotide; dinucleotide repeat; cytostatic; apoptosis;
KW cell cycle arrest; cell proliferation; caspase; cytokine; interleukin;
KW tumour necrosis factor; TNF; cancer; carcinoma; sarcoma; leukemia;
KW lymphoma; ss.
XX Synthetic.
OS
XX WO200144465-A2.
PN
XX
XX 21-JUN-2001.
PD
XX
XX 12-DEC-2000; 2000WO-CA001467.
PF
XX
XX 13-DEC-1999; 99US-0170325P.
PR
XX 29-AUG-2000; 2000US-0228925P.
PR
XX (BION-) BIONICHE LIFE SCI INC.
PA
XX Phillips NC, Filion MC;
PI
XX WPI; 2001-398150/42.
DR
XX Composition comprising synthetic oligonucleotides which comprise multiple repeats of dinucleotides such as GT, TG useful for treating cancer by inducing cell cycle arrest, inhibiting proliferation, activating caspases.
PT
XX Disclosure; Page 74; 77pp; English.

The present sequence is that of a synthetic oligonucleotide useful to the invention. The invention relates to a composition, comprising a 2 to 20 base 3'-OH, 5'-OH synthetic oligonucleotide which comprises multiple repeats of dinucleotides such as GT, TG, etc., according to specific formula and having cytostatic activity. The oligonucleotide compositions are useful for inducing cell cycle arrest, inhibition of proliferation, activation of caspases and induction of apoptosis or production of cytokines such as interleukin (IL)-1-beta, IL-6, IL-10, IL-12 and tumour necrosis factor (TNF)-alpha by immune system cells, in an animal having cancer such as primary carcinoma, secondary carcinoma, primary sarcoma and secondary sarcoma such as, leukemia, lymphoma, breast, prostate, colorectal, ovarian or bone cancer. The compositions induce apoptosis independent of Fas, p53/p21, p21/waf-1/CIP, p15(ink4A), p16(ink4), drug resistance, caspase 3, transforming growth factor (TGF)-beta 1 receptor and hormone dependence

Sequence 27 BP; 0 A; 0 C; 14 G; 13 T; 0 U; 0 Other;

Query Match 0.7%; Score 25.4; DB 1; Length 27;
Best Local Similarity 96.3%; Pred. No. 1.5e+02;
Matches 26; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2319 GTGTGCTGTGTGTGCCTGTGTGTGTGTG 2345
|||||
DB 1 GTGTGCTGTGTGTGTGTGTGTGTGTGTG 27

RESULT 186
AAH46001
ID AAH46001 standard; DNA; 27 BP.
XX AC
XX AAH46001;
XX
XX 12-SEP-2001 (first entry)
DT

RESULT 184
AAH24300
IID AAH24300 standard; DNA; 27 BP.
XX AC
XX AAH24300;
XX
XX 21-SEP-2001 (first entry)
DE
XX Synthetic antineoplastic oligonucleotide, SEQ ID NO:2.
XX Antineoplastic oligonucleotide; hyaluronic acid; HA; cytokine production;
KW interleukin; IL-6; IL-12; synergistic action; standard dose reduction;
KW side-effect reduction; drug resistance reduction;
KW immunosensitisation reduction; cancer; tumour; cytostatic; ss.
XX Synthetic.
OS
XX WO200147561-A1.
PN
XX
XX 05-JUL-2001.
PD
XX
XX 28-DEC-2000; 2000WO-CA001562.
PR
XX
XX 28-DEC-1999; 99US-0173375P.
PR
XX (BION-) BIONICHE LIFE SCI INC.
PA
XX Phillips NC, Filion MC;
PI
XX WPI; 2001-408766/43.
DR
XX Synergistic compositions comprising hyaluronic acid and Mycobacterium phlei DNA and cell walls, useful for treating cancers.

Example 7; Page 23; 27pp; English.

The invention relates to compositions for the treatment of cancers, comprising purified hyaluronic acid (HA) and a second antineoplastic agent such as Mycobacterium phlei DNA, a Mycobacterium phlei DNA/cell wall complex, a cytotoxic chemotherapeutic drug or a synthetic antineoplastic oligonucleotide. On its own, HA stimulates the production of the cytokines interleukin-6 (IL-6) and IL-12 by immune system cells. In combination, HA and the second antineoplastic agent of the composition act synergistically to potentiate each other's ability to inhibit proliferation and induce apoptosis in cancer cells. Due to the synergy between the HA and the second antineoplastic agent, a reduced standard dose of the second antineoplastic agent can be used without compromising the therapeutic effectiveness of the cancer treatment. The reduction in dose helps to reduce adverse side-effects and the development of drug resistance or immunosensitisation, thereby improving the quality of life for the patient. In addition, as HA is inexpensive and as most chemotherapeutic drugs are expensive, the combined use of HA and a chemotherapeutic drug can significantly reduce the cost of cancer treatment. The increase in dose effectiveness, decrease in toxicity and decrease in cost address provide important benefits for mammals, including humans. The present sequence represents a synthetic antineoplastic oligonucleotide which was used in a composition with HA in an exemplification of the invention

Sequence 27 BP; 0 A; 0 C; 14 G; 13 T; 0 U; 0 Other;

Query Match 0.7%; Score 25.4; DB 1; Length 27;
Best Local Similarity 96.3%; Pred. No. 1.5e+02;
Matches 26; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2319 GTGTGCTGTGTGTGCCTGTGTGTGTGTG 2345
|||||
DB 1 GTGTGCTGTGTGTGTGTGTGTGTGTGTG 27

[illegible]

XX	WPI; 2004-059052/06.
DX	
DR	Kit for diagnosing and treating T-cell associated diseases e.g.
PT	autoimmune, degenerative nervous system and infectious disease, comprises
PT	nucleic acid primers specifically priming and allowing amplification of a
PT	Vbeta gene.
PT	
XX	
PS	Disclosure; SEQ ID NO 770; 164pp; English.
PS	
CC	The invention relates to a kit for diagnosing and treating T-cell
CC	associated diseases which comprises a panel of nucleic acid primers
CC	specifically priming and allowing amplification of each Vbeta gene,
CC	VbetARNA or cDNA. The kit is useful for diagnosing organ transplant
CC	rejection and diagnosing and treating T-cell associated diseases.
CC	including autoimmune diseases, degenerative nervous system diseases,
CC	graft versus host diseases, hypersensitivity diseases, infectious diseases
CC	and neoplastic diseases. Autoimmune diseases include Addison's disease,
CC	atrophic gastritis. Degenerative nervous system diseases include Type
CC	sclerosis and Alzheimer's disease. Hypersensitivity diseases include multiple
CC	I hypersensitivities such as contact with allergens that lead to
CC	allergies, Type II hypersensitivities such as those present in
CC	Goodpasture's syndrome and Type IV hypersensitivities such as those
CC	manifested in leprosy. Infectious diseases include viral infections
CC	caused by viruses such as HIV, fungal infections such as those caused by
CC	the yeast genus Candida, parasitic infections such as those caused by
CC	schistosomes, filaria and bacterial infections such as those caused by
CC	Mycobacterium. Neoplastic diseases include lymphoproliferative diseases
CC	such as leukemias, lymphomas and cancers such as cancer of the brain,
CC	brest. The present sequence represents a Vbeta gene repeat sequence.
XX	
XX	Sequence 27 BP; 0 A; 0 C; 13 G; 14 T; 0 U; 0 Other;
QY	Query Match 0.7%; Score 25.4; DB 1; Length 27;
DB	Best Local Similarity 96.3%; Pred. No. 1.5e+02;
	Matches 26; Conservative 0; Mismatches 1; Indels 0; Gaps 0
Qy	2318 TGTGTCGTGTCGTGTCGCCTGTCGTGTCGT 2344
Db	1 TGTGTCGTGTCGTGTCGTGTCGTGTCGT 27
RESULT 190	
AAT66066/C	
ID	AAT66066 standard; DNA; 30 BP.
XX	
AC	AAT66066;
XX	
DT	25-MAR-2003 (revised)
DT	18-JUN-1997 (first entry)
XX	
DE	(dc-da)n.(dG-dT)n polymorphic repeat sequence #7.
XX	
KW	Polymorphism; repeat sequence; genetic marker; primer; amplification;
KW	PCR; polymerase chain reaction; paternity; maternity; human; pedigree;
KW	linkage analysis; genetic disease; animal; plant; breeding; locus;
KW	hybridisation; chromosome; ds.
XX	
OS	Homo sapiens.
XX	
PN	US5582979-A.
PD	10-DEC-1996.
XX	
PF	04-APR-1994; 94US-00222177.
XX	
PR	21-APR-1989; 89US-00341562.
PR	05-SEP-1991; 91US-00754351.
XX	
PA	(MARS-) MARSHFIELD CLINIC.
XX	
PI	Weber JL;
XX	

DR WPI; 1997-042299/04.
XX Detection of polymorphic genetic markers of the form (dC-dA)n(dG-dT)n -
PT using novel nucleic acid mols. as primers.
XX Example 8; Col 57-58; 186pp; English.
XX The invention relates to the isolation of polymorphic repeat sequences
CC having the sequence (dC-dA)n.(dG-dT)n which can be used as genetic
CC markers. Primers based on these sequences can be used to detect these
CC repeats, especially for use in e.g. paternity or maternity testing, human
CC genetic analysis such as linkage analysis of genetic disease, commercial
CC animal or plant breeding or pedigree analysis. The repeats, when
CC analysed, fall into 4 categories: 1) perfect repeats which are
CC alternating tandem CA repeats with no interruptions and without adjacent
CC repeats of another sequence; 2) imperfect repeats which are defined as 2
CC or more runs of uninterrupted CA repeats separated by no more than 3
CC consecutive non-repeat bases; 3) compound perfect repeats which are
CC uninterrupted runs of CA separated by no more than 3 consecutive non-
CC repeat bases from a run of at least 5 uninterrupted dinucleotide or
CC longer repeats of a sequence other than (dC-dA)n.(dG-dT)n, or from at
CC least 10 uninterrupted mononucleotides; and 4) imperfect compound repeats
CC which are defined as for the perfect compound repeats except that the
CC runs of CA are interrupted. This sequence is an example of an imperfect
CC repeat sequence of structure: (CA)5G(ACA)G(AC)7A. (Updated on 25-MAR-2003
XX to correct PF field.)
XX Sequence 30 BP; 15 A; 13 C; 2 G; 0 T; 0 U; 0 Other;
SQ Query Match 0.7%; Score 25.2; DB 1; Length 30;
Best Local Similarity 90.0%; Pred. No. 1.8e+02;
Matches 27; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 2318 TGTGTGTGTGTGTGCGGTGTGTGTGTG 2347
DB 30 TGTGTGTGTGTGTGCTGTGTGTGTGTG 1
RESULT 191
ADH70406
ID ADH70406 standard; DNA; 30 BP.
XX ADH70406;
AC ADH70406;
XX 25-MAR-2004 (first entry)
DT Human Vbeta gene repeat sequence #196.
DE human; T-cell associated disease; Vbeta; autoimmune disease;
XX degenerative nervous system disease; graft versus host disease;
KW hypersensitivity disease; infectious disease; neoplastic disease;
KW Addison's disease; atrophic gastritis;
KW degenerative nervous system disease; multiple sclerosis;
KW Alzheimer's disease; hypersensitivity disease; type I hypersensitivity;
KW allergy; type II hypersensitivity; Goodpasture's syndrome;
KW type IV hypersensitivity; leprosy; infectious disease; viral infection;
KW HIV; fungal infection; Candida; parasitic infection; schistosomiasis;
KW filaria; bacterial infection; Mycobacterium; neoplastic disease;
KW lymphoproliferative disease; leukaemia; lymphoma; cancer; brain cancer;
KW breast cancer; ds.
XX Homo sapiens.
XX US2002150891-A1.
PN 17-OCT-2002.
XX 05-MAR-1999; 99US-00263959.
XX 19-SEP-1994; 94US-00309335.
PR 19-SEP-1995; 95US-00531241.
XX (HOOD/) HOOD L E.
PA

PA (ROWE/) ROWEN L.
XX Hood LE, Rowen L;
XX WPI; 2004-059052/06.
XX Kit for diagnosing and treating T-cell associated diseases e.g.
PT autoimmune, degenerative nervous system and infectious disease, comprises
PT nucleic acid primers specifically priming and allowing amplification of a
PT Vbeta gene.
XX Disclosure; SEQ ID NO 600; 164pp; English.
XX The invention relates to a kit for diagnosing and treating T-cell
CC associated diseases which comprises a panel of nucleic acid primers
CC specifically priming and allowing amplification of each Vbeta gene,
CC VbetaRNA or cDNA. The kit is useful for diagnosing organ transplant
CC rejection and diagnosing and treating T-cell associated diseases
CC including autoimmune diseases, degenerative nervous system diseases,
CC graft versus host disease, hypersensitivity diseases, infectious diseases,
CC and neoplastic diseases. Autoimmune diseases include Addison's disease,
CC atrophic gastritis. Degenerative nervous system diseases include multiple
CC sclerosis and Alzheimer's disease. Hypersensitivity diseases include Type
CC I hypersensitivities such as contact with allergens that lead to
CC allergies, Type II hypersensitivities such as those present in
CC Goodpasture's syndrome and Type IV hypersensitivities such as those
CC manifested in leprosy. Infectious diseases include viral infections
CC caused by viruses such as HIV, fungal infections such as those caused by
CC the yeast genus Candida, parasitic infections such as those caused by
CC schistosomes, filaria and bacterial infections such as those caused by
CC Mycobacterium. Neoplastic diseases include lymphoproliferative diseases
CC such as leukaemias, lymphomas and cancers such as cancer of the brain,
CC breast. The present sequence represents a Vbeta gene repeat sequence.
XX Sequence 30 BP; 1 A; 1 C; 13 G; 15 T; 0 U; 0 Other;
SQ Query Match 0.7%; Score 25.2; DB 1; Length 30;
Best Local Similarity 90.0%; Pred. No. 1.8e+02;
Matches 27; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 2318 TGTGTGTGTGTGTGCGGTGTGTGTGTG 2347
DB 1 TGTGTGTGTGTGTGTGTGTGTGTGTGTG 30
RESULT 192
AAA54587/C
ID AAA54587 standard; DNA; 25 BP.
XX AAA54587;
AC AAA54587;
XX 11-APR-2001 (first entry)
DT Primer used for detecting mutant fibroblast growth factor receptor 3.
DE Fibroblast growth factor 3 receptor; FGFR3; mutant; detection; cancer;
XX carcinoma; lung cancer; breast cancer; colon cancer; skin cancer;
KW bladder; cervix; human; primer; ss.
KW Synthetic.
OS WO200068424-A2.
XX 16-NOV-2000.
PN 04-MAY-2000; 2000WO-EP004591.
XX 05-MAY-1999; 99US-0132705P.
PR (CURI-) INST CURIE.
XX (CNRS) CNRS CENT NAT RECH SCI.
PA Cappellen D, Chopin D, Radvanyi F, Ricol D, Thierry J;
XX

XX WPI; 2001-016103/02.
 XX Diagnosing carcinoma e.g. bladder or cervix carcinomas in a biological
 PT sample such as tissue, bone marrow or body fluid, preferably from animal
 PT or human, by identifying fibroblast growth factor receptor 3 mutations.
 XX Example 4; Page 14; 41pp; English.
 XX The identification of fibroblast growth factor receptor 3 (FGFR3)
 CC mutations in a biological sample such as tissue, bone marrow or body
 CC fluid e.g. urine, from a warm-blooded animal, preferably human is useful
 CC for diagnosing carcinomas such as human bladder and cervix carcinomas, or
 CC cancers associated with lung, breast, colon and skin. The pharmaceutical
 CC preparations comprising agents which inhibit the synthesis and expression
 CC of FGFR3 and so have an anti-proliferation effect on carcinomas can be
 CC used to treat cancer. Two primers (AAA54430, AAA54587) were used in PCR
 CC reactions on urine samples to detect the Y375C mutation in FGFR3
 XX Sequence 25 BP; 5 A; 4 C; 11 G; 5 T; 0 U; 0 Other;
 SQ Query Match 0.7%; Score 25; DB 1; Length 25;
 Best Local Similarity 100.0%; Pred. No. 1.5e+02;
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1011 CAAGATCTCCCGTCCCGCTCAAG 1035
 DB 25 CAAGATCTCCCGTCCCGCTCAAG 1
 RESULT 193
 ID AAA54586 standard; DNA; 25 BP.
 XX AAA54586;
 XX 11-APR-2001 (first entry)
 XX Primer used for detecting mutant fibroblast growth factor receptor 3.
 DE Fibroblast growth factor 3 receptor; FGFR3; mutant; detection; cancer;
 KW carcinoma; lung cancer; breast cancer; colon cancer; skin cancer;
 KW bladder; cervix; human; primer; ss.
 XX Synthetic.
 OS WO200068424-A2.
 PN 16-NOV-2000.
 XX 04-MAY-2000; 2000WO-EP004591.
 XX 05-MAY-1999; 99US-0132705P.
 XX (CURT-) INST CURIE.
 PA (CNRS) CNRS CENT NAT RECH SCI.
 XX Cappellen D, Chopin D, Radvanyi F, Ricol D, Thierry J;
 XX WPI; 2001-016103/02.
 XX Diagnosing carcinoma e.g. bladder or cervix carcinomas in a biological
 PT sample such as tissue, bone marrow or body fluid, preferably from animal
 PT or human, by identifying fibroblast growth factor receptor 3 mutations.
 XX Example 4; Page 13; 41pp; English.
 XX The identification of fibroblast growth factor receptor 3 (FGFR3)
 CC mutations in a biological sample such as tissue, bone marrow or body
 CC fluid e.g. urine, from a warm-blooded animal, preferably human is useful
 CC for diagnosing carcinomas such as human bladder and cervix carcinomas, or
 CC cancers associated with lung, breast, colon and skin. The pharmaceutical
 CC preparations comprising agents which inhibit the synthesis and expression

CC of FGFR3 and so have an anti-proliferation effect on carcinomas can be
 CC used to treat cancer. Two primers (AAA54429, AAA54586) were used in PCR
 CC reactions on urine samples to detect the G372C mutation in FGFR3
 XX Sequence 25 BP; 5 A; 4 C; 11 G; 5 T; 0 U; 0 Other;
 SQ Query Match 0.7%; Score 25; DB 1; Length 25;
 Best Local Similarity 100.0%; Pred. No. 1.5e+02;
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1011 CAAGATCTCCCGTCCCGCTCAAG 1035
 DB 25 CAAGATCTCCCGTCCCGCTCAAG 1
 RESULT 194
 ID ABQ81955
 XX ABQ81955 standard; DNA; 25 BP.
 XX ABQ81955;
 XX 19-NOV-2002 (first entry)
 XX Kaposi's Sarcoma TAG PCR primer SEQ ID NO:105.
 DE Human; Kaposi's sarcoma; tumour; angiogenesis; PCR primer; ss.
 KW Homo sapiens.
 OS EP1225233-A2.
 PN 24-JUL-2002.
 XX 23-JAN-2002; 2002EP-00075264.
 XX 23-JAN-2001; 2001EP-00200228.
 PR 28-SEP-2001; 2001EP-00203703.
 PR 28-SEP-2001; 2001US-0325722P.
 XX (AMST-) AMSTERDAM SUPPORT DIAGNOSTICS BV.
 PA Van Der Kuyl AC, Cornelissen M;
 PI WPI; 2002-668396/72.
 XX Determining presence of a tumor cell or angiogenesis, and the
 PT effectiveness of treatment, by detecting the presence of marker genes is
 PT useful to detect and monitor treatment of Kaposi's Sarcoma.
 XX Example 10; Page 23; 38pp; English.
 XX The present invention describes a method for determining if an individual
 CC has a tumour cell or site of angiogenesis, or if a treatment is effective
 CC in changing angiogenesis or changing a status of a set of target cells,
 CC comprising determining if a sample of the subject has an expression
 CC product of at least one marker gene. Also described is a compound capable
 CC of altering the expression or activity of Keratin 14, TIE 1, Saloadhesin
 CC or Siglec in a cell. Peripheral blood mononuclear cell (PBMC)-expressed
 CC Keratin 14, TIE 1, Saloadhesin or Siglec, and kits containing them from
 CC the present invention can be used in a diagnostic method, particularly as
 CC an indicator of angiogenesis or to determine presence of a tumour cell.
 CC The method of the invention is suitable to determine within a few days if
 CC a certain treatment against Kaposi's Sarcoma is successful. ABQ81851 to
 CC ABQ82006 represent nucleotide sequence used in the exemplification of the
 CC present invention
 XX Sequence 25 BP; 9 A; 4 C; 9 G; 3 T; 0 U; 0 Other;
 SQ Query Match 0.7%; Score 25; DB 1; Length 25;
 Best Local Similarity 100.0%; Pred. No. 1.5e+02;
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1648 GTGACCGAGACACGCTGATGAAGA 1672


```

XX OS Bos taurus.
XX XX
XX PN WO9213102-A1.
XX XX
XX PD 06-AUG-1992.
XX XX
XX PF 15-JAN-1992; 92WO-US000340.
XX XX
XX PR 15-JAN-1991; 91US-00642342.
XX XX
XX PA (GENM-) GENMARK.
XX XX
XX PI Georges M, Massey JM;
XX XX
XX DR WPI; 1992-284684/34.
XX XX
XX PT Polymorphic bovine DNA markers - used in genetic identification, gene
XX PT mapping, and selective breeding.
XX PS Table 7; Page 364; 517pp; English.
XX CC The sequence is that of a bovine microsatellite sequence obt'd. by
XX CC screening a library of bovine MboI DNA fragments of between 250 and 500
XX CC bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
XX CC clones cross-hybridised. Assuming independent distribution of
XX CC microsatellites and MboI sites, the frequency of (T6)n > 9 microsatellites
XX CC in the bovine genome is estimated at >100,000. The sequence information
XX CC for ca. 230 such bovine microsatellites is summarised in the
XX CC specification and indexed herein (see below). The sequences upstream and
XX CC downstream of the microsatellite sequence were used to generate the
XX CC required PCR primers for in vitro amplification of the corresp.
XX CC microsatellite (using the program OPTIPRIM). The microsatellites may be
XX CC used to identify individuals, for parentage testing, and in the genetic
XX CC mapping of economic trait loci, or genes involved in the determination of
XX CC economically important traits esp. in cattle, to allow selective
XX CC breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
XX CC field.)
XX CC
XX CC Sequence 26 BP; 0 A; 0 C; 13 G; 13 T; 0 U; 0 Other;
XX CC
XX CC Query Match 0.6%; Score 24.4; DB 1; Length 26;
XX CC Best Local Similarity 96.2%; Pred. No. 1.8e+02;
XX CC Matches 25; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX CC
XX QY 2318 TGTGTGTGTGTGTGTCGCGTGTGTG 2343
XX DB 1 TGTGTGTGTGTGTGTGTGTGTGTG 26
XX
XX RESULT 198
XX AAQ33684
XX ID AAQ33684 standard; DNA; 26 BP.
XX XX
XX AC AAQ33684;
XX XX
XX XX 25-MAR-2003 (revised)
XX DT 02-FEB-1993 (first entry)
XX XX
XX DE Microsatellite sequence from clone TGLA123.
XX XX
XX KW PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
XX KW genetic mapping; traits; amplification; ss.
XX XX
XX OS Bos taurus.
XX XX
XX XX WO9213102-A1.
XX PN
XX XX
XX PD 06-AUG-1992.
XX XX
XX PF 15-JAN-1992; 92WO-US000340.
XX XX
XX PR 15-JAN-1991; 91US-00642342.
XX XX

```

```

XX (GENM-) GENMARK.
XX PA
XX XX
XX PI Georges M, Massey JM;
XX XX
XX DR WPI; 1992-284684/34.
XX XX
XX PT Polymorphic bovine DNA markers - used in genetic identification, gene
XX PT mapping, and selective breeding.
XX PS Table 7; Page 203; 517pp; English.
XX XX
XX CC The sequence is that of a bovine microsatellite sequence obt'd. by
XX CC screening a library of bovine MboI DNA fragments of between 250 and 500
XX CC bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
XX CC clones cross-hybridised. Assuming independent distribution of
XX CC microsatellites and MboI sites, the frequency of (T6)n > 9 microsatellites
XX CC in the bovine genome is estimated at >100,000. The sequence information
XX CC for ca. 230 such bovine microsatellites is summarised in the
XX CC specification and indexed herein (see below). The sequences upstream and
XX CC downstream of the microsatellite sequence were used to generate the
XX CC required PCR primers for in vitro amplification of the corresp.
XX CC microsatellite (using the program OPTIPRIM). The microsatellites may be
XX CC used to identify individuals, for parentage testing, and in the genetic
XX CC mapping of economic trait loci, or genes involved in the determination of
XX CC economically important traits esp. in cattle, to allow selective
XX CC breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
XX CC field.)
XX CC
XX CC Sequence 26 BP; 0 A; 0 C; 13 G; 13 T; 0 U; 0 Other;
XX CC
XX CC Query Match 0.6%; Score 24.4; DB 1; Length 26;
XX CC Best Local Similarity 96.2%; Pred. No. 1.8e+02;
XX CC Matches 25; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX CC
XX QY 2319 GTGTGTGTGTGTGTGTCGCGTGTGTGTGT 2344
XX DB 1 GTGTGTGTGTGTGTGTGTGTGTGTGTGT 26
XX
XX RESULT 199
XX AAQ33704
XX ID AAQ33704 standard; DNA; 26 BP.
XX XX
XX AC AAQ33704;
XX XX
XX XX 25-MAR-2003 (revised)
XX DT 02-FEB-1993 (first entry)
XX XX
XX DE Microsatellite sequence from clone TGLA130.
XX XX
XX KW PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
XX KW genetic mapping; traits; amplification; ss.
XX XX
XX OS Bos taurus.
XX XX
XX XX WO9213102-A1.
XX PN
XX XX
XX PD 06-AUG-1992.
XX XX
XX PF 15-JAN-1992; 92WO-US000340.
XX XX
XX PR 15-JAN-1991; 91US-00642342.
XX XX
XX PA (GENM-) GENMARK.
XX XX
XX PI Georges M, Massey JM;
XX XX
XX DR WPI; 1992-284684/34.
XX XX
XX PT Polymorphic bovine DNA markers - used in genetic identification, gene
XX PT mapping, and selective breeding.
XX PS

```



```

PS Table 7; Page 211; 517pp; English.
XX The sequence is that of a bovine microsatellite sequence obtd. by
CC screening a library of bovine MboI DNA fragments of between 250 and 500
CC bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC clones cross-hybridised. Assuming independent distribution of
CC microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC in the bovine genome is estimated at >100, 000. The sequence information
CC for ca. 230 such bovine microsatellites is summarised in the
CC specification and indexed herein (see below). The sequences upstream and
CC downstream of the microsatellite sequence were used to generate the
CC required PCR primers for in vitro amplification of the corresp.
CC microsatellite (using the program OPTIPRIM). The microsatellites may be
CC used to identify individuals, for parentage testing, and in the genetic
CC mapping of economic trait loci, or genes involved the determinism of
CC economically important traits esp. in cattle, to allow selective
CC breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC field.)
XX Sequence 26 BP; 0 A; 0 C; 13 G; 13 T; 0 U; 0 Other;
SQ
Query Match 0.6%; Score 24.4; DB 1; Length 26;
Best Local Similarity 96.2%; Pred. No. 1.8e+02;
Matches 25; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2319 GTGTGTGTGTGTGTGTGTGTGTGTGTGT 2344
DB 1 GTGTGTGTGTGTGTGTGTGTGTGTGTGT 26
RESULT 200
AAQ33831
ID AAQ33831 standard; DNA; 26 BP.
XX
AC AAQ33831;
XX
DT 25-MAR-2003 (revised)
DT 02-FEB-1993 (first entry)
XX
DE Microsatellite sequence from clone TGLA231.
XX
KW PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW genetic mapping; traits; amplification; ss.
XX
OS Bos taurus.
XX
PN WO9213102-A1.
XX
PD 06-AUG-1992.
XX
PF 15-JAN-1992; 92WO-US000340.
XX
PR 15-JAN-1991; 91US-00642342.
XX
PA (GENM-) GENMARK.
XX
PI Georges M, Massey JM;
XX
DR WPI; 1992-284684/34.
XX
PT Polymorphic bovine DNA markers - used in genetic identification, gene
PT mapping, and selective breeding.
XX
PS Table 7; Page 262; 517pp; English.
XX
CC The sequence is that of a bovine microsatellite sequence obtd. by
CC screening a library of bovine MboI DNA fragments of between 250 and 500
CC bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC clones cross-hybridised. Assuming independent distribution of
CC microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC in the bovine genome is estimated at >100, 000. The sequence information
CC for ca. 230 such bovine microsatellites is summarised in the
CC specification and indexed herein (see below). The sequences upstream and
CC downstream of the microsatellite sequence were used to generate the
CC required PCR primers for in vitro amplification of the corresp.
CC microsatellite (using the program OPTIPRIM). The microsatellites may be
CC used to identify individuals, for parentage testing, and in the genetic
CC mapping of economic trait loci, or genes involved the determinism of
CC economically important traits esp. in cattle, to allow selective
CC breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC field.)
XX Sequence 26 BP; 0 A; 0 C; 13 G; 13 T; 0 U; 0 Other;
SQ
Query Match 0.6%; Score 24.4; DB 1; Length 26;
Best Local Similarity 96.2%; Pred. No. 1.8e+02;
Matches 25; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2318 TGTGTGTGTGTGTGTGTGTGTGTGTGTGT 2343
DB 1 TGTGTGTGTGTGTGTGTGTGTGTGTGTGT 26
RESULT 201
AAQ33837
ID AAQ33837 standard; DNA; 26 BP.
XX
AC AAQ33837;
XX
DT 25-MAR-2003 (revised)
DT 02-FEB-1993 (first entry)
XX
DE Microsatellite sequence from clone TGLA25.
XX
KW PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW genetic mapping; traits; amplification; ss.
XX
OS Bos taurus.
XX
PN WO9213102-A1.
XX
PD 06-AUG-1992.
XX
PF 15-JAN-1992; 92WO-US000340.
XX
PR 15-JAN-1991; 91US-00642342.
XX
PA (GENM-) GENMARK.
XX
PI Georges M, Massey JM;
XX
DR WPI; 1992-284684/34.
XX
PT Polymorphic bovine DNA markers - used in genetic identification, gene
PT mapping, and selective breeding.
XX
PS Table 7; Page 264; 517pp; English.
XX
CC The sequence is that of a bovine microsatellite sequence obtd. by
CC screening a library of bovine MboI DNA fragments of between 250 and 500
CC bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC clones cross-hybridised. Assuming independent distribution of
CC microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC in the bovine genome is estimated at >100, 000. The sequence information
CC for ca. 230 such bovine microsatellites is summarised in the
CC specification and indexed herein (see below). The sequences upstream and
CC downstream of the microsatellite sequence were used to generate the
CC required PCR primers for in vitro amplification of the corresp.
CC microsatellite (using the program OPTIPRIM). The microsatellites may be
CC used to identify individuals, for parentage testing, and in the genetic
CC mapping of economic trait loci, or genes involved the determinism of
CC economically important traits esp. in cattle, to allow selective
CC breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC field.)
XX Sequence 26 BP; 0 A; 0 C; 13 G; 13 T; 0 U; 0 Other;
SQ

```

XX
DT 29-JUL-2004 (first entry)
XX
DE Cow prion protein microsatellite locus primer #65.
XX
KW gene typing; polymorphic microsatellite loci; PML;
KW disease predisposition; microsatellite marker; prion disease;
KW cystic fibrosis; malignant hyperthermia syndrome; metabolic disease;
KW milk protein; hormone; transfection factor; pT7-blue-vector; cow;
KW microsatellite; PCR; primer; ss.
XX
OS Bos taurus.
XX
PN DE10236711-A1.
XX
PD 26-FEB-2004.
XX
XX 09-AUG-2002; 2002DB-01036711.
XX
XX 09-AUG-2002; 2002DB-01036711.
PR
PR (UYHO-) UNIV HOHENHEIM.
PA
PA Geldermann H, Preuss S, Han Y;
PI WPI; 2004-215730/21.
XX
DR
PS Example 3; Page 27; 64pp; German.
XX
CC The invention describes a method of typing (M1) a gene (I) that has one
CC or more polymorphic microsatellite loci (PML). The method comprises: PCR
CC amplification of at least one DNA region of (I) that includes PML, using
CC as template a DNA sample containing at least one segment of (I); and
CC determining the length of the resulting amplicon(s). Also described are:
CC a method of determining (M2) microsatellite markers (MM) for
CC predisposition to a disease, associated with a gene that includes one or
CC more PML; and prediagnosis (M3) of diseases associated with gene that
CC include PML. The method is used to identify microsatellite markers, in a
CC disease-related gene, that are associated with a predisposition to
CC diseases and for prediagnosis of such diseases, especially prion diseases
CC but also cystic fibrosis, malignant hyperthermia syndrome in pigs and
CC metabolic diseases; also to type genes that encode milk proteins,
CC hormones or transcription factors. The method is simpler, quicker and
CC particularly less expensive than known methods based on sequencing. This
CC sequence represents a primer used to genotype a region of the cow prion
CC protein (Prp) comprising a polymorphic microsatellite locus.

XX
SQ Sequence 26 BP; 13 A; 13 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 0.6%; Score 24.4; DB 1; Length 26;
Best Local Similarity 96.3%; Pred. No. 1.8e+02;
Matches 25; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2318 TGCTGTGCTGTGTGCTGTGTGTG 2343
| | | | | | | | | | | | | |
Db 26 TGCTGTGCTGTGTGTGTGTGTG 1

RESULT 204
AAQ33734
ID AAQ33734 standard; DNA; 34 BP.
XX
AC AAQ33734;
XX
DT 25-MAR-2003 (revised)
DT 02-FEB-1993 (first entry)
XX Microsatellite sequence from clone TGLA15.
XX


```

RESULT 209
ABQ81956/c
ID ABQ81956 standard; DNA; 24 BP.
XX
XX
AC ABQ81956;
XX
DT 19-NOV-2002 (first entry)
XX
DE Kaposi's Sarcoma TAG PCR primer SEQ ID NO:106.
XX
KW Human; Kaposi's sarcoma; tumour; angiogenesis; PCR primer; ss.
XX
OS Homo sapiens.
XX
PN BP1225233-A2.
XX
PD 24-JUL-2002.
XX
PF 23-JAN-2002; 2002EP-00075264.
XX
PR 23-JAN-2001; 2001EP-00200228.
XX
PR 28-SEP-2001; 2001EP-00203703.
XX
PR 28-SEP-2001; 2001US-0325722P.
XX
PA (AMST-) AMSTERDAM SUPPORT DIAGNOSTICS BV.
XX
XX Van Der Kuyl AC, Cornelissen M;
XX
XX WPI; 2002-668396/72.
XX
PT Determining presence of a tumor cell or angiogenesis, and the
PT effectiveness of treatment, by detecting the presence of marker genes is
PT useful to detect and monitor treatment of Kaposi's Sarcoma.
XX
XX Example 10; Page 23; 38pp; English.
XX
XX The present invention describes a method for determining if an individual
XX has a tumour cell or site of angiogenesis, or if a treatment is effective
XX in changing angiogenesis or changing a status of a set of target cells,
XX comprising determining if a sample of the subject has an expression
XX product of at least one marker gene. Also described is a compound capable
XX of altering the expression or activity of Keratin 14, TIE 1, Sialoadhesin
XX or Siglec in a cell. Peripheral blood mononuclear cell (PBMC)-expressed
XX Keratin 14, TIE 1, Sialoadhesin or Siglec, and kits containing them from
XX the present invention can be used in a diagnostic method, particularly as
XX an indicator of angiogenesis or to determine presence of a tumour cell.
XX The method of the invention is suitable to determine within a few days if
XX a certain treatment against Kaposi's Sarcoma is successful. ABQ81851 to
XX CC ABQ82006 represent nucleotide sequence used in the exemplification of the
XX present invention
XX
XX Sequence 24 BP; 5 A; 4 C; 7 G; 8 T; 0 U; 0 Other;
XX
Query Match 0.6%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1933 ACACAGCAGCTGTACATGATCATG 1956
DB 24 ACACAGCAGCTGTACATGATCATG 1

RESULT 210
ADCL3441/c
ID ADCL3441 standard; DNA; 24 BP.
XX
AC ADCL3441;
XX
DT 18-DEC-2003 (first entry)
XX
DE Kaposi's sarcoma tag PCR primer, SEQ ID No 108.
XX
KW marker gene; tumour; Kaposi's Sarcoma; peripheral blood mononuclear cell;

KW PBMC; expressed keratin 14; TIE 1; Sialoadhesin; Siglec 1; angiogenesis;
KW drug target; tag; SAGE library; KS3; KS4; PCR; primer; ss.
XX
XX Unidentified.
XX
PN BP1298221-A1.
XX
PD 02-APR-2003.
XX
PF 28-SEP-2001; 2001EP-00203703.
XX
PR 28-SEP-2001; 2001EP-00203703.
XX
PA (PRIM-) PRIMAGEN HOLDING BV.
XX
XX Van Der Kuyl AC, Cornelissen M;
XX
XX WPI; 2003-589342/56.
XX
XX Determining whether a treatment is effective in changing a status of a
XX certain set of target cells in an individual comprises determining
XX whether the sample comprises an expression product of at least one marker
XX gene.
XX
XX Disclosure; SEQ ID NO 108; 94pp; English.
XX
XX The invention relates to a novel method for determining whether a
XX treatment is effective in changing a status of a certain set of target
XX cells in an individual. The method comprises obtaining a sample from an
XX individual after initiation of the treatment; and determining whether the
XX sample comprises an expression product of at least one marker gene. The
XX marker gene and a proteinaceous molecule (which can bind to the protein
XX derived from the marker gene of the invention) are useful for determining
XX whether a treatment is effective in counteracting a tumour in an
XX individual, especially Kaposi's Sarcoma. Peripheral blood mononuclear
XX cell (PBMC) expressed keratin 14, TIE 1, Sialoadhesin, or Siglec 1
XX sequences or a fully defined sequence given in the specification, or
XX their analogues are useful as indicators for angiogenesis and for
XX detecting the presence of a tumour cell in an individual. The expression
XX product of a gene comprising a marker gene of the invention is useful as
XX a drug target. The compound is useful for preparing a medicament. This
XX polynucleotide sequence represents a PCR primer of a Kaposi's Sarcoma tag
XX sequence of the invention.
XX
XX Sequence 24 BP; 5 A; 4 C; 7 G; 8 T; 0 U; 0 Other;
XX
Query Match 0.6%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1933 ACACAGCAGCTGTACATGATCATG 1956
DB 24 ACACAGCAGCTGTACATGATCATG 1

RESULT 211
AAQ34077
ID AAQ34077 standard; DNA; 27 BP.
XX
AC AAQ34077;
XX
XX 25-MAR-2003 (revised)
DT 02-FEB-1993 (first entry)
XX
DE Microsatellite sequence from clone TGLA47.
XX
XX PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW genetic mapping; traits; amplification; ss.
XX
XX Bos taurus.
XX
XX WO9213102-A1.
XX

```


Thu Oct 28 12:48:21 2004

PR 05-MAY-1999; 99US-0132705P.
 XX (CURI-) INST CURIE.
 PA (CNRS) CNRS CENT NAT RECH SCI.
 XX Cappellen D, Chopin D, Radvanyi F, Ricol D, Thierry J;
 PI WPI; 2001-016103/02.
 XX Diagnosing carcinoma e.g. bladder or cervix carcinomas in a biological
 PT sample such as tissue, bone marrow or body fluid, preferably from animal
 PT or human, by identifying fibroblast growth factor receptor 3 mutations.
 XX Example 4; Page 13; 41pp; English.
 XX The identification of fibroblast growth factor receptor 3 (FGFR3)
 CC mutations in a biological sample such as tissue, bone marrow or body
 CC fluid e.g. urine, from a warm-blooded animal, preferably human is useful
 CC for diagnosing carcinomas such as human bladder and cervix carcinomas, or
 CC cancers associated with lung, breast, colon and skin. The pharmaceutical
 CC preparations comprising agents which inhibit the synthesis and expression
 CC of FGFR3 and so have an anti-proliferation effect on carcinomas can be
 CC used to treat cancer. Two primers (AA54428, AA54585) were used in PCR
 CC reactions on urine samples to detect the K652E mutation in FGFR3
 XX
 SQ Sequence 23 BP; 6 A; 4 C; 9 G; 4 T; 0 U; 0 Other;
 Query Match 0.6%; Score 23; DB 1; Length 23;
 Best Local Similarity 100.0%; Pred. No. 2.3e+02;
 Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1646 TGGTGACCGAGGACACGTCATG 1668
 DB 1 TGGTGACCGAGGACACGTCATG 23
 RESULT 226
 AAD40533
 ID AAD40533 standard; DNA; 23 BP.
 XX AAD40533;
 XX 30-OCT-2002 (first entry)
 DE Probe used for FGFR3 expression in human tissues.
 XX Human; stem cell; fibroblast growth factor receptor 3; FGFR3;
 XX osteoblast cell; bone density; osteoporosis; osteopathic; receptor;
 KW probe; ss.
 XX Homo sapiens.
 OS WO200250246-A2.
 XX 27-JUN-2002.
 XX 18-DEC-2001; 2001WO-US048270.
 XX 18-DEC-2000; 2000US-0255882P.
 PR 24-APR-2001; 2001US-0285691P.
 PR 23-JUL-2001; 2001US-0306879P.
 PR 10-SEP-2001; 2001US-0317974P.
 XX (GENE-) GENE LOGIC INC.
 PA (PROC) PROCTER & GAMBLE CO.
 XX Jaiswal N, Houghton A, Mertz L, Ji D, Cook JS, Axelrod DW;
 PI WPI; 2002-519881/55.
 XX Stimulating a population of stem cells to differentiate into osteoblast
 PT cells useful for treating osteoporosis, by contacting the cells with
 PT agent which increases fibroblast growth factor receptor 3 expression or

PT activity.
 XX Example 3; Page 58; 58pp; English.
 XX The invention relates to a method for stimulating a population of stem
 CC cells to differentiate into osteoblast cells by contacting the population
 CC with an agent which increases fibroblast growth factor receptor 3 (FGFR3)
 CC expression or activity, where increase in FGFR3 protein expression or
 CC activity results in differentiation of the stem cells into osteoblast
 CC cells. The method is useful for stimulating the population of stem cells
 CC to differentiate into osteoblast cells. The method is useful for
 CC increasing bone density. The method is useful for screening the agent
 CC that modulates the differentiation of population into osteoblast cells,
 CC increases bone density, or ameliorates the effects of osteoporosis. The
 CC method is useful for diagnosing a condition characterised by abnormal
 CC stem cell differentiation, bone density or rate of osteoblast formation
 CC and treating a patient with a condition characterised by an abnormal rate
 CC of osteoblast formation, bone density or osteoporosis. The present
 CC sequence is a probe used for human FGFR3 expression in human tissues
 XX
 SQ Sequence 23 BP; 5 A; 4 C; 7 G; 7 T; 0 U; 0 Other;
 Query Match 0.6%; Score 23; DB 1; Length 23;
 Best Local Similarity 100.0%; Pred. No. 2.3e+02;
 Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 3727 AAACCGCAGGTGCGATTTGTT 3749
 DB 1 AAACCGCAGGTGCGATTTGTT 23
 RESULT 227
 ABZ70239/c
 ID ABZ70239 standard; DNA; 24 BP.
 XX ABZ70239;
 AC ABZ70239;
 XX 25-APR-2003 (first entry)
 DE Murine tricarboxylic acid carrier 13.53 PCR primer #1.
 XX Murine; tricarboxylic acid carrier 13.53; tumour; cytostatic; haemopathy;
 KW HIV infection; anti-HIV; immunological disease; inflammation; PCR;
 KW primer; ss.
 XX Mus sp.
 OS CN1361126-A.
 XX 31-JUL-2002.
 XX 26-DEC-2000; 2000CN-00136313.
 XX 26-DEC-2000; 2000CN-00136313.
 XX (BODE-) BODE GENE DEV CO LTD SHANGHAI.
 XX Mao Y, Xie Y;
 PI WPI; 2002-751545/82.
 XX New polypeptide murine tricarboxylic acid carrier 13.53 and
 PT polynucleotides encoding this polypeptide.
 XX Example 2; Page 17 (Disclosure); 33pp; Chinese.
 XX The present invention relates to murine tricarboxylic acid carrier 13.53
 CC (see ABP59163). The protein is useful for treating various diseases, such
 CC as malignant tumours, haemopathy, HIV infection, immunological diseases
 CC and various inflammations. The present sequence is a PCR primer, which
 CC was used in an example from the invention
 XX Sequence 24 BP; 10 A; 12 C; 2 G; 0 T; 0 U; 0 Other;

CC downstream of the microsatellite sequence were used to generate the
 CC required PCR primers for in vitro amplification of the corresp.
 CC microsatellite (using the program OPRIM). The microsatellites may be
 CC used to identify individuals, for parentage testing, and in the genetic
 CC mapping of economic trait loci, or genes involved in the determination of
 CC economically important traits esp. in cattle, to allow selective
 CC breeding. See also AAQ3501-34437. (Updated on 25-MAR-2003 to correct PN
 CC field.)
 XX
 SQ Sequence 24 BP; 0 A; 0 C; 12 G; 12 T; 0 U; 0 Other;

Query Match 0.6%; Score 22.4; DB 1; Length 24;
 Best Local Similarity 95.8%; Pred. No. 2.9e+02;
 Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 2319 GTGTGTGTGTGTGTGTGTGTGTGTGT 2342
 DB 1 GTGTGTGTGTGTGTGTGTGTGTGTGT 24

RESULT 233
 AAQ34024
 ID AAQ34024 standard; DNA; 24 BP.

XX AC AAQ34024;
 XX
 DT 25-MAR-2003 (revised)
 DT 02-FEB-1993 (first entry)
 XX
 DE Microsatellite sequence from clone TGLA423.

XX PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
 KW genetic mapping; traits; amplification; ss.
 XX
 OS Bos taurus.

XX WO9213102-A1.
 XX
 PD 06-AUG-1992.

PF 15-JAN-1992; 92WO-US000340.
 XX
 PR 15-JAN-1991; 91US-00642342.
 XX
 PA (GENM-) GENMARK.

XX Georges M, Massey JM;
 XX WPI; 1992-284684/34.
 DR

XX Polymorphic bovine DNA markers - used in genetic identification, gene
 PT mapping, and selective breeding.

XX Table 7; Page 340; 517pp; English.

XX The sequence is that of a bovine microsatellite sequence obtd. by
 CC screening a library of bovine MboI DNA fragments of between 250 and 500
 CC bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
 CC clones cross-hybridised. Assuming independent distribution of
 CC microsatellites and MboI sites, the frequency of (76)n > 9 microsatellites
 CC in the bovine genome is estimated at >100, 000. The sequence information
 CC for ca. 230 such bovine microsatellites is summarised in the
 CC specification and indexed herein (see below). The sequences upstream and
 CC downstream of the microsatellite sequence were used to generate the
 CC required PCR primers for in vitro amplification of the corresp.
 CC microsatellite (using the program OPTIPRIM). The microsatellites may be
 CC used to identify individuals, for parentage testing, and in the genetic
 CC mapping of economic trait loci, or genes involved in the determination of
 CC economically important traits esp. in cattle, to allow selective
 CC breeding. See also AAQ3501-34437. (Updated on 25-MAR-2003 to correct PN
 CC field.)

XX Sequence 24 BP; 0 A; 0 C; 12 G; 12 T; 0 U; 0 Other;

Query Match 0.6%; Score 22.4; DB 1; Length 24;
 Best Local Similarity 95.8%; Pred. No. 2.9e+02;
 Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 2318 TGTGTGTGTGTGTGTGTGTGTGTGTGT 2341
 DB 1 TGTGTGTGTGTGTGTGTGTGTGTGTGT 24

RESULT 234
 AAQ33707
 ID AAQ33707 standard; DNA; 24 BP.

XX AC AAQ33707;
 XX
 DT 25-MAR-2003 (revised)
 DT 02-FEB-1993 (first entry)
 XX

DE Microsatellite sequence from clone TGLA131.

XX PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
 KW genetic mapping; traits; amplification; ss.
 XX

OS Bos taurus.

XX WO9213102-A1.
 XX
 PD 06-AUG-1992.

PF 15-JAN-1992; 92WO-US000340.
 XX
 PR 15-JAN-1991; 91US-00642342.
 XX

PA (GENM-) GENMARK.

XX Georges M, Massey JM;
 XX WPI; 1992-284684/34.
 DR

XX Polymorphic bovine DNA markers - used in genetic identification, gene
 PT mapping, and selective breeding.

XX Table 7; Page 213; 517pp; English.

XX The sequence is that of a bovine microsatellite sequence obtd. by
 CC screening a library of bovine MboI DNA fragments of between 250 and 500
 CC bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
 CC clones cross-hybridised. Assuming independent distribution of
 CC microsatellites and MboI sites, the frequency of (76)n > 9 microsatellites
 CC in the bovine genome is estimated at >100, 000. The sequence information
 CC for ca. 230 such bovine microsatellites is summarised in the
 CC specification and indexed herein (see below). The sequences upstream and
 CC downstream of the microsatellite sequence were used to generate the
 CC required PCR primers for in vitro amplification of the corresp.
 CC microsatellite (using the program OPTIPRIM). The microsatellites may be
 CC used to identify individuals, for parentage testing, and in the genetic
 CC mapping of economic trait loci, or genes involved in the determination of
 CC economically important traits esp. in cattle, to allow selective
 CC breeding. See also AAQ3501-34437. (Updated on 25-MAR-2003 to correct PN
 CC field.)

XX Sequence 24 BP; 0 A; 0 C; 12 G; 12 T; 0 U; 0 Other;

Query Match 0.6%; Score 22.4; DB 1; Length 24;
 Best Local Similarity 95.8%; Pred. No. 2.9e+02;
 Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 2318 TGTGTGTGTGTGTGTGTGTGTGTGTGT 2341
 DB 1 TGTGTGTGTGTGTGTGTGTGTGTGTGT 24

```
RESULT 235
AAT6096/c
ID AAT66096 standard; DNA; 24 BP.
XX
AC AAT66096;
XX
DT 25-MAR-2003 (revised)
DT 18-JUN-1997 (first entry)
XX
DE Repeat sequence found in the human chromosomal clone JW42.
XX
KW Polymorphism; repeat sequence; genetic marker; primer; amplification;
KW PCR; polymerase chain reaction; paternity; maternity; human; pedigree;
KW linkage analysis; genetic disease; animal; plant; breeding; locus;
KW hybridisation; chromosome; ds.
XX
OS Homo sapiens.
XX
PN US5582979-A.
XX
PD 10-DEC-1996.
XX
PF 04-APR-1994; 94US-0022177.
XX
PR 21-APR-1989; 89US-00341562.
PR 05-SEP-1991; 91US-00754351.
XX
PA (MARS-) MARSHFIELD CLINIC.
XX
PI Weber JL;
XX
XX WPI; 1997-042299/04.
XX
DR Detection of polymorphic genetic markers of the form (dC-dA)n(dG-dT)n -
PT using novel nucleic acid mols. as primers.
XX
PS Example 9; Col 61-62; 186pp; English.
XX
CC The invention relates to the isolation of polymorphic repeat sequences
CC having the sequence (dC-dA)n.(dG-dT)n which can be used as genetic
CC markers. Primers based on these sequences can be used to detect these
CC repeats, especially for use in e.g paternity or maternity testing, human
CC genetic analysis such as linkage analysis of genetic disease, commercial
CC animal or plant breeding or pedigree analysis. The sequences AAT66084-
CC T66107 represent repeat sequences of low informativeness found in
CC specific human genes. This repeat sequence is found in the human
CC chromosomal clone JW42. The sequence is amplified by primers AAT66097-8.
CC (Updated on 25-MAR-2003 to correct PF field.)
XX
SQ Sequence 24 BP; 12 A; 12 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 0.6%; Score 22.4; DB 1; Length 24;
Best Local Similarity 95.8%; Pred. No. 2.9e+02;
Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2318 TGTGTGTGTGTGTGTGTGTGTGTGTG 2341
DB 24 TGTGTGTGTGTGTGTGTGTGTGTGTG 1

RESULT 236
AAH46015
ID AAH46015 standard; DNA; 24 BP.
XX
AC AAH46015;
XX
DT 12-SEP-2001 (first entry)
XX
DE Synthetic oligonucleotide 15.
XX
KW Synthetic oligonucleotide; dinucleotide repeat; cytosstatic; apoptosis;
KW cell cycle arrest; cell proliferation; caspase; cytokine; interleukin;
KW tumour necrosis factor; TNF; cancer; carcinoma; sarcoma; leukemia;
```

```
lymphoma; ss.
XX
OS Synthetic.
XX
PN WO200144465-A2.
XX
PD 21-JUN-2001.
XX
PF 12-DEC-2000; 2000WO-CA001467.
XX
PR 13-DEC-1999; 99US-0170325P.
PR 29-AUG-2000; 2000US-0228925P.
XX
PA (BION-) BIONICHE LIFE SCI INC.
XX
PI Phillips NC, Filion MC;
XX
XX WPI; 2001-398150/42.
XX
DR Composition comprising synthetic oligonucleotides which comprise multiple
XX repeats of dinucleotides such as GT, TG useful for treating cancer by
PT inducing cell cycle arrest, inhibiting proliferation, activating
PT caspases.
XX
PS Example 4; Page 17; 77pp; English.
XX
CC The present sequence is that of a synthetic oligonucleotide useful to the
CC invention. The invention relates to a composition, comprising a 2 to 20
CC base 3'-OH, 5'-OH synthetic oligonucleotide which comprises multiple
CC repeats of dinucleotides such as GT, TG, etc. according to specific
CC formula and having cytostatic activity. The oligonucleotide compositions
CC are useful for inducing cell cycle arrest, inhibition of proliferation,
CC activation of caspases and induction of apoptosis or production of
CC cytokines such as interleukin (IL)-1-beta, IL-6, IL-10, IL-12 and tumour
CC necrosis factor (TNF)-alpha by immune system cells, in an animal having
CC cancer such as primary carcinoma, secondary carcinoma, breast, prostate,
CC and secondary sarcoma such as, leukemia, lymphoma, carcinoma, primary sarcoma
CC colorectal, ovarian or bone cancer. The compositions induce apoptosis
CC independent of Fas, p53/p21, p21/waf-1/CIP, p15(Ink4B), p16(Ink4), drug
CC resistance, caspase 3, transforming growth factor (TGF)-beta 1 receptor
CC and hormone dependence
XX
SQ Sequence 24 BP; 0 A; 0 C; 12 G; 12 T; 0 U; 0 Other;

Query Match 0.6%; Score 22.4; DB 1; Length 24;
Best Local Similarity 95.8%; Pred. No. 2.9e+02;
Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2318 TGTGTGTGTGTGTGTGTGTGTGTGTG 2341
DB 1 TGTGTGTGTGTGTGTGTGTGTGTGTG 24

RESULT 237
AAH46016
ID AAH46016 standard; DNA; 24 BP.
XX
AC AAH46016;
XX
DT 12-SEP-2001 (first entry)
XX
DE Synthetic oligonucleotide 16.
XX
KW Synthetic oligonucleotide; dinucleotide repeat; cytostatic; apoptosis;
KW cell cycle arrest; cell proliferation; caspase; cytokine; interleukin;
KW tumour necrosis factor; TNF; cancer; carcinoma; sarcoma; leukemia;
KW lymphoma; ss.
XX
OS Synthetic.
XX
PN WO200144465-A2.
XX
PD 21-JUN-2001.
```


PS Example 1; Page 19; 52pp; English.

XX The present invention relates to Simple Sequence Repeats (SSRs) from

CC clover species. SSRs, also called microsatellites, are based on a 1-7

CC nucleotide core element which is tandemly repeated. The SSR array is

CC embedded in complex flanking DNA. SSRs are ideal markers for genome

CC mapping, trait mapping and marker-assisted selection. The SSRs may be

CC used in methods for selecting genes in clover/ legume breeding. The SSRs

CC are also useful for DNA profiling of clover varieties and for testing the

CC purity of legume seed batches. The present sequence is a SSR motif, which

CC was used in the present invention

XX Sequence 24 BP; 11 A; 11 C; 2 G; 0 T; 0 U; 0 Other;

SQ Query Match 0.6%; Score 22.4; DB 1; Length 24;

Best Local Similarity 95.8%; Pred. No. 2.9e+02;

Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2321 GTGTGTGTGTGCGGTGTGTGT 2344

DB 24 GTGTGTGTGTGCGGTGTGTGTGT 1

RESULT 240

AB578584

ID ABS78584 standard; DNA; 24 BP.

XX AC ABS78584;

XX 13-DEC-2002 (first entry)

XX Angiogenesis inhibitory oligonucleotide #1068.

XX Angiogenesis inhibitor; ss; angiogenesis; solid tumour growth;

KW tumour metastasis; precancerous lesion; rheumatoid arthritis; psoriasis;

KW diabetic retinopathy; retinopathy of prematurity; macular degeneration;

KW corneal graft rejection; neovascular glaucoma; retrolental fibroplasia;

KW rubeosis; Osler-Webber Syndrome; myocardial angiogenesis;

KW plaque neovascularisation; telangiectasia; haemophilic joint;

KW angioblastoma; wound granulation; intestinal adhesion; atherosclerosis;

KW scleroderma; hypertrophic scar.

XX Synthetic.

OS WO200253141-A2.

XX PN 11-JUL-2002.

XX 14-DEC-2001; 2001WO-US048458.

XX 14-DEC-2000; 2000US-0255534P.

XX (COLE-) COLEY PHARM GROUP INC.

XX Bratzler RL;

XX WPI; 2002-566690/60.

XX Inhibiting angiogenesis in a subject, involves administering at least one

XX antiangiogenic nucleic acid molecule to the subject.

XX Claim 2; Page 38; 276pp; English.

XX The invention relates to inhibiting angiogenesis in a subject, comprising

CC administering at least one antiangiogenic nucleic acid molecule. Also

CC included is a kit comprising a first container housing the antiangiogenic

CC nucleic acids, and instructions for administering them to a subject

CC having a condition characterised by unwanted angiogenesis. The method is

CC useful for inhibiting angiogenesis associated with solid tumour growth,

CC tumour metastasis, precancerous lesion, rheumatoid arthritis, psoriasis,

CC corneal graft rejection, retinopathy of prematurity, macular degeneration,

CC rubeosis, Osler-Webber Syndrome, myocardial angiogenesis, plaque

CC neovascularisation, telangiectasia, haemophilic joints, angioblastoma, and

CC wound granulation, intestinal adhesions, atherosclerosis, scleroderma and

CC hypertrophic scars. The present sequence is an antiangiogenic nucleic

CC acid of the invention

XX Sequence 24 BP; 0 A; 0 C; 12 G; 12 T; 0 U; 0 Other;

SQ Query Match 0.6%; Score 22.4; DB 1; Length 24;

Best Local Similarity 95.8%; Pred. No. 2.9e+02;

Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2318 TGTGTGTGTGTGTGTGTGTGTGT 2341

DB 1 TGTGTGTGTGTGTGTGTGTGTGTGT 24

RESULT 241

AB257678

ID AB257678 standard; DNA; 24 BP.

XX AC AB257678;

XX 10-APR-2003 (first entry)

XX Human zinc finger protein 9.46 RT-PCR primer, SEQ ID NO:3.

XX Human; zinc finger protein 9.46; recombinant production; gene therapy;

KW malignant tumour; cancer; blood disease; human immunodeficiency virus;

KW HIV infection; immune disorder; inflammatory condition; cytostatic;

KW antiinflammatory; immunomodulator; reverse transcription-PCR; RT-PCR;

KW primer; ss.

XX Homo sapiens.

XX CN1361165-A.

XX 31-JUL-2002.

XX 26-DEC-2000; 2000CN-00136331.

XX 26-DEC-2000; 2000CN-00136331.

XX (BODE-) BODE GENE DEV CO LTD SHANGHAI.

XX Mao Y, Xie Y;

XX WPI; 2003-000239/01.

XX New polypeptide human zinc finger protein 9.46 and polynucleotides

XX encoding this polypeptide.

XX Example 2; Page 16 (Disclosure); 31pp; Chinese.

XX The invention relates to human zinc finger protein 9.46 (ABP58904) and

CC nucleic acids encoding it (AB257677). The protein has a molecular weight

CC of 9.46 kD. The invention also relates to a method for the recombinant

CC production of the protein, an antagonist of the protein, and the use of

CC the protein, gene and antagonist in therapeutic applications. Zinc finger

CC protein 9.46 can be used in the treatment of a variety of diseases such

CC as malignant tumours, blood diseases, HIV (human immunodeficiency virus)

CC infection, immune disorders and inflammatory conditions. Sequences

CC AB257678-AB257679 represent reverse transcription-PCR (RT-PCR) primers

CC used in an exemplification of the invention to isolate human zinc finger

CC protein 9.46 cDNA

XX Sequence 24 BP; 0 A; 0 C; 13 G; 11 T; 0 U; 0 Other;

SQ Query Match 0.6%; Score 22.4; DB 1; Length 24;

Best Local Similarity 95.8%; Pred. No. 2.9e+02;

Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2327 GTGTGTGTGTGTGTGTGTGTGTGTGT 2350

RESULT 250
AAZ933407

ID AAZ93407 standard; DNA; 31 BP.

XX AC AAZ93407;

XX AC

XX DT

XX DE

XX DE Degenerate conserved sequence of PTK domain.

XX KW Multiple linkage kinase; MLK; PYK; modulation; antiinflammatory;
antitumor; Alzheimer's disease; Huntington's disease; primer;
Parkinson's disease; amyotrophic lateral sclerosis; ischaemia; ss.
XX OS Synthetic.

XX PN WO200013015-A1.

XX PD

XX PF 09-MAR-2000.

XX PF 18-AUG-1999; 99WO-US018864.

XX PR 26-AUG-1998; 98US-0097980P.

XX PA (CEPH-) CEPHALON INC.

XX PI Maroney A, Walton KM, Dionne CA, Neff N, Knight E, Glicksman MA;
WPI; 2000-282953/24.

XX PT Identifying compounds that modulate multiple lineage kinase proteins,
useful e.g. for treating neurodegeneration or cancer, from their effect
on survival or death of kinase-expressing cells.

XX PS Example 19; Page 50; 158pp; English.

CC CC Compounds that modulate the activity of a multiple lineage kinase protein
(MLK) and promote either cell survival or cell death can be identified by
treating a cell that contains MLK with a test compound and determining if
it decreases or increases the activity of MLK and promotes cell survival
or death. Compounds identified as having MLK modulating activity have
applications as anti-neurodegenerative agents, antiinflammatory agents
and anticancer agents and are potentially useful for treatment of
neurodegenerative diseases (e.g. Alzheimer's, Huntington's and
Parkinson's diseases, amyotrophic lateral sclerosis, ischaemia etc.) and
malignant cell growth. DLK was cloned for its use in pFLAG-DLK by using
degenerate primers derived from the highly conserved VIB and IX
subdomains of PKR polypeptides. Two primers (AAZ93406, AAZ93407) were
used in the amplification reaction

XX SQ Sequence 31 BP; 7 A; 6 C; 6 G; 5 T; 0 U; 7 Other;

Query Match 0.6%; Score 22.2; DB 1; Length 31;
Best Local Similarity 70.4%; Pred No. 4.1e+02;
Matches 19; Conservative 7; Mismatches 1; Indels 0; Gaps 0;

OY 1740 GCTCCCCGCGAAGTGGATGGCGCTGA 1766
|||||:|||||:|||||:
||| GCTTCCTCCTTAAGTGAGVSGVCVCYGA 31

DB

RESULT 251
AAA27232

ID AAA27232 standard; DNA; 22 BP.

XX AC AAA27232;

XX XX

XX DT 20-SEP-2000 (first entry)

XX DE Forward PCR primer for FGFR3.

XX XX

KW Parkinson's disease; neurodegenerative disorder; PCR primer; FGFR3;
KW fibroblast growth factor R3; ss.
XX Rattus sp.
XX
XX
XX WO200029550-A2.
XX
XX
XX 25-MAY-2000.
XX
XX 18-NOV-1999; 99WO-US027613.
XX
XX 18-NOV-1998; 98US-00195569.
PR 22-OCT-1999; 99US-00425462.
XX
XX (CALY) CALIFORNIA INST OF TECHNOLOGY.
XX
XX Ceste M, Doyle J, Wold BJ, McKay R, Studer L;
XX
XX WPI; 2000-387772/33.
XX
XX Low oxygen culturing of central nervous system progenitor cells useful in
PT treatment of neurodegenerative disorders.
XX
XX Example 1; Page 36; 80pp; English.
XX
XX A method for increasing the differentiation of undifferentiated central
CC nervous system (CNS) cells in culture. This novel method involves
CC culturing the cells in low ambient oxygen conditions. Differentiated CNS
CC cells can be used to treat neurodegenerative diseases such as Parkinson's
CC disease. In order to determine the differentiated phenotype messenger RNA
CC levels can be measured using reverse transcription PCR. This involves
CC using PCR primers specific to certain genes. The present sequence is the
CC forward PCR primer used to monitor the message level of FGFR3
XX
XX Sequence 22 BP; 7 A; 5 C; 7 G; 3 T; 0 U; 0 Other;
SQ

Query Match 0.6%; Score 22; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 2.9e+02;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 162 ATCTCGGGAGATGACGAGAC 183
DB 1 ATCTCGGGAGATGACGAGAC 22

RESULT 252
AA27233/C
ID AAA27233 standard; DNA; 22 BP.
XX
XX AAA27233;
AC
XX
XX 20-SEP-2000 (first entry)
DT
XX Reverse PCR primer for FGFR3.
DE
XX
XX Parkinson's disease; neurodegenerative disorder; PCR primer; FGFR3;
KW fibroblast growth factor R3; ss.
XX
XX Rattus sp.
XX
XX WO200029550-A2.
PN
XX
XX 25-MAY-2000.
PD
XX
XX 18-NOV-1999; 99WO-US027613.
PF
XX
XX 18-NOV-1998; 98US-00195569.
PR 22-OCT-1999; 99US-00425462.
XX
XX (CALY) CALIFORNIA INST OF TECHNOLOGY.
PA
XX Ceste M, Doyle J, Wold BJ, McKay R, Studer L;
PI
XX

DR WPI; 2000-387772/33.
XX
XX Low oxygen culturing of central nervous system progenitor cells useful in
PT treatment of neurodegenerative disorders.
XX
XX Example 1; Page 36; 80pp; English.
XX
XX A method for increasing the differentiation of undifferentiated central
CC nervous system (CNS) cells in culture. This novel method involves
CC culturing the cells in low ambient oxygen conditions. Differentiated CNS
CC cells can be used to treat neurodegenerative diseases such as Parkinson's
CC disease. In order to determine the differentiated phenotype messenger RNA
CC levels can be measured using reverse transcription PCR. This involves
CC using PCR primers specific to certain genes. The present sequence is the
CC reverse PCR primer used to monitor the message level of FGFR3
XX
XX Sequence 22 BP; 4 A; 6 C; 5 G; 7 T; 0 U; 0 Other;
SQ

Query Match 0.6%; Score 22; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 2.9e+02;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 466 GAGACACAGTTGGCAGCATCC 487
DB 22 GAGACACAGTTGGCAGCATCC 1

RESULT 253
AAA30353
ID AAA30353 standard; DNA; 22 BP.
XX
XX AAA30353;
AC
XX
XX 14-SEP-2000 (first entry)
DT
XX
XX FGFR3 mRNA PCR primer #1.
DE
XX
XX Rat; cell differentiation; neurodegenerative disorder; stroke;
KW brain injury; spinal cord injury; Alzheimer's disease; epilepsy;
KW Huntington's disease; Parkinson's disease; neurological disorder;
KW cell transplantation; FGFR3; fibroblast growth factor receptor 3;
KW PCR primer; ss.
XX
XX Rattus sp.
OS
XX
XX WO200029549-A2.
PN
XX
XX 25-MAY-2000.
PD
XX
XX 18-NOV-1999; 99WO-US027532.
PF
XX
XX 18-NOV-1998; 98US-00195569.
PR 22-OCT-1999; 99US-00425462.
XX
XX (CALY) CALIFORNIA INST OF TECHNOLOGY.
PA
XX
XX Ceste M, Doyle J, Wold BJ, Morrison SJ, Anderson D;
PI
XX
XX WPI; 2000-387771/33.
DR
XX
XX Culturing of neural crest stem cells useful for treatment of
PT neurodegenerative disorders comprises culturing in low ambient oxygen
PT conditions.
XX
XX Example 1; Page 45; 107pp; English.
XX
XX The present sequence is a PCR primer for the fibroblast growth factor
CC receptor gene (FGFR3). It was used in reverse transcription PCR to
CC determine expression patterns of the FGFR3 gene in cultured cells. These
CC cells had been grown in low oxygen conditions, and had differentiated to
CC form various types of neuronal cell. The different expression patterns
CC can be used to determine which set of conditions promotes the
CC differentiation of each type of neurone. The different cell types can be

CC used for tissue transplantation, to treat disorders such as stroke, brain
 CC and spinal cord injury, Alzheimer's disease, Huntington's disease, other
 CC neurodegenerative disorders, epilepsy, Parkinson's disease, neurological
 CC disorders and psychiatric disorders

XX Sequence 22 BP; 7 A; 5 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 0.6%; Score 22; DB 1; Length 22;
 Best Local Similarity 100.0%; Pred. No. 2.9e+02;
 Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 162 ATCTCGGAGATGACGAGAC 183
 DB 1 ATCTCGGAGATGACGAGAC 22

RESULT 254
 AAA30354/C
 ID AAA30354 standard; DNA; 22 BP.

XX AAA30354;
 AC
 XX
 DT 14-SEP-2000 (first entry)
 DE FGFR3 mRNA PCR primer #2.
 XX Rat; cell differentiation; neurodegenerative disorder; stroke;
 KW brain injury; spinal cord injury; Alzheimer's disease; epilepsy;
 KW Huntington's disease; Parkinson's disease; neurological disorder;
 KW cell transplantation; FGFR3; fibroblast growth factor receptor 3;
 KW PCR primer; ss.

XX Rattus sp.
 OS
 XX WO200029549-A2.
 PN
 XX 25-MAY-2000.
 PD
 XX 18-NOV-1999; 99WO-US027532.
 PF
 XX 18-NOV-1998; 98US-00195569.
 PR
 XX 22-OCT-1999; 99US-00425462.
 XX (CALY) CALIFORNIA INST OF TECHNOLOGY.
 PA
 XX Ceste M, Doyle J, Wold BJ, Morrison SJ, Anderson D;
 PI
 XX WPI; 2000-387771/33.

XX Culturing of neural crest stem cells useful for treatment of
 XX neurodegenerative disorders comprises culturing in low ambient oxygen
 XX conditions.
 XX Example 1; Page 45; 107pp; English.

XX The present sequence is a PCR primer for the fibroblast growth factor
 XX receptor gene (FGFR3). It was used in reverse transcription PCR to
 XX determine expression patterns of the FGFR3 gene in cultured cells. These
 XX cells had been grown in low oxygen conditions, and had differentiated to
 XX form various types of neuronal cell. The different expression patterns
 XX can be used to determine which set of conditions promotes the
 XX differentiation of each type of neurone. The different cell types can be
 XX used for tissue transplantation, to treat disorders such as stroke, brain
 XX and spinal cord injury, Alzheimer's disease, Huntington's disease, other
 XX neurodegenerative disorders, epilepsy, Parkinson's disease, neurological
 XX disorders and psychiatric disorders

XX Sequence 22 BP; 4 A; 6 C; 5 G; 7 T; 0 U; 0 Other;

Query Match 0.6%; Score 22; DB 1; Length 22;
 Best Local Similarity 100.0%; Pred. No. 2.9e+02;
 Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 466 GAGAACCAAGTTTGGCAGCATCC 487
 DB 22 GAGAACCAAGTTTGGCAGCATCC 1

RESULT 255
 AAD21621/C
 ID AAD21621 standard; DNA; 22 BP.

XX AAD21621;
 AC
 XX
 DT 19-MAR-2002 (first entry)
 DE Sheep FGFR3 gene amplifying PCR primer #2.

XX Sheep; spider lamb syndrome; SLS; fibroblast growth factor receptor 3;
 KW FGFR; hereditary chondrodysplasia; semi-lethal congenital disorder;
 KW severe skeletal abnormality; genetic marker; PCR primer; chromosome 6;
 KW ss.

XX Ovis sp.

XX FH Key Location/Qualifiers
 FT misc_feature 8
 FT /*tag= a
 FT /note= "Represented in the specification as M in the
 FT sequence shown in column 24 of the specification"

XX US6306591-B1.

XX 23-OCT-2001.

XX 18-JUN-1998; 98US-00099749.

XX 18-JUN-1997; 97US-0050127P.

XX (UTAH) UNIV UTAH STATE.

XX Cockett NE, Beever JE;

XX WPI; 2001-662278/76.

XX Identifying a genetic marker for spider lamb syndrome, used to diagnose
 XX if sheep carry a gene for the syndrome, involves analyzing sheep DNA
 XX samples for mutations in fibroblast growth factor receptor 3.

XX Example 5; Col 29; 24pp; English.

XX The present invention relates to a method for identifying a genetic
 XX marker for spider lamb syndrome (SLS). The method comprising: obtaining a
 XX sheep DNA sample, and analysing the sample DNA with a probe to determine
 XX the presence or absence of a polymorphism in fibroblast growth factor
 XX receptor 3 (FGFR). The invention is used for diagnosing if sheep carry
 XX the gene for SLS, used to eliminate carriers of the syndrome from a
 XX flock. SLS or hereditary chondrodysplasia is a semi-lethal congenital
 XX disorder in sheep causing severe skeletal abnormalities. The present
 XX sequence is a PCR primer used to amplify sheep FGFR3 gene. The FGFR3 gene
 XX is located on chromosome 6

XX Sequence 22 BP; 3 A; 5 C; 8 G; 6 T; 0 U; 0 Other;
 Query Match 0.6%; Score 22; DB 1; Length 22;
 Best Local Similarity 100.0%; Pred. No. 2.9e+02;
 Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1985 AGAGGCCACCTTCAGCAGCT 2006
 DB 22 AGAGGCCACCTTCAGCAGCT 1

RESULT 256
 AA167714
 ID AA167714 standard; DNA; 22 BP.

XX	AAI67714;	Best Local Similarity 100.0%; Pred. No. 2.9e-02;			
XX		Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;			
DT	27-FEB-2002 (first entry)				
XX	Receptor FGFR3 cDNA amplifying forward primer.				
XX	Cell culturing; embryonic stem; ES; central nervous system; FGFR3;				
KW	dopaminergic; cholinergic; serotonergic; antiparkinsonian; neurotropic;				
KW	neuroprotective; anticonvulsant; tranquilizer; vulnerary; neuroleptic;				
XX	cerebroprotective; cell therapy; gene therapy; CNS; PCR primer; ss.				
OS	Homo sapiens.				
XX	WO200183715-A2.				
XX	08-NOV-2001.				
XX	01-MAY-2001; 2001WO-US014051.				
XX	01-MAY-2000; 2000US-0201005P.				
PA	(USGO) US GOVERNMENT.				
PA	(LEES/) LEE S.				
PA	(LUME/) LUMELSKY N.				
PA	(STUD/) STUDER L.				
XX	(MCKA/) MCKAY R D G.				
PI	Lee S, Lumelsky N, Studer L, McKay RDG;				
XX	WPI; 2002-049345/06.				
XX	Culturing cells such as neuronal cells for use in treating neurological				
PT	disorders, comprises generating embryoid bodies from undifferentiated				
PT	embryonic stem cells, selecting precursor cells, expanding and				
PT	differentiating them.				
XX	Example 10; Page 41; 66pp; English.				
XX	The invention provides a method of culturing cells. The method involves				
CC	expanding a culture of undifferentiated embryonic stem (ES) cells,				
CC	generating embryoid bodies (EB), culturing the bodies to select for				
CC	central nervous system (CNS) precursor cells (PC), culturing PC in an				
CC	expansion medium comprising a neurologic factor, and differentiating and				
CC	culturing the expanded PC to form a culture of differentiated neuronal				
CC	cells. The method is useful for culturing undifferentiated ES cells to				
CC	form differentiated neuronal cells which are useful for treating a				
CC	neurological disorder, especially Parkinson's disease in a patient. A				
CC	gene product such as tyrosine hydroxylase, nerve growth factor (NGF),				
CC	brain derived neurotrophic factor (BDNF), bFGF, glial derived growth				
CC	factor (GDNF) NT-3, and NT-4/5 can be introduced into a brain of a				
CC	subject. The method is useful for culturing dopaminergic, cholinergic and				
CC	serotonergic neuronal cells. The differentiated neuronal cells are useful				
CC	for treating neurological disorders such as Huntington's disease,				
CC	Alzheimer's disease, multiple sclerosis, severe seizure disorders				
CC	including epilepsy, familial dysautonomia as well as injury or trauma to				
CC	the nervous system such as neurotoxic injury or disorders of mood and				
CC	behavior such as addiction and schizophrenia, cerebrovascular disorders				
CC	such as stroke and CNS disorders resulting from aging. Assays are useful				
CC	for developing drugs capable of regulating the survival, proliferation or				
CC	genesis of neuronal cells and to screen for antagonist or agonist of				
CC	dopamine or serotonin. Cell cultures comprising 50%-85% neurons which				
CC	comprise 20-40% dopaminergic neurons and 1-3% astrocytes are useful for				
CC	studying the mechanism of neurotransmitter synthesis and release,				
CC	particularly for serotonin and dopamine, neuronal cell survival, and the				
CC	electrophysiochemical properties of differentiated neuronal cells.				
CC	Sequences AAI67692-721 represent gene-specific PCR primers for CNS and				
CC	dopaminergic specific regulatory genes, used for examining the				
CC	developmental progression of ES cells				
XX	Sequence 22 BP; 7 A; 5 C; 7 G; 3 T; 0 U; 0 Other;				
SQ	Query Match 0.6%; Score 22; DB 1; Length 22;				

QY	162 ATCTCGGAGATGACGAAGAC 183				
DB	1 ATCTCGGAGATGACGAAGAC 22				
RESULT 257					
AAI67715/c					
ID	AAI67715 standard; DNA; 22 BP.				
XX	AAI67715;				
XX	27-FEB-2002 (first entry)				
DE	Receptor FGFR3 cDNA amplifying reverse primer.				
XX	Cell culturing; embryonic stem; ES; central nervous system; FGFR3;				
KW	dopaminergic; cholinergic; serotonergic; antiparkinsonian; neurotropic;				
KW	neuroprotective; anticonvulsant; tranquilizer; vulnerary; neuroleptic;				
KW	cerebroprotective; cell therapy; gene therapy; CNS; PCR primer; ss.				
OS	Homo sapiens.				
XX	WO200183715-A2.				
XX	08-NOV-2001.				
XX	01-MAY-2001; 2001WO-US014051.				
XX	01-MAY-2000; 2000US-0201005P.				
XX	(USGO) US GOVERNMENT.				
PA	(LEES/) LEE S.				
PA	(LUME/) LUMELSKY N.				
PA	(STUD/) STUDER L.				
PA	(MCKA/) MCKAY R D G.				
PI	Lee S, Lumelsky N, Studer L, McKay RDG;				
XX	WPI; 2002-049345/06.				
XX	Culturing cells such as neuronal cells for use in treating neurological				
PT	disorders, comprises generating embryoid bodies from undifferentiated				
PT	embryonic stem cells, selecting precursor cells, expanding and				
PT	differentiating them.				
XX	Example 10; Page 41; 66pp; English.				
XX	The invention provides a method of culturing cells. The method involves				
CC	expanding a culture of undifferentiated embryonic stem (ES) cells,				
CC	generating embryoid bodies (EB), culturing the bodies to select for				
CC	central nervous system (CNS) precursor cells (PC), culturing PC in an				
CC	expansion medium comprising a neurologic factor, and differentiating and				
CC	culturing the expanded PC to form a culture of differentiated neuronal				
CC	cells. The method is useful for culturing undifferentiated ES cells to				
CC	form differentiated neuronal cells which are useful for treating a				
CC	neurological disorder, especially Parkinson's disease in a patient. A				
CC	gene product such as tyrosine hydroxylase, nerve growth factor (NGF),				
CC	brain derived neurotrophic factor (BDNF), bFGF, glial derived growth				
CC	factor (GDNF) NT-3, and NT-4/5 can be introduced into a brain of a				
CC	subject. The method is useful for culturing dopaminergic, cholinergic and				
CC	serotonergic neuronal cells. The differentiated neuronal cells are useful				
CC	for treating neurological disorders such as Huntington's disease,				
CC	Alzheimer's disease, multiple sclerosis, severe seizure disorders				
CC	including epilepsy, familial dysautonomia as well as injury or trauma to				
CC	the nervous system such as neurotoxic injury or disorders of mood and				
CC	behavior such as addiction and schizophrenia, cerebrovascular disorders				
CC	such as stroke and CNS disorders resulting from aging. Assays are useful				
CC	for developing drugs capable of regulating the survival, proliferation or				
CC	genesis of neuronal cells and to screen for antagonist or agonist of				
CC	dopamine or serotonin. Cell cultures comprising 50%-85% neurons which				
CC	comprise 20-40% dopaminergic neurons and 1-3% astrocytes are useful for				
CC	studying the mechanism of neurotransmitter synthesis and release,				
CC	particularly for serotonin and dopamine, neuronal cell survival, and the				
CC	electrophysiochemical properties of differentiated neuronal cells.				
CC	Sequences AAI67692-721 represent gene-specific PCR primers for CNS and				
CC	dopaminergic specific regulatory genes, used for examining the				
CC	developmental progression of ES cells				

CC comprise 20-40% dopaminergic neurons and 1-3% astrocytes are useful for
 CC studying the mechanism of neurotransmitter synthesis and release,
 CC particularly for serotonin and dopamine, neuronal cell survival, and the
 CC electrophysiochemical properties of differentiated neuronal cells.
 CC Sequences AAI67692-721 represent gene-specific PCR primers for CNS and
 CC dopaminergic specific regulatory genes, used for examining the
 CC developmental progression of ES cells
 XX Sequence 22 BP; 4 A; 6 C; 5 G; 7 T; 0 U; 0 Other;
 SQ

Query Match 0.6%; Score 22; DB 1; Length 22;
 Best Local Similarity 100.0%; Pred. No. 2.9e+02; Indels 0; Gaps 0;
 Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 466 GAGACAAAGTTTGGCAGCATCC 487
 |||||
 Db 22 GAGACAAAGTTTGGCAGCATCC 1

RESULT 258
 AAD55414
 ID AAD55414 standard; DNA; 22 BP.
 XX AC AAD55414;
 XX DT 07-AUG-2003 (first entry)
 XX DE Human FGFR-3 DNA specific PCR probe.
 XX Human; antisense; fibroblast growth factor receptor 3; prophylaxis;
 KW developmental disorder; hyperproliferative disorder; antisense therapy;
 KW FGFR-3; ACH; JTK4; CEK2; cancer; PCR; probe; ss.
 XX Homo sapiens.
 XX Key Location/Qualifiers
 FH modified_base 1/*tag= a
 FT /mod_base= OTHER
 FT /note= "FAM labelled"
 FT modified_base 22
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "TAMRA labelled"
 FT
 FT
 XX WO2003023004-A2.
 XX PN
 XX PD 20-MAR-2003.
 XX PF 06-SEP-2002; 2002WO-US028549.
 XX PR 10-SEP-2001; 2001US-00953047.
 XX (ISIS-) ISIS PHARM INC.
 XX PA
 XX PI Monia BP, Wyatt JR;
 XX WPI; 2003-313244/30.
 XX Novel compound targeted to a nucleic acid molecule encoding fibroblast
 PT growth factor receptor 3, useful for inhibiting the expression of the
 PT receptor and for treating an animal having cancer or developmental
 PT disorder.
 XX
 XX Example 13; Page 76; 120pp; English.
 XX The invention relates to antisense compounds targetted to a nucleic acid
 CC molecule encoding fibroblast growth factor (FGF) receptor 3 (also known
 CC as FGFR-3, ACH, JTK4 and CEK2) to inhibit its expression. Antisense
 CC compounds of the invention are useful for treating diseases or conditions
 CC associated with FGFR-3 such as developmental disorders or
 CC hyperproliferative disorders, especially cancer of colorectal, bladder,
 CC bone, lung, cervical, breast or skin. They are useful as research

CC reagents, therapeutics, prophylaxis, kits and diagnostics, and as tools
 CC in differential and/or combinatorial analyses to elucidate expression
 CC patterns of a portion of the genes expressed within cells and tissues.
 CC They are also useful in antisense therapy. The present sequence is human
 CC FGFR-3 DNA specific PCR probe. This probe is used in the exemplification
 CC of the invention
 XX Sequence 22 BP; 4 A; 10 C; 5 G; 3 T; 0 U; 0 Other;
 SQ

Query Match 0.6%; Score 22; DB 1; Length 22;
 Best Local Similarity 100.0%; Pred. No. 2.9e+02; Indels 0; Gaps 0;
 Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1271 CCGCAAGCCTGTCCACCGTAGC 1292
 |||||
 Db 1 CCGCAAGCCTGTCCACCGTAGC 22

RESULT 259
 ACF04260
 ID ACF04260 standard; DNA; 22 BP.
 XX AC ACF04260;
 XX DT 06-NOV-2003 (first entry)
 XX DE Murine embryonic cell line FGFR3R PCR primer #1.
 XX Embryonic stem cell; ES cell; mouse; differentiation; nerve cell;
 KW pancreatic islet cell; cell transplant therapy; antidiabetic;
 KW neuroprotective; nootropic; PCR; primer; ss.
 XX Mus sp.
 XX WO2003062405-A2.
 XX PN
 XX PD 31-JUL-2003.
 XX PF 27-JAN-2003; 2003WO-JP000699.
 XX PR 25-JAN-2002; 2002US-00054789.
 XX (OKUM-) OKUMA CONTACTLENS KENKYUSHO YG.
 PA (INOUE/) INOUE K.
 XX Inoue K, Kim D, Gu Y, Ishii M;
 WPI; 2003-598750/56.
 XX Inducing differentiation of mammalian embryonic stem (ES) cells into
 PT functioning cells, for treating e.g. diabetes, comprises culturing ES
 PT cells in a medium containing leukemia inhibitor factor and basic
 PT fibroblast growth factor.
 XX
 XX Example 5; Page 70; 70pp; English.
 XX The present invention relates to a method of inducing differentiation of
 CC mammalian embryonic stem cells into functioning cells, which comprises
 CC culturing embryonic stem cells in a medium comprising leukemia inhibitor
 CC factor and basic fibroblast growth factor. In particular, the invention
 CC relates to the differentiation of murine embryonic stem cells. The method
 CC is useful for inducing differentiation of mammalian embryonic stem cells
 CC into functioning cells. Other methods are useful for treating a mammalian
 CC patient having disorders in pancreatic function, and in nerve function.
 CC The cells are pancreatic islet like cell clusters and nerve like cells.
 CC Functioning cells induced from embryonic stem cells using the present
 CC method may be used for treating disorders in pancreatic islet function
 CC (e.g. diabetes), neuronal degeneration (e.g. Alzheimer's disease and
 CC Creutzfeldt-Jakob disease) or spinal cord disorders. The functioning
 CC cells are useful not only for cell transplant therapy, but for in vitro
 CC screening of various new drugs which affect or restore islet or nerve
 CC function, and for safety evaluation of new drugs. The present sequence is
 CC a PCR primer used in the exemplification of the invention

```
XX SQ Sequence 22 BP; 7 A; 5 C; 7 G; 3 T; 0 U; 0 Other;
Query Match 0.6%; Score 22; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 2.9e+02;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 162 ATCTCGGAGATGACGAAGAC 183
Db 1 ATCTCGGAGATGACGAAGAC 22

RESULT 260
ADKS1127/c
ID ADKS1127 standard; DNA; 22 BP.
XX AC ADKS1127;
XX DT 17-JUN-2004 (first entry)
XX DE Human NOVX protein-related PCR primer SeqID.
XX KW cytosstatic; NOVX-agonist; NOVX-antagonist; vaccine; gene therapy; cancer;
XX KW chromosome mapping; human; PCR; primer; ss.
XX OS Homo sapiens.
XX PN WO2003083046-A2.
XX PD 09-OCT-2003.
XX PF 01-APR-2003; 2003WO-US010142.
XX PR 02-APR-2002; 2002US-00115479.
XX PR 05-APR-2002; 2002US-0370349P.
XX PR 08-APR-2002; 2002US-0370969P.
XX PR 12-APR-2002; 2002US-0372019P.
XX PR 22-APR-2002; 2002US-0374379P.
XX PR 30-MAY-2002; 2002US-0384543P.
XX PR 03-JUN-2002; 2002US-00160619.
XX PR 15-AUG-2002; 2002US-0403748P.
XX PR 04-NOV-2002; 2002US-00287226.
XX PR 31-MAR-2003; 2003US-00403161.
XX PA (CURA-) CURAGEN CORP.
XX PI Anderson DW, Berto P, Boldog FL, Burgees CE, Caeman SJ, Furtak K;
PI Gorman L, Gould-Rothberg BE, Gunther E, Heyes MP, Li L, Spytek KA;
PI Stone DJ, Zhong M, Malyankar UM, Edinger SR, Patturajan M;
PI Rothenberg ME, Smithson G;
XX WPI; 2003-812539/76.
XX New NOVX polypeptide, useful for preparing a composition for treating or
XX preventing e.g. cancer or for chromosome mapping.
XX Example C; SEQ ID NO 148; 433pp; English.
XX This invention relates to novel isolated polypeptides and the DNA
XX sequences which encode them. The invention may be useful for the
XX development of compounds with a cytostatic activity (as NOVX-agonists or
XX antagonists) or vaccines. In addition, the disclosed sequences may be
XX useful for gene therapy. The polypeptide is useful for preparing a
XX composition for treating or preventing a pathological state in a mammal,
XX for example cancer or for chromosome mapping. The present sequence is
XX that of a PCR primer which was used in the exemplification of the
XX invention.
XX SQ Sequence 22 BP; 6 A; 8 C; 1 G; 7 T; 0 U; 0 Other;
Query Match 0.8%; Score 22; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 2.9e+02;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1343 TGTCTGAGATGAGATGATGAA 1364
Db 22 TGTCTGAGATGAGATGATGAA 1
|||||
RESULT 261
ADN03543
ID ADN03543 standard; DNA; 22 BP.
XX AC ADN03543;
XX DT 01-JUL-2004 (first entry)
XX DE Mouse FGF 3R cDNA amplifying RT-PCR primer #1.
XX KW Embryonic stem cell; ES cell; pancreatic islet-like cell;
XX KW type I diabetic; nerve-like cell; nerve function; cell therapy;
XX KW reverse transcription; RT; PCR; primer; mouse; ss; cell differentiation;
XX KW fibroblast growth factor receptor; FGF 3R.
XX OS Mus sp.
XX PN US2004072344-A1.
XX PD 15-APR-2004.
XX PF 25-JUL-2003; 2003US-00626772.
XX PR 25-JAN-2002; 2002US-00054789.
XX PA (INOUE) INOUE K.
XX PA (KIMD/) KIM D.
XX PA (GUY/) GU Y.
XX PA (ISHI/) ISHII M.
XX PI Inoue K, Kim D, Gu Y, Ishii M;
XX WPI; 2004-328577/30.
XX Inducing mammalian embryonic stem (ES) cell differentiation into
XX functioning cells, for treating e.g. diabetes, by culturing mammalian ES
XX cells in a medium having leukemia inhibitory factor and basic FGF to give
XX embryonic bodies.
XX Example 5; SEQ ID NO 47; 30pp; English.
XX The invention relates to a method for inducing differentiation of
XX mammalian embryonic stem (ES) cells into functioning cells. The method is
XX useful for inducing differentiation of mammalian ES cells into
XX functioning cells. The pancreatic islet-like cell clusters induced from
XX allogenic ES cells are useful for treating a mammalian patient having
XX disorders in pancreatic islet function, such as when the patient is a
XX type I diabetic patient. The nerve-like cells induced from allogenic ES
XX cells can be used for treating a mammalian patient having disorders in
XX nerve function. The method is also useful in cell therapy. The present
XX sequence is a reverse transcription (RT)-PCR primer used to amplify mouse
XX fibroblast growth factor receptor (FGF 3R) cDNA. This sequence is used to
XX illustrate the method of the invention.
XX SQ Sequence 22 BP; 7 A; 5 C; 7 G; 3 T; 0 U; 0 Other;
Query Match 0.6%; Score 22; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 2.9e+02;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 162 ATCTCGGAGATGACGAAGAC 183
Db 1 ATCTCGGAGATGACGAAGAC 22

RESULT 262
AAV44045/c
```


PA (BRIM) BRISTOL-MYERS SQUIBB CO.
XX Feder JN, Lee LM, Chen J, Jackson D, Ramanathan C, Siemers N;
PI Chang H;
XX WPI; 2002-636623/68.
XX New polynucleotide encoding a potassium channel alpha subunit polypeptide
PT or its variants, useful for diagnosing, preventing or treating a
PT pathological condition e.g. diabetes.
XX Disclosure; Page 34; 465pp; English.
XX The present invention relates to a new polynucleotide encoding potassium
CC channel alpha subunit (K-alphaM1) polypeptide. The K-alphaM1
CC polynucleotides, polypeptides and antibodies are useful for diagnosing,
CC preventing, treating or ameliorating a pathological condition or a
CC susceptibility to a pathological condition such as neuronal disorders
CC e.g. Addison's disease, male reproductive disorders e.g. infertility,
CC metabolic disorders e.g. diabetes, cardiac diseases e.g. congestive heart
CC failure, or wounds. The present nucleic acid sequence represents a single
CC nucleotide polymorphism (SNP) oligonucleotide, as described in the
CC invention
XX Sequence 31 BP; 11 A; 4 C; 16 G; 0 T; 0 U; 0 Other;
CC Query Match 0.6%; Score 22; DB 1; Length 31;
CC Best Local Similarity 83.3%; Pred. No. 4.3e+02;
CC Matches 25; Conservative 0; Mismatches 5; Indels 0; Gaps 0;
QY 172 GATGACGACGACGGGAGGACGAGGCTGAG 201
DB 2 GAAGACGACGACGGGAGGAGGAGGAGGACGAG 31
XX
XX RESULT 265
XX ABS64541
XX ID ABS64541 standard; DNA; 31 BP.
XX AC ABS64541;
XX DT 15-NOV-2002 (first entry)
XX DE Human K-alphaM1.v1 SNP polynucleotide #4.
XX KW Potassium channel alpha subunit; K-alphaM1; pathological condition;
XX neuronal disorder; Addison's disease; male reproductive disorder;
XX infertility; metabolic disorder; diabetes; cardiac disease;
XX congestive heart failure; wound; human; single nucleotide polymorphism;
XX SNP; K-alphaM1.v1; ds.
XX OS Homo sapiens.
XX PN WO200264732-A2.
XX PD 22-AUG-2002.
XX PF 01-NOV-2001; 2001WO-US045385.
XX PR 02-NOV-2000; 2000US-0245383P.
XX PR 21-DEC-2000; 2000US-0257780P.
XX PR 20-FEB-2001; 2001US-0269854P.
XX (BRIM) BRISTOL-MYERS SQUIBB CO.
XX Feder JN, Lee LM, Chen J, Jackson D, Ramanathan C, Siemers N;
PI Chang H;
XX WPI; 2002-636623/68.
XX New polynucleotide encoding a potassium channel alpha subunit polypeptide
PT or its variants, useful for diagnosing, preventing or treating a
PT pathological condition e.g. diabetes.
XX Disclosure; Page 34; 465pp; English.
XX The present invention relates to a new polynucleotide encoding potassium
CC channel alpha subunit (K-alphaM1) polypeptide. The K-alphaM1
CC polynucleotides, polypeptides and antibodies are useful for diagnosing,
CC preventing, treating or ameliorating a pathological condition or a
CC susceptibility to a pathological condition such as neuronal disorders
CC e.g. Addison's disease, male reproductive disorders e.g. infertility,
CC metabolic disorders e.g. diabetes, cardiac diseases e.g. congestive heart
CC failure, or wounds. The present nucleic acid sequence represents a single
CC nucleotide polymorphism (SNP) oligonucleotide, as described in the
CC invention
XX Sequence 31 BP; 11 A; 4 C; 16 G; 0 T; 0 U; 0 Other;
CC Query Match 0.6%; Score 22; DB 1; Length 31;
CC Best Local Similarity 83.3%; Pred. No. 4.3e+02;
CC Matches 25; Conservative 0; Mismatches 5; Indels 0; Gaps 0;
QY 172 GATGACGACGACGGGAGGACGAGGCTGAG 201
DB 2 GAAGACGACGACGGGAGGAGGAGGAGGACGAG 31
XX
XX RESULT 265
XX ABS64541
XX ID ABS64541 standard; DNA; 31 BP.
XX AC ABS64541;
XX DT 15-NOV-2002 (first entry)
XX DE Human K-alphaM1.v1 SNP polynucleotide #4.
XX KW Potassium channel alpha subunit; K-alphaM1; pathological condition;
XX neuronal disorder; Addison's disease; male reproductive disorder;
XX infertility; metabolic disorder; diabetes; cardiac disease;
XX congestive heart failure; wound; human; single nucleotide polymorphism;
XX SNP; K-alphaM1.v1; ds.
XX OS Homo sapiens.
XX PN WO200264732-A2.
XX PD 22-AUG-2002.
XX PF 01-NOV-2001; 2001WO-US045385.
XX PR 02-NOV-2000; 2000US-0245383P.
XX PR 21-DEC-2000; 2000US-0257780P.
XX PR 20-FEB-2001; 2001US-0269854P.
XX (BRIM) BRISTOL-MYERS SQUIBB CO.
XX Feder JN, Lee LM, Chen J, Jackson D, Ramanathan C, Siemers N;
PI Chang H;
XX WPI; 2002-636623/68.
XX New polynucleotide encoding a potassium channel alpha subunit polypeptide
PT or its variants, useful for diagnosing, preventing or treating a
PT pathological condition e.g. diabetes.
XX Disclosure; Page 34; 465pp; English.
XX The present invention relates to a new polynucleotide encoding potassium
CC channel alpha subunit (K-alphaM1) polypeptide. The K-alphaM1
CC polynucleotides, polypeptides and antibodies are useful for diagnosing,
CC preventing, treating or ameliorating a pathological condition or a
CC susceptibility to a pathological condition such as neuronal disorders
CC e.g. Addison's disease, male reproductive disorders e.g. infertility,
CC metabolic disorders e.g. diabetes, cardiac diseases e.g. congestive heart
CC failure, or wounds. The present nucleic acid sequence represents a single
CC nucleotide polymorphism (SNP) oligonucleotide, as described in the
CC invention
XX Sequence 31 BP; 11 A; 4 C; 16 G; 0 T; 0 U; 0 Other;
CC Query Match 0.6%; Score 22; DB 1; Length 31;
CC Best Local Similarity 83.3%; Pred. No. 4.3e+02;
CC Matches 25; Conservative 0; Mismatches 5; Indels 0; Gaps 0;
QY 172 GATGACGACGACGGGAGGACGAGGCTGAG 201
DB 2 GAAGACGACGACGGGAGGAGGAGGAGGACGAG 31
XX
XX RESULT 266
XX AAH40159/c
XX ID AAH40159 standard; DNA; 25 BP.
XX AC AAH40159;
XX DT 14-AUG-2001 (first entry)
XX DE SNP specific SNPE primer SEQ ID 2955.
XX KW Single nucleotide polymorphism; SNP; single nucleotide primer extension;
XX SNPE; genotyping; agammaglobulinemia; diabetes insipidus; cancer;
XX Lesch-Nyhan syndrome; muscular dystrophy; familial hypercholesterolemia;
XX polycystic kidney disease; osteogenesis imperfecta; autoimmune disease;
XX acute intermittent porphyria; rheumatoid arthritis; multiple sclerosis;
XX inflammation; forensic investigation; paternity analysis; primer; ss.
XX OS Homo sapiens.
XX PN WO200129262-A2.
XX PD 26-APR-2001.
XX PF 13-OCT-2000; 2000WO-US028436.
XX PR 15-OCT-1999; 99US-0160096P.
XX (ORCH-) ORCHID BIOSCIENCES INC.
XX Picoult-Newburg L, Pohl M;
XX WPI; 2001-290930/30.
XX New genotyping oligonucleotide, useful for detecting the presence,
PT absence or identity of single polynucleotide polymorphism in a nucleic
PT acid sample.
XX Claim 1; Page 65; 83pp; English.
XX Sequences AAH37205 - AAH40944 represent PCR primers, single nucleotide
CC primer extension (SNPE) primers, and the sequences of regions flanking
CC sites of single nucleotide polymorphisms SNPs. The present invention
CC includes kits for determining the presence or absence of a SNP, using the
CC oligonucleotides of the invention. The PCR primers are used to amplify a
CC SNP flanking sequence, the SNPE primer is used as a genotyping primer.
CC The oligonucleotides are useful for genotyping a nucleic acid sample by
CC performing a single-nucleotide primer extension reaction. The
CC oligonucleotides are useful for determining the presence, absence or

identity of a SNP and for genotyping nucleic acid samples, for e.g. to assess by association analysis the genotype of an individual or group of individuals, having a pathological phenotypic trait suspected of being caused by one or more SNPs. Phenotypic traits include diseases e.g. agammaglobulinaemia, diabetes insipidus, Jirsch-Nyhan syndrome, muscular dystrophy, familial hypercholesterolaemia, polycystic kidney disease, osteogenesis imperfecta and acute intermittent porphyria. Phenotypic traits also include symptoms of or susceptibility to multifactorial disease of which a component is or may be genetic such as autoimmune diseases, including, rheumatoid arthritis, multiple sclerosis, inflammation, cancer, nervous system diseases and infection by pathogenic microorganism. The method is also useful in forensic investigations and paternity analysis. The present sequence represents a single nucleotide primer extension (SNPE) primer specific for a human SNP containing DNA sequence

```

XX
SQ Sequence 25 BP; 11 A; 12 C; 2 G; 0 T; 0 U; 0 Other;
      Query Match      0.6%; Score 21.8; DB 1; Length 25;
      Best Local Similarity 92.0%; Pred. No. 3.5e+02;
      Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

2317 CTGTGTGTGTGTGCGTGTG 2341

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
84

RESULT 267
AAQ34000
IN AAQ34000 standard: DNA: 28 BP.

AAQ34000;	
25-MAR-2003	(revised)
02-FEB-1993	(first entry)

XX
nn Microsatellite sequence from clone TGLA40.
nn

XX selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KWI genetic mapping; traits; amplification; ss.

XX
OS
Bos tauru

XX
PN W09213102-A1.

XX
06-AUG-1992.XX
PF 15--TAN-1992: 92WO-US000340.

XX
PP 15-JAN-1991: 91US-00642342.

XX
PA (GENM-) GENMARK.

XX Georges M. Massey JM;
PT

XX WPI: 1992-284684/34.

XX Polymorphic bovine DNA markers - used in genetic identification, gene
PT mapping, and selective breeding.

xx
pg
table 7: page 330: 517pp; English.

XX The sequence is that of a bovine microsatellite sequence obtd. by
CC screening a library of bovine MboI DNA fragments of between 250 and 500
CC bp with an (AC)₁₅ and a (TC)₁₅ oligonucleotide probe. One out of 50
CC clones cross-hybridised. Assuming independent distribution of
CC microsatellites and MboI sites, the frequency of (TC)_n > 9 microsatellites
CC in the bovine genome is estimated at >100, 000. The sequence information
CC for ca. 230 such bovine microsatellites is summarised in the
CC specification and indexed herein (see below). The sequences upstream and
CC downstream of the microsatellite sequence were used to generate the
CC required PCR primers for in vitro amplification of the corresp.
CC microsatellite (using the program OPLPRIM). The microsatellites may be

used to identify individuals, for parentage testing, and in the genetic mapping of economic trait loci, or genes involved the determinism of economically important traits esp. in cattle, to allow selective breeding. See also AQ33501-34437. (Updated on 25-MAR-2003 to correct PN field.)

Sequence 28 RP: 2 A; 5 C; 12 G; 9 T; 0 U; 0 Other;

Query Match 0.6%; Score 21.6; DB 1; Length 28;
Best Local Similarity 85.7%; Pred. No. 4.3e+02;
Matches 24; Conservative 0; Mismatches 4; Indels

2328 TGTGTGCGTGTGTGTGTGTGTGTGCACA 2355

1 TGTGTGTGTGTGTGTGCGCGGCACA 28

RESULT 268

AAQ33663
ID AAQ33663 standard: DNA; 23 BP.

XX
AC
AA033663:XX
DE
25-MAR-2003 (revised)

DI 23-MAR-2003 (first entry)
DT 02-FEB-1993 (first entry)

XX virocentalite sequence from clone TGLA110.

XX PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
SS PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;

8
9
0

XX
DN
WC9213102-A1XX
PD
06-AUG-1992.

XX
PF 15-JAN-1992: 92WO-US000340.

XX
PP
15--JAN-1991: 91US-00642342.

XX
PA (GENM-) GENMARK.

XX Georges M. Massey JM;
PT

XX
DP WPT: 1992-284684/34.

XX Polymorphic bovine DNA markers - used in genetic identification, gene
PT mapping, and selective breeding.

xx
pg
Table 7: Page 195: 517pp: English.

The sequence is that of a bovine microsatellite sequence obtd. by
 screening a library of bovine MboI DNA fragments of between 250 and 500
 bp with an (AC)₁₅ and a (TC)₁₅ oligonucleotide probe. One out of 50
 clones cross-hybridised. Assuming independent distribution of
 microsatellites and MboI sites, the frequency of (T6)_n >9 microsatellites
 in the bovine genome is estimated at >100, 000. The sequence information
 for ca. 230 such bovine microsatellites is summarised in the
 specification and indexed herein (see below). The sequences upstream and
 downstream of the microsatellite sequence were used to generate the
 required PCR primers for in vitro amplification of the corresp.
 microsatellite (using the program OPTIPRIM). The microsatellites may be
 used to identify individuals, for parentage testing, and in the generic
 mapping of economic trait loci, or genes involved the determination of
 economically important traits esp. in cattle, to allow selective
 breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct pN
 field.)

Sequence 23 BP: 0 A; 0 C; 11 G; 12 T; 0 U; 0 Other;

Query Match	0.6%;	Score 21.4;	DB 1;	Length 23;
Best Local Similarity	95.7%;	Pred. No. 3.6e+02		

linkage analysis; genetic disease; animal; plant; breeding; locus; hybridisation; chromosome; ds.

Homo sapiens.

US5582979-A.

10-DEC-1996.

04-APR-1994; 94US-00222177.

21-APR-1989; 89US-00341562.

05-SEP-1991; 91US-00754351.

(MARS-) MARSHFIELD CLINIC.

Weber JL;

WPI; 1997-042299/04.

Detection of polymorphic genetic markers of the form (dc-da)n(dg-dt)n - using novel nucleic acid mols. as primers.

Example 9; Col 61-62; 186pp; English.

The invention relates to the isolation of polymorphic repeat sequences having the sequence (dc-da)n.(dg-dt)n which can be used as genetic markers. Primers based on these sequences can be used to detect these repeats, especially for use in e.g. paternity or maternity testing, human genetic analysis such as linkage analysis of genetic disease, commercial animal or plant breeding or pedigree analysis. The sequences AAT66084-T66107 represent repeat sequences of low informativeness found in specific human genes. This repeat sequence is found in the human chromosomal clone SW13. The sequence is amplified by primers AAT66106-7. (Updated on 25-MAR-2003 to correct PF field.)

Sequence 23 BP; 12 A; 11 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 0.6%; Score 21.4; DB 1; Length 23;
Best Local Similarity 95.7%; Pred. No. 3.6e+02;
Matches 22; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

2318 TGTGTGTGTGTGTGTGTGTGTGTGT 2340

23 TGTGTGTGTGTGTGTGTGTGTGTGT 1

RESULT 272

AAF60472/c

AAF60472 standard; DNA; 23 BP.

AC AAF60472;

27-APR-2001 (first entry)

Oligonucleotide clamp #17.

Oligonucleotide clamp; ds.

Unidentified.

US6180777-B1.

30-JAN-2001.

03-JAN-1997; 97US-00787321.

12-JAN-1996; 96US-0009918P.

(FARB) BAYER CORP.

Horn T;

WPI; 2001-201911/20.

Synthesizing branched nucleic acids useful as diagnostic and molecular probes, involves combining first units having haloalkylamino groups and second units having thiol or phosphorothioate groups.

Example 7; Col 19; 20pp; English.

The present invention relates to a method for synthesising a branched or multiply connected macromolecular structure, comprising oligonucleotide clamps (OC). The macromolecular structure is capable of specifically binding to a target molecule, and can therefore be used as probes. At least one OC comprises a target binding sequence that binds specifically and stably with the target molecule, and at least two OCs comprise signal generation moieties capable of generating a detectable signal in the presence of the target molecule. In addition the OCs are connected to one another by thioalkylamino, or thiophosphorylalkylamino bridges. The present sequence is an OC used in the present invention

Sequence 23 BP; 11 A; 12 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 0.6%; Score 21.4; DB 1; Length 23;

Best Local Similarity 95.7%; Pred. No. 3.6e+02;

Matches 22; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

2319 GTGTGTGTGTGTGTGTGTGTGTGT 2341

23 GTGTGTGTGTGTGTGTGTGTGTGT 1

RESULT 273

ABS97836/c

ID ABS97836 standard; DNA; 24 BP.

AC ABS97836;

23-DEC-2002 (first entry)

Human NADPH quinone oxidoreductase 2 (NQO2) polymorphic sequence #44.
Human; ds; cytochrome P450 A1; CYP450A1; UGT2B4; MDR1;
cytochrome P450 A2; CYP450A2; cytochrome P450 02E; CYP45002E1; LTF;
adrenergic receptor beta1; ADRB1; aryl hydrocarbon; AHR; MRP3; NR112;
aryl hydrocarbon receptor nuclear translocator; ARNT; cathepsin S; CTSS;
cyclooxygenase 2; COX2; diazepam binding inhibitor; DBI; haematological;
epoxide hydrolase 2; EPHX2; 5-lipoxygenase activating protein; FLAP;
glutathione-S-transferase 12; GST12; histamine-N-methyl transferase;
HNMT; kallikrein 2; KLK2; nicotinamide-N-methyl transferase; NNMT;
NADPH quinone oxidoreductase 2; NQO2; sulfotransferase thermolabile; STM;
UDP-glucuronosyl transferase 2B4; UDP-glucuronosyl transferase 2B7;
UGT2B7; UDP-glucuronosyl transferase; UGT2B15; urokinase receptor; uPA;
multidrug resistance 1; lactotransferrin; orphan nuclear receptor;
multidrug resistance associated protein 3; cancer; prostate;
acetylcholine muscarinic receptor; CHMR1; CHMR2; CHMR3; CHMR4; CHMR5;
altered drug metabolism; cardiovascular function; colorectal tumour;
central nervous system; pulmonary; immunological; SNP;
single nucleotide polymorphism.

Homo sapiens.

WO200257410-A2.

25-JUL-2002.

28-NOV-2001; 2001WO-US044838.

28-NOV-2000; 2000US-00724389.

(DNAS-) DNA SCI LAB INC.

Guida M, Hall J;

WPI; 2002-698522/75.


```

Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2324 TGTGTGTGCGTGTGTGTGT 2344
DB 1 TGTGTGTGCGTGTGTGTGT 21

RESULT 278
AAD21620
ID AAD21620 standard; DNA; 21 BP.
XX
AC AAD21620;
XX
DT 19-MAR-2002 (first entry)
XX
DE Sheep FGFR3 gene amplifying PCR primer #1.
XX
KW Sheep; spider lamb syndrome; SLS; fibroblast growth factor receptor 3;
KW FGFR; hereditary chondrodysplasia; semi-lethal congenital disorder;
KW severe skeletal abnormality; genetic marker; PCR primer; chromosome 6;
KW SS.
XX
OS Ovis sp.
XX
PN US6306591-B1.
XX
PD 23-OCT-2001.
XX
PP 18-JUN-1998; 98US-00099749.
XX
PR 18-JUN-1997; 97US-0050127P.
XX
PA (UTAH ) UNIV UTAH STATE.
XX
PI Cockett NE, Beaver JE;
XX
WPI; 2001-662278/76.
XX
DR
PT Identifying a genetic marker for spider lamb syndrome, used to diagnose
PT if sheep carry a gene for the syndrome, involves analyzing sheep DNA
PT samples for mutations in fibroblast growth factor receptor 3.
XX
PS Example 5; Col 24; 24pp; English.
XX
CC The present invention relates to a method for identifying a genetic
CC marker for spider lamb syndrome (SLS). The method comprising, obtaining a
CC sheep DNA sample, and analysing the sample DNA with a probe to determine
CC the presence or absence of a polymorphism in fibroblast growth factor
CC receptor 3 (FGFR). The invention is used for diagnosing if sheep carry
CC the gene for SLS, used to eliminate carriers of the syndrome from a
CC flock. SLS or hereditary chondrodysplasia is a semi-lethal congenital
CC disorder in sheep causing severe skeletal abnormalities. The present
CC sequence is a PCR primer used to amplify sheep FGFR3 gene. The FGFR3 gene
CC is located on chromosome 6
XX
SQ Sequence 21 BP; 3 A; 4 C; 8 G; 6 T; 0 U; 0 Other;

Query Match 0.6%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.6e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1425 CCTGTACGTGCTGGTGAGTA 1445
DB 1 CCTGTACGTGCTGGTGAGTA 21

RESULT 279
AAD55413/C
ID AAD55413 standard; DNA; 21 BP.
XX
AC AAD55413;
XX
DT 07-AUG-2003 (first entry)
XX

Human FGFR-3 DNA specific reverse PCR primer.
Human; antisense; fibroblast growth factor receptor 3; prophylaxis;
developmental disorder; hyperproliferative disorder; antisense therapy;
FGFR-3; ACH; JTK4; CEK2; cancer; PCR; primer; ss.
Homo sapiens.
WO2003023004-A2.
20-MAR-2003.
06-SEP-2002; 2002WO-US028549.
10-SEP-2001; 2001US-00953047.
(ISIS-) ISIS PHARM INC.
Monia BP, Wyatt JR;
WPI; 2003-313244/30.
Novel compound targeted to a nucleic acid molecule encoding fibroblast
growth factor receptor 3, useful for inhibiting the expression of the
receptor and for treating an animal having cancer or developmental
disorder.
Example 13; Page 76; 120pp; English.
The invention relates to antisense compounds targetted to a nucleic acid
molecule encoding fibroblast growth factor (FGF) receptor 3 (also known
as FGFR-3, ACH, JTK4 and CEK2) to inhibit its expression. Antisense
compounds of the invention are useful for treating diseases or conditions
associated with FGFR-3 such as developmental disorders or
hyperproliferative disorders, especially cancer of colorectal, bladder,
bone, lung, cervical, breast or skin. They are useful as research
reagents, therapeutics, prophylaxis, kits and diagnostics, and as tools
in differential and/or combinatorial analyses to elucidate expression
patterns of a portion of the genes expressed within cells and tissues.
They are also useful in antisense therapy. The present sequence is human
FGFR-3 DNA specific PCR primer. This primer is used in the
exemplification of the invention
SQ Sequence 21 BP; 3 A; 6 C; 4 G; 8 T; 0 U; 0 Other;

Query Match 0.6%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.6e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1297 AAGATGCTGAAGACGATGCC 1317
DB 21 AAGATGCTGAAGACGATGCC 1

RESULT 280
ADC64705
ID ADC64705 standard; DNA; 21 BP.
XX
AC ADC64705;
XX
DT 18-DEC-2003 (first entry)
XX
DE Fibroblast growth factor receptor 3-IIIC forward PCR primer.
XX
KW stem cell; dental follicle; tooth; membrane structure;
KW periodontal ligament; pluripotent mesenchymal stem cell; osteopathic;
KW antiinflammatory; stem cell therapy; tissue replacement; tissue repair;
KW transplantation; periodontal tissue; periodontitis; dental cementum;
KW gene therapy; PCR primer; ss.
XX
OS Synthetic.
XX

```

PN WO2003066840-A2.
 XX 14-AUG-2003.
 XX 05-FEB-2003; 2003WO-EP001131.
 XX 06-FEB-2002; 2002US-0354152P.
 XX (CAES-) STIFTUNG CAESAR.
 XX Schierholz J, Brenner N, Zeilhofer F, Hoffmann KH, Morsczech C;
 XX WPI; 2003-663591/62.
 XX Pluripotent embryonic-like stem cells derived from dental follicle,
 XX useful e.g. for engineering teeth or dental tissue, and for
 XX transplantation.
 XX Example; Page 23; 68pp; English.
 XX The present invention describes a stem cell (A) that is obtained from non
 XX -embryonic tissue isolated from the dental follicle of a (wisdom) tooth
 XX which can differentiate in vitro into a membrane structure that resembles
 XX periodontal ligament. Also described: (1) a stem cell (A1), derived from
 XX non-embryonic or post-natal animal cells or tissue, that is capable of
 XX self-renewal and differentiation to cells of endo-, ecto- or meso-dermal
 XX lineages; and (2) pluripotent mesenchymal stem cells (A2) obtained from
 XX (A). (A) has osteopathic and antiinflammatory activities, and can be used
 XX in stem cell therapy, and in tissue replacement. (A), and cells
 XX differentiated from them, can be used to prevent or treat cellular
 XX defects, dysfunction and/or disease, e.g. tissue repair or
 XX transplantation. They can especially be used to rebuild periodontal
 XX tissue (in cases of periodontitis) or dental cementum, and to improve
 XX healing of tooth extraction or skin lesions. They can also be used in
 XX association with a scaffold, for growing teeth (or associated bone) or
 XX arterial/venous vessels in the mouth or as gene therapy carriers. The
 XX present sequence represents a PCR primer which is used in an example from
 XX the present invention.
 XX Sequence 21 BP; 4 A; 6 C; 9 G; 2 T; 0 U; 0 Other;
 XX Query Match 0.6%; Score 21; DB 1; Length 21;
 XX Best Local Similarity 100.0%; Pred. No. 3.6e+02;
 XX Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 346 AACGCGAGGAGTTCGCGGC 366
 DB 1 AACGCGAGGAGTTCGCGGC 21
 RESULT 281
 ADC64703
 ID ADC64703 standard; DNA; 21 BP.
 AC ADC64703;
 XX 18-DEC-2003 (first entry)
 XX Fibroblast growth factor receptor 3-IIIB forward PCR primer.
 XX stem cell; dental follicle; tooth; membrane structure;
 XX periodontal ligament; pluripotent mesenchymal stem cell; osteopathic;
 XX antiinflammatory; stem cell therapy; tissue replacement; tissue repair;
 XX transplantation; periodontal tissue; periodontitis; dental cementum;
 XX gene therapy; PCR primer; ss.
 XX Synthetic.
 XX WO2003066840-A2.
 XX 14-AUG-2003.
 XX 05-FEB-2003; 2003WO-EP001131.

XX 06-FEB-2002; 2002US-0354152P.
 XX (CAES-) STIFTUNG CAESAR.
 XX Schierholz J, Brenner N, Zeilhofer F, Hoffmann KH, Morsczech C;
 XX WPI; 2003-663591/62.
 XX Pluripotent embryonic-like stem cells derived from dental follicle,
 XX useful e.g. for engineering teeth or dental tissue, and for
 XX transplantation.
 XX Example; Page 23; 68pp; English.
 XX The present invention describes a stem cell (A) that is obtained from non
 XX -embryonic tissue isolated from the dental follicle of a (wisdom) tooth
 XX which can differentiate in vitro into a membrane structure that resembles
 XX periodontal ligament. Also described: (1) a stem cell (A1), derived from
 XX non-embryonic or post-natal animal cells or tissue, that is capable of
 XX self-renewal and differentiation to cells of endo-, ecto- or meso-dermal
 XX lineages; and (2) pluripotent mesenchymal stem cells (A2) obtained from
 XX (A). (A) has osteopathic and antiinflammatory activities, and can be used
 XX in stem cell therapy, and in tissue replacement. (A), and cells
 XX differentiated from them, can be used to prevent or treat cellular
 XX defects, dysfunction and/or disease, e.g. tissue repair or
 XX transplantation. They can especially be used to rebuild periodontal
 XX tissue (in cases of periodontitis) or dental cementum, and to improve
 XX healing of tooth extraction or skin lesions. They can also be used in
 XX association with a scaffold, for growing teeth (or associated bone) or
 XX arterial/venous vessels in the mouth or as gene therapy carriers. The
 XX present sequence represents a PCR primer which is used in an example from
 XX the present invention.
 XX Sequence 21 BP; 4 A; 6 C; 9 G; 2 T; 0 U; 0 Other;
 XX Query Match 0.6%; Score 21; DB 1; Length 21;
 XX Best Local Similarity 100.0%; Pred. No. 3.6e+02;
 XX Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 346 AACGCGAGGAGTTCGCGGC 366
 DB 1 AACGCGAGGAGTTCGCGGC 21
 RESULT 282
 ADC51121/c
 ID ADC51121 standard; DNA; 21 BP.
 XX ADC51121;
 XX 17-JUN-2004 (first entry)
 XX Human NOVX protein-related PCR primer SeqID.
 XX cytosstatic; NOVX-agonist; NOVX-antagonist; vaccine; gene therapy; cancer;
 XX chromosome mapping; human; PCR; primer; ss.
 XX Homo sapiens.
 XX WO2003083046-A2.
 XX 09-OCT-2003.
 XX 01-APR-2003; 2003WO-US010142.
 XX 02-APR-2002; 2002US-00115479.
 XX 05-APR-2002; 2002US-0370349P.
 XX 08-APR-2002; 2002US-0370969P.
 XX 12-APR-2002; 2002US-0372019P.
 XX 22-APR-2002; 2002US-0374379P.
 XX 30-MAY-2002; 2002US-0384543P.
 XX 03-JUN-2002; 2002US-00160619.

```

PR 15-AUG-2002; 2002US-0403748P.
PR 04-NOV-2002; 2002US-00287226.
PR 31-MAR-2003; 2003US-00403161.
XX
XX (CURA-) CURAGEN CORP.
XX
PI Anderson DW, Bento P, Boldog FL, Burgess CE, Casman SJ, Furtak K;
PI Gorman L, Gould-Rothberg BE, Gunther E, Heyes MP, Li L, Spytek KA;
PI Stone DJ, Zhong M, Malyankar UM, Edinger SR, Patturajan M;
PI Rothenberg ME, Smithson G;
XX
XX WPI; 2003-812539/76.
XX
XX New NOVX polypeptide, useful for preparing a composition for treating or
XX preventing e.g. cancer or for chromosome mapping.
XX
XX Example C; SEQ ID NO 142; 433pp; English.
XX
XX This invention relates to novel isolated polypeptides and the DNA
XX sequences which encode them. The invention may be useful for the
XX development of compounds with a cytostatic activity (as NOVX-agonists or
XX antagonists) or vaccines. In addition, the disclosed sequences may be
XX useful for gene therapy. The polypeptide is useful for preparing a
XX composition for treating or preventing a pathological state in a mammal,
XX for example cancer or for chromosome mapping. The present sequence is
XX that of a PCR primer which was used in the exemplification of the
XX invention.
XX
XX Sequence 21 BP; 7 A; 3 C; 8 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 0.6%; Score 21; DB 1; Length 21;
XX Best Local Similarity 100.0%; Pred. No. 3.6e+02;
XX Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 742 GTTCTCTCCTTGACACAGTC 762
DB 21 GTTCTCTCCTTGACACAGTC 1
XX
RESULT 283
ADKS1124/c
ID ADKS1124 standard; DNA; 21 BP.
XX
XX AAQ52728;
XX AC AAQ52728;
XX
XX 29-JUN-1994 (first entry)
XX
XX Mouse fibroblast growth factor 3' DNA primer.
XX
XX Fibroblast growth factor; DNA primer; ss.
XX
XX Synthetic.
XX
XX US5270197-A.
XX
XX 14-DEC-1993.
XX
XX 20-DEC-1990; 90US-00631717.
XX
XX 20-DEC-1990; 90US-00631717.
XX
XX (HARD ) HARVARD COLLEGE.
XX PA (CHIL-) CHILDRENS MEDICAL CENT.
XX
XX Leder P, Klagsbrun M, Yayon A, Ornitz DM;
XX
XX WPI; 1993-404932/50.
XX
XX Cells having high-affinity heparin-binding growth factor binding sites -
XX are used for screening substances for e.g. anti-tumour agents or wound
XX healing promoters.
XX
XX Disclosure; Col 7; 37pp; English.
XX
XX This primer and its 5' partner (AAQ52727) correspond to regions highly
XX conserved among mouse BEK, human FLG and chicken fibroblast growth factor
XX CDNA
XX
XX Sequence 27 BP; 6 A; 10 C; 1 G; 10 T; 0 U; 0 Other;
XX
SQ

```

```

PR 15-AUG-2002; 2002US-0403748P.
PR 04-NOV-2002; 2002US-00287226.
PR 31-MAR-2003; 2003US-00403161.
XX
XX (CURA-) CURAGEN CORP.
XX
PI Anderson DW, Bento P, Boldog FL, Burgess CE, Casman SJ, Furtak K;
PI Gorman L, Gould-Rothberg BE, Gunther E, Heyes MP, Li L, Spytek KA;
PI Stone DJ, Zhong M, Malyankar UM, Edinger SR, Patturajan M;
PI Rothenberg ME, Smithson G;
XX
XX WPI; 2003-812539/76.
XX
XX New NOVX polypeptide, useful for preparing a composition for treating or
XX preventing e.g. cancer or for chromosome mapping.
XX
XX Example C; SEQ ID NO 142; 433pp; English.
XX
XX This invention relates to novel isolated polypeptides and the DNA
XX sequences which encode them. The invention may be useful for the
XX development of compounds with a cytostatic activity (as NOVX-agonists or
XX antagonists) or vaccines. In addition, the disclosed sequences may be
XX useful for gene therapy. The polypeptide is useful for preparing a
XX composition for treating or preventing a pathological state in a mammal,
XX for example cancer or for chromosome mapping. The present sequence is
XX that of a PCR primer which was used in the exemplification of the
XX invention.
XX
XX Sequence 21 BP; 7 A; 3 C; 8 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 0.6%; Score 21; DB 1; Length 21;
XX Best Local Similarity 100.0%; Pred. No. 3.6e+02;
XX Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 742 GTTCTCTCCTTGACACAGTC 762
DB 21 GTTCTCTCCTTGACACAGTC 1
XX
RESULT 283
ADKS1124/c
ID ADKS1124 standard; DNA; 21 BP.
XX
XX AAQ51124;
XX AC AAQ51124;
XX
XX 17-JUN-2004 (first entry)
XX
XX Human NOVX protein-related PCR primer SeqID.
XX
XX cytostatic; NOVX-agonist; NOVX-antagonist; vaccine; gene therapy; cancer;
XX chromosome mapping; human; PCR; primer; ss.
XX
XX Homo sapiens.
XX
XX WO2003083046-A2.
XX
XX 09-OCT-2003.
XX
XX 01-APR-2003; 2003WO-US010142.
XX
XX 02-APR-2002; 2002US-00115479.
XX
XX 05-APR-2002; 2002US-0370349P.
XX
XX 08-APR-2002; 2002US-0370969P.
XX
XX 12-APR-2002; 2002US-0372019P.
XX
XX 22-APR-2002; 2002US-0374379P.
XX
XX 30-MAY-2002; 2002US-0384543P.
XX
XX 03-JUN-2002; 2002US-00160619.
XX
XX 15-AUG-2002; 2002US-0403748P.
XX
XX 04-NOV-2002; 2002US-00287226.
XX
XX 31-MAR-2003; 2003US-00403161.
XX
XX (CURA-) CURAGEN CORP.
XX
XX

```

Query Match 0.6%; Score 21; DB 1; Length 27;
Best Local Similarity 100.0%; Pred. No. 4.8e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1349 AGATGAGATGATGAGATGA 1369
DB 27 AGATGAGATGATGAGATGA 7

RESULT 295
ABK66084/c
ID ABK66084 standard; DNA; 30 BP.

XX AC ABK66084;
XX 02-JUL-2002 (first entry)
XX Human gene specific PCR primer #172.
DE Primer; ss; DNA microarray; differential expression analysis; human.
XX Homo sapiens.

OS US6352829-B1.
XX 05-MAR-2002.
XX 05-JAN-1999; 99US-00225928.
XX 21-MAY-1997; 97US-00859998.
XX (CLON-) CLONTECH LAB INC.

XX Chenchik A, Jokhadze G, Bibilashvili R;
XX WPI; 2002-314699/35.

XX Producing sub-population of labeled nucleic acids, useful for analyzing
XX differences in RNA profiles between several different physiological
XX sources, using set of distinct gene specific primers.

XX Example 3; SEQ ID NO 172; 11pp; English.

XX The invention relates to producing a sub-population of labeled nucleic
XX acids (NAs) comprising contacting a NA sample from a physiological
XX source, with a pool of 50 distinct gene specific primers under suitable
XX conditions to enzymatically generate sub-population of NAs, where each
XX gene specific primer has a sequence complementary to a distinct mRNA, and
XX each labeled NA is generated using a single gene specific primer. The
XX method is useful for producing a sub-population of labeled NAs which is
XX useful for analysing the differences in the RNA profiles between several
XX different physiological sources, where the method comprises producing
XX subpopulation of labeled NAs for the different physiological sources,
XX comprising the populations for each physiological source to identify
XX differences in the population, where the comparison is preferably
XX performed by hybridising the labeled NAs for each of the distinct
XX physiological sources to an array of probe NAs stably associated with the
XX surface of a substrate to produce a hybridisation pattern for each of the
XX sources, and comparing the patterns for each of the sources, where
XX differential gene expression assays are utilised in differential
XX expression analysis of diseased or normal tissues e.g. neoplastic a normal
XX tissue, or different tissue or sub-tissue types. The present sequence is a
XX human gene specific PCR primer used in the method of the invention. Note:
XX The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from USPTO
XX at <http://wipo.segdata.uspto.gov/sequence.html?docID=6352829B1>

XX Sequence 30 BP; 8 A; 11 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 0.6%; Score 21; DB 1; Length 30;
Best Local Similarity 82.8%; Pred. No. 5.4e+02;
Matches 24; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

OY 1572 CCAGGTGGCCGGCGCATGGAGTACTTGG 1600
DB 29 CCAGTGGCTAAGGCGCATGGAGTCTTGG 1

RESULT 286
AAH40155/c
ID AAH40155 standard; DNA; 25 BP.

XX AC AAH40155;
XX 14-AUG-2001 (first entry)
XX SNP specific SNPE primer SEQ ID 2951.

XX Single nucleotide polymorphism; SNP; single nucleotide primer extension;
XX SNPE; genotyping; agammaglobulinaemia; diabetes insipidus; cancer;
XX Lesch-Nyhan syndrome; muscular dystrophy; familial hypercholesterolaemia;
XX polycystic kidney disease; osteogenesis imperfecta; autoimmune disease;
XX acute intermittent porphyria; rheumatoid arthritis; multiple sclerosis;
XX inflammation; forensic investigation; paternity analysis; primer; ss.

XX Homo sapiens.

XX WO200129262-A2.

XX 26-APR-2001.

XX 13-OCT-2000; 2000WO-US028436.

XX 15-OCT-1999; 99US-0160096P.

XX (ORCH-) ORCHID BIOSCIENCES INC.

XX Picoult-Newburg L, Pohl M;

XX WPI; 2001-290930/30.

XX New genotyping oligonucleotide, useful for detecting the presence,
XX absence or identity of single polynucleotide polymorphism in a nucleic
XX acid sample.

XX Claim 1; Page 65; 83pp; English.

XX Sequences AAH37205 - AAH40944 represent PCR primers, single nucleotide
XX primer extension (SNPE) primers, and the sequences of regions flanking
XX sites of single nucleotide polymorphisms SNPs. The present invention
XX includes kits for determining the presence or absence of a SNP, using the
XX oligonucleotides of the invention. The PCR primers are used to amplify a
XX SNP flanking sequence, the SNPE primer is used as a genotyping primer.
XX The oligonucleotides are useful for genotyping a nucleic acid sample by
XX performing a single-nucleotide primer extension reaction. The
XX oligonucleotides are useful for determining the presence, absence or
XX identity of a SNP and for genotyping nucleic acid samples, for e.g. to
XX assess by association analysis the genotype of an individual or group of
XX individuals, having a pathological phenotypic trait suspected of being
XX caused by one or more SNPs. Phenotypic traits include diseases e.g.
XX agammaglobulinaemia, diabetes insipidus, Lesch-Nyhan syndrome, muscular
XX dystrophy, familial hypercholesterolaemia, polycystic kidney disease,
XX osteogenesis imperfecta and acute intermittent porphyria. Phenotypic
XX traits also include symptoms of or susceptibility to multifactorial
XX disease of which a component is or may be genetic such as autoimmune
XX diseases, including, rheumatoid arthritis, multiple sclerosis,
XX inflammation, cancer, nervous system diseases and infection by pathogenic
XX microorganism. The method is also useful in forensic investigations and
XX paternity analysis. The present sequence represents a single nucleotide
XX primer extension (SNPE) primer specific for a human SNP containing DNA
XX sequence

XX Sequence 25 BP; 11 A; 11 C; 2 G; 1 T; 0 U; 0 Other;

Query Match 0.5%; Score 20.8; DB 1; Length 25;


```

RESULT 289
ACC79667/c
ID ACC79667 standard; DNA; 27 BP.
XX AC
XX ACC79667;
DT 27-AUG-2003 (first entry)
DE Human fibroblast growth factor 3 PCR primer SEQ ID NO:2.
XX KW
XX Human; fibroblast growth factor 3; FGFR3; flat epithelial cell; cancer;
KW flat epithelial cell cancer; PCR primer; ss.
XX OS
XX Homo sapiens.
OS Synthetic.
PN JP2002272474-A.
PD 24-SEP-2002.
XX PF
XX 22-MAR-2001; 2001JP-000833352.
PR 22-MAR-2001; 2001JP-000833352.
PA (ZERI ) ZERIA SHINYAKU KOGYO KK.
XX WPI; 2003-345602/33.
XX Inspection of flat epithelial cell, screening of treating or preventive
PT agents for flat epithelial cancers, the treating or preventive agents for
PT flat epithelial cancer.
XX Example; Page 7; 18pp; Japanese.
CC The present invention describes a method for the inspection of flat
CC epithelial cells in which it is judged that flat epithelial cells
CC separated from an organism can proceed to flat epithelial cancer when the
CC 2128th base in fibroblast growth factor receptor (FGFR) gene of the cells
CC is mutated from guanine to thymine. Also described is a method for
CC screening treating or preventive agents for flat epithelial cancers in
CC which a candidate substance of treating agent for flat epithelial cancer
CC is applied to flat epithelial cancer cells producing FGFR protein in
CC guanine to thymine (exon 17) amino acid in FGFR3 gene is mutated from
CC cysteine and said candidate substance is selected by using the facts that
CC the 2128th base in the flat epithelial cell FGFR3 gene after the
CC application returned to guanine and that the 697th amino acid of FGFR3
CC protein produced returned to glycine as the indices. The method is used
CC for the inspection of flat epithelial cells. The present sequence
CC represents a PCR primer for human FGFR3, which is used in an example from
CC the present invention
XX Sequence 27 BP; 5 A; 12 C; 5 G; 5 T; 0 U; 0 Other;
SQ
Query Match 0.5%; Score 20.6; DB 1; Length 27;
Best Local Similarity 85.2%; Pred. No. 5.3e+02;
Matches 23; Conservative 0; Mismatches 4; Indels 0; Gaps 0
QY 2180 GGGGCTCGCGACGTGAAGGCCACTG 2206
DB 27 GGGGCTCGCGACGTGAAGGAATTCG 1
RESULT 290
AAQ33810
ID AAQ33810 standard; DNA; 22 BP.
XX AAQ33810;
XX AAQ33810;

```



```

CC used to identify individuals, for percentage testing, and in the genetic
CC mapping of economic trait loci, or genes involved the determinism of
CC economically important traits esp. in cattle, to allow selective
CC breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC field.)
XX
SQ Sequence 22 BP; 0 A; 0 C; 11 G; 11 T; 0 U; 0 Other;
    Query Match          95.5%; Score 20.4; DB 1; Length 22;
    Best Local Similarity 95.5%; Pred. No. 4.4e+02;
    Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
    QY      2318 TGTGTCGTGTCGTGCCGTGTG 2339
        |||||
        1 TGTGTCGTGTCGTGTGTGTG 22
XX
RESULT 295
AAQ83952/c
ID AAQ83952 standard; DNA; 22 BP.
XX
AC AC
XX AAQ83952;
XX
DT 25-MAR-2003 (revised)
DT 04-OCT-1995 (first entry)
XX
XX Deletion n, for producing comb-type brached polymer.
XX Oligonucleotide clamp n, for producing comb-type brached polymer.
XX HIV; pol; nef; oligonucleotide clamp; branched; macromolecule; ss.
XX Synthetic.
XX
XX Key Location/Qualifiers
FH modified_base 1 /*tag= a
FT /*note= "Modified with BrCH2(=O)CNH-"
FT 8..9
FT /*tag= b
FT /*note= "C(pnp)A, pnp = a linkage or monomer containing a
FT bromoacetyl amino functionality, and p = phosphodiester
FT linkage"
FT 14..15
FT /*tag= c
FT /*note= "C(pnp)A, pnp = a linkage or monomer containing a
FT bromoacetyl amino functionality, and p = phosphodiester
FT linkage"
FT 21..22
FT /*tag= d
FT /*note= "C(pnp)A, pnp = a linkage or monomer containing a
FT bromoacetyl amino functionality, and p = phosphodiester
FT linkage"
XX
PN WO9501365-A1.
XX
PD 12-JAN-1995.
XX
XX PF 05-JUL-1994; 94WO-US007557.
XX
XX PR 02-JUL-1993; 93US-00087386.
XX
XX PA (LYNX-) LYNX THERAPEUTICS INC.
XX
XX Gryaznov SM;
PI
XX WPI; 1995-060944/08.
XX
DR Synthesis of branched polymers and novel branched polymeric structures -
PT used as molecular probes esp. for detecting poly-nucleotide(s).
PT
XX Example 8; Page 33; 52pp; English.
PS
XX The sequences given in AAQ83938, AAQ83952 and AAQ83940 are used in the
XX construction of an oligonucleotide clamp. The clamp is a comb-type
CC CC

```

screening a library of bovine MboI DNA fragments of between 250 and 500 bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50 clones cross-hybridised. Assuming independent distribution of microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites in the bovine genome is estimated at >100, 000. The sequence information for ca. 230 such bovine microsatellites is summarised in the microsatellites and indexed herein (see below). The sequences upstream and downstream of the microsatellite sequence were used to generate the required PCR primers for in vitro amplification of the corresp. microsatellite (using the program OPTIPRIM). The microsatellites may be used to identify individuals, for parentage testing, and in the genetic mapping of economic trait loci, or genes involved in the determination of economically important traits esp. in cattle, to allow selective breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN field.)

Sequence 22 BP; 0 A; 0 C; 11 G; 11 T; 0 U; 0 Other;

Query Match 0.5%; Score 20.4; DB 1; Length 22;
Best Local Similarity 95.5%; Pred. NO. 4.4e+02;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2318 TGTGTGTGTGTGTGTGGGTGTG 2339
|||||
DB 1 TGTGTGTGTGTGTGTGTGTGTG 22

RESULT 294

AAQ33991

ID ID AAQ33991 standard; DNA; 22 BP.

XX AC AC

XX AAQ33991;

XX 25-MAR-2003 (revised)

DT 02-FEB-1993 (first entry)

XX XX

XX Microsatellite sequence from clone TGLA39.

XX PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
genetic mapping; traits; amplification; ss.

XX Bos taurus.

XX WO9213102-A1.

XX 06-AUG-1992.

XX 15-JAN-1992; 92WO-US000340.

XX 15-JAN-1991; 91US-00642342.

XX (GENN-) GENMARK.

XX PA PA

XX Georges M, Massey JM;

XX WPI; 1992-284684/34.

XX Polymorphic bovine DNA markers - used in genetic identification, gene mapping, and selective breeding.

XX Table 7; Page 327; 517pp; English.

XX The sequence is that of a bovine microsatellite sequence obt'd. by screening a library of bovine MboI DNA fragments of between 250 and 500 bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50 clones cross-hybridised. Assuming independent distribution of microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites in the bovine genome is estimated at >100, 000. The sequence information for ca. 230 such bovine microsatellites is summarised in the microsatellites and indexed herein (see below). The sequences upstream and downstream of the microsatellite sequence were used to generate the required PCR primers for in vitro amplification of the corresp. microsatellite (using the program OPTIPRIM). The microsatellites may be

CC branched polymer which has 3' termini and was used to bind a target
 CC sequence comprising a segment of the HIV pol and nef genes in single
 CC stranded or double stranded forms. An oligonucleotide clamp is a compound
 CC capable of forming a covalently closed macromolecule or a stable circular
 CC complex after specifically binding to the target polynucleotide.
 CC Oligonucleotide clamps generally comprise one or more oligonucleotide
 CC moieties capable of specific binding to the target molecule and one or
 CC more pairs of binding moieties covalently linked to the oligonucleotide
 CC moieties. Upon annealing of the oligonucleotide moieties to the target
 CC polynucleotide, the binding moieties of a pair are brought into
 CC juxtaposition so that they form a stable covalent or non-covalent linkage
 CC or complex. The interaction of the binding moieties effectively clamps
 CC the specifically annealed oligonucleotide moieties to the target
 CC polynucleotide. (Updated on 25-MAR-2003 to correct PN field.)
 XX
 SQ Sequence 22 BP; 11 A; 11 C; 0 G; 0 T; 0 U; 0 Other;
 Query Match 0.5%; Score 20.4; DB 1; Length 22;
 Best Local Similarity 95.5%; Pred. No. 4.4e+02;
 Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2319 GTGTGTGTGTGTGTGTGTGTGTGT 2340
 DB |||||
 22 GTGTGTGTGTGTGTGTGTGTGTGT 1
 RESULT 296
 AAT65727/c
 ID AAT65727 standard; DNA; 22 BP.
 XX
 AC AAT65727;
 XX
 XX
 DT 25-MAR-2003 (revised)
 DT 17-JUN-1997 (first entry)
 XX
 DE Repeat sequence from polymorphic marker clone Mfd25.
 XX
 KW Polymorphism; repeat sequence; genetic marker; primer; amplification;
 KW PCR; polymerase chain reaction; paternity; maternity; human; pedigree;
 KW linkage analysis; genetic disease; animal; plant; breeding; locus;
 KW hybridisation; chromosome; ds.
 XX
 OS Homo sapiens.
 XX
 PN US5582979-A.
 XX
 PD 10-DEC-1996.
 XX
 PF 04-APR-1994; 94US-00222177.
 XX
 PR 21-APR-1989; 89US-00341562.
 PR 05-SEP-1991; 91US-00754351.
 XX
 XX (MARS-) MARSHFIELD CLINIC.
 PA
 PI Weber JI;
 XX
 DR WPI; 1997-0422299/04.
 XX
 XX Detection of polymorphic genetic markers of the form (dC-dA)n(dG-dT)n -
 PT using novel nucleic acid mois. as primers.
 PT
 XX Disclosure; Col 9-10; 186pp; English.
 PS
 XX The invention relates to the isolation of polymorphic repeat sequences
 CC having the sequence (dC-dA)n.(dG-dT)n which can be used as genetic
 CC markers. Primers based on these sequences can be used to detect these
 CC repeats, especially for use in e.g paternity or maternity testing, human
 CC genetic analysis such as linkage analysis of genetic disease, commercial
 CC animal or plant breeding or pedigree analysis. Clones containing the
 CC repeat sequences were isolated by hybridisation of chromosome-specific
 CC phage libraries with a synthetic poly(dC-dA).(dG-dT) probe. Over 100
 CC repeat blocks were isolated. The inserts from the clones were amplified

CC by primers AAT65798-T66047. Those clones where the repeat sequence has
 CC been determined are shown in AAT65704-797. This repeat sequence is from
 CC the marker clone Mfd25 which contains the repeat sequence having the
 CC formula: (AC)11. (Updated on 25-MAR-2003 to correct PF field.)
 XX
 SQ Sequence 22 BP; 11 A; 11 C; 0 G; 0 T; 0 U; 0 Other;
 Query Match 0.5%; Score 20.4; DB 1; Length 22;
 Best Local Similarity 95.5%; Pred. No. 4.4e+02;
 Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2319 GTGTGTGTGTGTGTGTGTGTGTGT 2340
 DB |||||
 22 GTGTGTGTGTGTGTGTGTGTGTGT 1
 RESULT 297
 AAT64468/c
 ID AAT64468 standard; DNA; 22 BP.
 XX
 AC AAT64468;
 XX
 DT 23-NOV-2001 (first entry)
 XX
 DE SSR motif #18.
 XX
 KW Simple Sequence Repeat; SSR; clover; microsatellite; genome mapping;
 KW trait mapping; marker-assisted selection; gene selection; legume;
 KW DNA profiling; breeding; ds.
 XX
 OS Unidentified.
 XX
 PN NZ509194-A.
 XX
 PD 25-MAY-2001.
 XX
 PF 03-JAN-2001; 2001NZ-00509194.
 XX
 PR 24-DEC-1999; 99AU-00004907.
 PR 28-MAR-2000; 2000AU-00006520.
 XX
 PA (AGRI-) AGRIC VICTORIA SERVICES PTY LTD.
 PI
 PI Koelliker R, Forster JW;
 XX
 DR WPI; 2001-431058/46.
 XX
 PT Novel simple sequence repeats in clover species useful for selection of
 PT genes in legume breeding, for profiling legume species varieties and for
 PT testing the purity of legume seed batches.
 XX
 PS Example 1; Page 19; 52pp; English.
 XX
 CC The present invention relates to Simple Sequence Repeats (SSRs) from
 CC clover species. SSRs, also called microsatellites, are based on a 1-7
 CC nucleotide core element which is tandemly repeated. The SSR array is
 CC embedded in complex flanking DNA. SSRs are ideal markers for genome
 CC mapping, trait mapping and marker-assisted selection. The SSRs may be
 CC used in methods for selecting genes in clover/ legume breeding. The SSRs
 CC are also useful for DNA profiling of clover varieties and for testing the
 CC purity of legume seed batches. The present sequence is a SSR motif, which
 CC was used in the present invention
 XX
 SQ Sequence 22 BP; 10 A; 10 C; 2 G; 0 T; 0 U; 0 Other;
 Query Match 0.5%; Score 20.4; DB 1; Length 22;
 Best Local Similarity 95.5%; Pred. No. 4.4e+02;
 Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2323 GTGTGTGTGTGTGTGTGTGTGTGT 2344
 DB |||||
 22 GTGTGTGTGTGTGTGTGTGTGTGT 1

Thu Oct 28 12:48:21 2004

vivlemore401-10.rng

```

AAL50671
ID AAL50671 standard; DNA; 26 BP.
XX
AC AAL50671;
XX
DT 16-JAN-2003 (first entry)
XX
DE Human uridine diphosphate glucuronosyltransferase gene polymorphism #5.
XX
KW Human; polymorphism; TA repeat; ds; UGT; thymidine-adenine repeat;
KW uridine diphosphate glucuronosyltransferase gene promoter; UGT1A1;
KW drug dosage optimisation; xenobiotic sensitivity.
XX
OS Homo sapiens.
XX
PN US2002115097-A1.
XX
PD 22-AUG-2002.
XX
XX 01-FEB-2002; 2002US-00061693.
XX
XX 16-FEB-1999; 99US-00251274.
XX
XX (ARCH-) ARCH DEV CORP.
XX
XX Rienzo AD, Iyer L, Ratain MJ;
XX WPI; 2002-740095/80.
XX
XX Detecting polymorphisms in uridine diphosphate glucuronosyltransferase
XX gene promoter, useful for optimizing drug dosages for a patient, involves
XX determining number of thymidine-adenine repeats in the promoter.
XX
XX Claim 8; Page 9; 13pp; English.
XX
XX The invention comprises a method for detecting polymorphisms in a uridine
XX diphosphate glucuronosyltransferase (UGT) gene promoter (preferably
XX UGT1A1). The method involves determining the number of thymidine-adenine
XX (TA) repeats in the promoter - as the number of TA repeats correlates
XX with expression of the UGT gene. The method of the invention is useful
XX for detecting polymorphisms in a UGT gene promoter. The method of the
XX invention is also useful in optimising drug dosages and predicting an
XX individual's sensitivity to xenobiotics for drugs and xenobiotics that
XX are glucuronidated by UGT. The present DNA sequence represents a UGT gene
XX TA repeat polymorphism
XX
XX Sequence 26 BP; 13 A; 0 C; 0 G; 13 T; 0 U; 0 Other;
XX
XX Query Match 0.5%; Score 20.4; DB 1; Length 26;
XX Best Local Similarity 95.5%; Pred. No. 5.4e+02;
XX Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 2823 TATATATACATATATATATATA 2844
DB 1 TATATATATATATATATATATA 22
XX
RESULT 308
AAL50671/c
ID AAL50671 standard; DNA; 26 BP.
XX
AC AAL50671;
XX
DT 16-JAN-2003 (first entry)
XX
DE Human uridine diphosphate glucuronosyltransferase gene polymorphism #5.
XX
KW Human; polymorphism; TA repeat; ds; UGT; thymidine-adenine repeat;
KW uridine diphosphate glucuronosyltransferase gene promoter; UGT1A1;
KW drug dosage optimisation; xenobiotic sensitivity.
XX
OS Homo sapiens.
XX
```

```

PN US2002115097-A1.
XX
PD 22-AUG-2002.
XX
XX 01-FEB-2002; 2002US-00061693.
XX
XX 16-FEB-1999; 99US-00251274.
XX
XX (ARCH-) ARCH DEV CORP.
XX
XX Rienzo AD, Iyer L, Ratain MJ;
XX WPI; 2002-740095/80.
XX
XX Detecting polymorphisms in uridine diphosphate glucuronosyltransferase
XX gene promoter, useful for optimizing drug dosages for a patient, involves
XX determining number of thymidine-adenine repeats in the promoter.
XX
XX Claim 8; Page 9; 13pp; English.
XX
XX The invention comprises a method for detecting polymorphisms in a uridine
XX diphosphate glucuronosyltransferase (UGT) gene promoter (preferably
XX UGT1A1). The method involves determining the number of thymidine-adenine
XX (TA) repeats in the promoter - as the number of TA repeats correlates
XX with expression of the UGT gene. The method of the invention is useful
XX for detecting polymorphisms in a UGT gene promoter. The method of the
XX invention is also useful in optimising drug dosages and predicting an
XX individual's sensitivity to xenobiotics for drugs and xenobiotics that
XX are glucuronidated by UGT. The present DNA sequence represents a UGT gene
XX TA repeat polymorphism
XX
XX Sequence 26 BP; 13 A; 0 C; 0 G; 13 T; 0 U; 0 Other;
XX
XX Query Match 0.5%; Score 20.4; DB 1; Length 26;
XX Best Local Similarity 95.5%; Pred. No. 5.4e+02;
XX Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 2823 TATATATACATATATATATATA 2844
DB 26 TATATATATATATATATATATA 5
XX
RESULT 309
ABZ24782
ID ABZ24782 standard; RNA; 26 BP.
XX
AC ABZ24782;
XX
DT 07-APR-2003 (first entry)
XX
DE Oligodeoxynucleic acid molecule ODN 21.
XX
KW Immunostimulant; oligodeoxynucleic acid; ODN; vaccine; ss.
XX
OS Synthetic.
XX
XX Key Location/Qualifiers
XX modified_base 1..26
XX /*tag= a
XX /mod_base= OTHER
XX /note= "thiophosphate backbone"
XX
PN WO200295027-A2.
XX
XX 28-NOV-2002.
XX
XX 17-MAY-2002; 2002WO-EP005448.
XX
XX 21-MAY-2001; 2001AT-00000805.
XX
XX (INTE-) INTERCELL BIOMEDIZINISCHE FORSCHUNGS.
XX (CIST-) CISTEM BIOLOGIES GMBH.
XX
```



```

PI Lingnau K, Schellack C, Schmidt W;
XX WPI; 2003-183880/18.
XX
XX New oligodeoxynucleic acid molecules useful for the preparation of
XX vaccine.
XX
XX Example 7; Page 31; 57pp; English.
XX
XX The present sequence is that of a thiosubstituted oligodeoxynucleic acid
XX (ODN) molecule. ODN 21, including deoxyuridine monophosphates. The
XX invention is based on the discovery that ODNs containing deoxyuridine
XX residues (U-ODNs) have an immunostimulatory effect comparable to, or in
XX many instances greater than, ODNs containing CpG motifs, producing higher
XX numbers of specific T cells to a given antigen. The U-ODNs do not induce
XX the systemic production of pro-inflammatory cytokines and, in contrast to
XX CpG ODNs, are not dependent on a specific motif or a palindromic
XX sequence. Use of a U-ODN for the preparation of a vaccine is claimed.
XX Combining the U-ODN with an antigen strongly increases the potential of
XX the antigen to raise the protection/immune response of a vaccinated
XX individual. An example of the invention demonstrated the generation of a
XX specific immune response against a melanoma-derived peptide (see
XX ABP58360) by injection of mice with the peptide in combination with ODN
XX 21
XX
XX Sequence 26 BP; 13 A; 0 C; 0 G; 0 T; 13 U; 0 Other;
SQ
Query Match 0.5%; Score 20.4; DB 1; Length 26;
Best Local Similarity 50.0%; Pred. No. 5.4e+02;
Matches 11; Conservative 10; Mismatches 1; Indels 0; Gaps 0;

QY 2823 TATATATACATATATATATATA 2844
DB 1 UAUUAUAUAUAUAUAUAUAUA 22

RESULT 310
ABZ24782/C
ID ABZ24782 standard; RNA; 26 BP.
XX
XX ABZ24782;
XX
XX 07-APR-2003 (first entry)
XX
XX Oligodeoxynucleic acid molecule ODN 21.
XX
XX Immunostimulant; oligodeoxynucleic acid; ODN; vaccine; ss.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
XX modified_base 1..26
XX /tag= a
XX /mod_base= OTHER
XX /note= "thiophosphate backbone"
XX
XX WO200295027-A2.
XX
XX 28-NOV-2002.
XX
XX 17-MAY-2002; 2002WO-EP005448.
XX
XX 21-MAY-2001; 2001AT-00000805.
XX
XX (INTE-) INTERCELL BIOMEDIZINISCHE FORSCHUNGS.
XX (CIST-) CISTEM BIOTECHNOLOGIES GMBH.
XX
XX Lingnau K, Schellack C, Schmidt W;
XX WPI; 2003-183880/18.
XX
XX New oligodeoxynucleic acid molecules useful for the preparation of
XX vaccine.

```

```

XX
XX Example 7; Page 31; 57pp; English.
XX
XX The present sequence is that of a thiosubstituted oligodeoxynucleic acid
XX (ODN) molecule. ODN 21, including deoxyuridine monophosphates. The
XX invention is based on the discovery that ODNs containing deoxyuridine
XX residues (U-ODNs) have an immunostimulatory effect comparable to, or in
XX many instances greater than, ODNs containing CpG motifs, producing higher
XX numbers of specific T cells to a given antigen. The U-ODNs do not induce
XX the systemic production of pro-inflammatory cytokines and, in contrast to
XX CpG ODNs, are not dependent on a specific motif or a palindromic
XX sequence. Use of a U-ODN for the preparation of a vaccine is claimed.
XX Combining the U-ODN with an antigen strongly increases the potential of
XX the antigen to raise the protection/immune response of a vaccinated
XX individual. An example of the invention demonstrated the generation of a
XX specific immune response against a melanoma-derived peptide (see
XX ABP58360) by injection of mice with the peptide in combination with ODN
XX 21
XX
XX Sequence 26 BP; 13 A; 0 C; 0 G; 0 T; 13 U; 0 Other;
SQ
Query Match 0.5%; Score 20.4; DB 1; Length 26;
Best Local Similarity 95.5%; Pred. No. 5.4e+02;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2823 TATATATACATATATATATATA 2844
DB 26 TATATATATATATATATATATA 5

RESULT 311
AAL50672
ID AAL50672 standard; DNA; 28 BP.
XX
XX AAL50672;
XX
XX 16-JAN-2003 (first entry)
XX
XX Human uridine diphosphate glucuronosyltransferase gene polymorphism #6.
XX
XX Human; polymorphism; TA repeat; ds; UGT; thymidine-adenine repeat;
XX uridine diphosphate glucuronosyltransferase gene promoter; UGT1A1;
XX drug dosage optimisation; xenobiotic sensitivity.
XX
XX Homo sapiens.
XX
XX OS
XX
XX PN US2002115097-A1.
XX
XX PD 22-AUG-2002.
XX
XX PF 01-FEB-2002; 2002US-00061693.
XX
XX PR 16-FEB-1999; 99US-00251274.
XX
XX PA (ARCH-) ARCH DEV CORP.
XX
XX PI Rienzo AD, Iyer L, Ratain MJ;
XX WPI; 2002-740095/80.
XX
XX Detecting polymorphisms in uridine diphosphate glucuronosyltransferase
XX gene promoter, useful for optimizing drug dosages for a patient, involves
XX determining number of thymidine-adenine repeats in the promoter.
XX
XX Claim 8; Page 9; 13pp; English.
XX
XX The invention comprises a method for detecting polymorphisms in a uridine
XX diphosphate glucuronosyltransferase (UGT) gene promoter (preferably
XX UGT1A1). The method involves determining the number of thymidine-adenine
XX (TA) repeats in the promoter - as the number of TA repeats correlates
XX with expression of the UGT gene. The method of the invention is useful
XX for detecting polymorphisms in a UGT gene promoter. The method of the
XX invention is also useful in optimising drug dosages and predicting an

```

Thu Oct 28 12:48:21 2004

viv@lemore401-10.rng

CC individual's sensitivity to xenobiotics for drugs and xenobiotics that
CC are glucuronidated by UGT. The present DNA sequence represents a UGT gene
CC TA repeat polymorphism

XX Sequence 28 BP; 14 A; 0 C; 0 G; 14 T; 0 U; 0 Other;
XX
XX Query Match 0.5%; Score 20.4; DB 1; Length 28;
XX Best Local Similarity 95.5%; Pred. No. 5.8e+02;
XX Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY .2823 TATATATACATATATATATATA 2844
DB 1 TATATATATATATATATATATA 22

RESULT 312
AAL50672/c
ID AAL50672 standard; DNA; 28 BP.

XX AAL50672;
XX 16-JAN-2003 (first entry)
XX Human uridine diphosphate glucuronosyltransferase gene polymorphism #6.
XX Human; polymorphism; TA repeat; ds; UGT; thymidine-adenine repeat;
XX uridine diphosphate glucuronosyltransferase gene promoter; UGT1A1;
XX drug dosage optimisation; xenobiotic sensitivity.
XX Homo sapiens.

OS US2002115097-A1.
XX 22-AUG-2002.
XX 01-FEB-2002; 2002US-00061693.
XX 16-FEB-1999; 99US-00251274.
XX (ARCH-) ARCH DEV CORP.

XX Rienza AD, Iyer L, Ratain MJ;
XX WPI; 2002-740095/80.
XX Detecting polymorphisms in uridine diphosphate glucuronosyltransferase
XX gene promoter, useful for optimizing drug dosages for a patient, involves
XX determining number of thymidine-adenine repeats in the promoter.

PS Claim 8; Page 9; 13pp; English.

XX The invention comprises a method for detecting polymorphisms in a uridine
XX diphosphate glucuronosyltransferase (UGT) gene promoter (preferably
XX UGT1A1). The method involves determining the number of thymidine-adenine
XX (TA) repeats in the promoter - as the number of TA repeats correlates
XX with expression of the UGT gene. The method of the invention is useful
XX for detecting polymorphisms in a UGT gene promoter. The method of the
XX invention is also useful in optimising drug dosages and predicting an
XX individual's sensitivity to xenobiotics for drugs and xenobiotics that
XX are glucuronidated by UGT. The present DNA sequence represents a UGT gene
XX TA repeat polymorphism

XX Sequence 28 BP; 14 A; 0 C; 0 G; 14 T; 0 U; 0 Other;

XX Query Match 0.5%; Score 20.4; DB 1; Length 28;
XX Best Local Similarity 95.5%; Pred. No. 5.8e+02;
XX Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY .2823 TATATATACATATATATATATA 2844
DB 28 TATATATATATATATATATATA 7

RESULT 313

ADK61709
ID ADK61709 standard; DNA; 28 BP.
XX
XX AC ADK61709;
XX 06-MAY-2004 (first entry)
XX Base containing SSR sequence #13.
XX rice variety; amplification genetic marker; ds.
XX Oryza sp.
XX JP2003319782-A.
XX 11-NOV-2003.
XX 02-MAY-2002; 2002JP-00130645.
XX 02-MAY-2002; 2002JP-00130645.
XX (HOKU-) HOKUREN NOGYO KYODO KUMIAI.
XX (HOKK-) HOKKAIDO GREEN BIO KENKYUSHO KK.

XX WPI; 2004-003560/01.

XX Identifying rice variety using base sequence containing SSR sequence and
XX amplifying genetic marker.
XX Claim 50; SEQ ID NO 13; 30pp; Japanese.
XX The present invention relates to identifying a rice variety as
XX amplification genetic marker and identifying whether test rice variety is
XX any one of the 32 rice varieties e.g., Kasalath, breath which came from
XX Hayamasari, Itailica Livorno, Dughan Shali, Aroz Da Terra, Fany, USSR22,
XX Nihonbare. The method is useful for identifying rice variety and
XX identifies excellent rice variety. The present sequence represents a base
XX - containing SSR sequence of the invention.

XX Sequence 28 BP; 14 A; 0 C; 0 G; 14 T; 0 U; 0 Other;

XX Query Match 0.5%; Score 20.4; DB 1; Length 28;
XX Best Local Similarity 95.5%; Pred. No. 5.8e+02;
XX Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY .2823 TATATATACATATATATATATA 2844
DB 1 TATATATATATATATATATATA 22

RESULT 314

ADK61709/c
ID ADK61709 standard; DNA; 28 BP.

XX AC ADK61709;
XX 06-MAY-2004 (first entry)
XX Base containing SSR sequence #13.
XX rice variety; amplification genetic marker; ds.
XX Oryza sp.
XX JP2003319782-A.
XX 11-NOV-2003.
XX 02-MAY-2002; 2002JP-00130645.
XX 02-MAY-2002; 2002JP-00130645.

QY .2823 TATATATACATATATATATATA 2844
DB 28 TATATATATATATATATATATA 7

PA (HOKU-) HOKUREN NOGYO KYODO KUMIAI.
 PA (HOKK-) HOKKAIDO GREEN BIO KENKYUSHO KK.
 XX WPI; 2004-003560/01.
 DR Identifying rice variety using base sequence containing SSR sequence and
 PT amplifying genetic marker.
 XX
 XX Claim 50; SEQ ID NO 13; 30pp; Japanese.
 XX
 CC The present invention relates to identifying a rice variety as
 CC amplification genetic marker and identifying whether test rice variety is
 CC any one of the 32 rice varieties e.g., Kasalath, breath which came or
 CC Hayamasari, Itailica Livorno, Dughan Shali, Arrozo Da Terra, Fany, USSR22,
 CC Nihonbare. The method is useful for identifying rice variety and
 CC identifies excellent rice variety. The present sequence represents a base
 CC - containing SSR sequence of the invention.
 XX
 XX Sequence 28 BP; 14 A; 0 C; 0 G; 14 T; 0 U; 0 Other;
 SQ
 Query Match 0.5%; Score 20.4; DB 1; Length 28;
 Best Local Similarity 95.5%; Pred. No. 5.8e+02;
 Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2823 TATATATACATATATATATATA 2844
 Db TATATATATATATATATATATA 7
 RESULT 315
 ACI58589/c
 ID ACI58589 standard; DNA; 25 BP.
 XX
 AC ACI58589;
 XX
 DT 13-OCT-2003 (first entry)
 DE Human microarray DNA oligonucleotide SEQ ID NO 58580.
 XX
 KW EST; ss; probe; expressed sequence tag; microarray; gene expression;
 KW genetic variation; biallelic marker; polymorphism; human;
 KW cross-species comparison.
 XX
 OS Homo sapiens.
 XX
 PN US2003104410-A1.
 XX
 PD 05-JUN-2003.
 XX
 PF 15-MAR-2002; 2002US-00098263.
 XX
 PR 16-MAR-2001; 2001US-0276759P.
 XX
 PA (AFFY-) AFFYMETRIX INC.
 XX
 PI Mittmann MP;
 XX
 DR WPI; 2003-567953/53.
 XX
 PT New array of nucleic acid probes, useful for in situ hybridization, in
 PT Southern, Northern or dot-blot hybridization to identify or detect the
 PT sequence or specific mutations of any gene.
 XX
 PS Claim 1; SEQ ID NO 58580; 9pp; English.
 XX
 CC The invention discloses a microarray comprising a plurality of nucleic
 CC acid probes including one of 2,018,500 fully defined sequences, or its
 CC perfect match, perfect mismatch, antisense match or antisense mismatch.
 CC Also disclosed is a method of gene expression analysis. The array is used
 CC in monitoring gene expression levels by hybridisation to a DNA library,
 CC in analysing gene expression levels by hybridisation to a DNA library,
 CC in monitoring gene expression levels by hybridisation to a DNA library,
 CC in analysis of genetic variation or in hybridisation of tag-labelled
 CC compounds. The nucleic acid probes are specifically designed for analysis
 CC of at least one target sequence. The method of analysis comprises
 CC hybridising at least one or more nucleic acids to at least two or more
 CC nucleic acid probes and detecting the hybridisation. The nucleic acid

CC hybridising at least one or more nucleic acids to at least two or more
 CC nucleic acid probes and detecting the hybridisation. The nucleic acid
 CC probes are attached to a solid support. The analysis comprises monitoring
 CC gene expression levels, identifying biallelic markers or polymorphisms,
 CC or family members of a gene and a cross-species comparison. Each of the
 CC nucleic acids further comprises a tag sequence. The array of nucleic acid
 CC probes is useful in in situ hybridisation, in Southern, Northern or dot-
 CC blot hybridisation to identify or detect the sequence or specific
 CC mutations of any gene, in mapping the 5' termini of mRNA molecules by
 CC primer extensions or in screening cDNA or genomic libraries or subclones
 CC for additional subclones containing segments of DNA that have been
 CC isolated and previously sequenced. The sequence presented is one of the
 CC nucleic acid probes incorporated in the microarray. Note: The sequence
 CC data for this patent can also be obtained in electronic format directly
 CC from USPTO at seqdata.uspto.gov/sequence.html
 XX
 XX Sequence 25 BP; 5 A; 3 C; 7 G; 10 T; 0 U; 0 Other;
 SQ
 Query Match 0.5%; Score 20.2; DB 1; Length 25;
 Best Local Similarity 88.0%; Pred. No. 5.4e+02;
 Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 3763 ACTTTCGAAAAATAAGACACCTG 3787
 Db ACTTACCGAAAACTTAAGACACCTG 1
 RESULT 316
 ACI58588/c
 ID ACI58588 standard; DNA; 25 BP.
 XX
 AC ACI58588;
 XX
 DT 13-OCT-2003 (first entry)
 DE Human microarray DNA oligonucleotide SEQ ID NO 58579.
 XX
 KW EST; ss; probe; expressed sequence tag; microarray; gene expression;
 KW genetic variation; biallelic marker; polymorphism; human;
 KW cross-species comparison.
 XX
 OS Homo sapiens.
 XX
 PN US2003104410-A1.
 XX
 PD 05-JUN-2003.
 XX
 PF 15-MAR-2002; 2002US-00098263.
 XX
 PR 16-MAR-2001; 2001US-0276759P.
 XX
 PA (AFFY-) AFFYMETRIX INC.
 XX
 PI Mittmann MP;
 XX
 DR WPI; 2003-567953/53.
 XX
 PT New array of nucleic acid probes, useful for in situ hybridization, in
 PT Southern, Northern or dot-blot hybridization to identify or detect the
 PT sequence or specific mutations of any gene.
 XX
 PS Claim 1; SEQ ID NO 58579; 9pp; English.
 XX
 CC The invention discloses a microarray comprising a plurality of nucleic
 CC acid probes including one of 2,018,500 fully defined sequences, or its
 CC perfect match, perfect mismatch, antisense match or antisense mismatch.
 CC Also disclosed is a method of gene expression analysis. The array is used
 CC in monitoring gene expression levels by hybridisation to a DNA library,
 CC in analysing gene expression levels by hybridisation of tag-labelled
 CC compounds. The nucleic acid probes are specifically designed for analysis
 CC of at least one target sequence. The method of analysis comprises
 CC hybridising at least one or more nucleic acids to at least two or more
 CC nucleic acid probes and detecting the hybridisation. The nucleic acid

CC probes are attached to a solid support. The analysis comprises monitoring
 CC gene expression levels, identifying allelic markers or polymorphisms,
 CC or family members of a gene and a cross-species comparison. Each of the
 CC nucleic acids further comprises a tag sequence. The array of nucleic acid
 CC probes is useful in situ hybridisation, in Southern, Northern or dot-
 CC blot hybridisation to identify or detect the sequence or specific
 CC mutations of any gene, in mapping the 5' termini of mRNA molecules by
 CC primer extensions or in screening cDNA or genomic libraries or subclones
 CC for additional subclones containing segments of DNA that have been
 CC isolated and previously sequenced. The sequence presented is one of the
 CC nucleic acid probes incorporated in the microarray. Note: The sequence
 CC data for this patent can also be obtained in electronic format directly
 CC from USPTO at seqdata.uspto.gov/sequence.html

XX SQ Sequence 25 BP; 5 A; 4 C; 6 G; 10 T; 0 U; 0 Other;

Query Match 0.5%; Score 20.2; DB 1; Length 25;
 Best Local Similarity 88.0%; Pred. No. 5.4e+02;
 Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 3763 ACTTCCGAAATTAAGACACTG 3787

Db 25 ACTTACCGAAAGTTAAGACACTG 1

RESULT 317

ADB38952

ID ADB38952 standard; DNA; 25 BP.

XX AC ADB38952;

XX 04-DEC-2003 (first entry)

DT Human interleukin 1RNic single nucleotide polymorphism (SNP) region 21.

XX DE

XX interleukin 1 gene cluster; IL-1 like gene;

XX IL-1 locus; single nucleotide polymorphisms; SNP; IL-1 haplotype;

XX inflammatory disease; IL-1 associated inflammatory phenotype;

XX primary inflammatory cytokine; IL-1 alpha; IL-1 beta; IL1A; IL1B; IL1RN;

XX IL-1 receptor antagonist; IL-1RA; anti-inflammatory; chromosome 2q13;

XX antiinflammatory; antiarthritic; hepatotropic; osteopathic; gene therapy;

XX arthritis; hepatic inflammation; chronic obstructive pulmonary disease;

XX osteoporosis; ds; IL-1RNic.

XX OS Homo sapiens.

XX Key Location/Qualifiers

XX variation replace(11,T)

XX /*tag= a

XX /standard_name= "Single nucleotide polymorphism"

XX WO2003064600-A2.

XX 07-AUG-2003.

XX 27-JAN-2003; 2003WO-US002232.

XX 25-JAN-2002; 2002US-0351951P.

XX (INTE-) INTERLEUKIN GENETICS INC.

XX Nicklin M, Duff G, Kornman K, Kolpin MR, Hsieh C, Govindaraju R;

XX Aziz N;

XX WPI; 2003-618359/58.

XX Determining whether the subject has or is predisposed to developing a

XX disease or condition that is associated with an IL-1 inflammatory

XX PT haplotype, useful for treating inflammation, comprises detecting an IL-1

XX allele.

XX Claim 18; Fig 10A; 96pp; English.

XX PS

CC This invention relates to the identification and use of genetic
 CC information from the human interleukin 1 (IL-1) gene cluster including
 CC the structure and organisation of novel IL-1 like genes found within the
 CC IL-1 locus as well as polymorphisms (single nucleotide polymorphisms;
 CC SNPs) and associated haplotypes within these genes. The invention also
 CC relates to the use of these polymorphisms and haplotypes for predicting
 CC IL-1 associated phenotypes (for example increased or decreased risk of
 CC inflammatory disease) and for treating IL-1 associated inflammatory
 CC phenotypes. IL-1 is a primary inflammatory cytokine and has been
 CC implicated in mediating both acute and chronic pathological inflammatory
 CC diseases. Two functionally similar molecules, IL-1 alpha and IL-1 beta,
 CC are encoded by genes IL1A and IL1B. A third gene of the family (IL1RN)
 CC encodes IL-1 receptor antagonist (IL-1RA), an anti-inflammatory non-
 CC signalling molecule that competes for receptor binding with IL-1 alpha
 CC and IL-1 beta. The IL-1 gene cluster is on the long arm of chromosome 2
 CC (2q13). Compounds which modulate the activity of IL-1 alpha, IL-1 beta or
 CC IL-1RA may have antiinflammatory, antiarthritic, hepatotropic or
 CC osteopathic activity. In addition, the sequences encoding the IL-1
 CC proteins may be useful for gene therapy. The methods and polynucleotide
 CC sequences may be useful for diagnosing and treating an inflammatory
 CC disease, for example arthritis, hepatic inflammation, chronic obstructive
 CC pulmonary disease and osteoporosis. The present sequence is that of the
 CC region surrounding and including a single nucleotide polymorphism of the
 CC invention in the human IL1RN gene.

XX SQ Sequence 25 BP; 0 A; 1 C; 11 G; 13 T; 0 U; 0 Other;

Query Match 0.5%; Score 20.2; DB 1; Length 25;

Best Local Similarity 88.0%; Pred. No. 5.4e+02;

Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 2319 GTGTGTGTGTGTGTGTCGTCGTGTGTG 2343

Db 1 GTGTGTGTGTGTGTGTGTGTGTGTGTG 25

RESULT 318

AA34894/c

ID AAX34894 standard; DNA; 20 BP.

XX AC AAX34894;

XX 28-JUN-1999 (first entry)

DT PCR primer used to amplify FGFR3.

XX DE

XX Immortalized human hair papilla cell; HPC; screening; hair growth;

XX SV40 viral Large T-antigen gene; deleted replication initiation point;

XX hair growth stimulating agent; PCR primer; ss.

XX OS Synthetic.

XX JP11089565-A.

XX 06-APR-1999.

XX 19-SEP-1997; 97JP-00271927.

XX 19-SEP-1997; 97JP-00271927.

XX (SHIS) SHISEIDO CO LTD.

XX WPI; 1999-281045/24.

XX Immortalised human hair papilla cells used for evaluation of hair growth

XX agent - are prepared by transfection of human hair papilla cells with

XX gene with deleted replication initiation point.

XX Example 2; Page 7; 23pp; Japanese.

XX The specification describes the preparation of immortalized human hair

XX papilla cells (HPC). The method comprises transfection of HPC with an

XX SV40 viral Large T-antigen gene with deleted replication initiation

CC point. The immortalized HPC can be used in a screening method for a hair
CC growth agent, by culture of immortalized HPC in the presence of a
CC substance to be tested and observation of the growth of the immortalized
CC HPC. HPC is also used in development of hair growth stimulating agents.
CC The present sequence represents a PCR primer, which is used in the course
CC of the invention

XX SQ Sequence 20 BP; 3 A; 6 C; 3 G; 8 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1297 AAGATGCTGAAGACGATGC 1316
|||||
DB 20 AAGATGCTGAAGACGATGC 1

RESULT 319
AAA54426/C
ID AAA54426 standard; DNA; 20 BP.
XX AC AAA54426;
XX DT 11-APR-2001 (first entry)
XX DE Primer used for detecting mutant fibroblast growth factor receptor 3.
XX KW Fibroblast growth factor 3 receptor; FGFR3; mutant; detection; cancer;
XX KW carcinoma; lung cancer; breast cancer; colon cancer; skin cancer;
XX KW bladder; cervix; human; primer; ss.
XX OS Synthetic.
XX PN WO200068424-A2.
XX PD 16-NOV-2000.
XX PF 04-MAY-2000; 2000WO-EP004591.
XX PR 05-MAY-1999; 99US-0132705P.
XX PA (CURI-) INST CURIE.
XX PA (CNRS) CNRS CENT NAT RECH SCI.
XX PI Cappellen D, Chopin D, Radvanyi F, Ricol D, Thiery J;
XX DR WPI; 2001-016103/02.

XX Diagnosing carcinoma e.g. bladder or cervix carcinomas in a biological
PT sample such as tissue, bone marrow or body fluid, preferably from animal
PT or human, by identifying fibroblast growth factor receptor 3 mutations.
XX Example 4; Page 13; 41pp; English.

XX The identification of fibroblast growth factor receptor 3 (FGFR3)
CC mutations in a biological sample such as tissue, bone marrow or body
CC fluid e.g. urine, from a warm-blooded animal, preferably human is useful
CC for diagnosing carcinomas such as human bladder and cervix carcinomas, or
CC cancers associated with lung, breast, colon and skin. The pharmaceutical
CC preparations comprising agents which inhibit the synthesis and expression
CC of FGFR3 and so have an anti-proliferation effect on carcinomas can be
CC used to treat cancer. Two primers (AAA54426, AAA54583) were used in PCR
CC reactions on urine samples to detect the S249C mutation in FGFR3
XX Sequence 20 BP; 2 A; 7 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 557 CCAACGACGCGGCTGCTG 576
|||||

DB 20 CCAACGACGCGGCTGCTG 1
RESULT 320
AAD55461/C
ID AAD55461 standard; DNA; 20 BP.
XX AC AAD55461;
XX DT 07-AUG-2003 (first entry)
XX DE Human FGFR-3 antisense oligonucleotide, ISIS #125165.
XX KW Human; antisense; fibroblast growth factor receptor 3; prophylaxis;
KW developmental disorder; hyperproliferative disorder; antisense therapy;
KW FGFR-3; ACH; JTK4; CEK2; cancer; phosphorothioate; ss.
XX OS Homo sapiens.
XX OS Synthetic.
XX FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidine residues
FT are 5-methylcytidines"
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX PN WO2003023004-A2.
XX PD 20-MAR-2003.
XX PF 06-SEP-2002; 2002WO-US028549.
XX PR 10-SEP-2001; 2001US-00953047.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Monia BP, Wyatt JR;
XX DR WPI; 2003-313244/30.
XX Novel compound targeted to a nucleic acid molecule encoding fibroblast
PT growth factor receptor 3, useful for inhibiting the expression of the
PT receptor and for treating an animal having cancer or developmental
PT disorder.
XX Claim 3; Page 79; 120pp; English.
XX The invention relates to antisense compounds targetted to a nucleic acid
CC molecule encoding fibroblast growth factor (FGF) receptor 3 (also known
CC as FGFR-3, ACH, JTK4 and CEK2) to inhibit its expression. Antisense
CC compounds of the invention are useful for treating diseases or conditions
CC associated with FGFR-3 such as developmental disorders or
CC hyperproliferative disorders, especially cancer of colorectal, bladder,
CC bone, lung, cervical, breast or skin. They are useful as research
CC reagents, therapeutics, prophylaxis, kits and diagnostics, and as tools
CC in differential and/or combinatorial analyses to elucidate expression
CC patterns of a portion of the genes expressed within cells and tissues.
CC They are also useful in antisense therapy. The present sequence is an
CC antisense oligonucleotide targetted to human FGFR-3
XX Sequence 20 BP; 5 A; 8 C; 5 G; 2 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.4e+02;

		Matches	20; Conservative	0; Mismatches	0; Indels	0; Gaps	0;
SQ	Sequence	20 BP; 6 A; 6 C; 6 G; 2 T; 0 U; 0 Other;					
	Query Match	0.5%; Score 20; DB 1; Length 20;					
QY	Best Local Similarity	100.0%; Pred. No. 4.4e+02;					
	Matches	20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;					
Db	127	CTGTGCCACTTCAGTGTGCG	146				
	20	CTGTGCCACTTCAGTGTGCG	1				
RESULT 322							
AAD55435/c							
ID	AAD55435 standard; DNA; 20 BP.						
XX							
AC	AAD55435;						
XX							
07-AUG-2003	(first entry)						
XX							
Human FGFR-3	antisense oligonucleotide, ISIS #125118.						
XX							
Human; antisense;	fibroblast growth factor receptor 3; prophylaxis;						
developmental disorder;	hyperproliferative disorder; antisense therapy;						
FGFR-3; ACH; JTK4; CEK2;	cancer; phosphorothioate; ss.						
XX							
Homo sapiens.							
OS	Synthetic.						
XX							
Key	Location/Qualifiers						
FT	modified_base	1..20					
FT		/*tag= a					
FT		/mod_base= OTHER					
FT		/note= "Phosphorothioate backbone; All cytidine residues					
FT		are 5-methylcytidines"					
FT	modified_base	1..5					
FT		/*tag= b					
FT		/mod_base= OTHER					
FT		/note= "2'-methoxyethyl (2'-MOE) nucleotides"					
FT	modified_base	16..20					
FT		/*tag= c					
FT		/mod_base= OTHER					
FT		/note= "2'-methoxyethyl (2'-MOE) nucleotides"					
XX							
WO2003023004-A2.							
XX							
20-MAR-2003.							
XX							
06-SEP-2002;	2002WO-US028549.						
XX							
10-SEP-2001;	2001US-00953047.						
XX							
(ISIS-)	ISIS PHARM INC.						
XX							
Monia BP, Wyatt JR;							
XX							
WPI; 2003-313244/30.							
XX							
Novel compound	targeted to a nucleic acid molecule encoding fibroblast						
growth factor receptor 3,	useful for inhibiting the expression of the						
receptor and for treating	an animal having cancer or developmental						
disorder.							
XX							
Claim 3; Page 78; 120pp; English.							
XX							
The invention	relates to antisense compounds targetted to a nucleic acid						
molecule encoding	fibroblast growth factor (FGF) receptor 3 (also known						
as FGFR-3, ACH, JTK4 and CEK2)	to inhibit its expression. Antisense						
compounds of the	invention are useful for treating diseases or conditions						
associated with	FGFR-3 such as developmental disorders or						
hyperproliferative	disorders, especially cancer of colorectal, bladder,						
bone, lung, cervical,	breast or skin. They are useful as research						
reagents, therapeutics,	prophylaxis, kits and diagnostics, and as tools						
in differential	and/or combinatorial analyses to elucidate expression						
patterns of a portion	of the genes expressed within cells and tissues.						
They are also	useful in antisense therapy. The present sequence is an						
antisense oligonucleotide	targetted to human FGFR-3						
XX							

CC patterns of a portion of the genes expressed within cells and tissues.
 CC They are also useful in antisense therapy. The present sequence is an
 CC antisense oligonucleotide targetted to human FGFR-3
 XX
 SQ Sequence 20 BP; 4 A; 6 C; 5 G; 5 T; 0 U; 0 Other;
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 4.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 584 ACGTGAGTCCACTGCAAG 603
 Db 20 ACGTGAGTCCACTGCAAG 1
 RESULT 323
 AAD55440/c
 ID AAD55440 standard; DNA; 20 BP.
 XX
 AC AAD55440;
 XX
 DT 07-AUG-2003 (first entry)
 XX
 DE Human FGFR-3 antisense oligonucleotide, ISIS #125135.
 XX
 KW Human; antisense; fibroblast growth factor receptor 3; prophylaxis;
 KW developmental disorder; hyperproliferative disorder; antisense therapy;
 KW FGFR-3; ACH; JTK4; CEK2; cancer; phosphorothioate; ss.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /tag= a
 FT /mod_base= OTHER
 FT /note= "Phosphorothioate backbone; All cytidine residues
 FT are 5-methylcytidines"
 FT modified_base 1..5
 FT /tag= b
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 FT modified_base 16..20
 FT /tag= c
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 XX
 PN WO2003023004-A2.
 XX
 PD 20-MAR-2003.
 XX
 PF 06-SEP-2002; 2002WO-US028549.
 XX
 PR 10-SEP-2001; 2001US-00953047.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Monia BP, Wyatt JR;
 XX
 XX WPI; 2003-313244/30.
 DR
 XX
 XX Novel compound targetted to a nucleic acid molecule encoding fibroblast
 PT growth factor receptor 3, useful for inhibiting the expression of the
 PT receptor and for treating an animal having cancer or developmental
 PT disorder.
 XX
 PS Example 15; Page 78; 120pp; English.
 XX
 CC The invention relates to antisense compounds targetted to a nucleic acid
 CC molecule encoding fibroblast growth factor (FGF) receptor 3 (also known
 CC as FGFR-3, ACH, JTK4 and CEK2) to inhibit its expression. Antisense
 CC compounds of the invention are useful for treating diseases or conditions
 CC associated with FGFR-3 such as developmental disorders or

CC hyperproliferative disorders, especially cancer of colorectal, bladder,
 CC bone, lung, cervical, breast or skin. They are useful as research
 CC reagents, therapeutics, prophylaxis, kits and diagnostics, and as tools
 CC in differential and/or combinatorial analyses to elucidate expression
 CC patterns of a portion of the genes expressed within cells and tissues.
 CC They are also useful in antisense therapy. The present sequence is an
 CC antisense oligonucleotide targetted to human FGFR-3
 XX
 SQ Sequence 20 BP; 2 A; 7 C; 7 G; 4 T; 0 U; 0 Other;
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 4.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1688 TGGCCCGGACGTGCACAC 1707
 Db 20 TGGCCCGGACGTGCACAC 1
 RESULT 324
 AAD55449/c
 ID AAD55449 standard; DNA; 20 BP.
 XX
 AC AAD55449;
 XX
 DT 07-AUG-2003 (first entry)
 XX
 DE Human FGFR-3 antisense oligonucleotide, ISIS #125151.
 XX
 KW Human; antisense; fibroblast growth factor receptor 3; prophylaxis;
 KW developmental disorder; hyperproliferative disorder; antisense therapy;
 KW FGFR-3; ACH; JTK4; CEK2; cancer; phosphorothioate; ss.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /tag= a
 FT /mod_base= OTHER
 FT /note= "Phosphorothioate backbone; All cytidine residues
 FT are 5-methylcytidines"
 FT modified_base 1..5
 FT /tag= b
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 FT modified_base 16..20
 FT /tag= c
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 XX
 PN WO2003023004-A2.
 XX
 PD 20-MAR-2003.
 XX
 PF 06-SEP-2002; 2002WO-US028549.
 XX
 PR 10-SEP-2001; 2001US-00953047.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Monia BP, Wyatt JR;
 XX
 XX WPI; 2003-313244/30.
 DR
 XX
 XX Novel compound targetted to a nucleic acid molecule encoding fibroblast
 PT growth factor receptor 3, useful for inhibiting the expression of the
 PT receptor and for treating an animal having cancer or developmental
 PT disorder.
 XX
 PS Claim 3; Page 79; 120pp; English.
 XX
 CC The invention relates to antisense compounds targetted to a nucleic acid

CC molecule encoding fibroblast growth factor (FGF) receptor 3 (also known
CC as FGFR-3, ACH, JTK4 and CEK2) to inhibit its expression. Antisense
CC compounds of the invention are useful for treating diseases or conditions
CC associated with FGFR-3 such as developmental disorders or
CC hyperproliferative disorders, especially cancer of colorectal, bladder,
CC bone, lung, cervical, breast or skin. They are useful as research
CC reagents, therapeutics, prophylaxis, kits and diagnostics, and as tools
CC in differential and/or combinatorial analyses to elucidate expression
CC patterns of a portion of the genes expressed within cells and tissues.
CC They are also useful in antisense therapy. The present sequence is an
CC antisense oligonucleotide targetted to human FGFR-3
XX
XX
SQ Sequence 20 BP; 2 A; 7 C; 6 G; 5 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2870 GTACAACGGAGGCTCGAC 2889
Db 20 GTACAACGGAGGCTCGAC 1
RESULT 325
AAD55484/c
ID AAD55484 standard; DNA; 20 BP.
XX
XX AAD55484;
AC
XX 07-AUG-2003 (first entry)
DT
XX Human FGFR-3 antisense oligonucleotide, ISIS #125190.
DE
XX Human; antisense; fibroblast growth factor receptor 3; prophylaxis;
XX developmental disorder; hyperproliferative disorder; antisense therapy;
KW FGFR-3; ACH; JTK4; CEK2; cancer; phosphorothioate; ss.
KW
XX Homo sapiens.
OS
XX Synthetic.
XX
XX Key Location/Qualifiers
FH modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidine residues
FT modified_base 1..5
FT /tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /tag= c
FT /mod_base= OTHER
FT /note= "2 -methoxyethyl (2'-MOE) nucleotides"
XX WO2003023004-A2.
XX
XX 20-MAR-2003.
PD
XX
XX 06-SEP-2002; 2002WO-US028549.
XX
XX 10-SEP-2001; 2001US-00953047.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Monia BP, Wyatt JR;
XX
XX WPI; 2003-313244/30.
XX
XX Novel compound targetted to a nucleic acid molecule encoding fibroblast
XX growth factor receptor 3, useful for inhibiting the expression of the
XX receptor and for treating an animal having cancer or developmental
XX disorder.

XX
PS Claim 3; Page 79; 120pp; English.
XX
CC The invention relates to antisense compounds targetted to a nucleic acid
CC molecule encoding fibroblast growth factor (FGF) receptor 3 (also known
CC as FGFR-3, ACH, JTK4 and CEK2) to inhibit its expression. Antisense
CC compounds of the invention are useful for treating diseases or conditions
CC associated with FGFR-3 such as developmental disorders or
CC hyperproliferative disorders, especially cancer of colorectal, bladder,
CC bone, lung, cervical, breast or skin. They are useful as research
CC reagents, therapeutics, prophylaxis, kits and diagnostics, and as tools
CC in differential and/or combinatorial analyses to elucidate expression
CC patterns of a portion of the genes expressed within cells and tissues.
CC They are also useful in antisense therapy. The present sequence is an
CC antisense oligonucleotide targetted to human FGFR-3
XX
XX
SQ Sequence 20 BP; 4 A; 6 C; 6 G; 4 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 471 CAAGTTGGCAGCATCCGC 490
Db 20 CAAGTTGGCAGCATCCGC 1
RESULT 326
AAD55486/c
ID AAD55486 standard; DNA; 20 BP.
XX
XX AAD55486;
AC
XX 07-AUG-2003 (first entry)
DT
XX Human FGFR-3 antisense oligonucleotide, ISIS #125192.
DE
XX Human; antisense; fibroblast growth factor receptor 3; prophylaxis;
XX developmental disorder; hyperproliferative disorder; antisense therapy;
KW FGFR-3; ACH; JTK4; CEK2; cancer; phosphorothioate; ss.
KW
XX Homo sapiens.
OS
XX Synthetic.
XX
XX Key Location/Qualifiers
FH modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidine residues
FT modified_base 1..5
FT /tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /tag= c
FT /mod_base= OTHER
FT /note= "2 -methoxyethyl (2'-MOE) nucleotides"
XX WO2003023004-A2.
XX
XX 20-MAR-2003.
PD
XX
XX 06-SEP-2002; 2002WO-US028549.
XX
XX 10-SEP-2001; 2001US-00953047.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Monia BP, Wyatt JR;
XX
XX WPI; 2003-313244/30.
XX

PT Novel compound targeted to a nucleic acid molecule encoding fibroblast
PT growth factor receptor 3, useful for inhibiting the expression of the
PT receptor and for treating an animal having cancer or developmental
PT disorder.
XX
PS Claim 3; Page 79; 120pp; English.
XX
CC The invention relates to antisense compounds targetted to a nucleic acid
CC molecule encoding fibroblast growth factor (FGF) receptor 3 (also known
CC as FGFR-3, ACH, JTK4 and CEK2) to inhibit its expression. Antisense
CC compounds of the invention are useful for treating diseases or conditions
CC associated with FGFR-3 such as developmental disorders or
CC hyperproliferative disorders, especially cancer of colorectal, bladder,
CC bone, lung, cervical, breast or skin. They are useful as research
CC reagents, therapeutics, prophylaxis, kits and diagnostics, and as tools
CC in differential and/or combinatorial analyses to elucidate expression
CC patterns of a portion of the genes expressed within cells and tissues.
CC They are also useful in antisense therapy. The present sequence is an
CC antisense oligonucleotide targetted to human FGFR-3
XX
SQ Sequence 20 BP; 1 A; 5 C; 7 G; 7 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.4e+02; Mismatches 0; Indels 0; Gaps 0;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 720 CACCACCGACAGGAGCTAG 739
DB 20 CACCACCGACAGGAGCTAG 1
|||||

RESULT 327
AAD55488/C
ID AAD55488 standard; DNA; 20 BP.
XX
AC AAD55488;
XX
DT 07-AUG-2003 (first entry)
XX
DE Human FGFR-3 antisense oligonucleotide, ISIS #125194.
XX
KW Human; antisense; fibroblast growth factor receptor 3; prophylaxis;
KW developmental disorder; hyperproliferative disorder; antisense therapy;
KW FGFR-3; ACH; JTK4; CEK2; cancer; phosphorothioate; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX

Key Location/Qualifiers
FH modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidine residues
FT are 5-methylcytidines"
FT modified_base 1..5
FT /tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 15..20
FT /tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX WO2003023004-A2.
PN
PD 20-MAR-2003.
XX
PF 06-SEP-2002; 2002WO-US028549.
XX
PR 10-SEP-2001; 2001US-00953047.
XX
PA (ISIS-) ISIS PHARM INC.
XX

PI Monia BP, Wyatt JR;
XX
DR WPI; 2003-313244/30.
XX
PT Novel compound targeted to a nucleic acid molecule encoding fibroblast
PT growth factor receptor 3, useful for inhibiting the expression of the
PT receptor and for treating an animal having cancer or developmental
PT disorder.
XX
PS Claim 3; Page 79; 120pp; English.
XX
CC The invention relates to antisense compounds targetted to a nucleic acid
CC molecule encoding fibroblast growth factor (FGF) receptor 3 (also known
CC as FGFR-3, ACH, JTK4 and CEK2) to inhibit its expression. Antisense
CC compounds of the invention are useful for treating diseases or conditions
CC associated with FGFR-3 such as developmental disorders or
CC hyperproliferative disorders, especially cancer of colorectal, bladder,
CC bone, lung, cervical, breast or skin. They are useful as research
CC reagents, therapeutics, prophylaxis, kits and diagnostics, and as tools
CC in differential and/or combinatorial analyses to elucidate expression
CC patterns of a portion of the genes expressed within cells and tissues.
CC They are also useful in antisense therapy. The present sequence is an
CC antisense oligonucleotide targetted to human FGFR-3
XX
SQ Sequence 20 BP; 6 A; 6 C; 6 G; 2 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.4e+02; Mismatches 0; Indels 0; Gaps 0;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 820 CATCACTCTGCGTGGCTGGT 839
DB 20 CATCACTCTGCGTGGCTGGT 1
|||||

RESULT 328
AAD55432/C
ID AAD55432 standard; DNA; 20 BP.
XX
AC AAD55432;
XX
DT 07-AUG-2003 (first entry)
XX
DE Human FGFR-3 antisense oligonucleotide, ISIS #125113.
XX
KW Human; antisense; fibroblast growth factor receptor 3; prophylaxis;
KW developmental disorder; hyperproliferative disorder; antisense therapy;
KW FGFR-3; ACH; JTK4; CEK2; cancer; phosphorothioate; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX

Key Location/Qualifiers
FH modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidine residues
FT are 5-methylcytidines"
FT modified_base 1..5
FT /tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX WO2003023004-A2.
PN
PD 20-MAR-2003.
XX
PF 06-SEP-2002; 2002WO-US028549.
XX

Thu Oct 28 12:48:21 2004

```

PD 10-SEP-2001; 2001US-00953047.
XX (ISIS-) ISIS PHARM INC.
PA Monia BP, Wyatt JR;
XX WPI; 2003-313244/30.
XX Novel compound targeted to a nucleic acid molecule encoding fibroblast
XX growth factor receptor 3, useful for inhibiting the expression of the
XX receptor and for treating an animal having cancer or developmental
XX disorder.
XX Claim 3; Page 78; 120pp; English.
XX The invention relates to antisense compounds targetted to a nucleic acid
XX molecule encoding fibroblast growth factor (FGF) receptor 3 (also known
XX as FGFR-3, ACH, JTK4 and CEK2) to inhibit its expression. Antisense
XX compounds of the invention are useful for treating diseases or conditions
XX associated with FGFR-3 such as developmental disorders or
XX hyperproliferative disorders, especially cancer of colorectal, bladder,
XX bone, lung, cervical, breast or skin. They are useful as research
XX reagents, therapeutics, prophylaxis, kits and diagnostics, and as tools
XX in differential and/or combinatorial analyses to elucidate expression
XX patterns of a portion of the genes expressed within cells and tissues.
XX They are also useful in antisense therapy. The present sequence is an
XX antisense oligonucleotide targetted to human FGFR-3
XX Sequence 20 BP; 1 A; 8 C; 7 G; 4 T; 0 U; 0 Other;
XX
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 230 ACTGGACACGCGCCGAGCGG 249
DB 20 ACTGGACACGCGCCGAGCGG 1

RESULT 329
AADS5453/C
ID AADS5453 standard; DNA; 20 BP.
AC AADS5453;
XX 07-AUG-2003 (first entry)
XX Human FGFR-3 antisense oligonucleotide, ISIS #125155.
XX Human; antisense; fibroblast growth factor receptor 3; prophylaxis;
XX developmental disorder; hyperproliferative disorder; antisense therapy;
XX FGFR-3; ACH; JTK4; CEK2; cancer; phosphorothioate; ss.
XX Homo sapiens.
XX Synthetic.
XX Key Location/Qualifiers
XX modified_base 1..20
XX /tag= a
XX /mod_base= OTHER
XX /note= "Phosphorothioate backbone; All cytidine residues
XX are 5-methylcytidines"
XX modified_base 1..5
XX /tag= b
XX /mod_base= OTHER
XX /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX modified_base 16..20
XX /tag= c
XX /mod_base= OTHER
XX /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX WO2003023004-A2.
XX PN

```

```

PD 20-MAR-2003.
XX 06-SEP-2002; 2002WO-US028549.
XX 10-SEP-2001; 2001US-00953047.
XX (ISIS-) ISIS PHARM INC.
XX Monia BP, Wyatt JR;
XX WPI; 2003-313244/30.
XX Novel compound targeted to a nucleic acid molecule encoding fibroblast
XX growth factor receptor 3, useful for inhibiting the expression of the
XX receptor and for treating an animal having cancer or developmental
XX disorder.
XX Claim 3; Page 79; 120pp; English.
XX The invention relates to antisense compounds targetted to a nucleic acid
XX molecule encoding fibroblast growth factor (FGF) receptor 3 (also known
XX as FGFR-3, ACH, JTK4 and CEK2) to inhibit its expression. Antisense
XX compounds of the invention are useful for treating diseases or conditions
XX associated with FGFR-3 such as developmental disorders or
XX hyperproliferative disorders, especially cancer of colorectal, bladder,
XX bone, lung, cervical, breast or skin. They are useful as research
XX reagents, therapeutics, prophylaxis, kits and diagnostics, and as tools
XX in differential and/or combinatorial analyses to elucidate expression
XX patterns of a portion of the genes expressed within cells and tissues.
XX They are also useful in antisense therapy. The present sequence is an
XX antisense oligonucleotide targetted to human FGFR-3
XX Sequence 20 BP; 1 A; 8 C; 5 G; 6 T; 0 U; 0 Other;
XX
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3157 CCGATAGAGGCGCGCCCAAG 3176
DB 20 CCGATAGAGGCGCGCCCAAG 1

RESULT 330
AADS5455/C
ID AADS5455 standard; DNA; 20 BP.
XX AADS5455;
XX 07-AUG-2003 (first entry)
XX Human FGFR-3 antisense oligonucleotide, ISIS #125157.
XX Human; antisense; fibroblast growth factor receptor 3; prophylaxis;
XX developmental disorder; hyperproliferative disorder; antisense therapy;
XX FGFR-3; ACH; JTK4; CEK2; cancer; phosphorothioate; ss.
XX Homo sapiens.
XX Synthetic.
XX Key Location/Qualifiers
XX modified_base 1..20
XX /tag= a
XX /mod_base= OTHER
XX /note= "Phosphorothioate backbone; All cytidine residues
XX are 5-methylcytidines"
XX modified_base 1..5
XX /tag= b
XX /mod_base= OTHER
XX /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX modified_base 16..20
XX /tag= c
XX /mod_base= OTHER
XX

```

```
FT XX /note= "2'-methoxyethyl (2'-MOE) nucleotides"  
PN WO2003023004-A2.  
XX 20-MAR-2003.  
XX 06-SEP-2002; 2002WO-US028549.  
XX 10-SEP-2001; 2001US-00953047.  
XX (ISIS-) ISIS PHARM INC.  
XX Monia BP, Wyatt JR;  
XX WPI; 2003-313244/30.  
XX Novel compound targeted to a nucleic acid molecule encoding fibroblast  
PT growth factor receptor 3, useful for inhibiting the expression of the  
PT receptor and for treating an animal having cancer or developmental  
PT disorder.  
XX Claim 3; Page 79; 120pp; English.  
XX The invention relates to antisense compounds targetted to a nucleic acid  
CC molecule encoding fibroblast growth factor (FGF) receptor 3 (also known  
CC as FGFR-3, ACH, JTK4 and CEK2) to inhibit its expression. Antisense  
CC compounds of the invention are useful for treating diseases or conditions  
CC associated with FGFR-3 such as developmental disorders or  
CC hyperproliferative disorders, especially cancer of colorectal, bladder,  
CC bone, lung, cervical, breast or skin. They are useful as research  
CC reagents, therapeutics, prophylaxis, kits and diagnostics, and as tools  
CC in differential and/or combinatorial analyses to elucidate expression  
CC patterns of a portion of the genes expressed within cells and tissues.  
CC They are also useful in antisense therapy. The present sequence is an  
CC antisense oligonucleotide targetted to human FGFR-3  
XX Sequence 20 BP; 9 A; 4 C; 4 G; 3 T; 0 U; 0 Other;  
SQ Query Match 0.5%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 4.4e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 3273 CTTTGTCTTTTCAGGAGA 3292  
DB 20 CTTTGTCTTTTCAGGAGA 1  
RESULT 331  
AAD55456/C  
ID AAD55456 standard; DNA; 20 BP.  
XX AAD55456;  
AC AAD55456;  
XX 07-AUG-2003 (first entry)  
DE Human FGFR-3 antisense oligonucleotide, ISIS #125160.  
XX Human; antisense; fibroblast growth factor receptor 3; prophylaxis;  
KW developmental disorder; hyperproliferative disorder; antisense therapy;  
KW FGFR-3; ACH; JTK4; CEK2; cancer; phosphorothioate; ss.  
XX Homo sapiens.  
OS Synthetic.  
XX Key Location/Qualifiers  
PH modified_base 1..20  
FT /tag= a  
FT /mod_base= OTHER  
FT /note= "Phosphorothioate backbone; All cytidine residues  
FT are 5-methylcytidines"  
FT modified_base 1..5  
FT /tag= b  
FT /mod_base= OTHER  
FT FT
```

```
FT FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"  
FT modified_base 16..20  
FT /tag= c  
FT /mod_base= OTHER  
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"  
XX WO2003023004-A2.  
XX 20-MAR-2003.  
XX 06-SEP-2002; 2002WO-US028549.  
XX 10-SEP-2001; 2001US-00953047.  
XX (ISIS-) ISIS PHARM INC.  
XX Monia BP, Wyatt JR;  
XX WPI; 2003-313244/30.  
XX Novel compound targeted to a nucleic acid molecule encoding fibroblast  
PT growth factor receptor 3, useful for inhibiting the expression of the  
PT receptor and for treating an animal having cancer or developmental  
PT disorder.  
XX Claim 3; Page 79; 120pp; English.  
XX The invention relates to antisense compounds targetted to a nucleic acid  
CC molecule encoding fibroblast growth factor (FGF) receptor 3 (also known  
CC as FGFR-3, ACH, JTK4 and CEK2) to inhibit its expression. Antisense  
CC compounds of the invention are useful for treating diseases or conditions  
CC associated with FGFR-3 such as developmental disorders or  
CC hyperproliferative disorders, especially cancer of colorectal, bladder,  
CC bone, lung, cervical, breast or skin. They are useful as research  
CC reagents, therapeutics, prophylaxis, kits and diagnostics, and as tools  
CC in differential and/or combinatorial analyses to elucidate expression  
CC patterns of a portion of the genes expressed within cells and tissues.  
CC They are also useful in antisense therapy. The present sequence is an  
CC antisense oligonucleotide targetted to human FGFR-3  
XX Sequence 20 BP; 8 A; 3 C; 3 G; 6 T; 0 U; 0 Other;  
SQ Query Match 0.5%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 4.4e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 3349 GCTGGTATTTTCATACAAAT 3368  
DB 20 GCTGGTATTTTCATACAAAT 1  
RESULT 332  
AAD55458/C  
ID AAD55458 standard; DNA; 20 BP.  
XX AAD55458;  
AC AAD55458;  
XX 07-AUG-2003 (first entry)  
DE Human FGFR-3 antisense oligonucleotide, ISIS #125162.  
XX Human; antisense; fibroblast growth factor receptor 3; prophylaxis;  
KW developmental disorder; hyperproliferative disorder; antisense therapy;  
KW FGFR-3; ACH; JTK4; CEK2; cancer; phosphorothioate; ss.  
XX Homo sapiens.  
OS Synthetic.  
XX Key Location/Qualifiers  
PH modified_base 1..20  
FT /tag= a  
FT /mod_base= OTHER  
FT /note= "Phosphorothioate backbone; All cytidine residues  
FT are 5-methylcytidines"  
FT modified_base 1..5  
FT /tag= b  
FT /mod_base= OTHER  
FT FT
```

Thu Oct 28 12:48:21 2004

```

FT      modified_base      1..20      /tag= a
FT      /mod_base= OTHER
FT      /note= "Phosphorothioate backbone; All cytidine residues
FT      are 5-methylcytidines"
FT      modified_base      1..5
FT      /tag= b
FT      /mod_base= OTHER
FT      /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT      modified_base      16..20
FT      /tag= c
FT      /mod_base= OTHER
FT      /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
XX      WO2003023004-A2.
XX
XX      20-MAR-2003.
XX
XX      06-SEP-2002; 2002WO-US028549.
XX
XX      10-SEP-2001; 2001US-00953047.
XX
XX      (ISIS-) ISIS PHARM INC.
XX
XX      Monia BP, Wyatt JR;
XX
XX      WPI; 2003-313244/30.
XX
XX      Novel compound targeted to a nucleic acid molecule encoding fibroblast
XX      growth factor receptor 3, useful for inhibiting the expression of the
XX      receptor and for treating an animal having cancer or developmental
XX      disorder.
XX
XX      Claim 3; Page 79; 120pp; English.
XX
XX      The invention relates to antisense compounds targetted to a nucleic acid
XX      molecule encoding fibroblast growth factor (FGF) receptor 3 (also known
XX      as FGFR-3, ACH, JTK4 and CEK2) to inhibit its expression. Antisense
XX      compounds of the invention are useful for treating diseases or conditions
XX      associated with FGFR-3 such as developmental disorders or
XX      hyperproliferative disorders, especially cancer of colorectal, bladder,
XX      bone, lung, cervical, breast or skin. They are useful as research
XX      reagents, therapeutics, prophylaxis, kits and diagnostics, and as tools
XX      in differential and/or combinatorial analyses to elucidate expression
XX      patterns of a portion of the genes expressed within cells and tissues.
XX      They are also useful in antisense therapy. The present sequence is an
XX      Antisense oligonucleotide targetted to human FGFR-3
XX
XX      Sequence 20 BP; 6 A; 7 C; 5 G; 2 T; 0 U; 0 Other;
XX
XX      Query Match      0.5%; Score 20; DB 1; Length 20;
XX      Best Local Similarity 100.0%; Pred. No. 4.4e+02;
XX      Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY      3424 CCTGTGTCAGGTTCCGATG 3443
Db      20 CCTGTGTCAGGTTCCGATG 1

RESULT 333
AAD55437/c
ID      AAD55437 standard; DNA; 20 BP.
AC      AAD55437;
XX
XX      07-AUG-2003 (first entry)
XX
XX      Human FGFR-3 antisense oligonucleotide, ISIS #125127.
XX
XX      Human; antisense; fibroblast growth factor receptor 3; prophylaxis;
XX      developmental disorder; hyperproliferative disorder; antisense therapy;
XX      FGFR-3; ACH; JTK4; CEK2; cancer; phosphorothioate; ss.
XX
XX      Homo sapiens.
XX      Synthetic.
XX
XX      Key      Location/Qualifiers
XX
XX      Query Match      0.5%; Score 20; DB 1; Length 20;
XX      Best Local Similarity 100.0%; Pred. No. 4.4e+02;
XX      Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY      897 AGGCATCCTCAGTACGGGG 916
Db      20 AGGCATCCTCAGTACGGGG 1

RESULT 334
AAD55443/c
ID      AAD55443 standard; DNA; 20 BP.
AC      AAD55443;
XX
XX      07-AUG-2003 (first entry)
XX
XX      Human FGFR-3 antisense oligonucleotide, ISIS #125144.
XX
XX      Human; antisense; fibroblast growth factor receptor 3; prophylaxis;
XX      developmental disorder; hyperproliferative disorder; antisense therapy;
XX      FGFR-3; ACH; JTK4; CEK2; cancer; phosphorothioate; ss.
XX
XX      Key      Location/Qualifiers
XX

```

OS Homo sapiens.
 OS Synthetic.
 XX Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "Phosphorothioate backbone; All cytidine residues
 FT are 5-methylcytidines"
 FT modified_base 1..5
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 FT modified_base 16..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 XX WO2003023004-A2.
 XX 20-MAR-2003.
 XX 06-SEP-2002; 2002WO-US028549.
 XX 10-SEP-2001; 2001US-00953047.
 XX (ISIS-) ISIS PHARM INC.
 XX Monia BP, Wyatt JR;
 XX WPI; 2003-313244/30.
 XX Novel compound targeted to a nucleic acid molecule encoding fibroblast
 PT growth factor receptor 3, useful for inhibiting the expression of the
 PT receptor and for treating an animal having cancer or developmental
 PT disorder.
 XX Claim 3; Page 78; 120pp; English.
 XX The invention relates to antisense compounds targetted to a nucleic acid
 CC molecule encoding fibroblast growth factor (FGF) receptor 3 (also known
 CC as FGFR-3, ACH, JTK4 and CEK2) to inhibit its expression. Antisense
 CC compounds of the invention are useful for treating diseases or conditions
 CC associated with FGFR-3 such as developmental disorders or
 CC hyperproliferative disorders, especially cancer of colorectal, bladder,
 CC bone, lung, cervical, breast or skin. They are useful as research
 CC reagents, therapeutics, prophylaxis, kits and diagnostics, and as tools
 CC in differential and/or combinatorial analyses to elucidate expression
 CC patterns of a portion of the genes expressed within cells and tissues.
 CC They are also useful in antisense therapy. The present sequence is an
 CC antisense oligonucleotide targetted to human FGFR-3
 XX Sequence 20 BP; 6 A; 7 C; 5 G; 2 T; 0 U; 0 Other;
 SQ Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 4.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2343 GTGTGTGTCACATCCGCGT 2362
 DB 20 GTGTGTGTCACATCCGCGT 1
 RESULT 335
 AAD55483/C
 ID AAD55483 standard; DNA; 20 BP.
 XX AC AAD55483;
 XX AC AAD55483;
 DT 07-AUG-2003 (first entry)
 XX DE Human FGFR-3 antisense oligonucleotide, ISIS #125189.
 XX

KW Human; antisense; fibroblast growth factor receptor 3; prophylaxis;
 KW developmental disorder; hyperproliferative disorder; antisense therapy;
 KW FGFR-3; ACH; JTK4; CEK2; cancer; phosphorothioate; ss.
 XX Homo sapiens.
 OS Synthetic.
 XX Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "Phosphorothioate backbone; All cytidine residues
 FT are 5-methylcytidines"
 FT modified_base 1..5
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 FT modified_base 16..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 XX WO2003023004-A2.
 XX 20-MAR-2003.
 XX 06-SEP-2002; 2002WO-US028549.
 XX 10-SEP-2001; 2001US-00953047.
 XX (ISIS-) ISIS PHARM INC.
 XX Monia BP, Wyatt JR;
 XX WPI; 2003-313244/30.
 XX Novel compound targeted to a nucleic acid molecule encoding fibroblast
 PT growth factor receptor 3, useful for inhibiting the expression of the
 PT receptor and for treating an animal having cancer or developmental
 PT disorder.
 XX Claim 3; Page 79; 120pp; English.
 XX The invention relates to antisense compounds targetted to a nucleic acid
 CC molecule encoding fibroblast growth factor (FGF) receptor 3 (also known
 CC as FGFR-3, ACH, JTK4 and CEK2) to inhibit its expression. Antisense
 CC compounds of the invention are useful for treating diseases or conditions
 CC associated with FGFR-3 such as developmental disorders or
 CC hyperproliferative disorders, especially cancer of colorectal, bladder,
 CC bone, lung, cervical, breast or skin. They are useful as research
 CC reagents, therapeutics, prophylaxis, kits and diagnostics, and as tools
 CC in differential and/or combinatorial analyses to elucidate expression
 CC patterns of a portion of the genes expressed within cells and tissues.
 CC They are also useful in antisense therapy. The present sequence is an
 CC antisense oligonucleotide targetted to human FGFR-3
 XX Sequence 20 BP; 4 A; 6 C; 3 G; 7 T; 0 U; 0 Other;
 SQ Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 4.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 466 GAGACACAGTTGGCAGCAT 485
 DB 20 GAGACACAGTTGGCAGCAT 1
 RESULT 336
 AAD55487/C
 ID AAD55487 standard; DNA; 20 BP.
 XX AC AAD55487;
 XX AC AAD55487;
 XX

DT	07-AUG-2003 (first entry)	AD55503 standard; DNA; 20 BP.
XX		
DE	Human FGFR-3 antisense oligonucleotide, ISIS #125193.	
XX		
KW	Human; antisense; fibroblast growth factor receptor 3; prophylaxis; developmental disorder; hyperproliferative disorder; antisense therapy; FGFR-3; ACH, JTK4; CEK2; cancer; phosphorothioate; ss.	
KW		
XX	Homo sapiens.	
OS	Synthetic.	
XX		
FH	Key	Location/Qualifiers
FT	modified_base	1. .20
FT		/*tag= a
FT		/mod_base= OTHER
FT		/note= "Phosphorothioate backbone; All cytidine residues are 5-methylcytidines"
FT	modified_base	1. .5
FT		/*tag= b
FT		/mod_base= OTHER
FT		/note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT	modified_base	16. .20
FT		/*tag= c
FT		/mod_base= OTHER
FT		/note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX		
XX	WO2003023004-A2.	
XX		
XX	20-MAR-2003.	
XX		
XX	06-SEP-2002; 2002WO-US028549.	
XX		
XX	10-SEP-2001; 2001US-00953047.	
XX		
XX	(ISIS-) ISIS PHARM INC.	
XX		
XX	Monia BP, Wyatt JR;	
XX		
XX	WPI; 2003-313244/30.	
XX		
XX	Novel compound targeted to a nucleic acid molecule encoding fibroblast growth factor receptor 3, useful for inhibiting the expression of the receptor and for treating an animal having cancer or developmental disorder.	
XX		
XX	Claim 3; Page 79; 120pp; English.	
XX		
XX	The invention relates to antisense compounds targetted to a nucleic acid molecule encoding fibroblast growth factor (FGF) receptor 3 (also known as FGFR-3, ACH, JTK4 and CEK2) to inhibit its expression. Antisense compounds of the invention are useful for treating diseases or conditions associated with FGFR-3 such as developmental disorders or hyperproliferative disorders, especially cancer of colorectal, bladder, bone, lung, cervical, breast or skin. They are useful as research reagents, therapeutics, prophylaxis, kits and diagnostics, and as tools in differential and/or combinatorial analyses to elucidate expression patterns of a portion of the genes expressed within cells and tissues. They are also useful in antisense therapy. The present sequence is an antisense oligonucleotide targetted to human FGFR-3	
XX		
SQ	Sequence 20 BP; 3 A; 7 C; 4 G; 6 T; 0 U; 0 Other;	
	Query Match	0.5%; Score 20; DB 1; Length 20;
	Best Local Similarity	100.0%; Pred. No. 4.4e+02;
	Matches	20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY	726 CGACAAGGAGCTAGAGGTTTC 745	
DB	20 CGACAAGGAGCTAGAGGTTTC 1	
	RESULT 337	
	AAD55503/c	

RESULT 338
AAD55445/C
ID AAD55445 standard; DNA; 20 BP.
XX
AC AAD55445;
XX
XX
DT 07-AUG-2003 (first entry)
XX
DE Human FGFR-3 antisense oligonucleotide, ISIS #125146.
XX
KW Human; antisense; fibroblast growth factor receptor 3; prophylaxis;
developmental disorder; hyperproliferative disorder; antisense therapy;
KW FGFR-3; ACH; JTK4; CEK2; cancer; phosphorothioate; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidine residues
are 5-methylcytidines"
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN WO2003023004-A2.
XX
PD 20-MAR-2003.
XX
PF 06-SEP-2002; 2002WO-US028549.
XX
PR 10-SEP-2001; 2001US-00953047.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Monia BP, Wyatt JR;
XX
DR WPI; 2003-313244/30.
XX
XX
PT Novel compound targeted to a nucleic acid molecule encoding fibroblast
growth factor receptor 3, useful for inhibiting the expression of the
receptor and for treating an animal having cancer or developmental
disorder.
XX
PS Claim 3; Page 78; 120pp; English.
XX
CC The invention relates to antisense compounds targetted to a nucleic acid
molecule encoding fibroblast growth factor (FGF) receptor 3 (also known
as FGFR-3, ACH, JTK4 and CEK2) to inhibit its expression. Antisense
compounds of the invention are useful for treating diseases or conditions
associated with FGFR-3 such as developmental disorders or
hyperproliferative disorders, especially cancer of colorectal, bladder,
bone, lung, cervical, breast or skin. They are useful as research
reagents, therapeutics, prophylaxis, kits and diagnostics, and as tools
in differential and/or combinatorial analyses to elucidate expression
patterns of a portion of the genes expressed within cells and tissues.
CC They are also useful in antisense therapy. The present sequence is an
antisense oligonucleotide targetted to human FGFR-3
XX
SQ Sequence 20 BP; 3 A; 8 C; 7 G; 2 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 2534 CTGGGCCCGACATGCTCGG 2553
DB 20 CTGGGCCCGACATGCTCGG 1
RESULT 339
AAD55460/C
ID AAD55460 standard; DNA; 20 BP.
XX
AC AAD55460;
XX
DT 07-AUG-2003 (first entry)
XX
DE Human FGFR-3 antisense oligonucleotide, ISIS #125164.
XX
KW Human; antisense; fibroblast growth factor receptor 3; prophylaxis;
developmental disorder; hyperproliferative disorder; antisense therapy;
KW FGFR-3; ACH; JTK4; CEK2; cancer; phosphorothioate; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidine residues
are 5-methylcytidines"
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN WO2003023004-A2.
XX
PD 20-MAR-2003.
XX
PF 06-SEP-2002; 2002WO-US028549.
XX
PR 10-SEP-2001; 2001US-00953047.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Monia BP, Wyatt JR;
XX
DR WPI; 2003-313244/30.
XX
XX
PT Novel compound targeted to a nucleic acid molecule encoding fibroblast
growth factor receptor 3, useful for inhibiting the expression of the
receptor and for treating an animal having cancer or developmental
disorder.
XX
PS Example 15; Page 79; 120pp; English.
XX
CC The invention relates to antisense compounds targetted to a nucleic acid
molecule encoding fibroblast growth factor (FGF) receptor 3 (also known
as FGFR-3, ACH, JTK4 and CEK2) to inhibit its expression. Antisense
compounds of the invention are useful for treating diseases or conditions
associated with FGFR-3 such as developmental disorders or
hyperproliferative disorders, especially cancer of colorectal, bladder,
bone, lung, cervical, breast or skin. They are useful as research
reagents, therapeutics, prophylaxis, kits and diagnostics, and as tools
in differential and/or combinatorial analyses to elucidate expression
patterns of a portion of the genes expressed within cells and tissues.
CC They are also useful in antisense therapy. The present sequence is an
antisense oligonucleotide targetted to human FGFR-3
XX
SQ Sequence 20 BP; 6 A; 6 C; 6 G; 2 T; 0 U; 0 Other;

CC They are also useful in antisense therapy. The present sequence is an
CC antisense oligonucleotide targeted to human FGFR-3
XX
SQ Sequence 20 BP; 3 A; 2 C; 5 G; 10 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 3767 TCCGAAAAATAAGACACCT 3786
DB 20 TCCGAAAAATAAGACACCT 1
RESULT 341
AAD55490/c
ID AAD55490 standard; DNA; 20 BP.
XX
AC AAD55490;
XX
DT 07-AUG-2003 (first entry)
XX
DE Human FGFR-3 antisense oligonucleotide, ISIS #125196.
XX
KW Human; antisense; fibroblast growth factor receptor 3; prophylaxis;
KW developmental disorder; hyperproliferative disorder; antisense therapy;
KW FGFR-3; ACH; JTK4; CEK2; cancer; phosphorothioate; ss.
XX
OS Homo sapiens.
XX Synthetic.
FH Key Location/Qualifiers
FT modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidine residues
FT modified_base 1..5
FT /tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
PN WO2003023004-A2.
XX
XX 20-MAR-2003.
XX
XX 06-SEP-2002; 2002WO-US028549.
XX
XX 10-SEP-2001; 2001US-00953047.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Monia BP, Wyatt JR;
XX WPI; 2003-313244/30.
XX
XX Novel compound targeted to a nucleic acid molecule encoding fibroblast
XX growth factor receptor 3, useful for inhibiting the expression of the
XX receptor and for treating an animal having cancer or developmental
XX disorder.
XX
XX Claim 3; Page 79; 120pp; English.
XX
XX The invention relates to antisense compounds targeted to a nucleic acid
XX molecule encoding fibroblast growth factor (FGF) receptor 3 (also known
XX as FGFR-3, ACH, JTK4 and CEK2) to inhibit its expression. Antisense
XX compounds of the invention are useful for treating diseases or conditions
XX associated with FGFR-3 such as developmental disorders or
XX hyperproliferative disorders, especially cancer of colorectal, bladder,
XX bone, lung, cervical, breast or skin. They are useful as research
XX reagents, therapeutics, prophylaxis, kits and diagnostics, and as tools
XX in differential and/or combinatorial analyses to elucidate expression
XX patterns of a portion of the genes expressed within cells and tissues.

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 3652 TTGCTTGCTGCAGGGCCAT 3671
DB 20 TTGCTTGCTGCAGGGCCAT 1
RESULT 340
AAD55462/c
ID AAD55462 standard; DNA; 20 BP.
XX
AC AAD55462;
XX
DT 07-AUG-2003 (first entry)
XX
DE Human FGFR-3 antisense oligonucleotide, ISIS #125166.
XX
KW Human; antisense; fibroblast growth factor receptor 3; prophylaxis;
KW developmental disorder; hyperproliferative disorder; antisense therapy;
KW FGFR-3; ACH; JTK4; CEK2; cancer; phosphorothioate; ss.
XX
OS Homo sapiens.
XX Synthetic.
FH Key Location/Qualifiers
FT modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidine residues
FT modified_base 1..5
FT /tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
PN WO2003023004-A2.
XX
XX 20-MAR-2003.
XX
XX 06-SEP-2002; 2002WO-US028549.
XX
XX 10-SEP-2001; 2001US-00953047.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Monia BP, Wyatt JR;
XX WPI; 2003-313244/30.
XX
XX Novel compound targeted to a nucleic acid molecule encoding fibroblast
XX growth factor receptor 3, useful for inhibiting the expression of the
XX receptor and for treating an animal having cancer or developmental
XX disorder.
XX
XX Claim 3; Page 79; 120pp; English.
XX
XX The invention relates to antisense compounds targeted to a nucleic acid
XX molecule encoding fibroblast growth factor (FGF) receptor 3 (also known
XX as FGFR-3, ACH, JTK4 and CEK2) to inhibit its expression. Antisense
XX compounds of the invention are useful for treating diseases or conditions
XX associated with FGFR-3 such as developmental disorders or
XX hyperproliferative disorders, especially cancer of colorectal, bladder,
XX bone, lung, cervical, breast or skin. They are useful as research
XX reagents, therapeutics, prophylaxis, kits and diagnostics, and as tools
XX in differential and/or combinatorial analyses to elucidate expression
XX patterns of a portion of the genes expressed within cells and tissues.

CC bone, lung, cervical, breast or skin. They are useful as research
CC reagents, therapeutics, prophylaxis, kits and diagnostics, and as tools
CC in differential and/or combinatorial analyses to elucidate expression
CC patterns of a portion of the genes expressed within cells and tissues.
CC They are also useful in antisense therapy. The present sequence is an
CC antisense oligonucleotide targetted to human FGFR-3
XX
SQ Sequence 20 BP; 7 A; 8 C; 4 G; 1 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 929 TGTTCATCTCTGCTGGCG 948
Db 20 TGTTCATCTCTGCTGGCG 1
RESULT 342
AAD55444/C
ID AAD55444 standard; DNA; 20 BP.
XX
AC AAD55444;
XX
DT 07-AUG-2003 (first entry)
XX
DE Human FGFR-3 antisense oligonucleotide, ISIS #125145.
XX
KW Human; antisense; fibroblast growth factor receptor 3; prophylaxis;
KW developmental disorder; hyperproliferative disorder; antisense therapy;
KW FGFR-3; ACH; JTK4; CEK2; cancer; phosphorothioate; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidine residues
FT are 5-methylcytidines"
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN WO2003023004-A2.
XX
PD 20-MAR-2003.
XX
PF 06-SEP-2002; 2002WO-US028549.
XX
PR 10-SEP-2001; 2001US-00953047.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Monia BP, Wyatt JR;
XX
DR WPI; 2003-313244/30.
XX
PT Novel compound targetted to a nucleic acid molecule encoding fibroblast
PT growth factor receptor 3, useful for inhibiting the expression of the
PT receptor and for treating an animal having cancer or developmental
PT disorder.
PS Claim 3; Page 78; 120pp; English.
XX
XX The invention relates to antisense compounds targetted to a nucleic acid
CC molecule encoding fibroblast growth factor (FGF) receptor 3 (also known

CC as FGFR-3, ACH, JTK4 and CEK2) to inhibit its expression. Antisense
CC compounds of the invention are useful for treating diseases or conditions
CC associated with FGFR-3 such as developmental disorders or
CC hyperproliferative disorders, especially cancer of colorectal, bladder,
CC bone, lung, cervical, breast or skin. They are useful as research
CC reagents, therapeutics, prophylaxis, kits and diagnostics, and as tools
CC in differential and/or combinatorial analyses to elucidate expression
CC patterns of a portion of the genes expressed within cells and tissues.
CC They are also useful in antisense therapy. The present sequence is an
CC antisense oligonucleotide targetted to human FGFR-3
XX
SQ Sequence 20 BP; 6 A; 9 C; 4 G; 1 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2457 CGAGGGGCGCTTGTCTCTGGG 2476
Db 20 CGAGGGGCGCTTGTCTCTGGG 1
RESULT 343
AAD55447/C
ID AAD55447 standard; DNA; 20 BP.
XX
AC AAD55447;
XX
DT 07-AUG-2003 (first entry)
XX
DE Human FGFR-3 antisense oligonucleotide, ISIS #125148.
XX
KW Human; antisense; fibroblast growth factor receptor 3; prophylaxis;
KW developmental disorder; hyperproliferative disorder; antisense therapy;
KW FGFR-3; ACH; JTK4; CEK2; cancer; phosphorothioate; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidine residues
FT are 5-methylcytidines"
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN WO2003023004-A2.
XX
PD 20-MAR-2003.
XX
PF 06-SEP-2002; 2002WO-US028549.
XX
PR 10-SEP-2001; 2001US-00953047.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Monia BP, Wyatt JR;
XX
DR WPI; 2003-313244/30.
XX
PT Novel compound targetted to a nucleic acid molecule encoding fibroblast
PT growth factor receptor 3, useful for inhibiting the expression of the
PT receptor and for treating an animal having cancer or developmental
PT disorder.
PS Claim 3; Page 78; 120pp; English.
XX
XX The invention relates to antisense compounds targetted to a nucleic acid
CC molecule encoding fibroblast growth factor (FGF) receptor 3 (also known

Thu Oct 28 12:48:21 2004

growth factor receptor 3, useful for inhibiting the expression of the receptor and for treating an animal having cancer or developmental disorder.

Claim 3; Page 79; 120pp; English.

The invention relates to antisense compounds targetted to a nucleic acid molecule encoding fibroblast growth factor (FGF) receptor 3 (also known as FGFR-3, ACH, JTK4 and CEK2) to inhibit its expression. Antisense compounds of the invention are useful for treating diseases or conditions associated with FGFR-3 such as developmental disorders or hyperproliferative disorders, especially cancer of colorectal, bladder, bone, lung, cervical, breast or skin. They are useful as research reagents, therapeutic, prophylaxis, kits and diagnostics, and as tools in differential and/or combinatorial analyses to elucidate expression patterns of a portion of the genes expressed within cells and tissues. They are also useful in antisense therapy. The present sequence is an antisense oligonucleotide targetted to human FGFR-3

Sequence 20 BP; 7 A; 6 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3374 TAATTGCTGTGTGCCAGG 3393
Db 20 TAATTGCTGTGTGCCAGG 1

RESULT 345
AAD55479/c
ID AAD55479 standard; DNA; 20 BP.
XX AAD55479;
AC AAD55479;
XX 07-AUG-2003 (first entry)
DT Human FGFR-3 antisense oligonucleotide, ISIS #125185.
DE Human; antisense; fibroblast growth factor receptor 3; prophylaxis;
KW developmental disorder; hyperproliferative disorder; antisense therapy;
KW FGFR-3; ACH; JTK4; CEK2; cancer; phosphorothioate; ss.
XX Homo sapiens.
OS Synthetic.
FH Key Location/Qualifiers
FT modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "phosphorothioate backbone; All cytidine residues
FT are 5-methylcytidines"
FT modified_base 1..5
FT /tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX WO2003023004-A2.
XX 20-MAR-2003.
XX 06-SEP-2002; 2002WO-US028549.
XX 10-SEP-2001; 2001US-00953047.
XX (ISIS-) ISIS PHARM INC.
XX Monia BP, Wyatt JR;
XX WPI; 2003-313244/30.
XX Novel compound targetted to a nucleic acid molecule encoding fibroblast

PS Claim 3; Page 79; 120pp; English..

XX The invention relates to antisense compounds targetted to a nucleic acid molecule encoding fibroblast growth factor (FGF) receptor 3 (also known as FGFR-3, ACH, JTK4 and CEK2) to inhibit its expression. Antisense compounds of the invention are useful for treating diseases or conditions associated with FGFR-3 such as developmental disorders or hyperproliferative disorders, especially cancer of colorectal, bladder, bone, lung, cervical, breast or skin. They are useful as research reagents, therapeutic, prophylaxis, kits and diagnostics, and as tools in differential and/or combinatorial analyses to elucidate expression patterns of a portion of the genes expressed within cells and tissues. They are also useful in antisense therapy. The present sequence is an antisense oligonucleotide targetted to human FGFR-3

Sequence 20 BP; 7 A; 4 C; 2 G; 7 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2798 CTATAAATAGATGCTGTGTA 2817
Db 20 CTATAAATAGATGCTGTGTA 1

RESULT 344
AAD55457/c
ID AAD55457 standard; DNA; 20 BP.
XX AAD55457;
AC AAD55457;
XX 07-AUG-2003 (first entry)
DT Human FGFR-3 antisense oligonucleotide, ISIS #125161.
DE Human; antisense; fibroblast growth factor receptor 3; prophylaxis;
KW developmental disorder; hyperproliferative disorder; antisense therapy;
KW FGFR-3; ACH; JTK4; CEK2; cancer; phosphorothioate; ss.
XX Homo sapiens.
OS Synthetic.
FH Key Location/Qualifiers
FT modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "phosphorothioate backbone; All cytidine residues
FT are 5-methylcytidines"
FT modified_base 1..5
FT /tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX WO2003023004-A2.
XX 20-MAR-2003.
XX 06-SEP-2002; 2002WO-US028549.
XX 10-SEP-2001; 2001US-00953047.
XX (ISIS-) ISIS PHARM INC.
XX Monia BP, Wyatt JR;
XX WPI; 2003-313244/30.
XX Novel compound targetted to a nucleic acid molecule encoding fibroblast

```
XX DR WPI; 2003-313244/30.
XX PT Novel compound targeted to a nucleic acid molecule encoding fibroblast
XX PT growth factor receptor 3, useful for inhibiting the expression of the
XX PT receptor and for treating an animal having cancer or developmental
XX PT disorder.
XX PS Claim 3; Page 79; 120pp; English.
XX CC The invention relates to antisense compounds targetted to a nucleic acid
XX CC molecule encoding fibroblast growth factor (FGF) receptor 3 (also known
XX CC as FGFR-3, ACH, JTK4 and CER2) to inhibit its expression. Antisense
XX CC compounds of the invention are useful for treating diseases or conditions
XX CC associated with FGFR-3 such as developmental disorders or
XX CC hyperproliferative disorders, especially cancer of colorectal, bladder,
XX CC bone, lung, cervical, breast or skin. They are useful as research
XX CC reagents, therapeutics, prophylaxis, kits and diagnostics, and as tools
XX CC in differential and/or combinatorial analyses to elucidate expression
XX CC patterns of a portion of the genes expressed within cells and tissues.
XX CC They are also useful in antisense therapy. The present sequence is an
XX CC antisense oligonucleotide targetted to human FGFR-3
XX SQ Sequence 20 BP; 3 A; 7 C; 7 G; 3 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 110 GGCTCAGCAGCGCGTACTG 129
DB 20 GGCTCAGCAGCGCGTACTG 1
RESULT 346
AAD55481/C
ID AAD55481 standard; DNA; 20 BP.
XX AC AAD55481;
XX DT 07-AUG-2003 (first entry)
XX DE Human FGFR-3 antisense oligonucleotide, ISIS #125187.
XX KW Human; antisense; fibroblast growth factor receptor 3; prophylaxis;
XX KW developmental disorder; hyperproliferative disorder; antisense therapy;
XX KW FGFR-3; ACH; JTK4; CER2; cancer; phosphorothioate; ss.
XX OS Homo sapiens.
XX OS Synthetic.
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidine residues
FT are 5-methylcytidines"
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX WO2003023004-A2.
XX PN 20-MAR-2003.
XX PD
XX PF 06-SEP-2002; 2002WO-US028549.
XX PR 10-SEP-2001; 2001US-00953047.
```

```
XX PA (ISIS-) ISIS PHARM INC.
XX PI Monia BP, Wyatt JR;
XX XPI; 2003-313244/30.
XX PT Novel compound targeted to a nucleic acid molecule encoding fibroblast
XX PT growth factor receptor 3, useful for inhibiting the expression of the
XX PT receptor and for treating an animal having cancer or developmental
XX PT disorder.
XX PS Example 15; Page 79; 120pp; English.
XX CC The invention relates to antisense compounds targetted to a nucleic acid
XX CC molecule encoding fibroblast growth factor (FGF) receptor 3 (also known
XX CC as FGFR-3, ACH, JTK4 and CER2) to inhibit its expression. Antisense
XX CC compounds of the invention are useful for treating diseases or conditions
XX CC associated with FGFR-3 such as developmental disorders or
XX CC hyperproliferative disorders, especially cancer of colorectal, bladder,
XX CC bone, lung, cervical, breast or skin. They are useful as research
XX CC reagents, therapeutics, prophylaxis, kits and diagnostics, and as tools
XX CC in differential and/or combinatorial analyses to elucidate expression
XX CC patterns of a portion of the genes expressed within cells and tissues.
XX CC They are also useful in antisense therapy. The present sequence is an
XX CC antisense oligonucleotide targetted to human FGFR-3
XX SQ Sequence 20 BP; 3 A; 8 C; 9 G; 0 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 262 CTGCTGCCGCGTCCGCCGC 281
DB 20 CTGCTGCCGCGTCCGCCGC 1
RESULT 347
AAD55499/C
ID AAD55499 standard; DNA; 20 BP.
XX AC AAD55499;
XX DT 07-AUG-2003 (first entry)
XX DE Human FGFR-3 antisense oligonucleotide, ISIS #125205.
XX KW Human; antisense; fibroblast growth factor receptor 3; prophylaxis;
XX KW developmental disorder; hyperproliferative disorder; antisense therapy;
XX KW FGFR-3; ACH; JTK4; CER2; cancer; phosphorothioate; ss.
XX OS Homo sapiens.
XX OS Synthetic.
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidine residues
FT are 5-methylcytidines"
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX WO2003023004-A2.
XX PN 20-MAR-2003.
```

```
XX PF 06-SEP-2002; 2002WO-US028549.
XX PD 10-SEP-2001; 2001US-00953047.
XX PF (ISIS-) ISIS PHARM INC.
XX PA Monia BP, Wyatt JR;
XX PI WPI; 2003-313244/30.
XX DR
XX XX Novel compound targeted to a nucleic acid molecule encoding fibroblast
XX PT growth factor receptor 3, useful for inhibiting the expression of the
XX PT receptor and for treating an animal having cancer or developmental
XX PT disorder.
XX PS Example 15; Page 79; 120pp; English.
XX CC The invention relates to antisense compounds targetted to a nucleic acid
XX CC molecule encoding fibroblast growth factor (FGF) receptor 3 (also known
XX CC as FGFR-3, ACH, JTK4 and CEK2) to inhibit its expression. Antisense
XX CC compounds of the invention are useful for treating diseases or conditions
XX CC associated with FGFR-3 such as developmental disorders or
XX CC hyperproliferative disorders, especially cancer of colorectal, bladder,
XX CC bone, lung, cervical, breast or skin. They are useful as research
XX CC reagents, therapeutics, prophylaxis, kits and diagnostics, and as tools
XX CC in differential and/or combinatorial analyses to elucidate expression
XX CC patterns of a portion of the genes expressed within cells and tissues.
XX CC They are also useful in antisense therapy. The present sequence is an
XX CC antisense oligonucleotide targetted to human FGFR-3
XX SQ Sequence 20 BP; 9 A; 2 C; 1 G; 8 T; 0 U; 0 Other;
XX Query Match 0.5%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 4.4e+02;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Oy 2820 TGGTATATATACATATATAT 2839
Db 20 TGGTATATATACATATATAT 1
RESULT 348
AAD55452/C
ID AAD55452 standard; DNA; 20 BP.
XX AC AAD55452;
XX DT 07-AUG-2003 (first entry)
XX DE Human FGFR-3 antisense oligonucleotide, ISIS #125154.
XX KW Human; antisense; fibroblast growth factor receptor 3; prophylaxis;
XX KW developmental disorder; hyperproliferative disorder; antisense therapy;
XX KW FGFR-3; ACH; JTK4; CEK2; cancer; phosphorothioate; ss.
XX OS Homo sapiens.
XX OS Synthetic.
XX PH Key Location/Qualifiers
XX FT modified_base 1..20
XX FT /tag= a
XX FT /mod_base= OTHER
XX FT /note= "Phosphorothioate backbone; All cytidine residues
XX FT modified_base 1..5
XX FT /tag= b
XX FT /mod_base= OTHER
XX FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX FT modified_base 16..20
XX FT /tag= c
XX FT /mod_base= OTHER
XX FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX FT
```

```
XX PN WO2003023004-A2.
XX XX 20-MAR-2003.
XX XX 06-SEP-2002; 2002WO-US028549.
XX XX 10-SEP-2001; 2001US-00953047.
XX XX (ISIS-) ISIS PHARM INC.
XX XX Monia BP, Wyatt JR;
XX XX WPI; 2003-313244/30.
XX XX Novel compound targeted to a nucleic acid molecule encoding fibroblast
XX PT growth factor receptor 3, useful for inhibiting the expression of the
XX PT receptor and for treating an animal having cancer or developmental
XX PT disorder.
XX PS Example 15; Page 79; 120pp; English.
XX CC The invention relates to antisense compounds targetted to a nucleic acid
XX CC molecule encoding fibroblast growth factor (FGF) receptor 3 (also known
XX CC as FGFR-3, ACH, JTK4 and CEK2) to inhibit its expression. Antisense
XX CC compounds of the invention are useful for treating diseases or conditions
XX CC associated with FGFR-3 such as developmental disorders or
XX CC hyperproliferative disorders, especially cancer of colorectal, bladder,
XX CC bone, lung, cervical, breast or skin. They are useful as research
XX CC reagents, therapeutics, prophylaxis, kits and diagnostics, and as tools
XX CC in differential and/or combinatorial analyses to elucidate expression
XX CC patterns of a portion of the genes expressed within cells and tissues.
XX CC They are also useful in antisense therapy. The present sequence is an
XX CC antisense oligonucleotide targetted to human FGFR-3
XX SQ Sequence 20 BP; 9 A; 1 C; 4 G; 6 T; 0 U; 0 Other;
XX Query Match 0.5%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 4.4e+02;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Oy 3121 TTTTAACTTATTGACAAACC 3140
Db 20 TTTTAACTTATTGACAAACC 1
RESULT 349
AAD55463/C
ID AAD55463 standard; DNA; 20 BP.
XX AC AAD55463;
XX DT 07-AUG-2003 (first entry)
XX DE Human FGFR-3 antisense oligonucleotide, ISIS #125167.
XX KW Human; antisense; fibroblast growth factor receptor 3; prophylaxis;
XX KW developmental disorder; hyperproliferative disorder; antisense therapy;
XX KW FGFR-3; ACH; JTK4; CEK2; cancer; phosphorothioate; ss.
XX OS Homo sapiens.
XX OS Synthetic.
XX PH Key Location/Qualifiers
XX FT modified_base 1..20
XX FT /tag= a
XX FT /mod_base= OTHER
XX FT /note= "Phosphorothioate backbone; All cytidine residues
XX FT modified_base 1..5
XX FT /tag= b
XX FT /mod_base= OTHER
XX FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
```

```
FT modified_base 16..20
FT /*tag= c
FT /mcd_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
XX WO2003023004-A2.
XX
XX 20-MAR-2003.
XX
XX 06-SEP-2002; 2002WO-US028549.
XX
XX 10-SEP-2001; 2001US-00953047.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Monia BP, Wyatt JR;
XX WPI; 2003-313244/30.
XX
XX Novel compound targeted to a nucleic acid molecule encoding fibroblast
XX growth factor receptor 3, useful for inhibiting the expression of the
XX receptor and for treating an animal having cancer or developmental
XX disorder.
XX
XX Claim 3; Page 79; 120pp; English.
XX
XX The invention relates to antisense compounds targetted to a nucleic acid
XX molecule encoding fibroblast growth factor (FGF) receptor 3 (also known
XX as FGFR-3, ACH, JTK4 and CEK2) to inhibit its expression. Antisense
XX compounds of the invention are useful for treating diseases or conditions
XX associated with FGFR-3 such as developmental disorders or
XX hyperproliferative disorders, especially cancer of colorectal, bladder,
XX bone, lung, cervical, breast or skin. They are useful as research
XX reagents, therapeutics, prophylaxis, kits and diagnostics, and as tools
XX in differential and/or combinatorial analyses to elucidate expression
XX patterns of a portion of the genes expressed within cells and tissues.
XX They are also useful in antisense therapy. The present sequence is an
XX antisense oligonucleotide targetted to human FGFR-3
XX
XX Sequence 20 BP; 4 A; 4 C; 5 G; 7 T; 0 U; 0 Other;
XX
XX Query Match 0.5%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 4.4e+02;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 3777 AAAGACACCTGGTGTGTAAC 3796
XX |||||
XX 20 AAAGACACCTGGTGTGTAAC 1
XX
XX RESULT 350
XX AAD55495/C
XX ID AAD55495 standard; DNA; 20 BP.
XX
XX AC AAD55495;
XX
XX DT 07-AUG-2003 (first entry)
XX
XX DE Human FGFR-3 antisense oligonucleotide, ISIS #125201.
XX
XX Human; antisense; fibroblast growth factor receptor 3; prophylaxis;
XX developmental disorder; hyperproliferative disorder; antisense therapy;
XX FGFR-3; ACH; JTK4; CEK2; cancer; phosphorothioate; ss.
XX
XX Homo sapiens.
XX OS Synthetic.
XX
XX Key Location/Qualifiers
XX modified_base 1..20
XX /*tag= a
XX /mcd_base= OTHER
XX /note= "Phosphorothioate backbone; All cytidine residues
XX are 5-methylcytidines"
```

```
FT modified_base 1..5
FT /*tag= b
FT /mcd_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
XX modified_base 16..20
XX /*tag= c
XX /mcd_base= OTHER
XX /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
XX WO2003023004-A2.
XX
XX 20-MAR-2003.
XX
XX 06-SEP-2002; 2002WO-US028549.
XX
XX 10-SEP-2001; 2001US-00953047.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Monia BP, Wyatt JR;
XX WPI; 2003-313244/30.
XX
XX Novel compound targeted to a nucleic acid molecule encoding fibroblast
XX growth factor receptor 3, useful for inhibiting the expression of the
XX receptor and for treating an animal having cancer or developmental
XX disorder.
XX
XX Claim 3; Page 79; 120pp; English.
XX
XX The invention relates to antisense compounds targetted to a nucleic acid
XX molecule encoding fibroblast growth factor (FGF) receptor 3 (also known
XX as FGFR-3, ACH, JTK4 and CEK2) to inhibit its expression. Antisense
XX compounds of the invention are useful for treating diseases or conditions
XX associated with FGFR-3 such as developmental disorders or
XX hyperproliferative disorders, especially cancer of colorectal, bladder,
XX bone, lung, cervical, breast or skin. They are useful as research
XX reagents, therapeutics, prophylaxis, kits and diagnostics, and as tools
XX in differential and/or combinatorial analyses to elucidate expression
XX patterns of a portion of the genes expressed within cells and tissues.
XX They are also useful in antisense therapy. The present sequence is an
XX antisense oligonucleotide targetted to human FGFR-3
XX
XX Sequence 20 BP; 6 A; 4 C; 9 G; 1 T; 0 U; 0 Other;
XX
XX Query Match 0.5%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 4.4e+02;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 2549 CTCGGCCTCTGCTTTGCAC 2568
XX |||||
XX 20 CTCGGCCTCTGCTTTGCAC 1
XX
XX RESULT 351
XX AAD55500/C
XX ID AAD55500 standard; DNA; 20 BP.
XX
XX AC AAD55500;
XX
XX DT 07-AUG-2003 (first entry)
XX
XX DE Human FGFR-3 antisense oligonucleotide, ISIS #125206.
XX
XX Human; antisense; fibroblast growth factor receptor 3; prophylaxis;
XX developmental disorder; hyperproliferative disorder; antisense therapy;
XX FGFR-3; ACH; JTK4; CEK2; cancer; phosphorothioate; ss.
XX
XX Homo sapiens.
XX OS Synthetic.
XX
XX Key Location/Qualifiers
XX modified_base 1..20
```

```

FT      /tag= a
FT      /mod_base= OTHER
FT      /note= "Phosphorothioate backbone; All cytidine residues
FT      are 5-methylcytidines"
FT      modified_base
FT      1. .5
FT      /tag= b
FT      /mod_base= OTHER
FT      /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT      modified_base
FT      16. .20
FT      /tag= c
FT      /mod_base= OTHER
FT      /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT      modified_base
FT      16. .20
FT      /tag= c
FT      /mod_base= OTHER
FT      /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX      WO2003023004-A2.
XX      20-MAR-2003.
XX      06-SEP-2002; 2002WO-US028549.
XX      10-SEP-2001; 2001US-00953047.
XX      (ISIS-) ISIS PHARM INC.
XX      Monia BP, Wyatt JR;
XX      WPI; 2003-313244/30.
XX      Novel compound targeted to a nucleic acid molecule encoding fibroblast
XX      growth factor receptor 3, useful for inhibiting the expression of the
XX      receptor and for treating an animal having cancer or developmental
XX      disorder.
XX      Claim 3; Page 79; 120pp; English.
XX      The invention relates to antisense compounds targetted to a nucleic acid
XX      molecule encoding fibroblast growth factor (FGF) receptor 3 (also known
XX      as FGFR-3, ACH, JTK4 and CEK2) to inhibit its expression. Antisense
XX      compounds of the invention are useful for treating diseases or conditions
XX      associated with FGFR-3 such as developmental disorders or
XX      hyperproliferative disorders, especially cancer of colorectal, bladder,
XX      bone, lung, cervical, breast or skin. They are useful as research
XX      reagents, therapeutics, prophylaxis, kits and diagnostics, and as tools
XX      in differential and/or combinatorial analyses to elucidate expression
XX      patterns of a portion of the genes expressed within cells and tissues.
XX      They are also useful in antisense therapy. The present sequence is an
XX      antisense oligonucleotide targetted to human FGFR-3
XX      Sequence 20 BP; 3 A; 9 C; 4 G; 4 T; 0 U; 0 Other;
XX      Query Match 0.5%; Score 20; DB 1; Length 20;
XX      Best Local Similarity 100.0%; Pred. No. 4.4e+02;
XX      Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY      3382 GTGTGTCCTCCAGCGAGGAGA 3401
Db      20 GTGTGTCCTCCAGCGAGGAGA 1
RESULT 352
AAD55438/c
ID      AAD55438 standard; DNA; 20 BP.
XX      AAD55438;
XX      07-AUG-2003 (first entry)
XX      Human FGFR-3 antisense oligonucleotide, ISIS #125128.
XX      Human; antisense; fibroblast growth factor receptor 3; prophylaxis;
XX      developmental disorder; hyperproliferative disorder; antisense therapy;
XX      FGFR-3; ACH, JTK4, CEK2; cancer; phosphorothioate; ss.
XX      Homo sapiens.

```

```

OS      Synthetic.
XX      Key Location/Qualifiers
XX      modified_base
XX      1. .20
XX      /tag= a
XX      /mod_base= OTHER
XX      /note= "Phosphorothioate backbone; All cytidine residues
XX      are 5-methylcytidines"
XX      modified_base
XX      1. .5
XX      /tag= b
XX      /mod_base= OTHER
XX      /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX      modified_base
XX      16. .20
XX      /tag= c
XX      /mod_base= OTHER
XX      /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX      WO2003023004-A2.
XX      20-MAR-2003.
XX      06-SEP-2002; 2002WO-US028549.
XX      10-SEP-2001; 2001US-00953047.
XX      (ISIS-) ISIS PHARM INC.
XX      Monia BP, Wyatt JR;
XX      WPI; 2003-313244/30.
XX      Novel compound targeted to a nucleic acid molecule encoding fibroblast
XX      growth factor receptor 3, useful for inhibiting the expression of the
XX      receptor and for treating an animal having cancer or developmental
XX      disorder.
XX      Claim 3; Page 78; 120pp; English.
XX      The invention relates to antisense compounds targetted to a nucleic acid
XX      molecule encoding fibroblast growth factor (FGF) receptor 3 (also known
XX      as FGFR-3, ACH, JTK4 and CEK2) to inhibit its expression. Antisense
XX      compounds of the invention are useful for treating diseases or conditions
XX      associated with FGFR-3 such as developmental disorders or
XX      hyperproliferative disorders, especially cancer of colorectal, bladder,
XX      bone, lung, cervical, breast or skin. They are useful as research
XX      reagents, therapeutics, prophylaxis, kits and diagnostics, and as tools
XX      in differential and/or combinatorial analyses to elucidate expression
XX      patterns of a portion of the genes expressed within cells and tissues.
XX      They are also useful in antisense therapy. The present sequence is an
XX      antisense oligonucleotide targetted to human FGFR-3
XX      Sequence 20 BP; 4 A; 5 C; 7 G; 4 T; 0 U; 0 Other;
XX      Query Match 0.5%; Score 20; DB 1; Length 20;
XX      Best Local Similarity 100.0%; Pred. No. 4.4e+02;
XX      Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY      1024 TTCCCGCTCAGCGAGGAGT 1043
Db      20 TTCCCGCTCAGCGAGGAGT 1
RESULT 353
AAD55442/c
ID      AAD55442 standard; DNA; 20 BP.
XX      AAD55442;
XX      07-AUG-2003 (first entry)
XX      Human FGFR-3 antisense oligonucleotide, ISIS #125143.
XX      Human; antisense; fibroblast growth factor receptor 3; prophylaxis;
XX

```

KW developmental disorder; hyperproliferative disorder; antisense therapy;
XX FGFR-3; ACH; JTK4; CEK2; cancer; phosphorothioate; ss.
XX
OS Homo sapiens.
XX Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidine residues
FT are 5-methylcytidines"
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX WO2003023004-A2.
XX
XX 20-MAR-2003.
XX
XX 06-SEP-2002; 2002WO-US028549.
XX
XX 10-SEP-2001; 2001US-00953047.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Monia BP, Wyatt JR;
XX WPI; 2003-313244/30.
XX
XX Novel compound targeted to a nucleic acid molecule encoding fibroblast
PT growth factor receptor 3, useful for inhibiting the expression of the
PT receptor and for treating an animal having cancer or developmental
PT disorder.
XX
XX Example 15; Page 78; 120pp; English.
XX
XX The invention relates to antisense compounds targetted to a nucleic acid
CC molecule encoding fibroblast growth factor (FGF) receptor 3 (also known
CC as FGFR-3, ACH, JTK4 and CEK2) to inhibit its expression. Antisense
CC compounds of the invention are useful for treating diseases or conditions
CC associated with FGFR-3 such as developmental disorders or
CC hyperproliferative disorders, especially cancer of colorectal, bladder,
CC bone, lung, cervical, breast or skin. They are useful as research
CC reagents, therapeutics, prophylaxis, kits and diagnostics, and as tools
CC in differential and/or combinatorial analyses to elucidate expression
CC patterns of a portion of the genes expressed within cells and tissues.
CC They are also useful in antisense therapy. The present sequence is an
CC antisense oligonucleotide targetted to human FGFR-3
XX
SQ Sequence 20 BP; 3 A; 6 C; 6 G; 5 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2211 CCAACAATGTGAGGGTCCC 2230
DB 20 CCAACAATGTGAGGGTCCC 1
RESULT 354
AAD55451/c
ID AAD55451 standard; DNA; 20 BP.
XX
AC AAD55451;
XX
DT 07-AUG-2003 (first entry)

XX Human FGFR-3 antisense oligonucleotide, ISIS #125153.
XX
XX Human; antisense; fibroblast growth factor receptor 3; prophylaxis;
KW developmental disorder; hyperproliferative disorder; antisense therapy;
KW FGFR-3; ACH; JTK4; CEK2; cancer; phosphorothioate; ss.
XX
XX Homo sapiens.
OS Synthetic.
OS
XX Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidine residues
FT are 5-methylcytidines"
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX WO2003023004-A2.
XX
XX 20-MAR-2003.
XX
XX 06-SEP-2002; 2002WO-US028549.
XX
XX 10-SEP-2001; 2001US-00953047.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Monia BP, Wyatt JR;
XX WPI; 2003-313244/30.
XX
XX Novel compound targeted to a nucleic acid molecule encoding fibroblast
PT growth factor receptor 3, useful for inhibiting the expression of the
PT receptor and for treating an animal having cancer or developmental
PT disorder.
XX
XX Example 15; Page 79; 120pp; English.
XX
XX The invention relates to antisense compounds targetted to a nucleic acid
CC molecule encoding fibroblast growth factor (FGF) receptor 3 (also known
CC as FGFR-3, ACH, JTK4 and CEK2) to inhibit its expression. Antisense
CC compounds of the invention are useful for treating diseases or conditions
CC associated with FGFR-3 such as developmental disorders or
CC hyperproliferative disorders, especially cancer of colorectal, bladder,
CC bone, lung, cervical, breast or skin. They are useful as research
CC reagents, therapeutics, prophylaxis, kits and diagnostics, and as tools
CC in differential and/or combinatorial analyses to elucidate expression
CC patterns of a portion of the genes expressed within cells and tissues.
CC They are also useful in antisense therapy. The present sequence is an
CC antisense oligonucleotide targetted to human FGFR-3
XX
SQ Sequence 20 BP; 6 A; 5 C; 4 G; 5 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 3034 GTAAGCTATTATGGGCC 3053
DB 20 GTAAGCTATTATGGGCC 1
RESULT 355
AAD55454/c
ID AAD55454 standard; DNA; 20 BP.

XX AAD55454;
 XX 07-AUG-2003 (first entry)
 XX Human FGFR-3 antisense oligonucleotide, ISIS #125156.
 DE Human; antisense; fibroblast growth factor receptor 3; prophylaxis;
 XX developmental disorder; hyperproliferative disorder; antisense therapy;
 KW FGFR-3; ACH; JTK4; CEK2; cancer; phosphorothioate; ss.
 XX Homo sapiens.
 OS Synthetic.
 XX Key Location/Qualifiers
 FH modified_base 1..20
 FT /tag= a
 FT /mod_base= OTHER
 FT /note= "Phosphorothioate backbone; All cytidine residues
 FT are 5-methylcytidines"
 FT modified_base 1..5
 FT /tag= b
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 FT modified_base 16..20
 FT /tag= c
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 FT WO2003023004-A2.
 XX 20-MAR-2003.
 XX 06-SEP-2002; 2002WO-US028549.
 XX 10-SEP-2001; 2001US-00953047.
 XX (ISIS-) ISIS PHARM INC.
 XX Monia BP, Wyatt JR;
 XX WPI; 2003-313244/30.
 XX Novel compound targeted to a nucleic acid molecule encoding fibroblast
 PT growth factor receptor 3, useful for inhibiting the expression of the
 PT receptor and for treating an animal having cancer or developmental
 PT disorder.
 XX Example 15; Page 79; 120pp; English.
 XX The invention relates to antisense compounds targetted to a nucleic acid
 CC molecule encoding fibroblast growth factor (FGF) receptor 3 (also known
 CC as FGFR-3, ACH, JTK4 and CEK2) to inhibit its expression. Antisense
 CC compounds of the invention are useful for treating diseases or conditions
 CC associated with FGFR-3 such as developmental disorders or
 CC hyperproliferative disorders, especially cancer of colorectal, bladder,
 CC bone, lung, cervical, breast or skin. They are useful as research
 CC reagents, therapeutics, prophylaxis, kits and diagnostics, and as tools
 CC in differential and/or combinatorial analyses to elucidate expression
 CC patterns of a portion of the genes expressed within cells and tissues.
 CC They are also useful in antisense therapy. The present sequence is an
 CC antisense oligonucleotide targetted to human FGFR-3
 XX Sequence 20 BP; 8 A; 4 C; 2 G; 6 T; 0 U; 0 Other;
 SQ
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 4.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 3248 GATTCAGTGAAGATATTTT 3267
 DB 20 GATTCAGTGAAGATATTTT 1

RESULT 356
 AAD55485/C
 ID AAD55485 standard; DNA; 20 BP.
 XX
 AC AAD55485;
 XX 07-AUG-2003 (first entry)
 XX Human FGFR-3 antisense oligonucleotide, ISIS #125191.
 DE Human; antisense; fibroblast growth factor receptor 3; prophylaxis;
 XX developmental disorder; hyperproliferative disorder; antisense therapy;
 KW FGFR-3; ACH; JTK4; CEK2; cancer; phosphorothioate; ss.
 XX Homo sapiens.
 OS Synthetic.
 XX Key Location/Qualifiers
 FH modified_base 1..20
 FT /tag= a
 FT /mod_base= OTHER
 FT /note= "Phosphorothioate backbone; All cytidine residues
 FT are 5-methylcytidines"
 FT modified_base 1..5
 FT /tag= b
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 FT modified_base 16..20
 FT /tag= c
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 FT WO2003023004-A2.
 XX 20-MAR-2003.
 XX 06-SEP-2002; 2002WO-US028549.
 XX 10-SEP-2001; 2001US-00953047.
 XX (ISIS-) ISIS PHARM INC.
 XX Monia BP, Wyatt JR;
 XX WPI; 2003-313244/30.
 XX Novel compound targeted to a nucleic acid molecule encoding fibroblast
 PT growth factor receptor 3, useful for inhibiting the expression of the
 PT receptor and for treating an animal having cancer or developmental
 PT disorder.
 XX Claim 3; Page 79; 120pp; English.
 XX The invention relates to antisense compounds targetted to a nucleic acid
 CC molecule encoding fibroblast growth factor (FGF) receptor 3 (also known
 CC as FGFR-3, ACH, JTK4 and CEK2) to inhibit its expression. Antisense
 CC compounds of the invention are useful for treating diseases or conditions
 CC associated with FGFR-3 such as developmental disorders or
 CC hyperproliferative disorders, especially cancer of colorectal, bladder,
 CC bone, lung, cervical, breast or skin. They are useful as research
 CC reagents, therapeutics, prophylaxis, kits and diagnostics, and as tools
 CC in differential and/or combinatorial analyses to elucidate expression
 CC patterns of a portion of the genes expressed within cells and tissues.
 CC They are also useful in antisense therapy. The present sequence is an
 CC antisense oligonucleotide targetted to human FGFR-3
 XX Sequence 20 BP; 1 A; 8 C; 8 G; 3 T; 0 U; 0 Other;
 SQ
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 4.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;


```
QY 667 GTGGGCCCGACGGCACACC 686
Db 20 GTGGGCCCGACGGCACACC 1

RESULT 357
AAD55489/c
ID AAD55489 standard; DNA; 20 BP.
XX
XX AAD55489;
XX
XX 07-AUG-2003 (first entry)
XX
XX Human FGFR-3 antisense oligonucleotide, ISIS #125195.
XX
XX Human; antisense; fibroblast growth factor receptor 3; prophylaxis;
KW developmental disorder; hyperproliferative disorder; antisense therapy;
KW FGFR-3; ACH; JTK4; CEK2; cancer; phosphorothioate; ss.
XX
XX Homo sapiens.
OS Synthetic.
OS
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidine residues
FT are 5-methylcytidines"
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
XX WO2003023004-A2.
XX
XX 20-MAR-2003.
XX
XX 06-SEP-2002; 2002WO-US028549.
XX
XX 10-SEP-2001; 2001US-00953047.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Monia BP, Wyatt JR;
XX
XX WPI; 2003-313244/30.
XX
XX Novel compound targeted to a nucleic acid molecule encoding fibroblast
XX growth factor receptor 3, useful for inhibiting the expression of the
XX receptor and for treating an animal having cancer or developmental
XX disorder.
XX
XX Claim 3; Page 79; 120pp; English.
XX
XX The invention relates to antisense compounds targetted to a nucleic acid
XX molecule encoding fibroblast growth factor (FGF) receptor 3 (also known
XX as FGFR-3, ACH, JTK4 and CEK2) to inhibit its expression. Antisense
XX compounds of the invention are useful for treating diseases or conditions
XX associated with FGFR-3 such as developmental disorders or
XX hyperproliferative disorders, especially cancer of colorectal, bladder,
XX bone, lung, cervical, breast or skin. They are useful as research
XX reagents, therapeutics, prophylaxis, kits and diagnostics, and as tools
XX patterns of a portion of the genes expressed within cells and tissues.
XX They are also useful in antisense therapy. The present sequence is an
XX antisense oligonucleotide targetted to human FGFR-3
XX
XX Sequence 20 BP; 6 A; 9 C; 5 G; 0 T; 0 U; 0 Other;
```

```
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 825 CTCTGGTGGCTGGTGGTC 844
Db 20 CTCTGGTGGCTGGTGGTC 1

RESULT 358
AAD55492/c
ID AAD55492 standard; DNA; 20 BP.
XX
XX AAD55492;
XX
XX 07-AUG-2003 (first entry)
XX
XX Human FGFR-3 antisense oligonucleotide, ISIS #125198.
XX
XX Human; antisense; fibroblast growth factor receptor 3; prophylaxis;
KW developmental disorder; hyperproliferative disorder; antisense therapy;
KW FGFR-3; ACH; JTK4; CEK2; cancer; phosphorothioate; ss.
XX
XX Homo sapiens.
OS Synthetic.
OS
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidine residues
FT are 5-methylcytidines"
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
XX WO2003023004-A2.
XX
XX 20-MAR-2003.
XX
XX 06-SEP-2002; 2002WO-US028549.
XX
XX 10-SEP-2001; 2001US-00953047.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Monia BP, Wyatt JR;
XX
XX WPI; 2003-313244/30.
XX
XX Novel compound targeted to a nucleic acid molecule encoding fibroblast
XX growth factor receptor 3, useful for inhibiting the expression of the
XX receptor and for treating an animal having cancer or developmental
XX disorder.
XX
XX Claim 3; Page 79; 120pp; English.
XX
XX The invention relates to antisense compounds targetted to a nucleic acid
XX molecule encoding fibroblast growth factor (FGF) receptor 3 (also known
XX as FGFR-3, ACH, JTK4 and CEK2) to inhibit its expression. Antisense
XX compounds of the invention are useful for treating diseases or conditions
XX associated with FGFR-3 such as developmental disorders or
XX hyperproliferative disorders, especially cancer of colorectal, bladder,
XX bone, lung, cervical, breast or skin. They are useful as research
XX reagents, therapeutics, prophylaxis, kits and diagnostics, and as tools
XX patterns of a portion of the genes expressed within cells and tissues.
XX They are also useful in antisense therapy. The present sequence is an
XX antisense oligonucleotide targetted to human FGFR-3
XX
XX They are also useful in antisense therapy. The present sequence is an
```

CC antisense oligonucleotide targetted to human FGFR-3
SQ Sequence 20 BP; 3 A; 9 C; 5 G; 3 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1434 GCTGGTGGAGTACGGGCCA 1453
DB 20 GCTGGTGGAGTACGGGCCA 1

RESULT 359
AAD55431/C
ID AAD55431 standard; DNA; 20 BP.
XX AC AAD55431;
XX 07-AUG-2003 (first entry)
XX Human FGFR-3 antisense oligonucleotide, ISIS #125112.
DE Human; antisense; fibroblast growth factor receptor 3; prophylaxis;
KW developmental disorder; hyperproliferative disorder; antisense therapy;
KW FGFR-3; ACH; JTK4; CEK2; cancer; phosphorothioate; ss.
XX Homo sapiens.
OS Synthetic.
XX Key Location/Qualifiers
FH modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "phosphorothioate backbone; All cytidine residues
FT are 5-methylcytidines"
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
PN WO2003023004-A2.
XX 20-MAR-2003.
XX 06-SEP-2002; 2002WO-US028549.
XX 10-SEP-2001; 2001US-00953047.
XX (ISIS-) ISIS PHARM INC.
XX Monia BP, Wyatt JR;
XX WPI; 2003-313244/30.
XX Novel compound targetted to a nucleic acid molecule encoding fibroblast
PT growth factor receptor 3, useful for inhibiting the expression of the
PT receptor and for treating an animal having cancer or developmental
PT disorder.
PS Claim 3; Page 78; 120pp; English.
XX The invention relates to antisense compounds targetted to a nucleic acid
CC molecule encoding fibroblast growth factor (FGF) receptor 3 (also known
CC as FGFR-3; ACH, JTK4 and CEK2) to inhibit its expression. Antisense
CC compounds of the invention are useful for treating diseases or conditions
CC associated with FGFR-3 such as developmental disorders or
CC hyperproliferative disorders, especially cancer of colorectal, bladder,
CC bone, lung, cervical, breast or skin. They are useful as research

CC reagents, therapeutics, prophylaxis, kits and diagnostics, and as tools
CC in differential and/or combinatorial analyses to elucidate expression
CC patterns of a portion of the genes expressed within cells and tissues.
CC They are also useful in antisense therapy. The present sequence is an
CC antisense oligonucleotide targetted to human FGFR-3
XX Sequence 20 BP; 3 A; 8 C; 4 G; 5 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 197 CTGAGGACACAGGTGTGGAC 216
DB 20 CTGAGGACACAGGTGTGGAC 1

RESULT 360
AAD55434/C
ID AAD55434 standard; DNA; 20 BP.
XX AC AAD55434;
XX 07-AUG-2003 (first entry)
XX Human FGFR-3 antisense oligonucleotide, ISIS #125116.
DE Human; antisense; fibroblast growth factor receptor 3; prophylaxis;
KW developmental disorder; hyperproliferative disorder; antisense therapy;
KW FGFR-3; ACH; JTK4; CEK2; cancer; phosphorothioate; ss.
XX Homo sapiens.
OS Synthetic.
XX Key Location/Qualifiers
FH modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "phosphorothioate backbone; All cytidine residues
FT are 5-methylcytidines"
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
PN WO2003023004-A2.
XX 20-MAR-2003.
XX 06-SEP-2002; 2002WO-US028549.
XX 10-SEP-2001; 2001US-00953047.
XX (ISIS-) ISIS PHARM INC.
XX Monia BP, Wyatt JR;
XX WPI; 2003-313244/30.
XX Novel compound targetted to a nucleic acid molecule encoding fibroblast
PT growth factor receptor 3, useful for inhibiting the expression of the
PT receptor and for treating an animal having cancer or developmental
PT disorder.
PS Claim 3; Page 78; 120pp; English.
XX The invention relates to antisense compounds targetted to a nucleic acid
CC molecule encoding fibroblast growth factor (FGF) receptor 3 (also known
CC as FGFR-3; ACH, JTK4 and CEK2) to inhibit its expression. Antisense
CC compounds of the invention are useful for treating diseases or conditions
CC associated with FGFR-3 such as developmental disorders or
CC hyperproliferative disorders, especially cancer of colorectal, bladder,
CC bone, lung, cervical, breast or skin. They are useful as research

CC compounds of the invention are useful for treating diseases or conditions
 CC associated with FGFR-3 such as developmental disorders or
 CC hyperproliferative disorders, especially cancer of colorectal, bladder,
 CC bone, lung, cervical, breast or skin. They are useful as research
 CC reagents, therapeutics, prophylaxis, kits and diagnostics, and as tools
 CC in differential and/or combinatorial analyses to elucidate expression
 CC patterns of a portion of the genes expressed within cells and tissues.
 CC They are also useful in antisense therapy. The present sequence is an
 CC antisense oligonucleotide targetted to human FGFR-3
 XX
 SQ Sequence 20 BP; 2 A; 5 C; 8 G; 5 T; 0 U; 0 Other;
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 4.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 483 CATCCGGCAGACGTACACGC 502
 Db 20 CATCCGGCAGACGTACACGC 1
 RESULT 361
 AAD55446/c
 ID AAD55446 standard; DNA; 20 BP.
 XX
 AC AAD55446;
 XX
 DT 07-AUG-2003 (first entry)
 XX
 DE Human FGFR-3 antisense oligonucleotide, ISIS #125147.
 XX
 KW Human; antisense; fibroblast growth factor receptor 3; prophylaxis;
 KW developmental disorder; hyperproliferative disorder; antisense therapy;
 KW FGFR-3; ACH; JTK4; CEK2; cancer; phosphorothioate; ss.
 XX
 OS Homo sapiens.
 OS Synthetic.
 OS
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /tag= a
 FT /mod_base= OTHER
 FT /note= "Phosphorothioate backbone; All cytidine residues
 FT are 5-methylcytidines"
 FT modified_base 1..5
 FT /tag= b
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 FT modified_base 16..20
 FT /tag= c
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 XX WO2003023004-A2.
 PN
 XX 20-MAR-2003.
 XX
 XX 06-SEP-2002; 2002WO-US028549.
 XX
 XX 10-SEP-2001; 2001US-00953047.
 XX
 XX (ISIS-) ISIS PHARM INC.
 XX Monia BP, Wyatt JR;
 XX WPI; 2003-313244/30.
 DR
 XX Novel compound targetted to a nucleic acid molecule encoding fibroblast
 XX growth factor receptor 3, useful for inhibiting the expression of the
 XX receptor and for treating an animal having cancer or developmental
 XX disorder.
 XX
 PS Claim 3; Page 78; 120pp; English.

XX
 CC The invention relates to antisense compounds targetted to a nucleic acid
 CC molecule encoding fibroblast growth factor (FGF) receptor 3 (also known
 CC as FGFR-3, ACH, JTK4 and CEK2) to inhibit its expression. Antisense
 CC compounds of the invention are useful for treating diseases or conditions
 CC associated with FGFR-3 such as developmental disorders or
 CC hyperproliferative disorders, especially cancer of colorectal, bladder,
 CC bone, lung, cervical, breast or skin. They are useful as research
 CC reagents, therapeutics, prophylaxis, kits and diagnostics, and as tools
 CC in differential and/or combinatorial analyses to elucidate expression
 CC patterns of a portion of the genes expressed within cells and tissues.
 CC They are also useful in antisense therapy. The present sequence is an
 CC antisense oligonucleotide targetted to human FGFR-3
 XX
 SQ Sequence 20 BP; 3 A; 8 C; 5 G; 4 T; 0 U; 0 Other;
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 4.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 2572 GGGACATCACAGGTGCGCT 2591
 Db 20 GGGACATCACAGGTGCGCT 1
 RESULT 362
 AAD55482/c
 ID AAD55482 standard; DNA; 20 BP.
 XX
 AC AAD55482;
 XX
 DT 07-AUG-2003 (first entry)
 XX
 DE Human FGFR-3 antisense oligonucleotide, ISIS #125188.
 XX
 KW Human; antisense; fibroblast growth factor receptor 3; prophylaxis;
 KW developmental disorder; hyperproliferative disorder; antisense therapy;
 KW FGFR-3; ACH; JTK4; CEK2; cancer; phosphorothioate; ss.
 XX
 OS Homo sapiens.
 OS Synthetic.
 OS
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /tag= a
 FT /mod_base= OTHER
 FT /note= "Phosphorothioate backbone; All cytidine residues
 FT are 5-methylcytidines"
 FT modified_base 1..5
 FT /tag= b
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 FT modified_base 16..20
 FT /tag= c
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 XX WO2003023004-A2.
 PN
 XX 20-MAR-2003.
 XX
 XX 06-SEP-2002; 2002WO-US028549.
 XX
 XX 10-SEP-2001; 2001US-00953047.
 XX
 XX (ISIS-) ISIS PHARM INC.
 XX Monia BP, Wyatt JR;
 XX WPI; 2003-313244/30.
 DR
 XX Novel compound targetted to a nucleic acid molecule encoding fibroblast
 XX growth factor receptor 3, useful for inhibiting the expression of the

PT receptor and for treating an animal having cancer or developmental disorder.
 PS Claim 3; Page 79; 120pp; English.
 CC The invention relates to antisense compounds targetted to a nucleic acid molecule encoding fibroblast growth factor (FGF) receptor 3 (also known as FGFR-3, ACH, JTK4 and CEK2) to inhibit its expression. Antisense compounds of the invention are useful for treating diseases or conditions associated with FGFR-3 such as developmental disorders or hyperproliferative disorders, especially cancer of colorectal, bladder, bone, lung, cervical, breast or skin. They are useful as research reagents, therapeutics, prophylaxis, kits and diagnostics, and as tools in differential and/or combinatorial analyses to elucidate expression patterns of a portion of the genes expressed within cells and tissues. They are also useful in antisense therapy. The present sequence is an antisense oligonucleotide targetted to human FGFR-3
 SQ Sequence 20 BP; 3 A; 8 C; 5 G; 4 T; 0 U; 0 Other;
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 4.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 396 GCATCAGCAGTGGAGCTGG 415
 Db 20 GCATCAGCAGTGGAGCTGG 1
 RESULT 363
 AAD55450/c
 ID AAD55450 standard; DNA; 20 BP.
 XX AAD55450;
 AC AAD55450;
 DT 07-AUG-2003 (first entry)
 DE Human FGFR-3 antisense oligonucleotide, ISIS #125152.
 XX Human; antisense; fibroblast growth factor receptor 3; prophylaxis; developmental disorder; hyperproliferative disorder; antisense therapy; FGFR-3; ACH; JTK4; CEK2; cancer; phosphorothioate; ss.
 OS Homo sapiens.
 OS Synthetic.
 PH Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "phosphorothioate backbone; All cytidine residues are 5-methylcytidines"
 FT modified_base 1..5
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 FT modified_base 16..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 WO2003023004-A2.
 20-MAR-2003.
 06-SEP-2002; 2002WO-US028549.
 10-SEP-2001; 2001US-00953047.
 (ISIS-) ISIS PHARM INC.
 Monia BP, Wyatt JR;

DR WPI; 2003-313244/30.
 XX Novel compound targetted to a nucleic acid molecule encoding fibroblast growth factor receptor 3, useful for inhibiting the expression of the receptor and for treating an animal having cancer or developmental disorder.
 PS Claim 3; Page 79; 120pp; English.
 CC The invention relates to antisense compounds targetted to a nucleic acid molecule encoding fibroblast growth factor (FGF) receptor 3 (also known as FGFR-3, ACH, JTK4 and CEK2) to inhibit its expression. Antisense compounds of the invention are useful for treating diseases or conditions associated with FGFR-3 such as developmental disorders or hyperproliferative disorders, especially cancer of colorectal, bladder, bone, lung, cervical, breast or skin. They are useful as research reagents, therapeutics, prophylaxis, kits and diagnostics, and as tools in differential and/or combinatorial analyses to elucidate expression patterns of a portion of the genes expressed within cells and tissues. They are also useful in antisense therapy. The present sequence is an antisense oligonucleotide targetted to human FGFR-3
 SQ Sequence 20 BP; 2 A; 9 C; 6 G; 3 T; 0 U; 0 Other;
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 4.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2884 TCGGACCTGGGGCAGG 2903
 Db 20 TCGGACCTGGGGCAGG 1
 RESULT 364
 AAD55480/c
 ID AAD55480 standard; DNA; 20 BP.
 XX AAD55480;
 AC AAD55480;
 DT 07-AUG-2003 (first entry)
 DE Human FGFR-3 antisense oligonucleotide, ISIS #125186.
 XX Human; antisense; fibroblast growth factor receptor 3; prophylaxis; developmental disorder; hyperproliferative disorder; antisense therapy; FGFR-3; ACH; JTK4; CEK2; cancer; phosphorothioate; ss.
 OS Homo sapiens.
 OS Synthetic.
 PH Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "phosphorothioate backbone; All cytidine residues are 5-methylcytidines"
 FT modified_base 1..5
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 FT modified_base 16..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 WO2003023004-A2.
 20-MAR-2003.
 06-SEP-2002; 2002WO-US028549.
 10-SEP-2001; 2001US-00953047.

```

PA (ISIS-) ISIS PHARM INC.
XX
XX Monia BP, Wyatt JR;
XX
XX WPI; 2003-313244/30.
XX
XX Novel compound targetted to a nucleic acid molecule encoding fibroblast
XX growth factor receptor 3, useful for inhibiting the expression of the
XX receptor and for treating an animal having cancer or developmental
XX disorder.
XX
XX Claim 3; Page 79; 120pp; English.
XX
XX The invention relates to antisense compounds targetted to a nucleic acid
XX molecule encoding fibroblast growth factor (FGF) receptor 3 (also known
XX as FGFR-3, ACH, JTK4 and CEK2) to inhibit its expression. Antisense
XX compounds of the invention are useful for treating diseases or conditions
XX associated with FGFR-3 such as developmental disorders or
XX hyperproliferative disorders, especially cancer of colorectal, bladder,
XX bone, lung, cervical, breast or skin. They are useful as research
XX reagents, therapeutics, prophylaxis, kits and diagnostics, and as tools
XX in differential and/or combinatorial analyses to elucidate expression
XX patterns of a portion of the genes expressed within cells and tissues.
XX They are also useful in antisense therapy. The present sequence is an
XX antisense oligonucleotide targetted to human FGFR-3
XX
XX Sequence 20 BP; 6 A; 5 C; 6 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 0.5%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 4.4e+02;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 122 GCGTACTGTGCCACTTCAGT 141
DB 20 GCGTACTGTGCCACTTCAGT 1

RESULT 365
AAD5497/C
ID AAD5497 standard; DNA; 20 BP.
XX
XX AAD5497;
XX
XX 07-AUG-2003 (first entry)
XX
XX Human FGFR-3 antisense oligonucleotide, ISIS #125203.
XX
XX Human; antisense; fibroblast growth factor receptor 3; prophylaxis;
XX developmental disorder; hyperproliferative disorder; antisense therapy;
XX FGFR-3; ACH; JTK4; CEK2; cancer; phosphorothioate; ss.
XX
XX Homo sapiens.
XX Synthetic.
XX
XX Key Location/Qualifiers
XX modified_base 1..20
XX /tag= a
XX /mod_base= OTHER
XX /note= "Phosphorothioate backbone; All cytidine residues
XX are 5-methylcytidines"
XX modified_base 1..5
XX /tag= b
XX /mod_base= OTHER
XX /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX modified_base 16..20
XX /tag= c
XX /mod_base= OTHER
XX /note= "2 -methoxyethyl (2'-MOE) nucleotides"
XX
XX WO2003023004-A2.
XX
XX 20-MAR-2003.
XX
XX

```

```

PF 06-SEP-2002; 2002WO-US028549.
XX
XX 10-SEP-2001; 2001US-00953047.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Monia BP, Wyatt JR;
XX
XX WPI; 2003-313244/30.
XX
XX Novel compound targetted to a nucleic acid molecule encoding fibroblast
XX growth factor receptor 3, useful for inhibiting the expression of the
XX receptor and for treating an animal having cancer or developmental
XX disorder.
XX
XX Claim 3; Page 79; 120pp; English.
XX
XX The invention relates to antisense compounds targetted to a nucleic acid
XX molecule encoding fibroblast growth factor (FGF) receptor 3 (also known
XX as FGFR-3, ACH, JTK4 and CEK2) to inhibit its expression. Antisense
XX compounds of the invention are useful for treating diseases or conditions
XX associated with FGFR-3 such as developmental disorders or
XX hyperproliferative disorders, especially cancer of colorectal, bladder,
XX bone, lung, cervical, breast or skin. They are useful as research
XX reagents, therapeutics, prophylaxis, kits and diagnostics, and as tools
XX in differential and/or combinatorial analyses to elucidate expression
XX patterns of a portion of the genes expressed within cells and tissues.
XX They are also useful in antisense therapy. The present sequence is an
XX antisense oligonucleotide targetted to human FGFR-3
XX
XX Sequence 20 BP; 2 A; 3 C; 9 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 0.5%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 4.4e+02;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 2601 CCACACCCCAAGCTGAGCCT 2620
DB 20 CCACACCCCAAGCTGAGCCT 1

RESULT 366
AAD5430/C
ID AAD5430 standard; DNA; 20 BP.
XX
XX AAD5430;
XX
XX 07-AUG-2003 (first entry)
XX
XX Human FGFR-3 antisense oligonucleotide, ISIS #125110.
XX
XX Human; antisense; fibroblast growth factor receptor 3; prophylaxis;
XX developmental disorder; hyperproliferative disorder; antisense therapy;
XX FGFR-3; ACH; JTK4; CEK2; cancer; phosphorothioate; ss.
XX
XX Homo sapiens.
XX Synthetic.
XX
XX Key Location/Qualifiers
XX modified_base 1..20
XX /tag= a
XX /mod_base= OTHER
XX /note= "Phosphorothioate backbone; All cytidine residues
XX are 5-methylcytidines"
XX modified_base 1..5
XX /tag= b
XX /mod_base= OTHER
XX /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX modified_base 16..20
XX /tag= c
XX /mod_base= OTHER
XX /note= "2 -methoxyethyl (2'-MOE) nucleotides"
XX
XX

```

PN WO2003023004-A2.
 PD 20-MAR-2003.
 XX 06-SEP-2002; 2002WO-US028549.
 XX 10-SEP-2001; 2001US-00953047.
 PR (ISIS-) ISIS PHARM INC.
 XX Monia BP, Wyatt JR;
 XX WPI; 2003-313244/30.
 XX Novel compound targeted to a nucleic acid molecule encoding fibroblast growth factor receptor 3, useful for inhibiting the expression of the receptor and for treating an animal having cancer or developmental disorder.
 XX Claim 3; Page 78; 120pp; English.
 XX The invention relates to antisense compounds targetted to a nucleic acid molecule encoding fibroblast growth factor (FGF) receptor 3 (also known as FGFR-3, ACH, JTK4 and CEK2) to inhibit its expression. Antisense compounds of the invention are useful for treating diseases or conditions associated with FGFR-3 such as developmental disorders or hyperproliferative disorders, especially cancer of colorectal, bladder, bone, lung, cervical, breast or skin. They are useful as research reagents, therapeutics, prophylaxis, kits and diagnostics, and as tools in differential and/or combinatorial analyses to elucidate expression patterns of a portion of the genes expressed within cells and tissues. They are also useful in antisense therapy. The present sequence is an antisense oligonucleotide targetted to human FGFR-3
 XX Sequence 20 BP; 3 A; 7 C; 4 G; 6 T; 0 U; 0 Other;
 SQ
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 4.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 162 ATCTCGGGAGATGACGAG 181
 DB 20 ATCTCGGGAGATGACGAG 1
 RESULT 367
 AAD55433/c
 ID AAD55433 standard; DNA; 20 BP.
 AC AAD55433;
 XX 07-AUG-2003 (first entry)
 XX Human FGFR-3 antisense oligonucleotide, ISIS #125114.
 XX Human; antisense; fibroblast growth factor receptor 3; prophylaxis;
 KW developmental disorder; hyperproliferative disorder; antisense therapy;
 KW FGFR-3; ACH; JTK4; CEK2; cancer; phosphorothioate; ss.
 XX Homo sapiens.
 OS Synthetic.
 XX Key Location/Qualifiers
 FH modified_base 1..20
 FT /tag= a
 FT /mod_base= OTHER
 FT /note= "Phosphorothioate backbone; All cytidine residues
 FT are 5-methylcytidines"
 FT modified_base 1..5
 FT /tag= b
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 FT modified_base 16..20

FT FT /*tag= c
 FT /mod_base= OTHER
 XX /note= "2 -methoxyethyl (2'-MOE) nucleotides"
 PN WO2003023004-A2.
 XX 20-MAR-2003.
 XX 06-SEP-2002; 2002WO-US028549.
 XX 10-SEP-2001; 2001US-00953047.
 PR (ISIS-) ISIS PHARM INC.
 XX Monia BP, Wyatt JR;
 XX WPI; 2003-313244/30.
 XX Novel compound targeted to a nucleic acid molecule encoding fibroblast growth factor receptor 3, useful for inhibiting the expression of the receptor and for treating an animal having cancer or developmental disorder.
 XX Claim 3; Page 78; 120pp; English.
 XX The invention relates to antisense compounds targetted to a nucleic acid molecule encoding fibroblast growth factor (FGF) receptor 3 (also known as FGFR-3, ACH, JTK4 and CEK2) to inhibit its expression. Antisense compounds of the invention are useful for treating diseases or conditions associated with FGFR-3 such as developmental disorders or hyperproliferative disorders, especially cancer of colorectal, bladder, bone, lung, cervical, breast or skin. They are useful as research reagents, therapeutics, prophylaxis, kits and diagnostics, and as tools in differential and/or combinatorial analyses to elucidate expression patterns of a portion of the genes expressed within cells and tissues. They are also useful in antisense therapy. The present sequence is an antisense oligonucleotide targetted to human FGFR-3
 XX Sequence 20 BP; 5 A; 4 C; 8 G; 3 T; 0 U; 0 Other;
 SQ
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 4.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 326 CCTCCATCTCTGGCTGAAG 345
 DB 20 CCTCCATCTCTGGCTGAAG 1
 RESULT 368
 AAD55439/c
 ID AAD55439 standard; DNA; 20 BP.
 AC AAD55439;
 XX 07-AUG-2003 (first entry)
 XX Human FGFR-3 antisense oligonucleotide, ISIS #125133.
 XX Human; antisense; fibroblast growth factor receptor 3; prophylaxis;
 KW developmental disorder; hyperproliferative disorder; antisense therapy;
 KW FGFR-3; ACH; JTK4; CEK2; cancer; phosphorothioate; ss.
 XX Homo sapiens.
 OS Synthetic.
 XX Key Location/Qualifiers
 FH modified_base 1..20
 FT /tag= a
 FT /mod_base= OTHER
 FT /note= "Phosphorothioate backbone; All cytidine residues
 FT are 5-methylcytidines"
 FT modified_base 1..5

```

FT FT      /*tag= b
FT FT      /mod_base= OTHER
FT FT      /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT FT      modified_base
FT FT      16..20
FT FT      /*tag= c
FT FT      /mod_base= OTHER
FT FT      /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX XX
XX XX      WO2003023004-A2.
XX XX
XX XX      20-MAR-2003.
XX XX
XX XX      06-SEP-2002; 2002WO-US028549.
XX XX
XX XX      10-SEP-2001; 2001US-00953047.
XX XX
XX XX      (ISIS-) ISIS PHARM INC.
XX XX
XX XX      Monia BP, Wyatt JR;
XX XX
XX XX      WPI; 2003-313244/30.
XX XX
XX XX      Novel compound targeted to a nucleic acid molecule encoding fibroblast
XX XX      growth factor receptor 3, useful for inhibiting the expression of the
XX XX      receptor and for treating an animal having cancer or developmental
XX XX      disorder.
XX XX
XX XX      Example 15; Page 78; 120pp; English.
XX XX
XX XX      The invention relates to antisense compounds targetted to a nucleic acid
XX XX      molecule encoding fibroblast growth factor (FGF) receptor 3 (also known
XX XX      as FGFR-3, ACH, JTK4 and CEK2) to inhibit its expression. Antisense
XX XX      compounds of the invention are useful for treating diseases or conditions
XX XX      associated with FGFR-3 such as developmental disorders or
XX XX      hyperproliferative disorders, especially cancer of colorectal, bladder,
XX XX      bone, lung, cervical, breast or skin. They are useful as research
XX XX      reagents, therapeutics, prophylaxis, kits and diagnostics, and as tools
XX XX      in differential and/or combinatorial analyses to elucidate expression
XX XX      patterns of a portion of the genes expressed within cells and tissues.
XX XX      They are also useful in antisense therapy. The present sequence is an
XX XX      antisense oligonucleotide targetted to human FGFR-3
XX XX
XX XX      Sequence 20 BP; 4 A; 5 C; 9 G; 2 T; 0 U; 0 Other;
XX XX
XX XX      Query Match      0.5%; Score 20; DB 1; Length 20;
XX XX      Best Local Similarity 100.0%; Pred. No. 4.4e+02;
XX XX      Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX XX
XX XX      1491 CCGGGCCTGGACTACTCT 1510
XX XX      |||||
XX XX      20 CCGGGCCTGGACTACTCT 1
XX XX
XX XX      RESULT 369
XX XX      AAD55498/c
XX XX      ID AAD55498 standard; DNA; 20 BP.
XX XX
XX XX      AAD55498;
XX XX
XX XX      07-AUG-2003 (first entry)
XX XX
XX XX      Human FGFR-3 antisense oligonucleotide, ISIS #125204.
XX XX
XX XX      Human; antisense; fibroblast growth factor receptor 3; prophylaxis;
XX XX      developmental disorder; hyperproliferative disorder; antisense therapy;
XX XX      FGFR-3; ACH; JTK4; CEK2; cancer; phosphorothioate; ss.
XX XX
XX XX      Homo sapiens.
XX XX      Synthetic.
XX XX
XX XX      Key Location/Qualifiers
XX XX      modified_base 1..20
XX XX      /*tag= a
FT FT

```

```

FT FT      /mod_base= OTHER
FT FT      /note= "Phosphorothioate backbone; All cytidine residues
FT FT      are 5-methylcytidines"
FT FT      modified_base
FT FT      1..5
FT FT      /*tag= b
FT FT      /mod_base= OTHER
FT FT      /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT FT      modified_base
FT FT      16..20
FT FT      /*tag= c
FT FT      /mod_base= OTHER
FT FT      /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX XX
XX XX      WO2003023004-A2.
XX XX
XX XX      20-MAR-2003.
XX XX
XX XX      06-SEP-2002; 2002WO-US028549.
XX XX
XX XX      10-SEP-2001; 2001US-00953047.
XX XX
XX XX      (ISIS-) ISIS PHARM INC.
XX XX
XX XX      Monia BP, Wyatt JR;
XX XX
XX XX      WPI; 2003-313244/30.
XX XX
XX XX      Novel compound targeted to a nucleic acid molecule encoding fibroblast
XX XX      growth factor receptor 3, useful for inhibiting the expression of the
XX XX      receptor and for treating an animal having cancer or developmental
XX XX      disorder.
XX XX
XX XX      Claim 3; Page 79; 120pp; English.
XX XX
XX XX      The invention relates to antisense compounds targetted to a nucleic acid
XX XX      molecule encoding fibroblast growth factor (FGF) receptor 3 (also known
XX XX      as FGFR-3, ACH, JTK4 and CEK2) to inhibit its expression. Antisense
XX XX      compounds of the invention are useful for treating diseases or conditions
XX XX      associated with FGFR-3 such as developmental disorders or
XX XX      hyperproliferative disorders, especially cancer of colorectal, bladder,
XX XX      bone, lung, cervical, breast or skin. They are useful as research
XX XX      reagents, therapeutics, prophylaxis, kits and diagnostics, and as tools
XX XX      in differential and/or combinatorial analyses to elucidate expression
XX XX      patterns of a portion of the genes expressed within cells and tissues.
XX XX      They are also useful in antisense therapy. The present sequence is an
XX XX      antisense oligonucleotide targetted to human FGFR-3
XX XX
XX XX      Sequence 20 BP; 3 A; 8 C; 3 G; 6 T; 0 U; 0 Other;
XX XX
XX XX      Query Match      0.5%; Score 20; DB 1; Length 20;
XX XX      Best Local Similarity 100.0%; Pred. No. 4.4e+02;
XX XX      Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX XX
XX XX      2729 ACGGCTACTGAAGATGGGA 2748
XX XX      |||||
XX XX      20 ACGGCTACTGAAGATGGGA 1
XX XX
XX XX      RESULT 370
XX XX      AAD55502/c
XX XX      ID AAD55502 standard; DNA; 20 BP.
XX XX
XX XX      AAD55502;
XX XX
XX XX      07-AUG-2003 (first entry)
XX XX
XX XX      Human FGFR-3 antisense oligonucleotide, ISIS #125208.
XX XX
XX XX      Human; antisense; fibroblast growth factor receptor 3; prophylaxis;
XX XX      developmental disorder; hyperproliferative disorder; antisense therapy;
XX XX      FGFR-3; ACH; JTK4; CEK2; cancer; phosphorothioate; ss.
XX XX
XX XX      Homo sapiens.
XX XX      Synthetic.
XX XX

```

```
XX Key Location/Qualifiers
FH modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidine residues
FT are 5-methylcytidines"
FT modified_base 1..5
FT /tag= b
FT /mod_base= OTHER
FT modified_base 16..20
FT /tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX WO2003023004-A2.
XX 20-MAR-2003.
XX 06-SEP-2002; 2002WO-US028549.
XX 10-SEP-2001; 2001US-00953047.
XX (ISIS-) ISIS PHARM INC.
XX Monia BP, Wyatt JR;
XX WPI; 2003-313244/30.
XX Novel compound targeted to a nucleic acid molecule encoding fibroblast
XX growth factor receptor 3, useful for inhibiting the expression of the
XX receptor and for treating an animal having cancer or developmental
XX disorder.
XX Claim 3; Page 79; 120pp; English.
XX The invention relates to antisense compounds targeted to a nucleic acid
XX molecule encoding fibroblast growth factor (FGF) receptor 3 (also known
XX as FGFR-3, ACH, JTK4 and CEK2) to inhibit its expression. Antisense
XX compounds of the invention are useful for treating diseases or conditions
XX associated with FGFR-3 such as developmental disorders or
XX hyperproliferative disorders, especially cancer of colorectal, bladder,
XX bone, lung, cervical, breast or skin. They are useful as research
XX reagents, therapeutics, prophylaxis, kits and diagnostics, and as tools
XX in differential and/or combinatorial analyses to elucidate expression
XX patterns of a portion of the genes expressed within cells and tissues.
XX They are also useful in antisense therapy. The present sequence is an
XX antisense oligonucleotide targeted to human FGFR-3
XX Sequence 20 BP; 3 A; 9 C; 6 G; 2 T; 0 U; 0 Other;
SQ Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 3626 GGCCCTGAGTCTGGCAGC 3645
DB 20 GGCCCTGAGTCTGGCAGC 1
RESULT 371
AAD55429/c
ID AAD55429 standard; DNA; 20 BP.
XX AAD55429;
AC AAD55429;
XX 07-AUG-2003 (first entry)
XX Human FGFR-3 antisense oligonucleotide, ISIS #125109.
XX Human; antisense; fibroblast growth factor receptor 3; prophylaxis;
XX developmental disorder; hyperproliferative disorder; antisense therapy;
KW
```

```
KW FGFR-3; ACH; JTK4; CEK2; cancer; phosphorothioate; ss.
XX Homo sapiens.
XX Synthetic.
XX Key Location/Qualifiers
FH modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidine residues
FT are 5-methylcytidines"
FT modified_base 1..5
FT /tag= b
FT /mod_base= OTHER
FT modified_base 16..20
FT /tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX WO2003023004-A2.
XX 20-MAR-2003.
XX 06-SEP-2002; 2002WO-US028549.
XX 10-SEP-2001; 2001US-00953047.
XX (ISIS-) ISIS PHARM INC.
XX Monia BP, Wyatt JR;
XX WPI; 2003-313244/30.
XX Novel compound targeted to a nucleic acid molecule encoding fibroblast
XX growth factor receptor 3, useful for inhibiting the expression of the
XX receptor and for treating an animal having cancer or developmental
XX disorder.
XX Claim 3; Page 78; 120pp; English.
XX The invention relates to antisense compounds targeted to a nucleic acid
XX molecule encoding fibroblast growth factor (FGF) receptor 3 (also known
XX as FGFR-3, ACH, JTK4 and CEK2) to inhibit its expression. Antisense
XX compounds of the invention are useful for treating diseases or conditions
XX associated with FGFR-3 such as developmental disorders or
XX hyperproliferative disorders, especially cancer of colorectal, bladder,
XX bone, lung, cervical, breast or skin. They are useful as research
XX reagents, therapeutics, prophylaxis, kits and diagnostics, and as tools
XX in differential and/or combinatorial analyses to elucidate expression
XX patterns of a portion of the genes expressed within cells and tissues.
XX They are also useful in antisense therapy. The present sequence is an
XX antisense oligonucleotide targeted to human FGFR-3
XX Sequence 20 BP; 3 A; 5 C; 8 G; 4 T; 0 U; 0 Other;
SQ Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 152 CAGACGCTCCATCTCGGGA 171
DB 20 CAGACGCTCCATCTCGGGA 1
RESULT 372
AAD55441/c
ID AAD55441 standard; DNA; 20 BP.
XX AAD55441;
AC AAD55441;
XX 07-AUG-2003 (first entry)
XX
```


DE Human FGFR-3 antisense oligonucleotide, ISIS #125142.
XX Human; antisense; fibroblast growth factor receptor 3; prophylaxis;
KW developmental disorder; hyperproliferative disorder; antisense therapy;
KW FGFR-3; ACH; JTK4; CEK2; cancer; phosphorothioate; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PH Key Location/Qualifiers
FT modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidine residues
FT modified_base 1..5
FT /tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides".
XX
PN WO2003023004-A2.
XX
XX 20-MAR-2003.
XX
XX 06-SEP-2002; 2002WO-US028549.
XX
XX 10-SEP-2001; 2001US-00953047.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Monia BP, Wyatt JR;
XX WPI; 2003-313244/30.
XX
XX Novel compound targeted to a nucleic acid molecule encoding fibroblast
PT growth factor receptor 3, useful for inhibiting the expression of the
PT receptor and for treating an animal having cancer or developmental
PT disorder.
XX
XX Claim 3; Page 78; 120pp; English.
XX
XX The invention relates to antisense compounds targetted to a nucleic acid
CC molecule encoding fibroblast growth factor (FGF) receptor 3 (also known
CC as FGFR-3, ACH, JTK4 and CEK2) to inhibit its expression. Antisense
CC compounds of the invention are useful for treating diseases or conditions
CC associated with FGFR-3 such as developmental disorders or
CC hyperproliferative disorders, especially cancer of colorectal, bladder,
CC bone, lung, cervical, breast or skin. They are useful as research
CC reagents, therapeutics, prophylaxis, kits and diagnostics, and as tools
CC in differential and/or combinatorial analyses to elucidate expression
CC patterns of a portion of the genes expressed within cells and tissues.
CC They are also useful in antisense therapy. The present sequence is an
CC antisense oligonucleotide targetted to human FGFR-3
XX
SQ Sequence 20 BP; 2 A; 8 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2185 TCCTGGACGTGAGGGCCAC 2204
DB 20 TCCTGGACGTGAGGGCCAC 1

RESULT 373
AAD55448/c
ID AAD55448 standard; DNA; 20 BP.
XX

AC AAD55448;
XX
DT 07-AUG-2003 (first entry)
XX
DE Human FGFR-3 antisense oligonucleotide, ISIS #125150.
XX
XX Human; antisense; fibroblast growth factor receptor 3; prophylaxis;
KW developmental disorder; hyperproliferative disorder; antisense therapy;
KW FGFR-3; ACH; JTK4; CEK2; cancer; phosphorothioate; ss.
XX
XX Homo sapiens.
OS Synthetic.
XX
XX Key Location/Qualifiers
FT modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidine residues
FT modified_base 1..5
FT /tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
XX WO2003023004-A2.
XX
XX 20-MAR-2003.
XX
XX 06-SEP-2002; 2002WO-US028549.
XX
XX 10-SEP-2001; 2001US-00953047.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Monia BP, Wyatt JR;
XX WPI; 2003-313244/30.
XX
XX Novel compound targeted to a nucleic acid molecule encoding fibroblast
PT growth factor receptor 3, useful for inhibiting the expression of the
PT receptor and for treating an animal having cancer or developmental
PT disorder.
XX
XX Claim 3; Page 79; 120pp; English.
XX
XX The invention relates to antisense compounds targetted to a nucleic acid
CC molecule encoding fibroblast growth factor (FGF) receptor 3 (also known
CC as FGFR-3, ACH, JTK4 and CEK2) to inhibit its expression. Antisense
CC compounds of the invention are useful for treating diseases or conditions
CC associated with FGFR-3 such as developmental disorders or
CC hyperproliferative disorders, especially cancer of colorectal, bladder,
CC bone, lung, cervical, breast or skin. They are useful as research
CC reagents, therapeutics, prophylaxis, kits and diagnostics, and as tools
CC in differential and/or combinatorial analyses to elucidate expression
CC patterns of a portion of the genes expressed within cells and tissues.
CC They are also useful in antisense therapy. The present sequence is an
CC antisense oligonucleotide targetted to human FGFR-3
XX
SQ Sequence 20 BP; 2 A; 9 C; 1 G; 8 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2853 GGAAGAGGAGGAGGCTGGTA 2872
DB 20 GGAAGAGGAGGAGGCTGGTA 1

RESULT 373
AAD55448/c
ID AAD55448 standard; DNA; 20 BP.
XX

RESULT 374	
AAD5501/C	
ID	AAD5501 standard; DNA; 20 BP.
XX	
AC	AAD5501;
XX	
DT	07-AUG-2003 (first entry)
XX	
DE	Human FGFR-3 antisense oligonucleotide, ISIS #125207.
XX	
KW	Human; antisense; fibroblast growth factor receptor 3; prophylaxis;
KW	developmental disorder; hyperproliferative disorder; antisense therapy;
KW	FGFR-3; ACH; JTK4; CEK2; cancer; phosphorothioate; ss.
XX	
OS	Homo sapiens.
OS	Synthetic.
XX	
FH	Key
DE	Location/Qualifiers
FT	modified_base 1..20
FT	/*tag= a
FT	/mod_base= OTHER
FT	/note= "phosphorothioate backbone; All cytidine residues
FT	are 5-methylcytidines"
FT	modified_base 1..5
FT	/*tag= b
FT	/mod_base= OTHER
FT	/note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT	modified_base 16..20
FT	/*tag= c
FT	/mod_base= OTHER
FT	/note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX	
PN	WO2003023004-A2.
XX	
XX	20-MAR-2003.
PD	
XX	
XX	06-SEP-2002; 2002WO-US028549.
PF	
XX	
XX	10-SEP-2001; 2001US-00953047.
PR	
XX	
XX	(ISIS-) ISIS PHARM INC.
PA	
XX	
XX	Monia BP, Wyatt JR;
PI	
XX	
DR	WPI; 2003-313244/30.
XX	
PT	Novel compound targeted to a nucleic acid molecule encoding fibroblast
PT	growth factor receptor 3, useful for inhibiting the expression of the
PT	receptor and for treating an animal having cancer or developmental
PT	disorder.
XX	
XX	Claim 3; Page 79; 120pp; English.
XX	
CC	The invention relates to antisense compounds targetted to a nucleic acid
CC	molecule encoding fibroblast growth factor (FGF) receptor 3 (also known
CC	as FGFR-3, ACH, JTK4 and CEK2) to inhibit its expression. Antisense
CC	compounds of the invention are useful for treating diseases or conditions
CC	associated with FGFR-3 such as developmental disorders or
CC	hyperproliferative disorders, especially cancer of colorectal, bladder,
CC	bone, lung, cervical, breast or skin. They are useful as research
CC	reagents, therapeutics, prophylaxis, kits and diagnostics, and as tools
CC	in differential and/or combinatorial analyses to elucidate expression
CC	patterns of a portion of the genes expressed within cells and tissues.
CC	They are also useful in antisense therapy. The present sequence is an
CC	antisense oligonucleotide targetted to human FGFR-3
XX	
XX	Sequence 20 BP; 9 A; 3 C; 2 G; 6 T; 0 U; 0 Other;
SQL	
	Query Match 0.5%; Score 20; DB 1; Length 20;
	Best Local Similarity 100.0%; Pred. No. 4.4e+02;
	Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0
QY	3506 TATTGTGTGACTTAACA 3525

```
Best Local Similarity 100.0%; Pred. No. 4.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2031 TACCGTGACGTCACCGACG 2050
    |||||
Db 20 TACCGTGACGTCACCGACG 1

RESULT 376
AAD5459/C
ID AAD5459 standard; DNA; 20 BP.
XX
AC AAD5459;
XX
DT 07-AUG-2003 (first entry)
XX
DE Human FGFR-3 antisense oligonucleotide, ISIS #125163.
XX
KW Human; antisense; fibroblast growth factor receptor 3; prophylaxis;
KW developmental disorder; hyperproliferative disorder; antisense therapy;
KW FGFR-3; ACH; JTK4; CEK2; cancer; phosphorothioate; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidine residues
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2 -methoxyethyl (2'-MOE) nucleotides"
XX
PN WO2003023004-A2.
XX
PD 20-MAR-2003.
XX
PF 06-SEP-2002; 2002WO-US028549.
XX
PR 10-SEP-2001; 2001US-00953047.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Monia BP, Wyatt JR;
XX
DR WPI; 2003-313244/30.
XX
PT Novel compound targeted to a nucleic acid molecule encoding fibroblast
PT growth factor receptor 3, useful for inhibiting the expression of the
PT receptor and for treating an animal having cancer or developmental
PT disorder.
XX
PS Claim 3; Page 79; 120pp; English.
XX
CC The invention relates to antisense compounds targetted to a nucleic acid
CC molecule encoding fibroblast growth factor (FGF) receptor 3 (also known
CC as FGFR-3, ACH, JTK4 and CEK2) to inhibit its expression. Antisense
CC compounds of the invention are useful for treating diseases or conditions
CC associated with FGFR-3 such as developmental disorders or
CC hyperproliferative disorders, especially cancer of colorectal, bladder,
CC bone, lung, cervical, breast or skin. They are useful as research
CC reagents, therapeutics, prophylaxis, kits and diagnostics, and as tools
CC in differential and/or combinatorial analyses to elucidate expression
CC patterns of a portion of the genes expressed within cells and tissues.
CC They are also useful in antisense therapy. The present sequence is an
CC antisense oligonucleotide targetted to human FGFR-3

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3565 GCTACCTTTCAAAGCTTGA 3584
    |||||
Db 20 GCTACCTTTCAAAGCTTGA 1

RESULT 377
AAD5491/C
ID AAD5491 standard; DNA; 20 BP.
XX
AC AAD5491;
XX
DT 07-AUG-2003 (first entry)
XX
DE Human FGFR-3 antisense oligonucleotide, ISIS #125197.
XX
KW Human; antisense; fibroblast growth factor receptor 3; prophylaxis;
KW developmental disorder; hyperproliferative disorder; antisense therapy;
KW FGFR-3; ACH; JTK4; CEK2; cancer; phosphorothioate; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidine residues
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2 -methoxyethyl (2'-MOE) nucleotides"
XX
PN WO2003023004-A2.
XX
PD 20-MAR-2003.
XX
PF 06-SEP-2002; 2002WO-US028549.
XX
PR 10-SEP-2001; 2001US-00953047.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Monia BP, Wyatt JR;
XX
DR WPI; 2003-313244/30.
XX
PT Novel compound targeted to a nucleic acid molecule encoding fibroblast
PT growth factor receptor 3, useful for inhibiting the expression of the
PT receptor and for treating an animal having cancer or developmental
PT disorder.
XX
PS Claim 3; Page 79; 120pp; English.
XX
CC The invention relates to antisense compounds targetted to a nucleic acid
CC molecule encoding fibroblast growth factor (FGF) receptor 3 (also known
CC as FGFR-3, ACH, JTK4 and CEK2) to inhibit its expression. Antisense
CC compounds of the invention are useful for treating diseases or conditions
CC associated with FGFR-3 such as developmental disorders or
CC hyperproliferative disorders, especially cancer of colorectal, bladder,
CC bone, lung, cervical, breast or skin. They are useful as research
CC reagents, therapeutics, prophylaxis, kits and diagnostics, and as tools
CC in differential and/or combinatorial analyses to elucidate expression
CC patterns of a portion of the genes expressed within cells and tissues.
CC They are also useful in antisense therapy. The present sequence is an
CC antisense oligonucleotide targetted to human FGFR-3
```

CC in differential and/or combinatorial analyses to elucidate expression
CC patterns of a portion of the genes expressed within cells and tissues.
CC They are also useful in antisense therapy. The present sequence is an
CC antisense oligonucleotide targetted to human FGFR-3
XX
SQ Sequence 20 BP; 0 A; 7 C; 8 G; 5 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1260 CAAGGACCGCGCGCCAGC 1279
Db 20 CAAGGACCGCGCGCCAGC 1
RESULT 378
AAD55493/C
ID RAD55493 standard; DNA; 20 BP.
XX
AC RAD55493;
XX
DT 07-AUG-2003 (first entry)
XX Human FGFR-3 antisense oligonucleotide, ISIS #125199.
XX Human; antisense; fibroblast growth factor receptor 3; prophylaxis;
XX developmental disorder; hyperproliferative disorder; antisense therapy;
XX FGFR-3; ACH; JTK4; CEK2; cancer; phosphorothioate; ss.
XX Homo sapiens.
XX Synthetic.
XX Key Location/Qualifiers
FH modified_base 1. .20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "phosphorothioate backbone; All cytidine residues
FT modified_base 1. .5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16. .20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX WO2003023004-A2.
XX PD 20-MAR-2003.
XX PF 06-SEP-2002; 2002WO-US028549.
XX PR 10-SEP-2001; 2001US-00953047.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Monia BP, Wyatt JR;
XX WPI; 2003-313244/30.
XX Novel compound targetted to a nucleic acid molecule encoding fibroblast
XX growth factor receptor 3, useful for inhibiting the expression of the
XX receptor and for treating an animal having cancer or developmental
XX disorder.
XX Claim 3; Page 79; 120pp; English.
XX The invention relates to antisense compounds targetted to a nucleic acid
XX molecule encoding fibroblast growth factor (FGF) receptor 3 (also known
XX as FGFR-3, ACH, JTK4 and CEK2) to inhibit its expression. Antisense
XX compounds of the invention are useful for treating diseases or conditions

CC associated with FGFR-3 such as developmental disorders or
CC hyperproliferative disorders, especially cancer of colorectal, bladder,
CC bone, lung, cervical, breast or skin. They are useful as research
CC reagents, therapeutics, prophylaxis, kits and diagnostics, and as tools
CC in differential and/or combinatorial analyses to elucidate expression
CC patterns of a portion of the genes expressed within cells and tissues.
CC They are also useful in antisense therapy. The present sequence is an
CC antisense oligonucleotide targetted to human FGFR-3
XX
SQ Sequence 20 BP; 1 A; 7 C; 8 G; 4 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1523 AGCGCGCCGAGGAGCAGCTC 1542
Db 20 AGCGCGCCGAGGAGCAGCTC 1
RESULT 379
RAD55496/C
ID AAD55496 standard; DNA; 20 BP.
XX
AC AAD55496;
XX
DT 07-AUG-2003 (first entry)
XX Human FGFR-3 antisense oligonucleotide, ISIS #125202.
XX Human; antisense; fibroblast growth factor receptor 3; prophylaxis;
XX developmental disorder; hyperproliferative disorder; antisense therapy;
XX FGFR-3; ACH; JTK4; CEK2; cancer; phosphorothioate; ss.
XX Homo sapiens.
XX Synthetic.
XX Key Location/Qualifiers
FH modified_base 1. .20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "phosphorothioate backbone; All cytidine residues
FT modified_base 1. .5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16. .20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX WO2003023004-A2.
XX PD 20-MAR-2003.
XX PF 06-SEP-2002; 2002WO-US028549.
XX PR 10-SEP-2001; 2001US-00953047.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Monia BP, Wyatt JR;
XX WPI; 2003-313244/30.
XX Novel compound targetted to a nucleic acid molecule encoding fibroblast
XX growth factor receptor 3, useful for inhibiting the expression of the
XX receptor and for treating an animal having cancer or developmental
XX disorder.
XX Claim 3; Page 79; 120pp; English.

CC	The invention relates to a nucleic acid
CC	molecule encoding fibroblast growth factor (FGF) receptor 3 (also known
CC	as FGFR-3, ACH, JTK4 and CEK2) to inhibit its expression. Antisense
CC	compounds of the invention are useful for treating diseases or conditions
CC	associated with FGFR-3 such as developmental disorders or
CC	hyperproliferative disorders, especially cancer of colorectal, bladder,
CC	bone, lung, cervical, breast or skin. They are useful as research
CC	reagents, therapeutics, prophylaxis, kits and diagnostics, and as tools
CC	in differential and/or combinatorial analyses to elucidate expression
CC	patterns of a portion of the genes expressed within cells and tissues.
CC	They are also useful in antisense therapy. The present sequence is an
CC	antisense oligonucleotide targetted to human FGFR-3
XX	
SQ	Sequence 20 BP; 4 A; 5 C; 8 G; 3 T; 0 U; 0 Other;
	Query Match 0.5%; Score 20; DB 1; Length 20;
	Best Local Similarity 100.0%; Pred. No. 4.4e+02;
	Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0
QY	2557 CTGCCTTTGCACCACGGGAC 2576
Db	20 CTGCCTTTGCACCACGGGAC 1
RESULT 380	
ADH93220	
ID	ADH93220 standard; DNA; 20 BP.
XX	
AC	ADH93220;
XX	
DT	22-APR-2004 (first entry)
XX	
DE	Human gene PCR primer #65.
DE	
XX	human; gene sequence; single nucleotide polymorphism; SNP;
KW	disease diagnosis; ss; PCR; primer.
XX	
OS	Homo sapiens.
XX	
PN	JP2003174883-A.
XX	
PD	24-JUN-2003.
XX	
PF	11-DEC-2001; 2001JP-00377637.
XX	
PR	11-DEC-2001; 2001JP-00377637.
XX	
PA	(KAGA-) KAGAKU GIJUTSU SHINKO JIGYODAN.
XX	
XX	WPI; 2003-819215/77.
DR	
XX	
PT	Polynucleotide for detecting single nucleotide polymorphisms existing in
PT	human gene, contains isolated human gene having specified sequence.
XX	
PS	Claim 2; SEQ ID NO 1057; 529bp; Japanese.
XX	
CC	The invention comprises isolated human gene sequences and PCR primer
CC	sequences which can be used to detect single nucleotide polymorphisms
CC	(SNPs). The DNA sequences of the invention are useful for detecting SNPs
CC	existing in human genes and for the diagnosis of human disease. The
CC	present DNA sequence represents a human gene PCR primer of the invention.
XX	
SQ	Sequence 20 BP; 6 A; 3 C; 7 G; 4 T; 0 U; 0 Other;
	Query Match 0.5%; Score 20; DB 1; Length 20;
	Best Local Similarity 100.0%; Pred. No. 4.4e+02;
	Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0
QY	464 TGGAGAACAACTTTGGCAGC 483
Db	1 TGGAGAACAACTTTGGCAGC 20

CC for the inspection of flat epithelial cells. The present sequence
CC represents a PCR primer for human FGFR3, which is used in an example from
CC the present invention
XX
SQ Sequence 20 BP; 2 A; 9 C; 5 G; 4 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 2188 CGGACGTGAAGGCCACTGG 2207
Db 20 CGGACGTGAAGGCCACTGG 1
RESULT 384
ADK51119
ID ADK51119 standard; DNA; 20 BP.
XX
AC ADK51119;
XX
DT 17-JUN-2004 (first entry)
XX
DE Human NOVX protein-related PCR primer SeqID.
XX
KW cytosstatic; NOVX-agonist; NOVX-antagonist; vaccine; gene therapy; cancer;
KW chromosome mapping; human; PCR; primer; ss.
XX
OS Homo sapiens.
XX
PN WO2003083046-A2.
XX
PD 09-OCT-2003.
XX
PF 01-APR-2003; 2003WO-US010142.
XX
PR 02-APR-2002; 2002US-00115479.
PR 05-APR-2002; 2002US-0370349P.
PR 08-APR-2002; 2002US-0370969P.
PR 12-APR-2002; 2002US-0372019P.
PR 22-APR-2002; 2002US-0374379P.
PR 30-MAY-2002; 2002US-0384543P.
PR 03-JUN-2002; 2002US-00160619.
PR 15-AUG-2002; 2002US-0403748P.
PR 04-NOV-2002; 2002US-00287226.
PR 31-MAR-2003; 2003US-00403161.
XX
PA (CURA-) CURAGEN CORP.
XX
PI Anderson DW, Bento P, Boldog FL, Burgess CE, Casman SJ, Furtak K;
PI Gorman L, Gould-Rothberg BE, Gunther E, Heyes MP, Li L, Spytek KA;
PI Stone DJ, Zhong M, Malyankar UM, Edinger SR, Patturajan M;
PI Rothenberg ME, Smithson G;
XX
XX WPI; 2003-812539/76.
XX
XX New NOVX polypeptide, useful for preparing a composition for treating or
PT preventing e.g. cancer or for chromosome mapping.
XX
PS Example C; SEQ ID NO 140; 433pp; English.
XX
XX This invention relates to novel isolated polypeptides and the DNA
CC sequences which encode them. The invention may be useful for the
CC development of compounds with a cytostatic activity (as NOVX-agonists or
CC antagonists) or vaccines. In addition, the disclosed sequences may be
CC useful for gene therapy. The polypeptide is useful for preparing a
CC composition for treating or preventing a pathological state in a mammal,
CC for example cancer or for chromosome mapping. The present sequence is
CC that of a PCR primer which was used in the exemplification of the
XX invention.
XX
SQ Sequence 20 BP; 4 A; 7 C; 4 G; 5 T; 0 U; 0 Other;

XX
DR WPI; 2003-819215/77.
XX
PT Polynucleotide for detecting single nucleotide polymorphisms existing in
PT human gene, contains isolated human gene having specified sequence.
XX
PS Claim 2; SEQ ID NO 1052; 529pp; Japanese.
XX
CC The invention comprises isolated human gene sequences and PCR primer
CC sequences which can be used to detect single nucleotide polymorphisms
CC (SNPs). The DNA sequences of the invention are useful for detecting SNPs
CC existing in human genes and for the diagnosis of human disease. The
CC present DNA sequence represents a human gene PCR primer of the invention.
XX
SQ Sequence 20 BP; 4 A; 7 C; 3 G; 6 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 462 CGTGGAGAACAGTTTGGCA 481
Db 20 CGTGGAGAACAGTTTGGCA 1
RESULT 383
ACC79688/c
ID ACC79688 standard; DNA; 20 BP.
XX
AC ACC79688;
XX
DT 27-AUG-2003 (first entry)
XX
DE Human fibroblast growth factor 3 exon 19 PCR primer #2.
XX
KW Human; fibroblast growth factor 3; FGF3; flat epithelial cell; cancer;
KW flat epithelial cell cancer; PCR primer; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN JP2002272474-A.
XX
PD 24-SEP-2002.
XX
PF 22-MAR-2001; 2001JP-00083352.
XX
PR 22-MAR-2001; 2001JP-00083352.
XX
PA (ZERI) ZERIA SHINYAKU KOGYO KK.
XX
XX WPI; 2003-345602/33.
XX
XX Inspection of flat epithelial cell, screening of treating or preventive
PT agents for flat epithelial cancers, the treating or preventive agents for
PT flat epithelial cancer.
XX
PS Example; Page 6; 18pp; Japanese.
XX
XX The present invention describes a method for the inspection of flat
CC epithelial cells in which it is judged that flat epithelial cells
CC separated from an organism can proceed to flat epithelial cancer when the
CC 2128th base in fibroblast growth factor receptor (FGFR) gene of the cells
CC is mutated from guanine to thymine. Also described is a method for
CC screening treating or preventive agents for flat epithelial cancers in
CC which a candidate substance of treating agent cells producing FGFR protein in
CC is applied to flat epithelial cancer cells. The polypeptide is useful for
CC which the 2128th (exon 17) amino acid in FGFR3 gene is mutated from
CC guanine to thymine or the 697th amino acid is mutated from glycine to
CC cysteine and said candidate substance is selected by using the facts that
CC the 2128th base in the flat epithelial cell FGFR3 gene after the
CC application returned to guanine and that the 697th amino acid of FGFR3
CC protein produced returned to glycine as the indices. The method is used

```
Query Match      0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 686 CCTACGTTACCGTGCTCAAG 705
DB 1 CCTACGTTACCGTGCTCAAG 20
|||||

RESULT 385
ADK51122
ID ADK51122 standard; DNA; 20 BP.
XX
AC ADK51122;
XX
DT 17-JUN-2004 (first entry)
XX
DE Human NOVX protein-related PCR primer SeqID.
XX
KW cytostatic; NOVX-agonist; NOVX-antagonist; vaccine; gene therapy; cancer;
KW chromosome mapping; human; PCR; primer; ss.
XX
OS Homo sapiens.
XX
PN WO2003083046-A2.
XX
PD 09-OCT-2003.
XX
PF 01-APR-2003; 2003WO-US010142.
XX
PR 02-APR-2002; 2002US-00115479.
XX
PR 05-APR-2002; 2002US-0370349P.
XX
PR 08-APR-2002; 2002US-0370969P.
XX
PR 12-APR-2002; 2002US-0372019P.
XX
PR 22-APR-2002; 2002US-0374379P.
XX
PR 30-MAY-2002; 2002US-0384543P.
XX
PR 03-JUN-2002; 2002US-00160619.
XX
PR 15-AUG-2002; 2002US-0403748P.
XX
PR 04-NOV-2002; 2002US-00287226.
XX
PR 31-MAR-2003; 2003US-00403161.
XX
PA (CURA-) CURAGEN CORP.
XX
PI Anderson DW, Bento P, Boldog FL, Burgess CE, Casman SV, Furtak K;
PI Gorman L, Gould-Rothberg BE, Gunther E, Hayes MP, Li L, Spytek KA;
PI Stone DJ, Zhong M, Malyankar UM, Edinger SR, Patturajan M;
PI Rothenberg ME, Smithson G;
XX
DR WPI; 2003-812539/76.
XX
XX New NOVX polypeptide, useful for preparing a composition for treating or
XX preventing e.g. cancer or for chromosome mapping.
XX
XX Example C; SEQ ID NO 143; 433pp; English.
XX
CC This invention relates to novel isolated polypeptides and the DNA
CC sequences which encode them. The invention may be useful for the
CC development of compounds with a cytostatic activity (as NOVX-agonists or
CC antagonists) or vaccines. In addition, the disclosed sequences may be
CC useful for gene therapy. The polypeptide is useful for preparing a
CC composition for treating or preventing a pathological state in a mammal,
CC for example cancer or for chromosome mapping. The present sequence is
CC that of a PCR primer which was used in the exemplification of the
CC invention.
XX
SQ Sequence 20 BP; 4 A; 7 C; 4 G; 5 T; 0 U; 0 Other;

Query Match      0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 686 CCTACGTTACCGTGCTCAAG 705
DB 1 CCTACGTTACCGTGCTCAAG 20
|||||

RESULT 386
ADK70840
ID ADK70840 standard; DNA; 20 BP.
XX
AC ADK70840;
XX
DT 06-MAY-2004 (first entry)
XX
DE 5' mRNA DNA preparation method related tag DNA sequence #8.
XX
KW DNA preparation; 5' mRNA; linker synthesis; primer synthesis;
KW gene regulation; gene expression; ss; tag.
XX
OS Unidentified.
XX
PN WO2003106672-A2.
XX
PD 24-DEC-2003.
XX
PF 12-JUN-2003; 2003WO-JP007514.
XX
PR 12-JUN-2002; 2002JP-00171851.
XX
PR 12-AUG-2002; 2002JP-00235294.
XX
PA (RIKE ) RIKEN KK.
XX
PA (DNAF-) DNAFORM KK.
XX
PI Hayashizaki Y, Carninci P, Harbers MT;
XX
DR WPI; 2004-082194/08.
XX
PT Preparing DNA fragment corresponding to nucleotide sequence of 5' end
PT region of mRNA, by preparing nucleic acid corresponding to nucleotide
PT sequence of 5' end of mRNA, cleaving nucleic acid with restriction
PT enzyme.
XX
PS Example 5; SEQ ID NO 40; 121pp; English.
XX
CC The invention comprises a method for preparing a DNA fragment
CC corresponding to a nucleotide sequence of a 5' end of an mRNA. The method
CC is useful for synthesising a nucleotide sequence to be used as a linker
CC or primer and selectively collecting multiple nucleic acid fragments
CC containing information on the nucleotide sequences at the 5' end of
CC multiple mRNA in a sample. The method is also useful for identifying
CC regions in the genome, which are required for gene regulation and gene
CC expression. The present DNA sequence was used in an example of the
CC invention.
XX
SQ Sequence 20 BP; 0 A; 1 C; 10 G; 9 T; 0 U; 0 Other;

Query Match      0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2319 GGTGTGTGTGTGTGTGTGTGT 2338
DB 1 GGTGTGTGTGTGTGTGTGTGT 20
|||||

RESULT 387
ABK50766/c
ID ABK50766 standard; DNA; 27 BP.
XX
AC ABK50766;
XX
DT 15-JUL-2002 (first entry)
XX
DE PCR primer #6, used for amplification of pear plant microsatellite DNA.
XX
KW Pear plant; microsatellite DNA; DNA marker; species discrimination;
```


PN W02003103581-A2.
 XX 18-DEC-2003.
 XX 05-JUN-2003; 2003WO-US017591.
 PF 05-JUN-2002; 2002US-0386637P.
 PR (GETH) GENENTECH INC.
 PA
 XX Ferrara N, Hillan KJ, Le Couter J;
 PI WPI; 2004-071254/07.
 XX
 XX Promoting liver growth or promoting hepatocyte proliferation in liver of
 PT subject, treating pathological liver condition e.g. cirrhosis in subject,
 PT by administering vascular endothelial growth factor receptor modulator.
 XX
 XX Example 4; Page 43; 64pp; English.
 XX
 CC The present invention describes a method for promoting (M1) liver growth
 CC or promoting (M2) hepatocyte proliferation in the liver of a subject,
 CC treating (M3) a pathological liver condition in a subject, or protecting
 CC (M4) liver from damage in the subject due to exposure to a hepatotoxic
 CC agent, which involves administering to the subject a vascular endothelial
 CC growth factor receptor (VEGFR) modulating agent (I). Also described: (1)
 CC an article of manufacture comprising a container, composition contained
 CC within the container and a label on the container instructing uses of the
 CC composition for promoting liver growth, where the composition comprises a
 CC VEGFR modulating agent in the amount effective to promote liver growth;
 CC and (2) a kit comprising a first container, a LABEL on the first
 CC container, and a composition contained within the first container, where
 CC the composition comprises a VEGFR modulating agent in the amount
 CC effective to promote liver growth, a second container comprising a buffer
 CC and an instruction for using the kit for promoting liver growth. (1) has
 CC hepatotropic and antiinflammatory activities, and can be used as a VEGFR
 CC modulator, and a liver growth promoter. (I) can be used for promoting
 CC liver growth or hepatocyte proliferation in the liver of a subject,
 CC treating a pathological liver condition in a subject such as liver
 CC failure, hepatitis, liver cirrhosis, toxic liver damage, medicamentary
 CC liver damage, hepatic encephalopathy, hepatic coma or hepatic necrosis,
 CC or for protecting liver from damage in a subject due to exposure to
 CC hepatotoxic agent. The VEGFR modulator create a local cascade of
 CC signaling events originating in sinusoidal endothelial cells following
 CC VEGF receptor activation, which is much more potent and beneficial in
 CC promoting hepatocyte proliferation and liver growth than systemic
 CC delivery of the principal liver mitogen, hepatocyte growth factor (HGF).
 CC The present sequence is used in the exemplification of the present
 CC invention.
 XX
 XX Sequence 23 BP; 4 A; 9 C; 5 G; 5 T; 0 U; 0 Other;
 XX
 Query Match 0.5%; Score 19.8; DB 1; Length 23;
 Best Local Similarity 91.3%; Pred. No. 5.5e+02;
 Matches 21; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2002 CAGCTGGTGAGACCTGGACCG 2024
 DB 23 CAGTTGGTGAGACCTGGACCG 1
 XX
 RESULT 392
 ADH70580/C
 ID ADH70580 standard; DNA; 23 BP.
 XX
 AC ADH70580;
 XX
 XX 25-MAR-2004 (first entry)
 XX Human Vbeta gene repeat sequence #370.
 DE human; T-cell associated disease; Vbeta; autoimmune disease;
 XX degenerative nervous system disease; graft versus host disease;
 KW

KW hypersensitivity disease; infectious disease; neoplastic disease;
 KW Addison's disease; atrophic gastritis;
 KW degenerative nervous system disease; multiple sclerosis;
 KW Alzheimer's disease; hypersensitivity disease; type I hypersensitivity;
 KW allergy; type II hypersensitivity; Goodpasture's syndrome; viral infection;
 KW type IV hypersensitivity; leprosy; infectious disease; schistosomiasis;
 KW HIV; fungal infection; Candida; parasitic infection; schistosomiasis;
 KW filaria; bacterial infection; Mycobacterium; neoplastic disease;
 KW lymphoproliferative disease; leukaemia; lymphoma; cancer; brain cancer;
 KW breast cancer; ds.
 XX Homo sapiens.
 OS
 XX US2002150891-A1.
 PN
 XX 17-OCT-2002.
 PD
 XX 05-MAR-1999; 99US-00263959.
 PF
 XX 19-SEP-1994; 94US-00309335.
 PR 19-SEP-1995; 95US-00531241.
 XX
 XX (HOOD//) HOOD L E.
 PA (ROWE//) ROWEN L.
 PA
 XX Hood LE, Rowen L;
 PI
 XX WPI; 2004-059052/06.
 DR
 XX Kit for diagnosing and treating T-cell associated diseases e.g.
 PT autoimmune, degenerative nervous system and infectious disease, comprises
 PT nucleic acid primers specifically priming and allowing amplification of a
 PT Vbeta gene.
 PT
 XX Disclosure; SEQ ID NO 774; 164pp; English.
 PS
 XX The invention relates to a kit for diagnosing and treating T-cell
 CC associated diseases which comprises a panel of nucleic acid primers
 CC specifically priming and allowing amplification of each Vbeta gene,
 CC VbetARNA or cDNA. The kit is useful for diagnosing organ transplant
 CC rejection and diagnosing and treating T-cell associated diseases
 CC including autoimmune diseases, degenerative nervous system diseases,
 CC graft versus host diseases, hypersensitivity diseases, infectious diseases,
 CC and neoplastic diseases. Autoimmune diseases include Addison's disease,
 CC atrophic gastritis. Degenerative nervous system diseases include multiple
 CC sclerosis and Alzheimer's disease. Hypersensitivity diseases include Type
 CC I hypersensitivities such as contact with allergens that lead to
 CC allergies, Type II hypersensitivities such as those present in
 CC Goodpasture's syndrome and Type IV hypersensitivities such as those
 CC manifested in leprosy. Infectious diseases include viral infections
 CC caused by viruses such as HIV, fungal infections such as those caused by
 CC the yeast genus Candida, parasitic infections such as those caused by
 CC schistosomes, filaria and bacterial infections such as those caused by
 CC Mycobacterium. Neoplastic diseases include lymphoproliferative diseases
 CC such as leukaemias, lymphomas and cancers such as cancer of the brain,
 CC breast. The present sequence represents a Vbeta gene repeat sequence.
 XX
 XX Sequence 23 BP; 12 A; 10 C; 0 G; 1 T; 0 U; 0 Other;
 XX
 Query Match 0.5%; Score 19.8; DB 1; Length 23;
 Best Local Similarity 91.3%; Pred. No. 5.5e+02;
 Matches 21; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2318 TGTGTGTGTGTGTGTGTGTGTGTGTGTGT 2340
 DB 23 TGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1
 XX
 RESULT 393
 AAZ98498/C
 ID AAZ98498 standard; DNA; 24 BP.
 XX
 AC AAZ98498;

PD 05-MAR-2002.
 XX
 PF 05-JAN-1999; 99US-00225928.
 XX
 PR 21-MAY-1997; 97US-00859998.
 XX
 PA (CLON-) CLONTECH LAB INC.
 XX
 PI Chenchik A, Johadze G, Bibilashvilli R;
 XX
 DR WPI; 2002-314699/35.
 XX
 PT Producing sub-population of labeled nucleic acids, useful for analyzing
 XX differences in RNA profiles between several different physiological
 PT sources, using set of distinct gene specific primers.
 XX
 PS Example 3; SEQ ID NO 350; 11pp; English.
 XX
 CC The invention relates to producing a sub-population of labeled nucleic
 CC acids (NAs) comprising contacting a NA sample from a physiological
 CC source, with a pool of 50 distinct gene specific primers under suitable
 CC conditions to enzymatically generate sub-population of NAs, where each
 CC gene specific primer has a sequence complementary to a distinct mRNA, and
 CC each labeled NA is generated using a single gene specific primer. The
 CC method is useful for producing a sub-population of labeled NAs which is
 CC useful for analysing the differences in the RNA profiles between several
 CC different physiological sources, where the method comprises producing
 CC subpopulation of labeled NAs for the different physiological sources,
 CC comprising the populations for each physiological source to identify
 CC differences in the population, where the comparison is preferably
 CC performed by hybridising the labeled NAs for each of the distinct
 CC physiological sources to an array of probe NAs stably associated with the
 CC surface of a substrate to produce a hybridisation pattern for each of the
 CC sources, and comparing the patterns for each of the sources, where
 CC differential gene expression assays are utilised in differential
 CC expression analysis of diseased a normal tissue e.g. neoplastic a normal
 CC tissue, or different tissue or subtype types. The present sequence is a
 CC human gene specific PCR primer used in the method of the invention. Note:
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from USPTO
 CC at <http://wipo.segdata.uspto.gov/sequence.html?docID=6352829B1>
 XX
 SQ Sequence 28 BP; 7 A; 6 C; 8 G; 7 T; 0 U; 0 Other;
 Query Match 0.5%; Score 19.6; DB 1; Length 28;
 Best Local Similarity 84.6%; Pred. No. 7.2e+02;
 Matches 22; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
 QY 1765 GAGCCCTGTTTGACCGAGTCTACAC 1790
 DB 27 GAGGCATTATTGACCGAGTCTACAC 2
 RESULT 401
 AAQ33891
 ID AAQ33891 standard; DNA; 21 BP.
 XX
 AC AAQ33891;
 XX
 DT 25-MAR-2003 (revised)
 DT 02-FEB-1993 (first entry)
 XX
 DE Microsatellite sequence from clone TGLA307.
 XX
 KW PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
 KW genetic mapping; traits; amplification; ss.
 XX
 OS Bos taurus.
 XX
 PN WO9213102-A1.
 XX
 PD 06-AUG-1992.
 XX

PF 15-JAN-1992; 92WO-US000340.
 XX
 PR 15-JAN-1991; 91US-00642342.
 XX
 PA (GENM-) GENMARK.
 XX
 PI Georges M, Massey JM;
 XX
 DR WPI; 1992-284684/34.
 XX
 PT Polymorphic bovine DNA markers - used in genetic identification, gene
 PT mapping, and selective breeding.
 XX
 PS Table 7; Page 286; 517pp; English.
 XX
 CC The sequence is that of a bovine microsatellite sequence obtd. by
 CC screening a library of bovine MboI DNA fragments of between 250 and 500
 CC bp with an (AC)₁₅ and a (TC)₁₅ oligonucleotide probe. One out of 50
 CC clones cross-hybridised. Assuming independent distribution of
 CC microsatellites and MboI sites, the frequency of (T6)_n > 9 microsatellites
 CC in the bovine genome is estimated at >100,000. The sequence information
 CC for ca. 230 such bovine microsatellites is summarised in the
 CC specification and indexed herein (see below). The sequences upstream and
 CC downstream of the microsatellite sequence were used to generate the
 CC required PCR primers for in vitro amplification of the corresp.
 CC microsatellite (using the program OPTIPRIM). The microsatellites may be
 CC used to identify individuals, for parentage testing, and in the genetic
 CC mapping of economic trait loci, or genes involved in the determination of
 CC economically important traits esp. in cattle, to allow selective
 CC breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
 CC field.)
 XX
 SQ Sequence 21 BP; 0 A; 0 C; 10 G; 11 T; 0 U; 0 Other;
 Query Match 0.5%; Score 19.4; DB 1; Length 21;
 Best Local Similarity 95.2%; Pred. No. 5.5e+02;
 Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2318 TGTGTGTGTGTGTGTGTGTGTGTGTGTGT 2338
 DB 1 TGTGTGTGTGTGTGTGTGTGTGTGTGTGT 21
 RESULT 402
 AAQ34015
 ID AAQ34015 standard; DNA; 21 BP.
 XX
 AC AAQ34015;
 XX
 DT 25-MAR-2003 (revised)
 DT 02-FEB-1993 (first entry)
 XX
 DE Microsatellite sequence from clone TGLA419.
 XX
 KW PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
 KW genetic mapping; traits; amplification; ss.
 XX
 OS Bos taurus.
 XX
 PN WO9213102-A1.
 XX
 PD 06-AUG-1992.
 XX
 PF 15-JAN-1992; 92WO-US000340.
 XX
 PR 15-JAN-1991; 91US-00642342.
 XX
 PA (GENM-) GENMARK.
 XX
 PI Georges M, Massey JM;
 XX
 DR WPI; 1992-284684/34.
 XX

PR 14-DEC-2000; 2000US-0255534P.
 XX (COLE-) COLEY PHARM GROUP INC.
 XX PA
 XX PI Bratzler RL;
 XX DR WPI; 2002-566690/60.
 XX
 XX Inhibiting angiogenesis in a subject, involves administering at least one
 PT antiangiogenic nucleic acid molecule to the subject.
 XX
 XX Claim 2; Page 35; 276pp; English.
 XX
 XX The invention relates to inhibiting angiogenesis in a subject, comprising
 CC administering at least one antiangiogenic nucleic acid molecule. Also
 CC included is a kit comprising a first container housing the antiangiogenic
 CC nucleic acids, and instructions for administering them to a subject
 CC having a condition characterised by unwanted angiogenesis. The method is
 CC useful for inhibiting angiogenesis associated with solid tumour growth,
 CC tumour metastasis, precancerous lesion, rheumatoid arthritis, psoriasis,
 CC diabetic retinopathy, retinopathy of prematurity, macular degeneration,
 CC corneal graft rejection, neovascular glaucoma, retrolental fibroplasia,
 CC rubeosis, Osler-Webber Syndrome, myocardial angiogenesis, plaque
 CC neovascularisation, telangiectasia, haemophilic joints, angiodiroma, and
 CC wound granulation, intestinal adhesions, atherosclerosis, scleroderma, and
 CC hypertrophic scars. The present sequence is an antiangiogenic nucleic
 CC acid of the invention
 XX
 XX Sequence 21 BP; 0 A; 0 C; 10 G; 11 T; 0 U; 0 Other;
 SQ
 Query Match 0.5%; Score 19.4; DB 1; Length 21;
 Best Local Similarity 95.2%; Pred. No. 5.5e+02;
 Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2318 TGTGTGTGTGTGTGTGTGTGT 2338
 DB 1 TGTGTGTGTGTGTGTGTGTGT 21
 RESULT 410
 ABS97830/C
 ID ABS97830 standard; DNA; 21 BP.
 XX
 XX ABS97830;
 XX
 XX 23-DEC-2002 (first entry)
 DT
 XX Human NADPH quinone oxidoreductase 2 (NQO2) polymorphic sequence #38.
 XX Human; ds; cytochrome P450 A1; CYP450A1; UGT2B4; MDR1;
 KW cytochrome P450 A2; CYP450A2; cytochrome P450 02E; CYP45002E1; LTF;
 KW adrenergic receptor beta1; ADRB1; aryl hydrocarbon; AHR; MRP3; NR1I2;
 KW aryl hydrocarbon receptor nuclear translocator; ARNT; cathepsin S; CTSS;
 KW cyclooxygenase 2; COX2; diazepam binding inhibitor; DBI; haematological;
 KW epoxide hydrolase 2; EPHX2; 5-lipoxygenase activating protein; FLAP;
 KW glutathione-S-transferase 12; GST12; histamine-N-methyl transferase;
 KW HNMT; kallikrein 2; KLK2; nicotinamide-N-methyl transferase; NNMT;
 KW NADPH quinone oxidoreductase 2; NQO2; sulfoxyltransferase thermolabile; STM;
 KW UDP-glucuronosyl transferase 2B4; UDP-glucuronosyl transferase 2B7;
 KW UGT2B7; UDP-glucuronosyl transferase; UGT2B15; uronidase receptor; uPA;
 KW multidrug resistance 1; lactotransferrin; orphan nuclear receptor;
 KW multidrug resistance associated protein 3; cancer; prostate;
 KW acetylcholine muscarinic receptor; CHMR1; CHMR2; CHMR3; CHMR4; CHMR5;
 KW altered drug metabolism; cardiovascular function; colorectal tumour;
 KW central nervous system; pulmonary; immunological; SNP;
 KW single nucleotide polymorphism.
 XX Homo sapiens.
 XX OS
 XX PN WO200257410-A2.
 XX
 XX 25-JUL-2002.
 PD
 XX

PF 28-NOV-2001; 2001WO-US044838.
 XX
 PR 28-NOV-2000; 2000US-00724389.
 XX
 XX (DNAS-) DNA SCI LAB INC.
 XX PI Guida M, Hall J;
 XX WPI; 2002-698522/75.
 XX
 XX Isolated nucleic acid molecules having polymorphisms in known human genes
 PT e.g. cytochrome P450 and cathepsin S useful as genetic linkage markers
 PT for locating, identifying and characterizing the genes responsible for
 PT disorder-related traits.
 XX
 XX Example 16; Page 130; 714pp; English.
 PS
 CC This invention relates to the sequence of an isolated nucleic acid
 CC molecule comprising at least one base variation from that of a known
 CC human cytochrome P450 A1 (CYP450A1), cytochrome P450 A2 (CYP450A2),
 CC cytochrome P450 02E1 (CYP45002E1), adrenergic receptor beta1 (ADBR1),
 CC aryl hydrocarbon (AHR), aryl hydrocarbon receptor nuclear translocator
 CC (ARNT), cathepsin S (CTSS), cyclooxygenase 2 (COX2), diazepam binding
 CC inhibitor (DBI), epoxide hydrolase 2 (EPHX2), 5-lipoxygenase activating
 CC protein (FLAP), glutathione-S-transferase 12 (GST12), histamine-N-methyl
 CC transferase (HNMT), NADPH quinone oxidoreductase 2 (NQO2),
 CC sulfoxyltransferase thermolabile (STM), UDP-glucuronosyl transferase 2B4
 CC (UGT2B4), UDP-glucuronosyl transferase 2B7 (UGT2B7), UDP-glucuronosyl
 CC transferase (UGT2B15), uronidase receptor (uPA), multidrug resistance 1
 CC (MRP1), lactotransferrin (LTF), multidrug resistance associated protein 3
 CC (MDR3), orphan nuclear receptor (NR1I2), or acetylcholine muscarinic
 CC receptor 1, 2, 3, 4, or 5 (CHMR1, CHMR2, CHMR3, CHMR4 or CHMR5) sequence.
 CC The polymorphisms in the human genes cited in the invention are useful as
 CC genetic linkage markers for locating and characterizing the genes that
 CC are responsible for specific traits within the genome and eventually
 CC identifying the genes responsible for a variety of disorder-related
 CC traits as a result of their e.g., overexpression, which may be used in diagnosing
 CC expression, mutation or underexpression. The nucleic acid molecules comprising the
 CC and/or treating the disorders. The nucleic acid molecules comprising the
 CC polymorphic sequences contained in CYP450A1, CYP450A2, CYP450E1,
 CC ARNT, EPHX2, GST12, NNMT, NQO2, NR1I2, STM, UGT2B4, UGT2B7, UGT2B15, AHR,
 CC MDR1 and/or MDR3 are useful for screening individuals for altered drug
 CC metabolism. The polymorphic sequences contained in CYP450A1, CYP450A2,
 CC AHR, MDR1 and/or MDR3 may also be used to screen individuals for
 CC susceptibility to cancer. Polymorphic sequences in ADRB1 or CHMR2 are
 CC used to screen for altered cardiovascular function, in COX2 for altered
 CC susceptibility to colorectal tumours, in DBI or CHMR1 for altered central
 CC nervous system function, in FLAP and HNMT for altered pulmonary,
 CC immunological or haematological function, in KLK2 for altered serine
 CC protease activity in the prostate, in LTF for altered immunological or
 CC haematological function, in CHMR3, CHMR4 or CHMR5 for altered central and
 CC peripheral nervous system function. The present sequence represents a
 CC polymorphic DNA sequence of the invention
 XX
 XX Sequence 21 BP; 10 A; 9 C; 1 G; 1 T; 0 U; 0 Other;
 SQ
 Query Match 0.5%; Score 19.4; DB 1; Length 21;
 Best Local Similarity 95.2%; Pred. No. 5.5e+02;
 Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2324 TGTGTGTGTGTGTGTGTGTGT 2344
 DB 21 TATGTGTGTGTGTGTGTGTGT 1
 RESULT 411
 ABS97832/C
 ID ABS97832 standard; DNA; 21 BP.
 XX
 XX ABS97832;
 XX
 XX 23-DEC-2002 (first entry)
 DT

XX DE Human NADPH quinone oxidoreductase 2 (NQO2) polymorphic sequence #40.
 XX KW Human; ds; cytochrome P450 A1; CYP4501A1; UGT2B4; MDR1;
 KW KW cytochrome P450 A2; CYP4501A2; cytochrome P450 O2E; CYP45002E1; LTF;
 KW KW adrenergic receptor beta1; ADRB1; aryl hydrocarbon; AHR; MRP3; NR1I2;
 KW KW aryl hydrocarbon receptor nuclear translocator; ARNT; cathepsin S; CTSS;
 KW KW cyclooxygenase 2; COX2; diazepam binding inhibitor; DBI; haematological;
 KW KW epoxide hydrolase 2; EPHX2; 5-lipoxygenase activating protein; FLAP;
 KW KW glutathione-S-transferase 12; GSTP2; histamine-N-methyl transferase;
 KW KW HMMT; kallikrein 2; KLK2; nicotinamide-N-methyl transferase; NNMT;
 KW KW NADPH quinone oxidoreductase 2; NQO2; sulfoltransferase thermolabile; STM;
 KW KW UDP-glucuronosyl transferase 2B4; UDP-glucuronosyl transferase 2B7;
 KW KW UGT2B7; UDP-glucuronosyl transferase; UGT2B15; urokinase receptor; uPA;
 KW KW multidrug resistance 1; lactotransferrin; orphan nuclear receptor;
 KW KW multidrug resistance associated protein 3; cancer; prostate;
 KW KW acetylcholine muscarinic receptor; CHMR1; CHMR2; CHMR3; CHMR4; CHMR5;
 KW KW altered drug metabolism; cardiovascular function; colorectal tumour;
 KW KW central nervous system; pulmonary; immunological; SNP;
 KW KW single nucleotide polymorphism.
 XX OS Homo sapiens.
 XX PN WO200257410-A2.
 XX PD 25-JUL-2002.
 XX PF 28-NOV-2001; 2001WO-US044838.
 XX PR 28-NOV-2000; 2000US-00724389.
 XX PA (DNAS-) DNA SCI LAB INC.
 XX PI Guida M, Hall J;
 XX WPI; 2002-698522/75.
 XX Isolated nucleic acid molecules having polymorphisms in known human genes
 PT e.g. cytochrome p450 and cathepsin S useful as genetic linkage markers
 PT for locating, identifying and characterizing the genes responsible for
 PT disorder-related traits.
 XX Example 16; Page 131; 714pp; English.
 PS This invention relates to the sequence of an isolated nucleic acid
 CC molecule comprising at least one base variation from that of a known
 CC human cytochrome P450 A1 (CYP4501A1), cytochrome P450 A2 (CYP4501A2),
 CC cytochrome P450 O2E1 (CYP45002E1), adrenergic receptor beta1 (ADRB1),
 CC aryl hydrocarbon (AHR), aryl hydrocarbon receptor nuclear translocator
 CC (ARNT), cathepsin S (CTSS), cyclooxygenase 2 (COX2), diazepam binding
 CC inhibitor (DBI), epoxide hydrolase 2 (EPHX2), 5-lipoxygenase activating
 CC protein (FLAP), glutathione-S-transferase 12 (GST12), histamine-N-methyl
 CC transferase (HMMT), kallikrein 2 (KLK2), nicotinamide -N-methyl
 CC transferase (NNMT), NADPH quinone oxidoreductase 2 (NQO2),
 CC sulfoltransferase thermolabile (STM), UDP-glucuronosyl transferase 2B4
 CC (UGT2B4), UDP-glucuronosyl transferase 2B7 (UGT2B7), UDP-glucuronosyl
 CC transferase (UGT2B15), urokinase receptor (uPA), multidrug resistance 1
 CC (MDR1), lactotransferrin (LTF), multidrug resistance associated protein 3
 CC (MRP3), orphan nuclear receptor (NR1I2), or acetylcholine muscarinic
 CC receptor 1, 2, 3, 4, or 5 (CHMR1, CHMR2, CHMR3, CHMR4 or CHMR5) sequence.
 CC The polymorphisms in the human genes cited in the invention are useful as
 CC genetic linkage markers for locating and characterizing the genes that
 CC are responsible for specific traits within the genome and eventually
 CC identifying the genes responsible for a variety of disorder-related
 CC traits as a result of their e.g., overexpression, constitutive
 CC expression, mutation or underexpression, which may be used in diagnosing
 CC and/or treating the disorders. The nucleic acid molecules comprising the
 CC polymorphic sequences contained in CYP4501A1, CYP4501A2, CYP4502E1,
 CC ARNT, EPHX2, GST12, NNMT, NQO2, NR1I2, STM, UGT2B4, UGT2B7, UGT2B15, AHR,
 CC MDR1 and/or MDR3 are useful for screening individuals for altered drug
 CC metabolism. The polymorphic sequences contained in CYP4501A1, CYP4501A2,
 CC AHR, MDR1 and/or MDR3 may also be used to screen individuals for
 CC susceptibility to cancer. Polymorphic sequences in ADRB1 or CHMR2 are

CC used to screen for altered cardiovascular function, in COX2 for altered
 CC susceptibility to colorectal tumours, in DBI or CHMR1 for altered central
 CC nervous system function, in FLAP and HMMT for altered pulmonary,
 CC immunological or haematological function, in KLK2 for altered serine
 CC protease activity in the prostate, in LTF for altered immunological or
 CC haematological function, in CHMR3, CHMR4 or CHMR5 for altered central and
 CC peripheral nervous system function. The present sequence represents a
 CC polymorphic DNA sequence of the invention
 XX Sequence 21 BP; 10 A; 9 C; 1 G; 1 T; 0 U; 0 Other;
 SQ
 Query Match 0.5%; Score 19.4; DB 1; Length 21;
 Best Local Similarity 95.2%; Pred. No. 5.5e+02;
 Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2324 TGTGTGTGTGCGTGTGTGTGT 2344
 DB 21 TGTGTGTGTGCGTGTGTGTGT 1
 RESULT 412
 ACH03241
 ID ACH03241 standard; DNA; 21 BP.
 XX ACH03241;
 AC ACH03241;
 XX 25-SEP-2003 (first entry)
 DT
 DE Immunostimulatory nucleic acid #876.
 XX Immunostimulatory; antiinflammatory; dermatological; antipsoriatic;
 KW antitumor; gene therapy; vaccine; non-allergic inflammatory disease;
 KW psoriasis; eczema; allergic contact dermatitis; latex dermatitis;
 KW inflammatory bowel disease; ulcerative colitis; Crohn's disease; ss.
 XX Synthetic.
 OS
 XX US2003050268-A1.
 PN 13-MAR-2003.
 PD 29-MAR-2002; 2002US-00112653.
 PF 29-MAR-2001; 2001US-0279642P.
 PR (KRIE/) KRIEG A. M.
 PA (BERG/) BERG D. J.
 XX Krieg AM, Berg DJ;
 DR WPI; 2003-521815/49.
 XX Treating non-allergic inflammatory diseases, such as psoriasis, eczema,
 PT allergic contact dermatitis, latex dermatitis or inflammatory bowel
 PT disease by administering an immunostimulatory nucleic acid.
 XX Disclosure; Page 32; 229pp; English.
 PS The invention describes a method of treating non-allergic inflammatory
 CC disease comprising administering to a subject having or at risk of
 CC developing a non-allergic inflammatory disease an immunostimulatory
 CC nucleic acid for prevention or treatment of the disease. The method is
 CC useful for treating non-allergic inflammatory diseases, such as
 CC psoriasis, eczema, allergic contact dermatitis, latex dermatitis or
 CC inflammatory bowel disease e.g., ulcerative colitis or Crohn's disease.
 CC This sequence represents an immunostimulatory nucleic acid
 XX Sequence 21 BP; 0 A; 0 C; 10 G; 11 T; 0 U; 0 Other;
 SQ
 Query Match 0.5%; Score 19.4; DB 1; Length 21;
 Best Local Similarity 95.2%; Pred. No. 5.5e+02;
 Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

PR 16-DEC-1998; 98EP-00204291.
XX (UYLI-) UNIV LIEGE.
PA (MELI-) MELICA HB.
PA (SEGH-) SEGHERSGENTEC NV.
XX
PI Andersson L, Georges M, Spincemaille G;
XX WPI; 2000-431612/37.
XX
XX Selecting a domestic animal for having desired genotypic properties
PT comprises testing the animal for the presence of a parentally imprinted
PT quantitative trait locus which is related to muscle mass and/or fat
PT deposition.
XX
XX Example 4; Fig 10; 107pp; English.
PS
XX The present invention describes a method (M1) for selecting a domestic
XX animal for having desired genotypic properties. The method comprises
CC testing the animal for the presence of a parentally imprinted
CC quantitative trait locus (QTL). The pig QTL is located at chromosome 2,
CC mapping at around position 2p1.7. Also described are: (1) an isolated
CC and/or recombinant nucleic acid (M1) comprising a parentally imprinted
CC QTL or its functional fragment; (2) an isolated and/or recombinant
CC nucleic acid (M2) comprising a synthetic parentally imprinted QTL derived
CC from at least one chromosome or its functional fragment; (3) an animal
CC such as pig selected for having desired genotypic or potential phenotypic
CC properties; (4) a transgenic animal comprising M1 or M2; and (5) sperm or
CC an embryo derived from the animal of (3) or (4). M1 or its fragment is
CC useful for selecting an animal destined for slaughter or a breeding
CC animal having desired genotypic or potential phenotypic properties. The
CC properties are related to muscle mass and/or fat deposition. The sperm or
CC an embryo are useful in breeding animals destined for slaughter. The
CC present sequence represents a microsatellite oligonucleotide, which is
CC given in an example from the present invention for the identification of
CC DNA sequence polymorphisms in the IGF2 (insulin-like growth factor 2) and
CC flanking loci
XX
XX Sequence 22 BP; 11 A; 0 C; 0 G; 11 T; 0 U; 0 Other;
SQ
Query Match 0.5%; Score 19.4; DB 1; Length 22;
Best Local Similarity 95.2%; Pred. No. 5.8e+02;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 2824 ATATATACATATATATATATA 2844
DB 22 ATATATATATATATATATA 2
XX
RESULT 418
AAF99705
ID AAF99705 standard; DNA; 22 BP.
XX
AC AAF99705;
XX
DT 12-JUN-2001 (first entry)
XX
DE Immunostimulatory nucleic acid #821.
XX
XX Vaccine; cytostatic; virucidal; bactericidal; fungicidal; anti-parasitic;
KW immunostimulatory; tumour; viral infection; bacterial infection;
KW fungal infection; parasitic infection; cancer; asthma;
KW infectious disease; allergy; immune deficiency; phosphorothioate; ss.
XX
OS Synthetic.
XX
XX WO200122972-A2.
XX
PD 05-APR-2001.
XX
PF 25-SEP-2000; 2000WO-US026383.
XX
PR 25-SEP-1999; 99US-0156113P.
PR 27-SEP-1999; 99US-0156135P.
PR 23-AUG-2000; 2000US-0227436P.
XX
XX (IOWA) UNIV IOWA RES FOUND.
PA (COLE-) COLEY PHARM GMBH.
XX
XX Krieg AM, Schetter C, Vollmer J;

PR 27-SEP-1999; 99US-0156135P.
PR 23-AUG-2000; 2000US-0227436P.
XX
PA (IOWA) UNIV IOWA RES FOUND.
PA (COLE-) COLEY PHARM GMBH.
XX
PI Krieg AM, Schetter C, Vollmer J;
XX WPI; 2001-273485/28.
XX
XX Vaccinating against tumors, infectious diseases, allergies and asthma
PT using immunostimulatory Py-rich and TG nucleic acids.
XX
PS Claim 101; Page 56; 338pp; English.
XX
XX The present invention relates to a method for stimulating an immune
XX response. The method comprises administering an immunostimulatory nucleic
XX acid to a non-rodent subject in sufficient quantity to stimulate an
XX immune response. The present sequence is one such immunostimulatory
XX nucleic acid. The immunostimulatory nucleic acids can be pyrimidine rich
XX (py-rich) or thymidine (T) rich. The method is used to vaccinate subjects
XX against tumour antigens, viral antigens (e.g. herpesviridae, retroviridae
XX and/or orthomyxoviridae), bacterial antigens (e.g. toxoplasma,
XX haemophilus, campylobacter, clostridium, Escherichia coli and/or
XX staphylococcus), fungal antigens and/or parasitic antigens. The method is
XX also useful for preventing cancer, asthma, infectious diseases, allergy or
XX immune deficiency. The present sequence can also be used to redirect a
XX Th2 to a Th1 immune response and to activate immune cells. Note: the
XX present sequence may have a phosphorothioate backbone
XX
XX Sequence 22 BP; 11 A; 0 C; 0 G; 11 T; 0 U; 0 Other;
SQ
Query Match 0.5%; Score 19.4; DB 1; Length 22;
Best Local Similarity 95.2%; Pred. No. 5.8e+02;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 2824 ATATATACATATATATATATA 2844
DB 1 ATATATATATATATATATA 21
XX
RESULT 419
AAF99705/c
ID AAF99705 standard; DNA; 22 BP.
XX
AC AAF99705;
XX
DT 12-JUN-2001 (first entry)
XX
DE Immunostimulatory nucleic acid #821.
XX
XX Vaccine; cytostatic; virucidal; bactericidal; fungicidal; anti-parasitic;
KW immunostimulatory; tumour; viral infection; bacterial infection;
KW fungal infection; parasitic infection; cancer; asthma;
KW infectious disease; allergy; immune deficiency; phosphorothioate; ss.
XX
OS Synthetic.
XX
XX WO200122972-A2.
XX
PD 05-APR-2001.
XX
PF 25-SEP-2000; 2000WO-US026383.
XX
PR 25-SEP-1999; 99US-0156113P.
PR 27-SEP-1999; 99US-0156135P.
PR 23-AUG-2000; 2000US-0227436P.
XX
XX (IOWA) UNIV IOWA RES FOUND.
PA (COLE-) COLEY PHARM GMBH.
XX
XX Krieg AM, Schetter C, Vollmer J;

DR WPI; 2001-273485/28.
 XX Vaccinating against tumors, infectious diseases, allergies and asthma
 PT using immunostimulatory Py-rich and TG nucleic acids.
 XX
 XX Claim 101; Page 56; 338pp; English.
 XX
 CC The present invention relates to a method for stimulating an immune
 CC response. The method comprises administering an immunostimulatory nucleic
 CC acid to a non-rodent subject in sufficient quantity to stimulate an
 CC immune response. The present sequence is one such immunostimulatory
 CC nucleic acid. The immunostimulatory nucleic acids can be pyrimidine rich
 CC (py-rich) or thymidine (T) rich. The method is used to vaccinate subjects
 CC against tumour antigens, viral antigens (e.g. herpesviridae, retroviridae
 CC and/or orthomyxoviridae), bacterial antigens (e.g. toxoplasma,
 CC haemophilus, campylobacter, clostridium, Escherichia coli and/or
 CC staphylococcus), fungal antigens and/or parasitic antigens. The method is
 CC also useful for preventing cancer, asthma, infectious disease, allergy or
 CC immune deficiency. The present sequence can also be used to redirect a
 CC Th2 to a Th1 immune response and to activate immune cells. Note: the
 CC present sequence may have a phosphorothioate backbone
 XX
 SQ Sequence 22 BP; 11 A; 0 C; 0 G; 11 T; 0 U; 0 Other;
 Query Match 0.5%; Score 19.4; DB 1; Length 22;
 Best Local Similarity 95.2%; Pred. No. 5.8e+02;
 Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 OY 2824 ATATATACATATATATATATA 2844
 DB 22 ATATATATATATATATATATA 2
 RESULT 420
 ABS78426
 ID ABS78426 standard; DNA; 22 BP.
 XX
 AC ABS78426;
 XX
 DT 13-DEC-2002 (first entry)
 XX
 DE Angiogenesis inhibitory oligonucleotide #910.
 XX
 KW Angiogenesis inhibitor; ss; angiogenesis; solid tumour growth;
 KW tumour metastasis; precancerous lesion; rheumatoid arthritis; psoriasis;
 KW diabetic retinopathy; retinopathy of prematurity; macular degeneration;
 KW corneal graft rejection; neovascular glaucoma; retrolental fibroplasia;
 KW rubeosis; Osler-Webber Syndrome; myocardial angiogenesis;
 KW plaque neovascularisation; telangiectasia; haemophilic joint;
 KW angiofibroma; wound granulation; intestinal adhesion; atherosclerosis;
 KW scleroderma; hypertrophic scar.
 XX
 OS Synthetic.
 XX
 PN WO200253141-A2.
 XX
 PD 11-JUL-2002.
 XX
 PF 14-DEC-2001; 2001WO-US048458.
 XX
 PR 14-DEC-2000; 2000US-0255534P.
 XX
 PA (COLE-) COLEY PHARM GROUP INC.
 XX
 PI Bratzler RL;
 XX
 DR WPI; 2002-566690/60.
 XX
 PT Inhibiting angiogenesis in a subject, involves administering at least one
 PT antiangiogenic nucleic acid molecule to the subject.
 XX
 XX Claim 2; Page 35; 276pp; English.

CC The invention relates to inhibiting angiogenesis in a subject, comprising
 CC administering at least one antiangiogenic nucleic acid molecule. Also
 CC included is a kit comprising a first container housing the antiangiogenic
 CC nucleic acids, and instructions for administering them to a subject
 CC having a condition characterised by unwanted angiogenesis. The method is
 CC useful for inhibiting angiogenesis associated with solid tumour growth,
 CC tumour metastasis, precancerous lesion, rheumatoid arthritis, psoriasis,
 CC diabetic retinopathy, retinopathy of prematurity, macular degeneration,
 CC corneal graft rejection, neovascular glaucoma, retrolental fibroplasia,
 CC rubeosis, Osler-Webber Syndrome, myocardial angiogenesis, plaque
 CC neovascularisation, telangiectasia, haemophilic joints, angiofibroma,
 CC wound granulation, intestinal adhesions, atherosclerosis, scleroderma and
 CC hypertrophic scars. The present sequence is an antiangiogenic nucleic
 CC acid of the invention
 XX
 SQ Sequence 22 BP; 11 A; 0 C; 0 G; 11 T; 0 U; 0 Other;
 Query Match 0.5%; Score 19.4; DB 1; Length 22;
 Best Local Similarity 95.2%; Pred. No. 5.8e+02;
 Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 OY 2824 ATATATACATATATATATATA 2844
 DB 1 ATATATATATATATATATATA 21
 RESULT 421
 ABS78426/C
 ID ABS78426 standard; DNA; 22 BP.
 XX
 AC ABS78426;
 XX
 DT 13-DEC-2002 (first entry)
 XX
 DE Angiogenesis inhibitory oligonucleotide #910.
 XX
 KW Angiogenesis inhibitor; ss; angiogenesis; solid tumour growth;
 KW tumour metastasis; precancerous lesion; rheumatoid arthritis; psoriasis;
 KW diabetic retinopathy; retinopathy of prematurity; macular degeneration;
 KW corneal graft rejection; neovascular glaucoma; retrolental fibroplasia;
 KW rubeosis; Osler-Webber Syndrome; myocardial angiogenesis;
 KW plaque neovascularisation; telangiectasia; haemophilic joint;
 KW angiofibroma; wound granulation; intestinal adhesion; atherosclerosis;
 KW scleroderma; hypertrophic scar.
 XX
 OS Synthetic.
 XX
 PN WO200253141-A2.
 XX
 PD 11-JUL-2002.
 XX
 PF 14-DEC-2001; 2001WO-US048458.
 XX
 PR 14-DEC-2000; 2000US-0255534P.
 XX
 PA (COLE-) COLEY PHARM GROUP INC.
 XX
 PI Bratzler RL;
 XX
 DR WPI; 2002-566690/60.
 XX
 PT Inhibiting angiogenesis in a subject, involves administering at least one
 PT antiangiogenic nucleic acid molecule to the subject.
 XX
 XX Claim 2; Page 35; 276pp; English.
 XX
 CC The invention relates to inhibiting angiogenesis in a subject, comprising
 CC administering at least one antiangiogenic nucleic acid molecule. Also
 CC included is a kit comprising a first container housing the antiangiogenic
 CC nucleic acids, and instructions for administering them to a subject
 CC having a condition characterised by unwanted angiogenesis. The method is
 CC useful for inhibiting angiogenesis associated with solid tumour growth,
 CC tumour metastasis, precancerous lesion, rheumatoid arthritis, psoriasis,

CC diabetic retinopathy, retinopathy of prematurity, macular degeneration,
CC corneal graft rejection, neovascular glaucoma, retrolental fibroplasia,
CC rubecosis, Osler-Webber Syndrome, myocardial angioneitis, plaque
CC neovascularisation, telangiectasia, haemophilic joints, angiofibroma,
CC wound granulation, intestinal adhesions, atherosclerosis, scleroderma and
CC hypertrophic scars. The present sequence is an antiangiogenic nucleic
CC acid of the invention
XX
SQ Sequence 22 BP; 11 A; 0 C; 0 G; 11 T; 0 U; 0 Other;

Query Match 0.5%; Score 19.4; DB 1; Length 22;
Best Local Similarity 95.2%; Pred. No. 5.8e+02;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2824 ATATATACATATATATATATA 2844
DB 22 ATATATATATATATATATA 2
||||| |||||||

RESULT 422
ACH03244
ID ACH03244 standard; DNA; 22 BP.
XX ACH03244;
AC ACH03244;
XX
DT 25-SEP-2003 (first entry)
DE Immunostimulatory nucleic acid #879.
XX
KW Immunostimulatory; antiinflammatory; dermatological; antipsoriatic;
KW antitumor; gene therapy; vaccine; non-allergic inflammatory disease;
KW psoriasis; eczema; allergic contact dermatitis; latex dermatitis;
KW inflammatory bowel disease; ulcerative colitis; Crohn's disease; ss.
XX
OS Synthetic.
XX
PN US2003050268-A1.
XX
PD 13-MAR-2003.
XX
PF 25-SEP-2003 (first entry)
XX
PR Immunostimulatory nucleic acid #879.
DE
XX
KW Immunostimulatory; antiinflammatory; dermatological; antipsoriatic;
KW antitumor; gene therapy; vaccine; non-allergic inflammatory disease;
KW psoriasis; eczema; allergic contact dermatitis; latex dermatitis;
KW inflammatory bowel disease; ulcerative colitis; Crohn's disease; ss.
XX
OS Synthetic.
XX
PN US2003050268-A1.
XX
PD 13-MAR-2003.
XX
PF 29-MAR-2002; 2002US-00112653.
XX
PR 29-MAR-2001; 2001US-0279642P.
XX
PA (KRIE//) KRIEG A M.
PA (BERG//) BERG D J.
PI Krieg AM, Berg DJ;
XX
XX WPI; 2003-521815/49.
XX
XX Treating non-allergic inflammatory diseases, such as psoriasis, eczema,
PT allergic contact dermatitis, latex dermatitis or inflammatory bowel
PT disease by administering an immunostimulatory nucleic acid.
XX
PS Disclosure; Page 32; 229pp; English.
XX
CC The invention describes a method of treating non-allergic inflammatory
CC disease comprising administering to a subject having or at risk of
CC developing a non-allergic inflammatory disease an immunostimulatory
CC nucleic acid for prevention or treatment of the disease. The method is
CC useful for treating non-allergic inflammatory diseases, such as
CC psoriasis, eczema, allergic contact dermatitis, latex dermatitis or
CC inflammatory bowel disease e.g., ulcerative colitis or Crohn's disease.
CC This sequence represents an immunostimulatory nucleic acid
XX
SQ Sequence 22 BP; 11 A; 0 C; 0 G; 11 T; 0 U; 0 Other;

Query Match 0.5%; Score 19.4; DB 1; Length 22;
Best Local Similarity 95.2%; Pred. No. 5.8e+02;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2824 ATATATACATATATATATATA 2844
DB 22 ATATATATATATATATATA 2
||||| |||||||

RESULT 424
ADB37207
ID ADB37207 standard; DNA; 22 BP.
XX
AC ADB37207;
XX
DT 04-DEC-2003 (first entry)
XX
DE Immunostimulatory nucleic acid #821.
XX
KW ds; allergy; asthma; poly-G nucleic acid; aerosol formulation;

DB 1 ATATATATATATATATATA 21
||||| |||||||

RESULT 423
ACH03244/c
ID ACH03244 standard; DNA; 22 BP.
XX
AC ACH03244;
XX
DT 25-SEP-2003 (first entry)
DE Immunostimulatory nucleic acid #879.
XX
KW Immunostimulatory; antiinflammatory; dermatological; antipsoriatic;
KW antitumor; gene therapy; vaccine; non-allergic inflammatory disease;
KW psoriasis; eczema; allergic contact dermatitis; latex dermatitis;
KW inflammatory bowel disease; ulcerative colitis; Crohn's disease; ss.
XX
OS Synthetic.
XX
PN US2003050268-A1.
XX
PD 13-MAR-2003.
XX
PF 29-MAR-2002; 2002US-00112653.
XX
PR 29-MAR-2001; 2001US-0279642P.
XX
PA (KRIE//) KRIEG A M.
PA (BERG//) BERG D J.
PI Krieg AM, Berg DJ;
XX
XX WPI; 2003-521815/49.
XX
XX Treating non-allergic inflammatory diseases, such as psoriasis, eczema,
PT allergic contact dermatitis, latex dermatitis or inflammatory bowel
PT disease by administering an immunostimulatory nucleic acid.
XX
PS Disclosure; Page 32; 229pp; English.
XX
CC The invention describes a method of treating non-allergic inflammatory
CC disease comprising administering to a subject having or at risk of
CC developing a non-allergic inflammatory disease an immunostimulatory
CC nucleic acid for prevention or treatment of the disease. The method is
CC useful for treating non-allergic inflammatory diseases, such as
CC psoriasis, eczema, allergic contact dermatitis, latex dermatitis or
CC inflammatory bowel disease e.g., ulcerative colitis or Crohn's disease.
CC This sequence represents an immunostimulatory nucleic acid
XX
SQ Sequence 22 BP; 11 A; 0 C; 0 G; 11 T; 0 U; 0 Other;

Query Match 0.5%; Score 19.4; DB 1; Length 22;
Best Local Similarity 95.2%; Pred. No. 5.8e+02;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2824 ATATATACATATATATATATA 2844
DB 22 ATATATATATATATATATA 2
||||| |||||||

RESULT 424
ADB37207
ID ADB37207 standard; DNA; 22 BP.
XX
AC ADB37207;
XX
DT 04-DEC-2003 (first entry)
XX
DE Immunostimulatory nucleic acid #821.
XX
KW ds; allergy; asthma; poly-G nucleic acid; aerosol formulation;

KW hypo-responsive subject; immunostimulatory.
 OS Synthetic.
 XX
 XX US2003087848-A1.
 XX
 PD 08-MAY-2003.
 XX
 XX 02-FEB-2001; 2001US-00776479.
 PF
 XX 03-FEB-2000; 2000US-0179991P.
 PR
 XX (BRAT/) BRATZLER R L.
 PA (PETE/) PETERSEN D M.
 PA (FOUR/) FOURN Y.
 XX
 XX Bratzler RL, Petersen DM, Fourn Y;
 PI WPI; 2003-657977/62.
 XX
 DR Treating and/or preventing allergy or asthma using an immunostimulatory
 PT nucleic acid alone or in combination with an asthma/allergy medicament.
 XX
 XX Disclosure; Page 17; 221pp; English.
 PS
 XX The invention relates to a method of treating or preventing allergy or
 CC asthma which comprises administering to a subject a poly-G nucleic acid
 CC in an aerosol formulation. The methods and compositions of the present
 CC invention are useful for diagnosing and/or treating asthma and allergy
 CC especially in a hypo-responsive subject. The present sequence represents
 CC an immunostimulatory nucleic acid of the invention.
 XX
 XX Sequence 22 BP; 11 A; 0 C; 0 G; 11 T; 0 U; 0 Other;
 SQ
 Query Match 0.5%; Score 19.4; DB 1; Length 22;
 Best Local Similarity 95.2%; Pred. No. 5.8e+02;
 Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 XX
 QY 2824 ATATATACATATATATATATA 2844
 DB ||||| ||||| ||||| ||||| |||||
 1 ATATATATATATATATATATA 21
 XX
 RESULT 425
 ADB37207/C
 ID ADB37207 standard; DNA; 22 BP.
 XX
 AC ADB37207;
 XX
 DT 04-DEC-2003 (first entry)
 XX
 DE Immunostimulatory nucleic acid #821.
 XX
 DE ds; allergy; asthma; poly-G nucleic acid; aerosol formulation;
 KW hypo-responsive subject; immunostimulatory.
 XX
 OS Synthetic.
 XX
 XX US2003087848-A1.
 PN
 XX 08-MAY-2003.
 PD
 XX 02-FEB-2001; 2001US-00776479.
 PF
 XX 03-FEB-2000; 2000US-0179991P.
 PR
 XX (BRAT/) BRATZLER R L.
 PA (PETE/) PETERSEN D M.
 PA (FOUR/) FOURN Y.
 XX
 XX Bratzler RL, Petersen DM, Fourn Y;
 PI WPI; 2003-657977/62.
 XX
 DR Treating and/or preventing allergy or asthma using an immunostimulatory
 PT nucleic acid alone or in combination with an asthma/allergy medicament.
 XX
 XX Disclosure; Page 17; 221pp; English.
 PS
 XX The invention relates to a method of treating or preventing allergy or
 CC asthma which comprises administering to a subject a poly-G nucleic acid
 CC in an aerosol formulation. The methods and compositions of the present
 CC invention are useful for diagnosing and/or treating asthma and allergy
 CC especially in a hypo-responsive subject. The present sequence represents
 CC an immunostimulatory nucleic acid of the invention.
 XX
 XX Sequence 22 BP; 11 A; 0 C; 0 G; 11 T; 0 U; 0 Other;
 SQ
 Query Match 0.5%; Score 19.4; DB 1; Length 22;
 Best Local Similarity 95.2%; Pred. No. 5.8e+02;
 Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 XX
 QY 2824 ATATATACATATATATATATA 2844
 DB ||||| ||||| ||||| ||||| |||||
 1 ATATATATATATATATATATA 21
 XX
 RESULT 426
 AAH39074/C
 ID AAH39074 standard; DNA; 24 BP.
 XX
 AC AAH39074;
 XX
 DT 14-AUG-2001 (first entry)
 XX
 DE SNP specific lower PCR primer SEQ ID 1870.
 XX
 DE Single nucleotide polymorphism; SNP; single nucleotide primer extension;
 KW SNP; genotyping; agammaglobulinaemia; diabetes insipidus; cancer; leukaemia;
 KW Lesch-Nyhan syndrome; muscular dystrophy; familial hypercholesterolaemia;
 KW polycystic kidney disease; osteogenesis imperfecta; autoimmune disease;
 KW acute intermittent porphyria; rheumatoid arthritis; multiple sclerosis;
 KW inflammation; forensic investigation; paternity analysis; PCR primer; ss.
 XX
 OS Homo sapiens.
 XX
 XX WO200129262-A2.
 PN
 XX 26-APR-2001.
 PD
 XX 13-OCT-2000; 2000WO-US028436.
 PF
 XX 15-OCT-1999; 99US-0160096P.
 PR
 XX (ORCH-) ORCHID BIOSCIENCES INC.
 PA
 XX Picoult-Newburg L, Pohl M;
 PI WPI; 2001-290930/30.
 DR
 XX New genotyping oligonucleotide, useful for detecting the presence,
 PT absence or identity of single polynucleotide polymorphism in a nucleic
 PT acid sample.
 XX
 XX Claim 1; Page 59; 83pp; English.
 PS
 XX Sequences AAH37205 - AAH40944 represent PCR primers, single nucleotide
 CC primer extension (SNPE) primers, and the sequences of regions flanking
 CC sites of single nucleotide polymorphisms SNPs. The present invention
 CC includes kits for determining the presence or absence of a SNP, using the
 CC oligonucleotides of the invention. The PCR primers are used to amplify a
 CC SNP flanking sequence, the SNPE primer is used as a genotyping primer.
 CC The oligonucleotides are useful for genotyping a nucleic acid sample by
 CC performing a single-nucleotide primer extension reaction. The
 CC oligonucleotides are useful for determining the presence, absence or
 CC identity of a SNP and for genotyping nucleic acid samples, for e.g. to

assess by association analysis the genotype of an individual or group of individuals, having a pathological phenotypic trait suspected of being caused by one or more SNPs. Phenotypic traits include diseases e.g. agammaglobulinemia, diabetes insipidus, Lesch-Nyhan syndrome, muscular dystrophy, familial hypercholesterolaemia, polycystic kidney disease, osteogenesis imperfecta and acute intermittent porphyria. Phenotypic traits also include symptoms of or susceptibility to multifactorial disease of which a component is or may be genetic such as autoimmune diseases, including, rheumatoid arthritis, multiple sclerosis, inflammation, cancer, nervous system diseases and infection by pathogenic microorganism. The method is also useful in forensic investigations and paternity analysis. The present sequence represents a PCR primer specific for a human SNP containing DNA sequence

Sequence 24 BP; 12 A; 11 C; 0 G; 1 T; 0 U; 0 Other;

Query Match 0.5%; Score 19.4; DB 1; Length 24;
Best Local Similarity 95.2%; Pred. No. 6.4e+02;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2318 TGTGTGTGTGTGTGTGTGTGTGTGTGT 2338

DB 21 TGTGTGTGTGTGTGTGTGTGTGTGTGT 1

RESULT 427

AAQ44016
ID AAQ44016 standard; DNA; 26 BP.

XX AC AAQ44016;

XX 25-MAR-2003 (revised)

DT 28-OCT-1993 (first entry)

XX Target sequence #8.

Purine; pyrimidine; tracts; therapeutic; diagnostic; control;

gene expression; mRNA synthesis suppression; ds.

XX Synthetic.

PN WO9312230-A1.

XX 24-JUN-1993.

XX 11-DEC-1992; 92WO-US010792.

XX 13-DEC-1991; 91US-00808452.

PR 21-JAN-1992; 92US-00826934.

XX (STRI) SRI INT.

PI Jayasena SD, Johnston BH;

XX WPI; 1993-214172/26.

New oligo-nucleotide(s) forming triple helix with target nucleic acid - contain purine and pyrimidine tracts in specific orientations, useful therapeutically or diagnostically e.g. for inactivating HIV RNA, etc.

XX Example; Fig 14a; 101pp; English.

The sequence is that of the target sequence #8 which was used in an experiment to determine the in vitro cleavage of target duplexes to evaluate the lengths of purine and pyrimidine tracts which are useful in obtaining oligonucleotides capable of triple helix formation with target nucleic acids. The complementary strand overhangs the 3' end by the sequence CTAG and the sense strand overhangs the complementary strand by the sequence AATT. (Updated on 25-MAR-2003 to correct PN field.)

XX Sequence 26 BP; 2 A; 1 C; 11 G; 12 T; 0 U; 0 Other;

Query Match 0.5%; Score 19.4; DB 1; Length 26;

Best Local Similarity 95.2%; Pred. No. 7e+02;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2319 GTGTGTGTGTGTGTGTGTGTGTGTGT 2339

DB 6 GTGTGTGTGTGTGTGTGTGTGTGTGT 26

RESULT 428

AAT84434
ID AAT84434 standard; DNA; 26 BP.

XX AC AAT84434;

XX 13-NOV-1997 (first entry)

DE KIT gene primer KITDEL2-FOR for pig coat colour determination.

XX KIT gene; pig; coat colour; pigmentation; primer; PCR;

KW polymerase chain reaction; ss.

XX Synthetic.

PN WO9705278-A1.

XX 13-FEB-1997.

XX 24-JUL-1996; 96WO-GB001794.

XX 27-JUL-1995; 95GB-00015385.

PR 12-DEC-1995; 95GB-00025384.

XX (DALG-) DALGETY PLC.

XX Andersson L, Moller MJ, Wales R, Siggins KW, Plastow GS;

XX WPI; 1997-145712/13.

Determn. of coat colour genotype in pigs by analysis of the KIT gene - for duplication or deletions, or analysis of KIT protein, used to establish breeding programmes for pigs of selected colour.

XX Claim 39; Page 43; 49pp; English.

XX Primer pairs KITDEL1-FOR (AAT84432) and KITDEL1-REV (AAT84433), and KITDEL2-FOR (AAT84434) and KITDEL2-REV (AAT84435), can be used in a claimed method for identifying the presence or absence of a deletion of the KIT gene sequence in pig genomic DNA. Other claimed primers (see AAT84420-27) are used to detect a duplication of the KIT gene. The 3 alleles for coat colour (i, inhibition of coat colour; I(p), patch; and I, development of colour) can be differentiated on the basis of duplication/deletion in the KIT gene. This allows breeding of pigs with the desired, usually white, coat colour

XX Sequence 26 BP; 6 A; 3 C; 8 G; 7 T; 0 U; 2 Other;

Query Match 0.5%; Score 19.4; DB 1; Length 26;

Best Local Similarity 80.0%; Pred. No. 7e+02;

Matches 20; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 1796 AGAGTGACGTCTGCTCTTGGGT 1820

DB 2 AAAGTGAYGTCTGCTCTTGGGT 26

RESULT 429

AAV80712
ID AAV80712 standard; DNA; 26 BP.

XX AC AAV80712;

XX 26-MAR-1999 (first entry)

DE KIT gene PCR forward primer KITDEL2-FOR.

XX Porcine; wild boar; meishan; pietrain; large white; hamshire; duroc;

KW differentiation; breed origin; alpha-MSHR; coat colour; stock purity;

KW alpha melanocyte-stimulating hormone receptor; KIT; PCR primer; ss.

XX Synthetic.

OS

XX WO9854360-A1.

PN

XX 03-DEC-1998.

PD

XX 27-MAY-1998; 98NO-GB001531.

PF

XX 30-MAY-1997; 97GB-00011214.

PR

XX 31-JAN-1998; 98GB-00001990.

PR

XX (PIGI-) PIG IMPROVEMENT CO UK LTD.

PA

XX Andersson L, Kijas J, Giuffra E, Evans GJ, Wales R, Plastow GS;

PI WPI; 1999-070222/06.

XX

DR Differentiating products from different animal breeds - by the analysis

XX of alleles of breed-determinant genes, at the nucleic acid or protein

PT level.

PT

XX Example 14; Page 53; 101pp; English.

PS

XX A method has been developed for: (a) differentiating animals and animal

CC products according to breed origin; (b) determining or testing the breed

CC origin of a product; or (c) validating an animal product. The method

CC comprises analysing a sample of the product for the allele(s) of at least

CC one breed-determinant (BD) gene. The present invention also describes:

CC (1) methods for determining the coat colour genotype of a pig by

CC determining; (i) the allele(s) of the alpha melanocyte-stimulating

CC hormone receptor (alpha-MSHR) gene; (ii) the amino acid sequence of an

CC alpha-MSHR protein at positions associated with coat colour, or the size

CC of the protein; (iii) detecting which microsatellites (or other linked

CC marker alleles), linked to the alpha-MSHR gene, or particular alleles of

CC it, are present; and (iv) analysing nucleic acid to determine if the KIT

CC gene carries a polymorphism associated with the coat colour genotype. The main

CC method of the invention is applied to samples from fish, birds and

CC mammals, especially pigs. Particular applications are confirming stated

CC origin of meats; in quality control; for maintaining stock purity, and in

CC breeding programmes (to confirm particular crosses). The method requires

CC only very small samples and many samples can be screened quickly and

CC inexpensively. The process can be made quantitative. The present sequence

CC represents a KIT gene PCR primer from the present invention

XX

SQ Sequence 26 BP; 6 A; 3 C; 8 G; 7 T; 0 U; 2 Other;

Query Match 0.5%; Score 19.4; DB 1; Length 26;

Best Local Similarity 80.0%; Pred. No. 7e+02; Mismatches 0; Gaps 0;

Matches 20; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

OY 1796 AGAGTGACGCTGGCTCTTGGGT 1820

DB 2 AAAGTGATGCTGGCTCTATSGAT 26

RESULT 430

AAAX00036/c

ID AAAX00036 standard; DNA; 24 BP.

XX

AC AAAX00036;

XX

DT 16-MAR-1999 (first entry)

XX

DE FGFR-3 PCR antisense primer.

XX

XX Neuroepithelial stem cell; lineage restricted intermediate precursor;

KW oligodendrocyte; astrocyte; self-renewal; neuron; differentiation;

KW

KW neural crest cell; fibroblast growth factor; FGF; FGFR; receptor; CNS;

XX central nervous system; glial cell; PCR primer; amplification; ss.

XX Synthetic.

OS

XX Homo sapiens.

XX WO9850526-A1.

PN

XX 12-NOV-1998.

PD

XX 07-MAY-1998; 98WO-US009630.

PF

XX 07-MAY-1997; 97US-00852744.

PR

XX 06-MAY-1998; 98US-00073881.

PR

XX (UTAH) UNIV UTAH RES FOUND.

PA

XX Rao MS, Mayer-Proschel M, Mujtaba T;

PI WPI; 1999-070093/06.

XX

DR Mammalian neuroepithelial stem cells and glial restricted precursor - can

XX self renew and differentiate into central nervous system cells, used for

PT generating various types of cells.

PT

XX Example 26; Page 58; 78pp; English.

PS

XX The present invention describes an isolated, pure population of mammalian

CC neuroepithelial stem cells, which are capable of self-renewal in adherent

CC feeder-cell-independent (ASCI) culture medium and differentiation to

CC central nervous system (CNS) neuronal or glial cells and to neuronal

CC crest stem cells. Also described is an isolated population of mammalian

CC CNS glial-restricted precursor (GRP) cells which can self-renew in the

CC ASCI culture medium and can differentiate to CNS glial cells but not to

CC CNS neuronal cells. The stem cells can be used to generate a population

CC of mammalian motor neurons by incubating the stem cells in a medium

CC promoting cell proliferation and neuronal differentiation. The medium

CC comprises laminin-coated plates and NEP medium lacking chick embryo

CC extract. The stem cells can also produce neural crest stem cells by

CC inducing the cells to differentiate in vitro. The inducing step comprises

CC replating the cells on a laminin-coated substrate and preferably

CC withdrawing a mitogen (preferably fibroblast growth factor; FGF) and

CC chick embryo extract. Inducing can also comprise adding a dorsalizing

CC agent to the cells, preferably a bone morphogenetic protein (BMP) such as

CC BMP-2, -4 or -7. The stem cells can be used to produce cells of the

CC peripheral nervous system, by inducing the stem cells to differentiate in

CC vitro to neural crest stem cells, and inducing these cells to

CC differentiate. AAAX00029 to AAAX00054 represent PCR primers which are used

CC in an example from the present invention to amplify different FGF and

CC FGFR genes

XX

SQ Sequence 24 BP; 4 A; 9 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 19.2; DB 1; Length 24;

Best Local Similarity 87.5%; Pred. No. 6.7e+02;

Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 984 GAAGGCGCTGGGCTCCCCACCGT 1007

DB 24 GAAGGCGCTGGGCTGCCACCGT 1

RESULT 431

AAZ98505/c

ID AAZ98505 standard; DNA; 24 BP.

XX

AC AAZ98505;

XX

DT 19-JUN-2000 (first entry)

XX

DE H. discus derived sequence #23.

XX

XX Satellite sequence; DNA fragmentation; microsatellite DNA; DNA marker;

KW

Db 1 CTTGTGACAGGACCTGGCGACCT 24

RESULT 433
AC180278/c
ID AC180278 standard; DNA; 25 BP.
XX AC AC180278;
XX DT 14-OCT-2003 (first entry)
XX DE Human microarray DNA oligonucleotide SEQ ID NO 80269.
XX KW EST; ss; probe; expressed sequence tag; microarray; gene expression;
XX KW genetic variation; biallelic marker; polymorphism; human;
XX KW cross-species comparison.
XX OS Homo sapiens.
XX PN US2003104410-A1.
XX PD 05-JUN-2003.
XX PF 15-MAR-2002; 2002US-00098263.
XX PR 16-MAR-2001; 2001US-0276759P.
XX PA (AFFY-) AFFYMETRIX INC.
XX PI Mitmann MP;
XX DR WPI; 2003-567953/53.
XX PT New array of nucleic acid probes, useful for in situ hybridization, in
XX PT Southern, Northern or dot-blot hybridization to identify or detect the
XX PT sequence or specific mutations of any gene.
XX PS Claim 1; SEQ ID NO 80269; 9pp; English.
XX CC The invention discloses a microarray comprising a plurality of nucleic
XX CC acid probes including one of 2,018,500 fully defined sequences, or its
XX CC perfect match, perfect mismatch, antisense match or antisense mismatch.
XX CC Also disclosed is a method of gene expression analysis. The array is used
XX CC in monitoring gene expression levels by hybridisation of a DNA library,
XX CC in analysis of genetic variation or in hybridisation of tag-labelled
XX CC compounds. The nucleic acid probes are specifically designed for analysis
XX CC of at least one target sequence. The method of analysis comprises
XX CC hybridising at least one or more nucleic acids to at least two or more
XX CC nucleic acid probes and detecting the hybridisation. The nucleic acid
XX CC probes are attached to a solid support. The analysis comprises monitoring
XX CC gene expression levels, identifying biallelic markers or polymorphisms,
XX CC or family members of a gene and a cross-species comparison. Each of the
XX CC nucleic acids further comprises a tag sequence. The array of nucleic acid
XX CC probes is useful in situ hybridisation, in Southern, Northern or dot-
XX CC blot hybridisation to identify or detect the sequence or specific
XX CC mutations of any gene, in mapping the 5' termini of mRNA molecules by
XX CC primer extensions or in screening cDNA or genomic libraries or subclones
XX CC for additional subclones containing segments of DNA that have been
XX CC isolated and previously sequenced. The sequence presented is one of the
XX CC nucleic acid probes incorporated in the microarray. Note: The sequence
XX CC data for this patent can also be obtained in electronic format directly
XX CC from USPTO at seqdata.uspto.gov/sequence.html
XX SQ Sequence 25 BP; 3 A; 8 C; 9 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 19.2; DB 1; Length 25;
Best Local Similarity 87.5%; Pred. No. 7e+02;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 2569 CACGGACATCAGCGGTGGCTC 2592
Db 24 CACGGACATCAGCGGTGGCTC 1

RESULT 434
AAD40531
ID AAD40531 standard; DNA; 19 BP.
XX AC AAD40531;
XX DT 30-OCT-2002 (first entry)
XX DE Forward RT-PCR primer used for FGFR3 expression in human tissues.
XX KW Human; stem cell; fibroblast growth factor receptor 3; FGFR3;
XX KW osteoblast cell; bone density; osteoporosis; osteopathic; receptor;
XX KW RT-PCR; primer; ss.
XX OS Homo sapiens.
XX PN WO200250246-A2.
XX PD 27-JUN-2002.
XX PF 18-DEC-2001; 2001WO-US048270.
XX PR 18-DEC-2000; 2000US-0255882P.
XX PR 24-APR-2001; 2001US-0285691P.
XX PR 23-JUL-2001; 2001US-0306879P.
XX PR 10-SEP-2001; 2001US-0317974P.
XX PA (GENE-) GENE LOGIC INC.
XX PI (PROC) PROCTER & GAMBLE CO.
XX DR Jaiswal N, Houghton A, Mertz L, Ji D, Cook JS, Axelrod DW;
XX WPI; 2002-519881/55.
XX PT Stimulating a population of stem cells to differentiate into osteoblast
XX PT cells useful for treating osteoporosis, by contacting the cells with
XX PT agent which increases fibroblast growth receptor 3 expression or
XX PT activity.
XX PS Example 3; Page 58; 58pp; English.
XX CC The invention relates to a method for stimulating a population of stem
XX CC cells to differentiate into osteoblast cells by contacting the population
XX CC with an agent which increases fibroblast growth factor receptor 3 (FGFR3)
XX CC expression or activity, where increase in FGFR3 protein expression or
XX CC activity results in differentiation of the stem cells into osteoblast
XX CC cells. The method is useful for stimulating the population of stem cells
XX CC to differentiate into osteoblast cells. The method is useful for
XX CC increasing bone density. The method is useful for screening the agent
XX CC that modulates the differentiation of population into osteoblast cells,
XX CC increases bone density, or ameliorates the effects of osteoporosis. The
XX CC method is useful for diagnosing a condition characterised by abnormal
XX CC stem cell differentiation, bone density or rate of osteoblast formation
XX CC and treating a patient with a condition characterised by an abnormal rate
XX CC of osteoblast formation, bone density or osteoporosis. The present
XX CC sequence is a RT-PCR primer used for human FGFR3 expression in human
XX CC tissues
XX SQ Sequence 19 BP; 3 A; 4 C; 8 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 3706 TGGTGGCCAGAGGTGTAC 3724
Db 1 TGGTGGCCAGAGGTGTAC 19

RESULT 435
AAD40532/c

ID AAD40532 standard; DNA; 19 BP.
 XX AC AAD40532;
 XX DT 30-OCT-2002 (first entry)
 XX DE Reverse RT-PCR primer used for FGFR3 expression in human tissues.
 XX KW Human; stem cell; fibroblast growth factor receptor 3; FGFR3;
 KW osteoblast cell; bone density; osteoporosis; osteopathic; receptor;
 KW RT-PCR; primer; ss.
 XX OS Homo sapiens.
 XX PN WO200250246-A2.
 XX PD 27-JUN-2002.
 XX PF 18-DEC-2001; 2001WO-US048270.
 XX PR 18-DEC-2000; 2000US-0255882P.
 XX PR 24-APR-2001; 2001US-0285691P.
 XX PR 23-JUL-2001; 2001US-0306879P.
 XX PR 10-SEP-2001; 2001US-0317974P.
 XX PA (GENE-) GENE LOGIC INC.
 XX PA (PROC) PROCTER & GAMBLE CO.
 XX PI Jaiswal N, Houghton A, Mertz L, Ji D, Cook JS, Axelrod DW;
 XX WPI; 2002-519881/55.
 XX DR Stimulating a population of stem cells to differentiate into osteoblast
 XX PT cells useful for treating osteoporosis, by contacting the cells with
 XX PT agent which increases fibroblast growth receptor 3 expression or
 XX PT activity.
 XX PS Example 3; Page 58; 58pp; English.
 XX CC The invention relates to a method for stimulating a population of stem
 CC cells to differentiate into osteoblast cells by contacting the population
 CC with an agent which increases fibroblast growth factor receptor 3 (FGFR3)
 CC expression or activity, where increase in FGFR3 protein expression or
 CC activity results in differentiation of the stem cells into osteoblast
 CC cells. The method is useful for stimulating the population of stem cells
 CC to differentiate into osteoblast cells. The method is useful for
 CC increasing bone density. The method is useful for screening the agent
 CC that modulates the differentiation of population into osteoblast cells,
 CC increases bone density, or ameliorates the effects of osteoporosis. The
 CC method is useful for diagnosing a condition characterised by abnormal
 CC stem cell differentiation, bone density or rate of osteoblast formation
 CC and treating a patient with a condition characterised by an abnormal rate
 CC of osteoblast formation, bone density or osteoporosis. The present
 CC sequence is a RT-PCR primer used for human FGFR3 expression in human
 CC tissues
 XX SQ Sequence 19 BP; 3 A; 3 C; 8 G; 5 T; 0 U; 0 Other;
 Query Match 0.5%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 3751 ACCGAGCGAGCACTTCC 3769
 DB 19 ACCGAGCGAGCACTTCC 1
 RESULT 436
 ABQ81991
 ID ABQ81991 standard; DNA; 19 BP.
 XX AC ABQ81991;
 XX

DT 19-NOV-2002 (first entry)
 XX DE Kaposi's Sarcoma TAG PCR primer SEQ ID NO:141.
 XX KW Human; Kaposi's sarcoma; tumour; angiogenesis; PCR primer; ss.
 XX OS Homo sapiens.
 XX PN EP1225233-A2.
 XX PD 24-JUL-2002.
 XX PF 23-JAN-2002; 2002EP-00075264.
 XX PR 23-JAN-2001; 2001EP-00200228.
 XX PR 28-SEP-2001; 2001EP-00203703.
 XX PR 28-SEP-2001; 2001US-0325722P.
 XX PA (AMST-) AMSTERDAM SUPPORT DIAGNOSTICS BV.
 XX PI Van Der Kuyl AC, Cornelissen M;
 XX WPI; 2002-668396/72.
 XX DR Determining presence of a tumor cell or angiogenesis, and the
 XX PT effectiveness of treatment, by detecting the presence of marker genes is
 XX PT useful to detect and monitor treatment of Kaposi's Sarcoma.
 XX PS Example 10; Page 24; 39pp; English.
 XX CC The present invention describes a method for determining if an individual
 CC has a tumour cell or site of angiogenesis, or if a treatment is effective
 CC in changing angiogenesis or changing a status of a set of target cells,
 CC comprising determining if a sample of the subject has an expression
 CC product of at least one marker gene. Also described is a compound capable
 CC of altering the expression or activity of Keratin 14, TIE 1, Salivohesin
 CC or Siglec in a cell. Peripheral blood mononuclear cell (PBMC)-expressed
 CC Keratin 14, TIE 1, Salivohesin or Siglec, and kits containing them from
 CC the present invention can be used in a diagnostic method, particularly as
 CC an indicator of angiogenesis or to determine presence of a tumour cell.
 CC The method of the invention is suitable to determine within a few days if
 CC a certain treatment against Kaposi's Sarcoma is successful. ABQ81851 to
 CC ABQ82006 represent nucleotide sequence used in the exemplification of the
 CC present invention
 XX SQ Sequence 19 BP; 7 A; 8 C; 1 G; 3 T; 0 U; 0 Other;
 Query Match 0.5%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1702 CACAACCTCGACTACTACA 1720
 DB 1 CACAACCTCGACTACTACA 19
 RESULT 437
 ADC13476
 ID ADC13476 standard; DNA; 19 BP.
 XX AC ADC13476;
 XX DT 18-DEC-2003 (first entry)
 XX DE Kaposi's sarcoma tag PCR primer, SEQ ID No 143.
 XX KW marker gene; tumour; Kaposi's Sarcoma; peripheral blood mononuclear cell;
 KW PBMC; expressed keratin 14; TIE 1; Salivohesin; Siglec 1; angiogenesis;
 KW drug target; tag; SAGE library; KS3; KS4; PCR; primer; ss.
 XX OS Unidentified.
 XX PN EP1298221-A1.

XX PD 02-APR-2003.
 XX XX
 XX PF 28-SEP-2001; 2001EP-00203703.
 XX XX
 XX PF 28-SEP-2001; 2001EP-00203703.
 XX XX
 XX PA (PRIM-) PRIMAGEN HOLDING BV.
 XX XX
 XX PI Van Der Kuyt AC, Cornelissen M;
 XX XX
 XX DR WPI; 2003-589342/56.
 XX XX
 XX PT Determining whether a treatment is effective in changing a status of a
 XX PT certain set of target cells in an individual comprises determining
 XX PT whether the sample comprises an expression product of at least one marker
 XX PT gene.
 XX PS Disclosure; SEQ ID NO 143; 94pp; English.
 XX CC The invention relates to a novel method for determining whether a
 XX CC treatment is effective in changing a status of a certain set of target
 XX CC cells in an individual. The method comprises obtaining a sample from an
 XX CC individual after initiation of the treatment; and determining whether the
 XX CC sample comprises an expression product of at least one marker gene. The
 XX CC marker gene and a proteinaceous molecule (which can bind to the protein
 XX CC derived from the marker gene of the invention) are useful for determining
 XX CC whether a treatment is effective in counteracting a tumour in an
 XX CC individual, especially Kaposi's Sarcoma. Peripheral blood mononuclear
 XX CC cell (PBMC) expressed keratin 14, TIE 1, Salivoadhesin, or Siglec 1
 XX CC sequences or a fully defined sequence given in the specification, or
 XX CC their analogues are useful as indicators for angiogenesis and for
 XX CC detecting the presence of a tumour cell in an individual. The expression
 XX CC product of a gene comprising a marker gene of the invention is useful as
 XX CC a drug target. The compound is useful for preparing a medicament. This
 XX CC polynucleotide sequence represents a PCR primer of a Kaposi's Sarcoma tag
 XX CC sequence of the invention.
 XX CC Sequence 19 BP; 7 A; 8 C; 1 G; 3 T; 0 U; 0 Other;
 XX
 XX Query Match 0.5%; Score 19; DB 1; Length 19;
 XX Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 XX Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 1702 CACAACCTCGACTACTACA 1720
 DB 1 CACAACCTCGACTACTACA 19
 RESULT 438
 ACC79684/C
 ID ACC79684 standard; DNA; 19 BP.
 XX AC ACC79684;
 XX DT 27-AUG-2003 (first entry)
 XX DE Human fibroblast growth factor 3 exon 17 PCR primer #2.
 XX KW Human; fibroblast growth factor 3; FGF3; flat epithelial cell; cancer;
 XX KW flat epithelial cell cancer; PCR primer; ss.
 XX OS Homo sapiens.
 XX OS Synthetic.
 XX PN JP2002272474-A.
 XX PD 24-SEP-2002.
 XX PF 22-MAR-2001; 2001JP-00083352.
 XX XX
 XX PF 22-MAR-2001; 2001JP-00083352.
 XX XX
 XX PR 22-MAR-2001; 2001JP-00083352.
 XX XX
 XX PS Example; Page 6; 18pp; Japanese.

PA (ZERI) ZERIA SHINYAKU KOGYO KK.
 XX WPI; 2003-345602/33.
 XX PT Inspection of flat epithelial cell, screening of treating or preventive
 XX PT agents for flat epithelial cancers, the treating or preventive agents for
 XX PT flat epithelial cancer.
 XX PS Example; Page 6; 18pp; Japanese.
 XX CC The present invention describes a method for the inspection of flat
 XX CC epithelial cells in which it is judged that flat epithelial cancer when the
 XX CC separated from an organism can proceed to flat epithelial cancer when the
 XX CC 2128th base in fibroblast growth factor receptor (FGFR) gene of the cells
 XX CC is mutated from guanine to thymine. Also described is a method for
 XX CC screening treating or preventive agents for flat epithelial cancers in
 XX CC which a candidate substance of treating agent for flat epithelial cancer
 XX CC is applied to flat epithelial cancer cells producing FGFR protein in
 XX CC which the 2128th (exon 17) amino acid in FGFR3 gene is mutated from
 XX CC guanine to thymine or the 697th amino acid is mutated from glycine to
 XX CC cysteine and said candidate substance is selected by using the facts that
 XX CC the 2128th base in the flat epithelial cell FGFR3 gene after the
 XX CC application returned to guanine and that the 697th amino acid of FGFR3
 XX CC protein produced returned to glycine as the indices. The method is used
 XX CC for the inspection of flat epithelial cells. The present sequence
 XX CC represents a PCR primer for human FGFR3, which is used in an example from
 XX CC the present invention
 XX CC Sequence 19 BP; 4 A; 5 C; 6 G; 4 T; 0 U; 0 Other;
 XX
 XX Query Match 0.5%; Score 19; DB 1; Length 19;
 XX Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 XX Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 2048 ACGAGTACTCGACCTGTC 2066
 DB 19 ACGAGTACTCGACCTGTC 1
 RESULT 439
 ACC79683
 ID ACC79683 standard; DNA; 19 BP.
 XX AC ACC79683;
 XX DT 27-AUG-2003 (first entry)
 XX DE Human fibroblast growth factor 3 exon 17 PCR primer #1.
 XX KW Human; fibroblast growth factor 3; FGF3; flat epithelial cell; cancer;
 XX KW flat epithelial cell cancer; PCR primer; ss.
 XX OS Homo sapiens.
 XX OS Synthetic.
 XX PN JP2002272474-A.
 XX PD 24-SEP-2002.
 XX PF 22-MAR-2001; 2001JP-00083352.
 XX XX
 XX PR 22-MAR-2001; 2001JP-00083352.
 XX XX
 XX PA (ZERI) ZERIA SHINYAKU KOGYO KK.
 XX WPI; 2003-345602/33.
 XX PT Inspection of flat epithelial cell, screening of treating or preventive
 XX PT agents for flat epithelial cancers, the treating or preventive agents for
 XX PT flat epithelial cancer.
 XX PS Example; Page 6; 18pp; Japanese.

PS Example C; SEQ ID NO 146; 433pp; English.

XX This invention relates to novel isolated polypeptides and the DNA

CC sequences which encode them. The invention may be useful for the

CC development of compounds with a cytostatic activity (as NOVX-agonists or

CC antagonists) or vaccines. In addition, the disclosed sequences may be

CC useful for gene therapy. The polypeptide is useful for preparing a

CC composition for treating or preventing a pathological state in a mammal,

CC for example cancer or for chromosome mapping. The present sequence is

CC that of a PCR primer which was used in the exemplification of the

CC invention.

XX Sequence 19 BP; 5 A; 5 C; 5 G; 4 T; 0 U; 0 Other;

SQ

Query Match 0.5%; Score 19; DB 1; Length 19;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1283 TCACCGTAGCGGTGAGAT 1301

DB 1 TCACCGTAGCGGTGAGAT 19

RESULT 441

ADQ27139

ID ADQ27139 standard; DNA; 19 BP.

XX

AC ADQ27139;

XX

DT 26-AUG-2004 (first entry)

XX

DE RNA interference target sequence #47.

XX

KW ss: detection; RNA interference; siRNA; gene silencing; gene expression;

KW cytotoxicity.

XX

OS Homo sapiens.

XX

PN WO2004048566-A1.

XX

PD 10-JUN-2004.

XX

PF 21-NOV-2003; 2003WO-JP014893.

XX

PR 22-NOV-2002; 2002JP-00340053.

XX

PA (NATO/) NATORI Y.

PA (SAIG/) SAIGO K.

PA (TEIK/) TEI K.

PA (NAIT/) NAITO Y.

XX

PI Saigo K, Tei K, Naito Y;

XX

WPI; 2004-487423/46.

XX

PT Detecting sequence of RNA interference useful for synthesizing siRNA, by

PT detecting regions in sequence fulfilling specific criteria such as base

PT at 3' terminal is adenine, thymine or uracil, base at 5' terminal is

PT guanine or cytosine.

XX

PS Disclosure; SEQ ID NO 61; 325pp; Japanese.

XX

CC The invention relates to a method of detecting the base sequence for RNA

CC interference by detecting the regions in the DNA sequence fulfilling the

CC following requirements such as: (i) the base at 3' terminal is adenine,

CC thymine or uracil; (ii) the base at 5' terminal is guanine or cytosine;

CC (iii) the seven base sequence at 3' terminal is rich in adenine, thymine

CC and uracil, and; (iv) there are bases in a such a number that it causes

CC RNA interference without showing cytotoxicity. The method is used for

CC designing and synthesizing siRNA causing RNA interference. This sequence

CC corresponds to an RNA interference target sequence of the invention.

XX

SQ Sequence 19 BP; 7 A; 8 C; 1 G; 3 T; 0 U; 0 Other;

CC The present invention describes a method for the inspection of flat

CC epithelial cells in which it is judged that flat epithelial cells

CC separated from an organism can proceed to flat epithelial cancer when the

CC 2128th base in fibroblast growth factor receptor (FGFR) gene of the cells

CC is mutated from guanine to thymine. Also described is a method for

CC screening treating or preventive agents for flat epithelial cancers in

CC which a candidate substance of treating agent for flat epithelial cancer

CC is applied to flat epithelial cancer cells producing FGFR protein in

CC which the 2128th (exon 17) amino acid in FGFR3 gene is mutated from

CC guanine to thymine or the 697th amino acid is mutated from glycine to

CC cysteine and said candidate substance is selected by using the facts that

CC the 2128th base in the flat epithelial cell FGFR3 gene after the

CC application returned to guanine and that the 697th amino acid of FGFR3

CC protein produced returned to glycine as the indices. The method is used

CC for the inspection of flat epithelial cells. The present sequence

CC represents a PCR primer for human FGFR3, which is used in an example from

CC the present invention

XX

SQ Sequence 19 BP; 5 A; 8 C; 3 G; 3 T; 0 U; 0 Other;

QY 1777 GACCGAGTCTACACTCACC 1795

DB 1 GACCGAGTCTACACTCACC 19

RESULT 440

ADK51125

ID ADK51125 standard; DNA; 19 BP.

XX

AC ADK51125;

XX

DT 17-JUN-2004 (first entry)

XX

DE Human NOVX protein-related PCR primer SeqID.

XX

KW cytostatic; NOVX-agonist; NOVX-antagonist; vaccine; gene therapy; cancer;

KW chromosome mapping; human; PCR; primer; ss.

XX

OS Homo sapiens.

XX

PN WO2003083046-A2.

XX

PD 09-OCT-2003.

XX

PF 01-APR-2003; 2003WO-US010142.

XX

PR 02-APR-2002; 2002US-00115479.

PR 05-APR-2002; 2002US-0370349P.

PR 08-APR-2002; 2002US-0370969P.

PR 12-APR-2002; 2002US-0372019P.

PR 22-APR-2002; 2002US-0374379P.

PR 30-MAY-2002; 2002US-0384543P.

PR 03-JUN-2002; 2002US-00160619.

PR 15-AUG-2002; 2002US-0403748P.

PR 04-NOV-2002; 2002US-00287226.

PR 31-MAR-2003; 2003US-00403161.

XX

PA (CURA-) CURAGEN CORP.

XX

PI Anderson DW, Bento P, Boldog FL, Burgess CE, Casman SJ, Furtak K;

PI Gorman L, Gould-Rothberg BE, Gunther E, Heyes MP, Li L, Spytek KA;

PI Stone DJ, Zhong M, Malyankar UM, Edinger SR, Patturajan M;

PI Rothenberg ME, Smithson G;

XX

WPI; 2003-812539/76.

XX

PT New NOVX polypeptide, useful for preparing a composition for treating or

PT preventing e.g. cancer or for chromosome mapping.

XX


```
Query Match      0.5%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1702 CACAACTCGACTACTACA 1720
DB 1 CACAACTCGACTACTACA 19
|||||
|||||

RESULT 442
ADQ27143
ID ADQ27143 standard; DNA; 19 BP.
XX AC
XX ADQ27143;
XX DT
XX 26-AUG-2004 (first entry)
XX DE
XX RNA interference target sequence #51.
XX ss; detection; RNA interference; siRNA; gene silencing; gene expression;
XX cytotoxicity.
XX Homo sapiens.
XX WO2004048566-A1.
XX PN
XX 10-JUN-2004.
XX PD
XX 21-NOV-2003; 2003WO-JP014893.
XX PF
XX 22-NOV-2002; 2002JP-00340053.
XX PR
XX (NATO/) NATORI Y.
XX PA
XX (SAIG/) SAIGO K.
XX PA (TEIK/) TEI K.
XX PA (NAIT/) NAITO Y.
XX XX
XX Saigo K, Tei K, Naito Y;
XX PI
XX WPI; 2004-487423/46.
XX DR
XX Detecting sequence of RNA interference useful for synthesizing siRNA, by
XX PT detecting regions in sequence fulfilling specific criteria such as base
XX PT at 3' terminal is adenine, thymine or uracil, base at 5' terminal is
XX PT guanine or cytosine.
XX PS
XX Disclosure; SEQ ID NO 65; 325pp; Japanese.
XX CC
XX The invention relates to a method of detecting the base sequence for RNA
XX CC interference by detecting the regions in the DNA sequence fulfilling the
XX CC following requirements such as: (i) the base at 3' terminal is adenine,
XX CC thymine or uracil; (ii) the base at 5' terminal is guanine or cytosine;
XX CC (iii) the seven base sequence at 3' terminal is rich in adenine, thymine
XX CC and uracil, and; (iv) there are bases in a such a number that it causes
XX CC RNA interference without showing cytotoxicity. The method is used for
XX CC designing and synthesizing siRNA causing RNA interference. This sequence
XX CC corresponds to an RNA interference target sequence of the invention.
XX XX
XX Sequence 19 BP; 4 A; 4 C; 6 G; 5 T; 0 U; 0 Other;

Query Match      0.5%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 589 GAGTTCCTGCAAGTGT 607
DB 1 GAGTTCCTGCAAGTGT 19
|||||
|||||

RESULT 443
ADQ27140
ID ADQ27140 standard; DNA; 19 BP.
```

```
XX ADQ27140;
XX 26-AUG-2004 (first entry)
XX DE
XX RNA interference target sequence #48.
XX ss; detection; RNA interference; siRNA; gene silencing; gene expression;
XX cytotoxicity.
XX Homo sapiens.
XX WO2004048566-A1.
XX PN
XX 10-JUN-2004.
XX PD
XX 21-NOV-2003; 2003WO-JP014893.
XX PF
XX 22-NOV-2002; 2002JP-00340053.
XX PR
XX (NATO/) NATORI Y.
XX PA
XX (SAIG/) SAIGO K.
XX PA (TEIK/) TEI K.
XX PA (NAIT/) NAITO Y.
XX XX
XX Saigo K, Tei K, Naito Y;
XX PI
XX WPI; 2004-487423/46.
XX DR
XX Detecting sequence of RNA interference useful for synthesizing siRNA, by
XX PT detecting regions in sequence fulfilling specific criteria such as base
XX PT at 3' terminal is adenine, thymine or uracil, base at 5' terminal is
XX PT guanine or cytosine.
XX PS
XX Disclosure; SEQ ID NO 62; 325pp; Japanese.
XX CC
XX The invention relates to a method of detecting the base sequence for RNA
XX CC interference by detecting the regions in the DNA sequence fulfilling the
XX CC following requirements such as: (i) the base at 3' terminal is adenine,
XX CC thymine or uracil; (ii) the base at 5' terminal is guanine or cytosine;
XX CC (iii) the seven base sequence at 3' terminal is rich in adenine, thymine
XX CC and uracil, and; (iv) there are bases in a such a number that it causes
XX CC RNA interference without showing cytotoxicity. The method is used for
XX CC designing and synthesizing siRNA causing RNA interference. This sequence
XX CC corresponds to an RNA interference target sequence of the invention.
XX XX
XX Sequence 19 BP; 6 A; 7 C; 3 G; 3 T; 0 U; 0 Other;

Query Match      0.5%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1931 GCACACGACCTGTACAT 1949
DB 1 GCACACGACCTGTACAT 19
|||||
|||||

RESULT 444
ADQ27141
ID ADQ27141 standard; DNA; 19 BP.
XX AC
XX ADQ27141;
XX DT
XX 26-AUG-2004 (first entry)
XX DE
XX RNA interference target sequence #49.
XX ss; detection; RNA interference; siRNA; gene silencing; gene expression;
XX cytotoxicity.
XX Homo sapiens.
XX WO2004048566-A1.
XX PN
```

XX PD 10-JUN-2004.
 XX PF 21-NOV-2003; 2003WO-JP014893.
 XX XX 22-NOV-2002; 2002JP-00340053.
 XX PA (NATO/) NATORI Y.
 XX PA (SAIG/) SAIGO K.
 XX PA (TEIK/) TEI K.
 XX PA (NAIT/) NAITO Y.
 XX PI Saigo K, Tei K, Naito Y;
 XX WPI; 2004-487423/46.
 XX The invention relates to a method of detecting the base sequence for RNA interference by detecting the regions in the DNA sequence fulfilling the following requirements such as: (i) the base at 3' terminal is adenine, thymine or uracil; (ii) the base at 5' terminal is guanine or cytosine; (iii) the seven base sequence at 3' terminal is rich in adenine, thymine and uracil, and; (iv) there are bases in a such a number that it causes RNA interference without showing cytotoxicity. The method is used for designing and synthesizing siRNA causing RNA interference. This sequence corresponds to an RNA interference target sequence of the invention.
 XX SQ Sequence 19 BP; 5 A; 5 C; 6 G; 3 T; 0 U; 0 Other;
 PS Disclosure; SEQ ID NO 63; 325pp; Japanese.
 CC The invention relates to a method of detecting the base sequence for RNA interference by detecting the regions in the DNA sequence fulfilling the following requirements such as: (i) the base at 3' terminal is adenine, thymine or uracil; (ii) the base at 5' terminal is guanine or cytosine; (iii) the seven base sequence at 3' terminal is rich in adenine, thymine and uracil, and; (iv) there are bases in a such a number that it causes RNA interference without showing cytotoxicity. The method is used for designing and synthesizing siRNA causing RNA interference. This sequence corresponds to an RNA interference target sequence of the invention.
 XX SQ Sequence 19 BP; 5 A; 5 C; 6 G; 3 T; 0 U; 0 Other;
 Query Match 0.5%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 455 CCTGCGTCGTGGAGAACAA 473
 DB 1 CCTGCGTCGTGGAGAACAA 19
 RESULT 445
 ADQ27138
 ID ADQ27138 standard; DNA; 19 BP.
 AC ADQ27138;
 XX 26-AUG-2004 (first entry)
 DE RNA interference target sequence #46.
 XX ss: detection; RNA interference; siRNA; gene silencing; gene expression;
 KW cytotoxicity.
 XX Homo sapiens.
 OS WO2004048566-A1.
 XX 10-JUN-2004.
 XX 21-NOV-2003; 2003WO-JP014893.
 XX 22-NOV-2002; 2002JP-00340053.
 XX (NATO/) NATORI Y.
 XX PA (SAIG/) SAIGO K.
 XX PA (TEIK/) TEI K.
 XX PA (NAIT/) NAITO Y.
 XX PI Saigo K, Tei K, Naito Y;

XX WPI; 2004-487423/46.
 XX Detecting sequence of RNA interference useful for synthesizing siRNA, by detecting regions in sequence fulfilling specific criteria such as base at 3' terminal is adenine, thymine or uracil, base at 5' terminal is guanine or cytosine.
 XX Disclosure; SEQ ID NO 60; 325pp; Japanese.
 XX The invention relates to a method of detecting the base sequence for RNA interference by detecting the regions in the DNA sequence fulfilling the following requirements such as: (i) the base at 3' terminal is adenine, thymine or uracil; (ii) the base at 5' terminal is guanine or cytosine; (iii) the seven base sequence at 3' terminal is rich in adenine, thymine and uracil, and; (iv) there are bases in a such a number that it causes RNA interference without showing cytotoxicity. The method is used for designing and synthesizing siRNA causing RNA interference. This sequence corresponds to an RNA interference target sequence of the invention.
 XX SQ Sequence 19 BP; 5 A; 7 C; 4 G; 3 T; 0 U; 0 Other;
 Query Match 0.5%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 676 GACGGCACACCCCTACGTTA 694
 DB 1 GACGGCACACCCCTACGTTA 19
 RESULT 446
 ADQ27142
 ID ADQ27142 standard; DNA; 19 BP.
 AC ADQ27142;
 XX 26-AUG-2004 (first entry)
 DE RNA interference target sequence #50.
 XX ss: detection; RNA interference; siRNA; gene silencing; gene expression;
 KW cytotoxicity.
 XX Homo sapiens.
 OS WO2004048566-A1.
 XX 10-JUN-2004.
 XX 21-NOV-2003; 2003WO-JP014893.
 XX 22-NOV-2002; 2002JP-00340053.
 XX (NATO/) NATORI Y.
 XX PA (SAIG/) SAIGO K.
 XX PA (TEIK/) TEI K.
 XX PA (NAIT/) NAITO Y.
 XX PI Saigo K, Tei K, Naito Y;
 XX WPI; 2004-487423/46.
 XX Detecting sequence of RNA interference useful for synthesizing siRNA, by detecting regions in sequence fulfilling specific criteria such as base at 3' terminal is adenine, thymine or uracil, base at 5' terminal is guanine or cytosine.
 XX Disclosure; SEQ ID NO 64; 325pp; Japanese.
 XX The invention relates to a method of detecting the base sequence for RNA interference by detecting the regions in the DNA sequence fulfilling the following requirements such as: (i) the base at 3' terminal is adenine, thymine or uracil, base at 5' terminal is adenine, thymine or cytosine, following requirements such as: (i) the base at 3' terminal is adenine, thymine or uracil; (ii) the base at 5' terminal is guanine or cytosine; (iii) the seven base sequence at 3' terminal is rich in adenine, thymine and uracil, and; (iv) there are bases in a such a number that it causes RNA interference without showing cytotoxicity. The method is used for designing and synthesizing siRNA causing RNA interference. This sequence corresponds to an RNA interference target sequence of the invention.
 XX SQ Sequence 19 BP; 5 A; 7 C; 4 G; 3 T; 0 U; 0 Other;

CC thymine or uracil; (ii) the base at 5' terminal is guanine or cytosine;
 CC (iii) the seven base sequence at 3' terminal is rich in adenine, thymine
 CC and uracil; and; (iv) there are bases in a such a number that it causes
 CC RNA interference without showing cytotoxicity. The method is used for
 CC designing and synthesizing siRNA causing RNA interference. This sequence
 CC corresponds to an RNA interference target sequence of the invention.

XX
 SQ Sequence 19 BP; 6 A; 6 C; 3 G; 4 T; 0 U; 0 Other;
 Query Match 0.5%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1934 CACAGACCTGTACATGAT 1952
 |||||
 Db 1 CACAGACCTGTACATGAT 19

RESULT 447
 ADQ61020
 ID ADQ61020 standard; RNA; 19 BP.
 XX
 AC ADQ61020;
 XX
 DT 09-SEP-2004 (first entry)
 XX
 DE Anti-FGPR3 siRNA related DNA sequence SEQ ID NO:722.
 KW ss; siRNA; gene silencing; Bcl-2; optimised; short interfering RNA;
 KW RNA interference.
 XX
 OS Synthetic.
 XX
 PN WO2004045543-A2.
 XX
 PD 03-JUN-2004.
 XX
 PF 14-NOV-2003; 2003WO-US036787.
 XX
 PR 14-NOV-2002; 2002US-0426137P.
 PR 10-SEP-2003; 2003US-0502050P.
 XX
 PA (DHAR-) DHARMA CON INC.
 PI Anastasia K, Angela R, Devin L, William M, Stephen S;

DR WPI; 2004-420527/39.
 XX
 PT Selecting siRNA by selecting an siRNA molecule of 19-25 nucleoside bases
 PT by selecting a target gene and measuring the functionality of the
 PT nucleotide sequences that are complementary to a stretch of nucleotides
 PT of the target sequence.
 XX
 PS Example 12; SEQ ID NO 722; 199pp; English.

XX The invention relates to a novel method for selecting siRNA (short
 CC interfering RNA) comprising selecting an siRNA molecule of 19-25
 CC nucleoside bases by selecting a target gene and measuring the
 CC functionality of sequences of 19-25 nucleotides in length that are
 CC substantially complementary to a stretch of nucleotides of the target
 CC sequence, where the functionality is dependent upon non-target specific
 CC criteria. Also claimed are methods for gene-silencing, developing an
 CC siRNA algorithm for selecting siRNA, selecting an siRNA with improved
 CC functionality, selecting hyperfunctional siRNA, an siRNA molecule
 CC effective at silencing Bcl-2, and a kit for gene silencing comprising the
 CC siRNA. The siRNA molecule comprises a sequence substantially similar to a
 CC sequence consisting of GGGAGAUGAUGAUGAUGA; GAAGACUUCUCUCAGUUG;
 CC GUACACACCGGAGAUAC; AGAUGAUGAUGAUGAUGA; GAAGACUUCUCUCAGUUG;
 CC CAUGCGCCUCUGUUGA; UCGCGCCUCUGUUGAUGAUGA; GAGAUGAUGAUGAUGA;
 CC GGAGAUGAUGAUGAUGAUGA; and GAAGACUUCUCUCAGUUG. The siRNA molecule
 CC comprises a sense strand and an anti-sense strand. The siRNA molecule
 CC comprises a hairpin. The siRNA molecule comprises between 18 and 30 base
 CC pairs. The kit comprises at least two siRNA, comprising a first optimised
 CC siRNA and a second optimised siRNA. The method is useful in selecting
 CC siRNA for generating a gene silencing reagent. The present sequence is

CC siRNA and a second optimised siRNA. The method is useful in selecting
 CC siRNA for generating a gene silencing reagent. The present sequence is
 CC the specification as DNA, but described as siRNA.

XX
 SQ Sequence 19 BP; 5 A; 6 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 383 GCATCAAGCTGGGCATCA 401
 |||||
 Db 1 GCATCAAGCTGGGCATCA 19

RESULT 448
 ADQ61022
 ID ADQ61022 standard; RNA; 19 BP.
 XX
 AC ADQ61022;
 XX
 DT 09-SEP-2004 (first entry)
 XX
 DE Anti-FGPR3 siRNA related DNA sequence SEQ ID NO:724.
 KW ss; siRNA; gene silencing; Bcl-2; optimised; short interfering RNA;
 KW RNA interference.
 XX
 OS Synthetic.
 XX
 PN WO2004045543-A2.
 XX
 PD 03-JUN-2004.
 XX
 PF 14-NOV-2003; 2003WO-US036787.
 XX
 PR 14-NOV-2002; 2002US-0426137P.
 PR 10-SEP-2003; 2003US-0502050P.
 XX
 PA (DHAR-) DHARMA CON INC.
 PI Anastasia K, Angela R, Devin L, William M, Stephen S;

DR WPI; 2004-420527/39.
 XX
 PT Selecting siRNA by selecting an siRNA molecule of 19-25 nucleoside bases
 PT by selecting a target gene and measuring the functionality of the
 PT nucleotide sequences that are complementary to a stretch of nucleotides
 PT of the target sequence.
 XX
 PS Example 12; SEQ ID NO 724; 199pp; English.

XX The invention relates to a novel method for selecting siRNA (short
 CC interfering RNA) comprising selecting an siRNA molecule of 19-25
 CC nucleoside bases by selecting a target gene and measuring the
 CC functionality of sequences of 19-25 nucleotides in length that are
 CC substantially complementary to a stretch of nucleotides of the target
 CC sequence, where the functionality is dependent upon non-target specific
 CC criteria. Also claimed are methods for gene-silencing, developing an
 CC siRNA algorithm for selecting siRNA, selecting an siRNA with improved
 CC functionality, selecting hyperfunctional siRNA, an siRNA molecule
 CC effective at silencing Bcl-2, and a kit for gene silencing comprising the
 CC siRNA. The siRNA molecule comprises a sequence substantially similar to a
 CC sequence consisting of GGGAGAUGAUGAUGAUGA; GAAGACUUCUCUCAGUUG;
 CC GUACACACCGGAGAUAC; AGAUGAUGAUGAUGAUGA; GAAGACUUCUCUCAGUUGA;
 CC CAUGCGCCUCUGUUGA; UCGCGCCUCUGUUGAUGAUGA; GAGAUGAUGAUGAUGA;
 CC GGAGAUGAUGAUGAUGAUGA; and GAAGACUUCUCUCAGUUG. The siRNA molecule
 CC comprises a sense strand and an anti-sense strand. The siRNA molecule
 CC comprises a hairpin. The siRNA molecule comprises between 18 and 30 base
 CC pairs. The kit comprises at least two siRNA, comprising a first optimised
 CC siRNA and a second optimised siRNA. The method is useful in selecting
 CC siRNA for generating a gene silencing reagent. The present sequence is

Query Match 0.5%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 675 GGACGGCACACCTAGCTT 693
DB 1 GGACGGCACACCTAGCTT 19

RESULT 451
ADN06744/c
ID ADN06744 standard; DNA; 20 BP.
AC ADN06744;
XX
XX
XX 15-JUL-2004 (first entry)
XX
XX Human FIAP related microsatellite marker SEQ ID NO:394.
XX leukotriene synthesis inhibitor; myocardial infarction;
KW acute coronary syndrome; antiatherosclerotic; cardiant; antianginal;
KW leukotriene biosynthesis inhibitor; leukotriene receptor antagonist;
KW 5-lipoxygenase activating protein; FLAP; human; chromosome 13;
KW chromosome 13q12; polymorphism; 5-lipoxygenase gene promoter;
KW 5-LO gene promoter; diabetes; hypertension; hypercholesterolaemia;
KW obesity; inflammatory marker; low density lipoprotein; cholesterol;
KW high density lipoprotein; angina; atherosclerosis; microsatellite marker;
KW 86.
XX Homo sapiens.
OS Synthetic.
XX
XX WO2004035741-A2.
XX
XX 29-APR-2004.
XX
XX 16-OCT-2003; 2003WO-US032556.
XX
XX 17-OCT-2002; 2002US-0419433P.
PR 21-FEB-2003; 2003US-0449331P.
XX
XX (DECO-) DECODE GENETICS EHF.
PA
XX Helgadottir A, Gurney ME, Gulcher JR;
PI WPI; 2004-357211/33.
DR
XX Use of leukotriene synthesis inhibitor for manufacture of a medicament
PT for treatment for myocardial infarction or susceptibility to myocardial
PT infarction in individual.
XX
XX Disclosure; SEQ ID NO 394; 306pp; English.

The present invention describes using a leukotriene synthesis inhibitor (I) for the manufacture of a medicament for the treatment of myocardial infarction or susceptibility to myocardial infarction in an individual. Also described is a method (M1) for the treatment of acute coronary syndrome (ACS) in an individual comprising administering (I). (I) has antiatherosclerotic, cardiant and antianginal activities, and can be used as a leukotriene biosynthesis inhibitor, and a leukotriene receptor antagonist. (I) can be used for the manufacture of a medicament for the treatment of myocardial infarction or susceptibility to myocardial infarction in an individual who has at least one risk factor chosen from an at-risk haplotype for myocardial infarction, an at-risk haplotype in the 5-lipoxygenase activating protein (FLAP) gene, a polymorphism in a FLAP nucleic acid and an at-risk polymorphism in the 5-lipoxygenase (5-LO) gene promoter; in an individual who has at least one risk factor chosen from diabetes, hypertension, hypercholesterolaemia, elevated lip(a), obesity, past or current smoker; in an individual having elevated inflammatory marker chosen from C-reactive protein (CRP), serum amyloid A, fibrinogen, leukotriene, leukotriene metabolite, interleukin-6, tissue necrosis factor-alpha, soluble vascular cell adhesion molecule (sVCAM),

soluble intervascular adhesion molecule (sICAM), E-selectin, matrix metalloproteinase type-1, matrix metalloproteinase type-2, matrix metalloproteinase type-3 and matrix metalloproteinase type-9; in an individual having increased low density lipoprotein (LDL) cholesterol and/or decreased high density lipoprotein (HDL) cholesterol; in an individual having increased leukotriene synthesis; in an individual having previous myocardial infarction or acute coronary syndrome (ACS) event, stable angina; or in an individual who has atherosclerosis or who requires treatment to restore blood flow in arteries. (M1) is useful for treating an individual suffering from acute coronary syndrome chosen from unstable angina, non-ST-elevation myocardial infarction (NSTEMI) and ST-elevation myocardial infarction (STEMI). The human FLAP gene is located on chromosome 13, more specifically to 13q12. The present sequence represents a microsatellite marker used in the exemplification of the present invention.

XX
XX Sequence 20 BP; 9 A; 10 C; 1 G; 0 T; 0 U; 0 Other;
XX
XX
XX Query Match 0.5%; Score 19; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.7e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2318 TGTGTGTGTGTGTGTGCGT 2336
DB 19 TGTGTGTGTGTGTGTGCGT 1

RESULT 452
ADE79941/c
ID ADE79941 standard; cDNA; 24 BP.
XX
XX ADE79941;
AC
XX
XX 29-JAN-2004 (first entry)
DT
XX Tyrosine kinase antisense oligonucleotide.
DE
XX ss; antisense; tyrosine kinase; epithelial type cell tumour.
KW
XX Synthetic.
OS
XX US2003124133-A1.
PN
XX 03-JUL-2003.
PD
XX 26-AUG-1998; 98US-00140378.
PF
XX 14-JUN-1993; 93US-00077254.
PR 16-AUG-1994; 94US-00292299.
PR
XX (JOHN/) JOHNSON J D.
PA (RUTT/) RUTTER W J.
PA (EDNA/) EDMAN J C.
PA
XX Johnson JD, Rutter WJ, Edman JC;
PI WPI; 2004-009136/01.
XX
XX A new polypeptide has a discoidin-type ligand binding domain and a tyrosine kinase domain and is useful to diagnose and treat a patient having tumors of epithelial type cells which express the polypeptide on their surface.
PT
XX Example 1; SEQ ID NO 3; 27pp; English.
PS
XX The invention relates to a composition comprising a polypeptide having a first domain with carbohydrate binding activity and a second domain with kinase activity, a first domain with discoidin-type ligand binding characteristics and a second domain with tyrosine kinase activity. The invention is useful to diagnose, prognose and treat a patient having tumors of epithelial type cells which express the polypeptide on their surface. The present sequence represents a tyrosine kinase antisense oligonucleotide.

Thu Oct 28 12:48:21 2004

```
XX SQ Sequence 24 BP; 1 A; 6 C; 7 G; 4 T; 0 U; 6 Other;
Query Match 0.5%; Score 19; DB 1; Length 24;
Best Local Similarity 69.6%; Pred. No. 7.1e+02;
Matches 16; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY 1618 CACAGGACCTGGCTGCCGCA 1640
Db 24 CAYCGGAYCTGGCYGCGSAA 2

RESULT 453
AAQ34131
ID AAQ34131 standard; DNA; 26 BP.
XX AC AAQ34131;
XX DT 25-MAR-2003 (revised)
XX DT 02-FEB-1993 (first entry)
XX DE Sequence of a microsatellite from clone TGLA70B.
XX KW PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
XX KW genetic mapping; traits; amplification; ss.
XX OS Bos taurus.
XX PN WO9213102-A1.
XX PD 06-AUG-1992.
XX PF 15-JAN-1992; 92WO-US000340.
XX PR 15-JAN-1991; 91US-00642342.
XX PA (GENM-) GENMARK.
XX PI Georges M, Massey JM;
XX WPI; 1992-284684/34.
XX Polymorphic bovine DNA markers - used in genetic identification, gene
XX mapping, and selective breeding.
XX PS Table 7; Page 383; 517pp; English.
XX The sequence is that of a bovine microsatellite sequence obt'd. by
XX screening a library of bovine MboI DNA fragments of between 250 and 500
XX bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
XX clones cross-hybridised. Assuming independent distribution of
XX microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
XX in the bovine genome is estimated at >100, 000. The sequence information
XX for ca. 230 such bovine microsatellites (see below). The sequences upstream and
XX specification and indexed herein (see below). The sequences upstream and
XX downstream of the microsatellite sequence were used to generate the
XX required PCR primers for in vitro amplification of the corresp.
XX microsatellite (using the program OPTIPRIM). The microsatellites may be
XX used to identify individuals, for parentage testing, and in the genetic
XX mapping of economically important traits esp. in cattle, to allow selective
XX breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
XX field.)
XX SQ Sequence 26 BP; 2 A; 1 C; 12 G; 11 T; 0 U; 0 Other;
Query Match 0.5%; Score 19; DB 1; Length 26;
Best Local Similarity 100.0%; Pred. No. 7.7e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2333 GCGTGTGTGTGTGTGTGTG 2351
Db 7 GCGTGTGTGTGTGTGTGTG 25
```

```
RESULT 454
AAAF63628/c
ID AAQ363628 standard; DNA; 27 BP.
XX AC AAQ363628;
XX DT 04-MAY-2001 (first entry)
XX DE Isogenic transgenic plant line related GSPLB4 SEQ ID NO:8.
XX KW Isogenic transgenic plant; line; T-DNA; transformation; cross-breeding;
XX KW hybrid; plant; characterisation; amplification; PCR primer; ss.
XX OS Plantae.
XX OS Synthetic.
XX PN WO200107632-A1.
XX PD 01-FEB-2001.
XX PF 25-JUL-2000; 2000WO-FR002130.
XX PR 28-JUL-1999; 99FR-00009990.
XX PA (RHOB-) RHOBIO.
XX PI Perez P, Garcia D;
XX WPI; 2001-168557/17.
XX Production of transgenic plant lines, useful for producing elite hybrids
XX with transgenic characteristics, includes selection for incorporation of
XX transgene into particular parent.
XX PS Example 3; Page 36; 44pp; French.
XX The present invention describes a method for the production of isogenic
XX transgenic plant lines (A) by transforming cells of a hybrid with T-DNA
XX vector containing a transgene (I), the hybrid being derived by crossing a
XX line of interest (LI) and a line suitable for transformation (LT).
XX Primary transformants are selected for integration of T-DNA into the LI
XX genome only, then back-crossed with LI and selection of products until
XX (A) are obtained. The method is used for introgression of several
XX transgenic characteristics into a plant. (I) may express an antisense
XX RNA, ribozyme or protein that confers resistance to disease or pathogens
XX and/or improves some agronomic or nutritional property. By selecting
XX primary transformants, the method allows introduction of genes without
XX additional fragments (representing a genetic burden) bound to the
XX transgene, i.e. it makes possible production of truly isogenic lines
XX which (I) can be transferred to a plant genome is increased, since the
XX number of backcrosses required is reduced and the genetic sources for
XX production of commercial hybrids is significantly broadened. The present
XX sequence represents a gene specific PCR primer for amplifying a left
XX border (LB) sequence (i.e. a GSPLB oligonucleotide) in an example from
XX the present invention
XX SQ Sequence 27 BP; 5 A; 9 C; 7 G; 6 T; 0 U; 0 Other;
Query Match 0.5%; Score 19; DB 1; Length 27;
Best Local Similarity 81.5%; Pred. No. 8e+02;
Matches 22; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 3639 GGGACAGCTGTCCCTTCCTTCCTGCAG 3665
Db 27 GAGCAGCTGAAGCTTCGATGCTGCAG 1

RESULT 455
AAQ33888
ID AAQ33888 standard; DNA; 22 BP.
```

```

XX AAQ33888;
XX AC
XX DT 25-MAR-2003 (revised)
XX DT 02-FEB-1993 (first entry)
XX DE Microsatellite sequence from clone TGLA306.
XX XX
XX KW PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
XX KW genetic mapping; traits; amplification; ss.
XX OS
XX OS Bos taurus.
XX XX
XX PN WO9213102-A1.
XX XX
XX PD 06-AUG-1992.
XX XX
XX PF 15-JAN-1992; 92WO-US000340.
XX XX
XX PR 15-JAN-1991; 91US-00642342.
XX XX
XX PA (GENM-) GENMARK.
XX XX
XX PI Georges M, Massey JM;
XX XX
XX DR WPI; 1992-284684/34.
XX XX
XX PT Polymorphic bovine DNA markers - used in genetic identification, gene
XX PT mapping, and selective breeding.
XX XX
XX PS Table 7; Page 285; 517pp; English.
XX CC
XX CC The sequence is that of a bovine microsatellite sequence obtd. by
XX CC screening a library of bovine MboI DNA fragments of between 250 and 500
XX CC bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
XX CC clones cross-hybridised. Assuming independent distribution of
XX CC microsatellites and MboI sites, the frequency of (TG)n >9 microsatellites
XX CC in the bovine genome is estimated at >100, 000. The sequence information
XX CC for ca. 230 such bovine microsatellites is summarised in the
XX CC specification and indexed herein (see below). The sequences upstream and
XX CC downstream of the microsatellite sequence were used to generate the
XX CC required PCR primers for in vitro amplification of the corresp.
XX CC microsatellite (using the program OPTIPRIM). The microsatellites may be
XX CC used to identify individuals, for parentage testing, and in the genetic
XX CC mapping of economic trait loci, or genes involved the determinism of
XX CC economically important traits esp. in cattle, to allow selective
XX CC breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
XX CC field.)
XX SQ Sequence 22 BP; 1 A; 0 C; 11 G; 10 T; 0 U; 0 Other;
XX
XX Query Match 0.5%; Score 18.8; DB 1; Length 22;
XX Best Local Similarity 90.9%; Pred. No. 6.7e+02;
XX Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 2330 TGTGCGTGTGTGTGTGTGTGTG 2351
XX | | | | | | | | | | | | | | | | | |
XX 1 TGTGCGTGTGTGTGTGTGTGTG 22
XX
XX RESULT 456
XX AAQ33716
XX ID AAQ33716 standard; DNA; 22 BP.
XX XX
XX AC AAQ33716;
XX XX
XX DT 25-MAR-2003 (revised)
XX DT 02-FEB-1993 (first entry)
XX XX
XX DE Microsatellite sequence from clone TGLA135.
XX XX
XX KW PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
XX KW genetic mapping; traits; amplification; ss.

```

```

XX OS Bos taurus.
XX XX
XX PN WO9213102-A1.
XX XX
XX PD 06-AUG-1992.
XX XX
XX PF 15-JAN-1992; 92WO-US000340.
XX XX
XX PR 15-JAN-1991; 91US-00642342.
XX XX
XX PA (GENM-) GENMARK.
XX XX
XX PI Georges M, Massey JM;
XX XX
XX DR WPI; 1992-284684/34.
XX XX
XX PT Polymorphic bovine DNA markers - used in genetic identification, gene
XX PT mapping, and selective breeding.
XX XX
XX PS Table 7; Page 216; 517pp; English.
XX CC
XX CC The sequence is that of a bovine microsatellite sequence obtd. by
XX CC screening a library of bovine MboI DNA fragments of between 250 and 500
XX CC bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
XX CC clones cross-hybridised. Assuming independent distribution of
XX CC microsatellites and MboI sites, the frequency of (TG)n >9 microsatellites
XX CC in the bovine genome is estimated at >100, 000. The sequence information
XX CC for ca. 230 such bovine microsatellites is summarised in the
XX CC specification and indexed herein (see below). The sequences upstream and
XX CC downstream of the microsatellite sequence were used to generate the
XX CC required PCR primers for in vitro amplification of the corresp.
XX CC microsatellite (using the program OPTIPRIM). The microsatellites may be
XX CC used to identify individuals, for parentage testing, and in the genetic
XX CC mapping of economic trait loci, or genes involved the determinism of
XX CC economically important traits esp. in cattle, to allow selective
XX CC breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
XX CC field.)
XX SQ Sequence 22 BP; 1 A; 0 C; 11 G; 10 T; 0 U; 0 Other;
XX
XX Query Match 0.5%; Score 18.8; DB 1; Length 22;
XX Best Local Similarity 90.9%; Pred. No. 6.7e+02;
XX Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 2316 TCTGTGTGTGTGTGTGTGTGTG 2337
XX | | | | | | | | | | | | | | | | | |
XX 1 TGTGTGTGTGTGTGTGTGTG 22
XX
XX RESULT 457
XX AAQ00035
XX ID AAQ00035 standard; DNA; 22 BP.
XX XX
XX AC AAQ00035;
XX XX
XX DT 16-MAR-1999 (first entry)
XX XX
XX DE FGFR-3 PCR sense primer.
XX XX
XX KW Neuroepithelial stem cell; lineage restricted intermediate precursor;
XX KW oligodendrocyte; astrocyte; self-renewal; neuron; differentiation;
XX KW neural crest cell; fibroblast growth factor; FGF; receptor; CNS;
XX KW central nervous system; glial cell; PCR primer; amplification; ss.
XX OS
XX OS Synthetic.
XX OS Homo sapiens.
XX XX
XX PN WO9850526-A1.
XX XX
XX PD 12-NOV-1998.
XX XX
XX PF 07-MAY-1998; 98WO-US009630.

```

XX 07-MAY-1997; 97US-00852744.
 PR 06-MAY-1998; 98US-00073881.
 XX (UTAH) UNIV UTAH RES FOUND.
 XX PA Rao MS, Mayer-Proschel M, Muftaba T;
 XX PI WPI; 1999-070093/06.
 XX DR Mammalian neuroepithelial stem cells and glial restricted precursor - can
 XX PT self renew and differentiate into central nervous system cells, used for
 XX PT generating various types of cells.
 XX PS Example 26; Page 58; 78pp; English.
 XX CC The present invention describes an isolated, pure population of mammalian
 CC neuroepithelial stem cells, which are capable of self-renewal in adherent
 CC feeder-cell-independent (AFCI) culture medium and differentiation to
 CC central nervous system (CNS) neuronal or glial cells and to neuronal
 CC crest stem cells. Also described is an isolated population of mammalian
 CC CNS glial-restricted precursor (GRP) cells which can self-renew in the
 CC AFCI culture medium and can differentiate to CNS glial cells but not to
 CC CNS neuronal cells. The stem cells can be used to generate a population
 CC of mammalian motor neurons by incubating the stem cells in a medium
 CC promoting cell proliferation and neuronal differentiation. The medium
 CC comprises laminin-coated plates and NRP medium lacking chick embryo
 CC extract. The stem cells can also produce neural crest stem cells by
 CC inducing the cells to differentiate in vitro. The inducing step comprises
 CC replating the cells on a laminin-coated substrate and preferably
 CC withdrawing a mitogen (preferably fibroblast growth factor; FGF) and
 CC chick embryo extract. Inducing can also comprise adding a dorsalizing
 CC agent to the cells, preferably a bone morphogenetic protein (BMP) such as
 CC BMP-2, -4 or -7. The stem cells can be used to produce cells of the
 CC peripheral nervous system, by inducing the stem cells to differentiate in
 CC vitro to neural crest stem cells, and inducing these cells to
 CC differentiate. AAX00029 to AAX00054 represent PCR primers which are used
 CC in an example from the present invention to amplify different FGF and
 CC FGFR genes
 XX SQ Sequence 22 BP; 5 A; 2 C; 9 G; 6 T; 0 U; 0 Other;
 Query Match 0.5%; Score 18.8; DB 1; Length 22;
 Best Local Similarity 90.9%; Pred. No. 6.7e+02;
 Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 409 AGCTTGTCATGGAACGCTGG 430
 DB 1 AGCTTGTCATGGAACGCTGG 22
 RESULT 458
 ABZ29984/C
 ID ABZ29984 standard; DNA; 22 BP.
 XX AC ABZ29984;
 XX DT 30-JAN-2003 (first entry)
 XX DE Candida albicans GRACE strain PCR primer SEQ ID NO 4135.
 XX KW Fungus; yeast; tetracycline; promoter; GRACE strain; biosynthesis;
 KW signal transduction; DNA replication; cell division; growth;
 KW proliferation; Candida albicans; fungicide; antifungal; PCR; primer; ss.
 XX OS Candida albicans.
 XX FN WO200253728-A2.
 XX PD 11-JUL-2002.
 XX PF 26-DEC-2001; 2001WO-US049486.

PR 29-DEC-2000; 2000US-0259128P.
 PR 20-FEB-2001; 2001US-00792024.
 PR 22-AUG-2001; 2001US-0314050P.
 XX (ELIT-) ELITRA PHARM INC.
 XX PA Roemer T, Jiang B, Boone C, Bussey H, Ohlsen KL;
 XX PI WPI; 2002-566694/60.
 XX DR Constructing strains for identifying gene products as effective targets
 XX PT for therapeutic intervention, by inactivating in the strain one allele of
 XX PT a gene and placing other allele of the gene under conditional expression.
 XX PS Claim 36; SEQ ID NO 4135; 167pp + Sequence Listing; English.
 XX CC The invention relates to constructing (M1) a strain of diploid fungal
 CC cells in which both alleles of a gene are modified, comprising modifying
 CC one allele by insertion or replacement by a cassette having an
 CC expressible selectable marker and modifying other allele by
 CC recombination, of a promoter replacement fragment with a heterologous
 CC promoter, so that expression of the second allele is regulated by the
 CC promoter. (M1) is useful for constructing a strain of diploid fungal
 CC cells in which both alleles of a gene are modified. The diploid fungal
 CC cells having both alleles modified are useful for identifying a gene that
 CC is essential to the survival or growth of a fungus, a gene that
 CC contributes to the virulence and/or pathogenicity of a fungus, a gene
 CC that contributes to the resistance of a diploid fungus to an antifungal
 CC agent, an antifungal agent that inhibits the growth of a diploid fungus
 CC and for identifying a therapeutic agent for treatment of a mammalian
 CC disease. (M1) is useful for identifying a compound which modulates the
 CC activity of a gene product, preferably enzymatic activity, carbon
 CC compound catabolism, biosynthetic, transporter, transcriptional,
 CC translational, signal transduction, DNA replication and cell division
 CC activity. The method is useful for identifying a compound having the
 CC ability to inhibit growth or proliferation of C. albicans cells and for
 CC treating infection by C. albicans. The present sequence is that of a PCR
 CC primer used in the method of the invention. Note: The sequence data for
 CC this patent is not represented in the printed specification but is based
 CC on sequence information supplied to Derwent by the European Patent Office
 XX SQ Sequence 22 BP; 9 A; 10 C; 2 G; 1 T; 0 U; 0 Other;
 Query Match 0.5%; Score 18.8; DB 1; Length 22;
 Best Local Similarity 90.9%; Pred. No. 6.7e+02;
 Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2322 TGTGTGTGTGTGCGTGTGTGTG 2343
 DB 22 TGTGTGTGTGTGCGTGTGTGTG 1
 RESULT 459
 AAA80357
 ID AAA80357 standard; DNA; 23 BP.
 XX AC AAA80357;
 XX DT 22-NOV-2000 (first entry)
 XX DE Human ASTH1I 5' region polymorphic site, SEQ ID NO:103 (a).
 XX KW ASTH1 locus; ASTH1I; ASTH1J; human; chromosome 11p; asthma;
 KW bronchial hyperreactivity; ets family; transcription factor;
 KW splice variant; genetic predisposition; polymorphism; antibody;
 KW drug screening; prophylaxis; therapy; diagnosis;
 KW single nucleotide polymorphism; SNP; ss.
 XX OS Homo sapiens.
 XX FH Key
 XX FT Location/Qualifiers
 XX FT replace(12..13,TGTGTA)
 XX FT /*tag= a

PR 18-MAR-1994; 94US-00214599.
XX (LYNX-) LYNX THERAPEUTICS INC.
XX Gryaznov SM, Schultz RG, Chen J;
XX WPI; 1995-344627/44.
XX
XX Oligo:nucleotide N3'-P5' phosphoramidate(s) - have improved resistance
XX toward phosphodiesterase digestion, and form stable duplexes with DNA and
XX RNA strands.
XX Disclosure; Page 54; 101pp; English.
XX The specification describes oligodeoxyribonucleotides having contiguous
XX nucleoside subunits joined by intersubunit linkages, where at least 3
XX contiguous subunits are joined by phosphoramidate intersubunits. The
XX oligodeoxyribonucleotides has a sequence of nucleoside subunits effective
XX to form a duplex with a target nucleic acid molecule. The
XX oligodeoxyribonucleotides are more resistant to nuclease digestion and
XX have improved RNA and dsDNA hybridisation characteristics, relative to
XX oligonucleotides not containing N3'-P5' phosphoramidate linkages. They
XX also have excellent antisense activity against complementary mRNA targets
XX in in-vitro cell growth inhibition assays. They also exhibit low
XX cytotoxicity. They may be used in diagnostic and therapeutic
XX applications, e.g., in combatting infectious agents such as bacteria,
XX viruses, etc. or in treatment of smooth muscle cell proliferation
XX disorders, inflammatory processes, certain genetic disorders, cancers,
XX etc. . The present sequence represents an oligonucleotide of the invention
XX
SQ Sequence 24 BP; 10 A; 0 C; 0 G; 14 T; 0 U; 0 Other;

Query Match 0.5%; Score 18.8; DB 1; Length 24;
Best Local Similarity 90.9%; Pred. No. 7.4e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2823 TATATATACATATATATATATA 2844
DB 22 TATATATAAAATATATATATA 1

RESULT 462
AAV59721/C
ID AAX59721 standard; DNA; 24 BP.
XX AC AAX59721;
XX DT 22-JUL-1999 (first entry)
XX DE Modified oligonucleotide containing N3'-P5' phosphoramidates.
XX KW Oligodeoxyribonucleotide; intersubunit linkage;
XX KW phosphoramidate intersubunit; antisense activity; nuclease resistant;
XX KW in-vitro cell growth inhibition assay; infection;
XX KW smooth muscle cell proliferation disorder; inflammatory process;
XX KW genetic disorder; cancer; ss.
XX OS Synthetic.
XX FH Key Location/Qualifiers
XX modified_base 1. .10
XX /+tag= a
XX /note= "each base is linked by N3'-P5' phosphoramidate
XX linkages"
XX modified_base 15. .24
XX /+tag= a
XX /note= "each base is linked by N3'-P5' phosphoramidate
XX linkages"
XX WO9525814-A1.
XX 28-SEP-1995.
XX

PF 20-MAR-1995; 95WO-US003575.
XX
XX 18-MAR-1994; 94US-00210505.
XX 18-MAR-1994; 94US-00214599.
XX (LYNX-) LYNX THERAPEUTICS INC.
XX PA Gryaznov SM, Schultz RG, Chen J;
XX PI WPI; 1995-344627/44.
XX DR Oligo:nucleotide N3'-P5' phosphoramidate(s) - have improved resistance
XX toward phosphodiesterase digestion, and form stable duplexes with DNA and
XX RNA strands.
XX Disclosure; Page 57; 101pp; English.
XX The specification describes oligodeoxyribonucleotides having contiguous
XX nucleoside subunits joined by intersubunit linkages, where at least 3
XX contiguous subunits are joined by phosphoramidate intersubunits. The
XX oligodeoxyribonucleotides has a sequence of nucleoside subunits effective
XX to form a duplex with a target nucleic acid molecule. The
XX oligodeoxyribonucleotides are more resistant to nuclease digestion and
XX have improved RNA and dsDNA hybridisation characteristics, relative to
XX oligonucleotides not containing N3'-P5' phosphoramidate linkages. They
XX also have excellent antisense activity against complementary mRNA targets
XX in in-vitro cell growth inhibition assays. They also exhibit low
XX cytotoxicity. They may be used in diagnostic and therapeutic
XX applications, e.g., in combatting infectious agents such as bacteria,
XX viruses, etc. or in treatment of smooth muscle cell proliferation
XX disorders, inflammatory processes, certain genetic disorders, cancers,
XX etc. . The present sequence represents an oligonucleotide of the invention
XX
SQ Sequence 24 BP; 10 A; 0 C; 0 G; 14 T; 0 U; 0 Other;

Query Match 0.5%; Score 18.8; DB 1; Length 24;
Best Local Similarity 90.9%; Pred. No. 7.4e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2823 TATATATACATATATATATATA 2844
DB 22 TATATATAAAATATATATATA 1

RESULT 463
AAV26338/C
ID AAV26338 standard; DNA; 24 BP.
XX AC AAV26338;
XX DT 07-AUG-1998 (first entry)
XX DE Human prostate cancer marker UC Band #210 identifying RT-PCR primer 1.
XX KW Prostate cancer; human; marker; diagnosis; treatment; RT-PCR primer; ss.
XX OS Synthetic.
XX OS Homo sapiens.
XX PN WO9804689-A1.
XX PD 05-FEB-1998.
XX PF 31-JUL-1996; 96WO-US012516.
XX PR 31-JUL-1996; 96WO-US012516.
XX PA (UROC-) UROCOR INC.
XX PI Veltri R, Ohara SM, An G, Ralph D;
XX DR WPI; 1998-130681/12.
XX

PT Human prostate cancer marker - useful for detection and treatment of
 PT human prostate cancer.
 PS Example 4; Page 121; 229pp; English.
 XX
 XX This primer is used in the relative quantitative RT-PCR to examine the
 CC expression of the genes which is used for the identification of markers
 CC of human prostate cancer. Isolated nucleic acid segments shown in
 CC AAV16881 to AAV16885, AAV16890 to AAV16903, AAV26351 and AAV26352 which
 CC can act as human prostate cancer markers are provided in the
 CC specification. The specification also provides methods for identifying
 CC markers for human prostate cancer and for detection of prostate cancer
 CC cells. The markers can be identified by amplifying human prostate RNA to
 CC provide nucleic acid amplification products, separating the products and
 CC identifying those RNA that are differentially expressed between human
 CC prostate cancers versus normal or benign human prostate. Prostate cancer
 CC cells in a sample can be detected by detecting a nucleic acid in a
 CC sample, the nucleic acid being a prostate cancer marker. Primers and
 CC probes derived from this marker can be used for the detection of prostate
 CC cancer cells in a sample. Antibodies against the protein encoded by the
 CC marker nucleic acid fragments, inhibitors of the protein and
 CC oligonucleotides antisense to the markers can be used in the treatment of
 CC prostate cancer. The antibodies can also be used for the diagnosis of
 CC human prostate cancer
 XX
 SQ Sequence 24 BP; 11 A; 10 C; 2 G; 1 T; 0 U; 0 Other;
 Query Match 0.5%; Score 18.8; DB 1; Length 24;
 Best Local Similarity 90.9%; Pred. No. 7.4e+02;
 Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2329 GTGTCGCTGTGTGTGTGTGT 2350
 DB 22 GTGTCATGTGTGTGTGTGT 1
 ||||| ||||| ||||| ||||| |||||
 RESULT 464
 AAX26085/c
 ID AAX26085 standard; DNA; 24 BP.
 XX
 AC AAX26085;
 XX
 DT 20-MAY-1999 (first entry)
 XX
 DE Prostate disease marker gene fragment amplifying RT-PCR primer.
 XX
 KW Prostate cancer; benign prostatic hyperplasia; marker gene; tumour;
 KW differentiation; Reverse Transcription Polymerase Chain Reaction;
 KW diagnostic; progression; cancer; metastasis; RT-PCR; primer; ss.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN US582864-A.
 XX
 PD 16-MAR-1999.
 XX
 PP 31-JUL-1996; 96US-00692787.
 XX
 PR 31-JUL-1995; 95US-0001655P.
 XX
 PA (UROC-) UROC INC.
 XX
 PI Veltri R, Ralph D, An G, O'hara SM;
 XX
 DR WPI; 1999-214055/18.
 XX
 XX Diagnosing prostate cancer and benign prostatic hyperplasia cells - using
 PT oligonucleotide probes specific for marker genes associated with tumor
 PT differentiation and progression in Reverse Transcription Polymerase Chain
 PT Reaction analysis.
 XX
 PS Example 4; Col 66; 74pp; English.

XX The invention relates to methods for diagnosing prostate cancer or benign
 CC prostatic hyperplasia cells in a biological sample. The method uses
 CC oligonucleotides specific for marker genes associated with tumour
 CC differentiation and progression in Reverse Transcription Polymerase Chain
 CC Reaction (RT-PCR) analysis. The methods are diagnostic techniques useful
 CC for detecting and monitoring the progression of benign prostatic
 CC hyperplasia and human prostate cancer (the most prevalent form of cancer
 CC and a major cause of death in males) prior to the tumor undergoing
 CC metastasis, therefore allowing the optimal method of treatment to be
 CC determined before the condition becomes life threatening
 XX
 SQ Sequence 24 BP; 11 A; 10 C; 2 G; 1 T; 0 U; 0 Other;
 Query Match 0.5%; Score 18.8; DB 1; Length 24;
 Best Local Similarity 90.9%; Pred. No. 7.4e+02;
 Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2329 GTGTCGCTGTGTGTGTGTGT 2350
 DB 22 GTGTCATGTGTGTGTGTGT 1
 ||||| ||||| ||||| ||||| |||||
 RESULT 465
 AAZ87571/c
 ID AAZ87571 standard; DNA; 24 BP.
 XX
 AC AAZ87571;
 XX
 DT 19-APR-2000 (first entry)
 XX
 DE Primer specific for cancer biomarker UC Band #210.
 XX
 KW Nucleic acid marker; biomarker; tumour; prostate cancer; bladder cancer;
 KW benign prostatic hyperplasia; BPH; breast cancer; human; immunodetection;
 KW diagnosis; PCR primer; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO9964631-A1.
 XX
 PD 16-DEC-1999.
 XX
 PP 11-JUN-1999; 99WO-US013151.
 XX
 PR 12-JUN-1998; 98US-00097199.
 XX
 PA (UROC-) UROC INC.
 XX
 PI An G, O'hara SM, Ralph D, Veltri RW;
 XX
 DR WPI; 2000-116557/10.
 XX
 PT Novel RNA biomarkers for diagnosis, prognosis and management of prostate,
 PT breast and bladder cancer.
 XX
 PS Example 2; Page 111; 191pp; English.
 XX
 XX The invention provides nucleic acid markers of prostate, breast and
 CC bladder cancer. The markers are indicators of malignant transformation of
 CC prostate, breast and bladder tissues and are diagnostic of the potential
 CC for metastatic spread of malignant prostate tumours. The nucleic acid can
 CC also be used as targets for therapeutic intervention in prostate cancer,
 CC benign prostatic hyperplasia (BPH), bladder cancer or breast cancer. The
 CC markers may be used to design specific probes and primers, for the rapid
 CC analysis of prostate, bladder or breast biopsy samples. The probes and
 CC primers may also be used for in situ hybridization or in situ PCR
 CC detection and diagnosis. They may also be used to identify and isolate
 CC full length gene sequences from various DNA libraries. Antibodies against
 CC the polypeptide products of the markers can be used to treat prostate
 CC cancer, bladder cancer or breast cancer. The encoded proteins may be used
 CC to detect antibodies. The proteins and antibodies can be used in
 CC immunodetection methods for detecting or quantifying the cancers, and for

CC clinical diagnosis of these cancers. The antibodies may also be used for
CC radioimaging to quantify and localize the encoded proteins
XX
SQ Sequence 24 BP; 11 A; 10 C; 2 G; 1 T; 0 U; 0 Other;
Query Match 0.5%; Score 18.8; DB 1; Length 24;
Best Local Similarity 90.9%; Pred. No. 7.4e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2329 GTGTGCGTGTGTGTGTGTGTGT 2350
DB 22 GTGTGATGTGTGTGTGTGTGTGT 1
RESULT 466
AAS03988/c
ID AAS03988 standard; DNA; 24 BP.
XX
AC AAS03988;
XX
DT 29-AUG-2001 (first entry)
XX
DE Biomarker UC band 210 primer #1 used in diagnosis/prognosis of cancer.
XX
KW Prostate; breast; bladder; cancer; biomarker; probe; diagnostic;
KW benign prostatic hyperplasia; BPH; therapeutic; human; primer; ss.
XX
OS Homo sapiens.
XX
PN US6218529-B1.
XX
PD 17-APR-2001.
XX
PF 12-JUN-1998; 98US-00097199.
XX
PR 31-JUL-1995; 95US-0001655P.
PR 11-JAN-1996; 96US-0013611P.
PR 31-JUL-1996; 96US-00692787.
XX
PA (UROC-) UROC INC.
XX
PI An G, O'hara SM, Ralph D, Veltri R;
XX
XX WPI; 2001-289845/30.
XX
DR New nucleic acids as biomarkers and targets useful for detecting,
XX diagnosing, prognosing, and in developing treatments for prostate, breast
XX and bladder cancer.
XX
PS Example 4; Col 71; 78pp; English.
XX
CC The sequence represents nucleic acid biomarker UC band 210 primer #1,
CC used in detection of prostate, breast and bladder cancer. Biomarker
CC nucleic acid sequences can be used as hybridisation probes and primers
CC that specifically hybridise to prostate cancer, benign prostatic
CC hyperplasia (BPH), bladder cancer or breast cancer markers. Proteins
CC encoded by the nucleic acid markers can be used to produce antibodies for
CC the detection of prostate, breast or bladder cancer. The nucleic acids
CC can be used as targets for therapeutic intervention in these diseases, in
CC the identification and isolation of full-length gene sequences, including
CC regulatory elements for gene expression, from genomic human DNA
CC libraries. The kits comprising the nucleic acid sequences are useful for
CC detecting bladder, breast or prostate cancer cells in a biological sample
XX
SQ Sequence 24 BP; 11 A; 10 C; 2 G; 1 T; 0 U; 0 Other;
Query Match 0.5%; Score 18.8; DB 1; Length 24;
Best Local Similarity 90.9%; Pred. No. 7.4e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2329 GTGTGCGTGTGTGTGTGTGTGT 2350
DB 22 GTGTGATGTGTGTGTGTGTGTGT 1

Db 22 GTGTGATGTGTGTGTGTGTGTGT 1
RESULT 467
ACI77097/c
ID ACI77097 standard; DNA; 25 BP.
XX
AC ACI77097;
XX
DT 14-OCT-2003 (first entry)
XX
DE Human microarray DNA oligonucleotide SEQ ID NO 77088.
XX
KW EST; ss; probe; expressed sequence tag; microarray; gene expression;
KW genetic variation; biallelic marker; polymorphism; human;
KW cross-species comparison.
XX
OS Homo sapiens.
XX
PN US2003104410-A1.
XX
PD 05-JUN-2003.
XX
PF 15-MAR-2002; 2002US-00098263.
XX
PR 16-MAR-2001; 2001US-0276759P.
XX
PA (APFY-) AFFYMETRIX INC.
XX
PI Mittmann MP;
XX
DR WPI; 2003-567953/53.
XX
PT New array of nucleic acid probes, useful for in situ hybridization, in
PT Southern, Northern or dot-blot hybridization to identify or detect the
PT sequence or specific mutations of any gene.
XX
PS Claim 1; SEQ ID NO 77088; 9pp; English.
XX
CC The invention discloses a microarray comprising a plurality of nucleic
CC acid probes including one of 2,018,500 fully defined sequences, or its
CC perfect match, perfect mismatch, antisense match or antisense mismatch.
CC Also disclosed is a method of gene expression analysis. The array is used
CC in monitoring gene expression levels by hybridisation to a DNA library,
CC in analysis of genetic variation or in hybridisation of tag-labelled
CC compounds. The nucleic acid probes are specifically designed for analysis
CC of at least one target sequence. The method of analysis comprises
CC hybridising at least one or more nucleic acids to at least two or more
CC nucleic acid probes and detecting the hybridisation. The nucleic acid
CC probes are attached to a solid support. The analysis comprises monitoring
CC gene expression levels, identifying biallelic markers or polymorphisms,
CC or family members of a gene and a cross-species comparison. Each of the
CC nucleic acids further comprises a tag sequence. The array of nucleic acid
CC probes is useful in situ hybridisation, in Southern, Northern or dot-
CC blot hybridisation to identify or detect the sequence or specific
CC mutations of any gene, in mapping the 5' termini of mRNA molecules by
CC primer extensions or in screening cDNA or genomic libraries or subclones
CC for additional subclones containing segments of DNA that have been
CC isolated and previously sequenced. The sequence presented is one of the
CC nucleic acid probes incorporated in the microarray. Note: The sequence
CC data for this patent can also be obtained in electronic format directly
CC from USPTO at seqdata.uspto.gov/sequence.html
XX
SQ Sequence 25 BP; 4 A; 9 C; 8 G; 4 T; 0 U; 0 Other;
Query Match 0.5%; Score 18.8; DB 1; Length 25;
Best Local Similarity 90.9%; Pred. No. 7.8e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2569 CACGGACATCACAGGTCGCC 2590
DB 22 CACGGACGTCACAGGTCGCC 1


```

XX AC AAS13762;
XX DT 08-MAY-2002 (first entry)
XX DE Simple sequence repeat, SSR, #34.
XX KW Simple sequence repeat; plant; ds; SSR; ryegrass; fescue; tandem repeat;
XX KW cereal profiling; grass profiling; seed batch purity testing.
XX OS Lolium perenne.
XX PN NZ509193-A.
XX PD 25-MAY-2001.
XX PF 03-JAN-2001; 2001NZ-00509193.
XX PR 24-DEC-1999; 99AU-00004906.
XX PR 04-MAY-2000; 2000AU-00007310.
XX PA (SAUS-) STATE SOUTH AUSTRALIA SOUTH AUSTRALIAN R.
XX PA (UYSC-) UNIV SOUTHERN CROSS.
XX PA (VICT-) STATE VICTORIA DEPT NATURAL RES & ENVIRO.
XX PA (UYAD-) UNIV ADELAIDE.
XX PA (ITMA-) INT MAIZE & WHEAT IMPROVEMENT CENT.
XX PI Forster JW, Jones ES;
XX DR WPI; 2001-512563/56.
XX PT New simple sequence repeats having 2 or more tandemly repeated nucleotide
XX PT core elements isolated from ryegrass and fescue, useful for selecting of
XX PT genes in grass or cereal breeding or profiling grass or cereal species
XX PT varieties.
XX PS Example 1; Fig 6; 72pp; English.
XX CC The invention relates to a substantially purified or isolated nucleic
XX CC acid (I) from ryegrass or fescue species including a simple sequence
XX CC repeat (SSR), having 2 or more tandemly repeated nucleotide core elements
XX CC 2-6 nucleotides in length. Also included are a nucleic acid primer
XX CC suitable for amplifying an SSR, identifying (M1) an SSR by preparing a
XX CC library of ryegrass or fescue genomic DNA enriched for SSRs and
XX CC identifying clones in the library containing SSRs, a library of ryegrass
XX CC or fescue genomic DNA enriched for SSRs prepared by the M1, selecting for
XX CC a gene in grass or cereal breeding by identifying an SSR that is closely
XX CC associated with the gene such that the SSR and the gene are
XX CC preferentially co-inherited, and selecting for the SSR in the breeding, a
XX CC method for DNA profiling grass or cereal species varieties by assessing
XX CC variation between SSR varieties and testing the purity of grass or cereal
XX CC seed batches by assessing variation within seed batch of an SSR. The SSRs
XX CC may be used in the selection of genes in grass or cereal breeding, for
XX CC profiling grass or cereal species varieties, for testing the purity of
XX CC grass or cereal seed batches, and for DNA profiling to establish the
XX CC distinct identity, uniformity and/or stability of a cultivar. The present
XX CC sequence is a ryegrass or fescue SSR
XX SQ Sequence 20 BP; 0 A; 0 C; 10 G; 10 T; 0 U; 0 Other;

Query Match 0.5%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.7e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2319 GTGTGTGTGTGTGTGTGTGTGTGTGTGT 2338
DB 1 GTGTGTGTGTGTGTGTGTGTGTGTGTGT 20

RESULT 483
AAS13705/c
ID AAS13705 standard; DNA; 20 BP.
XX

```

```

AC AAS13705;
XX DT 08-MAY-2002 (first entry)
XX DE Simple sequence repeat, SSR, #2.
XX KW Simple sequence repeat; plant; ds; SSR; ryegrass; fescue; tandem repeat;
XX KW cereal profiling; grass profiling; seed batch purity testing.
XX OS Poa.
XX PN NZ509193-A.
XX PD 25-MAY-2001.
XX PF 03-JAN-2001; 2001NZ-00509193.
XX PR 24-DEC-1999; 99AU-00004906.
XX PR 04-MAY-2000; 2000AU-00007310.
XX PA (SAUS-) STATE SOUTH AUSTRALIA SOUTH AUSTRALIAN R.
XX PA (UYSC-) UNIV SOUTHERN CROSS.
XX PA (VICT-) STATE VICTORIA DEPT NATURAL RES & ENVIRO.
XX PA (UYAD-) UNIV ADELAIDE.
XX PA (ITMA-) INT MAIZE & WHEAT IMPROVEMENT CENT.
XX PI Forster JW, Jones ES;
XX DR WPI; 2001-512563/56.
XX PT New simple sequence repeats having 2 or more tandemly repeated nucleotide
XX PT core elements isolated from ryegrass and fescue, useful for selecting of
XX PT genes in grass or cereal breeding or profiling grass or cereal species
XX PT varieties.
XX PS Claim 6; Page 51; 72pp; English.
XX CC The invention relates to a substantially purified or isolated nucleic
XX CC acid (I) from ryegrass or fescue species including a simple sequence
XX CC repeat (SSR), having 2 or more tandemly repeated nucleotide core elements
XX CC 2-6 nucleotides in length. Also included are a nucleic acid primer
XX CC suitable for amplifying an SSR, identifying (M1) an SSR by preparing a
XX CC library of ryegrass or fescue genomic DNA enriched for SSRs and
XX CC identifying clones in the library containing SSRs, a library of ryegrass
XX CC or fescue genomic DNA enriched for SSRs prepared by the M1, selecting for
XX CC a gene in grass or cereal breeding by identifying an SSR that is closely
XX CC associated with the gene such that the SSR and the gene are
XX CC preferentially co-inherited, and selecting for the SSR in the breeding, a
XX CC method for DNA profiling grass or cereal species varieties by assessing
XX CC variation between SSR varieties and testing the purity of grass or cereal
XX CC seed batches by assessing variation within seed batch of an SSR. The SSRs
XX CC may be used in the selection of genes in grass or cereal breeding, for
XX CC profiling grass or cereal species varieties, for testing the purity of
XX CC grass or cereal seed batches, and for DNA profiling to establish the
XX CC distinct identity, uniformity and/or stability of a cultivar. The present
XX CC sequence is a ryegrass or fescue SSR
XX SQ Sequence 20 BP; 10 A; 10 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 0.5%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.7e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2318 TGTGTGTGTGTGTGTGTGTGTGTGTGTGT 2337
DB 20 TGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1

RESULT 484
AAH75569
ID AAH75569 standard; DNA; 20 BP.
XX
XX AC AAH75569;

```

XX DT 06-NOV-2001 (first entry)
 XX DE Mre11 related probe.
 XX DE Yeast; Mre11; telomere length; nuclease; gene therapy; melanoma; ss;
 XX KW liver cancer; breast cancer; bladder cancer; brain cancer; prostate.
 XX OS Synthetic.
 XX PN WO200160996-A1.
 XX PD 23-AUG-2001.
 XX PF 14-FEB-2001; 2001WO-JP001024.
 XX PR 18-FEB-2000; 2000JP-00041929.
 XX PA (RIKE) RIKEN KK.
 XX PA (NISC-) JAPAN SCI & TECHNOLOGY CORP.
 XX PI Ohta K, Shibata T;
 XX DR WPI; 2001-541649/60.
 XX PT Controlling telomere length for gene therapy of telomere length related
 XX PT tumors comprises transformation using the modified Mre11 protein.
 XX PS Example 3; Page 16; 67pp; Japanese.
 XX CC The invention relates to control of telomere length in a cell by
 XX CC modifying the physiological activity of the Mre11 protein in the cell, by
 XX CC transformation of the cell with DNA encoding a foreign Mre11 protein
 XX CC which may be modified in the C-terminal and/or nuclease domain. The
 XX CC method is useful in gene therapy of telomere length-related diseases such
 XX CC as melanoma, liver cancer, breast cancer, bladder cancer and brain
 XX CC cancer. The present sequence is that of a Mre11 related probe of the
 XX CC invention
 XX SQ Sequence 20 BP; 0 A; 0 C; 10 G; 10 T; 0 U; 0 Other;
 Query Match 0.5%; Score 18.4; DB 1; Length 20;
 Best Local Similarity 95.0%; Pred. No. 6.7e+02;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2319 GTGTGTGTGTGTGTGTGTGTGTGTGT 2338
 DB 1 GTGTGTGTGTGTGTGTGTGTGTGTGT 20
 RESULT 485
 AAF62932/C
 ID AAF62932 standard; DNA; 20 BP.
 XX AC AAF62932;
 XX DT 08-MAY-2001 (first entry)
 XX DE Human PEPCCK-cytosolic antisense oligonucleotide ISIS 108106.
 XX KW Human; antiinflammatory; cytostatic; antisense gene therapy;
 XX KW phosphoenol pyruvate carboxykinase-cytosolic; PEPCCK-cytosolic; infection;
 XX KW inflammation; tumour formation; phosphorothioate; ss.
 XX OS Homo sapiens.
 XX PN US6187545-B1.
 XX PD 13-FEB-2001.
 XX PF 21-JAN-2000; 2000US-00488671.
 XX PR 21-JAN-2000; 2000US-00488671.

XX PA (ISIS-) ISIS PHARM INC.
 XX PI McKay R, Butler MM, Wyatt J, Cowsert LM;
 XX DR WPI; 2001-190979/19.
 XX PT Antisense compound capable of modulating the expression of phosphoenol
 XX PT pyruvate carboxykinase-cytosolic, useful for preventing or delaying
 XX PT infection, inflammation or tumor formation.
 XX PS Claim 1; Col 43; 64pp; English.
 XX CC The present sequence is one of a number of antisense compounds of up to
 XX CC 30 nucleobases in length that are capable of inhibiting the expression of
 XX CC phosphoenol pyruvate carboxykinase-cytosolic (PEPCCK-cytosolic). The
 XX CC antisense compounds are useful for inhibiting the expression of PEPCCK-
 XX CC cytosolic in cells or tissues. They are commonly used as research
 XX CC reagents and in diagnostics, e.g. to elucidate the function of particular
 XX CC genes. They are also useful for distinguishing between functions of
 XX CC various members of a biological pathway and for research use. The
 XX CC antisense compounds are also useful prophylactically, e.g. to prevent or
 XX CC delay infection, inflammation or tumour formation. The present sequence
 XX CC is a chimeric phosphorothioate oligonucleotide with 2'-MOE wings and a
 XX CC deoxy gap
 XX SQ Sequence 20 BP; 10 A; 10 C; 0 G; 0 T; 0 U; 0 Other;
 Query Match 0.5%; Score 18.4; DB 1; Length 20;
 Best Local Similarity 95.0%; Pred. No. 6.7e+02;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2319 GTGTGTGTGTGTGTGTGTGTGTGTGT 2338
 DB 20 GTGTGTGTGTGTGTGTGTGTGTGTGT 1
 RESULT 486
 AAF28355/C
 ID AAF28355 standard; DNA; 20 BP.
 XX AC AAF28355;
 XX DT 02-APR-2001 (first entry)
 XX DE DNA oligomer #5.
 XX KW Deoxynucleic S-Methylthiouracil; DNmt; antisense therapy;
 XX KW cardiovascular disease; inflammatory disease; neurocellular disease;
 XX KW antiviral therapy; human immunodeficiency virus; human-cytomegalovirus;
 XX KW influenza; herpes; infection; ss.
 XX OS Unidentified.
 XX PN US6169176-B1.
 XX PD 02-JAN-2001.
 XX PF 28-SEP-1999; 99US-00407675.
 XX PR 02-JUL-1998; 98US-0091481P.
 XX PR 11-DEC-1998; 98US-0111800P.
 XX PR 02-JUL-1999; 99US-00347443.
 XX PA (REGC) UNIV CALIFORNIA.
 XX PI Dev AP, Bruice TC;
 XX DR WPI; 2001-122276/13.
 XX PT Preparing novel deoxynucleic alkyl thiourea oligonucleotide for use in
 XX PT antisense therapy, by synthesizing oligonucleotides comprising backbone
 XX PT of alkyl or alkoxy thiourea linkages in solution or on solid phase.


```
RESULT 489
AAI64449
ID AAI64449 standard; DNA; 20 BP.
XX
XX AC AAI64449;
XX
XX DT 23-NOV-2001 (first entry)
XX
XX DE SSR motif #9.
XX
XX KW Simple Sequence Repeat; SSR; clover; microsatellite; genome mapping;
XX KW trait mapping; marker-assisted selection; gene selection; legume;
XX KW DNA profiling; breeding; ds.
XX
XX OS Unidentified.
XX
XX PN NZ509194-A.
XX
XX PD 25-MAY-2001.
XX
XX PF 03-JAN-2001; 2001NZ-00509194.
XX
XX PR 24-DEC-1999; 99AU-00004907.
XX PR 28-MAR-2000; 2000AU-00006520.
XX
XX PA (AGRI-) AGRIC VICTORIA SERVICES PTY LTD.
XX
XX PI Koelliker R, Forster JW;
XX
XX DR WPI; 2001-431058/46.
XX
XX PT Novel simple sequence repeats in clover species useful for selection of
XX PT genes in legume breeding, for profiling legume species varieties and for
XX PT testing the purity of legume seed batches.
XX
XX PS Claim 6; Page 35; 52pp; English.
XX
XX CC The present invention relates to Simple Sequence Repeats (SSRs) from
XX CC clover species. SSRs, also called microsatellites, are based on a 1-7
XX CC nucleotide core element which is tandemly repeated. The SSR array is
XX CC embedded in complex flanking DNA. SSRs are ideal markers for genome
XX CC mapping, trait mapping and marker-assisted selection. The SSRs may be
XX CC used in methods for selecting genes in clover/ legume breeding. The SSRs
XX CC are also useful for DNA profiling of clover varieties and for testing the
XX CC purity of legume seed batches. The present sequence is a SSR motif, which
XX CC was used in the present invention
XX
XX SQ Sequence 20 BP; 0 A; 0 C; 10 G; 10 T; 0 U; 0 Other;
Query Match 0.5%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.7e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

XX
XX DT 16-JAN-2003 (first entry)
XX
XX DE Human uridine diphosphate glucuronosyltransferase gene polymorphism #1.
XX
XX KW Human; polymorphism; TA repeat; ds; UGT; thymidine-adenine repeat;
XX KW uridine diphosphate glucuronosyltransferase gene promoter; UGT1A1;
XX KW drug dosage optimisation; xenobiotic sensitivity.
XX
XX OS Homo sapiens.
XX
XX PN AAL50667
XX ID AAL50667 standard; DNA; 20 BP.
XX
XX AC AAL50667;
XX
XX DT 16-JAN-2003 (first entry)
XX
XX DE Human uridine diphosphate glucuronosyltransferase gene polymorphism #1.
XX
XX KW Human; polymorphism; TA repeat; ds; UGT; thymidine-adenine repeat;
XX KW uridine diphosphate glucuronosyltransferase gene promoter; UGT1A1;
XX KW drug dosage optimisation; xenobiotic sensitivity.
XX
XX OS Homo sapiens.

RESULT 490
AAL50667
ID AAL50667 standard; DNA; 20 BP.
XX
XX AC AAL50667;
XX
XX DT 16-JAN-2003 (first entry)
XX
XX DE Human uridine diphosphate glucuronosyltransferase gene polymorphism #1.
XX
XX KW Human; polymorphism; TA repeat; ds; UGT; thymidine-adenine repeat;
XX KW uridine diphosphate glucuronosyltransferase gene promoter; UGT1A1;
XX KW drug dosage optimisation; xenobiotic sensitivity.
XX
XX OS Homo sapiens.
```

```
XX
XX PN US2002115097-A1.
XX
XX PD 22-AUG-2002.
XX
XX PF 01-FEB-2002; 2002US-00061693.
XX
XX PR 16-FEB-1999; 99US-00251274.
XX
XX PA (ARCH-) ARCH DEV CORP.
XX
XX RI Rienzo AD, Iyer L, Ratain MJ;
XX WI WPI; 2002-740095/80.
XX
XX PT Detecting polymorphisms in uridine diphosphate glucuronosyltransferase
XX PT gene promoter, useful for optimizing drug dosages for a patient, involves
XX PT determining number of thymidine-adenine repeats in the promoter.
XX
XX PS Claim 8; Page 9; 13pp; English.
XX
XX CC The invention comprises a method for detecting polymorphisms in a uridine
XX CC diphosphate glucuronosyltransferase (UGT) gene promoter (preferably
XX CC UGT1A1). The method involves determining the number of thymidine-adenine
XX CC (TA) repeats in the promoter - as the number of TA repeats correlates
XX CC with expression of the UGT gene. The method of the invention is useful
XX CC for detecting polymorphisms in a UGT gene promoter. The method of the
XX CC invention is also useful in optimising drug dosages and predicting an
XX CC individual's sensitivity to xenobiotics for drugs and xenobiotics that
XX CC are glucuronidated by UGT. The present DNA sequence represents a UGT gene
XX CC TA repeat polymorphism
XX
XX SQ Sequence 20 BP; 10 A; 0 C; 0 G; 10 T; 0 U; 0 Other;
Query Match 0.5%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.7e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

XX
XX QY 2823 TATATATACATATATATATATA 2842
XX DB 1 TATATATATATATATATATA 20
XXXXXXXXXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXXXXXXXXX

RESULT 491
AAL50667/c
ID AAL50667 standard; DNA; 20 BP.
XX
XX AC AAL50667;
XX
XX DT 16-JAN-2003 (first entry)
XX
XX DE Human uridine diphosphate glucuronosyltransferase gene polymorphism #1.
XX
XX KW Human; polymorphism; TA repeat; ds; UGT; thymidine-adenine repeat;
XX KW uridine diphosphate glucuronosyltransferase gene promoter; UGT1A1;
XX KW drug dosage optimisation; xenobiotic sensitivity.
XX
XX OS Homo sapiens.
XX
XX PN US2002115097-A1.
XX
XX PD 22-AUG-2002.
XX
XX PF 01-FEB-2002; 2002US-00061693.
XX
XX PR 16-FEB-1999; 99US-00251274.
XX
XX PA (ARCH-) ARCH DEV CORP.
XX
XX RI Rienzo AD, Iyer L, Ratain MJ;
XX WI WPI; 2002-740095/80.
XX
```

```
PT Detecting polymorphisms in uridine diphosphate glucuronosyltransferase
PT gene promoter, useful for optimizing drug dosages for a patient, involves
PT determining number of thymidine-adenine repeats in the promoter.
XX
PS Claim 8; Page 9; 13pp; English.
XX
CC The invention comprises a method for detecting polymorphisms in a uridine
CC diphosphate glucuronosyltransferase (UGT) gene promoter (preferably
CC UGT1A1). The method involves determining the number of thymidine-adenine
CC (TA) repeats in the promoter - as the number of TA repeats correlates
CC with expression of the UGT gene. The method of the invention is useful
CC for detecting polymorphisms in a UGT gene promoter. The method of the
CC invention is also useful in optimising drug dosages and predicting an
CC individual's sensitivity to xenobiotics for drugs and xenobiotics that
CC are glucuronidated by UGT. The present DNA sequence represents a UGT gene
CC TA repeat polymorphism
XX
SQ Sequence 20 BP; 10 A; 0 C; 0 G; 10 T; 0 U; 0 Other;

Query Match      0.5%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.7e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2823 TATATACATATATATA 2842
DB 20 TATATATATATATATATA 1

RESULT 492
AAL45125
ID AAL45125 standard; DNA; 20 BP.
XX
AC AAL45125;
XX
DT 24-MAY-2002 (first entry)
XX
DE Oligonucleotide synthesis method related DNA #4.
XX
KW Oligonucleotide synthesis; polynucleotide array; protecting group;
XX oxidation; ss.
XX
OS Synthetic.
XX
PN EP1176151-A1.
XX
PD 30-JAN-2002.
XX
PF 27-JUL-2001; 2001EP-00118360.
XX
PR 28-JUL-2000; 2000US-00627249.
XX
PA (AGIL-) AGILENT TECHNOLOGIES INC.
XX
PI Dellinger DJ, Perbost MGM, Betley JR, Caruthers M;
XX
DR WPI; 2002-156732/21.
XX
PT Synthesis of polynucleotide useful during fabrication of an array
PT involves coupling nucleoside phosphoramidite and a solid-supported
PT nucleoside and treating the product with an oxidation/deprotection
PT composition.
XX
PS Example 1; Page 15; 36pp; English.
XX
CC The present invention relates to a method for the synthesis of a
CC polynucleotide which involves coupling a second nucleoside to a first
CC nucleoside through a phosphate linkage, where the second nucleoside has a
CC non-carbonate protecting group protecting a hydroxyl, and exposing the
CC product to a composition which concurrently oxidizes the phosphate formed
CC to a phosphate and deprotects the protected hydroxyl of the second
CC nucleoside. The method is useful for synthesizing the polynucleotides,
CC for carrying out either 3' to 5' or 5' to 3' synthesis and for
CC fabricating an addressable array of polynucleotides on a substrate. The

CC present sequence is an oligonucleotide produced to demonstrate the method
CC of the invention
XX
SQ Sequence 20 BP; 0 A; 0 C; 10 G; 10 T; 0 U; 0 Other;

Query Match      0.5%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.7e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2318 TGTGTGTGTGTGTGCGTG 2337
DB 1 TGTGTGTGTGTGTGTGTG 20

RESULT 493
ABA96307/C
ID ABA96307 standard; DNA; 20 BP.
XX
AC ABA96307;
XX
DT 18-MAR-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 2.
XX
KW Immobilisation; Diels-Alder reaction; ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1 /*tag= a
FT /mod_base= OTHER
FT /note= "5, fluorescein label"
XX
PN WO200184234-A1.
XX
PD 08-NOV-2001.
XX
PF 01-MAY-2001; 2001WO-US013956.
XX
PR 01-MAY-2000; 2000US-0201561P.
XX
PR 30-JAN-2001; 2001US-0265020P.
XX
PA (PROL-) PROLIGO LLC.
XX
PI Pieken W, Wolter A, Sebesta DP, Leuck M, Latham-Timmons HA;
PI Pilon J, Husar GM;
XX
XX WPI; 2002-114155/15.
XX
PT New method for immobilizing a molecule on a support comprises reacting a
PT derivatized molecule with a derivatized support via a cycloaddition
PT reaction, shows high selectivity and efficiency.
XX
PS Example 6; Page 31; 86pp; English.
XX
CC The invention relates to a method for immobilising a molecule on a
CC support comprising reacting a derivatised molecule with a derivatised
CC support capable of reacting with the molecule via a cycloaddition
CC reaction. The method is used for immobilising molecules on a support
CC using cycloaddition reactions such as the Diels-Alder reaction. The
CC method shows better chemoselectivity, functional groups do not need to be
CC protected and it is highly efficient for immobilising molecules compared
CC to other methods. The present sequence is that of an oligonucleotide,
CC useful to the invention
XX
SQ Sequence 20 BP; 10 A; 10 C; 0 G; 0 T; 0 U; 0 Other;

Query Match      0.5%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.7e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2318 TGTGTGTGTGTGTGCGTG 2337
```


CC gene of the invention is useful for detecting the single nucleotide
 CC polymorphisms in human gene. The isolated human gene is also useful for
 CC diagnosis of disease and determination of side effect to a medical agent.
 CC The isolated human gene is also effective in detecting single nucleotide
 CC polymorphisms in a human gene. This polynucleotide sequence represents
 CC one of the PCR primers used in the single nucleotide polymorphism
 CC detection method of the invention.

XX
 SQ Sequence 20 BP; 0 A; 2 C; 9 G; 9 T; 0 U; 0 Other;
 Query Match 0.5%; Score 18.4; DB 1; Length 20;
 Best Local Similarity 95.0%; Pred. No. 6.7e+02;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2330 TGTGCTGTGTGTGTGTG 2349
 Db 1 TGTGCTGTGTGTGTGTG 20

RESULT 501
 ADM13954/c
 ID ADM13954 standard; DNA; 20 BP.
 AC ADM13954;
 XX
 DT 01-JUL-2004 (first entry)
 DE Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:141.
 KW chimeric; antisense oligonucleotide; phosphorothioate; human;
 KW microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
 KW microsomal prostaglandin E2 synthase inhibitor; cycostatic; antidiabetic;
 KW immunomodulator; cardiant; neuroprotective; antiinflammatory;
 KW neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
 KW immunomodulatory; cardiovascular; gene therapy; inflammation;
 KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
 KW reperfusion injury; ophthalmic disorder; immunological disorder;
 KW cardiovascular disorder; neurological disorder; ss.

OS Homo sapiens.
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "phosphorothioate linkages and all cytidine
 FT residues are 5-methylcytidines"
 FT modified_base 1..5
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "2'-O-methoxyethyls"
 FT modified_base 16..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "2'-O-methoxyethyls"
 XX WO2004028458-A2.
 XX
 PD 08-APR-2004.
 XX
 XX 25-SEP-2003; 2003WO-US030374.
 XX PF
 XX 25-SEP-2002; 2002US-0413549P.
 XX PR
 XX (PHAA) PHARMACIA CORP.
 XX PA
 XX Gierse JK;
 XX PI
 XX WPI; 2004-305094/28.
 XX DR
 XX New antisense compound, having a sequence targeted to a nucleic acid
 FT encoding mPGES-1, useful for preparing a composition for treating e.g.,

PT inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
 PT ischemia.
 XX
 PS Claim 4; SEQ ID NO 141; 132pp; English.
 XX
 CC The present sequence represents a chimeric antisense oligonucleotide
 CC targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
 CC human mPGES-1 gene is located on chromosome 9, more specifically to
 CC 9q34.3. The present invention also describes: (1) antisense compounds,
 CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
 CC mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
 CC inhibits its expression; (2) a method of inhibiting the expression of
 CC mPGES-1 in cells or tissues; and (3) a method of treating an animal
 CC having a disease or condition associated with mPGES-1. mPGES-1 chimeric
 CC antisense oligonucleotides and antisense compounds have cytostatic,
 CC antidiabetic, immunomodulator, cardiant, neuroprotective,
 CC antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
 CC ophthalmological, immunomodulatory and cardiovascular activities, and can
 CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
 CC can be used for preparing a composition for treating a disease or
 CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
 CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
 CC ophthalmic, immunological, cardiovascular or neurological disorder.
 XX
 SQ Sequence 20 BP; 10 A; 10 C; 0 G; 0 T; 0 U; 0 Other;
 Query Match 0.5%; Score 18.4; DB 1; Length 20;
 Best Local Similarity 95.0%; Pred. No. 6.7e+02;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2318 TGTGTGTGTGTGTGTGCGTG 2337
 Db 20 TGTGTGTGTGTGTGTGTGTG 1

RESULT 502
 ADM14466/c
 ID ADM14466 standard; DNA; 20 BP.
 AC ADM14466;
 XX
 DT 01-JUL-2004 (first entry)
 DE Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:653.
 KW chimeric; antisense oligonucleotide; phosphorothioate; human;
 KW microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
 KW microsomal prostaglandin E2 synthase inhibitor; cycostatic; antidiabetic;
 KW immunomodulator; cardiant; neuroprotective; antiinflammatory;
 KW neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
 KW immunomodulatory; cardiovascular; gene therapy; inflammation;
 KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
 KW reperfusion injury; ophthalmic disorder; immunological disorder;
 KW cardiovascular disorder; neurological disorder; ss.

XX Homo sapiens.
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "phosphorothioate linkages and all cytidine
 FT residues are 5-methylcytidines"
 FT modified_base 1..5
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "2'-O-methoxyethyls"
 FT modified_base 16..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "2'-O-methoxyethyls"
 XX

```

PN WO2004028458-A2.
XX
XX
XX 08-APR-2004.
XX
XX 25-SEP-2003; 2003WO-US030374.
XX
XX 25-SEP-2002; 2002US-0413549P.
XX
XX (PHAA ) PHARMACIA CORP.
XX
XX Gierse JK;
XX
XX WPI; 2004-305094/28.
XX
XX New antisense compound, having a sequence targeted to a nucleic acid
XX encoding mPGES-1, useful for preparing a composition for treating e.g.,
XX inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
XX ischemia.
XX
XX Claim 4; SEQ ID NO 653; 132pp; English.
XX
XX The present sequence represents a chimeric antisense oligonucleotide
XX targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
XX human mPGES-1 gene is located on chromosome 9, more specifically to
XX 9q34.3. The present invention also describes: (1) antisense compounds,
XX having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
XX mPGES-1, which specifically hybridize with the nucleic acid mPGES-1 and
XX inhibits its expression; (2) a method of inhibiting the expression of
XX mPGES-1 in cells or tissues; and (3) a method of treating an animal
XX having a disease or condition associated with mPGES-1. mPGES-1 chimeric
XX antisense oligonucleotides and antisense compounds have cytostatic,
XX antidiabetic, immunomodulatory, cardiant, neuroprotective,
XX antiinflammatory, neuroprotective, and cardiovascular activities, and can
XX be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
XX can be used for preparing a composition for treating a disease or
XX condition associated with mPGES-1 e.g., inflammation, Alzheimer's
XX disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
XX ophthalmic, immunological, cardiovascular or neurological disorder.
XX
XX Sequence 20 BP; 10 A; 10 C; 0 G; 0 T; 0 U; 0 Other;
XX
XX Query Match 0.5%; Score 18.4; DB 1; Length 20;
XX Best Local Similarity 95.0%; Pred. No. 6.7e+02;
XX Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX 2319 GTGTGTGTGTGTGTGTGTGTGTGTGTGT 2338
XX
XX 20 GTGTGTGTGTGTGTGTGTGTGTGTGTGT 1
XX
XX RESULT 503
XX ADM14546/C
XX ID ADM14546 standard; DNA; 20 BP.
XX
XX AC ADM14546;
XX
XX AC
XX
XX DT 01-JUL-2004 (first entry)
XX
XX DE Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:733.
XX
XX KW chimeric; antisense oligonucleotide; phosphorothioate; human;
XX microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
XX microsomal prostaglandin E2 synthase inhibitor; cytosolic; antidiabetic;
XX immunomodulatory; cardiant; neuroprotective; antiinflammatory;
XX neuroprotective; nontropic; antiarthritic; vasotropic; ophthalmic;
XX immunomodulatory; cardiovascular; gene therapy; inflammation;
XX Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
XX reperfusion injury; ophthalmic disorder; immunological disorder;
XX cardiovascular disorder; neurological disorder; ss.
XX
XX OS Homo sapiens.
XX
XX OS Synthetic.

```

```

XX Key Location/Qualifiers
XX modified_base 1..20
XX /tag= b
XX /mod_base= OTHER
XX /note= "phosphorothioate linkages and all cytidine
XX residues are 5-methylcytidines"
XX modified_base 1..5
XX /tag= a
XX /mod_base= OTHER
XX /note= "2'-O-methoxyethyls"
XX modified_base 16..20
XX /tag= c
XX /mod_base= OTHER
XX /note= "2'-O-methoxyethyls"
XX
XX WO2004028458-A2.
XX
XX PN
XX
XX PD 08-APR-2004.
XX
XX PF 25-SEP-2003; 2003WO-US030374.
XX
XX PR 25-SEP-2002; 2002US-0413549P.
XX
XX PA (PHAA ) PHARMACIA CORP.
XX
XX PI Gierse JK;
XX
XX WPI; 2004-305094/28.
XX
XX New antisense compound, having a sequence targeted to a nucleic acid
XX encoding mPGES-1, useful for preparing a composition for treating e.g.,
XX inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
XX ischemia.
XX
XX Claim 4; SEQ ID NO 733; 132pp; English.
XX
XX The present sequence represents a chimeric antisense oligonucleotide
XX targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
XX human mPGES-1 gene is located on chromosome 9, more specifically to
XX 9q34.3. The present invention also describes: (1) antisense compounds,
XX having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
XX mPGES-1, which specifically hybridize with the nucleic acid mPGES-1 and
XX inhibits its expression; (2) a method of inhibiting the expression of
XX mPGES-1 in cells or tissues; and (3) a method of treating an animal
XX having a disease or condition associated with mPGES-1. mPGES-1 chimeric
XX antisense oligonucleotides and antisense compounds have cytostatic,
XX antidiabetic, immunomodulatory, cardiant, neuroprotective,
XX antiinflammatory, neuroprotective, and cardiovascular activities, and can
XX be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
XX can be used for preparing a composition for treating a disease or
XX condition associated with mPGES-1 e.g., inflammation, Alzheimer's
XX disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
XX ophthalmic, immunological, cardiovascular or neurological disorder.
XX
XX Sequence 20 BP; 9 A; 9 C; 2 G; 0 T; 0 U; 0 Other;
XX
XX Query Match 0.5%; Score 18.4; DB 1; Length 20;
XX Best Local Similarity 95.0%; Pred. No. 6.7e+02;
XX Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX 2332 TCCGTGTGTGTGTGTGTGTGTGTGTGTGT 2351
XX
XX 20 TCCGTGTGTGTGTGTGTGTGTGTGTGTGT 1
XX
XX RESULT 504
XX ADM13955/C
XX ID ADM13955 standard; DNA; 20 BP.
XX
XX AC ADM13955;
XX
XX AC
XX
XX

```

DT 01-JUL-2004 (first entry)
XX Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:142.
XX
XX chimeric; antisense oligonucleotide; phosphorothioate; human;
KW microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
KW microsomal prostaglandin E2 synthase inhibitor; cytosolic; antidiabetic;
KW immunomodulator; cardiant; neuroprotective; antiinflammatory;
KW neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
KW immunomodulatory; cardiovascular; gene therapy; inflammation;
KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
KW reperfusion injury; ophthalmic disorder; immunological disorder;
KW cardiovascular disorder; neurological disorder; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
XX
PH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= b
FT /mod_base= OTHER
FT /note= "phosphorothioate linkages and all cytidine
FT residues are 5-methylcytidines"
FT modified_base 1..5
FT /*tag= a
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyls"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyls"
FT
FT
XX WO2004028458-A2.
XX
XX
XX 08-APR-2004.
XX
XX 25-SEP-2003; 2003WO-US030374.
XX
XX 25-SEP-2002; 2002US-0413549P.
XX
XX (PHAA) PHARMACIA CORP.
XX
XX Gierse JK;
XX
XX WPI; 2004-305094/28.
XX
XX New antisense compound, having a sequence targeted to a nucleic acid
PT encoding mPGES-1, useful for preparing a composition for treating e.g.,
PT inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
PT ischemia.
XX
XX Claim 4; SEQ ID NO 142; 132pp; English.
XX
XX The present sequence represents a chimeric antisense oligonucleotide
CC targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
CC human mPGES-1 gene is located on chromosome 9, more specifically to
CC 9q34.3. The present invention also describes: (1) antisense compounds,
CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
CC mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
CC inhibits its expression; (2) a method of inhibiting the expression of
CC mPGES-1 in cells or tissues; and (3) a method of treating an animal
CC having a disease or condition associated with mPGES-1. mPGES-1 chimeric
CC antisense oligonucleotides and antisense compounds have cytosolic,
CC antidiabetic, immunomodulator, cardiant, neuroprotective,
CC antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
CC ophthalmological, immunomodulatory and cardiovascular activities, and can
CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
CC can be used for preparing a composition for treating a disease or
CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
CC ophthalmic, immunological, cardiovascular or neurological disorder.
XX
XX Sequence 20 BP; 10 A; 10 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 0.5%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.7e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2319 GTGTGTGTGTGTGTGTGTGTGTGTGTGT 2338
DB 20 GTGTGTGTGTGTGTGTGTGTGTGTGTGT 1

RESULT 505
ADM14167/c
ID ADM14167 standard; DNA; 20 BP.
XX
XX AC ADM14167;
XX
XX DT 01-JUL-2004 (first entry)
XX
XX DE Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:354.
XX
XX KW chimeric; antisense oligonucleotide; phosphorothioate; human;
KW microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
KW microsomal prostaglandin E2 synthase inhibitor; cytosolic; antidiabetic;
KW immunomodulator; cardiant; neuroprotective; antiinflammatory;
KW neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
KW immunomodulatory; cardiovascular; gene therapy; inflammation;
KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
KW reperfusion injury; ophthalmic disorder; immunological disorder;
KW cardiovascular disorder; neurological disorder; ss.
XX
XX OS Homo sapiens.
OS Synthetic.
XX
XX PH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= b
FT /mod_base= OTHER
FT /note= "phosphorothioate linkages and all cytidine
FT residues are 5-methylcytidines"
FT modified_base 1..5
FT /*tag= a
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyls"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyls"
FT
FT
XX WO2004028458-A2.
XX
XX 08-APR-2004.
XX
XX 25-SEP-2003; 2003WO-US030374.
XX
XX 25-SEP-2002; 2002US-0413549P.
XX
XX (PHAA) PHARMACIA CORP.
XX
XX Gierse JK;
XX
XX WPI; 2004-305094/28.
XX
XX New antisense compound, having a sequence targeted to a nucleic acid
PT encoding mPGES-1, useful for preparing a composition for treating e.g.,
PT inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
PT ischemia.
XX
XX Claim 4; SEQ ID NO 354; 132pp; English.
XX
XX The present sequence represents a chimeric antisense oligonucleotide
CC targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
CC human mPGES-1 gene is located on chromosome 9, more specifically to
CC 9q34.3. The present invention also describes: (1) antisense compounds,
CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
CC mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
CC inhibits its expression; (2) a method of inhibiting the expression of
CC mPGES-1 in cells or tissues; and (3) a method of treating an animal
CC having a disease or condition associated with mPGES-1. mPGES-1 chimeric
CC antisense oligonucleotides and antisense compounds have cytosolic,
CC antidiabetic, immunomodulator, cardiant, neuroprotective,
CC antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
CC ophthalmological, immunomodulatory and cardiovascular activities, and can
CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
CC can be used for preparing a composition for treating a disease or
CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
CC ophthalmic, immunological, cardiovascular or neurological disorder.
XX
XX Sequence 20 BP; 10 A; 10 C; 0 G; 0 T; 0 U; 0 Other;

```
CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
CC mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
CC inhibits its expression; (2) a method of inhibiting the expression of
CC mPGES-1 in cells or tissues; and (3) a method of treating an animal
CC having a disease or condition associated with mPGES-1. mPGES-1 chimeric
CC antisense oligonucleotides and antisense compounds have cytostatic,
CC antiinflammatory, immunomodulatory, cardiant, neuroprotective,
CC ophthalmological, immunomodulatory and cardiovascular activities, and can
CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
CC ophthalmic, immunological, cardiovascular or neurological disorder.
XX
SQ Sequence 20 BP; 10 A; 10 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 0.5%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.7e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2319 GTGTGTGTGTGTGTGTGTGTGTGTGT 2338
Db 20 GTGTGTGTGTGTGTGTGTGTGTGTGT 1

RESULT 506
ADM14413/C
ID ADM14413 standard; DNA; 20 BP.
XX
AC ADM14413;
XX
XX 01-JUL-2004 (first entry)
XX Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:600.
XX chimeric; antisense oligonucleotide; phosphorothioate; human;
XX microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
XX microsomal prostaglandin E2 synthase inhibitor; cytostatic; antidiabetic;
XX immunomodulatory; cardiant; neuroprotective; antiinflammatory;
XX neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
XX immunomodulatory; cardiovascular; gene therapy; inflammation;
XX Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
XX reperfusion injury; ophthalmic disorder; immunological disorder;
XX cardiovascular disorder; neurological disorder; ss.
XX
XX Homo sapiens.
XX Synthetic.
XX
XX Key Location/Qualifiers
XX modified_base 1..20
XX /tag= b
XX /mod_base= OTHER
XX /note= "phosphorothioate linkages and all cytidine
XX residues are 5-methylcytidines"
XX
XX modified_base 1..5
XX /tag= a
XX /mod_base= OTHER
XX /note= "2'-O-methoxyethyls"
XX
XX modified_base 16..20
XX /tag= c
XX /mod_base= OTHER
XX /note= "2'-O-methoxyethyls"
XX
XX WO2004028458-A2.
XX
XX PN
XX PD 08-APR-2004.
XX
XX PF 25-SEP-2003; 2003WO-US030374.
XX
XX PR 25-SEP-2002; 2002US-0413549P.
XX
XX PA (PHAA ) PHARMACIA CORP.
```

```
XX Gierse JK;
PI
XX WPI; 2004-305094/28.
DR
XX
XX New antisense compound, having a sequence targeted to a nucleic acid
XX encoding mPGES-1, useful for preparing a composition for treating e.g.,
XX inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
XX ischaemia.
XX
XX Claim 4; SEQ ID NO 600; 132pp; English.
XX
XX The present sequence represents a chimeric antisense oligonucleotide
XX targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
XX human mPGES-1 gene is located on chromosome 9, more specifically to
XX 9q34.3. The present invention also describes: (1) antisense compounds,
XX having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
XX mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
XX inhibits its expression; (2) a method of inhibiting the expression of
XX mPGES-1 in cells or tissues; and (3) a method of treating an animal
XX having a disease or condition associated with mPGES-1. mPGES-1 chimeric
XX antisense oligonucleotides and antisense compounds have cytostatic,
XX antidiabetic, immunomodulator, cardiant, neuroprotective,
XX antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
XX ophthalmological, immunomodulatory and cardiovascular activities, and can
XX be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
XX condition associated with mPGES-1 e.g., inflammation, Alzheimer's
XX disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
XX ophthalmic, immunological, cardiovascular or neurological disorder.
XX
XX Sequence 20 BP; 10 A; 10 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 0.5%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.7e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2318 TGTGTGTGTGTGTGTGTGTGTGTGTGT 2337
Db 20 TGTGTGTGTGTGTGTGTGTGTGTGTGT 1

RESULT 507
ADM14345/C
ID ADM14345 standard; DNA; 20 BP.
XX
XX ADM14345;
XX
XX 01-JUL-2004 (first entry)
XX
XX Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:532.
XX
XX chimeric; antisense oligonucleotide; phosphorothioate; human;
XX microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
XX microsomal prostaglandin E2 synthase inhibitor; cytostatic; antidiabetic;
XX immunomodulator; cardiant; neuroprotective; antiinflammatory;
XX neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
XX immunomodulatory; cardiovascular; gene therapy; inflammation;
XX Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
XX reperfusion injury; ophthalmic disorder; immunological disorder;
XX cardiovascular disorder; neurological disorder; ss.
XX
XX Homo sapiens.
XX Synthetic.
XX
XX Key Location/Qualifiers
XX modified_base 1..20
XX /tag= b
XX /mod_base= OTHER
XX /note= "phosphorothioate linkages and all cytidine
XX residues are 5-methylcytidines"
XX
XX modified_base 1..5
XX /tag= a
```

```

FT      /mod_base= OTHER
FT      /notes= "2'-O-methoxyethyls"
FT      modified_base
FT      16..20
FT      /*tag= c
FT      /mod_base= OTHER
FT      /note= "2'-O-methoxyethyls"
FT
FT
PN      WO2004028458-A2.
XX
XX
XX      08-APR-2004.
XX
XX      25-SEP-2003; 2003WO-US030374.
XX
XX      25-SEP-2002; 2002US-0413549P.
XX      (PHAA ) PHARMACIA CORP.
XX
XX      Gierse JK;
XX
XX      WPI; 2004-305094/28.
XX
XX      New antisense compound, having a sequence targeted to a nucleic acid
XX      encoding mPGES-1, useful for preparing a composition for treating e.g.,
XX      inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
XX      ischemia.
XX
XX      Claim 4; SEQ ID NO 532; 132pp; English.
XX
XX      The present sequence represents a chimeric antisense oligonucleotide
XX      targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
XX      human mPGES-1 gene is located on chromosome 9, more specifically to
XX      9q34.3. The present invention also describes: (1) antisense compounds,
XX      having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
XX      mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
XX      inhibits its expression; (2) a method of inhibiting the expression of
XX      mPGES-1 in cells or tissues; and (3) a method of treating an animal
XX      having a disease or condition associated with mPGES-1. mPGES-1 chimeric
XX      antisense oligonucleotides and antisense compounds have cytostatic,
XX      anti-diabetic, immunomodulatory, cardiant, neuroprotective,
XX      anti-inflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
XX      ophthalmological, immunomodulatory and cardiovascular activities, and can
XX      be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
XX      can be used for preparing a composition for treating a disease or
XX      condition associated with mPGES-1 e.g., inflammation, Alzheimer's
XX      disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
XX      ophthalmic, immunological, cardiovascular or neurological disorder.
XX
XX      Sequence 20 BP; 10 A; 10 C; 0 G; 0 T; 0 U; 0 Other;

Query Match      0.5%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.7e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2319 GTGTGTGTGTGTGTGTGTGT 2338
Db      20 GTGTGTGTGTGTGTGTGTGT 1

RESULT 508
ID      ADM14426/c
XX      ADM14426 standard; DNA; 20 BP.
XX
XX      ADM14426;
XX
XX      01-JUL-2004 (first entry)
XX
XX      Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:613.
DE
DE      chimeric; antisense oligonucleotide; phosphorothioate; human;
KW      microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
KW      microsomal prostaglandin E2 synthase inhibitor; cytostatic; anti-diabetic;
KW      immunomodulator; cardiant; neuroprotective; anti-inflammatory;
KW      neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;

```

```

KW      immunomodulatory; cardiovascular; gene therapy; inflammation;
KW      Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
KW      reperfusion injury; ophthalmic disorder; immunological disorder;
KW      cardiovascular disorder; neurological disorder; ss.
XX
XX      Homo sapiens.
XX      Synthetic.
XX
XX      Key
XX      Location/Qualifiers
XX      modified_base
XX      1..20
XX      /*tag= b
XX      /mod_base= OTHER
XX      /note= "phosphorothioate linkages and all cytidine
XX      residues are 5-methylcytidines"
XX      modified_base
XX      1..5
XX      /*tag= a
XX      /mod_base= OTHER
XX      /note= "2'-O-methoxyethyls"
XX      modified_base
XX      16..20
XX      /*tag= c
XX      /mod_base= OTHER
XX      /note= "2'-O-methoxyethyls"
XX
XX      WO2004028458-A2.
XX
XX      08-APR-2004.
XX
XX      25-SEP-2003; 2003WO-US030374.
XX
XX      25-SEP-2002; 2002US-0413549P.
XX      (PHAA ) PHARMACIA CORP.
XX
XX      Gierse JK;
XX
XX      WPI; 2004-305094/28.
XX
XX      New antisense compound, having a sequence targeted to a nucleic acid
XX      encoding mPGES-1, useful for preparing a composition for treating e.g.,
XX      inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
XX      ischemia.
XX
XX      Claim 4; SEQ ID NO 613; 132pp; English.
XX
XX      The present sequence represents a chimeric antisense oligonucleotide
XX      targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
XX      human mPGES-1 gene is located on chromosome 9, more specifically to
XX      9q34.3. The present invention also describes: (1) antisense compounds,
XX      having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
XX      mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
XX      inhibits its expression; (2) a method of inhibiting the expression of
XX      mPGES-1 in cells or tissues; and (3) a method of treating an animal
XX      having a disease or condition associated with mPGES-1. mPGES-1 chimeric
XX      antisense oligonucleotides and antisense compounds have cytostatic,
XX      anti-diabetic, immunomodulatory, cardiant, neuroprotective,
XX      anti-inflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
XX      ophthalmological, immunomodulatory and cardiovascular activities, and can
XX      be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
XX      can be used for preparing a composition for treating a disease or
XX      condition associated with mPGES-1 e.g., inflammation, Alzheimer's
XX      disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
XX      ophthalmic, immunological, cardiovascular or neurological disorder.
XX
XX      Sequence 20 BP; 10 A; 10 C; 0 G; 0 T; 0 U; 0 Other;

Query Match      0.5%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.7e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2319 GTGTGTGTGTGTGTGTGTGT 2338
Db      20 GTGTGTGTGTGTGTGTGTGT 1

RESULT 508
ID      ADM14426/c
XX      ADM14426 standard; DNA; 20 BP.
XX
XX      ADM14426;
XX
XX      01-JUL-2004 (first entry)
XX
XX      Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:613.
DE
DE      chimeric; antisense oligonucleotide; phosphorothioate; human;
KW      microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
KW      microsomal prostaglandin E2 synthase inhibitor; cytostatic; anti-diabetic;
KW      immunomodulator; cardiant; neuroprotective; anti-inflammatory;
KW      neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;

```

CC	be used as mPGES-1 inhibitors and in gene therapy. The antisense compound	
CC	can be used for preparing a composition for treating a disease or	
CC	condition associated with mPGES-1 e.g., inflammation, Alzheimer's	
CC	disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or	
CC	ophthalmic, immunological, cardiovascular or neurological disorder.	
XX		
SQ	Sequence 20 BP; 10 A; 10 C; 0 G; 0 T; 0 U; 0 Other;	
	Query Match 0.5%; Score 18.4; DB 1; Length 20;	
	Best Local Similarity 95.0%; Pred. No. 6.7e+02;	
	Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0	
Qy	2319 GTGTGTGTGTGTGTGCGTGT 2338	
Dd	20 GTGTGTGTGTGTGTGTGTGT 1	
RESULT 510		
ADMI4130/c		
ID	ADMI4130 standard; DNA; 20 BP.	
XX		
AC	ADMI4130;	
XX		
DT	01-JUL-2004 (first entry)	
XX		
DE	Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:317.	
XX	chimeric; antisense oligonucleotide; phosphorothioate; human;	
KW	microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;	
KW	microsomal prostaglandin E2 synthase inhibitor; cytosolic; anti-diabetic;	
KW	immunomodulator; cardiant; neuroprotective; anti-inflammatory;	
KW	neuroprotective; nocotropic; anti-arthritis; vasotropic; ophthalmological;	
KW	immunomodulatory; cardiovascular; gene therapy; inflammation;	
KW	Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;	
KW	reperfusion injury; ophthalmic disorder; immunological disorder;	
KW	cardiovascular disorder; neurological disorder; ss.	
XX		
OS	Homo sapiens.	
OS	Synthetic.	
XX		
FH	Key Location/Qualifiers	
FT	modified_base 1..20	
FT	/*tag= b	
FT	/mod_base= OTHER	
FT	/note= "phosphorothioate linkages and all cytidine	
FT	residues are 5-methylcytidines"	
FT	1..5	
FT	modified_base	
FT	/*tag= a	
FT	/mod_base= OTHER	
FT	/note= "2'-O-methoxyethyls"	
FT	16..20	
FT	/*tag= c	
FT	/mod_base= OTHER	
FT	/note= "2'-O-methoxyethyls"	
XX		
PN	WO2004028458-A2.	
XX		
XX		
PD	08-APR-2004.	
XX		
PF	25-SEP-2003; 2003WO-US030374.	
XX		
PR	25-SEP-2002; 2002US-0413549P.	
XX		
PA	(PHAA) PHARMACIA CORP.	
XX		
PI	Gierse JK;	
XX		
DR	WPI; 2004-305094/28.	
XX		
PT	New antisense compound, having a sequence targeted to a nucleic acid	
PT	encoding mPGES-1, useful for preparing a composition for treating e.g.,	
PT	inflammation, Alzheimer's disease, arthritis, diabetes, cancer or	
PT	ischaemia.	


```
FT modified_base 1..20
FT /*tag= b
FT /mod_base= OTHER
FT /note= "phosphorothioate linkages and all cytidine
FT residues are 5-methylcytidines"
FT modified_base 1..5
FT /*tag= a
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyls"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyls"
XX
XX WO2004028458-A2.
XX
XX 08-APR-2004.
XX
XX 25-SEP-2003; 2003WO-US030374.
XX
XX 25-SEP-2002; 2002US-0413549P.
XX
XX (PHAA ) PHARMACIA CORP.
XX
XX Gierse JK;
XX
XX WPI; 2004-305094/28.
XX
XX New antisense compound, having a sequence targeted to a nucleic acid
XX encoding mPGES-1, useful for preparing a composition for treating e.g.,
XX inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
XX ischemia.
XX
XX Claim 4; SEQ ID NO 176; 132pp; English.
XX
XX The present sequence represents a chimeric antisense oligonucleotide
XX targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
XX human mPGES-1 gene is located on chromosome 9, more specifically to
XX 9q34.3. The present invention also describes: (1) antisense compounds,
XX having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
XX mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
XX inhibits its expression; (2) a method of inhibiting the expression of
XX mPGES-1 in cells or tissues; and (3) a method of treating an animal
XX having a disease or condition associated with mPGES-1. mPGES-1 chimeric
XX antisense oligonucleotides and antisense compounds have cytostatic,
XX antidiabetic, immunomodulator, cardiant, neuroprotective,
XX antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
XX ophthalmological, immunomodulatory and cardiovascular activities, and can
XX be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
XX can be used for preparing a composition for treating a disease or
XX condition associated with mPGES-1 e.g., inflammation, Alzheimer's
XX disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
XX ophthalmic, immunological, cardiovascular or neurological disorder.
XX
XX Sequence 20 BP; 10 A; 10 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 0.5%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred.No. 6.7e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2319 GTGTGTGTGTGTGTGTGTGT 2338
DB 20 GTGTGTGTGTGTGTGTGT 1

RESULT 513
ADM14297/c
ID ADM14297 standard; DNA; 20 BP.
XX
XX ADM14297;
XX
XX 01-JUL-2004 (first entry)
XX
```

```
DE Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:484.
XX
XX chimeric; antisense oligonucleotide; phosphorothioate; human;
XX microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
XX microsomal prostaglandin E2 synthase inhibitor; cytotatic; antidiabetic;
XX immunomodulator; cardiant; neuroprotective; antiinflammatory;
XX neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
XX immunomodulatory; cardiovascular; gene therapy; inflammation;
XX Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
XX reperfusion injury; ophthalmic disorder; immunological disorder;
XX cardiovascular disorder; neurological disorder; ss.
XX
XX Homo sapiens.
XX Synthetic.
XX
XX Key Location/Qualifiers
XX modified_base 1..20
XX /*tag= b
XX /mod_base= OTHER
XX /note= "phosphorothioate linkages and all cytidine
XX residues are 5-methylcytidines"
XX modified_base 1..5
XX /*tag= a
XX /mod_base= OTHER
XX modified_base 16..20
XX /*tag= c
XX /mod_base= OTHER
XX /note= "2'-O-methoxyethyls"
XX
XX WO2004028458-A2.
XX
XX 08-APR-2004.
XX
XX 25-SEP-2003; 2003WO-US030374.
XX
XX 25-SEP-2002; 2002US-0413549P.
XX
XX (PHAA ) PHARMACIA CORP.
XX
XX Gierse JK;
XX
XX WPI; 2004-305094/28.
XX
XX New antisense compound, having a sequence targeted to a nucleic acid
XX encoding mPGES-1, useful for preparing a composition for treating e.g.,
XX inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
XX ischemia.
XX
XX Claim 4; SEQ ID NO 484; 132pp; English.
XX
XX The present sequence represents a chimeric antisense oligonucleotide
XX targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
XX human mPGES-1 gene is located on chromosome 9, more specifically to
XX 9q34.3. The present invention also describes: (1) antisense compounds,
XX having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
XX mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
XX inhibits its expression; (2) a method of inhibiting the expression of
XX mPGES-1 in cells or tissues; and (3) a method of treating an animal
XX having a disease or condition associated with mPGES-1. mPGES-1 chimeric
XX antisense oligonucleotides and antisense compounds have cytostatic,
XX antidiabetic, immunomodulator, cardiant, neuroprotective,
XX antidiabetic, immunomodulator, cardiant, neuroprotective,
XX antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
XX ophthalmological, immunomodulatory and cardiovascular activities, and can
XX be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
XX can be used for preparing a composition for treating a disease or
XX condition associated with mPGES-1 e.g., inflammation, Alzheimer's
XX disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
XX ophthalmic, immunological, cardiovascular or neurological disorder.
XX
XX Sequence 20 BP; 10 A; 10 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 0.5%; Score 18.4; DB 1; Length 20;
```

```

Best Local Similarity 95.0%; Pred. No. 6.7e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2318 TGTGTGTGTGTGTGCGTGT 2337
Db 20 TGTGTGTGTGTGTGTGTG 1

RESULT 514
ADM14346/c
ID ADM14346 standard; DNA; 20 BP.
XX
AC ADM14346;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:533.
XX
KW chimeric; antisense oligonucleotide; phosphorothioate; human;
KW microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
KW microsomal prostaglandin E2 synthase inhibitor; cytosolic; antidiabetic;
KW immunomodulator; cardiant; neuroprotective; antiinflammatory;
KW neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
KW immunomodulatory; cardiovascular; gene therapy; inflammation;
KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
KW reperfusion injury; ophthalmic disorder; immunological disorder;
KW cardiovascular disorder; neurological disorder; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= b
FT /mod_base= OTHER
FT /note= "phosphorothioate linkages and all cytidine
FT residues are 5-methylcytidines"
FT modified_base 1..5
FT /*tag= a
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyls"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyls"
XX
PN WO2004028458-A2.
XX
PD 08-APR-2004.
XX
PF 25-SEP-2003; 2003WO-US030374.
XX
PR 25-SEP-2002; 2002US-0413549P.
XX
PA (PHAA ) PHARMACIA CORP.
XX
PI Gierse JK;
XX
DR WPI; 2004-305094/28.
XX
PT New antisense compound, having a sequence targeted to a nucleic acid
PT encoding mPGES-1, useful for preparing a composition for treating e.g.,
PT inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
PT ischemia.
XX
PS Claim 4; SEQ ID NO 533; 132pp; English.
XX
CC The present sequence represents a chimeric antisense oligonucleotide
CC targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
CC human mPGES-1 gene is located on chromosome 9, more specifically to
CC 9q34.3. The present invention also describes: (1) antisense compounds,
CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
CC mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and

```

```

inhibits its expression; (2) a method of inhibiting the expression of
mPGES-1 in cells or tissues; and (3) a method of treating an animal
having a disease or condition associated with mPGES-1. mPGES-1 chimeric
antisense oligonucleotides and antisense compounds have cytostatic,
antidiabetic, immunomodulator, cardiant, neuroprotective,
antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
ophthalmological, immunomodulatory and cardiovascular activities, and can
be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
can be used for preparing a composition for treating a disease or
condition associated with mPGES-1 e.g., inflammation, Alzheimer's
disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
ophthalmic, immunological, cardiovascular or neurological disorder.
XX
SQ Sequence 20 BP; 10 A; 10 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 0.5%; Score 18.4; DB:1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.7e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2319 GTGTGTGTGTGTGCGTGT 2338
Db 20 GTGTGTGTGTGTGTGTGT 1

RESULT 515
ADM14132/c
ID ADM14132 standard; DNA; 20 BP.
XX
AC ADM14132;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:319.
XX
KW chimeric; antisense oligonucleotide; phosphorothioate; human;
KW microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
KW microsomal prostaglandin E2 synthase inhibitor; cytosolic; antidiabetic;
KW immunomodulator; cardiant; neuroprotective; antiinflammatory;
KW neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
KW immunomodulatory; cardiovascular; gene therapy; inflammation;
KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
KW reperfusion injury; ophthalmic disorder; immunological disorder;
KW cardiovascular disorder; neurological disorder; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= b
FT /mod_base= OTHER
FT /note= "phosphorothioate linkages and all cytidine
FT residues are 5-methylcytidines"
FT modified_base 1..5
FT /*tag= a
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyls"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyls"
XX
PN WO2004028458-A2.
XX
PD 08-APR-2004.
XX
PF 25-SEP-2003; 2003WO-US030374.
XX
PR 25-SEP-2002; 2002US-0413549P.
XX
PA (PHAA ) PHARMACIA CORP.
XX
PI Gierse JK;

```



```
KW reperfusion injury; ophthalmic disorder; immunological disorder;
XX cardiovascular disorder; neurological disorder; ss.
OS Homo sapiens.
XX
XX Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= b
FT /mod_base= OTHER
FT /note= "phosphorothioate linkages and all cytidine
FT residues are 5-methylcytidines"
FT modified_base 1..5
FT /*tag= a
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyls"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyls"
XX WO2004028458-A2.
XX
XX PD 08-APR-2004.
XX
XX PF 25-SEP-2003; 2003WO-US030374.
XX
XX PR 25-SEP-2002; 2002US-0413549P.
XX
XX PA (PHAA ) PHARMACIA CORP.
XX
XX PI Gierse JK;
XX
XX DR WPI; 2004-305094/28.
XX
XX PT New antisense compound, having a sequence targeted to a nucleic acid
XX encoding mPGES-1, useful for preparing a composition for treating e.g.,
XX inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
XX ischemia.
XX
XX PS Claim 4; SEQ ID NO 316; 132pp; English.
XX
XX CC The present sequence represents a chimeric antisense oligonucleotide
XX targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
XX human mPGES-1 gene is located on chromosome 9, more specifically to
XX 9q34.3. The present invention also describes: (1) antisense compounds,
XX having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
XX mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
XX inhibits its expression; (2) a method of inhibiting the expression of
XX mPGES-1 in cells or tissues; and (3) a method of treating an animal
XX having a disease or condition associated with mPGES-1. mPGES-1 chimeric
XX antisense oligonucleotides and antisense compounds have cytostatic,
XX antidiabetic, immunomodulator, cardiant, neuroprotective,
XX antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
XX ophthalmological, immunomodulatory and cardiovascular activities, and can
XX be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
XX can be used for preparing a composition for treating a disease or
XX condition associated with mPGES-1 e.g., inflammation, Alzheimer's
XX disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
XX ophthalmic, immunological, cardiovascular or neurological disorder.
XX
XX SQ Sequence 20 BP; 10 A; 10 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 0.5%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.7e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2319 GTGTGTGTGTGTGTGTGTGT 2338
DB 20 GTGTGTGTGTGTGTGTGTGT 1

RESULT 518
```

```
ADM14134/c
ID ADM14134 standard; DNA; 20 BP.
XX
XX AC ADM14134;
XX
XX DT 01-JUL-2004 (first entry)
XX
XX DE Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:321.
XX
XX KW chimeric; antisense oligonucleotide; phosphorothioate; human;
XX microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
XX microsomal prostaglandin E2 synthase inhibitor; cytostatic; antidiabetic;
XX immunomodulator; cardiant; neuroprotective; antiinflammatory;
XX neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
XX immunomodulatory; cardiovascular; gene therapy; inflammation;
XX Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
XX reperfusion injury; ophthalmic disorder; immunological disorder;
XX cardiovascular disorder; neurological disorder; ss.
XX
XX OS Homo sapiens.
XX
XX OS Synthetic.
XX
XX FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= b
FT /mod_base= OTHER
FT /note= "phosphorothioate linkages and all cytidine
FT residues are 5-methylcytidines"
FT modified_base 1..5
FT /*tag= a
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyls"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyls"
XX WO2004028458-A2.
XX
XX PD 08-APR-2004.
XX
XX PF 25-SEP-2003; 2003WO-US030374.
XX
XX PR 25-SEP-2002; 2002US-0413549P.
XX
XX PA (PHAA ) PHARMACIA CORP.
XX
XX PI Gierse JK;
XX
XX DR WPI; 2004-305094/28.
XX
XX PT New antisense compound, having a sequence targeted to a nucleic acid
XX encoding mPGES-1, useful for preparing a composition for treating e.g.,
XX inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
XX ischemia.
XX
XX PS Claim 4; SEQ ID NO 321; 132pp; English.
XX
XX CC The present sequence represents a chimeric antisense oligonucleotide
XX targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
XX human mPGES-1 gene is located on chromosome 9, more specifically to
XX 9q34.3. The present invention also describes: (1) antisense compounds,
XX having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
XX mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
XX inhibits its expression; (2) a method of inhibiting the expression of
XX mPGES-1 in cells or tissues; and (3) a method of treating an animal
XX having a disease or condition associated with mPGES-1. mPGES-1 chimeric
XX antisense oligonucleotides and antisense compounds have cytostatic,
XX antidiabetic, immunomodulator, cardiant, neuroprotective,
XX antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
XX ophthalmological, immunomodulatory and cardiovascular activities, and can
XX be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
XX can be used for preparing a composition for treating a disease or
```



```
PF 25-SEP-2003; 2003WO-US030374.
XX
PR 25-SEP-2002; 2002US-0413549P.
XX
PA (PHAA ) PHARMACIA CORP.
XX
PI Gierse JK;
XX
XX WPI; 2004-305094/28.
XX
XX New antisense compound, having a sequence targeted to a nucleic acid
PT encoding mPGES-1, useful for preparing a composition for treating e.g.,
PT inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
PT ischemia.
XX
PS Claim 4; SEQ ID NO 485; 132pp; English.
XX
XX The present sequence represents a chimeric antisense oligonucleotide
CC targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
CC human mPGES-1 gene is located on chromosome 9, more specifically to
CC 9q34.3. The present invention also describes: (1) antisense compounds,
CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
CC mPGES-1, which specifically hybridize with the nucleic acid mPGES-1 and
CC inhibits its expression; (2) a method of inhibiting the expression of
CC mPGES-1 in cells or tissues; and (3) a method of treating an animal
CC having a disease or condition associated with mPGES-1. mPGES-1 chimeric
CC antisense oligonucleotides and antisense compounds have cytostatic,
CC antiinflammatory, immunomodulatory, cardiant, neuroprotective,
CC antiarthritic, vasotropic,
CC ophthalmological, immunomodulatory and cardiovascular activities, and can
CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
CC can be used for preparing a composition for treating a disease or
CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
CC ophthalmic, immunological, cardiovascular or neurological disorder.
XX
SQ Sequence 20 BP; 10 A; 10 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 0.5%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.7e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2318 TGTGTGTGTGTGTGCGTG 2337
DB 20 TGTGTGTGTGTGTGTGTG 1
|||||
|||||

RESULT 521
ADM14131/C
ID ADM14131 standard; DNA; 20 BP.
XX
AC ADM14131;
XX
XX 01-JUL-2004 (first entry)
DT
XX Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:318.
DE
XX chimeric; antisense oligonucleotide; phosphorothioate; human;
KW microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
KW microsomal prostaglandin E2 synthase inhibitor; cytostatic; antidiabetic;
KW immunomodulator; cardiant; neuroprotective; antiinflammatory;
KW neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
KW immunomodulatory; cardiovascular; gene therapy; inflammation;
KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
KW reperfusion injury; ophthalmic disorder; immunological disorder;
KW cardiovascular disorder; neurological disorder; ss.
XX
XX Homo sapiens.
OS
XX Synthetic.
OS
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= b
```

```
FT /mod_base= OTHER
FT /note= "phosphorothioate linkages and all cytidine
FT residues are 5-methylcytidines"
FT modified_base 1..5
FT /*tag= a
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyls"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyls"
XX
PN WO2004028458-A2.
XX
XX 08-APR-2004.
XX
XX 25-SEP-2003; 2003WO-US030374.
XX
XX 25-SEP-2002; 2002US-0413549P.
XX
XX (PHAA ) PHARMACIA CORP.
XX
XX Gierse JK;
XX
XX WPI; 2004-305094/28.
XX
XX New antisense compound, having a sequence targeted to a nucleic acid
PT encoding mPGES-1, useful for preparing a composition for treating e.g.,
PT inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
PT ischemia.
XX
XX Claim 4; SEQ ID NO 318; 132pp; English.
XX
XX The present sequence represents a chimeric antisense oligonucleotide
CC targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
CC human mPGES-1 gene is located on chromosome 9, more specifically to
CC 9q34.3. The present invention also describes: (1) antisense compounds,
CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
CC mPGES-1, which specifically hybridize with the nucleic acid mPGES-1 and
CC inhibits its expression; (2) a method of inhibiting the expression of
CC mPGES-1 in cells or tissues; and (3) a method of treating an animal
CC having a disease or condition associated with mPGES-1. mPGES-1 chimeric
CC antisense oligonucleotides and antisense compounds have cytostatic,
CC antiinflammatory, immunomodulatory, cardiant, neuroprotective,
CC antiarthritic, vasotropic,
CC ophthalmological, immunomodulatory and cardiovascular activities, and can
CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
CC can be used for preparing a composition for treating a disease or
CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
CC ophthalmic, immunological, cardiovascular or neurological disorder.
XX
SQ Sequence 20 BP; 10 A; 10 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 0.5%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.7e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2318 TGTGTGTGTGTGTGCGTG 2337
DB 20 TGTGTGTGTGTGTGTGTG 1
|||||
|||||

RESULT 521
ADM14131/C
ID ADM14131 standard; DNA; 20 BP.
XX
AC ADM14131;
XX
XX 01-JUL-2004 (first entry)
DT
XX Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:320.
DE
XX chimeric; antisense oligonucleotide; phosphorothioate; human;
KW microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
KW microsomal prostaglandin E2 synthase inhibitor; cytostatic; antidiabetic;
KW immunomodulator; cardiant; neuroprotective; antiinflammatory;
KW neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
KW immunomodulatory; cardiovascular; gene therapy; inflammation;
KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
KW reperfusion injury; ophthalmic disorder; immunological disorder;
KW cardiovascular disorder; neurological disorder; ss.
XX
XX Homo sapiens.
OS
XX Synthetic.
OS
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= b
```

```
FT /mod_base= OTHER
FT /note= "phosphorothioate linkages and all cytidine
FT residues are 5-methylcytidines"
FT modified_base 1..5
FT /*tag= a
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyls"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyls"
XX
PN WO2004028458-A2.
XX
XX 08-APR-2004.
XX
XX 25-SEP-2003; 2003WO-US030374.
XX
XX 25-SEP-2002; 2002US-0413549P.
XX
XX (PHAA ) PHARMACIA CORP.
XX
XX Gierse JK;
XX
XX WPI; 2004-305094/28.
XX
XX New antisense compound, having a sequence targeted to a nucleic acid
PT encoding mPGES-1, useful for preparing a composition for treating e.g.,
PT inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
PT ischemia.
XX
XX Claim 4; SEQ ID NO 318; 132pp; English.
XX
XX The present sequence represents a chimeric antisense oligonucleotide
CC targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
CC human mPGES-1 gene is located on chromosome 9, more specifically to
CC 9q34.3. The present invention also describes: (1) antisense compounds,
CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
CC mPGES-1, which specifically hybridize with the nucleic acid mPGES-1 and
CC inhibits its expression; (2) a method of inhibiting the expression of
CC mPGES-1 in cells or tissues; and (3) a method of treating an animal
CC having a disease or condition associated with mPGES-1. mPGES-1 chimeric
CC antisense oligonucleotides and antisense compounds have cytostatic,
CC antiinflammatory, immunomodulatory, cardiant, neuroprotective,
CC antiarthritic, vasotropic,
CC ophthalmological, immunomodulatory and cardiovascular activities, and can
CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
CC can be used for preparing a composition for treating a disease or
CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
CC ophthalmic, immunological, cardiovascular or neurological disorder.
XX
SQ Sequence 20 BP; 10 A; 10 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 0.5%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.7e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2318 TGTGTGTGTGTGTGCGTG 2337
DB 20 TGTGTGTGTGTGTGTGTG 1
|||||
|||||

RESULT 522
ADM14133/C
ID ADM14133 standard; DNA; 20 BP.
XX
AC ADM14133;
XX
XX 01-JUL-2004 (first entry)
DT
XX Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:320.
DE
XX
```


CC having a disease or condition associated with mPGES-1. mPGES-1 chimeric
 CC antisense oligonucleotides and antisense compounds have cytostatic,
 CC anti-diabetic, immunomodulatory, cardiant, neuroprotective,
 CC anti-inflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
 CC ophthalmological, immunomodulatory and cardiovascular activities, and can
 CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
 CC can be used for preparing a composition for treating a disease or
 CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
 CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
 CC ophthalmic, immunological, cardiovascular or neurological disorder.
 XX
 SQ Sequence 20 BP; 10 A; 10 C; 0 G; 0 T; 0 U; 0 Other;
 Query Match 0.5%; Score 18.4; DB 1; Length 20;
 Best Local Similarity 95.0%; Pred. No. 6.7e+02;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2318 TGTGTGTGTGTGTGCGTG 2337
 Db 20 TGTGTGTGTGTGTGTGTG 1
 RESULT 524
 ADM13952/c
 ID ADM13952 standard; DNA; 20 BP.
 XX
 AC ADM13952;
 DT
 DT 01-JUL-2004 (first entry)
 DE Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:139.
 XX
 KW chimeric; antisense oligonucleotide; phosphorothioate; human;
 KW microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
 KW microsomal prostaglandin E2 synthase inhibitor; cytosolic; anti-diabetic;
 KW immunomodulatory; cardiant; neuroprotective; anti-inflammatory;
 KW neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
 KW immunomodulatory; cardiovascular; gene therapy; inflammation;
 KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
 KW reperfusion injury; ophthalmic disorder; immunological disorder;
 KW cardiovascular disorder; neurological disorder; ss.
 XX
 OS Homo sapiens.
 OS Synthetic.
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /tag= b
 FT /mod_base= OTHER
 FT /note= "phosphorothioate linkages and all cytidine
 modified_base 1..5
 FT /tag= a
 FT /mod_base= OTHER
 FT /note= "2'-O-methoxyethyls"
 FT modified_base 16..20
 FT /tag= c
 FT /mod_base= OTHER
 FT /note= "2'-O-methoxyethyls"
 XX
 PN WO2004028458-A2.
 XX
 PD 08-APR-2004.
 XX
 XX
 PF 25-SEP-2003; 2003WO-US030374.
 XX
 PR 25-SEP-2002; 2002US-0413549P.
 XX
 PA (PHAA) PHARMACIA CORP.
 XX
 PI Gierse JK;
 XX
 XX WPI; 2004-305094/28.
 DR

XX New antisense compound, having a sequence targeted to a nucleic acid
 PT encoding mPGES-1, useful for preparing a composition for treating e.g.,
 PT inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
 PT ischemia.
 XX
 XX Claim 4; SEQ ID NO 139; 132pp; English.
 PS
 XX The present sequence represents a chimeric antisense oligonucleotide
 CC targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
 CC human mPGES-1 gene is located on chromosome 9, more specifically to
 CC 9q34.3. The present invention also describes: (1) antisense compounds,
 CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
 CC mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
 CC inhibits its expression; (2) a method of inhibiting the expression of
 CC mPGES-1 in cells or tissues; and (3) a method of treating an animal
 CC having a disease or condition associated with mPGES-1. mPGES-1 chimeric
 CC antisense oligonucleotides and antisense compounds have cytostatic,
 CC anti-diabetic, immunomodulatory, cardiant, neuroprotective,
 CC anti-inflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
 CC ophthalmological, immunomodulatory and cardiovascular activities, and can
 CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
 CC can be used for preparing a composition for treating a disease or
 CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
 CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
 CC ophthalmic, immunological, cardiovascular or neurological disorder.
 XX
 SQ Sequence 20 BP; 10 A; 10 C; 0 G; 0 T; 0 U; 0 Other;
 Query Match 0.5%; Score 18.4; DB 1; Length 20;
 Best Local Similarity 95.0%; Pred. No. 6.7e+02;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2318 TGTGTGTGTGTGTGCGTG 2337
 Db 20 TGTGTGTGTGTGTGTGTG 1
 RESULT 525
 ADM13988/c
 ID ADM13988 standard; DNA; 20 BP.
 XX
 AC ADM13988;
 DT
 DT 01-JUL-2004 (first entry)
 DE Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:175.
 XX
 KW chimeric; antisense oligonucleotide; phosphorothioate; human;
 KW microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
 KW microsomal prostaglandin E2 synthase inhibitor; cytosolic; anti-diabetic;
 KW immunomodulatory; cardiant; neuroprotective; anti-inflammatory;
 KW neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
 KW immunomodulatory; cardiovascular; gene therapy; inflammation;
 KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
 KW reperfusion injury; ophthalmic disorder; immunological disorder;
 KW cardiovascular disorder; neurological disorder; ss.
 XX
 OS Homo sapiens.
 OS Synthetic.
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /tag= b
 FT /mod_base= OTHER
 FT /note= "phosphorothioate linkages and all cytidine
 modified_base 1..5
 FT /tag= a
 FT /mod_base= OTHER
 FT /note= "2'-O-methoxyethyls"
 FT modified_base 16..20
 FT /tag= c

```

FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyls"
PN
XX
XX WO2004028458-A2.
XX
XX 08-APR-2004.
XX
XX 25-SEP-2003; 2003WO-US030374.
XX
XX 25-SEP-2002; 2002US-0413549P.
XX
XX (PHAA ) PHARMACIA CORP.
XX
XX Gierse JK;
XX
XX WPI; 2004-305094/28.
XX
XX New antisense compound, having a sequence targeted to a nucleic acid
XX encoding mPGES-1, useful for preparing a composition for treating e.g.,
XX inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
XX ischemia.
XX
XX Claim 4; SEQ ID NO 175; 132pp; English.
XX
XX The present sequence represents a chimeric antisense oligonucleotide
XX targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
XX human mPGES-1 gene is located on chromosome 9, more specifically to
XX 9q34.3. The present invention also describes: (1) antisense compounds,
XX having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
XX mPGES-1, which specifically hybridize with the nucleic acid mPGES-1 and
XX inhibits its expression; (2) a method of inhibiting the expression of
XX mPGES-1 in cells or tissues; and (3) a method of treating an animal
XX having a disease or condition associated with mPGES-1. mPGES-1 chimeric
XX antisense oligonucleotides and antisense compounds have cytostatic,
XX antidiabetic, immunomodulatory, cardiant, neuroprotective,
XX antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
XX ophthalmological, immunomodulatory and cardiovascular activities, and can
XX be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
XX can be used for preparing a composition for treating a disease or
XX condition associated with mPGES-1 e.g., inflammation, Alzheimer's
XX disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
XX ophthalmic, immunological, cardiovascular or neurological disorder.
XX
XX Sequence 20 BP; 10 A; 10 C; 0 G; 0 T; 0 U; 0 Other;
XX
Query Match 0.5%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.7e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 2319 GTGTGTGTGTGTGTGTGTGT 2338
Db 20 GTGTGTGTGTGTGTGTGTGT 1
RESULT 526
ADM14427/c
ID ADM14427 standard; DNA; 20 BP.
XX
XX ADM14427;
XX
XX 01-JUL-2004 (first entry)
XX
XX Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:614.
XX
XX chimeric; antisense oligonucleotide; phosphorothioate; human;
XX microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
XX microsomal prostaglandin E2 synthase inhibitor; cytostatic; antidiabetic;
XX immunomodulatory; cardiant; neuroprotective; antiinflammatory;
XX neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
XX immunomodulatory; cardiovascular; gene therapy; inflammation;
XX Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
XX reperfusion injury; ophthalmic disorder; immunological disorder;
XX cardiovascular disorder; neurological disorder; ss.

```

```

XX Homo sapiens.
XX Synthetic.
XX
XX Key Location/Qualifiers
XX modified_base 1..20
XX /mod_base= OTHER
XX /note= "phosphorothioate linkages and all cytidine
XX residues are 5-methylcytidines"
XX modified_base 1..5
XX /mod_base= OTHER
XX /note= "2'-O-methoxyethyls"
XX modified_base 16..20
XX /mod_base= OTHER
XX /note= "2'-O-methoxyethyls"
XX
XX WO2004028458-A2.
XX
XX 08-APR-2004.
XX
XX 25-SEP-2003; 2003WO-US030374.
XX
XX 25-SEP-2002; 2002US-0413549P.
XX
XX (PHAA ) PHARMACIA CORP.
XX
XX Gierse JK;
XX
XX WPI; 2004-305094/28.
XX
XX New antisense compound, having a sequence targeted to a nucleic acid
XX encoding mPGES-1, useful for preparing a composition for treating e.g.,
XX inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
XX ischemia.
XX
XX Claim 4; SEQ ID NO 614; 132pp; English.
XX
XX The present sequence represents a chimeric antisense oligonucleotide
XX targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
XX human mPGES-1 gene is located on chromosome 9, more specifically to
XX 9q34.3. The present invention also describes: (1) antisense compounds,
XX having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
XX mPGES-1, which specifically hybridize with the nucleic acid mPGES-1 and
XX inhibits its expression; (2) a method of inhibiting the expression of
XX mPGES-1 in cells or tissues; and (3) a method of treating an animal
XX having a disease or condition associated with mPGES-1. mPGES-1 chimeric
XX antisense oligonucleotides and antisense compounds have cytostatic,
XX antidiabetic, immunomodulatory, cardiant, neuroprotective,
XX antidiabetic, immunomodulatory, nootropic, antiarthritic, vasotropic,
XX antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
XX ophthalmological, immunomodulatory and cardiovascular activities, and can
XX be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
XX can be used for preparing a composition for treating a disease or
XX condition associated with mPGES-1 e.g., inflammation, Alzheimer's
XX disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
XX ophthalmic, immunological, cardiovascular or neurological disorder.
XX
XX Sequence 20 BP; 10 A; 10 C; 0 G; 0 T; 0 U; 0 Other;
XX
Query Match 0.5%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.7e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 2319 GTGTGTGTGTGTGTGTGTGT 2338
Db 20 GTGTGTGTGTGTGTGTGTGT 1
RESULT 527
AD081052/c
ID AD081052 standard; DNA; 20 BP.

```



```
XX FH Key Location/Qualifiers
XX FT modified_base 1..20
XX FT /*tag= b
XX FT /mod_base= OTHER
XX FT /note= "OTHER= Phosphorothioate backbone. All cytidines
XX FT are 5-methylcytidines"
XX FT modified_base 1..5
XX FT /*tag= a
XX FT /mod_base= OTHER
XX FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
XX FT modified_base 15..20
XX FT /*tag= c
XX FT /mod_base= OTHER
XX FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
XX FT
XX FT US2004110140-A1.
XX PN
XX PN
XX PD 10-JUN-2004.
XX PF 09-DEC-2002; 2002US-00315765.
XX PF
XX PR 09-DEC-2002; 2002US-00315765.
XX PR (ISIS-) ISIS PHARM INC.
XX PA
XX PI Bennett CF, Freier SM, Dobie KW;
XX PI WPI; 2004-440329/41.
XX DR
XX XX New oligonucleotide compound that inhibits expression of CDK9, useful for
XX PT preparing a composition for treating hyperproliferative disorder, e.g.
XX PT cancer.
XX PS
XX PS Example 15; SEQ ID NO 15; 49pp; English.
XX CC
XX CC The invention describes a new compound, having a sequence comprising 8-80
XX CC bp targeted to a nucleic acid encoding CDK9, specifically hybridises with
XX CC the nucleic acid encoding CDK9 comprising 7018-bp sequence and inhibits
XX CC expression of CDK9. Also described are: inhibiting the expression of CDK9
XX CC in cells or tissues; screening for a modulator of CDK9; a diagnostic
XX CC method for identifying a disease state; a kit or assay device comprising
XX CC the compound; and treating an animal having a disease or condition
XX CC associated with CDK9. The oligonucleotide compound is useful for
XX CC preparing a composition for treating hyperproliferative disorder, e.g.
XX CC cancer. This sequence represents a human cyclin-dependent kinase 9 (CDK9)
XX CC antisense oligonucleotide.
XX SQ Sequence 20 BP; 4 A; 8 C; 6 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 0.5%; Score 18.4; DB 1; Length 20;
XX Best Local Similarity 95.0%; Pred. No. 6.7e+02;
XX Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
OY 1675 GCAGACTTCGGGCTGGCCCG 1694
XX DB 20 GCAGACTTCGGGCTGGCCCG 1
XX
XX RESULT 530
XX ADQ26959
XX ID ADQ26959 standard; DNA; 20 BP.
XX
XX AC ADQ26959;
XX
XX DT 09-SEP-2004 (first entry)
XX
XX DE Human myosin heavy chain MYH14 exon 21 PCR primer M21-R.
XX KW ss; human; non-muscle myosin-family heavy chain protein; MYH14;
XX KW chromosome 19q13.3; Charcot-Marie-Tooth syndrome; brain;
XX KW peripheral nerve; ovary; intestine; primer; PCR.
XX XX
```

```
OS Homo sapiens.
XX DE10260633-A1.
XX
XX PD 24-JUN-2004.
XX
XX PF 16-DEC-2002; 2002DE-01060633.
XX
XX PR 16-DEC-2002; 2002DE-01060633.
XX
XX (RAUT/) RAUTENSTRAUSS B.
XX
XX Rautenstrauss B, Reis A, Leal A;
XX
XX WPI; 2004-469573/45.
XX
XX New isolated nucleic acid encoding the human myosin heavy chain protein
XX MYH14, useful for identifying mutations or alterations in nucleic acid,
XX derived from chromosome 19q 13.3.
XX
XX Disclosure; Page 4; 21pp; German.
XX
XX This invention describes a novel non-muscle, human myosin-family heavy
XX chain protein, designated MYH14 which maps to chromosome 19q13.3, a
XX region associated with Charcot-Marie-Tooth syndrome. MYH14 is associated
XX with brain, peripheral nerves, ovary and intestines and has closest
XX homology with the myosin family proteins MYH0, MYH10 and MYH11. The
XX product of the invention is used to identify mutations and alteration in
XX nucleic acids, by hybridisation. Computer-based comparison of the human
XX chromosomal 19q region with the rat sequence AF139055 (encoding a non-
XX muscle myosin heavy chain B) indicated a potential human homologue. A set
XX of exonic primers was designed and used to amplify cDNA derived from mRNA
XX isolated from the sciatic nerve. The 13 amplicons were sequenced and
XX assembled to form an approximately 6kb sequence that included an open
XX reading frame for MYH14, but lacked the polyadenylation signal. The
XX corresponding gene contains 40 exons (about 100 kb), entirely present
XX within the bacterial artificial chromosomes AC020906, AC010515 and
XX AC008655. The MYH14 protein corresponds to the hypothetical protein FLJ
XX 13881. This sequence represents a PCR primer used to amplify the human
XX MYH14 gene.
XX
XX Sequence 20 BP; 5 A; 11 C; 2 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 0.5%; Score 18.4; DB 1; Length 20;
XX Best Local Similarity 95.0%; Pred. No. 6.7e+02;
XX Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
OY 2102 ACACCCCGAGCTCCAGCTCC 2121
XX DB 1 ACACCCAGCTCCAGCTCC 20
XX
XX RESULT 531
XX ABN88973
XX ID ABN88973 standard; DNA; 21 BP.
XX
XX AC ABN88973;
XX
XX DT 22-AUG-2002 (first entry)
XX
XX DE Phosphorothioate 21mer oligonucleotide SEQ ID NO:2.
XX
XX KW Phosphorothioate; oligonucleotide synthesis; phosphoramidite; ss.
XX
XX OS Synthetic.
XX
XX Key Location/Qualifiers
XX modified_base 1..21
XX /*tag= a
XX /mod_base= OTHER
XX /note= "phosphorothioate linkages"
XX
XX WO200220543-A2.
XX PN
```


CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC

Sequence 24 BP: 8 A; 10 C; 3 G; 3 T; 0 U; 0 Other; XX
S0Sequence 24 BP: 8 A; 10 C; 3 G; 3 T; 0 U; 0 Other; XX
S0

DT	05-JUL-1999	(first entry)
XX		
DE	Human IL-3 receptor antisense oligonucleotide fragment.	
XX		
KW	Antisense oligonucleotide; multiple target; antisense treatment;	
KW	impaired respiration; inflammation; lung disease;	
KW	pulmonary vasoconstriction; inflammation; allergic rhinitis;	
KW	acute asthma; allergy; asthma; impeded respiration;	
KW	respiratory distress syndrome; pain; cystic fibrosis;	
KW	pulmonary hypertension; pulmonary vasoconstriction; emphysema;	
KW	chronic obstructive pulmonary disease; leukemia; lymphoma; carcinoma;	
KW	colon cancer; breast cancer; lung cancer; pancreatic cancer;	
KW	hepatocellular carcinoma; kidney cancer; melanoma; hepatic metastasis;	
KW	prostate cancer; es.	
XX		
OS	Synthetic.	
XX		
PN	WO9913886-A1.	
XX		
PD	25-MAR-1999.	
XX		
PF	17-SEP-1998; 98WO-US019419.	
XX		
PR	17-SEP-1997; 97US-0059160P.	
PR	09-JUN-1998; 98US-00093972.	
XX		
PA	(UYEC-) UNIV EAST CAROLINA.	
XX		
PI	Nyce JW;	
XX		
DR	WPI; 1999-229400/19.	
XX		
PT	New antisense oligonucleotides used in treatment of, e.g. pulmonary	
PT	vasoconstriction.	
XX		
PS	Disclosure; Page 48; 120pp; English.	
XX		
CC	The specification describes antisense oligonucleotides (AA52869-X55271)	
CC	directed against at least 2 mRNAs selected from target genes, coding and	
CC	non-coding regions of RNAs corresponding to target genes, gene initiation	
CC	codons, genomic flanking regions, intron-exon borders, the 5'-end, the 3'-	
CC	end and the juxta-section between coding and non-coding regions and all	
CC	segments of RNAs encoding proteins associated with one or more diseases,	
CC	conditions or mixtures. The antisense oligonucleotides may be derived	
CC	from sequences AA5272-74. These multiple target oligonucleotides	
CC	(specifically AA5280-271) can be used for the antisense treatment of	
CC	diseases and conditions. Typical diseases and conditions are those	
CC	associated with impaired respiration and inflammation, including lung	
CC	diseases, pulmonary vasoconstriction, inflammation, allergic rhinitis,	
CC	acute asthma, allergies, asthma, impeded respiration, respiratory	
CC	distress syndrome, pain, cystic fibrosis, pulmonary hypertension,	
CC	pulmonary vasoconstriction, emphysema, chronic obstructive pulmonary	
CC	disease (COPD), and cancers such as leukemias, lymphomas, carcinomas e.g.	
CC	colon cancer, breast cancer, lung cancer, pancreatic cancer,	
CC	hepatocellular carcinoma, kidney cancer, melanoma, hepatic metastases, as	
CC	well as all types of cancers which may metastasize or have metastasized	
CC	to the lungs, including breast and prostate cancer	
XX		
SQ	Sequence 23 BP; 0 A; 11 C; 10 G; 2 T; 0 U; 0 Other;	
	Query Match 0.5%; Score 18.2; DB 1; Length 23;	
	Best Local Similarity 87.0%; Pred. No. 8.3e+02;	
	Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;	
QY	1477 CGGGCGGGGGCCCCCGGGCCT 1499	
D _b		
1	1 CGTCCGGGGGGCCCCCGGGCCT 23	
RESULT 538		
AAFI9538		
ID	AAF19538 standard; DNA; 23 BP.	
XX		

AA19538;	Best Local Similarity 87.0%; Pred. No. 8.3e+02;				
14-MAR-2001 (first entry)	Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;				
Human IL3 receptor polynucleotide fragment #1105.					
Low adenosine antisense oligonucleotide; phosphorothioate; allergy;					
human; airway disorder; bronchoconstriction; lung inflammation;					
surfactant depletion; respiratory; bronchodilator; antiinflammatory;					
immunosuppressive; antiasthmatic; analgesic; hypotensive; cytostatic;					
respiratory obstruction; pulmonary obstruction; impeded respiration;					
surfactant hypoproduction; pulmonary vasoconstriction; asthma; RDS;					
respiratory distress syndrome; pain; cystic fibrosis; allergic rhinitis;					
pulmonary hypertension; emphysema; pulmonary transplantation rejection;					
chronic obstructive pulmonary disease; pulmonary infection; bronchitis;					
cancer; ss.					
Homo sapiens.					
WO200062736-A2.					
26-OCT-2000.					
24-MAR-2000; 2000WO-US008020.					
06-APR-1999; 99US-0127958P.					
(UYEC-) UNIV EAST CAROLINA.					
(NYCE/) NYCE J W.					
Nyce JW;					
WPI; 2000-679539/66.					
Low adenosine (A) content antisense oligonucleotides which do not trigger					
adenosine receptors during metabolism, useful e.g. for treating cancers					
and respiratory obstructions.					
Claim 14; Page 207; 1592pp; English.					
The present invention describes low adenosine (A) content antisense					
oligonucleotides and compositions (I) comprising them. In the antisense					
oligonucleotides the A is replaced by a 'Universal' or alternative base.					
(I) can have respiratory, bronchodilator, antiinflammatory, analgesic,					
immunosuppressive, antiasthmatic, hypotensive and cytostatic activities.					
The antisense oligonucleotides and (I) can be used to down-regulate the					
expression and or activity of target polypeptides associated with					
lung/respiratory disorders and malignancies, such as stimulating and					
activating peptide factors and transmitters, transcription factors,					
immunoglobulins and antibodies, antibody receptors, cytokines and					
chemokines, endogenously produced specific and non-specific enzymes,					
binding proteins, adhesion molecules and their receptors, cytokine and					
chemokine receptors, adenosine receptors, bradykinin receptors, central					
nervous system (CNS) and peripheral nervous and non-nervous system					
receptors, CNS and peripheral nervous and non-nervous system peptide					
transmitters, defensins, growth factors, vasoactive peptides and					
receptors, binding proteins and malignancy associated proteins. The					
antisense oligonucleotides may be used in this way to treat disorders					
including respiratory obstruction (especially pulmonary obstruction					
and/or bronchoconstriction) and/or lung inflammation, allergy(ies) and/or					
surfactant hypoproduction which are associated with a disease or					
condition selected from pulmonary vasoconstriction, inflammation,					
allergies, asthma, impeded respiration, respiratory distress syndrome					
(RDS), pain, cystic fibrosis (CF), allergic rhinitis (AR), pulmonary					
hypertension, emphysema, chronic obstructive pulmonary disease (COPD),					
pulmonary transplantation rejection, pulmonary infections, bronchitis,					
and/or cancer. AAF18434 to AAF21543 represent human polynucleotide					
fragments and antisense oligonucleotides used in the exemplification of					
the present invention					
Sequence 23 BP; 0 A; 11 C; 10 G; 2 T; 0 U; 0 Other;					
Query Match 0.5%; Score 18.2; DB 1; Length 23;					

Best Local Similarity 87.0%; Pred. No. 8.3e+02;					
Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;					
1477 CGGGCGCGCGCGCGCGCGCGCGCT 1499					
1 CGTCCGCGGGCGCGCGCGCGCGCT 23					
RESULT 539					
AB295232					
ID AB295232 standard; DNA; 23 BP.					
XX AB295232;					
DT 17-OCT-2003 (first entry)					
DE Human IL3 receptor antisense fragment no.1095.					
Human; antisense; lung dysfunction; nasal airway dysfunction;					
antiinflammatory steroid; ubiquinone; antiinflammatory; antiasthmatic;					
antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;					
antisense gene therapy; respiratory; lung; adenosine sensitivity;					
adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;					
lung inflammation; respiratory disease; ds.					
Homo sapiens.					
WO200285308-A2.					
31-OCT-2002.					
23-APR-2002; 2002WO-US013135.					
24-APR-2001; 2001US-0286137P.					
(EPITG-) EPIGENESIS PHARM INC.					
Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;					
Miller S, Tang L, Shahabuddin S;					
WPI; 2003-229219/22.					
Pharmaceutical composition for treating ailments associated with impaired					
respiration, has oligo(s) antisense to specific gene(s) or its					
corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or					
ubiquinone.					
Disclosure; SEQ ID NO 10474; 872pp; English.					
The invention relates to a novel pharmaceutical composition, which has a					
first active agent comprising an oligonucleotide antisense to the					
initiation codon, coding region, 5' or 3' end genomic flanking regions,					
5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of					
junctions of genes encoding a polypeptide associated with lung and/or					
nasal airway dysfunction and a second active agent comprising an					
antiinflammatory steroid and ubiquinone. A composition of the invention					
has antiinflammatory, antiasthmatic, antiasthmatic, hypotensive,					
immunosuppressive, and cytostatic activity. The composition may have a					
use in antisense gene therapy. The composition is useful for treating or					
preventing a respiratory, lung or malignant disease or condition, also					
for enhancing the prophylactic or therapeutic respiratory effect of an					
antiinflammatory steroid in a subject, for reducing or depleting levels					
of, or reducing sensitivity to adenosine, reducing levels of adenosine					
receptor, producing bronchodilation, increasing levels of ubiquinone or					
lung surfactant in a subject's tissue, or treating bronchoconstriction,					
lung inflammation, lung allergies, or a respiratory disease or condition.					
Note: The sequence data for this patent is not represented in the printed					
specification, but was obtained in electronic format directly from WIPO					
at ftp.wipo.int/pub/published_pct_sequences					
Sequence 23 BP; 0 A; 11 C; 10 G; 2 T; 0 U; 0 Other;					
Query Match 0.5%; Score 18.2; DB 1; Length 23;					

CC	distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary transplantation rejection, pulmonary infections, bronchitis or cancer.
CC	The reduced adenosine content of the anti-sense oligos corresponding to CC thymidines present in the target RNA serves to prevent the breakdown of the oligonucleotides into products that free adenosine into the system e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to CC prevent any unwanted effects due to it
XX	
SQ	Sequence 23 BP; 0 A; 11 C; 10 G; 2 T; 0 U; 0 Other;
Query Match	0.5%; Score 18.2; DB 1; Length 23;
Best Local Similarity	87.0%; Pred. No. 8.3e+02;
Matches	20; Conservative 0; Mismatches 3; Indels 0; Gaps 0
QY	1477 CGGCGCGCGCGCGCCCGCGGCGCT 1499
DB	1 CGTCCGCGGGGCCCCCGGCGCT 23
RESULT 541	
AAH43222/c	
ID	AAH43222 standard; cDNA; 24 BP.
XX	
AC	AAH43222;
XX	
DT	31-OCT-2001 (first entry)
XX	
DE	Human kelch protein 19 primer 1.
XX	
XX	Human; kelch protein 19; diagnosis; malignant tumor; hemopathy; PCR; HIV; inflammation; polymerase chain reaction; primer; amplify; probe; ss.
XX	
OS	Synthetic.
XX	
PN	WO200155427-A1.
XX	
PD	02-AUG-2001.
XX	
PF	15-JAN-2001; 2001WO-CN000057.
XX	
PR	26-JAN-2000; 2000CN-00111516.
XX	
PA	(BIOD-) BIODOOR GENE TECHNOLOGY LTD SHANGHAI.
XX	
PI	Mao Y, Xie Y;
XX	
DR	WFI; 2001-483267/52.
XX	
PT	Human kelch protein 19 and encoded polynucleotide, applicable in diagnosis and treatment of malignant tumor, hemopathy, HIV infection, immunological diseases and various inflammations.
XX	
PS	Example 3; Page 32; 36pp; Chinese.
XX	
CC	The sequences given in AAH43222-23 are primers which were used to amplify the cDNA encoding human kelch protein 19. Human kelch protein 19 and its corresponding polynucleotide may be used in the diagnosis and treatment of malignant tumor, hemopathy, HIV infection, immunological diseases and various inflammations
XX	
SQ	Sequence 24 BP; 9 A; 10 C; 5 G; 0 T; 0 U; 0 Other;
Query Match	0.5%; Score 18.2; DB 1; Length 24;
Best Local Similarity	87.0%; Pred. No. 8.7e+02;
Matches	20; Conservative 0; Mismatches 3; Indels 0; Gaps 0
QY	2320 TGTGTGTGTGTGTGCGGTGTGTGT 2342
DB	24 TGTGTGTGTGCTTGGTGTGTGTGT 2
RESULT 542	

ABK99282/c
ID ABK99282 standard; RNA; 25 BP.

XX
AC ABK99282;
XX

XX 21-OCT-2002 (first entry)
DT

XX Hepatitis C virus (HCV) NS5B replicase RNA synthesis template #12.
DE

XX Hepatitis C virus; HCV; NS5B replicase; ss; RNA polymerase.
KW

XX Synthetic.
OS

XX US2002064771-A1.
PN

XX 30-MAY-2002.
PD

XX 06-APR-2001; 2001US-00828034.
PF

XX 07-APR-2000; 2000US-0195852P.
PR

XX (ZHON/) ZHONG W.
PA

XX (HONG/) HONG Z.
PA

XX (FERR/) FERRARI E.
PA

XX Zhong W, Hong Z, Ferrari E;
PI

XX WPI; 2002-582330/62.
DR

XX Novel replicase complex comprising hepatitis C virus NS5B replicase, a 3
PT nucleotide-long template to which a 2 nucleotide-long primer is annealed,
PT and template and primer which do not form a stable duplex in the absence
PT of HCV NS5B.

XX Example; Page 6; 17pp; English.
PS

XX The invention relates to a replicase complex comprising a hepatitis C
CC virus (HCV) NS5B replicase protein, a linear nucleic acid template and a
CC complementary nucleic acid primer which is annealed to the 3' terminus of
CC the template, where the template is at least three nucleotides and the
CC primer is two or three nucleotides, and the template and primer do not
CC form a stable duplex in solution in the absence of the HCV NS5B protein.
CC The complex is useful for detecting HCV replicase activity and permits
CC establishment of sensitive RNA-dependent RNA polymerase assays to screen
CC and evaluate antiviral inhibitors and to improve the specificity and
CC efficacy of the inhibitors. The complex is also useful in the development
CC of a reliable system for determining kinetic and thermodynamic constants
CC of HCV NS5B-catalysed nucleotide incorporation and investigation of
CC mechanistic inhibitors for mis-incorporation or chain termination.
CC Specifically, the short RNA template and primer pairs are useful in
CC screening assays which are used for determining kinetic, thermodynamic
CC and mechanistic properties of NS5B replication and ultimately in the
CC development of inhibitors of NS5B. Newly identified inhibitors of
CC replicase activity may be used for developing anti-HCV pharmaceuticals.
CC Sequences ABK99271-ABK99296 represent HCV NS5B replicase RNA synthesis
CC templates

XX Sequence 25 BP; 0 A; 20 C; 5 G; 0 T; 0 U; 0 Other;
SQ

Query Match 0.5%; Score 18.2; DB 1; Length 25;
Best Local Similarity 87.0%; Pred. No. 9.1e+02;
Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2920 GGGCGGGCGTGGGGGGCGTGG 2942

DB 24 GGGCGGGCGGGGGCGGGGGG 2

RESULT 543

ACI55482

ID ACI55482 standard; DNA; 25 BP.

XX ACI55482;

AC

XX 13-OCT-2003 (first entry)
DT

XX Human microarray DNA oligonucleotide SEQ ID NO 55473.
DE

XX EST; ss; probe; expressed sequence tag; microarray; gene expression;
KW genetic variation; biallelic marker; polymorphism; human;
KW cross-species comparison.

XX Homo sapiens.
OS

XX US2003104410-A1.
PN

XX 05-JUN-2003.
PD

XX 15-MAR-2002; 2002US-00098263.
PF

XX 16-MAR-2001; 2001US-0276759P.
PR

XX (AFFY-) AFFYMETRIX INC.
PA

XX Mittmann MP;
PI

XX WPI; 2003-567953/53.
XX

XX New array of nucleic acid probes, useful for in situ hybridization, in
PT Southern, Northern or dot-blot hybridization to identify or detect the
PT sequence or specific mutations of any gene.

XX Claim 1; SEQ ID NO 55473; 9pp; English.
PS

XX The invention discloses a microarray comprising a plurality of nucleic
CC acid probes including one of 2,018,500 fully defined sequences, or its
CC perfect match, perfect mismatch, antisense match or antisense mismatch.
CC Also disclosed is a method of gene expression analysis. The array is used
CC in monitoring gene expression levels by hybridisation to a DNA library,
CC in analysis of genetic variation or in hybridisation of tag-labelled
CC compounds. The nucleic acid probes are specifically designed for analysis
CC of at least one target sequence. The method of analysis comprises
CC hybridising at least one or more nucleic acids to at least two or more
CC nucleic acid probes and detecting the hybridisation. The nucleic acid
CC probes are attached to a solid support. The analysis comprises monitoring
CC gene expression levels, identifying biallelic markers or polymorphisms,
CC or family members of a gene and a cross-species comparison. Each of the
CC nucleic acids further comprises a tag sequence. The array of nucleic acid
CC probes is useful in in situ hybridisation, in Southern, Northern or dot-
CC blot hybridisation to identify or detect the sequence or specific
CC mutations of any gene, in mapping the 5' termini of mRNA molecules by
CC primer extensions or in screening cDNA or genomic libraries or subclones
CC for additional subclones containing segments of DNA that have been
CC isolated and previously sequenced. The sequence presented is one of the
CC nucleic acid probes incorporated in the microarray. Note: The sequence
CC data for this patent can also be obtained in electronic format directly
CC from USPTO at seqdata.uspto.gov/sequence.html

XX Sequence 25 BP; 5 A; 8 C; 7 G; 5 T; 0 U; 0 Other;
SQ

Query Match 0.5%; Score 18.2; DB 1; Length 25;
Best Local Similarity 87.0%; Pred. No. 9.1e+02;
Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1328 ACCTGCGGACCTGGTCTGAG 1350

DB 3 ACCTGACGGACCCACGTCTGAG 25

RESULT 544

ADL99557

ID ADL99557 standard; DNA; 25 BP.

XX ADL99557;

XX 20-MAY-2004 (first entry)
DT

XX DE Single chain antibody sfv5AF related linker #3.

XX XX antipsoxiatic; antiinflammatory; neuroprotective; ophthalmological;

KW KW gastrointestinal; osteopathic; nephrotropic; gene therapy;

KW KW multimeric molecular complex; transcytotic transport;

KW KW paracellular transport; calcitonin; osteoporosis; renal failure; colitis;

KW KW gastroenteritis; inflammatory bowel disease; psoriasis;

KW KW Alzheimer's disease; optic neuropathy; ophthalmoplegia;

KW KW single chain antibody; sfv5AF; linker; heavy chain region; ds.

XX OS Synthetic.

XX XX US2003166160-A1.

PN XX 04-SEP-2003.

XX XX 06-SEP-2001; 2001US-00949039.

XX XX 06-SEP-2001; 2001US-00949039.

XX XX (HAWL/) HAWLEY S B.

XX XX (CHAP/) CHAPIN S.

PA (SHER/) SHERIDAN P L.

PA (HOUS/) HOUSTON L L.

PA (GLYN/) GLYNN J M.

XX XX Hawley SB, Chapin S, Sheridan PL, Houston LL, Glynn JM;

XX XX WPI; 2003-898076/82.

XX XX New multimeric molecular complex, useful for preparing a composition for

PT diagnosing or treating e.g. osteoporosis, renal failure, colitis,

PT gastroenteritis, inflammatory bowel disease, psoriasis or Alzheimer's

PT disease.

XX XX Example 5; Page 51; 91pp; English.

XX XX The invention describes a multimeric molecular complex comprising at

CC least 2 compounds, each of which has at least one targeting element

CC directed to a ligand that confers transcytotic or paracellular

CC transporting properties to a molecular complex specifically bound to the

CC ligand. Also described are: a compound comprising at least 2 targeting

CC elements directed to the ligand; a protein conjugate comprising a

CC biologically active calcitonin polypeptide having a chemical linkage to

CC at least one targeting element directed to the ligand; a pharmaceutical

CC composition comprising the compound; delivering a biologically active

CC agent to an animal; transporting a biologically active agent through an

CC epithelial barrier; treating a disease in an animal; and identifying a

CC disease in an animal. The complex is useful for preparing a composition

CC for diagnosing or treating diseases, e.g., osteoporosis, renal failure,

CC colitis, gastroenteritis, inflammatory bowel disease, psoriasis,

CC Alzheimer's disease, optic neuropathy or ophthalmoplegia. This sequence

CC represents a linker associated with the isolation of heavy chain regions

CC from the single chain antibody sfv5AF polypeptide, that targets the

CC polyanionoglobulin receptor (pigr) mediator of endocytosis, exocytosis

CC and forward and reverse transcytosis in epithelial cells,

XX XX Sequence 25 BP; 0 A; 0 C; 20 G; 0 T; 0 U; 5 Other;

SQ Query Match 0.5%; Score 18.2; DB 1; Length 25;

Best Local Similarity 73.9%; Pred. No. 9.1e+02;

Matches 17; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 2920 GGGGGGGCGTGGGGGGGGCGTGG 2942

DB 2 GGGGGGGGGCGGGGGGGGGGGGG 24

RESULT 545

ABS78791/c

ID ABS78791 standard; DNA; 26 BP.

XX

AC ABS78791;

XX 16-DEC-2002 (first entry)

XX Human NOVX probe Ag3765.

XX Human; NOVX; human disease; NOVX-associated disorder; cancer; addiction;

KW Hodgkin disease; Von Hippel-Lindau syndrome; Alzheimer's disease; stroke;

KW tuberculous sclerosis; hypercalcaemia; Parkinson's disease; depression;

KW Huntington's disease; cerebral palsy; epilepsy; Lesch-Nyhan syndrome;

KW multiple sclerosis; ataxia-telangiectasia; leukodystrophy; anxiety; pain;

KW obesity; Crohn's disease; osteoporosis; inflammatory bowel disease;

KW infertility; inflammatory bowel disease; atherosclerosis; hypertension;

KW scleroderma; haemophilia; diabetes; pancreatitis; autoimmune disease;

KW asthma; arthritis; immunodeficiency; HIV; viral infection; neurogenesis;

KW bacterial infection; parasitic infection; graft-versus-host disease;

KW cell differentiation; cell proliferation; haematopoiesis; wound healing;

KW angiogenesis; probe; ss.

XX OS Homo sapiens.

XX XX WO200272770-A2.

XX 19-SEP-2002.

XX 08-MAR-2002; 2002WO-US007283.

XX 08-MAR-2001; 2001US-0274281P.

PR 09-MAR-2001; 2001US-0274849P.

PR 12-MAR-2001; 2001US-0275235P.

PR 13-MAR-2001; 2001US-0275579P.

PR 13-MAR-2001; 2001US-0275601P.

PR 14-MAR-2001; 2001US-0276000P.

PR 20-MAR-2001; 2001US-0277239P.

PR 20-MAR-2001; 2001US-0277327P.

PR 20-MAR-2001; 2001US-0277338P.

PR 21-MAR-2001; 2001US-0277791P.

PR 22-MAR-2001; 2001US-0277833P.

PR 23-MAR-2001; 2001US-0278152P.

PR 26-MAR-2001; 2001US-0278894P.

PR 27-MAR-2001; 2001US-0279036P.

PR 28-MAR-2001; 2001US-0279344P.

PR 30-MAR-2001; 2001US-0280233P.

PR 02-APR-2001; 2001US-0280802P.

PR 02-MAY-2001; 2001US-0288148P.

PR 31-MAY-2001; 2001US-0294821P.

PR 31-OCT-2001; 2001US-0335302P.

PR 04-DEC-2001; 2001US-0338375P.

PR 07-MAR-2002; 2002US-00094466.

XX (CURA-) CURAGEN CORP.

XX Spytek KA, Vernet CA, Tchernev VT, Malyankar UM, Gerlach VL;

PI Li L, Zernhusen BP, Patturajan M, Gusev VY, Kekuda R, Pena CEA;

PI Zhong M, Ganggoli EA, Taupier RJ;

XX WPI; 2002-713508/77.

XX New NOVX polypeptides and polynucleotides, useful for preventing,

PT diagnosing or treating NOVX-associated disorders, e.g. diabetes, multiple

PT sclerosis, atherosclerosis, cancer, infections, osteoporosis or

PT Parkinson's disease.

XX Example C; Page 231; 266pp; English.

XX The present invention relates to a new polypeptide (NOVX). The NOVX

CC polypeptide, nucleic acid and antibody are useful in the manufacture of a

CC medicament for treating a syndrome associated with a human disease,

CC preferably a NOVX-associated disorder. The NOVX nucleic acids,

CC polypeptides and antibodies are useful for treating, preventing or

CC diagnosing diseases such as cancers, Hodgkin disease, Von Hippel-Lindau

CC syndrome, Alzheimer's disease, stroke, tuberculous sclerosis,

CC hypercalcaemia, Parkinson's disease, Huntington's disease, cerebral

CC palsy, epilepsy, Lesch-Nyhan syndrome, multiple sclerosis, ataxia-
 CC telangiectasia, leukodystrophies, addiction, anxiety, depression, pain,
 CC obesity, Crohn's disease, osteoporosis, inflammatory bowel disease,
 CC infertility, inflammatory bowel disease, atherosclerosis, hypertension,
 CC scleroderma, haemophilia, diabetes, pancreatitis, autoimmune disease,
 CC asthma, arthritis, immunodeficiencies, HIV, viral, bacterial or parasitic
 CC infections, or graft-versus-host disease. The nucleic acids and
 CC polypeptides may also be used as targets for the identification of small
 CC molecules that modulate or inhibit e.g. neurogenesis, cell
 CC differentiation, cell proliferation, haematopoiesis, wound healing and
 CC angiogenesis, in gene therapy, in generation of antibodies that bind
 CC immunospecifically to NOVX substances for use in therapeutic or
 CC diagnostic methods. The nucleic acids are further used as hybridisation
 CC probes, in chromosome mapping, tissue typing, preventive medicine, and
 CC pharmacogenomics. The present nucleic acid sequence represents a probe
 CC that was used in the methods of the invention for detection of human NOVX
 XX
 XX
 SQ Sequence 26 BP; 8 A; 14 C; 0 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 18.2; DB 1; Length 26;
 Best Local Similarity 87.0%; Pred. No. 9.5e+02;
 Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2321 GTCTGTGTGTGCGGTGTGTG 2343
 DB 24 GTCTGTGTGTGAGGTGTGGG 2

RESULT 546
 AAX77485/C
 ID AAX77485 standard; DNA; 18 BP.
 AC AAX77485;
 DT 05-AUG-1999 (first entry)
 XX US912147 primer 29.
 DE
 XX
 XX Primer; quantitation; genetic instability; tumour cell; detection;
 KW neoplastic transformation; carcinogenesis; ss.
 XX Synthetic.
 XX US912147-A.
 XX 15-JUN-1999.
 XX 22-OCT-1996; 96US-00734973.
 XX 22-OCT-1996; 96US-00734973.
 XX (HEAL-) HEALTH RES INC.
 XX Anderson G, Stoler D, Basik M;
 PI WPT; 1999-357197/30.
 XX Quantitating genetic instability.
 XX Claim 4; Col 27-28; 27pp; English.
 CC This invention describes a novel method for quantitating genetic
 CC instability independent of microsatellite alterations by treating a
 CC comparison pair comprising genomic DNA from tumour cells and genomic DNA
 CC with normal cells. The method involves the cells from the same individual
 CC with oligonucleotide primers selected from (i) a nucleotide sequence
 CC (CG)xRG, where R is a purine selected from adenine and guanine and x = 3-
 CC 7, (ii) a nucleotide sequence (CG)xRY, where R is as in (i) and Y is a
 CC pyrimidine selected from cytosine, thymine, and uracil and x = 3-7, (iii)
 CC a nucleotide sequence (CG)xRR, where R is as in (i) and x = 3-7, (iv) a
 CC nucleotide sequence (CG)xYY, where Y is a pyrimidine selected from
 CC cytosine, thymine, and uracil and x = 3-7, (v) a nucleotide sequence
 CC (CA)xRG, where R is a purine selected from adenine and guanine and x = 6-

CC 16, (vi) a nucleotide sequence (CA)xRY, where R is a purine selected from
 CC adenine and guanine and Y is a pyrimidine selected from cytosine,
 CC thymine, and uracil, and x = 6-16, (vii) a nucleotide sequence (CA)xRR,
 CC where R is a purine selected from adenine and guanine and x = 6-16,
 CC (viii) a nucleotide sequence (CA)xYY, where Y is a pyrimidine selected
 CC from cytosine, thymine, and uracil and x = 6-16, and (ix) a combination
 CC of the primers. The method is useful for detecting genomic instability
 CC which are commonly associated with the various stages of neoplastic
 CC transformation and carcinogenesis. The method is rapid and simple
 XX
 SQ Sequence 18 BP; 9 A; 8 C; 1 G; 0 T; 0 U; 0 Other;
 Query Match 0.5%; Score 18; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 6.6e+02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2316 TCTGTGTGTGTGTGTG 2333
 DB 18 TCTGTGTGTGTGTGTG 1
 RESULT 547
 AAS13764
 ID AAS13764 standard; DNA; 18 BP.
 AC AAS13764;
 XX 08-MAY-2002 (first entry)
 DT Simple sequence repeat, SSR, #36.
 DE Simple sequence repeat; plant; ds; SSR; ryegrass; fescue; tandem repeat;
 KW cereal profiling; grass profiling; seed batch purity testing.
 XX Lolium rigidum.
 XX NZ509193-A.
 XX 25-MAY-2001.
 XX 03-JAN-2001; 2001NZ-00509193.
 XX 24-DEC-1999; 99AU-00004906.
 XX 04-MAY-2000; 2000AU-00007310.
 XX (SAUS-) STATE SOUTH AUSTRALIA SOUTH AUSTRALIAN R.
 XX (UYSC-) UNIV SOUTHERN CROSS.
 XX (VICT-) STATE VICTORIA DEPT NATURAL RES & ENVIRO.
 XX (UYAD-) UNIV ADELAIDE.
 XX (ITWA-) INT MAIZE & WHEAT IMPROVEMENT CENT.
 XX Forster JW, Jones ES;
 XX WPI; 2001-512563/56.
 XX New simple sequence repeats having 2 or more tandemly repeated nucleotide
 XX core elements isolated from ryegrass and fescue, useful for selecting of
 XX genes in grass or cereal breeding or profiling grass or cereal species
 XX varieties.
 XX Example 1; Fig 6; 72pp; English.
 CC The invention relates to a substantially purified or isolated nucleic
 CC acid (I) from ryegrass or fescue species including a simple sequence
 CC repeat (SSR), having 2 or more tandemly repeated nucleotide core elements
 CC 2-6 nucleotides in length. Also included are a nucleic acid primer
 CC suitable for amplifying an SSR, identifying (M) an SSR by preparing a
 CC library of ryegrass or fescue genomic DNA enriched for SSRs and
 CC identifying clones in the library containing SSRs, a library of ryegrass
 CC or fescue genomic DNA enriched for SSRs prepared by the M1, selecting for
 CC a gene in grass or cereal breeding by identifying an SSR that is closely
 CC associated with the gene such that the SSR and the gene are
 CC preferentially co-inherited, and selecting for the SSR in the breeding, a

CC method for DNA profiling grass or cereal species varieties by assessing
 CC variation between SSR varieties and testing the purity of grass or cereal
 CC seed batches by assessing variation within seed batch of an SSR. The SSRs
 CC may be used in the selection of grass or cereal breeding, for
 CC profiling grass or cereal species varieties, for testing the purity of
 CC grass or cereal seed batches, and for DNA profiling to establish the
 CC distinct identity, uniformity and/or stability of a cultivar. The present
 CC sequence is a ryegrass or fescue SSR
 XX
 SQ Sequence 18 BP; 0 A; 1 C; 8 G; 9 T; 0 U; 0 Other;

Query Match 0.5%; Score 18; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 6.6e+02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2315 GTCTGTGTGTGTGTGTGT 2332
 DB 1 GTCTGTGTGTGTGTGT 18

RESULT 548
 AAD34804/C
 ID AAD34804 standard; DNA; 18 BP.

AC AAD34804;
 XX
 DT 16-JUL-2002 (first entry)
 XX
 DE Human FGFR3 allele detecting antisense PCR primer.

XX Human; chondrodysplasia; achondroplasia; transgenic mouse; therapy;
 KW fibroblast growth factor receptor 3; FGFR3; limb; midface hypoplasia;
 KW large skull; drug screening; drug development; transgenic; PCR; primer;
 KW ss.

XX Homo sapiens.

OS US6265632-B1.

PN 24-JUL-2001.

XX 26-AUG-1999; 99US-00383630.

XX 27-AUG-1998; 98IL-00125958.

XX (YEDA) YEDA RES & DEV CO LTD.
 PA (PROC-) PROCHON BIOTECH LTD.

XX Yayan A, Segev O;

XX WPI; 2001-463946/50.

XX New transgenic mice having a genetically modified fibroblast growth
 PT factor receptor gene, useful as a model for human chondrodysplasia, e.g.
 PT achondroplasia characterized by shortening of the limbs, midface
 PT hypoplasia or large skull.

PS Example; Col 14; 49pp; English.

XX The invention relates to an animal model for chondrodysplasia, more
 CC particularly, to a transgenic mouse model for achondroplasia. This
 CC transgenic mouse contains a fibroblast growth factor receptor 3 (FGFR3)
 CC gene including a G to A point mutation changing Gly to Arg in codon 380
 CC in its genome. The transgenic mouse is useful as a model for FGFR-
 CC associated chondrodysplasia, particularly FGFR3 achondroplasia, e.g.
 CC shortening of the limbs, midface hypoplasia and large skull. This model
 CC may be exploited to gain better understanding of the disease and as an
 CC experimental model with which experimental therapy to chondrodysplasias
 CC can be exercised. The transgenic mouse is particularly useful as a tool
 CC for screening, developing and evaluating drugs with a potential of
 CC relieving or abolishing chondrodysplasia syndromes and/or symptoms. The
 CC present sequence is a PCR primer used to detect human FGFR3 allele

XX

SQ Sequence 18 BP; 3 A; 5 C; 7 G; 3 T; 0 U; 0 Other;
 Query Match 0.5%; Score 18; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 6.6e+02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1048 CTGGAGTCCACGCGTCC 1065
 DB 18 CTGGAGTCCACGCGTCC 1

RESULT 549
 ABQ81992/c
 ID ABQ81992 standard; DNA; 18 BP.

XX AC ABQ81992;

XX 19-NOV-2002 (first entry)

XX Kaposi's Sarcoma TAG PCR primer SEQ ID NO:142.

XX Human; Kaposi's sarcoma; tumour; angiogenesis; PCR primer; ss.

XX Homo sapiens.

XX EP1225233-A2.

XX 24-JUL-2002.

XX 23-JAN-2002; 2002EP-00075264.

XX 23-JAN-2001; 2001EP-00200228.

XX 28-SEP-2001; 2001EP-00203703.

XX 28-SEP-2001; 2001US-0325722P.

XX (AMST-) AMSTERDAM SUPPORT DIAGNOSTICS BV.

XX Van Der Kuyl AC, Cornelissen M;

XX WPI; 2002-668396/72.

XX Determining presence of a tumor cell or angiogenesis, and the
 PT effectiveness of treatment, by detecting the presence of marker genes is
 PT useful to detect and monitor treatment of Kaposi's Sarcoma.

XX Example 10; Page 24; 38pp; English.

XX The present invention describes a method for determining if an individual
 CC has a tumour cell or site of angiogenesis, or if a treatment is effective
 CC in changing angiogenesis or changing a status of a set of target cells,
 CC comprising determining if a sample of the subject has an expression
 CC product of at least one marker gene. Also described is a compound capable
 CC of altering the expression or activity of Keratin 14, TIE 1, Salivoadhesin
 CC or Siglec in a cell. Peripheral blood mononuclear cell (PBMC)-expressed
 CC Keratin 14, TIE 1, Salivoadhesin or Siglec, and kits containing them from
 CC the present invention can be used in a diagnostic method, particularly as
 CC an indicator of angiogenesis or to determine presence of a tumour cell.
 CC The method of the invention is suitable to determine within a few days if
 CC a certain treatment against Kaposi's Sarcoma is successful. ABQ81851 to
 CC ABQ82006 represent nucleotide sequence used in the exemplification of the
 CC present invention

XX Sequence 18 BP; 2 A; 8 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 18; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 6.6e+02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1888 AAGCTGCTGAGGAGGCGC 1905
 DB 18 AAGCTGCTGAGGAGGCGC 1

RESULT 550
ADH70777/c
ID ADH70777 standard; DNA; 18 BP.
XX
AC ADH70777;
XX
DT 18-DEC-2003 (first entry)
XX
DE Kaposi's sarcoma tag PCR primer, SEQ ID NO 144.
XX
KW marker gene; tumour; Kaposi's Sarcoma; peripheral blood mononuclear cell;
KW PBMC; expressed keratin 14; TIE 1; Salivohesin; Siglec 1; angiogenesis;
KW drug target; tag; SAGE library; KS3; KS4; PCR; primer; ss.
OS
XX Unidentified.
XX
XX EP1298221-A1.
XX
XX 02-APR-2003.
XX
XX 28-SEP-2001; 2001EP-00203703.
XX
XX 28-SEP-2001; 2001EP-00203703.
XX
XX (PRIM-) PRIMAGEN HOLDING BV.
XX
XX Van Der Kuyt AC, Cornelissen M;
XX
XX WPI; 2003-589342/56.
XX
XX Determining whether a treatment is effective in changing a status of a
XX certain set of target cells in an individual comprises determining
XX whether the sample comprises an expression product of at least one marker
XX gene.
XX
XX Disclosure; SEQ ID NO 144; 94pp; English.
XX
XX The invention relates to a novel method for determining whether a
XX treatment is effective in changing a status of a certain set of target
XX cells in an individual. The method comprises obtaining a sample from an
XX individual after initiation of the treatment; and determining whether the
XX sample comprises an expression product of at least one marker gene. The
XX marker gene and a proteinaceous molecule (which can bind to the protein
XX derived from the marker gene of the invention) are useful for determining
XX whether a treatment is effective in counteracting a tumour in an
XX individual, especially Kaposi's Sarcoma. Peripheral blood mononuclear
XX cell (PBMC) expressed keratin 14, TIE 1, Salivohesin, or Siglec 1
XX sequences or a fully defined sequence given in the specification, or
XX their analogues are useful as indicators for angiogenesis and for
XX detecting the presence of a tumour cell in an individual. The expression
XX product of a gene comprising a marker gene of the invention is useful as
XX a drug target. The compound is useful for preparing a medicament. This
XX polynucleotide sequence represents a PCR primer of a Kaposi's Sarcoma tag
XX sequence of the invention.
XX
XX Sequence 18 BP; 2 A; 8 C; 3 G; 5 T; 0 U; 0 Other;
XX
Query Match 0.5%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 6.6e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1888 AAGCTGCTGAAGGAGGC 1905
DB 18 AAGCTGCTGAAGGAGGC 1
ADH70777/c
ID ADH70777 standard; DNA; 18 BP.
XX
AC ADH70777;
XX
XX 25-MAR-2004 (first entry)
DT

XX
DE Human Vbeta gene repeat sequence #567.
XX
KW human; T-cell associated disease; Vbeta; autoimmune disease;
KW degenerative nervous system disease; graft versus host disease;
KW hypersensitivity disease; infectious disease; neoplastic disease;
KW Addison's disease; atrophic gastritis;
KW degenerative nervous system disease; multiple sclerosis;
KW Alzheimer's disease; hypersensitivity; Goodpasture's syndrome;
KW allergy; type II hypersensitivity; leprosy; infectious disease; type I hypersensitivity;
KW type IV hypersensitivity; leprosy; infectious disease; schistosoma;
KW HIV; fungal infection; Candida; parasitic infection; schistosoma;
KW filaria; bacterial infection; Mycobacterium; neoplastic disease;
KW lymphoproliferative disease; leukaemia; lymphoma; cancer; brain cancer;
KW breast cancer; ds.
XX
XX Homo sapiens.
XX
XX US2002150891-A1.
XX
XX 17-OCT-2002.
XX
XX 05-MAR-1999; 99US-00263959.
XX
XX 19-SEP-1994; 94US-00309335.
XX
XX 19-SEP-1995; 95US-00531241.
XX
XX (HOOD/) HOOD L E.
XX
XX (ROWE/) ROWEN L.
XX
XX Hood LE, Rowen L;
XX
XX WPI; 2004-059052/06.
XX
XX Kit for diagnosing and treating T-cell associated diseases e.g.
XX autoimmune, degenerative nervous system and infectious disease, comprises
XX nucleic acid primers specifically priming and allowing amplification of a
XX Vbeta gene.
XX
XX Disclosure; SEQ ID NO 971; 164pp; English.
XX
XX The invention relates to a kit for diagnosing and treating T-cell
XX associated diseases which comprises a panel of nucleic acid primers
XX specifically priming and allowing amplification of each Vbeta gene,
XX VbetARNA or cDNA. The kit is useful for diagnosing organ transplant
XX rejection and diagnosing and treating T-cell associated diseases
XX including autoimmune diseases, degenerative nervous system diseases,
XX graft versus host disease, hypersensitivity diseases, infectious diseases
XX and neoplastic diseases. Autoimmune diseases include Addison's disease,
XX atrophic gastritis. Degenerative nervous system diseases include multiple
XX sclerosis and Alzheimer's disease. Hypersensitivity diseases include type
XX I hypersensitivities such as contact with allergens that lead to
XX allergies, Type II hypersensitivities such as those present in
XX Goodpasture's syndrome and Type IV hypersensitivities such as those
XX manifested in leprosy. Infectious diseases include viral infections
XX caused by viruses such as HIV, fungal infections such as those caused by
XX the yeast genus Candida, parasitic infections such as those caused by
XX schistosomes, filaria and bacterial infections such as those caused by
XX Mycobacterium. Neoplastic diseases include lymphoproliferative diseases
XX such as leukaemias, lymphomas and cancers such as cancer of the brain,
XX breast. The present sequence represents a Vbeta gene repeat sequence.
XX
XX Sequence 18 BP; 8 A; 0 C; 1 G; 9 T; 0 U; 0 Other;
XX
Query Match 0.5%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 6.6e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2826 ATATACATATATATATAT 2843
DB 18 ATATACATATATATATAT 1

RESULT 552
AD015049/c
ID AD015049 standard; RNA; 19 BP.
XX AC AD015049;
XX DT 01-JUL-2004 (first entry)
XX DE Human PDGFR-targeted siNA lower strand SEQ ID NO:480.
XX KW cytosolic; vasotrophic; nephrotropic; cerebroprotective;
KW treating leukaemia; solid tumors; restenosis; polycystic kidney disease;
KW bronchiolitis; glomerulonephritis; stroke; RNA interference;
KW short interfering nucleic acid; siNA; short interfering RNA; siRNA;
KW double-stranded RNA; micro-RNA; miRNA; short hairpin RNA; shRNA;
KW expression modulation; gene therapy; drug screening; diagnosis;
KW therapeutic target identification; pharmacogenomics;
KW gene function analysis; gene mapping; human;
KW platelet derived growth factor receptor; PDGFR; ss.
XX OS Homo sapiens.
XX PN WO2003072704-A2.
XX PD 04-SEP-2003.
XX PF 05-FEB-2003; 2003WO-US003473.
XX PR 20-FEB-2002; 2002US-0358580P.
XX PR 11-MAR-2002; 2002US-0363124P.
XX PR 06-JUN-2002; 2002US-0386782P.
XX PR 29-AUG-2002; 2002US-0406784P.
XX PR 05-SEP-2002; 2002US-0408378P.
XX PR 09-SEP-2002; 2002US-0409293P.
XX PR 15-JAN-2003; 2003US-0440129P.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Mcswiggen J, Beigelman L, Chowrira B;
XX WPI; 2003-731605/69.
XX PT New short interfering nucleic acid, useful e.g. for treatment and
PT diagnosis of tumors, downregulates expression of the platelet-derived
PT growth factor receptor gene.
XX PS Example 3; SEQ ID NO 480; 148pp; English.
XX CC The invention relates to short interfering nucleic acids (siNA) which
CC downregulate expression of the human platelet-derived growth factor
CC receptor (PDGFR) gene by RNA interference. The siNAs may or may not
CC comprise ribonucleotides and may be double or single stranded. They
CC further comprise sense and antisense regions, or alternatively are
CC assembled from a sense oligonucleotide and an antisense oligonucleotide.
CC Specifically, the siNAs include short interfering RNA (siRNA, double-
CC stranded RNA, micro-RNA (miRNA) and short hairpin RNA (shRNA). The siNAs
CC can be unmodified or chemically modified, can contain
CC deoxyribonucleotides, and can be chemically synthesised, expressed from a
CC vector or enzymatically synthesised. The invention also relates to kits
CC for the in vitro or in vivo delivery of siRNA; conjugates and/or
CC complexes of siRNA; and vectors that express siNA. The siNAs are used to
CC modulate expression of the PDGFR gene in cells, tissue explants or
CC organisms (e.g., by ex vivo gene therapy), or in grafts and transplants
CC for the treatment of a variety of conditions. They may be used for
CC treating leukaemia and solid tumors, restenosis, polycystic kidney
CC disease, bronchiolitis, glomerulonephritis and stroke. The siNAs are also
CC useful for drug screening, diagnosis, therapeutic target identification
CC and validation, genetic engineering, pharmacogenomics, studying gene
CC function, and gene mapping (e.g., of single nucleotide polymorphisms).
CC The present sequence represents the lower strand of a human PDGFR-
CC targeted double-stranded siNA, which is identical to the PDGFR transcript
CC target sequence.
XX

SO Sequence 19 BP; 6 A; 5 C; 5 G; 0 T; 3 U; 0 Other;
Query Match 0.5%; Score 18; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 7e+02; 0;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1820 TCCTGCTCTGGGAGATCT 1837
DB 18 TCCTGCTCTGGGAGATCT 1
RESULT 553
AD014738
ID AD014738 standard; RNA; 19 BP.
XX AC AD014738;
XX DT 01-JUL-2004 (first entry)
XX DE Human PDGFR-targeted siNA upper strand SEQ ID NO:169.
XX KW cytosolic; vasotrophic; nephrotropic; cerebroprotective;
KW treating leukaemia; solid tumors; restenosis; polycystic kidney disease;
KW bronchiolitis; glomerulonephritis; stroke; RNA interference;
KW short interfering nucleic acid; siNA; short interfering RNA; siRNA;
KW double-stranded RNA; micro-RNA; miRNA; short hairpin RNA; shRNA;
KW expression modulation; gene therapy; drug screening; diagnosis;
KW therapeutic target identification; pharmacogenomics;
KW gene function analysis; gene mapping; human;
KW platelet derived growth factor receptor; PDGFR; ss.
XX OS Homo sapiens.
XX PN WO2003072704-A2.
XX PD 04-SEP-2003.
XX PF 05-FEB-2003; 2003WO-US003473.
XX PR 20-FEB-2002; 2002US-0358580P.
XX PR 11-MAR-2002; 2002US-0363124P.
XX PR 06-JUN-2002; 2002US-0386782P.
XX PR 29-AUG-2002; 2002US-0406784P.
XX PR 05-SEP-2002; 2002US-0408378P.
XX PR 09-SEP-2002; 2002US-0409293P.
XX PR 15-JAN-2003; 2003US-0440129P.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Mcswiggen J, Beigelman L, Chowrira B;
XX WPI; 2003-731605/69.
XX PT New short interfering nucleic acid, useful e.g. for treatment and
PT diagnosis of tumors, downregulates expression of the platelet-derived
PT growth factor receptor gene.
XX PS Example 3; SEQ ID NO 169; 148pp; English.
XX CC The invention relates to short interfering nucleic acids (siNA) which
CC downregulate expression of the human platelet-derived growth factor
CC receptor (PDGFR) gene by RNA interference. The siNAs may or may not
CC comprise ribonucleotides and may be double or single stranded. They
CC further comprise sense and antisense regions, or alternatively are
CC assembled from a sense oligonucleotide and an antisense oligonucleotide.
CC Specifically, the siNAs include short interfering RNA (siRNA, double-
CC stranded RNA, micro-RNA (miRNA) and short hairpin RNA (shRNA). The siNAs
CC can be unmodified or chemically modified, can contain
CC deoxyribonucleotides, and can be chemically synthesised, expressed from a
CC vector or enzymatically synthesised. The invention also relates to kits
CC for the in vitro or in vivo delivery of siRNA; conjugates and/or
CC complexes of siRNA; and vectors that express siNA. The siNAs are used to
CC modulate expression of the PDGFR gene in cells, tissue explants or
CC organisms (e.g., by ex vivo gene therapy), or in grafts and transplants
CC for the treatment of a variety of conditions. They may be used for
CC treating leukaemia and solid tumors, restenosis, polycystic kidney
CC disease, bronchiolitis, glomerulonephritis and stroke. The siNAs are also
CC useful for drug screening, diagnosis, therapeutic target identification
CC and validation, genetic engineering, pharmacogenomics, studying gene
CC function, and gene mapping (e.g., of single nucleotide polymorphisms).
CC The present sequence represents the lower strand of a human PDGFR-
CC targeted double-stranded siNA, which is identical to the PDGFR transcript
CC target sequence.
XX

CC organisms (e.g., by ex vivo gene therapy), or in grafts and transplants
 CC for the treatment of a variety of conditions. They may be used for
 CC treating leukemia and solid tumours, restenosis, polycystic kidney
 CC disease, bronchiolitis, glomerulonephritis and stroke. The siNAs are also
 CC useful for drug screening, diagnosis, therapeutic target identification
 CC and validation, genetic engineering, pharmacogenomics, studying gene
 CC function, and gene mapping (e.g., of single nucleotide polymorphisms).
 CC The present sequence represents the upper strand of a human PDGFr-
 CC targeted double-stranded siNA, which is identical to the PDGFr transcript
 CC target sequence.

XX Sequence 19 BP; 3 A; 5 C; 5 G; 0 T; 6 U; 0 Other;

Query Match 0.5%; Score 18; DB 1; Length 19;

Best Local Similarity 66.7%; Pred. No. 7e+02;

Matches 12; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 1820 TCCTGCTGGGAGATCT 1837

Db 2 UCCUGCUCUGGAGAUU 19

RESULT 554

AAQ49455

ID AAQ49455 standard; DNA; 20 BP.

XX AAQ49455;

XX 06-MAY-1994 (first entry)

DT Primer for detecting polymorphisms among highly related plant species.

DE Detection; polymorphism; genetic fingerprinting; primer; ss.

XX Synthetic.

XX JP05244995-A.

XX 24-SEP-1993.

XX 24-SEP-1991; 91JP-00243122.

XX 24-SEP-1991; 91JP-00243122.

XX (KYOW) KYOWA HAKKO KOGYO KK.

XX WPI; 1993-338949/43.

XX Primer - for detecting polymorphism in DNA among highly interrelated rice
 PT plants or plants of family Brassicaceae.

XX Disclosure; Page 5; 6pp; Japanese.

XX The PCR primers (See also AAQ49449-54, AAQ49456) are used to detect
 CC polymorphisms among highly interrelated rice plants or among plants of
 CC family Brassicaceae. They can also be used for genetic fingerprinting of
 CC plants, allowing detection of polymorphism within one or the same species
 CC of plant

XX Sequence 20 BP; 0 A; 2 C; 9 G; 9 T; 0 U; 0 Other;

Query Match 0.5%; Score 18; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 7.4e+02;

Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2335 GTGTGTGTGTGTGTGTGC 2352

Db 2 GTGTGTGTGTGTGTGTGC 19

RESULT 555

ADM14399/c

ID ADM14399 standard; DNA; 20 BP.

XX

AC ADM14399;

XX 01-JUL-2004 (first entry)

XX Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:586.

XX chimeric; antisense oligonucleotide; phosphorothioate; human;
 KW microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
 KW microsomal prostaglandin E2 synthase inhibitor; cytosolic; antidiabetic;
 KW immunomodulator; cardiac; neuroprotective; antiinflammatory;
 KW neuroprotective; nocardic; antiarthritic; vasotropic; ophthalmological;
 KW immunomodulatory; cardiovascular; gene therapy; inflammation;
 KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
 KW reperfusion injury; ophthalmic disorder; immunological disorder;
 KW cardiovascular disorder; neurological disorder; ss.

XX Homo sapiens.

XX Synthetic.

XX Key Location/Qualifiers

FT modified_base 1..20

FT /tag= b

FT /mod_base= OTHER
 FT /note= "phosphorothioate linkages and all cytidine
 FT residues are 5-methylcytidines"

FT modified_base 1..5

FT /tag= a

FT /mod_base= OTHER

FT /note= "2'-O-methoxyethyls"

FT modified_base 16..20

FT /tag= c

FT /mod_base= OTHER

FT /note= "2'-O-methoxyethyls"

XX WO2004028458-A2.

XX 08-APR-2004.

XX 25-SEP-2003; 2003WO-US030374.

XX 25-SEP-2002; 2002US-0413549P.

XX (PHAA) PHARMACIA CORP.

XX Gierse JK;

XX WPI; 2004-305094/28.

XX New antisense compound, having a sequence targeted to a nucleic acid
 PT encoding mPGES-1, useful for preparing a composition for treating e.g.,
 PT inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
 PT ischemia.

XX Claim 4; SEQ ID NO 586; 132pp; English.

XX The present sequence represents a chimeric antisense oligonucleotide
 CC targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
 CC human mPGES-1 gene is located on chromosome 9, more specifically to
 CC 9q34.3. The present invention also describes: (1) antisense compounds,
 CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
 CC mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
 CC inhibits its expression; (2) a method of inhibiting the expression of
 CC mPGES-1 in cells or tissues; and (3) a method of treating an animal
 CC having a disease or condition associated with mPGES-1. mPGES-1 chimeric
 CC antisense oligonucleotides and antisense compounds have cytostatic,
 CC antidiabetic, immunomodulator, cardiac, neuroprotective,
 CC antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
 CC ophthalmological, immunomodulatory and cardiovascular activities, and can
 CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
 CC can be used for preparing a composition for treating a disease or
 CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
 CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or

CC ophthalmic, immunological, cardiovascular or neurological disorder.

XX Sequence 20 BP; 9 A; 10 C; 1 G; 0 T; 0 U; 0 Other;

QQ Query Match 0.5%; Score 18; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 7.4e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2334 CGTGTGTGTGTGTGTG 2351
Db 20 CGTGTGTGTGTGTGTG 3

RESULT 556
ADM14344/c
ID ADM14344 standard; DNA; 20 BP.
XX
AC ADM14344;
XX

DT 01-JUL-2004 (first entry)

DE Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:531.

XX chimeric; antisense oligonucleotide; phosphorothioate; human;
KW microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
KW microsomal prostaglandin E2 synthase inhibitor; cytosolic; antidiabetic;
KW immunomodulator; cardiant; neuroprotective; antiinflammatory;
KW neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
KW immunomodulatory; cardiovascular; gene therapy; inflammation;
KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
KW reperfusion injury; ophthalmic disorder; immunological disorder;
KW cardiovascular disorder; neurological disorder; ss.

XX Homo sapiens.
OS Synthetic.

XX

FH Key Location/Qualifiers
FT modified_base 1..20 /*tag= b
FT /*mod_base= OTHER
FT /note= "phosphorothioate linkages and all cytidine
FT residues are 5-methylcytidines"
FT modified_base 1..5 /*tag= a
FT /*mod_base= OTHER
FT /note= "2'-O-methoxyethyls"
FT modified_base 16..20 /*tag= c
FT /*mod_base= OTHER
FT /note= "2'-O-methoxyethyls"

XX WQ2004028458-A2.
XX
XX 08-APR-2004.
XX
XX 25-SEP-2003; 2003WO-US030374.
XX PF
XX 25-SEP-2002; 2002US-0413549P.
XX PR
XX (PHAA) PHARMACIA CORP.
XX
XX Gierse JK;
XX PI
XX WPI; 2004-305094/28.
XX DR
XX New antisense compound, having a sequence targeted to a nucleic acid
XX encoding mPGES-1, useful for preparing a composition for treating e.g.,
XX inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
XX ischemia.
XX
XX Claim 4; SEQ ID NO 531; 132pp; English.
XX PS
XX The present sequence represents a chimeric antisense oligonucleotide

CC targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
human mPGES-1 gene is located on chromosome 9, more specifically to
9q34.3. The present invention also describes: (1) antisense compounds,
having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
mPGES-1, which specifically hybridize with the nucleic acid mPGES-1 and
inhibits its expression; (2) a method of inhibiting the expression of
mPGES-1 in cells or tissues; and (3) a method of treating an animal
having a disease or condition associated with mPGES-1. mPGES-1 chimeric
antisense oligonucleotides and antisense compounds have cytostatic,
antidiabetic, immunomodulator, cardiant, neuroprotective,
antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
ophthalmological, immunomodulatory and cardiovascular activities, and can
be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
can be used for preparing a composition for treating a disease or
condition associated with mPGES-1 e.g., inflammation, Alzheimer's
disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
ophthalmic, immunological, cardiovascular or neurological disorder.

XX
SQ Sequence 20 BP; 9 A; 9 C; 2 G; 0 T; 0 U; 0 Other;

Query Match 0.5%; Score 18; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 7.4e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2334 CGTGTGTGTGTGTGTG 2351
Db 19 CGTGTGTGTGTGTGTG 2

RESULT 557
ADK96577/c
ID ADK96577 standard; DNA; 21 BP.
XX
AC ADK96577;
XX
DT 06-MAY-2004 (first entry)
DE Primer of the invention #2297.
XX human; single nucleotide polymorphism; SNP; ss; primer.
XX Synthetic.
XX
XX JP2003259875-A.
XX PD 16-SEP-2003.
XX 08-MAR-2002; 2002JP-00064373.
XX PF
XX 08-MAR-2002; 2002JP-00064373.
XX PR
XX (KAGA-) KAGAKU GIJUTSU SHINKO JIGYODAN.
XX PA
XX WPI; 2004-093977/10.
XX DR
XX Novel polynucleotide useful for PCR amplification along with two DNA
XX fragment from another set of sequences, or for detecting single
XX nucleotide polymorphism in human gene.
XX
XX Claim 2; SEQ ID NO 5606; 2627pp; Japanese.
XX
XX The present invention relates to a polynucleotide isolated from a human
XX gene and is useful for detecting a single nucleotide polymorphism in a
XX human gene or for diagnosing of disease. The invention enables the
XX detection of a single nucleotide polymorphism in a human gene. The
XX present sequence represents a primer of the invention.
XX
XX Sequence 21 BP; 8 A; 10 C; 1 G; 2 T; 0 U; 0 Other;

Query Match 0.5%; Score 18; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 7.9e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2331 GTCCGTGTGTGTGTGT 2348
 DB 20 GTCCGTGTGTGTGTGT 3

RESULT 558
 ADJ98020
 ID ADJ98020 standard; DNA; 21 BP.
 XX
 AC ADJ98020;
 XX
 DT 06-MAY-2004 (first entry)
 XX
 DE Human Flk-1/KDR DNA sequence, a target for siRNA inhibition SeqID 793.
 XX
 KW human; ss; short interfering RNA; siRNA; angiogenesis;
 KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
 KW Flk-1/KDR; Kinase domain region; diabetic retinopathy;
 KW age-related macular degeneration; inflammatory disease; psoriasis;
 KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilms' tumour;
 KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
 KW antipsoriatic; antirheumatic; antiarthritic.
 XX
 OS Homo sapiens.
 XX
 PN WO2004009769-A2.
 XX
 PD 29-JAN-2004.
 XX
 PF 18-JUL-2003; 2003WO-US022444.
 XX
 PR 24-JUL-2002; 2002US-0398417P.
 PR 14-NOV-2002; 2002US-00294228.
 XX
 PA (UYPE-) UNIV PENNSYLVANIA.
 XX
 PI Tolentino MJ, Reich SJ;
 XX
 DR WPI; 2004-203472/19.
 XX
 PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
 PT strands, useful for inhibiting expression of human vascular endothelial
 PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
 PT retinopathy and cancer.
 XX
 PS Disclosure; SEQ ID NO 793; 218pp; English.
 XX
 CC This invention relates to novel compositions that comprise short
 CC interfering RNA (siRNA) molecules, which can be used to inhibit
 CC angiogenesis. Specifically, it refers to siRNAs that target and cause
 CC RNAi-induced degradation of mRNA from human vascular endothelial growth
 CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
 CC region) genes, as well as mutants derived thereof. The present invention
 CC describes sense and antisense RNA strands that form an RNA duplex and
 CC bind to the target mRNA, such that expression is inhibited and the target
 CC degraded. As such, siRNA administered in combination with a therapeutic
 CC agent is useful for treating diseases associated with angiogenesis and
 CC the overexpression of VEGF, which include diabetic retinopathy, age-
 CC related macular degeneration, inflammatory disease, psoriasis and
 CC rheumatoid arthritis. Furthermore, it can be used to treat various
 CC cancers including breast, retinoblastoma, Wilms' tumour and lymphoma.
 CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
 CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
 CC antiarthritic activities. This oligonucleotide is a human Flk-1/KDR DNA
 CC oligo, a target for siRNA inhibition of the invention.
 XX
 SQ Sequence 21 BP; 5 A; 5 C; 6 G; 5 T; 0 U; 0 Other;
 Query Match 0.5%; Score 18; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 7.9e+02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1794 CCAGAGTGACGTCTGTC 1811

DB 4 CCAGAGTGACGTCTGTC 21
 RESULT 559
 AAX00049
 ID AAX00049 standard; DNA; 22 BP.
 XX
 AC AAX00049;
 XX
 DT 16-MAR-1999 (first entry)
 XX
 DE FGFR PCR sense primer.
 XX
 KW Neuroepithelial stem cell; lineage restricted intermediate precursor;
 KW oligodendrocyte; astrocyte; self-renewal; neuron; differentiation;
 KW neural crest cell; fibroblast growth factor; FGF; FGFR; receptor; CNS;
 KW central nervous system; glial cell; PCR primer; amplification; ss.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO9850526-A1.
 XX
 PD 12-NOV-1998.
 XX
 PF 07-MAY-1998; 98WO-US009630.
 XX
 PR 07-MAY-1997; 97US-00852744.
 PR 06-MAY-1998; 98US-00073881.
 XX
 PA (UTAH) UNIV UTAH RES FOUND.
 XX
 PI Rao MS, Mayer-Proschel M, Mujtaba T;
 XX
 DR WPI; 1999-070093/06.
 XX
 PT Mammalian neuroepithelial stem cells and glial restricted precursor - can
 PT self renew and differentiate into central nervous system cells, used for
 PT generating various types of cells.
 XX
 PS Example 26; Page 61; 78pp; English.
 CC
 CC The present invention describes an isolated, pure population of mammalian
 CC neuroepithelial stem cells, which are capable of self-renewal in adherent
 CC feeder-cell-independent (AFCI) culture medium and differentiation to
 CC central nervous system (CNS) neuronal or glial cells and to neuronal
 CC crest stem cells. Also described is an isolated population of mammalian
 CC CNS glial-restricted precursor (GRP) cells which can self-renew in the
 CC APCI culture medium and can differentiate to CNS glial cells but not to
 CC CNS neuronal cells. The stem cells can be used to generate a population
 CC of mammalian motor neurons by incubating the stem cells in a medium
 CC promoting cell proliferation and neuronal differentiation. The medium
 CC comprises laminin-coated plates and NEP medium lacking chick embryo
 CC extract. The stem cells can also produce neural crest stem cells by
 CC inducing the cells to differentiate in vitro. The inducing step comprises
 CC replating the cells on a laminin-coated substrate and preferably
 CC withdrawing a mitogen (preferably fibroblast growth factor; FGF) and
 CC chick embryo extract. Inducing can also comprise adding a dorsalizing
 CC agent to the cells, preferably a bone morphogenetic protein (BMP) such as
 CC BMP-2, -4 or -7. The stem cells can be used to produce cells of the
 CC peripheral nervous system, by inducing the stem cells to differentiate in
 CC vitro to neural crest stem cells, and inducing these cells to
 CC differentiate. AAX00029 to AAX00054 represent PCR primers which are used
 CC in an example from the present invention to amplify different FGF and
 CC FGFR genes
 XX
 SQ Sequence 22 BP; 8 A; 1 C; 8 G; 5 T; 0 U; 0 Other;
 Query Match 0.5%; Score 18; DB 1; Length 22;
 Best Local Similarity 100.0%; Pred. No. 8.3e+02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1347 TGAGATCGAGATGATGAA 1364
 Db 5 TGAGATCGAGATGATGAA 22

RESULT 560
 AAV38616/c
 ID AAT58080 standard; DNA; 21 BP.
 XX AC
 XX AAT58080;
 XX AC
 XX 25-MAR-2003 (revised)
 DT 18-MAR-1997 (first entry)
 XX XX
 XX ICAM-1 antisense oligonucleotide #10.
 DE DE
 XX XX
 XX Antisense; pre-mRNA; mature mRNA; vascular defect; tissue defect;
 KW human intercellular adhesion molecule-1; ICAM-1; inflammation;
 KW adult respiratory distress syndrome; multiple organ failure; GW1594;
 KW septic shock; ss.
 XX XX
 XX Synthetic.
 OS OS
 XX US5580969-A.
 PN PN
 XX 03-DEC-1996.
 PD PD
 XX 12-OCT-1993; 93US-00136118.
 PF PF
 XX 24-JUL-1992; 92US-00918259.
 PR PR
 XX (USNA) US SEC OF NAVY.
 PA PA
 XX Lee C, Hoke GD, Bradley MO, Williams TJ;
 PI PI
 XX WPI; 1997-033603/03.
 DR DR

PT Anti-sense oligo:nucleotide(s) for blocking ICAM-1 mRNA translation - for
 treating septic shock, adult respiratory distress syndrome etc.
 PS PS
 XX Claim 1; Col 21; 16pp; English.
 XX XX

CC The sequences given in AAT58071-85 represent oligonucleotides which are
 antisense to sequences contained in the pre-mRNA or mature mRNA
 CC transcript of human intercellular adhesion molecule-1 (ICAM-1). These
 CC oligonucleotides may be used for treating septic shock and the
 CC manifestations of septic shock, e.g. inflammation, and vascular and
 CC tissue defects. They are also useful in the treatment of septic shock
 CC associated diseases, e.g. adult respiratory distress syndrome, multiple
 CC organ failure etc. (Updated on 25-MAR-2003 to correct PF field.)
 XX XX
 SQ Sequence 21 BP; 11 A; 9 C; 0 G; 1 T; 0 U; 0 Other;

Query Match 0.5%; Score 17.8; DB 1; Length 21;
 Best Local Similarity 90.5%; Pred. No. 8.3e+02;
 Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2318 TGTGTGTGTGTGTGCGTGT 2338
 Db 21 TGTGTGTGTGTGTGTGTGTGT 1

RESULT 561
 AAV38616/c
 ID AAV38616 standard; DNA; 21 BP.
 XX AC
 XX AAV38616;
 XX AC
 XX 13-OCT-1998 (first entry)
 DT DT
 XX Human ICAM-1, E-selectin, VCAM-1 antisense oligonucleotide.
 DE DE
 XX ICAM-1; intracellular adhesion molecule-; E-selectin; VCAM-1;
 KW KW

KW vascular cell adhesion molecule-1; antisense; inflammatory; disease;
 KW treatment; septic shock; psoriasis; wounds; burns; acne; arthritis;
 KW organ rejection; inhibition; expression; ss.
 XX XX
 OS Synthetic.
 OS Homo sapiens.
 XX XX
 PN WO9824797-A1.
 PD PD
 XX 11-JUN-1998.
 XX XX
 XX 02-DEC-1996; 96WO-US019194.
 PF PF
 XX 02-DEC-1996; 96WO-US019194.
 PR PR
 XX (DYAD-) DYAD PHARM CORP.
 PA PA
 XX Hoke GD, Bradley MO, Williams TJ, Lee C;
 PI PI
 XX WPI; 1998-333253/29.
 DR DR

PT Antisense oligonucleotides to ICAM-1, E-selectin or VCAM-1 - useful for
 treating diseases having an inflammatory component, e.g. psoriasis,
 PT wounds and septic shock.
 PT XX
 XX Claim 8; Page 40; 48pp; English.
 PS PS
 XX XX

CC The sequence is that of an antisense oligonucleotide which is
 CC substantially complementary to at least a portion of the pre- or mature
 CC RNA transcript of human intracellular adhesion molecule (ICAM), E-
 CC selectin or vascular cell adhesion molecule (VCAM). It can be used to
 CC inhibit expression of these proteins. Inhibition of these proteins forms
 CC the basis for treatment of conditions and diseases that have an
 CC inflammatory component, e.g. acne, psoriasis, arthritis, organ rejection,
 CC wounds, burns, septic shock or inflammatory complications of septic shock
 CC XX
 SQ Sequence 21 BP; 11 A; 9 C; 0 G; 1 T; 0 U; 0 Other;

Query Match 0.5%; Score 17.8; DB 1; Length 21;
 Best Local Similarity 90.5%; Pred. No. 8.3e+02;
 Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2318 TGTGTGTGTGTGTGCGTGT 2338
 Db 21 TGTGTGTGTGTGTGTGTGTGT 1

RESULT 562
 AAZ18102/c
 ID AAZ18102 standard; DNA; 21 BP.
 XX AC
 XX AAZ18102;
 XX AC
 XX 11-OCT-1999 (first entry)
 DT DT
 XX PTK 6 gene specific primer.
 DE DE
 XX XX

KW Genetic proximity; gene expression; cell characterisation; homeobox gene;
 KW genetic defect; reverse transcriptase polymerase chain reaction; RT-PCR;
 KW kinase gene; protein phosphatase; P450; steroid receptor; cadherin;
 KW primer; ss.
 XX XX
 OS Synthetic.
 OS Homo sapiens.
 XX XX
 PN WO934016-A2.
 PD PD
 XX 08-JUL-1999.
 XX XX
 XX 28-DEC-1998; 98WO-IL000625.
 PF PF
 XX 29-DEC-1997; 97IL-00122793.
 PR PR
 XX 16-OCT-1998; 98IL-00126627.

DR P-PSDB; AAY14653.
XX
-PT Identifying and characterizing cells by comparing the pattern of gene
PT expression in a selected gene family.
XX
PS Claim 4; Page 43; 102pp; English.
XX
CC The invention provides a new method for identifying and characterising
CC cells. The method for determining the genetic proximity of a first cell
CC and a second cell comprises: (a) obtaining the first cell and the second
CC cell; (b) determining in the first cell and the second cell the pattern
CC of expression of genes in a selected gene family; and (c) calculating a
CC proximity index using a specified formula. The methods can be used for
CC characterising cells, e.g. for determining the origin of a cell, its
CC genetic status, whether it carries a genetic defect, or whether it is
CC transformed. They can be used for detecting a selected genetic defect in
CC an individual, e.g. a fetus. They can also be used for determining the
CC effect of a selected treatment on a test cell. They can also be used for
CC obtaining cells capable of expressing an homeobox related desired
CC property. The method uses reverse transcriptase polymerase chain reaction
CC (RT-PCR) for determining the pattern of gene expression in a selected
CC gene family. Sequences AA217803-218342 represent primers that can be used
CC in the RT-PCR reactions to determine the pattern of gene expression. The
CC gene family can be selected from a set of homeobox genes, kinase genes,
CC protein phosphatase genes, P450 enzyme genes, steroid receptor
CC superfamily genes or cadherin superfamily genes
XX
SQ Sequence 21 BP; 7 A; 8 C; 3 G; 3 T; 0 U; 0 Other;
Query Match 0.5%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 8.3e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1798 AGTCAGCTCTGCTCTTGGG 1818
Db 21 AGTCAGCTCTGCTCTTGGG 1
RESULT 565
AAZ18110/C
ID AAZ18110 standard; DNA; 21 BP.
XX
AC AAZ18110;
XX
DT 11-OCT-1999 (first entry)
XX
DE PTK 10 gene specific primer.
XX
KW Genetic proximity; gene expression; cell characterisation; homeobox gene;
KW genetic defect; reverse transcriptase polymerase chain reaction; RT-PCR;
KW kinase gene; protein phosphatase; P450; steroid receptor; cadherin;
KW primer; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
FN WO9934016-A2.
XX
PD 08-JUL-1999.
XX
PF 28-DEC-1998; 98WO-IL000625.
XX
PR 29-DEC-1997; 97IL-00122793.
PR 16-OCT-1998; 98IL-00126627.
XX
FA (GENE-) GENENA LTD.
XX
PI Vider B;
XX
XX WPI; 1999-419113/35.
DR P-PSDB; AAY14645.
XX
PT Identifying and characterizing cells by comparing the pattern of gene

PT expression in a selected gene family.
XX
PS Claim 4; Page 42; 102pp; English.
XX
CC The invention provides a new method for identifying and characterising
CC cells. The method for determining the genetic proximity of a first cell
CC and a second cell comprises: (a) obtaining the first cell and the second
CC cell; (b) determining in the first cell and the second cell the pattern
CC of expression of genes in a selected gene family; and (c) calculating a
CC proximity index using a specified formula. The methods can be used for
CC characterising cells, e.g. for determining the origin of a cell, its
CC genetic status, whether it carries a genetic defect, or whether it is
CC transformed. They can be used for detecting a selected genetic defect in
CC an individual, e.g. a fetus. They can also be used for determining the
CC effect of a selected treatment on a test cell. They can also be used for
CC obtaining cells capable of expressing an homeobox related desired
CC property. The method uses reverse transcriptase polymerase chain reaction
CC (RT-PCR) for determining the pattern of gene expression in a selected
CC gene family. Sequences AA217803-218342 represent primers that can be used
CC in the RT-PCR reactions to determine the pattern of gene expression. The
CC gene family can be selected from a set of homeobox genes, kinase genes,
CC protein phosphatase genes, P450 enzyme genes, steroid receptor
CC superfamily genes or cadherin superfamily genes
XX
SQ Sequence 21 BP; 7 A; 8 C; 3 G; 3 T; 0 U; 0 Other;
Query Match 0.5%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 8.3e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1798 AGTCAGCTCTGCTCTTGGG 1818
Db 21 AGTCAGCTCTGCTCTTGGG 1
RESULT 566
AAZ60082/C
ID AAZ60082 standard; DNA; 21 BP.
XX
AC AAZ60082;
XX
DT 25-APR-2000 (first entry)
XX
DE Reverse PCR primer -439/MIP-3beta used to amplify MIP-3beta ORF.
XX
KW Chemokine; PCR primer; macrophage inflammation protein 3beta;
KW dendritic cell; disease treatment; MIP-3beta; infection; cancer; allergy;
KW immune response initiation; autoimmune disease; tissue rejection; ss.
XX
OS Homo sapiens.
XX
FN EP974357-A1.
XX
PD 26-JAN-2000.
XX
PF 16-JUL-1998; 98EP-00401799.
XX
PR 16-JUL-1998; 98EP-00401799.
XX
PA (SCHE) SCHERING-PLOUGH.
XX
PI Caux C, Vanbervliet B, Lebecque S, Vicari A, Dieu M;
XX WPI; 2000-118300/11.
XX
PT Use of chemokines capable of directing migration of dendritic cells,
PT useful for treating microbial infections, cancer and autoimmune diseases.
XX
PS Disclosure; Col 13; 16pp; English.
XX
XX This sequence represents a PCR primer used to amplify the chemokine
CC macrophage inflammation protein 3 beta (MIP 3beta) coding sequence. The
CC PCR product is used in the analysis of dendritic cell response to

identity of a SNP and for genotyping nucleic acid samples, for e.g. to assess by association analysis the genotype of an individual or group of individuals, having a pathological phenotypic trait suspected of being caused by one or more SNPs. Phenotypic traits include diseases e.g. agammaglobulinaemia, diabetes insipidus, Lesch-Nyhan syndrome, muscular dystrophy, familial hypercholesterolaemia, polycystic kidney disease, osteogenesis imperfecta and acute intermittent porphyria. Phenotypic traits also include symptoms of or susceptibility to multifactorial disease of which a component is or may be genetic such as autoimmune diseases, including, rheumatoid arthritis, multiple sclerosis, inflammation, cancer, nervous system diseases and infection by pathogenic microorganism. The method is also useful in forensic investigations and paternity analysis. The present sequence represents a PCR primer specific for a human SNP containing DNA sequence

```

XX
SQ      Sequence 21 BP; 0 A; 3 C; 8 G; 10 T; 0 U; 0 Other;
      Query Match      0.5%; Score 17.8; DB 1; Length 21;
      Best Local Similarity 90.5%; pred. No. 8.3e+02;
      Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0
QY      2320  TGTGTGTGTGTGTGCGTGT 2340
Db      1    TCTGTGTGTGTGCGTGT 21

```

RESULT 568
ABL44374
ID ABL44374 standard; DNA; 21 BP.
XX
XX ABL44374; AC
XX
XX 11-APR-2002 (first entry)
DT
DT
XX
XX human chromosome 1p36-35 PCR primer
DE ID NO:1418.

XX Human; chromosome 1p36-35; chromosome 21q22.1; genetic analysis; genome;
KW PCR primer; ss.
XX
XX Homo sapiens.
OS
XX
XX JB2001321190-A.
DN

XX
PD 20-NOV-2001.
XX
XX
PF 12-MAR-2001; 2001JP-00068285.
XX
XX
PR 10-MAR-2000; 2000JP-00066716.
XX
XX (RIKA) RIKAGAKU KENKYUSHO.
PA (GENO-) GENOTEX YG.
XX
XX WPI; 2002-144136/19.
DR
XX
XX Arraying genome clones.
PT
XX
XX Claim 4; Page 32; 528pp; Japanese.

xx The present invention describes a method of arraying genome clones. The
cc method comprises: (a) clones of the genomic libraries contained in
cc multiwell plates numbered for discrimination are mixed in each of the
cc multiwell plates; (b) a primer designed based on the chromosome marker
cc sequence is added to the mixture to carry out an amplification reaction;
cc (c) a signal corresponding to the marker is detected from the resultant
cc amplified product to specify the discrimination Nos. of the multiwell
cc plates containing the clones having said marker sequence; (d) the order
cc of the markers is changed so that the same discrimination Nos. succeed
cc the maximum in the specified discrimination Nos. to array the multiwell
cc plates; (e) the clones in the multiwell plates of the specified
cc discrimination Nos. are mixed respectively in each wells of longitudinal
cc and lateral directions; (f) the mixed clones are cultured and the
cc resultant cultures are amplified by using the above primer; (g) signals
cc are detected from the amplified products; (h) the clones in the multiwell

(c) a signal corresponding to the marker is detected from the resultant amplified product to specify the discrimination Nos. of the multiwell plates containing the clones having said marker sequence; (d) the order of the markers is changed so that the same discrimination Nos. succeed to the maximum in the specified discrimination Nos. to array the multiwell plates; (e) the clones in the multiwell plates of the specified discrimination Nos. are mixed respectively in each wells of longitudinal and lateral directions; (f) the mixed clones are cultured and resultant cultures are amplified by using the above primer; (g) signals are detected from the amplified products; (h) the clones in the multiwell

CC plates are specified from the detected result; and (i) the clones are reconstituted as the positions on the chromosome and arrayed. The microarray is useful for gene analysis. ABL42957 to ABL45322 represent PCR primers for human chromosome 1p36-35 DNA, and ABL45323 to ABL45634 represent PCR primers for human chromosome 21q22.1, which are specifically claimed for use in the present invention

XX Sequence 21 BP; 0 A; 2 C; 9 G; 10 T; 0 U; 0 Other;

Query Match 0.5%; Score 17.8; DB 1; Length 21;
 Best Local Similarity 90.5%; Pred. No. 8.3e+02;
 Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2332 TGCCTGTGTGTGTGTGTGTGC 2352
 DB 1 TGTGTGTGTGTGTGTGTGC 21

RESULT 569
 ABS98544
 ID ABS98544 standard; DNA; 21 BP.
 XX
 AC ABS98544;
 XX
 DT 23-DEC-2002 (first entry)
 XX
 DE Human acetyl choline muscarinic receptor 3 polymorphic sequence #10.
 XX
 KW Human; ds; cytochrome P450 A1; CYP4501A1; UGT2B4; MDR1;
 KW cytochrome P450 A2; CYP4501A2; cytochrome P450 02E; CYP45002E1; LTF;
 KW adrenergic receptor beta1; ADRB1; aryl hydrocarbon; AHR; MRP3; NR1I2;
 KW aryl hydrocarbon receptor nuclear translocator; ARNT; cathepsin S; CTSS;
 KW cyclooxygenase 2; COX2; diazepam binding inhibitor; DBI; haematological;
 KW glutathione-S-transferase 12; EPHX2; 5-lipoxygenase activating protein; FLAP;
 KW HMT; kallikrein 2; KLK2; nicotinamide-N-methyl transferase; NNMT;
 KW NADPH quinone oxidoreductase 2; NQO2; sulfotransferase thermolabile; STM;
 KW UDP-glucuronosyl transferase 2B4; UDP-glucuronosyl transferase 2B7;
 KW UGT2B7; UDP-glucuronosyl transferase; UGT2B15; urokinase receptor; uPA;
 KW multidrug resistance 1; lactotransferrin; orphan nuclear receptor;
 KW multidrug resistance associated protein 3; cancer; prostate;
 KW acetylcholine muscarinic receptor; CHMR1; CHMR2; CHMR3; CHMR4; CHMR5;
 KW altered drug metabolism; cardiovascular function; colorectal tumour;
 KW central nervous system; pulmonary; immunological; SNP;
 KW single nucleotide polymorphism.

XX Homo sapiens.
 OS
 XX
 XX WO200257410-A2.
 XX
 XX 25-JUL-2002.
 XX
 XX 28-NOV-2001; 2001WO-US044838.
 XX
 XX 28-NOV-2000; 2000US-00724389.
 XX
 XX (DNAS-) DNA SCI LAB INC.
 XX
 XX Guida M, Hall J;
 XX
 XX WPI; 2002-698522/75.
 XX
 XX Isolated nucleic acid molecules having polymorphisms in known human genes e.g. cytochrome P450 and cathepsin S useful as genetic linkage markers for locating, identifying and characterizing the genes responsible for disorder-related traits.

XX Example 28; Page 160; 714pp; English.

XX This invention relates to the sequence of an isolated nucleic acid molecule comprising at least one base variation from that of a known human cytochrome P450 A1 (CYP4501A1), cytochrome P450 A2 (CYP4501A2), cytochrome P450 02E1 (CYP45002E1), adrenergic receptor beta1 (ADRB1),

CC aryl hydrocarbon (AHR), aryl hydrocarbon receptor nuclear translocator (ARNT), cathepsin S (CTSS), cyclooxygenase 2 (COX2), diazepam binding inhibitor (DBI), epoxide hydroxylase 2 (EPHX2), 5-lipoxygenase activating protein (FLAP), glutathione-S-transferase 12 (GST12), histamine-N-methyl transferase (NNMT), kallikrein 2) KLK2, nicotinamide-N-methyl transferase (NNMT), NADPH quinone oxidoreductase 2 (NQO2), sulfotransferase thermolabile (STM), UDP-glucuronosyl transferase 2B4 (UGT2B4), UDP-glucuronosyl transferase 2B7 (UGT2B7), UDP-glucuronosyl transferase (UGT2B15), urokinase receptor (uPA), multidrug resistance 1 (MDR1), lactotransferrin (LTF), multidrug resistance associated protein 3 (MRP3), orphan nuclear receptor (NR1I2), or acetylcholine muscarinic receptor 1, 2, 3, 4, or 5 (CHMR1, CHMR2, CHMR3, CHMR4 or CHMR5) sequence. The polymorphisms in the human genes cited in the invention are useful as genetic linkage markers for locating and characterizing the genes that are responsible for specific traits within the genome and eventually identifying the genes responsible for a variety of disorder-related traits as a result of their e.g. overexpression, constitutive expression, mutation or underexpression, which may be used in diagnosing and/or treating the disorders. The nucleic acid molecules comprising the polymorphic sequences contained in CYP4501A1, CYP4501A2, CYP4502E1, ARNT, EPHX2, GST12, NNMT, NQO2, NR1I2, STM, UGT2B4, UGT2B7, UGT2B15, AHR, MDR1 and/or MDR3 are useful for screening individuals for altered drug metabolism. The polymorphic sequences contained in CYP4501A1, CYP4501A2, AHR, MDR1 and/or MDR3 may also be used to screen individuals for susceptibility to cancer. Polymorphic sequences in ADRB1 or CHMR2 are used to screen for altered cardiovascular function, in COX2 for altered susceptibility to colorectal tumours, in DBI or CHMR1 for altered central nervous system function, in FLAP and NNMT for altered pulmonary, immunological or haematological function, in KLK2 for altered serine protease activity in the prostate, in LTF for altered immunological or haematological function, in CHMR3, CHMR4 or CHMR5 for altered central and peripheral nervous system function. The present sequence represents a polymorphic DNA sequence of the invention

XX
 SQ Sequence 21 BP; 10 A; 0 C; 1 G; 10 T; 0 U; 0 Other;

Query Match 0.5%; Score 17.8; DB 1; Length 21;
 Best Local Similarity 90.5%; Pred. No. 8.3e+02;
 Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2824 ATATATACATATATATATATATA 2844
 DB 1 ATATATATGTATATATATATA 21
 ||||| ||||| ||||| ||||| |||||

RESULT 570
 ABS98544/c
 ID ABS98544 standard; DNA; 21 BP.
 XX
 AC ABS98544;
 XX
 DT 23-DEC-2002 (first entry)
 XX
 DE Human acetyl choline muscarinic receptor 3 polymorphic sequence #10.
 XX
 KW Human; ds; cytochrome P450 A1; CYP4501A1; UGT2B4; MDR1;
 KW cytochrome P450 A2; CYP4501A2; cytochrome P450 02E; CYP45002E1; LTF;
 KW adrenergic receptor beta1; ADRB1; aryl hydrocarbon; AHR; MRP3; NR1I2;
 KW aryl hydrocarbon receptor nuclear translocator; ARNT; cathepsin S; CTSS;
 KW cyclooxygenase 2; COX2; diazepam binding inhibitor; DBI; haematological;
 KW epoxide hydroxylase 2; EPHX2; 5-lipoxygenase activating protein; FLAP;
 KW glutathione-S-transferase 12; GST12; histamine-N-methyl transferase; NNMT;
 KW kallikrein 2; KLK2; nicotinamide-N-methyl transferase; NNMT;
 KW NADPH quinone oxidoreductase 2; NQO2; sulfotransferase thermolabile; STM;
 KW UDP-glucuronosyl transferase 2B4; UDP-glucuronosyl transferase 2B7;
 KW UGT2B7; UDP-glucuronosyl transferase; UGT2B15; urokinase receptor; uPA;
 KW multidrug resistance 1; lactotransferrin; orphan nuclear receptor;
 KW multidrug resistance associated protein 3; cancer; prostate;
 KW acetylcholine muscarinic receptor; CHMR1; CHMR2; CHMR3; CHMR4; CHMR5;
 KW altered drug metabolism; cardiovascular function; colorectal tumour;
 KW central nervous system; pulmonary; immunological; SNP;
 KW single nucleotide polymorphism.

XX Fusion protein; stabilising polypeptide; proteolytic degradation;
KW resistance; half-life; autoimmune disease; inflammation; nitro drug;
KW IkappaB regulator protein; inflammatory bowel disease; in vivo imaging;
KW nitroreductase protein; enzyme therapy; prodrug therapy; protease;
KW cancer; pathological condition; minimal motif; PCR primer; ss.
XX
OS Synthetic.
OS Human herpesvirus 4.
XX
XX WO9822577-A1.
XX
XX 28-MAY-1998.
XX
XX 17-NOV-1997; 97WO-IB001508.
XX
XX 15-NOV-1996; 96US-0030986P.
PR 23-JUN-1997; 97US-0048945P.
XX
XX (MASU//) MASUCCI M G.
XX
XX Masucci MG;
XX
XX WPI; 1998-312463/27.
XX
XX New fusion proteins resistant to proteolytic degradation - comprising a
PT core protein with a stabilising polypeptide comprising a peptide sequence
PT containing glycine repeats.
XX
XX Disclosure; Page 72; 120pp; English.
XX
XX Sequences shown in AAV55812 to AAV55827 represent primers used in the
CC course of the invention for the immunisation of minimal motifs. The
CC invention provides a method for increasing the resistance of a core
CC protein to proteolytic degradation that comprises linking or inserting
CC onto or into the core protein a stabilising polypeptide of formula
CC [(Gly)X(Glyb)Y(Glyc)Z]n where Glya, Glyb, Glyc are 1-6 sequential Gly
CC residues and X, Y, Z are Ala, Ser, Val, Ile, Leu, Met, Phe, Pro or Thr
CC and n can be anything between 1-66. X, Y and Z need not be identical from
CC n repeat to n repeat. Alternatively a nucleic acid encoding a stabilising
CC polypeptide can be linked onto or inserted into a nucleic acid encoding a
CC core protein. The fusion proteins of the invention are more resistant to
CC degradation by proteases and, thus, have a longer half-life than the
CC unfused core protein. The products can be used for treating autoimmune
CC diseases, cancer and inflammation. In particular, the core protein may be
CC an IkappaB regulator protein for the treatment of inflammatory bowel
CC disease, or a nitroreductase protein which can activate nitro drugs in
CC enzyme/prodrug therapy to treat cancer or other pathological conditions.
CC The fusion proteins can also be used in diagnostic methods such as in
CC vivo imaging. (Updated on 27-AUG-2003 to correct OS field.)
XX
SQ Sequence 24 BP; 3 A; 14 C; 2 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 17.8; DB 1; Length 24;
Best Local Similarity 90.5%; Pred. No. 9.6e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2103 CACCCCGAGCTCCAGCTCCCTC 2123
DB 4 CACCCCGAGCTCCAGCTCCCTC 24
|||||

RESULT 580
AAH39357
ID AAH39357 standard; DNA; 24 BP.
XX
AC AAH39357;
XX
DT 14-AUG-2001 (first entry)
XX
DE SNP specific upper PCR primer SEQ ID 2153.
XX
KW Single nucleotide polymorphism; SNP; single nucleotide primer extension;

SNPE; genotyping; agammaglobulinaemia; diabetes insipidus; cancer;
KW Lesch-Nyhan syndrome; muscular dystrophy; familial hypercholesterolaemia;
KW polycystic kidney disease; osteogenesis imperfecta; autoimmune disease;
KW acute intermittent porphyria; rheumatoid arthritis; multiple sclerosis;
KW inflammation; forensic investigation; paternity analysis; PCR primer; ss.
XX
OS Homo sapiens.
XX
XX WO200129262-A2.
XX
XX 26-APR-2001.
XX
XX 13-OCT-2000; 2000WO-US028436.
XX
XX 15-OCT-1999; 99US-0160096P.
XX
XX (ORCH-) ORCHID BIOSCIENCES INC.
XX
XX Picoult-Newburg L, Pohl M;
XX
XX WPI; 2001-290930/30.
XX
XX New genotyping oligonucleotide, useful for detecting the presence,
PT absence or identity of single polynucleotide polymorphism in a nucleic
PT acid sample.
XX
XX Claim 1; Page 60; 83pp; English.
XX
XX Sequences AAH37205 - AAH40944 represent PCR primers, single nucleotide
CC primer extension (SNPE) primers, and the sequences of regions flanking
CC sites of single nucleotide polymorphisms SNPs. The present invention
CC includes kits for determining the presence or absence of a SNP, using the
CC oligonucleotides of the invention. The PCR primers are used to amplify a
CC SNP flanking sequence, the SNPE primer is used as a genotyping primer.
CC The oligonucleotides are useful for genotyping a nucleic acid sample by
CC performing a single-nucleotide primer extension reaction. The
CC oligonucleotides are useful for determining the presence, absence or
CC identity of a SNP and for genotyping nucleic acid samples, for e.g. to
CC assess by association analysis the genotype of an individual or group of
CC individuals, having a pathological phenotypic trait suspected of being
CC caused by one or more SNPs. Phenotypic traits include diseases e.g.
CC agammaglobulinaemia, diabetes insipidus, Lesch-Nyhan syndrome, muscular
CC dystrophy, familial hypercholesterolaemia, polycystic kidney disease,
CC osteogenesis imperfecta and acute intermittent porphyria. Phenotypic
CC traits also include symptoms of or susceptibility to multifactorial
CC disease of which a component is or may be genetic such as autoimmune
CC diseases, including, rheumatoid arthritis, multiple sclerosis,
CC inflammation, cancer, nervous system diseases and infection by pathogenic
CC microorganism. The method is also useful in forensic investigations and
CC paternity analysis. The present sequence represents a PCR primer specific
CC for a human SNP containing DNA sequence
XX
SQ Sequence 24 BP; 1 A; 0 C; 11 G; 12 T; 0 U; 0 Other;

Query Match 0.5%; Score 17.8; DB 1; Length 24;
Best Local Similarity 90.5%; Pred. No. 9.6e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2318 TGTGTGTGTGTGTGTGTGTGTGTGTGTGT 2338
DB 1 TGTGTGTGTGTGTGTGTGTGTGTGTGTGT 21
|||||

RESULT 581
ACI70111/C
ID ACI70111 standard; DNA; 25 BP.
XX
XX ACI70111;
XX
XX ACI70111;
XX
XX 14-OCT-2003 (first entry)
XX
XX Human microarray DNA oligonucleotide SEQ ID NO 70102.
DE
XX

KW EST; ss; probe; expressed sequence tag; microarray; gene expression;
 KW genetic variation; biallelic marker; polymorphism; human;
 KW cross-species comparison.
 XX Homo sapiens.
 XX US2003104410-A1.
 XX 05-JUN-2003.
 XX 15-MAR-2002; 2002US-00098263.
 XX 16-MAR-2001; 2001US-0276759P.
 XX (AFFY-) AFFYMETRIX INC.
 XX Mittmann MP;
 XX WPI; 2003-567953/53.
 XX New array of nucleic acid probes, useful for in situ hybridization, in
 XX Southern, Northern or dot-blot hybridization to identify or detect the
 XX sequence or specific mutations of any gene.
 XX Claim 1; SEQ ID NO 70102; 9pp; English.
 XX The invention discloses a microarray comprising a plurality of nucleic
 XX acid probes including one of 2,018,500 fully defined sequences, or its
 XX perfect match, perfect mismatch, antisense match or antisense mismatch.
 XX Also disclosed is a method of gene expression analysis. The array is used
 XX in monitoring gene expression levels by hybridisation to a DNA library,
 XX in analysis of genetic variation or in hybridisation of tag-labelled
 XX compounds. The nucleic acid probes are specifically designed for analysis
 XX of at least one target sequence. The method of analysis comprises
 XX hybridising at least one or more nucleic acids to at least two or more
 XX nucleic acid probes and detecting the hybridisation. The nucleic acid
 XX probes are attached to a solid support. The analysis comprises monitoring
 XX gene expression levels, identifying biallelic markers or polymorphisms,
 XX or family members of a gene and a cross-species comparison. Each of the
 XX nucleic acids further comprises a tag sequence. The array of nucleic acid
 XX probes is useful in in situ hybridisation, in Southern, Northern or dot-
 XX blot hybridisation to identify or detect the sequence or specific
 XX mutations of any gene, in mapping the 5' termini of mRNA molecules by
 XX primer extensions or in screening cDNA or genomic libraries or subclones
 XX for additional subclones containing segments of DNA that have been
 XX isolated and previously sequenced. The sequence presented is one of the
 XX nucleic acid probes incorporated in the microarray. Note: The sequence
 XX data for this patent can also be obtained in electronic format directly
 XX from USPTO at seqdata.uspto.gov/sequence.html
 XX Sequence 25 BP; 7 A; 4 C; 4 G; 10 T; 0 U; 0 Other;
 Query Match 0.5%; Score 17.8; DB 1; Length 25;
 Best Local Similarity 90.5%; Pred. No. 1e+03;
 Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2783 AACTAGTGATGATCTCTATTA 2803
 DB 24 AACAAAGTGATGATCTCTATTA 4
 RESULT 582
 AAI30472/c
 ID AAI30472 standard; DNA; 31 BP.
 XX AAI30472;
 XX 18-OCT-2001 (first entry)
 XX Human single nucleotide polymorphism (SNP) FGPR3 4.
 XX Human, resequence; genotype; disease; forensic; paternity testing;
 KW single nucleotide polymorphism; SNP; ss.

XX Homo sapiens.
 XX Key Location/Qualifiers
 FT Variation replace(16,T)
 FT /*tag= a
 FT /standard_name= "single nucleotide polymorphism"
 XX WO200166800-A2.
 XX 13-SEP-2001.
 XX 07-MAR-2001; 2001WO-US007268.
 XX 07-MAR-2000; 2000US-0187510P.
 XX 22-MAY-2000; 2000US-0206129P.
 XX (WHED) WHITEHEAD INST BIOMEDICAL RES.
 XX Cargill M, Ireland JS, Lander ES;
 XX WPI; 2001-522952/57.
 XX Nucleic acid molecules from the human genome which include polymorphic
 XX sites, useful in methods for predicting the presence, absence or severity
 XX of a particular phenotype or disorder (e.g. diabetes) associated with a
 XX particular genotype.
 XX Claim 1; Page 87; 145pp; English.
 XX The invention relates to the identification of nucleic acid molecules
 XX (AAI29513-AAI31314) from the human genome which include polymorphic sites
 XX which can predispose individuals to disease. Various genes from a number
 XX of individuals were resequenced and single nucleotide polymorphisms
 XX (SNPs) in these genes discovered. The method is useful for predicting the
 XX presence, absence or severity of a particular phenotype or disorder (e.g.
 XX diabetes) associated with a particular genotype. The nucleic acids
 XX containing the polymorphic sites may be useful in forensics and paternity
 XX testing.
 XX Sequence 31 BP; 3 A; 11 C; 12 G; 5 T; 0 U; 0 Other;
 Query Match 0.5%; Score 17.8; DB 1; Length 31;
 Best Local Similarity 90.5%; Pred. No. 1.2e+03;
 Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 3414 AGGGGCGGCGCCCTGTGTGCAG 3434
 DB 21 AGGGGCGGCGCCCTGTGTGCAG 1
 RESULT 583
 AAA30842/c
 ID AAA30842 standard; DNA; 24 BP.
 XX AAA30842;
 XX 15-SEP-2003 (revised)
 XX 29-AUG-2000 (first entry)
 XX Zebrafish PTH1R receptor coding sequence PCR primer For TM3.
 XX Zebrafish; PTH1R receptor; PTH3R receptor; diagnosis; cancer;
 KW parathyroid hormone type 1 receptor; parathyroid hormone type 3 receptor;
 KW PCR primer; ss.
 XX Danio rerio.
 XX WO200032771-A1.
 XX 08-JUN-2000.
 XX 28-MAY-1999; 99WO-US011883.

```

XX PR 30-NOV-1998; 98US-0110467P.
XX PA (JUEP/) JUEPPNER H.
XX PA (RUBI/) RUBIN D A.
XX PI Jueppner H, Rubin DA;
XX DR WPI; 2000-412319/35.
XX PT Novel zebrafish parathyroid hormone/parathyroid hormone related peptide
XX PT receptor 3 and isolated nucleic acid encoding zebrafish parathyroid
XX PT hormone receptor 1 for treating disorders associated with receptor
XX PT function.
XX PS Example 3; Page 43; 11lpp; English.
XX CC This sequence represents a PCR primer used to isolate DNA encoding the
XX CC parathyroid hormone receptor type 1 (PTH1R) receptor protein of the
XX CC invention. The invention also relates to a PTH3R receptor protein.
XX CC Antagonists of PTH1R or PTH3R can be used for the treatment of diseases
XX CC associated with an increase in PTH3R or PTH1R activity, respectively. The
XX CC peptides are used for diagnosis or prognosis of diseases and disorders
XX CC associated with PTH1R or PTH3R, such as cancer. The polypeptides can be
XX CC used as a molecular weight markers on sodium dodecyl sulphate
XX CC polyacrylamide gel electrophoresis (SDS-PAGE) gels, or on molecular sieve
XX CC gel filtration columns. Antigenic epitope-bearing peptides and
XX CC polypeptides are useful to raise antibodies, including monoclonal
XX CC antibodies, that bind specifically to a polypeptide. The peptides are
XX CC useful during diagnosis of diseases and disorders in mammals involving
XX CC PTH1R or PTH3R receptor expression or function. Mutations that affect
XX CC PTH1R or PTH3R sequence and/or expression levels of PTH1R or PTH3R could
XX CC be diagnostic for patients with disease or disorders of a developmental,
XX CC physiological or neurological nature. The nucleic acid molecules are
XX CC valuable for chromosome identification. The mapping of DNAs to
XX CC chromosomes is an important first step in correlating those sequences
XX CC with genes associated with disease. (Updated on 15-SEP-2003 to
XX CC standardise OS field)
XX SQ Sequence 24 BP; 5 A; 8 C; 2 G; 9 T; 0 U; 0 Other;
Query Match 0.5%; Score 17.6; DB 1; Length 24;
Best Local Similarity 83.3%; Pred. No. 1e+03;
Matches 20; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
OY 1344 GTCTGAGATCGAGATGATGAAGAT 1367
DB 24 GTCTGAGAGAGAGTCTCATGAAGAT 1
RESULT 584
AAA48458/c
ID AAA48458 standard; DNA; 24 BP.
XX AC AAA48458;
XX AC AAA48458;
XX DT 15-SEP-2003 (revised)
XX DT 27-OCT-2000 (first entry)
XX DE Zebrafish PTH1R cDNA PCR primer For TM3.
XX KW Zebrafish; PTH1R; parathyroid hormone type-1 receptor;
XX KW developmental disorder; physiological disorder; neurological disorder;
XX KW PCR primer; ss.
XX OS Danio rerio.
XX PN WO200032775-A1.
XX PD 08-JUN-2000.
XX PF 30-NOV-1999; 99WO-US028207.
XX XX

XX PR 30-NOV-1998; 98US-0110467P.
XX PA (JUEP/) JUEPPNER H.
XX PA (RUBI/) RUBIN D A.
XX PI Jueppner H, Rubin DA;
XX DR WPI; 2000-412323/35.
XX PT New nucleic acids encoding parathyroid hormone receptors PTH1R and PTH3R,
XX PT useful for treating diseases or disorders associated with impaired
XX PT receptor functions comprises a specific nucleotide sequence.
XX PS Example 3; Page 46; 11lpp; English.
XX CC The present sequence is a PCR primer for the parathyroid hormone type-1
XX CC receptor (PTH1R) gene from the zebrafish. It was used to amplify and
XX CC isolate cDNA encoding this protein. The gene and protein can be used to
XX CC detect diseases in man where the receptor is either overexpressed or
XX CC underexpressed, and they can be used to treat these diseases, which may
XX CC be developmental, physiological or neurological disorders. They can also
XX CC be used to identify agonists and antagonists which can be used in a
XX CC similar manner. In addition, the gene can be used for chromosome
XX CC identification. (Updated on 15-SEP-2003 to standardise OS field)
XX SQ Sequence 24 BP; 5 A; 8 C; 2 G; 9 T; 0 U; 0 Other;
Query Match 0.5%; Score 17.6; DB 1; Length 24;
Best Local Similarity 83.3%; Pred. No. 1e+03;
Matches 20; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
OY 1344 GTCTGAGATCGAGATGATGAAGAT 1367
DB 24 GTCTGAGAGAGAGTCTCATGAAGAT 1
RESULT 585
AAI68170
ID AAI68170 standard; DNA; 24 BP.
XX AC AAI68170;
XX DT 14-DEC-2001 (first entry)
XX DE Human molecular chaperone 18 PCR primer 1.
XX KW Human; molecular chaperone 18; cytosolic; virucidal; immunomodulatory;
XX KW antiinflammatory; haemostatic; neurotropic; neuroprotective; anti-HIV;
XX KW malignant neoplasm; HIV; infection; human immunodeficiency virus;
XX KW immunological disease; PCR primer; ss.
XX OS Homo sapiens.
XX PN WO200173072-A1.
XX PD 04-OCT-2001.
XX PF 26-MAR-2001; 2001WO-CN000503.
XX PR 29-MAR-2000; 2000CN-00115286.
XX XX (BIOW-) BIOWINDOW GENE DEV INC SHANGHAI.
XX PA Mao Y, Xie Y;
XX PI WPI; 2001-611637/70.
XX DR New polypeptide for the diagnosis and treatment of malignant neoplasm,
XX DR hemopathy, HIV infection, immunological diseases and inflammations,
XX PT comprises the human molecular chaperone 18 protein.
XX PS Example 2; Page 12; 36pp; Chinese.
XX XX

```


XX (BOEH) BOEHRINGER INGELHEIM INT GMBH.
 XX Hilberg F, Brandstetter I, Van Meel J, Bette P, Kleemann R;
 XX WPI; 2003-365180/35.
 XX Composition for treating mammary tumors associated with aberrant tyrosine
 PT kinase receptor activity in nonhuman animals, comprises one or more
 PT substances that inhibit the aberrant activity.
 XX Example 1; Page 21; 37pp; English.
 XX The present invention describes a composition (C) for treating mammary
 CC tumors associated with aberrant tyrosine kinase receptor activity in
 CC nonhuman animals. (C) comprises one or more substances that inhibit the
 CC aberrant tyrosine kinase receptor activity. (C) has cytostatic activity.
 CC (C) can be used as a tyrosine kinase receptor inhibitor, and an epidermal
 CC growth factor receptor (EGFR) inhibitor. (C) is especially useful for
 CC treating canine mammary tumors. The present sequence represents a PCR
 CC primer for human EGFR, which is used in an example from the present
 CC invention
 XX Sequence 24 BP; 6 A; 4 C; 7 G; 7 T; 0 U; 0 Other;
 Query Match 0.5%; Score 17.6; DB 1; Length 24;
 Best Local Similarity 83.3%; Pred. No. 1e+03;
 Matches 20; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
 QY 1945 TACATGATCATCGGGAGTCTGG 1968
 Db 1 TACATGATCATCGGCAAGTCTGG 24
 RESULT 589
 ADC42320/C
 ID ADC42320 standard; DNA; 24 BP.
 XX AC ADC42320;
 XX 18-DEC-2003 (first entry)
 XX Full length zebrafish parathyroid hormone receptor PTHrR primer PortW3.
 DE parathyroid hormone; PTH; PTH-related peptide; PTHrP;
 KW parathyroid hormone receptor; PTHR; chromosome identification; zebrafish;
 KW PTHrR; receptor; ss; primer; PCR.
 XX Danio rerio.
 XX US6541220-B1.
 XX 01-APR-2003.
 XX 30-NOV-1999; 99US-00449632.
 XX 30-NOV-1998; 98US-0110467P.
 XX (GEHO) GEN HOSPITAL CORP.
 XX Jueppner H, Rubin DA;
 XX WPI; 2003-754511/71.
 XX Novel nucleic acid comprising a polynucleotide encoding parathyroid
 PT hormone/parathyroid hormone-related peptide receptor, useful for
 PT chromosome identification.
 XX Example 3; SEQ ID NO 17; 52pp; English.
 XX The invention describes an isolated nucleic acid (I) comprising a
 CC polynucleotide having a nucleotide sequence chosen from nucleotide
 CC sequence encoding a parathyroid hormone (PTH)/PTH-related peptide (PTHrP)

CC receptor (PTHrR receptor) having a fully defined sequence of 536 amino
 CC acids as given in the specification, PTHrR receptor, mature PTHrR
 CC receptor, PTHrR extracellular or transmembrane domain, and their
 CC complement. (I) is useful for diagnosing and treating decrease in the
 CC standard or normal level of PTHrR receptor activity in an individual, and
 CC for chromosome identification. This sequence represents a primer used to
 CC isolate the full length cDNA encoding zebrafish PTHrR.
 XX Sequence 24 BP; 5 A; 8 C; 2 G; 9 T; 0 U; 0 Other;
 Query Match 0.5%; Score 17.6; DB 1; Length 24;
 Best Local Similarity 83.3%; Pred. No. 1e+03;
 Matches 20; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
 QY 1344 GTCTGAGATGAGATGATGAGAT 1367
 Db 24 GTCTGAGAGAGAGTCTGATGAGAT 1
 RESULT 590
 ADH61074/C
 ID ADH61074 standard; DNA; 24 BP.
 XX AC ADH61074;
 XX 25-MAR-2004 (first entry)
 XX Zebrafish PTHrR cDNA amplifying For TM3 RACE-PCR primer.
 DE Zebrafish; parathyroid hormone; PTH; parathyroid hormone related protein;
 KW PTHrP; parathyroid hormone related protein receptor; PTHrR; PTH3R;
 KW diagnosis; prognosis; pharmaceutical composition; chromosome assay;
 KW RACE-PCR; rapid amplification of cDNA end; primer; ss.
 XX Danio rerio.
 XX US2003162256-A1.
 XX 28-AUG-2003.
 XX 25-FEB-2003; 2003US-00372095.
 XX 30-NOV-1998; 98US-0110467P.
 PR 30-NOV-1999; 99US-00449632.
 XX (MASS-) MASSACHUSETTS GEN HOSPITAL.
 XX Jueppner H, Rubin DA;
 XX WPI; 2003-897927/82.
 XX New parathyroid hormone receptors designated PTHrR and PTH3R isolated
 PT from zebrafish are useful to diagnose and treat parathyroid hormone
 PT receptor-related diseases.
 XX Example 3; SEQ ID NO 17; 53pp; English.
 XX The present invention relates to novel parathyroid hormone (PTH) and
 CC parathyroid hormone related protein (PTHrP) receptors PTHrR and PTH3R
 CC isolated from zebrafish. The invention is useful in the diagnosis and
 CC prognosis of certain diseases and disorders that express significantly
 CC decreased levels of PTHrR and PTH3R. The invention is also useful in
 CC preparing pharmaceutical compositions and in chromosome assays. The
 CC present sequence is a RACE-PCR primer amplified by zebrafish PTHrR cDNA.
 XX Sequence 24 BP; 5 A; 8 C; 2 G; 9 T; 0 U; 0 Other;
 Query Match 0.5%; Score 17.6; DB 1; Length 24;
 Best Local Similarity 83.3%; Pred. No. 1e+03;
 Matches 20; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
 QY 1344 GTCTGAGATGAGATGATGAGAT 1367

PF	07-JUL-1997;	97WO-US011687.
XX		
PR	10-JUL-1996;	96US-00678039.
XX		
PA	(UTAH) UNIV UTAH RES FOUND.	
XX		
PI	Keating MT, Morris CA;	
XX		
DR	WPI; 1998-101185/09.	
XX		
PT	Diagnosing Williams syndrome cognitive profile from hemi-zygosity of	
PT	LIMK1 - gene on chromosome 7 encoding new kinase, allowing	
PT	differentiation from classic Williams syndrome and supra-vascular aortic	
PT	stenosis.	
XX		
PS	Example 3; Page 22; 62pp; English.	
XX		
CC	This oligonucleotide was designed to amplify the region of homology in	
CC	the kinase domains of PDGF receptor, HER2, HER3, FGF-FLG, FGF-BEK,	
CC	insulin receptor and IRR. It was used with another kinase homology domain	
CC	-based primer (see AAV05313) in the amplification of human LIM-kinase 1	
CC	(LIMK1) sequences. The LIMK1 gene is composed of 16 exons (see AAV05315	
CC	and AAT9599-199629) and is located 15.4 kb 3' of elastin in chromosome	
CC	7. It encodes a novel protein kinase (see AAW46576). Williams syndrome	
CC	cognitive profile (WSCP) is detected by determining zygosity of the LIMK	
CC	locus, with hemizyosity being indicative of impaired visuo-spatial	
CC	constructive cognition. Chromosome 7 deletion analysis allows	
CC	discrimination between WSCP, SVAS (supra-vascular aortic stenosis) and	
CC	Williams syndrome	
XX		
XX	Sequence 25 BP; 4 A; 10 C; 6 G; 5 T; 0 U; 0 Other;	
XX		
Query Match	/	0.5%; Score 17.6; DB 1; Length 25;
Best Local Similarity	83.3%;	Pred. No. 1.1e+03;
Matches	20; Conservative	0; Mismatches 4; Indels 0; Gaps
Qy	1744	CCCGTGAAGTGGATGGCGCTGAG 1767
Db	24	CCAGTCAAGTGGATGGCTCCGGAG 1
RESULT 593		
ABS75680		
ID	ABS75680 standard; DNA; 25 BP.	
XX		
AC	ABS75680;	
XX		
XX	27-DEC-2002 (first entry)	
DT		
XX		
DE	Human PAPP-Ea associated 25-mer SEQ ID 1206.	
XX		
XX	PAPP-E; human; pregnancy associated plasma protein E; abortive;	
KW	contraceptive; gene therapy; vaccine; pregnancy; antenatal; diagnosis;	
KW	dyogenetic pregnancy; primer; ss.	
XX		
OS	Homo sapiens.	
XX		
FN	US2002102252-A1.	
XX		
PD	01-AUG-2002.	
XX		
PF	06-APR-2001; 2001US-00827998.	
XX		
XX	26-MAY-2000; 2000US-0207456P.	
XX		
PA	(GUY/) GU Y.	
PA	(SHAN/) SHANNON M E.	
XX		
PI	Gu Y, Shannon ME;	
XX		
DR	WPI; 2002-697817/75.	
XX		
PT	New isolated nucleic acid encoding an isoform of human pregnancy	

PT associated plasma protein E, for preventing or aborting pregnancy.
 XX Example 2; Page 233; 353pp; English.
 CC This invention describes a novel isolated nucleic acid that encodes one
 CC of three new isoforms of human pregnancy associated plasma protein E,
 CC hPAPP-E. The products of the invention have abortive and contraceptive
 CC activity and can be used for gene therapy or in a vaccine. The nucleic
 CC acid, polypeptide encoded by it, or antibody to the polypeptide can be
 CC used in pharmaceutical compositions or vaccines for preventing or
 CC aborting pregnancy. PAPP-E is used in the antenatal diagnosis of
 CC dysgenetic pregnancies. The nucleic acids are used as probes to assess
 CC the level of PAPP-E isoform mRNA in chorionic villus samples, and the
 CC antibodies can be used to assess the expression levels of PAPP-E isoform
 CC proteins in chorionic villus samples, to diagnose dysgenetic pregnancies
 CC antenatally. This sequence represents an oligomer used in scanning the
 CC human PAPP-E genes described in the disclosure of the invention
 XX
 SQ Sequence 25 BP; 3 A; 0 C; 9 G; 13 T; 0 U; 0 Other;
 Query Match 0.5%; Score 17.6; DB 1; Length 25;
 Best Local Similarity 83.3%; Pred. No. 1.1e+03;
 Matches 20; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
 Qy 2321 GTGTGCTGTGCTGCTGTGCTGTGT 2344
 Db 2 GTGTGCTGTTTGTGAGTGTGTATT 25
 RESULT 594
 ABS75679
 ID ABS75679 standard; DNA; 25 BP.
 XX
 AC ABS75679;
 XX
 DT 27-DEC-2002 (first entry)
 XX
 DE Human PAPP-Ea associated 25-mer SEQ ID 1205.
 XX
 KW PAPP-E; human; pregnancy associated plasma protein E; abortive;
 KW contraceptive; gene therapy; vaccine; pregnancy; antenatal; diagnosis;
 KW dysgenetic pregnancy; primer; ss.
 XX
 OS Homo sapiens.
 XX
 PN US2002102252-A1.
 XX
 PD 01-AUG-2002.
 XX
 PF 06-APR-2001; 2001US-00827998.
 XX
 PR 26-MAY-2000; 2000US-0207456P.
 XX
 PS (GUIYY/) GU Y.
 XX (SHAN/) SHANNON M E.
 PA
 PI Gu Y, Shannon ME;
 XX WPI; 2002-697817/75.
 DR
 XX
 PT - New isolated nucleic acid encoding an isoform of human pregnancy
 PT associated plasma protein E, for preventing or aborting pregnancy.
 XX
 PS Example 2; Page 233; 353pp; English.
 XX
 CC This invention describes a novel isolated nucleic acid that encodes one
 CC of three new isoforms of human pregnancy associated plasma protein E,
 CC hPAPP-E. The products of the invention have abortive and contraceptive
 CC activity and can be used for gene therapy or in a vaccine. The nucleic
 CC acid, polypeptide encoded by it, or antibody to the polypeptide can be
 CC used in pharmaceutical compositions or vaccines for preventing or
 CC aborting pregnancy. PAPP-E is used in the antenatal diagnosis of
 CC dysgenetic pregnancies. The nucleic acids are used as probes to assess

CC the level of PAPP-E isoform mRNA in chorionic villus samples, and the
 CC antibodies can be used to assess the expression levels of PAPP-E isoform
 CC proteins in chorionic villus samples, to diagnose dysgenetic pregnancies
 CC antenatally. This sequence represents an oligomer used in scanning the
 CC human PAPP-E genes described in the disclosure of the invention
 XX
 SQ Sequence 25 BP; 3 A; 0 C; 10 G; 12 T; 0 U; 0 Other;
 Query Match 0.5%; Score 17.6; DB 1; Length 25;
 Best Local Similarity 83.3%; Pred. No. 1.1e+03;
 Matches 20; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
 Qy 2319 GTGTGCTGTGCTGCTGTGCTGTGT 2342
 Db 1 GAGTGTGCTTGTGAGTGTGTAT 24
 RESULT 595
 ABS75678
 ID ABS75678 standard; DNA; 25 BP.
 XX
 AC ABS75678;
 XX
 DT 27-DEC-2002 (first entry)
 XX
 DE Human PAPP-Ea associated 25-mer SEQ ID 1204.
 XX
 KW PAPP-E; human; pregnancy associated plasma protein E; abortive;
 KW contraceptive; gene therapy; vaccine; pregnancy; antenatal; diagnosis;
 KW dysgenetic pregnancy; primer; ss.
 XX
 OS Homo sapiens.
 XX
 PN US2002102252-A1.
 XX
 PD 01-AUG-2002.
 XX
 PF 06-APR-2001; 2001US-00827998.
 XX
 PR 26-MAY-2000; 2000US-0207456P.
 XX
 PS (GUIYY/) GU Y.
 XX (SHAN/) SHANNON M E.
 PA
 PI Gu Y, Shannon ME;
 XX WPI; 2002-697817/75.
 DR
 XX
 PT New isolated nucleic acid encoding an isoform of human pregnancy
 PT associated plasma protein E, for preventing or aborting pregnancy.
 XX
 PS Example 2; Page 233; 353pp; English.
 XX
 CC This invention describes a novel isolated nucleic acid that encodes one
 CC of three new isoforms of human pregnancy associated plasma protein E,
 CC hPAPP-E. The products of the invention have abortive and contraceptive
 CC activity and can be used for gene therapy or in a vaccine. The nucleic
 CC acid, polypeptide encoded by it, or antibody to the polypeptide can be
 CC used in pharmaceutical compositions or vaccines for preventing or
 CC aborting pregnancy. PAPP-E is used in the antenatal diagnosis of
 CC dysgenetic pregnancies. The nucleic acids are used as probes to assess
 CC the level of PAPP-E isoform mRNA in chorionic villus samples, and the
 CC antibodies can be used to assess the expression levels of PAPP-E isoform
 CC proteins in chorionic villus samples, to diagnose dysgenetic pregnancies
 CC antenatally. This sequence represents an oligomer used in scanning the
 CC human PAPP-E genes described in the disclosure of the invention
 XX
 SQ Sequence 25 BP; 3 A; 0 C; 11 G; 11 T; 0 U; 0 Other;
 Query Match 0.5%; Score 17.6; DB 1; Length 25;
 Best Local Similarity 83.3%; Pred. No. 1.1e+03;
 Matches 20; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 2319 GTCTGTCTGTCTGTCTGTCTGTCT 2342
Db 2 GACTGTGTGTGTGTGTGTGTGTGT 25

RESULT 596
ABS75682 standard; DNA; 25 BP.
XX AC ABS75682;
XX DT 27-DEC-2002 (first entry)
XX DE Human PAPP-Ea associated 25-mer SEQ ID 1208.
XX KW PAPP-E; human; pregnancy associated plasma protein E; abortive;
XX KW contraceptive; gene therapy; vaccine; pregnancy; antenatal; diagnosis;
XX KW dysgenetic pregnancy; primer; ss.
XX OS Homo sapiens.
XX PN US2002102252-A1.
XX DT 01-AUG-2002.
XX PF 06-APR-2001; 2001US-00827998.
XX PR 26-MAY-2000; 2000US-0207456P.
XX PA (GUY/) GU Y.
XX PA (SHAN/) SHANNON M E.
XX PI Gu Y, Shannon ME;
XX DR WPI; 2002-697817/75.
XX PT New isolated nucleic acid encoding an isoform of human pregnancy
XX PT associated plasma protein E, for preventing or aborting pregnancy.
XX PS Example 2; Page 234; 353pp; English.
XX CC This invention describes a novel isolated nucleic acid that encodes one
XX CC of three new isoforms of human pregnancy associated plasma protein E,
XX CC hPAPP-E. The products of the invention have abortive and contraceptive
XX CC activity and can be used for gene therapy or in a vaccine. The nucleic
XX CC acid, polypeptide encoded by it, or antibody to the polypeptide can be
XX CC used in pharmaceutical compositions or vaccines for preventing or
XX CC aborting pregnancy. PAPP-E is used in the antenatal diagnosis of
XX CC dysgenetic pregnancies. The nucleic acids are used as probes to assess
XX CC the level of PAPP-E isoform mRNA in chorionic villus samples, and the
XX CC antibodies can be used to assess the expression levels of PAPP-E isoform
XX CC proteins in chorionic villus samples, to diagnose dysgenetic pregnancies
XX CC antenatally. This sequence represents an oligomer used in scanning the
XX CC human PAPP-E genes described in the disclosure of the invention
SQ Sequence 25 BP; 3 A; 9 C; 9 G; 13 T; 0 U; 0 Other;
Query Match 0.5%; Score 17.6; DB 1; Length 25;
Best Local Similarity 83.3%; Pred. No. 1.1e+03;
Matches 20; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
QY 2322 TGTGTGTGTGTGTGTGTGTGTGTG 2345
Db 1 TGTGTGTGTGTGTGTGTGTGTGTG 24

RESULT 597
ACI87320/c
ID ACI87320 standard; DNA; 25 BP.
XX AC ACI87320;
XX DT 14-OCT-2003 (first entry)

Human microarray DNA oligonucleotide SEQ ID NO 87311.
EST; ss; probe; expressed sequence tag; microarray; gene expression;
genetic variation; biallelic marker; polymorphism; human;
cross-species comparison.
Homo sapiens.
US2003104410-A1.
05-JUN-2003.
15-MAR-2002; 2002US-00098263.
16-MAR-2001; 2001US-0276759P.
(AFFY-) AFFYMETRIX INC.
Mittmann MP;
WPI; 2003-567953/53.
New array of nucleic acid probes, useful for in situ hybridization, in
Southern, Northern or dot-blot hybridization to identify or detect the
sequence or specific mutations of any gene.
Claim 1; SEQ ID NO 87311; 9pp; English.
The invention discloses a microarray comprising a plurality of nucleic
acid probes including one of 2,018,500 fully defined sequences, or its
perfect match, perfect mismatch, antisense match or antisense mismatch.
Also disclosed is a method of gene expression analysis. The array is used
in monitoring gene expression levels by hybridisation to a DNA library,
in analysis of genetic variation or in hybridisation of tag-labelled
compounds. The nucleic acid probes are specifically designed for analysis
of at least one target sequence. The method of analysis comprises
hybridising at least one or more nucleic acids to at least two or more
nucleic acid probes and detecting the hybridisation. The nucleic acid
probes are attached to a solid support. The analysis comprises monitoring
gene expression levels, identifying biallelic markers or polymorphisms,
or family members of a gene and a cross-species comparison. Each of the
nucleic acids further comprises a tag sequence. The array of nucleic acid
probes is useful in situ hybridisation, in Southern, Northern or dot-
blot hybridisation to identify or detect the sequence or specific
mutations of any gene, in mapping the 5' termini of mRNA molecules by
primer extensions or in screening cDNA or genomic libraries or subclones
for additional subclones containing segments of DNA that have been
isolated and previously sequenced. The sequence presented is one of the
nucleic acid probes incorporated in the microarray. Note: The sequence
data for this patent can also be obtained in electronic format directly
from USPTO at seqdata.uspto.gov/sequence.html
SQ Sequence 25 BP; 4 A; 9 C; 5 G; 7 T; 0 U; 0 Other;
Query Match 0.5%; Score 17.6; DB 1; Length 25;
Best Local Similarity 83.3%; Pred. No. 1.1e+03;
Matches 20; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
QY 247 CGGATGGACGAAGCTGCTGGCC 270
Db 25 CGGATGGACGAAGCTGCTGGAC 2

RESULT 598
ACI80279/c
ID ACI80279 standard; DNA; 25 BP.
XX AC ACI80279;
XX DT 14-OCT-2003 (first entry)
XX DE Human microarray DNA oligonucleotide SEQ ID NO 80270.

KW tag-labelled compound; gene family; in situ hybridisation;
 KW library screening; Southern hybridisation; northern hybridisation;
 KW dot-blot hybridisation; gene sequence; mutation detection;
 KW target sequence; probe; PCR; primer; ss.

OS Unidentified.

XX US2003082596-A1.

XX 01-MAY-2003.

XX 08-AUG-2002; 2002US-00215112.

XX 08-AUG-2001; 2001US-0311040P.

XX (MITT/) MITTMANN M.

XX Mittmann M;

XX WPI; 2003-576608/54.

XX New probe array useful e.g. for monitoring gene expression levels, for
 XX analysing genetic variations, or for hybridizing tag-labelled compounds,
 XX comprises multiple nucleic acid probes.

PS Claim 1; SEQ ID NO 7601; 9pp; English.

XX The present invention relates to nucleic acid sequences that are
 CC complementary to particular genes, and can be used as probes for a
 CC variety of analyses such as gene expression analysis. Each probe
 CC comprises 9 or more consecutive nucleotides from at least one of 14936
 CC nucleotide sequences defined in the patent, or their perfect sense match,
 CC sense mismatch, antisense match or antisense mismatch oligonucleotides.
 CC The probes may be used in an array comprising at least 10 distinct
 CC nucleic acid probes. The array is useful in monitoring gene expression
 CC levels by hybridisation to a DNA library, in analysing genetic
 CC variations, and in hybridising tag-labelled compounds. The probes are
 CC useful for identifying family members of a gene. The probes are also
 CC useful in situ hybridisations, in screening cDNA or genomic libraries
 CC (or derived subclones) for additional clones containing segments of DNA
 CC that have been previously isolated and sequenced, in Southern, northern,
 CC or dot-blot hybridisation of genomic DNA to identify or detect the
 CC sequence of any gene or detect specific mutations in any gene, and in
 CC mapping the 5' termini of mRNA molecules by primer extensions. The
 CC nucleic acid sequences of the invention are also useful as PCR primers.
 CC The invention provides a large collection of nucleic acid sequences
 CC complementary to particular genes with a wide range of analytical uses.
 CC ACH50865-ACH65260 represent the target sequences of the invention. Note:
 CC The sequence data for this patent was obtained in electronic format
 CC directly from the USPTO web site at seqdata.uspto.gov/psipsdIDEntry.html

XX Sequence 25 BP; 9 A; 7 C; 7 G; 2 T; 0 U; 0 Other;

Query Match 0.5%; Score 17.6; DB 1; Length 25;
 Best Local Similarity 83.3%; Pred. No. 1.1e+03;
 Matches 20; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 3677 AGGTGGTCTCTCTTGGGGCCCA 3700

DB 24 ACGGTCGTCCTCTCTTGGTCTTA 1

RESULT 601

AD010905

ID AD010905 standard; DNA; 25 BP.

AC AD010905;

XX 15-JUL-2004 (first entry)

XX Single multiplex PCR primer #277.

DE ss; primer; simultaneous amplification;

XX ss; primer; simultaneous amplification;

KW single multiplex polymerase chain reaction; multifactorial disease;
 KW genetic alteration; pharmacogenetic reaction; genotyping; polymorphism;
 KW gene expression profiling.

OS Synthetic.

XX WO2004033649-A2.

XX 22-APR-2004.

XX 07-OCT-2003; 2003WO-US031874.

XX 07-OCT-2002; 2002US-0417009P.

XX (UYNE-) UNIV NEW JERSEY MEDICINE & DENTISTRY.

XX Li H, Li J;

XX WPI; 2004-340914/31.

XX Designing primers for simultaneous amplification of target DNA fragments
 XX in a single multiplex polymerase chain reaction, for high throughput
 XX multiplex DNA sequence amplification, comprises aligning two primers.

PS Disclosure; Page 34; 120pp; English.

XX The invention relates to a method of designing primers for simultaneous
 CC amplification of target DNA fragments in a single multiplex polymerase
 CC chain reaction by aligning a first primer and a second primer. The method
 CC comprises: (a) aligning a first primer and a second primer; and (b)
 CC selecting the first primer where the first primer at its 3' end does not
 CC contain four or more bases that are perfectly matching to the 3' end
 CC sequence of the first primer or a second primer, the first primer at its
 CC 3' end does not contain seven or more bases that are perfectly matching
 CC except one mismatch to the 3' end sequence of the first primer or the
 CC second primer the first primer at its 3' end does not contain six or
 CC more bases that are perfectly matching to a sequence anywhere of the
 CC first primer or the second primer, and the first primer at its 3' end
 CC does not contain eleven or more bases that are perfectly matching except
 CC one mismatch to a sequence anywhere of the first primer or the second
 CC primer. The method is useful for designing primers for simultaneous
 CC amplification of target DNA fragments in a single multiplex polymerase
 CC chain reaction. It is also useful in the identification of multiple genes
 CC related to multifactorial diseases, the genome-scale detection of genetic
 CC alterations, the studies in pharmacogenetic reactions, the genotyping
 CC genetic polymorphisms in a large population, the gene expression
 CC profiling in various samples and high throughput genotyping technologies.
 CC This sequence corresponds to an example of a primer of the invention.

XX Sequence 25 BP; 6 A; 4 C; 3 G; 12 T; 0 U; 0 Other;

Query Match 0.5%; Score 17.6; DB 1; Length 25;
 Best Local Similarity 83.3%; Pred. No. 1.1e+03;
 Matches 20; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 3361 ATACAAATTTCTTAATTCGTGTG 3384

DB 1 ATACACATTTTCTCTATTGTGTG 24

RESULT 602

AAQ33728

ID AAQ33728 standard; DNA; 19 BP.

XX AAQ33728;

XX 25-MAR-2003 (revised)

XX 02-FEB-1993 (first entry)

XX Microsatellite sequence from clone TGLA147.

XX PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;

XX genetic mapping; traits; amplification; ss.

CC designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase
CC other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.
CC Representative examples of ribozyme recognition sites are given in
CC AAA82415 to AAA86787. The ribozyme of the invention is useful for
CC inhibiting restenosis by introduction of the ribozyme into cells. The
CC ribozyme is resistant to endonuclease activity and hence is efficient in
CC restenosis treatment
XX

SQ Sequence 19 BP; 2 A; 8 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 0.5%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 8.2e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2550 TCGGCCTCTGCTTGCAC 2568
Db 1 TCGGCCTCTACCTTGCAC 19
|||||

RESULT 605
AAZ89471/C
ID AAZ89471 standard; DNA; 19 BP.

XX AAZ89471;

XX 16-JUN-2000 (first entry)

XX SSA primer 3 for amplifying A. thaliana and Z. mays DNA.

XX Simple sequence repeat; SSR; single site amplification; SSA; disease;
XX primer; ss.

XX Arabidopsis thaliana.

XX Zea mays.

XX US6054300-A.

XX 25-APR-2000.

XX 21-AUG-1997; 97US-00915609.

XX 21-AUG-1997; 97US-00915609.

XX (USDA) US SEC OF AGRIC.

XX McKendree WL;

XX WPI; 2000-328353/28.

XX Obtaining unknown DNA sequence flanking a single known sequence for use
XX as PCR templates, involves single site amplification with polymerase
XX having strand displacement capability.

XX Example 1; Col 9-10; llpp; English.

XX This invention describes a novel method for obtaining DNA of unknown
XX sequence flanking a single site of known sequence involves single site
XX amplification of circular DNA template flanking a target DNA of known
XX sequence using a polymerase having strand displacement capability. The
XX method is used for obtaining a particular target DNA sequence that can be
XX useful as templates that contain entire simple sequence repeat (SSR)
XX alleles for amplification (SSA) procedures e.g. PCR or can be employed as
XX molecular markers, e.g. in distinguishing between species, strains or
XX varieties within species or identifying the presence of a disease
XX condition. It also provides a marker for use in areas such as import and
XX export regulation, variety and ecotype identification, marker
XX development, forensic DNA fingerprinting, etc. The method can also be
XX used to generate a linear DNA molecule containing two target sequences
XX from one sequence within a single stranded DNA template and flanking
XX regions for these target sequences. It can also be used for e.g. for
XX cloning cDNA or genomic DNA which flanks any known short target sequence.
XX The present method can also be used to obtain entire coding regions of
XX genes based upon a known nucleic acid sequence or by using a degenerate

CC nucleic acid sequence derived from amino acid sequence back translation
CC using a polymerase having strand displacement capability which can
CC synthesize up to 10 kb fragments. This is especially useful for obtaining
CC plant genes which are usually less than 10 kb in length. The method
CC allows accelerated development of high resolution DNA markers that may be
CC used for fingerprinting, mapping etc., using small amounts of tissue
CC (less than 1 mug). It also allows the production of a PCR template with
CC knowledge of only one region of target DNA sequence, the size of which is
CC regulated only by the primer design. The present method also eliminates
CC genomic DNA library preparation and screening which are the most time
CC consuming steps, typically requiring no less than three months, with
CC total time for target DNA development being between 4-6 months. AAZ89469-
CC Z89474 represent primers used to illustrate the method of the invention
XX

SQ Sequence 19 BP; 9 A; 10 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 0.5%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 8.2e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2315 GTCTGTGTGTGTGTGTG 2333
Db 19 GTCTGTGTGTGTGTG 1
|||||

RESULT 606

AAZ89472

ID AAZ89472 standard; DNA; 19 BP.

XX AAZ89472;

XX 16-JUN-2000 (first entry)

XX SSA primer 4 for amplifying A. thaliana and Z. mays DNA.

XX Simple sequence repeat; SSR; single site amplification; SSA; disease;
XX primer; ss.

XX Arabidopsis thaliana.

XX Zea mays.

XX US6054300-A.

XX 25-APR-2000.

XX 21-AUG-1997; 97US-00915609.

XX 21-AUG-1997; 97US-00915609.

XX (USDA) US SEC OF AGRIC.

XX McKendree WL;

XX WPI; 2000-328353/28.

XX Obtaining unknown DNA sequence flanking a single known sequence for use
XX as PCR templates, involves single site amplification with polymerase
XX having strand displacement capability.

XX Example 1; Col 9-10; llpp; English.

XX This invention describes a novel method for obtaining DNA of unknown
XX sequence flanking a single site of known sequence involves single site
XX amplification of circular DNA template flanking a target DNA of known
XX sequence using a polymerase having strand displacement capability. The
XX method is used for obtaining a particular target DNA sequence that can be
XX useful as templates that contain entire simple sequence repeat (SSR)
XX alleles for amplification (SSA) procedures e.g. PCR or can be employed as
XX molecular markers, e.g. in distinguishing between species, strains or
XX varieties within species or identifying the presence of a disease
XX condition. It also provides a marker for use in areas such as import and
XX export regulation, variety and ecotype identification, marker
XX development, forensic DNA fingerprinting, etc. The method can also be

CC used to generate a linear DNA molecule containing two target sequences
 CC from one sequence within a single stranded DNA template and flanking
 CC regions for these target sequences. It can also be used for e.g. for
 CC cloning cDNA or genomic DNA which flanks any known short target sequence.
 CC The present method can also be used to obtain entire coding regions of
 CC genes based upon a known nucleic acid sequence or by using a degenerate
 CC nucleic acid sequence derived from amino acid sequence back translation
 CC using a polymerase having strand displacement capability which can
 CC synthesize up to 10 kb fragments. This is especially useful for obtaining
 CC plant genes which are usually less than 10 kb in length. The method
 CC allows accelerated development of high resolution DNA markers that may be
 CC used for fingerprinting, mapping etc., using small amounts of tissue
 CC (less than 1 mug). It also allows the production of a PCR template with
 CC knowledge of only one region of target DNA sequence, the size of which is
 CC regulated only by the primer design. The present method also eliminates
 CC genomic DNA library preparation and screening which are the most time
 CC consuming steps, typically requiring no less than three months, with
 CC total time for target DNA development being between 4-6 months. AAZ89469-
 CC Z89474 represent primers used to illustrate the method of the invention
 XX
 SQ Sequence 19 BP; 0 A; 0 C; 10 G; 9 T; 0 U; 0 Other;

Query Match 0.5%; Score 17.4; DB 1; Length 19;
 Best Local Similarity 94.7%; Pred. No. 8.2e+02;
 Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2315 GTCTGTGTGTGTGTGTG 2333
 |||||
 Db 1 GTGTGTGTGTGTGTGTG 19

RESULT 607
 AAC66739
 ID AAC66739 standard; DNA; 19 BP.
 AC AAC66739;
 XX
 XX 15-FEB-2001 (first entry)
 DT
 XX Heterologous insert sequence #2.
 DE
 XX Probe; cytostatic; antiviral; gene therapy; ss.
 KW
 XX Unidentified.
 OS
 XX WO200063365-A1.
 PN
 XX 26-OCT-2000.
 PD
 XX 21-APR-2000; 2000WO-US010909.
 PF
 XX 21-APR-1999; 99US-0130345P.
 PR
 XX (PANG-) PANGENE CORP.
 PA
 XX Belotserkovskii B, Reddy G, Zarling D;
 PI
 XX WPI; 2000-647516/62.

XX Composition for modulating transcription or replication of a pre-selected
 PT target sequence and for treating a plant or animal disease, comprises a
 PT recombinase and two probes, each containing a homology clamp and an
 PT anchoring sequence.
 XX Disclosure; Fig 9; 103pp; English.
 PS
 XX The present invention relates to a composition comprising a recombinase
 CC and two complementary single stranded probes each containing at least one
 CC homology clamp corresponding or complementary to a preselected target
 CC nucleic acid sequence and at least one anchoring sequence. The present
 CC sequence is a heterologous insert sequence used to generate the probes
 CC that can be used in the present invention. The composition of the present
 CC invention can be used to modulate transcription or replication of a pre-

CC selected target sequence, treat a disease state of a plant or animal
 CC caused by expression of a disease gene, detect a double stranded nucleic
 CC acid target sequence, isolate either strand of a double stranded target
 CC sequence, isolate either strand of a member of a gene family, produce a
 CC transgenic non-human organism or plant, determine the function of a
 CC double stranded nucleic acid target sequence and inhibit double stranded
 CC nucleic acid rotation or branch migration. In addition, the composition
 CC may be used to produce animal models for genetic defects
 XX
 SQ Sequence 19 BP; 0 A; 0 C; 9 G; 10 T; 0 U; 0 Other;

Query Match 0.5%; Score 17.4; DB 1; Length 19;
 Best Local Similarity 94.7%; Pred. No. 8.2e+02;
 Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2318 TGTGTGTGTGTGTGCGT 2336
 |||||
 Db 1 TGTGTGTGTGTGTGTG 19

RESULT 608
 AAC66738/c
 ID AAC66738 standard; DNA; 19 BP.
 AC AAC66738;
 XX
 XX 15-FEB-2001 (first entry)
 DT
 XX Heterologous insert sequence #1.
 DE
 XX Probe; cytostatic; antiviral; gene therapy; ss.
 KW
 XX Unidentified.
 OS
 XX WO200063365-A1.
 PN
 XX 26-OCT-2000.
 PD
 XX 21-APR-2000; 2000WO-US010909.
 PF
 XX 21-APR-1999; 99US-0130345P.
 PR
 XX (PANG-) PANGENE CORP.
 PA
 XX Belotserkovskii B, Reddy G, Zarling D;
 PI
 XX WPI; 2000-647516/62.

XX Composition for modulating transcription or replication of a pre-selected
 PT target sequence and for treating a plant or animal disease, comprises a
 PT recombinase and two probes, each containing a homology clamp and an
 PT anchoring sequence.
 XX Disclosure; Fig 9; 103pp; English.

PS

XX The present invention relates to a composition comprising a recombinase
 CC and two complementary single stranded probes each containing at least one
 CC homology clamp corresponding or complementary to a preselected target
 CC nucleic acid sequence and at least one anchoring sequence. The present
 CC sequence is a heterologous insert sequence used to generate the probes
 CC that can be used in the present invention. The composition of the present
 CC invention can be used to modulate transcription or replication of a pre-
 CC selected target sequence, treat a disease state of a plant or animal
 CC caused by expression of a disease gene, detect a double stranded nucleic
 CC acid target sequence, isolate either strand of a double stranded target
 CC sequence, isolate either strand of a member of a gene family, produce a
 CC transgenic non-human organism or plant, determine the function of a
 CC double stranded nucleic acid target sequence and inhibit double stranded
 CC nucleic acid rotation or branch migration. In addition, the composition
 CC may be used to produce animal models for genetic defects

XX Sequence 19 BP; 10 A; 9 C; 0 G; 0 T; 0 U; 0 Other;

CC with expression of the UGT gene, and the individuals sensitivity to
 CC xenobiotics is effected by glucuronidation activity. The methods
 CC preferably involve determining the presence of five, six or seven TA
 CC repeats in the promoter. Defects in glucuronidation is associated with
 CC Gilbert's syndrome (hyperbilirubinaemia) and Crigler-Najjar syndrome. The
 CC present sequence is the UGT1A1 promoter (TA)8 repeat region
 XX
 SQ Sequence 19 BP; 10 A; 0 C; 0 G; 9 T; 0 U; 0 Other;
 Query Match 0.5%; Score 17.4; DB 1; Length 19;
 Best Local Similarity 94.7%; Pred. No. 8.2e+02;
 Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2827 TATACATATATATATATAA 2845
 DB 1 TATATATATATATATAA 19
 RESULT 611
 ABK90423/C
 ID ABK90423 standard; DNA; 19 BP.
 XX
 AC ABK90423;
 XX
 DT 05-NOV-2002 (first entry)
 XX
 DE Human UGT1A1 promoter polymorphism (TA)8 repeat region.
 XX
 KW Human; ds; UGT1A1; promoter; Gilbert's syndrome; hyperbilirubinaemia;
 KW uridine diphosphate glucuronosyltransferase; Crigler-Najjar syndrome;
 KW UGT; polymorphism detection; TA repeat; glucuronidation; Irinotecan;
 KW TAS-103; xenobiotic.
 XX
 OS Homo sapiens.
 XX
 PN US6395481-B1.
 XX
 PD 28-MAY-2002.
 XX
 PF 16-FEB-1999; 99US-00251274.
 XX
 PR 16-FEB-1999; 99US-00251274.
 XX
 PA (ARCH-) ARCH DEV CORP.
 XX
 PI Di Rienzo A, Iyer L, Ratain MJ;
 XX
 DR WPI; 2002-588597/63.
 XX
 PT Detecting polymorphisms in uridine diphosphate glucuronosyltransferase
 PT gene promoter, useful for optimizing drug dosages for a patient,
 PT comprises determining the presence of five thymidine-adenine repeats in
 PT the promoter.
 XX
 PS Example 6; Col 11; 13pp; English.
 XX
 CC The invention relates to detecting (M1) polymorphisms in a uridine
 CC diphosphate glucuronosyltransferase (UGT) gene promoter by determining
 CC the presence of five thymidine-adenine (TA) repeats in the promoter,
 CC where the presence of the five TA repeats correlates with increased
 CC expression of the gene. The method is used for detecting polymorphisms in
 CC a UGT gene promoter, preferably a UGT 1 (UGT1A1) gene promoter. (M1) is
 CC useful for screening individuals for variation in glucuronidation
 CC activity, for optimising drug dosages for a patient, where the drugs
 CC (e.g. Irinotecan or TAS-103) are glucuronidated by UGT (preferably
 CC UGT1A1) and the activity of the drug is effected by its level of
 CC glucuronidation. The method preferably involves obtaining DNA from an
 CC individual, amplifying all or part of a UGT gene promoter (UGT1A1 gene
 CC promoter) contained in the DNA and determining the number of TA repeats
 CC in the promoter. Thus the DNA being amplified comprises all or part of
 CC UGT1A1 promoter. The DNA is amplified by a polymerase chain reaction and
 CC the number of TA repeats is determined by gel electrophoresis or by
 CC sequencing the amplified DNA. The polymorphism comprises an allele

CC consisting of five TA repeats (TA)5, six TA repeats (TA)6, or seven TA
 CC repeats (TA)7. The promoter has any one of the genotypes (TA)5/(TA)5,
 CC (TA)5/(TA)6, (TA)5/(TA)7, (TA)5/(TA)8, (TA)6/(TA)8, (TA)7/(TA)8 or
 CC (TA)8/(TA)8. (M1) is also useful for predicting an individual's
 CC sensitivity to xenobiotics that are glucuronidated by a UGT (preferably
 CC UGT1A1) gene product, the method comprising determining the number of TA
 CC repeats in a UGT gene promoter, where the number of TA repeats correlates
 CC with expression of the UGT gene, and the individuals sensitivity to
 CC xenobiotics is effected by glucuronidation activity. The methods
 CC preferably involve determining the presence of five, six or seven TA
 CC repeats in the promoter. Defects in glucuronidation is associated with
 CC Gilbert's syndrome (hyperbilirubinaemia) and Crigler-Najjar syndrome. The
 CC present sequence is the UGT1A1 promoter (TA)8 repeat region
 XX
 SQ Sequence 19 BP; 10 A; 0 C; 0 G; 9 T; 0 U; 0 Other;
 Query Match 0.5%; Score 17.4; DB 1; Length 19;
 Best Local Similarity 94.7%; Pred. No. 8.2e+02;
 Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 3462 TTATATATATCTATATATA 3480
 DB 19 TTATATATATATATATA 1
 RESULT 612
 AAL50681
 ID AAL50681 standard; DNA; 19 BP.
 XX
 AC AAL50681;
 XX
 DT 16-JAN-2003 (first entry)
 XX
 DE Human uridine diphosphate glucuronosyltransferase gene polymorphism #15.
 XX
 KW Human; polymorphism; TA repeat; ds; UGT; thymidine-adenine repeat;
 KW uridine diphosphate glucuronosyltransferase gene promoter; UGT1A1;
 KW drug dosage optimisation; xenobiotic sensitivity.
 XX
 OS Homo sapiens.
 XX
 PN US2002115097-A1.
 XX
 PD 22-AUG-2002.
 XX
 PF 01-FEB-2002; 2002US-00061693.
 XX
 PR 16-FEB-1999; 99US-00251274.
 XX
 PA (ARCH-) ARCH DEV CORP.
 XX
 PI Rienzo AD, Iyer L, Ratain MJ;
 XX
 DR WPI; 2002-740095/80.
 XX
 PT Detecting polymorphisms in uridine diphosphate glucuronosyltransferase
 PT gene promoter, useful for optimizing drug dosages for a patient, involves
 PT determining number of thymidine-adenine repeats in the promoter.
 XX
 PS Example 6; Page 3; 13pp; English.
 XX
 CC The invention comprises a method for detecting polymorphisms in a uridine
 CC diphosphate glucuronosyltransferase (UGT) gene promoter (preferably
 CC UGT1A1). The method involves determining the number of thymidine-adenine
 CC (TA) repeats in the promoter - as the number of TA repeats correlates
 CC with expression of the UGT gene. The method of the invention is useful
 CC for detecting polymorphisms in a UGT gene promoter. The method of the
 CC invention is also useful in optimising drug dosages and predicting an
 CC individual's sensitivity to xenobiotics for drugs and xenobiotics that
 CC are glucuronidated by UGT. The present DNA sequence represents a UGT gene
 CC TA repeat polymorphism
 XX
 SQ Sequence 19 BP; 10 A; 0 C; 0 G; 9 T; 0 U; 0 Other;

Thu Oct 28 12:48:21 2004

vivlemore401-10.rng

```

Query Match          0.5%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 8.2e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2827 TATACATATATATATATAA 2845
   |||||
Db 1 TATATATATATATATATAA 19

RESULT 613
AAL50681/c
ID AAL50681 standard; DNA; 19 BP.
XX AC AAL50681;
AC AC
DT 16-JAN-2003 (first entry)
DE Human uridine diphosphate glucuronosyltransferase gene polymorphism #15.
DE Human; polymorphism; TA repeat; ds; UGT; thymidine-adenine repeat;
KW uridine diphosphate glucuronosyltransferase gene promoter; UGT1A1;
KW drug dosage optimisation; xenobiotic sensitivity.
XX Homo sapiens.
XX OS
XX US2002115097-A1.
XX PN
XX PD 22-AUG-2002.
XX PF 01-FEB-2002; 2002US-00061693.
XX PR 16-FEB-1999; 99US-00251274.
XX PA (ARCH-) ARCH DEV CORP.
XX PI Rienzo AD, Iyer L, Ratain MJ;
XX DR WPI; 2002-740095/80.
XX CC Detecting polymorphisms in uridine diphosphate glucuronosyltransferase
PT gene promoter, useful for optimizing drug dosages for a patient, involves
PT determining number of thymidine-adenine repeats in the promoter.
XX Example 6; Page 3; 13pp; English.
XX CC The invention comprises a method for detecting polymorphisms in a uridine
CC diphosphate glucuronosyltransferase (UGT) gene promoter (preferably
CC UGT1A1). The method involves determining the number of thymidine-adenine
CC (TA) repeats in the promoter - as the number of TA repeats correlates
CC with expression of the UGT gene. The method of the invention is useful
CC for detecting polymorphisms in a UGT gene promoter. The method of the
CC invention is also useful in optimising drug dosages and predicting an
CC individual's sensitivity to xenobiotics for drugs and xenobiotics that
CC are glucuronidated by UGT. The present DNA sequence represents a UGT gene
CC TA repeat polymorphism
XX Sequence 19 BP; 10 A; 0 C; 0 G; 9 T; 0 U; 0 Other;

Query Match          0.5%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 8.2e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3462 TTATATATATCTCTATATATA 3480
   |||||
Db 19 TTATATATATATATATA 1

RESULT 614
ADD69517
ID ADD69517 standard; DNA; 19 BP.
XX AC ADD69517;

```

```

XX 15-JAN-2004 (first entry)
DT ISSR-related PCR primer 4.
DE inter-simple sequence repeat; ISSR; SSR; PCR; primer; genotyping; plant;
KW animal; Basmati rice; ss.
KW Unidentified.
OS WO2003085133-A2.
XX PN 16-OCT-2003.
XX PD 09-JAN-2003; 2003WO-IB000041.
XX PF 08-APR-2002; 2002IN-CH000260.
XX PR (DNAF-) CENT DNA FINGERPRINTING & DIAGNOSTICS.
XX PA Naggaraju JG;
XX PI WPI; 2003-804317/75.
XX DR New set of inter-simple sequence repeats (ISSR)-PCR primers for
PT genotyping eukaryotes, useful for genotyping diverse genomes of plant and
PT animal systems.
XX PT Disclosure; Page 19; 60pp; English.
XX PS The invention relates to a novel set of inter-simple sequence repeats
XX CC (ISSR)-PCR primers for genotyping eukaryotes. The primers of the
XX CC invention may be useful for genotyping diverse genomes of plant and
XX CC animal systems, in particular for distinguishing Basmati rice varieties
XX CC from non-Basmati rice varieties and traditional Basmati rice varieties
XX CC from evolved Basmati rice varieties. The current sequence is that of the
XX CC ISSR-related PCR primer of the invention.
XX Sequence 19 BP; 0 A; 0 C; 9 G; 10 T; 0 U; 0 Other;

Query Match          0.5%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 8.2e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2318 TGTGCTGTGTGTGTGCGGT 2336
   |||||
Db 1 TGTGCTGTGTGTGTGTGT 19

RESULT 615
ADF37387
ID ADF37387 standard; RNA; 19 BP.
XX AC ADF37387;
XX 12-FEB-2004 (first entry)
DT Human VEGFR3 short interfering nucleic acid (siNA) SEQ ID NO:1676.
DE double-stranded short interfering nucleic acid;
XX short interfering nucleic acid; siNA; downregulation;
KW vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW cytosolic; antidiabetic; ophthalmological; antiarthritic; antiproliferative;
KW nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW arthritis; psoriasis; endometriosis; angiofibroma;
KW polycystic kidney disease; ss.
XX OS Synthetic.
XX OS Homo sapiens.
XX PN WO2003070910-A2.
XX AC

```

```

PD 28-AUG-2003.
XX
XX 20-FEB-2003; 2003WO-US005022.
XX
XX 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 29-MAY-2002; 2002WO-US017674.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 04-NOV-2002; 2002US-0409293P.
PR 27-NOV-2002; 2002US-00287949.
PR 15-JAN-2003; 2003US-0440129P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Mcswiggen J, Beigelman L, Pavco P;
XX WPI; 2003-679876/64.
XX
XX New double-stranded interfering nucleic acid, useful e.g. for treatment
PT and diagnosis of cancer, downregulates the vascular endothelial growth
PT factor receptor gene.
XX
XX Example 3; SEQ ID NO 1676; 207pp; English.
XX
XX The present invention describes a double-stranded short interfering
XX nucleic acid (siNA) that downregulates expression of the vascular
XX endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
XX siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
XX delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
XX that express siNA; and (5) single-stranded siNA with similar properties.
XX The siNAs have antiangiogenic, cytostatic, antidiabetic,
XX ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
XX gynaecological activities. The siNA are useful for modulating
XX (downregulating) the expression of VEGFR genes. The siNA are potentially
XX useful for treating a wide range of angiogenesis-associated conditions,
XX particularly cancers, diabetic retinopathy, macular degeneration,
XX neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
XX and polycystic kidney disease. The siNA may also be useful for diagnosis,
XX drug screening, target identification and validation, genetic
XX engineering, studying gene function, and also for gene mapping (e.g. of
XX single-nucleotide polymorphisms). The present sequence is used in the
XX exemplification of the present invention.
XX
XX Sequence 19 BP; 7 A; 6 C; 4 G; 0 T; 2 U; 0 Other;
XX
XX Query Match 0.5%; Score 17.4; DB 1; Length 19;
XX Best Local Similarity 84.2%; Pred. No. 8.2e+02;
XX Matches 16; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
XX
OY 1609 AAGTGCATCCACAGGAC 1627
DB 1 AAGUGCAUCCACAGAGACC 19
XX
XX RESULT 616
XX ADF36100
XX ID ADF36100 standard; RNA; 19 BP.
XX
XX AC ADF36100;
XX
XX 12-FEB-2004 (first entry)
XX
XX Human.VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:389.
XX
XX double-stranded short interfering nucleic acid;
XX short interfering nucleic acid; siNA; downregulation;
XX vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
XX cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;

```

```

KW nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW arthritis; psoriasis; endometriosis; angiofibroma;
KW polycystic kidney disease; ss.
XX
XX Synthetic.
OS
XX Homo sapiens.
XX
XX WO2003070910-A2.
XX
XX 28-AUG-2003.
XX
XX 20-FEB-2003; 2003WO-US005022.
XX
XX 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 29-MAY-2002; 2002WO-US017674.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 04-NOV-2002; 2002US-00287949.
PR 27-NOV-2002; 2002US-00306747.
PR 15-JAN-2003; 2003US-0440129P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Mcswiggen J, Beigelman L, Pavco P;
XX WPI; 2003-679876/64.
XX
XX New double-stranded interfering nucleic acid, useful e.g. for treatment
PT and diagnosis of cancer, downregulates the vascular endothelial growth
PT factor receptor gene.
XX
XX Example 3; SEQ ID NO 389; 207pp; English.
XX
XX The present invention describes a double-stranded short interfering
XX nucleic acid (siNA) that downregulates expression of the vascular
XX endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
XX siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
XX delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
XX that express siNA; and (5) single-stranded siNA with similar properties.
XX The siNAs have antiangiogenic, cytostatic, antidiabetic,
XX ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
XX gynaecological activities. The siNA are useful for modulating
XX (downregulating) the expression of VEGFR genes. The siNA are potentially
XX useful for treating a wide range of angiogenesis-associated conditions,
XX particularly cancers, diabetic retinopathy, macular degeneration,
XX neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
XX and polycystic kidney disease. The siNA may also be useful for diagnosis,
XX drug screening, target identification and validation, genetic
XX engineering, studying gene function, and also for gene mapping (e.g. of
XX single-nucleotide polymorphisms). The present sequence is used in the
XX exemplification of the present invention.
XX
XX Sequence 19 BP; 0 A; 0 C; 9 G; 0 T; 10 U; 0 Other;
XX
XX Query Match 0.5%; Score 17.4; DB 1; Length 19;
XX Best Local Similarity 47.4%; Pred. No. 8.2e+02;
XX Matches 9; Conservative 9; Mismatches 1; Indels 0; Gaps 0;
XX
OY 2318 TGTGTGTGTGTGTGTGCGT 2336
DB 1 UGUGUGUGUGUGUGUGUGU 19
XX
XX RESULT 617
XX ADF37400
XX ID ADF37400 standard; RNA; 19 BP.
XX

```


CC drug screening, target identification and validation, genetic
 CC engineering, studying gene function, and also for gene mapping (e.g. of
 CC single-nucleotide polymorphisms). The present sequence is used in the
 CC exemplification of the present invention.

SQ Sequence 19 BP; 2 A; 4 C; 6 G; 0 T; 7 U; 0 Other;
 Query Match 0.5%; Score 17.4; DB 1; Length 19;
 Best Local Similarity 94.7%; Pred. No. 8.2e+02;
 Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1609 AAGTGCATCCACAGGACC 1627
 DB 19 AAGTGCATCCACAGGACC 1

RESULT 619
 ADF37647/c
 ID ADF37647 standard; RNA; 19 BP.
 XX
 AC ADF37647;
 DT 12-FEB-2004 (first entry)
 XX Human VEGFR3 short interfering nucleic acid (siNA) SEQ ID NO:1936.

XX double-stranded short interfering nucleic acid;
 KW short interfering nucleic acid; siNA; downregulation;
 KW vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
 KW cytotatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
 KW nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
 KW diabetic retinopathy; macular degeneration; neovascular glaucoma;
 KW arthritis; psoriasis; endometriosis; angiofibroma;
 KW polycystic kidney disease; ss.

XX Synthetic.
 OS Homo sapiens.
 XX
 XX WO2003070910-A2.
 XX 28-AUG-2003.
 XX 20-FEB-2003; 2003WO-US005022.
 XX 20-FEB-2002; 2002US-0358580P.
 XX 11-MAR-2002; 2002US-0363124P.
 XX 29-MAY-2002; 2002WO-US017674.
 XX 06-JUN-2002; 2002US-0386782P.
 XX 03-JUL-2002; 2002US-0393796P.
 XX 29-JUL-2002; 2002US-0399348P.
 XX 29-AUG-2002; 2002US-0406784P.
 XX 05-SEP-2002; 2002US-0408378P.
 XX 09-SEP-2002; 2002US-0409293P.
 XX 04-NOV-2002; 2002US-0409293P.
 XX 27-NOV-2002; 2002US-00287949.
 XX 15-JAN-2003; 2003US-0440129P.
 XX (RIBO-) RIBOZYME PHARM INC.
 XX Mcswiggen J, Beigelman L, Pavco P;
 XX WPI; 2003-679876/64.
 XX New double-stranded interfering nucleic acid, useful e.g. for treatment
 PT and diagnosis of cancer, downregulates the vascular endothelial growth
 PT factor receptor gene.
 XX Example 3; SEQ ID NO 1936; 207pp; English.
 XX The present invention describes a double-stranded short interfering
 CC nucleic acid (siNA) that downregulates expression of the vascular
 CC endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
 CC siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo

CC delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
 CC that express siNA; and (5) single-stranded siNA with similar properties.
 CC The siNAs have antiangiogenic, cytostatic, antidiabetic,
 CC ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
 CC gynaecological activities. The siNA are useful for modulating
 CC (downregulating) the expression of VEGFR genes. The siNA are potentially
 CC useful for treating a wide range of angiogenesis-associated conditions,
 CC particularly cancers, diabetic retinopathy, macular degeneration,
 CC neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
 CC and polycystic kidney disease. The siNA may also be useful for diagnosis,
 CC drug screening, target identification and validation, genetic
 CC engineering, studying gene function, and also for gene mapping (e.g. of
 CC single-nucleotide polymorphisms). The present sequence is used in the
 CC exemplification of the present invention.

XX
 SQ Sequence 19 BP; 3 A; 6 C; 9 G; 0 T; 1 U; 0 Other;
 Query Match 0.5%; Score 17.4; DB 1; Length 19;
 Best Local Similarity 94.7%; Pred. No. 8.2e+02;
 Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1843 CTGGGGGGCTCCCGTACC 1861
 DB 19 CTGGGGGGCTCCCGTACC 1

RESULT 620
 ADF36527/c
 ID ADF36527 standard; RNA; 19 BP.
 XX
 AC ADF36527;
 DT 12-FEB-2004 (first entry)
 XX Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:816.

XX double-stranded short interfering nucleic acid;
 KW short interfering nucleic acid; siNA; downregulation;
 KW vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
 KW cytotatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
 KW nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
 KW diabetic retinopathy; macular degeneration; neovascular glaucoma;
 KW arthritis; psoriasis; endometriosis; angiofibroma;
 KW polycystic kidney disease; ss.

XX Synthetic.
 OS Homo sapiens.
 XX
 XX WO2003070910-A2.
 XX 28-AUG-2003.
 XX 20-FEB-2003; 2003WO-US005022.
 XX 20-FEB-2002; 2002US-0358580P.
 XX 11-MAR-2002; 2002US-0363124P.
 XX 29-MAY-2002; 2002WO-US017674.
 XX 06-JUN-2002; 2002US-0386782P.
 XX 03-JUL-2002; 2002US-0393796P.
 XX 29-JUL-2002; 2002US-0399348P.
 XX 29-AUG-2002; 2002US-0406784P.
 XX 05-SEP-2002; 2002US-0408378P.
 XX 09-SEP-2002; 2002US-0409293P.
 XX 04-NOV-2002; 2002US-00287949.
 XX 27-NOV-2002; 2002US-00306747.
 XX 15-JAN-2003; 2003US-0440129P.
 XX (RIBO-) RIBOZYME PHARM INC.
 XX Mcswiggen J, Beigelman L, Pavco P;
 XX WPI; 2003-679876/64.

PT New double-stranded interfering nucleic acid, useful e.g. for treatment
PT and diagnosis of cancer, downregulates the vascular endothelial growth
factor receptor gene.
XX
PS Example 3; SEQ ID NO 816; 207pp; English.
XX
CC The present invention describes a double-stranded short interfering
CC nucleic acid (siNA) that downregulates expression of the vascular
CC endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC that express siNA; and (5) single-stranded siNA with similar properties.
CC The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC gynaecological activities. The siNA are useful for modulating
CC (downregulating) the expression of VEGFR genes. The siNA are potentially
CC useful for treating a wide range of angiogenesis-associated conditions,
CC particularly cancers, diabetic retinopathy, macular degeneration,
CC neovascular glaucoma, arthritis, psoriasis, endometriosis, angiodiroma,
CC and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC drug screening, target identification and validation, genetic
CC engineering, studying gene function, and also for gene mapping (e.g. of
CC single-nucleotide polymorphisms). The present sequence is used in the
CC exemplification of the present invention.
XX
SQ Sequence 19 BP; 10 A; 9 C; 0 G; 0 T; 0 U; 0 Other;
Query Match 0.5%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 8.2e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2318 TGTGTGTGTGTGTGTGTGCGT 2336
DB 19 TGTGTGTGTGTGTGTGT 1
RESULT 621
ACCT79668
ID ACC79668 standard; DNA; 19 BP.
XX
AC ACC79668;
XX
DT 27-AUG-2003 (first entry)
XX
DE Human fibroblast growth factor 3 mutagenesis primer SEQ ID NO:3.
XX
KW Human; fibroblast growth factor 3; FGF3; flat epithelial cell; cancer;
KW flat epithelial cell cancer; mutagenesis; primer; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
XX JP2002272474-A.
XX
XX 24-SEP-2002.
XX
XX 22-MAR-2001; 2001JP-00083352.
XX
XX 22-MAR-2001; 2001JP-00083352.
XX
XX (ZERI) ZERIA SHINYAKU KOGYO KK.
XX
XX WPI; 2003-345602/33.
XX
XX Inspection of flat epithelial cell, screening of treating or preventive
PT agents for flat epithelial cancers, the treating or preventive agents for
PT flat epithelial cancer.
XX
XX Example; Page 8; 18pp; Japanese.
PS
XX The present invention describes a method for the inspection of flat
CC epithelial cells in which it is judged that flat epithelial cells
CC separated from an organism can proceed to flat epithelial cancer when the

CC 2128th base in fibroblast growth factor receptor (FGFR) gene of the cells
CC is mutated from guanine to thymine. Also described is a method for
CC screening treating or preventive agents for flat epithelial cancers in
CC which a candidate substance of treating agent for flat epithelial cancer
CC is applied to flat epithelial cancer cells producing FGFR protein in
CC which the 2128th (exon 17) amino acid in FGFR3 gene is mutated from
CC guanine to thymine or the 697th amino acid is mutated from glycine to
CC cysteine and said candidate substance is selected by using the facts that
CC the 2128th base in the flat epithelial cell FGFR3 gene after the
CC application returned to guanine and that the 697th amino acid of FGFR3
CC protein produced returned to glycine as the indices. The method is used
CC for the inspection of flat epithelial cells. The present sequence
CC represents a mutagenesis primer for human FGFR3, which is used in an
CC example from the present invention
XX
SQ Sequence 19 BP; 2 A; 10 C; 3 G; 4 T; 0 U; 0 Other;
Query Match 0.5%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 8.2e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1855 CCGTACCCCGCATCCCTG 1873
DB 1 CCGTACCCCGCATCCCTG 19
RESULT 622
ADN34364
ID ADN34364 standard; RNA; 19 BP.
XX
AC ADN34364;
XX
DT 01-JUL-2004 (first entry)
XX
DE Lower strand of cyclin D1 targeted double stranded siNA #145.
XX
KW short interfering nucleic acid; siNA; cyclin; Cytostatic; Vasotropic;
KW cancer; cell-proliferation disorder; restenosis; drug screening;
KW genetic engineering; pharmacogenomics; gene mapping;
KW single nucleotide polymorphisms; ss.
XX
OS Homo sapiens.
XX
XX WO2003072705-A2.
XX
XX 04-SEP-2003.
XX
XX 06-FEB-2003; 2003WO-US003662.
XX
XX 20-FEB-2002; 2002US-0358580P.
XX
XX 11-MAR-2002; 2002US-0363124P.
XX
XX 06-JUN-2002; 2002US-0386782P.
XX
XX 29-AUG-2002; 2002US-0406784P.
XX
XX 05-SEP-2002; 2002US-0408378P.
XX
XX 09-SEP-2002; 2002US-0409293P.
XX
XX 17-SEP-2002; 2002US-0411275P.
XX
XX 15-JAN-2003; 2003US-0440129P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Thompson J, Mcswiggen J, Beigelman L;
XX WPI; 2003-689983/65.
XX
XX New short interfering nucleic acid, useful e.g. for treatment and
PT diagnosis of cancer and restenosis, down regulates expression of at least
PT one cyclin gene.
XX
XX Example 3; SEQ ID NO 384; 144pp; English.
PS
XX The present invention relates to a short interfering nucleic acid (siNA)
CC that down regulates expression of at least one cyclin gene by RNA
CC interference. siNA are used to modulate expression of cyclin genes, in

CC caused by viruses such as HIV, fungal infections such as those caused by
 CC the yeast genus Candida, parasitic infections such as those caused by
 CC schistosomes, filaria and bacterial infections such as those caused by
 CC Mycobacterium. Neoplastic diseases include lymphoproliferative diseases
 CC such as leukaemias, lymphomas and cancers such as cancer of the brain,
 CC breast. The present sequence represents a Vbeta gene repeat sequence.
 XX
 XX Sequence 19 BP; 10 A; 0 C; 0 G; 9 T; 0 U; 0 Other;

Query Match 0.5%; Score 17.4; DB 1; Length 19;
 Best Local Similarity 94.7%; Pred. No. 8.2e+02;
 Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2823 TATATATACATATATATAT 2841
 Db 1 TATATATATATATATATAT 19

RESULT 625
 AAZ88880
 ID AAZ88880 standard; DNA; 20 BP.
 XX
 AC AAZ88880;
 XX
 DT 25-MAY-2000 (first entry)
 XX
 DE Single stranded nucleic acid molecule (AT)4.
 XX
 KW Free energy parameter; thermodynamics; ss.
 XX
 OS Synthetic.
 XX
 PN US6027884-A.
 XX
 PD 22-FEB-2000.
 XX
 PF 11-DEC-1996; 96US-00763417.
 XX
 PR 17-JUN-1993; 93US-00078759.
 PR 08-APR-1994; 94US-00224840.
 PR 16-JUN-1994; 94US-00260200.
 XX
 PA (UYNV) UNIV NEW YORK STATE RES FOUND.
 XX
 PI Faldasz BD, Benight AS, Lane MJ;
 XX
 DR WPI; 2000-194826/17.

XX Producing double stranded nucleic acid molecules with preselected values
 PT for free energy parameters such as affinity for nucleic acid binding
 PT ligands.
 XX
 PS Disclosure; Col 71-72; 49pp; English.
 XX
 CC This invention describes novel methods of producing double stranded
 CC nucleic acid molecules with a preselected value for a free energy
 CC parameter (e.g. a preselected T_m or a preselected affinity for a nucleic
 CC acid binding ligand). The method involves preparing a first double
 CC stranded nucleic acid comprising a binding site for a nucleic acid-
 CC binding ligand. The first value of a first free energy parameter of the
 CC first double stranded nucleic acid has a preselected relationship with a
 CC first reference value of a first free energy parameter for a reference
 CC double-stranded nucleic acid comprising a reference binding site for the
 CC ligand. The first free energy parameter is a characteristic of the
 CC binding of a ligand of interest to its binding site and the preselected
 CC relationship is higher than, equal to or lower than (sic). The method
 CC comprises: (a) determining a test value for a test double stranded
 CC nucleic acid, comprising a test binding site for the ligand, of a second
 CC free energy parameter that is characteristic of the hybridization of the
 CC two complementary strands of double stranded nucleic acid; (b) comparing
 CC the first value to a reference value (second reference value) of the
 CC second free energy parameter for the reference double stranded nucleic
 CC acid; and (c) if the test value and the second reference value of the

CC second free energy parameter exhibit a test relationship that is the same
 CC as the preselected relationship, then preparing a first double stranded
 CC nucleic acid comprising all or part of the test nucleic acid, but if the
 CC test relationship is different than the preselected relationship,
 CC repeating step (a) and (b) on one or more additional test double stranded
 CC nucleic acids until an additional test double stranded nucleic acid is
 CC identified in which the test relationship is the same as the preselected
 CC relationship, and then preparing a first double stranded nucleic acid
 CC comprising all or part of the additional test nucleic acid. AAZ88875-
 CC 288882 represent the single stranded DNA molecules used to illustrate the
 CC method of the invention
 XX
 XX Sequence 20 BP; 9 A; 1 C; 1 G; 9 T; 0 U; 0 Other;

Query Match 0.5%; Score 17.4; DB 1; Length 20;
 Best Local Similarity 94.7%; Pred. No. 8.7e+02;
 Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3463 TATATATATCTATATATAT 3481
 Db 2 TATATATAGCTATATATAT 20

RESULT 626
 AAZ88880/c
 ID AAZ88880 standard; DNA; 20 BP.
 XX
 AC AAZ88880;
 XX
 DT 25-MAY-2000 (first entry)
 XX
 DE Single stranded nucleic acid molecule (AT)4.
 XX
 KW Free energy parameter; thermodynamics; ss.
 XX
 OS Synthetic.
 XX
 PN US6027884-A.
 XX
 PD 22-FEB-2000.
 XX
 PF 11-DEC-1996; 96US-00763417.
 XX
 PR 17-JUN-1993; 93US-00078759.
 PR 08-APR-1994; 94US-00224840.
 PR 16-JUN-1994; 94US-00260200.
 XX
 PA (UYNV) UNIV NEW YORK STATE RES FOUND.
 XX
 PI Faldasz BD, Benight AS, Lane MJ;
 XX
 DR WPI; 2000-194826/17.

XX Producing double stranded nucleic acid molecules with preselected values
 PT for free energy parameters such as affinity for nucleic acid binding
 PT ligands.
 XX
 PS Disclosure; Col 71-72; 49pp; English.
 XX
 CC This invention describes novel methods of producing double stranded
 CC nucleic acid molecules with a preselected value for a free energy
 CC parameter (e.g. a preselected T_m or a preselected affinity for a nucleic
 CC acid binding ligand). The method involves preparing a first double
 CC stranded nucleic acid comprising a binding site for a nucleic acid-
 CC binding ligand. The first value of a first free energy parameter of the
 CC first double stranded nucleic acid has a preselected relationship with a
 CC first reference value of a first free energy parameter for a reference
 CC double-stranded nucleic acid comprising a reference binding site for the
 CC ligand. The first free energy parameter is a characteristic of the
 CC binding of a ligand of interest to its binding site and the preselected
 CC relationship is higher than, equal to or lower than (sic). The method
 CC comprises: (a) determining a test value for a test double stranded
 CC nucleic acid, comprising a test binding site for the ligand, of a second
 CC free energy parameter that is characteristic of the hybridization of the
 CC two complementary strands of double stranded nucleic acid; (b) comparing
 CC the first value to a reference value (second reference value) of the
 CC second free energy parameter for the reference double stranded nucleic
 CC acid; and (c) if the test value and the second reference value of the

CC free energy parameter that is characteristic of the hybridization of the
 CC two complementary strands of double stranded nucleic acid; (b) comparing
 CC the first value to a reference value (second reference value) of the
 CC second free energy parameter for the reference double stranded nucleic
 CC acid; and (c) if the test value and the second reference value of the
 CC second free energy parameter exhibit a test relationship that is the same
 CC as the preselected relationship, then preparing a first double stranded
 CC nucleic acid comprising all or part of the test nucleic acid, but if the
 CC test relationship is different than the preselected relationship,
 CC repeating step (a) and (b) on one or more additional test double stranded
 CC nucleic acids until an additional test double stranded nucleic acid is
 CC identified in which the test relationship is the same as the preselected
 CC relationship, and then preparing a first double stranded nucleic acid
 CC comprising all or part of the additional test nucleic acid. AAZ88875-
 CC Z88882 represent the single stranded DNA molecules used to illustrate the
 CC method of the invention

SQ Sequence 20 BP; 9 A; 1 C; 1 G; 9 T; 0 U; 0 Other;
 Query Match 0.5%; Score 17.4; DB 1; Length 20;
 Best Local Similarity 94.7%; Pred. No. 8.7e+02;
 Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3463 TATATATATCTATATATAT 3481

Db 19 TATATATAGCTATATATAT 1

RESULT 627

AAF62964

ID AAF62964 standard; DNA; 20 BP.

XX AAF62964;

XX 08-MAY-2001 (first entry)

DE Mouse PEPCCK-cytosolic antisense oligonucleotide ISIS 113342.

XX Mouse; antiinflammatory; cytostatic; antisense gene therapy;
 KW phosphoenol pyruvate carboxykinase-cytosolic; PEPCCK-cytosolic; infection;
 KW inflammation; tumour formation; phosphorothioate; ss.

XX Mus musculus.

XX US6187545-B1.

XX 13-FEB-2001.

XX 21-JAN-2000; 2000US-00488671.

XX 21-JAN-2000; 2000US-00488671.

XX (ISIS-) ISIS PHARM INC.

XX McKay R, Butler MM, Wyatt J, Cowseert LM;

XX WPI; 2001-190979/19.

XX Antisense compound capable of modulating the expression of phosphoenol
 PT pyruvate carboxykinase-cytosolic, useful for preventing or delaying
 PT infection, inflammation or tumor formation.

XX Example 17; Col 44; 64pp; English.

XX The present sequence is one of a number of antisense compounds of up to
 CC 30 nucleobases in length that are capable of inhibiting the expression of
 CC phosphoenol pyruvate carboxykinase-cytosolic (PEPCCK-cytosolic). The
 CC antisense compounds are useful for inhibiting the expression of PEPCCK-
 CC cytosolic in cells or tissues. They are commonly used as research
 CC reagents and in diagnostics, e.g. to elucidate the function of particular
 CC genes. They are also useful for distinguishing between functions of
 CC various members of a biological pathway and for research use. The
 CC antisense compounds are also useful prophylactically, e.g. to prevent or

CC delay infection, inflammation or tumour formation. The present sequence
 CC is a chimeric phosphorothioate oligonucleotide with 2'-MOE wings and a
 CC deoxy gap

SQ Sequence 20 BP; 2 A; 0 C; 10 G; 8 T; 0 U; 0 Other;

Query Match 0.5%; Score 17.4; DB 1; Length 20;

Best Local Similarity 94.7%; Pred. No. 8.7e+02;

Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2325 GTGTGTGTGCGTGTGTGTG 2343

Db 1 GTGTGTGTGAGTGTGTGTG 19

RESULT 628

ABQ93169

ID ABQ93169 standard; DNA; 20 BP.

XX ABQ93169;

XX 29-AUG-2003 (revised)

DT 21-OCT-2002 (first entry)

DE T. tauschii/wheat D genome microsatellite cfd67 right PCR primer.

XX Microsatellite marker; wheat; D genome; mapping; genotyping;
 KW polymorphism; phenotypic trait; QTL; quantitative trait locus;
 KW disease-associated gene; development factor; quality factor;
 KW resistance factor; wheat product; identification; detection;
 KW genetically modified wheat; PCR; primer; ss.

XX Aegilops tauschii.

OS Triticum aestivum.

XX EP1217079-A1.

XX 26-JUN-2002.

XX 22-DEC-2000; 2000EP-00403659.

XX 22-DEC-2000; 2000EP-00403659.

XX (INRG) INRA INST NAT RECH AGRONOMIQUE.

XX Bernard M, Sourdille P, Guyomarch H;

XX WPI; 2002-550410/59.

XX Map of wheat D genome comprising the genome location of a microsatellite
 PT marker, useful for e.g. identifying genes responsible for a desired
 PT phenotypic trait, especially quantitative trait loci in wheat, and
 PT diseases.

XX Claim 4; Page 6; 105pp; English.

XX The invention relates to a map of the bread wheat D genome comprising the
 CC genome location of a microsatellite marker selected from a group of 185
 CC such markers (ABQ92733-ABQ92917). The invention also encompasses the use
 CC of left (ABQ92918-ABQ93102) and right (ABQ93103-ABQ93287) primers to
 CC amplify and detect the microsatellite markers, and to identify genes
 CC responsible for a phenotypic trait of interest in wheat. Wheat is an
 CC allohexaploid species consisting of 3 diploid genomes designated A, B and
 CC D, resulting from two successive intercrossings involving at least three
 CC different species. The D genome is thought to have been introduced in the
 CC most recent intercrossing, between the amphiploid AABB and Triticum
 CC tauschii (DD), probably involving only a limited number of genotypes of
 CC both species. Due to its polyploid genome, the large size of its genome,
 CC and its low level of polymorphism, the genetic mapping of wheat has to
 CC date been difficult. Microsatellites are tandemly repeated sequences
 CC between one and six nucleotides long, and are very polymorphic in length,
 CC mainly due to polymerase slippage during replication. This high degree of
 CC polymorphism makes them especially suitable for the genetic mapping of

species which show little intraspecies polymorphism, such as wheat. In addition, microsatellites are codominant, and exhibit Mendelian inheritance. The 185 microsatellite markers of the invention are developed from the ancestral diploid donor species *Triticum tauschii* and map to the wheat D genome, which is less polymorphic than the A or B genomes. These microsatellite markers thus help to overcome some of the problems associated with the genetic mapping of wheat. The wheat D genome map and the microsatellite markers and associated primers of the invention are useful for identifying genes responsible for a phenotypic trait of interest, most notably *QTLs* (quantitative trait loci). In particular they may be used for analysing genes and alleles implicated in disease and for identifying development factors, quality factors and factors conferring resistance to pathogens and xenobiotics. The microsatellite markers, and associated primers may be also be used in mapping and genotyping diploid and polyploid species of *Triticum*, particularly *Aegilops*, *Triticum monococcum*, *Triticum durum*, *Triticum aestivum*, or related species; for identifying cultivars and hybrids of *Triticum* and related species; to assess whether or not a product comprises wheat or a related species; and to assess whether or not a product comprises genetically modified wheat. The present sequence represents a specifically claimed *Triticum tauschii*/wheat genome D microsatellite marker right PCR primer of the invention. (Updated on 29-AUG-2003 to standardise OS field)

XX Sequence 20 BP; 0 A; 1 C; 8 G; 11 T; 0 U; 0 Other;

Query Match 0.5%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 8.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2330 TGTGCGGTGTGTGTGTGT 2348
DB 1 TGTGCGGTGTGTGTGTGT 19

RESULT 629
ABS97833/c
ID ABS97833 standard; DNA; 20 BP.
XX ABS97833;
AC ABS97833;
XX 23-DEC-2002 (first entry)
XX Human NADPH quinone oxidoreductase 2 (NQO2) polymorphic sequence #41.
XX Human; ds; cytochrome P450 A1; CYP450A1; UGT2B4; MDR1;
KW cytochrome P450 A2; CYP450A2; cytochrome P450 02E; CYP45002E1; LTF;
KW adrenergic receptor beta1; ADRB1; aryl hydrocarbon; AHR; MRP3; NR1I2;
KW aryl hydrocarbon receptor nuclear translocator; ARNT; cathepsin S; CTSS;
KW cyclooxygenase 2; COX2; diazepam binding inhibitor; DBI; haematological;
KW epoxide hydroxylase 2; EPXH2; 5-lipoxygenase activating protein; FLAP;
KW glutathione-S-transferase 12; GST12; histamine-N-methyl transferase;
KW HNMT; kallikrein 2; KLK2; nicotinamide-N-methyl transferase; NNMT;
KW NADPH quinone oxidoreductase 2; NQO2; sulfoxyltransferase 2B7;
KW UDP-glucuronosyl transferase 2B4; UDP-glucuronosyl transferase 2B7;
KW UGT2B7; UDP-glucuronosyl transferase; UGT2B15; urokinase receptor; uPA;
KW multidrug resistance 1; lactotransferrin; orphan nuclear receptor;
KW multidrug resistance associated protein 3; cancer; prostate;
KW acetylcholine muscarinic receptor; CHMR1; CHMR2; CHMR3; CHMR4; CHMR5;
KW altered drug metabolism; cardiovascular function; colorectal tumour;
KW central nervous system; pulmonary; immunological; SNP;
KW single nucleotide polymorphism.

XX Homo sapiens.
OS
XX WO200257410-A2.
XX
XX 25-JUL-2002.
XX
XX 28-NOV-2001; 2001WO-US044838.
XX
XX 28-NOV-2000; 2000US-00724389.
XX

(DNAS-) DNA SCI LAB INC.

Guida M, Hall J;

WPI; 2002-698522/75.

Isolated nucleic acid molecules having polymorphisms in known human genes e.g. cytochrome P450 and cathepsin S useful as genetic linkage markers for locating, identifying and characterizing the genes responsible for disorder-related traits.

Example 16; Page 131; 714pp; English.

This invention relates to the sequence of an isolated nucleic acid molecule comprising at least one base variation from that of a known human cytochrome P450 A1 (CYP450A1), cytochrome P450 A2 (CYP450A2), cytochrome P450 02E1 (CYP45002E1), adrenergic receptor beta1 (ADBR1), aryl hydrocarbon (AHR), aryl hydrocarbon receptor nuclear translocator (ARNT), cathepsin S (CTSS), cyclooxygenase 2 (COX2), diazepam binding inhibitor (DBI), epoxide hydroxylase 2 (EPXH2), 5-lipoxygenase activating protein (FLAP), glutathione-S-transferase 12 (GST12), histamine-N-methyl transferase (HNMT), kallikrein 2) KLK2, nicotinamide -N-methyl transferase (NNMT), NADPH quinone oxidoreductase 2 (NQO2), sulfoxyltransferase thermolabile (STM), UDP-glucuronosyl transferase 2B4 (UGT2B4), UDP-glucuronosyl transferase 2B7 (UGT2B7), UDP-glucuronosyl transferase (UGT2B15), urokinase receptor (uPA), multidrug resistance 1 (MDR1), lactotransferrin (LTF), multidrug resistance associated protein 3 (MRP3), orphan nuclear receptor (NR1I2), or acetylcholine muscarinic receptor 1, 2, 3, 4, or 5 (CHMR1, CHMR2, CHMR3, CHMR4 or CHMR5) sequence. The polymorphisms in the human genes cited in the invention are useful as genetic linkage markers for locating and characterising the genes that are responsible for specific traits within the genome and eventually identifying the genes responsible for a variety of disorder-related traits as a result of their e.g., overexpression, constitutive expression, mutation or underexpression, which may be used in diagnosing and/or treating the disorders. The nucleic acid molecules comprising the polymorphic sequences contained in CYP450A1, CYP450A2, CYP4502E1, ARNT, EPXH2, GST12, NNMT, NQO2, NR1I2, STM, UGT2B4, UGT2B7, UGT2B15, AHR, MDR1 and/or MDR3 are useful for screening individuals for altered drug metabolism. The polymorphic sequences contained in CYP450A1, CYP450A2, AHR, MDR1 and/or MDR3 may also be used to screen individuals for susceptibility to cancer. Polymorphic sequences in ADRB1 or CHMR2 are used to screen for altered cardiovascular function, in COX2 for altered susceptibility to colorectal tumours, in DBI or CHMR1 for altered central nervous system function, in FLAP and HNMT for altered pulmonary, immunological or haematological function, in KLK2 for altered serine protease activity in the prostate, in LTF for altered immunological or haematological function, in CHMR3, CHMR4 or CHMR5 for altered central and peripheral nervous system function. The present sequence represents a polymorphic DNA sequence of the invention

Sequence 20 BP; 10 A; 9 C; 0 G; 1 T; 0 U; 0 Other;

Query Match 0.5%; Score 17.4; DB 1; Length 20;

Best Local Similarity 94.7%; Pred. No. 8.7e+02;

Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2315 GTCTGTGTGTGTGTGTGTG 2333

DB 20 GTATGTGTGTGTGTGTG 2

RESULT 630

ADH93178

ID ADH93178 standard; DNA; 20 BP.

XX ADH93178;

XX 22-APR-2004 (first entry)

XX Human gene PCR primer #23.

XX human; gene sequence; single nucleotide polymorphism; SNP;

Thu Oct 28 12:48:21 2004

vivlemore401-10.rng

CC The present sequence represents a chimeric antisense oligonucleotide
CC targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
CC human mPGES-1 gene is located on chromosome 9, more specifically to
CC 9q34.3. The present invention also describes: (1) antisense compounds,
CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
CC mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
CC inhibits its expression; (2) a method of inhibiting the expression of
CC mPGES-1 in cells or tissues; and (3) a method of treating an animal
CC having a disease or condition associated with mPGES-1. mPGES-1 chimeric
CC antisense oligonucleotides and antisense compounds have cytostatic,
CC antiinflammatory, neuroprotective, cardiant, neuroprotective,
CC ophthalmological, immunomodulatory, and cardiovascular activities, and can
CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
CC ophthalmic, immunological, cardiovascular or neurological disorder.
XX
SQ Sequence 20 BP; 11 A; 9 C; 0 G; 0 T; 0 U; 0 Other;
Query Match 0.5%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. NO. 8.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 2318 TGTGTGTGTGTGTGTGTGT 2336
Db 20 TGTGTGTGTGTGTGTGTGT 2
RESULT 633
ADM14772/C
ID ADM14772 standard; DNA; 20 BP.
XX
AC ADM14772;
XX
XX
DT 01-JUL-2004 (first entry)
XX
XX Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:959.
DE
XX chimeric; antisense oligonucleotide; phosphorothioate; human;
KW microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
KW microsomal prostaglandin E2 synthase inhibitor; cytostatic; antidiabetic;
KW immunomodulator; cardiant; neuroprotective; antiinflammatory;
KW neuroprotective; nontropic; antiarthritic; vasotropic; ophthalmological;
KW immunomodulatory; cardiovascular; gene therapy; inflammation;
KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
KW reperfusion injury; ophthalmic disorder; immunological disorder;
KW cardiovascular disorder; neurological disorder; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= b
FT /mod_base= OTHER
FT /note= "phosphorothioate linkages and all cytidine
FT residues are 5-methylcytidines"
FT modified_base 1..5
FT /*tag= a
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyls"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyls"
XX
PN WO2004028458-A2.
XX
XX 08-APR-2004.
PD
XX 25-SEP-2003; 2003WO-US030374.
PF

XX
PR 25-SEP-2002; 2002US-0413549P.
XX
XX (PHAA) PHARMACIA CORP.
XX
XX Gierse JK;
XX
XX WPI; 2004-305094/28.
XX
XX New antisense compound, having a sequence targeted to a nucleic acid
XX encoding mPGES-1, useful for preparing a composition for treating e.g.,
XX inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
XX ischaemia.
XX
XX Claim 4; SEQ ID NO 959; 132pp; English.
XX
XX The present sequence represents a chimeric antisense oligonucleotide
XX targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
XX human mPGES-1 gene is located on chromosome 9, more specifically to
XX 9q34.3. The present invention also describes: (1) antisense compounds,
XX having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
XX mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
XX inhibits its expression; (2) a method of inhibiting the expression of
XX mPGES-1 in cells or tissues; and (3) a method of treating an animal
XX having a disease or condition associated with mPGES-1. mPGES-1 chimeric
XX antisense oligonucleotides and antisense compounds have cytostatic,
XX antidiabetic, immunomodulator, cardiant, neuroprotective,
XX antiinflammatory, neuroprotective, nontropic, antiarthritic, vasotropic,
XX ophthalmological, immunomodulatory and cardiovascular activities, and can
XX be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
XX condition associated with mPGES-1 e.g., inflammation, Alzheimer's
XX disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
XX ophthalmic, immunological, cardiovascular or neurological disorder.
XX
SQ Sequence 20 BP; 9 A; 8 C; 2 G; 1 T; 0 U; 0 Other;
Query Match 0.5%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. NO. 8.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 2332 TCGGTGTGTGTGTGTGTGT 2350
Db 19 TCCGTGTGTGTGTGTGTGT 1
RESULT 634
ADN58895/C
ID ADN58895 standard; DNA; 20 BP.
XX
XX ADN58895;
XX
XX 12-AUG-2004 (first entry)
XX
XX Mouse B7H antisense oligonucleotide ISIS 231397.
DE
XX B7H; autoimmune disease; ss; antisense; mouse.
XX
XX Mus musculus.
OS Synthetic.
XX
XX US2004102398-A1.
PN
XX 27-MAY-2004.
PD
XX 23-NOV-2002; 2002US-00303420.
XX
XX 23-NOV-2002; 2002US-00303420.
XX
XX (ISIS-) ISIS PHARM INC.
XX Monia BP, Dobie KW;
XX

AAH49075;
 12-NOV-2001 (first entry)
 Human LDLR gene associated primer #41.
 Neonate screening; prenatal screening; gene chip; diagnosis;
 phenylketonuria; maple syrup disease; galactosemia; homocysteinuria;
 medium-chain acyl-CoA-dehydrogenase deficiency; biotinidase deficiency;
 familial hypercholesterolemia; familial defective apolipoprotein-B;
 cystic fibrosis; Marfan syndrome; Smith-Lemli-Opitz syndrome;
 androgenital syndrome; ss.
 Homo sapiens.
 WO200153520-A2.
 26-JUL-2001.
 09-JAN-2001; 2001WO-EP000139.
 21-JAN-2000; 2000DE-01002446.
 (CULL/) CULLEN P.
 (SEED/) SEEDORF U.
 Cullen P, Seedorf U;
 WPI; 2001-457616/49.
 DNA chip, useful for neonatal or prenatal screening for many genetic
 diseases simultaneously, carries oligonucleotides complementary to
 phenotypically relevant reference sequences.
 Claim 4; Page 63; 101pp; German.
 This invention describes a novel nucleotide support (A; gene chip) which
 carries a selection of oligonucleotides (I) that are identical, or
 complementary, to segments of reference sequences relevant to at least
 two genetically determined phenotypes. (A) are used for simultaneous
 diagnosis of at least two of the following diseases: phenylketonuria
 (maple syrup disease), galactosemia, homocysteinuria, biotinidase
 deficiency, medium-chain acyl-CoA-dehydrogenase deficiency, familial
 hypercholesterolemia, familial defective apolipoprotein-B, cystic
 fibrosis, Marfan syndrome, Smith-Lemli-Opitz syndrome and androgenital
 syndrome. Specifically they are used in neonatal or prenatal diagnosis.
 (A) require a relatively small number of separate hybridization regions
 (about 500 for testing for 21 specified disorders), so can be used for
 simultaneous testing for many diseases. Testing is quick, inexpensive,
 reliable and more sensitive than current physiological methods. AAH48868-
 AAH489166 represent oligonucleotides used to illustrate the method of the
 invention

XX
 KW Arteriosclerosis; diagnosis; hybridisation; synergism; gene therapy;
 KW mutation; probe; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200272882-A2.
 XX
 PD 19-SEP-2002.
 XX
 PF 13-MAR-2002; 2002WO-EP002780.
 XX
 PR 13-MAR-2001; 2001DE-01011925.
 XX
 PA (OGHA-) OGHAM GMBH.
 XX
 PI Cullen P, Seedorf U;
 XX
 DR WPI; 2002-723374/78.
 XX
 PT Determining genetic risk of arteriosclerosis, for clinical diagnosis,
 PT comprises hybridizing patient nucleic acid with an array of probes
 PT derived from risk-associated reference genes and their mutations.
 XX
 PS Example 1; Page 128; 146pp; German.
 XX
 CC This invention describes a novel method for determining the genetic risk
 CC of arteriosclerosis both for clinical diagnosis and for population
 CC studies. The method comprises: (i) selecting risk-associated reference
 CC nucleic acid sequences, including their functionally characterizing
 CC mutations; (ii) applying probes from these sequences, or their
 CC complements, to a carrier; (iii) hybridising the probes with a nucleic
 CC acid from (or synthesised from) a patient sample; and (iv) detecting and
 CC evaluating the hybridisation pattern. The method provides a quick,
 CC inexpensive and informative diagnosis, and makes possible a
 CC multifactorial analysis for detecting e.g. synergism between different
 CC mutations or mutations that when present alone carry no risk but are risk
 CC -associated in presence of other mutations. The results may be combined
 CC with known risk-assessment methods to provide a more reliable diagnosis,
 CC especially important with new therapeutic methods (e.g. gene therapy)
 CC that are directed against specific genes. All relevant mutations in a
 CC reference sequence can be screened for in a single test and the method is
 CC well suited to automation. ABX09147-ABX09676 represent probes used to
 CC illustrate the method of the invention
 XX
 SQ Sequence 21 BP; 6 A; 7 C; 6 G; 2 T; 0 U; 0 Other;
 Query Match 0.5%; Score 17.4; DB 1; Length 21;
 Best Local Similarity 94.7%; Pred. No. 9.2e+02;
 Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 3667 GCCATGGCTCAGGTTGGTC 3685
 DB 21 GCCATTGCTCAGGTTGGTC 3
 RESULT 639
 ABS98543/c
 ID ABS98543 standard; DNA; 21 BP.
 XX
 AC ABS98543;
 XX
 DT 23-DEC-2002 (first entry)
 XX
 DE Human acetyl choline muscarinic receptor 3 polymorphic sequence #9.
 XX
 KW Human; ds; cytochrome P450 A1; CYP450A1; UGT2B4; MDR1;
 KW cytochrome P450 A2; CYP450A2; cytochrome P450 02E; CYP45002E1; LTF;
 KW adrenergic receptor beta1; ADRB1; aryl hydrocarbon; AHR; MRP3; NR112;
 KW aryl hydrocarbon receptor nuclear translocator; ARNT; cathepsin S; CTSS;
 KW cyclooxygenase 2; COX2; diazepam binding inhibitor; DBI; haematological;
 KW epoxide hydroxylase 2; EPHX2; 5-lipoxygenase activating protein; FLAP;
 KW Glutathione-S-transferase 12; GST12; histamine-N-methyl transferase;

HNMT; kallikrein 2; KUK2; nicotinamide-N-methyl transferase; NNMT;
NADPH quinone oxidoreductase 2; NQO2; sulfotransferase thermolabile; STM;
UDP-glucuronosyl transferase 2B4; UDP-glucuronosyl transferase 2B7;
UGT2B7; UDP-glucuronosyl transferase; UGT2B15; urokinase receptor; uPA;
multidrug resistance 1; lactotransferrin; orphan nuclear receptor;
multidrug resistance associated protein 3; cancer; prostate;
acetylcholine muscarinic receptor; CHMR1; CHMR2; CHMR3; CHMR4; CHMR5;
altered drug metabolism; cardiovascular function; colorectal tumour;
central nervous system; pulmonary; immunological; SNP;
single nucleotide polymorphism.

Homo sapiens.
WO200257410-A2.
25-JUL-2002.
28-NOV-2001; 2001WO-US044838.
28-NOV-2000; 2000US-00724389.
(DNAS-) DNA SCI LAB INC.
Guida M, Hall J;
WPI; 2002-698522/75.
Isolated nucleic acid molecules having polymorphisms in known human genes
e.g. cytochrome p450 and cathepsin S useful as genetic linkage markers
for locating, identifying and characterizing the genes responsible for
disorder-related traits.
Example 28; Page 159; 714pp; English.

This invention relates to the sequence of an isolated nucleic acid
molecule comprising at least one base variation from that of a known
human cytochrome P450 A1 (CYP450A1), cytochrome P450 A2 (CYP450A2),
cytochrome P450 2E1 (CYP4502E1), adrenergic receptor beta1 (ADRB1),
aryl hydrocarbon (AHR), aryl hydrocarbon receptor nuclear translocator
(ARNT), cathepsin S (CTSS), cyclooxygenase 2 (COX2), diazepam binding
inhibitor (DBI), epoxide hydroxylase 2 (EPHX2), 5-lipoxygenase activating
protein (FLAP), glutathione-S-transferase 12 (GST12), histamine-N-methyl
transferase (HNMT), NADPH quinone oxidoreductase 2 (NQO2),
sulfotransferase thermolabile (STM), UDP-glucuronosyl transferase 2B4
(UGT2B4), UDP-glucuronosyl transferase 2B7 (UGT2B7), UDP-glucuronosyl
transferase (UGT2B15), urokinase receptor (uPA), multidrug resistance 1
(MDR1), lactotransferrin (LTF), multidrug resistance associated protein 3
(MRP3), orphan nuclear receptor (NRI12), or acetylcholine muscarinic
receptor 1, 2, 3, 4, or 5 (CHMR1, CHMR2, CHMR3, CHMR4 or CHMR5) sequence.
The polymorphisms in the human genes cited in the invention are useful as
genetic linkage markers for locating and characterizing the genes that
are responsible for specific traits within the genome and eventually
identifying the genes responsible for a variety of disorder-related
traits as a result of their e.g., overexpression, constitutive
expression, mutation or underexpression, which may be used in diagnosing
and/or treating the disorders. The nucleic acid molecules comprising the
polymorphic sequences contained in CYP450A1, CYP450A2, CYP4502E1,
ARNT, EPHX2, GST12, NNMT, NQO2, NRI12, STM, UGT2B4, UGT2B7, UGT2B15, AHR,
MDR1 and/or MDR3 are useful for screening individuals for altered drug
metabolism. The polymorphic sequences contained in CYP450A1, CYP450A2,
AHR, MDR1 and/or MDR3 may also be used to screen individuals for
susceptibility to cancer. Polymorphic sequences in ADRB1 or CHMR2 are
used to screen for altered cardiovascular function, in COX2 for altered
susceptibility to colorectal tumours, in DBI or CHMR1 for altered central
nervous system function, in FLAP and HNMT for altered drug
immunological or haematological function, in KLU2 for altered serine
protease activity in the prostate, in LTF for altered immunological or
haematological function, in CHMR3, CHMR4 or CHMR5 for altered central and
peripheral nervous system function. The present sequence represents a
polymorphic DNA sequence of the invention

Sequence 21 BP; 9 A; 0 C; 2 G; 10 T; 0 U; 0 Other;

Query Match 0.5%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 9.2e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2823 TATATATACATATATATAT 2841
DB 19 TATATATACATATATATAT 1

RESULT 640
ADH70559/c
ID ADH70559 standard; DNA; 22 BP.

XX AC ADH70559;

XX DT 25-MAR-2004 (first entry)

XX DE Human Vbeta gene repeat sequence #349.

XX KW human; T-cell associated disease; Vbeta; autoimmune disease;
KW degenerative nervous system disease; graft versus host disease;
KW hypersensitivity disease; infectious disease; neoplastic disease;
KW Addison's disease; atrophic gastritis;
KW degenerative nervous system disease; multiple sclerosis;
KW Alzheimer's disease; hypersensitivity disease; type I hypersensitivity;
KW allergy; type II hypersensitivity; Goodpasture's syndrome;
KW type IV hypersensitivity; leprosy; infectious disease; viral infection;
KW HIV; fungal infection; candida; parasitic infection; schistosoma;
KW filaria; bacterial infection; Mycobacterium; neoplastic disease;
KW lymphoproliferative disease; leukaemia; lymphoma; cancer; brain cancer;
KW breast cancer; ds.

XX OS Homo sapiens.

XX PN US2002150891-A1.

XX PD 17-OCT-2002.

XX PF 05-MAR-1999; 99US-00263959.

XX PR 19-SEP-1994; 94US-00309335.

XX PR 19-SEP-1995; 95US-00531241.

XX (HOOD/) HOOD L E.

XX (ROWE/) ROWEN L.

XX PA Hood LE, Rowen L;

XX WPI; 2004-059052/06.

XX Kit for diagnosing and treating T-cell associated diseases e.g.
XX autoimmune, degenerative nervous system and infectious disease, comprises
XX nucleic acid primers specifically priming and allowing amplification of a
XX Vbeta gene.

XX Disclosure; SEQ ID NO 753; 164pp; English.

XX The invention relates to a kit for diagnosing and treating T-cell
XX associated diseases which comprises a panel of nucleic acid primers
XX specifically priming and allowing amplification of each Vbeta gene,
XX VbetaRNA or cDNA. The kit is useful for diagnosing organ transplant
XX rejection and diagnosing and treating T-cell associated diseases
XX including autoimmune diseases, degenerative nervous system diseases,
XX graft versus host disease, hypersensitivity diseases, infectious diseases
XX and neoplastic diseases. Autoimmune diseases include Addison's disease,
XX atrophic gastritis. Degenerative nervous system diseases include multiple
XX sclerosis and Alzheimer's disease. Hypersensitivity diseases include Type
XX I hypersensitivities such as contact with allergens that lead to
XX allergies, Type II hypersensitivities such as those present in
XX Goodpasture's syndrome and Type IV hypersensitivities such as those
XX manifested in leprosy. Infectious diseases include viral infections
XX caused by viruses such as HIV, fungal infections such as those caused by

CC the yeast genus Candida, parasitic infections such as those caused by
 CC schistosomes, filaria and bacterial infections such as those caused by
 CC Mycobacterium. Neoplastic diseases include lymphoproliferative diseases
 CC such as leukaemias, lymphomas and cancers such as cancer of the brain,
 CC breast. The present sequence represents a Vbeta gene repeat sequence.
 XX
 SQ Sequence 22 BP; 9 A; 0 C; 2 G; 11 T; 0 U; 0 Other;
 Query Match 0.5%; Score 17.4; DB 1; Length 22;
 Best Local Similarity 94.7%; Pred. No. 9.7e+02;
 Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2826 ATATACATATATATATATA 2844
 Db 22 ATATACATATATATATATA 4
 RESULT 641
 AAX34331
 ID AAX34331 standard; DNA; 23 BP.
 XX AC AAX34331;
 XX
 DT 06-JUL-1999 (first entry)
 DE Primer PTK3YK for human brain-specific tyrosine kinase (Byk) gene.
 XX Human; brain; tyrosine kinase; Byk; drug application; antigen; ss;
 KW nervous skin syndrome; PCR; primer; amplification.
 XX Synthetic.
 OS Homo sapiens.
 XX JP08256780-A.
 PN
 XX JP08256780-A.
 XX 08-OCT-1996.
 XX 17-MAR-1995; 95JP-00097411.
 XX 17-MAR-1995; 95JP-00097411.
 XX (CHUS) CHUGAI PHARM CO LTD.
 XX WPI; 1996-500368/50.
 XX Gene coding brain-specific tyrosine kinase - can be used to detect
 PT nervous skin syndrome related antigen.
 XX Example 1; Page 7; 31pp; Japanese.
 XX Primers AAX34328-X34331 were used to PCR amplify the gene encoding a
 CC human brain-specific tyrosine kinase (Byk; AAX34327). The coding DNA can
 CC be used in drug applications, especially to detect a nervous skin
 CC syndrome (sic) related antigen
 XX
 SQ Sequence 23 BP; 4 A; 5 C; 5 G; 1 T; 0 U; 8 Other;
 Query Match 0.5%; Score 17.4; DB 1; Length 23;
 Best Local Similarity 65.2%; Pred. No. 1e+03;
 Matches 15; Conservative 4; Mismatches 4; Indels 0; Gaps 0;
 QY 1618 CACAGGACCTGGCTGCCGCA 1640
 Db 1 CACMGNGAYCTSGCNGCNGNAA 23
 RESULT 642
 AAL45613
 ID AAL45613 standard; DNA; 24 BP.
 XX AC AAL45613;
 XX 21-JUN-2002 (first entry)
 DT

XX ATP dependent membrane conjugated zinc proteinase 10-45 PCR primer #2.
 DE Human; ATP dependent membrane conjugated zinc proteinase 10.45; enzyme;
 XX development disturbance; lipid metabolism disease; gene therapy; PCR;
 KW primer; ss.
 XX Homo sapiens.
 XX CN1327066-A.
 PN 19-DEC-2001.
 XX 05-JUN-2000; 2000CN-00116334.
 PF 05-JUN-2000; 2000CN-00116334.
 PR (BODE-) BODE GENE DEV CO LTD SHANGHAI.
 XX Mao Y, Xie Y;
 PI WPI; 2002-206994/27.
 DR New polypeptide-human ATP dependent membrane conjugated zinc proteinase
 PT 10.45 and polynucleotide for encoding such polypeptide.
 XX Example 2; Page 17(Disclosure); 34pp; Chinese.
 PS The present invention provides the protein and coding sequences of human
 CC ATP dependent membrane conjugated zinc proteinase 10.45. The sequences
 CC can be used in the treatment of developmental disturbances and lipid
 CC metabolism disease. The present sequence is a PCR primer for the coding
 CC sequence of the invention
 XX
 SQ Sequence 24 BP; 9 A; 3 C; 1 G; 11 T; 0 U; 0 Other;
 Query Match 0.5%; Score 17.4; DB 1; Length 24;
 Best Local Similarity 94.7%; Pred. No. 1.1e+03;
 Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2826 ATATACATATATATATATA 2844
 Db 5 ATATACATATATATATATA 23
 RESULT 643
 ABZ25283
 ID ABZ25283 standard; DNA; 24 BP.
 XX AC ABZ25283;
 XX 24-APR-2003 (first entry)
 DT Human zinc finger protein 234-72.38 PCR primer #2.
 XX Human; zinc finger protein 234-72.38; tumour; cytostatic; diabetes; PCR;
 KW primer; ss.
 XX Homo sapiens.
 OS CN1359947-A.
 XX 24-JUL-2002.
 PD 20-DEC-2000; 2000CN-00135164.
 PF 20-DEC-2000; 2000CN-00135164.
 PR (BODE-) BODE GENE DEV CO LTD SHANGHAI.
 XX Mao Y, Xie Y;
 PI WPI; 2002-733635/80.
 DR

XX Polypeptide-human zinc finger protein 234-72.38 and polynucleotide for
PT coding it.
XX
XX Example 3; Page 17 (Disclosure); 34pp; Chinese.
XX
XX The present invention relates to human zinc finger protein 234-72.38 (see
CC ABP59122). The protein can be used for treating diseases such as tumours
CC and diabetes. The present sequence is a PCR primer, which was used in an
CC example from the invention
XX
XX Sequence 24 BP; 10 A; 0 C; 4 G; 10 T; 0 U; 0 Other;
SQ
Query Match 0.5%; Score 17.4; DB 1; Length 24;
Best Local Similarity 94.7%; Pred. No. 1.1e+03;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 3475 TATATATATTTTATTCAGT 3493
DB 3 TAGATATAATTTTATTCAGT 21
RESULT 644
ABL56894
ID ABL56894 standard; DNA; 30 BP.
XX
XX ABL56894;
AC
XX
XX 26-JUL-2002 (first entry)
XX
XX Synthetic deoxyribooligonucleotide poly g.
DE
XX Concentration; quantification; mutation detection; polymorphic;
KW polymerase chain reaction; PCR; ss.
XX
XX Synthetic.
OS
XX EP1046717-A2.
PN
XX
XX 25-OCT-2000.
PD
XX
XX 20-APR-2000; 2000EP-00108643.
PF
XX
XX 20-APR-1999; 99JP-00111601.
PR
XX
XX (NIBI-) JAPAN BIOINDUSTRY ASSOC.
PA (AGEN) AGENCY OF IND SCI & TECHNOLOGY.
PA (KANK-) KANKYO ENG CO LTD.
XX
XX Kurane R, Kanagawa T, Kamagata Y, Kurata S, Yamada K, Yokomaku T;
PI Koyama O, Furusho K;
XX
XX WPI; 2000-657765/64.
DR
XX
XX Determining the concentration of a target nucleic acid, useful e.g. for
PT detecting genetic mutations, comprises using a fluorescently labeled
PT probe in which emission is reduced by binding to the target nucleic acid.
XX
XX Example 5; Page 21; 55pp; English.
PS
XX The invention relates to the determination of the concentration of a
CC nucleic acid target, using a fluorescently labeled probe which produces
CC reduced fluorescence emission when hybridised to the target nucleic acid.
CC The method comprises measuring the reduction in emission caused by
CC hybridisation. The new method is particularly used to quantify target
CC nucleic acids by a real-time polymerase chain reaction, e.g. for
CC quantifying microbial cells in co-cultures or symbiotic systems, for
CC detecting gene mutations or polymorphisms, and for analysing melting
CC curves of target nucleic acids to determine a Tm value. Methods of the
CC invention allow target nucleic acids to be quantified quickly, easily and
CC accurately. Particularly there is no need to remove unbound probe, and no
CC materials are introduced that inhibit amplification by Taq polymerase (so
CC conventional PCR conditions can be used). The specificity of PCR is kept
CC high (amplification of primer dimers is delayed), and the limit of
CC quantitation is reduced. Complex probes are not needed, and amplification

CC high (amplification of primer dimers is delayed), and the limit of
CC quantitation is reduced. Complex probes are not needed, and amplification
CC can be monitored in real time. The working graph for data analysis
CC (automatically generated by a computer) has a higher correlation is
CC coefficient than conventional graphs so more accurate quantitation is
CC possible. The current sequence represents a synthetic
CC deoxyribooligonucleotide that was used for investigating the base
CC selectivity of a target nucleic acid
XX
XX Sequence 30 BP; 4 A; 1 C; 0 G; 25 T; 0 U; 0 Other;
SQ
Query Match 0.5%; Score 17.4; DB 1; Length 30;
Best Local Similarity 77.8%; Pred. No. 1.3e+03;
Matches 21; Conservative 0; Mismatches 6; Indels 0; Gaps 0;
QY 3259 AGATATTTTATTTGCTTGTCTCTTTT 3285
DB 3 ATATATTTTTCCTTTTTCCTTTTTCCTTTT 29
RESULT 645
ABL56888
ID ABL56888 standard; DNA; 30 BP.
XX
XX ABL56888;
AC
XX
XX 26-JUL-2002 (first entry)
XX
XX Synthetic deoxyribooligonucleotide poly a.
DE
XX Concentration; quantification; mutation detection; polymorphic;
KW polymerase chain reaction; PCR; ss.
XX
XX Synthetic.
OS
XX EP1046717-A2.
PN
XX
XX 25-OCT-2000.
PD
XX
XX 20-APR-2000; 2000EP-00108643.
PF
XX
XX 20-APR-1999; 99JP-00111601.
PR
XX
XX (NIBI-) JAPAN BIOINDUSTRY ASSOC.
PA (AGEN) AGENCY OF IND SCI & TECHNOLOGY.
PA (KANK-) KANKYO ENG CO LTD.
XX
XX Kurane R, Kanagawa T, Kamagata Y, Kurata S, Yamada K, Yokomaku T;
PI Koyama O, Furusho K;
XX
XX WPI; 2000-657765/64.
DR
XX
XX Determining the concentration of a target nucleic acid, useful e.g. for
PT detecting genetic mutations, comprises using a fluorescently labeled
PT probe in which emission is reduced by binding to the target nucleic acid.
XX
XX Example 5; Page 21; 55pp; English.
PS
XX The invention relates to the determination of the concentration of a
CC nucleic acid target, using a fluorescently labeled probe which produces
CC reduced fluorescence emission when hybridised to the target nucleic acid.
CC The method comprises measuring the reduction in emission caused by
CC hybridisation. The new method is particularly used to quantify target
CC nucleic acids by a real-time polymerase chain reaction, e.g. for
CC quantifying microbial cells in co-cultures or symbiotic systems, for
CC detecting gene mutations or polymorphisms, and for analysing melting
CC curves of target nucleic acids to determine a Tm value. Methods of the
CC invention allow target nucleic acids to be quantified quickly, easily and
CC accurately. Particularly there is no need to remove unbound probe, and no
CC materials are introduced that inhibit amplification by Taq polymerase (so
CC conventional PCR conditions can be used). The specificity of PCR is kept
CC high (amplification of primer dimers is delayed), and the limit of
CC quantitation is reduced. Complex probes are not needed, and amplification

CC can be monitored in real time. The working graph for data analysis
 CC (automatically generated by a computer) has a higher correlation
 CC coefficient than conventional graphs so more accurate quantitation is
 CC possible. The current sequence represents a synthetic
 CC deoxyribonucleotide that was used for investigating the base
 CC selectivity of a target nucleic acid
 XX
 SQ Sequence 30 BP; 4 A; 0 C; 1 G; 25 T; 0 U; 0 Other;
 Query Match 0.5%; Score 17.4; DB 1; Length 30;
 Best Local Similarity 77.8%; Pred. No. 1.3e+03;
 Matches 21; Conservative 0; Mismatches 6; Indels 0; Gaps 0;
 QY 3259 AGATATTTTATTTGCTTGTGTCCTTTT 3285
 Db 3 ATATATTTTGTGTTTTTTTTTTT 29
 RESULT 646
 ABA97612
 ID ABA97612 standard; DNA; 30 BP.
 XX
 AC ABA97612;
 XX
 DT 11-APR-2002 (first entry)
 XX
 DE Poly a nucleotide sequence.
 XX
 KW ss; fluorochrome; nucleic acid probe; fluorescence.
 XX
 OS Unidentified.
 XX
 PN JP2001286300-A.
 PD 16-OCT-2001.
 XX
 PF 20-APR-2000; 2000JP-00120097.
 XX
 PR 20-APR-1999; 99JP-00111601.
 PR 24-AUG-1999; 99JP-00236666.
 PR 30-AUG-1999; 99JP-00242693.
 PR 01-FEB-2000; 2000JP-00028896.
 XX
 PA (BIOI-) BIOINDUSTRY KYOKAI SH.
 PA (KANK-) KANKYO ENG KK.
 PA (KEIZ-) KEIZAI SANGYOSHO SANGYO GIJUTSU SOGO KEN.
 XX
 DR WPI; 2002-134193/18.
 XX
 PT Measurement of nucleic acids, using a nucleic acid probe and analysis of
 PT the obtained data.
 XX
 PS Example 5; Page 17; 34pp; Japanese.
 CC This invention relates to a method for measuring nucleic acids using a
 CC nucleic acid probe labelled with a fluorochrome. The nucleic acid probe
 CC decreases the fluorescence of the fluorochrome when hybridised with a
 CC target nucleic acid, the decrease in the fluorescence is measured. The
 CC method can be used for measuring a target nucleic acid
 XX
 SQ Sequence 30 BP; 4 A; 0 C; 1 G; 25 T; 0 U; 0 Other;
 Query Match 0.5%; Score 17.4; DB 1; Length 30;
 Best Local Similarity 77.8%; Pred. No. 1.3e+03;
 Matches 21; Conservative 0; Mismatches 6; Indels 0; Gaps 0;
 QY 3259 AGATATTTTATTTGCTTGTGTCCTTTT 3285
 Db 3 ATATATTTTGTGTTTTTTTTTTT 29
 RESULT 647
 ABA97618
 ID ABA97618 standard; DNA; 30 BP.
 XX
 AC ABA97618;
 XX
 DT 11-APR-2002 (first entry)
 XX
 DE Poly g nucleotide sequence.
 XX
 KW ss; fluorochrome; nucleic acid probe; fluorescence.
 XX
 OS Unidentified.
 XX
 PN JP2001286300-A.
 PD 16-OCT-2001.
 XX
 PF 20-APR-2000; 2000JP-00120097.
 XX
 PR 20-APR-1999; 99JP-00111601.
 PR 24-AUG-1999; 99JP-00236666.
 PR 30-AUG-1999; 99JP-00242693.
 PR 01-FEB-2000; 2000JP-00028896.
 XX
 PA (BIOI-) BIOINDUSTRY KYOKAI SH.
 PA (KANK-) KANKYO ENG KK.
 PA (KEIZ-) KEIZAI SANGYOSHO SANGYO GIJUTSU SOGO KEN.
 XX
 DR WPI; 2002-134193/18.
 XX
 PT Measurement of nucleic acids, using a nucleic acid probe and analysis of
 PT the obtained data.
 XX
 PS Example 5; Page 17; 34pp; Japanese.
 CC This invention relates to a method for measuring nucleic acids using a
 CC nucleic acid probe labelled with a fluorochrome. The nucleic acid probe
 CC decreases the fluorescence of the fluorochrome when hybridised with a
 CC target nucleic acid, the decrease in the fluorescence is measured. The
 CC method can be used for measuring a target nucleic acid
 XX
 SQ Sequence 30 BP; 4 A; 0 C; 1 G; 25 T; 0 U; 0 Other;
 Query Match 0.5%; Score 17.4; DB 1; Length 30;
 Best Local Similarity 77.8%; Pred. No. 1.3e+03;
 Matches 21; Conservative 0; Mismatches 6; Indels 0; Gaps 0;
 QY 3259 AGATATTTTATTTGCTTGTGTCCTTTT 3285
 Db 3 ATATATTTTGTGTTTTTTTTTTT 29
 RESULT 648
 ABL95885
 ID ABL95885 standard; DNA; 30 BP.
 XX
 AC ABL95885;
 XX
 DT 19-JUN-2002 (first entry)
 XX
 DE Probe poly a for assaying nucleic acids.
 XX
 KW Probe; polymorphism detection; mutation detection; disease diagnosis;
 KW microbial identification; ss.
 XX
 OS Unidentified.
 XX
 PN WO200208414-A1.
 PD 31-JAN-2002.
 XX
 PF 27-JUN-2001; 2001WO-IB001147.
 XX
 PR 27-JUN-2000; 2000JP-00193133.

```

PR 03-AUG-2000; 2000JP-00236115.
PR 26-SEP-2000; 2000JP-00292483.
XX (NAAD-) NAT INST ADVANCED IND SCI & TECHNOLOGY.
PA (KANK-) KANKYO ENG CO LTD.
XX Kurane R, Kanagawa T, Kamagata Y, Torimura M, Kurata S, Yamada K;
PI Yokomaku T;
XX WPI; 2002-195876/25.
XX Fluorescently-labeled nucleic acid probes for assaying nucleic acids and
PT their polymorphism and mutation, particularly useful in science and
PT medicine for e.g. analytical applications, disease diagnosis and
PT microbial identification.
XX Example 12; Page 60; 152pp; Japanese.
XX The present invention relates to nucleic acid probes, which are useful
CC for assaying nucleic acids by hybridising with a target nucleic acid, in
CC which a single-stranded oligonucleotide is labelled with a fluorescent
CC substance and a quencher in a manner that the fluorescence intensity of
CC the hybridisation reaction system is increased after completion of the
CC hybridisation but no stem loop structure is formed. The probes are useful
CC for assaying nucleic acids and their polymorphism and mutation,
CC particularly useful for e.g. analytical applications, disease diagnosis
CC and microbial identification. The present sequence was used to illustrate
CC the invention
XX
XX Sequence 30 BP; 4 A; 1 C; 0 G; 25 T; 0 U; 0 Other;
SQ
Query Match 0.5%; Score 17.4; DB 1; Length 30;
Best Local Similarity 77.8%; Pred. No. 1.3e+03;
Matches 21; Conservative 0; Mismatches 6; Indels 0; Gaps 0;
QY 3259 AGATATTTTATTTGCTTTCCTTTT 3285
DB 3 ATATATTTTTCCTTTTTCCTTTT 29
RESULT 650
AAQ62397
ID AAQ62397 standard; DNA; 22 BP.
XX
XX AC AAQ62397;
XX
XX 25-MAR-2003 (revised)
DT 18-NOV-1994 (first entry)
XX
XX Vector pVAC1 construction primer #3.
XX
XX Vector; pVAC1; pRC/RSV; leader sequence; termination signal; PCR;
XX fusion protein; pSfi/Not.Tag1; pelB leader; human; immunoglobulin; VHL;
XX single chain; Fv; murine antibody; retroviral; envelope; amplify;
XX plasmid; vaccine; polymerase chain reaction; ss.
XX
XX Synthetic.
XX
XX WO9408008-A1.
XX
XX 14-APR-1994.
XX
XX 04-OCT-1993; 93WO-GB002054.
XX
XX 02-OCT-1992; 92GB-00020808.
XX
XX (MEDI-) MEDICAL RES COUNCIL.
XX
XX Hawkins RE, Russell SJ, Stevenson FK, Winter GP;
XX WPI; 1994-135575/16.
XX
XX Modulating immune response to a disease marker - by administering a
PT vector which expresses the disease marker to interact with the immune
PT system.
XX
XX Disclosure; Page 31; 77pp; English.
XX
XX The sequences given in AAQ62395-449 are primers which were used in the
CC construction of the vector pVAC1. This vector is based on the
CC commercially available vector pRC/RSV. Leader sequences and termination
CC signals were introduced into the vector to allow for production of fusion
CC proteins. The vector, pSfi/Not.Tag1, was modified to replace the pelB
CC leader with the human immunoglobulin VHL leader sequence that permits the

```

CC encoding of an Sfil cloning site without modification of the amino acid
 CC sequence. This fragment was then cloned as an EcoRI/Blunt-HindIII
 CC fragment into NotI/Blunt- HindIII cut vector pRC/RSV to give pVAC1. The
 CC single chain Fv for an individual patient can be inserted within the VH1
 CC leader sequence. This plasmid when encoding a single chain murine
 CC antibody/retroviral envelope fusion protein can be used as a plasmid
 CC vaccine and it induces a strong humoral response to the antibody moiety
 CC in BALB/c mice. (Updated on 25-MAR-2003 to correct PN field.)
 XX
 SQ Sequence 22 BP; 3 A; 3 C; 11 G; 5 T; 0 U; 0 Other;
 Query Match 0.5%; Score 17.2; DB 1; Length 22;
 Best Local Similarity 86.4%; Pred. No. 1e+03;
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 853 GAGGAGGAGCTGGTGGAGGCTG 874
 Db 1 GAGGTGCAGCTGGTGGAGTCTG 22
 RESULT 651
 AAD21616
 ID AAD21616 standard; DNA; 22 BP.
 XX
 AC AAD21616;
 XX
 DT 19-MAR-2002 (first entry)
 XX
 DE 5' PCR-RFLP primer used to detect nucleotide transversion in FGFR gene.
 XX
 KW Sheep; spider lamb syndrome; SLS; fibroblast growth factor receptor 3;
 KW FGFR; hereditary chondrodysplasia; semi-lethal congenital disorder;
 KW severe skeletal abnormality; genetic marker; PCR primer; RFLP;
 KW restriction length polymorphism; chromosome 6; ss.
 XX
 OS Ovis sp.
 XX
 PN US6306591-B1.
 XX
 PD 23-OCT-2001.
 XX
 PF 18-JUN-1998; 98US-00099749.
 XX
 PR 18-JUN-1997; 97US-0050127P.
 XX
 PA (UTAH) UNIV UTAH STATE.
 XX
 PI Cockett NE, Beaver JE;
 XX
 DR WPI; 2001-662278/76.
 XX
 PT Identifying a genetic marker for spider lamb syndrome, used to diagnose
 PT if sheep carry a gene for the syndrome, involves analyzing sheep DNA
 PT samples for mutations in fibroblast growth factor receptor 3.
 XX
 PS Claim 11; Col 23; 24pp; English.
 CC
 CC The present invention relates to a method for identifying a genetic
 CC marker for spider lamb syndrome (SLS). The method comprising, obtaining a
 CC sheep DNA sample, and analysing the sample DNA with a probe to determine
 CC the presence or absence of a polymorphism in fibroblast growth factor
 CC receptor 3 (FGFR). The invention is used for diagnosing if sheep carry
 CC the gene for SLS, used to eliminate carriers of the syndrome from a
 CC flock. SLS or hereditary chondrodysplasia is a semi-lethal congenital
 CC disorder in sheep causing severe skeletal abnormalities. The present
 CC sequence is a 5' PCR-RFLP primer used to detect nucleotide transversion
 CC in sheep FGFR3 gene. The FGFR3 gene is located on chromosome 6
 XX
 SQ Sequence 22 BP; 2 A; 11 C; 5 G; 4 T; 0 U; 0 Other;
 Query Match 0.5%; Score 17.2; DB 1; Length 22;
 Best Local Similarity 86.4%; Pred. No. 1e+03;
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 853 GAGGAGGAGCTGGTGGAGGCTG 874
 Db 1 GAGGTGCAGCTGGTGGAGTCTG 22
 RESULT 651
 AAD21616
 ID AAD21616 standard; DNA; 22 BP.
 XX
 AC AAD21616;
 XX
 DT 19-MAR-2002 (first entry)
 XX
 DE 5' PCR-RFLP primer used to detect nucleotide transversion in FGFR gene.
 XX
 KW Sheep; spider lamb syndrome; SLS; fibroblast growth factor receptor 3;
 KW FGFR; hereditary chondrodysplasia; semi-lethal congenital disorder;
 KW severe skeletal abnormality; genetic marker; PCR primer; RFLP;
 KW restriction length polymorphism; chromosome 6; ss.
 XX
 OS Ovis sp.
 XX
 PN US6306591-B1.
 XX
 PD 23-OCT-2001.
 XX
 PF 18-JUN-1998; 98US-00099749.
 XX
 PR 18-JUN-1997; 97US-0050127P.
 XX
 PA (UTAH) UNIV UTAH STATE.
 XX
 PI Cockett NE, Beaver JE;
 XX
 DR WPI; 2001-662278/76.
 XX
 PT Identifying a genetic marker for spider lamb syndrome, used to diagnose
 PT if sheep carry a gene for the syndrome, involves analyzing sheep DNA
 PT samples for mutations in fibroblast growth factor receptor 3.
 XX
 PS Claim 11; Col 23; 24pp; English.
 CC
 CC The present invention relates to a method for identifying a genetic
 CC marker for spider lamb syndrome (SLS). The method comprising, obtaining a
 CC sheep DNA sample, and analysing the sample DNA with a probe to determine
 CC the presence or absence of a polymorphism in fibroblast growth factor
 CC receptor 3 (FGFR). The invention is used for diagnosing if sheep carry
 CC the gene for SLS, used to eliminate carriers of the syndrome from a
 CC flock. SLS or hereditary chondrodysplasia is a semi-lethal congenital
 CC disorder in sheep causing severe skeletal abnormalities. The present
 CC sequence is a 5' PCR-RFLP primer used to detect nucleotide transversion
 CC in sheep FGFR3 gene. The FGFR3 gene is located on chromosome 6
 XX
 SQ Sequence 22 BP; 2 A; 11 C; 5 G; 4 T; 0 U; 0 Other;
 Query Match 0.5%; Score 17.2; DB 1; Length 22;
 Best Local Similarity 86.4%; Pred. No. 1e+03;
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1852 TCCCGGTACCCGGGCATCCCTG 1873
 Db 1 TCGCGGTACCCGTGGCATCCCG 22
 RESULT 652
 AAF74089
 ID AAF74089 standard; DNA; 22 BP.
 XX
 AC AAF74089;
 XX
 DT 30-APR-2001 (first entry)
 XX
 DE Primer #23.
 XX
 KW Solute carrier family 6 neurotransmitter transporter; seotonin 4; SLC6A4;
 KW genotyping; allele specific oligonucleotide; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200109161-A1.
 XX
 PD 08-FEB-2001.
 XX
 PF 31-JUL-2000; 2000WO-US020639.
 XX
 PR 29-JUL-1999; 99US-0146290P.
 XX
 PA (GENA-) GENAISSANCE PHARM INC.
 XX
 PI Denton RR, Duda A, Nandabalan K, Sanchis A, Stephens JC;
 DR WPI; 2001-123317/13.
 XX
 PT New isolated polynucleotide comprising a polymorphic variant for the
 PT solute carrier family 6 neurotransmitter transporter, serotonin member 4
 PT gene for identifying drugs for treating disorders related to expression
 PT of the protein.
 XX
 PS Example 1; Page 34; 152pp; English.
 XX
 CC The present invention relates to a polymorphic variant of a reference
 CC sequence for the solute carrier family 6 neurotransmitter transporter,
 CC serotonin member 4 (SLC6A4) gene or a fragment of it or a sequence
 CC complementary to the first sequence. The invention is used in producing a
 CC recombinant organism that can be used to express SLC6A4 for protein
 CC structure analysis and binding studies. A composition comprising a
 CC genotyping oligonucleotide is used to detect a polymorphism in the SLC6A4
 CC gene
 XX
 SQ Sequence 22 BP; 3 A; 8 C; 5 G; 6 T; 0 U; 0 Other;
 Query Match 0.5%; Score 17.2; DB 1; Length 22;
 Best Local Similarity 86.4%; Pred. No. 1e+03;
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 2395 TGCAGAGGTACCCCTGGGTGTC 2416
 Db 1 TCCAGAGCTACCCCTGGGTGTC 22
 RESULT 653
 ADB73475
 ID ADB73475 standard; DNA; 22 BP.
 XX
 AC ADB73475;
 XX
 DT 04-DEC-2003 (first entry)
 XX
 DE Human B cell receptor fusions PCR primer FRGFR1 exons 5-6.
 XX
 KW Human; ss; MLL; cancer; AF-4; CDK-6; SEPTIN6; ALL;

KW acute lymphoblastic leukaemia; AML; acute myeloid leukaemia;
KW chromosomal break point; chromosome 11q23; ATF; BCR; B cell receptor;
KW primer; PCR.
XX
XX
OS Homo sapiens.
XX
XX US2003096255-A1.
XX
XX 22-MAY-2003.
XX
XX 09-APR-2002; 2002US-00118783.
XX
PR 19-FEB-1997; 97US-0038624P.
PR 25-AUG-1997; 97US-0056938P.
PR 17-NOV-1997; 97US-0065911P.
PR 19-FEB-1998; 98US-00026033.
XX
XX (FELI/) FELIX C A.
PA (JONE/) JONES D H.
PA (RAPP/) RAPPAPORT E.
XX
XX Felix CA, Jones DH, Rappaport E;
XX
XX WPI; 2003-606415/57.
XX
XX Amplifying an unknown region that flanks a known region of a cancer-
PT associated DNA sequence by subjecting the panhandle structure to
PT extension and to PCR in the presence of a first primer homologous to the
PT second portion.
XX
XX Claim 6; Page 42; 80pp; English.
XX
XX The invention relates to amplifying an unknown region that flanks a known
CC region of a cancer-associated DNA sequence comprising providing a
CC template polynucleotide, ligating a loop-forming oligonucleotide to the
CC 3'-end of the sense strand, annealing the loop-forming oligonucleotide to the
CC with the first portion to generate a panhandle structure, subjecting the
CC panhandle structure to extension, and subjecting the panhandle structure
CC to PCR in the presence of a first primer homologous to the second
CC portion, where the unknown region is amplified. In the method of
CC amplifying an unknown region that flanks a known region of a cancer-
CC associated DNA sequence, the template polynucleotide comprises a sense
CC strand, comprising the known and unknown regions. The unknown region is
CC nearer the 3'-end of the sense strand than is the known region. The known
CC region is comprises a first or second portion. The first portion is
CC nearer the unknown region than is the second portion. The loop-forming
CC oligonucleotide is complementary to the first portion. The third region
CC complementary to the second portion is generated at the free end of the
CC loop-forming oligonucleotide. The cancer-associated DNA sequence
CC comprises ATF1 (not defined) or BCR (B cell receptor). The method is
CC useful for amplifying an unknown region that flanks a known region of a
CC cancer-associated DNA sequence. Also disclosed as new is the use of the
CC method in the analysis of the breakpoint region of the human MLL gene,
CC where the chromosomal breaks results in gene fusions with AP-4, CDK-6 and
CC SEPTIN6 and are associated with ALL and AML (acute lymphoblastic
CC leukaemia and acute myeloid leukaemia). MLL is located on chromosome
CC 11q23. The present sequence is a PCR primer used the method of the
CC invention to isolate the unknown region adjacent to the BCR cancer gene.
XX
XX Sequence 22 BP; 8 A; 3 C; 8 G; 3 T; 0 U; 0 Other;
SQ

Query Match 0.5%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 1e+03;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 644 ACCTGAGGTGAATGCGACAA 665
||| ||||| ||||| |||||
Db 1 ACATCGAGGTGAATGCGACAA 22

RESULT 654
ADO42630
ID ADO42630 standard; DNA; 22 BP.

XX
AC ADO42630;
XX
DT 15-JUL-2004 (first entry)
XX
DE Human NOVX PCR primer #69.
XX
KW Human; NOVX; PCR; ss; cancer; atherosclerosis; diabetes;
KW Alzheimer's disease; Parkinson's disease; graft-versus-host disease;
KW scleroderma; hypertension; haemophilia;
KW idiopathic thrombocytopenic purpura; immunodeficiency; AIDS;
KW dyslipidemia; obesity; Crohn's disease; bronchial asthma; anorexia;
KW cancer-associated cachexia; multiple sclerosis; fertility; primer.
XX
OS Homo sapiens.
XX
XX US2004058338-A1.
XX
XX 25-MAR-2004.
XX
XX 02-DEC-2002; 2002US-00307817.
XX
PR 03-DEC-2001; 2001US-0336881P.
PR 05-DEC-2001; 2001US-0336820P.
PR 07-DEC-2001; 2001US-0338285P.
PR 10-DEC-2001; 2001US-0338318P.
PR 10-DEC-2001; 2001US-0338989P.
PR 11-DEC-2001; 2001US-0339022P.
PR 11-DEC-2001; 2001US-0339314P.
PR 11-DEC-2001; 2001US-0339516P.
PR 11-DEC-2001; 2001US-0339517P.
PR 11-DEC-2001; 2001US-0339611P.
PR 12-DEC-2001; 2001US-0340981P.
PR 12-DEC-2001; 2001US-0341346P.
PR 14-DEC-2001; 2001US-0340390P.
PR 14-DEC-2001; 2001US-0340440P.
PR 14-DEC-2001; 2001US-0340565P.
PR 14-DEC-2001; 2001US-0340608P.
PR 14-DEC-2001; 2001US-0341144P.
PR 17-DEC-2001; 2001US-0341477P.
PR 17-DEC-2001; 2001US-0341540P.
PR 18-DEC-2001; 2001US-0341768P.
PR 20-DEC-2001; 2001US-0342592P.
PR 31-DEC-2001; 2001US-0344903P.
PR 01-FEB-2002; 2002US-0353286P.
PR 01-FEB-2002; 2002US-0353286P.
PR 26-FEB-2002; 2002US-0355999P.
PR 26-FEB-2002; 2002US-0359626P.
PR 26-FEB-2002; 2002US-0359671P.
PR 27-FEB-2002; 2002US-0359914P.
PR 27-FEB-2002; 2002US-0359956P.
PR 28-FEB-2002; 2002US-0360924P.
PR 28-FEB-2002; 2002US-0360964P.
PR 28-FEB-2002; 2002US-0361028P.
PR 28-FEB-2002; 2002US-0361256P.
PR 28-FEB-2002; 2002US-0361264P.
PR 05-MAR-2002; 2002US-0361770P.
PR 05-MAR-2002; 2002US-0362230P.
PR 13-MAR-2002; 2002US-0364181P.
PR 13-MAR-2002; 2002US-0364238P.
PR 15-MAR-2002; 2002US-0364978P.
PR 17-APR-2002; 2002US-0365025P.
PR 15-MAY-2002; 2002US-0380981P.
PR 16-MAY-2002; 2002US-0381004P.
PR 17-MAY-2002; 2002US-0381495P.
PR 28-MAY-2002; 2002US-0383534P.
PR 28-MAY-2002; 2002US-0383744P.
PR 29-MAY-2002; 2002US-0383829P.
PR 29-MAY-2002; 2002US-0384024P.
PR 02-JUL-2002; 2002US-0393332P.
PR 06-AUG-2002; 2002US-0401315P.
PR 07-AUG-2002; 2002US-0401788P.

20-AUG-2002; 2002US-0404676P.
 23-AUG-2002; 2002US-0405400P.
 23-AUG-2002; 2002US-0405684P.
 23-AUG-2002; 2002US-0405687P.
 23-AUG-2002; 2002US-0405698P.
 26-AUG-2002; 2002US-0406353P.
 XX (AGEE/) AGEE M L.
 PA (ALSO/) ALDOBROOK J P.
 PA (ANDE/) ANDERSON D W.
 PA (BERG/) BERGHS C.
 PA (BOLD/) BOLDOG F L.
 PA (BURG/) BURGESS C E.
 PA (CATI/) CATTERTON E.
 PA (DIPI/) DIPIPPO V A.
 PA (EDIN/) EDINGER S R.
 PA (EISE/) EISEN A.
 PA (ELLE/) ELLERMAN K.
 PA (GANG/) GANGOLLI E A.
 PA (GERL/) GERLACH V.
 PA (GORM/) GORMAN L.
 PA (ROTH/) ROTHBERG B G.
 PA (GUOX/) GUO X S.
 PA (HERR/) HERMANN J L.
 PA (HALV/) HALVORSEN Y.
 PA (JIWV/) JI W.
 PA (KEKU/) KEKUDA R.
 PA (KHRA/) KHRAMTSOV N V.
 PA (LARO/) LAROCHELLE W J.
 PA (LEPL/) LEPLEY D M.
 PA (LILL/) LI L.
 PA (MACD/) MACDOUGALL J R.
 PA (MILL/) MILLER C E.
 PA (ORTT/) ORT T.
 PA (PADI/) PADIGARU M.
 PA (PATT/) PATTURAJAN M.
 PA (PENA/) PENA C E A.
 PA (PEYM/) PEYMAN J A.
 PA (RIEG/) RIEGER D K.
 PA (ROTH/) ROTHENBERG M E.
 PA (SHEN/) SHENOY S G.
 PA (SMIT/) SMITHSON G.
 PA (SPAD/) SPADERNA S K.
 PA (SPYT/) SPYTEK K A.
 PA (STON/) STONE D J.
 PA (TAUP/) TAUPIER R J.
 PA (VERN/) VERNET C A M.
 PA (VOSS/) VOSS E Z.
 PA (ZHON/) ZHONG M.
 XX Agee ML, Alsbrook JP, Anderson DM, Berghs C, Boldog FL,
 PI Burgess CE, Catterton E, Dipippo VA, Edinger SR, Eisen A;
 PI Ellerman K, Gangolli EA, Gerlach V, Gorman L, Rothberg BG,
 PI Herrmann JL, Halvorsen Y, Ji W, Kekuda R, Khrantsov NV,
 PI Larochele WJ, Lepley DM, Li L, MacDougall JR, Miller CE, Ort T;
 PI Padigar M, Patturajan M, Pena CE, Peyman JA, Rieger DK;
 PI Rothenberg ME, Shenoy SG, Smithson G, Spaderna SK, Spytek KA;
 PI Stone DJ, Taupier RJ, Vernet CAM, Voss EZ, Zhong M;
 XX WPI; 2004-268786/25.
 XX New human NOVX polypeptides and nucleic acid molecules, useful for
 XX diagnosing, preventing or treating NOVX-associated disorder, e.g. cancer,
 PT atherosclerosis, diabetes, Alzheimer's disease, Parkinson's disease or
 PT scleroderma.
 XX Example D; SEQ ID NO 485; 610pp; English.
 XX The invention relates to human NOVX polypeptides and the polynucleotides
 XX encoding them. The invention also relates to antibodies specific to the
 CC NOVX polypeptides. The polypeptides, polynucleotides and antibodies are
 CC useful for manufacturing a medicament for treating a syndrome associated
 CC with a human disease, such as a pathology associated with the NOVX

CC polypeptide. The sequences are useful for diagnosing, treating or
 CC preventing a NOVX-associated disorder, e.g., cancer, atherosclerosis,
 CC diabetes, Alzheimer's disease, Parkinson's disease, graft-versus-host
 CC disease, scleroderma, hypertension, haemophilia, idiopathic
 CC thrombocytopenic purpura, immunodeficiencies, AIDS, dyslipidemia,
 CC obesity, Crohn's disease, bronchial asthma, anorexia, cancer-associated
 CC cachexia, multiple sclerosis or fertility. The nucleic acids may be used
 CC as hybridisation probes, in chromosome mapping, in tissue typing, in
 CC preventive medicine or in pharmacogenomics. This sequence represents a
 CC PCR primer used in analysis of expression of a human NOVX polynucleotide
 CC of the invention.
 XX
 SQ Sequence 22 BP; 8 A; 4 C; 6 G; 4 T; 0 U; 0 Other;
 Query Match 0.5%; Score 17.2; DB 1; Length 22;
 Best Local Similarity 86.4%; Pred No. 1e+03;
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 637 CTCAAGCACGCTGGAGGTGAATG 658
 |||||
 Db 1 CTAAAGCACATCGAGGTGAATG 22
 |||||
 RESULT 655
 ADP74810
 ID ADP74810 standard; DNA; 22 BP.
 XX
 AC ADP74810;
 XX
 DT 23-SEP-2004 (first entry)
 XX
 DE Trypanosoma brucei TSIF PCR primer.
 XX
 KW Trypanosoma brucei; trypanosome suppressive immunomodulating factor;
 KW TSIF; immunomodulating activity; Trypanozoon infection;
 KW immunosuppressive; gene therapy; immune response; autoimmune disorder;
 KW PCR; primer; ss.
 XX
 OS Trypanosoma brucei.
 OS Synthetic.
 XX
 PN WO2004056853-A2.
 XX
 PD 08-JUL-2004.
 XX
 PF 19-DEC-2003; 2003WO-EP051082.
 XX
 PR 23-DEC-2002; 2002EP-00080667.
 XX
 PA (VIBV-) VIB VZW.
 XX
 PI De Baetselier P, Beschlin A;
 XX
 DR WPI; 2004-500278/47.
 XX
 PT New polypeptide derived from Trypanosomes, useful in preparing a
 PT medicament for suppressing the immune response in a mammal for treating
 PT autoimmune disorders.
 XX
 PS Example; Page 28; 54pp; English.
 XX
 CC The present invention describes a Trypanosoma brucei trypanosome
 CC suppressive immunomodulating factor (TSIF) protein. The present invention
 CC also describes: (1) the TSIF protein having the primary structural
 CC information of amino acids 1-553 of the 833-amino acid sequence of SEQ ID
 CC NO:2 (ADP74801) or its fragment or allelic variant having
 CC immunomodulating activity; (2) an isolated polynucleotide comprising a
 CC 2826 base pair sequence of SEQ ID NO:1 (ADP74800) which encodes the TSIF
 CC polypeptide; (3) a vector comprising the nucleic acid; (4) a genetically
 CC engineered host cell comprising the expression vector; and (5) preparing
 CC a diagnostic assay for detecting the presence of a Trypanozoon infection
 CC in a mammal. TSIF has immunosuppressive activity, and can be used in gene
 CC therapy. The TSIF polypeptide or polynucleotide can be used in preparing

CC a medicament for suppressing the immune response in a mammal for treating
 CC autoimmune disorders. The present sequence represents a PCR primer for
 CC TS1F, which is used in an example from the present invention.

XX Sequence 22 BP; 7 A; 8 C; 4 G; 3 T; 0 U; 0 Other;
 SQ Query Match 0.5%; Score 17.2; DB 1; Length 22;
 Best Local Similarity 86.4%; Pred. No. 1.e+03;
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 602 AGGTGTACAGTGACGCACAGCC 623
 DB 1 AGGTATACACTGACGCACACCC 22

RESULT 656
 AAQ32277
 ID AAQ32277 standard; DNA; 23 BP.

XX AC AAQ32277;
 XX DT 25-MAR-2003 (revised)
 XX DT 22-APR-1993 (first entry)
 XX DE Human heavy chain PCL primer HuVH3aBACK.

XX KW Heavy chain; light chain; antibody; chimeric; variable; constant; domain;
 XX KW Fab; rescue; phagemid; PCR; ss.
 XX OS Synthetic.

XX PN WO9220791-A1.
 XX PD 26-NOV-1992.
 XX PF 15-MAY-1992; 92WO-GB000883.
 XX PR 15-MAY-1991; 91GB-00010549.
 XX PR 10-JUL-1991; 91WO-GB001134.
 XX PR 24-MAR-1992; 92GB-00006318.
 XX PA (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
 XX PA (MEDI-) MEDICAL RES COUNCIL.

XX PI Winter GP, Johnson KS, Griffiths AD, Smith AJH;
 XX WPI; 1992-415769/50.
 XX DR Prodn. of specific binding pair members - by producing libraries of
 XX PT polypeptide chains displayed by a package, and selection.
 XX PS Example 2; Page 72; 117pp; English.

XX CC Two preps. of PCR-amplified VH genes were made. Both preps. used an
 CC equimolar mixt. of the HUHF0R primers; in one of the preps, 6 separate
 CC PCR amplifications were performed with each of the HUHF0R primers
 CC individually (1a-6a). The template was cDNA prep. from RNA obtd. from B
 CC lymphocytes, and the prod. was further manipulated to yield the human VH
 CC domain. See also AAQ32260-349. (Updated on 25-MAR-2003 to correct PN
 CC field.)

XX SQ Sequence 23 BP; 3 A; 3 C; 12 G; 5 T; 0 U; 0 Other;
 Query Match 0.5%; Score 17.2; DB 1; Length 23;
 Best Local Similarity 86.4%; Pred. No. 1.e+03;
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 853 GAGGAGGAGCTGGTGGAGGCTG 874
 DB 1 GAGGTGACGCTGGTGGAGTCTG 22

RESULT 657

AAQ23702
 ID AAQ23702 standard; DNA; 23 BP.
 XX AC AAQ23702;

XX DT 23-SEP-2004 (revised)
 XX DT 21-MAY-1992 (first entry)
 XX DE Primer HuVH3aBACK for human immunoglobulin VH chain.

XX KW Fd; bacteriophage; gene III; filamentous; phagemid; capsid; coat; pilus;
 XX KW g3p; binding; adsorption; gene VIII; diverse repertoire;
 XX KW specific binding pairs; replicable genetic display package; ss.

XX OS Synthetic.

XX PN WO9201047-A.

XX PD 23-JAN-1992.

XX PF 10-JUL-1990; 90GB-00015198.

XX PR 10-JUL-1990; 90GB-00015198.

XX PR 19-OCT-1990; 90GB-00022845.

XX PR 12-NOV-1990; 90GB-00024503.

XX PR 06-MAR-1991; 91GB-00004744.

XX PR 15-MAY-1991; 91GB-00010549.

XX PA (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.

XX PA (MEDI-) MED RES COUNCIL.

XX PI McCafferty J, Pope AR, Johnson KS, Hoogenboom HRJ, Griffiths AD;

XX PI Jackson RH, Holliger KP, Marks JD;

XX DR WPI; 1992-056862/07.

XX PT Producing members of specific binding pairs - by expression in

XX PT recombinant host cells with a secreting replicable genetic display

XX PT package.

XX PS Disclosure; Page 7; 209pp; English.

XX CC The primer was used to amplify the H chain V region from a human
 CC monoclonal anti Rh-D cell line Fog-1 (Ig-k). It is one of 6 VH Back
 CC primers (AAQ23700-705) used together with the forward primer HulG1-
 CC 4CH1FOR (AAQ23716) for the H chain C region, to prepare a VH-CH1
 CC fragment. A corresponding light chain fragment, VK-CK, was prepd.
 CC separately, then the two chains assembled via a linker sequence to give an
 CC Fab construct. The PCR prod. was ligated into the vector, pJM1-Fab D1.3
 CC (AAQ23857) and the ligation mixt. used to transform E. coli cells. 96 of
 CC the resulting clones were screened for anti- Rh-D activity; 40%
 CC specifically agglutinated Rh-D positive but not Rh-D negative red blood
 CC cells, demonstrating a high frequency of successful splicing in the
 CC assembly process and the potential of this technique for one step cloning
 CC of human hybridomas. The pri- mers were also used to amplify a VH-CH1
 CC fragment to prepare an IgG- lambda monoclonal anti-Rh-D Fab from a
 CC lymphoblastic cell line (LCU). To determine the diversity of the
 CC resulting clones, VH and Lambda genes of 15 clones were PCR amplified. 3
 CC different H chain and 2 different light chain families were present. 5
 CC anti-Rh-D specific clones were identified out of 96 screened. The VH and
 CC Lambda genes had identical nucleotide sequences in each clone and were
 CC typical of anti-Rh-D V-genes. The results demonstrate the potential of
 CC the technique to assemble, clone and isolated human Ab fragments from
 CC polyclonal cell populations. See also AAQ21092-100, 103-116, 126-131;
 CC AAQ23463, 465-495, 693-719, 736-738, and 793-863

XX CC Revised record issued on 23-SEP-2004 : Correction to sequence location
 XX SQ Sequence 23 BP; 3 A; 3 C; 12 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 17.2; DB 1; Length 23;
 Best Local Similarity 86.4%; Pred. No. 1.e+03;
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 853 GAGGAGGAGCTGTGGAGGCTG 874
 DB 1 GAGGTGCAGCTGTGGAGGCTG 22

RESULT 658
 AAQ49744/C
 ID AAQ49744 standard; DNA; 23 BP.
 XX AC AAQ49744;
 XX AC AAQ49744;
 DT 25-MAR-2003 (revised)
 DT 10-MAR-1994 (first entry)
 XX PTK primer pTK2.
 DE PTK; tyrosine kinase; catalytic domain; c-kit; amplification; primer;
 KW polymerase chain reaction; PCR; ss.
 XX Synthetic.
 OS WO9315201-A1.
 PN 05-AUG-1993.
 XX 22-JAN-1993; 93WO-US000586.
 XX 22-JAN-1992; 92US-00826935.
 XX (NEWF-) NEW ENGLAND DEACONESS HOSPITAL.
 XX Abraham H, Groopman J, Cowley S, Scadden D;
 XX WPI; 1993-320330/40.
 XX New protein tyrosine kinase genes and proteins encoded by genes - are of
 PT human mega-karyocytic origin.
 PS Disclosure; Page 14; 60pp; English.
 CC PTK genes were identified using two sets of degenerative oligonucleotide
 CC primers: a first set which amplifies all PTK DNA segments (AAQ49743-44),
 CC and a second set which amplifies highly conserved sequences present in
 CC the catalytic domain of the c-kit subgroup of PTKs (AAQ49745-46). The PTK
 CC genes identified are described in AAQ49747-57 and AAR41897-02. (Updated
 CC on 25-MAR-2003 to correct FN field.)
 XX Sequence 23 BP; 8 A; 6 C; 6 G; 3 T; 0 U; 0 Other;
 Query Match 0.5%; Score 17.2; DB 1; Length 23;
 Best Local Similarity 86.4%; Pred. No. 1.1e+03;
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1801 GAGCTCTGGCTCTTGGGTCC 1822
 DB 23 GAGCTCTGGCTCTTGGGAATTC 2

RESULT 659
 AAQ39335
 ID AAQ39335 standard; DNA; 23 BP.
 XX AC AAQ39335;
 XX AC AAQ39335;
 DT 25-MAR-2003 (revised)
 DT 26-JUL-1993 (first entry)
 XX VH domain PCR amplification primer HuVH3aBACK.
 DE Polymerase chain reaction; murine; Mab32; monoclonal antibody; chimeric;
 KW mouse-human antibodies; antibody; prevention; human;
 KW anti-globulin response; PCR; ss.

XX Synthetic.
 OS WO9306213-A1.
 PN 01-APR-1993.
 XX 23-SEP-1992; 92WO-GB001755.
 XX 23-SEP-1991; 91GB-00020252.
 PR 25-SEP-1991; 91GB-00020377.
 PR 24-MAR-1992; 92GB-00006318.
 PR 24-MAR-1992; 92GB-00006372.
 PR 15-MAY-1992; 92WO-GB000883.
 XX (MEDI-) MEDICAL RES COUNCIL.
 PA (CAME-) CAMBRIDGE ANTIBODY TECHNOLOGY.
 XX Hoogenboom HRJM, Baier M, Jespers LSAT, Winter GP;
 PI WPI; 1993-117534/14.
 XX Producing human antibody polypeptide dimer specific for antigen -
 PT comprises use of chain shuffling using phage expression, useful for
 PT reducing anti globulin responses in humans for increased human
 PT characteristics.
 XX Example; Page 29; 109pp; English.
 XX The sequence is that of PCR primer HuVH3aBACK which was used,
 CC individually or in an equimolar mix of all 6 HuVHBACK primers (AAQ39333-
 CC Q39338), in the prepn. of PCR-amplified VH genes. It was used as part of
 CC a method of producing chimeric mouse-human antibodies or fragments which
 CC have the same binding specificity as a parent Ab but have increased human
 CC characteristics, preventing anti-globulin response in humans. (Updated on
 CC 25-MAR-2003 to correct FN field.)
 XX Sequence 23 BP; 3 A; 3 C; 12 G; 5 T; 0 U; 0 Other;
 Query Match 0.5%; Score 17.2; DB 1; Length 23;
 Best Local Similarity 86.4%; Pred. No. 1.1e+03;
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 853 GAGGAGGAGCTGTGGAGGCTG 874
 DB 1 GAGGTGCAGCTGTGGAGGCTG 22

RESULT 660
 AAQ48989
 ID AAQ48989 standard; DNA; 23 BP.
 XX AC AAQ48989;
 XX AC AAQ48989;
 DT 25-MAR-2003 (revised)
 DT 22-APR-1994 (first entry)
 XX Multimeric (SBP) antibody chain primer.
 DE SBP; specific binding pair members; antibody; RGDP;
 KW replicable genetic display package; recombination; PCR;
 KW polymerase chain reaction; ss.
 XX Synthetic.
 OS WO9319172-A1.
 PN 30-SEP-1993.
 XX 24-MAR-1993; 93WO-GB000605.
 XX 24-MAR-1992; 92GB-00006318.
 PR 15-MAY-1992; 92WO-GB000883.

XX (CAMP-) CAMBRIDGE ANTIBODY TECHNOLOGY.
PA (MEDI-) MEDICAL RES COUNCIL.
XX Johnson KS, Winter GP, Griffiths AD, Smith AJH, Waterhouse P;
XX WPI; 1993-320739/40.
DR Prodn. of specific binding pair members, e.g. antibody chains - by
XX display on surface of replicable genetic display packages.
PT Disclosure; Page 57; 81pp; English.
XX
XX The primers (AAQ4987-049045) are used in the amplification of Kappa and
CC lambda-chain genes of various antibodies. These genes are then recombined
CC into the same replicon, resulting in very diverse libraries of antibody
CC chains, e.g. from unimmunised donors. It is also useful for chain
CC shuffling, mutagenesis, humanising and CDR imprinting. (Updated on 25-MAR
CC -2003 to correct PN field.) (Updated on 25-MAR-2003 to correct PA field.)
XX
SQ Sequence 23 BP; 3 A; 3 C; 12 G; 5 T; 0 U; 0 Other;
Query Match 0.5%; Score 17.2; DB 1; Length 23;
Best Local Similarity 86.4%; Pred. No. 1.1e+03;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 853 GAGGAGGAGCTGGTGGAGGCTG 874
DB 1 GAGGTGCAGCTGGTGGAGTCTG 22

RESULT 661
AAT03086/c
ID AAT03086 standard; DNA; 23 BP.
XX
AC AAT03086;
XX
DT 14-FEB-1996 (first entry)
XX
DE Protein tyrosine-kinase PCR primer pTK2.
XX
XX Protein tyrosine-kinase; agonist; cell growth; differentiation;
XX polymerase chain reaction; primer; ss.
XX
OS Synthetic.
XX
PN WO9527061-A1.
XX
PD 12-OCT-1995.
XX
PF 04-APR-1995; 95WO-US0004228.
XX
PR 04-APR-1994; 94US-00222616.
XX
PA (GETH) GENENTECH INC.
XX
XX Bennett BD, Goeddel D, Lee JM, Matthews W, Tsai SP, Wood WI;
XX WPI; 1995-366160/47.
DR
XX
XX Agonist antibodies which activate specific protein tyrosine kinase(s) -
PT also activate chimeric proteins of kinase extracellular domain and Ig
PT constant domain, useful for studying, and therapeutic modulation of, cell
PT growth and differentiation.
XX
XX Example 1; Page 18; 125pp; English.
PS
XX A set of degenerate primers (AAT03085-86) designed to amplify all protein
CC tyrosine-kinase (pTK) sequences was used with a second set (AAT03087-88),
CC which amplified highly conserved sequences present in the catalytic
CC domain of the c-kit subgroup of pTKs, in a 2-step PCR to obtain probes
CC used to screen cDNA libraries for the identification of novel pTK genes
XX

SQ Sequence 23 BP; 8 A; 6 C; 6 G; 3 T; 0 U; 0 Other;
Query Match 0.5%; Score 17.2; DB 1; Length 23;
Best Local Similarity 86.4%; Pred. No. 1.1e+03;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1801 GAGGTCTGCTCTTGGGGTCC 1822
DB 23 GAGGTCTGCTCTTGGGAATTC 2

RESULT 662
AAT29179
ID AAT29179 standard; DNA; 23 BP.
XX
AC AAT29179;
XX
DT 25-JUL-1996 (first entry)
XX
DE HuVH3a 5' heavy chain primer.
XX
XX Polymerase chain reaction; PCR; amplify; primer; detection;
XX antibody gene; antigen specific antibody; activation; lymphocyte;
XX heavy chain; light chain; variable region; immunoglobulin; ss.
XX
OS Synthetic.
XX
PN JP07115978-A.
XX
PD 09-MAY-1995.
XX
PF 22-OCT-1993; 93JP-00287628.
XX
PR 22-OCT-1993; 93JP-00287628.
XX
XX (LTTK-) LTT KENYUSHO KK.
XX
XX WPI; 1995-202838/27.
XX
XX Detection and cloning of an antibody gene - using PCR, dissociating the
XX gene into single strands and isolating the gene from a cDNA mixture.
XX
XX Example; Page 6; 7pp; Japanese.
XX
XX The sequences given in AAT29175-88 are primers which were used in the
XX method of the invention for the detection of antibody genes which encode
XX antigen specific antibodies. The method comprises activating a lymphocyte
XX with an antigen and synthesizing cDNA from the mRNA contained in the
XX lymphocyte. Heavy and/or light chain coding regions are amplified using
XX primers corresponding to part of the variable region of the
XX immunoglobulin. The cDNA encoding the amplified gene is melted to
XX generate single stranded fragments. The cDNA encoding the antibody of
XX interest is separated from the other cDNA by the difference in single
XX stranded higher order structure
XX
SQ Sequence 23 BP; 3 A; 3 C; 12 G; 5 T; 0 U; 0 Other;
Query Match 0.5%; Score 17.2; DB 1; Length 23;
Best Local Similarity 86.4%; Pred. No. 1.1e+03;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 853 GAGGAGGAGCTGGTGGAGGCTG 874
DB 1 GAGGTGCAGCTGGTGGAGTCTG 22

RESULT 663
AAX76600
ID AAX76600 standard; DNA; 23 BP.
XX
AC AAX76600;
XX
XX 11-AUG-1999 (first entry)
DT

```

XX DE Human sfv library construction PCR primer SEQ ID NO:12.
XX PF
XX KW Human; sfv library; single chain monoclonal antibody fusion reagent;
XX KW transcriptions regulation; screening; diagnosis; HIV; Hepatitis A;
XX KW Hepatitis B respiratory syncytial virus; Junin virus; cytomegalovirus;
XX KW Herpes simplex virus; rubella; Varicella-Zoster virus; hantavirus;
XX KW Epstein-Barr virus; measles; dengue; Ebola inter alia; cancer;
XX KW gene therapy; PCR primer; ss.
XX OS Synthetic.
XX OS Homo sapiens.
XX PN WO928502-A1.
XX PD 10-JUN-1999.
XX PF 28-NOV-1997; 97WO-US021407.
XX PR 28-NOV-1997; 97WO-US021407.
XX PA (INVI-) INVITROGEN CORP.
XX PI Hoeffler JP, Russell M;
XX DR WPI; 1999-371138/31.
XX PT Antibodies from libraries useful in treating viral infections and cancer.
XX PS Claim 23; Page 83; 132pp; English.
XX CC The present invention describes methods of screening a DNA construct
XX CC library for a single chain monoclonal antibody fusion reagent capable of
XX CC binding a transcriptional associated biomolecule in vivo. The antibodies
XX CC are useful in treating Hepatitis A and B respiratory syncytial virus,
XX CC HIV, Junin virus, Herpes simplex I and II, rubella, cytomegalovirus,
XX CC Varicella-Zoster virus, Epstein-Barr virus, measles, hantavirus, dengue,
XX CC Ebola inter alia and cancer. Expression vectors that encode the fusion
XX CC antibodies may be used in gene therapy. The methods can be used to create
XX CC and isolate the fusion antibodies. The monoclonal antibody fusion reagent
XX CC can be used to regulate transcription in vivo. AAX76591 to AAX76674
XX CC represent specifically claimed PCR primers used in the construction of a
XX CC human sfv library
XX CC
XX CC Sequence 23 BP; 3 A; 3 C; 12 G; 5 T; 0 U; 0 Other;
XX CC
Query Match 0.5%; Score 17.2; DB 1; Length 23;
Best Local Similarity 86.4%; Pred. No. 1.1e+03;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
OY 853 GAGGAGGAGCTGTCGAGGCTG 874
DB 1 GAGGTGCAGCTGTCGAGTCTG 22
RESULT 664
AAZ43845
ID AAZ43845 standard; DNA; 23 BP.
XX AC
XX AC AAZ43845;
XX DT
XX DT 23-MAR-2000 (first entry)
XX DE Human IgG4 heavy chain PCR primer huVH3aback.
XX KW Human; IgG4; heavy chain; primer; antibody; factor VIII; hemostatic;
XX KW hemophilia A; amplification; ss.
XX OS Homo sapiens.
XX PN WO958680-A2.
XX PD 18-NOV-1999.

```

```

XX 07-MAY-1999; 99WO-NL000285.
XX 08-MAY-1998; 98EP-00201543.
XX (SANO-) STICHTING SANQUIN BLOEDVOORZIENING.
XX Voorberg JJ, Van Den Brink EN, Turenhout EAM;
XX WPI; 2000-053102/04.
XX New polynucleotide, polypeptide and antibody useful for diagnosing the
XX presence of neutralizing antibodies against factor VIII and for treatment
XX of hemophilia A patients with these antibodies.
XX Example 2; Page 19; 61pp; English.
XX This invention describes a novel polynucleotide (I) (and complements and
XX hybridizable polynucleotides) comprising a contiguous nucleotide sequence
XX coding for a human antibody with factor VIII specificity which has
XX hemostatic activity. (I) is useful a primer or probe for detecting the
XX presence of inhibitory antibodies directed against factor VIII. The
XX polypeptides of the invention and the antibodies generated from them are
XX useful in compositions for neutralizing factor VIII inhibiting antibodies
XX in hemophilia A patients. AAZ43841-243858 represent primers used in the
XX amplification of a human IgG4 heavy chain which is used in the method of
XX the invention
XX Sequence 23 BP; 3 A; 3 C; 12 G; 5 T; 0 U; 0 Other;
XX
Query Match 0.5%; Score 17.2; DB 1; Length 23;
Best Local Similarity 86.4%; Pred. No. 1.1e+03;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
OY 853 GAGGAGGAGCTGTCGAGGCTG 874
DB 1 GAGGTGCAGCTGTCGAGTCTG 22
RESULT 665
ABA03074
ID ABA03074 standard; DNA; 23 BP.
XX AC
XX AC ABA03074;
XX DT
XX DT 05-FEB-2002 (first entry)
XX DE PCR primer Hu VH3-5'.
XX KW Human; serum albumin; HA; antiinflammatory; immunosuppressive; cardiac;
XX KW nontropic; neuroprotective; gene therapy; immune disorder; wound healing;
XX KW hyperproliferative disorder; renal disorder; cardiovascular disorder;
XX KW respiratory disorder; neurological disease; endocrine disorder;
XX KW reproductive system disorder; infectious disease;
XX KW gastrointestinal disorder; PCR primer; ss.
XX OS Homo sapiens.
XX PN WO200179444-A2.
XX PD 25-OCT-2001.
XX PF 12-APR-2001; 2001WO-US012013.
XX PR 12-APR-2000; 2000US-0229358P.
XX PR 25-APR-2000; 2000US-0199384P.
XX PR 21-DEC-2000; 2000US-0256931P.
XX PA (HUMA-) HUMAN GENOME SCI INC.
XX PI Rosen CA, Haseltine WA;
XX DR WPI; 2001-616755/71.

```

```

XX Alumin fusion proteins comprising a therapeutic protein and albumin,
PT useful in the treating immune system disorders (e.g. transplant
PT rejection), blood related disorders (e.g. myocardial infarction) and
PT hyperproliferative disorders.
XX
XX Disclosure; Page 538; 606pp; English.
XX
CC The present invention relates to albumin fusion proteins, which comprise
CC a therapeutic protein and albumin. The albumin fusion proteins are useful
CC in the treatment, prevention, diagnosis, and/or detection of
CC diseases/disorders such as immune system disorders (e.g. transplant
CC rejection), blood related disorders (e.g. myocardial infarction),
CC hyperproliferative disorders (e.g. childhood acute myeloid leukemia),
CC renal disorders (e.g. glomerulonephritis), cardiovascular disorders (e.g.
CC atherosclerosis), respiratory disorders (e.g. non-allergic rhinitis),
CC neurological diseases (e.g. Alzheimer's disease), endocrine disorders
CC (e.g. pheochromocytoma), reproductive system disorders (e.g. syphilis),
CC infectious diseases (e.g. measles), gastrointestinal disorders (e.g.
CC irritable bowel syndrome) and wound healing. In the present invention,
CC human serum albumin (HA; see AAM52567) was used to generate fusion
CC proteins. The present sequence was used to illustrate the invention
XX
XX Sequence 23 BP; 3 A; 3 C; 12 G; 5 T; 0 U; 0 Other;
XX
Query Match 0.5%; Score 17.2; DB 1; Length 23;
Best Local Similarity 86.4%; Pred. No. 1.1e+03;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
XX
QY 853 GAGGAGGAGCTGTGGAGGCTG 874
DB 1 GAGGTGACGCTGTGGAGTCTG 22
XX
RESULT 666
AAD20057
ID AAD20057 standard; DNA; 23 BP.
XX
AC AAD20057;
XX
DT 18-DEC-2001 (first entry)
XX
DE Human antibody VH gene amplifying PCR primer, Hu VH3-5'.
XX
KW Human; albumin; HA; immune system disorder; transplant rejection;
KW blood related disorder; myocardial infarction; glomerulonephritis;
KW hyperproliferative disorder; childhood acute myeloid leukemia; VH;
KW heavy chain variable domain; renal cell carcinoma; antileukemic;
KW cardiovascular disorder; respiratory disorder; non-allergic rhinitis;
KW neurological disease; Alzheimer's disease; endocrine disorder; measles;
KW pheochromocytoma; reproductive system disorder; neuroprotective; syphilis;
KW infectious disease; gastrointestinal disorder; wound healing; nontropic;
KW irritable bowel syndrome; HIV; human immunodeficiency virus infection;
KW cytostatic; antiinflammatory; gene therapy; immunosuppressive; cardiac;
KW anthratic; antirheumatic; renal disorder; antimicrobial; vulnery;
KW arrhythmia; melanoma; PCR primer; ss.
XX
OS Homo sapiens.
XX
FN WO200179480-A1.
XX
PD 25-OCT-2001.
XX
PF 12-APR-2001; 2001WO-US011991.
XX
PR 12-APR-2000; 2000US-0229358P.
PR 25-APR-2000; 2000US-0199384P.
PR 21-DEC-2000; 2000US-0256931P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Haseltine WA;
XX

```

```

DR WPI; 2001-616756/71.
XX
XX Alumin fusion proteins comprising a therapeutic protein and albumin,
PT useful in the treating metastatic renal cell carcinoma, metastatic
PT melanoma, malignant melanoma, renal cell carcinoma, HIV (human
PT immunodeficiency virus) or infection.
XX
XX Example 60; Page 315; 394pp; English.
XX
CC The invention relates to human albumin (HA) fusion proteins and their
CC corresponding nucleic acid sequences. Therapeutic proteins fused to
CC albumin or its fragments have an extended shelf-life. The albumin fusion
CC proteins are useful in the treatment, prevention, diagnosis, and/or
CC detection of diseases, disorders such as immune system disorders (e.g.
CC transplant rejection), blood related disorders (e.g. myocardial
CC infarction), hyperproliferative disorders (e.g. childhood acute myeloid
CC leukaemia, metastatic renal cell carcinoma, metastatic melanoma,
CC malignant melanoma, renal cell carcinoma), renal disorders (e.g.
CC glomerulonephritis), cardiovascular disorders (e.g. arrhythmias),
CC respiratory disorders (e.g. non-allergic rhinitis), neurological diseases
CC (e.g. Alzheimer's disease), endocrine disorders (e.g. pheochromocytoma),
CC reproductive system disorders (e.g. syphilis), infectious diseases (e.g.
CC measles), gastrointestinal disorders (e.g. irritable bowel syndrome), HIV
CC (human immunodeficiency virus) infection and wound healing. Nucleic acids
CC encoding albumin fusion protein is used in gene therapy. The present
CC sequence is a PCR primer used to amplify human heavy chain variable
CC domain (VH) gene. Note: The present sequence is incorrectly referred as
CC SEQ ID NO: 38 in page 315 of the specification
XX
XX Sequence 23 BP; 3 A; 3 C; 12 G; 5 T; 0 U; 0 Other;
XX
Query Match 0.5%; Score 17.2; DB 1; Length 23;
Best Local Similarity 86.4%; Pred. No. 1.1e+03;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
XX
QY 853 GAGGAGGAGCTGTGGAGGCTG 874
DB 1 GAGGTGACGCTGTGGAGTCTG 22
XX
RESULT 667
AAD13302
ID AAD13302 standard; DNA; 23 BP.
XX
XX AAD13302;
XX
DT 16-OCT-2001 (first entry)
XX
DE Human VH domain amplifying PCR primer Hu VH3-5'.
XX
KW Human; G-protein chemokine receptor; CCR5; HDGNR10; inflammation; HIV;
KW human immunodeficiency virus; antimicrobial; vasodilator; vulnery;
KW cytostatic; immunosuppressive; nontropic; neuroprotective; gene therapy;
KW neurodegenerative disorder; Kaposi's sarcoma; autoimmune disease;
KW rheumatoid arthritis; cancer; breast; ovary; adrenal gland; bone marrow;
KW gastrointestinal tract; lung; liver; immune disorder; Addison's disease;
KW haemolytic anaemia; autoimmune thyroiditis; diabetes mellitus; allergy;
KW multiple sclerosis; ulcerative colitis; Crohn's disease; wound healing;
KW cardiovascular disorder; myocardial ischaemia; PCR primer; VH domain; ss.
XX
OS Homo sapiens.
XX
FN WO200158916-A2.
XX
PD 16-AUG-2001.
XX
PF 09-FEB-2001; 2001WO-US004153.
XX
PR 09-FEB-2000; 2000US-0181258P.
PR 09-MAR-2000; 2000US-0187999P.
PR 22-SEP-2000; 2000US-0234336P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI

```

```

XX PI Rosen CA, Roschke V, Li Y, Ruben SM;
XX PF WPI; 2001-488966/53.
XX DR
XX PT Isolated nucleic acid encoding a human G-protein chemokine receptor
XX PT (CCR5) HDGMR10 polypeptide, useful for preventing or treating autoimmune
XX PT diseases e.g. rheumatoid arthritis, hyperproliferative disorders and
XX PT neurodegenerative disorders.
XX PA
XX PI Rosen CA, Roschke V, Li Y, Ruben SM;
XX PF WPI; 2001-488966/53.
XX DR
XX PT The invention relates to human G-protein chemokine receptor (CCR5)
XX PT HDGMR10 polypeptides and polynucleotides. CCR5 HDGMR10 antibodies are
XX PT useful for treating, preventing or ameliorating a disease or disorder
XX PT associated with inflammation, defective or aberrant chemotaxis of immune
XX PT cells, HIV infection (such as Pneumocystis carinii pneumonia or Kaposi's
XX PT sarcoma) or defective or aberrant T-cell antigen presenting cell
XX PT interaction. The disease or disorder may also be an infectious disease
XX PT (e.g. a viral infection such as an early stage HIV infection, a
XX PT cytomegalovirus infection, or a poxvirus infection), an autoimmune
XX PT disease (e.g. rheumatoid arthritis) or a neurodegenerative disorder. The
XX PT disease or disorder may be associated with aberrant CCR5 expression, lack
XX PT of CCR5 function, aberrant CCR5 ligand expression, or lack of CCR5 ligand
XX PT function. CCR5 HDGMR10 protein is used as a food additive or preservative
XX PT to increase or decrease storage capabilities. CCR5 HDGMR10 DNA are useful
XX PT for chromosome identification and in gene therapy. CCR5 HDGMR10 DNA,
XX PT protein, antibodies, agonists and antagonists are also useful in the
XX PT diagnosis, treatment and prevention of cancer (breast, ovary, adrenal
XX PT gland, bone, bone marrow, gastrointestinal tract, liver, lung,
XX PT urogenital); immune disorders (Addison's disease, allergies, autoimmune
XX PT haemolytic anaemia, autoimmune thyroiditis, diabetes mellitus, Crohn's
XX PT disease, multiple sclerosis, rheumatoid arthritis and ulcerative colitis)
XX PT ; cardiovascular disorders (myocardial ischaemia) and wound healing. The
XX PT present sequence is a PCR primer used to amplify human VH domain. The CDR
XX PT regions of VH domain specifically binds to the G-protein chemokine
XX PT receptor (CCR5) protein of the invention
XX SQ
XX Sequence 23 BP; 3 A; 3 C; 12 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 0.5%; Score 17.2; DB 1; Length 23;
XX Best Local Similarity 86.4%; Pred. No. 1.1e+03;
XX Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
XX
XX QY 853 GAGGAGGAGCTGCTGGAGGCTG 874
XX ||||| ||||| ||||| ||||| |||||
XX DB 1 GAGGTGCAGCTGCTGGAGTCTG 22
XX
XX RESULT 668
XX AAD13201
XX ID AAD13201 standard; DNA; 23 BP.
XX
XX AC AAD13201;
XX AC
XX XX 16-OCT-2001 (first entry)
XX DT
XX DE Human VH domain amplifying PCR primer Hu VH3-5'.
XX
XX Human G-protein chemokine receptor; CCR5; HDGMR10; inflammation;
XX human immunodeficiency virus; antimicrobial; vasodilator; vulnerability; HIV;
XX cytostatic; immunosuppressive; neutrotropic; neuroprotective; gene therapy;
XX neurodegenerative disorder; Kaposi's sarcoma; autoimmune disease;
XX rheumatoid arthritis; cancer; breast; ovary; adrenal gland; bone marrow;
XX gastrointestinal tract; lung; liver; immune disorder; Addison's disease;
XX haemolytic anaemia; autoimmune thyroiditis; diabetes mellitus; allergy;
XX multiple sclerosis; ulcerative colitis; Crohn's disease; wound healing;
XX cardiovascular disorder; myocardial ischaemia; PCR primer; VH domain; ss.
XX
XX Homo sapiens.
XX OS
XX WO200158915-A2.
XX PN
XX

```

```

PD 16-AUG-2001.
XX 09-FEB-2001; 2001WO-US004152.
XX 09-FEB-2000; 2000US-0181258P.
XX 09-MAR-2000; 2000US-0187999P.
XX 22-SEP-2000; 2000US-0234336P.
XX (HUMA-) HUMAN GENOME SCI INC.
XX
XX Rosen CA, Roschke V, Li Y, Ruben SM;
XX WPI; 2001-488966/53.
XX
XX Isolated nucleic acid encoding a human G-protein chemokine receptor
XX (CCR5) HDGMR10 polypeptide, useful for preventing or treating autoimmune
XX diseases e.g. rheumatoid arthritis, hyperproliferative disorders and
XX neurodegenerative disorders.
XX
XX Example 55; Page 438; 495pp; English.
XX
XX The invention relates to human G-protein chemokine receptor (CCR5)
XX HDGMR10 protein and their corresponding DNA. CCR5 HDGMR10 antibodies are
XX useful for treating, preventing or ameliorating a disease or disorder
XX associated with inflammation, defective or aberrant chemotaxis of immune
XX cells, HIV infection (such as Pneumocystis carinii pneumonia or Kaposi's
XX sarcoma) or defective or aberrant T-cell antigen presenting cell
XX interaction. The disease or disorder may also be an infectious disease
XX (e.g. a viral infection such as an early stage HIV infection, a
XX cytomegalovirus infection, or a poxvirus infection), an autoimmune
XX disease (e.g. rheumatoid arthritis) or a neurodegenerative disorder. The
XX disease or disorder may be associated with aberrant CCR5 expression, lack
XX of CCR5 function, aberrant CCR5 ligand expression, or lack of CCR5 ligand
XX function. CCR5 HDGMR10 protein is used as a food additive or preservative
XX to increase or decrease storage capabilities. CCR5 HDGMR10 DNA are useful
XX for chromosome identification and in gene therapy. CCR5 HDGMR10 DNA,
XX protein, antibodies, agonists and antagonists are also useful in the
XX diagnosis, treatment and prevention of cancer (breast, ovary, adrenal
XX gland, bone, bone marrow, gastrointestinal tract, liver, lung,
XX urogenital); immune disorders (Addison's disease, allergies, autoimmune
XX haemolytic anaemia, autoimmune thyroiditis, diabetes mellitus, Crohn's
XX disease, multiple sclerosis, rheumatoid arthritis and ulcerative colitis)
XX ; cardiovascular disorders (myocardial ischaemia) and wound healing. The
XX present sequence is a PCR primer used for amplifying human VH domain. The
XX VH domain contains CDR regions which bind to G-protein chemokine receptor
XX (CCR5) protein
XX
XX Sequence 23 BP; 3 A; 3 C; 12 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 0.5%; Score 17.2; DB 1; Length 23;
XX Best Local Similarity 86.4%; Pred. No. 1.1e+03;
XX Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
XX
XX QY 853 GAGGAGGAGCTGCTGGAGGCTG 874
XX ||||| ||||| ||||| ||||| |||||
XX DB 1 GAGGTGCAGCTGCTGGAGTCTG 22
XX
XX RESULT 669
XX AAD13201
XX ID AAD13201 standard; DNA; 23 BP.
XX
XX AC AAD13201;
XX AC
XX XX 01-AUG-2002 (first entry)
XX DT
XX DE Human VH domain PCR primer Hu VH3-5' SEQ ID NO:38.
XX
XX Human growth hormone; hGH; albumin; human serum albumin; HSA;
XX albumin fusion protein; cytostatic; anorectic; immunosuppressive;
XX antidiabetic; antirheumatic; antiarthritic; psoriatic; cancer;
XX non-Hodgkin's lymphoma; obesity; transplant rejection; psoriasis;
XX type I diabetes mellitus; rheumatoid arthritis; PCR primer; ss.
XX

```

```
XX Homo sapiens.
OS Synthetic.
XX WO200179442-A2.
XX 25-OCT-2001.
XX 12-APR-2001; 2001WO-US011850.
XX 12-APR-2000; 2000US-0229358P.
XX 25-APR-2000; 2000US-0199384P.
XX 21-DEC-2000; 2000US-0256931P.
XX (HUMA-) HUMAN GENOME SCI INC.
XX Rosen CA, Haseltine WA;
XX WPI; 2001-611723/70.
XX New albumin fusion proteins, useful for treating diseases and disorders
PT such as cancer, comprise therapeutic protein fused to albumin.
XX Example 60; Page 343; 413pp; English.
XX The present invention describes an albumin fusion protein (I) comprising
CC a therapeutic protein; X and (a fragment or variant of) albumin
CC comprising a the fully defined sequence in AB079006 of 585 amino acids,
CC (where the fragment or variant has albumin or therapeutic protein: X
CC activity). (I) can have cytostatic, anorectic, immunosuppressive,
CC antidiabetic, antirheumatic, antiarthritic and psoriatic activities.
CC Albumin fusion proteins are stabilised therapeutic proteins e.g.
CC antibodies to C5, C242 and CD80 useful for treating various diseases and
CC disorders such as non-Hodgkin's lymphoma, cancer, obesity, transplant
CC rejection, type I diabetes mellitus, rheumatoid arthritis and psoriasis.
CC Fusing albumin to therapeutic proteins stabilises the therapeutic
CC protein, extends the shelf life and retains the in vitro or in vivo
CC biological activity. It also reduces the need to formulate protein
CC solutions with large excesses of carrier proteins to prevent loss of
CC therapeutic proteins due to factors such as binding to the container. The
CC fusion proteins are easily dispensed with a simple formulation requiring
CC minimal post storage manipulation. The fusion of therapeutic proteins to
CC albumin confers stability in aqueous or other solution. The present
CC sequence represents a PCR primer which is used in an example from the
XX present invention
XX Sequence 23 BP; 3 A; 3 C; 12 G; 5 T; 0 U; 0 Other;
Query Match 0.5%; Score 17.2; DB 1; Length 23;
Best Local Similarity 86.4%; Pred. No. 1.1e+03;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 853 GAGGAGGAGCTGTGGAGGCTG 874
Db 1 GAGGTGACGCTGTGTGAGTCTG 22
RESULT 670
AAH23018
ID AAH23018 standard; DNA; 23 BP.
XX AC AAH23018;
XX 17-SEP-2001 (first entry)
XX VEGFR-1 gene specific forward primer.
XX Vascular endothelial growth factor; VEGF; antisense; angiogenesis;
XX cell proliferation; Kaposi's sarcoma; cancer; melanoma; cytostatic;
XX antisense therapy; RT-PCR; primer; VEGFR-1; ss.
XX Synthetic.
OS Homo sapiens.
```

```
XX WO200152904-A2.
XX 26-JUL-2001.
XX 19-JAN-2001; 2001WO-US000019.
XX 19-JAN-2000; 2000US-00487023.
XX (GILL/) GILL P S.
XX Gill PS, Masood R;
XX WPI; 2001-451898/48.
XX Novel antisense oligonucleotides useful for inhibiting vascular
PT endothelial growth factor expression, angiogenesis and for treating
PT cancer, e.g., Kaposi's sarcoma, ovarian cancer and prostate cancer.
XX Example 12; Page 56; 105pp; English.
XX The invention provides a composition comprising one or more antisense
CC oligonucleotides directed against vascular endothelial growth factor
CC (VEGF) where the antisense oligonucleotides inhibits proliferation of
CC cells exhibiting autocrine VEGF activity at an IC50 concentration of
CC between 0.5-2.5 micro Ma. The antisense oligonucleotides may be directed
CC against VEGF for inhibiting cancer cell proliferation and angiogenesis.
CC Preferably the oligonucleotide AAH23032 (a modified version of AAH22984)
CC is used and may be utilized to treat Kaposi's sarcoma, ovarian cancer,
CC prostate cancer, pancreatic cancer or melanoma. Sequences AAH23012-023
CC represent gene-specific primers used in RT-PCR amplification of VEGF
XX receptors
XX Sequence 23 BP; 6 A; 4 C; 9 G; 4 T; 0 U; 0 Other;
Query Match 0.5%; Score 17.2; DB 1; Length 23;
Best Local Similarity 86.4%; Pred. No. 1.1e+03;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1573 CAGGTGGCCCGGGCGCATGGAGT 1594
Db 1 CAAGTGGCAGAGCGCATGGAGT 22
RESULT 671
ABK51873
ID ABK51873 standard; DNA; 23 BP.
XX AC ABK51873;
XX 13-AUG-2002 (first entry)
XX PCR primer #3 used to amplify human VH or VL domain.
XX Human; G-protein chemokine receptor; CCR5; HDGMR10; inflammation;
XX immune cell chemotaxis; autoimmune disease; rheumatoid arthritis;
XX neurodegeneration; viral infection; Kaposi sarcoma; cancer;
XX hyperproliferative disease; neurological disease; PCR; primer; VH domain;
XX VL domain; ss.
XX Homo sapiens.
XX US2002048786-A1.
XX 25-APR-2002.
XX 09-FEB-2001; 2001US-00779879.
XX 09-FEB-2000; 2000US-0181258P.
XX 09-MAR-2000; 2000US-0187999P.
XX 22-SEP-2000; 2000US-0234336P.
XX (ROSE/) ROSEN C A.
```


XX DR WPI; 2002-643455/69.

XX PT New human G-protein Chemokine Receptor gene (HDGNR10) useful for

XX PT treating, preventing, ameliorating or monitoring diseases or disorders

XX PT associated with aberrant expression of HDGNR10 e.g. cancer.

XX PS Example 55; Page 471; 562pp; English.

XX CC The invention describes an isolated polynucleotide encoding a first

XX CC antibody at least 95-100% identical to a second antibody consisting of an

XX CC amino acid sequence comprising at least one, two or three CDR regions of

XX CC a variable heavy (VH) or variable light (VL) domain of the antibody

XX CC expressed by a hybridoma cell line consisting of XF3.5F1, XF11.1F8,

XX CC XF3.6A2, XF3.10B8, XF27/28.36A12, XF27/28.36F11 or XF27/28.43E2. The antibody

XX CC is useful treating, preventing, ameliorating, prognosing or monitoring

XX CC cancers or other diseases or disorders e.g. immunologic deficiency

XX CC syndromes such as blood protein disorders and ataxia telangiectasia,

XX CC inflammation associated disorders such as endotoxin lethality, nephritis

XX CC and inflammatory bowel disease, conditions associated with an increase in

XX CC certain haematopoietic cells such as histiocytosis, defective or aberrant

XX CC chemotaxis of immune cells or T-cell antigen presenting cell interaction,

XX CC an infectious disease, an autoimmune disease such as Addison's disease,

XX CC dermatitis and rheumatoid arthritis, allergies, a neurodegenerative

XX CC disorder, a viral infection e.g. HIV infection, cytomegalovirus or

XX CC poxvirus infection, a pneumocystis carinii infection, Kaposi's sarcoma,

XX CC cardiovascular disorders such as atherosclerosis, lymphocytopenias, or a

XX CC disease or disorder associated with aberrant expression of novel human G-

XX CC protein chemokine receptor (CCR5) HDGNR10. This sequence represents a

XX CC primer associated with the production of vectors, host cells and

XX CC antibodies directed to HDGNR10

XX SQ Sequence 23 BP; 3 A; 3 C; 12 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 17.2; DB 1; Length 23;

Best Local Similarity 86.4%; Pred. No. 1.1e+03;

Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 853 GAGGAGGAGCTGTGGAGGCTG 874

DB 1 GAGGTGCAGCTGTGGAGTCTG 22

RESULT 676

ID ABQ83145

AC ABQ83145 standard; DNA; 23 BP.

AC ABQ83145;

XX 16-JAN-2003 (first entry)

XX Human HGPRMY27 antibody VH domain PCR primer SEQ ID NO:40.

XX Homo sapiens.

XX Human; G protein coupled receptor; GPCR; HGPRMY27; antiinflammatory;

XX antiinfectivity; pulmonary; cytostatic; nephrotropic; hormonal;

XX circulatory; gene therapy; inflammatory disorder; reproductive disorder;

XX pulmonary disorder; cancer; renal disorder; connective tissue disorder;

XX endocrine disorder; antibody; PCR primer; ss.

XX Homo sapiens.

XX WO200272755-A2.

XX 19-SEP-2002.

XX 06-MAR-2002; 2002WO-US006796.

XX 07-MAR-2001; 2001US-0273808P.

XX 27-MAR-2001; 2001US-0278983P.

XX (BRIM) BRISTOL-MYERS SQUIBB CO.

PI Ramanathan C, Feder J, Mintier G, Cacace A, Barber L;

XX WPI; 2002-657945/70.

XX PT New polynucleotide encoding a human G-protein coupled receptor for

XX PT preventing, treating, or ameliorating e.g. an inflammatory, reproductive,

XX PT pulmonary, renal connective tissue, or endocrine disorder.

XX PS Example 34; Page 298; 356pp; English.

XX CC The present invention describes a human G protein coupled receptor

XX CC (GPCR), designated HGPRMY27 (I). (I) has antiinflammatory,

XX CC antiinfectivity, pulmonary, cytostatic, nephrotropic, hormonal and

XX CC circulatory activities, and can be used in gene therapy. (I) or the

XX CC protein encoded by it can be used to prevent, treat, or ameliorate a

XX CC medical condition, such as inflammatory disorders, reproductive

XX CC disorders, pulmonary disorders, cancer, renal disorders, connective

XX CC tissue disorders, endocrine disorders, or disorders involving aberrations

XX CC in tubular tissues. They can also be used to diagnose a pathological

XX CC condition or a susceptibility to (I). The protein can be used to screen

XX CC for candidate compounds capable of modulating activity of a GPCR

XX CC polypeptide. The present sequence represents a PCR primer for the VH

XX CC domain of an antibody against human HGPRMY27, which is used in an

XX CC example from the present invention

XX SQ Sequence 23 BP; 3 A; 3 C; 12 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 17.2; DB 1; Length 23;

Best Local Similarity 86.4%; Pred. No. 1.1e+03;

Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 853 GAGGAGGAGCTGTGGAGGCTG 874

DB 1 GAGGTGCAGCTGTGGAGTCTG 22

RESULT 677

ID ABT09824

XX ABT09824 standard; DNA; 23 BP.

XX ABT09824;

XX 05-DEC-2002 (first entry)

XX K-beta M6 related VH domain PCR primer SEQ ID No 30.

XX Cytostatic; cardiant; neuroprotective; immunomodulator; antimigraine;

XX sedative; gynaecological; potassium channel beta subunit; K-betaM6;

XX gastrointestinal; reproductive; neural; sleep; low DNA repair capacity;

XX hyperpotassium channel activity; cardiovascular; melatonin synthesis;

XX mammary cancer tumorigenesis; pineal gland associated disorder;

XX pulmonary disorder; immune disorder; NF-kB activity; migraine headache;

XX low free-radical buffering capacity; delayed sleep phase syndrome;

XX circadian cycle; melatonin secretion; cancer; PCR; primer; ss.

XX Homo sapiens.

XX WO200270727-A2.

XX 12-SEP-2002.

XX 21-FEB-2002; 2002WO-US005674.

XX 21-FEB-2001; 2001US-0270132P.

XX 27-MAR-2001; 2001US-0278953P.

XX (BRIM) BRISTOL-MYERS SQUIBB CO.

XX Feder J, Lee L, Chen J, Jackson DG, Ramanathan C, Siemers N;

XX Chang H;

XX WPI; 2002-713455/77.

PT New polynucleotide encoding human potassium channel beta subunit
PT polypeptide, useful for diagnosing, preventing, treating or ameliorating
PT e.g. cancer.
XX
PS Example 34; Page 281; 332pp; English.
XX
CC The invention relates to an isolated polynucleotide encoding a potassium
CC channel beta subunit (K+betaM6) polypeptide or its variants. The human
CC potassium beta subunit polynucleotide or polypeptide is useful for
CC diagnosing, preventing, treating or ameliorating a pathological condition
CC such as gastrointestinal, reproductive, neural, sleep, cardiovascular or
CC pulmonary disorders, a disorder related to hyperpotassium channel
CC activity, an immune disorder related to aberrant NF-kB activity, pineal
CC gland associated disorders, migraine headaches, disorders associated with
CC aberrant melatonin synthesis and/or release or with low DNA repair
CC capacities or low free-radical buffering capacity, delayed sleep phase
CC syndrome, aberrations in circadian cycle, mammary cancer tumorigenesis,
CC age related disorders associated with decreased melatonin secretion, or
CC cancer. This polynucleotide sequence represents a PCR primer relating to
CC the potassium channel beta subunit (K+betaM6) of the invention
XX
SQ Sequence 23 BP; 3 A; 3 C; 12 G; 5 T; 0 U; 0 Other;
Query Match 0.5%; Score 17.2; DB 1; Length 23;
Best Local Similarity 86.4%; Pred. No. 1.1e+03;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 853 GAGGAGGAGCTGGTGAGGCTG 874
|||||
Db 1 GAGGTGCAGCTGGTGAGGCTG 22
|||||
RESULT 678
ABK93297
ID ABK93297 standard; DNA; 23 BP.
XX
AC ABK93297;
XX
DT 27-AUG-2002 (first entry)
XX
DE PCR primer #3 for amplifying human antibody VH domain.
XX
KW Albumin fusion protein; therapeutic protein X; human albumin; HA;
KW human serum albumin; HSA; cancer; reproductive disorder;
KW digestive disorder; immune disorder; endocrine disorder;
KW haematopoietic disorder; neural disorder; connective disorder;
KW cytostatic; antiinfertility; antiinflammatory; antitumor;
KW immunomodulator; anti-HIV; antidiabetic; haemostatic; neutropic;
KW neuroprotective; antiparkinsonian; antimicrobial; neuroleptic;
KW osteopathic; antiarthritic; VH domain; PCR; primer; ss.
XX
OS Homo sapiens.
XX
PN WO20017137-A1.
XX
PD 18-OCT-2001.
XX
PF 12-APR-2001; 2001WO-US011988.
XX
PR 12-APR-2000; 2000US-0229358P.
PR 25-APR-2000; 2000US-0199384P.
PR 21-DEC-2000; 2000US-0256931P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Haseltine WA;
XX
DR WPI; 2002-010886/01.
XX
XX New fusion protein for treating disease e.g. diabetes comprises an
PT albumin fused to a therapeutic protein.
XX
PS Example 60; Page 512; 2102pp; English.

XX
CC The present invention relates to albumin fusion proteins comprising a
CC therapeutic protein X and human albumin (HA, also known as human serum
CC albumin, HSA). The proteins are useful for treating a disease or disorder
CC that may be modulated by therapeutic protein X. The albumin extends the
CC shelf-life of protein X, and may increase its biological in vitro/in vivo
CC activity. The protein is useful for treating and diagnosing disorders
CC such as cancer, reproductive disorders, digestive disorders (e.g. Crohn's
CC disease, ulcerative colitis), immune disorders (e.g. acquired
CC immunodeficiency syndrome, AIDS), endocrine disorders (e.g. diabetes),
CC haematopoietic disorders, neural disorders (e.g. Alzheimer's,
CC Parkinson's, Creutzfeldt-Jacob disease, encephalomyelitis, meningitis,
CC schizophrenia), and connective disorders (e.g. osteoporosis, arthritis).
CC ABK93295-ABK93304 domains PCR primers used to amplify DNA encoding
CC human antibody VH domains in the examples of the present invention
XX
SQ Sequence 23 BP; 3 A; 3 C; 12 G; 5 T; 0 U; 0 Other;
Query Match 0.5%; Score 17.2; DB 1; Length 23;
Best Local Similarity 86.4%; Pred. No. 1.1e+03;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 853 GAGGAGGAGCTGGTGAGGCTG 874
|||||
Db 1 GAGGTGCAGCTGGTGAGGCTG 22
|||||
RESULT 679
AAD42429
ID AAD42429 standard; DNA; 23 BP.
XX
AC AAD42429;
XX
DT 24-FEB-2003 (first entry)
XX
DE Human HDGNR10 antibody VH domain amplifying PCR primer, Hu VH3-5'.
XX
KW Human; G-protein chemokine receptor; CCR5; HDGNR10 protein; cancer;
KW inflammation; viral infection; autoimmune disease; neurodegeneration;
KW rheumatoid arthritis; Pneumocystis carinii infection; Kaposi's sarcoma;
KW hyperproliferative disease; heavy chain variable domain; PCR; primer; VH;
KW ss.
XX
OS Homo sapiens.
XX
PN US2002061834-A1.
XX
PD 23-MAY-2002.
XX
PF 09-FEB-2001; 2001US-00779880.
XX
PR 09-FEB-2000; 2000US-0181258P.
PR 09-MAR-2000; 2000US-0187999P.
PR 22-SEP-2000; 2000US-0234336P.
XX
PA (ROSE/) ROSEN C A.
PA (ROSC/) ROSCHKE V.
PA (LIYY/) LI Y.
PA (RUBE/) RUBEN S M.
XX
PI Rosen CA, Roschke V, Li Y, Ruben SM;
XX
DR WPI; 2002-499674/53.
XX
XX New nucleic acid encoding antibodies to the human CCR5 receptor HDGNR10,
PT useful for treatment, prevention and diagnosis of e.g. cancer, also
PT related antibodies.
XX
PS Example 55; Page 171; 186pp; English.
XX
CC The invention relates to human G-protein chemokine receptor (CCR5), CCR5
CC HDGNR10 proteins and nucleic acid molecules encoding such proteins. CCR5
CC antibodies are used for the treatment or prevention of inflammation,

CC defective or aberrant chemotaxis of immune cells or T cell antigen-
 CC presenting cell interaction, viral infections (specifically human immune
 CC deficiency (including its early stages), cytomegalovirus (CMV),
 CC autoimmune disease, rheumatoid arthritis, neurodegeneration, Pneumocystis
 CC carinii infection, Kaposi's sarcoma or any condition associated with
 CC aberrant expression of CCR5 or their ligands. They are also used for the
 CC detection, diagnosis, prognosis and monitoring of cancers or other
 CC hyperproliferative diseases. The present sequence is a PCR primer used to
 CC amplify human HDGMR10 antibody heavy chain variable (VH) domain
 XX
 SQ Sequence 23 BP; 3 A; 3 C; 12 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 17.2; DB 1; Length 23;
 Best Local Similarity 86.4%; Pred. No. 1.1e+03;
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 853 GAGGAGGAGCTGGTGGAGGCTG 874
 DB 1 GAGGTGCAGCTGGTGGAGTCTG 22

RESULT 680
 AAD46081
 ID AAD46081 standard; DNA; 23 BP.

XX AAD46081;

XX 27-DEC-2002 (first entry)

XX Human K+betaM2 antibody VH domain amplifying 5' PCR primer, VH3.

XX Human; potassium channel beta-subunit; K+betaM2 protein; neural disorder;
 KW reproductive disorder; metabolic disorder; premature puberty; nephritis;
 KW endocrine disorder; memory disorder; neuroendocrine condition; asthma;
 KW spermatogenesis; renal disease; learning deficiency; Alzheimer's disease;
 KW neurodegenerative disease; proliferative disorder; autoimmune disease;
 KW carcinoma tumour; blood coagulation disease; blood platelet disease;
 KW rheumatoid arthritis; allergy; hyperproliferative disease; gene therapy;
 KW graft-versus-host disease; organ rejection; antistress; thrombolytic;
 KW antiinflammatory; neuroprotective; anti-Parkinsonian; immunosuppressive;
 KW nephrotropic; cytostatic; nontropic; hypotensive; vulnary; PCR; primer;
 ss.

XX Homo sapiens.

XX WO200266601-A2.

XX 29-AUG-2002.

XX 24-JAN-2002; 2002WO-US002332.

XX 24-JAN-2001; 2001US-0263872P.

XX 14-FEB-2001; 2001US-0269794P.

XX (BRIM) BRISTOL-MYERS SQUIBB CO.

XX Feder J, Lee L, Chen J, Jackson D, Ramanathan C, Siemers N;

XX Chang H, Carroll P;

XX WPI; 2002-691617/74.

XX New potassium channel beta-subunit, K+betaM2, proteins and nucleic acids,
 PT useful for diagnosing, treating and/or preventing e.g. reproductive,
 PT neural, metabolic, endocrine, memory, neurodegenerative disorders or
 PT diseases.

XX Example 19; Page 358; 366pp; English.

XX The present invention relates to human potassium channel beta-subunit
 CC (K+betaM2) proteins and polynucleotides encoding such proteins. The
 CC K+betaM2 sequences are useful for diagnosing, treating and/or preventing
 CC reproductive disorders, neural disorders, disorders related to aberrant
 CC potassium regulation or hyper potassium channel activity, metabolic

CC disorders (e.g. premature puberty), endocrine disorders (e.g. aberrant
 CC growth hormone synthesis and/or secretion), memory disorder, disorders of
 CC the testis (e.g. spermatogenesis), neuroendocrine condition related to
 CC aberrant thyroid hormone release, renal disease or disorders (e.g.
 CC nephritis), disorders related to aberrant higher brain function (e.g.
 CC learning deficiencies), neurodegenerative diseases (e.g. Alzheimer's
 CC disease), proliferative disorders (e.g. carcinoma tumour) and disorders
 CC involving excessive smooth muscle tone or excitability (e.g. asthma).
 CC They may be used to modulate haemostatic or thrombolytic activity, to
 CC treat or prevent blood coagulation diseases or disorders, blood platelet
 CC diseases, wounds, autoimmune diseases, disorders or conditions (e.g.
 CC rheumatoid arthritis), allergic reactions (e.g. asthma), organ rejection
 CC or graft-versus-host disease, and hyperproliferative diseases. K+betaM2
 CC sequences are also used in gene therapy. The present DNA sequence is a
 CC PCR primer which is used for amplifying the VH domain of antibodies
 CC directed against human K+betaM2 DNA. This sequence is used in the
 CC exemplification of the invention

XX Sequence 23 BP; 3 A; 3 C; 12 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 17.2; DB 1; Length 23;

Best Local Similarity 86.4%; Pred. No. 1.1e+03;

Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 853 GAGGAGGAGCTGGTGGAGGCTG 874

DB 1 GAGGTGCAGCTGGTGGAGTCTG 22

RESULT 681

AAL49669

XX AAL49669 standard; DNA; 23 BP.

XX AAL49669;

XX 27-NOV-2002 (first entry)

XX Anti-HGPR4 antibody VH domain PCR primer SEQ ID NO: 40.

XX Human; glycine receptor alpha subunit 4; HGPR4; HGPR4sv; splice variant;
 KW cardiovascular disorder; reproductive disorder; neural disorder;
 KW cardiac; antiarrhythmic; antianginal; antiarrhythmic; antiulcer;
 KW nontropic; neuroprotective; antibacterial; virucide; protozoicide;
 KW nervous system disorder; gastrointestinal disorder; gene therapy;
 KW infection; PCR; primer; ss.

XX Unidentified.

XX WO200266606-A2.

XX 29-AUG-2002.

XX 13-FEB-2002; 2002WO-US004329.

XX 16-FEB-2001; 2001US-0269535P.

XX (BRIM) BRISTOL-MYERS SQUIBB CO.

XX Feder J, Lee L, Chen J, Jackson DG, Ramanathan C, Siemers N;

XX Chang H;

XX WPI; 2002-674925/72.

XX New isolated nucleic acid molecules encoding human glycine receptor A4
 PT (HGPR4) polypeptides, useful for preventing, treating and ameliorating
 PT conditions, e.g. neural or gastrointestinal disorders.

XX Example 24; Page 341; 349pp; English.

XX The present invention provides the protein and coding sequences of the
 CC human glycine receptor alpha 4 (HGPR4) and its splice variant HGPR4sv.
 CC The sequences can be used in the treatment of neural disorders,
 CC gastrointestinal disorders, disorders related to hyper glycine receptor

```
CC activity, cardiovascular disorders, reproductive disorders, or bacterial,  
CC viral and parasitic infections. The present sequence is a PCR primer used  
XX in the exemplification of the invention  
SQ Sequence 23 BP; 3 A; 3 C; 12 G; 5 T; 0 U; 0 Other;  
  
Query Match 0.5%; Score 17.2; DB 1; Length 23;  
Best Local Similarity 86.4%; Pred. No. 1.1e+03;  
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
  
QY 853 GAGGAGGAGCTGTTGGAGGCTG 874  
||||| ||||||| |||||  
Db 1 GAGTGCAGCTGTTGGAGTCTG 22  
  
RESULT 682  
AAK98428  
ID AAK98428 standard; DNA; 23 BP.  
XX  
AC AAK98428;  
XX  
DT 08-AUG-2002 (first entry)  
XX  
DE Human V gene library PCR primer HuVHB3.  
XX  
KW Human; PAPalpa; fibroblast activating protein alpha; antibody; Ab;  
KW gene therapy; cancer; wound healing; inflammation; cytostatic; PCR;  
KW primer; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200168708-A2.  
XX  
PD 20-SEP-2001.  
XX  
PF 16-MAR-2001; 2001WO-EP004716.  
XX  
PR 17-MAR-2000; 2000DE-01013286.  
PR 11-SEP-2000; 2000GB-00022216.  
XX  
PA (BOEH ) BOEHRINGER INGELHEIM PHARMA KG.  
XX  
PI Park J, Garin-Chesa P, Pfizenmaier K, Moosmayer D, Mersmann M;  
PI Schmidt A;  
XX  
XX WPI; 2002-041180/05.  
XX  
XX 16-MAR-2001; 2001WO-EP004716.  
XX  
XX 17-MAR-2000; 2000DE-01013286.  
PR 11-SEP-2000; 2000GB-00022216.  
XX  
XX (BOEH ) BOEHRINGER INGELHEIM PHARMA KG.  
XX  
PI Park J, Garin-Chesa P, Pfizenmaier K, Moosmayer D, Mersmann M;  
PI Schmidt A;  
XX  
XX WPI; 2002-041180/05.  
XX  
XX New human humanized antibody that specifically binds to fibroblasts  
PT activating protein alpha, useful for treating cancer or tumor, and for  
PT imaging tumors associated with activated stromal fibroblasts, e.g. lung  
PT or breast cancer.  
XX  
PS Disclosure; Fig 4C; 109pp; English.  
XX  
XX The present invention relates to a human or humanised antibody (Ab) which  
CC specifically binds to fibroblast activating protein alpha (FAPalpa). The  
CC antibodies are useful for preparing a composition for the treatment of  
CC cancer, and for imaging tumours associated with activated stromal  
CC fibroblasts, such as colorectal cancer, non-small-cell lung cancer,  
CC breast cancer, head and neck cancer, ovarian cancer, lung cancer, bladder  
CC cancer, pancreatic cancer and metastatic brain cancer, and diseases  
CC associated with the same, such as inflammation and wound healing. The  
CC present sequence is a PCR primer described in the exemplification of the  
CC invention  
XX  
SQ Sequence 23 BP; 3 A; 3 C; 12 G; 5 T; 0 U; 0 Other;  
  
Query Match 0.5%; Score 17.2; DB 1; Length 23;  
Best Local Similarity 86.4%; Pred. No. 1.1e+03;  
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
  
QY 853 GAGGAGGAGCTGTTGGAGGCTG 874  
||||| ||||||| |||||  
SQ Sequence 23 BP; 3 A; 3 C; 12 G; 5 T; 0 U; 0 Other;  
  
RESULT 684  
ADJ33353  
ID ADJ33353 standard; DNA; 23 BP.  
XX  
AC ADJ33353;  
XX  
DT 15-APR-2004 (first entry)  
XX  
DE Human VH domain PCR primer, SEQ ID 60.
```

```
Db 1 GAGTGCAGCTGTTGGAGTCTG 22  
  
RESULT 683  
AAK98469  
ID AAK98469 standard; DNA; 23 BP.  
XX  
AC AAK98469;  
XX  
DT 08-AUG-2002 (first entry)  
XX  
DE Human V gene library PCR primer HUVHB3.  
XX  
KW Human; PAPalpa; fibroblast activating protein alpha; antibody; Ab;  
KW gene therapy; cancer; wound healing; inflammation; cytostatic; PCR;  
KW primer; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200168708-A2.  
XX  
PD 20-SEP-2001.  
XX  
PF 16-MAR-2001; 2001WO-EP004716.  
XX  
PR 17-MAR-2000; 2000DE-01013286.  
PR 11-SEP-2000; 2000GB-00022216.  
XX  
PA (BOEH ) BOEHRINGER INGELHEIM PHARMA KG.  
XX  
PI Park J, Garin-Chesa P, Pfizenmaier K, Moosmayer D, Mersmann M;  
PI Schmidt A;  
XX  
XX WPI; 2002-041180/05.  
XX  
XX New human humanized antibody that specifically binds to fibroblasts  
PT activating protein alpha, useful for treating cancer or tumor, and for  
PT imaging tumors associated with activated stromal fibroblasts, e.g. lung  
PT or breast cancer.  
XX  
PS Disclosure; Fig 5; 109pp; English.  
XX  
XX The present invention relates to a human or humanised antibody (Ab) which  
CC specifically binds to fibroblast activating protein alpha (FAPalpa). The  
CC antibodies are useful for preparing a composition for the treatment of  
CC cancer, and for imaging tumours associated with activated stromal  
CC fibroblasts, such as colorectal cancer, non-small-cell lung cancer,  
CC breast cancer, head and neck cancer, ovarian cancer, lung cancer, bladder  
CC cancer, pancreatic cancer and metastatic brain cancer, and diseases  
CC associated with the same, such as inflammation and wound healing. The  
CC present sequence is a PCR primer described in the exemplification of the  
CC invention  
XX  
SQ Sequence 23 BP; 3 A; 3 C; 12 G; 5 T; 0 U; 0 Other;  
  
Query Match 0.5%; Score 17.2; DB 1; Length 23;  
Best Local Similarity 86.4%; Pred. No. 1.1e+03;  
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
  
QY 853 GAGGAGGAGCTGTTGGAGGCTG 874  
||||| ||||||| |||||  
Db 1 GAGTGCAGCTGTTGGAGTCTG 22  
  
RESULT 684  
ADJ33353  
ID ADJ33353 standard; DNA; 23 BP.  
XX  
AC ADJ33353;  
XX  
DT 15-APR-2004 (first entry)  
XX  
DE Human VH domain PCR primer, SEQ ID 60.
```

XX Potassium channel beta subunit; K+betaM4; K+betaM5;
 KW hyper potassium channel activity; hepatic disorder; neural disorder;
 KW gastrointestinal disorder; reproductive disorder; immune disorder;
 KW cardiovascular disorder; renal disorder; immune disorder; apoptosis;
 KW infectious disease; inflammatory disorder; cancer; Hepatotropic;
 KW Cerebroprotective; Neuroprotective; Gastrointestinal; Gynecological;
 KW Immunomodulator; Cardiovascular; Immunostimulant; Immunosuppressive;
 KW Nephrotropic; Antiinflammatory; Cytostatic; Gene Therapy; human; VH; PCR;
 KW primer; ss.
 XX
 XX Homo sapiens.
 XX
 XX WO20026604-A2.
 XX
 XX PD 06-SEP-2002.
 XX
 XX PF 28-FEB-2002; 2002WO-US006003.
 XX
 XX PR 28-FEB-2001; 2001US-0272190P.
 XX
 XX PR 07-MAR-2001; 2001US-0274258P.
 XX
 XX PA (BRIM) BRISTOL-MYERS SQUIBB CO.
 XX
 XX PI Feder J, Lee L, Chen J, Jackson DG, Ramanathan C, Siemers N;
 PI Chang H, Carroll P;
 XX
 XX WPI; 2002-706983/76.
 XX
 XX New isolated K-betaM4 or K-betaM5 nucleic acid molecule, useful for
 PT preventing, treating or ameliorating a medical condition related to hyper
 PT potassium channel activity such as cancer, immune, neural and
 PT cardiovascular disorders.
 XX
 XX Example 33; SEQ ID NO 60; 381pp; English.
 XX
 XX The present invention relates to human potassium channel beta subunits,
 CC K-betaM4 and K-betaM5, cDNA sequences (I, ADJ33294 and ADJ33316), and
 CC encoded proteins sequences (II, ADJ33295 and ADJ33317). The invention is
 CC useful for preventing, treating or ameliorating a medical condition by
 CC administering (i) or (ii) to a mammalian subject, where the medical
 CC condition is a disorder related to hyper potassium channel activity
 CC selected from a hepatic, neural, gastrointestinal, reproductive, immune,
 CC cardiovascular or renal disorder, or an immune disorder related to
 CC aberrant apoptosis or innate immunity, an infectious disease, an
 CC inflammatory disorder and cancer. The present sequence is a primer used
 CC in an example from the invention for amplifying VH domains, for
 CC identifying and cloning VH domains of antibodies directed against the
 CC K-betaM4 or K-betaM5 proteins.
 XX
 XX Sequence 23 BP; 3 A; 3 C; 12 G; 5 T; 0 U; 0 Other;
 XX
 XX Query Match 0.5%; Score 17.2; DB 1; Length 23;
 XX Best Local Similarity 86.4%; Pred. No. 1.1e+03;
 XX Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 XX
 XX QY 853 GAGGAGGAGCTGGTGGAGGCTG 874
 XX
 XX Db 1 GAGGTGACGCTGGTGGAGTCTG 22
 XX
 XX RESULT 685
 XX ABT42680
 XX ID ABT42680 standard; DNA; 23 BP.
 XX
 XX AC ABT42680;
 XX
 XX DT 17-SEP-2003 (first entry)
 XX
 XX XX Human GPCR related VH antibody cloning primer SEQ ID 142.
 XX
 XX Neuroprotective; antiinflammatory; immunosuppressive; cytostatic; neural;
 KW nephrotropic; cardiac; human G-protein receptor; HGRBM28; HGRBM29;

KW HGRBM29v1; HGRBM29v2; HGRBM28; HGRBM29; immune disorder; pulmonary;
 KW inflammatory; haematopoietic; gastrointestinal; small intestine; cancer;
 KW proliferative; aberrant p27 regulation; FEN1; cell cycle; DNA repair;
 KW apoptosis; spleen; lymph node; reproductive; oesophageal; metabolic;
 KW endocrine; colon; cervix; lung; squamous cell; renal; cardiovascular;
 KW placental; testis; heart; gene therapy; PCR; primer; ss.
 XX
 XX Homo sapiens.
 XX
 XX WO200283856-A2.
 XX
 XX PD 24-OCT-2002.
 XX
 XX PF 11-APR-2002; 2002WO-US011525.
 XX
 XX PR 11-APR-2001; 2001US-0283145P.
 XX
 XX PR 11-APR-2001; 2001US-0283161P.
 XX
 XX PR 03-MAY-2001; 2001US-0288468P.
 XX
 XX PR 25-JUN-2001; 2001US-0300619P.
 XX
 XX PA (BRIM) BRISTOL-MYERS SQUIBB CO.
 XX
 XX PI Bol D, Feder J, Mintier G, Ramanathan C, Hawken DR;
 XX
 XX WPI; 2003-075538/07.
 XX
 XX New G-protein coupled receptors, HGRBM28 and HGRBM29, and their
 PT variants, useful for treating, preventing or ameliorating e.g.
 PT hematopoietic, neural, pulmonary, gastrointestinal, inflammatory or
 PT proliferative disorders.
 XX
 XX Example 39; Page 427; 501pp; English.
 XX
 XX This invention relates to an isolated nucleic acid molecule comprising a
 CC polynucleotide encoding a human G-protein receptor, including HGRBM28,
 CC HGRBM29, HGRBM29v1 or HGRBM29v2 polypeptides. The HGRBM28 or
 CC HGRBM29 polypeptides and nucleic acids are useful for treating,
 CC preventing or ameliorating a medical condition, e.g. an immune disorder,
 CC an inflammatory disorder, an inflammatory disorder in which G-protein
 CC coupled receptors are either directly or indirectly associated with the
 CC disorder, a haematopoietic disorder, a neural disorder, a pulmonary
 CC disorder, a gastrointestinal disorder, a disorder affecting the small
 CC intestine, a proliferative disorder, a cancer, a disorder related to
 CC aberrant p27 regulation, a disorder related to aberrant FEN1 regulation,
 CC a disorder related to aberrant cell cycle regulation, a disorder related
 CC to aberrant DNA repair regulation, a disorder related to aberrant
 CC apoptosis regulation, a disorder of the spleen, a disorder of the lymph
 CC nodes, a male or female reproductive disorder, a proliferative disorder,
 CC metabolic disorder, an endocrine disorder, a squamous cell or tissues, a renal
 CC disorder, a cardiovascular disorder, a placental disorder, and a disorder
 CC of the testes, heart or lymph nodes. The isolated polynucleotides of the
 CC invention may be used to treat disorders by gene therapy. This
 CC polynucleotide sequence represents a Human G-protein coupled receptor
 CC HGRBM28 PCR primer relating to the invention
 XX
 XX Sequence 23 BP; 3 A; 3 C; 12 G; 5 T; 0 U; 0 Other;
 XX
 XX Query Match 0.5%; Score 17.2; DB 1; Length 23;
 XX Best Local Similarity 86.4%; Pred. No. 1.1e+03;
 XX Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 XX
 XX QY 853 GAGGAGGAGCTGGTGGAGGCTG 874
 XX
 XX Db 1 GAGGTGACGCTGGTGGAGTCTG 22
 XX
 XX RESULT 686
 XX AAL59941
 XX ID AAL59941 standard; DNA; 23 BP.
 XX
 XX AC AAL59941;
 XX

DT 27-AUG-2003 (first entry)
 XX Human antibody VH domain amplifying primer, Hu VH3-5'.
 XX Human; TNF-related apoptosis-inducing ligand; Kaposi's sarcoma; cancer;
 KW hyperproliferative disorder; rheumatoid arthritis; Parkinson's disease;
 KW neurodegenerative disorder; Alzheimer's disease; Hashimoto's disease;
 KW allergic disorder; acquired immune deficiency syndrome; ocular disorder;
 KW myasthenia gravis; autoimmune disorder; Huntington's disease; vaccine;
 KW septic shock; multiple sclerosis; inflammatory disorder; liver injury;
 KW infectious diseases; myelodysplastic syndrome; cardiovascular disorder;
 KW graft-versus-host disease; toxin-induced liver disease; cachexia; AIDS;
 KW cerebrovascular disorder; thrombotic microangiopathy; aplastic anaemia;
 KW ischaemic injury; anorexia; diabetes; ulcerative colitis; psoriasis;
 KW asthma; AIDS; therapy; TRAIL receptor; tumour necrosis factor; TRAIL-R;
 KW PCR; primer; ss.
 XX Homo sapiens.
 XX WO2003042367-A2.
 XX 22-MAY-2003.
 XX 13-NOV-2002; 2002WO-US036431.
 XX 14-NOV-2001; 2001US-0331309P.
 PR 07-MAY-2002; 2002US-0377973P.
 PR 15-AUG-2002; 2002US-0403376P.
 XX (HUMA-) HUMAN GENOME SCI INC.
 XX Salcedo T, Roschke V, Ruben SM, Rosen CA;
 XX WPI; 2003-449572/42.
 XX Novel antibody against TNF-related apoptosis inducing ligand, useful for
 PT preventing, treating and ameliorating cancers and other
 PT hyperproliferative disorders, binds immunospecifically to TRAIL receptor
 PT 4 polypeptide.
 XX Example 5; Page 325; 405pp; English.
 XX The invention relates to antibodies that immunospecifically bind to
 CC tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)
 CC receptors (TRAIL-R). Antibodies of the invention are useful for treating,
 CC preventing or ameliorating cancer (e.g. cancers of pancreas, uterine,
 CC breast, colon, lung and gastrointestinal and Kaposi's sarcoma) and other
 CC hyperproliferative disorders, neurodegenerative disorders (e.g.
 CC Parkinson's disease, Alzheimer's disease and Huntington's disease),
 CC autoimmune disorders (e.g. lupus, rheumatoid arthritis, multiple
 CC sclerosis, myasthenia gravis, Hashimoto's disease and immunodeficiency
 CC syndrome), inflammatory disorders (e.g. asthma, allergic disorders and
 CC rheumatoid arthritis), infectious diseases (e.g. acquired immune
 CC deficiency syndrome; AIDS, herpes viral infections and other viral
 CC infections), myelodysplastic syndromes (e.g. aplastic anaemia), graft-
 CC versus-host disease, ischaemic injury, liver injury, toxin-induced liver
 CC disease, septic shock, cachexia, anorexia and proliferative disorders.
 CC Antibodies of the invention are also useful for treating cardiovascular
 CC disorders, cerebrovascular disorders, thrombotic microangiopathies,
 CC diabetes, ocular disorders associated with neovascularisation, psoriasis,
 CC and ulcerative colitis and for wound healing. The invention is also used
 CC to prepare vaccines. The present sequence is a PCR primer used to amplify
 CC human antibody VH domain. This primer is used in the exemplification of
 CC the invention
 XX Sequence 23 BP; 3 A; 3 C; 12 G; 5 T; 0 U; 0 Other;
 SQ
 Query Match 0.5%; Score 17.2; DB 1; Length 23;
 Best Local Similarity 86.4%; Pred. No. 1.1e+03;
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 853 GAGGAGGAGCTGGTGGAGCTG 874
 ||||| ||||| ||||| ||||| |||||

Db 1 GAGGTGCAGCTGGTGGAGCTG 22
 RESULT 687
 ABQ76996
 ID ABQ76996 standard; DNA; 23 BP.
 XX ABQ76996;
 AC ABQ76996;
 DT 03-APR-2003 (first entry)
 XX Human anti-VEGF2 antibody VH domain PCR primer HUVH3-5'.
 XX Human; VH domain; VL domain; vascular endothelial growth factor; VEGF-2;
 KW cytostatic; cardiac; cardiovascular; antiinflammatory; antirheumatic;
 KW antiarthritic; antidiabetic; ophthalmological; antiallergic; vulnary;
 KW immunosuppressive; dermatological; antiposioritic; proliferative disorder;
 KW cancer; cardiovascular disorder; arrhythmia; cerebrovascular disorder;
 KW cerebral anoxia; inflammatory disease; infectious disease; angiogenesis;
 KW autoimmune disease; Systemic Lupus Erythematosus; wound healing;
 KW vascular tissue repair; gene therapy; vaccine; PCR; primer; ss.
 XX Homo sapiens.
 OS
 XX WO200283850-A2.
 XX 24-OCT-2002.
 XX 12-APR-2002; 2002WO-US011405.
 XX 13-APR-2001; 2001US-0283408P.
 XX (HUMA-) HUMAN GENOME SCI INC.
 XX Rosen CA, Albert VR, Ruben SM, Wager RE;
 XX WPI; 2003-093008/08.
 XX New isolated polynucleotide encoding an antibody which inhibits vascular
 PT endothelial growth factor (VEGF)-2 polypeptide, useful for diagnosing or
 PT treating diseases associated with aberrant VEGF-2 expression or function,
 PT e.g. cancer.
 XX Example 32; Page 236; 344pp; English.
 XX This invention describes a novel isolated polynucleotide encoding a first
 CC antibody comprising an amino acid sequence selected from at least one,
 CC two or three complementarity determining (CDR) region(s) of a VH and/or
 CC VL domain of a second antibody that immunospecifically binds to a
 CC vascular endothelial growth factor (VEGF)-2 polypeptide. The products of
 CC the invention have cytostatic, cardiovascular, antirheumatic, vulnary,
 CC antiinflammatory, antiarthritic, antidiabetic, ophthalmological, and
 CC cardiac, antiallergic, immunosuppressive, dermatological and
 CC antipsoriasis activity. The polynucleotide is useful in diagnosing,
 CC treating, preventing, prognosing, ameliorating or monitoring diseases
 CC associated with aberrant VEGF-2 or VEGF-2 receptor expression or lack of
 CC VEGF-2 or VEGF-2 receptor function, such as cancer and other
 CC proliferative disorders, cardiovascular disorders (arrhythmias),
 CC cerebrovascular disorders (e.g. cerebral anoxia), inflammatory diseases,
 CC infectious diseases, autoimmune diseases (e.g. rheumatoid arthritis,
 CC Systemic Lupus Erythematosus, allergies), diabetic retinopathy or
 CC psoriasis. The polynucleotide, polypeptide and antibodies described in
 CC the invention may also be used to stimulate angiogenesis, wound healing,
 CC and promoting vascular tissue repair. The polynucleotide and polypeptide
 CC may also be used for in vitro purposes related to scientific research,
 CC synthesis of DNA and manufacture of DNA vectors and for the production of
 CC diagnostics and therapeutics e.g. gene therapy and in vaccines to treat
 CC human diseases. This sequence represents a PCR primer used in the
 CC isolation and amplification of polynucleotides described in the
 CC disclosure of the invention
 XX Sequence 23 BP; 3 A; 3 C; 12 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 17.2; DB 1; Length 23;
 Best Local Similarity 86.4%; Pred. No. 1.1e+03;
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 853 GAGGAGGAGCTGGTGAGGCTG 874
 DB 1 GAGGTGACGCTGGTGAGGCTG 22

RESULT 688
 ABX08573
 ID ABX08573 standard; DNA; 23 BP.
 AC ABX08573;
 XX
 XX
 XX
 DT 20-JAN-2003 (first entry)
 XX
 DE Human anti-TRAIL receptor antibody VH PCR primer Hu VH3-5'.
 XX PCR; ss; primer; human; TRAIL receptor; tumour necrosis factor; TNF;
 KW TNF-related apoptosis-inducing ligand; antibody; VH; cancer;
 KW heavy chain variable region; TR4; TR5; TR7; TR10; apoptosis;
 KW hyperproliferative disorder; hybridoma cell line; Kaposi's sarcoma;
 KW graft-versus-host disease; GVHD; infectious disease; AIDS;
 KW acquired immunodeficiency syndrome; neurodegenerative disorder;
 KW Alzheimer's disease; Parkinson's disease; autoimmune disease;
 KW multiple sclerosis; Behcet's disease; lupus erythematosus;
 KW inflammatory disease; rheumatoid arthritis; psoriasis; wound healing;
 KW cardiovascular disorder; angiogenesis; immune response;
 KW chemotherapeutic agent.
 XX
 XX Homo sapiens.
 OS
 XX
 PN WO200279377-A2.
 XX
 XX
 PD 10-OCT-2002.
 XX
 XX 07-NOV-2001; 2001WO-US042996.
 PF
 XX 08-NOV-2000; 2000US-0246612P.
 PR 16-NOV-2000; 2000US-0248847P.
 PR 27-NOV-2000; 2000US-0252904P.
 PR 04-JUN-2001; 2001US-0295018P.
 PR 09-OCT-2001; 2001US-0327359P.
 XX
 PA (HUMA-) HUMAN GENOME SCI INC.
 XX
 XX Salcedo T, Roschke V, Ruben SM, Rosen CA;
 PI
 XX WPI; 2003-040669/03.
 XX
 XX Novel antibody for treating, or preventing disease or disorder, comprises
 PT amino acid sequence having identity to other amino acid sequence of
 PT either variable heavy/light chain-complementarity determining regions.
 XX
 XX Example 5; Page 312; 375pp; English.
 PS
 XX The invention relates to an isolated antibody comprising a first amino
 CC acid sequence having 95 % identity to a second amino acid sequence of
 CC either variable heavy chain or light chain-complementarity determining
 CC regions (VHCDRI)/VHCDRI, VHCDR2/VHCDR2 or VHCDR3/VHCDR3 appearing as
 CC ABG71906-ABG71911 being specific for human TRAIL receptors 1-4 (TNF
 CC (tumour necrosis factor)-related apoptosis-inducing ligand receptor, also
 CC known as TR4, TR5, TR7 and TR10). Also included are an isolated cell that
 CC produces the antibody, an antibody that binds the same epitope on a TR4
 CC polypeptide as the antibodies detailed above, detecting expression of a
 CC TR4 polypeptide (or detecting, diagnosing, prognosing or monitoring
 CC cancers, and other hyperproliferative disorders) using the antibodies, a
 CC hybridoma cell line selected from the hybridoma cell lines contained in
 CC ATCC Deposit No. PTA-3149, PTA-2687, PTA-3369, PTA-2730, PTA-2729, PTA-
 CC 2728, PTA-3368, and PTA-2731 and the antibodies expressed by these
 CC hybridoma cell lines. The antibodies of the invention are useful for
 CC diagnosing or treating a disease or disorder associated with increased or

CC decreased apoptosis, e.g. cancer (such as colon, breast, uterine,
 CC pancreatic, lung, gastrointestinal, and Kaposi's sarcoma), graft-versus-
 CC host disease (GVHD), infectious disease, acquired immunodeficiency
 CC syndrome (AIDS), or neurodegenerative disorders (e.g. Alzheimer's
 CC disease, Parkinson's disease), autoimmune disorders like multiple
 CC sclerosis, Behcet's disease, lupus erythematosus, inflammatory diseases,
 CC such as rheumatoid arthritis, and psoriasis, cardiovascular disorders, in
 CC promoting angiogenesis, wound healing, and in regulating immune response.
 CC Many other diseases and disorders are listed in the specification. The
 CC antibody is administered in combination with a chemotherapeutic agent
 CC selected from irinotecan, paclitaxel (TAXOL (R)), and gemcitabine. The
 CC antibody is useful as a diagnostic tool to monitor the expression of
 CC TRAIL receptor expression on cells, to detect, purify, and target the
 CC polypeptides, and in immunoassays for qualitatively and quantitatively
 CC measuring levels of TRAIL receptor polypeptides. The present sequence is
 CC a PCR primer used to amplify a nucleic acid encoding the heavy chain
 CC variable region of an anti-TRAIL receptor antibody
 XX
 SQ Sequence 23 BP; 3 A; 3 C; 12 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 17.2; DB 1; Length 23;
 Best Local Similarity 86.4%; Pred. No. 1.1e+03;
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 853 GAGGAGGAGCTGGTGAGGCTG 874
 DB 1 GAGGTGACGCTGGTGAGGCTG 22

RESULT 689
 AAD49552
 ID AAD49552 standard; DNA; 23 BP.
 AC AAD49552;
 XX
 XX
 DT 24-MAR-2003 (first entry)
 XX
 DE Human VH gene amplifying PCR primer, Hu VH3-5'.
 XX
 XX Human; vascular endothelial growth factor; VEGF-2; inflammatory disease;
 KW proliferative disorder; tumour; breast; cancer; brain; prostate; colon;
 KW lymphangioma; infection; Kaposi's sarcoma; psoriasis; immunosuppressive;
 KW rheumatoid arthritis; diabetic retinopathy; gene therapy; antimicrobial;
 KW cytostatic; ophthalmological; autoimmune disease; VH; PCR; primer; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200283849-A2.
 XX
 XX 24-OCT-2002.
 XX
 XX 12-APR-2002; 2002WO-US011404.
 PF
 XX 13-APR-2001; 2001US-0283391P.
 PR 07-SEP-2001; 2001US-0317600P.
 PR
 XX (HUMA-) HUMAN GENOME SCI INC.
 XX
 XX Rosen CA, Albert VR, Ruben SM, Wager RE;
 PI
 XX WPI; 2003-093007/08.
 DR
 XX New vascular endothelial growth factor (VEGF)- 2 antibodies, for
 PT treating, preventing or ameliorating a disease or disorder, such as
 PT inflammatory diseases, proliferative disorders, autoimmune disorders or
 PT diabetic retinopathy.
 XX
 PS Example 32; Page 241; 399pp; English.
 XX The invention relates to vascular endothelial growth factor (VEGF)-2
 CC antibodies. VEGF-2 antibodies are useful for treating, preventing or
 CC ameliorating a disease or disorder, such as inflammatory diseases or
 CC disorders, proliferative disorders, tumours, tumour metastasis, breast

CC cancer, brain cancer, prostate cancer, colon cancer, lymphangioma, an
 CC infectious disease, Kaposi's sarcoma, an autoimmune disease, rheumatoid
 CC arthritis, psoriasis, diabetic retinopathy, a disease or disorder
 CC associated with aberrant VEGF-2 (receptor) expression, or a disease or
 CC disorder associated with the lack of VEGF-2 (receptor) function. The
 CC antibody is also useful for detecting, diagnosing, prognosing, or
 CC monitoring cancers and other hyperproliferative disorders. VEGF-2 is also
 CC used in gene therapy. The present sequence is a PCR primer used for
 CC amplifying human VH gene. This sequence is used in the exemplification of
 CC the invention

SQ Sequence 23 BP; 3 A; 3 C; 12 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 17.2; DB 1; Length 23;

Best Local Similarity 86.4%; Pred. No. 1.1e+03;

Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 853 GAGGAGGAGCTGGTGGAGGCTG 874

Db 1 GAGGTGCAGCTGGTGGAGTCTG 22

RESULT 690

ABX99237

ID ABX99237 standard; DNA; 23 BP.

AC ABX99237;

XX 21-MAY-2003 (first entry)

XX Anti-CAN-12 antibody VH region PCR primer Hu VH3.

XX Human; ss; PCR; CAN-12; calpain; cysteine protease; cytostatic;

XX protein co-ordinate data; antiinflammatory; neuroprotective; primer;

XX immunosuppressive; inotropic; vulnary; analgesic; gene therapy;

XX vaccine; neurodegenerative condition; musculo-degenerative condition;

XX cancer; multiple sclerosis; a blood disorder; autoimmune disorder;

XX oesophagitis; oesophageal motility disorder;

XX chromosome 2p16-p21. antibody; heavy chain variable region;

XX light chain variable region.

XX Homo sapiens.

XX WO200288303-A2.

XX 07-NOV-2002.

XX 02-APR-2002; 2002WO-US010419.

XX 03-APR-2001; 2001US-0281253P.

XX 04-MAY-2001; 2001US-0288768P.

XX 06-JUN-2001; 2001US-0296180P.

XX 25-JUN-2001; 2001US-0300620P.

XX (BRIM) BRISTOL-MYERS SQUIBB CO.

XX Chen J, Duclos F, Feder JN, Nelson TC, Seiler S, Vaz RJ;

XX WPI; 2003-156689/15.

XX New isolated nucleic acid molecule for diagnosing, treating or preventing

XX disorders, e.g. neuro- and musculo-degenerative conditions or cancer,

XX related to the CAN-12 or CAN-12v2 polypeptides.

XX Example 35; Page 454; 737pp; English.

XX The invention relates to an isolated nucleic acid molecule comprising a

XX polynucleotide having a sequence that is at least 95% identical to the

XX human cDNAs for CAN-12 or its variants (CAN-12v1 and CAN12v2), including

XX various functional fragments defined in the specification. CAN-12 is a

XX calpain family cysteine protease, the gene for which is located on

XX chromosome 2p16-p21. Also included are the encoded CAN-12 proteins

XX (including fragments), CAN-12 recombinant vectors, host cells, anti-CAN-

CC 12 antibodies, a computer for producing a 3-dimensional representation of
 CC a molecule or a molecule complex which comprises the structural
 CC coordinates of CAN-12 and CAN-12v2 models given in the specifications, a
 CC method for identifying a mutant with altered biological properties,
 CC function or activity of CAN-12 and CAN-12v2 and a method for designing or
 CC selecting compounds as potential modulators of CAN-12 and CAN-12v2. The
 CC nucleic acid molecule and the polypeptide are useful in diagnosing,
 CC treating and/or preventing various diseases and disorders related to the
 CC CAN-12 or CAN-12v2 polypeptides, particularly neuro- and musculo-
 CC degenerative conditions, such as cancer, multiple sclerosis, blood
 CC disorders, autoimmune disorders, oesophagitis or other oesophageal
 CC motility disorders. Many other diseases and disorders are listed in the
 CC specification. The methods may be used in identifying agonists and
 CC antagonists of the above polypeptide and polynucleotide. The present
 CC sequence is a PCR primer used to clone DNAs encoding the VH and VL (heavy
 CC and light chain variable regions) molecules of anti-CAN-12 antibodies
 CC

SQ Sequence 23 BP; 3 A; 3 C; 12 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 17.2; DB 1; Length 23;

Best Local Similarity 86.4%; Pred. No. 1.1e+03;

Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 853 GAGGAGGAGCTGGTGGAGGCTG 874

Db 1 GAGGTGCAGCTGGTGGAGTCTG 22

RESULT 691

ACC48653

ID ACC48653 standard; DNA; 23 BP.

AC ACC48653;

XX 11-AUG-2003 (first entry)

XX Human antibody heavy chain variable region PCR primer Hu VH3-5'.

XX Human; potassium channel; K-betaM8; cardiovascular; vasotropic; cardiant;

XX antiangular; neuroprotective; osteopathic; cytostatic; immunosuppressive;

XX antibacterial; antipsoriatic; antiinflammatory; gynaecological;

XX immunostimulant; antirheumatic; antiarthritic; antianaemic; haemostatic;

XX dermatological; antiarteriosclerotic; virucide; vulnary; antiasthmatic;

XX gene therapy; antibody; PCR; primer; ss.

XX Homo sapiens.

XX WO2003020910-A2.

XX 13-MAR-2003.

XX 04-SEP-2002; 2002WO-US028180.

XX 04-SEP-2001; 2001US-0317087P.

XX 16-OCT-2001; 2001US-0329666P.

XX (BRIM) BRISTOL-MYERS SQUIBB CO.

XX Feder JN, Lee LM, Chang H;

XX WPI; 2003-290187/28.

XX New human potassium channel beta subunit (K-betaM8) polypeptide or

XX polynucleotide, useful for preventing, treating or ameliorating e.g.

XX breast or colon cancer, arthritis, asthma, multiple sclerosis,

XX osteoarthritis or ischemia.

XX Example 32; Page 284; 308pp; English.

XX The present sequence is PCR primer Hu VH3-5', which is designed to

XX amplify human antibody heavy chain variable regions (VH). It is one of a

XX set of primers (see ACC48651-86) used in the identification and cloning

XX of VH and VL domains of antibodies directed against the novel human

potassium channel beta subunit, K-betaM8 (see ABR41902). The VH and VL domains can be used to generate expression vectors. Antibodies directed to K-betaM8 are useful for affinity purification of the polypeptide, in diagnostic assays and imaging, in immunophenotyping, and in therapeutic applications, including the use of nucleic acids encoding the antibodies in antibody-based gene therapy. Disorders that may be treated include a male reproductive disorder, a testicular disorder, testicular cancer, a neural disorder, a disorder related to aberrant calcium, potassium or potassium channel regulation, a pulmonary disorder, an immune system disorder, a female reproductive disorder, breast cancer, colon cancer, a disorder associated with mis-regulation of NFkB, an inflammatory disorder, an innate immunity disorder, a disorder associated with a failure to initiate and/or sustain an adequate inflammatory response, rheumatoid arthritis, asthma, multiple sclerosis, osteoarthritis, a T-cell mediated autoimmune disease, or psoriasis

Sequence 23 BP: 3 A; 3 C; 12 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 17.2; DB 1; Length 23;
Best Local Similarity 86.4%; Pred. No. 1.1e+03;
Matches 19: Conservative 0; Mismatches 3; Indels

QY 853 GAGGAGGAGCTGGTGGAGGCTG 874
pb 1 GAGGTGCAGCTGGTGGAGTCTG 22

RESULT 692

AAD54813
 ID AAD54813 standard: DNA: 23 BP.

AC AAD54813:

DT 26-JUN-2003 (first entry)

Human TR4 antibody VH domain amplifying PCR primer, Hu VH3

TRAIL receptor; TR4; cancer; Kaposi's sarcoma; cerebellar degeneration;
hyperplastic disorder; neurodegenerative disorder; immune disorder;
Alzheimer's disease; Parkinson's disease; amyotrophic lateral sclerosis;
retinitis pigmentosa; Huntington's disease; Hashimoto's thyroiditis;
rheumatoid arthritis; multiple sclerosis; Sjogren's syndrome; asthma;
biliary cirrhosis; Behcet's disease; Crohn's disease; allergic disorder;
glomerulonephritis; immune deficiency syndrome; myaschemia gravis;
polymyositis; inflammatory disorder; rheumatoid arthritis; septic shock;
infectious disease; acquired immunodeficiency syndrome; viral infection;
AIDS; proliferative disorder; myelodysplastic syndrome; aplastic anaemia;
ischaemic injury; myocardial infarction; reperfusion injury; cachexia;
anorexia; stroke; cardiovascular disorder; peripheral artery disease;
limb ischaemia; arrhythmia; congestive heart failure; neovascularisation;
ocular disorder; wound healing; angiogenesis; transplantation; primer;
PCR; human; ss.

OS Homo sapiens.

XX PN W0200297033-A2.

05-DEC-2002

XX
PF 07-MAY-2002: 2002WO-US014268-XX
PP 25-MAY-2001. 2001UIS-0293473P.

PR 04-JUN-2001; 2001US-0294981F.
PR 03-AUG-2001; 2001US-0309176P

21-SEP-2001; 2001US-0323807P.
00 OCT 2001 2001US 03237354P
00 OCT 2001 2001US 03237354P

PR 07-NOV-2001; 2001US-0331044P.
14 NOV 2001 023733Z
14 NOV 2001 023733Z

PR 20-DEC-2001; 2001US-0341237P.

1
 2
 3
 4
 5
 6
 7
 8
 9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
 100
 101
 102
 103
 104
 105
 106
 107
 108
 109
 110
 111
 112
 113
 114
 115
 116
 117
 118
 119
 120
 121
 122
 123
 124
 125
 126
 127
 128
 129
 130
 131
 132
 133
 134
 135
 136
 137
 138
 139
 140
 141
 142
 143
 144
 145
 146
 147
 148
 149
 150
 151
 152
 153
 154
 155
 156
 157
 158
 159
 160
 161
 162
 163
 164
 165
 166
 167
 168
 169
 170
 171
 172
 173
 174
 175
 176
 177
 178
 179
 180
 181
 182
 183
 184
 185
 186
 187
 188
 189
 190
 191
 192
 193
 194
 195
 196
 197
 198
 199
 200
 201
 202
 203
 204
 205
 206
 207
 208
 209
 210
 211
 212
 213
 214
 215
 216
 217
 218
 219
 220
 221
 222
 223
 224
 225
 226
 227
 228
 229
 230
 231
 232
 233
 234
 235
 236
 237
 238
 239
 240
 241
 242
 243
 244
 245
 246
 247
 248
 249
 250
 251
 252
 253
 254
 255
 256
 257
 258
 259
 260
 261
 262
 263
 264
 265
 266
 267
 268
 269
 270
 271
 272
 273
 274
 275
 276
 277
 278
 279
 280
 281
 282
 283
 284
 285
 286
 287
 288
 289
 290
 291
 292
 293
 294
 295
 296
 297
 298
 299
 300
 301
 302
 303
 304
 305
 306
 307
 308
 309
 310
 311
 312
 313
 314
 315
 316
 317
 318
 319
 320
 321
 322
 323
 324
 325
 326
 327
 328
 329
 330
 331
 332
 333
 334
 335
 336
 337
 338
 339
 340
 341
 342
 343
 344
 345
 346
 347
 348
 349
 350
 351
 352
 353
 354
 355
 356
 357
 358
 359
 360
 361
 362
 363
 364
 365
 366
 367
 368
 369
 370
 371
 372
 373
 374
 375
 376
 377
 378
 379
 380
 381
 382
 383
 384
 385
 386
 387
 388
 389
 390
 391
 392
 393
 394
 395
 396
 397
 398
 399
 400
 401
 402
 403
 404
 405
 406
 407
 408
 409
 410
 411
 412
 413
 414
 415
 416
 417
 418
 419
 420
 421
 422
 423
 424
 425
 426
 427
 428
 429
 430
 431
 432
 433
 434
 435
 436
 437
 438
 439
 440
 441
 442
 443
 444
 445
 446
 447
 448
 449
 450
 451
 452
 453
 454
 455
 456
 457
 458
 459
 460
 461
 462
 463
 464
 465
 466
 467
 468
 469
 470
 471
 472
 473
 474
 475
 476
 477
 478
 479
 480
 481
 482
 483
 484
 485
 486
 487
 488
 489
 490
 491
 492
 493
 494
 495
 496
 497
 498
 499
 500
 501
 502
 503
 504
 505
 506
 507
 508
 509
 510
 511
 512
 513
 514
 515
 516
 517
 518
 519
 520
 521
 522
 523
 524
 525

XX

PI Salcedo T, Ruben SM, Dobson CL, Vaughan TJ;
XX WPI; 2003-140454/13.
DR

Novel antibody useful for treating cancers and other hyperproliferative disorders, immunospecifically binds to TRAIL receptor and comprises variable heavy or light chain complementarity determining regions.

PS Example 5; Page 224; 301pp; English.

The present invention relates to novel antibodies that immunospecifically bind to TRAIL receptor (TR4). Sequences of the invention are useful for treating, preventing or ameliorating cancer (e.g. colon, breast, uterine, pancreatic, lung, gastrointestinal or central nervous system cancer e.g. medulloblastoma, neuroblastoma, glioblastoma and Kaposi's sarcoma) in human. They are useful for detecting expression of TR4 polypeptide and detecting, diagnosing, prognosing or monitoring cancers and other hyperproliferative disorders. Antibodies of the invention are useful for treating, preventing or ameliorating neurodegenerative disorders (e.g. Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, retinitis pigmentosa, cerebellar degeneration and Huntington's disease), immune disorders (e.g. lupus, rheumatoid arthritis, multiple sclerosis, Sjogren's syndrome, biliary cirrhosis, Bence's disease, Crohn's disease, polymyositis, immune-related glomerulonephritis, myasthenia gravis, Hashimoto's thyroiditis and immune deficiency syndrome), inflammatory disorders (e.g. asthma, allergic disorders and rheumatoid arthritis), infectious diseases (e.g. acquired immunodeficiency syndrome (AIDS), herpes viral infections and other viral infections) and proliferative disorders. They are also useful for treating myelodysplastic syndromes (e.g. aplastic anaemia), ischaemic injury (such as that caused by stroke, myocardial infarction and reperfusion injury), septic shock, cachexia, anaemia and toxin-induced liver diseases (such as alcohol). They are also useful for treating cardiovascular disorders including peripheral artery diseases such as limb ischaemia, arrhythmia, congestive heart failure and cardiovascular tuberculoasis, diseases or disorders associated with neovascularisation and ocular disorders, for wound healing, for promoting angiogenesis and as adjuvants to enhance immune responsiveness to specific antigen e.g. viral antigen. They are also useful in the preparation or recovery from surgery, trauma, radiation therapy and transplantation. The present sequence is human TR4 antibody VH domain amplifying PCR primer. This sequence is used in the exemplification of the invention

Sequence 23 BP: 3 A; 3 C; 12 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 17.2; DB 1; Length 23;
Best Local Similarity 86.4%; Pred. No. 1.1e+03;
Matches 19; Conservative 0; Mismatches 3; Indels

QY 853 GAGGAGGAGCTGGTGGAGGCTG 874
||| | ||||| ||| |||
dh 1 GAGGTGCAGCTGGTGGAGTCTG 22

RESULT 693

ACD28137

ID ACD28137 standard; DNA; 23 BP.

AC ACD28137;

DT 25-SEP-2003 (first entry)

Human heavy chain variable region gene cDNA library PCR primer #3.

Human, antigen; platelet glycoprotein; GPIIb; fibrin; ss; PCR; primer;
anti-platelet binding protein; heavy chain variable region;
phage display library; platelet aggregation thrombus formation;
thromboembolism; unstable angina; saphenous vein bypass graft;
percutaneous transluminal coronary angioplasty; atrial fibrillation;
valvular heart disease; cerebrovascular disease; Trousseau's syndrome;
peripheral vascular disease; arterial thromboembolism;
acute disseminated intravascular coagulation; extracorporeal device;
prosthetic heart valve; auxiliary-subclavian venous thrombosis.

XX Homo sapiens.
 XX US2003027207-A1.
 XX 06-FEB-2003.
 XX 27-FEB-2001; 2001US-00794189.
 XX 29-FEB-2000; 2000US-0185628P.
 XX (FILP/) FILPULA D R.
 XX Filpula DR;
 XX WPI; 2003-554858/52.
 XX Novel nucleic acid molecule encoding anti-platelet binding protein which
 PT is useful for inhibiting platelet aggregation or platelet mediated
 PT thrombus formation in blood and for treating venous thromboembolism.
 XX Example 1; Page 17; 30pp; English.
 XX The invention relates to a nucleic acid molecule, or its complement, that
 CC encodes an anti-platelet binding protein, isolated from a phage display
 CC library by an in vitro selection process that comprises screening a
 CC diverse human antibody variable domain expression library against at
 CC least one human platelet antigen, and the human antibody variable domain
 CC expression library expresses single-chain proteins. Also included are an
 CC expression vector comprising the nucleic acid operably lined to a
 CC promoter, a host cell comprising the vector, a non-human mammal
 CC comprising the cells producing the anti-platelet binding protein, an anti
 CC -platelet binding protein encoded by the nucleic acid that binds to
 CC activated or non-activated human platelet glycoprotein IIb/IIIa receptor
 CC (and inhibits platelet aggregation or thrombus formation), a
 CC substantially isolated and purified human antibody (or its fragment) that
 CC binds to a platelet antigen that comprises an active antigen-binding site
 CC of the anti-platelet binding protein, and a conjugate comprising a non-
 CC antigenic polymer covalently linked to the single-chain antigen-binding
 CC polypeptide (i.e. the anti-platelet binding protein). The host cell and
 CC the anti-platelet binding protein are useful for inhibiting platelet
 CC aggregation or platelet mediated thrombus formation in blood. The anti-
 CC platelet binding protein is present in the blood in a concentration of 1
 CC pg-1 mg/ml of whole blood. The vector is useful for inhibiting platelet
 CC aggregation or platelet mediated formation of fibrin in a blood vessel,
 CC the blood vessel having an endothelial lining in need of treatment. The
 CC vector, the host cell, the anti-platelet binding protein or the conjugate
 CC are useful for preventing or treating conditions such as venous
 CC thromboembolism, unstable angina, saphenous vein bypass grafts,
 CC percutaneous transluminal coronary angioplasty, atrial fibrillation,
 CC valvular heart disease, cerebrovascular disease, peripheral vascular
 CC disease, secondary prevention of arterial thromboembolism, primary
 CC prevention of arterial thromboembolism, acute disseminated intravascular
 CC coagulation, chronic disseminated intravascular coagulation (Trousseau's
 CC syndrome). The host cell and the anti-platelet binding protein are useful
 CC for coating surfaces of medical devices and/or appliances to prevent
 CC thrombus formation, prevent occlusion of extracorporeal devices, e.g.
 CC intravascular cannulas, prosthetic heart valves, vascular access shunts
 CC in haemodialysis patients, haemodialysis machines, and cardiopulmonary
 CC bypass machines, and for reducing the incidence of auxiliary-subclavian
 CC venous thrombosis in patients with long-term indwelling central vein
 CC catheters. The present sequence is a PCR primer used in the isolation of
 CC a cDNA library of human heavy chain variable region (VH) genes in order
 CC to construct a single chain phage display antibody library for anti-
 CC platelet binding protein antibodies

DB 1 GAGGTGCAGCTGGTGGAGTCTG 22
 RESULT 694
 AAL62799
 ID AAL62799 standard; DNA; 23 BP.
 XX AAL62799;
 AC AAL62799;
 XX 06-OCT-2003 (first entry)
 DT XX
 DE Human VH domain amplifying PCR primer, Hu VH3-5'.
 XX Human; protein coordinate data; heavy chain variable domain; VH; cancer;
 KW complementarity determining region; CDR; light chain variable domain; VL;
 KW TRAIL receptor 7; TR7; tumour-necrosis factor; KILLER; death receptor 5;
 KW DR5; TRAIL receptor 2; TRAIL-R2; TNF-related apoptosis-inducing ligand;
 KW Kaposi's sarcoma; central nervous system; medulloblastoma; neuroblastoma;
 KW glioblastoma; graft versus host disease; antibody therapy; nontropic;
 KW AIDS; acquired immune deficiency syndrome; neurodegenerative disorder;
 KW immunosuppressive; neuroprotective; antibody therapy; PCR; primer; ss.
 XX Homo sapiens.
 OS WO2003054216-A2.
 XX 03-JUL-2003.
 XX 19-DEC-2002; 2002WO-US040597.
 XX 20-DEC-2001; 2001US-0341237P.
 PR 05-APR-2002; 2002US-0369877P.
 PR 04-JUN-2002; 2002US-0384828P.
 PR 18-JUL-2002; 2002US-0396591P.
 PR 15-AUG-2002; 2002US-0403370P.
 PR 13-NOV-2002; 2002US-0425737P.
 XX (HUMA-) HUMAN GENOME SCI INC.
 XX Salcedo T, Albert VR, Rosen CA, Humphreys R, Vaughan TJ;
 PI WPI; 2003-569250/53.
 XX New antibody or its fragment, useful for treating, preventing or
 PT ameliorating a cancer, e.g. colon, breast, uterine, pancreatic, lung or
 PT gastrointestinal cancer, or Kaposi's sarcoma or, graft versus host
 PT disease, AIDS.
 XX Example 4; Page 241; 301pp; English.
 XX The invention relates to an isolated antibody or its fragments such as
 CC VHCOR1 (heavy chain variable domain complementarity determining region),
 CC VHCOR2, VHCOR3, VHCOR4 (light chain variable domain complementarity
 CC determining region), VHCOR5 or VHCOR6. The antibody or its fragment
 CC immunospecifically binds TRAIL (tumour necrosis factor; TNF-related
 CC apoptosis-inducing ligand) receptor 7 (TR7). TR7 is also referred to as
 CC TRAIL receptor 2 (TRAIL-R2), death receptor 5 (DR5) and KILLER. The
 CC antibody or its fragment is useful for treating, preventing or
 CC ameliorating a cancer, e.g. colon, breast, uterine, pancreatic, lung or
 CC gastrointestinal cancer or Kaposi's sarcoma or cancer of the central
 CC nervous system such as medulloblastoma, neuroblastoma or glioblastoma or
 CC graft versus host disease, AIDS (acquired immune deficiency syndrome) or
 CC a neurodegenerative disorder. The invention is useful in antibody
 CC therapy. The present sequence is human VH domain amplifying PCR primer
 XX Sequence 23 BP; 3 A; 3 C; 12 G; 5 T; 0 U; 0 Other;
 SQ Query Match 0.5%; Score 17.2; DB 1; Length 23;
 Best Local Similarity 86.4%; Pred. No. 1.1e+03;
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 853 GAGGAGGAGCTGGTGGAGGCTG 874

Db	1	GAGGTGCAGCTGGTGGAGTCTG 22	QY	853	GAGGAGGAGCTGGTGGAGGCTG 874
			Db	1	GAGGTGCAGCTGGTGGAGTCTG 22
RESULT 695					
ACD91445					
ID	ACD91445	standard; DNA; 23 BP.			
AC	ACD91445;				
DT	22-SEP-2003	(first entry)			
XX	Human heavy chain variable region related PCR primer #3.				
XX	Human; G-protein coupled receptor; HGPBRMY25; immune disease;				
XX	inflammatory disease; arthritis; asthma; AIDS; psoriasis;				
XX	graft-versus-host disease; systemic lupus erythematosus;				
XX	reproductive disorder; varicocele; orchitis; neural disorder;				
XX	Alzheimer's disease; Parkinson's disease; depression; schizophrenia;				
XX	cardiovascular disorder; hypertension; acute heart failure;				
XX	pulmonary disorder; endocrine disorder; obesity; diabetes; anorexia;				
XX	bone disorder; osteoporosis; pain; cancer; chromosome identification;				
XX	gene therapy; PCR; primer; ss; variable heavy chain; VH.				
OS	Homo sapiens.				
XX	US2003060409-A1.				
XX	27-MAR-2003.				
XX	21-FEB-2002; 2002US-00081775.				
XX	21-FEB-2001; 2001US-0270134P.				
XX	27-MAR-2001; 2001US-0278952P.				
XX	(RAMA/) RAMANATHAN C S.				
PA	(FEDE/) FEDER J N.				
PA	(MINT/) MINTIER G A.				
XX	Ramanathan CS, Feder JN, Mintier GA;				
XX	WPI; 2003-521919/49.				
XX	New nucleic acid molecule encoding a human G-protein coupled receptor				
XX	(HGPBRMY25) is useful for diagnosing, preventing or treating diseases				
XX	involving the receptor, e.g. inflammation, diabetes, asthma, hypertension				
XX	or cancer.				
XX	Example 37; Page 110; 139pp; English.				
XX	The invention describes an isolated nucleic acid molecule comprising a				
XX	sequence that is at least 95% identical to a polynucleotide encoding				
XX	novel human G-protein coupled receptor HGPBRMY25. The nucleic acid				
XX	molecule, polypeptide and antibody are useful in diagnosing, preventing,				
XX	treating or ameliorating medical conditions where GPCR is directly or				
XX	indirectly involved, such as immune or inflammatory diseases (e.g.				
XX	arthritis, asthma, AIDS, graft-versus-host disease, psoriasis or systemic				
XX	lupus erythematosus), reproductive disorders (e.g. varicocele or				
XX	orchitis), neural disorders (e.g. Alzheimer's disease, Parkinson's				
XX	disease, depression or schizophrenia), cardiovascular disorders (e.g.				
XX	hypertension or acute heart failure), pulmonary disorders, endocrine				
XX	disorders (e.g. obesity, diabetes or anorexia), bone disorders (e.g.				
XX	osteoporosis), pain or cancer. The polynucleotide may also be used in				
XX	chromosome identification, in identifying organisms from minute				
XX	biological samples, or as molecular weight markers. This sequence				
XX	represents a primer used to isolate DNA encoding human variable heavy				
XX	(VH) chain domains of anti-HGPBRMY25-antibodies				
SQ	Sequence 23 BP; 3 A; 3 C; 12 G; 5 T; 0 U; 0 Other;				
	Query Match 0.5%; Score 17.2; DB 1; Length 23;				
	Best Local Similarity 86.4%; Pred. No. 1.1e+03;				
	Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;				

QY	853	GAGGAGGAGCTGGTGGAGGCTG 874	QY	853	GAGGAGGAGCTGGTGGAGGCTG 874
Db	1	GAGGTGCAGCTGGTGGAGTCTG 22	Db	1	GAGGTGCAGCTGGTGGAGTCTG 22
RESULT 696					
ADA09673					
ID	ADA09673	standard; DNA; 23 BP.			
XX	ADA09673;				
DT	06-NOV-2003	(first entry)			
XX	Human anti-HGPBRMY26 antibody heavy chain PCR primer Hu VH-3 5'.				
XX	ss; human; HGPBRMY26; G protein-coupled receptor;				
XX	male reproductive condition; amine disorder; testicular disorder;				
XX	testicular cancer; choriocarcinoma; nonseminoma; seminoma;				
XX	spermatogenesis; infertility; Klinefelter's syndrome; XX male;				
XX	epididymitis; genital wart; germinal cell aplasia of the testis;				
XX	cryptorchidism; varicocele; immotile cilia syndrome; viral orchitis;				
XX	premature puberty; incomplete puberty; Kallman syndrome;				
XX	Cushing's syndrome; hyperprolactinaemia; haemochromatosis;				
XX	congenital adrenal hyperplasia; follicle stimulating hormone deficiency;				
XX	granulomatous disease; PCR; primer; antibody; heavy chain; light chain;				
XX	VH; VL.				
OS	Homo sapiens.				
XX	US2003064381-A1.				
XX	03-APR-2003.				
XX	07-MAR-2002; 2002US-00092771.				
XX	07-MAR-2001; 2001US-0273963P.				
XX	27-MAR-2001; 2001US-0278927P.				
XX	(FEDE/) FEDER J N.				
XX	(RAMA/) RAMANATHAN C S.				
XX	(MINT/) MINTIER G A.				
XX	(CACA/) CACACE A.				
XX	(BARB/) BARBER L E.				
XX	Feder JN, Ramanathan CS, Mintier GA, Cacace A, Barber LE;				
XX	WPI; 2003-555589/52.				
XX	New human G-protein coupled receptor HGPBRMY26 polypeptides and nucleic				
XX	acids, useful for preventing, treating or ameliorating e.g. testicular				
XX	disorder, choriocarcinoma, infertility, viral orchitis, or Cushing's				
XX	syndrome.				
XX	Example 35; Page 106; 149pp; English.				
XX	The invention relates to an isolated nucleic acid molecule encoding a G				
XX	protein-coupled receptor HGPBRMY26. The nucleotide sequence comprises				
XX	sequential nucleotide deletions from either the C-terminus or the N-				
XX	terminus. Also included are an isolated polypeptide encoded by the				
XX	nucleic acid, a recombinant vector comprising the nucleic acid, making a				
XX	recombinant host cell comprising the nucleic acid, diagnosing a				
XX	pathological condition or a susceptibility to a pathological condition in				
XX	testicular tissue of a subject, identifying a compound that modulates the				
XX	biological activity of a human G-protein coupled receptor HGPBRMY26 (and				
XX	a member consisting of NFAT/CRE or NFAT G alpha 15, all undefined), and				
XX	screening for candidate compounds capable of modulating activity of the				
XX	HGPBRMY26 polypeptide. The HGPBRMY26 polypeptides, polynucleotides,				
XX	compounds or pharmaceutical preparations comprising HGPBRMY26 are useful				
XX	for preventing, treating or ameliorating a male reproductive condition;				
XX	an amine disorder or a condition where G-protein coupled receptors are				
XX	(indirectly involved in disease progression, a testicular disorder,				
XX	testicular cancer, choriocarcinoma, nonseminoma, seminoma,				

CC spermatogenesis, infertility, Klinefelter's syndrome, XX male.
 CC epididymitis, genital warts, germinal cell aplasia of the testis,
 CC cryptorchidism, varicocele, immature cilia syndrome, viral orchitis,
 CC premature puberty; incomplete puberty, Kallman syndrome, Cushing's
 CC syndrome, hyperprolactinaemia, haemochromatosis, congenital adrenal
 CC hyperplasia, follicle stimulating hormone (FSH) deficiency and
 CC granulomatous disease. The present sequence is a PCR primer used in the
 CC isolation sequences encoding heavy or light chains (VH or VL) of anti-
 CC HGPBMY26 antibodies.

XX
 SQ Sequence 23 BP; 3 A; 3 C; 12 G; 5 T; 0 U; 0 Other;
 Query Match 0.5%; Score 17.2; DB 1; Length 23;
 Best Local Similarity 86.4%; Pred. No. 1.1e+03;
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 853 GAGGAGGAGCTGGTGGAGGCTG 874
 ||||| ||||| ||||| ||||| |||||
 Db 1 GAGGTGCAGCTGGTGGAGTCTG 22

RESULT 697
 AAD59740
 ID AAD59740 standard; DNA; 23 BP.
 XX
 AC AAD59740;
 XX
 DT 18-DEC-2003 (first entry)
 XX
 DE Human HGPBMY14 antibody VH gene amplifying primer, Hu VH3-5'.

XX
 KW G-protein coupled receptor; GPCR; HGPBMY14; neuropeptide Y receptor;
 KW proliferative disorder; testicular cancer; NF-kB; diabetes mellitus;
 KW autoimmune disorder; male reproductive disorder; appetite disorder; VH;
 KW eating disorder; neurodegenerative disorder; human; PCR; primer; ss.
 XX
 OS Homo sapiens.
 XX
 PN US2003100057-A1.
 XX
 PD 29-MAY-2003.
 XX
 PF 05-FEB-2002; 2002US-00067649.
 XX
 PR 05-FEB-2001; 2001US-0266525P.
 PR 16-OCT-2001; 2001US-0329897P.
 XX
 PA (FEDE/) FEDER J N.
 PA (RAMA/) RAMANATHAN C S.
 PA (NELS/) NELSON T C.
 PA (KORN/) KORNACKER M.
 PA (RYSE/) RYSECK R.
 PA (CACA/) CACACE A.
 PA (BARB/) BARBER L E.
 XX
 PI Feder JN, Ramanathan CS, Nelson TC, Kornacker M, Ryseck R;
 PI Cacace A, Barber LE;
 XX
 DR WPI; 2003-687761/65.
 XX
 PT New nucleic acid, useful for preparing a composition for treating a
 PT disorder e.g., testicular cancer, autoimmune or neurodegenerative
 PT disorders, or diabetes mellitus.
 XX
 PS Example 30; Page 111; 166pp; English.

XX
 CC The invention relates to G-protein coupled receptor (GPCR), HGPBMY14 and
 CC its corresponding nucleic acid sequence. HGPBMY14 sequences are useful
 CC for preventing or treating a disorder directly linked to aberrant
 CC neuropeptide Y receptor activity or to aberrant DNA synthesis, an eating
 CC or appetite disorder, male reproductive disorder or proliferative
 CC disorder e.g., testicular cancer. These are useful for detecting (a
 CC susceptibility to) a pathological condition. HGPBMY14 is useful for

CC identifying its binding partners, including agonists and antagonists.
 CC Antagonists to the polypeptide is useful in treating a disorder related
 CC to aberrant NF-kB activity or a proliferative disorder. HGPBMY14 DNA and
 CC protein are also useful in treating neurodegenerative or autoimmune
 CC disorders, or diabetes mellitus. The present sequence is a RT-PCR primer
 CC used for amplifying human HGPBMY14 antibody VH gene

XX
 SQ Sequence 23 BP; 3 A; 3 C; 12 G; 5 T; 0 U; 0 Other;
 Query Match 0.5%; Score 17.2; DB 1; Length 23;
 Best Local Similarity 86.4%; Pred. No. 1.1e+03;
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 853 GAGGAGGAGCTGGTGGAGGCTG 874
 ||||| ||||| ||||| ||||| |||||
 Db 1 GAGGTGCAGCTGGTGGAGTCTG 22

RESULT 698
 AAD06499
 ID AAD06499 standard; DNA; 23 BP.
 XX
 AC AAD06499;
 XX
 DT 01-JAN-2004 (first entry)
 XX
 DE Human VH domain PCR primer SEQ ID NO:35.
 XX
 KW human; chemokine betal; Ckbl; anti-HIV; neuroprotective; antithyroid;
 KW antithyroid; antirheumatic; immunosuppressive; nontropic;
 KW antinflammatory; antiaesthetic; antiallergic; osteopathic;
 KW nephrotic; tuberculous; virucide; immune disorder; haematopoietic disorder;
 KW antimicrobial; infection; HIV; immune disorder; Grave's disease; arthritis;
 KW autoimmune disorder; multiple sclerosis; Grave's disease; arthritis;
 KW rheumatoid arthritis; transplant rejection; neurodegenerative disorder;
 KW Alzheimer's disease; inflammatory disease; asthma; allergic disorder;
 KW inflammatory bowel disease; osteoarthritis; colitis;
 KW inflammatory kidney disease; glomerulonephritis; infectious disease;
 KW tuberculosis; hepatitis infection; herpes viral infection;
 KW viral infection; proliferative disorder; atherosclerosis;
 KW human serum albumin; HSA; PCR primer; ss.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO200297038-A2.
 XX
 PD 05-DEC-2002.
 XX
 PF 24-MAY-2002; 2002WO-US016525.
 XX
 PR 25-MAY-2001; 2001US-0293212P.
 XX
 PA (HUMA-) HUMAN GENOME SCI INC.
 XX
 PI Bell A, Ruben SM;
 XX
 DR WPI; 2003-140456/13.
 XX
 PT Novel human chemokine betal protein comprising deletion in amino acids
 PT from amino and/or carboxy terminus, and is a fusion protein further
 PT comprising human serum albumin, is useful for treating multiple
 PT sclerosis, asthma.
 XX
 PS Example 46; SEQ ID NO 35; 423pp; English.

XX
 CC The present invention describes a human chemokine betal (Ckbl) protein
 CC (I) comprising a deletion in amino acid residues from the amino terminus
 CC and/or carboxy terminus of the 93 residue amino acid sequence (SI, see
 CC ADD06466). (I) has anti-HIV neuroprotective, antithyroid, antiarthritic,
 CC antirheumatic, immunosuppressive, nontropic, antiinflammatory, tuberculous,
 CC antiaesthetic, antiallergic, osteopathic, nephrotrophic, tuberculous,
 CC virucide, antiatherosclerotic and antimicrobial activities. (I) is useful

CC for preventing infection, preferably viral (human immunodeficiency virus
 CC (HIV)) infection, in a cell, by contacting the cell with (I). (I) is also
 CC useful for treating a disease, such as HIV infection or immune disorders,
 CC haematopoietic disorders, autoimmune disorders, multiple sclerosis,
 CC Grave's disease, arthritis, rheumatoid arthritis, transplant rejection,
 CC neurodegenerative disorders, Alzheimer's disease, inflammatory disease,
 CC asthma, allergic disorders, inflammatory bowel disease, osteoarthritis,
 CC colitis, inflammatory kidney diseases, glomerulonephritis, infectious
 CC disease, tuberculosis, hepatitis infections, herpes viral infection,
 CC viral infection, proliferative disorders or atherosclerosis, in an
 CC individual. (I) inhibits or abolishes the ability of HIV to bind to,
 CC enter into/fuse with (infect), and/or replicate in CCR5 expressing cells.
 CC (I) also acts a CCR5 agonist or antagonist, stimulate chemotaxis of
 CC CCR5-expressing cells, inhibit CCR5 ligand binding to a CCR5 molecule, or
 CC upregulate or downregulate CCR5 expression. (I) is useful as an
 CC immunological probe for the differential identification of the tissues or
 CC cell-types. (I)-human serum albumin (HSA) fusion proteins are useful for
 CC diagnosing, treating and preventing various disorders in mammals,
 CC preferably in humans. (I)-HSA fusion proteins are also useful as
 CC molecular weight markers on sodium dodecyl sulfate polyacrylamide gel
 CC electrophoresis techniques, for raising antibodies, and to test the
 CC biological activities of the Cxbl protein. (I)-HSA fusion proteins are
 CC useful for screening for molecules that bind to the Cxbl protein portion
 CC of the fusion protein. The present sequence is used in the
 CC exemplification of the present invention.

XX Sequence 23 BP; 3 A; 3 C; 12 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 17.2; DB 1; Length 23;

Best Local Similarity 86.4%; Pred. No. 1.1e+03;

Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 853 GAGGAGAGCTGCTGGAGCTG 874

Db 1 GAGGTGACGCTGCTGGAGCTG 22

RESULT 699

ADC83653

ID ADC83653 standard; DNA; 23 BP.

AC ADC83653;

DT 01-JAN-2004 (first entry)

DE LTRPC3 VH domain PCR primer, SEQ ID 272.

XX Cytostatic; Nephrotropic; Gynecological; Nootropic; Neuroprotective;
 KW Antiinflammatory; Osteopathic; Dermatological; Vasotropic; Endocrine;
 KW Antianemic; Ophthalmological; Gene therapy; Human;
 KW transient receptor potential channel; renal disorder; calcium regulation;
 KW neural disorder; Alzheimer's disease; cancer; reproductive disorder;
 KW cerebellum disorders; choroid plexus neoplasm; prion disorder;
 KW multiple sclerosis; movement disorder; amyotrophic lateral sclerosis;
 KW early onset pulverulent cataract; infantile nephronophthisis;
 KW hypomagnesemia with secondary hypocalcemia; osteoporosis;
 KW DNA-repair deficiency; xeroderma pigmentosum; UV sensitivity;
 KW gamma irradiation sensitivity; pyrimidine dimer sensitivity;
 KW chemical mutagenesis; Bloom's syndrome; skin blood vessel dilation;
 KW signal transduction; FEN1; calcium channel; LTRPC3; PCR; primer; ss.

OS Homo sapiens.

XX WO2003012063-A2.

XX 13-FEB-2003.

XX 01-AUG-2002; 2002WO-US024445.

XX 02-AUG-2001; 2001US-0309544P.

XX (BRIM) BRISTOL-MYERS SQUIBB CO.

XX

PI Lee N, Chen J, Feder JN, Wu S, Lee L, Blonar MA, Bol D;
 PI Levesque PC, Sun L;

XX WPI; 2003-278394/27.

XX New human transient receptor potential channel (LTRPC3) nucleic acid,
 PT useful in preventing, treating or ameliorating a medical condition, such
 PT as renal disorder, neural disorder e.g., Alzheimer's disease, or cancer.

XX Example 34; Page 436; 508pp; English.

XX The present invention relates to novel proteins and their coding
 CC sequences (ADC83400-ADC83405) encoding human transient receptor potential
 CC channels. The coding sequences are useful for preparing a medicament for
 CC preventing, treating or ameliorating a medical condition, such as renal
 CC disorders; a disorder related to aberrant calcium regulation; neural
 CC disorders e.g., Alzheimer's disease; cancer; a reproductive disorder;
 CC cerebellum disorders; various choroid plexus neoplasms; prion disorders;
 CC multiple sclerosis; movement disorders; a disorder that maps to or is
 CC associated with chromosome locus 9q21.11-21.31; amyotrophic lateral
 CC sclerosis; early onset pulverulent cataract; infantile nephronophthisis;
 CC hypomagnesemia with secondary hypocalcemia; osteoporosis; DNA-repair
 CC deficiencies; xeroderma pigmentosum; UV sensitivity; gamma irradiation
 CC sensitivity; pyrimidine dimer sensitivity; chemical mutagenesis; Bloom's
 CC syndrome; blood vessel dilations in the skin; conditions involving
 CC increased levels of apurinic/aprimidinic/abasic sites; disorders related
 CC to aberrant signal transduction; and disorders related to misregulation
 CC of FEN1 expression or activity. The present sequence is a PCR primer,
 CC which was used in an example from the invention.

XX Sequence 23 BP; 3 A; 3 C; 12 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 17.2; DB 1; Length 23;

Best Local Similarity 86.4%; Pred. No. 1.1e+03;

Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 853 GAGGAGAGCTGCTGGAGCTG 874

Db 1 GAGGTGACGCTGCTGGAGCTG 22

RESULT 700

ADD68036

ID ADD68036 standard; DNA; 23 BP.

AC ADD68036;

XX 15-JAN-2004 (first entry)

DE Human VH domain DNA, PCR primer #3.

XX Albumin fusion protein; therapeutic protein; HIV; osteoporosis; cancer;
 KW wound; autoimmune disease; cardiovascular disease; hepatitis;
 KW multiple sclerosis; psoriasis; graft-versus-host disease; stroke;
 KW atherosclerosis; inflammation; anti-HIV; osteopathic; cytostatic;
 KW vulnerability; cardiac; hepatotropic; neuroprotective; antipsoriatic;
 KW immunosuppressive; cerebroprotective; antiarteriosclerotic;
 KW antiinflammatory; human; VH domain; PCR; primer; ss.

XX Homo sapiens.

XX US2003125247-A1.

XX 03-JUL-2003.

XX 12-APR-2001; 2001US-00833041.

XX 12-APR-2000; 2000US-0229358P.

XX 25-APR-2000; 2000US-0199384P.

XX 21-DEC-2000; 2000US-0256931P.

XX (ROSE/) ROSEN C A.

XX (HASE/) HASELTINE W A.

```

XX Rosen CA, Haseltine WA;
PI WPI; 2003-810996/76.
XX
XX New albumin fusion protein for diagnosing, preventing or treating
PT diseases (e.g. HIV, cancer, atherosclerosis or stroke) comprises a
PT therapeutic protein (e.g. cathepsin K or vascular endothelial growth
PT factor) and an albumin.
XX
XX Disclosure; SEQ ID NO 38; 180pp; English.
XX
XX The present invention relates to albumin fusion proteins comprising any
CC of the therapeutic proteins listed in the specification, or their
CC fragments or variants, and an albumin protein or its fragments or
CC variants. The invention also discloses pharmaceutical compositions
CC comprising the albumin fusion proteins, a kit comprising the albumin
CC fusion proteins, and methods for treating a disease or disorder in a
CC patient, that is modulated by the therapeutic protein or its fragment or
CC variant. The compositions and methods of the invention are useful in
CC diagnosing, preventing, treating or ameliorating diseases or disorders,
CC such as HIV, osteoporosis, cancer, wounds, autoimmune diseases,
CC cardiovascular diseases, hepatitis, multiple sclerosis, psoriasis, graft-
CC versus-host disease, stroke, atherosclerosis and inflammation. The
CC present sequence represents a PCR primer. Note: The present sequence is
CC given in the Sequence listing but is not mentioned elsewhere in the
CC specification. The present sequence given as SEQ ID No:38 in the Sequence
CC listing differs from that given on page 129.
XX
XX Sequence 23 BP; 3 A; 3 C; 12 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 17.2; DB 1; Length 23;
Best Local Similarity 86.4%; Pred. No. 1.1e+03;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 853 GAGGACGAGCTGCTGGAGCTG 874
DB 1 GAGGTCAGCTGCTGGAGCTG 22

RESULT 701
AAD61497
ID AAD61497 standard; DNA; 23 BP.
XX
XX AAD61497;
XX
XX 15-JAN-2004 (first entry)
XX
XX Human MMP-29 antibody VH domain amplifying 5' PCR primer, VH3.
XX
XX Human; metalloprotease; MMP-29; immune disorder; reproductive disorder;
XX testicular disorder; gastrointestinal disorder; cardiovascular disorder;
XX ovarian disorder; hepatic disorder; pulmonary disorder; renal disorder;
XX metabolic disorder; neural disorder; inflammatory disease; sclerosis;
XX skeletal muscle disorder; amyotrophic lateral sclerosis; gene therapy;
XX immunomodulatory; anti-infectivity; cytostatic; hepatotropic; pulmonary;
XX nephrotropic; cardiant; vascular; neuroprotective; nootropic; muscular;
XX PCR; primer; ss.
XX
XX Homo sapiens.
XX
XX US2003109021-A1.
XX
XX 12-JUN-2003.
XX
XX 26-APR-2002; 2002US-00133797.
XX
XX 26-APR-2001; 2001US-0286764P.
XX
XX (WUSS/) WU S.
XX
XX (CHEN/) CHEN J.
XX
XX (FEDER/) FEDER J N.
XX
XX (LEE/) LEE L.

PA (KRYST/) KRYSTEK S R.
XX
XX Wu S, Chen J, Feder JN, Lee L, Krystek SR;
XX WPI; 2003-801369/75.
XX
XX New nucleic acid encoding a metalloprotease (MMP-29) useful for
PT diagnosing a pathological condition or a susceptibility to a medical
PT condition in a subject.
XX
XX Example 37; Page 134; Opp; English.
XX
XX The present invention relates to novel metalloprotease (MMP-29) proteins
CC and polynucleotides encoding such proteins. Sequences of the invention
CC are used to diagnose a pathological condition or a susceptibility to a
CC medical condition in a subject. They are useful for preventing, treating,
CC or ameliorating medical conditions such as immune condition or disorders,
CC reproductive conditions, female reproductive disorders, male reproductive
CC disorders, ovarian disorders, testicular disorders, gastrointestinal
CC disorders, cancer, hepatic disorders, pulmonary disorders, metabolic
CC disorders, renal disorders, cardiovascular diseases, inflammatory diseases,
CC skeletal muscle disorders, inflammatory diseases, inflammatory diseases
CC where proteases are either directly or indirectly involved in disease
CC progression, sclerosis, amyotrophic lateral sclerosis, juvenile form of
CC amyotrophic lateral sclerosis or a disorder associated with aberrations
CC of chromosome 2q32. MMP-29 sequences are also useful in gene therapy. The
CC present sequence is human MMP-29 antibody VH domain amplifying PCR
CC primer. This sequence is used in the exemplification of the invention
XX
XX Sequence 23 BP; 3 A; 3 C; 12 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 17.2; DB 1; Length 23;
Best Local Similarity 86.4%; Pred. No. 1.1e+03;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 853 GAGGACGAGCTGCTGGAGCTG 874
DB 1 GAGGTCAGCTGCTGGAGCTG 22

RESULT 702
AAD67296
ID ADD67296 standard; DNA; 23 BP.
XX
XX ADD67296;
XX
XX 15-JAN-2004 (first entry)
XX
XX Human antibody related PCR primer SEQ ID NO:14.
XX
XX apparatus combination; binding site collection; pattern recognition;
XX profiling; screening; ss; PCR primer.
XX
XX Synthetic.
XX
XX Homo sapiens.
XX
XX WO2003062402-A2.
XX
XX 31-JUL-2003.
XX
XX 24-JAN-2003; 2003WO-US002397.
XX
XX 24-JAN-2002; 2002US-0352011P.
XX
XX (POIN-) POINTILLISTE INC.
XX
XX Ault-Riche D, Kassner PD;
XX WPI; 2003-636736/60.
XX
XX New combination comprising an addressable collection of binding sites,
PT software comprising instructions for pattern recognition and an imager
PT for detecting patterns, useful for profiling a sample.

```

XX Disclosure; SEQ ID NO 14; 309pp; English.

XX The present invention describes a combination of apparatus (1)

XX comprising: (a) an addressable collection of binding sites; and (b)

XX software comprising instructions for pattern recognition and/or an imager

XX for detecting patterns. The addressable collection of binding sites

XX comprises: (a) capture agents, where each capture agent is preselected to

XX specifically bind to a pre-selected tag; and (b) tagged reagents, each

XX comprising one of the pre-selected tags, where each locus in the

XX collection comprises the same capture agent, where the tagged reagent

XX comprises a molecule and a tag, each tag is pre-selected to specifically

XX bind to a capture agent, where each tag is bound to a capture agent,

XX forming a complex of the tagged reagent with the capture agent, where

XX each locus comprises tagged reagents and where each of the different

XX molecules at each locus comprises the same pre-selected tag. Also

XX described: (1) a system for profiling samples; (2) a method for profiling

XX a sample; (3) a computer system or computer readable medium comprising

XX the database produced by the method of profiling a sample; (4) a method

XX for preparing a capture system that displays a collection of binding

XX sites; (5) a positionally addressable collection of binding sites

XX comprising capture agents bound to a solid support and tagged reagents;

XX and (6) a method for screening samples. The combination (1) is useful for

XX profiling a sample. The present sequence is used in the exemplification

XX of the present invention.

XX Sequence 23 BP; 3 A; 3 C; 12 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 17.2; DB 1; Length 23;

Best Local Similarity 86.4%; Pred. No. 1.1e+03;

Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 853 GAGGAGGAGCTGCTGGAGGCTG 874

Db 1 GAGGTGCAGCTGCTGGAGGCTG 22

RESULT 703

AAD62328

ID AAD62328 standard; DNA; 23 BP.

XX

AC AAD62328;

DT 15-JAN-2004 (first entry)

XX PCR primer used to amplify human HEAG2 VH domain, Hu VR3.

XX Human; HEAG2; potassium channel; aberrant amygdala function; autism;

XX fear; neurodevelopmental disorder; psychopathological; schizophrenia;

XX aggression; memory; emotional disorder; aberrant hypothalamus function;

XX leptin receptor disorder; energy-expenditure disorder; motion sickness;

XX food intake disorder; bone remodeling disease; bone disorder; nocturnal;

XX neurophysin-related disorder; appetite suppression; neuroleptic; therapy;

XX neuroprotective; osteopathic; anorectic; antiemetic; VH domain; primer;

XX PCR; ss.

XX Homo sapiens.

OS US2003114354-A1.

PN 19-JUN-2003.

XX

PD 19-JUN-2002; 2002US-00174613.

XX

PF 19-JUN-2001; 2001US-0299378P.

XX

PR 25-JUN-2001; 2001US-0300614P.

XX

XX (FEDE/) FEDER J N.

PA (LEEL/) LEE L.

XX

PA (CHEN/) CHEN J.

XX

PA (JACK/) JACKSON D.

XX

PA (RAMA/) RAMANATHAN C S.

XX

PA (SIEM/) SIEMERS N O.

PA (CHAN/) CHANG H.

PA (DUC/) DUCLOS F.

XX (KRY/) KRYSTEK S R.

PI Feder JN, Lee L, Chen J, Jackson D, Ramanathan CS, Siemers NO;

PI Chang H, Duclos F, Krystek SR;

XX WPI; 2003-810910/76.

XX Computer for producing three-dimensional representation of molecule or

XX molecular complex of PAS domain of potassium channel protein, useful in

XX designing compounds as potential modulators for treatment of

XX neurodevelopmental disorders.

XX Example 32; Page 108; Opp; English.

XX The present invention provides novel polynucleotides encoding HEAG2

XX (human potassium channel) polypeptides, fragments and homologues thereof.

XX The invention is useful for producing three-dimensional representation of

XX a molecule or molecular complex comprising the structural coordinates of

XX the PAS domain of HEAG2. The invention is also useful for treating

XX conditions such as disorder associated with aberrant amygdala function,

XX fear, neurodevelopmental psychopathological disorders, schizophrenia,

XX autism, aggression, memory, emotional disorders, aberrant hypothalamus

XX function, leptin receptor disorders, food intake disorders, energy-

XX expenditure disorders, physiological functions, neurophysin-related

XX disorders, bone disorders, bone remodeling disease, appetite suppression

XX and motion sickness. The present sequence is PCR primer used to amplify

XX human HEAG2 VH domain. This sequence is used in the exemplification of

XX the invention

XX Sequence 23 BP; 3 A; 3 C; 12 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 17.2; DB 1; Length 23;

Best Local Similarity 86.4%; Pred. No. 1.1e+03;

Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 853 GAGGAGGAGCTGCTGGAGGCTG 874

Db 1 GAGGTGCAGCTGCTGGAGGCTG 22

RESULT 704

ADF15971

ID ADF15971 standard; DNA; 23 BP.

XX

AC ADF15971;

XX 12-FEB-2004 (first entry)

XX Human albumin fusion protein-related PCR primer SeqID1058.

XX albumin fusion protein; albumin activity; human serum albumin;

XX serum osmotic pressure; shelf-life; stability; antidiabetic;

XX gene therapy; diabetes mellitus; PCR; primer; ss; human.

XX Homo sapiens.

OS WO2003060071-A2.

PN 24-JUL-2003.

XX

PD 23-DEC-2002; 2002WO-US040891.

XX

PF 21-DEC-2001; 2001US-0341811P.

XX

PR 24-JAN-2002; 2002US-0350358P.

XX

PR 28-JAN-2002; 2002US-0351360P.

XX

PR 26-FEB-2002; 2002US-0359370P.

XX

PR 28-FEB-2002; 2002US-0360000P.

XX

PR 27-MAR-2002; 2002US-0367500P.

XX

PR 08-APR-2002; 2002US-0370227P.

XX

PR 10-MAY-2002; 2002US-0378950P.

XX

PR 24-MAY-2002; 2002US-0382617P.

PR 28-MAY-2002; 2002US-0383123P.
 PR 05-JUN-2002; 2002US-0385708P.
 PR 10-JUL-2002; 2002US-0394625P.
 PR 24-JUL-2002; 2002US-0398008P.
 PR 09-AUG-2002; 2002US-0402131P.
 PR 13-AUG-2002; 2002US-0402708P.
 PR 18-SEP-2002; 2002US-0411355P.
 PR 18-SEP-2002; 2002US-0411426P.
 PR 02-OCT-2002; 2002US-0414984P.
 PR 11-OCT-2002; 2002US-0417611P.
 PR 23-OCT-2002; 2002US-0420246P.
 PR 05-NOV-2002; 2002US-0423623P.
 XX
 PA (HUMA-) HUMAN GENOME SCI INC.
 PA (DELZ) DELTA BIOTECHNOLOGY LTD.
 PA (PRIN-) PRINCIPIA PHARM CORP.
 XX
 PI Ballance DJ, Turner AJ, Rosen CA, Haseltine WA;
 XX
 DR WPI; 2003-598517/56.
 XX
 PR New albumin fusion protein, useful for preparing a composition for
 PT treating diabetes mellitus.
 XX
 PS Example 107; SEQ ID NO 1058; 24pp; English.
 XX
 CC This invention relates to a novel albumin fusion protein having albumin
 CC or biological activity. Human serum albumin is responsible for a
 CC significant proportion of the osmotic pressure of serum and also
 CC functions as a carrier of endogenous and exogenous ligands. The fusion of
 CC albumin to a therapeutic protein may increase shelf-life and stability of
 CC the therapeutic protein. The albumin fusion protein of the invention may
 CC allow production of compositions with antidiabetic activity whilst the
 CC nucleotide sequence which encodes it may be useful for gene therapy. The
 CC albumin fusion protein is useful for preparing a composition for treating
 CC diabetes mellitus. The present sequence is that of a PCR primer which was
 CC used in the exemplification of the invention. Note: The sequence data for
 CC this patent did not form part of the printed specification, but was
 CC obtained in electronic format directly from WIPO at
 CC ftp.wipo.int/pub/publishedpct_sequences
 XX
 SQ Sequence 23 BP; 3 A; 3 C; 12 G; 5 T; 0 U; 0 Other;
 Query Match 0.5%; Score 17.2; DB 1; Length 23;
 Best Local Similarity 86.4%; Pred. No. 1.1e+03;
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 853 GAGGAGGAGCTGTGGAGGCTG 874
 ||||| ||||| ||||| ||||| |||||
 Db 1 GAGGTGCAGCTGTGGAGTCTG 22
 RESULT 705
 ADF72145
 ID ADF72145 standard; DNA; 23 BP.
 XX
 AC ADF72145;
 XX
 DT 12-FEB-2004 (first entry)
 XX
 DE Human immunoglobulin variable heavy chain primer seq id 25.
 XX
 KW cytostatic; CCR5 modulator; antibody; G-protein chemokine receptor; CCR5;
 KW cancer detection; cancer diagnosis; cancer prognosis; cancer monitoring;
 KW cancer; hyperproliferative disorder; human; HDGHR10; PCR; primer; ss;
 KW immunoglobulin; heavy chain; variable region.
 XX
 OS Homo sapiens.
 XX
 PN US2003166024-A1.
 XX
 PD 04-SEP-2003.
 XX

PF 01-MAY-2002; 2002US-00135839.
 XX
 PR 09-FEB-2000; 2000US-0181258P.
 PR 09-MAR-2000; 2000US-0187999P.
 PR 22-SEP-2000; 2000US-0234336P.
 PR 09-FEB-2001; 2001US-00779879.
 XX
 PA (HUMA-) HUMAN GENOME SCI INC.
 XX
 PI Rosen CA, Roschke V, Li Y, Ruben SM;
 XX
 DR WPI; 2003-898066/82.
 XX
 PT New polypeptide comprising domains of an antibody that binds G-protein
 PT chemokine receptor CCR5 is useful to detect, diagnose, prognose or
 PT monitor cancers and other hyperproliferative disorders and to treat or
 PT prevent a disease or disorder.
 XX
 PS Example 55; SEQ ID NO 25; 179pp; English.
 XX
 CC The invention describes a new isolated polynucleotide that encodes an
 CC antibody (AB1) comprising an amino acid sequence of at least one, two or
 CC three complementarity determining regions (CDR) of a heavy chain variable
 CC (VH) domain of an antibody (AB2) that immunospecifically binds to a G-
 CC protein chemokine receptor (CCR5), at least one, two or three CDR regions
 CC of a light chain variable (VL) domain of AB2 or at least one, two or
 CC three CDR regions of both a VH and a VL domain of AB2. The antibody is
 CC useful for detecting, diagnosing, prognosing or monitoring cancers and
 CC other hyperproliferative disorders and for treating, preventing or
 CC ameliorating a disease or disorder. This sequence represents a primer
 CC used in the isolation of an immunoglobulin heavy chain variable region
 CC from antibodies of the invention.
 XX
 SQ Sequence 23 BP; 3 A; 3 C; 12 G; 5 T; 0 U; 0 Other;
 Query Match 0.5%; Score 17.2; DB 1; Length 23;
 Best Local Similarity 86.4%; Pred. No. 1.1e+03;
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 853 GAGGAGGAGCTGTGGAGGCTG 874
 ||||| ||||| ||||| ||||| |||||
 Db 1 GAGGTGCAGCTGTGGAGTCTG 22
 RESULT 706
 ADF70252
 ID ADF70252 standard; DNA; 23 BP.
 XX
 AC ADF70252;
 XX
 DT 12-FEB-2004 (first entry)
 XX
 DE Human protease-42 protein-related VH domain PCR primer SeqID70.
 XX
 KW protease-42; thiol protease; protein co-ordinate data; C2 family;
 KW calpain superfamily; hepatotropic; nephrotropic; gynaecological;
 KW antiinflammatory; cytostatic; vasotropic; cardiant; ophthalmological;
 KW auditory; gene therapy; vaccine; hypercalpain activity;
 KW protease regulation; calcium regulation; cell cycle regulation;
 KW female reproductive tract disorder; infertility; carcinoma;
 KW sexual inflammatory disease; endometriosis;
 KW placental dysfunctional uterine bleeding; pelvic aromatase deficiency;
 KW premature menopause; pelvic inflammatory disease; tubal pregnancy;
 KW Chlamydia infection; neural disorder; hepatic disorder; immune disorder;
 KW haematopoietic disorder; renal disorder; pulmonary disorder;
 KW inflammation; gastrointestinal disorder; colon cancer;
 KW proliferative disorder; colon; gastrointestinal tissue; hearing disorder;
 KW colon adenocarcinoma; ischaemia-reperfusion injury; myocarditis; PCR;
 KW hearing loss; multiple sclerosis; cataract; myocardiitis; human; PCR;
 KW primer; ss; VH domain.
 XX
 OS Homo sapiens.


```
XX ADF18235;
XX 12-FEB-2004 (first entry)
XX Antibody heavy chain variable region PCR primer Hu VH3-5'.
XX Human; TL5; cytostatic; anti-HIV; immunosuppressive; immunostimulant;
XX virucide; dermatological; antiinflammatory; antirheumatic; antiarthritic;
XX neuroprotective; muscular-gen.; antiasthmatic; antiallergic; antibody;
XX PCR; gene; ss.
XX Homo sapiens.
XX WO2003089575-A2.
XX 30-OCT-2003.
XX 10-APR-2003; 2003WO-US010956.
XX 15-APR-2002; 2002US-0372087P.
XX (HUMA-) HUMAN GENOME SCI INC.
XX (ROSE/) ROSEN C A.
XX (RUBE/) RUBEN S M.
XX Rosen CA, Ruben SM;
XX WPI; 2003-854097/79.
XX New antibody that specifically bind to TL5, useful for diagnosing,
XX preventing, treating or ameliorating diseases (e.g. cancer, autoimmune
XX disease, inflammation or transplant rejection), and in immunophenotyping
XX or epitope mapping.
XX Example 2; SEQ ID NO 13; 195pp; English.
XX The present sequence is that of PCR primer Hu VH3-5' for the human heavy
XX chain variable region (VH). A set of primer sequences ADF18233-ADF18268
XX was used in the identification and cloning of VH and VL domains from
XX antibody-expressing cell lines. The invention relates to antibodies that
XX specifically bind to TL5. These are used in the diagnosis, prevention or
XX treatment of a disease or disorder such as an autoimmune disease,
XX rheumatoid arthritis, graft versus host disease, lymphadenopathy,
XX transplant rejection, cancer (especially colon cancer, breast cancer,
XX uterine cancer, pancreatic cancer, lung cancer, gastrointestinal cancer
XX and Kaposi's sarcoma), an immunodeficiency syndrome, or an inflammatory
XX disease such as asthma or allergy.
XX Sequence 23 BP; 3 A; 3 C; 12 G; 5 T; 0 U; 0 Other;
Query Match 0.5%; Score 17.2; DB 1; Length 23;
Best Local Similarity 86.4%; Pred. No. 1.1e+03;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 853 GAGGAGGAGCTGCTGGAGGCTG 874
Db 1 GAGTGCAGCTGCTGGAGTCTG 22
RESULT 709
AC ACF58403
ID ACF58403 standard; DNA; 23 BP.
XX ACF58403;
XX 12-FEB-2004 (first entry)
XX Anti-TR2 antibody VH domain amplifying primer Hu VH3-5'.
XX TR2; orphan nuclear receptor; cytostatic; immunosuppressive; virucide;
XX immunostimulant; dermatological; antiinflammatory; antirheumatic;
XX antiarthritic; neuroprotective; muscular; antiasthmatic; antiallergic;
```

```
KW gene therapy; vaccine; scFv; TR01G03; PCR; primer; ss.
XX Synthetic.
XX WO2003086301-A2.
XX 23-OCT-2003.
XX 10-APR-2003; 2003WO-US010955.
XX 12-APR-2002; 2002US-0371722P.
XX (HUMA-) HUMAN GENOME SCI INC.
XX Rosen CA, Ruben SM;
XX WPI; 2003-853871/79.
XX New antibodies that specifically bind to orphan nuclear receptor useful
XX for diagnosing, preventing, treating or ameliorating diseases, e.g.
XX cancer, autoimmune diseases, inflammation or viral infection.
XX Example 2; Page 156; Opp; English.
XX The invention relates to an isolated antibody (A1) that specifically
XX binds orphan nuclear receptor TR2 or that competitively inhibits the
XX binding of an antibody to TR2. The antibody and methods are useful in
XX inhibiting the growth of or killing orphan nuclear receptor TR2
XX expressing cells and treating, preventing or ameliorating a disease or
XX disorder selected from an autoimmune disease, graft-versus-host disease,
XX transplant rejection, cancer, herpes simplex virus infection and an
XX immunodeficiency, e.g. lupus erythematosus, rheumatoid arthritis, multiple
XX sclerosis, myasthenia gravis, or inflammatory disorders (e.g. asthma or
XX allergies). The antibody may also be used in immunoassays for
XX qualitatively and quantitatively measuring levels of TR2 polypeptides in
XX biological samples, in immunophenotyping of cell lines and biological
XX samples, or in epitope mapping. Sequences ACF58401-436 represent PCR
XX primers for amplifying the VH and VL domains of an anti-TR2 antibody
XX Sequence 23 BP; 3 A; 3 C; 12 G; 5 T; 0 U; 0 Other;
Query Match 0.5%; Score 17.2; DB 1; Length 23;
Best Local Similarity 86.4%; Pred. No. 1.1e+03;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 853 GAGGAGGAGCTGCTGGAGGCTG 874
Db 1 GAGTGCAGCTGCTGGAGTCTG 22
RESULT 710
ADG30372
ID ADG30372 standard; DNA; 23 BP.
XX ADG30372;
XX 26-FEB-2004 (first entry)
XX PCR primer Hu VH3-5' used to amplify human VH domain cDNA.
XX GNAD; VH; CDR; complementarity determining region; VL; scFv; PCR;
XX single chain antibody; antidiabetic; type II diabetes; human; PCR;
XX primer; ss.
XX Homo sapiens.
XX WO2003085093-A2.
XX 16-OCT-2003.
XX 28-MAR-2003; 2003WO-US009625.
XX 01-APR-2002; 2002US-0368813P.
```

XX (HUMA-) HUMAN GENOME SCI INC.
 XX Baker KP, Albert VR, Chowdhury P;
 XX WPI; 2003-804305/75.
 XX
 XX New antibody that specifically binds to GMAD polypeptide, useful for
 PT diagnosing, monitoring, treating, preventing or ameliorating type II
 PT diabetes.
 XX
 XX Claim 2; SEQ ID NO 5; 410pp; English.
 XX
 XX The invention relates to a novel antibody that specifically binds to a
 CC GMAD polypeptide comprising a first amino acid sequence that is at least
 CC 95% identical to a second amino acid sequence of a VH CDR
 CC (complementarity determining region) or VL CDR of an scFv (single chain
 CC antibody molecule). The antibody of the invention demonstrates
 CC antidiabetic activity and may be useful for diagnosing, monitoring,
 CC treating, preventing or ameliorating type II diabetes. The current
 CC sequence is that of the PCR primer which was used in the exemplification
 CC of the invention.
 XX
 XX Sequence 23 BP; 3 A; 3 C; 12 G; 5 T; 0 U; 0 Other;
 SQ
 Query Match 0.5%; Score 17.2; DB 1; Length 23;
 Best Local Similarity 86.4%; Pred. No. 1.1e+03;
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 853 GAGGAGGAGCTGGTGGAGGCTG 874
 |||||
 Db 1 GAGGTGACGCTGGTGGAGTCTG 22
 RESULT 711
 ID ADG25299 standard; DNA; 23 BP.
 XX
 XX ADG25299;
 XX
 XX 26-FEB-2004 (first entry)
 DT
 XX Human heavy chain variable domain primer seq id 38.
 DE
 XX synaescological; antiinflammatory; cytostatic; vasotropic;
 KW neuroprotective; gene therapy; vaccine; methionine activity disorder;
 KW methionine activity deficiency; hypermethionine activity;
 KW protease regulation; cell cycle regulation; neural disorder;
 KW metabolic disorder; vascular disorder; immune disorder;
 KW inflammatory condition; proliferative disorder; colon cancer;
 KW ovarian cancer; human; methionine aminopeptidase; Protease-39;
 KW heavy chain variable domain; primer; ss.
 XX
 XX Homo sapiens.
 OS
 XX US2003204070-A1.
 PN
 XX 30-OCT-2003.
 PD
 XX 23-JAN-2003; 2003US-00350516.
 PF
 XX 23-JAN-2002; 2002US-0351251P.
 PR
 XX 08-MAR-2002; 2002US-0362872P.
 XX
 XX (CHEN/) CHEN J.
 PA (FEDE/) FEDER J. N.
 PA (NELS/) NELSON T. C.
 PA (BASS/) BASSOLINO D. A.
 PA (KRSY/) KRYSZEK S. R.
 PA (NAGL/) NAGLICH J.
 XX
 XX Chen J, Feder JN, Nelson TC, Bassolino DA, Krystek SR, Naglich J;
 PI
 XX

DR WPI; 2003-900678/82.
 XX
 XX New nucleic acid encoding a human methionine aminopeptidase, useful for
 PT preparing a composition for diagnosing, preventing or treating e.g.,
 PT neural, metabolic, vascular, immune or inflammatory disorders or ovarian
 PT cancer.
 XX
 XX Example 34; SEQ ID NO 38; 183pp; English.
 PS
 XX The invention describes a new isolated nucleic acid molecule comprising:
 CC a polynucleotide fragment or complement of the cDNA sequence; a
 CC bp sequence; a polynucleotide fragment of the cDNA sequence; a
 CC polynucleotide sequence comprising nucleotides 4-1404 or 1-1404 of the
 CC 1404-bp sequence; or a polynucleotide sequence encoding a polypeptide, or
 CC its fragment, domain or epitope. The polynucleotide sequence does not
 CC hybridize to a nucleotide sequence having only A or T residues. The
 CC polypeptide comprises a fully defined 335-amino acid sequence, or its
 CC amino acids 2-335 without the start methionine or 1-335 including the
 CC start methionine. The nucleic acid is useful for preparing a composition
 CC for diagnosing, preventing, treating or ameliorating a medical or
 CC pathological condition comprising a disorder related to aberrant or
 CC methionine activity, a disorder associated with deficiencies in
 CC methionine activity, a disorder associated with hypermethionine activity,
 CC a disorder related to aberrant protease regulation, a disorder related to
 CC aberrant cell cycle regulation, neural disorders, metabolic disorders,
 CC vascular disorders, immune disorders, an inflammatory condition,
 CC proliferative disorder of the colon or ovarian cancer. This sequence
 CC represents a primer used to isolate DNA encoding a human heavy chain
 CC variable domain of antibodies directed against novel human methionine
 CC aminopeptidase, Protease-39.
 XX
 XX Sequence 23 BP; 3 A; 3 C; 12 G; 5 T; 0 U; 0 Other;
 SQ
 Query Match 0.5%; Score 17.2; DB 1; Length 23;
 Best Local Similarity 86.4%; Pred. No. 1.1e+03;
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 853 GAGGAGGAGCTGGTGGAGGCTG 874
 |||||
 Db 1 GAGGTGACGCTGGTGGAGTCTG 22
 RESULT 712
 ADF88105/C
 ID ADF88105 standard; DNA; 23 BP.
 XX
 XX ADF88105;
 AC
 XX 26-FEB-2004 (first entry)
 DT
 XX Single nucleotide polymorphism detection primer, SEQ ID No 1688.
 DE
 XX human; single nucleotide polymorphism; microarray; side effect; ss;
 KW primer; PCR.
 KW
 XX Synthetic.
 OS
 XX Homo sapiens.
 OS
 XX JP2003235571-A.
 PN
 XX 26-AUG-2003.
 PD
 XX 12-FEB-2002; 2002JP-00034717.
 PF
 XX 12-FEB-2002; 2002JP-00034717.
 PR
 XX (KAGA-) KAGAKU GIUTSU SHINKO JIGYODAN.
 PA
 XX WPI; 2003-820454/77.
 XX
 XX Novel polynucleotide useful for detecting single nucleotide polymorphisms
 PT in human gene.
 PT
 XX


```

DR WPI; 2003-598501/56.
XX
XX New albumin fusion protein, useful for preparing a composition for
PT treating diabetes mellitus.
PT
XX Example 91; SEQ ID NO 344; 1086pp; English.
XX
XX The invention relates to fusion proteins comprising human serum albumin
CC (ADH21530) and a therapeutic polypeptide such as a therapeutic protein,
CC antibody or peptide or their variants or fragments. The therapeutic
CC protein may be fused to the N-terminus, the C-terminus or both termini of
CC albumin via a linker. The albumin component of the fusion proteins
CC prolongs the shelf-life and the in vitro and vivo biological activity of
CC the proteins compared with those of the corresponding therapeutic
CC proteins on their own. The invention also relates to nucleic acids
CC encoding albumin fusion proteins, vectors and host cells comprising an
CC albumin fusion protein nucleic acid, compositions and kits comprising an
CC albumin fusion protein, the method of extending the shelf-life of a
CC therapeutic protein by fusion with albumin, and the treatment of disease
CC using an albumin fusion protein. The albumin fusion proteins may be used
CC in the treatment of metabolic/endocrine disorders, diabetes and diabetes-
CC related conditions. Specifically the albumin fusion proteins may be used
CC to treat type 1 and type 2 diabetes, hyperglycaemia, neural disorders
CC (especially neuropathy), retinopathy, cardiovascular disorders
CC (especially heart disease, renal disorders and obesity. The proteins may
CC also be used in a method of maintaining a basal glucose level in a
CC patient and in a method of losing weight. The present sequence is
CC related to the invention.
XX
XX Sequence 23 BP; 3 A; 3 C; 12 G; 5 T; 0 U; 0 Other;
SQ
Query Match 0.5%; Score 17.2; DB 1; Length 23;
Best Local Similarity 86.4%; Pred. No. 1.1e+03;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 853 GAGGAGGAGCTGTGGAGGCTG 874
DB 1 GAGGTGACAGCTGTGGAGTCTG 22
RESULT 715
ADG68058
ID ADG68058 standard; DNA; 23 BP.
AC ADG68058;
XX
XX 11-MAR-2004 (first entry)
XX
XX Human TRP-PLIK2 gene-related Ab VH domain PCR primer SeqID274.
XX
XX TRP-PLIK2; transient receptor potential channel; antiinflammatory;
XX gynaecological; immunomodulatory; cardiant; cytostatic; neuroprotective;
XX antiviral; anti-HIV; gene therapy; immune disorder;
XX haematopoietic disorder; inflammatory disorder; renal disorder;
XX reproductive disorder; hepatic disorder;
XX hyper transient receptor potential activity; prostate cancer;
XX testicular cancer; chromosome 9q21 aberration;
XX ankyrotrophic lateral sclerosis; frontotemporal dementia;
XX early-onset pulverulent cataract; infantile nephronophthisis;
XX hypomagnesaemia;
XX secondary hypocalcaemia familial haemophagocytic lymphohistiocytosis;
XX neuron degeneration; neurogenic inflammation; allergy; immunodeficiency;
XX excessive immune activation; visual defect; hearing disorder; pain;
XX cancer; hypertension; cardiovascular disease; Calcium homeostasis;
XX osteoporosis; hypercalciuric stone disease; chronic renal failure;
XX proliferative disorder; ischaemia-reperfusion injury; heart failure;
XX immuno-compromised condition; HIV infection; NF-kappa-B regulation;
XX apoptosis regulation; NF-kappa-B activity; human; PCR; primer; ss.
XX Homo sapiens.
OS
XX WO200294999-A2.
XX

```

```

PD 28-NOV-2002.
XX
XX 22-MAY-2002; 2002WO-US016164.
XX
XX 22-MAY-2001; 2001US-0292599P.
XX
XX 08-MAR-2002; 2002US-0362944P.
XX
XX (BRIM ) BRISTOL-MYERS SQUIBB CO.
XX
XX Lee N, Chen J, Feder J, Wu S, Chang H, Lee L, Blonar M, Bol D;
XX WPI; 2003-148463/14.
XX
XX New TRP-PLIK2 nucleic acid and its splice variants, useful for
XX manufacturing a medicament for preventing, treating or ameliorating a
XX medical condition, e.g. renal, inflammatory or reproductive disorders.
XX
XX Example 33; SEQ ID NO 274; 457pp; English.
XX
XX This invention relates to a novel isolated human TRP-PLIK2 (transient
XX receptor potential channel) nucleic acid sequence and the protein encoded
XX by it. The invention may be useful for the development of compounds with
XX an antiinflammatory, gynaecological, immunomodulatory, cardiant,
XX cytostatic, neuroprotective, antiviral or anti-HIV activity. In addition,
XX the DNA sequence may be useful for gene therapy. The invention may
XX therefore be useful for manufacturing a medicament for preventing,
XX treating or ameliorating a medical condition, for example immune
XX disorders, haematopoietic disorders, inflammatory disorders, renal
XX disorders, reproductive disorders, hepatic disorders, a disorder related
XX to hyper transient receptor potential activity, prostate cancer,
XX testicular cancer, diseases related to chromosome 9q21.2-22 aberrations,
XX amyotrophic lateral sclerosis with frontotemporal dementia, early-onset
XX pulverulent cataract, infantile nephronophthisis, hypomagnesaemia with
XX secondary hypocalcaemia familial haemophagocytic lymphohistiocytosis,
XX neuron degeneration, neurogenic inflammation, allergy,
XX immunodeficiency/excessive immune activation, visual defects, hearing
XX disorder, pain, cancer, hypertension, cardiovascular diseases, diseases
XX associated with disturbances in Calcium homeostasis including
XX osteoporosis, hypercalciuric stone disease, chronic renal failure,
XX proliferative disorders, ischaemia-reperfusion injury, heart failure,
XX immuno-compromised conditions, HIV infection, disorders associated with
XX aberrant NF-kappa-B regulation, disorders associated with aberrant
XX apoptosis regulation, disorders in which decreasing increasing NF-kappa-B
XX activity would be therapeutically desirable and disorders in which
XX decreasing or increasing IkB activity would be therapeutically desirable.
XX
XX Sequence 23 BP; 3 A; 3 C; 12 G; 5 T; 0 U; 0 Other;
SQ
Query Match 0.5%; Score 17.2; DB 1; Length 23;
Best Local Similarity 86.4%; Pred. No. 1.1e+03;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 853 GAGGAGGAGCTGTGGAGGCTG 874
DB 1 GAGGTGACAGCTGTGGAGTCTG 22
RESULT 716
ABT17138
ID ABT17138 standard; DNA; 23 BP.
XX
XX ABT17138;
XX
XX 10-APR-2003 (first entry)
XX
XX Human VEGF-2 related PCR primer SEQ ID No 38.
XX
XX Cytostatic; cardiant; cardiovascular; antiinflammatory; antirheumatic;
XX antiarthritic; antidiabetic; ophthalmological; antiallergic;
XX immunosuppressive; dermatological; antiparasitic; vulnary; antibody;
XX CDR region; VH domain; VL domain; immunospecific; VEGF-2; cancer;
XX proliferative disorder; cardiovascular disorder; arrhythmia;
XX cerebrovascular disorder; cerebral anoxia; inflammatory disease;
XX

```

KW infectious disease; autoimmune disease; rheumatoid arthritis;
 KW Systemic Lupus Erythematosus; allergy; diabetic retinopathy; psoriasis;
 KW angiogenesis; wound healing; vascular tissue repair; human; PCR; primer;
 KW ss.
 XX Unidentified.
 XX WO200283704-A1.
 PN 24-OCT-2002.
 XX 12-APR-2002; 2002WO-US011474.
 XX 13-APR-2001; 2001US-0283385P.
 PR 24-JAN-2002; 2002US-0350366P.
 XX (HUMA-) HUMAN GENOME SCI INC.
 PA Rosen CA, Albert VR, Ruben SM, Wager RE;
 PI WPI; 2003-092991/08.
 XX New isolated polynucleotide encoding an antibody which inhibits a VEGF-2
 PT polypeptide, useful for diagnosing, treating or preventing diseases
 PT associated with aberrant VEGF-2 expression or function, e.g. cancer or
 PT inflammation.
 XX Example 32; Page 240; 425pp; English.
 XX The invention relates to an isolated polynucleotide encoding a first
 CC antibody at least 95-100% identical to a second antibody comprising an
 CC amino acid sequence selected from at least one, two or three CDR
 CC region(s) of a VH or VL domain where the first antibody
 CC immunospecifically inhibits a VEGF-2 polypeptide. The isolated
 CC polynucleotide is useful in diagnosing, treating, preventing, prognosing,
 CC ameliorating or monitoring diseases associated with aberrant VEGF-2 or
 CC VEGF-2 receptor expression or lack of VEGF-2 or VEGF-2 receptor function,
 CC such as cancer and other proliferative disorders, cardiovascular
 CC disorders (arrhythmias), cerebrovascular disorders (e.g. cerebral
 CC anoxia), inflammatory diseases, infectious diseases, autoimmune diseases
 CC (e.g. rheumatoid arthritis, Systemic Lupus Erythematosus, allergies),
 CC diabetic retinopathy or psoriasis. The polynucleotide, polypeptide and
 CC antibodies may also be used to stimulate angiogenesis, wound healing, and
 CC promoting vascular tissue repair. The polynucleotide and polypeptide may
 CC also be used for in vitro purposes related to scientific research,
 CC synthesis of DNA and manufacture of DNA vectors, and for the production
 CC of diagnostics and therapeutics to treat human diseases. This
 CC polynucleotide sequence represents a PCR primer used in the
 CC exemplification of the invention
 XX Sequence 23 BP; 3 A; 3 C; 12 G; 5 T; 0 U; 0 Other;
 SQ Query Match 0.5%; Score 17.2; DB 1; Length 23;
 Best Local Similarity 86.4%; Pred. No. 1.1e+03;
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 853 GAGGAGGAGCTGTGGAGGCTG 874
 DB 1 GAGGTGACAGCTGTGGAGGCTG 22
 RESULT 717
 ID ACA54716
 XX ACA54716 standard; DNA; 23 BP.
 AC ACA54716;
 XX 05-JUN-2003 (first entry)
 DT Human NF-kappaB associated antibody VH domain PCR primer #3.
 DE Human; nuclear factor-kappaB; NF-kappaB; immune disorder; cancer;
 XX inflammatory disorder; apoptosis; hepatic disorder; Hodgkin's lymphoma;
 KW

KW haematopoietic tumour; hyper-IgM syndrome; viral infection; asthma;
 KW hypohidrotic ectodermal dysplasia; human immunodeficiency virus; HIV;
 KW X-linked anhidrotic ectodermal dysplasia; al incontinentia pigmenti;
 KW influenza; rheumatoid arthritis; inflammatory bowel disease; colitis;
 KW atherosclerosis; cachexia; euthyroid sick syndrome; stroke; EAE;
 KW experimental allergic encephalomyelitis; autoimmune disorder; wound;
 KW hyper immune activity; acute phase response; hypercongenital condition;
 KW birth defect; necrotic lesion; organ transplant rejection; pancreas;
 KW signal transduction; hyperproliferative disorder; diabetes mellitus;
 KW vitamin B12 malabsorption; neurological disorder; Huntington's chorea;
 KW Turner's syndrome; bacterial infection; cardiovascular disorder;
 KW infertility; psoriasis; haemolytic anaemia; anti-inflammatory; anti-HIV;
 KW cytoskeletal; hepatotropic; virucide; antineoplastic; antiallergic;
 KW antidiabetic; immunomodulator; antidiabetic; antiallergic;
 KW neuroprotective; immunosuppressive; vulnary; antibacterial;
 KW antiinfectivity; antianaemic; antipsoriatic; cerebroprotective; cardiant;
 XX antiarteriosclerotic; PCR; primer; ss.
 OS Homo sapiens.
 XX WO200286076-A2.
 PN 31-OCT-2002.
 XX 19-APR-2002; 2002WO-US012636.
 PF 19-APR-2001; 2001US-0284962P.
 PR 26-APR-2001; 2001US-0286645P.
 PR 09-JAN-2002; 2002US-0346986P.
 XX (BRIM) BRISTOL-MYERS SQUIBB CO.
 PA Carman J, Feder J, Nadler S;
 PI WPI; 2003-093119/08.
 XX Novel NF-kappaB-associated polypeptides and polynucleotides useful for
 DR diagnosing, treating and preventing cancer, hepatic disorders, aberrant
 XX apoptosis, viral infections, autoimmune disorders, asthma and stroke.
 XX Example 33; Page 407; 608pp; English.
 XX The present invention relates to the isolation of human nuclear factor-
 CC kappaB (NF-kappaB) associated polypeptides and polynucleotides. The NF-
 CC kappaB associated polypeptide and polynucleotide sequences are useful for
 CC preventing, treating or ameliorating various disorders including immune
 CC disorders, inflammatory disorders, cancers, disorders relating to
 CC aberrant apoptosis, hepatic disorders, Hodgkin's lymphomas,
 CC haematopoietic tumours, hyper-IgM syndromes, hypohidrotic ectodermal
 CC dysplasia, X-linked anhidrotic ectodermal dysplasia, immunodeficiency, al
 CC incontinentia pigmenti, viral infections (e.g. those caused by human
 CC immunodeficiency virus (HIV), human T-cell lymphotropic virus (HTLV),
 CC hepatitis B, hepatitis C, Epstein Barr virus (EBV), influenza),
 CC rheumatoid arthritis, inflammatory bowel disease, colitis, asthma,
 CC atherosclerosis, cachexia, euthyroid sick syndrome, stroke, experimental
 CC allergic encephalomyelitis (EAE), autoimmune disorders, disorders related
 CC to hyper immune activity, disorders related to aberrant acute phase
 CC responses, hypercongenital conditions, birth defects, necrotic lesions,
 CC wounds, organ transplant rejection, disorders related to aberrant signal
 CC transduction, hyperproliferative disorders, diseases of the pancreas
 CC (e.g. diabetes mellitus, vitamin B12 malabsorption), neurological
 CC disorders (e.g. Huntington's chorea), Turner's syndrome, bacterial
 CC infections, cardiovascular disorders, infertility, psoriasis and
 CC haemolytic anaemia. The present sequence represents a PCR primer used in
 CC the examples of the present invention
 XX Sequence 23 BP; 3 A; 3 C; 12 G; 5 T; 0 U; 0 Other;
 SQ Query Match 0.5%; Score 17.2; DB 1; Length 23;
 Best Local Similarity 86.4%; Pred. No. 1.1e+03;
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 853 GAGGAGGAGCTGTGGAGGCTG 874

Db 1 GAGGTGCAGCTGCTGGAGTCTG 22

RESULT 718
 ABX08633
 ID ABX08633 standard; DNA; 23 BP.
 AC ABX08633;
 XX
 XX
 DT 20-JAN-2003 (first entry)
 XX
 DE PCR primer #3 for DNA encoding VH domain of anti-APEX4 human antibody.
 XX
 KW Human; immunoglobulin superfamily; Ig; APEX4; sepsis; acne;
 KW antigen presenting cell expression 4; immunological disorder;
 KW rheumatoid arthritis; inflammatory bowel disease; activation;
 KW host-versus-graft disease; haematopoietic disorder; migration;
 KW leukocyte proliferation; differentiation; T-cell activation;
 KW B-cell activation; natural killer cell; spleen disorder;
 KW inflammatory disorder; proliferative disorder; neoplasm;
 KW immunosuppressive; antiinflammatory; antiarthritis; cytostatic;
 KW dermatological; PCR; primer; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200277173-A2.
 XX
 PD 03-OCT-2002.
 XX
 PF 22-MAR-2002; 2002WO-US008721.
 XX
 PR 22-MAR-2001; 2001US-0278037P.
 PR 03-APR-2001; 2001US-0281223P.
 XX
 PA (BRIM) BRISTOL-MYERS SQUIBB CO.
 XX
 PI Finger J;
 XX
 WPI; 2003-040582/03.
 XX
 PS New APEX (antigen presenting cell expression) 4 and APEX4v1 proteins and
 PT nucleic acids, useful for treating or preventing e.g. immunological
 PT disorders, hematopoietic and/or proliferative diseases.
 PS
 PS Example 28; Page 296; 368pp; English.
 XX
 CC The present invention relates to the isolation of a novel member of the
 CC immunoglobulin (Ig) superfamily, human antigen presenting cell expression
 CC (APEX)4, and variants (APEX4v1) and splice variants (APEX4sv1) thereof.
 CC The polypeptides of the invention are useful for treating, preventing or
 CC ameliorating medical conditions, such as immunological disorders (e.g.
 CC rheumatoid arthritis, inflammatory bowel disease, sepsis, acne or host-
 CC versus-graft disease), haematopoietic disorders, disorders related to
 CC aberrant leukocyte proliferation, differentiation, migration or
 CC activation, disorders related to aberrant T-cell or B-cell activation,
 CC disorders of the spleen, inflammatory disorders, and proliferative
 CC disorders (e.g. neoplasms). APEX4, APEX4v1 and APEX4sv1 polypeptides, and
 CC polynucleotides encoding them are useful for modulating proliferation,
 CC differentiation, migration and activation in various cells, tissues and
 CC organisms. The polynucleotides sequences are useful in chromosome
 CC identification, chromosome mapping, as molecular weight markers, and in
 CC gene therapy. The present sequence represents a PCR primer used in the
 CC examples of the present invention
 XX
 SQ Sequence 23 BP; 3 A; 3 C; 12 G; 5 T; 0 U; 0 Other;
 Query Match 0.5%; Score 17.2; DB 1; Length 23;
 Best Local Similarity 86.4%; Pred. No. 1.1e+03;
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 853 GAGGAGGAGCTGCTGGAGTCTG 874

Db 1 GAGGTGCAGCTGCTGGAGTCTG 22

RESULT 719
 ABT15964
 ID ABT15964 standard; DNA; 23 BP.
 AC ABT15964;
 XX
 XX
 DT 28-MAR-2003 (first entry)
 XX
 DE B7-specific antibody VH domain PCR primer - SEQ ID No 81.
 XX
 KW PCR; ss; gene therapy; B7-related fusion protein; BSL2; viral infection;
 KW immune response modulation; inflammatory response modulation; cancer;
 KW transplantation rejection; graft versus host disease; asthma; herpes;
 KW chronic obstructive pulmonary disease; HIV; encephalitis; psoriasis;
 KW autoimmune disease; rheumatoid arthritis; multiple sclerosis; primer.
 XX
 OS Unidentified.
 XX
 PN WO200299119-A2.
 XX
 PD 12-DEC-2002.
 XX
 PF 06-JUN-2002; 2002WO-US018049.
 XX
 PR 06-JUN-2001; 2001US-00875338.
 PR 15-FEB-2002; 2002US-00077023.
 XX
 PA (BRIM) BRISTOL-MYERS SQUIBB CO.
 XX
 PI Mikesell GE, Shen H;
 XX
 WPI; 2003-140629/13.
 XX
 PS New isolated B7-related nucleic acid fusion molecules and fusion
 PT polypeptides, useful for diagnostic applications, modulating the
 PT activation of immune or inflammatory response cells, preventing or
 PT treating cancer or psoriasis.
 XX
 PS Example 14; Page 161; 188pp; English.
 XX
 CC The invention comprises the amino acid and coding sequence of B7-related
 CC (BSL2) fusion proteins. The B7-related fusion proteins of the invention
 CC are useful for modulating the activation of immune or inflammatory
 CC response cells (e.g. T cells). The B7-related fusion proteins are useful
 CC for treating or preventing: transplantation rejection; cancer; viral
 CC disease; asthma; chronic obstructive pulmonary disease; graft versus host
 CC infections (e.g. HIV, herpes or encephalitis); and autoimmune disease
 CC (e.g. rheumatoid arthritis, multiple sclerosis or psoriasis). The present
 CC DNA sequence represents a PCR primer that was used to amplify the DNA
 CC encoding the variable domain of an antibody that is specific for a B7-
 CC related protein
 XX
 SQ Sequence 23 BP; 3 A; 3 C; 12 G; 5 T; 0 U; 0 Other;
 Query Match 0.5%; Score 17.2; DB 1; Length 23;
 Best Local Similarity 86.4%; Pred. No. 1.1e+03;
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 853 GAGGAGGAGCTGCTGGAGTCTG 874

RESULT 720
 ACC78591
 ID ACC78591 standard; DNA; 23 BP.
 XX
 AC ACC78591;
 XX


```

DT 18-AUG-2003 (first entry)
XX Human VH domains amplifying forward primer VH3-5'.
DE
XX
XX Albumin; HA; cytotaxtic; antibacterial; virucide; fungicide; anti-HIV;
XX antiasthmatic; osteopathic; antiarthritic; antiinflammatory; nootropic;
XX neuroprotective; anti-thyroid; anti-ulcer; hepatotropic; vulnerary;
XX protein therapy; growth hormone; hGH; VL; VH; PCR; primer; ss.
XX
XX Homo sapiens.
XX WO2003030821-A2.
XX
XX 17-APR-2003.
XX
XX 04-OCT-2002; 2002WO-US031794.
XX
XX 05-OCT-2001; 2001US-0327281P.
XX
XX (HUMA-) HUMAN GENOME SCI INC.
XX
XX Rosen CA, Haseltine WA;
XX
XX WPI; 2003-468174/44.
XX
XX New albumin fusion protein comprising a therapeutic protein:X, and
XX albumin, its variant or fragment, useful for treating a cancer, AIDS
XX asthma, leukemia, sepsis, endometriosis, osteoporosis, atherosclerosis,
XX autism, or emphysema.
XX
XX Example 60; Page 391; 455pp; English.
XX
XX The invention relates to an albumin fusion protein comprising a
XX therapeutic protein:X, and albumin, its variant or fragment. The albumin
XX fusion protein has the formula R1-L-R2; R2-L-R1; or R1-L-R2-L-R1 where R1
XX is therapeutic protein:X or fragment, L is a peptide linker and R2 is
XX albumin. The albumin fusion protein is useful for treating a disease or
XX disorder that is modulated by therapeutic protein:X (claimed), such as
XX cancer; infections (bacterial, viral, fungal, parasitic); or immune
XX (AIDS, asthma); hematopoietic (leukemia, sepsis); reproductive (cystic
XX fibrosis, endometriosis); musculoskeletal (osteoporosis, osteoarthritis);
XX cardiovascular (congestive heart failure, atherosclerosis); neural/
XX sensory (ataxia, attention deficit disorders, autism); respiratory
XX (emphysema, bronchitis); endocrine (goiter, glomerulonephritis);
XX digestive (ulcer, cirrhosis); or connective/epithelial (lupus, keloids)
XX disorders. Sequences ACC78589-624 represent PCR primers for amplifying
XX human VH and VL domains, that can be used to create multifusion proteins
XX
XX Sequence 23 BP; 3 A; 3 C; 12 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 0.5%; Score 17.2; DB 1; Length 23;
XX Best Local Similarity 86.4%; Pred. No. 1.1e+03;
XX Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
XX
QY 853 GAGGAGGAGCTGTGGAGGCTG 874
Db 1 GAGGTGCAGCTGTGTGAGTCTG 22
|||||
RESULT 721
ABX90509
ID ABX90509 standard; DNA; 23 BP.
XX
XX AC ABX90509;
XX
XX 01-MAY-2003 (first entry)
XX
XX Human VEGFR-1 RT-PCR primer #1.
XX
XX Antisense; ss; PCR; VEGF; vascular endothelial growth factor; human;
XX cancer; angiogenesis; neoplastic proliferation; cellular proliferation;
XX primer; RT-PCR; reverse transcriptase PCR.
XX

```

```

OS Homo sapiens.
XX
XX US2002165174-A1.
XX
XX 07-NOV-2002.
XX
XX 13-MAR-2001; 2001US-00805761.
XX
XX 31-JAN-1997; 97US-0037004P.
XX
XX 30-JAN-1998; 98US-00016541.
XX
XX 19-JAN-2000; 2000US-00487023.
XX
XX 19-JAN-2001; 2001WO-US000019.
XX
XX (GILL/) GILL P S.
XX
XX (MASO/) MASOOD R.
XX
XX Gill PS, Masood R;
XX
XX WPI; 2003-255224/25.
XX
XX New composition comprising an antisense oligonucleotide directed against
XX vascular endothelial growth factor, useful for preparing a composition
XX for treating cancer.
XX
XX Example 12; Page 19; 54pp; English.
XX
XX The invention relates to a composition comprising an antisense
XX oligonucleotide directed against vascular endothelial growth factor
XX (VEGF). The antisense oligonucleotide is useful for preparing a
XX composition treating cancer, neoplastic proliferation, abnormal cellular
XX proliferation and preventing angiogenesis. The present sequence is a
XX reverse transcriptase (RT)-PCR primer for a VEGF or related gene, used to
XX clone the coding region for expression in tumour cell lines. The cell
XX lines were used to test prospective antisense oligonucleotides
XX
XX Sequence 23 BP; 6 A; 4 C; 9 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 0.5%; Score 17.2; DB 1; Length 23;
XX Best Local Similarity 86.4%; Pred. No. 1.1e+03;
XX Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
XX
QY 1573 CAGGTGCGCCGGGCGATGGAGT 1594
Db 1 CAAGTGGCCAGAGCATGGAGT 22
|||||
RESULT 722
ACA61414
ID ACA61414 standard; DNA; 23 BP.
XX
XX AC ACA61414;
XX
XX 15-AUG-2003 (first entry)
XX
XX Human HGPRBMY39 antibody VH domain PCR primer Hu VH3-5'.
XX
XX Human; ss; G-protein coupled receptor; HGPRBMY39; cancer; PCR; primer;
XX male reproductive disorder; testicular disorder; immune disorder;
XX inflammatory disorder; developmental disorder; leukaemia; VH;
XX bone marrow disorder; testicular cancer; proliferative disorder;
XX neural disorder; Alzheimer's disease; prion disorder; antibody;
XX bone metabolism disorder; heavy chain variable region.
XX
XX Homo sapiens.
XX
XX WO2003023007-A2.
XX
XX 20-MAR-2003.
XX
XX 06-SEP-2002; 2002WO-US028582.
XX
XX 07-SEP-2001; 2001US-0317793P.
XX
XX 27-NOV-2001; 2001US-0333658P.
XX

```

XX PA (BRIM) BRISTOL-MYERS SQUIBB CO.
 XX PI Ramanathan CS, Gopal S, Mintier G, Feder JN;
 XX XX
 XX DR WPI; 2003-313245/30.
 XX
 XX PT New human G-protein coupled receptor, HGPBRM39, useful for treating or
 XX PT preventing e.g. immune, inflammatory, developmental, proliferative,
 XX PT neural, reproductive, bone marrow or prion disorders.
 XX XX
 XX PS Example 37; Page 313; 359pp; English.
 XX
 XX CC The invention relates to an isolated nucleic acid encoding a human G-
 XX CC protein coupled receptor HGPBRM39 (or its fragment domain or epitope),
 XX CC its complement or a polynucleotide capable of hybridising under stringent
 XX CC conditions to it. Also included are a HGPBRM39 recombinant vector, a
 XX CC recombinant host cell comprising the vector sequences (used to express
 XX CC and make the protein), an isolated HGPBRM39 polypeptide, and an anti-
 XX CC HGPBRM39 antibody. The HGPBRM39 polynucleotides and polypeptide is
 XX CC useful for preventing, treating or ameliorating e.g. a (male)
 XX CC reproductive disorder, a testicular disorder or cancer; a disorder
 XX CC related to aberrant G-protein coupled signalling, particularly N-formyl
 XX CC peptide receptor dependent signalling; a disorder related to aberrant G-
 XX CC protein coupled receptor dependent phosphatidylinositol-calcium
 XX CC signalling; a disorder related to aberrant G-protein couple receptor
 XX CC dependent phosphatidylinositol or calcium second messenger activation; an
 XX CC immune disorder; an inflammatory disorder; a developmental disorder; a
 XX CC disorder that would benefit from inhibition of a leukotriene B4-dependent
 XX CC proinflammatory signal; aberrant N-formyl peptide signalling; aberrant
 XX CC neutrophil activation; a disorder associated with hyper neutrophil
 XX CC activation; a disorder associated with below normal neutrophil activation
 XX CC ; a disorder related to aberrant intracellular and/or extracellular
 XX CC oxidation states; a disorder related to aberrant superoxide generation;
 XX CC leukaemia; a bone marrow disorder; cancer; proliferative disorders;
 XX CC neural disorders; a disorder related to aberrant neutrophil chemotaxis;
 XX CC Alzheimer's disease; prion disorders; and a bone metabolism disorder. The
 XX CC present sequence is a PCR primer used to isolate DNA encoding a heavy
 XX CC chain variable region (VH) of an anti-HGPBRM39 antibody
 XX
 XX SQ Sequence 23 BP; 3 A; 3 C; 12 G; 5 T; 0 U; 0 Other;
 XX
 XX Query Match 0.5%; Score 17.2; DB 1; Length 23;
 XX Best Local Similarity 86.4%; Pred. No. 1.1e+03;
 XX Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 XX
 XX QY 853 GAGGAGGAGCTGGTGGAGCTG 874
 XX ||||| ||||| ||||| ||||| |||||
 XX 1 GAGGTGACGCTGGTGGAGTCTG 22
 XX
 XX RESULT 723
 XX ADJ79912
 XX ID ADJ79912 standard; DNA; 23 BP.
 XX AC
 XX ADJ79912;
 XX
 XX DT 06-MAY-2004 (first entry)
 XX
 XX DE Primer #3 for VH region of anti-human K channel K-alphaM2 antibody gene.
 XX
 XX KW immunosuppressive; antidepressant; nephrotropic; tranquilizer;
 XX KW antidiabetic; neutropenic; antinfertility; virucide; cytostatic;
 XX KW antiarthritic; antirheumatic; anti-HIV; antiaesthetic; antipsoriatic;
 XX KW immunostimulant; antidiabetic; antinflammatory; antilipemic;
 XX KW osteopathic; potassium agonist; potassium antagonist; gene therapy;
 XX KW potassium channel alpha subunit; diagnosis; rheumatoid arthritis; AIDS;
 XX KW psoriasis; psoriasis; neutropenia; diabetes; pancreatitis;
 XX KW osteoporosis; hypertriglyceridemia; infertility; testicular cancer;
 XX KW viral orchitis; memory disorder; obsessive/compulsive disorder;
 XX KW addition; dopamine regulation; serotonin regulation; dysphoria;
 XX KW depression; irritability; anxiety; immunophenotyping; phosphorylation;
 XX KW ss; primer.

XX OS Homo sapiens.
 XX XX
 XX PN WO2003050235-A2.
 XX XX
 XX PD 19-JUN-2003.
 XX
 XX PF 19-JUL-2002; 2002WO-US023407.
 XX XX
 XX PR 19-JUL-2001; 2001US-0306577P.
 XX XX
 XX PA (BRIM) BRISTOL-MYERS SQUIBB CO.
 XX
 XX PI Feder J, Lee L, Chang H;
 XX WPI; 2003-577292/54.
 XX
 XX PT New isolated human potassium channel alpha subunit, K-alphaM2 polypeptide,
 XX PT useful for diagnosing, preventing, treating or ameliorating a medical
 XX PT condition, for example a neural disorder, an immune disorder or a
 XX PT metabolic disorder.
 XX
 XX PS Example 31; SEQ ID NO 43; 313pp; English.
 XX
 XX CC The invention relates to an isolated human potassium channel alpha
 XX CC subunit, K-alphaM2 polypeptide. The K-alphaM2 polypeptide and
 XX CC polynucleotide are useful for diagnosing, preventing, treating or
 XX CC ameliorating a medical condition, such as a neural disorder, an immune
 XX CC disorder (e.g. rheumatoid arthritis, AIDS, asthma, leukemia, psoriasis or
 XX CC neutropenia), a disorder related to aberrant potassium regulation, a
 XX CC metabolic disorder (e.g. diabetes, pancreatitis, osteoporosis or
 XX CC hypertriglyceridemia), a reproductive disorder, a renal disorder, a male
 XX CC reproductive disorder (e.g. infertility, testicular cancer or viral
 XX CC orchitis), a memory disorder, an obsessive/compulsive disorder, an
 XX CC addiction, a disorder related to aberrant dopamine or serotonin
 XX CC regulation, dysphoria, depression, irritability, anxiety, or depression,
 XX CC irritability or anxiety associated with treating drug addiction, learning
 XX CC disorders, memory disorders, or affective disorders. Antibodies against
 XX CC the polypeptide are useful for the affinity purification of the
 XX CC polypeptides from recombinant cell culture, in diagnostic assays to
 XX CC detect the presence or quantification of the polypeptides, or for
 XX CC immunophenotyping. Vectors and host cells containing the gene are useful
 XX CC for recombinantly producing the polypeptides. This sequence corresponds
 XX CC to a PCR primer to amplify a heavy chain variable region from an anti-
 XX CC human potassium channel K-alphaM2 antibody gene.
 XX
 XX SQ Sequence 23 BP; 3 A; 3 C; 12 G; 5 T; 0 U; 0 Other;
 XX
 XX Query Match 0.5%; Score 17.2; DB 1; Length 23;
 XX Best Local Similarity 86.4%; Pred. No. 1.1e+03;
 XX Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 XX
 XX QY 853 GAGGAGGAGCTGGTGGAGCTG 874
 XX ||||| ||||| ||||| ||||| |||||
 XX 1 GAGGTGACGCTGGTGGAGTCTG 22
 XX
 XX RESULT 724
 XX ADJ93146
 XX ID ADJ93146 standard; DNA; 23 BP.
 XX AC
 XX ADJ93146;
 XX
 XX DT 06-MAY-2004 (first entry)
 XX
 XX DE Anti-human GCRP HGPBRM30 antibody VH region PCR primer Hu-VH3.
 XX
 XX KW ds; Gene; immunosuppressive; cardiant; antiinflammatory; cytostatic;
 XX KW anti-HIV; antirheumatic; antiarthritic; antibacterial; antiseborrheic;
 XX KW dermatological; antipsoriatic; neuroprotective; neutropic;
 XX KW antiparkinsonian; antidiabetic; ophthalmological; antiaesthetic;
 XX KW antidepressant; neuroleptic; hypotensive; tranquilizer; hypertensive;
 XX KW anorectic; metabolic; virucide; osteopathic; antianginal; vulnary;

KW gene therapy; G-protein coupled receptor protein; HGPBMY30;
KW immune disorder; cardiovascular disorder; inflammatory disorder;
KW metabolic disorder; reproductive disorder; testicular cancer;
KW neural disorder; endocrine disorder; gastrointestinal disorder;
KW Alzheimer's disease; Parkinson's disease; diabetes; dwarfism; asthma;
KW schizophrenia; obesity; anorexia; osteoporosis; angina pectoris;
KW myocardial infarction.
XX Homo sapiens.
OS WO200296946-A1.
PN 05-DEC-2002.
XX 30-MAY-2002; 2002WO-US017085.
XX 30-MAY-2001; 2001US-029441P.
XX (BRIM) BRISTOL-MYERS SQUIBB CO.
XX Feder JN, Mintier GA, Ramanathan C;
XX WPI; 2003-140445/13.
XX Novel human G-protein coupled receptor, HGPBMY30 polypeptide useful for
PT preventing and treating e.g. immune disorders, cardiovascular disorders
PT or inflammatory disorders.
XX Example 37; SEQ ID NO 49; 343pp; English.
XX The invention relates to an isolated human G-protein coupled receptor,
CC HGPBMY30 polypeptide or a sequence having 95% identity to the above
CC mentioned sequences. (I) is useful for preventing or treating a medical
CC condition, selected from an immune disorder; a cardiovascular disorder;
CC an inflammatory disorder in which G-protein coupled receptors are either
CC directly, or indirectly, associated with the disorder; a metabolic
CC disorder; a reproductive disorder; a male reproductive disorder;
CC testicular cancer; a neural disorder; an endocrine disorder;
CC gastrointestinal disorder; (I) and (II) are also useful for detecting,
CC prognosing, preventing, treating, and/or ameliorating the diseases such
CC as hematopoietic and pulmonary disorders, Alzheimer's, Parkinson's
CC diseases, diabetes, dwarfism, color blindness, retinal pigmentosa,
CC asthma, expression, schizophrenia, sleeplessness, hypertension, anxiety,
CC stress, renal failure, acute heart failure, hypotension, obesity,
CC anorexia, HIV infections, osteoporosis, angina pectoris, and myocardial
CC infarction. (I) and (II) are useful for modulating signal transduction
CC activity. (I) and (II) are useful as an inhibitor of chemotaxis, as a
CC food additive or preservative, and for modifying the activities of (I).
CC (I) and (II) also useful to modulate mammalian characteristics, such as
CC body height, weight, hair color, eye color, skin, percentage of adipose
CC tissue, pigmentation, size and shape, to change a mammal's mental state
CC or physical state by influencing biorhythms, cardiac rhythms,
CC depression, tendency for violence, tolerance for pain, reproductive
CC capabilities, hormonal or endocrine levels, appetite, libido, memory,
CC stress, or other cognitive qualities. This sequence corresponds to a PCR
CC primer for the variable heavy region of an antibody targeted to the novel
CC HGPBMY30 protein.
XX SQ Sequence 23 BP; 3 A; 3 C; 12 G; 5 T; 0 U; 0 Other;
Query Match 0.5%; Score 17.2; DB 1; Length 23;
Best Local Similarity 86.4%; Pred. No. 1.1e+03;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 853 GAGGAGGAGCTGTGGGGCTG 874
Db 1 GAGGTGAGCTGTGGAGTCTG 22
RESULT 725
ADE83880
ID ADE83880 standard; DNA; 23 BP.
XX

AC ADE83880;
XX 29-JAN-2004 (first entry)
DE Chemokine beta-4 binding antibody PCR primer Hu VH3-5' SEQ ID NO:39.
XX antibody; chemokine beta-4; CK-B4; single chain Fvs; scFvs;
KW antipsoriatic; dermatological; antiinflammatory; immunosuppressive;
KW antirheumatic; antiarthritic; cerebroprotective; cytostatic; anti-HIV;
KW vulnary; dermatitis; autoimmune disease; rheumatoid arthritis;
KW systemic lupus erythematosus; autoimmune encephalitis; cancer;
KW HIV infection; wound; inflammatory disorder; human; psoriasis;
KW PCR primer; ss.
XX Synthetic.
OS Homo sapiens.
XX WO2003092597-A2.
XX 13-NOV-2003.
XX 30-APR-2003; 2003WO-US013414.
XX 01-MAY-2002; 2002US-0376561P.
XX (HUMA-) HUMAN GENOME SCI INC.
XX Rosen CA, Ruben SM;
XX WPI; 2004-022614/02.
XX New antibody that specifically binds to a chemokine beta-4 polypeptide,
PT useful for diagnosing, treating, preventing or ameliorating psoriasis,
PT rheumatoid arthritis, systemic lupus erythematosus, cancer, HIV infection
PT and wounds.
XX Example 2; SEQ ID NO 39; 181pp; English.
XX The present invention describes an antibody (I) that specifically binds
CC to a chemokine beta-4 (CK-B4) polypeptide. Where (I) comprises a first
CC amino acid sequence at least 95% identical to a second amino acid
CC sequence comprising a VH complementarity determining region (CDR) or VL
CC CDR of any of the single chain Fvs (scFvs) from any of 17 fully defined
CC sequences of 245-253 amino acids (ADE83861 to ADE83877). Also described:
CC (1) a kit comprising (I); (2) an isolated nucleic acid molecule encoding
CC (I); (3) a vector comprising the isolated nucleic acid of (2); (4) a host
CC cell comprising the vector of (3); (5) a cell line engineered to express
CC (I); (6) an antibody that binds the same epitope as (I); (7) an antibody
CC that competitively inhibits the binding (I) to a CK-B4 polypeptide; (8) a
CC method for detecting aberrant expression of CK-B4 polypeptide, comprising
CC assaying the level of CK-B4 polypeptide expression in a first biological
CC sample of an individual using at least one of (I), and comparing the
CC level of CK-B4 polypeptide assayed in the biological sample with a
CC standard level of CK-B4 polypeptide expression or level of CK-B4
CC polypeptide in a second, normal biological sample, where an increase or
CC decrease in the assayed level of CK-B4 polypeptide in the first
CC biological sample compared to the standard level is indicative of
CC aberrant expression; and (9) a method of treating, preventing or
CC ameliorating psoriasis, dermatitis or an autoimmune disease, comprising
CC administering (I) to the animal. (I) has antipsoriatic, dermatological,
CC antiinflammatory, immunosuppressive, antirheumatic, antiarthritic,
CC cerebroprotective, cytostatic, anti-HIV and vulnary activities. The
CC methods and compositions of the present invention are useful for
CC diagnosing, treating, preventing or ameliorating psoriasis, dermatitis or
CC an autoimmune disease such as rheumatoid arthritis, systemic lupus
CC erythematosus and autoimmune encephalitis. They can also be used in
CC cancer, HIV infection, wounds and inflammatory disorders. The present
CC sequence is used in the exemplification of the present invention.
XX SQ Sequence 23 BP; 3 A; 3 C; 12 G; 5 T; 0 U; 0 Other;
Query Match 0.5%; Score 17.2; DB 1; Length 23;
Best Local Similarity 86.4%; Pred. No. 1.1e+03;

Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 853 GAGGAGGAGCTGGTGGAGGCTG 874
 |||||
 Db 1 GAGGTGCAGCTGGTGGAGTCTG 22

RESULT 726
 ADG34320
 ID ADG34320 standard; DNA; 23 BP.

XX AC ADG34320;
 XX
 DT 26-FEB-2004 (first entry)
 XX
 DE Human neurokinin B antibody VH PCR primer HuVH3-5' SEQ ID NO:43.
 XX
 DE antibody; neurokinin B; hypotensive; gynaecological; gene therapy;
 KW hypertension; pre-eclampsia; NKB; ss; PCR; primer.
 KW
 XX Synthetic.
 OS
 XX WO2003102136-A2.
 PN
 XX 11-DEC-2003.
 PD
 XX 29-MAY-2003; 2003WO-US016802.
 PF
 XX 30-MAY-2002; 2002US-0383802P.
 PR
 XX (HUMA-) HUMAN GENOME SCI INC.
 PA
 XX Rosen CA, Ruben SM;
 PI WPI; 2004-053456/05.
 XX
 DR New antibody that specifically binds neurokinin B, useful for preparing a
 PT composition for treating or preventing hypertension or preeclampsia.
 PT
 XX Example 2; SEQ ID NO 43; 127pp; English.
 PS
 XX The invention relates to a novel antibody specifically binding neurokinin
 CC B. An antibody of the invention has hypotensive, and gynaecological
 CC activity, and may have a use in gene therapy. The antibody is useful for
 CC preparing a composition for treating or preventing hypertension or pre-
 CC eclampsia. The present sequence is used in the exemplification of the
 CC invention.
 CC
 XX Sequence 23 BP; 3 A; 3 C; 12 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 17.2; DB 1; Length 23;
 Best Local Similarity 86.4%; Pred. No. 1.1e+03;
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 853 GAGGAGGAGCTGGTGGAGGCTG 874
 |||||
 Db 1 GAGGTGCAGCTGGTGGAGTCTG 22

RESULT 727
 ADH13834
 ID ADH13834 standard; DNA; 23 BP.

XX AC ADH13834;
 XX
 DT 11-MAR-2004 (first entry)
 XX
 DE Human VEGF-2-specific antibody VH domain PCR primer #3.
 DE
 XX antibody; vascular endothelial growth factor 2; VEGF-2; cancer;
 KW hyperproliferative disorder; inflammatory disorder; autoimmune disease;
 KW rheumatoid arthritis; psoriasis; diabetic retinopathy; PCR; ss; primer;
 KW VH domain.

XX Unidentified.
 OS
 XX WO2003097660-A1.
 PN
 XX 27-NOV-2003.
 PD
 XX 19-AUG-2002; 2002WO-US026246.
 PF
 XX 12-APR-2002; 2002WO-US011474.
 PR
 XX (HUMA-) HUMAN GENOME SCI INC.
 PA
 XX Rosen CA, Albert VR, Ruben SM, Wager RE;
 PI WPI; 2004-022839/02.
 XX
 DR New polynucleotide encoding VEGF-2 antibody, useful in detecting, cancers.
 PT diagnosing, prognosing, monitoring, treating or preventing e.g. cancers.
 PT
 XX Example 32; SEQ ID NO 38; 410pp; English.
 PS
 XX The invention comprises a DNA sequence encoding an antibody which
 CC immunospecifically inhibits vascular endothelial growth factor 2 (VEGF-2)
 CC protein. The antibody of the invention is useful for detecting,
 CC diagnosing, monitoring, treating or preventing cancers or other
 CC hyperproliferative disorders, inflammatory disorders, autoimmune disease,
 CC rheumatoid arthritis, psoriasis, and diabetic retinopathy. The present
 CC DNA sequence represents a PCR primer that was used in an example of the
 CC invention.
 CC
 XX Sequence 23 BP; 3 A; 3 C; 12 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 17.2; DB 1; Length 23;
 Best Local Similarity 86.4%; Pred. No. 1.1e+03;
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 853 GAGGAGGAGCTGGTGGAGGCTG 874
 |||||
 Db 1 GAGGTGCAGCTGGTGGAGTCTG 22

RESULT 728
 ADG75494
 ID ADG75494 standard; DNA; 23 BP.

XX AC ADG75494;
 XX
 DT 11-MAR-2004 (first entry)
 XX
 DE Anti-HLLRCR-1 antibody VH domain PCR primer #3.
 DE
 XX Human; leucine-rich repeat cardiac receptor-1; HLLRCR-1; ss; PCR;
 KW cardiovascular disorder; reproductive disorder; neural disorder;
 KW apoptotic disorder; aberrant cell adhesion;
 KW aberrant cell matrix organisation; cancer; lung cancer;
 KW proliferated condition of the lung; colon cancer;
 KW long term memory; dementia; cognition; learning; development;
 KW Parkinson's disease; neuron attrition; Alzheimer's disease;
 KW long term potentiation; volatile vapour; brain trauma; movement disorder;
 KW ataxia; protein-protein interaction disorder;
 KW cell-to-cell communication disorder; signal transduction disorder;
 KW caspase recruitment disorder; primer; antibody; VH; VL;
 KW heavy chain variable region; light chain variable region.
 XX
 OS Homo sapiens.
 XX
 PN US2003186267-A1.
 XX
 PD 02-OCT-2003.
 XX
 XX 11-OCT-2002; 2002US-00271078.

XX PR 11-OCT-2001; 2001US-0328478P.
XX PA (FEDE/) FEDER J N.
XX PA (RAMA/) RAMANATHAN C S.
XX PA (MINT/) MINTIER G.
XX PI Feder JN, Ramanathan CS, Mintier G;
XX WPI; 2004-031999/03.
XX Isolated nucleic acid molecule for e.g. diagnosing and treating
XX cardiovascular condition, comprises polynucleotide encoding human leucine
XX -rich repeat cardiac receptor-1 protein having amino acid sequence of
XX specific length.
XX Example 34; SEQ ID NO 55; 164pp; English.
XX The invention relates to an isolated nucleic acid molecule comprising a
XX polynucleotide encoding the full-length human leucine-rich repeat cardiac
XX receptor-1 (HLR-1) protein appearing as ADG7544land ADG75443. Also
XX included are a recombinant vector comprising the isolated nucleic acid
XX molecule, a recombinant host cell comprising the vector sequences, the
XX isolated HLR-1 polypeptide, an isolated antibody that binds
XX specifically to the isolated polypeptide, making an isolated polypeptide
XX (by culturing the recombinant host cell expressing the isolated
XX polypeptide, and recovering the polypeptide), diagnosing a pathological
XX condition or a susceptibility to a pathological condition in a subject
XX (by determining the presence or absence of a mutation in the
XX polynucleotide, and diagnosing a pathological condition or a
XX susceptibility to a pathological condition based on the presence or
XX absence of the mutation) and preventing, treating or ameliorating a
XX medical condition by administering a polypeptide or its modulator to a
XX mammalian subject. The HLR-1 protein and nucleic acid are used for
XX diagnosing, preventing, treating or ameliorating a cardiovascular
XX disorder, reproductive disorder, neural disorder, disorder related to
XX aberrant apoptosis modulation, a disorder related to aberrant cell
XX adhesion, a disorder related to aberrant cell matrix organisation,
XX cancer, lung cancer, related proliferated condition of the lung, colon
XX cancer, related proliferated condition of the colon, memory disorders,
XX establishment of short term memory, establishment of long term memory,
XX dementia, cognition, learning, development of long term potentiation,
XX disorder associated with neuron attrition, Alzheimer's disease,
XX Parkinson's disease, disorders that accompany sniffing of volatile
XX vapours, disorders that accompany severe trauma to the brain, disorders
XX associated with the brain, particularly memory disorders, movement
XX disorders including Parkinson's, other forms of ataxia, disorder
XX associated with aberrant protein-protein interaction, aberrant cell-to-
XX cell communication, aberrant signal transduction, or aberrant caspase
XX recruitment (many other diseases and disorders are listed in the
XX specification). The invention provides human sequence that encodes a
XX leucine-rich repeat containing protein with homology to the leucine-rich
XX repeat containing protein known as NoGo receptor that is primarily
XX expressed in the brain and is thought to be responsible for modulating
XX neurite growth. The present sequence is a PCR primer used to isolate
XX nucleic acid encoding a VH or VL chain of an anti-HLR-1 antibody.
XX SQ Sequence 23 BP; 3 A; 3 C; 12 G; 5 T; 0 U; 0 Other;
Query Match 0.5%; Score 17.2; DB 1; Length 23;
Best Local Similarity 86.4%; Pred. No. 1.1e+03;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 853 GAGGAGGAGCTGCTGGAGGCTG 874
Db 1 GAGGTGAGCTGCTGGAGTCTG 22
RESULT 729
ADH61821
ID ADH61821 standard; DNA; 23 BP.
XX
AC ADH61821;

XX DT 25-MAR-2004 (first entry)
XX DE Human G protein chemokine receptor-related PCR primer SeqID15.
XX KW G-protein chemokine receptor; HSATU68; cytostatic; anti-HIV;
XX KW antiinflammatory; anti-diabetic; immunosuppressive; nontropic;
XX KW neuroprotective; vaccine; gene therapy; infectious disease; silicosis;
XX KW sarcoidosis; adult respiratory syndrome; ARDS;
XX KW hyperproliferative disorder; lymphoblastic leukaemia; brain tumour;
XX KW breast cancer; Kaposi's sarcoma; Hodgkin's sarcoma; myeloid leukaemia;
XX KW urethral cancer; gastrointestinal disorder; gastric reflux;
XX KW peptic oesophagitis; liver disorder; intrahepatic cholestasis;
XX KW hepatorenal syndrome; pancreatic disease; neoplasm; pancreas cell tumour;
XX KW islet cell tumour; gallbladder disease; bile duct tumour;
XX KW neurological disease; Alzheimer's disease; cardiovascular disease;
XX KW cardiac oedema; pulmonary heart disease; reproductive disorder;
XX KW testicular atrophy; gonorrhoea; renal disorder; kidney failure;
XX KW urinary disorder; endocrine disorder; diabetes mellitus;
XX KW diabetes insipidus; immunoresponsiveness; B-cell function;
XX KW lymphoid tissue regeneration; protein co-ordinate data; PCR; primer; ss.
XX OS Unidentified.
XX PN US200324426-A1.
XX PD 04-DEC-2003.
XX PF 11-APR-2003; 2003US-00411284.
XX PR 11-JAN-1996; 96WO-US000499.
XX PR 21-DEC-1998; 98US-00101518.
XX PR 12-APR-2002; 2002US-0371725P.
XX PA (LIYY/) LI Y.
XX PI Li Y;
XX WPI; 2004-033959/03.
XX Novel isolated human G-protein chemokine receptor HSATU68 polypeptide,
XX useful for preventing, treating or ameliorating medical conditions such
XX as leukemia.
XX Example 13; SEQ ID NO 15; 168pp; English.
XX This invention relates to a novel isolated human G-protein chemokine
XX receptor polypeptide (HSATU68) and the DNA sequence which encodes it. The
XX invention may be useful for the development of compounds with a
XX cytostatic, anti-HIV, antiinflammatory, anti-diabetic, immunosuppressive,
XX nontropic or neuroprotective activity which act as agonists or
XX antagonists of the receptor of the invention. In addition, the invention
XX may be useful for the development of a vaccine or for gene therapy. The
XX invention is useful for diagnosing a pathological condition or a
XX susceptibility to a pathological condition and for developing methods for
XX treating, preventing diseases, disorders or conditions associated with
XX aberrant expression and/or activity of the receptor of the invention such
XX as infectious diseases which includes silicosis, sarcoidosis. The
XX invention may also be used for the development of treatments for adult
XX respiratory syndrome (ARDS), hyperproliferative disorders such as acute
XX childhood lymphoblastic leukaemia, brain tumours, breast cancer, Kaposi's
XX sarcoma, Hodgkin's sarcoma, myeloid leukaemia and urethral cancer,
XX gastrointestinal disorders such as gastric reflux and peptic
XX oesophagitis, liver disorders such as intrahepatic cholestasis and
XX hepatorenal syndrome, pancreatic diseases such as neoplasms or pancreas
XX and islet cell tumours, gallbladder diseases such as bile duct tumour,
XX neurological diseases such as Alzheimer's disease, cardiovascular
XX diseases such as cardiac oedema, pulmonary heart disease, reproductive
XX disorders such as testicular atrophy, gonorrhoea, renal disorders such as
XX kidney failure, urinary disorders, endocrine disorders such as diabetes
XX mellitus, diabetes insipidus, for stimulating B-cell responsiveness to
XX pathogens, an agent to increase serum immunoglobulin concentrations, to
XX boost immunoresponsiveness among individuals having an acquired loss of B

CC -cell function and as therapy for generation and/or regeneration of
 CC lymphoid tissues following surgery, trauma or genetic defect. The present
 CC sequence is that of a degenerate PCR primer which was used to amplify a
 CC region of a VH or VL gene during the exemplification of the invention
 XX

Sequence 23 BP; 3 A; 3 C; 12 G; 5 T; 0 U; 0 Other;
 Query Match 0.5%; Score 17.2; DB 1; Length 23;
 Best Local Similarity 86.4%; Pred. No. 1.1e+03;
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 853 GAGGAGGAGCTGTGGAGGCTG 874
 DB 1 GAGGTGACAGCTGTGGAGTCTG 22

RESULT 730
 ADH76560
 ID ADH76560 standard; DNA; 23 BP.
 XX ADH76560;
 DT 22-APR-2004 (first entry)
 XX HNTTBMV1 antibody VH domain primer, SEQ ID 61.
 XX human neurotransmitter transporter; HNTTBMV1; PTA-4803; antidepressant;
 KW immunosuppressive; neuroleptic; neuroprotective; hypotensive;
 KW hypertensive; analgesic; anorectic; anabolic; antiparkinsonian;
 KW neuroleptic; tranquilizer; antidiabetic; hypnotic; gene therapy; dopamine;
 KW opioid peptide; serotonin; GABA; glutamate; primer; ss.
 OS Homo sapiens.

US2003219774-A1.
 27-NOV-2003.
 13-DEC-2002; 2002US-00319315.
 14-DEC-2001; 2001US-0340436P.
 (SHAR// SHARMA R.
 (RAMA// RAMANATHAN C S.
 (WEST// WESTPHAL R.
 (FEDE// FEDER J N.
 (LEEL// LEE L M.
 Sharma R, Ramanathan CS, Westphal R, Feder JN, Lee LM;
 WPI; 2004-010866/01.

New human neurotransmitter transporter polypeptides and nucleic acid
 molecules useful for diagnosing, preventing or treating for e.g.
 disorders related to aberrant neurotransmitter transport or affective or
 psychotic disorders.
 Example 30; SEQ ID NO 61; 131pp; English.

The invention relates to a novel isolated nucleic acid molecule encoding
 a human neurotransmitter transporter. The invention further comprises:
 a recombinant vector comprising the above nucleic acid molecule; a method
 of making a recombinant host cell comprising the above nucleic acid
 molecule; an isolated polypeptide comprising a sequence selected from:
 the full length protein or a polypeptide fragment, domain or epitope of a
 sequence having 727 amino acids or the encoded sequence included in ATCC
 Deposit Number PTA-4803, having neurotransmitter transporter activity; a
 polypeptide comprising amino acids 2-727 of a sequence having 727 amino
 acids minus the start methionine; and a polypeptide comprising amino
 acids 1-727 of the sequence having 727 amino acids; an isolated antibody
 that binds specifically to the above polypeptide; a recombinant host cell
 produced by the above method and that expresses the above polypeptide; a
 method of making an isolated polypeptide; a method for preventing,

CC treating or ameliorating a medical condition; and methods of diagnosing a
 CC pathological condition or a susceptibility to a pathological condition in
 CC a subject. The human neurotransmitter transporter nucleic acid has the
 CC following activities: antidepressant, immunosuppressive, neuroleptic,
 CC neuroprotective, hypotensive, hypertensive, analgesic, anorectic,
 CC anabolic, antiparkinsonian, neuroleptic, tranquilizer, antidiabetic, and
 CC hypnotic. The human neurotransmitter transporter nucleic acid can be used
 CC useful in diagnosing, preventing or treating a pathologic or medical
 CC condition selected from a disorder related to aberrant neurotransmitter
 CC transport; affective disorders, psychotic disorders, neurological
 CC disorders; metabolic disorders, immune-related disorders, hypotension,
 CC hypertension, endocrinal diseases, growth disorders, neuropathic pain,
 CC obesity, anorexia, bulimia, Parkinson's disease, dementias, behavioral
 CC disorder; memory disorders; cognitive disorders; disorders associated
 CC with aberrant serotonin expression and/or activity; anxiety, fear,
 CC depression, sleep, pain, disorders associated with aberrant maintenance
 CC of an attentive or alert state; attention deficit disorders; disorders
 CC affecting the 'reward centre' of the brain; disorders affecting the
 CC synthesis, and/or effecting the release of neurotransmitters such as
 CC dopamine, opioid peptides, serotonin, GABA, and glutamate; addictive
 CC disorders; homeostatic disorders; neuroendocrine disorders; disorders
 CC affecting the establishment of long term potentiation; circadian rhythm
 CC disorders; disorders associated with the establishment of aberrant
 CC sleep/wake cycles; dopaminergic functional disorders; neuronal
 CC transmission system disorders, and pain. This polynucleotide sequence
 CC represents a primer used in the exemplification of the invention.

Sequence 23 BP; 3 A; 3 C; 12 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 17.2; DB 1; Length 23;
 Best Local Similarity 86.4%; Pred. No. 1.1e+03;
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 853 GAGGAGGAGCTGTGGAGGCTG 874
 DB 1 GAGGTGACAGCTGTGGAGTCTG 22

RESULT 731
 ADI58176
 ID ADI58176 standard; DNA; 23 BP.

XX ADI58176;
 DT 22-APR-2004 (first entry)

Reg IV-specific single chain antibody fragment (scFv) PCR primer #3.
 antibody; regeneration IV; Reg IV; single chain antibody fragment; scFv;
 inflammatory bowel disorder; ulcerative colitis; Crohn's disease;
 diabetes; non-insulin dependent diabetes; insulin dependent diabetes;
 cancer; human; PCR; ss; primer.

Homo sapiens.
 OS
 WO2004003144-A2.

08-JAN-2004.
 26-JUN-2003; 2003WO-US019908.

01-JUL-2002; 2002US-0392382P.
 (HUMA-) HUMAN GENOME SCI INC.

Rosen CA;
 WPI; 2004-071976/07.

Novel antibody, useful for treating, preventing or ameliorating
 inflammatory bowel disorder, cancer of the gastrointestinal tract or
 diabetes (non-insulin dependent diabetes or insulin dependent diabetes).